<SEC-DOCUMENT>0001493152-26-013242.txt : 20260327
<SEC-HEADER>0001493152-26-013242.hdr.sgml : 20260327
<ACCEPTANCE-DATETIME>20260327170036
ACCESSION NUMBER:		0001493152-26-013242
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260327
DATE AS OF CHANGE:		20260327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Calidi Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001855485
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				862967193
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40789
		FILM NUMBER:		26808340

	BUSINESS ADDRESS:	
		STREET 1:		4475 EXECUTIVE DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-794-9600

	MAIL ADDRESS:	
		STREET 1:		4475 EXECUTIVE DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	First Light Acquisition Group, Inc.
		DATE OF NAME CHANGE:	20210406
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:CLDI="http://calidibio.com/20251231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2025%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_037_CLDI_calidibio.com_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250101_20251231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001855485 -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_form10%2Dk.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_sqft_8_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_063_AUD_0_iso4217%2D%2DAUD -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001855485</ix:nonNumeric>
  <ix:nonFraction name="CLDI:TermNotesPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:TermNotesPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:TermNotesPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0139" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-12-31" id="xdx2ixbrl0175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2025-12-31" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0363" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0366" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0602" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0740" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:ProceedsFromRegisteredDirectOffering" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:ProceedsFromIssuanceOfNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0778" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0781" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0784" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0793" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:RepaymentOfConvertibleNotePayable" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:PaymentOfDebtIssuanceCosts" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:MachineryAndEquipmentAcquiredThroughFinancingLeases" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl0836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockPerConversionOfConvertibleNote" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfConvertibleNoteForLegalSettlement" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockInLieuOfCashForServices" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0853" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:DebtDiscountOnConvertibleNotes" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0856" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0978" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_ContingentlyIssuableWarrantMember" id="xdx2ixbrl0981" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_ContingentlyIssuableWarrantMember" id="xdx2ixbrl0982" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl1035" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl1036" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1040" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1041" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember" id="xdx2ixbrl1045" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember" id="xdx2ixbrl1046" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember" id="xdx2ixbrl1049" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember" id="xdx2ixbrl1051" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl1060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember" id="xdx2ixbrl1061" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="xdx2ixbrl1064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="xdx2ixbrl1065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember" id="xdx2ixbrl1076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember" id="xdx2ixbrl1079" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember" id="xdx2ixbrl1081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="xdx2ixbrl1099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorAAndDirectorEMember" id="xdx2ixbrl1171" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorFAndRelativeOfOfficerAMember" id="xdx2ixbrl1176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorFMember" id="xdx2ixbrl1182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorDMember" id="xdx2ixbrl1186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorAOneMember" id="xdx2ixbrl1191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorATwoMember" id="xdx2ixbrl1201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_RelativeOfOfficerAMember" id="xdx2ixbrl1211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_OfficerGMember" id="xdx2ixbrl1217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_OfficerAMember" id="xdx2ixbrl1222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_CompanyARelatedToDirectorGMember" id="xdx2ixbrl1227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_CompanyARelatedToDirectorGMember" id="xdx2ixbrl1232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2025-12-31" id="xdx2ixbrl1352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2025-12-31" id="xdx2ixbrl1356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember" id="xdx2ixbrl1485" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" id="xdx2ixbrl1761" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" id="xdx2ixbrl1776" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl1791" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl1820" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" id="xdx2ixbrl1850" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember" id="xdx2ixbrl1861" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" id="xdx2ixbrl1876" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl1951" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl1966" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl1982" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl1997" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" id="xdx2ixbrl2012" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl2199" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl2201" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl2213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl2221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2233" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl2235" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2321" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2342" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:IncomeTaxReconciliationEnactmentOfNewTaxLaws" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2346" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2350" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2364" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2386" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2398" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2402" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2406" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2410" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2414" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2418" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2425" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2435" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationStockIssuanceCost" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2439" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2441" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2443" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxPaidForeignAfterRefundReceived" contextRef="From2025-01-01to2025-12-31" id="xdx2ixbrl2451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxPaidForeignAfterRefundReceived" contextRef="From2025-01-012025-12-31_country_AU" id="xdx2ixbrl2453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-12-31" id="xdx2ixbrl2496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-12-31" id="xdx2ixbrl2497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="From2024-01-012024-12-31" id="xdx2ixbrl2526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-12-31" id="xdx2ixbrl2632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2025-12-31" id="xdx2ixbrl2636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CLDI:FinanceLeaseLiabilityPaymentsDueAfterYearFour" contextRef="AsOf2025-12-31" id="xdx2ixbrl2638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cldi-20251231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-01-01to2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-102024-07-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-10</xbrli:startDate>
        <xbrli:endDate>2024-07-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-272025-10-27_custom_NovaCellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-27</xbrli:startDate>
        <xbrli:endDate>2025-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-27_custom_NovaCellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-17_custom_NovaCellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-172024-09-17_custom_NovaCellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-17</xbrli:startDate>
        <xbrli:endDate>2024-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MinimumMember_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_srt_MaximumMember_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-272022-10-27_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:GovernmentGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-27</xbrli:startDate>
        <xbrli:endDate>2022-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-272022-10-27_custom_GovernmentGrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:GovernmentGrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-27</xbrli:startDate>
        <xbrli:endDate>2022-10-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:GovernmentGrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_EarnoutSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:EarnoutSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ContingentlyIssuableWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:ContingentlyIssuableWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ContingentlyIssuableWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:ContingentlyIssuableWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsMember11025046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivateWarrantsMember11025062">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicWarrantsMember11025078">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrivateWarrantsMember11025078">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PrivateWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorAAndDirectorEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAAndDirectorEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorAAndDirectorEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAAndDirectorEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorFAndRelativeOfOfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndRelativeOfOfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorFAndRelativeOfOfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndRelativeOfOfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorFOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorFOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorATwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorATwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorATwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorATwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_DirectorFAndDirectorAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndDirectorAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DirectorFAndDirectorAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndDirectorAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RelativeOfOfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:RelativeOfOfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RelativeOfOfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:RelativeOfOfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OfficerGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OfficerGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_OfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_OfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CompanyARelatedToDirectorGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CompanyARelatedToDirectorGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CompanyARelatedToDirectorGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DirectorsAAndEMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorsAAndEMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-22_custom_DirectorFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_DirectorFMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-01_custom_DirectorDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-01_custom_DirectorDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-01_custom_DirectorAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-01_custom_DirectorAMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-31_custom_AJCCapitalMember_srt_MaximumMember_custom_GuarantyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-31_custom_AJCCapitalMember_custom_GuarantyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_AJCCapitalMember_custom_GuarantyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AJCCapitalMember_custom_GuarantyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31_custom_DirectorAThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-12_custom_DirectorAThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_custom_RelativeOfOfficerAMember_us-gaap_LoansPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:RelativeOfOfficerAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-08_custom_OfficerGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-082025-08-08_custom_OfficerGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-08</xbrli:startDate>
        <xbrli:endDate>2025-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-17_custom_OfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-172025-09-17_custom_OfficerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-17</xbrli:startDate>
        <xbrli:endDate>2025-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_CompanyARelatedToDirectorGMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CompanyARelatedToDirectorGMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-18_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TermNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TermNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TermNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TermNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_BridgeLoanPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:BridgeLoanPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BridgeLoanPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:BridgeLoanPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-31_custom_TwoThousandTwentyOneTermNoteMember_custom_InvestorAndDirectorMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyOneTermNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:InvestorAndDirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyOneTermNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyOneTermNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_TwoThousandTwentyTwoTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-08_custom_TwoThousandTwentyTwoTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_TwoThousandTwentyTwoTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyThreeTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_TwoThousandTwentyThreeTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-232024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-23</xbrli:startDate>
        <xbrli:endDate>2024-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyFourBridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-19</xbrli:startDate>
        <xbrli:endDate>2024-01-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyFourBridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_TwoThousandTwentyFourBridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyFourBridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:TwoThousandTwentyFourPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-18_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01_custom_PromissoryNoteLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PromissoryNoteLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PromissoryNoteLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PromissoryNoteLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PromissoryNoteLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PromissoryNoteLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-19_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_VotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:VotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_NonvotingCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-18_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-31_custom_SeriesBWarrantsAndSeriesCWarrantsMember_custom_InducementOfferLetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesBWarrantsAndSeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-31_custom_SeriesBOneWarrantsMember_custom_InducementOfferLetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-31_custom_SeriesDCommonStockMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesDCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-26_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-26_us-gaap_WarrantMember_custom_SubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-26_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-262024-07-26_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-26</xbrli:startDate>
        <xbrli:endDate>2024-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-262024-07-26_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-26</xbrli:startDate>
        <xbrli:endDate>2024-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-112024-10-11_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-11</xbrli:startDate>
        <xbrli:endDate>2024-10-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-042025-02-04_custom_MarketOfferingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:MarketOfferingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-04</xbrli:startDate>
        <xbrli:endDate>2025-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-052025-02-05_custom_MarketOfferingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:MarketOfferingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-05</xbrli:startDate>
        <xbrli:endDate>2025-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-042025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-04</xbrli:startDate>
        <xbrli:endDate>2025-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-23</xbrli:startDate>
        <xbrli:endDate>2024-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesECommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesECommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-23</xbrli:startDate>
        <xbrli:endDate>2024-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesFCommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesFCommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-23</xbrli:startDate>
        <xbrli:endDate>2024-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-242024-10-24_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-24</xbrli:startDate>
        <xbrli:endDate>2024-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-24_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-14</xbrli:startDate>
        <xbrli:endDate>2024-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-152024-11-15_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-15</xbrli:startDate>
        <xbrli:endDate>2024-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-14</xbrli:startDate>
        <xbrli:endDate>2024-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-092025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-09</xbrli:startDate>
        <xbrli:endDate>2025-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-28</xbrli:startDate>
        <xbrli:endDate>2025-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-28</xbrli:startDate>
        <xbrli:endDate>2025-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGCommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesGCommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-28</xbrli:startDate>
        <xbrli:endDate>2025-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-28_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:JulyWarrantInducementOfferMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-092025-07-09_custom_JulyWarrantInducementOfferMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:JulyWarrantInducementOfferMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-09</xbrli:startDate>
        <xbrli:endDate>2025-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember_custom_SeriesHCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:JulyWarrantInducementOfferMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesHCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-20</xbrli:startDate>
        <xbrli:endDate>2025-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-202025-08-20_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-20</xbrli:startDate>
        <xbrli:endDate>2025-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:PreFundedWarrantUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-20</xbrli:startDate>
        <xbrli:endDate>2025-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-20_custom_RepresentativeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:RepresentativeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:RestrictedStockUnitsVestedAndUnreleasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:RestrictedStockUnitsVestedAndUnreleasedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RedemptionOfWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="CLDI:TriggeringEventAxis">CLDI:SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RedemptionOfWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="CLDI:TriggeringEventAxis">CLDI:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesBOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesBOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesBOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesBOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesCOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesCOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SeriesCOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SeriesCOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesCOneWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesCOneWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesDWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesDWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsAndSeriesFWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsAndSeriesFWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesGPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesGPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_SeriesIPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_SeriesIPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_WarrantMember11030265">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember11030281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_WarrantMember11030281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_WarrantMember11030312">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-12_custom_TwoThousandTwentyThreePlanMember_custom_AdministratorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:AdministratorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-152024-07-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-15</xbrli:startDate>
        <xbrli:endDate>2024-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-042025-08-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-04</xbrli:startDate>
        <xbrli:endDate>2025-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-282023-08-28_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-28</xbrli:startDate>
        <xbrli:endDate>2023-08-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember11030718">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-182023-01-18_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-18</xbrli:startDate>
        <xbrli:endDate>2023-01-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-18_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_srt_AmericasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_AmericasMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_NonUsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_PriorDecemberTwentySeventeenthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">CLDI:PriorDecemberTwentySeventeenthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-12-31_custom_AfterDecemberTwentySeventeenthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">CLDI:AfterDecemberTwentySeventeenthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_country_DE">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-10_custom_SanDiegoLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SanDiegoLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SanDiegoLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-10</xbrli:startDate>
        <xbrli:endDate>2022-10-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-102022-10-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-10</xbrli:startDate>
        <xbrli:endDate>2022-10-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_MrCamaisaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:MrCamaisaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SanDiegoLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-10</xbrli:startDate>
        <xbrli:endDate>2022-10-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-01_custom_StemVacOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-012025-07-01_custom_StemVacOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-01</xbrli:startDate>
        <xbrli:endDate>2025-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_StemVacOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_StemVacOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-01_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-07_custom_NorthwesternAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:NorthwesternAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-152024-12-15_custom_NorthwesternAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:NorthwesternAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-15</xbrli:startDate>
        <xbrli:endDate>2024-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-222021-07-22_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-22</xbrli:startDate>
        <xbrli:endDate>2021-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:GeorgeNgMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-222023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:GeorgeNgMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-22</xbrli:startDate>
        <xbrli:endDate>2023-06-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:GeorgeNgMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31_custom_MrCamaisaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:MrCamaisaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31_custom_MrLeftwichMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:MrLeftwichMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-12_custom_MrLeftwichMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:MrLeftwichMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-03_custom_MrLeftwichMember_custom_SettlementOfDeferredCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:MrLeftwichMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLDI:SettlementOfDeferredCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-102023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-10</xbrli:startDate>
        <xbrli:endDate>2023-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-10</xbrli:startDate>
        <xbrli:endDate>2023-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-10</xbrli:startDate>
        <xbrli:endDate>2023-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-222025-08-22_custom_Dr.CamisaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.CamisaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-22</xbrli:startDate>
        <xbrli:endDate>2025-08-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-12-31_custom_Dr.CamisaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.CamisaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-08_custom_Dr.MinevMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.MinevMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-082025-08-08_custom_Dr.MinevMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.MinevMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-08</xbrli:startDate>
        <xbrli:endDate>2025-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-17_custom_Ms.CampbellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Ms.CampbellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-172025-09-17_custom_Ms.CampbellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Ms.CampbellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-17</xbrli:startDate>
        <xbrli:endDate>2025-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_CommonStockUnitsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:CommonStockUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-06</xbrli:startDate>
        <xbrli:endDate>2026-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:PreFundedWarrantUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-06</xbrli:startDate>
        <xbrli:endDate>2026-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:PreFundedWarrantUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:UnderwritersWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:UnderwritersWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-06</xbrli:startDate>
        <xbrli:endDate>2026-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesJWarrantsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesJWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesKWarrantsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesKWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesLWarrantsMember_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesLWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-06_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesGCommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesGCommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesHCommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesHCommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesICommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesICommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-03-052026-03-05_us-gaap_SubsequentEventMember_custom_CommonStockPurchaseWarrantsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001855485</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-05</xbrli:startDate>
        <xbrli:endDate>2026-03-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="AUD">
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="xdx2ixbrl0981" toRefs="Footnote000986"/>
  <ix:relationship fromRefs="xdx2ixbrl0982" toRefs="Footnote000986"/>
  <ix:relationship fromRefs="Fact001016" toRefs="Footnote001024"/>
  <ix:relationship fromRefs="Fact001017" toRefs="Footnote001024"/>
  <ix:relationship fromRefs="Fact001174" toRefs="Footnote001235"/>
  <ix:relationship fromRefs="Fact001179" toRefs="Footnote001238"/>
  <ix:relationship fromRefs="Fact001184" toRefs="Footnote001243"/>
  <ix:relationship fromRefs="Fact001189" toRefs="Footnote001252"/>
  <ix:relationship fromRefs="Fact001194" toRefs="Footnote001257"/>
  <ix:relationship fromRefs="Fact001199" toRefs="Footnote001264"/>
  <ix:relationship fromRefs="Fact001204" toRefs="Footnote001273"/>
  <ix:relationship fromRefs="Fact001209" toRefs="Footnote001282"/>
  <ix:relationship fromRefs="Fact001214" toRefs="Footnote001283"/>
  <ix:relationship fromRefs="Fact001219" toRefs="Footnote001288"/>
  <ix:relationship fromRefs="Fact001224" toRefs="Footnote001295"/>
  <ix:relationship fromRefs="Fact001229" toRefs="Footnote001302"/>
  <ix:relationship fromRefs="Fact001234" toRefs="Footnote001302"/>
  <ix:relationship fromRefs="Fact001640" toRefs="Footnote002028"/>
  <ix:relationship fromRefs="Fact001641" toRefs="Footnote002028"/>
  <ix:relationship fromRefs="Fact001655" toRefs="Footnote002029"/>
  <ix:relationship fromRefs="Fact001656" toRefs="Footnote002029"/>
  <ix:relationship fromRefs="Fact001805" toRefs="Footnote002038"/>
  <ix:relationship fromRefs="Fact001806" toRefs="Footnote002038"/>
  <ix:relationship fromRefs="xdx2ixbrl1820" toRefs="Footnote002051"/>
  <ix:relationship fromRefs="Fact001821" toRefs="Footnote002051"/>
  <ix:relationship fromRefs="Fact001835" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="Fact001836" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="xdx2ixbrl1850" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="Fact001851" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="xdx2ixbrl1861" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="Fact001862" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="xdx2ixbrl1876" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="Fact001877" toRefs="Footnote002068"/>
  <ix:relationship fromRefs="Fact001891" toRefs="Footnote002081"/>
  <ix:relationship fromRefs="Fact001892" toRefs="Footnote002081"/>
  <ix:relationship fromRefs="Fact001906" toRefs="Footnote002081"/>
  <ix:relationship fromRefs="Fact001907" toRefs="Footnote002081"/>
  <ix:relationship fromRefs="Fact001921" toRefs="Footnote002081"/>
  <ix:relationship fromRefs="Fact001922" toRefs="Footnote002081"/>
  <ix:relationship fromRefs="Fact001936" toRefs="Footnote002100"/>
  <ix:relationship fromRefs="Fact001937" toRefs="Footnote002100"/>
  <ix:relationship fromRefs="xdx2ixbrl1951" toRefs="Footnote002109"/>
  <ix:relationship fromRefs="Fact001952" toRefs="Footnote002109"/>
  <ix:relationship fromRefs="xdx2ixbrl1966" toRefs="Footnote002109"/>
  <ix:relationship fromRefs="Fact001967" toRefs="Footnote002109"/>
  <ix:relationship fromRefs="Fact002159" toRefs="Footnote002419"/>
  <ix:relationship fromRefs="Fact002161" toRefs="Footnote002419"/>
  <ix:relationship fromRefs="Fact002340" toRefs="Footnote002419"/>
  <ix:relationship fromRefs="xdx2ixbrl2342" toRefs="Footnote002419"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20250101__20251231_zYABDCZg8Yn1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000015" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--DocumentAnnualReport_c20250101__20251231_zL4fuP61A38j"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_906_edei--DocumentPeriodEndDate_c20250101__20251231_zRVHsF38Xzte"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20250101__20251231_zYDgCMftU8Zh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20250101__20251231_zb8kOdG5qnx3"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000019" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentTransitionReport_c20250101__20251231_zaCSYsgDzVN4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_905_edei--EntityFileNumber_c20250101__20251231_zgS0c4Aqhcbd"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000021" name="dei:EntityFileNumber">001-40789</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20250101__20251231_zxFclXu72zL6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000022" name="dei:EntityRegistrantName">CALIDI
BIOTHERAPEUTICS, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20250101__20251231_zHIMGvBGAwdl"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20250101__20251231_zDSsrsIqAf3g"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000024" name="dei:EntityTaxIdentificationNumber">86-2967193</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20250101__20251231_zK2BQokJxQx2"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000025" name="dei:EntityAddressAddressLine1">4475
    Executive Drive</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20250101__20251231_zNspe3jRKUO9"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20250101__20251231_zjCuzHDHbHAg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000027" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250101__20251231_zaErCAIadRKa"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:stateprovnameen" id="Fact000028" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric> </span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20250101__20251231_zAykF6xdFNz"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000029" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--CityAreaCode_c20250101__20251231_z2dwelFRRYQ7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000030" name="dei:CityAreaCode">(858)</ix:nonNumeric></span>
<span id="xdx_905_edei--LocalPhoneNumber_c20250101__20251231_zl2zgSRZjRL4"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000031" name="dei:LocalPhoneNumber">794-9600</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20250101__20251231_zXPzazNqA3a6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000032" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20250101__20251231_zUAPzatfEo94"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000033" name="dei:TradingSymbol">CLDI</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20250101__20251231_zLG0HnF33Zl6"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">NYSE
    American LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744; <span id="xdx_90E_edei--EntityWellKnownSeasonedIssuer_c20250101__20251231_z6TDiDXnOWWc"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#9744; <span id="xdx_902_edei--EntityVoluntaryFilers_c20250101__20251231_zKV663Me43v1"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000036" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. <span id="xdx_90A_edei--EntityCurrentReportingStatus_c20250101__20251231_znAXFV50sB52"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20250101__20251231_zqOYxcc0SLsi"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityFilerCategory_c20250101__20251231_zY7GhOWbV4Bk"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000039" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntitySmallBusiness_c20250101__20251231_zY8pytOcX88h"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000040" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do
    not check if a smaller reporting company)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250101__20251231_z8dYJMA4XL0a"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000041" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_90E_edei--EntityExTransitionPeriod_c20250101__20251231_zYmr2IiSIw6l"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_901_edei--IcfrAuditorAttestationFlag_c20250101__20251231_zghbZqnB0Zcg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_901_edei--DocumentFinStmtErrorCorrectionFlag_c20250101__20251231_zaQ1F2I4elxd"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). Yes
&#9744; No &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <span id="xdx_90C_edei--EntityShellCompany_dbF_c20250101__20251231_zpvg4ntiEwJg"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2025 (the last business
day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $<span id="xdx_90F_edei--EntityPublicFloat_iI_pn5n6_c20250630_zdZp0BV6xfaj"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2025-06-30" id="Fact000046" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2026, there were <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_c20260320_zyaN62OY7L4f"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-20" id="Fact000047" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,895,725</ix:nonFraction></span> shares of registrant&#8217;s common stock outstanding, excluding 150,000 non-voting common stock
held in escrow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Documents
incorporated by reference:</b> <span id="xdx_90D_edei--DocumentsIncorporatedByReferenceTextBlock_c20250101__20251231_zUwJbJTHcxJ"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000048" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-K ANNUAL REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Fiscal Year Ended December 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ct_001">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ct_002">SELECTED DEFINITIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ct_003">SUMMARY OF RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Y-001">PART
    I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-002">BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Y-003">RISK
    FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_001">UNRESOLVED
    STAFF COMMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_002">CYBERSECURITY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_003">PROPERTIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_004">LEGAL
    PROCEEDINGS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_005">MINE
    SAFETY DISCLOSURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#sp_006">PART
    II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_007">MARKET
    FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_008">RESERVED</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#sp_009">MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_018">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_019">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_020">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_021">CONTROLS AND PROCEDURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_008">OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_009">DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENTS INSPECTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#HK_011">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_010">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_012">EXECUTIVE COMPENSATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_013">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_014">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_015">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">135</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#HK_016">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_017">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#gok_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM 10-K SUMMARY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">141<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><a href="#gok_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>142</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><a href="#gok_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ct_001"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (&#8220;Securities
Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). These forward-looking statements
include, among other things, statements regarding our and our management team&#8217;s expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified
by words such as &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;outlook,&#8221;
&#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;may,&#8221;
&#8220;might,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;would,&#8221;
&#8220;will,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; and other similar words and expressions, but the absence of these words
does not mean that a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements
about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a biotechnology company with a limited operating history and have not generated any revenue to date from product sales;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have no products approved for commercial sale and have not generated revenues. We have incurred significant operating losses since
    our inception and we anticipate that we will incur continued losses for the foreseeable future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    need to raise substantial additional funding. If we are unable to raise capital when needed, or if at all, we will be forced to
    delay, reduce or eliminate some of our product development programs or commercialization efforts , or cease our operations altogether. In addition, the issuance of a
    substantial number of shares of common stock as a result of a financing could adversely affect the price of our common
    stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to realize the expected benefits of the Business Combination;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain the listing of our securities on the NYSE American;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial and business performance, including our financial projections and business metrics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    market opportunity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our strategy, future operations, financial position, estimated revenues and losses, forecasts, projected costs, prospects and
    plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expectations
    regarding the time during which we will be an emerging growth company under the JOBS Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain or recruit officers, key employees and directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of the regulatory environment and complexities with compliance related to such environment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expected costs associated with our research and development initiatives, including investments in technology and product development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to secure sufficient funding and alternative source of funding to support when needed and on terms favorable to us to support
    our business objective, product development, other operations or commercialization efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enroll patients in our proposed clinical trials and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of governmental laws and regulations; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain, maintain, protect and enforce sufficient patent and other intellectual property rights for our drug candidates
    and technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in this report are based on our current expectations and beliefs concerning future developments
and their potential effects on our business. There can be no assurance that future developments affecting our business will be those
that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control)
or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section entitled
&#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties
emerge from time to time and it is not possible for us to predict all such risk factors, nor can we assess the effect of all such risk
factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from
those contained in any forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of the
assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements made by us in this report speak only as of the date of this report. Except to the extent required under the
federal securities laws and rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;), we disclaim any obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect
the occurrence of unanticipated events. In light of these risks and uncertainties, there is no assurance that the events or results suggested
by the forward-looking statements will in fact occur, and you should not place undue reliance on these forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;registrant,&#8221; or &#8220;Registrant,&#8221;
&#8220;Calidi,&#8221; &#8220;Calidi Biotherapeutics,&#8221; and the &#8220;Company&#8221; refer to Calidi Biotherapeutics, Inc., a Delaware
corporation (f/k/a First Light Acquisition Group, Inc., a Delaware corporation), and its consolidated subsidiaries following the Business
Combination. Unless the context otherwise requires, references to &#8220;FLAG&#8221; refer to First Light Acquisition Group, Inc., a
Delaware corporation, prior to the Business Combination. Unless the context otherwise requires, references to &#8220;Calidi NV&#8221;
means Calidi Biotherapeutics (Nevada), Inc. (formerly Calidi Biotherapeutics, Inc.), a Nevada corporation and our wholly-owned subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ct_002"></span>SELECTED
DEFINITIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires or has otherwise been defined, the following defined terms shall have the meaning set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>anchor
investors</i>&#8221; means certain unaffiliated qualified institutional buyers or institutional accredited investors who have each entered
into an Investment Agreement pursuant to which such anchor investors have purchased in the aggregate 12,106 founder shares from our
Sponsor and Metric at approximately $0.003 per share;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Business
Combination</i>&#8221; means the business combination of FLAG with Calidi pursuant to the terms and conditions of the Merger Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Bylaws</i>&#8221;
means the Amended and Restated Bylaws, as amended, in effect as of the date of this report;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Calidi&#8221;
or &#8220;Calidi Biotherapeutics</i>&#8221; means Calidi Biotherapeutics, Inc., a Delaware corporation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Charter</i>&#8221;
or &#8220;<i>Second Amended and Restated Certificate of Incorporation</i>&#8221; means the Second Amended and Restated Certificate of
Incorporation in effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Closing</i>&#8221;
means the closing of the Merger and all of the transactions contemplated by the Merger Agreement in accordance with the terms of the
Merger Agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Closing
Date</i>&#8221; means the date on which the Business Combination was consummated which occurred on September 12, 2023;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>common
stock</i>&#8221; or &#8220;Common Stock&#8221; means Calidi Common Stock following the Business Combination, with the rights and preferences
and subject to the terms and conditions set forth in the Charter;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>DGCL</i>&#8221;
means the Delaware General Corporation Law, as amended;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Exchange
Act</i>&#8221; means the Securities Exchange Act of 1934, as amended;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>FLAG</i>&#8221;
means First Light Acquisition Group, Inc., a Delaware corporation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Investment
Agreement</i>&#8221; means each of the investment agreements entered into between our Sponsor, Metric and the anchor investors pursuant
to which such anchor investors have purchased in the aggregate 12,106 founder shares from our Sponsor and Metric at approximately $0.003
per share;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Insiders</i>&#8221;
are to, collectively, certain prior directors and officers of FLAG, including Thomas A. Vecchiolla, Michael J. Alber, Michael Reuttgers,
William J. Fallon, and Jeanne Tisinger;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Metric</i>&#8221;
means Metric Finance Holdings I, LLC, a Delaware limited liability company and an affiliate of Guggenheim Securities, LLC;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Calidi
Common Stock</i>&#8221; means, following the consummation of the Business Combination, the common stock, par value $0.0001 per share,
of Calidi Biotherapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Registration
Rights Agreements</i>&#8221; mean certain agreements requiring the Company to register the holders&#8217; shares of common stock with
the Securities and Exchange Commission consisting of that certain (i) Amended And Restated Registration Rights Agreement dated September
12, 2023; (ii) Voting and Lock-Up Agreement dated as of January 9, 2023, and amended on April 12, 2023, and (iii) Series B Preferred
Stock Investors&#8217; Rights Agreement dated June 16, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Series
B Financing</i>&#8221; means the equity financing contemplated by the Securities Purchase Agreements between Calidi Biotherapeutics,
Inc., and Jackson Investment Group, LLC and Calidi Cure, LLC, dated June 16, 2023, to secure commitments for the purchase of Series B
Convertible Preferred Stock of Calidi.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Sponsor</i>&#8221;
means First Light Acquisition Group, LLC, a Delaware series limited liability company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<i>Sponsor
Shares</i>&#8221; means 46,060 shares of common stock (net of cancellations from the original 47,917 shares of common stock sold) in
the aggregate originally sold to the Sponsor and Metric at $0.003 per share, and subsequently sold to the anchor investors at the same
purchase price or transferred other shareholders as an inducement to complete and finance the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ct_003"></span>SUMMARY
OF RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not
address every aspect of our risk factors, all of the risks that we face, or other factors not presently known to us or that we currently
believe are immaterial. As a result, the below summary risks do not contain all of the information that may be important to you, and
you should read the summary risks together with the more detailed and complete discussion of risks set forth under the heading &#8220;Risk
Factors&#8221; in Part I, Item 1A of this annual report, as well as elsewhere in this Annual Report and our other filings with the U.S.
Securities and Exchange Commission (SEC), before making investment decisions regarding our common stock. Additional risks, beyond those
summarized below or discussed elsewhere in this Annual Report, may apply to our activities or operations as currently conducted or as
we may conduct them in the future or in the markets in which we operate or may in the future operate.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consistent
with the foregoing, we are exposed to a variety of risks, including risks associated with the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business, Financial Position and Capital Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are a biotechnology company with a limited operating history and have not generated any revenue
                                            to date from product sales.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have insufficient cash to continue our operations for the next 12 months and our continued
                                            operations are dependent on us raising capital and these conditions give rise to substantial
                                            doubt over the Company&#8217;s ability to continue as a going concern.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have incurred significant operating losses since our inception and anticipate that we will
                                            incur continued losses for the foreseeable future.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have no products approved for commercial sale and have not generated any revenue from product
                                            sales.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            enveloped vaccina virus and engineered allogeneic stem cell product candidates represent
                                            a novel approach to cancer treatment that creates significant challenges.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
                                            publicity regarding stem cell-based immunotherapy could have a material adverse impact on
                                            our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            need to raise substantial additional funding. If we are unable to raise capital when needed,
                                            or if at all, we would be forced to delay, reduce or eliminate some or all of our product
                                            development programs or cease operations altogether.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Product Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            business is highly dependent on the success of our RedTail product candidates. If we are
                                            unable to obtain approval for our RedTail product candidates and effectively commercialize
                                            any of them for the treatment of patients in its approved indications, our business would
                                            be significantly harmed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            preclinical studies and clinical trials may fail to demonstrate adequately the safety and
                                            efficacy of any of our product candidates, which would prevent or delay development, regulatory
                                            approval, and commercialization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim,
                                            top line and preliminary data from our clinical trials that we announce or publish from time
                                            to time may change as more patient data become available and are subject to regulatory audit
                                            and verification procedures that could result in material changes in the final data.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            of earlier studies and trials of our product candidates may not be predictive of future trial
                                            results.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            product candidates are based on a novel approach to the treatment of cancer using vaccinia
                                            virus enveloped in a cellular membrane, allogeneic neural stem cell, and allogeneic adipose-derived
                                            mesenchymal stem cell (&#8220;AD-MSC&#8221;) loaded with an oncolytic virus which makes it
                                            difficult to predict the time and cost of product candidate development and subsequently
                                            obtaining regulatory approval, if at all.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Government Regulation and Commercialization of Our Product Candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            regulatory approval processes of the FDA and other regulatory authorities are lengthy, time
                                            consuming and inherently unpredictable. If we are not able to obtain, or experience delays
                                            in obtaining, required regulatory approvals, we will not be able to commercialize our current
                                            and future product candidates as expected, and our ability to generate revenue may be materially
                                            impaired.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates,
                                            may not lead to a faster development or regulatory review or approval process and it does
                                            not increase the likelihood that our product candidates will receive marketing approval.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be able to file INDs or IND amendments to commence additional clinical trials on
                                            the timelines we expect, and even if we are able to, the FDA or other regulatory authority
                                            may not permit us to proceed.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            approved, our investigational products regulated as biologics may face competition from biosimilars
                                            approved through an abbreviated regulatory pathway.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
                                            legislative reform measures may have a negative impact on our business, financial condition,
                                            results of operations and prospects.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unstable
                                            global economic and geopolitical conditions may have serious adverse consequences on our
                                            business, financial condition, stock price and results of operations.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Legal and Compliance Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face potential product liability exposure, and if successful claims are brought against us,
                                            we may incur substantial liability and have to limit the commercialization of any approved
                                            products and/or our product candidates.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            employees, independent contractors, consultants, commercial partners, principal investigators
                                            or contract research organizations <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&#8220;CROs&#8221;)</span> may engage in misconduct or other improper activities, including noncompliance with
                                            regulatory standards and requirements and insider trading, which could have a material adverse
                                            effect on our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
                                            of or liabilities under environmental, health and safety laws and regulations could subject
                                            us to fines, penalties or other costs that could have a material adverse effect on the success
                                            of our business.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Reliance on Third Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 20.65pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            depend on banks insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) to safeguard
                                            our cash deposits critical to our operations, including to fund our payroll to our employees,
                                            and should our depository bank be put into receivership by the FDIC we could experience delays
                                            in accessing our cash deposits or lose our cash deposits that may exceed the FDIC insured
                                            amounts of $250,000.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 20.65pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            rely on third parties, including independent clinical investigators and CROs to conduct and
                                            sponsor some of the clinical trials of our product candidates. Any failure by a third party
                                            to meet its obligations with respect to the clinical development of our product candidates
                                            may delay or impair our ability to obtain regulatory approval for our product candidates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 38.65pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Intellectual Property</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            rights to develop and commercialize certain of our product candidates are subject and may
                                            in the future be subject, in part, to the terms and conditions of licenses granted to us
                                            by third parties. If we fail to comply with our obligations under our current or future intellectual
                                            property license agreements or otherwise experience disruptions to our business relationships
                                            with our current or any future licensors, we could lose intellectual property rights that
                                            are important to our business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may enter into license or other collaboration agreements in the future that may impose certain
                                            obligations on us. If we fail to comply with our obligations under such future agreements
                                            with third parties, we could lose license rights that may be important to our future business.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
                                            parties may assert that we are employing their proprietary technology without authorization.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
                                            parties may assert that our employees or consultants have wrongfully used or disclosed confidential
                                            information, misappropriated trade secrets, or are in breach of non-competition or non-solicitation
                                            agreements with our competitors.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
                                            and maintaining our patent protection depends on compliance with various procedural, document
                                            submission, fee payment and other requirements imposed by governmental patent agencies, and
                                            our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            issued patents covering our product candidates could be found invalid or unenforceable if
                                            challenged in court or the USPTO.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
                                            in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents
                                            in general, thereby impairing our ability to protect our products.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Ownership of Our Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            price of our stock may be volatile, which could result in substantial losses for investors.
                                            Further, an active, liquid and orderly trading market for our common stock may not be sustained,
                                            and we do not know what the market price of our common stock will be, and as a result it
                                            may be difficult for you to sell your shares of our common stock.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            securities or industry analysts do not publish research or publish inaccurate or unfavorable
                                            research about our business, our stock price and trading volume could decline.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we fail to comply with the continued listing standards of the NYSE American, our common stock
                                            could be delisted. If it is delisted, the market value and the liquidity of our common stock
                                            would be impacted.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
                                            the Trading Price of our Common Stock has decreased, it is unlikely that we will receive
                                            any Settlement Amount Under the Forward Purchase Agreements.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-002"></span>ITEM
1 &#8211; BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic
medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for
systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune
clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to
metastatic locations. We expect to file an investigational new drug <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&#8220;</span>IND&#8221;) application for a Phase I trial by the end of 2026 with CLD-401, the first compound from the
RedTail platform, delivering IL-15 superagonist to the tumor microenvironment (&#8220;TME&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RedTail platform is the culmination of over a decade of work around genetic engineering of viruses and allows for the systemic administration
of a proprietarily-modified oncolytic virus that can:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survive
                                            in circulation and home to metastatic tumor sites;</span></td>
</tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Only
                                            replicates in tumor cells;</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Induce
                                            immuogenic kill in tumor cells and immune priming in the TME; and</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Deliver
                                            genetic medicine payloads like IL-15 superagonist for expression in the TME.</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            legacy SuperNova and NeuroNova stem cell based oncolytic virus platforms are designed to:</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Protect
                                            oncolytic viruses from neutralizing antibodies and complement inactivation and innate immune
                                            cell inactivation;</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Enhance
                                            oncolytic viral amplification inside the allogeneic cells; and</span></td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Modify
                                            the TME to allow improvements in cell targeting and viral amplification at the tumor site.</span></td></tr>
     </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncolytic
viruses have been pursued as therapeutic platforms in oncology because of their ability to preferentially infect and replicate within
cancer cells, resulting in both direct lysis of the tumor cells as well as activation of an antitumor immune response, while leaving
normal, healthy cells unharmed. Despite the promises of oncolytic viruses, a major obstacle against their therapeutic use has been their
rapid elimination by the patient&#8217;s immune system; this has meant that oncolytic viruses have been largely relegated to being used
for local delivery to tumors but have not been successful in patients with extensive metastatic disease. The only approved oncolytic
virus therapy is T-VEC (Imlygic&#174;), a modified herpes simplex virus (&#8220;HSV&#8221;) for the treatment of patients with melanoma given intratumorally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been working on oncolytic viruses for over a decade. Our NeuroNova investigational drug candidate is currently in a Phase 1 trial
being run and funded by our partner, City of Hope, in an investigator-initiated trial and we have an open IND for a Phase 1 trial for
our SuperNova investigational drug candidate (CLD-201). In July 2025 we were granted Fast Track Designation to CLD-201 by the U.S. Food
and Drug Administration (&#8220;FDA&#8221;) for the treatment of patients with soft tissue sarcoma. The platforms used in NeuroNova and SuperNova use
oncolytic viruses embedded in stem cells to facilitate initial viral amplification and expansion at the tumor sites. This approach has
shown substantial benefit over unprotected virus in preclinical studies of intratumoral delivery, but stem cell encapsulation does not
allow for systemic delivery of virus to tumor metastases in animal models. The size of the stem cells prohibited efficient dissemination
into metastatic sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, we used the learnings from NeuroNova and SuperNova to create RedTail, a novel oncolytic viral platform that avoids immune clearance
allowing for systemic delivery. RedTail utilizes a proprietary form of enveloped virus with genetic modifications, including engineered
expression of CD55 on the enveloped virus, to avoid immune clearance. The virus used in RedTail has been further proprietarily engineered
to specifically replicate only in tumor tissue where the virus also has the ability to deliver genetic medicines to the tumor microenvironment.
Because the virus is not encapsulated in stem cells, it is thousands of times smaller than the NeuroNova or SuperNova products and disseminates
efficiently into metastatic sites in syngeneic animal models. In addition, the virus can be engineered to express genetic medicines while
replicating in the tumor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLD-401,
the first lead derived from the RedTail platform. CLD-401 is enveloped and overexpressed CD55 on its outer membrane. It is tropic for
tumor cells and, when replicating, expresses IL-15 superagonist at high concentrations in the tumor microenvironment. In animal models,
CLD-401 can be given systemically and clear metastatic sites in syngeneic tumor mouse models with demonstrated enhanced biological efficacy.
The combination of the RedTail virus with its genetic payload drives complete tumor eradication in the tumor models compared to the RedTail
virus alone. We believe that RedTail, given its systemic administration and targeting to metastatic sites and its delivery of genetic
medicines, represents a major advancement in the space of oncolytic virus in oncology. The company is developing additional leads from
the RedTail platform including compounds that simultaneously express a bispecific T-cell engager (&#8220;TCE&#8221;) and a T-cell activator as well
as compounds for use outside of oncology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy is to pioneer next generation targeted therapies with the potential to deliver genetic medicines to distal
sites of disease. We intend to achieve this strategy by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing
    to advance our enveloped oncolytic virotherapy platform.</i></b> Our RedTail platform is comprised of an enveloped oncolytic vaccinia
    virus. In preclinical studies, RedTail has shown an ability to target lung cancer and disseminated cancer disease due to its ability
    to survive in the bloodstream. Our goal is to utilize this product candidate to target lung cancer and metastatic solid tumors. We
    believe that this approach may allow for potentially greater antitumor activity and lower toxicity when compared to existing modalities
    for treating selected disseminated indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Collaborating
with industry partners in pursuit of combination therapies. </i></b>In addition to our monotherapy trials, we intend to explore combination
therapy studies using our RedTail platform in conjunction with certain other immuno-therapies that are already approved or under clinical
development.</span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advancing
    clinical programs over the next 12 months. </i></b>We anticipate submitting to the FDA for our lead RedTail product candidate,
    CLD-401, for a first-in-human Phase 1 clinical trial in patients with metastatic solid tumors by the end of 2026. In parallel, we
    are pursuing initiation of a phase I study in Australia for CLD-401.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continuing
    to pursue cost-efficient manufacturing. </i></b>Manufacturing of enveloped viruses involves a series of
    complex steps. We believe an important element of our commercialization plans involves the efficient and scalable production of GMP-grade material.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursuing
    opportunistically out-licensing of our enveloped virus and stem cell derived products. </i></b>Our enveloped virus and stem cell
    production capabilities enable us to selectively out-license our cell banked or cell derived products to third parties. We
    anticipate entering into one or more distribution relationships in order to pursue this opportunity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>RedTail
for Metastatic Solid Tumors</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RedTail platform utilizes an engineered vaccinia virus enveloped by a cell membrane and engineered to express CD55. In syngeneic animal
models, the RedTail virus is capable of being systemically administered and homing to metastatic sites. The RedTail virus can be further
engineered to induce expression of a genetic medicine at the site of tumor metastases. Metastatic solid tumors involve cancer cells that
break away from where they first formed (primary cancer) and travel through the blood or lymph system to form new tumors, known as metastatic
tumors, in other parts of the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lead compound from the RedTail platform is CLD-401. In syngeneic animal models, CLD-401 is capable of homing to metastatic tumor sites
after systemic administration. Once at the tumor sites, CLD-401 can induce lytic cell death of tumor cells and induce high levels of
IL-15 superagonist expression restricted to the metastatic tumor sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CLD-201
(SuperNova<sup>&#8482;</sup>) for Solid Tumors (Breast Cancer, Sarcoma, and Head and Neck)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLD-201
is composed of CAL1 vaccinia virus (AKA ACAM1000 or ACAM2000) loaded into the allogeneic AD-MSC cell line VP-001 and is our first internally
developed product candidate utilizing our SuperNova<sup>&#8482;</sup> Platform targeting multiple solid tumors (Breast Cancer, Sarcoma,
and Head and Neck). Based on our pre-clinical studies, we believe CLD-201 has therapeutic potential for the treatment of multiple solid
tumors such as, head and neck cancer, breast cancer and sarcoma. Our IND application was approved by the FDA in April 2025 for the clinical
development of CLD-201 and in July 2025 we were granted Fast Track Designation to CLD-201 by the FDA for the treatment of patients with
soft tissue sarcoma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CLD-101
(NeuroNova<sup>&#8482;</sup>) for Newly Diagnosed High Grade Glioma (&#8220;HGG&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CLD-101
is our product candidate utilizing our NeuroNova&#8482; Platform targeting HGG. Our partner, Northwestern University, has an open IND
for a Phase 1b/2 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>CLD-101
(NeuroNova<sup>&#8482;</sup>) for Recurrent HGG</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
partner City of Hope is conducting clinical studies on CLD-101 utilizing our NeuroNova<sup>&#8482;</sup> Platform for the indication
of recurring HGG using the same allogeneic neural stem cell bank and oncolytic adenovirus being used in our clinical trials for newly
diagnosed HGG discussed above. City of Hope dosed the first patient in May 2023 in a Phase 1 clinical trial with CLD-101 for recurring
HGG. This program is supported by a grant from CIRM awarded to the City of Hope.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new product candidates is highly competitive. We face competition from major pharmaceutical, specialty
pharmaceutical and biotechnology companies among others with respect to our RedTail, NeuroNova<sup>&#8482;</sup>, and SuperNova<sup>&#8482;</sup>
product candidates and will face similar competition with respect to any product candidates that we may seek to develop or commercialize
in the future. We compete in pharmaceutical, biotechnology and other related markets that develop immune-oncology therapies for the treatment
of cancer. There are other companies working to develop viral immunotherapies for the treatment of cancer including divisions of large
pharmaceutical and biotechnology companies of various sizes. The large pharmaceutical and biotechnology companies that have commercialized
and/or are developing immuno-oncology treatments for cancer include AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Inc., Merck &amp;
Co., Novartis, Pfizer and Genentech, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the products and therapies developed by our competitors are based on scientific approaches that are the same as or similar to our
approach, including with respect to the use of viral immunotherapy with oncolytic viruses. Other competitive products and therapies
are based on entirely different approaches. We are aware that Oncorus, Inc., Replimune Group, Inc., Amgen Inc., ImmVira Co., Ltd.,
IconOVir Bio, Inc., Candel Therapeutics, Inc., CG Oncology, Inc., Genelux Corporation, Imugene Limited, Viromissile, Oncolytics
Biotech Inc., and FerGene, Inc., among others, are developing viral immunotherapies that may have utility for the treatment of
indications that we are targeting. Potential competitors also include academic institutions, government agencies and other public
and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for
research, development, manufacturing and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies we compete against or may compete against in the future have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in concentration of
even more resources among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel, in establishing clinical trial sites and enrolling subjects for our clinical
trials and in acquiring technologies complementary to, or necessary for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer,
more effective, have fewer or less severe side effects, or are more convenient or are less expensive than any products that we or our
collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may
obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the
market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy,
safety, convenience and price, if required, the level of biosimilar or generic competition and the availability of reimbursement from
government and other third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Manufacturing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing process of extracellular enveloped viruses and allogeneic cell product candidates involves a series of complex and
precise steps. A critical component of our success in this area will be through our research collaboration with our subsidiary,
StemVac. The StemVac team has decades of deep experience in process and assay development and optimization of virus and cell-based
and enveloped oncolytic virus manufacturing of advanced therapeutic biological products. The development services provided by
StemVac are highly specialized to meet our needs in developing a cost- and time-effective program as compared to services provided
by an outsourced entity. We are engaged in developing scalable processes for both upstream and downstream for oncolytic virus, stem
cells and final products containing both oncolytic virus cells and enveloped oncolytic viruses. We believe our processes will have
the potential to facilitate the generation of targeted therapies with the potential to deliver genetic medicines to distal sites of disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assembled a management team with extensive experience in developing and manufacturing biological, viral and gene therapies. We have
strong in-house process development capabilities for oncolytic viruses cell banks and combinatory products and are currently leveraging
external CDMOs to implement our in-house developed processes to produce drug substance and drug product. We require that our CDMOs produce
drug substance and finished drug product in accordance with Current Good Manufacturing Practices (&#8220;CGMPs&#8221;) and all other applicable laws and regulations. We maintain agreements with our manufacturers that include
confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. We do not have
long-term supply arrangements in place with our CDMOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not own or operate any manufacturing facilities. For our CLD-101 product candidate, we procured the neural stem cell bank
from City of Hope and we extended the cell bank at a commercial ready CDMO. The master virus seed for NeuroNova oncolytic virus production
(&#8220;<i>CRAd-S-pk7</i>&#8221;) was procured from Northwestern University and an extended master virus bank was manufactured at City of Hope.
For our CLD-201 product candidate, the AAA cell bank, VP-001, was produced by VetStem Biopharma. The CAL1virus for CLD-201 was manufactured
at Genscript ProBio in China. Pilot and/or initial GMP batches for both product candidates (CLD-101 and CLD-201), should those programs
advance, are anticipated to be produced by an early-stage CDMO on an as-need basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to invest in our internal development capabilities to establish critical in-house manufacturing expertise to support our
pipeline of product candidates. We expect to continue to invest in building proprietary processes that will enable us to be at a
competitive advantage when manufacturing product candidates for our clinical programs. In the near term, we intend to continue to
rely on third party CDMOs while we evaluate whether to establish our own CGMP manufacturing facilities for the production of
CGMP-grade material in order to secure our supply chain for clinical studies and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Commercialization</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize
our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have limited sales,
marketing or commercial product distribution capabilities and have no experience as a company commercializing products. We intend to
build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further
advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure
and manufacturing needs may all influence or alter our commercialization plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other major oncology
markets and countries for our investigational products, to operate without infringing valid and enforceable patents and proprietary rights
of others, and to prevent others from infringing on our proprietary or intellectual property rights. We seek to protect our proprietary
position by (1) filing, in the U.S. and certain other regions/countries (including the EU), patent applications intended to cover our
investigational products, and maintaining any issued patents in our major markets; (2) maintaining and advancing, and where possible
expanding, existing patents and patent applications covering the composition-of-matter of our investigational products, their methods
of use and related discoveries, their formulations and methods of manufacture, and related technologies, inventions and improvements
that may be commercially important to our business; and (3) filing, in the U.S. and certain other regions/countries, new patent applications
on novel therapeutic uses of our investigational products. We may also rely on trade secrets and know-how to protect aspects of our business
that are not amenable to, or that we do not consider appropriate for, patent protection, and which is difficult to reverse engineer.
We seek to protect our confidential information in part through confidentiality agreements with third parties, including corporate partners,
collaborators, and vendors. If our trade secrets or confidential information are known or independently discovered by competitors, or
if we enter into disputes over ownership of inventions, our business or results of operations could be adversely affected. We also intend
to take advantage of regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available.
We may also seek to rely on regulatory protection afforded through Orphan Drug Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy includes filing for patent protection of our intellectual property we consider important to our business in jurisdictions that
include the United States, Europe, and Japan and other jurisdictions we consider commercially relevant to protect our ability to market
our product candidates. We believe that our issued patents, and pending patent applications cover our technology platforms and product
candidates until approximately 2045.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent portfolio currently includes five main patent families to protect our current development programs and secure our next generation
programs for the use of stem cell-mediated immunotherapy and oncolytic viral therapy for the treatment of cancer. We, however, are allowing
patents and pending applications in two of the families (see below) to lapse by non-payment of annuities and/or failure to respond to
official actions in order to focus on the more recently filed applications that comprehensively cover the Red Tail program. The patent
families that are being allowed to lapse are the families directed to 1) <i>Combination Immunotherapy Approach for Treatment of Cancer</i>,
and 2) <i>Cell-Based Vehicles for Potentiation of Viral Therapy. </i>We believe the remaining patent coverage for our SuperNova program
is sufficiently robust to prevent any intellectual property challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
more recently filed applications, which are directed to the &#8220;Red Tail&#8221; technology, include modified vaccinia viruses designed
for systemic administration, and will provide protection until 2045, and possibly beyond. This newest patent family
(the fifth family) is directed to modified vaccinia viruses that have advantageous properties, including serum resistance for systemic
administration. These applications focus on the serum resistant (EEV) form of the viruses and modifications thereof. Two PCT applications
are pending. The applications describe and claim the viruses, the modifications of the viruses that enhance serum resistance, modifications
of the outer membrane of the viruses; and other aspects of the technology. Methods for manufacturing the viruses also are included, as
are modified cells for culturing the viruses to enhance properties of the viruses. The two PCT applications comprehensively describe
and claim all aspects of the &#8220;Red Tail&#8221; virus program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second family of patents, <b><i>Smallpox Vaccine for Cancer Treatment</i>, </b>encompasses the use of adipose-derived stromal vascular
fraction stem cells and other types of cells to deliver oncolytic viruses in autologous and allogeneic settings for the treatment of
all cancer tumor types and has potential patent coverage until at least 2038. Claims encompassing use of other stem cells to deliver
the smallpox vaccine virus also have been issued. We believe this patent family encompasses the delivery of the treatment by any route
of administration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    claims encompass the use of adipose-derived stem cells and other cells to deliver vaccinia virus have been issued in the United States
    (US; 4 patents), Japan (JP), South Korea (KR), Eurasia (EA), China (CN), Mexico (MX), Singapore (SG), and Canada (CA) and are pending
    in Eurasia, China, Europe,<span style="text-decoration: line-through">,</span> Hong Kong, and the U.S. (allowed)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fourth patent family, <b><i>Enhanced Systems for Cell-Mediated Oncolytic Viral Therapy,</i></b> encompasses the use of an improved
method to potentiate and deliver all naturally occurring and armed viruses using stem cells, named SuperNova<sup>&#8482;</sup> and
has potential patent coverage until at least 2039. SuperNova<sup>&#8482;</sup> is composed of live cells, cell-derived factors,
amplified viruses, as well as viral-encoded immunomodulators and recombinant proteins that act immediately upon administration. The
pending patent applications also encompass the delivery of the treatment by any route of administration and protection of our single
cryopreserved vial for use in hospital settings. This fourth patent family has been filed in the US, Australia, Canada, China,
Eurasia, Europe, India, Japan, and S. Korea, also encompasses next generation engineered vaccinia viruses encoding additional
therapeutic protein-based immunotherapies (checkpoint inhibitors, co-stimulators, cytokines, antiangiogenetic, and others). Patents
have issued in the US, Japan, Eurasia, and Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we and our subsidiaries own or have rights to trademarks, trade names and service marks that we use in connection with the operation
of our business, including &#8220;Calidi,&#8221; Calidi Biotherapeutics,&#8221; &#8220;SuperNova, &#8220;NeuroNova,&#8221; &#8220;SNV-1,&#8221;
&#8220;SNV,&#8221; &#8220;NNV,&#8221; &#8220;NNV1,&#8221; and &#8220;NNV2.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Northwestern
University</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2021, we entered into a sublicensable license agreement with Northwestern University (&#8220;Northwestern&#8221;) (the &#8220;Northwestern
Agreement&#8221;) for the exclusive commercialization rights to the IND and with a non-exclusive license to data generated from
Northwestern&#8217;s phase 1 clinical trial treating malignant glioma patients with an engineered oncolytic adenovirus delivered by neural
stem cells (&#8220;<i>NSC-CRAd-S-pk7</i>&#8221;). Under the Northwestern Agreement, among other rights, Northwestern granted to us a
worldwide, twelve-year exclusive license for the commercial development of <i>NSC-CRAd-S-pk7</i> or other oncolytic viruses for therapeutic
and preventive uses in oncology and a right of reference to Northwestern&#8217;s IND application which relates to the treatment of newly
diagnosed HGG, and right of reference to Northwestern&#8217;s IND 17365. In exchange, we paid Northwestern an upfront payment of $400,000
cash and a best-efforts commitment to fund up to $10 million towards a phase 2 clinical trial of <i>NSC-CRAd-S-pk7</i> or other oncolytic
viruses. We also agreed to share twenty percent (20%) of any sublicensing revenue we may generate and a 1% assignment or transfer fee
for any consideration received following our assignment to rights to any third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement has a term of 12 years unless further extended by mutual agreement. We have the right to terminate the agreement upon 90 days
written notice for any reason. Northwestern has the right to terminate the agreement at any time if the license to all patents and patent
applications claiming priority to U.S. Provisional Patent Application 61/780,752 (the &#8220;Patent Rights License&#8221;) entered into with the University
of Chicago (on behalf of itself, City of Hope, and the University of Alabama at Birmingham) is no longer in effect, unless the Patent
Rights License is breached by the University of Chicago, City of Hope, or the University of Alabama, or if we have engaged in any criminal
or unethical behavior or have untaken an action adverse to Northwestern. Either party has a right to terminate the agreement upon the
breach of the other party that is not cured within 90 days after notice of the breach is provided. Northwestern has the right to immediately
terminate the agreement in the event we file a petition in bankruptcy, make any general assignment for the benefit of creditors, or a
receiver is appointed to take custody or control of our property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, we entered into a worldwide, non-exclusive, sublicensable royalty free Material License Agreement to license the <i>NSC-CRAd-S-pk7</i>
oncolytic virus materials which we intend to use to continue advancing our research, development and commercialization efforts. Northwestern
retained the rights to the material not transferred and to non-exclusively license the materials for Non-Commercial Research and has
agreed not to grant further commercial licenses during the term of the agreement. We paid Northwestern a one-time license fee of $100,000
in exchange for the transferred materials. The agreement has a term of 12 years. We have a right to terminate the agreement for any reason
upon 90 days written notice. Either party has the right to terminate the agreement upon the material breach by the other party unless
such breach is cured within a 90 day notice period. Northwestern may immediately terminate the agreement upon written notice if we file
a petition, or a petition is filed against us, under any bankruptcy or insolvency law, if we make any general assignment for the benefit
of creditors, or a receiver is appointed to take possession or control of our property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2024, we entered into an Investigator-Initiated Clinical Trial Agreement for Northwestern to conduct a clinical trial (the
&#8220;CTA&#8221;) under the protocol referenced &#8220;A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in Combination
with N-Acetylcysteine amid and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma&#8221; (the &#8220;Study&#8221;).
In connection with the Study, Northwestern granted Calidi a non-exclusive, transferable and sublicensable license to use all available
de-identified data collected from the Study, including, but not limited to, survival data, patient pathology, and immune studies data
for the purpose of product development and regulatory filings. We shall have the right of reference to the IND that is being used by
Northwestern for the Study. Northwestern agrees to provide a letter of authorization and right of reference to Calidi for Calidi&#8217;s
right of reference to and including, without limitation, all content, data and previous human experience, in the NU IND 17365. In consideration
of the data use license granted by Northwestern to Calidi under the CTA, Calidi provided to Northwestern required quantities of the study
drug. Calidi is further required to pay Northwestern the following: a non-creditable and non-refundable one-time milestone payment of
$250,000 upon reaching an aggregate of $2,000,000 of net sales of a licensed product; (b) a non-creditable and nonrefundable one-time
milestone payment of $500,000 upon reaching an aggregate of $10,000,000 of net sales of a licensed product; and (c) sublicensing royalty
of twenty percent (20%) of any sublicensing revenue resulting from the grant of rights hereunder. This sublicensing royalty shall be
cumulative, meaning it shall be imposed only once with respect to a single unit of sublicensing revenue, regardless of whether the sublicensing
revenue derives from the CTA, or the June 7, 2021 Northwestern Agreement described above, or both. Calidi is further required to pay
a 1% assignment or transfer fee for any consideration received following our assignment to rights to any third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
license provides commercial exclusivity for a period of 12 years unless so long as Calidi maintains the Patent Rights Licensed (described
in the June 7, 2021, license) unless the Patent Rights License is terminated for a material breach by the University of Chicago, City
of Hope, or University of Alabama at Birmingham, Northwestern reserves the rights for itself to use the licensed data for any purpose
and to provide the licensed data to any third party solely for non-commercial research purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CTA shall terminate upon the completion of the parties&#8217; Study-related activities. Either party has the right to terminate the Study
upon thirty (30) days prior written notice to the other. The Study may also be terminated immediately at any time for cause, which includes
the following: material breach by either party, which cannot be cured within 90 days of the breach notification; the Patent Rights License
described in the June 7, 2021 license is no longer in effect, except in the case of breach by University of Chicago, City of Hope, or
University of Alabama at Birmingham; Calidi has engaged in any criminal or unethical behavior; Calidi&#8217;s bankruptcy; and if it is
determined by the Study&#8217;s principal-investigator, Northwestern&#8217;s Institutional Review Board or Scientific Review Committee,
or the Food and Drug Administration that the Study is inappropriate, impractical, or inadvisable to continue, in order to protect the
Study subjects&#8217; rights, welfare, and safety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>University
of Chicago</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, we entered into an exclusive license agreement with the University of Chicago for patents jointly owned by the University
of Chicago. City of Hope and University of Alabama at Birmingham (the &#8220;<i>University of Chicago Agreement</i>&#8221;) for patents
covering cancer therapies using an oncolytic adenovirus loaded into allogeneic neural stem cells for the treatment of HGG. Pursuant to
the University of Chicago Agreement, University of Chicago transferred its IND to us for the commercial development of a licensed product,
as defined in the University of Chicago Agreement. This agreement grants to us commercial sublicensable exclusive license to neural stem
cells with the adenovirus known as CRAd-S-pk7 for oncolytic virotherapy, as well as a non-exclusive license to associated know-how. The
University of Chicago reserves the right to practice the licensed patents, or to license the patents to third parties, solely for non-commercial
purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the University of Chicago Agreement, we paid an upfront fee of $180,000 in cash and issued 347 shares of our common stock. The University
of Chicago Agreement requires us to pay an annual maintenance fee of $10,000 until the first commercial sale. The University of Chicago
Agreement also provides for us to pay a percentage of net sales, the royalties of which can be reduced by 50% with certain royalty stacking
provisions if royalties are also to be paid to third-parties, generated for any product that falls within a valid claim of the licensed
patents for specific periods of between 2% and 6%; 2% for net sales generated for any product sold in any country without a valid claim
and to pay up to $18.7 million if all of the following milestones are achieved during the clinical trials and post commercialization
of the licensed product:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencement
    of a Phase 2 clinical trial with a Licensed Product ($800,000);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencement
    of a Phase 3 clinical trial with a Licensed Product ($1,800,000);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Submission of an NDA, BLA for a Licensed Product ($2,500,000);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Commercial Sale of a Licensed Product ($3,600,000); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cumulative
    Net Sales of all Licensed Products reach one billion dollars ($10,000,000).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of the issuance of these condensed consolidated financial statements, it is not probable that we will incur these payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, we have also agreed to twenty percent (20%) of sublicense revenue we may generate. Calidi is further required
to pay the lesser of $1,000,000 or 1% assignment or transfer fee for any consideration received following our assignment to rights to
any third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the University of Chicago Agreement will expire on the later of: (i) the expiration date of the last to expire of the Licensed
Patents; and (ii) ten (10) years from the First Commercial Sale, unless earlier terminated pursuant to the terms of this Agreement. University
of Chicago (&#8220;University&#8221;) has the right to terminate the agreement upon 21 days written notice for our failure to make any
payment when due, with the right to cure the default by payment before the expiration of the notice period. University also has the right
to immediately terminate the agreement if we fail to achieve development milestones within the time frame contemplated by the agreement.
Furthermore, University has the right to terminate the agreement if we are in material breach of any other obligation under the agreement
not specified above upon 30 days written notice unless we cure the breach within the notice period. In addition, if we file a petition
under any bankruptcy or insolvency law, and such petition is not dismissed within 60 days of such filing, the agreement will automatically
terminate at the end of such 60-day period unless University provides us with written notice that the agreement will not terminate. Upon
our liquidation or dissolution, the agreement will automatically terminate. If we fail to begin commercial sales of a Licensed Product
within 8 years, University may terminate the agreement anytime thereafter on written notice. We have the right to terminate the agreement
for any reason upon written notice to university and the agreement will terminate at the end of the Calendar Quarter following the Calendar
Quarter during which we provided our notice of termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Collaboration
Agreement with Personalized Stem Cells, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, we entered into a collaboration and license agreement with Personalized Stem Cells, Inc. (the &#8220;<i>PSC Agreement</i>&#8221;).
Under the terms of the PSC Agreement, we provided two tested SVF cell line banks for use in a Covid-19 Project for use in the generation
of a Master Cell Bank (&#8220;MCB&#8221;) by Personalized Stem Cells, Inc. (&#8220;PSC&#8221;). Fifty percent (50%) ownership of the MCB would be retained by PSC
for use in clinical trials for the treatment of Covid-19 and we are entitled to retain the other 50% ownership in the MCB to pursue our
development of our product candidates. We are also entitled to full access and use of all clinical data from the Covid-19 Project for
our use in developing our product candidates. The agreement is for an unspecified term, but can be terminated by either party upon the
material breach of the other party if such breach is not cured within a 30 day written notice period, or immediately upon written notice
if the breach is incapable of being cured. We contributed $100,000 in cost towards the manufacturing of the MCB by PSC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and licensure
under the Public Health Service Act (&#8220;PHS Act&#8221;), and other federal, state, local and foreign statutes and regulations. The FD&amp;C Act
and corresponding regulations govern, among other things, the research, development, clinical trial, testing, manufacturing, quality
control, approval, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, marketing, promotion, export
and import, advertising, post-approval monitoring, and post-approval reporting involving biological products. The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require
the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
even if we obtain the required regulatory approvals for our products, pharmaceutical companies are subject to myriad federal, state,
and foreign healthcare laws, rules, and regulations governing all aspects of our operations, including, but not limited to, our relationships
with healthcare professionals, healthcare institutions, distributors of our products, and sales and marketing personnel; governmental
and other third-party payor coverage and reimbursement of our products; and data privacy and security. Such laws, rules, and regulations
are complex, continuously evolving, and, in many cases, have not been subject to extensive interpretation by applicable regulatory agencies
or the courts. We are required to invest significant time and financial resources in policies, procedures, processes, and systems to
ensure compliance with these laws, rules, and regulations, and our failure to do so may result in the imposition of substantial monetary
or other penalties by federal or state regulatory agencies, give rise to reputational harm, or otherwise have a material adverse effect
on our results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
biological products development process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a biological product candidate may be licensed for marketing in the U.S. generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of nonclinical laboratory tests and animal studies performed in accordance with FDA&#8217;s good laboratory practices, or GLPs, requirements
    and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an application for an investigational new drug application, or IND, which must become effective before human clinical
    trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of the protocol and related documentation by an IRB or ethics committee at each clinical trial site before each trial may be initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials according to GCPs, requirements and any additional requirements for the protection
    of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product
    candidate for its intended use;</span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
    of and submission to the FDA of a BLA for marketing approval that includes sufficient evidence of establishing the safety, purity,
    and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of a BLA to accept and file the application;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-license inspection of the manufacturing facility or facilities where the biological product is produced
    to assess compliance with current good manufacturing practices, or CGMPs, to assure that the facilities, methods and controls are
    adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA in accordance with any
    applicable expedited programs or designations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees for FDA review of the BLA (unless a fee waiver applies); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications for use in
    the U.S.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pre-clinical
Studies and the IND Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
testing any biological product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also
referred to as nonclinical studies, include laboratory evaluations of the product&#8217;s biological characteristics, chemistry, toxicity
and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical
tests must comply with federal regulations and requirements including GLPs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing an initial clinical trial in humans with a product candidate in the U.S., an IND must be submitted to the FDA and the FDA
must allow the IND to proceed. An IND is an exemption from the FD&amp;C Act that allows an unapproved product candidate to be shipped
in interstate commerce for use in an investigational clinical trial and a request for FDA allowance that such investigational product
may be administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment and administration.
In support of a request for an IND, the clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing
information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND.
An IND must become effective before human clinical trials may begin. Once submitted, the IND automatically becomes effective 30 days
after receipt by the FDA, unless the FDA places the IND on a full or partial clinical hold within that 30-day time period. In such a
case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial or part of the study can begin. Submission
of an IND therefore may or may not result in FDA authorization to begin a clinical trial. The FDA also may impose clinical holds on a
sponsor&#8217;s IND at any time before or during clinical trials due to, among other considerations, unreasonable or significant safety
concerns, inability to assess safety concerns, lack of qualified investigators, a misleading or materially incomplete investigator brochure,
study design deficiencies, interference with the conduct or completion of a study designed to be adequate and well-controlled for the
same or another investigational product, insufficient quantities of investigational product, lack of effectiveness, or non-compliance.
If the FDA imposes a clinical hold, studies may not recommence without FDA authorization and then only under terms authorized by the
FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
Trials</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified
investigators, generally physicians not employed by or under control of the trial sponsor. Clinical trials are conducted under protocols
detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and
the parameters and criteria to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped
if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the
IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements,
including the requirement that all research subjects provide informed consent. An IRB representing each institution participating in
the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must
conduct continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol
and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. An IRB can
suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being
conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm
to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board
or committee (&#8220;DSMB&#8221;). This group provides authorization as to whether or not a trial may move forward at designated check points based
on access that only the group maintains to available data from the trial and may recommend halting the clinical trial if it determines
that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information about certain clinical trials must also be submitted within specific timeframes to the NIH for public dissemination on its
ClinicalTrials.gov website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials typically are conducted in three sequential phases that may overlap or be combined:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1. The biological product candidate is initially introduced into healthy human subjects and tested for safety. In the case of some
    products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer
    to healthy volunteers, the initial human testing is often conducted in patients. These studies are designed to test the safety, dosage
    tolerance, absorption, metabolism and distribution of the biological product candidate in humans, the side effects associated with
    increasing doses, and, if possible, to gain early evidence of effectiveness.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2. The biological product candidate is evaluated in a limited patient population with a specific disease or condition to identify
    possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and
    to determine dosage tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information
    prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3. The biological product candidate is administered to an expanded patient population to further evaluate dosage, clinical efficacy,
    potency, and safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish
    the overall risk/benefit ratio of the product candidate and provide an adequate basis for approval and product labeling.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FDA released a draft guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development
of Oncology Drugs and Biologics,&#8221; which outlines how developers can utilize an adaptive trial design commonly referred to as a
seamless trial design in early stages of oncology biological product development (i.e., the first-in-human clinical trial) to compress
the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design
of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency
to biological product development and reduce developmental costs and time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may also be
made a condition to approval of the BLA. Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials
could result in withdrawal of approval for products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry
and physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities
in accordance with CGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products,
the Public Health Service Act, or PHS Act, emphasizes the importance of manufacturing control for products whose attributes cannot be
precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and,
among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological
product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that
the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the FDA and the European Medicines Agency (&#8220;EMA&#8221;) provide expedited pathways for the development of biological product candidates for treatment of rare diseases, particularly
life threatening diseases with high unmet medical need. Such biological product candidates may be eligible to proceed to registration
following a single clinical trial in a limited patient population, sometimes referred to as a Phase 1/2 trial, but which may be deemed
a pivotal or registrational trial following review of the trial&#8217;s design and primary endpoints by the applicable regulatory agencies.
Determination of the requirements to be deemed a pivotal or registrational trial is subject to the applicable regulatory authority&#8217;s
scientific judgement and these requirements may differ in the U.S. and the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical
data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the
FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events,
any findings from other studies, tests in laboratory animals or <i>in vitro</i> testing that suggest a significant risk for human subjects,
or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator
brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies
for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven
calendar days after the sponsor&#8217;s initial receipt of the information. Regulatory authorities, the IRB or the sponsor may suspend
a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk
or that the trial is unlikely to meet its stated objectives. Some trials also include oversight by an independent group of qualified
experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or
not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial
if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
review and approval processes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful the completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or
more indications. The BLA must include results of product development, laboratory and animal studies, human clinical trials, information
on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes
require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that
any approval will be granted on a timely basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before
the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of
submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted
application also is subject to review to determine if it is substantially complete before the FDA accepts it for filing. In most cases,
the submission of a BLA is subject to a substantial application user fee, although the fee may be waived under certain circumstances.
Under the performance goals and policies implemented by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs,
the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the
applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates,
and the review process is often significantly extended by FDA requests for additional information or clarification. This review typically
takes twelve months from the date the BLA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221;
decision. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise
provides additional information or clarification regarding information already provided in the submission within the last three months
before the PDUFA goal date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine,
among other things, whether the proposed product is safe, pure and potent for its intended use and whether the product is being manufactured
in accordance with CGMP to ensure its continued safety, purity and purity. The FDA may refer applications for novel biological products
or biological products that present difficult or novel questions of safety or efficacy to an advisory committee, typically a panel that
includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and
under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully
when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation
Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor
of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product
unless it determines that the manufacturing processes and facilities are in compliance with CGMP requirements and adequate to assure
consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect
one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.
To assure CGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training,
record keeping, production and quality control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA for a novel product (e.g., new active ingredient, new indication,
etc.) must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant
pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA
does not apply to any biological product for an indication for which orphan designation has been granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing
of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies
that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted
product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant
might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay
or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product.
Further, the FDA may require that certain contraindications, warnings, precautions or interactions be included in the product labeling.
The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise
limit the scope of any approval. The FDA also may condition approval on, among other things, changes to proposed labeling or the development
of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing
requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase
4 post-market trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization,
and may limit further marketing of the product based on the results of these post-marketing trials. In addition, new government requirements,
including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline
for regulatory approval or otherwise impact ongoing development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
product designation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a biological product intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or 200,000 or more individuals in the U.S.
and for which there is no reasonable expectation that the cost of developing and making a biological product available in the U.S. for
this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting
a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed
publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and
approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphan
product designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers. If a product that has orphan product designation subsequently receives the first FDA approval for a
particular active ingredient for the disease or condition for which it has such designation, the product is entitled to orphan product
exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the
same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan
product exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product
has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.
Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the
same biological product as defined by the FDA or if a product candidate is determined to be contained within the competitor&#8217;s product
for the same indication or disease. If a biological product designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan product exclusivity. In addition, orphan drug exclusive marketing rights
in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if
the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer
of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease
or condition. Orphan drug status in the European Union has similar, but not identical, benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expedited
development and review programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval and priority review,
that are intended to expedite or simplify the process for the development and FDA review of drugs and biologics that are intended for
the treatment of serious or life-threatening diseases or conditions. To be eligible for fast-track designation, new drugs and biological
product candidates must be intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address
unmet medical needs for the disease or condition. Fast-track designation applies to the combination of the product and the specific indication
for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a fast-track
product at any time during the clinical development of the product. One benefit of fast-track designation, for example, is that the FDA
may consider for review sections of the marketing application on a rolling basis before the complete application is submitted if certain
conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application
and the payment of applicable user fees before the FDA may initiate a review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA&#8217;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy if
the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough
therapy designation comes with all of the benefits of fast-track designation. The FDA may take other actions appropriate to expedite
the development and review of the product candidate, including holding meetings with the sponsor and providing timely advice to, and
interactive communication with, the sponsor regarding the development program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate is eligible for priority review if it treats a serious or life-threatening disease or condition and, if approved, would
provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition.
The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated
for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application in
six months once it is filed, compared to ten months for a standard review. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a product candidate may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness
in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive
accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing
that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an
effect on an intermediate clinical endpoint other than survival or irreversible morbidity or mortality, that is reasonably likely to
predict irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the
condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor
of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to
verify the clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In
addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely
impact the timing of the commercial launch of the product. The FDA may withdraw approval of a drug or indication approved under accelerated
approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-approval
requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rigorous
and extensive FDA regulation of biological products continues after approval, particularly with respect to CGMP requirements, as well
as requirements relating to record keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution,
and advertising and promotion of the product. Manufacturers of products are required to comply with applicable requirements in the CGMP
regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements
applicable to biological products, include reporting of CGMP deviations that may affect the identity, potency, purity and overall safety
of a distributed product, record keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information,
and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official
lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before
it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot
of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of
all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products,
such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research
related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the
prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling
(known as &#8220;<i>off-label use</i>&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving
the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result
in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after
approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA
sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds, warning or untitled letters,
product recalls, product seizures, total or partial suspension of production or distribution, product detentions or refusal to permit
the import or export of the product, restrictions on the marketing or manufacturing of the product, injunctions, fines, refusals of government
contracts, mandated corrective advertising or communications with doctors or other stakeholders, debarment, restitution, disgorgement
of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biological
product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to
register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA
and certain state agencies for compliance with CGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and
effort in the area of production and quality control to maintain CGMP compliance. Discovery of problems with a product after approval
may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market.
In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other
types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further
FDA review and approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
patent term restoration and marketing exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of the FDA approval of a biological product, some of a sponsor&#8217;s U.S. patents may be eligible
for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of
up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent
term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The
patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus
the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological
product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.
In addition, a patent can only be extended once and only for a single product. The U.S. PTO, in consultation with the FDA, reviews and
approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent
term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length
of the clinical trials and other factors involved in the filing of the relevant BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
biological product can obtain pediatric market exclusivity in the U.S. Pediatric exclusivity, if granted, adds six months to existing
exclusivity periods, including some regulatory exclusivity periods tied to patent terms. This six-month exclusivity, which runs from
the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance
with an FDA-issued &#8220;Written Request&#8221; for such a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA,
includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval
pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. This
amendment to the PHS Act attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful
differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical
studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product
and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products
administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without
increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated
with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured,
pose significant hurdles to implementation that are still being worked out by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years
after the date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable
product based on the reference biological product until 12 years after the date of first licensure of the reference product. &#8220;First
licensure&#8221; typically means the initial date the particular product at issue was licensed in the U.S. Date of first licensure does
not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is
for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product
(or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological
product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or
strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency.
The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce
the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions,
have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant
uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
regulation of companion diagnostics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates may require use of an <i>in vitro</i> diagnostic to identify appropriate patient populations. These diagnostics, often
referred to as companion diagnostics, are regulated as medical devices. In the U.S., the FD&amp;C Act and its implementing regulations
and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and
clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion,
sales and distribution, export and import and post-market surveillance. Unless an exemption applies, companion diagnostic tests require
marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable
to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
use of companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require
approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August 6, 2014, the FDA issued
a final guidance document addressing the development and approval process for &#8220;<i>In Vitro</i> Companion Diagnostic Devices.&#8221;
According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug
or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling.
The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product
candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already
approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be
considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of
the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug
are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if
the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details
of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a
draft guidance document intended to further assist sponsors of therapeutic products and sponsors of <i>in vitro</i> companion diagnostic
devices on issues related to co-development of these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval
of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these <i>in vitro</i> companion diagnostics
in conjunction with the review of therapeutic candidates such as those we are developing involves coordination of review by the FDA&#8217;s
Center for Biologics Evaluation and Research and by the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including
the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves
a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s
safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing
and labeling. PMA applications are also subject to an application fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PMAs
for certain devices must generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to
establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic,
the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple
users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities
for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality
assurance requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval
letter or a not-approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval
of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure
final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved
indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that
the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling,
promotion, sale and distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will issue an order denying approval of the
PMA or issue a not approvable order. A not approvable letter will outline the deficiencies in the application and, where practical, will
identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which
case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment
to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval
or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed,
and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and
require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for
the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings
with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the
applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality
assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to
periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and
other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated
by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could
be liable for damages and governmental fines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Government
regulation outside of the United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we are subject to a variety of regulations in other jurisdictions governing, among other things,
research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution,
reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our products.
Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to
country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the
ethical principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements,
we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product
recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the U.S. have
a similar process that requires the submission of a clinical trial application (&#8220;CTA&#8221;) much like the IND prior to the commencement of human
clinical trials. In the European Union, for example, a CTA must be submitted for each clinical trial to each country&#8217;s national
competent authority, or NCA, and at least one independent ethics committee, or EC, much like the FDA and an IRB, respectively. Once the
CTA is approved in accordance with a country&#8217;s requirements, the corresponding clinical trial may proceed. Under the current regime
(the EU Clinical Trials Directive 2001/20/EC or Clinical Trials Regulation (EU) No 536/2014) all suspected unexpected serious adverse
reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the EU Member State
where they occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which will replace the Clinical Trials Directive 2001/20/EC.
It will overhaul the current system of approvals for clinical trials in the EU. Specifically, the new Regulation, which will be directly
applicable in all Member States (meaning that no national implementing legislation in each EU Member State is required), aims at simplifying
and streamlining the approval of clinical trials in the EU. For instance, the new Regulation provides for a streamlined application procedure
via a single entry point and strictly defined deadlines for the assessment of clinical trial applications. The new Regulation took effect
January 31, 2022, with a transition period through January 31, 2023, after which all new CTAs must be submitted through the new central
information system (&#8220;CTIS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Union drug review and approval</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Economic Area (&#8220;EEA&#8221;) medicinal products can only be commercialized after obtaining a marketing
authorization. To obtain regulatory approval of a medicinal product in the EEA, we must submit a marketing authorization application
(&#8220;MAA&#8221;). A centralized marketing authorization is issued by the European Commission through the centralized procedure,
based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA, and is valid throughout the
EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan
medicinal products, advanced-therapy medicinal products such as (gene-therapy, somatic cell-therapy or tissue-engineered medicines),
and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative
disorders, diabetes, auto-immune and other immune dysfunctions, and viral diseases. The centralized procedure is optional for
products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic,
scientific or technical innovation or which are in the interest of public health in the EEA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure the maximum timeframe for the evaluation of a MAA by the EMA is 210 days, excluding clock stops, when additional
written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the
timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together
with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued
within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases,
when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation.
The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible
that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer
appropriate to conduct an accelerated assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
application used to submit the BLA in the U.S. is similar to that required in the European Union, although there may be certain specific
requirements, for example those set out in Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products, covering gene therapy,
somatic cell therapy and tissue-engineered medicinal products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
and market exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and
an additional two years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing
the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic
or biosimilar marketing authorization in the EEA, during a period of eight years from the date on which the reference product was first
authorized in the EEA. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization application
can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration
of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years
of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during
the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies.
There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify
for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed
period of data exclusivity, another company may market another version of the product if such company obtained a marketing authorization
based on a MAA with a completely independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
drug designation and exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
receiving orphan designation in the EEA can receive ten years of market exclusivity, during which time no &#8220;similar medicinal product&#8221;
may be placed on the market. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active
substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication.
An orphan product can also obtain an additional two years of market exclusivity in the European Union where an agreed Pediatric Investigation
Plan for pediatric studies has been complied with. No extension to any supplementary protection certificate can be granted on the basis
of pediatric studies for orphan indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
criteria for designating an &#8220;orphan medicinal product&#8221; in the EEA are similar in principle to those in the U.S. Under Article
3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if it meets the following criteria: (1) it is intended
for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition
affects no more than five (5) in ten thousand (10,000) persons in the EEA when the application is made, or (b) it is unlikely that the
product, without the benefits derived from orphan status, would generate sufficient return in the European Union to justify the necessary
investment in its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized
for marketing in the EEA, or if such a method exists, the product will be of significant benefit to those affected by the condition,
as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or
fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic
indication. The application for orphan drug designation must be submitted before the application for marketing authorization. The applicant
will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending
at the time the marketing authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration
of, the regulatory review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market
exclusivity. Additionally, marketing authorization may be granted to a similar medicinal product for the same indication at any time
if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    marketing authorization holder of the authorized product consents to a second orphan medicinal product application; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    marketing authorization holder of the authorized product cannot supply enough orphan medicinal product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, companies developing a new medicinal product must agree upon a Pediatric Investigation Plan, or PIP, with the EMA&#8217;s pediatric
committee, or PDCO, and must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies (e.g., because the
relevant disease or condition occurs only in adults). The PIP sets out the timing and measures proposed to generate data to support a
pediatric indication of the drug for which marketing authorization is being sought. The marketing authorization application for the product
must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has
been granted by the PDCO of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate
the efficacy and safety of the product in adults, in which case the pediatric clinical trials must be completed at a later date. Products
that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are
eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of
approval) even where the trial results are negative. In the case of orphan medicinal products, a two year extension of the orphan market
exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in
compliance with the PIP are developed and submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-approval
controls</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing,
marketing, promotion and sale of the medicinal product. These include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person
    for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected
    serious adverse reactions and submission of periodic safety update reports, or PSURs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and
    documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific
    obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may
    include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization
    safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, or
    SmPC, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited
    in the European Union. Although general requirements for advertising and promotion of medicinal products are established under European
    Union directives, the details are governed by regulations in each European Union Member State and can differ from one country to
    another.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing
the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even
if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government
health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide
coverage, and establish adequate reimbursement levels for, the product. In the United States, the principal decisions about reimbursement
for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department
of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare
and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists
among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process
for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price
or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging
the prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls
to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might
not include all of the approved products for a particular indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure
above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to
provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered
medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once
the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party
payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further,
one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement
for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement
procedures in some E.U. Member States, including France, Germany, Ireland, Italy and Sweden. The HTA process, which is governed by the
national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact
and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country
is conducted. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary
between E.U. Member States. The HTA generally focuses on the clinical efficacy and effectiveness, safety, cost and cost-effectiveness
of individual medicinal products as well as their potential implications for the&#160;healthcare system. Those elements of medicinal
products are compared with other treatment options available on the market. The outcome of HTA regarding specific medicinal products
will often influence the pricing and reimbursement status granted to medicinal products by the regulatory authorities of individual E.U.
Member States. A negative HTA of one of our products by a leading and recognized HTA body could not only undermine our ability to obtain
reimbursement for such product in the E.U. Member State in which such negative assessment was issued, but also in other E.U. Member States.
For example, E.U. Member States that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in other countries
with a developed HTA framework, when adopting decisions concerning the pricing and reimbursement of a specific medicinal product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2021, the European Parliament and the Council adopted Regulation (EU) 2021/2282 (&#8220;HTAR&#8221;), a regulation on health
technology assessment. HTAR entered into force on January 11, 2022 and applies from January 12, 2025 onwards, requiring, among other
things, joint clinical assessments of certain new <i>medicines</i> for the treatment of cancer and advanced therapy medicinal products.
This is followed by a further three-year transitional period during which EU member states must fully adapt to the new system, until
eventually all medicinal products fall within the scope of HTAR as of 2030.&#160;It is intended to boost E.U. level cooperation among
E.U. Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at the
E.U. level for joint clinical assessments in these areas. HTAR provides that E.U. Member States will be able to use common HTA tools,
methodologies and procedures across the E.U., working together in four main areas, including joint clinical assessment of the innovative
health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from
HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation
in other areas. Individual E.U. Member States continue to be responsible for assessing non-clinical (e.g., economic, social, ethical)
aspects of health technology, and making decisions on pricing and reimbursement. The EC has stated that the role of the HTA regulation
is not to influence pricing and reimbursement decisions in the individual E.U. Member States, but there can be no assurance that the
HTA regulation will not have effects on pricing and reimbursement decisions. On February 3, 2025, the EC opened the first request submission
period for joint scientific consultations under HTAR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain reimbursement or pricing approval in some countries, including the E.U. Member States, we may be required to conduct studies that
compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. There can
be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or
that it will be feasible to conduct additional cost-effectiveness studies, if required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain of the E.U. Member States, medicinal products that are designated as orphan medicinal products may be exempted or waived from
having to provide certain clinical, cost-effectiveness and other economic data in connection with their filings for pricing/reimbursement
approval.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Review
and Approval of Medical Products in the United Kingdom</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 1, 2025, the Medicines and Healthcare Products Regulatory Agency (&#8220;MHRA&#8221;), is responsible for approving all medicinal
products destined for the United Kingdom market (Great Britain and Northern Ireland). The MHRA relies on the Human Medicines Regulations
2012 (SI 2012/1916) (as amended) (the &#8220;HMR&#8221;), as the basis for regulating medicines. The HMR has incorporated into domestic
law the body of EU law instruments governing medicinal products that existed prior to the United Kingdom&#8217;s withdrawal from the
EU. On April 28, 2025, the U.K. Parliament adopted amendments to improve and strengthen the clinical trials regulatory regime in the
United Kingdom. These revisions will take effect on April 28, 2026, and were needed to replace the prior requirements in the United Kingdom
that were based on the repealed CTD, which has been replaced by the CTR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MHRA has established the Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;), for sponsors of potentially transformative medicines
or drug-device combination products that address unmet medical needs and for which there is evidence of safe use in human but confirmatory
trials have not yet started. It is designed to reduce the end-to-end timeline for research and development, regulatory approval and timely
adoption of new technologies to benefit patients and the healthcare system in the United Kingdom. To these ends, the ILAP comprises an
Innovation Passport designation, a Target Development profile and a toolkit to support all stages of the design, development and approval
process. As with expedited review and approval programs in other jurisdictions, the designation of our product candidates under the ILAP
does not guarantee approval of a candidate product in the United Kingdom by the MHRA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as of January 1, 2024, an international recognition procedure (&#8220;IRP&#8221;), applies in the United Kingdom and is designed
to facilitate approval of pharmaceutical products in the United Kingdom. The IRP is open to sponsors that have previously received an
authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators (&#8220;RRs&#8221;). The RRs include the
FDA, EMA and regulators in the EEA member states for approvals in the EU centralized procedure and mutual recognition procedure, and
the FDA for approvals granted in the United States. The RR assessment must have undergone a full and standalone review. RR assessments
based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion is an RR authorization for the
purposes of IRP.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Healthcare Laws and Compliance Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which
we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers
and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business
or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing
approval. In the United States, these laws include, without limitation, state and federal anti- kickback, false claims, physician transparency,
and patient data privacy and security laws and regulations, including but not limited to those described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering,
    paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly
    or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase,
    order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program
    such as Medicare and Medicaid. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific
    intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for
    each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs.
    In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback
    Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, prohibit individuals or entities from,
    among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that
    are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material
    to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing
    or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held
    liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221;
    the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to
    bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity
    is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false
    claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare
    or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#8217;s selection
    of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an
    exception applies.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully
    executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly
    and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare
    offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the
    delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity
    may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing
    regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating
    to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation
    of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil
    and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to
    file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees
    and costs associated with pursuing federal civil actions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care
    and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers
    of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s
    Health Insurance Program, for certain payments and &#8220;transfers of value&#8221; provided to physicians (currently defined to
    include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment
    interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend
    to include transfers of value made in the previous year to certain non-physician providers such as physician assistants and nurse
    practitioners.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state and foreign laws and regulations, including, but not limited to, state anti-kickback and false claims laws, may be broader
    in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies
    to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant federal government compliance guidance;
    require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare
    providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign
    laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ
    from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions,
convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations
that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement,
exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting
obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with
these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities
with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to similar actions, penalties
and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations
by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employees
and Human Capital Resources</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had 29 total employees in the U.S. and at our German wholly-owned subsidiary, StemVac GmbH. Of these employees,
24 perform research and development functions. None of our employees are represented by a labor union and we believe we maintain good
relations with our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing
and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and
reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Business Combination and Related Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2023, First Light Acquisition Group, Inc., a Delaware corporation (&#8220;FLAG&#8221;) consummated a series of
transactions that resulted in the merger of FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG
(&#8220;Merger Sub&#8221;) and Calidi Biotherapeutics, Inc., a Nevada corporation (&#8220;Calidi NV&#8221;) pursuant to the
Agreement and Plan of Merger (as the same has been or may be amended, modified, supplemented or waived from time to time, the
&#8220;Merger Agreement&#8221;) dated as of January 9, 2023 by and among FLAG, Calidi NV, First Light Acquisition Group, LLC, in the
capacity as representative for the stockholders of FLAG (the &#8220;Sponsor&#8221; or the &#8220;Purchaser Representative&#8221;)
and Allan J. Camaisa, in the capacity as representative of the stockholders of Calidi NV (&#8220;Seller Representative&#8221;). On
August 28, 2023, FLAG held the Special Meeting, at which meeting the FLAG stockholders considered and adopted, among other matters,
a proposal to approve the business combination. Pursuant to the terms of the Merger Agreement, the business combination was effected
through the merger of Merger Sub with and into Calidi NV, with Calidi NV surviving such merger as a wholly-owned subsidiary of FLAG
(the &#8220;Merger,&#8221; and the transactions contemplated by the Merger Agreement, the &#8220;Business Combination&#8221;).
Following the consummation of the Business Combination, FLAG was renamed &#8220;Calidi Biotherapeutics, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Business Combination, all outstanding stock of Calidi NV were cancelled in exchange for the right to receive newly issued
shares of Common Stock of Calidi Biotherapeutics, Inc., par value $0.0001 per share (&#8220;Common Stock&#8221;), and all outstanding
options to purchase Calidi NV stock were exchanged for options exercisable for newly issued shares of Calidi Biotherapeutics, Inc. Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total consideration received by Calidi Security Holders at the Closing of the transactions by the Merger Agreement is the newly issued
shares of Common Stock and securities convertible or exchangeable for newly issued shares of Common Stock with an aggregate value equal
$250.0 million, plus an adjustment of $23.8 million pursuant to the net debt adjustment provisions of the Merger Agreement by reason
of the Series B Financing (the &#8220;Merger Consideration&#8221;), with each Calidi NV Stockholder receiving for each share of Calidi
NV Common Stock held (after giving effect to the exchange or conversion of all outstanding Calidi NV Preferred Stock for shares of Calidi
NV Common Stock and treating all vested in-the-money Calidi NV Convertible Securities (including, on a net exercise basis, all outstanding
Calidi NV warrants and vested qualified Calidi NV Options but excluding all vested non-qualified stock options) as if such securities
had been exercised as of immediately prior to the Merger, but excluding all unvested Calidi NV Options and any treasury stock) a number
of shares of Common Stock equal to a conversion ratio of approximately 0.003. As a result, the Calidi NV Security Holders received an
aggregate of 228,130 shares of newly issued Common Stock as Merger Consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an additional consideration, each Calidi NV Stockholder was entitled to earn, on a pro rata basis, up to 150,000 shares of non-voting
common stock (the &#8220;Escalation Shares&#8221;). During the Escalation Period, Calidi NV Stockholders may be entitled to receive up
to 150,000 Escalation Shares with incremental releases of 37,500 shares upon the achievement of each share price hurdle if the trading
price of Common Stock is $1,440.00, $1,680.00, $1,920.00 and $2,160.00, respectively, for a period of any 20 days within any 30-consecutive-day
trading period. The Escalation Shares are in escrow and have been outstanding from and after the Closing, subject to cancellation if
the applicable price targets are not achieved. While in escrow, the shares will be non-voting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of FLAG Class A Common Stock who did not redeem their shares obtained the right to receive up to 716 additional Non-Redeeming Continuation
Shares. Upon the consummation of the Business Combination, 22,395 FLAG public shares were redeemed for aggregate redemption payments
of approximately $28.2 million from the Trust. The remaining approximate $15.0 million funds in the Trust were distributed as follows:
i) $12.5 million to the Seller investors pursuant to the Forward Purchase Agreements and Non-Redemption Agreements discussed above, ii)
$1.8 million to Calidi in connection with the Non-Redemption Agreements discussed above, and iii) $0.7 million in cash to Calidi available
in the Trust from non-redeeming shareholders discussed below. The Escalation Shares and the Non-Redeeming Continuation Shares are determined
to be equity classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forward
Purchase Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28 and August 30, 2023, FLAG and Calidi NV entered into Forward Purchase Agreements as a derivative security with each of the
Sellers for an OTC Equity Prepaid Forward Transaction. This derivative security purchased from the Sellers is based on the value of our
common stock to be settled in cash in three years subject to reset price features and earlier termination as set forth in the Forward
Purchase Agreement. For purposes of the Forward Purchase Agreement, FLAG is referred to as the &#8220;Counterparty&#8221; prior to the
consummation of the Business Combination, while Calidi is referred to as the &#8220;Counterparty&#8221; after the consummation of the
Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FLAG
and the Sellers entered into the Forward Purchase Agreements, and related Non-Redemption Agreements and FPA Funding Amount PIPE Subscription
Agreements each as defined below, in conjunction with and as an inducement to the Sellers to invest in a concurrent Series B Financing
by Calidi in order to provide financing to the combined company. FLAG and Calidi NV entered into the Forward Purchase Agreements, as
derivative securities, with the Sellers as a condition to the Sellers&#8217; participation in Calidi NV&#8217;s Series B Financing and
to potentially receive a settlement amount of $1,200.00 per share provided that the Company&#8217;s trading price remained above or equal
to the Initial Reset Price. In addition, entering into these agreements provided the combined company with cash (through the Non-Redemption
Agreements) in order to meet a cash closing condition to complete the Business Combination. The Forward Purchase Agreements, Non-Redemption
Agreements and PIPE Subscription Agreement collectively provided approximately $2.6 million, and the Series B financing in Calidi provided
approximately $24.5 million, to the combined company. As discussed above, the Forward Purchase Agreements and related Non-Redemption
Agreements and FPA Funding Amount PIPE Subscription Agreement were entered into as an inducement to the Sellers to invest in a concurrent
Series B Financing by Calidi NV and were not entered into to provide a source of liquidity to the combined company. Further, as discussed
below, because of certain reset price features of the Forward Purchase Agreement, and a Settlement Amount Adjustment of $240.00 per share,
based on our current trading price, it is unlikely that the combined company will receive any funds as a result of the eventual settlement
of the Forward Purchase Agreements. Calidi is subject to the following risks associated with the Forward Purchase Agreement: (i) a reduced
settlement amount if it conducts a Dilutive Offering or Sellers elect an Optional Early Termination and the then reset price is below
$1,200.00, and (ii) no settlement amount if Calidi conducts a Dilutive Offering or Sellers elect an Optional Early Termination and the
then reset price is at or below $240.00 per share. Calidi NV, however, benefited from the Series B investment. Calidi will also benefit
if at the time of settlement, the price of its common stock is above $1,200.00 per share. The Sellers benefit if at the time of settlement
the price of common stock is above $1,200.00, but are subject to risk if Calidi&#8217;s stock price decreases and there is no Dilutive
Offering or the reset price is at $1,200.00. Sellers will also benefit from the Settlement Amount Adjustment of $240.00 per share which
has the effect of reducing the Settlement Amount due to the Counterparty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Forward Purchase Agreement, the Sellers purchased up to an aggregate of up to 8,334 shares, par value $0.0001 per
share, of FLAG Class A Common Stock concurrent with the Business Combination closing pursuant to Seller&#8217;s respective FPA Funding
Amount PIPE Subscription Agreement (as defined below), less, the number of FLAG Class A Common Stock purchased by Sellers separately
from third parties who had previously elected to redeem their shares through a broker in the open market and subsequently reversed the
redemption election (&#8220;Recycled Shares&#8221;). Sellers were not required to purchase an amount of FLAG Class A Common Stock in
the event that following such purchase, each Seller&#8217;s ownership would exceed 9.9% of the total FLAG Class A Common Stock outstanding
immediately after giving effect to such purchase, unless Seller, at its sole discretion, waives such 9.9% ownership limitation. The number
of shares subject to a Forward Purchase Agreement is subject to reduction following a termination of the Forward Purchase Agreement with
respect to such shares as described under &#8220;Optional Early Termination&#8221; in the Forward Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Forward Purchase Agreements provide that Sellers will be paid directly an aggregate cash amount (the &#8220;Prepayment Amount&#8221;)
equal to the product of (i) the Number of Shares as set forth in each Pricing Date Notice and (ii) the redemption price per share as
defined in Section 9.2(a) of FLAG&#8217;s Amended and Restated Certificate of Incorporation, as amended (the &#8220;Initial Price&#8221;)
less (iii) an amount equal to 0.50% of the product of (i) the Recycled Shares multiplied by (ii) the Initial Price paid by Seller to
Counterparty on the Prepayment Date (which amount shall be netted from the Prepayment Amount) (the &#8220;Prepayment Shortfall&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Counterparty paid to Sellers the Prepayment Amounts directly from FLAG&#8217;s Trust Account representing the net proceeds of the sale
of the units in the Counterparty&#8217;s initial public offering and the sale of private placement warrants (the &#8220;Trust Account),
except that to the extent the Prepayment Amount payable to a Seller is to be paid from the purchase of Additional Shares by such Seller
pursuant to the terms of its FPA Funding Amount PIPE Subscription Agreement, such amount will be netted against such proceeds, with such
Seller being able to reduce the purchase price for the Additional Shares by the Prepayment Amount. On the Business Combination Closing
Date, Sellers were paid an aggregate of $12,479,252 from the Trust Account pursuant to the Forward Purchase Agreements and Non-Redemption
Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Business Combination Closing, the reset price (the &#8220;Reset Price&#8221;) was initially $1,200.00; provided, however, that the
Reset Price may be reduced immediately to any lower price at which the Counterparty sells, issues or grants any FLAG Class A Common Stock
or securities convertible or exchangeable into FLAG Class A Common Stock (excluding any secondary transfers) (a &#8220;Dilutive Offering&#8221;),
then the Reset Price shall be modified to equal such reduced price as of such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2023, the date of the Business Combination Closing, a net 5,496 shares of common stock were issued to the Sellers under
the Forward Purchase Agreements with the possibility of an additional 2,057 shares to be issued in the future at the election of the
Sellers. Except for the possible issuance of 2,057 shares at the election of the Sellers for no additional consideration, no further
shares are anticipated to be issued under the Forward Purchase Agreements. Under the terms of the Forward Purchase Agreements, Sellers
are obligated to pay us a settlement amount based on the value of 8,334 shares times the Forward Purchase Agreement reset price of $1,200.00
per share which is subject to adjustment in the event we conduct an offering or the seller elects an optional early termination at less
than the current reset price. In addition, pursuant to the Forward Purchase Agreement, the settlement amount is subject to a further
reduction settlement amount adjustment equal to the number of shares times $240.00.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the cash settlement date, in the event a Valuation Date (as defined below) is determined by the Seller, a cash settlement amount equal
to (1) the number of shares as of the Valuation Date, multiplied by (2) the closing price of the shares immediately preceding the Valuation
Date. In the event that Valuation Date is determine other than by the Seller, a cash settlement amount equal to the number of shares
as of the Valuation Date less the number of unregistered shares, multiplied by the volume weighted daily VWAP price over the valuation
period shall be paid to the Counter Party. The foregoing cash settlement amount is subject to adjustment by the Settlement Amount Adjustment.
The Settlement Amount Adjustment is equal to (1) the maximum number of shares as of the Valuation Date multiplied by (2) $240.00 per share,
and the Settlement Amount Adjustment will be automatically netted from the cash settlement amount. If the Settlement Amount Adjustment
exceeds the cash settlement amount, the Counterparty will pay the Seller in FLAG Class A Common Stock or in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time and on any date following the Trade Date (any such date, an &#8220;OET Date&#8221;), Seller may terminate its Forward Purchase
Agreement by providing notice to the Counterparty (the &#8220;OET Notice&#8221;) which OET Notice shall specify the quantity by which
the number of shares shall be reduced (such quantity, the &#8220;Terminated Shares&#8221;); provided that &#8220;Terminated Shares&#8221;
includes only such quantity of shares by which the number of shares is to be reduced and included in an OET Notice and does not include
any other share sales, shortfall sale shares or sales of shares that are designated as shortfall sales (which designation can be made
only up to the amount of shortfall sale proceeds), any share consideration sales or any other shares, whether or not sold, which shares
will not be included in any OET Notice when calculating the number of Terminated Shares. The effect of an OET Notice shall be to reduce
the number of shares by the number of Terminated Shares specified in such OET Notice. As of each OET Date, the Counterparty shall be
entitled to an amount from the Seller equal to the product of (x) the number of Terminated Shares and (y) the Reset Price in respect
of such OET Date, except that no such amount will be due to Counterparty upon any Shortfall Sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time and on any date following the Trade Date (any such date, a &#8220;Shortfall Sale Date&#8221;) Seller may sell Shortfall
Sale Shares. Seller shall not have any Early Termination Obligation in connection with any Shortfall Sale Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
and until the proceeds from Shortfall Sales Shares equal 100% of the Prepayment Shortfall, in the event that the product of (x) the difference
between (i) the number of shares as specified in the pricing date notice, less (ii) any Shortfall Sale Shares as of such measurement
time, multiplied by (y) the VWAP Price, is less than (z) the difference between (i) the Prepayment Shortfall, less (ii) the proceeds
from Shortfall Sales, then the Counterparty, at its option shall within five (5) business days either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
Pay in cash an amount equal to the Shortfall Variance; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
Issue and deliver to Seller such number of additional shares that are equal to (1) the Shortfall Variance, divided by (2) 90% of the
VWAP Price (the &#8220;Shortfall Variance Shares&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Valuation Date will be the earliest to occur of (a) 36 months after of the closing date, (b) the date specified by a Seller in a written
notice to be delivered to the Counterparty at a Seller&#8217;s discretion after the occurrence of any of (v) a Shortfall Variance Registration
Failure, (w) a VWAP Trigger Event (x) a Delisting Event, (y) a Registration Failure or (z) unless otherwise specified therein, upon any
Additional Termination Event and (c) the date specified by Seller in a written notice to be delivered to Counterparty at Seller&#8217;s
sole discretion (which Valuation Date shall not be earlier than the day such notice is effective) (the &#8220;Valuation Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
has agreed to waive any redemption rights under FLAG&#8217;s Amended and Restated Certificate of Incorporation, as amended, with respect
to any FLAG Class A Common Stock purchased through the FPA Funding Amount PIPE Subscription Agreement and any Recycled Shares in connection
with the Business Combination, that would require redemption by FLAG of the Class A Common Stock. Such waiver may reduce the number of
FLAG Class A Common Stock redeemed in connection with the Business Combination, and such reduction could alter the perception of the
potential strength of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the Business Combination, in the event Seller sells its Calidi&#8217;s common stock (FLAG Class A Common Stock) above the Reset Price,
Counterparty will receive the Reset Price from Seller and Seller will keep the excess of the sales price above the Reset Price. In the
event Seller sells Calidi&#8217;s common stock below the Reset Price, Seller will pay Calidi the price of the sale of the Calidi common
stock less $240.00 per share which will be kept by Seller. In the event Seller sells Calidi common stock for $240.00 or less per shares,
there will be no proceeds to Calidi and the Forward Purchase Agreement will be terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we need to seek additional financing for our operations at current trading prices, which are significantly below the initial $1,200.00
per share reset price, such financing at our current trading price will reduce the Forward Purchase Agreement initial $1,200.00 reset price,
and the settlement amount that we may receive from the Sellers, if any. Therefore, in light of our current trading price and after giving
further effect to the reduction settlement amount adjustment of $240.00 per share, it is unlikely that Sellers will pay, and that we
will receive any funds in connection with the settlement of the Forward Purchase.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, Calidi and one of the sellers mutually terminated and cancelled 2,834 shares per the Forward Purchase Agreement described
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FPA
Funding Amount PIPE Subscription Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2023, and August 30, 2023, FLAG entered into a subscription agreement (the &#8220;FPA Funding Amount PIPE Subscription Agreement&#8221;)
with the Seller. Pursuant to the FPA Funding PIPE Subscription Agreement, the FPA Funding PIPE Subscriber agreed to subscribe for and
purchase, and FLAG agreed to issue and sell to the FPA Funding PIPE Subscriber, on the Business Combination Closing date, an aggregate
number of shares of FLAG Class A Common Stock equal to the Maximum Number of Shares, less the Recycled Shares in connection with the
Forward Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Redemption
Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2023, and August 30, 2023, FLAG entered into a non-redemption agreement (the &#8220;Non-Redemption Agreement&#8221;) with
Seller, pursuant to which Seller agreed to reverse the redemption of FLAG Class A Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standby
Equity Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd., a Cayman
Island exempt limited partnership (&#8220;Yorkville&#8221;). Pursuant to the SEPA, the Company will have the right, but not the obligation,
to sell to Yorkville up to $25.0 million of its shares of Common Stock, par value $0.0001 per share, at the Company&#8217;s request any
time during the 36 months following the execution of the SEPA. The maximum advance under the SEPA is the lower of (i) an amount equal
to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an advance notice, or
(ii) 41,667 shares. For the SEPA to be utilized, the shares underlying the agreement need to be registered on a Form S-1 filed with the
SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for Yorkville&#8217;s commitment to purchase the Common Stock at the Company&#8217;s direction upon the terms and subject
to the conditions set forth in the SEPA, upon execution of the SEPA, the Company paid a structuring fee of $25,000 to an affiliate of
Yorkville and issued 1,157 shares of Common Stock to Yorkville (the &#8220;Commitment Fee Shares&#8221;). The Commitment Fee Shares were
determined by dividing $0.3 million by the lowest daily VWAP of the Common Stock during the 10 Trading Days immediately prior to December
10, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2025, the Company delivered to Yorkville a Notice of Termination of the SEPA, dated as of December 10, 2023, by and between
the Company and Yorkville. Termination of the SEPA became effective as of January 23, 2025, as mutually agreed by the Company and Yorkville.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of the termination, there were no outstanding borrowings, advance notices or shares of common stock to be issued under the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscription
Agreement </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2024, the Board approved the Subscription Agreement dated July 28, 2024 (the &#8220;Agreement&#8221;) entered with an accredited
investor (the &#8220;Investor&#8221;), a related-party. Pursuant to the Agreement, Calidi sold to the Investor and the Investor purchased,
(i) 58,235 shares of Common Stock at a purchase price of $17.172 per share (90% of the per share closing price of Calidi shares of common
stock on the NYSE American LLC on July 22, 2024); and (ii) warrants to purchase 50,000 shares of Calidi&#8217;s common stock at an exercise
price of $22.80 (120% of the per share closing price of Calidi&#8217;s shares of common stock on the NYSE American LLC on July 22, 2024),
for an aggregate purchase price of $1.0 million (the &#8220;Private Placement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board approved the appointment of the Investor, a distinguished physician and expert in stem cell therapy, to the Company&#8217;s
Scientific and Medical Advisory Board (&#8220;SMAB&#8221;). The appointment was made in accordance with the SMAB Consulting
Agreement dated July 28, 2024, pursuant to which agreement the Investor was awarded 417 stock options, with a standard four-year
vesting period. The Investor resigned from the SMAB in October 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Financings</i></b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January
2025 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2025, the Company conducted a CMPO Agreement with Ladenburg acting as the &#8220;Placement Agent&#8221;, pursuant to which
the Company agreed to issue and sell in a public offering 416,667 shares of the Company&#8217;s common stock, par value $0.0001 per share,
at a purchase price of $10.20 per Share. The closing of the offering took place on January 10, 2025. The gross proceeds from the offering
were approximately $4.3 million, before deducting placement agent fees and other offering expenses payable by the Company and excluding
the net proceeds, if any, from the exercise of the Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Common Stock were offered by the Company pursuant to a shelf registration statement on Form S-3, which was declared effective
by the Securities Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Placement Agent common stock warrants to purchase up to 20,834 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>March
2025 Registered Direct Offering and Concurrent Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2025, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the
Company agreed to issue to the Purchaser, (i) in a registered offering, 277,084 shares of the Company&#8217;s common stock, par value
$0.0001 per share, at a purchase price of $7.80 per Share, (ii) pre-funded warrants ( &#8220;PFW&#8221;) to purchase up to an aggregate
of 227,334 shares of Common Stock at a purchase price of $7.788 per Pre-funded Warrant and an exercise price of $0.001 per share (the
&#8220;Pre-funded Warrant Shares&#8221;) and (iii) in a concurrent private placement, Series G common stock purchase warrants to purchase
up to 504,417 shares of Common Stock (the &#8220;Series G Common Warrants&#8221; or the &#8220;Common Warrants&#8221;). Such registered
direct offering and concurrent private placement are referred to herein as the &#8220;March Registered Direct Offering and Concurrent
Private Placement&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares, the PFW, and the PFW Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-284229),
which was declared effective by the Securities Exchange Commission on February 7, 2025. The Series G Warrants and the Warrant Shares
were issued in a concurrent private placement and without registration under the Securities Act, and in reliance on the exemption provided
in Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Placement Agent common stock warrants to purchase up to 25,221 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>July
2025 Warrant Inducement Offer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 9, 2025, the Company entered into a warrant inducement offer agreement (the &#8220;July Warrant Inducement Offer&#8221;) with 7
holders of the Company&#8217;s existing Series A warrants, Series B-1 warrants, Series C-1 warrants, Series D warrants, Series E warrants,
and Series F warrants (together the &#8220;Existing Warrants&#8221;). Pursuant to the July Warrant Inducement Offer, such warrant holders
immediately exercised some, or all, of their respective outstanding Existing Warrants to purchase an aggregate of 549,596 shares of the
Company&#8217;s common stock, at a reduced exercise price of $8.40, for total gross proceeds of approximately $4.6 million, prior to
deducting placement agent fees and offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of some or all of the Existing Warrants for cash, the Company issued unregistered new Series
H common stock warrants (&#8220;Series H Warrants&#8221;) to purchase up to 549,587 shares of common stock. See further warrant details
below. The Company filed a resale registration statement on Form S-3 (File No. 333-288784), to register the shares underlying the Series
H Warrants, which registration statement was declared effective by the Securities Exchange Commission on July 25, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August
2025 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2025, the Company entered into an underwriting agreement with Ladenburg Thalmann &amp; Co. Inc., as representative of the
various underwriters (the &#8220;Representative&#8221;), in connection with the issuance and public sale offering of various securities
(the &#8220;August Public Offering&#8221;), including: (i) 1,922,764 common stock units (&#8220;Common Stock Unit&#8221;), which includes
the 450,000 Common Stock Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) 1,528,000 pre-funded
warrant units (&#8220;Pre-Funded Unit&#8221;), resulting in gross proceeds of approximately $6.9 million, before deducting underwriting
discounts and commissions and other estimated offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consists of (i) one share of common stock of the Company, par value $0.0001, and (ii) one Series I warrant, and each
Pre-Funded Unit consists of (i) one pre-funded warrant and (ii) one Series I warrant. Each Common Stock Unit was sold to the public at
a price of $2.00 per Common Stock Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units and Pre-Funded Units were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333- 289670),
which was declared effective by the Securities Exchange Commission on August 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the August Public Offering, the Company also issued to the Representative (or its designees) certain warrants (the &#8220;Representative
Warrants&#8221;) to purchase up to 172,538 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>At
the Market Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, the Company issued 534,265 common shares for $3.2 million of net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>March 2026 Confidentially Marketed Public Offering (CMPO)</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann
&amp; Co. Inc., as sole underwriter (&#8220;Underwriter&#8221;), in connection with the issuance and sale (the &#8220;Offering&#8221;)
of: (i) 2,278,731 common stock units (&#8220;Common Stock Units&#8221;), which includes 1,575,000 Common Stock Units purchased pursuant
to the exercise, in full, of the Over-Allotment Option, sold to the public at a price of $0.50 per Common Stock Unit, and (ii) 9,815,900
pre-funded warrant units (&#8220;Pre-Funded Units&#8221;), sold to the public at a price of $0.499 per Pre-Funded Unit, resulting in
gross proceeds of approximately $6.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
In connection with the Offering, the Company also issued to the Underwriter (or its designees) a warrant (the &#8220;Underwriter&#8217;s
Warrant&#8221;) to purchase up to 604,732 shares of Common Stock of the Company, par value $0.0001. The Underwriter&#8217;s Warrant has
an exercise price of $0.625, is exercisable on or after the date of issuance, and will expire on March 9, 2031.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consisted of (i) one share of Common Stock, (ii) one Series J common stock warrant (&#8220;Series J Warrants&#8221;)
to purchase one share of Common Stock (or pre-funded warrants to purchase one share of Common Stock in lieu thereof), (iii) one Series
K common stock warrant (&#8220;Series K Warrants&#8221;) to purchase one share of Common Stock (or pre-funded warrants to purchase one
share of Common Stock in lieu thereof), and (iv) one Series L common stock warrant (&#8220;Series L Warrants&#8221; and together with
the Series J Warrants and the Series K Warrants, the &#8220;Common Warrants&#8221;) to purchase one share of Common Stock (or pre-funded
warrants to purchase one share of Common Stock in lieu thereof). Each Pre-Funded Unit consisted of (i) one pre-funded warrant (the &#8220;Pre-Funded
Warrants&#8221;), (ii) one Series J Warrant, (iii) one Series K Warrant, and (iv) one Series L Warrant. The Common Warrants included
in the Pre-Funded Units are identical to the Common Warrants included in the Common Stock Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series J Warrants have an initial exercise price of $0.50 per share. The Series J Warrants are exercisable immediately, subject to certain
limitations described herein. The Series J Warrants expire five (5) years from the date of issuance. The Series K Warrants have an initial
exercise price of $0.50 per share. The Series K Warrants are exercisable immediately, subject to certain limitations described herein.
The Series K Warrants will expire one (1) year from the date of issuance. The Series L Warrants have an initial exercise price of $0.50
per share. The Series L Warrants are exercisable immediately, subject to certain limitations described herein. The Series L Warrants
expire six (6) months from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units, the Pre-Funded Units, the shares of Common Stock comprising the Common Stock Units, the Common Warrants, the Pre-Funded
Warrants, the shares of Common Stock issuable upon exercise of the Common Warrants, and the Pre-Funded Warrants were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-284229), that was filed with the Securities Exchange Commission
(&#8220;SEC&#8221;) on January 10, 2025 and declared effective on February 7, 2025, including the prospectus forming a part of the registration
statement, a final prospectus supplement thereto, which was filed with the SEC on March 9, 2026, pursuant to Rule 424(b) under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the related registration statement filed with the SEC on March 5, 2026
under Rule 462(b) of the Securities Act, which became automatically effective upon filing. The Offering closed on March 9, 2026 (the
&#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, the Company also entered into a warrant agency agreement (the &#8220;Warrant Agency Agreement&#8221;) with Equiniti Trust
Company, LLC, as warrant agent (the &#8220;Warrant Agent&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Since the
closing of the Offering, 2,291,000 Pre-Funded Warrants have been exercised.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2026, the Company entered into an Amendment to Common Stock Purchase Warrants Agreement (the &#8220;Warrant
Amendment&#8221;) with certain investors, that participated in the March 2026 CMPO described above, in
connection with the terms of certain of the Company&#8217;s outstanding common warrants to purchase shares of Common Stock (the
&#8220;Existing Warrants&#8221;). As originally issued, the Existing Warrants provided for the purchase of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">504,417
    shares of common stock, on exercise of the series G common stock warrants at an exercise price of $8.3448 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279,168
    shares of common stock, on exercise of the series H common stock warrants at an exercise price of $8.40 per share; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,000
    shares of common stock, on exercise of the series I common stock warrants at an exercise price of $2.00 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the Warrant Amendment, the exercise price for each of such Existing Warrants was reduced to $0.50 per share, subject to further adjustment
as set forth in the Existing Warrants and any other document governing the terms thereunder. All other terms and conditions of the Existing
Warrants remain unchanged and in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2024, the Company filed a First Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with
the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the shares of the Company&#8217;s common
stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), effective on July 15, 2024 (the &#8220;2024 Reverse Stock Split&#8221;).
As a result of the 2024 Reverse Stock Split, every ten shares of issued and outstanding Common Stock were automatically combined into
one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as
a result of the 2024 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2024 Reverse Stock Split
were rounded up to the next whole number. The number of authorized shares of Common Stock under the Company&#8217;s Second Amended and
Restated Certificate of Incorporation, as amended, remained unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2025, the Company filed a Second Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation,
as amended, with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split of the shares of the Company&#8217;s
Common Stock, par value $0.0001 per share, effective on August 4, 2025 (the &#8220;2025 Reverse Stock Split&#8221;). As a result of the
2025 Reverse Stock Split, every twelve shares of issued and outstanding Common Stock were automatically combined into one issued and
outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the
2025 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2025 Reverse Stock Split were rounded
up to the next whole number. The number of authorized shares of Common Stock under the Company&#8217;s Second Amended and Restated Certificate
of Incorporation, as amended, remained unchanged. Trading of the Company&#8217;s shares of Common Stock on the NYSE American, LLC commenced
on a split-adjusted basis on August 5, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to share and per share amounts for all periods presented in the audited consolidated financial statements have been retrospectively
restated to reflect the 2024 Reverse Stock Split and 2025 Reverse Stock Split. All rights to receive shares of common stock under outstanding
securities, including but not limited to, warrants, options, and restricted stock units (&#8220;RSUs&#8221;) were adjusted to give effect
to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise price and the number of shares
of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of shares of
Common Stock reserved for future issuance under the Company&#8217;s 2023 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delisting
of Public Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 17, 2024, Calidi received notice from the NYSE that Calidi&#8217;s public warrants to purchase common stock are no longer suitable
for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of such public warrants, and that
the NYSE Regulation has determined to commence proceedings to delist the public warrants. The public warrants currently trade on the
OTC Pink Marketplace under the symbol CLDWW.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Y-003"></span>ITEM
1A &#8211; RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below,
together with all of the other information in this report, including the section titled &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes included herein,
before making an investment decision in our securities. Our business, results of operations, financial condition, and prospects could
also be harmed by risks and uncertainties that are not presently known to us or that we currently believe are not material. If any of
the risks actually occur, our business, results of operations, financial condition, and prospects could be materially and adversely affected.
Unless otherwise indicated, references in these risk factors to our business being harmed will include harm to our business, reputation,
brand, financial condition, results of operations, and prospects. In such event, the market price of our securities could decline. You
also should read the section entitled &#8220;Special Note Regarding Forward Looking Statements&#8221; above for a discussion of what
types of statements are forward-looking statements, as well as the significance of such statements in the context of this report. The
risk factors below do not address all the risks relating to securities, business and operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related to Our Business, Financial Position and Capital Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a biotechnology company with a limited operating history and have not generated any revenue to date from product
sales</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. Since inception, we have focused substantially
all of our efforts and financial resources on raising capital and developing our initial product candidates. We have incurred net losses
since our inception, and we had an accumulated deficit of approximately $141.6 million as of December 31, 2025. For the years ended December
31, 2025 and December 31, 2024, we reported net losses of approximately $20.1 million and $22.2 million, respectively. We have no products
approved for commercial sale and, therefore, have never generated any revenue from product sales, and we do not expect to do so in the
foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and even if our clinical development
efforts result in positive data, our product candidates may not receive regulatory approval or be successfully introduced and marketed
at prices that would permit us to operate profitably. Calidi has no other experience as a company conducting clinical trials, submitting
applications for regulatory approvals, such as a New Drug Application (&#8220;NDA&#8221;), or commercializing any products. We expect
to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior
losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; deficit
and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We have insufficient cash
to continue our operations for the next 12 months and our continued operations are dependent on us raising capital and these conditions
give rise to substantial doubt over the Company&#8217;s ability to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we had
approximately $5.6 million in cash, accumulated deficit of approximately $141.6 million and working capital of approximately $2.3 million.
We believe that our existing cash and cash equivalents as of December 31, 2025, and our anticipated expenditures and commitments for the
next twelve months, will not enable us to fund our operating expenses and capital expenditure requirements for the twelve months from
December 31, 2025. These conditions give rise to substantial doubt over the Company&#8217;s ability to continue as a going concern. We
will need to raise additional capital to support our operations and execute our business plan. We will be required to pursue sources of
additional capital through various means, including debt or equity financings. Newly issued securities may include preferences, superior
voting rights, and the issuance of warrants or other convertible securities that will have additional dilutive effects. Further, the sale
of or the perception of the sale of a substantial number of our common stock by selling securityholders pursuant to a registration statement
filed with the SEC will adversely affect the price of our common stock due to our limited trading volume. In addition, the sale of a substantial
number of our common stock by such selling securityholders will adversely affect the share price that we may obtain in future financings
and may adversely affect our ability to conduct and complete future financings. We cannot assure that additional funds will be available
when needed from any source or, if available, will be available on terms that are acceptable to us and may cause existing shareholders
both book value and ownership dilution. Further, we may incur substantial costs in pursuing future capital and/or financing, including
investment banking fees, legal fees, accounting fees, printing and distribution expenses and other costs. We may also be required to recognize
non-cash expenses in connection with certain securities we may issue, such as convertible notes and warrants, which will adversely impact
our financial condition and results of operations. Our ability to obtain needed financing may be impaired by such factors as the weakness
of capital markets, and the fact that we have not been profitable, which could impact the availability and cost of future financings.
If the amount of capital we are able to raise from financing activities is not sufficient to satisfy our capital needs, we may have to
reduce our operations accordingly.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable
future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our operating losses have resulted from costs incurred in connection with our research and development programs and from general
and administrative costs associated with our operations. We expect our research and development expenses to significantly increase in
connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain marketing approval
for our product candidates, we will incur significant sales, marketing and manufacturing expenses. Because of the Business Combination,
we will incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant
and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing
biopharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even
if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of our future losses is uncertain, and our quarterly operating results may fluctuate significantly or may fall below the expectations
of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating
results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult
to predict, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change
in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to successfully enroll and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may
change from time to time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the cost of manufacturing our product candidates, which may vary depending on the quantity of production, and the success of achieving
commercial scale manufacturing operations in our new facility or at third-party manufacturers;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to attract, hire and retain qualified personnel;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
expenditures that we will or may incur to develop additional product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the level of demand for our product candidates should they receive approval, which may vary significantly;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential
future therapeutics that compete with our product candidates; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
future accounting pronouncements or changes in our accounting policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.
As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability
could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue
or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if
the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline
substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have no products approved for commercial sale and have not generated any revenue from product sales.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our product
candidates, and we do not expect to generate any revenue from the sale of products in the near future, if any. We do not expect to generate
significant revenue unless and until we obtain marketing approval of, and begin to sell, one or more of our product candidates. Our ability
to generate revenue depends on a number of factors, including, but not limited to, our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully complete our ongoing and planned preclinical studies and clinical trials for our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
timely file and receive acceptance of our Investigational New Drug applications (&#8220;INDs&#8221;), in order to commence our planned clinical trials
or future clinical trials;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully enroll subjects in, and complete, clinical trials for our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
timely file Biologics License Applications (&#8220;BLAs&#8221;) and receive regulatory approvals for our product candidates from the
FDA and other regulatory authorities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
initiate and successfully complete all safety studies required to obtain U.S. and foreign marketing approval for our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
establish commercial manufacturing capabilities through third-party manufacturers for clinical supply and commercial manufacturing of
our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
launch commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
maintain a continued acceptable safety profile of the product candidates following approval;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtain and maintain acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
position our products to effectively compete with other therapies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtain and maintain favorable coverage and adequate reimbursement by third-party payors for our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
enforce and defend intellectual property rights and claims with respect to our product candidates; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
hire additional staff, including clinical, scientific and management personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals
for our product candidates, we may not be able to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
enveloped vaccina virus and engineered allogeneic stem cell product candidates represent a novel
approach to cancer treatment that creates significant challenges</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a pipeline of enveloped vaccina virus and allogeneic stem cell product candidates engineered from healthy donor
adipose-derived mesenchymal stem cells to potentiate and deliver oncolytic viruses to the tumor site and
are intended for use in any patient with certain cancers. Advancing these novel product candidates creates significant challenges
for us, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
manipulating and manufacturing our product candidates to required specifications and in a timely manner to support our clinical trials,
and, if approved, commercialization;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
sourcing clinical and, if approved, commercial supplies of adipose and neuronal stem- and other cell types used to manufacture our product
candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
understanding and addressing intra-donor variability in the quality and type of donor-derived stem cells, which could ultimately negatively
affect our ability to produce a product reliably and consistently, if at all;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
understanding and addressing the sourcing of stem cells for our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
educating medical personnel regarding the potential side effect profile of our product candidates, if approved, such as the potential
for serious adverse events;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
using medicines to manage adverse side effects or the potential for serious adverse events of our product candidates which may not adequately
control such side effects or serious adverse events, and/or may have a detrimental impact on the efficacy of treatment;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
conditioning patients with chemotherapy and possibly checkpoint inhibitors in advance of administering our product candidates, which
may increase the risk of adverse side effects or serious adverse events;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtaining regulatory approval, as the FDA and other regulatory authorities have limited experience with the development and regulation
of enveloped vaccina virus and allogeneic stem cell therapies for cancer; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
establishing sales and marketing capabilities upon obtaining regulatory approval, if any, in order to gain market acceptance of a novel
therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
publicity regarding stem cell-based immunotherapy could have a material adverse impact on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are not utilizing embryonic stem cells, we utilize neural stem cells that have been derived from fetal tissue. Adverse publicity due
to ethical and social controversies surrounding the use of such cells or any adverse reported side effects from any stem cell, dendritic
or other cell therapy clinical trial or due to the failure of such trials to demonstrate that these therapies are efficacious could materially
and adversely affect our ability to raise capital or recruit managerial or scientific personnel or obtain research grants. In addition,
in August of 2017, when we were formerly known as StemImmune, Inc., we experienced adverse publicity when the FDA incorrectly identified
us as a Stem Cell Clinic, associated with Stem Cell Clinics that the FDA subsequently sued in federal court for alleged violations of
the Federal Food, Drug and Cosmetics Act. While we were never named in the FDA&#8217;s litigation, our business was temporarily disrupted
and our management was forced to spend time correcting the misinformation and rebuilding our reputation with the FDA and state regulatory
authorities. Because the use of human stem cells may be controversial to some segments of society, we may experience adverse publicity
again, which may disrupt our business and distract our executive management from executing on our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need to raise substantial additional funding. If we are unable to raise capital when needed, or if at all, we would be forced to delay,
reduce or eliminate some or all of our product development programs or cease operations altogether.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of biopharmaceutical products is capital intensive. We are currently advancing our product candidates through
pre-clinical testing and clinical development across a number of potential indications. We have in-licensed our product candidate
CLD-101 for newly diagnosed high grade glioma (&#8220;HGG&#8221;) that has completed a Phase 1 clinical trial sponsored by
Northwestern University. Our second program using our SuperNova&#8482; technology has completed a limited physician
investigator-sponsored pre-IND open-label, nonrandomized dose-escalation study prospectively reviewed by the International Cell
Surgical Society Institutional Review Board. This study involved a TK-positive oncolytic vaccinia virus delivered by autologous
adipose stromal vascular fraction stem cells and was completed in 2018. Since the completion of the study, the FDA has asserted that
in-human studies involving autologous adipose stromal vascular fraction stem cells are regulated under the Federal Food, Drug, and
Cosmetics Act and require an IND from the FDA in order to conduct clinical trials. We have received IND approval from
the FDA to initiate a Phase 1 clinical trial for our product candidate CLD-201 that utilizes allogeneic adipose-derived mesenchymal
stem cell (&#8220;AD-MSC&#8221;) line VP-001 loaded with tumor selective &#8220;CAL1&#8221; oncolytic vaccinia virus strain. Our
third program involving enveloping vaccinia virus within a cellular membrane is in IND-enabling studies.
Consequently, we expect our expenses to significantly increase in connection with our ongoing activities, particularly as we
continue our pre-clinical studies and initiate our planned clinical trials or initiate future trials on other product candidates and
pursue the research and development of, and seek marketing approval for, our product candidates. In addition, depending on the
status of regulatory approvals or, if we obtain marketing approval for any of our product candidates, we expect to incur significant
commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional
funds sooner if we choose to pursue additional indications and/or geographies for our product candidates or otherwise expand more
rapidly than we presently anticipate. If we are unable to raise capital when needed or on attractive terms, we would be forced to
delay, reduce or eliminate certain of our research and development programs or future commercialization efforts, and may be unable
to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our
business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on and could increase significantly as a result of many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the scope, progress, results and costs of product discovery, preclinical and clinical development, laboratory testing and clinical trials
for the development of our product
candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the timing of, and the costs involved in, obtaining marketing approvals for our product candidates in our initial target indications and our other potential product candidates that we may develop;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
if approved, the costs of commercialization activities for our product candidates for
any approved indications or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility
of a collaborator that we may contract with in the future, including the costs and timing of establishing product sales, marketing, distribution
and manufacturing capabilities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the scope, prioritization and number of our research and development programs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the costs, timing and outcome of regulatory review of our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the achievement of milestones or occurrence of other developments that trigger payments under any additional collaboration agreements
we may enter into;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements,
if any;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
intellectual property-related claims;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the extent to which we acquire or in-license other product candidates and technologies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the costs of securing manufacturing arrangements for commercial production;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the emergence of competing oncolytic viral immunotherapies as well as immuno-oncology therapies in general and other adverse market developments;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product
candidates; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and uncertain
process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly,
we will need to continue to rely on additional financing to achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. Disruptions in the financial markets in general have made equity and debt financing
more difficult to obtain, and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that
future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing,
including a potential private investment in public equity, if any, may adversely affect the holdings or the rights of our stockholders
and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price
of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence
of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants,
such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to
seek funds through arrangements with collaborators or otherwise at an earlier stage than otherwise would be desirable and we may be required
to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may
have a material adverse effect on our business, operating results and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or all of our
research or development programs or the commercialization of any product candidate or be unable to expand or continue our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Product Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is highly dependent on the success of our RedTail product candidates. If we
are unable to obtain approval for our RedTail product candidates and effectively
commercialize any of them for the treatment of patients in its approved indications, our business would be significantly
harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and future success depend on our ability to obtain regulatory approval of, and then successfully commercialize, our RedTail
product candidates. CLD-401 is in the early stages of development and has not been administered on human patients. The preclinical
results to date may not predict outcomes for our planned clinical trial or any future studies of CLD-401 or
any enveloped virus product candidate. Because CLD-401 is the first enveloped virus product to
be in pre IND studies for the clinic, its failure, or the failure of other enveloped virus therapies, may significantly influence
physicians&#8217; and regulators&#8217; opinions regarding the viability of our entire RedTail platform. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates will require additional clinical and non-clinical development, regulatory review and approval in multiple
jurisdictions, a substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts
before we can generate any revenue from product sales. In addition, because CLD-401 is our most advanced product candidate from the
RedTail platform and our other developing product candidates are based on similar technology, if CLD-401 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues, or other problems, our
development plans and business would be significantly harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
preclinical studies and clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates,
which would prevent or delay development, regulatory approval, and commercialization.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate the safety and efficacy of our
product candidates for use in each target indication through lengthy, complex, and expensive preclinical studies and clinical
trials. Failure can occur at any time during the preclinical study and clinical trial processes and there is a high risk of failure,
so we may never succeed in developing marketable products. Any preclinical studies or clinical trials that we may conduct may not
demonstrate the safety and efficacy necessary to obtain regulatory approval to market any of our product candidates. If the results
of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our
product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there
are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such
product candidates. In some instances, there can be significant variability in safety or efficacy results between different
preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures
set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial
protocols and the rate of dropout among clinical trial participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
of our trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our trials could be suspended
or terminated, and the FDA or other regulatory authorities could order us to cease further development of or deny approval of our product
candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of
enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business,
financial condition and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Interim,
top line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data
become available and are subject to regulatory audit and verification procedures that could result in material changes in the final data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim, top line or preliminary data from our clinical trials. We may decide to conduct an interim analysis
of the data after a certain number or percentage of patients have been enrolled, or after only a part of the full follow-up period but
before completion of the trial. Similarly, we may report top line or preliminary results of primary and key secondary endpoints before
the final trial results are completed. Preliminary, top line and interim data from our clinical trials may change as more patient data
or analyses become available. Preliminary, top line or interim data from our clinical trials are not necessarily predictive of final
results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrolment continues, more
patient data become available and we issue our final clinical trial report. The data also remains subject to audit and verification
procedures that may result in the final data being materially different from the preliminary data we previously published. As a result,
preliminary, interim and top line data should be viewed with caution until the final data are available. Material adverse changes in
the final data compared to the interim data could significantly harm our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the interim, topline, or preliminary data that we report differ from more complete results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain marketing authorization for, and commercialize, our product candidates may
be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of earlier studies and trials of our product candidates may not be predictive of future trial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Success
in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. Product candidates in
later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and initial clinical trials. As we commence new clinical trials and continue our ongoing clinical trials, issues may arise that
could suspend or terminate such clinical trials. A number of companies in the biotechnology and pharmaceutical industries have suffered
significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks
have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations
made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies
and trials, we cannot be certain that we will not face similar setbacks. In addition, the results of our preclinical animal studies,
including our oncology mouse studies and animal studies, may not be predictive of the results of outcomes in human clinical trials. For
example, our oncology product candidates that are in preclinical development may demonstrate different chemical and biological properties
in patients than they do in laboratory animal studies or may interact with human biological systems in unforeseen or harmful ways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
some of past, ongoing and planned clinical trials utilize an &#8220;open-label&#8221; study design. An &#8220;open-label&#8221; clinical
trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either
an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and
sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic
effect, as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject
to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an
experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms
may have improved notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator
bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received
treatment and may interpret the information of the treated group more favorably given this knowledge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates are based on a novel approach to the treatment of cancer using vaccinia virus enveloped in a cellular membrane,
allogeneic neural stem cell, and allogeneic adipose-derived mesenchymal stem cell (&#8220;AD-MSC&#8221;) loaded with an oncolytic
virus which makes it difficult to predict the time and cost of product
candidate development and subsequently obtaining regulatory approval, if at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concentrated all of our research and development efforts on our product candidates, and our future success depends on the successful
development of these therapeutic approaches. CLD-101 for newly diagnosed HGG utilizes <i>NSC-CRAd-S-pk7</i>, an engineered oncolytic
adenovirus delivered by neural stem cells to activate the innate and adaptive immune system. To our knowledge, there are no FDA-approved
products for the treatment of cancer that utilize the adenovirus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the novel nature of our product candidates to create significant challenges in obtaining regulatory approval. Few viral immunotherapies have been approved
globally or by the FDA to date. While the first viral immunotherapy, talimogene laherparepvec (Imlygic, Amgen), has received FDA approval,
regulatory agencies have reviewed relatively few viral immunotherapy product candidates such as our product candidates.
This may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product
candidates. Further, any viral immunotherapies that are approved may be subject to extensive post-approval regulatory requirements, including
requirements pertaining to manufacturing, distribution and promotion. We may need to devote significant time and resources to compliance
with these requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy
data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability
to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s
recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy,
and approval may not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our product candidates are live, gene-modified viruses for which the FDA, and other regulatory authorities and other public
health authorities, such as the Centers of Disease Control and Prevention and hospitals involved in clinical studies, have established
heightened safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use
of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development,
manufacturing or commercialization of our product candidates. We may also experience delays in transferring our process to commercial
partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable
basis, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there has been limited historical clinical trial experience for the development of products that utilize the adenovirus. Moreover,
the design and conduct of our clinical trials utilizing vaccinia virus enveloped in a cellular membrane and both neural stem cells
and adipose-derived mesenchymal stem cells (&#8220;AD-MSC&#8221;) to deliver
oncolytic viruses differs from the design and conduct of previously conducted clinical trials in this area. As a result, there is
substantial risk that the design or outcomes of our clinical trials will not be satisfactory to support marketing
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may develop our product candidates in combination with other therapies, which exposes us to additional risks related to other agents
or active pharmaceutical or biological ingredients used in combination with our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may develop our product candidates to be used with one or more currently approved other therapies. Even if any product
candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we
would continue to be subject to the risks that the FDA or other regulatory authorities could revoke approval of the therapy used in combination
with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination
therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates
for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from
the market or being less successful commercially.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA or other regulatory authorities revoke their approval of these other drugs or revoke their approval of, or if safety, efficacy,
manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may
be unable to obtain approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also evaluate our future product candidates in combination with one or more other cancer therapies that have not yet been approved
for marketing by the FDA or other regulatory authorities. We will not be able to market any product candidate we develop in combination
with any such unapproved cancer therapies that do not ultimately obtain marketing approval. In addition, unapproved therapies face the
same risks described with respect to our product candidates currently in development and clinical trials, including the potential for
serious adverse effects, delays in their clinical trials and lack of FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negative
developments in the field of immuno-oncology and, in particular, oncolytic viral immunotherapy, could damage public perception of any
of our product candidates and negatively affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of adenovirus we use in our CLD-101 product candidates or ACAM2000, a thymidine kinase (TK)-positive strain of
vaccinia virus (used as the current smallpox vaccine in the United States) we are using in our CLD-401 and CLD-201 product
candidates, will depend in part on public acceptance of the use of
immuno-oncology, and, in particular, oncolytic viral immunotherapy. Adverse events in clinical trials of our current product candidates or vaccinia virus based product candidates which we may develop, or
in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in
the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a
decrease in demand for any adenovirus-, vaccinia virus or ACAM2000-based product candidates that we may develop. These events could
also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is
influenced by claims that the use of oncolytic immunotherapies is unsafe, whether related to our therapies or those of our
competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial
subjects may be discouraged from enrolling in our clinical trials. In addition, responses by national or state governments to
negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any
product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. More restrictive statutory regimes,
government regulations or negative public opinion would have an adverse effect on our business, financial condition, prospects and
results of operations and may delay or impair the development and commercialization of our product candidates or demand for any
products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development
programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates consist of modified viruses. Adverse developments in clinical trials of other immunotherapy products based on viruses,
like oncolytic viruses, may result in a disproportionately negative effect for our technologies as compared to other products in the
field of infectious disease and immuno-oncology that are not based on viruses. Future negative developments in the biopharmaceutical
industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the
testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for our
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Difficulty
in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifying
and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of completion
of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing our product candidates,
and we may experience delays in our clinical trials if we encounter difficulties in enrolment. We may not be able to initiate or continue
clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate
in these trials as required by the FDA or other regulatory authorities, or as needed to provide appropriate statistical power for a given
trial. In particular, because we are focused on patients with brain cancer for the development of CLD-101 for newly diagnosed HGG and
CLD-101 for recurrent HGG, our ability to enroll eligible patients may be limited or enrolment may be slower than we anticipate due to
the small eligible patient population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the potentially small target populations for our planned clinical trials, particularly in brain cancer, the eligibility criteria
will further limit the pool of available trial participants as we will require that patients have specific characteristics, such as a
certain severity or stage of disease progression, to include them in a trial. Additionally, the process of finding eligible patients
may prove costly. We also may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical trials
because of the perceived risks and benefits of the product candidate under evaluation, the availability and efficacy of competing therapies
and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices
of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting
studies, and obtaining regulatory approval of potential products may be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
enrolment of patients further depends on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the proximity of patients to clinical trial sites;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
patient referral practices of physicians;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the design of the clinical trial, including the number of site visits and invasive assessments required;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain and maintain patient consents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reporting of the preliminary results of any of our clinical trials;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
factors we may not be able to control, such as the COVID-19 pandemic that limited patient participation, hiring of principal investigators
and availability of staff or clinical sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as
our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might
have opted to enroll in our clinical trials may instead opt to enroll in a clinical trial being conducted by one of our competitors.
Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical
trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such
clinical trial sites. Moreover, because certain of our product candidates represent a departure from more commonly used methods for cancer
treatment and because certain of our product candidates have not been tested in humans before, potential patients and their doctors may
be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in any future clinical trial of our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects
of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed
or prevented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive marketing approval for our current or future product candidates, our current or future product candidates may not achieve
broad market acceptance, which would limit the revenue that we generate from their sales.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our current or future product candidates, if approved by the FDA or other applicable regulatory authorities, will
depend upon the awareness and acceptance of our current or future product candidates among the medical community, including physicians,
patients and healthcare payors. Market acceptance of our current or future product candidates, if approved, will depend on a number of
factors, including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the efficacy of our current or future product candidates as demonstrated in clinical trials, and, if required by any applicable regulatory
authority in connection with the approval for the applicable indications, to provide patients with incremental health benefits, as compared
with other available medicines;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
limitations or warnings contained in the labeling approved for our current or future product candidates by the FDA or other applicable
regulatory authorities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the prevalence and severity of adverse events associated with our product candidates or those products with which they may be co-administered
in immuno-oncology and, in particular, oncolytic viral immunotherapies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the clinical indications for which our current or future product candidates are approved;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
availability of alternative treatments already approved or expected to be commercially launched in the near future;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the potential and perceived advantages of our current or future product candidates over current treatment options or alternative treatments,
including future alternative treatments;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the willingness of the target patient populations to try new therapies or treatment methods and of physicians to prescribe these therapies
or methods in immuno-oncology and, in particular, oncolytic viral immunotherapies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the need to dose such product candidates in combination with other therapeutic agents, and related costs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the strength of marketing and distribution support and timing of market introduction of competitive products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
publicity concerning our products or competing products and treatments;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
pricing and cost effectiveness;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the effectiveness of our sales and marketing strategies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to increase awareness of our current or future product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain sufficient third-party coverage or reimbursement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the ability or willingness of patients to pay out-of-pocket in the absence of third-party coverage; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
potential product liability claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our current or future product candidates are approved but do not achieve an adequate level of acceptance by patients, physicians and
payors, we may not generate sufficient revenue from our current or future product candidates to become or remain profitable. Before granting
reimbursement approval, healthcare payors may require us to demonstrate that our current or future product candidates, in addition to
treating these target indications, also provide incremental health benefits to patients. Our efforts to educate the medical community,
patient organizations and third-party payors about the benefits of our current or future product candidates may require significant resources
and may never be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face substantial competition, which may result in others discovering, developing or commercializing product candidates before or more
successfully than we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new product candidates is highly competitive. We face competition from major pharmaceutical, specialty
pharmaceutical and biotechnology companies among others with respect to our product candidates and will face similar competition with respect to any product candidates that we may seek to develop or commercialize in
the future. We compete in pharmaceutical, biotechnology and other related markets that develop immuno-oncology therapies for the treatment
of cancer. There are other companies working to develop viral immunotherapies for the treatment of cancer, including divisions of large
pharmaceutical and biotechnology companies of various sizes. The large pharmaceutical and biotechnology companies that have commercialized
and/or are developing immuno-oncology treatments for cancer include AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck, Novartis,
Pfizer and Roche/Genentech.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the products and therapies developed by our competitors are based on scientific approaches that are the same as or similar to our
approach, including with respect to the use of viral immunotherapy with adenovirus and other oncolytic viruses. Other competitive products
and therapies are based on entirely different approaches. We are aware that Oncorus, Replimune, Amgen, Immavir, Fergene and IconOVir,
among others, are developing viral immunotherapies that may have utility for the treatment of indications that we are targeting. Potential
competitors also include academic institutions, government agencies and other public and private research organizations that conduct
research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the companies we compete against or may compete against in the future have significantly greater financial resources and expertise
in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing
approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in concentration of
even more resources among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel, in establishing clinical trial sites and enrolling subjects for our clinical
trials and in acquiring technologies complementary to, or necessary for, our programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer,
more effective, have fewer or less severe side effects, or are more convenient or are less expensive than any products that we or our
collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we
may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter
the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy,
safety, convenience and price, and if required, the level of biosimilar or generic competition and the availability of reimbursement
from government and other third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation and Commercialization of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory approval processes of the FDA and other regulatory authorities are lengthy, time consuming and inherently unpredictable. If
we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize our current and future product candidates as expected, and our ability to generate
revenue may be materially impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
time required to obtain approval by the FDA and other regulatory authorities is unpredictable, but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.
In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&#8217;s clinical development and may vary among jurisdictions. These regulatory requirements may require
us to amend our clinical trial protocols, including to comply with the protocols of any applicable Special Protocol Assessment (&#8220;SPA&#8221;)
we receive from the FDA; conduct additional preclinical studies or clinical trials that may require regulatory or independent institutional
review board, or IRB, approval; or otherwise cause delays in obtaining approval or rejection of an application. Any delay in obtaining
or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product
candidate, which may materially harm our business, financial condition, results of operations, stock price and prospects. Regulatory
authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data
are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of
the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. The
number and types of preclinical studies and clinical trials that will be required for regulatory approval also varies depending on the
product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any
particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change
during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, and there may be varying interpretations
of data obtained from preclinical studies or clinical trials, any of which may cause delays or limitations in the approval or a decision
not to approve an application. It is possible that our current and future
product candidates will never obtain the appropriate regulatory approvals necessary for us to commence product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, changes in or the enactment of additional statutes, promulgation of regulations or issuance of guidance during preclinical
or clinical development, or comparable changes in the regulatory review process for each submitted product application, may cause delays
in the approval or rejection of an application. For example, in December 2022, with the passage of Food and Drug Omnibus Reform Act,
or FDORA, Congress required sponsors to develop and submit a Diversity Action Plan, or DAP, for each Phase 3 clinical trial or any other
&#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrolment of more diverse patient
populations in late-stage clinical trials of FDA regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance
outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have
the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. On
January 27, 2025, in response to an Executive Order issued by President Trump on January 21, 2025, on Diversity, Equity and Inclusion
programs, the FDA removed this draft guidance from its website. This action raises questions about the applicability of statutory obligations
to submit DAPs and the agency&#8217;s current thinking on best practices for clinical development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration
of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly larger number of patients
are exposed to the product candidate or when patients are exposed for a longer period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our current or any future product candidates could also
result in denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications or the inclusion
of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed
or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without
statements necessary or desirable for successful commercialization, or may result in requirements for costly post-marketing testing and
surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from commercializing
and generating revenues from the sale of our current and future product
candidates. Any such limitations or restrictions could similarly impact any supplemental marketing approvals we may obtain for our product candidates. Undesirable side effects may limit the potential market for any approved
products or could result in restrictions on manufacturing processes, the discontinuation of the sales and marketing of the product, or
withdrawal of product approvals. We could also be sued and held liable for harm caused to patients, or become subject to fines, injunctions
or the imposition of civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our current and future product candidates are associated with serious
adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development or limit development
of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent,
less severe or more acceptable from a risk-benefit perspective. The therapeutic-related side effects could affect patient recruitment
or the ability of enrolled patients to complete the trial or result in potential product liability claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Since the start of President Trump&#8217;s administration in 2025 (the &#8220;Trump Administration&#8221;), U.S.
policy changes have been implemented at a rapid pace and additional change is likely. It is difficult to predict how executive actions
that may be taken under the current administration may affect the FDA&#8217;s ability to exercise its regulatory authority. If any actions
impose constraints on the FDA&#8217;s ability to engage in routine oversight and product review activities in the normal course, our business
may be negatively impacted. Additionally, the Trump Administration or other parts of the federal government could adopt legislation, regulations
or policies that adversely affect our business or create a more challenging and costly environment to pursue the development, approval
and commercialization of our product candidates. Recent developments at the FDA include announcement of a plan to phase out animal testing
for monoclonal antibodies and certain other drugs, the proposed rare disease evidence principles program to facilitate approval of drugs
to treat rare diseases with very small patient populations with significant unmet medical need and with a known genetic defect that is
the major driver of the pathophysiology, and the announcement of a new Commissioner&#8217;s National Priority Voucher program for companies
supporting certain U.S. national health priorities and interests. &#160;To the extent our competitors are selected for this new voucher
pilot program, or are otherwise able to participate in any of these initiatives intended to accelerate drug development and application
review, and obtain faster approval than us, our competitive position may be harmed.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development
or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek Breakthrough Therapy designation for some, or all, of our future product candidates. A Breakthrough Therapy is defined as a drug
or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints. Sponsors of product candidates that have been designated as Breakthrough
Therapies are eligible to receive more intensive FDA guidance on developing an efficient drug development program, an organizational
commitment involving senior managers, and eligibility for rolling review and priority review. Drugs and biologics designated as Breakthrough
Therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the
criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event,
the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval
compared to product candidates developed and considered for approval that have not received Breakthrough Designation and does not assure
ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may
later decide that the product no longer meets the conditions for qualification. Thus, even though we may seek Breakthrough Therapy designation
current or some or all of our future product candidates for
the treatment of various cancers, there can be no assurance that we will receive breakthrough therapy designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accelerated
approval by the FDA, even if granted for certain of our current or future product candidates, may not lead to a faster development or
regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek approval of certain of our current or future product candidates using the FDA&#8217;s accelerated approval pathway. A product
may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage
over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As
a condition of approval, the FDA may require that a sponsor of a product receiving accelerated approval perform adequate and well-controlled
post-marketing clinical trials. These confirmatory trials must be completed with due diligence by the sponsor. In addition, the FDA currently
requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the
commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory
review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Disruptions at the FDA
and other governmental agencies and regulatory authorities could negatively affect the review of our regulatory submissions or impact
our ability to access the public markets, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The ability
of the FDA and other regulatory authorities to review and approve regulatory submissions can be affected by a variety of factors, including
statutory, regulatory and policy changes, inadequate government budget funding levels, their ability to accept user fees, or a reduction
in the FDA&#8217;s workforce and its ability to hire and retain key personnel, disruptions caused by government shutdowns and public health
crises. There have been mass layoffs of federal government employees since the start of the Trump Administration in January 2025, the
full impact of which remains unclear. Average review times at the agency have fluctuated as a result. In addition, government funding
of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities,
is subject to the political process, which is inherently fluid and unpredictable. The Trump Administration has made and is expected to
continue to make changes in the leadership of various U.S. federal regulatory agencies. In addition, changes to U.S. federal government
policy since January 2025 have led to, in some cases, legal challenges and uncertainty around the funding, functioning and policy priorities
of the U.S. federal regulatory agencies, including the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We are unable
to predict the extent to which the current U.S. federal administration may impose or seek to impose additional leadership or policy changes
at the U.S. federal regulatory agencies responsible for regulating our business or changes to rules and policies impacting our operations.
It is also unclear how executive actions or other potential actions by the Trump Administration or other parts of the federal government
will impact the FDA or other regulatory authorities that oversee our business. Government proposals to reduce or eliminate budgetary deficits
or limit federal agency personnel may include reduced allocations to the FDA and other related government agencies. These budgetary pressures
may reduce the FDA&#8217;s ability to perform its responsibilities, potentially affecting our ability to progress development of our product
candidates or obtain regulatory approval for our product candidates and could result in delays in our potential clinical trial timelines.
Disruptions at the FDA and other agencies or comparable foreign regulatory authorities may also slow the time necessary for the review
and approval of INDs, which would adversely affect our business. A significant reduction in the FDA&#8217;s workforce or the FDA&#8217;s
budget, or any future prolonged government shutdown, could significantly impact the ability of the FDA to timely review and process our
regulatory submissions or take other actions critical to the development, manufacturing or marketing of our product candidates, if approved,
which could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In October and November 2025, the U.S. federal government
endured the longest government shutdown in U.S. history due to the failure of Congress to pass an appropriations budget for fiscal year
2026, and a subsequent partial government shutdown ensued in January and February of 2026. There can be no assurance that there will not
be similar shutdowns of the federal government in the future. While there were some exemptions from these shutdowns with respect to certain
aspects of the work carried out by the FDA, including essential safety oversight and ongoing reviews of certain existing applications
where there was carryover funding, other work of the FDA during that time, such as acceptance of new applications, was suspended and the
FDA workforce was reduced. These and similar events may impact the functioning of the FDA, including but not limited subsequent government
shutdowns or global health concerns, and could prevent the FDA or other regulatory authorities from conducting their regular inspections,
reviews or other regulatory activities, could significantly impact the ability of the FDA or other regulatory authorities to timely review
and process our regulatory submissions, which could have a material adverse effect on our business. In addition, any future government
shutdown could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue
our operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our development efforts are successful, we may not obtain regulatory approval of our current or any future product candidates in the United States or other jurisdictions, which would prevent us from commercializing
our current and future product candidates. Even if we obtain regulatory
approval for our current and future product candidates, any such approval
may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our ability
to successfully commercialize our current or any future product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market or promote or sell our current or any future
product candidates before we receive regulatory approval from the FDA or other regulatory authorities, and we may never receive such
regulatory approval. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information
to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy for that indication.
Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of
manufacturing facilities and clinical trial sites by, the regulatory authorities. If we do not receive approval from the FDA and other
regulatory authorities for any of our current and future product candidates,
we will not be able to commercialize such product candidates in the United States or in other jurisdictions. If significant delays in
obtaining approval for and commercializing our current and future product
candidates occur in any jurisdictions, our business, financial condition, results of operations, stock price and prospects will be materially
harmed. Even if our current and future product candidates are approved,
they may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or
other conditions of approval;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
not be approved with label statements necessary or desirable for successful commercialization; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a Risk Evaluation
and Mitigation Strategy, or REMS, to monitor the safety or efficacy of the products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously submitted a Biologics License Application, or BLA, to the FDA, or a similar marketing application to other regulatory
authorities, for our product candidates, and we can provide
no assurance that we will ultimately be successful in obtaining regulatory approval for claims that are necessary or desirable for successful
marketing, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in product candidate manufacturing or formulation may result in additional costs or delay.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it
is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in
an effort to optimize processes and results. Any of these changes could cause our current or any future product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the altered materials. Changes in third-party manufacturers and manufacturing processes may also
require additional testing, or notification to, or approval by the FDA or another regulatory authority. Such changes could be further
delayed due to development of commercial scale manufacturing operations in our new facility or at third-party manufacturers. This could
delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more
clinical trials, increase clinical trial costs, delay approval of our current and future product candidates and jeopardize our ability to commence product sales and generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inadequate
funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217;
operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from
being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on
which the operation of our business may rely, which could negatively impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes.
Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other
government agencies on which our operations may rely, including those that fund research and development activities, is subject to the
political process, which is inherently fluid and unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
legislative and regulatory proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they
have historically operated. We cannot be sure whether additional legislative changes or executive orders will be enacted, or whether
any of the FDA&#8217;s regulations, guidance or interpretations will be changed, or what the impact of such changes on the agency
and its scientific review staff, if any, may be. For example, the next FDA user fee reauthorization package (PDUFA VIII) entered
stakeholder negotiations beginning in mid-2025, with an agreement anticipated to be sent to Congress in early 2027 for purposes of
initiating the legislative process. Reauthorization of the prescription drug user fee program would need to be finalized by Congress
by the end of September 2027 in order to avoid a disruption in FDA&#8217;s review goals for NDAs and other activities supported by
user fees assessed against industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary
government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut
down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government
employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA
to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future
government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize
and continue our operations. Future government shutdowns or slowdowns could also result in delays in the Company&#8217;s interactions
with the SEC and other government agencies, which could impact the Company&#8217;s ability to access the public markets and obtain necessary
capital in order to properly capitalize and continue its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our current or any future product candidates receive regulatory approval,
we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit
how we manufacture and market our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product candidate for which we may obtain marketing approval will be subject to extensive and ongoing requirements of and review by the
FDA and other regulatory authorities, including requirements related to the manufacturing processes, post-approval clinical data, labeling,
packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional activities
for such product. These requirements further include submissions of safety and other post-marketing information, including manufacturing
deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with current good manufacturing
practice, or CGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records
and documents, and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses, including
the duration of use, for which the product may be marketed or to the conditions of approval, or contain requirements for potentially
costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product.
The FDA may also require a REMS, in order to approve a product candidate, which could entail requirements for a medication guide, physician
communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other
risk minimization tools.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other regulatory authorities will continue to closely monitor the safety profile of any product even after approval. If the FDA
or other regulatory authorities become aware of new safety information after approval of any of our current and future product candidates, they may withdraw approval, issue public safety alerts, require labeling
changes or establishment of a REMS or similar strategy, impose significant restrictions on a product&#8217;s indicated uses or marketing,
or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Any such restrictions could
limit sales of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections
by the FDA to monitor and ensure compliance with CGMPs and other FDA regulatory requirements. Application holders must further notify
the FDA, and depending on the nature of the change, obtain FDA pre-approval for product and manufacturing changes. Manufacturers and
manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing
procedures conform to current GMP regulations and implementing tracking and tracing requirements for certain prescription pharmaceutical
products. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with current
GMP and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue
to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other
problems with any products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and
after approval, may yield various negative results, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
restrictions on manufacturing, distribution, or marketing of such products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
restrictions on the labeling, including required additional warnings, such as boxed warnings, contraindications, precautions, and restrictions
on the approved indication or use;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
modifications to promotional pieces;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
issuance of corrective information;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
requirements to conduct post-marketing studies or other clinical trials;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
clinical holds or termination of clinical trials;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
requirements to establish or modify a REMS or similar strategy;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes to the way the product is administered to patients;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
liability for harm caused to patients or subjects;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reputational harm;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the product becoming less competitive;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
warning or untitled letters;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension of marketing or withdrawal of the products from the market;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing
warnings or other safety information about the product;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusal to approve pending applications or supplements to approved applications that we submit;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
recalls of products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
fines, restitution or disgorgement of profits or revenues;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension or withdrawal of marketing approvals;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusal to permit the import or export of our products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product seizure or detention;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion
from federal healthcare programs, consent decrees, or corporate integrity agreements; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
injunctions or the imposition of civil, criminal or administrative penalties, including imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of any particular product or could substantially increase
the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues
from its marketing and sale. Any of these events could further have other material and adverse effects on our operations and business
and could adversely impact our business, financial condition, results of operations, stock price and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the FDA&#8217;s policies or those of other regulatory authorities may change and could impose extensive and ongoing regulatory requirements
and obligations on any product candidate for which we obtain marketing approval. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained and be subject to regulatory enforcement action, which would adversely affect our business,
prospects and ability to achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
approval by the FDA or other regulatory authorities is limited to those specific indications and conditions for which approval has been
granted, and we may be subject to substantial fines, criminal penalties, injunctions or other enforcement actions if we are determined
to be promoting the use of our products for unapproved or &#8220;off-label&#8221; uses, or in a manner inconsistent with the approved
labeling, resulting in damage to our reputation and business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval.
Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing
review by the FDA, Department of Justice, Department of Health and Human Services&#8217; Office of Inspector General, state attorneys
general, members of Congress and the public. When the FDA or other regulatory authorities issue regulatory approval for a product candidate,
the regulatory approval is limited to those specific uses and indications for which a product is approved. If we are not able to obtain
FDA approval for desired uses or indications for our current and future
product candidates, we may not market or promote them for those indications and uses, referred to as off-label uses, and our business,
financial condition, results of operations, stock price and prospects will be materially harmed. We also must sufficiently substantiate
any claims that we make for any products, including claims comparing those products to other companies&#8217; products, and must abide
by the FDA&#8217;s strict requirements regarding the content of promotion and advertising.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Physicians
may choose to prescribe products for uses that are not described in the product&#8217;s labeling and for uses that differ from those
tested in clinical trials and approved by the regulatory authorities. Regulatory authorities in the United States generally do not restrict
or regulate the behavior of physicians in their choice of treatment within the practice of medicine. Regulatory authorities do, however,
restrict communications by biopharmaceutical companies concerning off-label use.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have impermissibly promoted any of our current and future
product candidates, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce
the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off-label uses, and a company that
is found to have improperly promoted a product may be subject to significant sanctions. The federal government has levied large civil
and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion.
The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct
is changed or curtailed. In the United States, engaging in the impermissible promotion of any products, following approval, for off-label
uses can also subject us to false claims and other litigation under federal and state statutes. These include fraud and abuse and consumer
protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict
the manner in which we promote or distribute therapeutic products and conduct our business. These restrictions could include corporate
integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment
from government contracts and refusal of orders under existing government contracts. These False Claims Act lawsuits against manufacturers
of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements
pertaining to certain sales practices and promoting off-label uses. In addition, False Claims Act lawsuits may expose manufacturers to
follow-on claims by private payers based on fraudulent marketing practices. This growth in litigation has increased the risk that a biopharmaceutical
company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree
to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare
programs. If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully
defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations,
stock price and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions on promotional
statements. If, after our current or any future product candidates obtains
marketing approval, the FDA determines that our promotional activities violate its regulations and policies pertaining to product promotion,
it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance
of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment
of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement
actions. Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities, and
regulatory agencies in various countries may enforce violations of such codes with civil penalties. If we become subject to regulatory
and enforcement actions, our business, financial condition, results of operations, stock price and prospects will be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are
able to, the FDA or other regulatory authority may not permit us to proceed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or other regulatory authorities may require us to file separate INDs for additional clinical trials we plan to conduct with our current
lead product candidates. We may not be able to file
any additional INDs required for our current product candidates and any future product candidates on the timelines we expect. For example,
we may experience manufacturing delays or other delays with IND-enabling studies, including due to a contagious disease outbreak such
as the COVID-19 pandemic on suppliers, study sites or third-party contractors and vendors on whom we depend. Moreover, we cannot be sure
that submission of an IND will result in the FDA or other regulatory authorities allowing further clinical trials to begin, or that,
once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree
with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will
not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing
INDs or to a new IND. Any failure to file INDs on the expected timelines to obtain regulatory approvals for our trials may prevent us
from completing our clinical trials or commercializing our products on a timely basis, if at all. There are similar risks related to
the review and authorization of our protocols and amendments by other regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory
pathway.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the
ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval
pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA,
an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product
was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years
from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still
market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the
other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate
impact, implementation and meaning are subject to uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity.
However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not
consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic
competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also
been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of
our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will
depend on a number of marketplace and regulatory factors that are still developing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition
from such biosimilars, with the attendant competitive pressure and consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual
markets for our product candidates may be smaller than our estimates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future target patient populations are based on our beliefs and estimates regarding the incidence or prevalence of certain
types of the indications that may be addressable by our product candidates, which is derived from a variety of sources, including scientific
literature and surveys of clinics. Our projections may prove to be incorrect and the number of potential patients may turn out to be
lower than expected. The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors
including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance
by the medical community, patient access, the success of competing therapies and product pricing and reimbursement. Further, the market
opportunity for viral immunotherapies is hard to estimate given that it is an emerging field with few globally or FDA-approved therapies,
none of which have yet to enjoy broad market acceptance. Even if we obtain significant market share for our product candidates, because
the potential target populations could be small, we may never achieve profitability without obtaining regulatory approval for additional
indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform measures may have a material adverse effect on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system
that could prevent or delay marketing approval of our current or any future product candidates, restrict or regulate post-approval activities
and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation
of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements,
(ii) additions or modifications to product labeling, (iii) the recall or discontinuation of our products or (iv) additional record-keeping
requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in
March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers,
and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition
by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by
manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care
organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part
D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018,
effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA,
and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently
undergoing legal and constitutional challenges in the Fifth Circuit Court and the United States Supreme Court; the Trump Administration
has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden
on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of
pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing
the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. We cannot predict what affect further
changes to the ACA would have on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select
Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through
2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs.
This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments,
will remain in effect through 2030 unless additional Congressional action is taken. These Medicare sequester reductions were suspended
from May 1, 2020 through June 30, 2021 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012 among other things, reduced
Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute
of limitations period for the government to recover overpayments to providers from three to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically,
there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things,
bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the federal level, budget proposals may contain further drug price control measures that could be enacted during the budget process or
in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs
under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs
for low income patients. Additionally, the prior presidential administration released a &#8220;Blueprint&#8221; to lower drug prices
and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating
power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out
of pocket costs of product candidates paid by consumers. The HHS has already started the process of soliciting feedback on some of these
measures and, at the same time, is immediately implementing others under its existing authority. For example, in May 2019, the Centers
for Medicare and Medicaid Services, or CMS, issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a
type of prior authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was
effective January 1, 2019. On March 10, 2020, the prior administration sent &#8220;principles&#8221; for drug pricing to Congress, calling
for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to
cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump
administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained
proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize
manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. Additionally,
on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing
that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020,
effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November
20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions
from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price
reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as
a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, the CMS issued
an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments
for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021.
On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation
of the interim final rule. It is unclear whether the current administration will work to reverse these measures or pursue similar policy
initiatives. Any new laws or regulations that result in additional reductions in Medicare and other healthcare funding could have a material
adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on October 1, 2020, the FDA issued a final rule allowing for the importation of certain prescription drugs from Canada. FDA also issued
a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code, or NDC, for an FDA-approved
drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. The regulatory
and market implications of the final rule and guidance are unknown at this time, but legislation, regulations or policies allowing the
reimportation of drugs, if enacted and implemented, could decrease the price we receive for our products and adversely affect our future
revenues and prospects for profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients
to access certain investigational new product candidates that have completed a Phase I clinical trial and that are undergoing investigation
for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without
obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its
product candidates At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using
bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other
health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product
pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit
the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for
our current or future product candidates or additional pricing pressures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue prospects could be affected by changes in healthcare spending and policy in the U.S. and abroad. We operate in a highly regulated
industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related
to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business,
operations and financial condition. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow
or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties
are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and
we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may
be adopted in the future, including repeal, replacement or significant revisions to the ACA. We cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
For example, the Trump Administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship
with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs. If
we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve or sustain
our business operations. The continuing efforts of the government, insurance companies, managed care organizations and other payors of
healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the demand for our current or future product candidates, if we obtain regulatory approval;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to set a price that we believe is fair for our products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain coverage and reimbursement approval for a product;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to generate revenue and achieve or maintain profitability;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the level of taxes that we are required to pay; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the availability of capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors,
which may adversely affect our future profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If,
in the future, we are unable to establish sales and marketing and patient support capabilities or enter into agreements with third parties
to sell and market our current or future product candidates, we may not be successful in commercializing our current or future product
candidates if and when they are approved, and we may not be able to generate any revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have a sales or marketing infrastructure and have limited experience in the sales, marketing, patient support or distribution
of products. To achieve commercial success for any approved product candidate for which we retain sales and marketing responsibilities,
we must build our sales, marketing, patient support, managerial and other non-technical capabilities or make arrangements with third
parties to perform these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate
in sales activities with our collaborators for, some of our current or future product candidates if and when they are approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are risks involved with both establishing our own sales and marketing and patient support capabilities and entering into arrangements
with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and
could delay any drug launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing
capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization
expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
own include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use any future products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies
with more extensive product lines; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into arrangements with third parties to perform sales, marketing, patient support and distribution services, our drug revenues
or the profitability of these drug revenues to us are likely to be lower than if we were to market and sell any current or future product
candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell
and market our current or future product candidates or may be unable to do so on terms that are favorable to us. We likely will have
little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our
current or future product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our
own or in collaboration with third parties, we will not be successful in commercializing our current or future product candidates. Further,
our business, results of operations, financial condition and prospects will be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any product candidate for which we receive regulatory approval does not achieve broad market acceptance among physicians, patients, healthcare
payors, and the medical community, the revenues that we generate from its sales will be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors,
and others in the medical community. Commercial success also will depend, in large part, on the coverage and reimbursement of our product
candidates by third-party payors, including private insurance providers and government payors. The degree of market acceptance of any
approved product would depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the efficacy, safety and tolerability as demonstrated in clinical trials;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the timing of market introduction of such product candidate as well as competitive products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the clinical indications for which the product is approved;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
acceptance by physicians, major operators of cancer or neurology clinics and patients of the product as a safe, tolerable and effective
treatment;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the potential and perceived advantages of the product candidate over alternative treatments;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the safety and tolerability of the product candidate in a broader patient group;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the cost of treatment in relation to alternative treatments;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the availability of adequate reimbursement by third party payors and government authorities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in regulatory requirements by government authorities for the product candidate;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
relative convenience and ease of administration;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the prevalence and severity of side effects and adverse events;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the effectiveness of our sales and marketing efforts; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
favorable or unfavorable publicity relating to the product or relating to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully launch and secure market acceptance of our pipeline candidates may be impacted by contagious disease outbreaks such as the COVID-19
pandemic, the potential impact of which we may be able to predict or quantify with any degree of certainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and
patients, we may not generate sufficient revenue from these products and we may not become profitable, which would have a material adverse
effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to develop additional product candidates, our commercial opportunity could be limited</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect initially to develop our current product candidates. A key part of our strategy, however, is to pursue clinical development of additional product candidates. Developing,
obtaining marketing approval for, and commercializing additional product candidates will require substantial funding and will be
subject to the risks of failure inherent in medical product development. We cannot assure you that we will be able to successfully
advance any of these additional product candidates through the development process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain approval from the FDA or other regulatory authorities to market additional product candidates for the treatment of solid
tumors, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace,
or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional
product candidates our commercial opportunity may be limited and our business, financial condition, results of operations, stock price
and prospects may be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual
damages, reputational harm and diminished profits and future earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not currently have any drugs on the market, if we begin commercializing our current or future product candidates, we will be subject
to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments
in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and
prescription of any current or future product candidates for which we obtain marketing approval. Our future arrangements with third-party
payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain
the business or financial arrangements and relationships through which we market, sell and distribute our current or future product candidates
for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving
or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for,
or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs
such as Medicare and Medicaid. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers
on the one hand and prescribers, purchasers, and formulary managers on the other hand. The term remuneration has been interpreted broadly
to include anything of value. A person or entity does not need to have actual knowledge of the statute or specific intent to violate
it in order to have committed a violation. On November 20, 2020, the Office of Inspector General, or OIG, finalized further modifications
to the federal Anti-Kickback Statute. Under the final rules, OIG added safe harbor protections under the Anti-Kickback Statute for certain
coordinated care and value-based arrangements among clinicians, providers, and others. This rule (with exceptions) became effective January
19, 2021. We continue to evaluate what effect, if any, this rule will have on our business;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against
individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are
false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In
addition, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors
if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. False Claims Act liability is potentially significant
in the healthcare industry because the statute provides for treble damages and mandatory penalties. Government enforcement agencies and
private whistleblowers have investigated pharmaceutical companies for or asserted liability under the False Claims Act for a variety
of alleged promotional and marketing activities, such as providing free products to customers with the expectation that the customers
would bill federal programs for the products; providing consulting fees and other benefits to physicians to induce them to prescribe
products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid Rebate
Program. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false of fraudulent claim for purposes of the False Claims Act;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing
a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact
or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar
to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to
violate it in order to have committed a violation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the ACA require
manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s
Health Insurance Program to report to the Department of Health and Human Services information related to physician payments and other
transfers of value and the ownership and investment interests of such physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors) and their immediate family members. Effective January 1, 2022, these reporting obligations will extend
to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing
regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses
as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health
information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually
identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal
penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages
or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing
federal civil actions; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements
and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and
some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and
the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information
related to payments to physicians and other health care providers or marketing expenditures, and state laws governing the privacy and
security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our
business activities could be subject to challenge and may not comply under one or more of such laws, regulations and guidance. Law enforcement
authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged
under these laws. Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations
could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply
with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.
If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of
these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or
restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity
agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability
to operate our business and our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face potential liability if we obtain identifiable patient health information from clinical trials sponsored by us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
healthcare providers, including certain research institutions from which we may obtain patient health information, are subject to privacy
and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business
associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under
HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the
facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information
from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of
individually identifiable health information. In addition, in the future, we may maintain sensitive personally identifiable information,
including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and
directly from individuals (or their healthcare providers) who may enroll in patient assistance programs if we choose to implement such
programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of
a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU General Data Protection Regulation, or GDPR, also confers a private right of action on data subjects and consumer associations to
lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations
of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may increase our responsibility and
liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in
place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the
GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices,
and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection
with our European activities. Further, the United Kingdom&#8217;s decision to leave the European Union, referred to as Brexit, has created
uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from
the United Kingdom will be regulated now that the United Kingdom has left the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, California recently enacted and has proposed companion regulations to the California Consumer Privacy Act, or CCPA, which went
into effect January 1, 2020. The CCPA creates new individual privacy rights for California consumers (as defined in the law) and places
increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies
to provide certain disclosures to consumers about its data collection, use and sharing practices, and to provide affected California
residents with ways to opt-out of certain sales or transfers of personal information. As of March 28, 2020, the California State Attorney
General has proposed varying versions of companion draft regulations which are not yet finalized. Despite the delay in adopting regulations,
the California State Attorney General commenced enforcement actions against violators on July 1, 2020. While there are currently exceptions
for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact our
business activities. On August 14, 2020, implementing regulations were finalized and became effective as of that date. While clinical
trial data and information governed by HIPAA are currently exempt from the current version of the CCPA, other personal information may
be applicable and possible changes to the CCPA may broaden its scope. We continue to monitor the impact the CCPA may have on our business
activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our
operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217;
health information. Patients about whom we or our collaborators may obtain health information, as well as the providers who may share
this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may
be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security
laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found
liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or third-party CROs, or other contractors or consultants fail to comply with applicable federal,
state/provincial or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our
contractors&#8217; ability to develop and commercialize our therapeutic candidates and could harm or prevent sales of any affected therapeutics
that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing
our therapeutics. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote
substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to
liability, breaches of data security or reputational damage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are subject to other state and foreign equivalents of each of the healthcare laws described above, among others, some of which may
be broader in scope and may apply regardless of the payor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable
materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally
contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from
these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any
resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal
fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, several legislative and regulatory
changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict
or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we may obtain marketing
approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to
reduce healthcare costs and improve the quality of healthcare. We expect that additional U.S. federal healthcare reform measures will
be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and
services, which could result in reduced demand for our current or future product candidates or additional pricing pressures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is currently unclear how certain new measures, including the drug pricing provisions of the IRA, will ultimately be effectuated, we
cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more
stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely
affect our business, results of operations and financial condition. In addition, it is unclear whether the new Trump Administration will
reverse or modify any existing regulatory requirements, pursue new reform initiatives or otherwise influence the overall healthcare regulatory
environment, and even if proposed, whether such changes or modifications would be implemented or withstand potential litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
we seek and obtain regulatory approval in the United States, we expect that these and other healthcare reform measures that may be adopted
in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any
approved product, which could have an adverse effect on demand for our product candidates. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. and international trade policies may adversely impact our business and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. government has made statements and taken actions that have led to certain changes and may lead to additional changes to U.S. and
international trade policies. For example, President Trump has imposed, or is likely to impose, a series of tariffs on certain products
manufactured outside the United States, and it is unknown whether and to what extent additional tariffs (or other new laws or regulations)
will be adopted, or the effect that any such actions would have on us or our industry. Any unfavorable government policies on international
trade, such as export controls, capital controls or tariffs, may affect the demand for our product candidates, the competitive position
of our product candidates, and import or export of raw materials and products used in our development and clinical manufacturing activities.
If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated
or if the U.S. government takes retaliatory trade actions due to the ongoing trade tensions, such changes could have an adverse effect
on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
global economic and geopolitical conditions may have serious adverse consequences on our business, financial condition, stock price and
results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including
severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment
rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the potential
for significant changes in U.S policies or regulatory environment given the new administration, military conflict, including the ongoing
conflicts between Russia and Ukraine, and in the Middle East, terrorism, or other geopolitical events. Sanctions imposed by the United
States and other countries in response to such conflicts, including in Ukraine, may also continue to adversely impact the financial markets
and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability.
There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur.
Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable
and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt
or equity financing more difficult, more costly, and more dilutive. Furthermore, our stock price may decline due in part to the volatility
of the stock market and the general economic downturn. Failure to secure any necessary financing in a timely manner and on favorable
terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay,
scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential
in-licenses or acquisitions. In addition, there is a risk that one or more of our current service providers, manufacturers and other
partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule
and on budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative
impacts on our business operations. For example, during the prior Trump administration, increased tariffs were implemented on goods imported
into the U.S., particularly from China, Canada, and Mexico. On February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada
and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff on imports from China. Historically,
tariffs have led to increased trade and political tensions, between not only the U.S. and China, but also between the U.S. and other
countries in the international community. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods.
Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities
between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global
financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a
material adverse effect on our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Employee Matters, Managing Growth and General Business Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive
officers, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment
agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key
person&#8221; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing,
accounting, legal and sales and marketing personnel will also be critical to our success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization
objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers
and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry
with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition
to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable
terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition
for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants
and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization
strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory
contracts with other entities that may limit their availability to us. Our success as a public company also depends on implementing and
maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and
retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to expand our development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution
capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our development, regulatory,
manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities. We expect to experience
significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical,
regulatory affairs and, if any product candidate receives marketing approval, sales, marketing and distribution. To manage our anticipated
future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations
or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our
management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt
our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
increasing use of social media platforms presents new risks and challenges.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
media is increasingly being used to communicate about our clinical development programs and the diseases our therapeutics are being developed
to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following approval of our
product candidates, if any. Social media practices in the biotechnology and biopharmaceutical industry continue to evolve and regulations
and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance
with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation
related to off-label marketing or other prohibited activities and heightened scrutiny by the FDA, the SEC and other regulators. For example,
patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse
event. If such disclosures occur, there is a risk that trial enrolment may be adversely impacted, that we may fail to monitor and comply
with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate
interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our
product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments
about us on any social networking website. In addition, we may encounter attacks on social media regarding our company, management, product
candidates or products. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur
liability, face regulatory actions or incur other harm to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of our third-party CROs that we may use in the future, or other contractors or consultants, may fail
or suffer security breaches, which could result in a material disruption of our product candidates&#8217; development programs. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our implementation of security measures, our internal computer systems, and those of our CROs that we may use in the future, information
technology suppliers and other contractors and consultants are vulnerable to damage from computer viruses, cyberattacks and other unauthorized
access, natural disasters, terrorism, war, and telecommunication and electrical failures. If such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss of clinical
trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of
or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur
liability and the further development of any of our product candidates could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural disaster, pandemic or other
catastrophic event. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on our employees and consultants, CDMOs and CROs that we may use in the future, as well as regulatory agencies and other parties,
for the continued operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite
any precautions we take for natural disasters or other catastrophic events, these events, including terrorist attack, pandemics, hurricanes,
fire, floods and ice and snowstorms, could result in significant disruptions to our research and development, preclinical studies, clinical
trials, and, ultimately, commercialization of our products. Long-term disruptions in the infrastructure caused by events, such as natural
disasters, the outbreak of war, the escalation of hostilities and acts of terrorism or other &#8220;acts of God,&#8221; particularly
involving cities in which we have offices, manufacturing or clinical trial sites, could adversely affect our businesses. Although we
carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our
coverage might not respond or be adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event
affecting us, our CDMOs or CROs, regulatory agencies or other parties with which we are engaged could have a significant negative impact
on our operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Past
statements and proposed action by the United States House of Representatives has been critical of the Chinese biopharmaceutical industry
and may raise scrutiny as to the use of our contract manufacturer in China. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The U. S. House of
Representatives has been become critical of the Chinese biopharmaceutical industry with a focus on their alleged ties to the Chinese
Communist Party and handling of Americans&#8217; data. Proposed action by the House of Representatives included legislation that could
restrict the ability of U.S. biopharmaceutical companies to collaborate with certain Chinese entities without losing the ability to contract
with the U.S. government. We have utilized ProBio in China for manufacturing of the &#8220;CAL1&#8221; oncolytic vaccinia virus strain. While ProBio is not
currently identified as a &#8220;biotechnology company of concern&#8221; as set forth in the proposed legislation, in the event that ProBio
is defined as such, or their activities are otherwise scrutinized by the U.S. government, this determination could adversely affect our
ability to contract manufacture the CAL1 oncolytic vaccinia virus strain to be use with our allogeneic adipose-derived mesenchymal stem
cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably
assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management,
and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that
any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities
that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors
or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related
party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two
or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
recurring losses from operations since inception and requirement for additional funding to finance our operations raise substantial doubt
about our ability to continue as a going concern. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
recurring losses from operations since inception and required additional funding to finance our operations raise substantial doubt about
our ability to continue as a going concern. These conditions could materially limit our ability to raise additional funds through the
issuance of new debt or equity securities or otherwise. There is no assurance that sufficient financing will be available when needed,
or at all, to allow us to continue as a going concern. The perception that we may not be able to continue as a going concern may also
make it more difficult to operate our business due to concerns about our ability to meet our contractual obligations. Our ability to
continue as a going concern is contingent upon, among other factors, the sale of our securities. There is no assurance that sufficient
financing will be available when needed, or at all, to allow us to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to secure additional capital, we may be required to curtail our clinical and research and development initiatives and take
additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations.
These measures could cause significant delays in our clinical and regulatory efforts, which is critical to the realization of our business
plan. The consolidated financial statements do not include any adjustments that may be necessary should we be unable to continue as a
going concern. It is not possible for us to predict at this time the potential success of our business. The revenue and income potential
of our proposed business and operations are currently unknown. If we cannot continue as a viable entity, you may lose some or all of
your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial
results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm
our business and the trading price of our common stock. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection
with Section 404 of the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal
deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective
or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls
could also cause investors to lose confidence in our reported financial information, which could harm our business and have a negative
effect on the trading price of our stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required
to assess the effectiveness of these controls annually. However, for as long as we are an Emerging Growth Company (&#8220;EGC&#8221;)
under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal
control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. We could be an EGC until the last day of our fiscal
year following the fifth anniversary of the consummation of FLAG&#8217;s IPO on September 14, 2021. Our assessment of internal controls
and procedures may not detect material weaknesses in our internal control over financial reporting. Undetected material weaknesses in
our internal control over financial reporting could lead to financial restatements and require us to incur the expense of remediation,
which could have a negative effect on the trading price of our stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarter ended June 30, 2023, FLAG&#8217;s Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls
and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective, due to the material weaknesses
in FLAG&#8217;s internal control over financial reporting. FLAG identified a material weakness in internal controls over financial reporting
related to the fact that it had not yet designed and maintained effective controls relating to the accounting for derivatives and presentation
of our statement of cash flows due to the lack of a sufficient number of trained professionals with an appropriate level of accounting
knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. In addition,
during the quarter ended June 30, 2023, FLAG identified material weaknesses in internal controls due to the fact that it had not yet
designed and maintained effective internal controls related to the evaluation and recording of troubled debt restructuring within the
financial statements and recording of accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a privately held company, Calidi was not required to have, and did not have, a well defined disclosure and financial controls and procedures
or systems of internal controls over financial reporting that are generally required of publicly held companies. For the year ended December
31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective
at the reasonable assurance level. However, no assurance can be given that our existing internal controls over financial reporting will
meet the requirements under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Legal and Compliance Matters </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have
to limit the commercialization of any approved products and/or our product candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to
the risk of product liability claims. We face inherent risk of product liability related to the testing of our product candidates in
human clinical trials, including liability relating to the actions and negligence of our investigators, and will face an even greater
risk if we commercially sell any product candidates that we may develop. For example, we may be sued if any product candidate we develop
allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the
product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts.
Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or selling our
products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit
commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless
of merit or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
loss of revenue from decreased demand for our products and/or product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
impairment of our business reputation or financial stability;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
costs of related litigation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
substantial monetary awards to patients or other claimants;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
diversion of management attention;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
withdrawal of clinical trial participants and potential termination of clinical trial sites or entire clinical programs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability to commercialize our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
significant negative media attention;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
decreases in our stock price;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
initiation of investigations and enforcement actions by regulators; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have sufficient insurance coverage in place for our business operations. However, our insurance coverage may not reimburse
us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly
expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect
us against losses due to liability. Failure to obtain and retain sufficient product liability insurance at an acceptable cost could prevent
or inhibit the commercialization of products we develop. On occasion, large judgments have been awarded in class action lawsuits based
on therapeutics that had unanticipated side effects. A successful product liability claim or series of claims brought against us could
cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash, and materially harm our business,
financial condition, results of operations, stock price and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as import and export control laws, customs
laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations,
stock price and prospects. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws
that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries
from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business
or gain some other business advantage. We also may participate in collaborations and relationships with third parties whose actions,
if non-compliant, could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict
the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in
which existing laws might be administered or interpreted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including regulations administered by the government
of the United States, including applicable import and export control regulations, economic sanctions on countries and persons, anti-money
laundering laws, customs requirements and currency exchange regulations, collectively referred to as the trade control laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or
other legal requirements, including trade control laws. If we are not in compliance with applicable anti-corruption laws or trade control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects. Likewise,
any investigation of any potential violations of these anti-corruption laws or trade control laws by United States or other authorities
could also have an adverse impact on our reputation, our business, financial condition, results of operations, stock price and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security
laws, we could face substantial penalties and our business, financial condition, results of operations, stock price and prospects will
be materially harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to many federal and state healthcare laws, including those described in &#8220;Business &#8212; Government Regulation&#8221;
such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Acts, the civil monetary penalties statute, the
Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992, or VHCA HIPAA, the FCPA, the
ACA and similar state laws. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare,
Medicaid or other third-party payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement
programs, government procurement, and patients&#8217; rights are and will be applicable to our business. We would be subject to healthcare
fraud and abuse and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct
our business. In the European Union, the data privacy laws are generally stricter than those which apply in the United States and include
specific requirements for the collection of personal data of European Union persons or the transfer of personal data outside of the European
Union to the United States to ensure that European Union standards of data privacy will be applied to such data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our operations, including our arrangements with physicians and other healthcare providers, some of whom receive share options or
other financial interest in the business as compensation for services provided, are found to be in violation of any federal or state
healthcare law, or any other governmental laws or regulations that apply to us, we may be subject to penalties, including civil, criminal,
and administrative penalties, damages, fines, disgorgement, suspension and debarment from government contracts, and refusal of orders
under existing government contracts, exclusion from participation in U.S. federal or state health care programs, corporate integrity
agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate
our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do
business is found not to be in compliance with applicable laws, it or they may be subject to criminal, civil or administrative sanctions,
including but not limited to, exclusions from participation in government healthcare programs, which could also materially affect our
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot
be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal, state and foreign privacy, data protection,
security, reimbursement, and fraud laws may prove costly. Any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation
of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in tax laws or in their implementation or interpretation may adversely affect our business and financial condition. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax
Cuts and Jobs Act, or TCJA, which significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among
other things, contains significant changes to corporate taxation, including reducing the corporate tax rate from a top marginal rate
of 35% to a flat rate of 21%, limiting the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain
small businesses), limiting the deduction for NOLs arising in taxable years beginning after December 31, 2017 to 80% of current year
taxable income and elimination of NOL carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such
NOLs may be carried forward indefinitely), imposing a one-time taxation of offshore earnings at reduced rates regardless of whether they
are repatriated, eliminating U.S. tax on foreign earnings (subject to certain important exceptions), allowing immediate deductions for
certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions
and credits. It is uncertain if and to what extent various states will conform to the TCJA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings
may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in the Company or its stockholders&#8217;
tax liability or require changes in the manner in which the Company operates in order to minimize or mitigate any adverse effects of
changes in tax law or in the interpretation thereof. We urge prospective investors in our common stock to consult with their legal and
tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of
investing in or holding our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the government or third-party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or
if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better
value, our revenue and prospects for profitability will be limited. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and reimbursement from
third-party payors. Such third-party payors include government health programs such as Medicare and Medicaid, managed care providers,
private health insurers, and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new
therapeutic products when more established or lower cost therapeutic alternatives are already available or subsequently become available,
even if our products are alone in a class. If reimbursement is not available, or is available only to limited levels, our product candidates
may be competitively disadvantaged, and we may not be able to successfully commercialize our product candidates. Even if coverage is
provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain a market share sufficient to
realize a sufficient return on our or their investments. Alternatively, securing favorable reimbursement terms may require us to compromise
pricing and prevent us from realizing an adequate margin over cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Marketing approvals,
pricing, and reimbursement for new therapeutic products vary widely from country to country. Current and future legislation may significantly
change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries
require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to
continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product
in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time
periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing
limitations may hinder our ability to recoup our or their investment in one or more product candidates, even if our product candidates
obtain marketing approval. Our ability to commercialize our product candidates will depend in part on the extent to which coverage and
reimbursement for these products and related treatments will be available from government health administration authorities, private
health insurers and other organizations. Regulatory authorities and third-party payors, such as private health insurers, and health maintenance
organizations, decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused
on cost containment, both in the United States and elsewhere. Several third-party payors are requiring that companies provide them with
predetermined discounts from list prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding
therapeutic differentiators within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions
based on performance goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for products exists among third-party
payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, we believe that future
coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. Third-party
coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available or adequate
in either the United States or international markets, which could have a negative effect on our business, financial condition, results
of operations, stock price and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
coverage is approved, the resulting reimbursement payment rates might not be adequate. If payors subject our product candidates to maximum
payment amounts, or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are
less expensive when compared to our product candidates. Additionally, if payors require high copayments, beneficiaries may seek alternative
therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any products to the satisfaction of hospitals,
other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time
and financial and other resources. Our products might not ultimately be considered cost-effective. Adequate third-party coverage and
reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment
in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, federal programs impose penalties on manufacturers of therapeutics in the form of mandatory additional rebates and/or discounts
if commercial prices increase at a rate greater than the Consumer Price Index-Urban, and these rebates and/or discounts, which can be
substantial, may impact our ability to raise commercial prices. A few states have also passed or are considering legislation intended
to prevent significant price increases. Regulatory authorities and third-party payors have attempted to control costs by limiting coverage
and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably.
These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers,
or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us
to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated
product revenues. If the realized prices for our products, if any, decrease or if governmental and other third-party payors do not provide
adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the
indications for which the product is approved by the FDA or other regulatory authorities. Such delays have made it increasingly common
for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a limited period
in order to ensure that patients are able to access the drug. Moreover, eligibility for reimbursement does not imply that any therapeutic
will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution.
Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may only be temporary.
Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement
rates may also be based on reimbursement levels already set for lower cost products or may be incorporated into existing payments for
other services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, third-party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies,
benchmarking against other therapies, seeking performance-based discounts, and challenging the prices charged. We cannot be sure that
coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate.
An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product
candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our overall financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, independent contractors, consultants, commercial partners, principal investigators or CROs may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could have a material
adverse effect on our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, independent contractors, consultants, commercial
partners, principal investigators, contract manufacturing organizations or CROs could include intentional, reckless, negligent, or unintentional
failures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information to the FDA, properly
calculate pricing information required by federal programs, report financial information or data accurately or disclose unauthorized
activities to us. This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical
trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter
this type of misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure
to be in compliance with such laws or regulations. Moreover, it is possible for a whistleblower to pursue a False Claims Act case against
us even if the government considers the claim unmeritorious and declines to intervene, which could require us to incur costs defending
against such a claim. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, financial condition, results of operations, stock price and prospects,
including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Violations
of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that
could have a material adverse effect on the success of our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling,
use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites. Our operations involve
the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce
hazardous waste products. We would incur substantial costs as a result of violations of or liabilities under environmental requirements
in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party
claims. Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we
cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our
use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also
could incur significant costs associated with civil or criminal fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on banks insured by the Federal Deposit Insurance Corporation (FDIC) to safeguard our cash deposits critical to our operations,
including to fund our payroll to our employees, and should our depository bank be put into receivership by the FDIC we could experience
delays in accessing our cash deposits or lose our cash deposits that may exceed the FDIC insured amounts of $250,000. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual
events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional
counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors
about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.
Our ability to pay our employees and to fund our anticipated clinical trials depends on the safety and soundness of the banks that hold
our cash deposits. If our depository bank experiences losses or a rapid loss of deposits, it may be put into receivership by the FDIC
and its applicable banking regulatory authority. For example, on March 10, 2023, the Federal Deposit Insurance Corporation took control
and was appointed receiver of Silicon Valley Bank. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were also
put into receivership. As of March 10, 2023, we maintained our payroll account with Silicon Valley Bank, as well as our general operating
account and a restricted cash balance account that served as security for our office lease. We did not experience any material delay
in accessing our cash deposits with Silicon Valley Bank and have moved or are in the process of moving our operating and payroll accounts
to another bank. However, if our new bank or other banks and financial institutions enter receivership or become insolvent in the future
in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash
equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest
rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced the
Bank Term Funding Program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities
held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer
withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. Additionally,
there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in
the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be
significantly impaired by factors that affect us, the financial institutions with which we have relationships, or the financial services
industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability
to perform obligations under various types of financial, credit or liquidity agreements or arrangements, the loss of uninsured deposits,
disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects
for companies in the financial services industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by our
anticipated suppliers or future collaboration partners, which in turn, could have a material adverse effect on our future business operations
and results of operations and financial condition. For example, a collaboration partner may fail to make payments when due, default under
their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as
a customer. In addition, a future supplier or future collaboration partner could be adversely affected by any of the liquidity or other
risks that are described above or by the loss of the ability to draw on existing credit facilities involving a troubled or failed financial
institution. Any supplier or collaboration partner bankruptcy or insolvency, or the failure of any collaboration partner to make payments
when due, or any breach or default by a supplier or collaboration partner, or the loss of any significant supplier or collaboration partner
relationships, could result in material losses to us and may have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
certain product candidates, we depend, or will depend, on development and commercialization collaborators to develop and conduct clinical
trials with, obtain regulatory approvals for, and if approved, market and sell product candidates. If such collaborators fail to perform
as expected, the potential for us to generate future revenue from such product candidates would be significantly reduced and our business
would be harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain product candidates, we depend, or will depend, on our development and commercial collaborators to develop, conduct clinical trials
of, and, if approved, commercialize product candidates. We have entered into collaborations with Northwestern University and the City
of Hope for a Phase 2 clinical trial in newly diagnosed HGG patients. We cannot provide assurance that our collaborators will be successful
in or that they will devote sufficient resources to these collaborations. If our current or future collaboration and commercialization
partners do not perform in the manner we expect or fail to fulfill their responsibilities in a timely manner, or at all, if our agreements
with them terminate or if the quality or accuracy of the clinical data they obtain is compromised, the clinical development, regulatory
approval and commercialization efforts related to their and our product candidates and products could be delayed or terminated and it
could become necessary for us to assume the responsibility at our own expense for the clinical development of such product candidates.
Moreover, our ability to generate revenues from these collaborations and product candidates will depend on such collaborators&#8217;
abilities to perform in the manner we expect or fulfill their responsibilities in a timely manner, and delays by collaborators, or caused
by other collaboration contract obligations, may result in a delay of our ability to disclose data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current collaborations and any future collaborations that we enter into are subject to numerous risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators have significant discretion in determining the efforts and resources that they will apply to the collaborations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators may not perform their obligations as expected or fail to fulfill their responsibilities in a timely manner, or at all;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect
not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in
the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create
competing priorities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators may delay preclinical studies or clinical trials, provide insufficient funding for clinical trials, stop a preclinical
study or clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product
candidate for clinical testing;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators could fail to make timely regulatory submissions for a product candidate;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or
commercialized under a collaboration and, consequently, may have limited ability to inform our shareholders about the status of such
product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized
under terms that are more economically attractive than ours;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the collaborations may not result in product candidates to develop and/or preclinical studies or clinical trials conducted as part of
the collaborations may not be successful;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product candidates developed with collaborators may be viewed by our collaborators as competitive with their own product candidates or
products, which may cause collaborators to stop commercialization of our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not
commit sufficient resources to the marketing and distribution of any such product candidate; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way
as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential
litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our
product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the
continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. If
one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation
in the business and financial communities could be adversely affected. Any failure to successfully develop or commercialize our product
candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial
condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
conflicts arise with our development and commercialization collaborators or licensors, they may act in their own self-interest, which
may be adverse to the interests of our company. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future experience disagreements with our development and commercialization collaborators or licensors. Conflicts may arise
in our collaboration and license arrangements with third parties due to one or more of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
disputes with respect to milestone, royalty and other payments that are believed due under the applicable agreements;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
disagreements with respect to the ownership of intellectual property rights or scope of licenses;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
disagreements with respect to the scope of any reporting obligations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
disagreements with respect to contract interpretation or the preferred course of development;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities,
or to permit public disclosure of these activities; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
disputes with respect to a collaborator&#8217;s or our development or commercialization efforts with respect to our products and product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflicts
with our development and commercialization collaborators or licensors could materially adversely affect our business, financial condition
or results of operations and future growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on third parties, including independent clinical investigators and CROs to conduct and sponsor some of the clinical trials of our
product candidates. Any failure by a third party to meet its obligations with respect to the clinical development of our product candidates
may delay or impair our ability to obtain regulatory approval for our product candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third parties, including independent clinical investigators, academic partners, medical
institutions, regulatory affairs consultants and third-party CROs, to conduct our preclinical studies and clinical trials, including
in some instances sponsoring such clinical trials, and to engage with regulatory authorities and monitor and manage data for our ongoing
preclinical and clinical programs. While we have, or will have, agreements governing the activities of such third parties, we will control
only certain aspects of their activities and have limited influence over their actual performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative
arrangements or do so on commercially reasonable terms. In addition, there is a natural transition period when a new contract research
organization begins work. As a result, delays would likely occur, which could negatively impact our ability to meet our expected clinical
development timelines and harm our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable
protocol and legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory
responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and
guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA and other regulatory authorities for all of
our products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors,
principal investigators and trial sites. If we fail to exercise adequate oversight over any of our academic partners or CROs or if we
or any of our academic partners or CROs do not successfully carry out their contractual duties or obligations, fail to meet expected
deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical
protocols or regulatory requirements, or for any other reasons, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA, the EMA or other regulatory authorities may require us to perform additional clinical trials before approving our marketing
applications. We cannot assure you that upon a regulatory inspection of us, our academic partners or our CROs or other third parties
performing services in connection with our clinical trials, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under applicable CGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements
with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs.
These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting
clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs.
If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines
or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may
be delayed in obtaining, marketing approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in
our efforts to, successfully commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, with respect to investigator-sponsored trials that may be conducted, we do not control the design or conduct of these trials,
and it is possible that the FDA or EMA will not view these investigator-sponsored trials as providing adequate support for future clinical
trials or market approval, whether controlled by us or third parties, for any one or more reasons, including elements of the design or
execution of the trials or safety concerns or other trial results. We expect that such arrangements will provide us certain information
rights with respect to the investigator-sponsored trials, including the ability to obtain a license to obtain access to use and reference
the data, including for our own regulatory submissions, resulting from the investigator-sponsored trials. However, we do not have control
over the timing and reporting of the data from investigator-sponsored trials, nor do we own the data from the investigator-sponsored
trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained,
we would likely be further delayed or prevented from advancing further clinical development. Further, if investigators or institutions
breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared
to the firsthand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability
to design and conduct any future clinical trials ourselves may be adversely affected. Additionally, the FDA or EMA may disagree with
the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored
trials, or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored trials. If so, the FDA
or EMA may require us to obtain and submit additional preclinical, manufacturing, or clinical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the manufacturers upon which we may rely fail to produce our product candidates in the volumes that we require on a timely basis, or
fail to comply with stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization
of, or be unable to meet demand for, our product candidates and may lose potential revenues. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on third-party contract manufacturers to manufacture our clinical trial product supplies and for commercial scale manufacturing.
There can be no assurance that our clinical development will not be limited, interrupted, or of satisfactory quality or continue to be
available at acceptable prices. In particular, any replacement of our contract manufacturer could require significant effort and expertise
because there may be a limited number of qualified replacements. Any delays in obtaining adequate supplies of our product candidates
that meet the necessary quality standards may delay our development or commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our product candidates
or programs. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. There
are a limited number of manufacturers that operate under CGMP regulations and that are both capable of manufacturing and filling our
viral product for us and willing to do so. If our existing third-party manufacturers, or the third parties that we engage in the future,
should cease to work with us, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to
meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason we are
unable to obtain adequate supplies of our product candidates or the therapeutic substances used to manufacture them, it will be more
difficult for us to develop our product candidates and compete effectively. Further, even if we do establish such collaborations or arrangements,
our third-party manufacturers may breach, terminate, or not renew these agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
problems or delays we experience in preparing for commercial scale manufacturing of a product candidate or component may result in a
delay in product development timelines and FDA or other regulatory authority approval of the product candidate or may impair our ability
to manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention,
or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial
condition, results of operations, stock price and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of biopharmaceutical products requires significant expertise and capital investment, including the development of advanced
manufacturing techniques and process controls. Manufacturers of therapeutics often encounter difficulties in production, particularly
in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability
of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly
enforced federal, state, and foreign regulations. Our contract manufacturers may not perform as agreed. If our manufacturers were to
encounter these or other difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
manufacturers of our product candidates may be unable to comply with our specifications, applicable CGMP requirements or other FDA, state
or foreign regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or other
contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product
testing. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA or other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing
facilities. Any such deviations may also require remedial measures that may be costly and/or time consuming for us or a third party to
implement and that may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure of a facility.
Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. Any delays in obtaining
products or product candidates that comply with the applicable regulatory requirements may result in delays to clinical trials, product
approvals, and commercialization. It may also require that we conduct additional studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are ultimately responsible for the manufacturing of our product candidates and therapeutic substances, other than through our contractual
arrangements, we have little control over our manufacturers&#8217; compliance with these regulations and standards. If the FDA or another
regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval
in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market our product candidates, if approved. Any new manufacturers would need to either obtain or develop the
necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment. We
must also receive FDA approval for the use of any new manufacturers for commercial supply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement
actions against our manufacturers or us (including fines and civil and criminal penalties, including imprisonment) suspension or restrictions
of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of
clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product
candidate, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits
under the civil False Claims Act, corporate integrity agreements, consent decrees, withdrawal of product approval, environmental or safety
incidents and other liabilities. If the safety of any quantities supplied is compromised due to our manufacturers&#8217; failure to adhere
to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
failure or refusal to supply our product candidates or components for our product candidates that we may develop could delay, prevent
or impair our clinical development or commercialization efforts. Any change in our manufacturers could be costly because the commercial
terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes
could be significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we may rely on third parties to manufacture our product candidates, and because we collaborate with various organizations and academic
institutions on the development of our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary
technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research
agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning
research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our
confidential information, such as trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information
increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others,
or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and
trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive
position and may have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish data potentially
relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance
and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In
other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties.
Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements,
independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise
protected rights at the time of publication. A competitor&#8217;s discovery of our trade secrets would impair our competitive position
and have an adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
rights to develop and commercialize certain of our product candidates are subject and may in the future be subject, in part, to the terms
and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual
property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors,
we could lose intellectual property rights that are important to our business</i>. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are and expect to continue to be reliant upon third-party licensors for certain patent and other intellectual property rights that are
important or necessary to the development of some of our technology and product candidates. For example, we rely on licenses from Northwestern
University and City of Hope to certain development, commercialization, regulatory and patent rights. These license agreements impose,
and we expect that any future license agreement will impose, specified diligence, milestone payment, royalty, commercialization, development
and other obligations on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts
to develop and commercialize licensed products, in order to maintain the licenses. For more information on the terms of these license
agreements, see &#8220;Business &#8212;Intellectual Property.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
our licensors have, or may in the future have, the right to terminate a license if we materially breach the agreement and fail to cure
such breach within a specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current
or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license
agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize certain of our product candidates
and technology, lose patent protection, experience significant delays in the development and commercialization of certain of our product
candidates and technology, and incur liability for damages. If these in-licenses are terminated, or if the underlying intellectual property
fails to provide the intended exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval
of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development and commercialization
of certain of our product candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in
connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors,
including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual
property that is subject to our existing licenses and to compete with any product candidates we may develop and our technology. Any of
the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the scope of rights granted under the license agreement and other interpretation-related issues;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our or our licensors&#8217; ability to obtain, maintain and defend intellectual property and to enforce intellectual property rights
against third parties;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the extent to which our technology, product candidates and processes infringe, misappropriate or otherwise violate the intellectual property
of the licensor that is not subject to the license agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the sublicensing of patent and other intellectual property rights under our license agreements;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our diligence, development, regulatory, commercialization, financial or other obligations under the license agreement and what activities
satisfy those diligence obligations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current
or future licensors and us and our partners; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the priority of invention of patented technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our license agreements are, and future license agreements are likely to be, complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be
our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition,
if disputes over intellectual property that we have licensed or any other dispute related to our license agreements prevent or impair
our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates and technology. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
agreements we may enter into in the future may be non-exclusive. Accordingly, third parties may also obtain non-exclusive licenses from
such licensors with respect to the intellectual property licensed to us under such license agreements. Accordingly, these license agreements
may not provide us with exclusive rights to use such licensed patent and other intellectual property rights, or may not provide us with
exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which
we may wish to develop or commercialize our technology and any product candidates we may develop in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
some of our in-licensed patent and other intellectual property rights may in the future be subject to third-party interests such as co-ownership.
If we are unable to obtain an exclusive license to such third-party co-owners&#8217; interest, in such patent and other intellectual
property rights, such third-party co-owners may be able to license their rights to other third parties, including our competitors, and
our competitors could market competing products and technology. We or our licensors may need the cooperation of any such co-owners of
our licensed patent and other intellectual property rights in order to enforce them against third parties, and such cooperation may not
be provided to us or our licensors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we may not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent
applications that we license from third parties. It is possible that our licensors&#8217; filing, prosecution and maintenance of the
licensed patents and patent applications, enforcement of patents against infringers or defense of such patents against challenges of
validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, and accordingly, we cannot be certain
that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent
with the best interests of our business. If our licensors fail to file, prosecute, maintain, enforce and defend such patents and patent
applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right
to develop and commercialize any of our technology and any product candidates we may develop that are the subject of such licensed rights
could be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
our owned and in-licensed patent rights may be subject to a reservation of rights by one or more third parties. When new technologies
are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such
funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent
rights to the U.S. government and timely electing title to such inventions. A failure to meet these obligations may lead to a loss of
rights or the unenforceability of relevant patents or patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights
and technology, and we may not be able to ensure their protection. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies
and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to
manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability
to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon
the extent to which we have rights under valid and enforceable patents that cover these activities and whether a court would issue an
injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope
of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar
or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications
at a reasonable cost or in a timely manner. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets.
It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to
obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution
of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant
on our licensors or licensees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
strength of patents in the biotechnology and biopharmaceutical field involves complex legal and scientific questions and can be uncertain.
The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates
or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge
the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore,
even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates,
or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications and
patents we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop,
and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period
of time during which we could market our product candidates under patent protection would be reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that we were the first to file any patent application related to our technology and directed to our product candidates,
and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that we are the first to invent the inventions covered by pending patent applications and patents, and, if we are not,
we may be subject to priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date
before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the United States Patent and Trademark
Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications
and patents. Similarly, for United States applications in which at least one claim is not entitled to a priority date before March 16,
2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#8217;s
disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be
prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also
may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless,
ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would
be declared by a court to be valid or enforceable or that even if found valid and enforceable, would adequately protect our product candidates,
or would be found by a court to be infringed by a competitor&#8217;s technology or product. We may analyze patents or patent applications
of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product
candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts
or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will
develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual
property rights, or will design around the claims of patents that may issue that cover our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted
in 2013, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221;
system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be
entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act
includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted,
redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only
recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent
law, including the &#8220;first-to-file&#8221; provisions, only became effective in March 2013. In addition, the courts have yet to address
many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined
and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding
the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
others may be able to make or use compounds that are similar to the compositions of our product candidates but that are not covered by
the claims of our patents or those of our licensors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents
and patent applications funded by U.S. government grants, leading to the loss of patent rights;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
it is possible that our pending patent applications will not result in issued patents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be,
or parts of our or their patents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
it is possible that others may circumvent our owned or in-licensed patents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims
covering our products or technology similar to ours;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent
as the laws of the United States;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our owned, co-owned, or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be
held invalid or unenforceable as a result of legal challenges by third parties;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inventors of our owned, co-owned, or in-licensed patents or patent applications may become involved with competitors, develop products
or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as
inventors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the co-owners of certain of our patent applications may become involved with, or license or assign the co-owned applications to competitors,
or become hostile to us or the patents or patent applications on which they are named as co-owners;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or
include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications
to be held invalid or unenforceable;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent
or competing products to ours that are outside the scope of our patents;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we may not develop additional proprietary technologies for which we can obtain patent protection;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive
rights; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the patents of others may have an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply
with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future
business</i></b><i>. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements
in the future pertaining to the in-license of rights to additional candidates. Such agreements may impose various diligence, milestone
payment, royalty, insurance or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners
may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered
by such licensed intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the scope of rights granted under the license agreement and other interpretation-related issues;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject
to the licensing agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the sublicensing of patent and other rights under our collaborative development relationships;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
and us and our partners; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the priority of invention of patented technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain
provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement
that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse
effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may
be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our
business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any
other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such
activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in
valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors
initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual
property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous
than had we conducted them ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention
assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially
where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential
nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the
case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our
proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and
providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests
fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming,
and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent
legal recourse by us. For example, our clinical development strategy includes our techniques for obtaining, processing and preserving
neuronal-derived stem cells and adipose-derived mesenchymal stem cells that are proprietary and confidential. If one or more third parties
obtain or are otherwise able to replicate these techniques, an important feature and differentiator of our clinical development strategy
will become available to potential competitors. If any of our confidential or proprietary information, such as our trade secrets, were
to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position
could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a
third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources
even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual
means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and
techniques or otherwise gain access to our trade secrets or disclose our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,
we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or
consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs
developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential
and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions
conceived by the individual, and which are related to our current or planned business or research and development or made during normal
working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other
appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology
by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best
practices, in protecting our trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-party
claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary
technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents
and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for
challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before
the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future
litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary
technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which
are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and biopharmaceutical
industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement
of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various
types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications
filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies
or methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may
divert our management&#8217;s attention from our core business;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes
on or violates the third-party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay
treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies,
unless the third-party licenses its product rights to us, which it is not required to do;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant
cross-licenses to intellectual property rights for our products and any license that is available may be non-exclusive, which could result
in our competitors gaining access to the same intellectual property; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary
expenditures and time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material
adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect
on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential
information could be compromised by disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our
use of the tissue samples or other biological materials, which they provide to us, or otherwise arising from the collaboration. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
collaborate with institutions, universities, medical centers, physicians and researchers in scientific matters and expect to continue
to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators, or the
written agreements we have do not cover intellectual property rights. Also, we rely on numerous third parties to provide us with tissue
samples and biological materials that we use to conduct our research activities and develop our product candidates. If we cannot successfully
negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party collaborator&#8217;s
materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator&#8217;s samples, or
data developed in a collaborator&#8217;s study, we may be limited in our ability to capitalize on the market potential of these inventions
or developments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may assert that we are employing their proprietary technology without authorization. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods
of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently
pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or
their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any third-party patent were held by a court of competent jurisdiction to cover our product candidates, intermediates used in the manufacture
of our product candidates or our materials generally, aspects of our formulations or methods of use, the holders of any such patent may
be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires
or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable
terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all,
our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.
Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.
In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade
companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain
one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial
time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available
on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to
advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable
cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates,
which could harm our business significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may assert that our employees or consultants have wrongfully used or disclosed confidential information, misappropriated trade
secrets, or are in breach of non-competition or non-solicitation agreements with our competitors</i></b><i>. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or
other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us
are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how
of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer
or other third parties. We may also be subject to claims that we caused an employee to breach the terms of their non-competition or non-solicitation
agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary
information of a former employer or competitor or other party. Litigation may be necessary to defend against these claims. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.
Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims
may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities.
In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and,
if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of
our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available
for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their
substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth
of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others.
We may develop products containing our compounds and pre-existing biopharmaceutical compounds. We may be unable to acquire or in-license
any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as
necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable
terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party
intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property
rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be
feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies
licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with
these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s
rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the
specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property
rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required
third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development
of such program and our business and financial condition could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established,
or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights
that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a
competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual
property surrounding the additional product candidates that we may seek to acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming
and unsuccessful. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required
to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide
that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at
issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation
or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly
and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent
claims in an ex-parte re-examination, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume
our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European
Patent Office, or EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume
our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed
to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications
in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the
scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology
covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first
to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology
similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could
require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions
similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in
an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one
of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on inventions owned by or
in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interference
or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority
of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a
loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from
the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms
or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Litigation or interference
proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract
our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets
or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime
of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse
can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in
which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of
patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application
include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure
to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and
irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material
adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates,
the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent
litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous
grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before
administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,
inter partes review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings
could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following
legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be
certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution.
If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately
protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of
patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability
to protect our products. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding
the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability
are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside
the United States, the first to file a patent application was entitled to the patent. On March 16, 2013, under the Leahy-Smith America
Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system
in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled
to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files
a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention
of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from
invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential
for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file
any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s
patents or patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also
may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional
procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes
review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard
in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding
sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first
presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims
that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the
America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed
patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent positions of companies in the development and commercialization of biopharmaceuticals are particularly uncertain.
Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights
of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability
of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations
governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our
ability to protect and enforce our intellectual property in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates
in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside
the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect
intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have
not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where
we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products
in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of, and may require a compulsory
license to, patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties
in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of
our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of
our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts
and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. non-provisional filing date. Various extensions such as patent term adjustments and/or extensions, may
be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are
obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient
rights to exclude others from commercializing products similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially
harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S.
patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984
Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term
lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of
14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method
for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example,
failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines,
failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable
time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension
or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent
expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based
on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our stock may be volatile, which could result in substantial losses for investors. Further, an active, liquid and orderly trading
market for our common stock may not be sustained, and we do not know what the market price of our common stock will be, and as a result
it may be difficult for you to sell your shares of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our common stock is listed on the NYSE American, the market for our shares has demonstrated varying levels of trading activity. Furthermore,
an active trading market for our shares may not be sustained in the future. You may not be able to sell your shares quickly or at the
market price if trading in shares of our common stock is not active. An inactive market may also impair our ability to raise capital
by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products
by using shares of our common stock as consideration, which could have a material adverse effect on our business, financial condition,
and results of operations. Further, the trading price of our common stock is likely to be highly volatile and could be subject to wide
fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition, the
stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively
affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation
has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This
type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which
could have a material adverse effect on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price
and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us
or our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
one or more of the analysts covering us downgrades our stock or publishes inaccurate or unfavorable research about our business, our
stock price may decline. In addition, if one or more of these analysts ceases coverage of our company or fails to publish reports on
us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
and issuances of our common stock or other securities could result in additional dilution of the percentage ownership of our shareholders
and could cause our share price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we sell additional shares of common stock, convertible securities or other equity securities, existing shareholders may be materially
diluted by subsequent sales and new investors could gain rights, preferences, and privileges senior to existing holders of our common
stock. Pursuant to our obligations under certain registration rights agreements, we have registered on a registration statement filed
with the SEC 5,026,613 warrants to purchase our common stock. Until such time that it is no longer effective, the registration statement
registering such securities will permit the resale of these shares. The resale, or perceived potential resale, of a substantial number
of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult
for other shareholders to sell their holdings at times and prices that they determine are appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Sponsor, Metric, anchor investors and other investors purchased or received as an inducement to facilitate the Business Combination the
Sponsor Shares that were acquired by the Sponsor, Metric or anchor investors at $0.003 per share price which is significantly below the
current market price of a share of our common stock and such holder could sell their shares and generate a significant profit while causing
the trading price of our common stock to decline significantly.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the Sponsor, Metric, anchor investors and other investors purchased or received their founders shares at a $0.003 per share, significantly
below the current market price of a share of our common stock, such holder could sell their shares and generate a significant profit
while causing the trading price of our common stock to decline significantly. Those purchasers of our common stock who acquired their
shares at a price greater than our common stock&#8217;s current trading price, may not experience a similar profit or rate of return
realized by a holder of the founder shares due to the difference in such purchaser&#8217;s purchase price and the current trading price
for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing standards of the NYSE American, our common stock could be delisted. If it is delisted, the
market value and the liquidity of our common stock would be impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continued listing of our common stock on the NYSE American is contingent on our continued compliance with a number of listing standards.
The NYSE American retains substantial discretion to, at any time and without notice, suspend dealings in or remove from any security
from listing. In order to maintain this listing, we must maintain certain share prices, financial and share distribution targets, including
maintaining a minimum amount of shareholders&#8217; equity and a minimum number of public shareholders. In addition to these objective
standards, the NYSE American may delist the securities of any issuer: (i) if, in its opinion, the issuer&#8217;s financial condition
and/or operating results appear unsatisfactory; (ii) if it appears that the extent of public distribution or the aggregate market value
of the security has become so reduced as to make continued listing on the NYSE American inadvisable; (iii) if the issuer sells or disposes
of principal operating assets or ceases to be an operating company; (iv) if an issuer fails to comply with the NYSE American&#8217;s
listing requirements; (v) if an issuer&#8217;s common stock sells at what the NYSE American considers a &#8220;low selling price&#8221;
and the issuer fails to correct this via a reverse split of shares after notification by the NYSE American; or (vi) if any other event
occurs or any condition exists which makes continued listing on the NYSE American, in its opinion, inadvisable. There is no assurance
that we will remain in compliance with these standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delisting
from the NYSE American would adversely affect our ability to raise additional financing through the public or private sale of equity
securities, significantly affect the ability of investors to trade our securities and negatively affect the value and liquidity of our
common stock. Delisting also could limit our strategic alternatives and attractiveness to potential counterparties and have other negative
results, including the potential loss of employee confidence, decreased analyst coverage of our securities, the loss of institutional
investors or interest in business development opportunities. Moreover, we committed in connection with the sale of securities to use
commercially reasonable efforts to maintain the listing of our common stock during such time that certain warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the Trading Price of our Common Stock has decreased, it is unlikely that we will receive any Settlement Amount Under the Forward Purchase
Agreements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with and as an inducement to accredited investors to invest in a concurrent Series B Financing by Calidi, FLAG and certain
accredited investors (&#8220;Sellers&#8221;) entered into an OTC Equity Prepaid Forward Transaction (&#8220;Forward Purchase Agreements&#8221;).
This derivative security purchased from the Sellers is based on the value of our common stock to be settled in cash in three years subject
to reset price features and earlier termination as set forth in the Forward Purchase Agreement. The Forward Purchase Agreements and related
agreements cover up to an aggregate 8,334 shares of our common stock at an initial reset price of $1,200.00 per share. FLAG and Calidi
entered into the Forward Purchase Agreements with the Sellers as a condition precedent to the Sellers&#8217; participation in Calidi&#8217;s
Series B Financing. On September 12, 2023, the date of and as part of the Business Combination Closing, Sellers received a net 5,501
shares of common stock pursuant to the Forward Purchase Agreements and may receive an additional 2,057 shares upon the election of the
Sellers. Except for the possible issuance of 2,057 shares at the election of the Sellers for no additional consideration, no further
shares will be issued under nor be subject to the Forward Purchase Agreements. Under the terms of the Forward Purchase Agreements, Sellers
are obligated to pay us a settlement amount based on the product of 8,334 shares times the reset price of $1,200.00 per share which is
subject to adjustment in the event we conduct an offering or Seller elects an optional early termination at less than the current reset
price. In addition, pursuant to the Forward Purchase Agreement, the settlement amount is subject to a further reduction settlement amount
adjustment equal to the number of subject shares times $240.00. Because we need to seek additional financing for our operations at current
trading prices, which are significantly below the initial $1,200.00 per share reset price, such financing at our current trading price will
have the effect of reducing the Forward Purchase Agreement initial $1,200.00 reset price, and the settlement amount that we may receive from
the Sellers, if any. Therefore, in light of our current trading price and after giving further effect to the reduction settlement amount
adjustment of $240.00 per share, it is unlikely Sellers will pay and that we will receive any funds in connection with the settlement
of the Forward Purchase Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_001"></span>ITEM
1B - UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_002"></span>ITEM
1C - Cybersecurity </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_982_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20250101__20251231_gBFCRMPFAIAMT-PAO_zfLgkJpq90od" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000054-01" escape="true" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risk Management and Strategy </b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_C09_gBFCRMPFAIAMT-PAO_zOXc7DJWGWE8"><ix:continuation continuedAt="ConU000054-02" id="ConU000054-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C07_gBFCRMPFAIAMT-PAO_zX6lxkm9mAY6"><ix:continuation continuedAt="ConU000054-03" id="ConU000054-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our business operations, we use information technology, enterprise applications, communications tools, cloud network solutions, and related
systems to manage our operations, including to manage our building systems, vendor relationships, accounting and recordkeeping, and communications,
among other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and implemented a cybersecurity risk management program intended to protect our confidential and proprietary data, and
information technology and systems, from cybersecurity threats, including unauthorized access or attack. We leverage the <span style="background-color: white">SOC
2 TYPE II Cybersecurity Framework</span> as a guide to help us identify, assess, and manage cybersecurity risks relevant to the business.
This does not imply that we meet any particular technical standards, specifications, or requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_z8kUlrtVHL0h" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our
processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting
risks, reputational risks, personal data theft, fraud, and other potential risks, are <span id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zEt31mjqkBc7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric></span> into our overall enterprise risk management
process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management
process to other legal, compliance, strategic, operational, and financial risk areas.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management program includes the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zUWh7b63Blrh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000057" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">a
    multidisciplinary team comprised of personnel from information technology (&#8220;IT&#8221;), internal audit, accounting, and legal,
    as well as third-party cybersecurity experts principally responsible for directing (i) our cybersecurity risk assessment processes,
    (ii) our security processes, and (iii) our response to cybersecurity incidents, and a third-party security operations center.</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20250101__20251231_zHrhPwGDwmbd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000058" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, services, and our broader
    enterprise IT environment.</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">internal
    and third-party security tools to monitor our systems, identify cybersecurity risks, and test our IT environment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    use of third-party cybersecurity experts, where appropriate, to assess, test or otherwise assist with aspects of our security processes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    cybersecurity incident response plan and business continuity plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cybersecurity
    training for employees and key business partners with access to our systems.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:continuation></div><!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0F_gBFCRMPFAIAMT-PAO_zmOnnEWb85jb"><ix:continuation continuedAt="ConU000054-04" id="ConU000054-03">&#160;</ix:continuation></span></span></p>

<div id="xdx_C0C_gBFCRMPFAIAMT-PAO_zPCr3bxrePva"><ix:continuation continuedAt="ConU000054-05" id="ConU000054-04"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zAZTzy62pWOl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000059" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">a
    third-party cybersecurity risk management process for service providers and vendors who access our systems.</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    employees, as well as third parties who have access to our systems, to treat confidential and private information and data with care,
    including performing controls relating to such data; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cybersecurity
    risk insurance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also seek to engage reputable service providers that maintain cybersecurity programs or controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not identified risks from known cybersecurity threats within the prior fiscal year, including as a result of any prior cybersecurity
incident, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of
operations, or financial condition. Please refer to &#8220;Item 1A, Risk Factors&#8221; in this report for additional information about
certain ongoing risks related to our information technology that, if realized, are reasonably likely to materially affect us, including
our operations, business strategy, results of operations, or financial condition.</span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_C04_gBFCRMPFAIAMT-PAO_zmy51TQtOq47"><ix:continuation id="ConU000054-05"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p id="xdx_98D_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20250101__20251231_gBFCRROMTB-SYRV_zZZtfXsyRB1k" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" continuedAt="ConU000062-01" escape="true" id="Fact000062" name="cyd:CybersecurityRiskRoleOfManagementTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Governance </b></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_C09_gBFCRROMTB-SYRV_zD2UkNJt4S9g"><ix:continuation continuedAt="ConU000062-02" id="ConU000062-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C0C_gBFCRROMTB-SYRV_zEgKTtr2lFgc"><ix:continuation id="ConU000062-02"><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity
is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zRtHrDPYdBW6" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000063" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The
Board, in coordination with the Audit Committee, oversees the Company&#8217;s enterprise risk management process, including the management
of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party
cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management&#8217;s processes
to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes.</ix:nonNumeric></span> The Audit
Committee periodically provides updates on these matters to the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including
an independent third-party expert we have retained to identify and assess material risks from cybersecurity threats, their severity,
and potential mitigation steps. <span id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zfQOOwY64LW" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000064" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">The <span id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zt0tw5FZIhHh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000065" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">CISO</ix:nonNumeric></span> is primarily responsible for leading our cybersecurity risk assessment and management processes.
Our executive staff, supported by external IT, currently serves as our CISO. The CISO regularly reviews and assesses cybersecurity initiatives,
including our incident response plan, as well as cybersecurity compliance, training, and risk management efforts.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div></ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_003"></span>ITEM
2 - PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters is located at 4475 Executive Drive, Suite 200, San Diego, California, 92121 where we lease approximately 6,221
square feet of lab space and 8,977 square feet of office space, under a lease that expires in February 2027. Our main telephone number
is (858) 794-9600. For the year ended December 31, 2025, our base rent was approximately $0.1 million per month plus a management fee
equal to 3.0% of base rent. Base monthly rent will increase annually by 3.0%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">StemVac
GmbH, our wholly-owned subsidiary based in Bernried, Germany, operates in approximately 4,047 square feet of office space and
laboratory space under a lease that expires in March 2027. For the year ended December 31, 2025, our rent was approximately &#8364;4
thousand (or approximately $4.5 thousand) per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
rent expense was approximately $1.5 million for each of the years ended December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our leased property is in good condition and suitable for the conduct of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_004"></span>ITEM
3 - LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
proceedings </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to litigation and contingencies in the ordinary course of its business, including those related to its business, business
transactions, employee-related matters, and other matters. Other than the matters discussed below, we are not currently party to any
other material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Former
Chief Accounting Officer and Interim Chief Financial Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 15, 2023, Tony Kalajian, the Company&#8217;s prior Chief Accounting Officer and interim Chief Financial Officer, filed a complaint
in the Superior Court of the State of California County of San Diego against the Company, Mr. Camaisa, the Company&#8217;s director and
former Chief Executive Officer, and Ms. Pizarro, the Company&#8217;s former Chief Corporate Development Officer and Chief Legal Officer,
alleging defamation and constructive discharge of Mr. Kalajian&#8217;s position of Chief Accounting Officer and interim Chief Financial
Officer (Case No. 37-2023-00049813-CU-DF-CTL) (the &#8220;Primary Case&#8221;). Mr. Kalajian is seeking an unspecified amount in damages
under his employment contract, damages to be proven at trial, punitive damages, and attorney&#8217;s fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company initiated arbitration proceedings against Mr. Kalajian for breach of fiduciary duty, constructive fraud,
conversation, and declaratory relief (the &#8220;Kalajian Arbitration&#8221;), seeking to recover from Mr. Kalajian bonuses Mr. Kalajian
caused to be paid to himself, Hazel Sanchez, the former Controller, and his accounting team. The bonuses (the &#8220;Accounting Bonuses&#8221;)
were not authorized by the Company&#8217;s Board of Directors or Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2023, Hazel Sanchez, the Company&#8217;s prior Controller, filed a complaint in the Superior Court of the State of California
County of San Diego against the Company, Mr. Camaisa, and Ms. Pizarro, alleging defamation, constructive discharge, violation of California
Family Rights Act, and wrongful discharge. Ms. Sanchez is seeking an unspecified amount in damages under her employment contract, damages
to be proven at trial, punitive damages, and attorney&#8217;s fees (the &#8220;Sanchez Case&#8221;). In February 2024, the Company filed
a Cross-Complaint against Ms. Sanchez for breach of fiduciary duty, constructive fraud, conversation, and declaratory relief seeking
to recover the Accounting Bonuses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, Mr. Kalajian also filed a Petition for Writ of Mandate in the Superior Court of California, County of San Diego, seeking
to compel the production of certain corporate records from the Company. This case was voluntarily dismissed in March 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2024, Mr. Kalajian filed a complaint in the Superior Court of the State of California, County of San Diego against the Company
alleging intentional conversion and violation of Section 158 of the Delaware General Corporations Code (the &#8220;Conversion Case&#8221;)
due to the Company&#8217;s failure to remove a restrictive legend from 1,162 shares of the Company&#8217;s Common Stock. Mr. Kalajian
is seeking compensatory damages to be proven at trial, punitive damages and attorney&#8217;s fees, and an order requiring removal of
the restrictive legend from his share certificates. The Company intends to vigorously defend itself. This case is deemed related to and
consolidated with the Primary Case above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Primary Case, Kalajian Arbitration, Sanchez Case, and Conversion Case were deemed related and ultimately consolidated. A trial date has
been set for November 6, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Former
Executive Assistant</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, the Company filed a lawsuit in San Diego Superior Court against a former executive assistant alleging breach of fiduciary
duty to the Company, constructive fraud, conversion, and misappropriation and improper disclosure of confidential and proprietary information
in violation of her proprietary information and inventions agreement, non-disclosure agreement, and severance agreement with the Company
(Case No. 25CU034887C). The Company is seeking injunctive relief and damages. The case is in its early stages, and the outcome is uncertain.
Management does not currently expect this matter to have a material adverse effect on the Company&#8217;s financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Securities
Matter</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 29, 2024, Mr. Yian Zeng filed a complaint against the Company related to securities fraud under California Corporations Code
&#167;25401, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and
constructive fraud in the US District Court, Southern District of California (Case Number 3:24-cv-02026-H-KSC). The Company
vigorously opposes this case and categorically denies all claims. On April 9, 2025 and January 21, 2026, the parties engaged in
mandatory settlement conferences which resulted in no resolution of the case. Discovery has been completed. A final pre-trial
conference has been set for October 19, 2026, but no trial date has been set. At this time, the Company is unable to evaluate the
outcome of this case or estimate the amount or range of potential loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_005"></span>ITEM
4 - MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sp_006"></span><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_007"></span>ITEM
5 - MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock are listed on the NYSE under the symbol &#8220;CLDI&#8221;. Prior to the Business Combination, FLAG&#8217;s Units, Class
A Common Stock and Public Warrants were listed on the NYSE American under the symbols &#8220;FLAGU,&#8221; &#8220;FLAG&#8221; and &#8220;FLAGW,&#8221; respectively. On March 20, 2026 the closing price of our common
stock was $0.28 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of March 20, 2026,
there were 10,895,725 shares of common stock issued and outstanding, which excludes 150,000 shares of non-voting common stock held in escrow,
held by approximately 221 holders of record and 95,834 Public Warrants outstanding held by one <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holder
of record. Such numbers do not include beneficial owners holding the Company&#8217;s securities through nominee names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any cash dividends on our common stock to date. We currently intend to retain any future earnings and do not expect to
pay any dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of the
Board, subject to applicable laws, and will depend on a number of factors, including our financial condition, results of operations,
capital requirements, contractual restrictions, general business conditions and other factors that the Board may deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchases
of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides certain information with respect to our equity compensation plans in effect as of December 31 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities to be</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>issued upon</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>exercise of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options and rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>average exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>price of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>options and rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>available for</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>future issuance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>under equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>plans (excluding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>reflected in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>column (a)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by shareholders<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">43,425</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">276.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by shareholders<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,497</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by shareholders<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by shareholders<sup>(4)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60,534</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">5.63</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,822</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,312</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares of common stock to be issued upon exercise of outstanding options granted under the 2019 Equity Incentive Plan of Calidi (the
    &#8220;2019 Plan&#8221;), which options were assumed by us in connection with the Business Combination. </span></td></tr>
</table>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
shares of common stock to be issued upon exercise of outstanding options and restricted stock units under the 2023 Equity Incentive Plan
(the &#8220;2023 Plan&#8221;) which was approved by our shareholders on August 28, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the number of shares of common stock reserved as authorized for the grant of options under the Employee Stock Purchase Plan (the
    &#8220;2023 ESPP&#8221;), which was approved by our shareholders on August 28, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents shares of common stock to be issued upon exercise of outstanding options granted as inducement awards
in accordance with Section 711 of NYSE American LLC Company Guide.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_008"></span>ITEM
6 - RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="sp_009"></span>ITEM
7 - MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited
consolidated financial statements and related notes thereto included elsewhere in this Annual Report on Form 10-K for the period ended
December 31, 2025 (this &#8220;Annual Report&#8221;). The following discussion and analysis of our financial condition and results of
operations contains forward-looking statements that involve a number of risks, uncertainties and assumptions. Actual events or results
may differ materially from our expectations. Important factors that could cause actual results to differ materially from those stated
or implied by our forward-looking statements include, but are not limited to, those set forth in the &#8220;Risk Factors&#8221; section
of this annual report, many of which are outside of our control. All forward-looking statements included in this annual report are based
on information available to us as of the time we file and, except as required by law, we undertake no obligation to update publicly or
revise any forward-looking statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to
deliver genetic medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus
designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from
immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to
metastatic locations. We expect to file an IND for a Phase I trial by the
end of 2026 with CLD-401, the first compound from the RedTail platform, delivering IL-15 superagonist to the tumor microenvironment
(&#8220;TME&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
RedTail platform is the culmination of over a decade of work around genetic engineering of viruses and allows for the systemic administration
of a proprietarily-modified oncolytic virus that can:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survive
    in circulation and home to metastatic tumor sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Only replicates in tumor cells;</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induce
    immuogenic kill in tumor cells and immune priming in the TME; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliver
    genetic medicine payloads like IL-15 superagonist for expression in the TME.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legacy SuperNova and NeuroNova platforms are designed to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protect
    oncolytic viruses from neutralizing antibodies and complement inactivation and innate immune cell inactivation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhance
    oncolytic viral amplification inside the allogeneic cells; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modify
    the TME to allow improvements in cell targeting and viral amplification at the tumor site.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncolytic
viruses have been pursued as therapeutic platforms in oncology because of their ability to preferentially infect and replicate within
cancer cells, resulting in both direct lysis of the tumor cells as well as activation of an antitumor immune response, while leaving
normal, healthy cells unharmed. Despite the promises of oncolytic viruses, a major obstacle against their therapeutic use has been their
rapid elimination by the patient&#8217;s immune system; this has meant that oncolytic viruses have been largely relegated to being used
for local delivery to tumors but have not been successful in patients with extensive metastatic disease. The only approved oncolytic
virus therapy is T-VEC (Imlygic&#174;), a modified herpes simplex virus (HSV) for the treatment of patients with melanoma given intratumorally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been working on protecting oncolytic viruses from immune clearance for over a decade. Our NeuroNova investigational drug candidate
is currently in a Phase 1 trial being run and funded by our partner, City of Hope, in an investigator-initiated trial and we have an
open IND for a Phase 1 trial for our SuperNova investigational drug candidate (CLD-201). In July 2025 we were granted Fast Track Designation
to CLD-201 by the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcoma. The platforms used
in NeuroNova and SuperNova use oncolytic viruses embedded in stem cells to avoid immune clearance and facilitate initial viral amplification
and expansion at the tumor sites. This approach has shown substantial benefit over unprotected virus in preclinical studies of intratumoral
delivery, but stem cell encapsulation does not allow for systemic delivery of virus to tumor metastases in animal models. The size of
the stem cells prohibited efficient dissemination into metastatic sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, we used the learnings from NeuroNova and SuperNova to create RedTail, a novel oncolytic viral platform for systemic delivery.
The virus used in RedTail has been proprietarily engineered to avoid immune clearance and to specifically replicate in tumor tissue where
the virus also has the ability to deliver genetic medicines to the tumor microenvironment. RedTail utilizes a proprietary form of enveloped
virus with genetic modifications, including engineered expression of CD55 on the enveloped virus, to avoid immune clearance. Because
the virus is not encapsulated in stem cells, it is thousands of times smaller than the NeuroNova or SuperNova products and disseminates
efficiently into metastatic sites in syngeneic animal models. In addition, the virus can be engineered to express genetic medicines while
replicating in the tumor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">CLD-401, the first lead derived
from the RedTail platform. CLD-401 is enveloped and overexpressed CD55 on its outer membrane. It is tropic for tumor cells and, when replicating,
expresses IL-15 superagonist at high concentrations in the tumor microenvironment. In animal models, CLD-401 can be given systemically
and clear metastatic sites in syngeneic tumor mouse models with demonstrated enhanced biological efficacy. The combination of the RedTail
virus with its genetic payload drives complete tumor eradication in the tumor models compared to the RedTail virus alone. We believe that
RedTail, given its systemic administration and targeting to metastatic sites and its delivery of genetic medicines, represents a major
advancement in the space of oncolytic virus in oncology. The company is developing additional leads from the RedTail platform including
compounds that simultaneously express a bispecific T-cell engager (TCE) and a T-cell activator as well as compounds for use outside of
oncology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, our operations have focused on organizing and staffing our company, business planning, raising capital, acquiring and developing
our technology, establishing our intellectual property portfolio, identifying potential product candidates and undertaking preclinical
studies and manufacturing. We do not have any products approved for sale and have not generated any revenue from product sales. We have
funded our operations primarily through private sales of common stock, warrants, convertible promissory notes, term debt, and the issuance
of publicly traded securities. These investments have included and have been made by various related parties, including our former chief
executive officer and former chairman of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have incurred significant operating losses. Our net loss was $20.1 million for the year ended December 31, 2025. As of
December 31, 2025, we had an accumulated deficit of $141.6 million. We expect to continue to incur significant and increasing expenses
and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical
development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain
and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in economic conditions, including rising interest rates, public health issues, lower consumer confidence, volatile equity capital markets,
tariffs, ongoing supply chain disruptions, and the impacts of geopolitical conflicts, may also affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval
for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party
commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support
product sales, marketing, manufacturing and distribution activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can
generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private
equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances, and licensing
arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable
terms, or at all. Our inability to raise capital or enter into such agreements as, and when needed, could have a material adverse effect
on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our operating plan, we believe we do not have sufficient cash on hand to support current operations for at least one year from the
date of issuance of our consolidated financial statements as of and for the year ended December 31, 2025. We have concluded that this
circumstance raises substantial doubt about our ability to continue as a going concern. See Note 1 to our audited consolidated financial
statements. In addition, we will be required to raise additional capital through the issuance of our equity securities to support our
operations which will have an ownership and economic dilutive effect to our current shareholders who purchased their shares of common
stock at prices above our current trading price, and such capital raising may adversely affect the price of our common stock. Further,
the sale of or the perception of a sale of a substantial number of our common stock by certain selling securityholders pursuant to another
registration statement filed with the SEC will adversely affect the price of our common stock due to our limited trading volume, adversely
affect the share price that we may obtain in future financings, and may adversely affect our ability to conduct and complete future financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional discussion on our liquidity, see the section below and further disclosures in the section titled <i>&#8220;Liquidity and Capital
Resources&#8221; </i>included herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 9, 2025, we entered into an inducement offer letter agreement (the &#8220;Warrant Inducement Offer&#8221;) with seven holders of
our existing Series A warrants, Series B-1 warrants, Series C-1 warrants, Series D warrants, Series E warrants, and Series F warrants
(together the &#8220;Existing Warrants&#8221;). Pursuant to the Warrant Inducement Offer, such warrant holders immediately exercised
some or all of their respective outstanding Existing Warrants at a reduced exercise price, to purchase an aggregate of 549,596 shares
of our common stock. The gross proceeds from the exercise of the induced warrants were $4.6 million, prior to deducting placement agent
fees and offering expenses. In consideration for the immediate exercise of some or all of the Existing Warrants for cash, we issued unregistered
new Series H common stock warrants (&#8220;Series H Warrants&#8221;) to purchase up to 549,587 shares of common stock. We filed a resale
registration statement on Form S-3 (File No. 333-288784), to register the shares underlying the Series H Warrants, which registration
statement was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 25, 2025. The Warrant Inducement
Offer closed on July 10, 2025. For additional discussion of this Warrant Inducement Offer, see the section below and further disclosures
in the section titled <i>&#8220;Liquidity and Capital Resources &#8211; Financing Activities&#8221; </i>included herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2025, the Compensation Committee of Calidi approved the elimination of the position of President, Medical and Scientific Affairs,
held by Dr. Boris Minev. As a result, Dr. Minev ceased to serve as an executive officer and a Section 16 officer of Calidi, effective
July 29, 2025. On August 8, 2025, we executed a General Release of Claims and Separation Agreement with Dr. Minev effective on August
15, 2025. Pursuant to the terms of the Agreement, we are obligated to pay Dr. Minev, (i) $0.1 million in relation to a negotiated bonus
for the NNV1 and SNV1 IND approvals within 10 days following the Revocation Period (which is seven business days from August 8, 2025,
and excluding such date), and (ii) $0.2 million separation pay in the form of compensation continuation over six months pursuant to our
regular and customary payroll schedule, less all regular and customary payroll withholdings and shall pay Dr. Minev&#8217;s COBRA premiums
for six months, commencing August 2025, upon timely election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2025, we entered into an underwriting agreement with Ladenburg Thalmann &amp; Co. Inc., as representative of the various underwriters,
in connection with the issuance and public sale offering of various securities (the &#8220;August Public Offering&#8221;), including:
(i) 1,922,764 common stock units (&#8220;Common Stock Unit&#8221;), which includes the 450,000 Common Stock Units purchased pursuant
to the exercise, in full, of the Over-Allotment Option and (ii) 1,528,000 pre-funded warrant units, resulting in gross proceeds of approximately
$6.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The August Public Offering
closed on August 21, 2025. For additional discussion of this Warrant Inducement Offer, see the section below and further disclosures
in the section titled &#8220;<i>Liquidity and Capital Resources &#8211; Financing Activities</i>&#8221; included herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 16, 2025, the Board approved the elimination of the position of Chief Legal Officer and, as a result, the termination of the
employment agreement with Ms. Wendy Pizarro Campbell (the &#8220;Employment Agreement&#8221;), effective as of October 17, 2025 (&#8220;Effective
Date&#8221;). Per the terms of the Employment Agreement, Ms. Campbell was given a 30-day written notice of termination. On the Effective
Date, and as a result of the termination of the Employment Agreement, Ms. Campbell ceased to serve as an executive officer and Section
16 officer of Calidi. On September 17, 2025, we executed a General Release of Claims and Separation Agreement (&#8220;Agreement&#8221;)
with Ms. Campbell effective on September 24, 2025 (the &#8220;Effective Date&#8221;). Pursuant to the terms of the Agreement, on the
Effective Date, we are obligated to pay i) a bonus in the amount of $0.1 million, upon the successful and effective corporate spin-off,
out-licensing, or similar transaction relating to Nova Cell, Inc. (&#8220;Nova Cell&#8221;) prior to October 31, 2025, and (ii) $0.2 million severance pay in the form
of compensation continuation over six months pursuant to our regular and customary payroll schedule, less all regular and customary payroll
withholdings and shall pay Ms. Campbell&#8217;s COBRA premiums for six months, commencing October 2025, upon timely election. As of December
31, 2025, we paid the bonus of $0.1 million in connection with the sale of the investment in Nova Cell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2025, we entered into a Stock Repurchase Agreement (the &#8220;SRA&#8221;) and Material Purchase Agreement (the
&#8220;MPA&#8221; and together with the SRA the &#8220;Agreements&#8221;), with, a then majority owned subsidiary, Nova Cell. In
accordance with the Agreements, we sold and transferred all 22,500,000 of our shares of common stock in Nova Cell (the
&#8220;Repurchased Shares&#8221;), representing an ownership interest of 75%, back to Nova Cell, for a purchase price of $6.0
million (the &#8220;Purchase Price&#8221;). The Purchase Price for the Repurchased Shares was or shall be satisfied (A) in part by
cancellation of indebtedness under the September 17, 2024, promissory note, net of specified offsets (including a $50 thousand cash
offset), resulting in an Indebtedness Cancellation Amount of $1.2 million, and (B) the balance, by Deferred Consideration of $4.8
million payable after closing, as more fully described in the SRA. As of December 31, 2025, no Deferred Consideration has been
recognized, and the full amount remains constrained until underlying uncertainties are resolved. After the Deferred Consideration is
fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or
derivative of the materials listed on Schedule A to the MPA ending on the tenth anniversary of Nova Cell&#8217;s first product sale.
Furthermore, as part of the Agreements, we sold and transferred certain materials to Nova Cell as listed on Schedule 1 to the MPA.
Following the closing of the Agreements, Nova Cell is no longer our subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2025, we presented new data on our first therapeutic candidate from our RedTail platform, CLD-401, at the Society of Immunotherapy
for Cancer (&#8220;SITC&#8221;) Annual Meeting.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2026, the Company entered into an Amendment to Common Stock Purchase Warrants Agreement (the &#8220;Warrant Amendment&#8221;)
with certain investors that participated in the March Offering described below, in connection with the terms of certain of the Company&#8217;s
outstanding common warrants to purchase shares of Common Stock (the &#8220;Existing Warrants&#8221;). As originally issued, the Existing
Warrants provided for the purchase of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">504,417
                                            shares of common stock, on exercise of the series G common stock warrants at an exercise
                                            price of $8.3448 per share;</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279,168
                                            shares of common stock, on exercise of the series H common stock warrants at an exercise
                                            price of $8.40 per share; and</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,000
                                            shares of common stock, on exercise of the series I common stock warrants at an exercise
                                            price of $2.00 per share.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the Warrant Amendment, the exercise price for each of such Existing Warrants was reduced to $0.50 per share, subject to further adjustment
as set forth in the Existing Warrants and any other document governing the terms thereunder. All other terms and conditions of the Existing
Warrants remain unchanged and in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, we entered into an Underwriting Agreement with the Underwriter, in connection with the Offering of: (i) 2,278,731 Common
Stock Units, which includes 1,575,000 Common Stock Units purchased pursuant to the exercise, in full, of the Over-Allotment Option, sold
to the public at a price of $0.50 per Common Stock Unit, and (ii) 9,815,900 pre-funded warrant units Pre-Funded Units, sold to the public
at a price of $0.499 per Pre-Funded Unit, resulting in gross proceeds of approximately $6.0 million, before deducting underwriting discounts
and commissions and other estimated offering expenses. For more details in relation to the Offering, see <i>&#8220;Financing and Financing-Related
Transactions Subsequent to December 31, 2025&#8221; </i>below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Operating Results</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate
discovery efforts, preclinical studies and clinical trials under our research programs, which include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel
    and related expenses, including salaries, benefits and stock-based compensation expense for our research and development personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of funding research performed by third parties that conduct research and development and preclinical and clinical activities on our
    behalf;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of manufacturing drug product and drug supply related to our current or future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of conducting preclinical studies and clinical trials of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    and professional fees related to research and development activities, including equity-based compensation to non-employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of maintaining our laboratory, including purchasing laboratory supplies and non-capital equipment used in our preclinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with clinical regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility
    costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other
    supplies; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    for maintaining licenses and other amounts due under our third-party licensing agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to
completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical
and clinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances
at the end of any reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
track external research and development costs on a program-by-program basis beginning, with respect to each program, upon our
internal nomination of a candidate in that program for further preclinical and clinical development. External costs include fees
paid to consultants, contractors and vendors, including contract development and manufacturing organizations (&#8220;CDMOs&#8221;),
and clinical research organizations (&#8220;CROs&#8221;), in connection with our preclinical, clinical and manufacturing activities
and license milestone payments related to candidate development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development of our product candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing, and estimated
costs of the efforts that will be necessary to complete development of our current or future product candidates. We are also unable to
predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if they are approved. This is
due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies and clinical trials and
    other research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an appropriate safety profile;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    enrollment in and completion of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    our product candidates show safety and efficacy in our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of marketing approvals from applicable regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercializing
    product candidates, if and when approved, whether alone or in collaboration with others; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued
    acceptable safety profile of the products following any regulatory approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly
change the costs and timing associated with the development of those product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials. We expect research and development costs to increase significantly for the foreseeable future as we commence clinical
trials and continue the development of our current and future product candidates. However, we do not believe that it is possible at this
time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization
of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined
with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control
will impact our clinical development programs and plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses include salaries and other compensation-related costs, including stock-based compensation, for personnel
in executive, finance and accounting, operations, and administrative roles. Other significant costs include professional
service and consulting fees including legal fees relating to intellectual property and corporate matters, accounting fees, and costs for consultants utilized to supplement our personnel, insurance costs, travel costs, facility and office-related costs
not included in research and development expenses and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as our business expands to support expected growth
in research and development activities, including our future clinical programs. These increases will likely include increased costs related
to the hiring of additional personnel and fees to outside service providers, among other expenses. We also anticipate continued expenses
associated with being a public company, including costs for audit, legal, regulatory and tax-related services related to compliance with
the rules and regulations of the SEC, and listing standards applicable to companies listed on a national securities exchange, director
and officer insurance premiums, and investor relations costs. In addition, if we obtain regulatory approval for any of our product candidates
and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales
and marketing team to support product sales, marketing and distribution activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (Expenses), Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expenses), net, primarily includes the changes in fair value of warrants and derivatives. The changes in the fair value of these
instruments are recorded in change in fair value of other liabilities and derivatives, and change in fair value of other liabilities,
and derivatives &#8211; related party, included as a component of other income (expense), net, in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense primarily consists of amortization of discounts on term notes, including from related parties, and other interest expense incurred
from financing leases and other obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income also includes grant income generated from a grant awarded to us by the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;)
in December 2022. Proceeds from the CIRM grant are recognized over the period necessary to match the related research and development
expenses when it is probable that we have complied with the CIRM conditions and will receive the proceeds pursuant to the milestones
defined in the grant as reimbursement of those expenditures. Any CIRM grant proceeds received in advance of having incurred the related
research and development expenses are recorded in accrued expenses and other current liabilities and recognized as grant income in our
consolidated statements of operations when the related research and developments expenses are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Provision</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have incurred net operating losses primarily for U.S. federal and state income tax purposes and have not reflected any
benefit of such net operating loss carryforwards for any periods presented in this Form 10-K. The income tax provision in the
periods presented is entirely attributable to amounts recorded from StemVac, GmbH operations, our wholly-owned German subsidiary
that provides research and development services to us under a cost-plus development agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of Year Ended December 31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our results of operations for the year ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and
    development</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,737</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,878</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(859</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,503</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(12,898</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,395</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total operating expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,240</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21,776</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,536</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss from operations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,240</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21,776</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,536</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense), net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total other income (expenses),
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(419</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">611</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before income taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,048</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(22,195</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,147</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Income tax provision</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(20,063</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(22,209</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses for the year ended December 31, 2025, and 2024 were $9.7 million and $8.9 million, respectively. The $0.8 million
increase was primarily attributable to increases in consulting costs of $0.5 million, rent expenses of $0.3 million, drug manufacturing
and preclinical expenses of $0.2 million, and office expenses of $0.2 million, partially offset by decrease in salaries and benefits
of $0.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for the year ended December 31, 2025 and 2024 were $10.5 million and $12.9 million, respectively. The $2.4
million decrease was primarily due to decreases in insurance costs of $0.7 million, legal expenses of $0.6 million, salaries and benefits
of $0.3 million, accounting expenses of $0.3 million, public company expenses of $0.2 million, investor relations expenses of $0.2 million,
and rent expenses of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income (Expense), Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income (expense), net for the year ended December 31, 2025 and 2024 were $0.2 million other income and $0.4 million other expense,
respectively. The $0.6 million decrease in net expenses primarily relates to a decrease in interest expense of $0.7 million,
increase in other income of $0.2 million, primarily related to the gain on sale of our investment in Nova Cell, partially offset by
a net change in fair value of other liabilities and derivatives of $0.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S<i>ources
of Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have funded our operations primarily through private sales of common stock, warrants, promissory notes, term debt, and
the issuance of publicly traded securities. Certain of these investments were with various related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, we had a cash balance of $5.6 million and restricted cash of $0.2 million. Our debt and liability obligations as
of December 31, 2025 include $2.4 million in accounts payable and accrued expenses and other current liabilities, including related party
amounts, $1.7 million in operating lease liabilities, $0.6 million in promissory notes, $0.3 million in finance lease liabilities, and
$0.1 million in warrant liabilities, including related party amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to continue as a going concern is dependent upon our ability to raise additional funding. We plan to raise additional capital
through public or private equity or debt financings to fulfill our operating and capital requirements for at least 12 months from the
date of the issuance of the financial statements. However, we may not be able to secure such financing in a timely manner or on favorable
terms, if at all. Thus, we estimate that based on our current liquidity resources, there is substantial doubt about our ability to continue
as a going concern within 12 months from the date of issuance of these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financing
and Financing-Related Transactions Subsequent to December 31, 2025</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><i>March 2026 Confidentially
Marketed Public Offering (CMPO)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, we entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co.
Inc., as sole underwriter (&#8220;Underwriter&#8221;), in connection with the issuance and sale (the &#8220;Offering&#8221;) of: (i)
2,278,731 common stock units (&#8220;Common Stock Units&#8221;), which includes 1,575,000 Common Stock Units purchased pursuant to the
exercise, in full, of the Over-Allotment Option, sold to the public at a price of $0.50 per Common Stock Unit, and (ii) 9,815,900 pre-funded
warrant units (&#8220;Pre-Funded Units&#8221;), sold to the public at a price of $0.499 per Pre-Funded Unit, resulting in gross proceeds
of approximately $6.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection
with the Offering, we also issued to the Underwriter (or its designees) a warrant (the &#8220;Underwriter&#8217;s Warrant&#8221;) to
purchase up to 604,732 shares of Common Stock of Calidi, par value $0.0001. The Underwriter&#8217;s Warrant has an exercise price of
$0.625, is exercisable on or after the date of issuance, and will expire on March 9, 2031.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consisted of (i) one share of Common Stock, (ii) one Series J common stock warrant (&#8220;Series J Warrants&#8221;)
to purchase one share of Common Stock (or pre-funded warrants to purchase one share of Common Stock in lieu thereof), (iii) one Series
K common stock warrant (&#8220;Series K Warrants&#8221;) to purchase one share of Common Stock (or pre-funded warrants to purchase one
share of Common Stock in lieu thereof), and (iv) one Series L common stock warrant (&#8220;Series L Warrants&#8221; and together with
the Series J Warrants and the Series K Warrants, the &#8220;Common Warrants&#8221;) to purchase one share of Common Stock (or pre-funded
warrants to purchase one share of Common Stock in lieu thereof). Each Pre-Funded Unit consisted of (i) one pre-funded warrant (the &#8220;Pre-Funded
Warrants&#8221;), (ii) one Series J Warrant, (iii) one Series K Warrant, and (iv) one Series L Warrant. The Common Warrants included
in the Pre-Funded Units are identical to the Common Warrants included in the Common Stock Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series J Warrants have an initial exercise price of $0.50 per share. The Series J Warrants are exercisable immediately, subject to certain
limitations described herein. The Series J Warrants expire five (5) years from the date of issuance. The Series K Warrants have an initial
exercise price of $0.50 per share. The Series K Warrants are exercisable immediately, subject to certain limitations described herein.
The Series K Warrants will expire one (1) year from the date of issuance. The Series L Warrants have an initial exercise price of $0.50
per share. The Series L Warrants are exercisable immediately, subject to certain limitations described herein. The Series L Warrants
expire six (6) months from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units, the Pre-Funded Units, the shares of Common Stock comprising the Common Stock Units, the Common Warrants, the Pre-Funded
Warrants, the shares of Common Stock issuable upon exercise of the Common Warrants, and the Pre-Funded Warrants were offered by Calidi
pursuant to a shelf registration statement on Form S-3 (File No. 333-284229), that was filed with the Securities Exchange Commission
(&#8220;SEC&#8221;) on January 10, 2025 and declared effective on February 7, 2025, including the prospectus forming a part of the registration
statement, a final prospectus supplement thereto, which was filed with the SEC on March 9, 2026, pursuant to Rule 424(b) under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the related registration statement filed with the SEC on March 5, 2026
under Rule 462(b) of the Securities Act, which became automatically effective upon filing. The Offering closed on March 9, 2026 (the
&#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, we also entered into a warrant agency agreement (the &#8220;Warrant Agency Agreement&#8221;) with Equiniti Trust Company,
LLC, as warrant agent (the &#8220;Warrant Agent&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Since the closing of the Offering,
2,291,000 Pre-Funded Warrants have been exercised.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2026, we entered into an Amendment to Common Stock Purchase Warrants Agreement (the &#8220;Warrant Amendment&#8221;) with certain
investors, that participated in the March 2026 CMPO described above, in connection with the terms of certain of our outstanding
common warrants to purchase shares of Common Stock (the &#8220;Existing Warrants&#8221;). As originally issued, the Existing Warrants
provided for the purchase of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">504,417
    shares of common stock, on exercise of the series G common stock warrants at an exercise price of $8.3448 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279,168
    shares of common stock, on exercise of the series H common stock warrants at an exercise price of $8.40 per share; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,190,000
    shares of common stock, on exercise of the series I common stock warrants at an exercise price of $2.00 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the Warrant Amendment, the exercise price for each of such Existing Warrants was reduced to $0.50 per share, subject to further adjustment
as set forth in the Existing Warrants and any other document governing the terms thereunder. All other terms and conditions of the Existing
Warrants remain unchanged and in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
Obligations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calidi&#8217;s
outstanding debt obligations as of December 31, 2025, are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Promissory
    note</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">90</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">690</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total debt</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">90</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">690</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Less: current portion
    of long-term debt</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(90</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Long-term debt, net
    of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">600</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, Calidi had outstanding warrants to purchase up to 5,026,613 shares of Common Stock, consisting of the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Private Warrants to purchase Common
    Stock</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,938</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Public Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,834</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants to purchase Restricted Shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">53,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Placement Agent Warrants to purchase Common
    Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">256,418</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series A Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">54,308</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series B-1 Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,442</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C-1 Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,253</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series D Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,318</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series G Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">504,417</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series H Warrants to purchase Common Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">549,587</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Series I Warrants to purchase
    Common Stock</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,450,764</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,026,613</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Commitments
and Contingencies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2022, Calidi entered into an Office Lease Agreement (the &#8220;San Diego Lease&#8221;) that serves as Calidi&#8217;s
principal executive and administrative offices and laboratory facility. To secure and execute the San Diego Lease, Mr. Allan J.
Camaisa, former Chief Executive Officer, provided a personal Guaranty of Lease of up to $0.9 million (the &#8220;Guaranty&#8221;) to the lessor for Calidi&#8217;s
future performance under the San Diego Lease agreement. As consideration for the Guaranty, Calidi agreed to pay Mr. Camaisa 10% of
the Guaranty amount for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life
of the lease, with all amounts accrued and payable at the termination of the San Diego Lease or release of Mr. Camaisa from the
Guaranty by the lessor, whichever occurs first. The amount due was partially settled in April 2025. The San Diego Lease has an initial term of 4 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2025, StemVac, GmbH entered into a finance lease agreement for laboratory equipment with an initial term that expires on May 31, 2029,
with total payments of approximately &#8364;0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further entered into separate license agreements with Northwestern University and City of Hope and the University of Chicago, wherein
Calidi may be liable to make certain contingent payments, under certain conditions that are in our control, pursuant to the terms and
conditions of the license agreements. As of December 31, 2025, we do not believe it probable that we will incur these payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
commitments and contingencies include various operating and financing leases for equipment, office facilities, and other property containing
future minimum lease payments totaling $2.1 million and certain manufacturing and other supplier agreements with vendors principally for
manufacturing drug products for clinical trials and continuing the development of the CLD-101, CLD-201, and CLD-401 programs totaling $0.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Related
Party Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see Note 6 to our consolidated financial statements for more information on our related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flow Summary for the Year Ended December 31, 2025 and 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows a summary of our cash flows for the year ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Change</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash (used in) provided by:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(21,293</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(19,694</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,599</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(170</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(154</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">963</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,459</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,906</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Effect of exchange rate
    on cash</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(13</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(208</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Net (decrease) increase
    in cash and restricted cash</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,990</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,642</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,632</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(152</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $21.3 million for the year ended December 31, 2025, primarily resulting from our net loss of $20.1
million. Our net loss was reduced by certain non-cash items that included $2.1 million in stock-based compensation, $1.7 million in depreciation
and amortization expense, partially increased by $4.8 million from the change in our operating assets and liabilities, and $0.2 million
from the gain on the sale of our investment in Nova Cell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $19.7 million for the year ended December 31, 2024, primarily resulting from our net loss of $22.2
million. Our net loss was reduced by certain non-cash items that included $3.0 million in stock-based compensation, $1.5 million in depreciation
and amortization expense, partially increased by $1.7 million from the change in our operating assets and liabilities, and $0.3 million
from the change in fair value of debt and other liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $0.2 million for the year ended December 31, 2025, which primarily related to the purchase of certain
machinery and equipment and cash disposed of in the sale of our investment in Nova Cell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $16,000 for the year ended December 31, 2024, which primarily related to the purchase of certain
machinery and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $17.5 million for the year ended December 31, 2025, which primarily related to proceeds
from public offerings of our securities of $9.9 million, proceeds from July Inducement Offer of $4.1 million, proceeds from the
March Registered Direct Offering and Concurrent Private Placement of $3.5 million , and proceeds of $3.3 million from sales under
our At The Market facility, partially offset by repayment of term notes payable of $2.2 million, including related party amounts,
payment of financing costs of $0.8 million, repayment of bridge loan payable of $0.2 million and repayment of finance lease
obligations of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $27.4 million for the year ended December 31, 2024, which primarily related to proceeds from
the November Public Offering of $6.8 million, proceeds from the April Public Offering of $5.4 million, proceeds from the exercise of
common stock and pre-funded warrants of $4.8 million, proceeds from the At the Market Offering of $3.1 million, proceeds from issuance
of convertible notes payable of $3.0 million, proceeds from the May Inducement Offer of $2.1 million, proceeds from issuance of noncontrolling
interest of $2.0 million, proceeds from the October Public Offering of $1.8 million, proceeds from the issuance of common shares and
warrants per subscription agreement of $1.0 million, proceeds from issuance of promissory note of $0.6 million, and related party proceeds
from issuance of a bridge loan payable of $0.2 million, partially offset by payment of financing costs of $1.5 million, repayment of
convertible notes payable of $1.5 million, repayment of term notes payable of $0.3 million, and repayment of finance lease obligations
of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Funding
Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase in connection with our ongoing activities, particularly as we continue our research and development,
initiate clinical trials, and seek marketing approval for our current and any of our future product candidates. In addition, if we obtain
marketing approval for any of our current or our future product candidates, we expect to incur significant commercialization expenses
related to product sales, marketing, manufacturing and distribution, which costs we may seek to offset through entry into collaboration
agreements with third parties. Furthermore, we expect to continue to incur additional costs associated with operating as a public company.
Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to
raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs
or future commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operating plan, available cash and additional access to capital discussed above under the &#8220;<i>Liquidity and Capital
Resources</i>&#8221; section, we believe we do not have sufficient cash on hand to support current operations for at least one year from
the date of issuance of the consolidated financial statements as of and for the year ended December 31, 2025 appearing elsewhere in this
Form 10-K. To finance our operations, we will need to raise substantial additional capital, which cannot be assured. We have concluded
that this circumstance raises substantial doubt about our ability to continue as a going concern for at least one year from the date
that our consolidated financial statements were issued. See Note 1 to our consolidated financial statements appearing elsewhere in this
Form 10-K for additional information on our assessment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of conducting preclinical studies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of manufacturing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of discovery, preclinical and clinical development, laboratory testing, and clinical trials for
    product candidates we may develop, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, and outcome of regulatory review of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    achievement of milestones or occurrence of other developments that trigger payments under any license or collaboration agreements
    we might have at such time;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for
    any of our product candidates for which we receive marketing approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive
    marketing approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights,
    and defending intellectual property-related claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    headcount growth and associated costs as we expand our business operations and research and development activities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of operating as a public company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing cash will not be sufficient to complete development of our current product candidates. Accordingly, we will be required to obtain
further funding to achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of public
or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and
licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership
interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect
the rights as a common stockholder. Additional debt financing, if available, may involve agreements that include restrictive covenants
that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends,
that could adversely impact our ability to conduct our business. If we raise funds through potential collaborations, strategic alliances
or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams,
research programs or product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional
funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which
have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation
of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the balance sheet and the reported amounts
of expenses during the reporting period. Our estimates are based on historical trends and other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies and estimates are described in more detail in Note 2 to the consolidated financial statements as of and
for the year ended December 31, 2025 and 2024 appearing elsewhere in this Annual Report on Form 10-K. We determined that none of our significant accounting policies and estimates are deemed to be critical accounting estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into agreements in the normal course of business with vendors for preclinical and clinical studies, preclinical and clinical supply
and manufacturing services, professional consultants for expert advice, and other vendors for other services for operating purposes.
We have certain manufacturing and other supplier agreements with vendors principally for manufacturing drug products for clinical trials
and continuing the development of our product candidates totaling $0.5 million in future purchase commitments. However,
these contracts do not contain any minimum purchase commitments and are cancellable at any time by us, generally upon 30 days prior written
notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have entered into license and royalty agreements for intellectual property with certain parties. Such arrangements require
ongoing payments, including payments upon achieving certain development, regulatory and commercial milestones, receipt of sublicense
income, as well as royalties on commercial sales. Payments under these arrangements are expensed as incurred and are recorded as research
and development expenses. We may pay amounts under such agreements at the time of execution or annual fees. We have not paid any royalties
under these agreements to date. We have not included the annual license fee payments contractual obligations because the license agreements
are cancelable by us and therefore, we believe that our non-cancelable obligations under these agreements are not material. We have not
included potential royalties or milestone obligations because they are contingent upon the occurrence of future events and the timing
and likelihood of such potential obligations are not known with certainty. For further information regarding these agreements and amounts
that could become payable in the future under these agreements, please see the sub-section entitled &#8220;License Agreements&#8221;
within the &#8220;Item 1. Business&#8221; section herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quantitative
and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in interest rates because we do not have any cash equivalents
or interest-bearing investments at this time. Our debt typically contains a fixed interest rate or is issued to certain lenders, including
related party lenders, with other equity instruments, such as warrants, in lieu of a stated cash interest rate. We currently do not have
debt with an interest rate that is variable and fluctuates with changes in interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have employees
and are contracted with and may continue to contract with foreign vendors that are located in Europe, particularly in Germany, where
we operate through our wholly-owned subsidiary, StemVac GmbH. In October 2022, we also formed Calidi Biotherapeutics Australia Pty Ltd,
a wholly-owned subsidiary in Australia, for purposes of operating in that country for a portion of our planned clinical trial activities
for our SNV1 program. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the year ended December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company and Smaller Reporting Company Status</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; (&#8220;EGC&#8221;), under the Jumpstart Our Business Startups Act of 2012, (the &#8220;JOBS
Act&#8221;). Section 107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section
7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of the delayed
adoption of new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting
standards as private entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an EGC, we may also take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions,
as an EGC:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are presenting only two years of audited financial statements and only two years of related Management&#8217;s Discussion and Analysis
    of Financial Condition and Results of Operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    will avail ourselves of the exemption from providing an auditor&#8217;s attestation report on our internal control over financial
    reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    will avail ourselves of the exemption from complying with any requirement that may be adopted by the Public Company Accounting Oversight
    Board (&#8220;PCAOB&#8221;), regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional
    information about the audit and the financial statements, known as the auditor discussion and analysis;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are providing reduced disclosure about our executive compensation arrangements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    will not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an EGC until the earliest of (i) December 31, 2026, (ii) the last day of the fiscal year in which we have total annual gross
revenues of $1.235 billion or more, (iii) the date on which we have issued more than $1 billion in non-convertible debt during the previous
rolling three-year period, or (iv) the date on which we are deemed to be a large accelerated filer under the Securities Exchange Act
of 1934, as amended, (the &#8220;Exchange Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates plus the proposed
aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than
$100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if
either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100
million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a smaller reporting company at the time we cease to be an EGC, we may continue to rely on exemptions from certain disclosure requirements
that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two
most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to EGCs, smaller reporting companies
have reduced disclosure obligations regarding executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Form 10-K, we do not expect that any
recently issued accounting standards will have a material impact on our financial statements or will otherwise apply to our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_018"></span>ITEM
7A - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required
under this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_019"></span>ITEM
8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this item begin on page F-1 with the index to financial statements followed by the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_020"></span>ITEM
9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_021"></span>ITEM
9A - CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered
by this report. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company
in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange
Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes
that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving
their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were
effective at the reasonable assurance level as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company&#8217;s
internal control over financial reporting is a process designed under the supervision of the Company&#8217;s principal executive officer
and principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of the Company&#8217;s financial statements for external purposes in accordance with generally accepted accounting principles. Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. All internal control
systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide
only reasonable assurances with respect to financial statement preparation and presentation. Additionally, projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision of management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the
effectiveness of our internal control over financial reporting based on the framework in Internal Control - Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and subsequent guidance prepared by the Commission
specifically for smaller public companies as of December 31, 2025. Based on such evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include an attestation report of the Company&#8217;s independent registered public accounting firm
regarding the effectiveness of the Company&#8217;s internal control over financial reporting, as such report is not required due to the
Company&#8217;s status as a smaller reporting company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no changes in the Company&#8217;s internal controls over financial reporting during the fiscal quarter ended December 31, 2025,
that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_008"></span>ITEM
9B - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--NoInsiderTradingFlag_dbT_c20250101__20251231_zNqEWh34E7l8" title="No Insider Trading Flag" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt:booleantrue" id="Fact000067" name="CLDI:NoInsiderTradingFlag">None</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_009"></span>ITEM
9C - DISCLOSURE REGARDING FOREIGN JURISDICTION THAT PREVENTS INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_011"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_010"></span>ITEM
10 - DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers and Directors </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company is managed by or under the direction of its board of directors. The following table sets forth certain information regarding
our current executive officers and directors, as well as their respective ages, as of March 20, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Poma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Jackson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">Antonio F. Santidrian</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">48</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chief Scientific Officer and Head of Technical Operations</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">Allan J. Camaisa</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">66</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0">Director</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    R. Stewart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director<sup>(1)(3)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
    Leftwich</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director<sup>(2)(3)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    A. Schoeneck</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairman of the Board<sup>(1)(2)(3)</sup></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    E. Peoples</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director<sup>(2)</sup></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Member of audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Member of the compensation committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Member of the nomination and corporate governance committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the biographies of our directors and executive officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eric Poma, Ph.D. </b>Dr. Poma was appointed as the Chief Executive Officer and director of Calidi effective April 22, 2025. Most recently, Dr.
Poma served as CEO and as a member of the board of directors at Molecular Templates (NASDAQ: MTEM), a clinical-stage biotechnology company,
from February 2009 until January 2025. From March 2005 to September 2008, Dr. Poma served as Vice President, Business Development of
Innovive Pharmaceuticals. From 2001 to 2005, Dr. Poma held various senior level positions at Imclone Systems, Inc. From 2000 to 2001
Dr. Poma served as an analyst at Eagle Growth Investors, LLC. Dr. Poma received a Ph.D. in Microbiology and Immunology from University
of North Carolina at Chapel Hill, an M.B.A. from Leonard N. Stern School of Business and a Bachelor of Science in Biology from University
of North Carolina at Chapel Hill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Andrew
Jackson<i>. </i></b>Mr. Jackson has been the Chief Financial Officer since October 30, 2023 and Corporate Secretary since October
2025. Mr. Jackson is a financial executive with over 35 years of corporate finance
experience with success in publicly traded companies and venture capital backed startups. Mr. Jackson most recently served as Chief
Financial Officer of Ernexa Therapeutics Inc. from May 2022 to May 2023. Prior to his position at Ernexa Therapeutics, Mr. Jackson
served as the Chief Financial Officer of Ra Medical Systems, Inc. from April 2018 until May 2022, and as its Interim Chief Executive
Officer from August 2019 to March 2020. From October 2016 to April 2018, he was Chief Financial Officer for AltheaDx, Inc, a
molecular diagnostics company specializing in precision medicine. From March 2014 to March 2016, Mr. Jackson held senior financial
positions, including Chief Financial Officer, at Celladon Corporation, a publicly traded, clinical stage biotechnology company. From
April 2013 to March 2014, he held senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson
received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University
of Minnesota. He is a certified public accountant (inactive).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Antonio
F. Santidrian, Ph.D<i>. </i></b>Dr. Santidrian has been the Chief Scientific Officer since July 2023 and the Head of Technical Operations
since January 2025. Dr. Santidrian joined Calidi in 2015 as Associate Director and is an accomplished scientist with over 24 years of
experience in anti-cancer translational research. Dr. Santidrian has focused his scientific career on developing superior cancer drugs
and on biological drugs to improve human health. From March 2008 to September 2015, Dr. Santidrian led translational studies at The Scripps
Research Institute for several small molecule and biologic drugs to treat breast cancer metastasis. Dr. Santidrian worked closely on
translational cancer studies for the development of ACADRA to treat chronic lymphocytic leukemia (CLL) at the University of Barcelona
(Spain). Dr. Santidrian is the recipient of a fellowship from the August Pi i Sunyer Foundation, the Ministry of Science and Education
(Spain) and the Susan G. Komen Breast Cancer Foundation. Dr. Santidrian received a degree in Pharmacy from the University of Barcelona
in 2001 and a Ph.D. in biomedicine, specializing in anti-cancer therapies in 2006 from the University of Barcelona in Barcelona, Spain</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allan
J. Camaisa.</b> Mr. Camaisa has been a director of Calidi since February 2018 and resigned as the Chairman and Chief Executive Officer
of the Company effective April 21, 2025. Mr. Camaisa is a serial entrepreneur, investor, and technologist, with proven leadership skills
in bootstrapping startups. His accomplishments include four successful exits sold to publicly-traded Fortune 1000 companies, authorship
of seven US patents, and an Ernst &amp; Young Entrepreneur of the Year award. Mr. Camaisa was previously a director of snaploT, Inc.,
a self-service enabled clinical platform designed to create, launch, and manage clinical trials from January 2013 to September 2020.
From August 2014 to May 2017, Mr. Camaisa was the CEO and Chairman of Parallel 6, Inc., a digital mobile/cloud software platform for
managing pharmaceutical patient clinical trials. In 2005, Mr. Camaisa founded Anakam, Inc., a software security company for managing
digital access to medical records, and also served as Anakam&#8217;s Chief Executive Officer from January 2005 to October 2010. Before
beginning his career in business, Mr. Camaisa served eight years as a surface warfare officer in the US Navy. He graduated from the United
States Naval Academy with a B.S. in Engineering, and also completed the Owner/President Management program at Harvard Business School.
Mr. Camaisa is well qualified to serve as our director because of his extensive leadership experience serving as a director on the board
of directors of other companies, including in the healthcare sector.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scott
Leftwich. </b>Mr. Leftwich was an early investor and has been a director of Calidi since May 2019. In addition, since 2017 Mr. Leftwich
has been an investor and member of the Board of Advisors at Skopos Labs, Inc. Mr. Leftwich&#8217;s experience includes serving in various
executive positions in private companies, overseeing substantial growth and liquidity events with Fortune 1000 companies. From December
2011 to April 2016, Mr. Leftwich was the CEO and General Manager at InterMedHx, LLC, a healthcare software company, which was acquired
by Cerner Corporation in 2014. From September 2005 to December 2011, he was the COO and general manager at Anakam, Inc., a security software
company focused on the protection of personal healthcare information within patient-facing portals. Anakam was acquired by Equifax (NYSE:
EFX) in 2010. Mr. Leftwich is also a retired Naval officer who served as a P-3 pilot in the Navy and retired with the rank of Commander.
Mr. Leftwich holds an MBA (with honors) from Harvard Business School, in addition to a B.S. (with distinction) from the US Naval Academy.
Mr. Leftwich is well qualified to serve as our director based on the above qualifications and his executive experience in public and
private companies in the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>James
A. Schoeneck. </b>Mr. Schoeneck has been a director of Calidi since July 2020, he was appointed as the Chairman of the Board
effective April 22, 2025. Mr. Schoeneck is also currently a member and Chairman of the Board at Fibrogen Inc (Nasdaq: FGEN) since
April 2010, and also previously served as its Interim CEO from January 2019 to February 2020. From November 2015 to March 2018, Mr.
Schoeneck was a director of Anaptysbio, Inc (Nasdaq: ANAB), a therapeutic antibody development company for severe disease. He was
previous a director of the Board of Depomed, Inc. in 2007, and also served as its President and CEO from April, 2011 to March, 2017,
and led Depomed&#8217;s transformation into a commercial specialty pharmaceutical company. From 2005 until 2011, he was CEO of
BrainCells Inc, a privately-held biopharmaceutical company. Mr. Schoeneck&#8217;s diverse biotech experience further includes
serving as CEO of ActivX BioSciences, Inc., a development-stage biotechnology company from 2003 to 2004, three years as President
and CEO of Prometheus Laboratories Inc, a pharmaceutical and diagnostics product company, from 1999 to 2003, as well as three years
from 1996 to 1999 as Vice President, Commercial and General Manager, Immunology, at Centocor Inc (now Janssen Biotech, Inc.). Mr.
Schoeneck holds a B.S. in Education from Jacksonville State University. Mr. Schoeneck is well qualified to serve as our director
based on the above qualifications, his executive management leadership, and his extensive experience in the biotechnology and
pharmaceutical industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alan
R. Stewart. </b>Mr. Stewart has been a director of Calidi since October 10, 2023. Mr. Stewart has extensive experience as a financial
executive and board member with a proven track record in diverse industries. He is currently the Chief Financial Officer of Soundthinking,
Inc., a publicly traded SaaS software company specializing in wide-area acoustic gunshot detection. Since his appointment, he has successfully
led the company through an IPO on the Nasdaq market, facilitated significant growth, and completed acquisitions of technology providers.
Mr. Stewart&#8217;s prior roles include serving as President of Fit Advisors, LLC, where he launched a successful consultancy and completed
numerous M&amp;A transactions in various industries. He also served as a Managing Director at RA Capital Advisors, LLC, specializing
in M&amp;A and financing transactions. Mr. Stewart has a strong educational background, holding an M.B.A. in Finance from Harvard Business
School and a Bachelor of Science with Distinction in Oceanography from the United States Naval Academy. He has served as a FINRA Licensed
Agent with Series 63 and Series 79 credentials (Inactive).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>George
E. Peoples, Jr., M.D., F.A.C.S</b>. Dr. Peoples was appointed as a director of Calidi effective July 1, 2024. Dr. Peoples served 30 years
of active duty as a surgeon and research scientist in the military. Dr. Peoples is currently a Professor of Surgery at Uniformed Services
University of the Health Sciences (USUHS) and a Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). In addition,
Dr. Peoples is also the Founder and CEO of Cancer Insight, and the Founder and a director of the Cancer Vaccine Development Program.
He also currently serves as a Board Member for Texas Biomedical Research Institute since 2019 and as a Trustee for San Antonio Medical
Foundation since 2017. Dr. Peoples is a graduate of the United States Military Academy, West Point and the Johns Hopkins School of Medicine.
He completed his surgical training at Harvard&#8217;s Brigham and Women&#8217;s Hospital and also completed a postdoctoral fellowship
at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC prior
to becoming the Chief of Surgical Oncology at WRAMC. He has published over 300 peer-reviewed manuscripts, abstracts, and book chapters
on immuno-oncology and cancer vaccine development. Dr. Peoples received his M.D. from Johns Hopkins University School of Medicine in
1988 and his Bachelor of Science from the United States Military Academy in 1984.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships and Arrangements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers. Except as provided in the Merger Agreement in connection
with the Business Combination, there are no arrangements or understandings with any other person under which any of our directors and
officers was elected or appointed as a director or executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth below, our directors and executive officers have not been involved in any of the following events during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            bankruptcy petition filed by or against such person or any business of which such person
                                            was a general partner or executive officer either at the time of the bankruptcy or within
                                            two years prior to that time;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding
                                            traffic violations and other minor offenses);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                            of any court of competent jurisdiction, permanently or temporarily enjoining him from or
                                            otherwise limiting his involvement in any type of business, securities or banking activities
                                            or to be associated with any person practicing in banking or securities activities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures
                                            Trading Commission to have violated a Federal or state securities or commodities law, and
                                            the judgment has not been reversed, suspended, or vacated;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            subject of, or a party to, any Federal or state judicial or administrative order, judgment
                                            decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged
                                            violation of any Federal or state securities or commodities law or regulation, any law or
                                            regulation respecting financial institutions or insurance companies, or any law or regulation
                                            prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated,
                                            of any self-regulatory organization, any registered entity or any equivalent exchange, association,
                                            entity or organization that has disciplinary authority over its members or persons associated
                                            with a member.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2025, Molecular Templates, Inc. (&#8220;MTEM&#8221;), and its affiliate, Molecular Templates OpCo, Inc., commenced chapter
11 cases&#160;as debtors in possession in voluntary proceedings under Chapter 11 of the United States Code, 11 U.S.C. &#167;&#167; 101-1532,
as amended from time to time in the&#160;United States Bankruptcy Court for the District of Delaware. Dr. Poma, our Chief Executive Officer
and Director, was chief executive officer of MTEM from February 2009 to December 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Composition </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and affairs will be managed under the direction of our board of directors. Mr. Schoeneck serves as Chair of the board of directors.
The primary responsibilities of the board of directors will be to provide oversight, strategic guidance, counselling and direction to
our management. The board of directors of will meet on a regular basis and additionally as required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of the Bylaws, the board of directors may establish the authorized number of directors from time to time by
resolution. As of the date of this report, the board of directors consists of six (6) members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the Second Amended and Restated Certificate of Incorporation, the board of directors is divided into three
classes, as nearly equal in number as possible and designated Class I, Class II and Class III. The current directors of Class I, Class II and Class III are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric E. Poma and Alan R. Stewart serve as the Class I directors, with the term of their directorship expiring at
the stockholders&#8217; annual meeting to be held in 2027;</span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George E. Peoples and James A. Schoeneck serve as the Class II directors, with the term of their directorship expiring
at the stockholders&#8217; annual meeting to be held in 2028;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allan J. Camaisa and Scott Leftwich serve as the Class III directors, with the term of their directorship expiring
at the stockholders&#8217; annual meeting to be held in 2026.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the appointment of the directors to the committees, the board of directors undertook a review of the independence of
each director. Based on information provided by each director concerning her or his background, employment and affiliations, the board
of directors determined that none of the directors, other than Mr. Camaisa, has any relationships that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director and that each of the directors is &#8220;independent&#8221;
as that term is defined under the NYSE listing standards. In making these determinations, the board of directors of considered the current
and prior relationships that each non-employee director has with the Company and all other facts and circumstances the board of directors
deems relevant in determining their independence, including the beneficial ownership of our securities by each non-employee director
and the transactions described in the section entitled &#8220;<i>Related Party Transactions</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors in Risk Oversight </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the key functions of the board of directors is to have informed oversight of our risk management process. The board of directors does
not have a standing risk management committee, but rather administers this oversight function directly through our board of directors
as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective
areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and the
audit committee will have the responsibility to consider and discuss the major financial risk exposures and the steps our management
will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and
management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. The compensation committee
also assesses and monitors whether the compensation plans, policies and programs comply with applicable legal and regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of the Business Combination, the board of directors reconstituted the audit committee, compensation committee, and nominating
and corporate governance committee. On the Closing Date, our board of directors adopted new charters for nominating and corporate governance
committee, compensation committee and audit committee (the &#8220;Charters&#8221;). Copies of the Charters for each committee are available
on the investor relations portion of website at <i>www.calidibio.com.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee consists of the following members: Alan R. Stewart and James A. Schoeneck. Our board of directors has determined
that each member of the audit committee satisfies the independence requirements under the NYSE listing standards and Rule
10A-3(b)(1) of the Exchange Act. The chairman of our audit committee is Alan R. Stewart. Our board of directors of directors has
determined that James A. Schoeneck is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each
member of our audit committee can read and understand fundamental financial statements in accordance with applicable listing
standards. In arriving at these determinations, our board of directors has examined each audit committee member&#8217;s scope of
experience and the nature of his or her employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting
and financial reporting processes, systems of internal control and financial statement audits, and to oversee our independent registered
public accounting firm. Specific responsibilities of our audit committee include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">helping
    our board of directors oversee our corporate accounting and financial reporting processes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing with our management the adequacy and effectiveness of our disclosure controls and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
    with design and implementation of our risk assessment functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered
    public accounting firm to audit our financial statements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent accountants, our interim and year-end operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    related person transactions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and reviewing a report by the independent registered public accounting firm at least annually that describes our internal quality
    control procedures, any material issues with such procedures and any steps taken to deal with such issues when required by applicable
    law; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
    or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting
    firm.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation
Committee </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee consists of the following members: James A. Schoeneck, Scott Leftwich and George E. Peoples. The chairman of
our compensation committee is James A. Schoeneck. Our board of directors has determined that each member of the compensation
committee satisfies the independence requirements under the listing standards of the NYSE, and is a &#8220;non-employee
director&#8221; as defined in Rule 16b-3 promulgated under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation
policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior
management, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
responsibilities of our compensation committee include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to our board of directors the compensation of our chief executive officer and other executive officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and recommending to our board of directors the compensation of our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering
    our equity incentive plans and other benefit programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans,
    change-of-control protections and any other compensatory arrangements for our executive officers and other senior management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and evaluating with the chief executive officer the succession plans for our executive officers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nominating
and Corporate Governance Committee </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee consists of the following members: Scott Leftwich, James A. Schoeneck and Alan
R. Stewart. The chairman of our nominating and corporate governance committee Scott Leftwich. Our board of directors has determined
that each member of the nominating and corporate governance committee satisfies the independence requirements under the listing
standards of the NYSE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying
    and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders,
    to serve on our board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">considering
    and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of
    directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    with our chief executive officer the plans for succession to the offices of our executive officers and make recommendations to our
    board of directors with respect to the selection of appropriate individuals to succeed to these positions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and making recommendations to our board of directors regarding corporate governance guidelines and matters; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    periodic evaluations of the board of directors&#8217; performance, including committees of the board of directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Committee Interlocks </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the members of the compensation committee has ever been an executive officer or employee of the Company. None of our executive officers
currently serve, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other
entity that has one or more executive officers that serve as a member of our board of directors or compensation committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Director Compensation Policy </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors will review director compensation periodically to ensure that director compensation remains competitive such that
we will be able to recruit and retain qualified directors. We intend to develop a director compensation program that is designed to align
compensation with our business objectives and the creation of stockholder value, while enabling us to attract, retain, incentivize and
reward directors who contribute to our long-term success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Liability and Indemnification of Directors and Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter limits a director&#8217;s liability to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation
will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any transaction from which the director derives an improper personal benefit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any unlawful payment of dividends or redemption of shares; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any breach of a director&#8217;s duty of loyalty to the corporation or its stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 55.05pt; text-align: justify; text-indent: -18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware
law and the Bylaws provide that we will, in certain situations, indemnify our directors and officers and may indemnify other employees
and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to
advancement, direct payment, or reimbursement of reasonable expenses (including attorneys&#8217; fees and disbursements) in advance of
the final disposition of the proceeding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have entered into separate indemnification agreements with our directors and officers. These agreements, among other things,
require us to indemnify our directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines, and settlement
amounts incurred by a director or officer in any action or proceeding arising out of their services as one of our directors or officers
or any other company or enterprise to which the person provides services at its request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which our directors and officers are insured against
liability for actions taken in their capacities as directors and officers. We believe these provisions in the Charter and Bylaws and
these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the
opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics for Employees, Executive Officers, and Directors </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and
directors. The Code of Conduct is available at the investors section of our website at <i>www.calidibio.com</i>. Information contained
on or accessible through this website is not a part of this report, and the inclusion of such website address in this report is an inactive
textual reference only. Any amendments to the Code of Conduct, or any waivers of its requirements, are expected to be disclosed on our
website to the extent required by applicable rules and exchange requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
in our Code of Conduct is our Insider Information and Securities Trading Policy, or the Insider Trading Policy. The Insider Trading Policy
is available at the investors section of our website at <i>www.calidibio.com</i>. No person who is aware of material, non-public information
about Calidi may, directly or indirectly, buy or sell our securities or engage in another action to take advantage of such information.
It is also against the law to trade or to &#8220;tip&#8221; others who might make an investment decision based on material, non-public
information about Calidi.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
executed a standard form of indemnification agreement (&#8220;Indemnification Agreement&#8221;) with each of our Board members and executive
officers (each, an &#8220;Indemnitee&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to and subject to the terms, conditions and limitations set forth in the Indemnification Agreement, we agreed to indemnify each Indemnitee,
against any and all expenses incurred in connection with the Indemnitee&#8217;s service as our officer, director and or agent, or is
or was serving at our request as a director, officer, employee, agent or advisor of another corporation, partnership, joint venture,
trust, limited liability company, or other entity or enterprise but only if the Indemnitee acted in good faith and in a manner he reasonably
believed to be in or not opposed to our best interest, and in the case of a criminal proceeding, had no reasonable cause to believe that
his conduct was unlawful. In addition, the indemnification provided in the indemnification agreement is applicable whether or not negligence
or gross negligence of the Indemnitee is alleged or proven. Additionally, the Indemnification Agreement establishes processes and procedures
for indemnification claims, advancement of expenses and costs and contribution obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers and directors and persons who own more than
10% of a registered class of our equity securities, to file with the SEC initial statements of beneficial ownership, reports of changes
in ownership and Annual Reports concerning their ownership, of Common Stock and other of our equity securities on Forms 3, 4, and 5,
respectively. Executive officers, directors and greater than 10% stockholders are required by SEC regulations to furnish us with copies
of all Section 16(a) reports they file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based solely on our review of
Forms 3, 4 and 5 and amendments thereto filed electronically with the SEC during the most recent fiscal year, we believe that all reports
required by Section 16(a) for transactions in the fiscal year ended December 31, 2025, were timely filed except for the following due
to administrative oversight: Form 4 filed one business days late on April 25, 2025 reporting the inducement grant of stock options to
Dr. Poma on April 22, 2025; and the Form 4s filed two business days late on July 15, 2025 reporting the issuance of the respective non-qualified
stock option grants of George E. Peoples, Alan R. Stewart, Scott Leftwich and James A. Schoeneck under the 2023 Plan on July 9, 2025.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_012"></span>ITEM
11 - EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Calidi
Executive Officer and Director Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following disclosure concerns the compensation arrangements of Calidi&#8217;s named executive officers and directors for the fiscal year
ended December 31, 2025 and December 31, 2024. Such disclosure should be read together with the compensation tables and related disclosures
provided below and in conjunction with Calidi&#8217;s financial statements and related notes appearing elsewhere in this report. As an
emerging growth company, Calidi has opted to comply with the executive compensation disclosure rules applicable to &#8220;smaller reporting
companies&#8221; as such term is defined in the rules promulgated under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding total compensation awarded to, earned by, and paid to the named executive officers of
Calidi for services rendered to Calidi in all capacities for the fiscal year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NAME AND </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRINCIPAL </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POSITION</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">YEAR</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">SALARY<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BONUS<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTION AWARDS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)<sup>(1)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">NON-QUALIFIED DEFERRED COMPENSATION EARNINGS <br/>
($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ALL OTHER COMPENSATION<br/>
 ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">TOTAL<br/>
 ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%; text-align: left">Eric Poma</td><td style="width: 2%">&#160;</td>
    <td style="width: 10%; text-align: center">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">358,038</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">267,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">47,891</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">673,898</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Executive Officer<sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allan J. Camaisa<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,846</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">753,816</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">982,662 </td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Director, Former Chief Executive Officer and Chairman of the Board</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,780</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">509,121</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Andrew Jackson</td><td>&#160;</td>
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">593,965</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,805</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">516,880</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Antonio F. Santidrian<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,606</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">576,994</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Chief Scientific Officer and Head of Technical Operations</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,198</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,437</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    column reflects the aggregate grant date fair value of option awards granted during the year measured pursuant to Financial Accounting
    Standard Board Accounting Standards Codification Topic 718, the basis for computing stock-based compensation in Calidi&#8217;s consolidated
    financial statements. This calculation assumes that the named executive officer will perform the requisite service for the award
    to vest in full as required by SEC rules. The assumptions we used in valuing options are described in Note 9 to Calidi&#8217;s consolidated
    financial statements included in this report. These amounts do not reflect the actual economic value that will be realized, if any,
    by the named executive officer upon vesting of the stock options, the exercise of the stock options, or the sale of the common stock
    underlying such stock options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    column reflects the aggregate value of other categories of payment, consisting of costs of severance, paid time off payout, medical,
    dental, vision, life and disability insurance coverage, 401(k) match, lease guarantee payout (See Note 6), commuter reimbursement
    fees and cell phone plan costs, paid by Calidi.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dr. Poma was appointed as the Chief Executive Officer effective April 22, 2025.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Camaisa resigned as Chief Executive Officer and Chairman of the Board of Directors effective April 21, 2025. Mr. Camaisa remains on
    the Board of Directors, but does not receive any additional compensation in his capacity as a Director. In connection with Mr. Camaisa&#8217;s resignation, we executed a General
Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr. Camaisa. Pursuant to the Release Agreement, we are
obligated to pay Mr. Camisa $0.5 million separation pay in the form of compensation continuation over 12 months pursuant to our regular
and customary payroll schedule, less all regular and customary payroll withholdings and shall also pay Mr. Camisa COBRA premiums for 12
months, commencing May 2025. Mr. Camaisa shall also be entitled to receive a transition/consulting pay of $10,000 per month during the
transition period. Included in &#8220;All Other Compensation&#8221; is $0.4 million related to Mr. Camaisa&#8217;s separation and transition
payments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Santidrian was appointed an executive officer on September 3, 2025.</span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity
Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek to motivate and reward our named executive officers for achievements relative to our corporate goals and expectations
for each fiscal year. Each of our named executive officers is eligible to receive an annual performance bonus payable in cash of up to
50% for Mr. Poma, up to 35% for Mr. Jackson, up to 35% for Mr. Santidrian and up to 35% for other executive officers, as approved
by our board of directors from time to time based on the achievement of individual and company-wide annual performance goals as determined
by our compensation committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to January 1, 2019, we adopted the 2016 Stock Plan (the &#8220;2016 Plan&#8221;) under which we were authorized to grant stock options,
restricted stock, a stock appreciation right, or a restricted stock unit award. In June 2019, we adopted the 2019 Equity Incentive Plan
(the &#8220;2019 Plan&#8221;) to replace the 2016 Plan. Other than the change of plan name and incorporation state, all the terms of
the 2016 Plan were carried over into the 2019 Plan. In adopting the 2019 Plan, we terminated the 2016 Plan and may no longer grant any
additional stock options or sell any stock under restricted stock purchase agreements under the 2016 Plan; however, stock options issued
under the 2016 Plan will continue to be in effect in accordance with their terms and the terms of the 2019 Plan, which are substantially
the same terms as the 2016 Plan, until the exercise or expiration of the individual options awards. In connection with the Business Combination,
we assumed the outstanding options granted under the 2019 Plan. Upon completion of the Business Combination on September 12, 2023, we
adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221; or the &#8220;Incentive Plan&#8221;). Since only the outstanding
options under the 2019 Plan were assumed, we may no longer grant any additional stock options or sell any stock under restricted stock
purchase agreements under the 2019 Plan; however, stock options issued under the 2019 Plan will continue to be in effect in accordance
with their terms and the terms of the 2023 Plan until the exercise or expiration of the individual options awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2019 Plan reserved the right for the Board of Directors as the administrator of the plan (the &#8220;Administrator&#8221;) to issue
up to shares pursuant to 166,666 equity awards, which was increased to up to 212,500 in May 2022, including stock options
(&#8220;Options&#8221;), restricted stock awards (&#8220;Restricted Stock&#8221;), dividend equivalents awards, stock payment
awards, restricted stock units (&#8220;RSUs&#8221;) and/or stock appreciation rights (&#8220;SARs&#8221;, together with Options,
Restricted Stock and RSUs, &#8220;Awards&#8221;), according to its discretion. Awards may be granted under the 2019 Plan to our
employees, directors, and consultants. As of December 31, 2024, the Administrator has not issued any Restricted Stock, RSUs,
dividend equivalents awards, stock payment awards or SARs. Stock options remain as the sole outstanding type of award under the 2019
Plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2019 Plan, awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic
installments or upon the attainment of performance goals, or upon the occurrence of specified events depending on the Administrator&#8217;s
discretion. The Administrator has broad authority to determine the terms and conditions of any Award granted pursuant to the 2019 Plan
including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations
on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations
or waivers thereof as the Administrator, in its sole discretion may determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Awards may be granted under the 2019 Plan with a term of more than ten years and no Awards granted may be exercised after the expiration
of ten years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The 2023 Plan reserved the right for the Compensation Committee or by the
Board of Directors acting as the Compensation Committee, as the administrator of the plan (the &#8220;Administrator&#8221;) to issue up
to 32,815 equity awards, which was increased to up to 282,815 in July 2025, including stock options (&#8220;Options&#8221;), restricted
stock awards (&#8220;Restricted Stock&#8221;), dividend equivalents awards, stock payment awards, restricted stock units (&#8220;RSUs&#8221;)
and/or stock appreciation rights (&#8220;SARs&#8221;, together with Options, Restricted Stock and RSUs, &#8220;Awards&#8221;), according
to its discretion. Awards may be granted under the 2023 Plan to our employees, directors, and consultants. As of December 31, 2025, the
Administrator has issued RSUs and stock options under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2023 Plan, Awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic
installments or upon the attainment of performance goals, or upon the occurrence of specified events depending on the Administrator&#8217;s
discretion. The Administrator has broad authority to determine the terms and conditions of any Award granted pursuant to the 2023 Plan
including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations
on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations
or waivers thereof as the Administrator, in its sole discretion may determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Awards may be granted under the 2023 Plan with a term of more than ten years and no Awards granted may be exercised after the expiration
of ten years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 18, 2023, the Board approved a repricing of approximately 0.2 million stock options previously granted at an exercise price of
$1,112.40 per share to the then current fair value of $853.20 per share pursuant to an updated valuation report. The year ended December
31, 2025 includes a noncash compensation charge of approximately $62 thousand in connection with this repricing. The year ended December
31, 2024 included a noncash compensation charge of approximately $0.1 million in connection with this repricing. The stock option repricing
and the acceleration of vesting were accounted for as a modification under ASC 718.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2023, upon closing of the FLAG Merger, the number of equity awards issued and available for grant were retrospectively
adjusted pursuant to the conversion ratio of approximately 0.003. The mechanism of conversion resulted in the fair value of each option
prior to the Closing equal to the fair value of each option after. All stock option activity presented in these statements has been retrospectively
adjusted to reflect the conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024, we effected a 1-for-10 Reverse Stock Split. As a result, proportionate adjustments were made to the per share exercise
price and the number of shares of Common Stock that may be purchased upon exercise of outstanding stock options granted by Calidi, and
the number of shares of Common Stock reserved for future issuance under the 2023 Equity Incentive Plan. All stock option activity presented
in these statements has been retrospectively adjusted to reflect the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 4, 2025, we effected a 1-for-12 Reverse Stock Split. As a result, proportionate adjustments were made to the per share exercise
price and the number of shares of Common Stock that may be purchased upon exercise of outstanding stock options granted by Calidi, and
the number of shares of Common Stock reserved for future issuance under the 2023 Equity Incentive Plan. All stock option activity presented
in these statements has been retrospectively adjusted to reflect the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the 2023 Plan may be either &#8220;incentive stock options&#8221; within the meaning of Section 422(b) of
the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or &#8220;non-qualified&#8221; stock options that do not qualify
incentive stock options. Incentive stock options may be granted only to the Company&#8217;s employees and employees of domestic subsidiaries,
as applicable. The exercise price of stock options shall be equal to or greater than the fair market value of common stock on the date
the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the
grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined
as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee
in any calendar year may not exceed $0.1 million, otherwise it will be classified as a Non-Qualified Stock Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of an option may be payable in cash or in common stock, or in a combination of cash and common stock, or other legal consideration
for the issuance of stock as the Board or Administrator may approve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
options vest over four years and will be exercisable only while the optionee remains an employee, director or consultant, or during the
three months thereafter, but in the case of the termination of an employee, director, or consultant&#8217;s services due to death or
disability, the period for exercising a vested option shall be extended to the earlier of twelve months after termination or the expiration
date of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards as of December 31, 2025</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information about equity awards granted to Calidi&#8217;s named executive officers that remained outstanding
as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">OPTION AWARDS</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">NAME</td><td style="text-transform: uppercase; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-transform: uppercase; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="text-transform: uppercase"><b>date</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NUMBER OF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNDERLYING</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNEXERCISED</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OPTIONS (#)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXERCISABLE</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NUMBER OF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNDERLYING UNEXERCISED</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OPTIONS (#)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNEXERCISABLE</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OPTION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXERCISE </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PRICE ($)</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OPTION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXPIRATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DATE</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: left">Eric Poma</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: center">4/22/2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">60,534</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5.63</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right">4/22/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">9/03/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/03/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Allan J. Camaisa (granted to AJC Capital, of which Mr. Camaisa is the sole member except for the grants on February 1, 2022, December 21, 2023 and June 17, 2024 which were granted to Mr. Camaisa individually)</td><td>&#160;</td>
    <td style="text-align: center">7/01/2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,774</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/01/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">7/01/2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/01/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">7/01/2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/01/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/01/2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/01/2027</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/01/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/01/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/01/2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/01/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/01/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/01/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/30/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/30/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/02/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/02/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/02/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/02/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/01/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853.20</td><td style="text-align: left"><sup>(1)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/01/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/01/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">320</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">853.20</td><td style="text-align: left"><sup>(1)</sup>&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/01/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/21/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">216.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/21/2033</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/17/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/17/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Andrew Jackson</td><td>&#160;</td>
    <td style="text-align: center">6/17/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,147</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">9/03/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/03/2035</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Antonio F. Santidrian</td><td>&#160;</td>
    <td style="text-align: center">12/27/2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/27/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/15/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/15/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/30/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/30/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/17/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/17/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/17/2034</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">9/03/2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/03/2035</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    January 18, 2023, the $1,112.40 exercise price per share was adjusted to $853.20 per share pursuant to a January 2023 valuation and
a repricing of certain stock options approved by Calidi&#8217;s Board of Directors. All vesting conditions remained unchanged.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.45pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Agreements
with Named Executive Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have employment agreements or offer letters with each of our named executive officers. The material terms of each of these agreements
are described below. These agreements provide for base salaries and incentive compensation, and each component reflects the scope of
each named executive officer&#8217;s anticipated responsibilities and the individual experience they bring to our company. The employment
of each of our named executive officers is &#8220;at will&#8221; and may be terminated at any time. In addition, each of our named executive
officers has executed a form of our standard proprietary information and inventions agreement. In addition, we have employment agreements
and arrangements with our other executive officers which provide for similar benefits, participation in bonus plans and severance payments
upon a qualifying termination or Change in Control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b>Eric Poma, PhD</b>.
On April 22, 2025, we entered into an employment agreement with Eric Poma to serve as Chief Executive Officer. Dr. Poma has an annual
base salary of $535,000 and is eligible to receive an annual bonus representing up to 50% of Dr. Poma&#8217;s base salary, subject to
the approval of the Board of Directors. In addition, subject to approval by the Board of Directors, we agreed to grant Dr. Poma 60,534
incentive stock option to purchase Calidi common stock at an exercise price equal to the fair market value per share of our common stock
on the date of grant (the &#8220;Stock Options&#8221;). Vesting of Stock Options will commence on the Effective Date (&#8220;Vesting
Commencement Date&#8221;) and shall have a one (1) year cliff wherein 25% shall vest upon the one (1) year anniversary of the Vesting
Commencement Date, and thereafter, 1/36th of the remaining shares subject to the Stock Options shall vest on the last day of each one
month period of Dr. Poma&#8217;s service as an employee, so that all of the shares subject to the Stock Options shall be vested on the
fourth (4th) anniversary of the Vesting Commencement Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Andrew
Jackson</b>. On October 25, 2023, we entered into an employment agreement with Andrew Jackson to serve as Chief Financial Officer, which
became effective on October 30, 2023. Mr. Jackson has an annual base salary of $430,000 and is eligible to receive an annual bonus representing
up to 35% of Mr. Jackson&#8217;s base salary, subject to the approval of the Board of Directors. In addition, subject to approval by
the Board of Directors, we agreed to grant Mr. Jackson 2,500 incentive stock option to purchase Calidi common stock at an exercise
price equal to the fair market value per share of our common stock on the date of grant (the &#8220;Stock Options&#8221;).
Vesting of Stock Options will commence on the Effective Date (&#8220;Vesting Commencement Date&#8221;) and shall have a one (1) year
cliff wherein 25% shall vest upon the one (1) year anniversary of the Vesting Commencement Date, and thereafter, 1/36th of the remaining
shares subject to the Stock Options shall vest on the last day of each one month period of Mr. Jackson&#8217;s service as an employee,
so that all of the shares subject to the Stock Options shall be vested on the fourth (4th) anniversary of the Vesting Commencement Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Antonio F. Santidrian, PhD.
</b>On September 1, 2021, we entered into an employment agreement with Antonio F. Santidrian to serve as Senior Vice President, Global
Head of Research and Development. Dr. Santidrian has an annual base salary of $220,000 which will be increased to $280,000 upon Calidi
raising a one-time lump sum of $10 million in capital or more. Dr. Santidrian is eligible to receive an annual bonus representing up to
30% of his base salary, subject to the approval of the Board of Directors.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 16, 2022, Dr. Santidrian&#8217;s
employment agreement was amended to increase his annual base salary to $280,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 16, 2023, we entered into a new and superseding
employment agreement with Dr. Santidrian to serve as Chief Scientific Officer. He will continue to receive an annual base salary of $280,000
which will increase to $363,000 upon Calidi completing Series B funding and Dr. Santidrian is eligible to receive an annual bonus representing
up to 35% of his base salary, subject to the approval of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 30, 2025, we amended
Dr. Santidrian&#8217;s employment contract with Dr. Santidrian to serve as Chief Scientific Officer and Head of Technical Operations.
Dr. Santidrian&#8217;s annual base salary was increased to $400,000. All other terms and conditions remained the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Allan
J. Camaisa. </b>On September 1, 2021, we entered into an employment agreement with Allan J. Camaisa. Mr. Camaisa is entitled to an initial
annual base salary of $29,120, which will be increased to an annual base salary of $410,000, in the event we complete a single capital
raise of $10 million or more. Mr. Camaisa may also be eligible to receive an annual cash performance bonus under our bonus plan of up
to 50% as approved from time to time by the board of directors pursuant to targets set by the compensation committee. Under his employment
agreement, Mr. Camaisa also received an option to purchase 867 shares of the Company&#8217;s common stock and additional stock options
may also be granted to him from time to time as determined by the board of directors. Such stock options shall have an exercise price
equal to the &#8220;Fair Market Value&#8221; per share of the Company&#8217;s common stock on the date of grant and will be granted pursuant
to the Company&#8217;s 2019 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 1, 2022, Calidi and Mr. Camaisa entered into an updated employment agreement, which superseded the September 1, 2021 Camaisa
Agreement (&#8220;Camaisa Updated Employment Agreement&#8221;). Under the Camaisa Updated Employment Agreement, Calidi increased Mr.
Camaisa&#8217;s initial annual base salary to $31,200 (increased to $43,240 to comply with California non-exempt employee requirements)
effective as of January 1, 2022. Under the Camaisa Updated Employment Agreement, Calidi recognized that from January 1, 2019, through
December 31, 2019, Mr. Camaisa received a deferred annual base salary of $240,000 which has been paid from January 1, 2020, through January
31, 2022, Mr. Camaisa received a deferred annual base salary of $400,000 per year which has been paid; and effective February 1, 2022,
Mr. Camaisa&#8217;s deferred base salary was increased to $450,000 and continued to accrue at that rate. Upon the completion the Business
Combination, Mr. Camaisa&#8217;s annual base salary was adjusted to $450,000 and his accrued and unpaid deferred compensation was paid.
Mr. Camaisa&#8217;s employment agreement also provides for certain severance benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2025, in connection with the resignation of Mr. Camaisa as Chief Executive Officer, we executed a General Release of Claims
and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr. Camaisa. Mr. Camaisa will continue to serve as a Class III director
of the Company and will assume the title of &#8220;CEO Emeritus&#8221;. Pursuant to the Release Agreement, we are obligated to pay Mr.
Camisa $0.5 million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
schedule, less all regular and customary payroll withholdings and shall also be liable to pay Mr. Camisa COBRA premiums for 12 months,
commencing May 2025. Mr. Camaisa shall also be entitled to receive a transition/consulting pay of $10,000 per month during the transition
period. Mr. Camaisa received $0.1 million consulting pay in 2025 and the consulting agreement was terminated effective December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2022, in order for us to secure and execute the San Diego Lease discussed in Note 11, Mr. Camaisa, provided a personal Guaranty
of Lease of up to $0.9 million (the &#8220;Guaranty&#8221;) to the lessor for the Company&#8217;s future performance under the San Diego
Lease agreement. As consideration for the Guaranty, we agreed to pay Mr. Camaisa 10% of the Guaranty amount for the first year of the
San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with all amounts accrued and payable
at the termination of the San Diego Lease or release of Mr. Camaisa from the Guaranty by the lessor, whichever occurs first. Mr. Camaisa
received $0.2 million during the fiscal year ended 2025 in connection with the lease guarantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Payments Upon Termination or Change in Control </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to their respective employment agreements, each named executive officer is entitled to receive amounts described below upon a qualifying
termination or Change in Control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eric
Poma, PhD</b>. Dr. Poma&#8217;s employment agreement may be terminated, in writing with at least thirty (30) days&#8217; prior
written notice, by the Company for or without cause or by Dr. Poma with or without good reason. If Dr. Poma&#8217;s employment is
terminated without cause or he resigns with good reason, Dr. Poma will receive the following severance benefits, including but not
limited to, his fully earned but unpaid base salary; nine (9) months&#8217;(&#8220;Severance Period&#8221;) pay at Dr. Poma&#8217;s
monthly base salary rate, payable in a lump sum or in instalments subject to the Company&#8217;s discretion; and additional stock
award acceleration under the circumstances described therein. In the event Dr. Poma&#8217;s employment is terminated without cause
or he resigns with good reason following a change in control, the Severance Period shall be increased to 24 (twenty-four) months and the
cash severance shall instead be paid in a lump sum. Such post-termination payments and benefits are conditioned on Dr. Poma&#8217;s
execution and non-revocation of a general release of claims in favor of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Andrew
Jackson</b>. Mr. Jackson&#8217;s employment agreement may be terminated, in writing with at least thirty (30) days&#8217; prior written
notice, by the Company for or without cause or by Mr. Jackson with or without good reason. If Mr. Jackson&#8217;s employment is terminated
without cause or he resigns with good reason, Mr. Jackson will receive the following severance benefits, including but not limited to,
his fully earned but unpaid base salary; six (6) months&#8217;(&#8220;Severance Period&#8221;) pay at Mr. Jackson&#8217;s monthly base
salary rate, payable in a lump sum or in instalments subject to the Company&#8217;s discretion; and additional stock award acceleration
under the circumstances described therein. In the event Mr. Jackson&#8217;s employment is terminated without cause or he resigns with
good reason following a change in control, the Severance Period shall be increased to 12 (twelve) months and the cash severance shall
instead be paid in a lump sum. Such post-termination payments and benefits are conditioned on Mr. Jackson&#8217;s execution and non-revocation
of a general release of claims in favor of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b>Antonio F. Santidrian,
PhD. </b>Dr. Santidrian&#8217;s employment agreement may be terminated, in writing with at least thirty (30) days&#8217; prior written
notice, by the Company for or without cause or by Dr. Santidrian with or without good reason. If Dr. Santidrian&#8217;s employment is
terminated without cause or he resigns with good reason, Dr. Santidrian will receive the following severance benefits, including but
not limited to, his fully earned but unpaid base salary; six (6) months&#8217;(&#8220;Severance Period&#8221;) pay at Dr. Santidrian&#8217;s
monthly base salary rate, payable in a lump sum or in instalments subject to the Company&#8217;s discretion; and additional stock award
acceleration under the circumstances described therein. In the event Dr. Santidrian&#8217;s employment is terminated without cause or
he resigns with good reason following a change in control, the Severance Period shall be increased to 12 (twelve) months and the cash
severance shall instead be paid in a lump sum. Such post-termination payments and benefits are conditioned on Dr. Santidrian&#8217;s
execution and non-revocation of a general release of claims in favor of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension
Benefits </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan sponsored by
Calidi during the fiscal year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonqualified
Deferred Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers did not participate in, nor earn any benefits under, a nonqualified deferred compensation plan sponsored by
Calidi during the fiscal year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Benefits
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the named executive officers is eligible to participate in Calidi&#8217;s standard employee benefit plans and programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>401(k)
Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a 401(k) plan intended to qualify as a tax-qualified plan under Section 401 of the Code with the 401(k) plan&#8217;s related
trust intended to be tax exempt under Section 501(a) of the Code. The 401(k) plan provides that each participant may contribute up to
the lesser of 100% of his or her compensation or the statutory limit, which was $23,500 for calendar year 2025. Employees&#8217; pre-tax
contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives
according to the participant&#8217;s directions. Employees are immediately and fully vested in their contributions. As a tax-qualified
retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed
from the 401(k) plan. Effective January 1, 2023, the 401(k) plan was changed to a safe harbor plan under which we will make safe harbor
contributions equal to 100% of a participant&#8217;s elective deferral, not to exceed 4% of compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Benefits </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
named executive officers are eligible to participate in our health and welfare plans to the same extent as all full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally have not provided perquisites or personal benefits except in limited circumstances, and except as set forth above under &#8220;Summary
Compensation Table,&#8221; we did not provide any perquisites or personal benefits to our named executive officers in fiscal year ended
December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025
Non-Employee Director Compensation </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of non-employee directors earned or paid for services rendered to
Calidi for the year ended December 31, 2025. Mr. Camaisa also served as our director. Mr. Camaisa&#8217;s compensation as named executive
officer is set forth above under &#8220;Summary Compensation Table.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">NAME</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FEES EARNED </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OR</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PAID IN CASH</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OPTION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AWARDS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><sup>(1)</sup></b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">RESTRICTED STOCK</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">UNITS</p></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">TOTAL</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; font-size: 10pt; text-align: left">James A. Schoeneck</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">81,042</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">81,976</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">163,018</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Scott Leftwich<sup>(2)</sup></span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">53,750</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">68,313</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">122,063</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">George E. Peoples</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">46,250</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">68,313</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">114,563</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Alan R. Stewart</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">58,750</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">68,313</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">127,063</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">239,792</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">286,915</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">526,707</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    column reflects the aggregate grant date fair value of option awards granted during the year measured pursuant to Financial Accounting
    Standard Board Accounting Standards Codification Topic 718, the basis for computing stock-based compensation in our consolidated
    financial statements. This calculation assumes that the director will perform the requisite service for the award to vest in full
    as required by SEC rules. The assumptions we used in valuing options are described in Note 9 to our consolidated financial statements
    included in this report. These amounts do not reflect the actual economic value that will be realized by the director upon vesting
    of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain fees earned by Mr. Leftwich prior to January 1, 2021 totaling $0.6 million (see Notes 6 and 12) were deferred and paid in January 2025 and excluded
from the table above.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NUMBER OF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SHARES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SUBJECT TO</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OUTSTANDING</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OPTIONS AS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DECEMBER 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NUMBER OF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SHARES SUBJECT TO</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OUTSTANDING </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RESTRICTED</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>STOCK UNITS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>AS OF</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DECEMBER 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-size: 10pt; text-align: left">Scott Leftwich</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right">18,719</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 16%; font-size: 10pt; text-align: right">&#8212;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">James A. Schoeneck</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">18,662</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Alan R. Stewart</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">13,544</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">George E. Peoples</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">13,364</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8212;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee
Director Compensation Policy </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide cash and/or equity-based compensation to certain of our directors for the time and effort necessary to serve as a member of our
board of directors. In addition, all of our directors are entitled to reimbursement of direct expenses incurred in connection with attending
meetings of the board or committees thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company Status </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, as defined in the JOBS Act. As an emerging growth company, we will be exempt from certain requirements
related to executive compensation, including, but not limited to, Compensation Discussion and Analysis disclosure, the requirements to
hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our
Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection
and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation of Executive Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee oversees the compensation policies, plans and programs and review and determine compensation to be paid to executive
officers, directors and other senior management, as appropriate. The compensation policies for the Company are intended to provide for
compensation that is sufficient to attract, motivate and retain executives of the Company and potential other individuals and to establish
an appropriate relationship between executive compensation and the creation of stockholder value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any modifications or recommendations by the compensation committee, the executive officers and directors of the Company currently
receive substantially the same compensation that they receive from Calidi prior to the Business Combination, and also be subject to substantially
the same severance terms under their respective employment agreement and arrangements with Calidi. The description of the employment
agreements and arrangements is forth in the sections titled &#8220;<i>Executive Compensation &#8212; Calidi Executive Officer and Director
Compensation</i>&#8221; and section titled, &#8220;<i>Certain Relationships and Related Person Transactions &#8212; Calidi Related Party
Transactions</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee
Benefit and Stock Plans </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-based
compensation is an important foundation in the executive compensation packages as we believe it will maintain a strong link between executive
incentives and the creation of stockholder value. It is anticipated that the performance and equity-based compensation will be an important
component of the total executive compensation package for maximizing stockholder value while, at the same time, attracting, motivating
and retaining high-quality executives. Formal guidelines for the allocations of cash and equity-based compensation have not yet been
determined, but it is expected that the Incentive Plan will be an important element of our compensation arrangements for both executive
officers and directors, and that the executive officers will also be eligible to participate in the 2023 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
Stock Options </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Business Combination, all outstanding options to purchase Calidi stock were assumed by the Company and the Assumed Options
are currently exercisable for newly issued shares of common stock of Calidi, subject to the terms of their applicable plan and agreement
pursuant to which to original options were granted. As such each Assumed Option is subject to the terms and conditions set forth in the
Calidi Equity Plan (except any references therein to Calidi or Calidi Common Stock will instead mean our common stock, and except for
any other terms that are rendered inoperative by the Transactions). Each Assumed Option has the right to acquire a number of shares of
our common stock equal to (as rounded down to the nearest whole number) the product of (A) the number of shares of Calidi Common Stock
which the Calidi Option had the right to acquire immediately prior to the Effective Time, multiplied by (B) the Conversion Ratio; (ii)
have an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of the Calidi Option
(in U.S. Dollars), divided by (B) the Conversion Ratio; and is subject to the same vesting schedule as the applicable Calidi Option.
As of December 31, 2026, there were 43,425 Assumed Options issued and outstanding under the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Equity Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of director approved the 2023 Equity Incentive Plan (&#8220;Incentive Plan&#8221;), subject to the approval of our stockholders.
On August 28, 2023, the Incentive Plan was approved by our stockholder and the Incentive Plan became effective upon the consummation
of the Business Combination. The Company is authorized to grant equity awards to eligible service providers following consummation of
the Business Combination. The purpose of the Incentive Plan is to provide incentives to attract, retain, and motivate eligible persons
whose present and potential contributions are important to the success of Company, its parents, subsidiaries and affiliates that exist
now or in the future, by offering them an opportunity to participate in the Company&#8217;s future performance through the grant of Awards
(as defined in the Incentive Plan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of the Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material features of the Incentive Plan are described below. The following description of the Incentive Plan is a summary only. This
summary is not a complete statement of the Incentive Plan and is qualified in its entirety by reference to the complete text of the Incentive
Plan, a copy of which has been filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration.
</i>The Incentive Plan is expected to be administered by Calidi&#8217;s compensation committee, all of the members of which are outside
directors as defined under applicable federal tax laws, or by the board of directors of Calidi acting in place of the compensation committee
(the &#8220;Incentive Plan Administrator&#8221;). Subject to the terms and conditions of the Incentive Plan, the compensation committee
will have the authority, among other things, to select the persons to whom awards may be granted, construe and interpret the Incentive
Plan, determine the number of shares of common stock or other consideration subject to awards, determine the terms of such awards and
prescribe, amend and rescind the rules and regulations relating to the plan or any award granted thereunder, as well as to make all other
determinations necessary or advisable for the administration of the Incentive Plan. The Incentive Plan provides that the Calidi Board
or compensation committee may delegate its authority, including the authority to grant awards, to one or more executive officers to the
extent permitted by applicable law, except, however, that awards granted to non-employee directors may only be established by Calidi&#8217;s
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Types
of Awards. </i>The Incentive Plan allows for the grant of incentive stock options, nonqualified stock options (&#8220;NSOs&#8221;), stock
appreciation rights (&#8220;SARs&#8221;), restricted stock awards, restricted stock units (&#8220;RSUs&#8221;), other stock-based awards
and other cash-based awards (collectively, the &#8220;Awards&#8221;) at the discretion of the Incentive Plan Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share
Reserve. </i>Subject to Sections 2.6 and 21 in the Incentive Plan, the total number of shares of Common Stock (the
&#8220;Shares&#8221;) reserved and available for grant and issuance pursuant to the Incentive Plan is 282,815 (comprised of 32,815
Shares, which is equal to 10% of the issued and outstanding shares of Calidi determined as of immediately after the closing of the
Merger and 250,000 Shares approved at Calidi&#8217;s Annual Meeting of Shareholders held on July 9, 2025). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lapsed
or Returned Awards</i>. If Shares are subject to issuance upon exercise of an option or SAR granted under the Incentive Plan but which
cease to be subject to the option or SAR for any reason other than exercise of the option or SAR, are subject to Awards granted under
the Incentive Plan that are forfeited or are repurchased by Calidi at the original issue price, are subject to Awards granted under Incentive
Plan that otherwise terminate without such Shares being issued or are surrendered pursuant to an Exchange Program (as defined in the
Incentive Plan), the Shares subject to such awards will again be available for issuance under the Incentive Plan. If options or stock
appreciation rights granted under the Incentive Plan are exercised or RSUs are settled, only the number of shares actually issued upon
exercise or settlement of such awards will reduce the number of shares available under the Incentive Plan. If an award is paid out in
cash or other property rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance
under the Incentive Plan. Shares used to satisfy the tax withholding obligations related to an RSU or used to pay the exercise price
of an Award or withheld to satisfy the tax withholding obligations related to an Award will become available for grant and issuance in
connection with subsequent Awards under this Plan. Shares that otherwise become available for grant and issuance due to the foregoing
will not include Shares subject to Awards that initially became available because of the substitution clause in Section 21.2 in the Incentive
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
issued under the Incentive Plan may be authorized but unissued shares or treasury shares. As of the date hereof, no awards have been
granted under the Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
Stock Option Limit. </i>No more than 250,000 shares of Calidi&#8217;s Common Stock may be issued under the Incentive Plan upon the exercise
of ISOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual
Limitation on Compensation of Non-Employee Directors. </i>Non-employee directors are eligible to receive any type of Award offered under
this Plan except ISOs<i>. </i>The grant date fair value of awards granted to each non-employee director during any fiscal year of Calidi
may not exceed $750,000 (on a per-director basis). This limit is increased to $1,000,000 in the fiscal year a non-employee director is
initially appointed or elected to Calidi&#8217;s Board. A Non-employee director may elect to receive his or her annual retainer payments
and/or meeting fees from Calidi in the form of cash or Awards or a combination thereof, if permitted, and as determined, by the Incentive
Plan Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility.
</i>Employees (including officers), directors and consultants who render services to Calidi or a parent or subsidiary thereof (whether
now existing or subsequently established) are eligible to receive awards under the Incentive Plan. ISOs may only be granted to employees
of Calidi or a parent or subsidiary thereof (whether now existing or subsequently established). As of and assuming closing of the Merger,
approximately 13 persons (including 8 executive officers and 5 non-employee directors) would be eligible to participate in the Incentive
Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>International
Participation. </i>The Incentive Plan Administrator has the authority to determine which subsidiaries of Calidi will be covered by the
Incentive Plan, determine which individuals outside the United States are eligible to participate in the Incentive Plan, modify the terms
and conditions of any Award granted to individuals outside the United States or foreign nationals to comply with applicable foreign laws,
policies, customs, and practices, establish subplans and modify applicable grant terms and take any action that the Incentive Plan Administrator
determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Repricing.
</i>The Incentive Plan Administrator has full authority to reprice options and stock appreciation rights (where such repricing is a reduction
in the exercise price of outstanding options or SARs, the consent of the affected participants is not required provided written notice
is provided to them) and to approve programs in which options and stock appreciation rights are exchanged for cash or other equity awards
on terms the Incentive Plan Administrator determines, with the consent of the respective participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options. </i>A stock option is the right to purchase a certain number of shares of stock at a fixed exercise price which, pursuant to
the Incentive Plan, may not be less than 100% of the fair market value of Calidi Common Stock on the date of grant. Subject to limited
exceptions, an option may have a term of up to 10 years and will generally expire sooner if the option holder&#8217;s service terminates.
Options will vest at the rate determined by the Incentive Plan Administrator. An option holder may pay the exercise price of an option
in cash, or, with the Incentive Plan Administrator&#8217;s consent, with shares of stock the option holder already owns, with proceeds
from an immediate sale of the option shares through a broker approved by the Incentive Plan Administrator, through a net exercise procedure
or by any other method permitted by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Incentive Plan Administrator may grant ISOs or NSOs to eligible employees and shall further determine the number of Shares subject to
the option, the exercise price of the option, the period during which the option may vest and be exercised, and all other terms and conditions
of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to awards granted as ISOs, to the extent that the aggregate fair market value of Calidi Common Stock with respect to which such
ISOs are exercisable for the first time by an option holder during any calendar year under all of Calidi&#8217;s stock plans exceeds
one hundred thousand dollars ($100,000), such options will generally be treated as NSOs. No ISO may be granted to any person who, at
the time of the grant, owns or is deemed to own stock possessing more than 10% of Calidi&#8217;s total combined voting power or that
of any parent or subsidiary of Calidi unless (a) the option exercise price is at least 110% of the fair market value of the stock subject
to the option on the date of grant and (b) the term of the ISO does not exceed five years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights. </i>A stock appreciation right provides the recipient with the right to the appreciation in a specified number of
shares of stock. The Incentive Plan Administrator shall determine the terms of each SAR, including the number of Shares subject to the
SAR, the exercise price, which may not be less than the fair market value of Calidi Common Stock on the date of grant, and exercise period,
the consideration to be distributed on exercise and settlement of the SAR, and the effect of the termination of service on each SAR.
Subject to limited exceptions, a stock appreciation right may have a term of up to 10 years and will generally expire sooner if the recipient&#8217;s
service terminates. SARs will vest at the rate determined by the Incentive Plan Administrator. Upon exercise of a SAR, the recipient
will receive an amount in cash, stock, or a combination of stock and cash determined by the Incentive Plan Administrator, equal to the
excess of the fair market value of the shares being exercised over their exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards. </i>A restricted stock award is an offer by Calidi to sell to an eligible employee that are subject to restrictions. Shares
of restricted stock may be issued under the Incentive Plan pursuant to a restricted stock award agreement, for such consideration as
the Incentive Plan Administrator may determine, including cash, services rendered or to be rendered to Calidi or such other forms of
consideration permitted under applicable law. The Incentive Plan Administrator in its discretion shall determine the number of shares
that may be purchased, the purchase price (if any), the restrictions under which the Shares will be subject, and all other terms and
conditions of the restricted stock award. Recipients of restricted stock generally have all of the rights of a shareholder with respect
to those shares, including voting rights, however any dividends and other distributions on restricted stock will generally be subject
to the same restrictions on transferability and forfeitability as the underlying shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units. </i>A restricted stock unit is a right to receive a share, at no cost to the recipient, upon satisfaction of certain conditions,
including vesting conditions, established by the Incentive Plan Administrator pursuant to a restricted stock unit agreement. RSUs vest
at the rate determined by the Incentive Plan Administrator and any unvested RSUs will generally be forfeited upon termination of the
recipient&#8217;s service, provided that no RSU will have a term longer than 10 years. If the RSU is being earned upon satisfaction of
performance criteria, the Incentive Plan Administer shall determine the nature, length, and starting date for the RSU, select from among
the performance criteria to be used to measure the performance, if any, and determine the number of Shares deemed subject to the RSU.
Settlement of RSUs may be made in the form of cash, stock or a combination of cash and stock, as determined by the Incentive Plan Administrator
in its sole discretion. Recipients of RSUs generally will have no voting or dividend rights prior to the time the vesting conditions
are satisfied and the award is settled. At the Incentive Plan Administrator&#8217;s discretion and as set forth in the applicable restricted
stock unit agreement, RSUs may provide for the right to dividend equivalents which will generally be subject to the same conditions and
restrictions as the RSUs to which they pertain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
to Capital Structure. </i>In the event of certain changes in capitalization, including a stock split, reverse stock split or stock dividend,
proportionate adjustments will be made in the number and kind of shares available for issuance under the Incentive Plan, the limit on
the number of shares that may be issued under the Incentive Plan as ISOs, the number and kind of shares subject to each outstanding award
and/or the exercise price of each outstanding award, subject to any required action by the Calidi Board or Calidi Stockholders and in
compliance with applicable securities or other laws. No fractional shares shall be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
Transactions; Change in Control. </i>If Calidi is party to a merger, consolidation or certain Change in Control transactions, each outstanding
award will be treated as described in the definitive transaction agreement, which need not treat all outstanding awards in an identical
manner, and, may include the continuation, assumption or substitution of an outstanding award, the cancellation of an outstanding award
after an opportunity to exercise or the cancellation of an outstanding award in exchange for a payment equal to the value of the shares
subject to such award less any applicable exercise price. In general, if an award held by a participant who remains in service at the
effective time of a Change in Control transaction is not continued, assumed or substituted, then the award will vest in full. In the
event such successor or acquiring corporation (if any) refuses to assume, convert, replace or substitute outstanding awards pursuant
to a Corporate Transaction (as defined in the Incentive Plan), then the Incentive Plan Administrator will notify each participant that
such participant&#8217;s award will, if exercisable, be exercisable for a period of time determined by the Incentive Plan Administrator
in its sole discretion, and such award will terminate upon the expiration of such period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability
of Awards. </i>Unless the Incentive Plan Administrator determines otherwise, an award generally will not be transferable other than by
beneficiary designation, a will or the laws of descent and distribution. The Incentive Plan Administrator may permit transfer of an award
in a manner consistent with applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
and Termination. </i>The Incentive Plan Administrator may amend or terminate the Incentive Plan at any time. Any such amendment or termination
will not affect outstanding awards. If not sooner terminated, the Incentive Plan will terminate automatically 10 years after its adoption
by the FLAG Board. Shareholder approval is not required for any amendment of the Incentive Plan, unless required by applicable law, government
regulation or exchange listing standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Federal Income Tax Aspects of Awards Under the Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is a brief summary of the U.S. federal income tax aspects of awards that may be made under the Incentive Plan based on existing U.S.
federal income tax laws as of the date of this report. This summary covers only the basic tax rules. It does not describe a number of
special tax rules, including the alternative minimum tax and various elections that may be applicable under certain circumstances. It
also does not reflect provisions of the income tax laws of any municipality, state or foreign country in which a holder may reside, nor
does it reflect the tax consequences of a holder&#8217;s death. Therefore, no one should rely on this summary for individual tax compliance,
planning or decisions. Participants in the Incentive Plan should consult their own professional tax advisors concerning tax aspects of
awards under the Incentive Plan. The discussion below concerning tax deductions that may become available to the Company under U.S. federal
tax law is not intended to imply that the Company will necessarily obtain a tax benefit from those deductions. The tax consequences of
awards under the Incentive Plan depend upon the type of award. Changes to tax laws following the date of this report could alter the
tax consequences described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
Stock Options. </i>No taxable income is recognized by an option holder upon the grant or vesting of an ISO, and no taxable income is
recognized at the time an ISO is exercised unless the option holder is subject to the alternative minimum tax. The excess of the fair
market value of the purchased shares on the exercise date over the exercise price paid for the shares is includable in alternative minimum
taxable income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the option holder holds the purchased shares for more than one year after the date the ISO was exercised and more than two years after
the ISO was granted (the &#8220;required ISO holding periods&#8221;), then the option holder will generally recognize long-term capital
gain or loss upon disposition of such shares. The gain or loss will equal the difference between the amount realized upon the disposition
of the shares and the exercise price paid for such shares. If the option holder disposes of the purchased shares before satisfying either
of the required ISO holding periods, then the option holder will recognize ordinary income equal to the fair market value of the shares
on the date the ISO was price paid for the shares (or, if less, the amount realized on a sale of such shares). Any additional gain will
be a capital gain and will be treated as short-term or long-term capital gain depending on how long the shares were held by the option
holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nonqualified
Stock Options. </i>No taxable income is recognized by an option holder upon the grant or vesting of an NSO, provided the NSO does not
have a readily ascertainable fair market value. If the NSO does not have a readily ascertainable fair market value, the option holder
will generally recognize ordinary income in the year in which the option is exercised equal to the excess of the fair market value of
the purchased shares on the exercise date over the exercise price paid for the shares. If the option holder is an employee or former
employee, the option holder will be required to satisfy the tax withholding requirements applicable to such income. Upon resale of the
purchased shares, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital
gain or loss depending on how long the shares were held by the option holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights. </i>In general, no taxable income results upon the grant of a SAR. A participant will generally recognize ordinary
income in the year of exercise equal to the value of the shares or other consideration received. In the case of a current or former employee,
this amount is subject to income tax withholding. Upon resale of the shares acquired pursuant to a SAR, any subsequent appreciation or
depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss depending on how long the shares
were held by the recipient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards. </i>A participant who receives an award of restricted stock generally does not recognize taxable income at the time of
the award. Instead, the participant recognizes ordinary income when the shares vest, subject to withholding if the participant is an
employee or former employee. The amount of taxable income is equal to the fair market value of the shares on the vesting date(s) less
the amount, if any, paid for the shares. Alternatively, a participant may make a one-time election to recognize income at the time the
participant receives restricted stock in an amount equal to the fair market value of the restricted stock (less any amount paid for the
shares) on the date of the award by making an election under Section 83(b) of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Unit. </i>In general, no taxable income results upon the grant of an RSU. The recipient will generally recognize ordinary income,
subject to withholding if the recipient is an employee or former employee, equal to the fair market value of the shares that are delivered
to the recipient upon settlement of the RSU. Upon resale of the shares acquired pursuant to an RSU, any subsequent appreciation or depreciation
in the value of the shares will be treated as short-term or long-term capital gain or loss depending on how long the shares were held
by the recipient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Section
409A. </i>The foregoing description assumes that Section 409A of the Code does not apply to an award. In general, options and stock appreciation
rights are exempt from Section 409A if the exercise price per share is at least equal to the fair market value per share of the underlying
stock at the time the option or stock appreciation right was granted. RSUs are subject to Section 409A unless they are settled within
two and one half months after the end of the later of (a) the end of the Company&#8217;s fiscal year in which vesting occurs or (b) the
end of the calendar year in which vesting occurs. Restricted stock awards are not generally subject to Section 409A. If an award is subject
to Section 409A and the provisions for the exercise or settlement of that award do not comply with Section 409A, then the participant
would be required to recognize ordinary income whenever a portion of the award vested (regardless of whether it had been exercised or
settled). This amount would also be subject to a 20% U.S. federal tax <i>in addition to </i>the U.S. federal income tax at the participant&#8217;s
usual marginal rate for ordinary income, plus premium interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
Treatment. </i>The Company will generally be entitled to an income tax deduction at the time and to the extent a participant recognizes
ordinary income as a result of an award granted under the Incentive Plan. However, Section 162(m) of the Code may limit the deductibility
of certain awards granted under the Incentive Plan. Although the Incentive Plan Administrator considers the deductibility of compensation
as one factor in determining executive compensation, the Incentive Plan Administrator retains the discretion to award and pay compensation
that is not deductible as it believes that it is in the shareholders&#8217; best interests to maintain flexibility in the approach to
executive compensation and to structure a program that the Company considers to be the most effective in attracting, motivating and retaining
key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
Plan Benefits </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits
to be received under the Incentive Plan are not determinable since they depend on awards to be established by the Incentive Plan Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
with the SEC </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company filed a registration statement on Form S-8 registering the shares of our common stock reserved for issuance
under the Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023
Employee Stock Purchase Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the consummation of the Business Combination, our Board approved and adopted, subject to our stockholders approval, the 2023 Employee
Stock Purchase Plan, hereinafter the 2023 ESPP. The purpose of the 2023 ESPP is to provide a means whereby the Company can align the
long-term financial interests of its employees with the financial interests of its shareholders. In addition, the board of directors
believes that the ability to allow its employees to purchase shares of our common stock will help it to attract, retain, and motivate
employees and encourages them to devote their best efforts to our business and financial success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2023 our stockholders approved the 2023 ESPP which became effective on the consummation of the Business Combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of the 2023 ESPP </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material features of the 2023 ESPP are described below. The following description of the 2023 ESPP is a summary only. This summary is
not a complete statement of the 2023 ESPP and is qualified in its entirety by reference to the complete text of the 2023 ESPP, a copy
of which has been filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose.
</i>The purpose of the 2023 ESPP is to provide a means by which eligible employees of Calidi and certain designated companies may be
given an opportunity to purchase shares of New Calidi Common Stock following the closing of the Business Combination, to assist New Calidi
in retaining the services of eligible employees, to secure and retain the services of new employees and to provide incentives for such
persons to exert maximum efforts for New Calidi&#8217;s success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan includes two components: a 423 Component and a Non-423 Component. Calidi intends that the 423 Component will qualify as options
issued under an &#8220;employee stock purchase plan&#8221; as that term is defined in Section 423(b) of the Code. Except as otherwise
provided in the 2023 ESPP or determined by Calidi board of directors, the Non-423 Component will operate and be administered in the same
manner as the 423 Component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Share
Reserve</i>. The maximum number of shares of New Calidi Common Stock that may be issued under the 2023 ESPP was to be set by the New
Calidi Board at a number that represents approximately 2.0% of New Calidi&#8217;s issued and outstanding Common Stock immediately after
the closing of the Business Combination (after giving effect to the Redemption) or such lesser amount as determined by the Board at such
time. The number of shares of New Calidi Common Stock available for issuance under the 2023 ESPP upon it becoming effective could not
exceed 32,815. The number of shares of New Calidi Common Stock that may be issued under the 2023 ESPP was set by the New Calidi Board
at 32,815. Shares subject to purchase rights granted under the 2023 ESPP that terminate without having been exercised in full will not
reduce the number of shares available for issuance under the 2023 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration</i>.
New Calidi Board, or a duly authorized committee thereof, will administer the 2023 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Limitations</i>.
New Calidi employees and the employees of any of its designated affiliates, will be eligible to participate in the 2023 ESPP, provided
they may have to satisfy one or more of the following service requirements before participating in the 2023 ESPP, as determined by the
administrator: (1) customary employment with Calidi or one of its affiliates for more than 20 hours per week and five or more months
per calendar year or (2) continuous employment with Calidi or one of its affiliates for a minimum period of time, not to exceed two years,
prior to the first date of an offering. In addition, New Calidi Board may also exclude from participation in the 2023 ESPP employees
who are &#8220;highly compensated employees&#8221; (within the meaning of Section 423(b)(4)(D) of the Code) or a subset of such highly
compensated employees. If this proposal is approved by the FLAG stockholders, all the employees of New Calidi and its related corporations
will be eligible to participate in the 2023 ESPP following the closing of the Business Combination. An employee may not be granted rights
to purchase stock under the 2023 ESPP (a) if such employee immediately after the grant would own stock possessing 5% or more of the total
combined voting power or value of all classes of New Calidi capital stock or (b) to the extent that such rights would accrue at a rate
that exceeds $25,000 worth of New Calidi capital stock for each calendar year that the rights remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 ESPP is intended to qualify as an employee stock purchase plan under Section 423 of the Code. The administrator may specify offerings
with a duration of not more than 27 months and may specify one or more shorter purchase periods within each offering. Each offering will
have one or more purchase dates on which shares of New Calidi Common Stock will be purchased for the employees who are participating
in the offering. The administrator, in its discretion, will determine the terms of offerings under the 2023 ESPP. The administrator has
the discretion to structure an offering so that if the fair market value of a share of New Calidi Common Stock on any purchase date during
the offering period is less than or equal to the fair market value of a share of New Calidi Common Stock on the first day of the offering
period, then that offering will terminate immediately, and the participants in such terminated offering will be automatically enrolled
in a new offering that begins immediately after such purchase date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
participant may not transfer purchase rights under the 2023 ESPP other than by will, the laws of descent and distribution, or as otherwise
provided under the 2023 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Payroll
Deductions</i>. The 2023 ESPP permits participants to purchase shares of New Calidi Common Stock through payroll deductions of up to
15% of their earnings. Unless otherwise determined by the administrator, the purchase price of the shares will be 85% of the lower of
the fair market value of New Calidi Common Stock on the first day of an offering or on the date of purchase. Participants may end their
participation at any time during an offering and will be paid their accrued contributions that have not yet been used to purchase shares,
without interest. Participation ends automatically upon termination of employment with New Calidi and its related corporations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Withdrawal</i>.
Participants may withdraw from an offering by delivering a withdrawal form to New Calidi and terminating their contributions. Such withdrawal
may be elected at any time prior to the end of an offering, except as otherwise provided by the plan administrator. Upon such withdrawal,
New Calidi will distribute to the employee his or her accumulated but unused contributions without interest, and such employee&#8217;s
right to participate in that offering will terminate. However, an employee&#8217;s withdrawal from an offering does not affect such employee&#8217;s
eligibility to participate in any other offerings under the 2023 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
of Employment</i>. A participant&#8217;s rights under any offering under the 2023 ESPP will terminate immediately if the participant
either (i) is no longer employed by New Calidi or any of its parent or subsidiary companies (subject to any post-employment participation
period required by law) or (ii) is otherwise no longer eligible to participate. In such event, New Calidi will distribute to the participant
his or her accumulated but unused contributions, without interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
Transactions</i>. In the event of certain specified significant corporate transactions, such as a merger or Change in Control, a successor
corporation may assume, continue, or substitute each outstanding purchase right. If the successor corporation does not assume, continue,
or substitute for the outstanding purchase rights, the offering in progress will be shortened and a new purchase date will be set. The
participants&#8217; purchase rights will be exercised on the new purchase date and such purchase rights will terminate immediately thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment
and Termination</i>. New Calidi Board of directors has the authority to amend, suspend, or terminate the 2023 ESPP, at any time and for
any reason, provided certain types of amendments will require the approval of Calidi Stockholders. Any benefits privileges, entitlements
and obligations under any outstanding purchase rights granted before an amendment, suspension or termination of the Plan will not be
materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such purchase
rights were granted, (ii) as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations, or
(iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. The 2023 ESPP will remain in effect until terminated
by New Calidi Board in accordance with the terms of the 2023 ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Federal Income Tax Consequences </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the principal U.S. federal income tax consequences to participants and Calidi with respect to participation
in the 2023 ESPP. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign
jurisdiction in which a participant may reside. The information is based upon current U.S. federal income tax rules and therefore is
subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation,
each participant should consult the participant&#8217;s tax adviser regarding the federal, state, local, and other tax consequences of
the grant or exercise of a purchase right or the sale or other disposition of New Calidi Common Stock acquired under the 2023 ESPP. The
2023 ESPP is not qualified under the provisions of Section 401(a) of the Code and is not subject to any of the provisions of the Employee
Retirement Income Security Act of 1974, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>423
Component of the 2023 ESPP </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights
granted under the 423 Component of the 2023 ESPP are intended to qualify for favorable U.S. federal income tax treatment associated with
rights granted under an employee stock purchase plan which qualifies under the provisions of Section 423 of the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
participant will be taxed on amounts withheld for the purchase of shares of New Calidi Common Stock as if such amounts were actually
received. Otherwise, no income will be taxable to a participant as a result of the granting or exercise of a purchase right until a sale
or other disposition of the acquired shares. The taxation upon such sale or other disposition will depend upon the holding period of
the acquired shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the shares are sold or otherwise disposed of more than two years after the beginning of the offering period and more than one year after
the shares are transferred to the participant, then the lesser of the following will be treated as ordinary income: (i) the excess of
the fair market value of the shares at the time of such sale or other disposition over the purchase price; or (ii) the excess of the
fair market value of the shares as of the beginning of the offering period over the purchase price (determined as of the beginning of
the offering period). Any further gain or any loss will be taxed as a long-term capital gain or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the shares are sold or otherwise disposed of before the expiration of either of the holding periods described above, then the excess
of the fair market value of the shares on the purchase date over the purchase price will be treated as ordinary income at the time of
such sale or other disposition. The balance of any gain will be treated as capital gain. Even if the shares are later sold or otherwise
disposed of for less than their fair market value on the purchase date, the same amount of ordinary income is attributed to the participant,
and a capital loss is recognized equal to the difference between the sales price and the fair market value of the shares on such purchase
date. Any capital gain or loss will be short-term or long-term, depending on how long the shares have been held.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-423
Component </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
participant will be taxed on amounts withheld for the purchase of shares of New Calidi Common Stock as if such amounts were actually
received. Under the Non-423 Component, a participant will recognize ordinary income equal to the excess, if any, of the fair market value
of the underlying stock on the date of exercise of the purchase right over the purchase price. If the participant is employed by Calidi
or one of its affiliates, that income will be subject to withholding taxes. The participant&#8217;s tax basis in those shares will be
equal to their fair market</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
of Liability and Indemnification Matters </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter limits the liability of our current and former directors and officers for monetary damages to the fullest extent permitted by
Delaware law. Delaware law provides that directors and officers of a corporation will not be personally liable for monetary damages for
any breach of fiduciary duties as directors, except liability for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payments of dividends or unlawful stock repurchases or redemptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    transaction from which the director derived an improper personal benefit; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    officer in any action by or in the right of the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable
remedies such as injunctive relief or rescission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter authorizes us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law.
The Bylaws provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may
indemnify our other employees and agents. The Bylaws also provide that, on satisfaction of certain conditions, we will advance expenses
incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance
on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless
of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to
continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide
for indemnification for related expenses including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of
these individuals in connection with any action, proceeding or investigation. We believe that the Charter and Bylaws provisions and indemnification
agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#8217;
and officers&#8217; liability insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
limitation of liability and indemnification provisions in our Charter and Bylaws may discourage stockholders from bringing a lawsuit
against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors
and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment
may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required
by these indemnification provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive officers or persons controlling
us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_013"></span>ITEM
12 &#8211; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table and the accompanying
footnotes sets forth information regarding the beneficial ownership of shares of Common Stock of the Company as of March 20, 2026 by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known by the Company to be the beneficial owner of more than 5% of the outstanding shares of Common Stock
on March 20, 2026;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of the Company&#8217;s executive officers and directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    executive officers and directors of the Company as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security
if they possess sole or shared voting (which includes the power to vote or to direct the voting of) or investment power (which includes
the power to dispose of or to direct the disposition of) that security, including options and warrants that are currently exercisable
or exercisable within sixty (60) days. To our knowledge, no shares beneficially owned by any executive officer, director or director
nominee have been pledged as security. In addition, this table is based upon information Schedules 13D or 13G filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The beneficial ownership information below is based on an aggregate of
approximately 10,895,725 shares (excluding 150,000 Non-Voting Common Stock held in escrow) of Common Stock issued and outstanding as of March
20, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise noted in the footnotes to the following table, and subject to applicable community property laws, the persons and entities
named in the table have sole voting and investment power with respect to their beneficially owned securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Beneficial Owners<sup>(1)</sup></b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
                                            Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Beneficially</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owned</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of <br/> Common Stock**</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Officers and Directors:</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Poma<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65,133</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allan
    J. Camaisa<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,317</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Jackson<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Antonio Santidrian<sup>(5)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,596</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
    Leftwich<sup>(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">292,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    R. Stewart<sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,901</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    A. Schoeneck<sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188,149</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    E. Peoples<sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,359</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Executive Officers and Directors as a Group (eight individuals)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">661,630</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5%
    Shareholders:</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Gavrilov Ognian
Anguelov<sup>(10)</sup></p>
</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">700,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than one percent (1%).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on 10,895,725 shares of common stock outstanding as of March 20, 2026, which excludes 150,000 Non-Voting Common Stock held in escrow
    which may be issued upon achieving certain share price hurdles and includes shares issuable within sixty (60) days to the following
    entities or individuals respectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise noted, the business address of each of the following entities or individuals is c/o Calidi Biotherapeutics, Inc., 4475
    Executive Drive, Suite 200, San Diego, California 92121.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 25,000 shares of Common Stock held by Eric Poma, (ii) 15,133 shares of Common Stock issuable upon exercise
of vested options within sixty (60) days held by Mr. Poma, and (iii) 25,000 shares of Common Stock issuable upon exercise of warrants
within sixty (60) days held by Mr. Poma.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 6,394 shares of Common Stock held by Allan Camaisa, (ii) 1,563 shares of Common Stock issuable upon
exercise of vested options within sixty (60) days held by Mr. Camaisa, (iii) 3,915 shares of Common Stock issuable upon exercise of warrants
within sixty (60) days held by Mr. Camaisa, (iv) 22,887 shares of Common Stock issuable upon exercise of vested options within sixty (60)
days held by AJC Capital, LLC (&#8220;AJC&#8221;), (v) 19,860 shares of Common Stock held by AJC, and (vi) 50,698 shares of Common Stock
held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa
may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 2,500 shares of Common Stock held by Andrew Jackson, (ii) 1,562 shares of Common Stock issuable upon
exercise of vested options within sixty (60) days held by Mr. Jackson, and (iii) 2,500 shares of Common Stock issuable upon exercise of
warrants within sixty (60) days held by Mr. Jackson.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 2,524 shares of Common Stock held by Antonio Santidrian, and (ii) 1,072 shares of Common Stock issuable
upon exercise of vested options within sixty (60) days held by Mr. Santidrian.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 130,650 shares of Common Stock held by Scott Leftwich, (ii) 16,815 shares of Common Stock issuable upon
exercise of vested options within sixty (60) days held by Mr. Leftwich, (iii) 129,167 shares of Common Stock issuable upon exercise of
warrants within sixty (60) days held by Mr. Leftwich, (iv) 14,672 shares of Common Stock held by SECBL, LLC (&#8220;SECBL&#8221;), and
(v) 1,309 shares of Common Stock held by WEBCL, LLC (&#8220;WEBCL&#8221;). Mr. Leftwich is the managing member of SECBL and WEBCL; as
such, Mr. Leftwich may be deemed to have beneficial ownership of the common stock held by SECBL and WEBCL.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 2,416 shares of Common Stock held by Alan Stewart and (ii) 11,485 shares of Common Stock issuable upon
exercise of vested options within sixty (60) days held by Mr. Stewart.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes (i) 76,134 shares of Common Stock held by James Schoeneck, (ii) 16,376 shares of Common Stock issuable upon
exercise of vested options within sixty (60) day held by Mr. Schoeneck, (iii) 347 shares of Common Stock held by Mr. Schoeneck and his
wife, (iv) 8,033 shares of Common Stock held by the James &amp; Cynthia Schoeneck Family Trust, of which Mr. Schoeneck is a trustee, and
(v) 87,259 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by the James &amp; Cynthia Schoeneck
Family Trust, of which Mr. Schoeneck is a trustee. As such, Mr. Schoeneck may be deemed to have shared voting, investment and dispositive
power with respect to the shares held by the James &amp; Cynthia Schoeneck Family Trust. Mr. Schoeneck disclaims beneficial ownership
of these shares except to the extent of his pecuniary interest, if any, therein.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(9)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes shares of Common Stock issuable upon exercise of vested options within sixty (60) days held by George Peoples.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">(10)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the Schedule 13D filed by Gavrilov Ognian Anguelov on March 9, 2026. Mr. Anguelov&#8217;s address is <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2315
Capitol Avenue, Sacramento, CA 95816.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_014"></span>ITEM
13 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as set forth below and compensation arrangements, including employment, and indemnification arrangements, discussed, there have
been no transactions since January 1, 2021, in which the amount involved in the transaction exceeded or will exceed the lesser of $120,000
or one percent of the average of our total assets as at the year-end for the last two completed fiscal years, and to which any of our
directors, executive officers or beneficial holders of more than 5% of our capital stock, or any immediate family member of, or person
sharing the household with, any of these individuals, had or will have a direct or indirect material interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Audit
Committee&#8217;s written charter, our Audit Committee has the responsibility to review, approve and oversee transactions between the
Company and any related person (as defined in Item 404 of Regulation S-K) and any potential conflict of interest situations on an ongoing
basis, in accordance with our policies and procedures, and to develop policies and procedures for the Audit Committee&#8217;s approval
of related party transactions.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Related Party</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Description of investment or transaction</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br/>
 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Director A and Director E</td><td style="width: 2%">&#160;</td>
    <td style="width: 42%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current term notes payable, net of discount, including accrued interest<sup>(1) </sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,702</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director F and relative of Officer A</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses<sup>(2) </sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director F</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance accrual<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director D</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance accrual<sup>(4) </sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">434</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director A</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory services included in accrued expenses<sup>(5) </sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director F</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease guaranty<sup>(6) </sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director A</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other liabilities<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">638</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Director F and Director A</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant liability<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Relative of Officer A</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan payable<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">223</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Officer G</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance accrual<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Officer A</td><td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance accrual<sup>(11)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Company A related to Director G</td><td>&#160;</td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable and accrued expenses<sup>(12)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024,
    related party term note payable amounts due to Directors A and E totaled $2.7 million. See Note 7 in our consolidated financial statements
    for further details.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts owed to Director
    F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to a relative of Officer
    A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were
    approximately $48 thousand and $38 thousand for the years ended December 31, 2025 and 2024, respectively.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 22, 2025, the
    Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr. Camaisa, (Director
    F referenced above), and is obligated to pay Director F $0.5 million separation pay in the form of compensation continuation over
    12 months pursuant to our regular and customary payroll schedule, less all regular and customary payroll withholdings and shall also
    be liable to pay Director F COBRA premiums for 12 months, commencing May 2025, of which $0.2 million is outstanding as of December
    31, 2025. Director F shall also be entitled to receive transition and consulting pay of $10,000 per month during the transition period.
    The agreement terminated on December 31, 2025 and $0.1 million was expensed under the agreement. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 1, 2022, the
    Company appointed a then current board member (Director D referenced above), George K. Ng, as President and Chief Operating Officer
    of the Company under an Employment Agreement (the &#8220;Ng Agreement&#8221;). Under the Ng Agreement, Mr. Ng was entitled to a base
    annual salary of $0.5 million and a signing bonus of $0.3 million, payable in three equal monthly installments. Mr. Ng was eligible
    for standard change in control and severance benefits. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 23, 2023, the Company
    entered into a Separation and Release Agreement with Mr. Ng which included a severance accrual and accrued interest as of December
    31, 2024 (see Note 11 in our consolidated financial statements). The lump sum payment and accrued interest was settled in January
    2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2022, the Company
    entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain strategic and advisory
    services. Director A received an advisory fee of $9,166 per month not to exceed $0.1 million per annum, accrued and payable upon
    the Company raising $10 million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement terminated
    on August 31, 2023. The accrued advisory fees were settled in January 2025.</span></td></tr>

</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2022, in order
    for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal Guaranty of Lease
    of (the &#8220;Guaranty&#8221;) up to $0.9 million to the lessor for the Company&#8217;s future performance under the San Diego Lease
    agreement. As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount for the first year
    of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with all amounts accrued
    and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor, whichever occurs
    first. As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present value, including
    accrued interest as of the period shown, of approximately $14,000 and $0.2 million, respectively, payment due to Director F upon
    the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability. The amount due
    to Director F was partially settled in April 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2023, the Company
    entered into an agreement with Director A for deferred compensation including advisory fees for $0.5 million, which was paid in January
    2025 (see Note 11). The $0.5 million note bore interest at 24% through August 12, 2024, at which time the note was amended and replaced
    with an interest rate of 14% per annum. The deferred compensation and advisory fees were settled in January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 8 in our consolidated
    financial statements for disclosures around Warrants. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2024, the Company
    entered into a loan agreement with a relative of Officer A for a loan payable for $0.2 million, which bears interest at 12%. The
    loan was settled in full in January 2025. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2025, the
    Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay to Officer G $0.1 million
    in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $0.2 million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer G&#8217;s COBRA premiums for six months, commencing August 2025. As of December 31, 2025,
    $0.1 million of severance pay and related benefits were included in related party accrued expenses and other liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 17, 2025,
    the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to pay to Officer A i)
    a bonus in the amount of $0.1 million, upon the successful and effective corporate spin-off, out-licensing, or similar transaction
    relating to Nova Cell prior to October 31, 2025, and (ii) $0.2 million severance pay in the form of compensation continuation over
    six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary payroll withholdings
    and shall pay Officer A&#8217;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025, $0.2 million of
    severance pay and related benefits were included in related party accrued expenses and other liabilities.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 13, 2024, the
    Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for contract research organization
    (&#8220;CRO&#8221;) services and other clinical development services. As part of the Master Services Agreement, the Company is obligated
    to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for services. As of December 31, 2025,
    the Company accrued $0.1 million due to Company A, included in related party accounts payable and accrued expenses. Furthermore,
    during the year ended December 31, 2025, the Company incurred $0.6 million in expenses related to services from Company A.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the appointment of the directors to the committees, the board of directors undertook a review of the independence of
each director. Based on information provided by each director concerning her or his background, employment and affiliations, the board
of directors determined that none of the directors, other than Mr. Camaisa, has any relationships that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director and that each of the directors is &#8220;independent&#8221;
as that term is defined under the NYSE listing standards. In making these determinations, the board of directors of considered the current
and prior relationships that each non-employee director has with the Company and all other facts and circumstances the board of directors
deems relevant in determining their independence, including the beneficial ownership of our securities by each non-employee director
and the transactions described in this section.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_015"></span>ITEM
14 - PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Independent
Auditor</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal years ended December 31, 2025 and 2024, the Company&#8217;s independent public accounting firm was CBIZ CPAs P.C. (&#8220;CBIZ&#8221;)
and Marcum LLP (&#8220;Marcum&#8221;), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
Paid to Principal Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate fees billed by our Independent Registered Public Accounting Firm, for the fiscal years ended December 31, 2025 and 2024 are
as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">451</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">461</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    related fees(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    fees(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other fees(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">451</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">461</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees represent fees for professional services provided in connection with the audit of our annual financial statements and the review
    of our quarterly financial statements and those services normally provided in connection with statutory or regulatory filings or
    engagements including comfort letters, consents and other services related to SEC matters. This information is presented as of the
    latest practicable date for this annual report.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit-related
    fees represent fees for assurance and related services that are reasonably related to the performance of the audit or review of our
    financial statements and not reported above under &#8220;Audit Fees.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CBIZ
    did not provide us with tax compliance, tax advice or tax planning services.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other fees include fees billed by our independent auditors for products or services other than as described in the immediately preceding
    three categories. No such fees were incurred during the fiscal years ended December 31, 2025 or 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee&#8217;s policy is to pre-approve all audit and permissible non-audit services provided by our independent registered
public accounting firm, the scope of services provided by our independent registered public accounting firm and the fees for the services
to be performed. These services may include audit services, audit-related services, tax services and other services. Pre-approval is
detailed as to the particular service or category of services and is generally subject to a specific budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm and management are required to periodically report to the audit committee regarding the
extent of services provided by our independent registered public accounting firm in accordance with this preapproval, and the fees for
the services performed to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the services relating to the fees described in the table above were approved by our audit committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_016"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_017"></span>ITEM
15 - EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)
The following documents are filed as part of this Form 10-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following financial statements of Calidi Biotherapeutics, Inc. and Report of CBIZ CPAs P.C., independent registered public accounting
firm, are included in this report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_001">Report of Independent Registered Public Accounting Firm</a></span> (PCAOB ID 199)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#bs_002">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID 688)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#HK_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2025 and 2024</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#HK_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#HK_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Total Equity for the Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#HK_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#HK_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Financial Statement Schedules: All schedules have been omitted because the required information is included in the financial statements
or notes thereto or because they are not required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Exhibits:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 72pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exhibits required by Item 601 of Regulation S-K are listed in subparagraph (b) below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The following exhibits are filed as part of this Report</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225024489/ex1-1.htm" style="-sec-extract: exhibit">Underwriting Agreement, dated August 20, 2025 (incorporated herein by reference to Exhibit 1.1 to Form S-1 filed with the SEC on August 15, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">1.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex1-1.htm" style="-sec-extract: exhibit">Underwriting Agreement, dated March 6, 2026 (incorporated herein by reference to Exhibit 1.1 to Form 8-K filed with the SEC on March 11, 2026).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523004705/d425996dex21.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger, dated as of January 9, 2023, by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc., Calidi, First Light Acquisition Group, LLC and Allan Camaisa (incorporated by reference to Exhibit 2.1 to Form 8-K filed on January 9, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523032729/d442631dex21.htm" style="-sec-extract: exhibit">Amendment No. 1, dated as of February 9, 2023, to Agreement and Plan of Merger, dated as of January 9, 2023, by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc., Calidi, First Light Acquisition Group, LLC and Allan Camaisa (incorporated by reference to Exhibit 2.1 to Form 8-K filed on February 10, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523173151/d521495dex21.htm" style="-sec-extract: exhibit">Amendment No. 2, dated as of June 16, 2023, to Agreement and Plan of Merger, dated as of January 9, 2023, by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc., Calidi, First Light Acquisition Group, LLC and Allan Camaisa (incorporated by reference to Exhibit 2.1 to Form 8-K filed on June 23, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex31.htm" style="-sec-extract: exhibit">Second Amended And Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex32.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to Form 8-K filed on September 19,
    2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224008601/ex3-1.htm" style="-sec-extract: exhibit">Amendment to the Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 1, 2024).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224027867/ex3-1.htm" style="-sec-extract: exhibit">First Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on July 15, 2024).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225022592/ex3-1.htm" style="-sec-extract: exhibit">Second Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 7, 2025).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312521255074/d156305dex44.htm" style="-sec-extract: exhibit">Form of Warrant Agreement between Continental Stock Transfer &amp; Trust Company and the Registrant, dated September 9, 2021 (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-1 filed on August 24, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312521255074/d156305dex43.htm" style="-sec-extract: exhibit">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1 filed on August 24, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex43.htm" style="-sec-extract: exhibit">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.3 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex44.htm" style="-sec-extract: exhibit">Amendment to Warrant Agreement dated September 12, 2023, among Calidi Biotherapeutics, Inc., Continental Stock Transfer &amp; Trust Company and Equiniti Trust Company, LLC. (incorporated by reference to Exhibit 4.4 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224004091/ex4-5.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.5 to Form S-1 filed on January 29, 2024).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224005218/ex4-8.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.8 to Amendment No. 1 to Form S-1 filed on February 7, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant (Convertible Note) (incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 1, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224015390/ex4-13.htm" style="-sec-extract: exhibit">Form of Global Warrant Certificate (incorporated by reference to Exhibit 4.13 to Form 8-K filed on April 19, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224022229/ex4-1.htm" style="-sec-extract: exhibit">Form of New Series D Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on May 31, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224022572/ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on June 4, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224029384/ex4-1.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant, dated as of July 28, 2024 (incorporated by reference to Exhibit 4.1 to Form 8-K filed on July 29, 2024).</a>
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224042406/ex4-1.htm" style="-sec-extract: exhibit">Form of the Series E Common Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on October 24, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224042406/ex4-2.htm" style="-sec-extract: exhibit">Form of the Series F Common Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed on October 24, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224042406/ex4-3.htm" style="-sec-extract: exhibit">Form of the Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on October 24, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224046330/ex4-3.htm" style="-sec-extract: exhibit">Form of the Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on November 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315225001567/ex4-3.htm" style="-sec-extract: exhibit">Form of the Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on January 10, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225001969/ex4-1.htm" style="-sec-extract: exhibit">Form of the Pre-funded Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on April 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225001969/ex4-2.htm" style="-sec-extract: exhibit">Form of the Series G Common Warrant (incorporated by reference to Exhibit 4.2 to Form 8-K filed on April 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225001969/ex4-3.htm" style="-sec-extract: exhibit">Form of the Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K filed on April 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">4.19</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225018553/ex4-1.htm" style="-sec-extract: exhibit">Form of the Series H Common Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on July 10, 2025).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225024489/ex4-21.htm" style="-sec-extract: exhibit">Form of Pre-funded Warrant (incorporated herein by reference to Exhibit 4.21 to Form S-1 filed with the SEC on August 15, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225024489/ex4-20.htm" style="-sec-extract: exhibit">Form of Series I Common Warrant (incorporated herein by reference to Exhibit 4.20 to Form S-1 filed with the SEC on August 15, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225024489/ex4-22.htm" style="-sec-extract: exhibit">Form of Representative Warrant (incorporated herein by reference to Exhibit 4.22 to Form S-1 filed with the SEC on August 15, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-funded Warrant (incorporated herein by reference to Exhibit 4.1 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-2.htm" style="-sec-extract: exhibit">Form of Series J Common Warrant (incorporated herein by reference to Exhibit 4.2 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-3.htm" style="-sec-extract: exhibit">Form of Series K Common Warrant (incorporated herein by reference to Exhibit 4.3 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-4.htm" style="-sec-extract: exhibit">Form of Series L Common Warrant (incorporated herein by reference to Exhibit 4.4 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-5.htm" style="-sec-extract: exhibit">Form of Series Representative Warrant (incorporated herein by reference to Exhibit 4.5 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex4-6.htm" style="-sec-extract: exhibit">Form of Warrant Amendment (incorporated herein by reference to Exhibit 4.6 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523004705/d425996dex101.htm" style="-sec-extract: exhibit">Form of Voting and Lock-Up Agreement, dated as of January 9, 2023, by and among First light Acquisition Group, Inc., Calidi and certain holders of Calidi Biotherapeutics, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on January 9, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523004705/d425996dex102.htm" style="-sec-extract: exhibit">Sponsor Agreement dated as of January 9, 2023, by and among First Light Acquisition Group, Inc., Calidi, First Light Acquisition Group, LLC and certain other parties thereto (incorporated by reference to Exhibit 10.2 to Form 8-K filed on January 9, 2023).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523004705/d425996dex103.htm" style="-sec-extract: exhibit">Form of Amended and Restated Registration Rights Agreement, dated as of September 12, 2023, by and among First Light Acquisition Group, Inc., Calidi, First Light Acquisition Group, LLC, Metric Finance Holdings I, LLC and related parties (incorporated by reference to Exhibit 10.3 to Form 8-K filed on January 9, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523200665/d431982ds4a.htm#annexg431982_7" style="-sec-extract: exhibit">Calidi Biotherapeutics, Inc. 2023 Equity Incentive Plan (incorporated by reference to Annex G to the Proxy Statement/Prospectus dated August 4, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523200665/d431982ds4a.htm#annexh431982_8" style="-sec-extract: exhibit">Calidi Biotherapeutics, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Annex H to the Proxy Statement/Prospectus dated August 4, 2023 ).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523100731/d431982dex106.htm" style="-sec-extract: exhibit">License Agreement, dated June 7, 2021, by and among Calidi and Northwestern University. (incorporated by reference to Exhibit 10.6 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523100731/d431982dex107.htm" style="-sec-extract: exhibit">License Agreement, dated July 22, 2021, by and among Calidi and University of Chicago (incorporated by reference to Exhibit 10.7 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523180782/d431982dex108.htm" style="-sec-extract: exhibit">Collaboration Agreement, dated April 9, 2020, by and among Calidi and Personalized Stem Cells, Inc. (incorporated by reference to Exhibit 10.8 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523100731/d431982dex109.htm" style="-sec-extract: exhibit">Employment Agreement, dated February 1, 2022, by and among Calidi and Allan Camaisa (incorporated by reference to Exhibit 10.9 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523200665/d431982dex1012.htm" style="-sec-extract: exhibit">License Agreement, dated October 14, 2021, by and among Calidi and Northwestern University (incorporated by reference to Exhibit 10.12 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523192507/d431982dex1013.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated June 16, 2023, by and among Calidi, Jackson Investment Group, LLC and Calidi Cure, LLC (incorporated by reference to Exhibit 10.13 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523192507/d431982dex1014.htm" style="-sec-extract: exhibit">Share Transfer Agreement, dated June 16, 2023, by and among First Light Acquisition Group, Inc., Jackson Investment Group, LLC and Metric Finance Holdings I, LLC (incorporated by reference to Exhibit 10.14 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523192507/d431982dex1015.htm" style="-sec-extract: exhibit">Share Transfer Agreement, dated June 16, 2023, by and among First Light Acquisition Group, Inc., Calidi Cure, LLC and Metric Finance Holdings I, LLC (incorporated by reference to Exhibit 10.15 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523192507/d431982dex1016.htm" style="-sec-extract: exhibit">Series B Preferred Stock Investors&#8217; Rights Agreement, dated June 16, 2023, by and among Calidi and the Investors party thereto (incorporated by reference to Exhibit 10.16 to Amendment No. 5 to Form S-4 filed on August 1, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523200665/d431982ds4a.htm#ii431982_1" style="-sec-extract: exhibit">Voting and Lock-Up Agreement, dated June 16, 2023, by and among Calidi, First Light Acquisition Group, Inc. and Jackson Investment Group, LLC (incorporated by reference to Annex E-2 to the Proxy statement/Prospectus dated August 4, 2023).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: left">10.16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523100724/d438294dex101.htm" style="-sec-extract: exhibit">Form of Amendment No. 1, dated as of April 12, 2023, to the Voting Agreement, dated as of January 9, 2023, by and among First light Acquisition Group, Inc., Calidi and certain equity holders of Calidi Biotherapeutics, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on April 13, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.17</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523173151/d521495dex101.htm" style="-sec-extract: exhibit">Amendment No. 1, dated as of June 16, 2023, to the Sponsor Agreement, dated as of January 9, 2023, by and among First light Acquisition Group, Inc., Calidi, First Light Acquisition Group, LLC, Metric Finance Holdings I, LLC and certain parties thereto (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 23, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.18</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex1020.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.20 to Form 8-K filed on September 19, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.19</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex1021.htm" style="-sec-extract: exhibit">Escrow Services Agreement, dated September 12, 2023, between Equiniti Trust Company, LLC and the Company (incorporated by reference to Exhibit 10.21 to Form 8-K filed on September 19, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.20</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/d526016dex101.htm" style="-sec-extract: exhibit">Forward Purchase Agreement (incorporated by reference Exhibit 10.1 to Form 8-K filed on August 29, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.21</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/d526016dex102.htm" style="-sec-extract: exhibit">FPA Funding Amount PIPE Subscription Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on August 29, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.22</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/d526016dex103.htm" style="-sec-extract: exhibit">Non-Redemption Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on August 29, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.23</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex101.htm" style="-sec-extract: exhibit">Non-Redemption Agreement (incorporated by reference Exhibit 10.1 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.24</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex102.htm" style="-sec-extract: exhibit">Non-Redemption Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.25</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex103.htm" style="-sec-extract: exhibit">New Money PIPE Subscription Agreement (incorporated by reference to Exhibit 10.3 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.26</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex104.htm" style="-sec-extract: exhibit">Forward Purchase Agreement (incorporated by reference to Exhibit 10.4 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.27</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex105.htm" style="-sec-extract: exhibit">Forward Purchase Agreement (incorporated by reference to Exhibit 10.5 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.28</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex106.htm" style="-sec-extract: exhibit">Forward Purchase Agreement (incorporated by reference to Exhibit 10.6 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.29</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex107.htm" style="-sec-extract: exhibit">FPA Funding Amount PIPE Subscription Agreement (incorporated by reference to Exhibit 10.7 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.30</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex108.htm" style="-sec-extract: exhibit">FPA Funding Amount PIPE Subscription Agreement (incorporated by reference to Exhibit 10.8 to Form 8-K filed on August 31, 2023)</a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 0.75in">10.31</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523225571/d554604dex109.htm" style="-sec-extract: exhibit">FPA Funding Amount PIPE Subscription Agreement (incorporated by reference to Exhibit 10.9 to Form 8-K filed on August 31, 2023)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.32</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex1031.htm" style="-sec-extract: exhibit">Share and Warrant Cancellation Agreement (incorporated by reference to Exhibit 10.31 to Form 8-K filed on September 19, 2023).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">10.33</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/ex10-1.htm" style="-sec-extract: exhibit">Standby Equity Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 12, 2023)</a></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315223038596/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement, dated October 25, 2023 by and between Calidi and Andrew Jackson (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 30, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224014529/ex10-38.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.38 to Form S-1/A filed on April 15, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224004091/ex10-39.htm" style="-sec-extract: exhibit">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.39 to Form S-1 filed on January 29, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/ex10-1.htm" style="-sec-extract: exhibit">Convertible Promissory Note Purchase Agreement dated January 26, 2024 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on February 1, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224004619/ex10-2.htm" style="-sec-extract: exhibit">Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.2 to Form 8-K filed on February 1, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224009678/ex10-1.htm" style="-sec-extract: exhibit">Settlement Agreement dated March 8, 2024 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on March 12, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224009678/ex10-2.htm" style="-sec-extract: exhibit">Form of Convertible Promissory Note ($2,000,000) (incorporated by reference to Exhibit 10.2 to Form 8-K filed on March 12, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224022229/ex10-1.htm" style="-sec-extract: exhibit">Form of Inducement Letter (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 31, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224026477/ex10-1.htm" style="-sec-extract: exhibit">Loan Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 8, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224026477/ex10-2.htm" style="-sec-extract: exhibit">Promissory Note (incorporated by reference to Exhibit 10.2 to Form 8-K filed on July 8, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224029384/ex10-1.htm" style="-sec-extract: exhibit">Subscription Agreement, dated as of July 28, 2024 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 29, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224029384/ex10-2.htm" style="-sec-extract: exhibit">Form of the Scientific and Medical Advisory Board Consulting Agreement dated July 28, 2024, by and among Calidi Biotherapeutics, Inc. and Dr. Ronald Rigor (incorporated by reference to Exhibit 10.2 to Form 8-K filed on July 29, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224042406/ex10-1.htm" style="-sec-extract: exhibit">Form of the Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 24, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224042406/ex10-2.htm" style="-sec-extract: exhibit">Form of the Placement Agency Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on October 24, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224046330/ex10-1.htm" style="-sec-extract: exhibit">Form of the Placement Agency Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on November 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315225001567/ex10-1.htm" style="-sec-extract: exhibit">Form of the Placement Agency Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on January 10, 2025).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225001969/ex10-1.htm" style="-sec-extract: exhibit">Form of the Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on April 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225001969/ex10-2.htm" style="-sec-extract: exhibit">Form of the Placement Agency Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on April 1, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/ex10-1.htm" style="-sec-extract: exhibit">General Release of Claims and Transition Agreement by and between the Company and Allan Camaisa dated April 21, 2025 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on April 23, 2025).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/ex10-2.htm" style="-sec-extract: exhibit">Executive Employment Agreement by and between the Company and Eric Poma dated April 22, 2025 (incorporated by reference to Exhibit 10.2 to Form 8-K filed on April 23, 2025).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225018553/ex10-1.htm" style="-sec-extract: exhibit">Form of Inducement Letter (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 10, 2025).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225024190/ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Release of Claims and Transition Agreement by and between the Company and Dr. Boris Minev dated August 8, 2025 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on August 14, 2025).</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225024489/ex4-23.htm" style="-sec-extract: exhibit">Form of Warrant Agency Agreement (incorporated herein by reference to Exhibit 4.23 to Form S-1 filed with the SEC on August 15, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/ex10-1.htm" style="-sec-extract: exhibit">General Release of Claims and Separation Agreement by and between the Company and Wendy Pizarro Campbell dated September 17, 2025 (incorporated herein by reference to Exhibit 10.1 to Form 8-K filed with the SEC on September 19, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315225014293/ex10-2.htm" style="-sec-extract: exhibit">Consultation Agreement by and between the Company and Wendy Pizarro Campbell effective October 18, 2025 (incorporated herein by reference to Exhibit 10.2 to Form 8-K filed with the SEC on September 19, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/ex10-1.htm" style="-sec-extract: exhibit">Stock Repurchase Agreement dated October 27, 2025 (incorporated herein by reference to Exhibit 10.1 to Form 8-K filed with the SEC on October 31, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315225020390/ex10-2.htm" style="-sec-extract: exhibit">Material Purchase Agreement dated October 27, 2025 (incorporated herein by reference to Exhibit 10.2 to Form 8-K filed with the SEC on October 31, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315226009701/ex10-1.htm" style="-sec-extract: exhibit">Form of Warrant Agency Agreement (incorporated herein by reference to Exhibit 10.1 to Form 8-K filed with the SEC on March 11, 2026).</a></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex141.htm" style="-sec-extract: exhibit">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14.1 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000164117225008365/ex16-1.htm" style="-sec-extract: exhibit">Letter from Marcum LLP to the SEC, dated May 2, 2025 (incorporated by reference to Exhibit 16.1 to Form 8-K filed on May 2, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">Subsidiaries of the Company</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex23-1.htm">Independent Registered Public Accounting Firm&#8217;s Consent of Marcum LLP</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex23-2.htm">Independent Registered Public Accounting Firm&#8217;s Consent of CBIZ CPAs P.C.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">31.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm">Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">31.2*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm">Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">32.1**</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm">Certificate of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">32.2**</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm">Certificate of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">97.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000149315224010158/ex97-1.htm" style="-sec-extract: exhibit">Compensation Recoupment (Clawback) Policy (incorporated by reference to Exhibit 97.1 to Form 10-K filed on March 15, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex992.htm" style="-sec-extract: exhibit">Nominating and Corporate Governance Committee Charter (incorporated by reference to Exhibit 99.2 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex993.htm" style="-sec-extract: exhibit">Compensation Committee Charter (incorporated by reference to Exhibit 99.3 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1855485/000119312523237077/d894152dex994.htm" style="-sec-extract: exhibit">Audit Committee Charter (incorporated by reference to Exhibit 99.4 to Form 8-K filed on September 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.
    SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to item 601(b)(10) of Regulation S-K, certain information has been excluded because it is both not material and the type of
    information that the registrant treats as private or confidential.</span> The Company agrees to furnish, on a supplemental basis, a
    complete unredacted copy of such exhibit to the Securities and Exchange Commission upon request.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="gok_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
16 &#8211; FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="gok_002"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI BIOTHERAPEUTICS,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric Poma&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Poma</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric Poma</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Poma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Principal
    Executive Officer</i>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Andrew Jackson</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Jackson</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>Principal
    Financial and Accounting Officer</i>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><i>/s/
    Allan J. Camaisa</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Director</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">March 27, 2026</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Allan J.
Camaisa</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Alan R. Stewart</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    R. Stewart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ James A. Schoeneck</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    A. Schoeneck</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Scott Leftwich</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
    Leftwich</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ George E. Peoples</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    E. Peoples</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="gok_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#bs_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID <span id="xdx_900_edei--AuditorFirmId_c20250101__20251231_zcCws3sSEmui"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000068" name="dei:AuditorFirmId">199</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#bs_002">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID <span id="xdx_908_edei--AuditorFirmId_c20240101__20241231_z1VacWUhp31h"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000069" name="dei:AuditorFirmId">688</ix:nonNumeric></span>)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_002">Consolidated
    Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_003">Consolidated
    Statements of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_005">Consolidated
    Statements of Total Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_006">Consolidated
    Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#HK_007">Notes
    to the Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 145; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="bs_001"></span>Report of Independent
Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calidi
Biotherapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_982_edei--AuditorOpinionTextBlock_c20250101__20251231_zYtaT08Oj0Ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000070" name="dei:AuditorOpinionTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Calidi Biotherapeutics, Inc. (the &#8220;Company&#8221;) as of December 31,
2025 , the related consolidated statements of operations, comprehensive loss, total equity and cash flows for the year ended December
31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations
and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States
of America.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise
additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span style="font-variant: small-caps">CBIZ CPAs P.C.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--AuditorName_c20250101__20251231_zEgGILHH75vh"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000071" name="dei:AuditorName">CBIZ
CPAs P.C</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2019 (such date takes into account the acquisition of the attest business of Marcum
<span style="font-variant: small-caps">llp</span> by CBIZ CPAs P.C. effective November 1, 2024).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--AuditorLocation_c20250101__20251231_zifseixvuNE7"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact000072" name="dei:AuditorLocation">Costa
Mesa, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2026</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="bs_002"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calidi
Biotherapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Calidi Biotherapeutics, Inc. (the &#8220;Company&#8221;) as of December 31,
2024, the related consolidated statements of operations, comprehensive loss<b>,</b> total equity and cash flows for the year ended December
31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations
and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States
of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more
fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise
additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <span style="font-variant: small-caps">llp</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--AuditorName_c20240101__20241231_zEgLGn4evyC3"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000073" name="dei:AuditorName">Marcum
 LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
served as the Company&#8217;s auditor from 2022 to 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--AuditorLocation_c20240101__20241231_zOhESr8Nlc48"><ix:nonNumeric contextRef="From2024-01-012024-12-31" id="Fact000074" name="dei:AuditorLocation">Costa
Mesa, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2025 (except for the effects of the reverse stock-split described in Note 1, as to which the date is August 15, 2025)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_002"></span>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>In
thousands, except for par value data</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_pn3n3_zjanUOGOfoT" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20251231_zFIRoxcTvO58" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231_zj6ifMHs8s81" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsAbstract_iB_zY9c1HOcK7sc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zINY91N92Sg5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Cash_i02I_maACzmrL_zfoagG7KtLd7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,591</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzmrL_z7mv5zNBx6Jh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">656</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">636</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtACzmrL_maAzPrd_zisiNLbYMAb6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,256</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,227</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsNoncurrentAbstract_i01B_zScQEowGBb7b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NONCURRENT
    ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maAzPrd_zl9BERvp1Ed7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">781</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">869</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maAzPrd_znPZPLw4KbD2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,682</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,934</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherAssetsNoncurrent_i02I_maAzPrd_z9404ZckAVGi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_i01TI_mtAzPrd_zyAYhAkqwwn9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,857</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,182</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zpjuEKXHAEQ1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES
    AND TOTAL EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesCurrentAbstract_i01B_zNy5lW05QPW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zp3kuFftSHk2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">595</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwRUTiCTqdTf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzLTc_z0NMyt7PleZk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zZDjsy5do9ad" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,276</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,858</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zV4j6RTjx6vi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzLTc_zGrQiElvGJvg" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--TermNotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zs3znFopWiZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    notes payable, net of discount, including accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0130">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:TermNotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">251</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--TermNotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zB7gwUMDQrId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party term notes payable, net of discount, including accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:TermNotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,702</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--TermNotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzLTc_z7nqUL74QDg1" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
notes payable, net of discount, including accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0136">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:TermNotesPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,702</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--LoansPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzLTc_zjqyqjcMwGV6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party bridge loan payable, including accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0139">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzLTc_zoOtGYfTmzI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party other current liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0142">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">638</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzLTc_zOxX9uNhG7Me" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    lease liability, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzLTc_zyHLNPLB7uwc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use liability, current</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,405</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,204</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_maLzAP0_mtLCzLTc_zCzyfntMpmGl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,935</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,496</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zr2F1nvmIDcc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NONCURRENT
    LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLzAP0_zfARUBAUEUCi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use liability, noncurrent</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,845</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLzAP0_zb3gJi47qxf4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    lease liability, noncurrent</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--PromissoryNote_i02I_maLzAP0_zNkbrze5pzU" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:PromissoryNote" contextRef="AsOf2025-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:PromissoryNote" contextRef="AsOf2024-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--WarrantLiability_i02I_maLzAP0_zsNOarpogl12" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:WarrantLiability" contextRef="AsOf2025-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:WarrantLiability" contextRef="AsOf2024-12-31" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--RelatedPartyWarrantLiability_i02I_maLzAP0_zXW378Qz3Dql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party warrant liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:RelatedPartyWarrantLiability" contextRef="AsOf2025-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:RelatedPartyWarrantLiability" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i01TI_mtLzAP0_maLASEz1bc_zoQtGVuitdqi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,098</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,214</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz1bc_zsAijTJi9x4g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies (Note 11)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0175">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0176">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_zGEqsJ6ny7s7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maSEzroz_zZqYtHXp2CU9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251231_zvVQegM7RZv3" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zAWuvYJ29RXj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20251231_zhXziLt76Iq6" title="Common stock, shares authorized"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pn3n3_c20241231_zgzgRHqvy7xa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">330,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20251231_zXROfnh6VY4l" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20251231_zLAnhK7z6Phj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7,217</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pn3n3_c20241231_zxLlsUyWkHq4" title="Common stock, share issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pn3n3_c20241231_z6S2t79IPxQl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,730</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2025 and 2024,
    respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_maSEzroz_zUIxUOCjXOkg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,392</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123,277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzroz_zL4CL31iX2Nh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    other comprehensive loss, net of tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzroz_zFmuxPplWsW6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">141,621</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">121,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_mtSEzroz_maSEIPAzLGL_z0TFT3gLydX3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&#8217; equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,759</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,534</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--MinorityInterest_i02I_maSEIPAzLGL_z1OGLKoKcWpk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncontrolling
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0212">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2024-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_mtSEIPAzLGL_maLASEz1bc_zDKUbKE3bmff" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,759</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,968</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz1bc_zvUggEC5gEU7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES AND TOTAL EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,857</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,182</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_003"></span>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(In
thousands, except per share data)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_pn3n3_zMFj7fRaPpn1" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zDFo3zV3NVL" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231_zacXa4HP845k" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zjvABiARuUmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING
    EXPENSES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01N_di_maOEzF5v_z6PVwW1qEV4b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,737</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,878</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--SellingGeneralAndAdministrativeExpense_i01N_di_maOEzF5v_zXPZFnZDpeV2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,503</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-012024-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,898</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingExpenses_i01NT_di_mtOEzF5v_msOILzgNa_zj3fUOjEYRkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,240</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,776</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_i01T_maILFCOz7GX_mtOILzgNa_zl3KkR348MMk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,240</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,776</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zIBt0FcJwWPf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
    INCOME (EXPENSES), NET</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zwEy3JcklK05" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">131</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">372</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzlmru6aocrl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense &#8211; related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpenseNonoperating_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_msNIEzI8G_zx7hWZ4WWOc6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember" id="Fact000246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr id="xdx_404_ecustom--ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_i01N_di_msNIEzI8G_zsiRqPlnMgue" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" contextRef="From2025-01-01to2025-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" contextRef="From2024-01-012024-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">285</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_i01N_di_msNIEzI8G_zLpxv3cMR1D" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives &#8211; related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" contextRef="From2025-01-01to2025-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" contextRef="From2024-01-012024-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--GrantIncome_i01_maNIEzI8G_zVSmxLYpb805" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:GrantIncome" contextRef="From2025-01-01to2025-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:GrantIncome" contextRef="From2024-01-012024-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--GainOnSaleOfInvestments_i01_maNIEzI8G_zi3akq06Ngt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on sale of investment in Nova Cell</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_i01_maNIEzI8G_zABDxZUlfQJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_maILFCOz7GX_mtNIEzI8G_zYbmMxSCBK6g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income (expenses), net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">192</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">419</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOz7GX_maPLzkTJ_zlu9CtkeRcM9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LOSS
    BEFORE INCOME TAXES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,048</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,195</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msPLzkTJ_zXPZ6kkwR5R2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provision</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_iT_mtPLzkTJ_maNILATzCCT_zFpdiNHgESpc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msNILATzCCT_zRsXKBSyO3fd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributable to noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtNILATzCCT_maNILATzCHm_znmIdJbjPxLk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS ATTRIBUTABLE TO CONTROLLING INTEREST</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,906</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,143</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_ecustom--DeemedDividendOnWarrants_maNILATzCHm_zI8oEeuMqIx2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed
    dividend on warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:DeemedDividendOnWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,673</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:DeemedDividendOnWarrants" contextRef="From2024-01-012024-12-31" id="Fact000282" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,671</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzCHm_zzibYIMSUjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,579</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-012024-12-31" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,814</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20250101__20251231_zpXzqMvRXni2" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20250101__20251231_zy2PWRp6Ik6g" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">5.95</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zpGkpeAP4nC5" title="Net loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zGhimSEKp8al" title="Net loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-12-31" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">35.70</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average common stock shares outstanding; basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20251231_z8jzqGFVpB45" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20251231_zSafhY0ntqec" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-01-01to2025-12-31" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,302</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zcpDtgfjs2ef" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zLRZflZxiLW" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">667</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_004"></span>CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(In
thousands)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_pn3n3_zGLRx9zZLwuj" summary="xdx: Statement -  Consolidated Statements of Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20250101__20251231_zltvn1SHXua8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zjmPBA7PeFZ2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
                                            Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_iT_maCINOTzytX_zZj7RWPQbDV6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_iB_zh7QVYHgtnqh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    comprehensive income, net of tax:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCINOTzytX_zQL2EI2MFUGb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_iT_mtCINOTzytX_maCINOTzhMS_zljdYbQavuGd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPREHENSIVE
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000312" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,048</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,190</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_msCINOTzhMS_zdYDAEx8tzK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    loss attributable to noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzhMS_zXgdbJa3FPTl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPREHENSIVE
    LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-01-01to2025-12-31" id="Fact000318" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,891</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-12-31" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,124</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_005"></span>CONSOLIDATED
STATEMENTS OF TOTAL EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<i>In
thousands, except share amounts</i>)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zPQC6oiI7rgk" summary="xdx: Statement - Consolidated Statements of Total Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zZkl55lvqG9f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zyCxE95GqPp8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zPfmeQBiPSs6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    (Loss)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zmyBPlT0UXqh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--ParentMember_zzReSBMsj40a" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zEwdJpp9zFO6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_zvCxfzDLIma5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional<br/>
    Paid-in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated<br/>
    Other<br/> Comprehensive</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total<br/>
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non
    controlling</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    (Loss)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_431_c20250101__20251231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zSmV9wHxtHqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlamFAfNW1Ga" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,730,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123,277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">121,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_ParentMember" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,534</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000327" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,968</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zCIOu44y5xZ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock through At the Market Offering</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCGFMFCGx4wd" title="Issuance of common stock through At the Market Offering, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">534,265</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,201</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,201</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-01-01to2025-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,201</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_zwAFCY3At8da" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFdZt7NyCtnh" title="Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">416,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000342" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,607</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,607</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,607</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_zYdpnTZ9VXK3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVRcVcfubzZ2" title="Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,084</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,423</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,423</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,423</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_zXhUAAylgJkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock through August Public Offering</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzBZWAKXza0b" title="Issuance of common stock through August Public Offering, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,922,764</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,767</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,768</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" contextRef="From2025-01-01to2025-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,768</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_zpcqpFyLimxb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of pre-funded warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5oMWzOCeW49" title="Exercise of pre-funded warrants, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,759,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000375" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_zCuKM4jdi4J7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock through July Inducement Offer, net of financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4YGtLGjKo2g" title="Issuance of common shares through July Inducement Offer, net of financing costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">549,596</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,004</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_zENyWXG5FtIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for Reverse Stock Split fractional shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZla8UxaufPj" title="Issuance of common stock for Reverse Stock Split fractional shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,029</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zSDrIvsUPUab" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock unit shares released</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7jDX10G5OK7" title="Restricted stock unit shares released, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact000409" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,038</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueSaleOfInvestment_zflQFXiYqap8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
    of investment in Nova Cell</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueSaleOfInvestment" contextRef="From2025-01-01to2025-12-31" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zvMQEat2XRz9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000420" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-12-31" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zJmAIhee4vl4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-01-01to2025-12-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_zsR5W9WYe672" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember" id="Fact000438" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,906</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_ParentMember" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,906</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">157</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_434_c20250101__20251231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zbH9p0Q9Auga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3891OFp1zSa" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,216,994</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_CommonStockMember" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,392</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">141,621</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31_us-gaap_ParentMember" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,759</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2025-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,759</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQpDqiEmW10i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zZYqzEoMKTuh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zDlIf9Yq3y1k" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    (Loss)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zZQeRAj04JQj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--ParentMember_ztvqKmXxg3V8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_z6FBoiV2KOGd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_zqLdkv7ka3e6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional<br/>
    Paid-in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated<br/>
    Other<br/> Comprehensive</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total<br/>
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non
    controlling</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    (Loss)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zFcZ6bdmVQdi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zirRVMkMmFfc" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000461" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">296,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,384</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000455" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99,572</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_ParentMember" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,235</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,235</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43D_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zn8NlxNHQPKb" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmroRlfN0sw6" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">296,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">91,384</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">99,572</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_ParentMember" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,235</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,235</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zuCTnNpD34p5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in lieu of cash for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoX38alqs5m4" title="Issuance of common stock in lieu of cash for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14,589</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-01-012024-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_z1k9IaTFGJQe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in lieu of cash for SEPA commitment fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z79A5Q7bRyy" title="Issuance of common stock in lieu of cash for commitment fee, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,157</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" contextRef="From2024-01-012024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_z6HnuT8izBb9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock to Calidi stockholders as result of Merger</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgVmefvPQYKk" title="Issuance of common stock to Calidi stockholders as result of Merger, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000501" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">132</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0498">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentsToAdditionalPaidInCapitalFinancingFees_zM0hdnRToKa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">327</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">327</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees" contextRef="From2024-01-012024-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">327</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_za8IF43Kjvmb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and pre-funded warrants through April Public Offering, net of financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyaanG8Xfjw3" title="Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000519" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,271</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000512" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,822</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,822</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0516">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" contextRef="From2024-01-012024-12-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,822</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zLYG7amlv66d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock per Convertible Note conversion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zALUum8snkr2" title="Issuance of common stock per Convertible Note conversion, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000529" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">176,731</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_zgycvNYqDpbk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock through May Inducement Offer, net of financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcMwcoHAioK3" title="Issuance of common shares through May Inducement Offer, net of financing costs, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000539" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,151</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,818</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,818</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" contextRef="From2024-01-012024-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,818</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_zGuYc8EUlqz3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of common stock warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0uFyLTS8VIk" title="Exercise of common stock warrants, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">256,886</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000542" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,803</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,803</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" contextRef="From2024-01-012024-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,803</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_z3SrNxf2t326" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of pre-funded warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBEXX6NDJZQ" title="Exercise of pre-funded warrants, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,375</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000555" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" contextRef="From2024-01-012024-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_zmlYosBqk7Sg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of restricted stock units for liability settlement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000562" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000565" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_zD90P6CvccS1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants for legal settlement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAU17sUE1qa6" title="Issuance of common stock and warrants for legal settlement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000577" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">308</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000573" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">308</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0574">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31" id="Fact000575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">308</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_zR8kk7bGfv9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for Reverse Stock Split fractional shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt73ufoq51j8" title="Issuance of common stock for Reverse Stock Split fractional shares, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000587" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,621</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0579">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0581">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0583">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0584">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0585">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_zsKYeoU2MZ46" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants per subscription agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxCYPZjdRgYb" title="Issuance of common shares and warrants per subscription agreement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,235</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0591">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0592">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0594">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_z6QPkKBT2eKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants for registered direct offering</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI0kX2I620ik" title="Issuance of common stock and warrants for registered direct offering, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0599">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000600" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,631</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0601">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0602">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,631</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0604">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" contextRef="From2024-01-012024-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,631</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_zMx2lDf5XLv5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock through At the Market Offering</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBEcsYzxtvAh" title="Issuance of common stock through At the Market Offering, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,355</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" contextRef="From2024-01-012024-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_z6otwd7Sz0jf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock through November Public Offering, net of financing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYQ35x5sQVj8" title="Issuance of common stock through November Public Offering, net of financing, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">369,823</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000620" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0622">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0624">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" contextRef="From2024-01-012024-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,662</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueInvestment_zpaSaoxjEvZa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in Nova Cell</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0632">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000634" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:StockIssuedDuringPeriodValueInvestment" contextRef="From2024-01-012024-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zKkPFPmUidwd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock unit shares released</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_uShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYhBrmDwD3v6" title="Restricted stock unit shares released, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000645" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,205</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0637">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0639">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0641">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zDgvBkpsaO8j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0652">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zhESVss1m8qb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation adjustments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0656">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0658">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0660">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-01-012024-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProfitLoss_zQy1IkcBy6Nj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0663">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0665">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,143</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_ParentMember" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,143</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000668" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000669" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zXpf63ccTj98" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdMrwuKkBSte" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,730,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123,277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000673" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000674" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">121,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_ParentMember" id="Fact000675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,534</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,968</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zFVLiZi7px54" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7DzL0xjhNI1" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,730,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123,277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000683" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">121,715</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_ParentMember" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,534</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000686" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,968</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_006"></span>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(In
thousands)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_112_pn3n3_zocQtE4bJNp" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20250101__20251231_z5XHzZ3jeVr7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_zFxh3PbnYJdl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z1iNxMn9SLt4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM OPERATING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_i01_maNCPBUzJkZ_zxAq0onxiT23" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2025-01-01to2025-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-01-012024-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zErrFfH9m705" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DepreciationAndAmortization_i02_maNCPBUzJkZ_zLyHshwCjAAd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2025-01-01to2025-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,651</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,535</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzJkZ_z2DwSGdL0sF6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of debt discount and financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_maNCPBUzJkZ_zsPKdGCyr2Yb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueOfOtherLiabilitiesAndDerivatives_i02_maNCPBUzJkZ_zQvBhElruQY5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivatives" contextRef="From2025-01-01to2025-12-31" id="Fact000709" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivatives" contextRef="From2024-01-012024-12-31" id="Fact000710" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">324</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--GainOnSaleOfInvestments_i02N_di_msNCPBUzJkZ_zjiRWNtXAUwf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on sale of investment in Nova Cell</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z4AYGgYN0IHb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in operating assets and liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzJkZ_zZxWahIllps3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-01-01to2025-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-012024-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,801</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzJkZ_zpQ64vD0vZQe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000721" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,328</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-012024-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maNCPBUzJkZ_z23C9miJHJli" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,993</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000725" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,854</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzJkZ_zgBv8QmOpNXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right of use liability</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2025-01-01to2025-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-012024-12-31" id="Fact000728" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,017</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzB1t_mtNCPBUzJkZ_zjUG9J87l11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21,293</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-012024-12-31" id="Fact000731" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,694</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zWzvGpZf734d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM INVESTING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireMachineryAndEquipment_i01N_di_msNCPBUzJgf_z3q70ej5bsnb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
    of machinery and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2025-01-01to2025-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2024-01-012024-12-31" id="Fact000737" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsToAcquireInvestments_i01N_di_msNCPBUzJgf_zsqHGbDajGz4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    disposed in sale of investment in Nova Cell</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2025-01-01to2025-12-31" id="Fact000739" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0740">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzJgf_maCCERCzB1t_zJWPKOzt1lfj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">170</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-012024-12-31" id="Fact000743" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zxtn1opxNBWc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromPublicOfferings_i01_maNCPBUzUVY_zij3c68H8f9e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from public offerings</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromPublicOfferings" contextRef="From2025-01-01to2025-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,883</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromPublicOfferings" contextRef="From2024-01-012024-12-31" id="Fact000749" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,946</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromWarrantInducementFinancing_i01_maNCPBUzUVY_zn6y0D945dee" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from warrant inducement financing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromWarrantInducementFinancing" contextRef="From2025-01-01to2025-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,136</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromWarrantInducementFinancing" contextRef="From2024-01-012024-12-31" id="Fact000752" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,140</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromRegisteredDirectOffering_i01_maNCPBUzUVY_z7DeRmSCU93a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from registered direct offering</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromRegisteredDirectOffering" contextRef="From2025-01-01to2025-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,503</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maNCPBUzUVY_znkQo70imBN3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Proceeds from at the market offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-01-01to2025-12-31" id="Fact000757" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,268</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-012024-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,119</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzUVY_zvZedJJ4Thoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from exercise of pre-funded warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-01to2025-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RepaymentsOfDebtAndCapitalLeaseObligations_i01N_di_msNCPBUzUVY_zjdMhFSWOHLc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of financing lease obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2025-01-01to2025-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2024-01-012024-12-31" id="Fact000764" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msNCPBUzUVY_zoizgaLarVE5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of principal on term notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-01-012024-12-31" id="Fact000767" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_ecustom--RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_i01N_di_msNCPBUzUVY_zW6kh14KsXq6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of principal on related party bridge loan payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" contextRef="From2025-01-01to2025-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0770">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzUVY_zArE8EXLKvvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of financing costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2025-01-01to2025-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">846</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2024-01-012024-12-31" id="Fact000773" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,554</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_msNCPBUzUVY_zcCaWda1hjfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of principal on related party term notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2025-01-01to2025-12-31" id="Fact000775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromIssuanceOfNoncontrollingInterest_i01_maNCPBUzUVY_zlLMHsafhtRd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of noncontrolling interest in Nova Cell</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0778">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromIssuanceOfNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact000779" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzUVY_zYUQJCqiq1U4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of convertible notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0781">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2024-01-012024-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzUVY_z0qcw0tMJB9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party proceeds from issuance of loan payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-012024-12-31" id="Fact000785" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfDebt_i01_maNCPBUzUVY_zi6KyhaFGeT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of promissory note</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement_i01_maNCPBUzUVY_zOi4n2REuSo2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of common stock and warrants per subscription agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" contextRef="From2024-01-012024-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzUVY_z8bTZpOsYBx7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from exercise of common stock warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0793">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31" id="Fact000794" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,803</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--RepaymentOfConvertibleNotePayable_i01N_di_msNCPBUzUVY_zSH2y2FB6jCd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of convertible note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0796">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:RepaymentOfConvertibleNotePayable" contextRef="From2024-01-012024-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_ecustom--PaymentOfDebtIssuanceCosts_i01N_di_msNCPBUzUVY_zDi2571eoeIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
    of debt issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0799">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:PaymentOfDebtIssuanceCosts" contextRef="From2024-01-012024-12-31" id="Fact000800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzUVY_maCCERCzB1t_z8PAoN8CvwD1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,459</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-012024-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,365</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCCERCzB1t_zEcabOluhoXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of exchange rate changes on cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2025-01-01to2025-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2024-01-012024-12-31" id="Fact000806" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzB1t_zrB438kwjAy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    (DECREASE) INCREASE IN CASH AND RESTRICTED CASH</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-01-01to2025-12-31" id="Fact000808" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,990</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-012024-12-31" id="Fact000809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,642</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_iB_zRD3cANZbcG5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    AND RESTRICTED CASH BALANCE:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z5XHAb5UOJIj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    beginning of the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000814" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,809</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000815" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,167</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z20JAu27qDgb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    end of the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000817" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,819</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000818" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,809</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zyv0duzjRpdj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPPLEMENTAL
    DISCLOSURE OF CASH FLOW INFORMATION</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_zEuUOw47DPJ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact000823" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,265</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-012024-12-31" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--CashPaidForIncomeTaxes_i01_zYm39z65FaUe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:CashPaidForIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact000826" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:CashPaidForIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_z7fSd95H6Mu9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPPLEMENTAL
    SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--DeemedDividendOnWarrants_i01N_di_zJFbzcq8lpz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deemed
    dividend on warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeemedDividendOnWarrants" contextRef="From2025-01-01to2025-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,673</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeemedDividendOnWarrants" contextRef="From2024-01-012024-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,671</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--MachineryAndEquipmentAcquiredThroughFinancingLeases_i01_zAHQwrjtuZi4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment acquired through financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:MachineryAndEquipmentAcquiredThroughFinancingLeases" contextRef="From2025-01-01to2025-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0836">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities_i01_zInU0kpuGUh8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing fees included in accounts payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" contextRef="From2025-01-01to2025-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-012024-12-31" id="Fact000839" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">91</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockPerConversionOfConvertibleNote_i01_z18pZWKZeUg4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock per conversion of convertible note</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockPerConversionOfConvertibleNote" contextRef="From2024-01-012024-12-31" id="Fact000842" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,071</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfConvertibleNoteForLegalSettlement_i01_zjjn0gj8pwXg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of convertible note for legal settlement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0844">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfConvertibleNoteForLegalSettlement" contextRef="From2024-01-012024-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonStockInLieuOfCashForServices_i01_zdcDlkdfKoDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in lieu of cash for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockInLieuOfCashForServices" contextRef="From2024-01-012024-12-31" id="Fact000848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">289</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices_i01_z99u7R3satZf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party issuance of common stock in lieu of cash for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" contextRef="From2024-01-012024-12-31" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommonStockAndWarrantsForLegalSettlement_i01_zQ4hQs5lhgw7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock and warrants for legal settlement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0853">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockAndWarrantsForLegalSettlement" contextRef="From2024-01-012024-12-31" id="Fact000854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">308</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--DebtDiscountOnConvertibleNotes_i01_z2VFYsnil6Uc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    discount on Convertible Notes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DebtDiscountOnConvertibleNotes" contextRef="From2024-01-012024-12-31" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_i01_zmoQdXKBmi0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock in lieu of cash for SEPA commitment fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" contextRef="From2024-01-012024-12-31" id="Fact000860" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfRestrictedStockUnitsForLiabilitySettlement_i01_zCynAx1KJ7wh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of restricted stock units for liability settlement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:IssuanceOfRestrictedStockUnitsForLiabilitySettlement" contextRef="From2024-01-012024-12-31" id="Fact000863" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">133</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CALIDI
BIOTHERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="HK_007"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000865" name="us-gaap:NatureOfOperations"><p id="xdx_808_eus-gaap--NatureOfOperations_zyRs3sqVBFpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82B_z6SIGxn0cgDl">Organization and Nature of Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2023, First Light Acquisition Group, Inc., a Delaware corporation (&#8220;FLAG&#8221;) consummated a series of transactions
that resulted in the merger of FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG and Calidi Biotherapeutics.
Inc., a Nevada corporation (&#8220;Calidi&#8221; and the transactions the &#8220;Business Combination&#8221;). Following the consummation
of the Business Combination, FLAG was renamed &#8220;Calidi Biotherapeutics, Inc.&#8221; and Calidi was renamed &#8220;Calidi Biotherapeutics
(Nevada), Inc. and became a wholly owned subsidiary of the Company. Unless the context otherwise requires, the &#8220;Company&#8221;
refers to Calidi Biotherapeutics, Inc., a Delaware corporation (f/k/a First Light Acquisition Group, Inc., a Delaware corporation) and
its consolidated subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a biotechnology company that is pioneering the development of targeted therapies with the potential to
deliver genetic medicines to distal sites of disease. The Company&#8217;s proprietary RedTail platform features an engineered
enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended
to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent
genetic medicine(s) to metastatic locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations to date have focused on organization and staffing, business planning, raising capital, licensing, acquiring
and developing technology, establishing intellectual property portfolio, identifying potential product candidates and undertaking preclinical
studies, process development and manufacturing for preclinical and clinical trials. The Company&#8217;s product candidates are subject
to long development cycles and the Company may be unsuccessful in its efforts to develop, obtain regulatory approval for or market its
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, possible failure of preclinical studies or clinical trials, the need to obtain marketing approval for its product candidates, development
by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government
regulations, the need to successfully commercialize and gain market acceptance of any of the Company&#8217;s products that are approved
and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant
additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize
significant revenue from product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2024, the Company filed a First Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with
the Secretary of State of the State of Delaware to effect a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240710__20240710_zv1gDIQi7Eo4" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-07-102024-07-10" id="Fact000867" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10 reverse stock split</ix:nonNumeric></span> of the shares of the Company&#8217;s common
stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240710_z7bDjUWq4mf5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-07-10" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (&#8220;Common Stock&#8221;), effective on July 15, 2024 (the &#8220;2024 Reverse Stock Split&#8221;).
As a result of the 2024 Reverse Stock Split, every ten shares of issued and outstanding Common Stock were automatically combined into
one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as
a result of the 2024 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2024 Reverse Stock Split
were rounded up to the next whole number. The number of authorized shares of Common Stock under the Company&#8217;s Second Amended and
Restated Certificate of Incorporation, as amended, remained unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2025, the Company filed a Second Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation,
as amended, with the Secretary of State of the State of Delaware to effect a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250801__20250801_zwAdhSjdvUa6" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-08-012025-08-01" id="Fact000871" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-12 reverse stock split</ix:nonNumeric></span> of the shares of the Company&#8217;s
Common Stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250801_zfRjzpOigpL2" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-08-01" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, effective on August 4, 2025 (the &#8220;2025 Reverse Stock Split&#8221;). As a result of the
2025 Reverse Stock Split, every twelve shares of issued and outstanding Common Stock were automatically combined into one issued and
outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the
2025 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2025 Reverse Stock Split were rounded
up to the next whole number. The number of authorized shares of Common Stock under the Company&#8217;s Second Amended and Restated Certificate
of Incorporation, as amended, remained unchanged. Trading of the Company&#8217;s shares of Common Stock on the NYSE American, LLC commenced
on a split-adjusted basis on August 5, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to share and per share amounts for all periods presented in the consolidated financial statements have been retrospectively
restated to reflect the 2024 Reverse Stock Split and 2025 Reverse Stock Split. All rights to receive shares of common stock under outstanding
securities, including but not limited to, warrants, options, and restricted stock units (&#8220;RSUs&#8221;) were adjusted to give effect
to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise price and the number of shares
of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of shares of
Common Stock reserved for future issuance under the Company&#8217;s 2023 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement
of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has experienced recurring losses from operations and negative cash flows from operating activities, has a significant
accumulated deficit and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit
of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20251231_zk06nREp42Wf" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-12-31" id="Fact000875" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">141.6</ix:nonFraction></span>
million at December 31, 2025. During the year ended December 31, 2025, the Company used $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20251231_z2dAqc8NaTji" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-01-01to2025-12-31" id="Fact000877" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">21.3</ix:nonFraction></span>
million in cash for operating activities. As of December 31, 2025, the Company had cash of $<span id="xdx_908_eus-gaap--Cash_iI_pn5n6_c20251231_zJ251Rwzisu9" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000879" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span>
million and restricted cash of $<span id="xdx_907_eus-gaap--RestrictedCash_iI_pn5n6_c20251231_zFhtPyLf6uyf" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2025-12-31" id="Fact000881" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million. Management expects operating losses and negative cash flows to continue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
estimates that based on the Company&#8217;s liquidity resources, there is substantial doubt about the Company&#8217;s ability to continue
as a going concern within 12 months from the date of issuance of the consolidated financial statements. The accompanying consolidated
financial statements have been prepared on the basis of the Company continuing to operate in the normal course of business and does not
reflect any adjustments to the assets and liabilities related to the substantial doubt of its ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
ability to continue as a going concern is dependent upon its ability to raise additional funding. Management plans to raise additional
capital through public or private equity or debt financings to fulfill its operating and capital requirements for at least 12 months
from the date of the issuance of the financial statements. However, the Company may not be able to secure such financing in a timely
manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing
stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the
Company&#8217;s existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in economic conditions, including rising interest rates, public health issues, lower consumer confidence, volatile equity capital markets,
ongoing supply chain disruptions and the impacts of geopolitical conflicts, may affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000883" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_ztW1lsLHlSw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_823_zEJl2lTSmiz">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000885" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaPR1G4GYZla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements as of and for the year ended December 31, 2025 and 2024, have been prepared in accordance
with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and in conformity with accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards
Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000887" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zXJtSJ4WYRZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles
of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company include the accounts of its wholly owned subsidiary, Calidi Biotherapeutics
(Nevada), Inc., a company incorporated in the state of Nevada Calidi Biotherapeutics, Inc., StemVac GmbH (&#8220;StemVac&#8221;), a company
organized under the laws of Germany, Calidi Biotherapeutics Australia Pty Ltd (&#8220;Calidi Australia&#8221;), a wholly owned Australian
subsidiary, Nova Cell, Inc. (&#8220;Nova Cell&#8221;), a subsidiary incorporated in the state of Nevada, and Redtail Biopharma, Inc.
(&#8220;Redtail&#8221;), a wholly owned subsidiary incorporated in the state of Nevada. StemVac&#8217;s primary operating activities
include process development and other research and development activities for the Company under a cost-plus intercompany development
agreement funded by the Company. Calidi Australia&#8217;s principal purpose is for conducting certain parts of the SNV1 clinical enabling
activities in Australia. Nova Cell&#8217;s primary operating activities were expanding potential uses of the Company&#8217;s AAA stem
cell programs from oncology to other fields that require regenerative medical applications, such as cosmetics, orthopedics, auto-immune
diseases, and various other therapies. Redtail&#8217;s primary operating activities will be to expand on the Company&#8217;s systemic
antitumor virotherapies. Both Nova Cell and Redtail were incorporated in May 2024. As of December 31, 2025, the Company no longer has
an investment in Nova Cell. Redtail has had no activity to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
interest entities (&#8220;VIEs&#8221;) are legal entities that either have an insufficient amount of equity at risk for the entity to
finance its activities without additional subordinated financial support or, as a group, the holders of equity investment at risk lack
the ability to direct the entity&#8217;s activities that most significantly impact economic performance through voting or similar rights,
or do not have the obligation to absorb the expected losses or the right to receive expected residual returns of the entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all VIEs in which the Company is involved, it assesses whether it is the primary beneficiary on an ongoing basis. In circumstances where
the Company has both the power to direct the activities that most significantly impact the VIEs performance and the obligation to absorb
losses or the right to receive the benefits of the VIE that could be significant, the Company would conclude that it is the primary beneficiary
of the VIE, and the Company consolidates the VIE. In situations where the Company is not deemed to be the primary beneficiary of the
VIE, it does not consolidate the VIE and only recognizes the Company&#8217;s interests in the VIE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to October 27, 2025, the Company owned 75% of Nova Cell&#8217;s fully-diluted capitalization, with the remaining 25% owned by a related
party investor (see Note 8). Under the rules of determining whether an entity was a VIE, the Company has a controlling financial interest
and is deemed to be the primary beneficiary of Nova Cell and therefore consolidated Nova Cell&#8217;s financial statements. Since the
Company owns less than 100% of Nova Cell, the Company recorded net loss attributable to noncontrolling interest in its consolidated statements
of operations equal to the percentage of the economic or ownership interests retained in Nova Cell by the noncontrolling party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#8220;SRA&#8221;) and Material Purchase Agreement (the
&#8220;MPA&#8221; and together with the SRA the &#8220;Agreements&#8221;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zpwpUeXfXZM7" title="Shares sold and transferred"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-10-272025-10-27_custom_NovaCellMember" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500,000</ix:nonFraction></span> of its shares of common stock in Nova Cell (the &#8220;Repurchased Shares&#8221;), representing an
ownership interest of <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_ztNgHQys4Usd" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-10-27_custom_NovaCellMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>%, back to Nova Cell, for a purchase price of $<span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zylGdAbm1u0i" title="Purchase price for repurchased shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-10-272025-10-27_custom_NovaCellMember" id="Fact000893" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million (the &#8220;Purchase Price&#8221;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $<span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zJqT9AIilb5l" title="Promissory note, net cash offset"><ix:nonFraction name="us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset" contextRef="AsOf2024-09-17_custom_NovaCellMember" id="Fact000895" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> thousand cash offset), resulting in an Indebtedness Cancellation Amount of $<span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zepHBhXDlXm4" title="Indebtedness cancellation amount"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2024-09-172024-09-17_custom_NovaCellMember" id="Fact000897" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million,
and (B) the balance, by Deferred Consideration of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zYzDxd2VApd2" title="Deferred consideration"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-09-17_custom_NovaCellMember" id="Fact000899" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million payable after closing, as more fully described in the SRA. The Deferred Consideration is fully constrained until underlying uncertainties
are resolved, such that a significant reversal of cumulative consideration will not occur in future periods. Thus, the Company has not
recognized any Deferred Consideration as of December 31, 2025. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#8217;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for
a fair presentation of the Company&#8217;s financial condition and results of operations. All material intercompany accounts and transactions
have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000901" name="us-gaap:UseOfEstimates"><p id="xdx_840_eus-gaap--UseOfEstimates_zSrrKuYyyr3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the
reported amounts during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment,
including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing
of potential commercialization of acquired in-process intangible assets, applicable discount rates, comparable companies or transactions,
liquidity events, determination of fair value of financial instruments under the fair value option of accounting, assumptions related
to the going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived assets, key assumptions
in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred
income taxes, assumptions used to value common stock, debt and debt-like instruments, warrants, and stock-based awards and other equity
instruments. Actual results may differ materially from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000903" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4NZUyodDGPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zU8kxk7y1Rr8">Reclassification</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on our previously reported results of operations or accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000905" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zxDisQ28BcAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and Restricted Cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity date of ninety days or less to be cash equivalents.
Cash and cash equivalents include cash in readily available checking, money market accounts and brokerage accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies cash that has contractual or legal restrictions imposed by third parties as restricted cash, which is restricted as
to withdrawal or use except for the specified purpose under a contract. The Company classifies restricted cash as either part of prepaids
and other current assets, or as part of other noncurrent assets, depending on the term and nature of the underlying contract with a financial
institution, which requires the Company to hold a fixed amount of funds in a restricted money market account as collateral to the financial
institution for the Company&#8217;s corporate credit card program with that financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000907" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none">Schedule of Cash and Cash Equivalents</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2025-12-31" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-12-31" id="Fact000910" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,591</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within prepaid expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="AsOf2025-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">119</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000916" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    cash and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,819</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,809</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zONRAFzaFDbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000921" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zd0jFDmgJAZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Machinery
and Equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
and equipment are stated at cost, less accumulated depreciation, and includes assets purchased under financing leases. Depreciation is
computed using the straight-line method over the estimated useful lives of the assets, generally over a period of <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember_zhXYWkAGeupl" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000923" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember_z9vLH2fyzJn9" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000925" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years. For equipment
purchased under financing leases, the Company depreciates the equipment based on the shorter of the useful life of the equipment or the
term of the lease, ranging from <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zRKXfPGmJur3" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_srt_MinimumMember_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000927" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zvVdMqTbK9ia" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2025-12-31_srt_MaximumMember_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000929" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years, depending on the nature and classification of the financing lease. Maintenance and repairs
are expensed as incurred, whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed
of, the cost and the related accumulated depreciation are removed from the respective accounts, and any resulting gain or loss is reflected
in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000931" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zHTo1XpBpLmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, <i>Leases</i>. The Company determines if an arrangement is a lease at inception.
Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated
statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define
criteria to determine &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the
fair value of the underlying asset.&#8221; For lease classification determination, the Company continues to use: (i) greater than or
equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset; and (ii) greater
than or equal to 90% to determine whether the present value of the sum of lease payments is substantially all of the fair value of the
underlying asset. The Company accounts for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
operating leases, the Company recognizes right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for leases with terms greater
than 12 months in the consolidated balance sheets, while leases with terms of 12 months or less are not capitalized. ROU assets represent
the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate commensurate with
the lease term, based on the information available at commencement date, in determining the present value of lease payments. The Company
uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes
lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will
exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company discloses
the amortization of ROU assets and operating lease payments as a net amount within &#8220;Depreciation and amortization&#8221; on the
consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
leases are included in machinery and equipment, and in finance lease liability, current and noncurrent, in the consolidated balance sheets.
The Company discloses the amortization of finance ROU assets within &#8220;Depreciation and amortization&#8221; on the consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 11 for further disclosures in accordance with ASC 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000933" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zrW6I3Z6DNB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the impairment of long-lived assets, which consist primarily of right-of-use assets for operating leases and machinery
and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not
be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected
undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to
the excess of the assets carrying value over its fair value is recorded in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000935" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCCQwj744sq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 820, <i>Fair Value Measurement</i>, which among other things, defines fair value, establishes a consistent framework
for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring
or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants. Accordingly, fair value is a market-based measurement determined based
on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value, which are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets and liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities;
    quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data
    for substantially the full term of the assets or liabilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which
    require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation
hierarchy. If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities
with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2
inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. See Note 3 for fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000937" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zWqPIpln7jfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives in accordance with ASC 815. The Company values its derivatives using the Black-Scholes option-pricing model or
other acceptable valuation models, as applicable, with the assistance of valuation specialists. Derivative instruments accounted for
as liabilities are valued at inception and subsequent valuation dates for each reporting period the derivative instrument remains outstanding.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at
each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates equity or liability classification for common stock warrants in accordance with ASC 480, <i>Distinguishing Liabilities
from Equity</i>, and ASC 815, <i>Derivatives and Hedging</i>, and accounts for common stock warrants as liabilities if the warrant requires
net cash settlement, or gives the holder the option of net cash settlement, or it otherwise does not meet other equity classification
criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement,
or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified
as equity. Warrants that meet the definition of a derivative financial instrument and the equity scope exception in ASC 815-10-15-74(a)
are classified as equity, are initially measured at fair value on the grant date, and are not subject to remeasurement provided that
the Company continues to meet the criteria for equity classification. Warrants that are classified as liabilities are accounted for at
fair value and remeasured at each reporting date until exercise, expiration, or modification that results in equity classification. Any
change in the fair value of the warrants is recorded and presented under change in fair value of other liabilities and derivatives or
change in fair value of other liabilities and derivatives &#8211; related party, as applicable, in the consolidated statements of operations.
The classification of warrants, including whether warrants should be recorded as liabilities or as equity, is re-assessed at the end
of each reporting period. The fair value of liability-classified warrants is determined using the Black-Scholes option-pricing model
(&#8220;Black-Scholes model&#8221;), which includes Level 3 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000939" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_847_eus-gaap--DebtPolicyTextBlock_zRkBtHjrd9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
Issuance Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs incurred to obtain debt financings are deferred and are amortized over the term of the debt using the effective interest
method for all debt financings in which the fair value option has not been elected. Debt issuance costs on debt financings in which the
fair value option is not elected are recorded as a reduction to the carrying value of the debt and are amortized to interest expense
or interest expense &#8211; related party, as applicable, in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
any debt financing in which the Company has elected the fair value option, any debt issuance costs associated with the debt financing
are immediately recognized in interest expense in the consolidated statements of operations and are not deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000941" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zJS5yJ5MWWkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has not generated any revenues from commercial products. The Company analyzes its research collaboration arrangements
to assess whether they are within the scope of ASC 808, <i>Collaborative Arrangements</i>, to determine whether such arrangements involve
joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks
and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC
808, the Company assesses whether aspects of the arrangement are within the scope of other accounting literature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those
aspects of the arrangement within the scope of ASC 606, <i>Revenue from Contracts with Customers</i>, by applying the following five-step
model: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract,
including whether they are distinct within the context of the contract; (iii) determination of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition
of revenue when, or as, performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within the
contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service
is distinct. The Company considers the intended benefit of the contract in assessing whether a promised good or service is separately
identifiable from other promises in the contract. If a promised good or service is not distinct, the Company combines that good or service
with other promised goods or services until it identifies a bundle of goods or services that is distinct. The Company may provide options
to additional goods or services in such arrangements exercisable at a customer&#8217;s discretion. The Company assesses if these options
provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights
requires judgments related to the determination of the value of the underlying good and services to the optional price, if any, that
may be offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the transaction price based on the amount of consideration that the Company expects to receive for transferring the
promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company then allocates
the transaction price to each performance obligation based on the relative standalone selling prices (&#8220;SSP&#8221;). SSP is determined
at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors,
including factors that were contemplated in negotiating the agreement with the customer and estimated costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will
be entitled by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated
variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which
it is probable that a significant reversal of cumulative revenue recognized will not occur. At each reporting period, the Company re-evaluates
the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate
of the overall transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as)
the performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of
an output or input method. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in
the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve
months, deferred revenue will be classified in current liabilities. Revenue recognized, if any, prior to contractual billings made to
the customer, and if the Company expects to have an unconditional right to receive consideration in the next twelve months, these contractual
assets are included in other current assets in the Company&#8217;s consolidated balance sheets. As of December 31, 2025, and December
31, 2024, there are no deferred revenue or contractual assets recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company further analyzes changes to contracts from customers to assess whether they qualify as a contract modification within the scope
of ASC 606. The Company considers that a contract modification exists when the parties to a contract approve a modification that either
creates new, or changes, existing enforceable rights and obligations of the parties to the contract. The Company considers that a contract
approval could be approved in writing, by oral agreement, or implied by customary practices. Whenever a change in the scope or price,
or both, of a contract is approved by the parties to the contract, the Company analyzes whether the contract modification qualifies as
a separate contract or a contract combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract modification as a separate contract when (i) the scope of the contract increases because of the addition
of promised goods or services that are distinct and (ii) the price of the contract increases by an amount of consideration that reflects
the Company&#8217;s SSP of the additional promised goods or services and any appropriate adjustments to that price to reflect the circumstances
of the particular contract. If the modification is not accounted for as a separate contract, the Company analyzes whether one of the
following should occur: (i) a termination of the original contract and the creation of a new contract, (ii) a cumulative catch-up adjustment
to the original contract, or (iii) a combination of (i) and (ii) in a way that faithfully reflects the economics of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000943" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zlZPizkzwqT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, using the asset and liability method, which requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in
the consolidated financial statements or in the Company&#8217;s tax returns. Deferred taxes are determined based on the difference between
the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which
the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.
The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by analyzing
carryback capacity in periods with taxable income, reversal of existing taxable temporary differences and estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies. The Company&#8217;s judgments regarding future taxable
income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If the
Company&#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased,
which may have a material impact on the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized, if any. First, the tax position must be evaluated to determine the likelihood that
it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company recognizes any interest and penalties related to uncertain
tax positions in income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2025 and 2024.
The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material
deviation for the year ended December 31, 2025 and 2024. The Company is currently unaware of any tax issues under review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#8220;CAMT&#8221;) on adjusted
financial statement income on applicable corporations for taxable years beginning after December 31, 2022. The Company does not expect
the CAMT will have a material impact to its consolidated income tax provision (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted. The OBBBA included various provisions with multiple effective
dates, including, but not limited to, immediate expensing of domestic research and development expenditures and provision for immediate
expensing of machinery and equipment purchases. The OBBBA did not have a material impact on the Company&#8217;s results of operations.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an
&#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by 5% stockholders increases
by more than 50% over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income may be limited. The annual limitation may result in the expiration of net operating losses
before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31, 2021. There was an ownership
change identified on March 26, 2018 after the Company&#8217;s Series A-2 preferred stock issuance. The Company has not undertaken a Section
382 study through December 31, 2025. The Company&#8217;s ability to utilize their net operating loss carryforwards and other tax attributes
to offset future taxable income or tax liabilities may be limited as a result of ownership changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000945" name="CLDI:GovernmentGrantsPolicyTextBlock"><p id="xdx_849_ecustom--GovernmentGrantsPolicyTextBlock_zVDiXvjsr4Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2022, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) approved the Company&#8217;s application for
a CIRM grant for the Company&#8217;s continued development of the SNV1 program. CIRM awarded the Company approximately $<span id="xdx_90F_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zJ2bjw4tI9jb"><ix:nonFraction name="us-gaap:ProceedsFromOtherOperatingActivities" contextRef="From2022-10-272022-10-27_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember" id="Fact000946" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of CIRM funding conditioned that the Company co-fund
approximately $<span id="xdx_908_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember_zYGxk6lkwsUg"><ix:nonFraction name="us-gaap:ProceedsFromOtherOperatingActivities" contextRef="From2022-10-272022-10-27_custom_GovernmentGrantsMember" id="Fact000947" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the requirements of the CIRM application. On
December 28, 2022, the Company received the Notice of Award from CIRM for this grant. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from the CIRM grant are recognized over the period necessary to match the related research and development expenses when it is probable
that the Company has complied with the CIRM conditions and will receive the proceeds pursuant to the milestones defined in the grant
as reimbursement of those expenditures. The CIRM grant proceeds, if any, received in advance of having incurred the related research
and development expenses are recorded in accrued expenses and other current liabilities and recognized as grant income included in other
income, net, on the Company&#8217;s consolidated statements of operations when the related research and developments expenses are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025 and 2024, the Company recognized approximately $<span id="xdx_900_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20251231_zMHspUb7PSTk" title="Grant income"><ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="AsOf2025-12-31" id="Fact000949" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">50,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20241231_zYUqCnBJGwse" title="Grant income"><ix:nonFraction name="us-gaap:GrantsReceivableCurrent" contextRef="AsOf2024-12-31" id="Fact000951" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively, in grant income
in the accompanying consolidated statements of operations. The Company drew $<span id="xdx_90E_ecustom--GrantsReceivableWithdrawn_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zwakLFuBX1w9" title="Government grants award withdrawn"><ix:nonFraction name="CLDI:GrantsReceivableWithdrawn" contextRef="AsOf2025-12-31_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember" id="Fact000953" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million in funds based on the operational
milestones defined in the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000955" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg1hra5jIUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are expensed as incurred. Research and development expenses consist of costs incurred to discover, research
and develop drug candidates, including compensation-related expenses for research and development personnel, preclinical and clinical
activities, costs of manufacturing, overhead expenses including facilities and laboratory expenses, materials and supplies, amounts paid
to consultants and outside service providers, and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
and annual license payments related to acquired technologies or technology licenses which have not yet reached technological feasibility
and have no alternative future use are also included in research and development expense in the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000957" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zMk4V2F5MIgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and compensation-related expenses for personnel in executive, finance and accounting,
operations, and administrative functions. General and administrative expenses also include fees for legal, patent
prosecution, legal settlements, consulting, accounting and audit services as well as insurance, outside service providers, direct and
allocated facility-related costs and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000959" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVnzNm7bwVwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Translation Adjustments and Other Comprehensive Income or Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">StemVac,
the Company&#8217;s wholly owned subsidiary, is located and operates in Germany and its functional currency is the Euro. Calidi Australia,
the Company&#8217;s wholly owned subsidiary, is located and operates in Australia and its functional currency is the Australian Dollar
(&#8220;AUD&#8221;). Accordingly, StemVac&#8217;s and Calidi Australia&#8217;s assets and liabilities are translated using respective
published exchange rates in effect at the consolidated balance sheet date. Expenses and cash flows are translated using respective approximate
weighted average exchange rates for the reporting period. Resulting foreign currency translation adjustments are recorded as other comprehensive
income or loss, net of tax, in the consolidated statements of comprehensive income or loss and included as a component of accumulated
other comprehensive income or loss on the consolidated balance sheets. For the year ended December 31, 2025 and 2024, comprehensive loss
includes such foreign currency translation adjustments and was insignificant for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000961" name="CLDI:ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock"><p id="xdx_847_ecustom--ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_zGqMFuHbODu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Transaction Gains and Losses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
transactions denominated in currencies other than the U.S. dollar, the Company recognizes foreign currency transaction gains and losses
in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The Company&#8217;s
foreign currency transaction gains and losses are principally generated by intercompany transfers to StemVac denominated in Euros to
pay for the research and development activities performed by StemVac under an intercompany development agreement with the Company. Furthermore,
the Company&#8217;s foreign currency transaction gains and losses include intercompany transfers to Calidi Australia denominated in AUD
to pay for the research and development activities performed by Calidi Australia. These foreign currency remeasurement gains and losses
are included in other income, net, and were insignificant for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000963" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zTTPKIkGwNV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC
718, <i>Compensation &#8212; Stock Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service condition is recognized in the period of the forfeiture. Generally,
and unless otherwise specified, the Company grants stock options with service-based only vesting conditions and records the expense for
these awards using the straight-line method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award
recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company estimates its expected stock
volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics
similar to the Company. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221;
method for awards that qualify as &#8220;plain-vanilla&#8221; options provided under Staff Accounting Bulletin, Topic 14 (&#8220;SAB
Topic 14&#8221;), as necessary. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at
the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero,
based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000965" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdSJcb0wxfOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss per share of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that
determines earnings per share for the holders of the Company&#8217;s shares of Common Stock and participating securities. However, the
participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation
of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating)
are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per
share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock
method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share
attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common
stock shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic
net loss per share for the periods presented herein because common stock equivalent shares from the outstanding warrants, earnout shares,
stock option awards, restricted stock units, and contingently issuable warrants were antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000967" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zguB1VYdIPX4" style="display: none">Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    for common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember" id="Fact000969" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,026</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000970" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">911</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000972" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">278</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000973" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">77</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout
    shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-012025-12-31_custom_EarnoutSharesMember" id="Fact000975" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">150</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_custom_EarnoutSharesMember" id="Fact000976" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">150</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingently
    issuable warrants<sup id="xdx_F46_zns0PDiMhGnk">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    common stock equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-12-31" id="Fact000984" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,454</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31" id="Fact000985" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,140</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zcSEsseQ4qb1">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000986" xml:lang="en-US">The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zAGEgYvJxZz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000988" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztqbLrgSIasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (or CODM), the Executive Management Team, consisting of the following individuals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Head of Technical Operations</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company views its operations and manages its business as a single reportable segment whose operations include the research, development
and commercialization efforts of platforms to potentiate oncolytic virus therapies on a consolidated basis, as further described in Note
1. The Company manages its Research and Development (&#8220;R&amp;D&#8221;) activities on a consolidated basis. The Company expects to
generate future income from a combination of license fees and other upfront payments, funded R&amp;D agreements, milestone payments,
product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing
of the successful commercialization of the Company&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss is the measure of segment profit or loss used by the CODM in making decisions regarding resource allocation and evaluating financial
performance, which is also reported on the consolidated statements of operations and comprehensive loss. The CODM does not evaluate its
reportable segment using asset or liability information.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact000990" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected financial information with respect to the Company&#8217;s single operating segment for the year ended
December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zKYWOXFybRQj" style="display: none">Schedule
of Operating Segment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING
    EXPENSES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
    and benefits</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact000992" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact000993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,249</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact000995" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">801</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:GeneralInsuranceExpense" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact000996" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,442</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact000998" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,324</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact000999" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,951</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:Consulting" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001001" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:Consulting" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001002" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,578</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
    and maintenance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:RentAndMaintenance" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001004" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,358</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:RentAndMaintenance" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,136</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    &amp; research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:ClinicalResearchAndDevelopment" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001007" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,760</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:ClinicalResearchAndDevelopment" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,353</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:Depreciation" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001010" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">386</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001011" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">402</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001013" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001014" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">324</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items <sup id="xdx_F44_zsI0gVfAWZ5g">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:OtherSegmentItems" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001016" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,801</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:OtherSegmentItems" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001017" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,408</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provision</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001019" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001020" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember" id="Fact001022" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,063</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember" id="Fact001023" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,209</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0A_zCZCERNSjsG7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001024" xml:lang="en-US">Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zjzQiw5SfnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001026" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQmoR4lv77yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Adopted Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, <i>Improvements to Income Tax Disclosures (Topic 740)</i>. The ASU requires disaggregated
information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid.
The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for
annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 for the annual
period beginning January 1, 2025, on a prospective basis. The adoption of this guidance did not have a significant
impact on the Company&#8217;s financial statements, other than disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001028" name="CLDI:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock"><p id="xdx_846_ecustom--NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_z6lkr7Di3Vfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement </i>and in January 2025, issued ASU 2025-01 <i>Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i> to clarify the effective
date of ASU 2024-03. ASU 2024-03 requires the disaggregation of certain costs and expenses in the notes to the financial statements to
provide enhanced transparency into the expense captions presented on the face of the income statement. The ASU is effective for annual
periods beginning after December 15, 2026 and for interim reporting periods within annual reporting periods beginning after December
15, 2027. The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-06, <i>Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40): Targeted
Improvements to the Accounting for Internal-Use Software</i>. ASU 2025-06 updates the accounting for internal-use software by replacing
former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software
only when management has authorized and committed funding and it is probable that the project will be completed and the software will
be used to perform the intended function. ASU 2025-06 also supersedes website development cost guidance, moving it to ASC 350-40. These
amendments are effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting ASU 2025-06.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic
606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>.
ASU 2025-07 refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration
under ASC 606. This ASU is effective for annual periods and interim periods beginning after December 15, 2026, with early adoption permitted.
The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently evaluating
the impact of adopting ASU 2025-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the FASB issued ASU No. 2025-09, <i>Derivatives and Hedging (Topic 815): Hedge Accounting Improvements</i>. ASU 2025-09
clarifies certain aspects of the guidance on hedge accounting and addresses several incremental hedge accounting issues arising from
global reference rate reform. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within
those annual reporting periods The Company is currently evaluating the impact of adopting ASU 2025-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2025, the FASB issued ASU No. 2025-11, <i>Interim Reporting (Topic 270): Narrow-Scope Improvements,</i> which is intended to
improve the navigability of the guidance in ASC 270 and clarify when it applies. Under the amendments, an entity is subject to ASC 270
if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content of such
financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since
the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027, and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2025-11.</span></p>

</ix:nonNumeric><p id="xdx_85F_zmLcQ6ZXYX28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001030" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z1LDIbnIuC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_823_zLaSFEvqW13c">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001032" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zQoGr3VpRVdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, inclusive of
related party components, as of December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zYWW0lu5GxOi" style="display: none">Schedule
of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWmx7Qc7H0S6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziASyE6z4iTd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW2Ceu4JuOo5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zeUrRR3X8Fn7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z01xipjyNeTe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash held in money market accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" id="Fact001034" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1035">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1036">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember" id="Fact001037" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zvdICRvuY924" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001039" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1040">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1041">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2025-12-31" id="Fact001042" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zzyhoyvStrb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember" id="Fact001044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_PublicWarrantsMember" id="Fact001047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zpu1J8KaEUW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember" id="Fact001050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1051">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_custom_PrivateWarrantsMember" id="Fact001052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zz40boSVcyfb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    warrant liabilities, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member" id="Fact001055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2025-12-31" id="Fact001057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">115</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEM6Xl7O87W4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zv0XyOqlwQpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm97BMO9HOq3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_z1QWjKyP15Vi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zeruEnVVYona" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash held in money market accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember" id="Fact001059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1060">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_MoneyMarketFundsMember" id="Fact001062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_z0qTfmSaeADe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    Purchase Agreement Derivative Asset included in other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="Fact001066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="Fact001067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zs7M1XCLaB07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2024-12-31" id="Fact001072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zpQ1D7GVfiJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember" id="Fact001074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1076">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember" id="Fact001077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zlFUkdiOREOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember" id="Fact001080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember" id="Fact001082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zRhOUeGFqiH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    warrant liabilities, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact001084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" id="Fact001085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31" id="Fact001087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">128</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zyNvNTz385E6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash, prepaid expenses and other current assets, accounts payable, accrued expenses,
and other current liabilities. The carrying value of these financial instruments is generally considered to approximate their fair values
because of the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001089" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zqIlEF0l2MT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of valued instruments for the year ended December 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zSY7A1YXlaXe" style="display: none">Schedule
of Changes in Fair Value of Level 3 Valued Instruments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zg9NawD3tghe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    <br/> Purchase<br/> Agreement<br/> Derivative <br/> Asset, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRgqIL5PVQJj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    <br/> Warrants, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zG3wQ6iduqC9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    <br/> warrants, at <br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zfHUyIt0RyOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046" id="Fact001091" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember11025046" id="Fact001092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember11025062" id="Fact001093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zNIOi0IXJTnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2025-01-012025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="Fact001095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2025-01-012025-12-31_custom_PublicWarrantsMember" id="Fact001096" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2025-01-012025-12-31_custom_PrivateWarrantsMember" id="Fact001097" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zumwr3PJozah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1099">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2025-12-31_custom_PublicWarrantsMember11025078" id="Fact001100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2025-12-31_custom_PrivateWarrantsMember11025078" id="Fact001101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of valued instruments for the years ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zWfJAwNvg2se" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    <br/> Purchase<br/> Agreement<br/> Derivative <br/> Asset, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRXHCZ66zKMc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    <br/> Warrants, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_z0wHOCgTVSRe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    <br/> warrants, at <br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zchLF49GxBX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="Fact001103" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">230</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_custom_PublicWarrantsMember" id="Fact001104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">575</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_custom_PrivateWarrantsMember" id="Fact001105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zRRZPdfYd0Oe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="Fact001107" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">230</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_custom_PublicWarrantsMember" id="Fact001108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">575</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-12-31_custom_PrivateWarrantsMember" id="Fact001109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zjfr9zexva2d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember" id="Fact001111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_PublicWarrantsMember" id="Fact001112" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">465</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_PrivateWarrantsMember" id="Fact001113" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">78</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zwfpjT1pTduh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046" id="Fact001115" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember11025046" id="Fact001116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember11025062" id="Fact001117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zFX2CuEjR6m3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046" id="Fact001119" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember11025046" id="Fact001120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember11025062" id="Fact001121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_z7BIDe6h7Sq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001123" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock"><p id="xdx_804_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zcwJ5yn88KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_827_zfRVJFQVjqfl">Selected Balance Sheet Components</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued
Expenses and Other Current Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001125" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zl3HwUvYkCt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, accrued expenses and other current liabilities were comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B5_zC74RHRU2xGk" style="display: none">Schedule
of Accrued Expenses and Other Current Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20251231_z6RE0nZO3Mid" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zldBaOSXryB2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--AccruedCompensation_iI_pn3n3_maAPAOAzybc_zt0oc8Dog6d3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AccruedCompensation" contextRef="AsOf2025-12-31" id="Fact001127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">884</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AccruedCompensation" contextRef="AsOf2024-12-31" id="Fact001128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,344</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--AccruedVendorAndOtherExpenses_iI_pn3n3_maAPAOAzybc_z9diIryQWrKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    vendor and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AccruedVendorAndOtherExpenses" contextRef="AsOf2025-12-31" id="Fact001130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">922</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:AccruedVendorAndOtherExpenses" contextRef="AsOf2024-12-31" id="Fact001131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">994</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzybc_zlQaTtvTOSQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-12-31" id="Fact001133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,806</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,338</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zgOEPSV6HWB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 11 for additional commitments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prepaid
Expenses and Other Current Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001136" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3rDlS7PfK6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, prepaid expenses and other current assets were comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zpYPMGNGVhLb" style="display: none">Schedule
of Prepaid Expenses and Other Current Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_zL5CzaHNFOna" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zcIA2pAU61j5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--PrepaidExpenses_iI_maPECz6zE_zlhRYKAUiHV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:PrepaidExpenses" contextRef="AsOf2025-12-31" id="Fact001138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="CLDI:PrepaidExpenses" contextRef="AsOf2024-12-31" id="Fact001139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maPECz6zE_zQmOQo8zUkO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2025-12-31" id="Fact001141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">288</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECz6zE_zE0XWeQF3IP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-12-31" id="Fact001144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">249</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECz6zE_zE1XdS9Ryd86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-12-31" id="Fact001147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">656</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">636</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zlTGJIuafnTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001150" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmitJninqEB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82A_zmL0qBXF1oTk">Machinery and Equipment, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001152" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMMjj6pnDrvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, machinery and equipment, net, was comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zHnlGiayBZi9" style="display: none">Schedule
of Machinery and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20251231_zRQ7iMay90Vl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231_zv9ULlTW7Ivf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzw2F_znFRuAZbJnjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-12-31" id="Fact001154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,575</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact001155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,224</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzw2F_zV4tavT1WV07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-12-31" id="Fact001157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,794</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,355</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzw2F_zjoGaAtrKfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">781</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">869</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zjh4hp5LMYLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense amounted to approximately $<span id="xdx_906_eus-gaap--OtherDepreciationAndAmortization_pn5n6_c20250101__20251231_zF4SKmnZ00X6" title="Depreciation and amortization expense"><span id="xdx_901_eus-gaap--OtherDepreciationAndAmortization_pn5n6_c20240101__20241231_zQObO9v270tb" title="Depreciation and amortization expense"><ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2025-01-01to2025-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:OtherDepreciationAndAmortization" contextRef="From2024-01-012024-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></ix:nonFraction></span></span> million for the year ended December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001167" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFuzCwFJpwIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_828_zyZaQmqXs1Ki">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001169" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zP1Mzp0wj211" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the various significant related party transactions and investments in the Company for the periods presented
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zIbKqbn9Ytxg" style="display: none">Schedule
of Related Party Transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Party</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of investment or transaction</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250101__20251231_ztr38XZpt7Q1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zMA6Of7icfB8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_zEWw10UjFlga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A and Director E</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_fKDEp_zlWLI0MH4aBe" title="Description of investment or transaction"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorAAndDirectorEMember" id="Fact001174" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Current
    term notes payable, net of discount, including accrued interest</ix:nonNumeric></span><sup>(1) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorAAndDirectorEMember" id="Fact001172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,702</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_zR1WtBFW8XJ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F and relative of Officer A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_fKDIp_zeQY78y2Fs4j" title="Description of investment or transaction"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorFAndRelativeOfOfficerAMember" id="Fact001179" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Accounts
    payable and accrued expenses</ix:nonNumeric></span><sup>(2) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorFAndRelativeOfOfficerAMember" id="Fact001177" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zesQnfyIvbod" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_fKDMp_z61oDwq1ner8" title="Description of investment or transaction"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorFMember" id="Fact001184" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Severance
    accrual</ix:nonNumeric></span><sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorFMember" id="Fact001181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zgvbYUb0hpj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_fKDQp_zgg77HjNBqEc" title="Description of investment or transaction"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorDMember" id="Fact001189" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Severance
    accrual</ix:nonNumeric></span><sup>(4) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorDMember" id="Fact001187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_zo2OQ8scPVpk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_fKDUp_zKdMvxbE8em3" title="Description of investment or transaction"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorAOneMember" id="Fact001194" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Advisory
    services included in accrued expenses</ix:nonNumeric></span><sup>(5) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1191">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorAOneMember" id="Fact001192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_zHvV1LI0GJD5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_fKDYp_zjClDrqjEaUd" title="Description of investment or transaction"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorFOneMember" id="Fact001199" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Lease
    guaranty</ix:nonNumeric></span><sup>(6) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorFOneMember" id="Fact001196" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorFOneMember" id="Fact001197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">186</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_zt5rXNeaWwY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_fKDcp_zDjXix5Ogoqg" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorATwoMember" id="Fact001204" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Other
    liabilities</ix:nonNumeric></span><sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorATwoMember" id="Fact001202" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">638</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_zZIlg6Z8RiZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F and Director A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_fKDgp_zkWtDGrB7dA3" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_DirectorFAndDirectorAMember" id="Fact001209" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Warrant
    liability</ix:nonNumeric></span><sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_DirectorFAndDirectorAMember" id="Fact001206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_DirectorFAndDirectorAMember" id="Fact001207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_zdk3Fg2goI0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
    of Officer A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_fKDkp_zDM26tRjdZMe" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RelativeOfOfficerAMember" id="Fact001214" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Loan
    payable</ix:nonNumeric></span><sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_RelativeOfOfficerAMember" id="Fact001212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z6ZAQI2hMW8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    G</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_fKDEwKQ_____zAnBEno9S9Bd" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_OfficerGMember" id="Fact001219" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Severance
    accrual</ix:nonNumeric></span><sup>(10)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_OfficerGMember" id="Fact001216" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zBTlKfG8gpQh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_fKDExKQ_____z5loD8rJKBDi" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_OfficerAMember" id="Fact001224" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Severance
    accrual</ix:nonNumeric></span><sup>(11)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_OfficerAMember" id="Fact001221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1222">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zLyvD6ZMzaX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    A related to Director G</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zPHkzA353yU1" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember" id="Fact001229" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Accounts
    payable and accrued expenses</ix:nonNumeric></span><sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember" id="Fact001226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1227">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z1HHAGVCWrwl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zTM4EfyjiDKj" title="Related party transaction description"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember" id="Fact001234" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">Accounts
    payable and accrued expenses</ix:nonNumeric></span><sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember" id="Fact001231" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">130</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1232">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span id="xdx_F01_ztnzOa04RqCj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zSe82xXNXjfc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001235" xml:lang="en-US">As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $<span id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49" title="Related party note payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-12-31_custom_DirectorsAAndEMember" id="Fact001237" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million. See Note 7 for further details.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zeZVcS9Dqklc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z6UoF5ncbVI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001238" xml:lang="en-US">Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $<span id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj" title="Legal fees" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2025-01-012025-12-31_srt_OfficerMember" id="Fact001240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></span> thousand
and $<span id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04" title="Legal fees" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-01-012024-12-31_srt_OfficerMember" id="Fact001242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></span> thousand for the years ended December 31, 2025 and 2024, respectively.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span id="xdx_F06_zwaUnSY2Q1O7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_ziDxrKiIKwTh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001243" xml:lang="en-US">On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $<span id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb" title="Loans" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2025-04-22_custom_DirectorFMember" id="Fact001245" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $<span id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1" title="Loan outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2025-12-31_custom_DirectorFMember" id="Fact001247" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $<span id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2" title="Consulting pay" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CLDI:ConsultingPay" contextRef="AsOf2025-12-31_custom_DirectorFMember" id="Fact001249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,000</ix:nonFraction></span>
    per month during the transition period. The agreement terminated on December 31, 2025 and $<span id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j" title="Expenses" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2025-01-012025-12-31_custom_DirectorFMember" id="Fact001251" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
    million was expensed under the agreement.</ix:footnote> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F06_zCwfBc4wtI2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zoKQxvM2cIa1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001252" xml:lang="en-US">On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#8220;Ng Agreement&#8221;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $<span id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck" title="Annual salary" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2022-02-012022-02-01_custom_DirectorDMember" id="Fact001254" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million and a signing bonus of $<span id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4" title="Bonus payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2022-02-01_custom_DirectorDMember" id="Fact001256" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits.</ix:footnote> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 23, 2023, the Company entered into a Separation and Release Agreement with Mr. Ng which included a severance accrual and accrued
    interest as of December 31, 2024 (see Note 11). The lump sum payment and accrued interest was settled in January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0B_zb3j8Q9Vyk9i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zmweNB3Xu47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001257" xml:lang="en-US">On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $<span id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6" title="Monthly advisory fee" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:NoninterestExpenseInvestmentAdvisoryFees" contextRef="From2022-04-012022-04-01_custom_DirectorAMember" id="Fact001259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,166</ix:nonFraction></span> per month not to exceed $<span id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5" title="Advisory fee" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:NoninterestExpenseInvestmentAdvisoryFees" contextRef="From2022-04-012022-04-01_custom_DirectorAMember_srt_MaximumMember" id="Fact001261" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million per annum, accrued
    and payable upon the Company raising $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf" title="Equity proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-04-012022-04-01_custom_DirectorAMember" id="Fact001263" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_zLX2J83iRIF8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zQ7YPE1vTlO8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001264" xml:lang="en-US">In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#8220;Guaranty&#8221;) up to $<span id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P" title="Guaranty of lease amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CLDI:GuarantyOfLeaseAmount" contextRef="From2022-10-012022-10-31_custom_AJCCapitalMember_srt_MaximumMember_custom_GuarantyMember" id="Fact001266" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million to the lessor for the Company&#8217;s future performance under
    the San Diego Lease agreement. <span id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok" title="Lease agreement description" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonNumeric contextRef="From2022-10-012022-10-31_custom_AJCCapitalMember_custom_GuarantyMember" id="Fact001268" name="us-gaap:LessorOperatingLeaseDescription">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.</ix:nonNumeric></span> As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $<span id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z" title="Lease payment due" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" contextRef="From2025-01-012025-12-31_custom_AJCCapitalMember_custom_GuarantyMember" id="Fact001270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6" title="Lease payment due" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" contextRef="From2024-01-012024-12-31_custom_AJCCapitalMember_custom_GuarantyMember" id="Fact001272" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0D_zW1ETmqueNwd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zSwPhnNeBrE5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001273" xml:lang="en-US">In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc" title="Deferred compensation" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="AsOf2023-08-31_custom_DirectorAThreeMember" id="Fact001275" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million,
    which was paid in January 2025 (see Note 11). The $<span id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-08-31_custom_DirectorAThreeMember" id="Fact001277" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million note bore interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4" title="Note bears interest percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-08-31_custom_DirectorAThreeMember" id="Fact001279" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne" title="Note bears interest percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-08-12_custom_DirectorAThreeMember" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% per annum. The deferred compensation and advisory fees were settled in
    January 2025.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zrzyrqrQZdM3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zZ51rLXa3lQe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001282" xml:lang="en-US">See
    Note 8 for disclosures around Warrants.</ix:footnote> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F04_z9c88oDDUFK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_z5IDR1Bfps6b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001283" xml:lang="en-US">In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $<span id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8" title="Officer loans payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2024-01-31_custom_RelativeOfOfficerAMember_us-gaap_LoansPayableMember" id="Fact001285" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, which bears
    interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe" title="Officer loans payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-31_custom_RelativeOfOfficerAMember_us-gaap_LoansPayableMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%. The loan was settled in full in January 2025.</ix:footnote> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zIlcmPGCq4w" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zj5egqFCgyC6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001288" xml:lang="en-US">On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $<span id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2" title="Bonus payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-08-08_custom_OfficerGMember" id="Fact001290" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $<span id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc" title="Separation pay" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CLDI:SeparationPay" contextRef="From2025-08-082025-08-08_custom_OfficerGMember" id="Fact001292" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#8217;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $<span id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9" title="Severance pay" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2025-01-012025-12-31_custom_OfficerGMember" id="Fact001294" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0D_zdfDOmomXt94" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zFrDDUS3lLNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001295" xml:lang="en-US">On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $<span id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1" title="Bonus payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-09-17_custom_OfficerAMember" id="Fact001297" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $<span id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6" title="Severance pay" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2025-09-172025-09-17_custom_OfficerAMember" id="Fact001299" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#8217;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $<span id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf" title="Severance pay" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2025-01-012025-12-31_custom_OfficerAMember" id="Fact001301" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span id="xdx_F07_zNo8J4qqMSEh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_z3zx8HiEP4Cj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001302" xml:lang="en-US">On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#8220;CRO&#8221;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $<span id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl" title="Accounts payable and accrued expenses" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-12-31_custom_CompanyARelatedToDirectorGMember" id="Fact001304" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $<span id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h" title="Expenses related to services" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2025-12-31_custom_CompanyARelatedToDirectorGMember" id="Fact001306" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
    million in expenses related to services from Company A.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zd3sjtf5v6f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001308" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zk6rljKHwxna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_828_zEr7zCsMUf1b">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001310" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zSxdPkDzMrL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s outstanding debt obligations as of December 31, 2025 and 2024, including related party components, are as follows (in
thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zirP9PQvheZ8" style="display: none">Schedule of Outstanding Debt Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMNeRAr6KClg" title="Unpaid Balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-12-31_custom_PromissoryNoteMember" id="Fact001312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKCKbGpGiGI8" title="Accrued Interest" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2025-01-012025-12-31_custom_PromissoryNoteMember" id="Fact001314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z6ZkdmTBDAy5" title="Net Carrying Value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2025-12-31_custom_PromissoryNoteMember" id="Fact001316" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion of long-term debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20251231_zutYKlGSssd5" title="Less: current portion of long-term debt" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2025-12-31" id="Fact001318" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    debt, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_iI_pn3n3_c20251231_zA54mlhaoCTi" title="Long-term debt, net of current portion" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2025-12-31" id="Fact001320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zihzq1dJs6U5" title="Unpaid Balance" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_TermNotesPayableMember" id="Fact001322" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zLeuVlzlCvw5" title="Accrued Interest" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_TermNotesPayableMember" id="Fact001324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">753</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zArGCDUwtam7" title="Net Carrying Value" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_TermNotesPayableMember" id="Fact001326" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,953</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bridge
    loan payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zTd7tM8TbDx4" title="Unpaid Balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_BridgeLoanPayableMember" id="Fact001328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_z0lkMUcpXkx9" title="Accrued Interest" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_BridgeLoanPayableMember" id="Fact001330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zdV8IJWhiNLl" title="Net Carrying Value" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_BridgeLoanPayableMember" id="Fact001332" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zH2QKTdCPxZf" title="Unpaid Balance" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_PromissoryNoteMember" id="Fact001334" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztY1VpfkvPGk" title="Accrued Interest" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_PromissoryNoteMember" id="Fact001336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPWkTf1r0jR1" title="Net Carrying Value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31_custom_PromissoryNoteMember" id="Fact001338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">645</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231_znzJmfZxSXSl" title="Unpaid Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31" id="Fact001340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_zzRJejM3acQe" title="Accrued Interest" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31" id="Fact001342" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231_zCTWD2iLH2a4" title="Net Carrying Value" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-12-31" id="Fact001344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion of long-term debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20241231_zp2GdBcNR8Rj" title="Less: current portion of long-term debt" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-12-31" id="Fact001346" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,221</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    debt, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20241231_zj6QHi1ArYGk" title="Long-term debt, net of current portion" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-12-31" id="Fact001348" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zDOkMkUPN8Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001350" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbqjTc8gnZAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scheduled
maturities of outstanding debt, net of discounts as of December 31, 2025 are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_ziMD1VTWsl08" style="display: none">Schedule of Maturities of Outstanding Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending December 31:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20251231_zn9Uaygh0G7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDICAzCCI_zRtuHODsChNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDICAzCCI_z6a8msyqcAQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2025-12-31" id="Fact001354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDICAzCCI_zZwEgYv3LbL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028
    and thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_pn3n3_maDICAzCCI_zDI0WWw1ZV54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plus:
    accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2025-12-31" id="Fact001358" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzCCI_zh5K2dMn52Xk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2025-12-31" id="Fact001360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zElWa7uIzSU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion includes a description of the Company&#8217;s outstanding debt as of December 31, 2025 and 2024. The weighted average
interest rate related to the Company&#8217;s outstanding debt was approximately <span id="xdx_901_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20251231_zLMOiZwq2vVj" title="Weighted average interest rate"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="AsOf2025-12-31" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% and <span id="xdx_90D_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20241231_zxq292wWGFT1" title="Weighted average interest rate"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="AsOf2024-12-31" id="Fact001364" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.4</ix:nonFraction></span>% as of December 31, 2025 and 2024, respectively.
Interest expense related to the Company&#8217;s outstanding debt totaled approximately $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231_zEeQFQW2a7Wl" title="Interest expense debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2025-01-01to2025-12-31" id="Fact001366" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231_zsrU2GYoa16c" title="Interest expense debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2024-01-012024-12-31" id="Fact001368" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million for the year ended
December 31, 2025 and 2024, respectively, which is reported within other income, net, in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Term
Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Term Note Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the Company entered into a note agreement with a related party investor and director to borrow up to $<span id="xdx_909_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20210131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember__srt--TitleOfIndividualAxis__custom--InvestorAndDirectorMember__srt--RangeAxis__srt--MaximumMember_zPCUkYAuKd6i" title="Line of credit"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2021-01-31_custom_TwoThousandTwentyOneTermNoteMember_custom_InvestorAndDirectorMember_srt_MaximumMember" id="Fact001370" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million (&#8220;2021
Term Note&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the interest rate of the 2021 Term Notes was <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember_zpxi9Nu7ycje" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyOneTermNoteMember" id="Fact001372" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>%, and the total carrying value, including accrued interest was
approximately $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember_za1KpnGuoDM5" title="Interest Payable"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyOneTermNoteMember" id="Fact001374" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million. The total outstanding principal and accrued interest of 2021 Term Note of $<span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20250131_zRS3X9WUWiz9" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2025-01-31" id="Fact001376" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million was settled in full
in January 2025. As of that date, the 2021 Term Notes were no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022
Term Notes Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November and December 2022, the Company issued $<span id="xdx_906_eus-gaap--NotesPayable_iI_pn5n6_c20221130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_z8gMvISByd35" title="Secured term notes payable"><span id="xdx_904_eus-gaap--NotesPayable_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zp8xTvJkFNVl" title="Secured term notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-11-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001378" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001380" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></ix:nonFraction></span></span> million of secured term notes payable (the &#8220;2022 Term Notes&#8221;) to investors,
including to related parties (see Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3 and November 8, 2023, the Company settled in cash $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231003__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zQNcpdwoAcLf" title="Debt instrument, accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-10-03_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001382" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million and $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231108__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zVSwHFIA9a0l" title="Debt instrument, accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-08_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001384" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively, of the principal of 2022 Term
Notes plus accrued interest. Said term notes payable were no longer outstanding as of the settlement dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the interest rate of the 2022 Term Notes was <span id="xdx_904_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zEtVm58JGAv7" title="Interest rate"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001386" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% per annum, for a total principal of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_z3WJzxrZf2td" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001388" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, and <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember__srt--RangeAxis__srt--MaximumMember_zFex1oUhwKm2" title="Interest rate"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember_srt_MaximumMember" id="Fact001390" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% per
annum, for a total principal of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zjfD9Dsh4791" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001392" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. As of December 31, 2024, the total carrying value, including accrued interest, was $<span id="xdx_90F_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zRuTXnTszdRd" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001394" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span>
million. The total outstanding principal and accrued interest of 2022 Term Notes of $<span id="xdx_900_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20250131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zabwvSkTeJF1" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2025-01-31_custom_TwoThousandTwentyTwoTermNotePayableMember" id="Fact001396" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million was settled in full in January 2025.
As of that date, the 2022 Term Notes were no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
Term Notes Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January through September 2023, the Company issued $<span id="xdx_909_eus-gaap--NotesPayable_iI_pn5n6_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zwZ5GE64K3C9" title="Secured term notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-09-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001398" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction></span> million of secured term notes payable (the &#8220;2023 Term Notes&#8221;) to
investors, including to related parties (see Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, as agreed upon above in connection with the Closing of the FLAG Merger, the Company settled in cash $<span id="xdx_904_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20231003__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zVk3j5LOsbci"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2023-10-03_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001399" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million of
principal of 2023 Term Notes plus accrued interest and said term notes payable were no longer outstanding as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company settled in cash $<span id="xdx_901_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zTOb18T6Jsq8" title="Debt principal and accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001401" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million of principal of 2023 Term Notes plus accrued interest. On
December 23, 2024, the Company executed a debt amendment on $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zebUYr0Puvm2" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001403" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million of the 2023 Term Notes, which modified the repayment terms commencing
on February 1, 2025, such that the Company will pay the holder, a related party, $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20241223__20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_z5MNxzDW0cZ6" title="Installment payable"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-12-232024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001405" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million each month until the 2023 Term Notes&#8217;
principal and interest are fully paid. The principal shall continue accruing interest of <span id="xdx_902_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zZJ6HIVft6Wb" title="Interest rate percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% per annum until fully paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the interest rate was <span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zHZZ0f7E7Ivj" title="Interest rate percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% per annum for a total principal of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zqHfhlly4bI3" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember" id="Fact001411" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million and <span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zVIHn5rKhrhg" title="Interest rate percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% per annum for a total principal
of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_ztWWcIckxed4" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember" id="Fact001415" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million, respectively. As of December 31, 2024, the total carrying value, including accrued interest and net of debt discount,
was $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zLuyol1eX6ge" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001417" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the total outstanding principal and accrued interest of the 2023 Term Notes of $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zpLSbX8UTXxb" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember" id="Fact001419" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million was fully paid in accordance
with the agreement and was no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Bridge Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 19, 2024, the Company received approximately $<span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zS69a7Md0Vj1" title="Loans received"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember" id="Fact001421" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million in aggregate proceeds from the issuance of certain bridge loans (the
&#8220;2024 Bridge Loan&#8221;), which mature <span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dc_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zGDZcVeJwNZ3" title="Maturity period"><ix:nonNumeric contextRef="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember" format="ixt-sec:durwordsen" id="Fact001423" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric></span> from the issuance date and bear simple interest of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zQPYVz2I2Ku8" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum. As consideration
for the 2024 Term Loans, the Company issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zYlgl8FaClEd" title="Restricted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75</ix:nonFraction></span> shares of restricted common stock to the Lender.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the total carrying value of the 2024 Bridge Loan, including accrued interest and net of debt discount, was $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zmnHR9u3qfvb" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2025-01-31_custom_TwoThousandTwentyFourBridgeLoanMember" id="Fact001429" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million which was settled in full in January 2025. As of that date, the 2024 Bridge Loan was no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2024, the Company entered into a convertible promissory note purchase agreement (the &#8220;2024 Purchase Agreement&#8221;)
with an Accredited Investor (the &#8220;Investor&#8221;) for a loan in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_zJ6KKKp4zX7f" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember" id="Fact001431" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million (the &#8220;2024 Convertible
Note Loan&#8221;). In connection with the Convertible Note Loan, the Company issued a one-year convertible promissory note evidencing
the aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_zM2yFngD0Pf2" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember" id="Fact001433" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million under the Loan, which accrues at a <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_z2HH6dDJMttl" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember" id="Fact001435" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% simple interest rate per annum (the &#8220;2024
Convertible Note&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2024, pursuant to the April Public Offering, the Company&#8217;s $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240418__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zk2hKhuneAIl" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2024-04-18_us-gaap_ConvertibleNotesPayableMember" id="Fact001437" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million convertible note, inclusive of outstanding principal
and accrued interest, was automatically converted into shares of Common Stock Units, with terms identical to those sold in the April
Public Offering. As of that date, the convertible note was no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Promissory
Note Loan Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, the Company entered into a Loan Agreement with a third party lender (the &#8220;Lender&#8221;). Under the Loan Agreement,
the Lender agreed to loan the Company the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240701__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_zcGtfjzWbh7e" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-07-01_custom_PromissoryNoteLoanAgreementMember" id="Fact001439" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million pursuant to the terms of the promissory note dated July 1,
2024 (the &#8220;Promissory Note&#8221;), which bears a simple interest rate at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240701__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_zf9mn1ORfD33" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-07-01_custom_PromissoryNoteLoanAgreementMember" id="Fact001441" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% per annum and matures on the third calendar year
from July 1, 2024 (the &#8220;Maturity Date&#8221;) unless due earlier due to an event of a default. The Company agreed to pay annual
payments of accrued interest after each calendar year from the Payment Date until any remaining interest is paid in full on the Maturity
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the total carrying value of the promissory note, including accrued interest, was $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_z8UCwU5OT0rc" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2025-01-012025-12-31_custom_PromissoryNoteLoanAgreementMember" id="Fact001443" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_z2HXOsTVORL6" title="Carrying value, including accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2024-01-012024-12-31_custom_PromissoryNoteLoanAgreementMember" id="Fact001445" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001447" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM94V1KZySP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_821_zbj6MRYVN0C7">Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Amended and Restated Certificate of Incorporation filed on September 19, 2023 (&#8220;the Amended Articles&#8221;), the
Company is authorized to issue a total of <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zFFI3bavVd54" title="Number of shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-19_us-gaap_PreferredStockMember" id="Fact001449" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zt5GPi5ulNz6" title="Preferred stock par value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-19_us-gaap_PreferredStockMember" id="Fact001451" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share. As of December 31, 2025 and
2024, there were <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zzKsbvgoPOz9" title="Preferred stock outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zBK3KuQbR9v1" title="Preferred stock outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember" id="Fact001453" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember" id="Fact001455" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amended Articles, the Company is authorized to issue <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zuWGhUQvuMDf" title="Common stock shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31" id="Fact001457" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">330,000,000</ix:nonFraction></span> shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zaibsqOvDTMi" title="Common stock par value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-12-31" id="Fact001459" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, of which
<span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zqzRxyBfiGX6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_custom_VotingCommonStockMember" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">312,000,000</ix:nonFraction></span> shares are designated as Voting Common Stock (&#8220;Common Stock&#8221;) and <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zbkPSkRaUaaa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-12-31_us-gaap_NonvotingCommonStockMember" id="Fact001463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,000,000</ix:nonFraction></span> are designated as Non-Voting Common
Stock (the &#8220;Non-Voting Common Stock&#8221;). As of December 31, 2025 and December 31, 2024, there were <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_z6qN0BsLNdp8" title="Common stock shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zTYNV53Rqexa" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-12-31" id="Fact001465" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31" id="Fact001467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,216,994</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zmqA5YCSY3B8" title="Common stock shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zY68yBsxSRDf" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact001469" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,730,051</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock issued and outstanding, respectively, and <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zptAcI6lGMq6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-12-31_us-gaap_NonvotingCommonStockMember" id="Fact001473" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of non-voting common stock outstanding. Since inception
to date, <span id="xdx_90E_ecustom--CommonStockDividend_iI_do_c20251231_zY0FCQgzyTNe" title="Common stock dividend"><ix:nonFraction name="CLDI:CommonStockDividend" contextRef="AsOf2025-12-31" id="Fact001475" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> dividends have been declared or paid. Issuance costs related to common stock issuances during all periods presented were
immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001477" name="CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock"><p id="xdx_89D_ecustom--DiscloserOFCommonStockReservedForFurtureTableTextBlock_zRT2pG2i2nji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, common stock reserved for future issuance consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zU95Wcr2GHmf" style="display: none">Schedule
of Common Stock Reserved</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231_zNEUsLzr3llb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zzu59mG1aF0e" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4T92FbIxBcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock warrants outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-12-31_us-gaap_WarrantMember" id="Fact001479" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,026,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_us-gaap_WarrantMember" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">910,299</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockOptionsIssuedAndOutstandingMember_ztr8eJzSXMEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock options issued and outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember" id="Fact001482" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,822</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,245</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--RestrictedStockUnitsVestedAndUnreleasedMember_z2JFgf5R1kV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units vested and unreleased</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1485">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,039</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zvq1KzbydcJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    available for future issuance under the 2023 Equity Incentive Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember" id="Fact001488" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,497</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember" id="Fact001489" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,409</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_zVwIf82UdAU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    reserved under the 2023 Employee Stock Purchase Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" id="Fact001491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,815</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" id="Fact001492" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,815</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_zei2jceJH5S5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock reserved
    for future issuance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-12-31" id="Fact001494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,433,747</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-12-31" id="Fact001495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,029,807</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z0aaoBJIT833" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2024, in connection with the April Public Offering, the Company sold an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlnJrnxICc3" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-18_us-gaap_CommonStockMember" id="Fact001497" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">110,271</ix:nonFraction></span> Common Stock Units and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418_zNDYTJcUkStf" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-18" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,375</ix:nonFraction></span>
Pre-Funded Warrant (&#8220;PFW&#8221;) Units at an effective combined purchase price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDd3OQifhFa" title="Purchase price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-04-18_us-gaap_CommonStockMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">48.00</ix:nonFraction></span> per Common Stock Unit or PFW Unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consists of: (i) one share of the Company&#8217;s voting common stock, (ii) a Series A warrant to purchase one share
common stock, (iii) a Series B warrant to purchase one Series B Unit, with each Series B Unit consisting of (a) one share of common stock
and (b) a Series B-1 Warrant to purchase one share of common stock, and (iv) a Series C warrant to purchase one Series C Unit, with each
Series C Unit consisting of (a) one share of common stock and (b) a Series C-1 Warrant to purchase one share of common stock. See further
warrant details per each issued series below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
PFW Unit consists of: (i) a pre-funded warrant to purchase one share of common stock, (ii) a Series A warrant to purchase one share common
stock, (iii) a Series B warrant to purchase one Series B Unit, with each Series B Unit consisting of (a) one share of common stock and
(b) a Series B-1 Warrant to purchase one share of common stock, and (iv) a Series C warrant to purchase one Series C Unit, with each
Series C Unit consisting of (a) one share of common stock and (b) a Series C-1 Warrant to purchase one share of common stock. See further
warrant details per each issued series below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg Thalmann &amp; Co. Inc. (&#8220;Ladenburg&#8221;), acting as the &#8220;Placement Agent&#8221;, common stock
warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJdCNiHTUY83" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-04-18_us-gaap_WarrantMember" id="Fact001503" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,333</ix:nonFraction></span> shares of common stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>May
2024 Warrant Inducement Offer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, following the closing of the May 2024 Warrant Inducement Offer, warrant holders immediately exercised some or all of their
respective outstanding Series B Warrants and Series C Warrants to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsAndSeriesCWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zkgc95lxOPZ9" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-31_custom_SeriesBWarrantsAndSeriesCWarrantsMember_custom_InducementOfferLetterAgreementMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,153</ix:nonFraction></span> shares of the Company&#8217;s
common stock, Series B-1 Warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesBOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zYmEZUEbyAm2" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-31_custom_SeriesBOneWarrantsMember_custom_InducementOfferLetterAgreementMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,275</ix:nonFraction></span> shares of common stock and Series C-1 Warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesCOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zrOQJqpD6ux2" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember" id="Fact001509" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,878</ix:nonFraction></span> shares
of common stock, at a reduced exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesCOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zJi3X0R3szB6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.00</ix:nonFraction></span>. In consideration for the immediate exercise of some or all of the existing warrants
for cash, the Company agreed to issue unregistered new Series D Warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesDCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zoOx82TBe9Cj" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-31_custom_SeriesDCommonStockMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,153</ix:nonFraction></span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg, acting as the &#8220;Placement Agent&#8221;, common stock warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZSIhruMsAI3" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-31_us-gaap_WarrantMember" id="Fact001515" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,458</ix:nonFraction></span> shares of common
stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2024, the Board of Directors of the Company approved a Subscription Agreement dated July 28, 2024 with an accredited investor,
a related-party (the &#8220;Investor&#8221;). Pursuant to the Agreement, the Company sold to the Investor and the Investor purchased,
(i) <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240726_zo3q2wH3xf8b" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-07-26" id="Fact001517" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,235</ix:nonFraction></span> shares of Common Stock at a purchase price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxXptYUDOWNj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-26_us-gaap_CommonStockMember" id="Fact001519" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.172</ix:nonFraction></span> per share; and (ii) warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zdkTDAG7kCge" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-07-26_us-gaap_WarrantMember_custom_SubscriptionAgreementMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHz3nFOZIS87" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-26_us-gaap_WarrantMember" id="Fact001523" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.80</ix:nonFraction></span>, for an aggregate purchase price of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240726__20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wuFcZ8JFj3" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-262024-07-26_us-gaap_WarrantMember" id="Fact001525" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nova
Cell Investment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2024, the Board of Directors of the Company acknowledged a strategic investment of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zlx3Gm1SyoIg" title="Issuance of stock, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-262024-07-26_custom_BoardOfDirectorsMember" id="Fact001527" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million by an accredited
investor, a related-party, (the &#8220;Investor&#8221;) into Nova Cell, a subsidiary of the Company, in exchange for the issuance of
<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zlQuhOnDbH5k" title="Issuance of stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-262024-07-26_custom_BoardOfDirectorsMember" id="Fact001529" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500,000</ix:nonFraction></span> shares of Nova Cell&#8217;s common stock to the Investor, representing <span id="xdx_900_ecustom--PercentageOfStrategicInvestment_dp_uPure_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNXAGWB20l6e" title="Percentage of strategic investment"><ix:nonFraction name="CLDI:PercentageOfStrategicInvestment" contextRef="From2024-07-262024-07-26_custom_BoardOfDirectorsMember" id="Fact001531" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of Nova Cell&#8217;s current fully-diluted capitalization.
Nova Cell&#8217;s common stock was not adjusted when the Company effected its 2024 Reverse Stock Split and 2025 Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#8220;SRA&#8221;) and Material Purchase Agreement (the
&#8220;MPA&#8221; and together with the SRA the &#8220;Agreements&#8221;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zKyazEqJf2C4" title="Shares sold and transferred"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-10-272025-10-27_custom_NovaCellMember" id="Fact001533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500,000</ix:nonFraction></span> of its shares of common stock in Nova Cell (the &#8220;Repurchased Shares&#8221;), representing an
ownership interest of <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_zTibGf61lbzj" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2025-10-27_custom_NovaCellMember" id="Fact001535" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>%, back to Nova Cell, for a purchase price of $<span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zsAHGqwc5L9c" title="Purchase price for repurchased shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-10-272025-10-27_custom_NovaCellMember" id="Fact001537" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million (the &#8220;Purchase Price&#8221;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $<span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zgWHTV8g2Pud" title="Promissory note, net cash offset"><ix:nonFraction name="us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset" contextRef="AsOf2024-09-17_custom_NovaCellMember" id="Fact001539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span> thousand cash offset), resulting in an Indebtedness Cancellation Amount of $<span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zKhIIMN85uH8" title="Indebtedness cancellation amount"><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="From2024-09-172024-09-17_custom_NovaCellMember" id="Fact001541" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million,
and (B) the balance, by Deferred Consideration of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zrxAyHZmx1z1" title="Deferred consideration"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-09-17_custom_NovaCellMember" id="Fact001543" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million payable after closing, as more fully described in the SRA. As of December 31, 2025, no Deferred Consideration has been recognized,
and the full amount remains constrained until underlying uncertainties are resolved. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable
to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#8217;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell as listed on Schedule 1
to the MPA. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>At
The Market Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 11, 2024, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with Ladenburg, under
which the Company may, from time to time, in its sole discretion, issue and sell through Ladenburg, acting as agent or principal, shares
of the Company&#8217;s common stock, par value $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zATRFp0t7pni" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001545" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, initially having an aggregate offering price of up to $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pn5n6_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zxw8H3D6x951" title="Common stock par value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001547" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USDPShares">5.1</ix:nonFraction></span> million.
Pursuant to the Sales Agreement, Ladenburg may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221;
offering as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Ladenburg will use commercially
reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon instructions
from the Company (including any price or size limits or other customary parameters or conditions the Company may impose).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay Ladenburg a cash commission of <span id="xdx_904_ecustom--CashCommissionPercentage_iI_dp_uPure_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zLco14TltBDe" title="Cash commission percentage"><ix:nonFraction name="CLDI:CashCommissionPercentage" contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% of the aggregate gross sales proceeds of shares sold through Ladenburg under the Sales
Agreement. The Company also agreed to reimburse Ladenburg for certain specified expenses, including the fees and disbursements of its
counsel, in an amount not to exceed $<span id="xdx_903_ecustom--DisbursementsCounsel_iI_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zlTSkmlso3cj" title="Disbursements counsel"><ix:nonFraction name="CLDI:DisbursementsCounsel" contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>, in addition to certain ongoing disbursements of its legal counsel up to $<span id="xdx_90B_eus-gaap--LegalFees_c20241011__20241011__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zKVxPed6qT0g" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2024-10-112024-10-11_custom_SalesAgreementMember" id="Fact001553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></span> in connection
with diligence bring downs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Sales Agreement, the Company may also sell shares to Ladenburg as principal for its own account at prices agreed upon
at the time of sale. If the Company sells shares to Ladenburg as principal, it will enter into a separate terms agreement with Ladenburg
in substantially the form attached to the Sales Agreement. The Company is not obligated to sell any shares under the Sales Agreement.
The offering of the shares pursuant to the Sales Agreement may be terminated by either the Company or Ladenburg, as permitted therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2025, the Company increased the maximum aggregate offering amount of the shares of the Company&#8217;s common stock, par
value $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250204__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zNIwLLGsZ241" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, issuable under the Sales Agreement from $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250204__20250204__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_zWpXErfvEhBf" title="Aggregate offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-02-042025-02-04_custom_MarketOfferingAgreementMember" id="Fact001557" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.1</ix:nonFraction></span> million to $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250205__20250205__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_z6XEU1lhgHvj" title="Aggregate offering price"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2025-02-052025-02-05_custom_MarketOfferingAgreementMember" id="Fact001559" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">11.2</ix:nonFraction></span> million by filing a prospectus supplement under
the Sales Agreement for an aggregate of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240204__20250204__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zhijrDapBxcb" title="Sales agreement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-02-042025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember" id="Fact001561" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.1</ix:nonFraction> </span>million. During the year ended December 31, 2025, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhdgPcCOZMB8" title="Issued common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact001563" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">534,265</ix:nonFraction></span> shares of common
stock for gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsQ0s2wHznff" title="Proceeds from issued common shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember" id="Fact001565" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span> million under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>October
2024 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors (the &#8220;Purchasers&#8221;),
pursuant to which the Company agreed to issue to the Purchasers, (i) in a registered direct offering, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAWODDkNxvI"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,836</ix:nonFraction></span> shares of the Company&#8217;s
common stock, par value $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmp6ucnQs2R5" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, at a purchase price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8CeDtEXkqGc" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001570" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span> per share, and (ii) in a concurrent private placement, Series
E common stock purchase warrants to purchase up to <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesECommonWarrantsMember_zQtx9VAvpSe9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesECommonWarrantsMember" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,836</ix:nonFraction></span> shares of Common Stock (the &#8220;Series E Common Warrants&#8221;) and Series
F common stock purchase warrants to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFCommonWarrantsMember_zx3gS3IbMjw9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesFCommonWarrantsMember" id="Fact001572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">170,836</ix:nonFraction></span> shares of Common Stock (the &#8220;Series F Common Warrants&#8221; and together
with the Series E Common Warrants, the &#8220;Common Warrants&#8221;). Such registered direct offering and concurrent private placement
are referred to herein as the &#8220;Transactions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the Transactions took place on October 24, 2024. The gross proceeds from the Transactions were approximately $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20241024__20241024__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zA4mwdSy7qOd" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-10-242024-10-24_custom_PlacementAgentWarrantsMember" id="Fact001574" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million,
before deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if any, from
the exercise of the Common Warrants or common stock warrants issued to the Placement Agent (defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg, acting as the &#8220;Placement Agent&#8221;, common stock warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241024__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zk3vZmOHGnr4" title="Number of shares purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-10-24_custom_PlacementAgentWarrantsMember" id="Fact001576" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,542</ix:nonFraction></span> shares of common
stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2024, the Company conducted a CMPO with Ladenburg acting as the &#8220;Placement Agent&#8221;, pursuant to which the Company
agreed to issue in a public offering <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241114__20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQenvJcrGeb9" title="Public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001578" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">369,823</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFQYZsBJEQNe" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001580" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, at a purchase price
of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCGnD7TDtap9" title="Purchase price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001582" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.28</ix:nonFraction></span> per share. The gross proceeds from the offering, which closed on November 15, 2024, were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241115__20241115__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdwp73nJ1Cfj" title="Gross proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-11-152024-11-15_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001584" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.5</ix:nonFraction></span> million, before
deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise
of the Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by the Company pursuant to a shelf-registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Placement Agent common stock warrants to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241114__20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNoiqmApglwl" title="Placement agent common stock warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember" id="Fact001586" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,492</ix:nonFraction></span> shares of common stock. See further warrant details
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January
2025 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2025, the Company conducted a CMPO Agreement with Ladenburg acting as the &#8220;Placement Agent&#8221;, pursuant to which
the Company agreed to issue and sell in a public offering <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250109__20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyXHKCN4Utr7" title="Public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-01-092025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">416,667</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKghwc1QyEq9" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001590" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share,
at a purchase price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfEVEkeIkRd4" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001592" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.20</ix:nonFraction></span> per Share. The gross proceeds from the offering, which closed on January 10, 2025, were approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250109__20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS939R3HFnv7" title="Gross proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-092025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember" id="Fact001594" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span>
million, before deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if
any, from the exercise of the Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Placement Agent common stock warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOh1L0PPeuVh" title="Purchase of shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember" id="Fact001596" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,834</ix:nonFraction></span> shares of common stock. See further warrant details
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>March
2025 Registered Direct Offering and Concurrent Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2025, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the
Company agreed to issue to the Purchaser, (i) in a registered direct offering, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcg7xYmvn7Hd" title="Stock issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001598" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">277,084</ix:nonFraction></span> shares of the Company&#8217;s common stock (the
&#8220;Shares&#8221;), par value $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWj5RdgHa0Li" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001600" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, at a purchase price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zADv4gZFzzN" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001602" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.80</ix:nonFraction> </span>per Share, (ii) pre-funded warrants (&#8220;PFW&#8221;)
to purchase up to an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_ziJaiBogf91f" title="Stock issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact001604" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">227,334</ix:nonFraction></span> shares of Common Stock at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zf2LO1kZZRTb" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact001606" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.788</ix:nonFraction></span> per Pre-funded Warrant and an exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zMiMVwSuUnKj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact001608" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (the &#8220;Pre-funded Warrant Shares&#8221; or the &#8220;PFW Shares&#8221;) and (iii) in a concurrent private
placement, Series G common stock purchase warrants to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonWarrantsMember_zWvxgXNs8rQa" title="Common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGCommonWarrantsMember" id="Fact001610" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">504,417</ix:nonFraction></span> shares of common stock (the &#8220;Series G Warrants&#8221;
or the &#8220;Common Warrants&#8221;). Such registered direct offering and concurrent private placement are referred to herein as the
&#8220;March Registered Direct Offering and Concurrent Private Placement.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares, the PFW, and the PFW Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-284229),
which was declared effective by the Securities and Exchange Commission on February 7, 2025. The Series G Warrants were issued in a concurrent
private placement and without registration under the Securities Act, and in reliance on the exemption provided in Section 4(a)(2) under
the Securities Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg, acting as the &#8220;Placement Agent&#8221;, common stock warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250328__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKOuayq1fSe5" title="Purchase of shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-03-28_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember" id="Fact001612" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,221</ix:nonFraction></span> shares of common
stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>July
2025 Warrant Inducement Offer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 9, 2025, the Company entered into a warrant inducement offer agreement (the &#8220;July Warrant Inducement Offer&#8221;) with seven
holders of the Company&#8217;s existing Series A warrants, Series B-1 warrants, Series C-1 warrants, Series D warrants, Series E warrants,
and Series F warrants (together the &#8220;Existing Warrants&#8221;). Pursuant to the July Warrant Inducement Offer, such warrant holders
immediately exercised some, or all, of their respective outstanding Existing Warrants to purchase an aggregate of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_ztcMr4bRjMl2" title="Purchase of warrants, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember" id="Fact001614" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">549,596</ix:nonFraction></span> shares of the
Company&#8217;s common stock, at a reduced exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_zD96unmtx4we" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember" id="Fact001616" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span>, for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250709__20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_zoAsyHihNHT2" title="Gross proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-07-092025-07-09_custom_JulyWarrantInducementOfferMember" id="Fact001618" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.6</ix:nonFraction></span> million, prior to
deducting placement agent fees and offering expenses. Note that Ladenburg acted as the &#8220;Placement Agent&#8221; in the July Warrant
Inducement Offer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of some or all of the Existing Warrants for cash, the Company issued unregistered new Series
H common stock warrants (&#8220;Series H Warrants&#8221;) to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember_zjNTP2dpcyKj" title="Purchase of warrants, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember_custom_SeriesHCommonStockWarrantsMember" id="Fact001620" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">549,587</ix:nonFraction></span> shares of common stock. See further warrant details
below. The Company filed a resale registration statement on Form S-3 (File No. 333-288784), to register the shares underlying the Series
H Warrants, which registration statement was declared effective by the Securities and Exchange Commission on July 25, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August
2025 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2025, the Company entered into an underwriting agreement with Ladenburg, as representative of the various underwriters (the
&#8220;Representative&#8221;), in connection with the issuance and public sale offering of various securities (the &#8220;August Public
Offering&#8221;), including: (i) <span id="xdx_903_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zr3sYXN8KRr9" title="Issuance of common stock through august public offering, shares"><ix:nonFraction name="CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares" contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember" id="Fact001622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,922,764</ix:nonFraction></span> common stock units (&#8220;Common Stock Unit&#8221;), which includes the <span id="xdx_905_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zfj0IIfW79Fh" title="Issuance of common stock through august public offering, shares"><ix:nonFraction name="CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares" contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember" id="Fact001624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,000</ix:nonFraction></span> Common Stock
Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) <span id="xdx_90D_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zP5P50Woz6ul" title="Issuance of common stock through august public offering, shares"><ix:nonFraction name="CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares" contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember" id="Fact001626" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,528,000</ix:nonFraction></span> pre-funded warrant units (&#8220;Pre-Funded
Unit&#8221;), resulting in gross proceeds of approximately $<span id="xdx_90D_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingValue_pn5n6_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zoQA6DZv5CW5" title="Gross proceeds"><ix:nonFraction name="CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingValue" contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember" id="Fact001628" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></span> million, before deducting underwriting discounts and commissions and
other estimated offering expenses. The August Public Offering closed on August 21, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--CommonStockUnitPerShareDescription_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zYIsIAJqCzf9" title="Common stock unit per share description"><ix:nonNumeric contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember" id="Fact001630" name="CLDI:CommonStockUnitPerShareDescription">Each
Common Stock Unit consists of (i) one share of common stock of the Company, par value $0.0001, and (ii) one Series I warrant to purchase
one share common stock, and each Pre-Funded Unit consists of (i) one pre-funded warrant to purchase one share common stock, and (ii)
one Series I warrant to purchase one share common stock. Each Common Stock Unit was sold to the public at a price of $2.00 per Common
Stock Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit.</ix:nonNumeric></span> See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units and Pre-Funded Units were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333- 289670),
which was declared effective by the Securities and Exchange Commission on August 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the August Public Offering, the Company also issued to the Representative (or its designees) certain warrants (the &#8220;Representative
Warrants&#8221;) to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250820__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_ziha8uwFcddg" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-08-20_custom_RepresentativeWarrantsMember" id="Fact001632" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">172,538</ix:nonFraction></span> shares of common stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact001634" name="CLDI:ScheduleOfOutstandingWarrantsTextBlock"><p id="xdx_89A_ecustom--ScheduleOfOutstandingWarrantsTextBlock_zfUEjplfNhKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the Company had outstanding warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231_zwpIRC1k4m5d" title="Purchase of shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31" id="Fact001636" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,026,613</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zArg26kfajRk" title="Purchase of shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact001638" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">910,299</ix:nonFraction></span> shares of common stock, respectively,
consisting of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zaOCfoDFvQsc" style="display: none">Schedule
of Outstanding Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20251231_zt1cD7aewJkg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20241231_zGcjM197DTXl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    date</span></td></tr>
  <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgPI1YF6YQKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants to purchase Common Stock<sup id="xdx_F47_z6tyoNYW74H9">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" id="Fact001640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,938</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" id="Fact001641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15,938</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zPnNjNrABJWc" title="Exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zBLrmU8MfELg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" id="Fact001645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,380.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zFOSnd84WJIg" title="Issuance date"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zUxUSFeE6PEe" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001647" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001649" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">September
    12, 2023</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zuuTiMLGd41l" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgi48eD4KR84" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001651" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001653" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September
    12, 2028</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zUVdlL0BaiVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants to purchase Common Stock<sup id="xdx_F49_z0mrR375bVd2">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" id="Fact001655" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">95,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" id="Fact001656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">95,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zyVFDM8eVpxb" title="Exercise price"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zQULLMXm97K6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" id="Fact001658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" id="Fact001660" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USDPShares">1,380.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zxcbb1ukdC6k" title="Issuance date"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zDggh4IodK2g" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001662" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001664" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">September
    12, 2023</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_z4liAvuhhqxd" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zXqH06rbbU6h" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001666" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001668" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September
    12, 2028</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zRVBT6OtXQeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Restricted Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" id="Fact001670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,334</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" id="Fact001671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,334</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zO5Z4ONebg69" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_z2qM0oU5XHMe" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" id="Fact001673" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" id="Fact001675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">158.40</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zUJLcykvwPFf" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zAlM0j3fOEzl" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" format="ixt:datemonthdayyearen" id="Fact001677" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" format="ixt:datemonthdayyearen" id="Fact001679" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">February
    21, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zCrmwgfNzpjj" title="Expiration date"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zH6XTXdFLiV6" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" format="ixt:datemonthdayyearen" id="Fact001681" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember" format="ixt:datemonthdayyearen" id="Fact001683" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February
    21, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z8vVu2fbocdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Restricted Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" id="Fact001685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" id="Fact001686" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">50,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zV55UrC9J21j" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z5KnjmHS6E25" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" id="Fact001688" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" id="Fact001690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.80</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zbLT0yqBgGgf" title="Issuance date"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zjpg5mki66jg" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" format="ixt:datemonthdayyearen" id="Fact001692" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" format="ixt:datemonthdayyearen" id="Fact001694" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">July
    28, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zoioWBZIMGhk" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_ziMWpzLjgupe" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" format="ixt:datemonthdayyearen" id="Fact001696" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember" format="ixt:datemonthdayyearen" id="Fact001698" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">July
    28, 2027</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zeZNWsyvHhpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" id="Fact001700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,333</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6,333</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zAwBxePIkUjb" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zmQB8auENy31" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" id="Fact001703" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" id="Fact001705" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">79.20</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zjCKIMye3hR2" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zyofz5iOEo6l" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001707" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001709" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">April
    18, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zlBByEOYXPMg" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zXIw0zFkiLIi" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001711" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001713" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
    18, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zRG3mxhBCYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" id="Fact001715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,458</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" id="Fact001716" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,458</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zKIgIbpzC1ig" title="Exercise price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zmpqo9cGiIh9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" id="Fact001718" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" id="Fact001720" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zuC38sqnOXVe" title="Issuance date"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zcEimW9CHDwc" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001722" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001724" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">June
    3, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zh52pGdW7iY5" title="Expiration date"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zB3FkifcG6m" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001726" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001728" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June
    3, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zGpRg5Cjwixd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" id="Fact001730" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,542</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" id="Fact001731" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,542</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zYqG1ppSgiUh" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zji1jYZc0pPj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" id="Fact001733" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" id="Fact001735" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zOLqDczScrZf" title="Issuance date"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_z39r5jRN8Xgk" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001737" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001739" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">October
    24, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_znMKkRG0xyD7" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zEFPgYkpeVI5" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001741" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001743" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
    24, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zZVb2ifZHIB8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" id="Fact001745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">18,492</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" id="Fact001746" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">18,492</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zp5fzsTgXPRk" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zVOSoRBesXui" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.35</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zYgNY8sFtbV8" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_ziM0m1pNuWie" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" format="ixt:datemonthdayyearen" id="Fact001752" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" format="ixt:datemonthdayyearen" id="Fact001754" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">November
    15, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zIuC2g4Wt7A" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zvDPE8DF8yeh" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" format="ixt:datemonthdayyearen" id="Fact001756" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" format="ixt:datemonthdayyearen" id="Fact001758" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May
    15, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zXhwbxUCGCfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" id="Fact001760" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">20,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zRJ7x7PBpZ05" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zdDOtu5Gy3C" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" id="Fact001763" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" id="Fact001765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.75</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zhjJtbjLxlkk" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_z96k4eclodXh" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001767" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001769" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">January
    10, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zGXxb2E388ah" title="Expiration date"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zl6zoeGXGbp3" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001771" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001773" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January
    10, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_z2bnVOBJgyA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" id="Fact001775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">25,221</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zfRSuMQ0VzV7" title="Exercise price"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zy4bYiOnjp3g" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" id="Fact001778" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" id="Fact001780" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.75</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_ztjFqf8aO60h" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zo8VkNfwBptg" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" format="ixt:datemonthdayyearen" id="Fact001782" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" format="ixt:datemonthdayyearen" id="Fact001784" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">March
    31, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zZepBsWw9Uml" title="Expiration date"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zGXqAA2tfpSf" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" format="ixt:datemonthdayyearen" id="Fact001786" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" format="ixt:datemonthdayyearen" id="Fact001788" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March
    31, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zEuVwluocZK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative
    Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" id="Fact001790" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">172,538</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1791">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zJrrNhRqghwi" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zl162NBSwsic" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" id="Fact001793" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" id="Fact001795" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdEpCKIeJ7Ib" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zTQ3XXZ2mqV9" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001797" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001799" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">August
    21, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdpyOqOwiEle" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zHj8H0hmY7n5" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001801" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001803" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August
    21, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z2qFIt86FJR1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A Warrants to purchase Common Stock<sup id="xdx_F4E_zxG56Br7YiY2">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" id="Fact001805" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">54,308</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" id="Fact001806" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">87,643</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zcPrXXsxl0Ug" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z0T7YlqVq6A4" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" id="Fact001808" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" id="Fact001810" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zhx14koTOfI3" title="Issuance date"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zMH8vvPjIc8l" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001812" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001814" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">April
    18, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zxbeX8BwyTil" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zUzp6cT3xaN7" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001816" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001818" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
    18, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zRXRNz5giG4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B Warrants to purchase Common Stock<sup id="xdx_F4B_zNjffbTUWvC6">(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" id="Fact001821" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">57,451</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zmdUis4QApd1" title="Exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_z5zBuCDXO66l" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" id="Fact001823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" id="Fact001825" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zuo4398kBeN1" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zl1V7NoF89Ue" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001827" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001829" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">April
    18, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zgXFtLgEU3Yk" title="Expiration date"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zTOmfaCvW7e5" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001831" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001833" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
    18, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_409_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zxK56C9OewM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F48_zi6B9OdyvFwl">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" id="Fact001835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,442</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" id="Fact001836" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">22,276</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zMIYuaYfcbLa" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zKVxTROyMJFc" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" id="Fact001838" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" id="Fact001840" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zLtZZYwOpUhh" title="Issuance date"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zTBty83PwKeh" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001842" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001844" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">June
    3, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_z9APXtma4jC4" title="Expiration date"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zSAZb5EBebHg" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001846" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001848" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June
    3, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zuSbugofQ88a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F48_zUhKoE2S0fgk">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1850">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" id="Fact001851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">16,667</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_z6Q2iO7wrkh9" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zl2esj0kAFWh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" id="Fact001853" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" id="Fact001855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zLKKaPSxogyi"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zaV2ONdzup92"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001856" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001857" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">July
    19, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zNeVoftq6pge"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_ztFKpEwufmX4"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001858" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001859" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">July
    19, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockThreeMember_zCkDawhXMcV9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F4B_zvinK6tDmePi">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1861">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember" id="Fact001862" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,334</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKZS5M9IGtAb" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zb3bKc7Ydp18" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" id="Fact001864" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" id="Fact001866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKjBW1bV4H51" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z7Uc62PczQ67" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001868" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001870" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">July
    22, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zFw4BJGU3RB6" title="Expiration date"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z9YgJj0yOcul" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001872" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001874" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">July
    22, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zi58jpi6AbWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F4D_zwXyMJUAW6sf">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1876">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" id="Fact001877" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">16,251</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zwJ8XnPvSTne" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zM3LfOlLY3H4" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" id="Fact001879" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember" id="Fact001881" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zd6a768WbR78" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zeYk8d2n02P7" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001883" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001885" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">November
    13, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zZTv3yM7zNW9" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zWQrU2BdNnfl" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001887" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember" format="ixt:datemonthdayyearen" id="Fact001889" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">November
    13, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z7ujrgbVlbr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F4E_zLwFIY6fTcya">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" id="Fact001891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">17,918</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" id="Fact001892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">59,586</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zgpBGmZrf6Ac" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zg5kyH8SM1cb" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" id="Fact001894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" id="Fact001896" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z75eDQh1xCTf" title="Issuance date"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z1qOlKItkiF8" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001898" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001900" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">June
    3, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zq5QIba6ar77" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zSZHwcDX2mz8" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001902" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001904" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June
    3, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zJzt3bIaEs03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F43_zc78ko79Ispk">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" id="Fact001906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,167</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" id="Fact001907" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,167</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_z5wdghE4PKA6" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zenUJTI5yCBb" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" id="Fact001909" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" id="Fact001911" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zSBMp3LEQtQc" title="Issuance date"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zj7lqydZBNHa" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001913" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001915" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">August
    8, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zDJmd6Ur5tM8" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zvgGsMNGC1p4" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001917" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember" format="ixt:datemonthdayyearen" id="Fact001919" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August
    7, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zJkgO7hFEuW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F4F_zzxez496UVzc">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" id="Fact001921" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,168</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" id="Fact001922" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,168</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zrxgJl4GeaWg" title="Exercise price"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zxGPUeoRt4d" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" id="Fact001924" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" id="Fact001926" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_znsFzg1LuOEi" title="Issuance date"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zc8MccSdQq7f" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001928" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001930" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">August
    16, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zY7Qo5GVpeag" title="Expiration date"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_z6hpCbI1Lmi" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001932" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember" format="ixt:datemonthdayyearen" id="Fact001934" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August
    15, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z2JOJYvwMOEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    D Warrants to purchase Common Stock<sup id="xdx_F4B_zG5lQ2yItPt4">(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" id="Fact001936" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">18,318</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" id="Fact001937" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">89,153</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z16vwHbNh0Xg" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zUruHHO5ez2e" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" id="Fact001939" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" id="Fact001941" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zvGciJAxMT72" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zCJRExu8H2ed" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001943" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001945" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">June
    3, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zF0K0c2rH383" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zVzpD6Ujyszl" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001947" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001949" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">December
    3, 2029</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zIiCncH8XL19" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    E Warrants to purchase Common Stock<sup id="xdx_F45_zpm863jw6ng2">(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1951">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" id="Fact001952" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">170,836</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zlJJoSlZTg2k" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zEd7oC1C0zu9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" id="Fact001954" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" id="Fact001956" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.56</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zbdKGTDqyMe5" title="Issuance date"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zU1nxSdCqZRc" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001958" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001960" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">October
    24, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z3zozdSBbRZ6" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z9z4SmAWT7Uj" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001962" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001964" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
    24, 2026</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zcyV1hRWckwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    F Warrants to purchase Common Stock<sup id="xdx_F4A_zlTwV30ZGCpg">(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1966">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" id="Fact001967" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">170,836</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNa9hD16C08j" title="Exercise price"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNp6cIBAGzq7" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" id="Fact001969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" id="Fact001971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.56</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zC9N51yiELM6" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zLuJsjrmAE8h" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001973" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001975" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">October
    24, 2024</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zys2Z2jMKAzd" title="Expiration date"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zoQUUA1BJyS7" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001977" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001979" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April
    24, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zd0cmXTTpCU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    G Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" id="Fact001981" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">504,417</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zhf66P3Rp22b" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBfcttBteGNj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" id="Fact001984" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" id="Fact001986" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.34</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBun3MQzBom6" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zVGtsejpShZe" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001988" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001990" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">March
    31, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_z5gD9u8fUuB2" title="Expiration date"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zDZtzijcIfq6" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001992" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact001994" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September
    30, 2032</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zYJrUiT4A1ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    H Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" id="Fact001996" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">549,587</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1997">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zQQ4PJRklOO5" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zeyBs7AL6XDb" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" id="Fact001999" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" id="Fact002001" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zJulfPSosXt3" title="Issuance date"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zLHZL6Dl1L04" title="Issuance date"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002003" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002005" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">July
    10, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zKP7QEZhGH0h" title="Expiration date"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zOprzkzV9Xg4" title="Expiration date"><ix:nonNumeric contextRef="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002007" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002009" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January
    10, 2031</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zrxXLSswYqoh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    I Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" id="Fact002011" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">3,450,764</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2012">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_znVkhYZ2rki4" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zzmaptg7Mxhi" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" id="Fact002014" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" id="Fact002016" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zf5M0aVWiWk6" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zwlQJh5khrwi" title="Issuance date"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002018" name="CLDI:ClassOfWarrantOrRighstIssuanceDate"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002020" name="CLDI:ClassOfWarrantOrRighstIssuanceDate">August
    21, 2025</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zObUZb63f0c6" title="Expiration date"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zUj54wVc0HX4" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002022" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember" format="ixt:datemonthdayyearen" id="Fact002024" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August
    21, 2030</ix:nonNumeric></ix:nonNumeric></span></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_zXPhLVZlmw2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31" id="Fact002026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,026,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31" id="Fact002027" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">910,299</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F02_zklbGtvDjmx2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_znuGs7SC36K5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002028" xml:lang="en-US">The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#8217;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zhchokdSYADf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1B_zxZ3YvKW1fL2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002029" xml:lang="en-US">The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#8217;s common stock.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--PublicWarrantRedemptionDescription_pid_c20250101__20251231_ztb6ktS0f7Gb" title="Public warrant redemption description" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" id="Fact002031" name="CLDI:PublicWarrantRedemptionDescription">The
    Company may redeem the outstanding Public Warrants for $<span id="xdx_90C_ecustom--RedemptionOfOutstandingWarrantsPerShare_pid_c20250101__20251231_z0eZIco0ySvh" title="Redemption of outstanding warrants per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CLDI:RedemptionOfOutstandingWarrantsPerShare" contextRef="From2025-01-01to2025-12-31" id="Fact002033" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.12</ix:nonFraction></span> per warrant upon at least <span id="xdx_900_ecustom--ClassOfWarrantsRedemptionNoticePeriod_dtD_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_zIroWV3Kn0of" title="Class of warrants, redemption notice period" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" format="ixt-sec:durday" id="Fact002035" name="CLDI:ClassOfWarrantsRedemptionNoticePeriod">30</ix:nonNumeric></span> days&#8217; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $<span id="xdx_90B_eus-gaap--SharePrice_iI_uUSDPShares_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_zKgdq3sn9i9g" title="Share Price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" id="Fact002037" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USDPShares">2,160.00</ix:nonFraction></span> per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company accounts for the Public Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because
    the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accounting treatment of derivative financial instruments in accordance with ASC 815 requires that the Company record a derivative
    liability upon the closing of the FLAG Merger (see Note 2).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 17, 2024, the Company received notice from the NYSE that the Company&#8217;s Public Warrants to purchase common stock are
    no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of such public
    warrants, and that the NYSE Regulation has determined to commence proceedings to delist the public warrants. The Public Warrants
    may be traded on the OTC Pink Marketplace under the symbol CLDWW.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F00_za4loOSPtY25" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F19_z1lSebrMsjPb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002038" xml:lang="en-US">During
                                            the year ended December 31, 2024, Series A warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesAWarrantsMember" id="Fact002040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">60,418</ix:nonFraction></span> shares of common stock
                                            were exercised at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesAWarrantsMember" id="Fact002042" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></span> per share and the Company received gross proceeds of approximately
                                            $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576" title="Received dross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-12-31_custom_SeriesAWarrantsMember" id="Fact002044" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series A warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z5zyhc1WQVrb" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember" id="Fact002046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">33,335</ix:nonFraction></span> shares of common stock were exercised at a reduced exercise
    price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zM4YvTH3n71e" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember" id="Fact002048" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zoKof3dAYb4h" title="Received dross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsMember" id="Fact002050" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F00_zk1EX9rWw8s9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F14_zOJRQAZQHvG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002051" xml:lang="en-US">Series
                                            B warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember" id="Fact002053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">22,275</ix:nonFraction></span> shares of common stock were exercised at a reduced exercise
                                            price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.00</ix:nonFraction></span> in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember" id="Fact002057" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million. During the year ended December 31, 2024, Series B warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesBWarrantsMember" id="Fact002059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">68,335</ix:nonFraction></span>
                                            shares of common stock were exercised at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesBWarrantsMember" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></span> per share and the Company received gross
                                            proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-012024-12-31_custom_SeriesBWarrantsMember" id="Fact002063" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outstanding Series B warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zCjS5nkk7RNl" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" id="Fact002065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">57,451</ix:nonFraction></span> shares of common stock expired in April 2025. As of December 31, 2025, <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_do_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zJcPptm4wsz" title="Warrants outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember" id="Fact002067" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares">no</ix:nonFraction></span> Series
    B warrants remained outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zCbhZ5JVIGuf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F10_zNpmXQC9ahDe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002068" xml:lang="en-US">During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesBOneWarrantsMember" id="Fact002070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">27,082</ix:nonFraction></span> shares of common
                                            stock were exercised at $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesBOneWarrantsMember" id="Fact002072" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></span> per share and the Company received gross proceeds of approximately
                                            $<span id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-012024-12-31_custom_SeriesBOneWarrantsMember" id="Fact002074" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series B-1 warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zJzhCq7uqT78" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesBOneWarrantsMember" id="Fact002076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">62,086</ix:nonFraction></span> shares of common stock were exercised at a reduced exercise
    price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zKWSRj6VjYF9" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesBOneWarrantsMember" id="Fact002078" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zpYGyKGAeYG2" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesBOneWarrantsMember" id="Fact002080" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zCd37e8Jcx98" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1C_z7McP3RC7sPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002081" xml:lang="en-US">In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsMember" id="Fact002083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,167</ix:nonFraction></span> shares of
                                            common stock were exercised at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsMember" id="Fact002085" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.00</ix:nonFraction></span> per share and the Company received gross proceeds of
                                            approximately $<span id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesCOneWarrantsMember" id="Fact002087" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_SeriesCOneWarrantsMember" id="Fact002089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">47,936</ix:nonFraction></span> shares of common stock were exercised at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SeriesCOneWarrantsMember" id="Fact002091" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.24</ix:nonFraction></span> per share and the Company
                                            received gross proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-012024-12-31_custom_SeriesCOneWarrantsMember" id="Fact002093" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series C-1 warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zsOkklPTY0P5" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsOneMember" id="Fact002095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">41,668</ix:nonFraction></span> shares of common stock were exercised at a reduced exercise
    price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zelVqow1sFad" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsOneMember" id="Fact002097" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zV1AZQnnrJB7" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesCOneWarrantsOneMember" id="Fact002099" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zPih12spboPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F19_z4prBB1WV3Ea" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002100" xml:lang="en-US">The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $<span id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3" title="Deemed dividend" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CLDI:Deemeddividend" contextRef="AsOf2025-12-31_custom_SeriesDWarrantsMember" id="Fact002102" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.</ix:footnote></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series D warrants to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zAy8T0RnQ5F8" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesDWarrantsMember" id="Fact002104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">70,835</ix:nonFraction></span> shares of common stock were exercised at a reduced exercise
    price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zHckoL4rqJD2" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesDWarrantsMember" id="Fact002106" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zExkhm7GdCK" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesDWarrantsMember" id="Fact002108" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F08_z79dDFrQyW69" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zTzPNn9dfsxj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002109" xml:lang="en-US">During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember" id="Fact002111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">341,672</ix:nonFraction></span> shares of common stock each were exercised
    at a reduced exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember" id="Fact002113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span> per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember" id="Fact002115" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zw2x6xA5wMr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, Series G pre-funded warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn3n3_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zIMMlwKBj4P2" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesGPreFundedWarrantsMember" id="Fact002117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">227,334</ix:nonFraction></span> shares of common stock were exercised at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zp9TKcGaDSE8" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesGPreFundedWarrantsMember" id="Fact002119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.012</ix:nonFraction></span> per
share for gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pn3n3_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zzoladFoOXya" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesGPreFundedWarrantsMember" id="Fact002121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span>, and Series I pre-funded warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn3n3_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zhx59spSMne5" title="Number of shares purchased" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-12-31_custom_SeriesIPreFundedWarrantsMember" id="Fact002123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,528,000</ix:nonFraction></span> shares of common stock were
exercised at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zZsOTErFGnk1" title="Warrants exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-12-31_custom_SeriesIPreFundedWarrantsMember" id="Fact002125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share for gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromNotesPayable_pn3n3_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zU0n0BRUINl7" title="Gross proceeds" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2025-01-012025-12-31_custom_SeriesIPreFundedWarrantsMember" id="Fact002127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span>. As such, no Series G pre-funded warrants or Series I pre-funded
warrants were outstanding as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002129" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI9zvMdBUoVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s aggregate warrant activity for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zN4RTrBvgykj" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz2jDt26kuD4" title="Number of Warrants, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265" id="Fact002131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">910,299</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjKyow3I4Dza" title="Weighted Average Exercise Price, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265" id="Fact002133" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">185.16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgckS06Oe9s4" title="Weighted Average Remaining Contractual Life (Years)" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281" format="ixt-sec:duryear" id="Fact002135" name="CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms">3.63</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z38OhOA5wXR" title="Number of Warrants, Issued" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281" id="Fact002137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,478,695</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyvU3Dx4CT4c" title="Number of Warrants, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281" id="Fact002139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,304,930</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetsFP6qOM73" title="Number of Warrants, Cancelled" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281" id="Fact002141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,451</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8GKp22zH831" title="Number of Warrants, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2025-12-31_us-gaap_WarrantMember11030312" id="Fact002143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,026,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5c4cCUUR2d9" title="Weighted Average Exercise Price, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" contextRef="AsOf2025-12-31_us-gaap_WarrantMember11030312" id="Fact002145" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.97</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoKmLVctvhY1" title="Weighted Average Remaining Contractual Life (Years)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281" format="ixt-sec:duryear" id="Fact002147" name="CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms">4.79</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s aggregate warrant activity for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price
                                            <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgX2i38dnYCe" title="Number of Warrants, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,772</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwS16fLKZb5f" title="Weighted Average Exercise Price, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact002151" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,380.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7sOYX74ZK9k" title="Weighted Average Remaining Contractual Life (Years)" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact002153" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.72</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9lVq9FwLa7" title="Number of Warrants, Issued" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281" id="Fact002155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,176,804</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z71n7KcESiyc" title="Number of Warrants, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281" id="Fact002157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,222</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted
    into Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z9Oku9Hupf42" title="Number of Warrants, Cancelled" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281" id="Fact002159" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">28,055</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zAeJ5lPSI06f" title="Number of Warrants, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265" id="Fact002161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">910,299</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo7VftXyfc8e" title="Weighted Average Exercise Price, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265" id="Fact002163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">185.16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEGRpY5Qpcik" title="Weighted Average Remaining Contractual Life (Years)" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281" format="ixt-sec:duryear" id="Fact002165" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.63</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zs7323Dd0Ihi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002167" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zD2T4dlLrNlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_825_zP7G4TGIwXpi">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Incentive Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of the Business Combination on September 12, 2023, the Company adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;).
The 2023 Plan reserved the right for the Compensation Committee or by the Board of Directors acting as the Compensation Committee, as
the administrator of the plan (the &#8220;Administrator&#8221;) to issue up to <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230912__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--TitleOfIndividualAxis__custom--AdministratorMember_zupByNRwm5ti" title="Number of shares reserved"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-09-12_custom_TwoThousandTwentyThreePlanMember_custom_AdministratorMember" id="Fact002169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,815</ix:nonFraction></span> equity awards, including stock options (&#8220;Options&#8221;),
restricted stock awards (&#8220;Restricted Stock&#8221;), dividend equivalents awards, stock payment awards, restricted stock units (&#8220;RSUs&#8221;)
and/or stock appreciation rights (&#8220;SARs&#8221;, together with Options, Restricted Stock and RSUs, &#8220;Awards&#8221;), according
to its discretion. On July 9, 2025, the Company&#8217;s stockholders approved an amendment to the 2023 Plan to increase the aggregate
number of shares of common stock authorized for grant under the 2023 Plan from <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250709__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--RangeAxis__srt--MinimumMember_zqTyX4QSO8X3" title="Number of shares reserved"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MinimumMember" id="Fact002171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">32,815</ix:nonFraction></span> to <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250709__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--RangeAxis__srt--MaximumMember_zQGP7s8uYCcb" title="Number of shares reserved"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MaximumMember" id="Fact002173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">282,815</ix:nonFraction></span>. Awards may be granted under the 2023
Plan to our employees, directors, and consultants. As of December 31, 2025, the Administrator has issued RSUs and stock options under
the 2023 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2023 Plan, Awards may vest and thereby become exercisable, subject to forfeiture restrictions, (1) on the date of grant, (2) in periodic
installments, (3) upon the attainment of performance goals, or (4) upon the occurrence of specified events depending on the Administrator&#8217;s
discretion. The Administrator has broad authority to determine the terms and conditions of any Award granted pursuant to the 2023 Plan
including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations
on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations
or waivers thereof as the Administrator, in its sole discretion may determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Awards may be granted under the 2023 Plan with a term of more than ten years and no Awards granted may be exercised after the expiration
of ten years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024 and August 4, 2025, the Company effected a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20240715__20240715_zYwzsdIzoCs6" title="Reverse stock split"><ix:nonNumeric contextRef="From2024-07-152024-07-15" id="Fact002175" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span> Reverse Stock Split and a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20250804__20250804_zliZ8Lhl9p94" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-08-042025-08-04" id="Fact002177" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-12</ix:nonNumeric></span> Reverse Stock Split, respectively.
As a result of each respective Reverse Stock Split, proportionate adjustments were made to the per share exercise price and the number
of shares of common stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of
shares of common stock reserved for future issuance under the Company&#8217;s 2023 Plan. All stock option activity presented in these
statements has been retrospectively adjusted to reflect the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2023, the Company approved the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;), which became effective on
the consummation of the FLAG Merger. Under the 2023 ESPP, eligible employees may purchase a limited number of shares of common stock
at a discount of up to <span id="xdx_906_ecustom--CommonStockDiscounRate_pid_dp_uPure_c20230828__20230828__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_z9scwl30pMf3" title="Number of shares issued of common stock at discount rate"><ix:nonFraction name="CLDI:CommonStockDiscounRate" contextRef="From2023-08-282023-08-28_custom_EmployeeStockPurchasePlanMember" id="Fact002179" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of the market value of such stock at pre-determined and plan-defined dates. There have been no issuances of
common stock under the 2023 ESPP to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the 2023 Plan may be either &#8220;incentive stock options&#8221; within the meaning of Section 422(b) of the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or &#8220;non-qualified&#8221; stock options that do not qualify incentive
stock options. Incentive stock options may be granted only to the Company&#8217;s employees and employees of domestic subsidiaries, as
applicable. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztWXzM30ZAk1" title="Description of term and exercise price of options"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember11030718" id="Fact002181" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">The exercise price of stock options shall be equal to or greater than the fair market value of common stock on the date the
option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the
grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined
as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee
in any calendar year may not exceed $0.1 million, otherwise it will be classified as a non-qualified stock option.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of an option may be payable in cash or in common stock, or in a combination of cash and common stock, or other legal consideration
for the issuance of stock as the Board or Administrator may approve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrLY2NWF4j4f" title="Descriptiion of options vesting"><ix:nonNumeric contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember11030718" id="Fact002183" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">options vest over four years and will be exercisable only while the optionee remains an employee, director or consultant, or during the
three months thereafter, but in the case of the termination of an optionee&#8217;s services due to death or disability, the period for
exercising a vested option shall be extended to the earlier of twelve months after termination or the expiration date of the option.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee
Benefit Plans Securities Registration Statement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company filed a Registration Statement on Form S-8, which includes a Reoffer Prospectus which may be used for reoffers
and resales of shares of the Company. The Reoffer Prospectus covers the shares issuable to the holders pursuant to awards granted by
the Company under the 2023 Plan. The Company will not receive any proceeds from the sale of the shares offered by the Reoffer Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 178; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Awards Activity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002185" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z7xIaenxH4sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the 2023 Plan option activity and related information follows (in thousands, except weighted averages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zfEuhibvMzL2" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic
                                            Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK7kC1ajijW2" title="Number of Options Outstanding, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">77</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztRaZJZJFvU2" title="Weighted Average Exercise Price, Balance" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002189" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">220.92</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSpaP75uL3ci" title="Weighted Average Remaining Contractual Life (Years), Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact002191" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.67</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zefFLnTWCDKg" title="Aggregate Intrinsic Value, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKe1Ruauxv7b" title="Number of Options Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002195" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">217</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCWFrdBuwki" title="Weighted Average Exercise Price, Options granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002197" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.23</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpYflv2WEsYd" title="Number of Options Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2199">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0rvqdIRJlL" title="Weighted Average Exercise Price, Options granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2201">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    forfeited or cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYBD9YroCVBg" title="Number of Options Forfeited or cancelled" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002203" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0buq0fQQjLd" title="Weighted Average Exercise Price, Options forfeited or cancelled" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002205" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">252.37</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoM6ZjChWrv5" title="Number of Options Outstanding, Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTFSrkB3V5kl" title="Weighted Average Exercise Price, Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">49.57</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HXOYBinOu4" title="Weighted Average Remaining Contractual Life (Years), Outstanding"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact002211" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.39</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEh0gbt0G4c" title="Aggregate Intrinsic Value, Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2213">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVY2amDXb4Li" title="Number of Options Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">78</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAhQUpKWRJRd" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" id="Fact002217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">160.73</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHcrzjARNxw4" title="Weighted Average Remaining Contractual Life (Years), Exercisable"><ix:nonNumeric contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact002219" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.54</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ0Xgxt9ks5" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zRooPPLh8yNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002223" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0V8ViB7a2cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the 2023 Plan restricted stock unit (RSU) activity and related information follows (in thousands, except weighted average
grant date fair value):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zwCCANd9cbH3" style="display: none">Summary
of Restricted Stock Unit Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant-Date
                                            Fair Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYP9cSw5Qb6" title="Number of Units Outstanding, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRgmbX7LNmcj" title="Weighted Average Grant Date Fair Value, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    and released</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZugKRLLFGo1" title="Number of Units Outstanding, Vested" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpw41DTyfZe6" title="Weighted Average Grant Date Fair Value, Vested" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002231" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.80</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzEsqaDp2sml" title="Number of Units Outstanding, Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2233">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLgdS2RSgSTg" title="Weighted Average Grant Date Fair Value, Ending" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2235">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zqFcJcwzXpna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002237" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zCzZoUFkWN5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations
for the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDiKQSAqinMj" style="display: none">Schedule
of Stock-Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zKOpDXF8G51l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zr8StlecTXPh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zraVVi4t1ank" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">426</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember" id="Fact002240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zUGIRtAM3tRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact002242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,682</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember" id="Fact002243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,206</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zBL22iwa4ICg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2025-01-01to2025-12-31" id="Fact002245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31" id="Fact002246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,957</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zpUqrOZ5dV71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 18, 2023, the Board approved a repricing of approximately <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn5n6_c20230118__20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJRMOsgG1w1d" title="Options granted approved for repricing"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-182023-01-18_us-gaap_EmployeeStockOptionMember" id="Fact002248" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">0.2</ix:nonFraction> </span>million stock options previously granted at an exercise price of
$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbbkayw0naG3" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-01-18_us-gaap_EmployeeStockOptionMember" id="Fact002250" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,112.40</ix:nonFraction></span> per share to the then current fair value of $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO02JJ1mcZDc" title="Exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-01-18_us-gaap_EmployeeStockOptionMember" id="Fact002252" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">853.20</ix:nonFraction></span> per share pursuant to an updated valuation report. For each of the years
ended December 31, 2025 and 2024, the Company recorded a noncash compensation charge of approximately $<span id="xdx_906_ecustom--NoncashCompensation_pn5n6_c20250101__20251231_z3rzkqROs8l" title="Noncash compensation charge in connection with repricing"><span id="xdx_901_ecustom--NoncashCompensation_pn5n6_c20240101__20241231_z2zc3dDlsrGj" title="Noncash compensation charge in connection with repricing"><ix:nonFraction name="CLDI:NoncashCompensation" contextRef="From2025-01-01to2025-12-31" id="Fact002254" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="CLDI:NoncashCompensation" contextRef="From2024-01-012024-12-31" id="Fact002256" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></ix:nonFraction></span></span> million in connection with
this repricing. The stock option repricing and the acceleration of vesting were accounted for as a modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the total unamortized stock-based compensation expense related to stock options was approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20251231_zf2gMDpc4HJl" title="Total unamortized stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2025-12-31" id="Fact002258" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million,
expected to be amortized over an estimated weighted average life of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231_zEMBRRQxq2Pl" title="Estimated weighted average life"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact002260" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.9</ix:nonNumeric></span> years. The weighted-average estimated fair value of stock options
with service-conditions granted during the year ended December 31, 2025 and 2024 was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231_zhBIl59XK0ik" title="Weighted-average estimated fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-01-01to2025-12-31" id="Fact002262" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.11</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zwllCtCMkreb" title="Weighted-average estimated fair value of stock options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31" id="Fact002264" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.28</ix:nonFraction></span> per share, respectively, using
the Black-Scholes option pricing model with the following weighted-average assumptions:</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002266" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zu40kxVf1Mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zdpUKtuCZav8" style="display: none">Schedule
of Stock Options Valuation Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20251231_zYwzAD1nqNb7" title="Expected volatility" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2025-01-01to2025-12-31" id="Fact002268" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87.84</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zzjUP5wAMfF2" title="Expected volatility" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-012024-12-31" id="Fact002270" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.63</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20251231_zH4VG3ESa7eb" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2025-01-01to2025-12-31" id="Fact002272" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.93</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zz8KbtNzL8nk" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31" id="Fact002274" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.21</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    option life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231_zGfjSZ8LnwK7" title="Expected option life (in years)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" format="ixt-sec:duryear" id="Fact002276" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.78</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zftGv0RrkSD7" title="Expected option life (in years)" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-01-012024-12-31" format="ixt-sec:duryear" id="Fact002278" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.64</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_zBtbVzIc1lTf" title="Expected dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2025-01-01to2025-12-31" id="Fact002280" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zO5GP7caLrCh" title="Expected dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31" id="Fact002282" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AD_zigRZD3ZpVj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when
a disqualified disposition has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002284" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zHExlPqNWiEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82C_z5Z5FPvHfbp1">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002286" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zmI7X7eorJAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income/(Loss)
before provision for income taxes consisted of the following for the year ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zaVuKwfY3u7l" style="display: none">Schedule
of Income (Loss) Before Provision for Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_z1eur2KiQjJ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z0n1aWp4zFjd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zqb4CfXSPFlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-12-31_srt_AmericasMember" id="Fact002288" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,100</ix:nonFraction><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_srt_AmericasMember" id="Fact002289" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--NonUsMember_zYhOssVld3l2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-012025-12-31_us-gaap_NonUsMember" id="Fact002291" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">52</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31_us-gaap_NonUsMember" id="Fact002292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zrDgzR435E9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2025-01-01to2025-12-31" id="Fact002294" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20,048</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-12-31" id="Fact002295" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">22,195</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zQ3h5mKaKxIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 179; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002297" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkQC7wARcWlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax expense (benefit) by jurisdiction for the year ended December 31, 2025 and 2024, were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zckABzOflrB9" style="display: none">Schedule
of Income Tax Expenses (Benefit) by Jurisdiction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zdfhLeHvkoCb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zx5hjdGzc0rb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_znNSLSOmYZ31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zAup2wou2llc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2302">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2303">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zVp9UCS1JTDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    and local</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2306">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zBvgZLB1XXee" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pn3n3_mtCITEBziCv_maITEBzUqw_zZMx6aSiZtwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002312" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zKTEcVxovTUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_z1kpVraKSUdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2317">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2318">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zK1WBnJwE7Za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    and local</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2320">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2321">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zBsepxvobkVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2323">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2324">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pn3n3_mtDITEBzDw6_maITEBzUqw_zbTUpQrnkXRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2326">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2327">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUqw_zxpscxQO7gtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-012024-12-31" id="Fact002330" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_z2cPIjZ0vmW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has incurred net operating losses primarily for U.S. federal and state income tax purposes and has not reflected
any benefit of such net operating loss carryforwards for any periods presented herein. For the year ended December 31, 2025 and 2024,
no U.S. provision or benefit for income taxes was recorded and an insignificant amount of German provision for income taxes was recorded
as presented on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002332" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuqKCNsp7pKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the benefit for income taxes to the amount computed
by applying the <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zQYz2ZJJiQ1k" title="Federal statutory income tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002334" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2025, after the
adoption of ASU 2023-09, is as follows (in thousands, except for percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span id="xdx_8BA_zi89feMC8pgg" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231_zvsulSOwOOFf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjN0_zihwnEwvat8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">U.S. Federal statutory tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002336" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,210</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zdCaSR0PS2I" title="U.S. Federal statutory tax rate, percentage" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002338" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjN0_zMd2U5dnfb7c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State tax, net of federal income tax effect<sup id="xdx_F49_zfMUB8EowxWh">(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2025-01-01to2025-12-31" id="Fact002340" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20250101__20251231_fKDEp_ziSPJNckHKx4" title="State tax, net of federal income tax effect, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationEnactmentOfNewTaxLaws_maITEBzjN0_zeb36ZS0ig89" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Enactment of new tax laws</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_pid_dp_uPure_maABC_c20250101__20251231_znorpo3hbvr5" title="Enactment of new tax laws, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2346">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maITEBzjN0_zrh65z92s1pl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of cross-border tax laws</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_c20250101__20251231_zT42c40qxkWh" title="Effect of cross-border tax laws, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2350">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBzjN0_zvDLKSApPOKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" contextRef="From2025-01-01to2025-12-31" id="Fact002352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20250101__20251231_z7oSHzsu1zi" title="Tax credits, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2025-01-01to2025-12-31" id="Fact002354" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjN0_zq5pT7QibJ4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact002356" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,519</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zs8DOk37luLg" title="Change in valuation allowance, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact002358" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAbstract_iB_zUKpPQtL6vtl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Nontaxable or non-deductible items</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_i01_maITEBzjN0_zWye46LLe00l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-deductible expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" contextRef="From2025-01-01to2025-12-31" id="Fact002362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maABC_c20250101__20251231_ztk6cDIBHb0k" title="Non-deductible expenses, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2364">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_maITEBzjN0_z0CPv64gkyJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2025-01-01to2025-12-31" id="Fact002366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20250101__20251231_zlb9t8L8Gc91" title="Stock based compensation, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2025-01-01to2025-12-31" id="Fact002368" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxSettlements_maITEBzjN0_z6MunjaJDdIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Worldwide changes in unrecognized tax benefits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxSettlements" contextRef="From2025-01-01to2025-12-31" id="Fact002370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">342</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maABC_c20250101__20251231_zY4B7GQpnN93" title="Worldwide changes in unrecognized tax benefits, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" contextRef="From2025-01-01to2025-12-31" id="Fact002372" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherReconcilingItemsAbstract_iB_zjqX7cLSigw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i01_maITEBzjN0_zgknsduMTri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred tax adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zbbFMSpxyShc" title="Deferred tax adjustments, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="From2025-01-01to2025-12-31" id="Fact002378" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_i01N_di_msITEBzjN0_zwrlSKQZHIo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact002380" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">348</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_iN_pid_dpi_uPure_msABC_c20250101__20251231_zd8usvK6Y6u5" title="Non-controlling interest, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" contextRef="From2025-01-01to2025-12-31" id="Fact002382" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i01_maITEBzjN0_zh8MyuRsHJ49" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2025-01-01to2025-12-31" id="Fact002384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20250101__20251231_zaR1I0mJwQM6" title="Other, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2386">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_maABC_zJLZG6onMXka" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Other, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_maABC_zepi2og8IZJf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Other, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_maABC_znEh3CYo1Nz8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issuance cost</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Other, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_maABC_z2J7LMVTXxBk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    startup costs</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Other, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign tax effects</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Germany</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_maITEBzjN0_zeeaLUSXxKVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Foreign employee stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CLDI:IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" contextRef="From2025-01-01to2025-12-31" id="Fact002396" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zcO0S1CaBQZk" title="Foreign employee stock based compensation, percentage" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2398">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_maITEBzjN0_zR99C4Yh4P63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rate differential</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CLDI:IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" contextRef="From2025-01-01to2025-12-31" id="Fact002400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zHo20NYC5TK6" title="Germany Rate differential, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_maITEBzjN0_zvmJdpCP8Q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CLDI:IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" contextRef="From2025-01-01to2025-12-31" id="Fact002404" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_pid_dp_uPure_maABC_c20250101__20251231_zmN6R4wflEAj" title="Germany Other, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2406">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_maITEBzjN0_zAlI68y5rrZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rate differential</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CLDI:IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" contextRef="From2025-01-01to2025-12-31" id="Fact002408" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_pid_dp_uPure_maABC_c20250101__20251231_zkS90xGUv0H1" title="Australia Rate differential, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2410">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_maITEBzjN0_zMgrgYgslGr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CLDI:IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" contextRef="From2025-01-01to2025-12-31" id="Fact002412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zAIEDsplK743" title="Australia Change in valuation allowance, percentage" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2414">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjN0_zbJfxINKh827" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2025-01-01to2025-12-31" id="Fact002416" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20250101__20251231_zyyiiUtlerG6" title="Reconciliation of income tax benefit, percentage" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2418">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zct2ZTKa2Ewf" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zpfi7Hnizt45" style="font-size: 10pt"><ix:footnote id="Footnote002419" xml:lang="en-US">California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.</ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 2023-09 on a prospective basis. A reconciliation of the benefit for income taxes to the amount computed by
applying the <span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_z0obmmRCZSM3" title="Federal statutory income tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact002421" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%
statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2024, before the adoption of ASU
2023-09, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none">Schedule
of U.S. Federal Income Tax Rates Indicated to Pretax Loss From Operations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed
    tax benefit at U.S. federal statutory tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20240101__20241231_zUtR4pIQ7Qn2" title="Computed tax benefit at U.S. federal statutory tax rate, percentage" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-012024-12-31" id="Fact002423" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent
    differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20240101__20241231_zPeXQHLDEdz6" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2425">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    tax benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20240101__20241231_zm3EOrHZAze5" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-012024-12-31" id="Fact002427" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20240101__20241231_zyCqFkjZl2x2" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="From2024-01-012024-12-31" id="Fact002429" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_uPure_maABC_c20240101__20241231_zo82EFPPaf47" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" contextRef="From2024-01-012024-12-31" id="Fact002431" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20240101__20241231_ze35NAHYbBfj" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-012024-12-31" id="Fact002433" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20240101__20241231_zrz97QRAWPJ3" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2435">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_uPure_maABC_c20240101__20241231_z4Th7nho2OHb" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" contextRef="From2024-01-012024-12-31" id="Fact002437" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issuance cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_uPure_maABC_c20240101__20241231_zV3fgVtZr0z" title="US Federal Statutory Tax Rate, percentage" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2439">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    startup costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_uPure_maABC_c20240101__20241231_zRUZsXSHTcE3" title="US Federal Statutory Tax Rate, percentage" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2441">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Pretax loss from operations
    rates total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20240101__20241231_zptrl9LReBn" title="US Federal Statutory Tax Rate, percentage" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2443">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zUTggjNHmEM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002445" name="CLDI:ScheduleOfIncomeTaxPaidTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfIncomeTaxPaidTableTextBlock_zsK4I0lG0F21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon adoption of ASU 2023-09, cash paid for income taxes, net of refunds
received, were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zQCoIBBAqDQ5" style="display: none">Schedule
of Cash Paid for Income Taxes, Net of Refunds Received</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zOyPWllijAh9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNztd0_zu9pWrQTBJn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Federal taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2447">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxPaidStateAfterRefundReceived_maITPNztd0_zjijZGDohw26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State and local taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CLDI:IncomeTaxPaidStateAfterRefundReceived" contextRef="From2025-01-01to2025-12-31" id="Fact002449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNztd0_zEoebRvZdd0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign taxes:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--AU_maITPNztd0_zUyGgN4WEJqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2453">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--DE_maITPNztd0_zlvxgcoZqgNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 80%; padding-bottom: 1pt">Germany</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxPaidForeignAfterRefundReceived" contextRef="From2025-01-012025-12-31_country_DE" id="Fact002455" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_iT_mtITPNztd0_zo5AniFJEie9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total cash paid for income taxes, net of refunds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2025-01-01to2025-12-31" id="Fact002457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zD74HNRTmYHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of cash paid for income taxes during the year ended December&#160;31,
2024 was $<span id="xdx_904_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20240101__20241231_zG3AOyO0UAfl" title="Cash income taxes paid"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-012024-12-31" id="Fact002459" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002461" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQS7jlZ9G3md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary components of the deferred tax assets and liabilities at December 31, 2025 and 2024 were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zxgqp710OTae" style="display: none">Schedule
of Components of Deferred Tax Assets and Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zcGtguKFDa0c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231_zrgbsgdOSbd7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax assets/(liabilities):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzO0o_zYioH31KvUH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-12-31" id="Fact002463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,920</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact002464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,221</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzO0o_zKla1Ij2pK0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development credit carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-12-31" id="Fact002466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">928</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-12-31" id="Fact002467" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">931</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzO0o_ziwHtGMhOVu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    and other compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-12-31" id="Fact002469" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,355</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact002470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_pn3n3_maDTAGzO0o_zuiGZRyvi3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeferredTaxAssetsLeaseLiabilities" contextRef="AsOf2025-12-31" id="Fact002472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">479</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeferredTaxAssetsLeaseLiabilities" contextRef="AsOf2024-12-31" id="Fact002473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">859</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_pn3n3_maDTAGzO0o_zQnEXaYAVlJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
    research and development expenditures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" contextRef="AsOf2025-12-31" id="Fact002475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,520</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" contextRef="AsOf2024-12-31" id="Fact002476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGzO0o_zoJFXsy61izl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeferredTaxAssetsDepreciationAndAmortization" contextRef="AsOf2025-12-31" id="Fact002478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,315</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="CLDI:DeferredTaxAssetsDepreciationAndAmortization" contextRef="AsOf2024-12-31" id="Fact002479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,393</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzO0o_zKs7xlP8fKhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities and other reserves</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2025-12-31" id="Fact002481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="AsOf2024-12-31" id="Fact002482" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">446</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzO0o_maDTANzVsW_zTwaQun8fFn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-12-31" id="Fact002484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,695</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact002485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,232</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_iNI_pn3n3_di_maDITLzwdK_zkSeahFfBNNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    and other assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" contextRef="AsOf2025-12-31" id="Fact002487" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="CLDI:DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" contextRef="AsOf2024-12-31" id="Fact002488" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">830</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzwdK_msDTANzVsW_zMlbqVgsTI8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2025-12-31" id="Fact002490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact002491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">830</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzVsW_zNGTS671QiE1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-12-31" id="Fact002493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact002494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,402</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzVsW_zL10150kJI13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2496">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2497">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zM2uJ66TQeWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2025, the Company had net operating loss carryforwards
of approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOgZIAc6JSd8" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31_us-gaap_DomesticCountryMember" id="Fact002499" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">89.2</ix:nonFraction></span> million for U.S. federal income tax purposes and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkj1HGtiNLS5" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact002501" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">106.2</ix:nonFraction></span> million for state income tax purposes. Federal net operating
losses of $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--TaxPeriodAxis__custom--PriorDecemberTwentySeventeenthMember_zDSgOvW7VeK3" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31_custom_PriorDecemberTwentySeventeenthMember" id="Fact002503" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span> million generated on or prior to December 31, 2017, expire in varying amounts between 2034 and 2037, while federal net
operating losses of $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--TaxPeriodAxis__custom--AfterDecemberTwentySeventeenthMember_zKRERLRCduHg" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-12-31_custom_AfterDecemberTwentySeventeenthMember" id="Fact002505" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">81.2</ix:nonFraction></span> million generated after December 31, 2017 carryforward indefinitely. The state net operating losses expire in
varying amounts between 2034 and 2044.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2025, the Company has research and development credit
carryforwards for federal purposes of $<span id="xdx_908_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMfHFTCzX1uf" title="Research and development credits carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-12-31_us-gaap_DomesticCountryMember" id="Fact002507" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million and for state purposes of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z7ppTV09XF6f" title="Research and development credits carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact002509" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million. The federal credits will expire between 2040
and 2045, while the state credits have no expiration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization
of the net operating loss carryforwards and credits may be subject to substantial annual limitation due to the ownership change limitations
provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration
of net operating losses before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31,
2021. There was an ownership change identified on March 26, 2018 after the Company&#8217;s Series A-2 preferred stock issuance. The Company
has not undertaken a Section 382 study through December 31, 2025. Our ability to utilize our net operating loss carryforwards and other
tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The Company established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits
from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20250101__20251231_zC9sAWgi96Cj" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2025-01-01to2025-12-31" id="Fact002511" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million and $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zdHZENlEVbre" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-012024-12-31" id="Fact002513" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.5</ix:nonFraction></span>
million for the year ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has uncertain tax benefits (&#8220;UTBs&#8221;) totaling approximately $<span id="xdx_907_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20251231_zAtjKiUsot7f"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2025-12-31" id="Fact002514" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> million and $<span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20241231_z4IoYphUDlyh"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact002515" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
as of December 31, 2025 and 2024, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs
had no effect on the effective tax rate and there would be no cash tax impact for any period presented. The Company does not expect its
UTBs to change significantly over the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002517" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zy6NAeHPiGFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zgihqkianum3" style="display: none">Schedule
of Unrecognized Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_zcFoJl7Bw0Hg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_z0TYewQukNRi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_zrCnkqJg47k4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at the beginning of the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact002519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,799</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact002520" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,517</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_pn3n3_zSm0LSQLFUhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions
    based on tax positions related to current year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2025-01-01to2025-12-31" id="Fact002522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2024-01-012024-12-31" id="Fact002523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_zlmPVM42Odcg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    based on tax positions related to prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="From2025-01-01to2025-12-31" id="Fact002525" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">283</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2526">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_zd71cGelRVnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2025-12-31" id="Fact002528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,364</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact002529" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,799</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zGtiHAveAKi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files tax returns in the U.S. for federal purposes and California for state purposes, and in Germany and Australia for its foreign subsidiaries. For jurisdictions in which tax filings
have been filed, all tax years remain open for examination by the federal and California state authorities for three and four years,
respectively, from the date of utilization of any net operating losses or credits. The Company is not currently under audit by any taxing
jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in
assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes
the Company has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments,
if any, could be significantly different than the amounts recorded in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002531" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPOK3y5GljO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_829_zn3eriuoQBCj">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
and Financing Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2022, the Company entered into an Office Lease Agreement (the &#8220;San Diego Lease&#8221;) of a building containing <span id="xdx_90D_eus-gaap--AreaOfLand_iI_usqft_c20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_ziLzBvAbzwbj" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-10-10_custom_SanDiegoLeaseAgreementMember" id="Fact002533" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">15,197</ix:nonFraction></span>
square feet of rentable space located in San Diego, California (the &#8220;Premises&#8221;), which serves as the Company&#8217;s principal
executive and administrative offices and laboratory facility. The Company completed constructing tenant improvements at the Premises
on February 27, 2023, and moved into the Premises by the end of March 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
secure and execute the San Diego Lease, Mr. Allan J. Camaisa (or &#8220;Mr. Camaisa&#8221;) provided a personal Guaranty of Lease of
up to $<span id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z8hJaebAkvAi" title="Guaranty of lease, value"><ix:nonFraction name="CLDI:GuarantyOfLeaseAmount" contextRef="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember_srt_MaximumMember" id="Fact002535" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span>
million (the &#8220;Guaranty&#8221;) to the lessor for the Company&#8217;s future performance under the San Diego Lease agreement. <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20221010__20221010_zpGz8husti7a" title="Lease agreement description"><ix:nonNumeric contextRef="From2022-10-102022-10-10" id="Fact002537" name="us-gaap:LesseeOperatingLeaseDescription">As
consideration for the Guaranty, the Company agreed to pay Mr. Camaisa 10% of the Guaranty amount for the first year of the San Diego
Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease</ix:nonNumeric></span>, with all amounts accrued and payable
at the termination of the San Diego Lease or release of Mr. Camaisa from the Guaranty by the lessor, whichever occurs
first. Mr. Camaisa received $<span id="xdx_906_ecustom--GuarantyOfLeaseAmount_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MrCamaisaMember_z5NWwFd03aH9" title="Guaranty of lease, value"><ix:nonFraction name="CLDI:GuarantyOfLeaseAmount" contextRef="From2025-01-012025-12-31_custom_MrCamaisaMember" id="Fact002539" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million during the fiscal year ended 2025 in connection with the lease guarantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
San Diego Lease has an initial term of <span id="xdx_90A_ecustom--OperatingLeaseTermOfContractLeaseInitialTerm_dtM_c20230301__20230301_zDGppQxXD3l3" title="Operating lease, term of contract, lease initial term"><ix:nonNumeric contextRef="From2023-03-012023-03-01" format="ixt-sec:durmonth" id="Fact002541" name="CLDI:OperatingLeaseTermOfContractLeaseInitialTerm">48</ix:nonNumeric></span> calendar months, from the first day of the first full month following which the &#8220;Commencement
Date&#8221; occurs (the &#8220;Term&#8221;), which was March 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
on the Commencement Date, the Company pays base monthly rent in the amount of $<span id="xdx_902_eus-gaap--PaymentsForRent_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zsejvp3Zi0r6" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember" id="Fact002543" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million during the first 12 months of the Term, plus
a management fee equal to <span id="xdx_904_ecustom--LeaseTermsOperatingLeasesAnnualIncreaseInRent_pid_dp_uPure_c20221010__20221010_zAeCqlq9r4R1" title="Lease terms, operating leases annual increase in rent"><ix:nonFraction name="CLDI:LeaseTermsOperatingLeasesAnnualIncreaseInRent" contextRef="From2022-10-102022-10-10" id="Fact002545" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% of base rent. Base monthly rent will increase annually, over the base monthly rent then in effect, by <span id="xdx_90A_ecustom--LeaseTermsOperatingLeasesAnnualIncreaseInRent_pid_dp_uPure_c20221010__20221010_zyLsYlU4yYA4" title="Lease terms, operating leases annual increase in rent"><ix:nonFraction name="CLDI:LeaseTermsOperatingLeasesAnnualIncreaseInRent" contextRef="From2022-10-102022-10-10" id="Fact002547" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to base monthly rent and management fees, the Company pays in monthly installments its share of (a) all costs and expenses,
other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing
(including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the
Premises are located (&#8220;Expenses&#8221;), and (b) all real estate taxes and assessments on the Premises and the building in which
the Premises are located, all personal property taxes for property that is owned by Landlord and used in connection with the operation,
maintenance and repair of the Premises (&#8220;Taxes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
execution of the San Diego Lease, the Company provided the lessor a payment of $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zE0y0yEwxzN" title="Lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember" id="Fact002549" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million as first month base rent and prepaid operating
expenses, and a letter of credit in the amount of $<span id="xdx_909_eus-gaap--LettersOfCreditOutstandingAmount_iI_pn5n6_c20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zRzXSPkGVVTi" title="Letter of credit amount"><ix:nonFraction name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="AsOf2022-10-10_custom_SanDiegoLeaseAgreementMember" id="Fact002551" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million issued by a bank in the name of the lessor. To obtain the letter of credit,
the Company has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws
on the letter of credit by the lessor. The restricted cash may not be used for any other purpose (see Note 2). The prepaid rent was included
in the initial accounting of the San Diego Lease, as presented in the tables below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2022, StemVac entered into an office lease which includes laboratory space which expires on March 31, 2027, with monthly payments
of &#8364;<span id="xdx_90B_eus-gaap--PaymentsForRent_uEUR_c20220401__20220401__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_z3shSbxrFqQ2" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-04-012022-04-01_custom_StemVacOfficeLeaseAgreementMember" id="Fact002553" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">4,047</ix:nonFraction></span> Euros per month. On July 1, 2025, StemVac entered into a finance lease agreement for laboratory equipment with an initial
term that expires on May 31, 2029, with monthly payments of approximately &#8364;<span id="xdx_906_eus-gaap--PaymentsForRent_uEUR_c20250701__20250701__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_zVndkENgfev" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2025-07-012025-07-01_custom_StemVacOfficeLeaseAgreementMember" id="Fact002555" format="ixt:numdotdecimal" decimals="0" unitRef="EUR">2,976</ix:nonFraction></span> Euros per month. The lease commencement date was
June 1, 2025. The lease agreement includes an option to renew the lease for an additional twelve months, which must be exercised by providing
six months&#8217; prior notice before the end of the initial lease term; however, the Company is not reasonably certain to extend the
initial lease term and therefore additional lease payments associated with the automatic renewal are excluded from the lease term. The
lease also contains a purchase option that the Company is not reasonably certain to exercise at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease expense recognized during each of the years ended December 31, 2025 and 2024 was approximately $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_zdtbhpHcMHW" title="Operating lease expense"><span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_z9eQRvEs82f3" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-01-012025-12-31_custom_StemVacOfficeLeaseAgreementMember" id="Fact002557" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-01-012024-12-31_custom_StemVacOfficeLeaseAgreementMember" id="Fact002559" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></ix:nonFraction></span></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also party to certain financing leases for machinery and equipment (see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002561" name="CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_zjJcUdsV82A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents supplemental cash flow information related to operating and financing leases for the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zIEWyOnuK0Hh" style="display: none">Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250101__20251231_zVgR4TMa6cWi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20240101__20241231_z2O3hxNxW3p5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for amounts included in the measurement of lease liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zE9lHKMwv1dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2025-01-01to2025-12-31" id="Fact002563" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,467</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-12-31" id="Fact002564" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,424</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zwgbEPczKbpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    cash flows from financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2025-01-01to2025-12-31" id="Fact002566" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2024-01-012024-12-31" id="Fact002567" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zMCqdQoMchmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    cash flows from financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2025-01-01to2025-12-31" id="Fact002569" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-01-012024-12-31" id="Fact002570" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zfZL4LbEGWXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002572" name="CLDI:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_z7POe9VVVW36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents supplemental balance sheet information related to operating and financing leases for the periods presented (in
thousands, except weighted averages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zzivUjMbH66g" style="display: none">Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20251231_zeUZUbKLDkCl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zg5QPJAo5gIk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zjptdiItgEMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-12-31" id="Fact002574" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,682</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact002575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,934</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzLs4_zhvI1rU3CG7d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease liabilities, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact002577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,405</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact002578" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,204</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzLs4_zErKs72ddsR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease liabilities, noncurrent</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact002580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">277</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact002581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,845</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzLs4_zmbAHBUGsGbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,682</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact002584" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_iI_pn3n3_maPPAENzCH7_zXL1SWMuK1Kf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" contextRef="AsOf2025-12-31" id="Fact002586" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">779</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" contextRef="AsOf2024-12-31" id="Fact002587" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">588</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iNI_pn3n3_di_msPPAENzCH7_zp0geCKJ9JDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" contextRef="AsOf2025-12-31" id="Fact002589" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">463</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" contextRef="AsOf2024-12-31" id="Fact002590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">333</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_iTI_pn3n3_mtPPAENzCH7_zfNhCxxzcpSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" contextRef="AsOf2025-12-31" id="Fact002592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">316</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" contextRef="AsOf2024-12-31" id="Fact002593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">255</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_maFLLzNvC_zGD0wv9kWj3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-12-31" id="Fact002595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">111</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact002596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_maFLLzNvC_zQP67sLDO6P7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncurrent
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2025-12-31" id="Fact002598" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact002599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_mtFLLzNvC_zoLsaW172gHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    financing lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-12-31" id="Fact002602" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average remaining lease term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zXh8NPFoUwj2" title="Weighted average remaining lease term, Operating leases (in years)"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:duryear" id="Fact002604" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.2</ix:nonNumeric></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zWdlNhVMVNL8" title="Weighted average remaining lease term, Operating leases (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact002606" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.2</ix:nonNumeric></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zeWhdokfJzNj" title="Weighted average remaining lease term, Financing leases (in years)"><ix:nonNumeric contextRef="AsOf2025-12-31" format="ixt-sec:duryear" id="Fact002608" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">2.7</ix:nonNumeric></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3QXnlbPtHuf" title="Weighted average remaining lease term, Financing leases (in years)"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact002610" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">3.2</ix:nonNumeric></span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr8xPw3WQtL1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-12-31" id="Fact002612" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.70</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact002613" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.75</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zZdFtnio05D7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-12-31" id="Fact002615" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.05</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact002616" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.13</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zzHqzMuAkbk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002618" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock"><p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zOihmUTUOme4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents future minimum lease commitments as of December 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zrbvmxSlKA3h" style="display: none">Schedule
of Future Minimum Lease Commitments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zrCrNBg9wKvk" title="Operating Leases, 2026" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact002620" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zcoYAGtcgefj" title="Financing Leases, 2026" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-12-31" id="Fact002622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zECw0oPKmbX6" title="Operating Leases, 2027" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact002624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zFAwlGX09Rjl" title="Financing Leases, 2027" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-12-31" id="Fact002626" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zexL69dvRUje" title="Operating Leases, 2028" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-12-31" id="Fact002628" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmReNXTKils8" title="Financing Leases, 2028" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-12-31" id="Fact002630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z5cozyuTQpJc" title="Operating Leases, 2029" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2632">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zlZ2svW4Kw3k" title="Financing Leases, 2029" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2025-12-31" id="Fact002634" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030
    and thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zM7iUfRRvjF8" title="Operating Leases, 2030 and thereafter" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2636">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zruLPX0rgbri" title="Financing Leases, 2030 and thereafter" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2638">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmtaJlAhhCB1" title="Operating Leases, Total minimum lease payments" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact002640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,809</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z8cP0VsZT5x5" title="Financing Leases, Total minimum lease payments" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2025-12-31" id="Fact002642" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">319</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    amounts representing interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_ztrK0QO5otPe" title="Operating Leases, Less: amounts representing interest" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact002644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_zOMifW6juZWl" title="Financing Leases, Less: amounts representing interest" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-12-31" id="Fact002646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present
    value of net minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z3YOipHV72nb" title="Operating Leases, Present value of net minimum lease payments" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,682</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zHO9irHCvb7i" title="Financing Leases, Present value of net minimum lease payments" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2025-12-31" id="Fact002650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z2YRPJqUptc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation
&#8212; General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation,
business transactions, employee-related matters, and other matters. At each reporting date, the Company evaluates whether a potential
loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that
addresses accounting for contingencies. If it is probable that a loss will result and the amount of the loss can be reasonably estimated,
the Company will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated,
the Company discloses the claim if the likelihood of a potential loss is reasonably possible, and the amount involved could be material.
The Company expenses the costs related to legal proceedings as incurred. See other legal matters discussed below. Other than the matters
discussed below, the Company is not currently party to any material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
Proceedings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former
Chief Accounting Officer and Interim Chief Financial Officer, and Controller</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 15, 2023, Tony Kalajian, the Company&#8217;s prior Chief Accounting Officer and interim Chief Financial Officer, filed a complaint
in the Superior Court of the State of California County of San Diego against the Company, Mr. Camaisa, the Company&#8217;s director and
former Chief Executive Officer, and Ms. Pizarro, the Company&#8217;s former Chief Corporate Development Officer and Chief Legal Officer,
alleging defamation and constructive discharge of Mr. Kalajian&#8217;s position of Chief Accounting Officer and interim Chief Financial
Officer (Case No. 37-2023-00049813-CU-DF-CTL) (the &#8220;Primary Case&#8221;). Mr. Kalajian is seeking an unspecified amount in damages
under his employment contract, damages to be proven at trial, punitive damages, and attorney&#8217;s fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company initiated arbitration proceedings against Mr. Kalajian for breach of fiduciary duty, constructive fraud,
conversation, and declaratory relief, seeking to recover from Mr. Kalajian bonuses Mr. Kalajian caused to be paid to himself, Hazel Sanchez,
the former Controller, and his accounting team. The bonuses (the &#8220;Accounting Bonuses&#8221;) were not authorized by the Company&#8217;s
Board of Directors or Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2023, Hazel Sanchez, the Company&#8217;s prior Controller, filed a complaint in the Superior Court of the State of California
County of San Diego against the Company, Mr. Camaisa, and Ms. Pizarro, alleging defamation, constructive discharge, violation of California
Family Rights Act, and wrongful discharge. Ms. Sanchez is seeking an unspecified amount in damages under her employment contract, damages
to be proven at trial, punitive damages, and attorney&#8217;s fees. In February 2024, the Company filed a Cross-Complaint against Ms.
Sanchez for breach of fiduciary duty, constructive fraud, conversation, and declaratory relief seeking to recover the Accounting Bonuses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, Mr. Kalajian also filed a Petition for Writ of Mandate in the Superior Court of California, County of San Diego, seeking
to compel the production of certain corporate records from the Company. This case is deemed related to the Primary Case above and was
dismissed by stipulation in March 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2024, Mr. Kalajian filed a complaint in the Superior Court of the State of California, County of San Diego against the Company
alleging intentional conversion and violation of Section 158 of the Delaware General Corporations Code due to the Company&#8217;s failure
to remove a restrictive legend from <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240501__20240501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTyT8tLsHB79" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-05-012024-05-01_us-gaap_CommonStockMember" id="Fact002652" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,162</ix:nonFraction></span> shares of the Company&#8217;s Common Stock. Mr. Kalajian is seeking compensatory damages to
be proven at trial, punitive damages and attorney&#8217;s fees, and an order requiring removal of the restrictive legend from his share
certificates. The Company intends to vigorously defend itself. This case is deemed related to and consolidated with the Primary Case
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Primary Case,
Kalajian Arbitration, Sanchez Case, and Conversion Case were deemed related and ultimately consolidated. A trial date has been set for
November 6, 2026.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former
Executive Assistant</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, the Company filed a lawsuit in San Diego Superior Court against a former executive assistant alleging breach of fiduciary
duty to the Company, constructive fraud, conversion, and misappropriation and improper disclosure of confidential and proprietary information
in violation of her proprietary information and inventions agreement, non-disclosure agreement, and severance agreement with the Company
(Case No. 25CU034887C). The Company is seeking injunctive relief and damages. The case is in its early stages, and the outcome is uncertain.
Management does not currently expect this matter to have a material adverse effect on the Company&#8217;s financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Securities
Matter</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 29, 2024, Mr. Yian Zeng filed a complaint against the Company related to securities fraud under California Corporations Code
&#167;25401, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive
fraud in the U.S. District Court, Southern District of California (Case Number 3:24-cv-02026-H-KSC). The Company vigorously opposes this
case and categorically denies all claims. On April 9, 2025, the parties engaged in a mandatory settlement conference which resulted in
no resolution of the case. Discovery has been completed. A pre-trial conference has been set for
October 19, 2026, but no trial date has been set. At this time, the Company is unable to evaluate the outcome of this case or estimate the amount or range of potential
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Contracts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment and severance benefit contracts with certain executive officers and other employees. Under the provisions
of the contracts, the Company may be required to incur severance obligations for matters relating to changes in control, as defined,
and certain terminations of those executives and employees. As of December 31, 2025, the Company incurred severance obligations for certain
executive officers and other employees, as discussed below. See Note 6 for further information on the accruals for such severance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Manufacturing
and Other Supplier Contracts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into certain manufacturing and other supplier agreements with vendors principally for manufacturing drug products
for clinical trials and continued development of the CLD-101, CLD-201, and CLD-401 programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the remaining expected commitments were approximately $<span id="xdx_90B_ecustom--RemainingExpectedCommitments_iI_pn5n6_c20251231_zJLI1WUoJ1je" title="Remaining expected commitments"><ix:nonFraction name="CLDI:RemainingExpectedCommitments" contextRef="AsOf2025-12-31" id="Fact002654" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million and $<span id="xdx_908_ecustom--RemainingExpectedCommitments_iI_pn5n6_c20241231_ztENlLBFixs3" title="Remaining expected commitments"><ix:nonFraction name="CLDI:RemainingExpectedCommitments" contextRef="AsOf2024-12-31" id="Fact002656" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreements with Northwestern University</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2021, the Company entered into a License Agreement with Northwestern University (&#8220;Northwestern&#8221;) (the &#8220;Northwestern
Agreement&#8221;) for the exclusive commercialization rights to the investigational new drug (&#8220;IND&#8221;) and with a non-exclusive
license to data generated from Northwestern&#8217;s phase 1 clinical trial treating malignant glioma patients with an engineered oncolytic
adenovirus delivered by neural stem cells (&#8220;<i>NSC-CRAd-S-pk7</i>&#8221;). Under the Northwestern Agreement, among other rights,
Northwestern granted to the Company a worldwide, twelve-year exclusive license for the commercial development of <i>NSC-CRAd-S-pk7</i>
or other oncolytic viruses for therapeutic and preventive uses in oncology, a right of reference to Northwestern&#8217;s IND application
which relates to the treatment of newly diagnosed High Grade Glioma (&#8220;HGG&#8221;), and right of reference to Northwestern&#8217;s
IND 17365.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Northwestern Agreement, the Company agreed to a best-efforts commitment to fund up to $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_pn6n6_c20210607__us-gaap--TypeOfArrangementAxis__custom--NorthwesternAgreementMember_zXYEzR4wNTBc"><ix:nonFraction name="us-gaap:OtherCommitment" contextRef="AsOf2021-06-07_custom_NorthwesternAgreementMember" id="Fact002657" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million towards a phase 2 clinical trial of <i>NSC-CRAd-S-pk7</i>
or other oncolytic viruses. Subject to the terms and conditions of the Northwestern Agreement, Northwestern may become entitled to receive
contingent payments from the Company based on (i) sublicense royalty payments of double-digit percentage for any sublicensing revenue
that the Company earns, if any, and, (ii) in the event of an assignment or transfer of licensed data, with the consent of Northwestern,
a low single digit percentage of the fair market value of any consideration received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Company entered into a Material License Agreement with Northwestern to license the <i>NSC-CRAd-S-pk7</i> oncolytic
virus materials which the Company intends to use to continue advancing its research, development and commercialization efforts of the
NNV1 and NNV2 programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2024, the Company entered into an Investigator-Initiated Clinical Trial Agreement for Northwestern to conduct a clinical
trial (the &#8220;CTA&#8221;) under the protocol referenced &#8220;A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in
Combination with N-Acetylcysteine amid and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma&#8221; (the &#8220;Study&#8221;).
In connection with the Study, Northwestern granted the Company a non-exclusive, transferable and sublicensable license to use all available
de-identified data collected from the Study, including, but not limited to, survival data, patient pathology, and immune studies data.
Under the CTA, among other rights, Northwestern also granted to the Company a worldwide, twelve-year exclusive license to the data, a
right of reference to Northwestern&#8217;s IND application which relates to the treatment of newly diagnosed HGG, and right of reference
to Northwestern&#8217;s IND 17365.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the data use license granted by Northwestern to the Company under the CTA, the Company shall pay Northwestern the following:
<span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--NorthwesternAgreementMember_zYfuOv26S2Gg"><ix:nonNumeric contextRef="From2024-12-152024-12-15_custom_NorthwesternAgreementMember" id="Fact002658" name="us-gaap:OtherCommitmentsDescription">a non-creditable and non-refundable one-time milestone payment of $0.3 million upon reaching an aggregate of $2.0 million of net sales
of a licensed product; (b) a non-creditable and nonrefundable one-time milestone payment of $0.5 million upon reaching an aggregate of
$10.0 million of net sales of a licensed product; (c) sublicensing royalty of 20% of any sublicensing revenue resulting from the grant
of rights hereunder; and (d) in the event of an assignment or transfer of licensed data, with the consent of Northwestern, a low single
digit percentage of the fair market value of any consideration received. This sublicensing royalty shall be cumulative, meaning it shall
be imposed only once with respect to a single unit of sublicensing revenue, regardless of whether the sublicensing revenue derives from
the CTA, or the June 7, 2021 Northwestern Agreement described above, or both.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to terminate the CTA upon 30 days&#8217; notice, and the right to terminate the License and Material Transfer Agreements
upon 90 days&#8217; notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of issuance of these consolidated financial statements, it is not probable that the Company will incur these payments, if
any at all. The Company will record the contingent payments if and when they become payable, in accordance with the applicable guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreement with City of Hope and the University of Chicago</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company entered into an Exclusive License Agreement with the University of Chicago (the &#8220;University of Chicago
Agreement&#8221;) for patents jointly owned by the University of Chicago, City of Hope, and the University of Alabama at Birmingham covering
cancer therapies using an oncolytic adenovirus loaded into allogeneic neural stem cells for treatment of HGG. Pursuant to the University
of Chicago Agreement, University of Chicago transferred its IND to the Company for the commercial development of a licensed product,
as defined in the University of Chicago Agreement. This agreement grants to the Company commercial sublicensable exclusive license to
neural stem cells with the adenovirus known as CRAd-S-pk7 for oncolytic virotherapy, as well as a non-exclusive license to associated
know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
University of Chicago Agreement provides for the Company to pay royalties in low single digit percentage of net sales generated for any
product of the licensed patents for specific periods, and to pay up to $<span id="xdx_909_eus-gaap--PaymentsForRoyalties_pn5n6_c20210722__20210722__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z2ssViZg1wzf" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2021-07-222021-07-22_custom_LicenseAgreementMember" id="Fact002660" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">18.7</ix:nonFraction> </span>million if certain milestones are achieved during the clinical
trials and post commercialization of the licensed product. The Company is further obligated to pay a sublicensing royalty of 20% of any
sublicensing revenue resulting from the grant of rights, and in the event of an assignment or transfer of licensed data, with the consent
of Northwestern, a low single digit percentage of the fair market value of any consideration received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of the issuance of these consolidated financial statements, it is not probable that the Company will incur these payments.
The Company will record the contingent payments if and when they become payable, in accordance with the applicable guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Company may provide indemnification of varying scope under the Company&#8217;s agreements with other
companies or consultants, typically the Company&#8217;s clinical research organizations, investigators, clinical sites, suppliers and
others. Pursuant to these agreements, the Company will generally agree to indemnify, hold harmless, and reimburse the indemnified parties
for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties that relate to certain situations
such as Company&#8217;s negligent actions, breaching agreements, failure to comply with laws and regulations, and third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to the Company. The Company&#8217;s office
and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of
the lessor for environmental law matters and injuries to persons or property of others, arising from the Company&#8217;s use or occupancy
of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration
of the particular research, development, services, lease, or other agreement to which they relate. The potential future payments the
Company could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts.
Historically, the Company has not been subject to any claims or demands for indemnification. The Company also maintains various liability
insurance policies that limit the Company&#8217;s financial exposure. As a result, the Company&#8217;s management believes that the fair
value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements
as of December 31, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Separation
Agreement with Former Chief Operating Officer and President</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2023, the Company entered into a Separation and Release Agreement (&#8220;Separation Agreement&#8221;) with George K. Ng,
former Chief Operating Officer and President, effective on that date. In accordance with the provisions of the Separation Agreement,
the Company will pay Mr. Ng in the amount of $<span id="xdx_903_eus-gaap--OtherLiabilities_iI_pn5n6_c20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zYRWYMTHa72c" title="Payment to related party"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember" id="Fact002662" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million payable in a lump sum due one year after the effective date, and in the event that this amount is not paid when due, the
unpaid amount will accrue interest at the rate of <span id="xdx_906_ecustom--CommitmentFeePercentage_iI_pid_dp_uPure_c20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zjFo9rmvfVaf" title="Commitment fee percentage"><ix:nonFraction name="CLDI:CommitmentFeePercentage" contextRef="AsOf2023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember" id="Fact002664" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
per annum to be paid no later than the <span id="xdx_90C_eus-gaap--LongtermPurchaseCommitmentPeriod_dc_c20230622__20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zn6xquaSUapf" title="Payment period"><ix:nonNumeric contextRef="From2023-06-222023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember" format="ixt-sec:durwordsen" id="Fact002666" name="us-gaap:LongtermPurchaseCommitmentPeriod">two
year</ix:nonNumeric></span> anniversary of the effective date. The Company also paid for certain benefits, including healthcare for six months
following the effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company made a payment of $<span id="xdx_904_eus-gaap--OtherLiabilities_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_z5gpwYQb0Dca" title="Payment to related party"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2024-06-30_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember" id="Fact002668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> and executed an Amendment to extend the due date to January 2025. The liability was
settled in full in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Settlement,
Deferral or Payment of Deferred Compensation of Certain Executives and a Director</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023, Mr. Camaisa, a director and former Chief Executive Officer of the Company, and Mr. Leftwich, a director of the Company,
entered into certain amendments with respect to their deferred compensation arrangements in connection with the FLAG Merger. Mr. Camaisa
agreed to settle approximately $<span id="xdx_909_eus-gaap--DeferredCompensationEquity_iI_pn5n6_c20230831__srt--TitleOfIndividualAxis__custom--MrCamaisaMember_zw53qiiC6G9e" title="Deferred compensation"><ix:nonFraction name="us-gaap:DeferredCompensationEquity" contextRef="AsOf2023-08-31_custom_MrCamaisaMember" id="Fact002670" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million of deferred compensation with <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230831__srt--TitleOfIndividualAxis__custom--MrCamaisaMember_zrSDfcHAQuJk" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-08-31_custom_MrCamaisaMember" id="Fact002672" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,972</ix:nonFraction></span> FLAG warrants which were issued at the closing of the
FLAG Merger in September 2023, and Mr. Leftwich agreed to defer approximately $<span id="xdx_905_eus-gaap--DeferredCompensationEquity_iI_pn5n6_c20230831__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zG2D0PKtAXhd" title="Deferred compensation equity"><ix:nonFraction name="us-gaap:DeferredCompensationEquity" contextRef="AsOf2023-08-31_custom_MrLeftwichMember" id="Fact002674" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million of deferred compensation, combined with the
deferral of certain term notes discussed above, to January 1, 2025, which include accrued interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zqkWKCh2JDS7" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-08-31_custom_MrLeftwichMember" id="Fact002676" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% per annum payable at maturity.
All notes and deferred compensation of Mr. Leftwich were amended on August 12, 2024, to reduce the interest rate to <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zVn6dHO4gx6" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-08-12_custom_MrLeftwichMember" id="Fact002678" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% per annum. This
deferred compensation was included in accrued expenses and other current liabilities in the consolidated balance sheet at December 31,
2024. On January 3, 2025, the $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_iI_pn5n6_c20250103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrLeftwichMember__us-gaap--AwardTypeAxis__custom--SettlementOfDeferredCompensationMember_zgRqf47Anmi5" title="Deferred compensation and accrued interest amount in cash"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" contextRef="AsOf2025-01-03_custom_MrLeftwichMember_custom_SettlementOfDeferredCompensationMember" id="Fact002680" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million of deferred compensation and accrued interest due to Mr. Leftwich was settled in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Standby
Equity Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd., a Cayman
Island exempt limited partnership (&#8220;Yorkville&#8221;). Pursuant to the SEPA, the Company will have the right, but not the obligation,
to sell to Yorkville up to $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20231210__20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z1ZeRpcOkqpj" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-12-102023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002682" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">25.0</ix:nonFraction></span> million of its shares of common stock, par value $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zTkBrySF5WZ6" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002684" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, at the Company&#8217;s request any
time during the 36 months following the execution of the SEPA. The maximum advance under the SEPA is the lower of <span id="xdx_901_ecustom--EquityPurchaseDescription_c20231210__20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zUqg26h3468c" title="Equity purchase description"><ix:nonNumeric contextRef="From2023-12-102023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002686" name="CLDI:EquityPurchaseDescription">(i) an amount equal
to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an advance notice, or
(ii) 41,667 shares. For the SEPA to be utilized, the shares underlying the agreement need to be registered on a Form S-1 filed with the
SEC.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for Yorkville&#8217;s commitment to purchase the common stock at the Company&#8217;s direction upon the terms and subject
to the conditions set forth in the SEPA, upon execution of the SEPA, the Company paid a structuring fee of $<span id="xdx_906_eus-gaap--PaymentsForFees_c20231210__20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleMember_zRpSevxekAj5" title="Payments  for fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember" id="Fact002688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> to an affiliate of
Yorkville and issued <span id="xdx_905_eus-gaap--SharesIssued_iI_pid_c20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleMember_zxOtkyDESjcc" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember" id="Fact002690" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,157</ix:nonFraction></span> shares of common stock to Yorkville (the &#8220;Commitment Fee Shares&#8221;). The Commitment Fee Shares were
determined by dividing $<span id="xdx_902_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn5n6_c20231210__20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zsx1s96g7en1" title="Commitment Fee"><ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" contextRef="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember" id="Fact002692" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million by the lowest daily VWAP of the common stock during the 10 trading days immediately prior to December
10, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2025, the Company delivered a Notice of Termination of the SEPA, dated as of December 10, 2023, by and between the Company
and Yorkville. Termination of the SEPA was mutually agreed upon and became effective as of January 23, 2025. At the time of the termination,
there were no outstanding borrowings, advance notices or shares of common stock to be issued under the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Release of Claims and Transition Agreement with Former Chief Executive Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr.
Camaisa, a director and former Chief Executive Officer of the Company. Mr. Camaisa will continue to serve as a Class III director of
the Company, and will assume the title of &#8220;CEO Emeritus&#8221;. Pursuant to the Release Agreement, the Company is obligated to
pay Mr. Camisa $<span id="xdx_902_ecustom--SeparationPay_pn5n6_c20250822__20250822__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_zJpunbg4kFwd" title="Separation pay"><ix:nonFraction name="CLDI:SeparationPay" contextRef="From2025-08-222025-08-22_custom_Dr.CamisaMember" id="Fact002694" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million separation pay in the form of compensation continuation over 12 months pursuant to the Company&#8217;s regular
and customary payroll schedule, less all regular and customary payroll withholdings and shall also be liable to pay Mr. Camisa COBRA
premiums for 12 months, commencing May 2025. Mr. Camaisa shall also be entitled to receive a transition/consulting pay of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20250822__20250822__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_z7ecSrhVJx0j" title="Consulting pay"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2025-08-222025-08-22_custom_Dr.CamisaMember" id="Fact002696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> per
month during the transition period and incurred costs of $<span id="xdx_90C_ecustom--IncurredCosts_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_zRznM8jUs8wh" title="Incurred costs"><ix:nonFraction name="CLDI:IncurredCosts" contextRef="From2025-01-012025-12-31_custom_Dr.CamisaMember" id="Fact002698" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Release of Claims and Separation Agreement with Former Executive Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Dr. Minev (the &#8220;Agreement&#8221;),
Executive Officer, effective August 15, 2025. Pursuant to the terms of the Agreement, the Company is obligated to pay Dr. Minev, (i)
$<span id="xdx_905_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.MinevMember_z5DGSNbN1uac" title="Bonus payable"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-08-08_custom_Dr.MinevMember" id="Fact002700" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals within 10 days following the Revocation Period (which
is seven business days from August 8, 2025, and excluding such date), and (ii) $<span id="xdx_90F_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.MinevMember_zOuolHyyAw87" title="Separation pay"><ix:nonFraction name="CLDI:SeparationPay" contextRef="From2025-08-082025-08-08_custom_Dr.MinevMember" id="Fact002702" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million severance pay in the form of compensation
continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary payroll
withholdings and shall pay Dr. Minev&#8217;s COBRA premiums for six months, commencing August 2025, upon timely election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Release of Claims and Separation Agreement with Former Chief Legal Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2025, the Company executed a General Release of Claims and Separation Agreement (the &#8220;Agreement&#8221;) with Ms.
Campbell, former Chief Legal Officer, effective September 24, 2025 (the &#8220;Effective Date&#8221;). Pursuant to the terms of the Agreement,
on the Effective Date, the Company is obligated to pay $<span id="xdx_900_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Ms.CampbellMember_zl0Z6qodxaF7" title="Bonus payable"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="AsOf2025-09-17_custom_Ms.CampbellMember" id="Fact002704" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million severance pay in the form of compensation continuation over six months
pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary payroll withholdings, and shall
pay Ms. Campbell&#8217;s COBRA premiums for six months, commencing October 2025, upon timely election. Note that pursuant to the terms
of the Agreement, as of December 31, 2025, the Company also paid Ms. Campbell a bonus in the amount of approximately $<span id="xdx_90C_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Ms.CampbellMember_zd9kploJxh6h" title="Severance pay"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2025-09-172025-09-17_custom_Ms.CampbellMember" id="Fact002706" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million, upon
the successful and effective sale of the investment in Nova Cell (see Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 187; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-01-01to2025-12-31" escape="true" id="Fact002708" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zg8RNugb7Sfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_825_zTzMiazaCqE7">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>March
2026 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann
&amp; Co. Inc., as sole underwriter (&#8220;Underwriter&#8221;), in connection with the issuance and sale (the &#8220;Offering&#8221;)
of: (i) <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zF5TOIoGeTea" title="Issuance and sale of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_CommonStockUnitsMember_custom_UnderwritingAgreementMember" id="Fact002710" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,278,731</ix:nonFraction></span> common stock units (&#8220;Common Stock Units&#8221;), which includes <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zOLZwurE570g" title="Shares purchased"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_CommonStockUnitsMember_custom_UnderwritingAgreementMember" id="Fact002712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,575,000</ix:nonFraction></span> Common Stock Units purchased pursuant
to the exercise, in full, of the Over-Allotment Option, sold to the public at a price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zx2s4GJSj2Hb" title="Shares price sold"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember" id="Fact002714" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per Common Stock Unit, and (ii) <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zzhESGsqTUig" title="Issuance and sale of shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember" id="Fact002716" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,815,900</ix:nonFraction></span>
pre-funded warrant units (&#8220;Pre-Funded Units&#8221;), sold to the public at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_ztVRmFdp3PAi" title="Shares price sold"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember" id="Fact002718" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.499</ix:nonFraction></span> per Pre-Funded Unit, resulting in
gross proceeds of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zGt837EmyFEd" title="Gross proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember" id="Fact002720" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million, before deducting underwriting discounts and commissions and other estimated offering expenses.
In connection with the Offering, the Company also issued to the Underwriter (or its designees) a warrant (the &#8220;Underwriter&#8217;s
Warrant&#8221;) to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zF438ZVnCZtk" title="Warrant purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember" id="Fact002722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">604,732</ix:nonFraction></span> shares of Common Stock of the Company, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zza2ndLR3dgl" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember" id="Fact002724" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>. The Underwriter&#8217;s Warrant has
an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zBCcXqgmg6rd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember" id="Fact002726" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.625</ix:nonFraction></span>, is exercisable on or after the date of issuance, and will expire on <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zNEKKbCI3Zdf" title="Warrant expire date"><ix:nonNumeric contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember" id="Fact002728" name="us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized">March 9, 2031</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consisted of (i) one share of Common Stock, (ii) one Series J common stock warrant (&#8220;Series J Warrants&#8221;)
to purchase one share of Common Stock (or pre-funded warrants to purchase one share of Common Stock in lieu thereof), (iii) one Series
K common stock warrant (&#8220;Series K Warrants&#8221;) to purchase one share of Common Stock (or pre-funded warrants to purchase one
share of Common Stock in lieu thereof), and (iv) one Series L common stock warrant (&#8220;Series L Warrants&#8221; and together with
the Series J Warrants and the Series K Warrants, the &#8220;Common Warrants&#8221;) to purchase one share of Common Stock (or pre-funded
warrants to purchase one share of Common Stock in lieu thereof). Each Pre-Funded Unit consisted of (i) one pre-funded warrant (the &#8220;Pre-Funded
Warrants&#8221;), (ii) one Series J Warrant, (iii) one Series K Warrant, and (iv) one Series L Warrant. The Common Warrants included
in the Pre-Funded Units are identical to the Common Warrants included in the Common Stock Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series J Warrants have an initial exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zdNnmvomwAb3" title="Initial exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesJWarrantsMember_custom_UnderwritingAgreementMember" id="Fact002730" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share. The Series J Warrants are exercisable immediately, subject to certain
limitations described herein. The Series J Warrants expire five (<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zTqcuerND9zl" title="Warrants expire year"><ix:nonNumeric contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesJWarrantsMember_custom_UnderwritingAgreementMember" format="ixt-sec:duryear" id="Fact002732" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>) years from the date of issuance. The Series K Warrants have an initial
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zeewpThVX86j" title="Initial exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesKWarrantsMember_custom_UnderwritingAgreementMember" id="Fact002734" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share. The Series K Warrants are exercisable immediately, subject to certain limitations described herein.
The Series K Warrants will expire one (<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zq3wApjM7Rjb" title="Warrants expire year"><ix:nonNumeric contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesKWarrantsMember_custom_UnderwritingAgreementMember" format="ixt-sec:duryear" id="Fact002736" name="us-gaap:WarrantsAndRightsOutstandingTerm">1</ix:nonNumeric></span>) year from the date of issuance. The Series L Warrants have an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z1MsjJ57uqbj" title="Initial exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesLWarrantsMember_custom_UnderwritingAgreementMember" id="Fact002738" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span>
per share. The Series L Warrants are exercisable immediately, subject to certain limitations described herein. The Series L Warrants
expire six (<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_za6v92U1WAzh" title="Warrants expire year"><ix:nonNumeric contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesLWarrantsMember_custom_UnderwritingAgreementMember" format="ixt-sec:durmonth" id="Fact002740" name="us-gaap:WarrantsAndRightsOutstandingTerm">6</ix:nonNumeric></span>) months from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units, the Pre-Funded Units, the shares of Common Stock comprising the Common Stock Units, the Common Warrants, the Pre-Funded
Warrants, the shares of Common Stock issuable upon exercise of the Common Warrants, and the Pre-Funded Warrants were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-284229), that was filed with the Securities Exchange Commission
(&#8220;SEC&#8221;) on January 10, 2025 and declared effective on February 7, 2025, including the prospectus forming a part of the registration
statement, a final prospectus supplement thereto, which was filed with the SEC on March 9, 2026, pursuant to Rule 424(b) under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the related registration statement filed with the SEC on March 5, 2026
under Rule 462(b) of the Securities Act, which became automatically effective upon filing. The Offering closed on March 9, 2026 (the
&#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, the Company also entered into a warrant agency agreement (the &#8220;Warrant Agency Agreement&#8221;) with Equiniti Trust
Company, LLC, as warrant agent (the &#8220;Warrant Agent&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in">Since the
closing of the Offering, <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz16vwaTY8Ij" title="Pre funded warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember" id="Fact002742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,291,000</ix:nonFraction></span> Pre-Funded Warrants have been exercised.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2026, the Company entered into an Amendment to Common Stock Purchase Warrants Agreement (the &#8220;Warrant Amendment&#8221;)
with certain investors, that participated in the March 2026 CMPO described above, in connection with the terms of certain
of the Company&#8217;s outstanding common warrants to purchase shares of Common Stock (the &#8220;Existing Warrants&#8221;). As originally
issued, the Existing Warrants provided for the purchase of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<span id="xdx_905_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkRTwAEJNS" title="Shares of common stock"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember" id="Fact002744" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">504,417</ix:nonFraction></span> shares of common stock, on exercise of the series G common stock warrants at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_z9tr0uLm5m13" title="warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember" id="Fact002746" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.3448</ix:nonFraction></span> per share;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<span id="xdx_90B_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCXakqVOMz9" title="Shares of common stock"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember" id="Fact002748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">279,168</ix:nonFraction></span> shares of common stock, on exercise of the series H common stock warrants at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zki4nAVQ3ke1" title="warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember" id="Fact002750" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.40</ix:nonFraction></span> per share; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<span id="xdx_900_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesICommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy6jP8a536K7" title="Shares of common stock"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember" id="Fact002752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,190,000</ix:nonFraction></span> shares of common stock, on exercise of the series I common stock warrants at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesICommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zU8uxZuGH2El" title="warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember" id="Fact002754" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></span> per share.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the Warrant Amendment, the exercise price for each of such Existing Warrants was reduced to $<span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_c20260305__20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zEUR3pHvlgQd" title="warrants exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2026-03-052026-03-05_us-gaap_SubsequentEventMember_custom_CommonStockPurchaseWarrantsAgreementMember" id="Fact002756" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share, subject to further adjustment
as set forth in the Existing Warrants and any other document governing the terms thereunder. All other terms and conditions of the Existing
Warrants remain unchanged and in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_812_ze0a5CNay5Dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 188; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
























<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ex21-1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Subsidiary</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction
    of Organization</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calidi
    Biotherapeutics (Nevada), Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">StemVac
    GmbH*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calidi
    Biotherapeutics Australia Pty Ltd**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retail
    Biopharma, Inc.***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
StemVac GmbH is a wholly owned subsidiary of Calidi Biotherapeutics (Nevada), Inc., which is a wholly owned subsidiary of Calidi
Biotherapeutics, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Calidi Biotherapeutics Australia Pty Ltd is a wholly owned subsidiary of Calidi Biotherapeutics (Nevada), Inc., which is a wholly
owned subsidiary of Calidi Biotherapeutics, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
Redtail Biopharma, Inc. is a wholly owned subsidiary of Calidi Biotherapeutics, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Forms S-3 (File Nos. 333-288784, 333-284229 and 333-282456),
Form S-3MEF (File No. 333-294074) and Form S-8 (File No. 333-282455) of our report dated March 31, 2025 (except for the effects of the
reverse stock-split described in Note 1, as to which the date is August 15, 2025), with respect to the consolidated financial statements
of Calidi Biotherapeutics, Inc. included in this Annual Report on Form 10-K for the year ended December 31, 2025.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costa
Mesa, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements of Calidi Biotherapeutics, Inc. on Forms S-3 (File Nos. 333-288784,
333-284229 and 333-282456), Form S-3MEF (File No. 333-294074) and Form S-8 (File No. 333-282455) of our report dated March 27, 2026,
with respect to the consolidated financial statements of Calidi Biotherapeutics, Inc. included in this Annual Report on Form 10-K for
the year ended December 31, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<FONT STYLE="font-variant: small-caps">CBIZ CPAs P.C. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costa
Mesa, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Eric Poma, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Annual
    Report on Form 10-K of Calidi Biotherapeutics, Inc. (the &ldquo;Registrant&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
    report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
    Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
    and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report
    any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s most recent
    fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal control
    over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the
    equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the Registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the Registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eric Poma</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
Poma</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Andrew Jackson, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Annual
    Report on Form 10-K of Calidi Biotherapeutics, Inc. (the &ldquo;Registrant&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
    report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
    Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
    and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report
    any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s most recent
    fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal control
    over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the
    equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the Registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the Registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew Jackson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Jackson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Calidi Biotherapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the
capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that to his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
    with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Eric Poma</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Poma</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Calidi Biotherapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December
31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the
capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, that to his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
    with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 27, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew Jackson</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Jackson</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>cldi-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2BybP9z5Z86ekhvWB2bXkqnyAoQCKCpiKP5+1W8aIN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:CLDI="http://calidibio.com/20251231" elementFormDefault="qualified" targetNamespace="http://calidibio.com/20251231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://calidibio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
          <link:definition>00000005 - Statement -  Consolidated Statements of Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/StatementsOfTotalEquity" id="StatementsOfTotalEquity">
          <link:definition>00000006 - Statement - Consolidated Statements of Total Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperations" id="OrganizationAndNatureOfOperations">
          <link:definition>999015 - Disclosure - Organization and Nature of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999016 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>999017 - Disclosure - Fair Value Measurements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SelectedBalanceSheetComponents" id="SelectedBalanceSheetComponents">
          <link:definition>999018 - Disclosure - Selected Balance Sheet Components</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/MachineryAndEquipmentNet" id="MachineryAndEquipmentNet">
          <link:definition>999019 - Disclosure - Machinery and Equipment, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999020 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/Debt" id="Debt">
          <link:definition>999021 - Disclosure - Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" id="ConvertiblePreferredStockCommonStockAndStockholdersEquity">
          <link:definition>999022 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999023 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999024 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999025 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999026 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999027 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>999029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" id="SelectedBalanceSheetComponentsTables">
          <link:definition>999030 - Disclosure - Selected Balance Sheet Components (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/MachineryAndEquipmentNetTables" id="MachineryAndEquipmentNetTables">
          <link:definition>999031 - Disclosure - Machinery and Equipment, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>999032 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/DebtTables" id="DebtTables">
          <link:definition>999033 - Disclosure - Debt (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" id="ConvertiblePreferredStockCommonStockAndStockholdersEquityTables">
          <link:definition>999034 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999035 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999036 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999037 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" id="OrganizationAndNatureOfOperationsDetailsNarrative">
          <link:definition>999038 - Disclosure - Organization and Nature of Operations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" id="ScheduleOfCashAndCashEquivalentsDetails">
          <link:definition>999039 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" id="ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails">
          <link:definition>999040 - Disclosure - Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" id="ScheduleOfOperatingSegmentDetails">
          <link:definition>999041 - Disclosure - Schedule of Operating Segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>999043 - Disclosure - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" id="ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails">
          <link:definition>999044 - Disclosure - Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>999045 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>999046 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" id="ScheduleOfMachineryAndEquipmentNetDetails">
          <link:definition>999047 - Disclosure - Schedule of Machinery and Equipment, Net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" id="MachineryAndEquipmentNetDetailsNarrative">
          <link:definition>999048 - Disclosure - Machinery and Equipment, net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" id="ScheduleOfRelatedPartyTransactionsDetails">
          <link:definition>999049 - Disclosure - Schedule of Related Party Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" id="ScheduleOfRelatedPartyTransactionsDetailsParenthetical">
          <link:definition>999050 - Disclosure - Schedule of Related Party Transactions (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" id="ScheduleOfOutstandingDebtObligationsDetails">
          <link:definition>999051 - Disclosure - Schedule of Outstanding Debt Obligations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" id="ScheduleOfMaturitiesOfOutstandingDebtDetails">
          <link:definition>999052 - Disclosure - Schedule of Maturities of Outstanding Debt (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999053 - Disclosure - Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" id="ScheduleOfCommonStockReservedDetails">
          <link:definition>999054 - Disclosure - Schedule of Common Stock Reserved (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" id="ScheduleOfOutstandingWarrantsDetails">
          <link:definition>999055 - Disclosure - Schedule of Outstanding Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" id="ScheduleOfOutstandingWarrantsDetailsParenthetical">
          <link:definition>999056 - Disclosure - Schedule of Outstanding Warrants (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>999057 - Disclosure - Schedule of Warrant Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" id="ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative">
          <link:definition>999058 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" id="SummaryOfStockOptionActivityDetails">
          <link:definition>999059 - Disclosure - Summary of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" id="SummaryOfRestrictedStockUnitActivityDetails">
          <link:definition>999060 - Disclosure - Summary of Restricted Stock Unit Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999061 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" id="ScheduleOfStockOptionsValuationAssumptionsDetails">
          <link:definition>999062 - Disclosure - Schedule of Stock Options Valuation Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999063 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" id="ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
          <link:definition>999064 - Disclosure - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" id="ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails">
          <link:definition>999065 - Disclosure - Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" id="ScheduleOfReconciliationOfIncomeTaxBenefitDetails">
          <link:definition>999066 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" id="ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails">
          <link:definition>999067 - Disclosure - Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999068 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" id="ScheduleOfUnrecognizedTaxBenefitDetails">
          <link:definition>999069 - Disclosure - Schedule of Unrecognized Tax Benefit (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999070 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" id="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails">
          <link:definition>999071 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" id="ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails">
          <link:definition>999072 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" id="ScheduleOfFutureMinimumLeaseCommitmentsDetails">
          <link:definition>999073 - Disclosure - Schedule of Future Minimum Lease Commitments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999074 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://calidibio.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999075 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cldi-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cldi-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cldi-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cldi-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <element id="CLDI_NovaCellMember" name="NovaCellMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GovernmentGrantsMember" name="GovernmentGrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CaliforniaInstituteForRegenerativeMedicineMember" name="CaliforniaInstituteForRegenerativeMedicineMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EarnoutSharesMember" name="EarnoutSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ContingentlyIssuableWarrantMember" name="ContingentlyIssuableWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PrivateWarrantsMember" name="PrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ForwardPurchaseAgreementDerivativeAssetMember" name="ForwardPurchaseAgreementDerivativeAssetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorAAndDirectorEMember" name="DirectorAAndDirectorEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorFAndRelativeOfOfficerAMember" name="DirectorFAndRelativeOfOfficerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorFMember" name="DirectorFMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorDMember" name="DirectorDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorAOneMember" name="DirectorAOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorFOneMember" name="DirectorFOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorATwoMember" name="DirectorATwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorFAndDirectorAMember" name="DirectorFAndDirectorAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RelativeOfOfficerAMember" name="RelativeOfOfficerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_OfficerGMember" name="OfficerGMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_OfficerAMember" name="OfficerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CompanyARelatedToDirectorGMember" name="CompanyARelatedToDirectorGMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorsAAndEMember" name="DirectorsAAndEMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorAMember" name="DirectorAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AJCCapitalMember" name="AJCCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GuarantyMember" name="GuarantyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DirectorAThreeMember" name="DirectorAThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TermNotesPayableMember" name="TermNotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_BridgeLoanPayableMember" name="BridgeLoanPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyOneTermNoteMember" name="TwoThousandTwentyOneTermNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_InvestorAndDirectorMember" name="InvestorAndDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyTwoTermNotePayableMember" name="TwoThousandTwentyTwoTermNotePayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyThreeTermNotePayableMember" name="TwoThousandTwentyThreeTermNotePayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" name="TwoThousandTwentyThreeTermNotePayableTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyFourBridgeLoanMember" name="TwoThousandTwentyFourBridgeLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyFourPurchaseAgreementMember" name="TwoThousandTwentyFourPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PromissoryNoteLoanAgreementMember" name="PromissoryNoteLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_VotingCommonStockMember" name="VotingCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" name="SeriesBWarrantsAndSeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_InducementOfferLetterAgreementMember" name="InducementOfferLetterAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesBOneWarrantsMember" name="SeriesBOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesCOneWarrantsMember" name="SeriesCOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesDCommonStockMember" name="SeriesDCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SubscriptionAgreementMember" name="SubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_MarketOfferingAgreementMember" name="MarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesECommonWarrantsMember" name="SeriesECommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesFCommonWarrantsMember" name="SeriesFCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgencyAgreementMember" name="PlacementAgencyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesGCommonWarrantsMember" name="SeriesGCommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_JulyWarrantInducementOfferMember" name="JulyWarrantInducementOfferMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesHCommonStockWarrantsMember" name="SeriesHCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PreFundedWarrantUnitsMember" name="PreFundedWarrantUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RepresentativeWarrantsMember" name="RepresentativeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommonStockOptionsIssuedAndOutstandingMember" name="CommonStockOptionsIssuedAndOutstandingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" name="RestrictedStockUnitsVestedAndUnreleasedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" name="TwoThousandTwentyThreeEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" name="TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PrivateWarrantsToPurchaseCommonStockMember" name="PrivateWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PublicWarrantsToPurchaseCommonStockMember" name="PublicWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_WarrantsToPurchaseRestrictedSharesMember" name="WarrantsToPurchaseRestrictedSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_WarrantsToPurchaseRestrictedSharesOneMember" name="WarrantsToPurchaseRestrictedSharesOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" name="PlacementAgentWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" name="PlacementAgentWarrantsToPurchaseCommonStockOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" name="PlacementAgentWarrantsToPurchaseCommonStockTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" name="PlacementAgentWarrantsToPurchaseCommonStockThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" name="PlacementAgentWarrantsToPurchaseCommonStockFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" name="PlacementAgentWarrantsToPurchaseCommonStockFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" name="RepresentativeWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesAWarrantsToPurchaseCommonStockMember" name="SeriesAWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesBWarrantsToPurchaseCommonStockMember" name="SeriesBWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" name="SeriesB1WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" name="SeriesB1WarrantsToPurchaseCommonStockOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" name="SeriesB1WarrantsToPurchaseCommonStockThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" name="SeriesB1WarrantsToPurchaseCommonStockTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" name="SeriesB1WarrantsToPurchaseCommonStockFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" name="SeriesC1WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" name="SeriesC1WarrantsToPurchaseCommonStockOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" name="SeriesC1WarrantsToPurchaseCommonStockTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesDWarrantsToPurchaseCommonStockMember" name="SeriesDWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesEWarrantsToPurchaseCommonStockMember" name="SeriesEWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesFWarrantsToPurchaseCommonStockMember" name="SeriesFWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesGWarrantsToPurchaseCommonStockMember" name="SeriesGWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesHWarrantsToPurchaseCommonStockMember" name="SeriesHWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesIWarrantsToPurchaseCommonStockMember" name="SeriesIWarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RedemptionOfWarrantsMember" name="RedemptionOfWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" name="SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" name="SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesCOneWarrantsOneMember" name="SeriesCOneWarrantsOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesDWarrantsMember" name="SeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" name="SeriesEWarrantsAndSeriesFWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesGPreFundedWarrantsMember" name="SeriesGPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesIPreFundedWarrantsMember" name="SeriesIPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TwoThousandTwentyThreePlanMember" name="TwoThousandTwentyThreePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AdministratorMember" name="AdministratorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ResearchAndDevelopmentExpensesMember" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GeneralAndAdministrativeExpensesMember" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PriorDecemberTwentySeventeenthMember" name="PriorDecemberTwentySeventeenthMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AfterDecemberTwentySeventeenthMember" name="AfterDecemberTwentySeventeenthMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SanDiegoLeaseAgreementMember" name="SanDiegoLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_MrCamaisaMember" name="MrCamaisaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StemVacOfficeLeaseAgreementMember" name="StemVacOfficeLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_NorthwesternAgreementMember" name="NorthwesternAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeparationAndReleaseAgreementMember" name="SeparationAndReleaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GeorgeNgMember" name="GeorgeNgMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_MrLeftwichMember" name="MrLeftwichMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SettlementOfDeferredCompensationMember" name="SettlementOfDeferredCompensationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_YorkvilleMember" name="YorkvilleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_Dr.CamisaMember" name="Dr.CamisaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_Dr.MinevMember" name="Dr.MinevMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_Ms.CampbellMember" name="Ms.CampbellMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommonStockUnitsMember" name="CommonStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_UnderwritersWarrantMember" name="UnderwritersWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesJWarrantsMember" name="SeriesJWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesKWarrantsMember" name="SeriesKWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesLWarrantsMember" name="SeriesLWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesGCommonStockWarrantsMember" name="SeriesGCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommonStockPurchaseWarrantsAgreementMember" name="CommonStockPurchaseWarrantsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeriesICommonStockWarrantsMember" name="SeriesICommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TermNotesPayableCurrent" name="TermNotesPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PromissoryNote" name="PromissoryNote" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RelatedPartyWarrantLiability" name="RelatedPartyWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" name="ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" name="ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GrantIncome" name="GrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DeemedDividendOnWarrants" name="DeemedDividendOnWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" name="IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" name="IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" name="IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" name="IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" name="IssuanceOfCommonSharesThroughAugustPublicOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" name="StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" name="StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" name="StockIssuedDuringPeriodValueSaleOfInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" name="StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" name="StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" name="AdjustmentsToAdditionalPaidInCapitalFinancingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" name="StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" name="StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" name="AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" name="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StockIssuedDuringPeriodValueInvestment" name="StockIssuedDuringPeriodValueInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" name="ChangeInFairValueOfOtherLiabilitiesAndDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ProceedsFromPublicOfferings" name="ProceedsFromPublicOfferings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ProceedsFromWarrantInducementFinancing" name="ProceedsFromWarrantInducementFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ProceedsFromRegisteredDirectOffering" name="ProceedsFromRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" name="RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" name="ProceedsFromIssuanceOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" name="ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RepaymentOfConvertibleNotePayable" name="RepaymentOfConvertibleNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PaymentOfDebtIssuanceCosts" name="PaymentOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CashPaidForIncomeTaxes" name="CashPaidForIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases" name="MachineryAndEquipmentAcquiredThroughFinancingLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" name="FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote" name="IssuanceOfCommonStockPerConversionOfConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfConvertibleNoteForLegalSettlement" name="IssuanceOfConvertibleNoteForLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockInLieuOfCashForServices" name="IssuanceOfCommonStockInLieuOfCashForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" name="RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" name="IssuanceOfCommonStockAndWarrantsForLegalSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DebtDiscountOnConvertibleNotes" name="DebtDiscountOnConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" name="IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" name="IssuanceOfRestrictedStockUnitsForLiabilitySettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GovernmentGrantsPolicyTextBlock" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" name="ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" name="NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock" name="DiscloserOFCommonStockReservedForFurtureTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ScheduleOfOutstandingWarrantsTextBlock" name="ScheduleOfOutstandingWarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock" name="ScheduleOfIncomeTaxPaidTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" name="ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AccountingPoliciesTable" name="AccountingPoliciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CLDI_Consulting" name="Consulting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RentAndMaintenance" name="RentAndMaintenance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ClinicalResearchAndDevelopment" name="ClinicalResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" name="ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_OtherSegmentItems" name="OtherSegmentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GrantsReceivableWithdrawn" name="GrantsReceivableWithdrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AccruedCompensation" name="AccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_AccruedVendorAndOtherExpenses" name="AccruedVendorAndOtherExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PrepaidExpenses" name="PrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ConsultingPay" name="ConsultingPay" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_GuarantyOfLeaseAmount" name="GuarantyOfLeaseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_SeparationPay" name="SeparationPay" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ClassOfWarrantOrRighstIssuanceDate" name="ClassOfWarrantOrRighstIssuanceDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_TriggeringEventAxis" name="TriggeringEventAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="CLDI_TriggeringEventDomain" name="TriggeringEventDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PublicWarrantRedemptionDescription" name="PublicWarrantRedemptionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RedemptionOfOutstandingWarrantsPerShare" name="RedemptionOfOutstandingWarrantsPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ClassOfWarrantsRedemptionNoticePeriod" name="ClassOfWarrantsRedemptionNoticePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_Deemeddividend" name="Deemeddividend" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommonStockDividend" name="CommonStockDividend" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_PercentageOfStrategicInvestment" name="PercentageOfStrategicInvestment" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CashCommissionPercentage" name="CashCommissionPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DisbursementsCounsel" name="DisbursementsCounsel" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" name="IssuanceOfCommonSharesThroughAugustPublicOfferingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommonStockUnitPerShareDescription" name="CommonStockUnitPerShareDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_StatementOfIncomeLocationBalanceAxis" name="StatementOfIncomeLocationBalanceAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="CLDI_StatementOfIncomeLocationBalanceDomain" name="StatementOfIncomeLocationBalanceDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommonStockDiscounRate" name="CommonStockDiscounRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_NoncashCompensation" name="NoncashCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" name="IncomeTaxReconciliationEnactmentOfNewTaxLaws" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" name="EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" nillable="true" xbrli:periodType="duration" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" name="EffectiveIncomeTaxRateReconciliationStockIssuanceCost" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" name="EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" name="IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" name="EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" name="IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" name="EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" name="IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" name="EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" name="IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" name="EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" name="IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" name="EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract" name="ScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" name="ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CLDI_IncomeTaxPaidStateAfterRefundReceived" name="IncomeTaxPaidStateAfterRefundReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" name="DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour" name="FinanceLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" name="OperatingLeaseTermOfContractLeaseInitialTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" name="LeaseTermsOperatingLeasesAnnualIncreaseInRent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_RemainingExpectedCommitments" name="RemainingExpectedCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_CommitmentFeePercentage" name="CommitmentFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_EquityPurchaseDescription" name="EquityPurchaseDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CLDI_IncurredCosts" name="IncurredCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>cldi-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Cover" roleURI="http://calidibio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#BalanceSheets" roleURI="http://calidibio.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://calidibio.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfOperations" roleURI="http://calidibio.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfTotalEquity" roleURI="http://calidibio.com/role/StatementsOfTotalEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfCashFlows" roleURI="http://calidibio.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#OrganizationAndNatureOfOperations" roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#FairValueMeasurements" roleURI="http://calidibio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SelectedBalanceSheetComponents" roleURI="http://calidibio.com/role/SelectedBalanceSheetComponents" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNet" roleURI="http://calidibio.com/role/MachineryAndEquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#RelatedPartyTransactions" roleURI="http://calidibio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Debt" roleURI="http://calidibio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquity" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensation" roleURI="http://calidibio.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxes" roleURI="http://calidibio.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingencies" roleURI="http://calidibio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SubsequentEvents" roleURI="http://calidibio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#FairValueMeasurementsTables" roleURI="http://calidibio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SelectedBalanceSheetComponentsTables" roleURI="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNetTables" roleURI="http://calidibio.com/role/MachineryAndEquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#RelatedPartyTransactionsTables" roleURI="http://calidibio.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#DebtTables" roleURI="http://calidibio.com/role/DebtTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensationTables" roleURI="http://calidibio.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxesTables" roleURI="http://calidibio.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://calidibio.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#OrganizationAndNatureOfOperationsDetailsNarrative" roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCashAndCashEquivalentsDetails" roleURI="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" roleURI="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOperatingSegmentDetails" roleURI="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" roleURI="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfMachineryAndEquipmentNetDetails" roleURI="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNetDetailsNarrative" roleURI="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfRelatedPartyTransactionsDetails" roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfRelatedPartyTransactionsDetailsParenthetical" roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingDebtObligationsDetails" roleURI="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfMaturitiesOfOutstandingDebtDetails" roleURI="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#DebtDetailsNarrative" roleURI="http://calidibio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCommonStockReservedDetails" roleURI="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingWarrantsDetails" roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingWarrantsDetailsParenthetical" roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfStockOptionActivityDetails" roleURI="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfRestrictedStockUnitActivityDetails" roleURI="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" roleURI="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" roleURI="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" roleURI="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" roleURI="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" roleURI="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfUnrecognizedTaxBenefitDetails" roleURI="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://calidibio.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" roleURI="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" roleURI="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfFutureMinimumLeaseCommitmentsDetails" roleURI="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://calidibio.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableCurrent" xlink:label="loc_CLDITermNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_CLDITermNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNote" xlink:label="loc_CLDIPromissoryNote" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_CLDIPromissoryNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantLiability" xlink:label="loc_CLDIWarrantLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_CLDIWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelatedPartyWarrantLiability" xlink:label="loc_CLDIRelatedPartyWarrantLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_CLDIRelatedPartyWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantIncome" xlink:label="loc_CLDIGrantIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CLDIGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaapGainOnSaleOfInvestments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainOnSaleOfInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeemedDividendOnWarrants" xlink:label="loc_CLDIDeemedDividendOnWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_CLDIDeemedDividendOnWarrants" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement -  Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfTotalEquity" xlink:title="00000006 - Statement - Consolidated Statements of Total Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivatives" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaapGainOnSaleOfInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainOnSaleOfInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromPublicOfferings" xlink:label="loc_CLDIProceedsFromPublicOfferings" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIProceedsFromPublicOfferings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromWarrantInducementFinancing" xlink:label="loc_CLDIProceedsFromWarrantInducementFinancing" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIProceedsFromWarrantInducementFinancing" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromRegisteredDirectOffering" xlink:label="loc_CLDIProceedsFromRegisteredDirectOffering" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIProceedsFromRegisteredDirectOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:label="loc_CLDIRepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIRepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" xlink:label="loc_CLDIProceedsFromIssuanceOfNoncontrollingInterest" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIProceedsFromIssuanceOfNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:label="loc_CLDIProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepaymentOfConvertibleNotePayable" xlink:label="loc_CLDIRepaymentOfConvertibleNotePayable" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIRepaymentOfConvertibleNotePayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PaymentOfDebtIssuanceCosts" xlink:label="loc_CLDIPaymentOfDebtIssuanceCosts" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CLDIPaymentOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/OrganizationAndNatureOfOperations" xlink:title="999015 - Disclosure - Organization and Nature of Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/FairValueMeasurements" xlink:title="999017 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SelectedBalanceSheetComponents" xlink:title="999018 - Disclosure - Selected Balance Sheet Components" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNet" xlink:title="999019 - Disclosure - Machinery and Equipment, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/RelatedPartyTransactions" xlink:title="999020 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Debt" xlink:title="999021 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" xlink:title="999022 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensation" xlink:title="999023 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxes" xlink:title="999024 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SubsequentEvents" xlink:title="999026 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999027 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/FairValueMeasurementsTables" xlink:title="999029 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" xlink:title="999030 - Disclosure - Selected Balance Sheet Components (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNetTables" xlink:title="999031 - Disclosure - Machinery and Equipment, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/RelatedPartyTransactionsTables" xlink:title="999032 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/DebtTables" xlink:title="999033 - Disclosure - Debt (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" xlink:title="999034 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensationTables" xlink:title="999035 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxesTables" xlink:title="999036 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingenciesTables" xlink:title="999037 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:title="999038 - Disclosure - Organization and Nature of Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999039 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" xlink:title="999040 - Disclosure - Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" xlink:title="999041 - Disclosure - Schedule of Operating Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Consulting" xlink:label="loc_CLDIConsulting" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CLDIConsulting" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RentAndMaintenance" xlink:label="loc_CLDIRentAndMaintenance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CLDIRentAndMaintenance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClinicalResearchAndDevelopment" xlink:label="loc_CLDIClinicalResearchAndDevelopment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CLDIClinicalResearchAndDevelopment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:label="loc_CLDIChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CLDIChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OtherSegmentItems" xlink:label="loc_CLDIOtherSegmentItems" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_CLDIOtherSegmentItems" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999043 - Disclosure - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" xlink:title="999044 - Disclosure - Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999045 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccruedCompensation" xlink:label="loc_CLDIAccruedCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_CLDIAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccruedVendorAndOtherExpenses" xlink:label="loc_CLDIAccruedVendorAndOtherExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_CLDIAccruedVendorAndOtherExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999046 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrepaidExpenses" xlink:label="loc_CLDIPrepaidExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_CLDIPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" xlink:title="999047 - Disclosure - Schedule of Machinery and Equipment, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" xlink:title="999048 - Disclosure - Machinery and Equipment, net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="999049 - Disclosure - Schedule of Related Party Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:title="999050 - Disclosure - Schedule of Related Party Transactions (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" xlink:title="999051 - Disclosure - Schedule of Outstanding Debt Obligations (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" xlink:title="999052 - Disclosure - Schedule of Maturities of Outstanding Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDebtInstrumentCarryingAmount" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/DebtDetailsNarrative" xlink:title="999053 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" xlink:title="999054 - Disclosure - Schedule of Common Stock Reserved (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" xlink:title="999055 - Disclosure - Schedule of Outstanding Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" xlink:title="999056 - Disclosure - Schedule of Outstanding Warrants (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999057 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" xlink:title="999058 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" xlink:title="999059 - Disclosure - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" xlink:title="999060 - Disclosure - Summary of Restricted Stock Unit Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999061 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="999062 - Disclosure - Schedule of Stock Options Valuation Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999063 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:title="999064 - Disclosure - Schedule of Income (Loss) Before Provision for Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" xlink:title="999065 - Disclosure - Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="999066 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:label="loc_CLDIIncomeTaxReconciliationEnactmentOfNewTaxLaws" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CLDIIncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCredits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxSettlements" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxSettlements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:label="loc_CLDIIncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CLDIIncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:label="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:label="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:label="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:label="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlements" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationStockIssuanceCost" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" xlink:title="999067 - Disclosure - Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="loc_us-gaapIncomeTaxPaidFederalAfterRefundReceived" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxesPaidNet" xlink:to="loc_us-gaapIncomeTaxPaidFederalAfterRefundReceived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxPaidStateAfterRefundReceived" xlink:label="loc_CLDIIncomeTaxPaidStateAfterRefundReceived" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxesPaidNet" xlink:to="loc_CLDIIncomeTaxPaidStateAfterRefundReceived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="loc_us-gaapIncomeTaxPaidForeignAfterRefundReceived" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxesPaidNet" xlink:to="loc_us-gaapIncomeTaxPaidForeignAfterRefundReceived" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999068 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_CLDIDeferredTaxAssetsLeaseLiabilities" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CLDIDeferredTaxAssetsLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="loc_CLDIDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CLDIDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_CLDIDeferredTaxAssetsDepreciationAndAmortization" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CLDIDeferredTaxAssetsDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:label="loc_CLDIDeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_CLDIDeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" xlink:title="999069 - Disclosure - Schedule of Unrecognized Tax Benefit (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="999071 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="999072 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:to="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:to="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiability" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiability" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:title="999073 - Disclosure - Schedule of Future Minimum Lease Commitments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999074 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999075 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>cldi-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Cover" roleURI="http://calidibio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#BalanceSheets" roleURI="http://calidibio.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://calidibio.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfOperations" roleURI="http://calidibio.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfTotalEquity" roleURI="http://calidibio.com/role/StatementsOfTotalEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfCashFlows" roleURI="http://calidibio.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#OrganizationAndNatureOfOperations" roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#FairValueMeasurements" roleURI="http://calidibio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SelectedBalanceSheetComponents" roleURI="http://calidibio.com/role/SelectedBalanceSheetComponents" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNet" roleURI="http://calidibio.com/role/MachineryAndEquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#RelatedPartyTransactions" roleURI="http://calidibio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Debt" roleURI="http://calidibio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquity" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensation" roleURI="http://calidibio.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxes" roleURI="http://calidibio.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingencies" roleURI="http://calidibio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SubsequentEvents" roleURI="http://calidibio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#FairValueMeasurementsTables" roleURI="http://calidibio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SelectedBalanceSheetComponentsTables" roleURI="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNetTables" roleURI="http://calidibio.com/role/MachineryAndEquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#RelatedPartyTransactionsTables" roleURI="http://calidibio.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#DebtTables" roleURI="http://calidibio.com/role/DebtTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensationTables" roleURI="http://calidibio.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxesTables" roleURI="http://calidibio.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://calidibio.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#OrganizationAndNatureOfOperationsDetailsNarrative" roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCashAndCashEquivalentsDetails" roleURI="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" roleURI="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOperatingSegmentDetails" roleURI="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" roleURI="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfMachineryAndEquipmentNetDetails" roleURI="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNetDetailsNarrative" roleURI="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfRelatedPartyTransactionsDetails" roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfRelatedPartyTransactionsDetailsParenthetical" roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingDebtObligationsDetails" roleURI="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfMaturitiesOfOutstandingDebtDetails" roleURI="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#DebtDetailsNarrative" roleURI="http://calidibio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCommonStockReservedDetails" roleURI="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingWarrantsDetails" roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingWarrantsDetailsParenthetical" roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfStockOptionActivityDetails" roleURI="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfRestrictedStockUnitActivityDetails" roleURI="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" roleURI="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" roleURI="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" roleURI="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" roleURI="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" roleURI="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfUnrecognizedTaxBenefitDetails" roleURI="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://calidibio.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" roleURI="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" roleURI="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfFutureMinimumLeaseCommitmentsDetails" roleURI="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://calidibio.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCash_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_70" xlink:to="loc_us-gaapOtherAssetsNoncurrent_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableCurrent" xlink:label="loc_CLDITermNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_CLDITermNotesPayableCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLoansPayableCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNote" xlink:label="loc_CLDIPromissoryNote_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_CLDIPromissoryNote_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantLiability" xlink:label="loc_CLDIWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_CLDIWarrantLiability_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelatedPartyWarrantLiability" xlink:label="loc_CLDIRelatedPartyWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_CLDIRelatedPartyWarrantLiability_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapMinorityInterest_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapOperatingExpenses_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapInterestExpenseNonoperating_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantIncome" xlink:label="loc_CLDIGrantIncome_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_CLDIGrantIncome_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaapGainOnSaleOfInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapGainOnSaleOfInvestments_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapNonoperatingIncomeExpense_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeemedDividendOnWarrants" xlink:label="loc_CLDIDeemedDividendOnWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CLDIDeemedDividendOnWarrants_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement -  Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfTotalEquity" xlink:title="00000006 - Statement - Consolidated Statements of Total Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_360" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_360" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_360" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_360" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_360" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_360" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_360" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_360" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_360" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:label="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares_360" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_360" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_360" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_360" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_360" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_CLDIStockIssuedDuringPeriodValueReverseStockSplits_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueReverseStockSplits_360" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_360" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_360" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_360" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" xlink:label="loc_CLDIStockIssuedDuringPeriodValueSaleOfInvestment_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueSaleOfInvestment_360" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_360" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_360" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_360" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_360" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_360" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" xlink:label="loc_CLDIStockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_360" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_360" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_360" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_360" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" xlink:label="loc_CLDIAdjustmentsToAdditionalPaidInCapitalFinancingFees_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIAdjustmentsToAdditionalPaidInCapitalFinancingFees_360" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_360" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_360" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_360" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_360" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_360" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_360" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:label="loc_CLDIAdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIAdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_360" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_360" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_360" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_360" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_360" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_360" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_360" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_360" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_360" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_360" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_360" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_360" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_360" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueInvestment" xlink:label="loc_CLDIStockIssuedDuringPeriodValueInvestment_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueInvestment_360" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_360" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_360" xlink:type="arc" order="52" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/OrganizationAndNatureOfOperations" xlink:title="999015 - Disclosure - Organization and Nature of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/FairValueMeasurements" xlink:title="999017 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SelectedBalanceSheetComponents" xlink:title="999018 - Disclosure - Selected Balance Sheet Components" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNet" xlink:title="999019 - Disclosure - Machinery and Equipment, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/RelatedPartyTransactions" xlink:title="999020 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/Debt" xlink:title="999021 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" xlink:title="999022 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensation" xlink:title="999023 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxes" xlink:title="999024 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SubsequentEvents" xlink:title="999026 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999027 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/FairValueMeasurementsTables" xlink:title="999029 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" xlink:title="999030 - Disclosure - Selected Balance Sheet Components (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNetTables" xlink:title="999031 - Disclosure - Machinery and Equipment, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/RelatedPartyTransactionsTables" xlink:title="999032 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/DebtTables" xlink:title="999033 - Disclosure - Debt (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" xlink:title="999034 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensationTables" xlink:title="999035 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxesTables" xlink:title="999036 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingenciesTables" xlink:title="999037 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:title="999038 - Disclosure - Organization and Nature of Operations (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999039 - Disclosure - Schedule of Cash and Cash Equivalents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" xlink:title="999040 - Disclosure - Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EarnoutSharesMember" xlink:label="loc_CLDIEarnoutSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CLDIEarnoutSharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ContingentlyIssuableWarrantMember" xlink:label="loc_CLDIContingentlyIssuableWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CLDIContingentlyIssuableWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" xlink:title="999041 - Disclosure - Schedule of Operating Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccountingPoliciesTable" xlink:label="loc_CLDIAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CLDIAccountingPoliciesTable" xlink:to="loc_srtConsolidationItemsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralInsuranceExpense_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Consulting" xlink:label="loc_CLDIConsulting_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIConsulting_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RentAndMaintenance" xlink:label="loc_CLDIRentAndMaintenance_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIRentAndMaintenance_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClinicalResearchAndDevelopment" xlink:label="loc_CLDIClinicalResearchAndDevelopment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIClinicalResearchAndDevelopment_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:label="loc_CLDIChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OtherSegmentItems" xlink:label="loc_CLDIOtherSegmentItems_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIOtherSegmentItems_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLDINovaCellMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_CLDINovaCellMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GovernmentGrantsMember" xlink:label="loc_CLDIGovernmentGrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIGovernmentGrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="loc_CLDICaliforniaInstituteForRegenerativeMedicineMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDICaliforniaInstituteForRegenerativeMedicineMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:label="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNotesPayable_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherOperatingActivities" xlink:label="loc_us-gaapProceedsFromOtherOperatingActivities_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromOtherOperatingActivities_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGrantsReceivableCurrent_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantsReceivableWithdrawn" xlink:label="loc_CLDIGrantsReceivableWithdrawn_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CLDIGrantsReceivableWithdrawn_140" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999043 - Disclosure - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:label="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsMember" xlink:label="loc_CLDIPublicWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_CLDIPublicWarrantsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsMember" xlink:label="loc_CLDIPrivateWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_CLDIPrivateWarrantsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_370" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_370" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" xlink:title="999044 - Disclosure - Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaapFairValueByBalanceSheetGroupingTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:label="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsMember" xlink:label="loc_CLDIPublicWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIPublicWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsMember" xlink:label="loc_CLDIPrivateWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIPrivateWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_160" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999045 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999046 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" xlink:title="999047 - Disclosure - Schedule of Machinery and Equipment, Net (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" xlink:title="999048 - Disclosure - Machinery and Equipment, net (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="999049 - Disclosure - Schedule of Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAAndDirectorEMember" xlink:label="loc_CLDIDirectorAAndDirectorEMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAAndDirectorEMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFAndRelativeOfOfficerAMember" xlink:label="loc_CLDIDirectorFAndRelativeOfOfficerAMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFAndRelativeOfOfficerAMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFMember" xlink:label="loc_CLDIDirectorFMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorDMember" xlink:label="loc_CLDIDirectorDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAOneMember" xlink:label="loc_CLDIDirectorAOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFOneMember" xlink:label="loc_CLDIDirectorFOneMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFOneMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorATwoMember" xlink:label="loc_CLDIDirectorATwoMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorATwoMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFAndDirectorAMember" xlink:label="loc_CLDIDirectorFAndDirectorAMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFAndDirectorAMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelativeOfOfficerAMember" xlink:label="loc_CLDIRelativeOfOfficerAMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIRelativeOfOfficerAMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerGMember" xlink:label="loc_CLDIOfficerGMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerGMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerAMember" xlink:label="loc_CLDIOfficerAMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerAMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CompanyARelatedToDirectorGMember" xlink:label="loc_CLDICompanyARelatedToDirectorGMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDICompanyARelatedToDirectorGMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:title="999050 - Disclosure - Schedule of Related Party Transactions (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorsAAndEMember" xlink:label="loc_CLDIDirectorsAAndEMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorsAAndEMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtOfficerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFMember" xlink:label="loc_CLDIDirectorFMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorDMember" xlink:label="loc_CLDIDirectorDMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorDMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAMember" xlink:label="loc_CLDIDirectorAMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AJCCapitalMember" xlink:label="loc_CLDIAJCCapitalMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIAJCCapitalMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAThreeMember" xlink:label="loc_CLDIDirectorAThreeMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAThreeMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelativeOfOfficerAMember" xlink:label="loc_CLDIRelativeOfOfficerAMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIRelativeOfOfficerAMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerGMember" xlink:label="loc_CLDIOfficerGMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerGMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerAMember" xlink:label="loc_CLDIOfficerAMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerAMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CompanyARelatedToDirectorGMember" xlink:label="loc_CLDICompanyARelatedToDirectorGMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDICompanyARelatedToDirectorGMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaapGuaranteeObligationsByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapGuaranteeObligationsByNatureAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaapGuaranteeObligationsNatureDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGuaranteeObligationsByNatureAxis" xlink:to="loc_us-gaapGuaranteeObligationsNatureDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaapGuaranteeObligationsNatureDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGuaranteeObligationsByNatureAxis" xlink:to="loc_us-gaapGuaranteeObligationsNatureDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyMember" xlink:label="loc_CLDIGuarantyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGuaranteeObligationsNatureDomain" xlink:to="loc_CLDIGuarantyMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaapLoansPayableMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapLoansPayableMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLegalFees_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansPayable_270" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ConsultingPay" xlink:label="loc_CLDIConsultingPay_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CLDIConsultingPay_270" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherExpenses_270" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages_270" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent_270" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:label="loc_us-gaapNoninterestExpenseInvestmentAdvisoryFees_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNoninterestExpenseInvestmentAdvisoryFees_270" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_270" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyOfLeaseAmount" xlink:label="loc_CLDIGuarantyOfLeaseAmount_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CLDIGuarantyOfLeaseAmount_270" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="loc_us-gaapLessorOperatingLeaseDescription_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseDescription_270" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeLeasePayments_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeLeasePayments_270" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent_270" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_270" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationPay" xlink:label="loc_CLDISeparationPay_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CLDISeparationPay_270" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSeveranceCosts1_270" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_270" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities_270" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" xlink:title="999051 - Disclosure - Schedule of Outstanding Debt Obligations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNoteMember" xlink:label="loc_CLDIPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDIPromissoryNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableMember" xlink:label="loc_CLDITermNotesPayableMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITermNotesPayableMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_BridgeLoanPayableMember" xlink:label="loc_CLDIBridgeLoanPayableMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDIBridgeLoanPayableMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtCurrent_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt_120" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" xlink:title="999052 - Disclosure - Schedule of Maturities of Outstanding Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/DebtDetailsNarrative" xlink:title="999053 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyOneTermNoteMember" xlink:label="loc_CLDITwoThousandTwentyOneTermNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyOneTermNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyTwoTermNotePayableMember" xlink:label="loc_CLDITwoThousandTwentyTwoTermNotePayableMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyTwoTermNotePayableMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeTermNotePayableMember" xlink:label="loc_CLDITwoThousandTwentyThreeTermNotePayableMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeTermNotePayableMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" xlink:label="loc_CLDITwoThousandTwentyThreeTermNotePayableTwoMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeTermNotePayableTwoMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyFourBridgeLoanMember" xlink:label="loc_CLDITwoThousandTwentyFourBridgeLoanMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyFourBridgeLoanMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_InvestorAndDirectorMember" xlink:label="loc_CLDIInvestorAndDirectorMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIInvestorAndDirectorMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyFourPurchaseAgreementMember" xlink:label="loc_CLDITwoThousandTwentyFourPurchaseAgreementMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDITwoThousandTwentyFourPurchaseAgreementMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNoteLoanAgreementMember" xlink:label="loc_CLDIPromissoryNoteLoanAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIPromissoryNoteLoanAgreementMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaapDebtWeightedAverageInterestRate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtWeightedAverageInterestRate_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_310" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_310" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" xlink:title="999054 - Disclosure - Schedule of Common Stock Reserved (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="loc_CLDICommonStockOptionsIssuedAndOutstandingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDICommonStockOptionsIssuedAndOutstandingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" xlink:label="loc_CLDIRestrictedStockUnitsVestedAndUnreleasedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDIRestrictedStockUnitsVestedAndUnreleasedMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreeEquityIncentivePlanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeEquityIncentivePlanMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreeEmployeeStockPurchasePlanMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeEmployeeStockPurchasePlanMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" xlink:title="999055 - Disclosure - Schedule of Outstanding Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIPrivateWarrantsToPurchaseCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPrivateWarrantsToPurchaseCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIPublicWarrantsToPurchaseCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPublicWarrantsToPurchaseCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantsToPurchaseRestrictedSharesMember" xlink:label="loc_CLDIWarrantsToPurchaseRestrictedSharesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIWarrantsToPurchaseRestrictedSharesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantsToPurchaseRestrictedSharesOneMember" xlink:label="loc_CLDIWarrantsToPurchaseRestrictedSharesOneMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIWarrantsToPurchaseRestrictedSharesOneMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockOneMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockOneMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockTwoMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockTwoMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockThreeMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockThreeMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFourMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFourMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFiveMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFiveMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIRepresentativeWarrantsToPurchaseCommonStockMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIRepresentativeWarrantsToPurchaseCommonStockMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesAWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesAWarrantsToPurchaseCommonStockMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesAWarrantsToPurchaseCommonStockMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockOneMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockOneMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockThreeMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockThreeMember_620" xlink:type="arc" order="621" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockTwoMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockTwoMember_640" xlink:type="arc" order="641" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockFourMember_680" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockFourMember_680" xlink:type="arc" order="681" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesC1WarrantsToPurchaseCommonStockMember_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesC1WarrantsToPurchaseCommonStockMember_720" xlink:type="arc" order="721" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" xlink:label="loc_CLDISeriesC1WarrantsToPurchaseCommonStockOneMember_760" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesC1WarrantsToPurchaseCommonStockOneMember_760" xlink:type="arc" order="761" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" xlink:label="loc_CLDISeriesC1WarrantsToPurchaseCommonStockTwoMember_800" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesC1WarrantsToPurchaseCommonStockTwoMember_800" xlink:type="arc" order="801" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesDWarrantsToPurchaseCommonStockMember_840" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesDWarrantsToPurchaseCommonStockMember_840" xlink:type="arc" order="841" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesEWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesEWarrantsToPurchaseCommonStockMember_880" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesEWarrantsToPurchaseCommonStockMember_880" xlink:type="arc" order="881" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesFWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesFWarrantsToPurchaseCommonStockMember_920" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesFWarrantsToPurchaseCommonStockMember_920" xlink:type="arc" order="921" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesGWarrantsToPurchaseCommonStockMember_960" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesGWarrantsToPurchaseCommonStockMember_960" xlink:type="arc" order="961" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesHWarrantsToPurchaseCommonStockMember_1000" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesHWarrantsToPurchaseCommonStockMember_1000" xlink:type="arc" order="1001" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesIWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesIWarrantsToPurchaseCommonStockMember_1040" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesIWarrantsToPurchaseCommonStockMember_1040" xlink:type="arc" order="1041" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1080" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1080" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1080" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1080" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClassOfWarrantOrRighstIssuanceDate" xlink:label="loc_CLDIClassOfWarrantOrRighstIssuanceDate_1080" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIClassOfWarrantOrRighstIssuanceDate_1080" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_1080" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_1080" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" xlink:title="999056 - Disclosure - Schedule of Outstanding Warrants (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RedemptionOfWarrantsMember" xlink:label="loc_CLDIRedemptionOfWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIRedemptionOfWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesAWarrantsMember" xlink:label="loc_CLDISeriesAWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesAWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsMember" xlink:label="loc_CLDISeriesBWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBOneWarrantsMember" xlink:label="loc_CLDISeriesBOneWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBOneWarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsMember" xlink:label="loc_CLDISeriesCOneWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesCOneWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsOneMember" xlink:label="loc_CLDISeriesCOneWarrantsOneMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesCOneWarrantsOneMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDWarrantsMember" xlink:label="loc_CLDISeriesDWarrantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesDWarrantsMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" xlink:label="loc_CLDISeriesEWarrantsAndSeriesFWarrantsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesEWarrantsAndSeriesFWarrantsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGPreFundedWarrantsMember" xlink:label="loc_CLDISeriesGPreFundedWarrantsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesGPreFundedWarrantsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesIPreFundedWarrantsMember" xlink:label="loc_CLDISeriesIPreFundedWarrantsMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesIPreFundedWarrantsMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TriggeringEventAxis" xlink:label="loc_CLDITriggeringEventAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_CLDITriggeringEventAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TriggeringEventDomain" xlink:label="loc_CLDITriggeringEventDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_CLDITriggeringEventAxis" xlink:to="loc_CLDITriggeringEventDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TriggeringEventDomain" xlink:label="loc_CLDITriggeringEventDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_CLDITriggeringEventAxis" xlink:to="loc_CLDITriggeringEventDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" xlink:label="loc_CLDISharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CLDITriggeringEventDomain" xlink:to="loc_CLDISharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:label="loc_CLDISharePriceEqualOrExceedsEighteenRupeesPerDollarMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CLDITriggeringEventDomain" xlink:to="loc_CLDISharePriceEqualOrExceedsEighteenRupeesPerDollarMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantRedemptionDescription" xlink:label="loc_CLDIPublicWarrantRedemptionDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIPublicWarrantRedemptionDescription_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RedemptionOfOutstandingWarrantsPerShare" xlink:label="loc_CLDIRedemptionOfOutstandingWarrantsPerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIRedemptionOfOutstandingWarrantsPerShare_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClassOfWarrantsRedemptionNoticePeriod" xlink:label="loc_CLDIClassOfWarrantsRedemptionNoticePeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIClassOfWarrantsRedemptionNoticePeriod_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Deemeddividend" xlink:label="loc_CLDIDeemeddividend_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIDeemeddividend_320" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999057 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" xlink:title="999058 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_VotingCommonStockMember" xlink:label="loc_CLDIVotingCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIVotingCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesECommonWarrantsMember" xlink:label="loc_CLDISeriesECommonWarrantsMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesECommonWarrantsMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesFCommonWarrantsMember" xlink:label="loc_CLDISeriesFCommonWarrantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesFCommonWarrantsMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGCommonWarrantsMember" xlink:label="loc_CLDISeriesGCommonWarrantsMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesGCommonWarrantsMember_480" xlink:type="arc" order="482" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHCommonStockWarrantsMember" xlink:label="loc_CLDISeriesHCommonStockWarrantsMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesHCommonStockWarrantsMember_520" xlink:type="arc" order="522" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" xlink:label="loc_CLDISeriesBWarrantsAndSeriesCWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesBWarrantsAndSeriesCWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBOneWarrantsMember" xlink:label="loc_CLDISeriesBOneWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesBOneWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsMember" xlink:label="loc_CLDISeriesCOneWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesCOneWarrantsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDCommonStockMember" xlink:label="loc_CLDISeriesDCommonStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesDCommonStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsMember" xlink:label="loc_CLDIPlacementAgentWarrantsMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDIPlacementAgentWarrantsMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantsMember" xlink:label="loc_CLDIPreFundedWarrantsMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDIPreFundedWarrantsMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepresentativeWarrantsMember" xlink:label="loc_CLDIRepresentativeWarrantsMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDIRepresentativeWarrantsMember_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_InducementOfferLetterAgreementMember" xlink:label="loc_CLDIInducementOfferLetterAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIInducementOfferLetterAgreementMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SubscriptionAgreementMember" xlink:label="loc_CLDISubscriptionAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISubscriptionAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SalesAgreementMember" xlink:label="loc_CLDISalesAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISalesAgreementMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MarketOfferingAgreementMember" xlink:label="loc_CLDIMarketOfferingAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIMarketOfferingAgreementMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SecuritiesPurchaseAgreementMember" xlink:label="loc_CLDISecuritiesPurchaseAgreementMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISecuritiesPurchaseAgreementMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgencyAgreementMember" xlink:label="loc_CLDIPlacementAgencyAgreementMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIPlacementAgencyAgreementMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_JulyWarrantInducementOfferMember" xlink:label="loc_CLDIJulyWarrantInducementOfferMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIJulyWarrantInducementOfferMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritingAgreementMember" xlink:label="loc_CLDIUnderwritingAgreementMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIUnderwritingAgreementMember_530" xlink:type="arc" order="532" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_BoardOfDirectorsMember" xlink:label="loc_CLDIBoardOfDirectorsMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIBoardOfDirectorsMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLDINovaCellMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_CLDINovaCellMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_540" xlink:type="arc" order="542" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantUnitsMember" xlink:label="loc_CLDIPreFundedWarrantUnitsMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDIPreFundedWarrantUnitsMember_550" xlink:type="arc" order="552" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_580" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_580" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_580" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_580" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_580" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_580" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_580" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockDividend" xlink:label="loc_CLDICommonStockDividend_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDICommonStockDividend_580" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_580" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_580" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_580" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PercentageOfStrategicInvestment" xlink:label="loc_CLDIPercentageOfStrategicInvestment_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIPercentageOfStrategicInvestment_580" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_580" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_580" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_580" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:label="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset_580" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness_580" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNotesPayable_580" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_580" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CashCommissionPercentage" xlink:label="loc_CLDICashCommissionPercentage_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDICashCommissionPercentage_580" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DisbursementsCounsel" xlink:label="loc_CLDIDisbursementsCounsel_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIDisbursementsCounsel_580" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLegalFees_580" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_580" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_580" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_580" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_580" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_580" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_580" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:label="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares_580" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:label="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingValue_580" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockUnitPerShareDescription" xlink:label="loc_CLDICommonStockUnitPerShareDescription_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDICommonStockUnitPerShareDescription_580" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" xlink:title="999059 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" xlink:title="999060 - Disclosure - Summary of Restricted Stock Unit Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999061 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_CLDIStatementOfIncomeLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_CLDIStatementOfIncomeLocationBalanceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_CLDIStatementOfIncomeLocationBalanceDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceAxis" xlink:to="loc_CLDIStatementOfIncomeLocationBalanceDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_CLDIStatementOfIncomeLocationBalanceDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceAxis" xlink:to="loc_CLDIStatementOfIncomeLocationBalanceDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ResearchAndDevelopmentExpensesMember" xlink:label="loc_CLDIResearchAndDevelopmentExpensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CLDIResearchAndDevelopmentExpensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GeneralAndAdministrativeExpensesMember" xlink:label="loc_CLDIGeneralAndAdministrativeExpensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CLDIGeneralAndAdministrativeExpensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="999062 - Disclosure - Schedule of Stock Options Valuation Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999063 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EmployeeStockPurchasePlanMember" xlink:label="loc_CLDIEmployeeStockPurchasePlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDIEmployeeStockPurchasePlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdministratorMember" xlink:label="loc_CLDIAdministratorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIAdministratorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockDiscounRate" xlink:label="loc_CLDICommonStockDiscounRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CLDICommonStockDiscounRate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NoncashCompensation" xlink:label="loc_CLDINoncashCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CLDINoncashCompensation_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_130" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:title="999064 - Disclosure - Schedule of Income (Loss) Before Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AmericasMember" xlink:label="loc_srtAmericasMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAmericasMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" xlink:title="999065 - Disclosure - Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="999066 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" xlink:title="999067 - Disclosure - Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:label="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU" xlink:label="loc_countryAU_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE" xlink:label="loc_countryDE_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryDE_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="loc_us-gaapIncomeTaxPaidFederalAfterRefundReceived_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPaidFederalAfterRefundReceived_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxPaidStateAfterRefundReceived" xlink:label="loc_CLDIIncomeTaxPaidStateAfterRefundReceived_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIncomeTaxPaidStateAfterRefundReceived_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="loc_us-gaapIncomeTaxPaidForeignAfterRefundReceived_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPaidForeignAfterRefundReceived_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaidNet_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999068 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" xlink:title="999069 - Disclosure - Schedule of Unrecognized Tax Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PriorDecemberTwentySeventeenthMember" xlink:label="loc_CLDIPriorDecemberTwentySeventeenthMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_CLDIPriorDecemberTwentySeventeenthMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AfterDecemberTwentySeventeenthMember" xlink:label="loc_CLDIAfterDecemberTwentySeventeenthMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_CLDIAfterDecemberTwentySeventeenthMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxesPaidNet_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="999071 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="999072 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:title="999073 - Disclosure - Schedule of Future Minimum Lease Commitments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999074 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SanDiegoLeaseAgreementMember" xlink:label="loc_CLDISanDiegoLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISanDiegoLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrCamaisaMember" xlink:label="loc_CLDIMrCamaisaMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIMrCamaisaMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StemVacOfficeLeaseAgreementMember" xlink:label="loc_CLDIStemVacOfficeLeaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIStemVacOfficeLeaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NorthwesternAgreementMember" xlink:label="loc_CLDINorthwesternAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDINorthwesternAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LicenseAgreementMember" xlink:label="loc_CLDILicenseAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDILicenseAgreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationAndReleaseAgreementMember" xlink:label="loc_CLDISeparationAndReleaseAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISeparationAndReleaseAgreementMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StandbyEquityPurchaseAgreementMember" xlink:label="loc_CLDIStandbyEquityPurchaseAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIStandbyEquityPurchaseAgreementMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GeorgeNgMember" xlink:label="loc_CLDIGeorgeNgMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIGeorgeNgMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrLeftwichMember" xlink:label="loc_CLDIMrLeftwichMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIMrLeftwichMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Dr.CamisaMember" xlink:label="loc_CLDIDr.CamisaMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDr.CamisaMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Dr.MinevMember" xlink:label="loc_CLDIDr.MinevMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDr.MinevMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Ms.CampbellMember" xlink:label="loc_CLDIMs.CampbellMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIMs.CampbellMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrCamaisaMember" xlink:label="loc_CLDIMrCamaisaMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIMrCamaisaMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrLeftwichMember" xlink:label="loc_CLDIMrLeftwichMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIMrLeftwichMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SettlementOfDeferredCompensationMember" xlink:label="loc_CLDISettlementOfDeferredCompensationMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLDISettlementOfDeferredCompensationMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_YorkvilleMember" xlink:label="loc_CLDIYorkvilleMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLDIYorkvilleMember_250" xlink:type="arc" order="253" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAreaOfLand_350" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyOfLeaseAmount" xlink:label="loc_CLDIGuarantyOfLeaseAmount_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIGuarantyOfLeaseAmount_350" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_350" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" xlink:label="loc_CLDIOperatingLeaseTermOfContractLeaseInitialTerm_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIOperatingLeaseTermOfContractLeaseInitialTerm_350" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRent_350" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" xlink:label="loc_CLDILeaseTermsOperatingLeasesAnnualIncreaseInRent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDILeaseTermsOperatingLeasesAnnualIncreaseInRent_350" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_350" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount_350" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_350" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_350" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RemainingExpectedCommitments" xlink:label="loc_CLDIRemainingExpectedCommitments_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIRemainingExpectedCommitments_350" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment_350" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription_350" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_350" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherLiabilities_350" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommitmentFeePercentage" xlink:label="loc_CLDICommitmentFeePercentage_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDICommitmentFeePercentage_350" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaapLongtermPurchaseCommitmentPeriod_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLongtermPurchaseCommitmentPeriod_350" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCompensationEquity_350" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_350" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_350" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrentAndNoncurrent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrentAndNoncurrent_350" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_350" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_350" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EquityPurchaseDescription" xlink:label="loc_CLDIEquityPurchaseDescription_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIEquityPurchaseDescription_350" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForFees_350" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesIssued_350" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount_350" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationPay" xlink:label="loc_CLDISeparationPay_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDISeparationPay_350" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_350" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncurredCosts" xlink:label="loc_CLDIIncurredCosts_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIIncurredCosts_350" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent_350" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSeveranceCosts1_350" xlink:type="arc" order="31" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://calidibio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999075 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockUnitsMember" xlink:label="loc_CLDICommonStockUnitsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDICommonStockUnitsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantUnitsMember" xlink:label="loc_CLDIPreFundedWarrantUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDIPreFundedWarrantUnitsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritersWarrantMember" xlink:label="loc_CLDIUnderwritersWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDIUnderwritersWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritingAgreementMember" xlink:label="loc_CLDIUnderwritingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIUnderwritingAgreementMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockPurchaseWarrantsAgreementMember" xlink:label="loc_CLDICommonStockPurchaseWarrantsAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDICommonStockPurchaseWarrantsAgreementMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesJWarrantsMember" xlink:label="loc_CLDISeriesJWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesJWarrantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesKWarrantsMember" xlink:label="loc_CLDISeriesKWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesKWarrantsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesLWarrantsMember" xlink:label="loc_CLDISeriesLWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesLWarrantsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGCommonStockWarrantsMember" xlink:label="loc_CLDISeriesGCommonStockWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesGCommonStockWarrantsMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHCommonStockWarrantsMember" xlink:label="loc_CLDISeriesHCommonStockWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesHCommonStockWarrantsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesICommonStockWarrantsMember" xlink:label="loc_CLDISeriesICommonStockWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesICommonStockWarrantsMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_100" xlink:type="arc" order="104" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_180" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SettlementOfDeferredCompensationMember" xlink:label="loc_CLDISettlementOfDeferredCompensationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLDISettlementOfDeferredCompensationMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>cldi-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="CLDI_NovaCellMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NovaCellMember" xlink:to="CLDI_NovaCellMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_NovaCellMember_lbl" xml:lang="en-US">Nova Cell [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GovernmentGrantsMember" xlink:label="CLDI_GovernmentGrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GovernmentGrantsMember" xlink:to="CLDI_GovernmentGrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GovernmentGrantsMember_lbl" xml:lang="en-US">Government Grants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="CLDI_CaliforniaInstituteForRegenerativeMedicineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="CLDI_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CaliforniaInstituteForRegenerativeMedicineMember_lbl" xml:lang="en-US">California Institute For Regenerative Medicine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EarnoutSharesMember" xlink:label="CLDI_EarnoutSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EarnoutSharesMember" xlink:to="CLDI_EarnoutSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EarnoutSharesMember_lbl" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ContingentlyIssuableWarrantMember" xlink:label="CLDI_ContingentlyIssuableWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ContingentlyIssuableWarrantMember" xlink:to="CLDI_ContingentlyIssuableWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ContingentlyIssuableWarrantMember_lbl" xml:lang="en-US">Contingently Issuable Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsMember" xlink:label="CLDI_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PublicWarrantsMember" xlink:to="CLDI_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsMember" xlink:label="CLDI_PrivateWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PrivateWarrantsMember" xlink:to="CLDI_PrivateWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PrivateWarrantsMember_lbl" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:label="CLDI_ForwardPurchaseAgreementDerivativeAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:to="CLDI_ForwardPurchaseAgreementDerivativeAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ForwardPurchaseAgreementDerivativeAssetMember_lbl" xml:lang="en-US">Forward Purchase Agreement Derivative Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAAndDirectorEMember" xlink:label="CLDI_DirectorAAndDirectorEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAAndDirectorEMember" xlink:to="CLDI_DirectorAAndDirectorEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorAAndDirectorEMember_lbl" xml:lang="en-US">Director A and Director E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFAndRelativeOfOfficerAMember" xlink:label="CLDI_DirectorFAndRelativeOfOfficerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFAndRelativeOfOfficerAMember" xlink:to="CLDI_DirectorFAndRelativeOfOfficerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorFAndRelativeOfOfficerAMember_lbl" xml:lang="en-US">Director F and Relative of Officer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFMember" xlink:label="CLDI_DirectorFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFMember" xlink:to="CLDI_DirectorFMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorFMember_lbl" xml:lang="en-US">Director F [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorDMember" xlink:label="CLDI_DirectorDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorDMember" xlink:to="CLDI_DirectorDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorDMember_lbl" xml:lang="en-US">Director D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAOneMember" xlink:label="CLDI_DirectorAOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAOneMember" xlink:to="CLDI_DirectorAOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorAOneMember_lbl" xml:lang="en-US">Director A One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFOneMember" xlink:label="CLDI_DirectorFOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFOneMember" xlink:to="CLDI_DirectorFOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorFOneMember_lbl" xml:lang="en-US">Director F One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorATwoMember" xlink:label="CLDI_DirectorATwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorATwoMember" xlink:to="CLDI_DirectorATwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorATwoMember_lbl" xml:lang="en-US">Director A Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFAndDirectorAMember" xlink:label="CLDI_DirectorFAndDirectorAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFAndDirectorAMember" xlink:to="CLDI_DirectorFAndDirectorAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorFAndDirectorAMember_lbl" xml:lang="en-US">Director F and Director A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelativeOfOfficerAMember" xlink:label="CLDI_RelativeOfOfficerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RelativeOfOfficerAMember" xlink:to="CLDI_RelativeOfOfficerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RelativeOfOfficerAMember_lbl" xml:lang="en-US">Relative of OfficerA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerGMember" xlink:label="CLDI_OfficerGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OfficerGMember" xlink:to="CLDI_OfficerGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_OfficerGMember_lbl" xml:lang="en-US">Officer G [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerAMember" xlink:label="CLDI_OfficerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OfficerAMember" xlink:to="CLDI_OfficerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_OfficerAMember_lbl" xml:lang="en-US">Officer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CompanyARelatedToDirectorGMember" xlink:label="CLDI_CompanyARelatedToDirectorGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CompanyARelatedToDirectorGMember" xlink:to="CLDI_CompanyARelatedToDirectorGMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CompanyARelatedToDirectorGMember_lbl" xml:lang="en-US">Company A related to Director G [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorsAAndEMember" xlink:label="CLDI_DirectorsAAndEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorsAAndEMember" xlink:to="CLDI_DirectorsAAndEMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorsAAndEMember_lbl" xml:lang="en-US">Directors A and E [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAMember" xlink:label="CLDI_DirectorAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAMember" xlink:to="CLDI_DirectorAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorAMember_lbl" xml:lang="en-US">Director A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AJCCapitalMember" xlink:label="CLDI_AJCCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AJCCapitalMember" xlink:to="CLDI_AJCCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AJCCapitalMember_lbl" xml:lang="en-US">AJC Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyMember" xlink:label="CLDI_GuarantyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GuarantyMember" xlink:to="CLDI_GuarantyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GuarantyMember_lbl" xml:lang="en-US">Guaranty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAThreeMember" xlink:label="CLDI_DirectorAThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAThreeMember" xlink:to="CLDI_DirectorAThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DirectorAThreeMember_lbl" xml:lang="en-US">Director A Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableMember_lbl" xml:lang="en-US">Loans Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNoteMember" xlink:label="CLDI_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PromissoryNoteMember" xlink:to="CLDI_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableMember" xlink:label="CLDI_TermNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TermNotesPayableMember" xlink:to="CLDI_TermNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TermNotesPayableMember_lbl" xml:lang="en-US">Term Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_BridgeLoanPayableMember" xlink:label="CLDI_BridgeLoanPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_BridgeLoanPayableMember" xlink:to="CLDI_BridgeLoanPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_BridgeLoanPayableMember_lbl" xml:lang="en-US">Bridge Loan Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyOneTermNoteMember" xlink:label="CLDI_TwoThousandTwentyOneTermNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyOneTermNoteMember" xlink:to="CLDI_TwoThousandTwentyOneTermNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyOneTermNoteMember_lbl" xml:lang="en-US">2021 Term Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_InvestorAndDirectorMember" xlink:label="CLDI_InvestorAndDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_InvestorAndDirectorMember" xlink:to="CLDI_InvestorAndDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_InvestorAndDirectorMember_lbl" xml:lang="en-US">Investor and Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyTwoTermNotePayableMember" xlink:label="CLDI_TwoThousandTwentyTwoTermNotePayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyTwoTermNotePayableMember" xlink:to="CLDI_TwoThousandTwentyTwoTermNotePayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyTwoTermNotePayableMember_lbl" xml:lang="en-US">2022 Term Note Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeTermNotePayableMember" xlink:label="CLDI_TwoThousandTwentyThreeTermNotePayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeTermNotePayableMember" xlink:to="CLDI_TwoThousandTwentyThreeTermNotePayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyThreeTermNotePayableMember_lbl" xml:lang="en-US">2023 Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" xlink:label="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" xlink:to="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember_lbl" xml:lang="en-US">2023 Note Payable Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyFourBridgeLoanMember" xlink:label="CLDI_TwoThousandTwentyFourBridgeLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyFourBridgeLoanMember" xlink:to="CLDI_TwoThousandTwentyFourBridgeLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyFourBridgeLoanMember_lbl" xml:lang="en-US">2024 Bridge Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyFourPurchaseAgreementMember" xlink:label="CLDI_TwoThousandTwentyFourPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyFourPurchaseAgreementMember" xlink:to="CLDI_TwoThousandTwentyFourPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyFourPurchaseAgreementMember_lbl" xml:lang="en-US">2024 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNoteLoanAgreementMember" xlink:label="CLDI_PromissoryNoteLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PromissoryNoteLoanAgreementMember" xlink:to="CLDI_PromissoryNoteLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PromissoryNoteLoanAgreementMember_lbl" xml:lang="en-US">Promissory Note Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_VotingCommonStockMember" xlink:label="CLDI_VotingCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_VotingCommonStockMember" xlink:to="CLDI_VotingCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_VotingCommonStockMember_lbl" xml:lang="en-US">Voting Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xml:lang="en-US">Nonvoting Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" xlink:label="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" xlink:to="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember_lbl" xml:lang="en-US">Series B Warrants And Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_InducementOfferLetterAgreementMember" xlink:label="CLDI_InducementOfferLetterAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_InducementOfferLetterAgreementMember" xlink:to="CLDI_InducementOfferLetterAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_InducementOfferLetterAgreementMember_lbl" xml:lang="en-US">Inducement Offer Letter Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBOneWarrantsMember" xlink:label="CLDI_SeriesBOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBOneWarrantsMember" xlink:to="CLDI_SeriesBOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesBOneWarrantsMember_lbl" xml:lang="en-US">Series B-1 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsMember" xlink:label="CLDI_SeriesCOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesCOneWarrantsMember" xlink:to="CLDI_SeriesCOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesCOneWarrantsMember_lbl" xml:lang="en-US">Series C-1 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDCommonStockMember" xlink:label="CLDI_SeriesDCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesDCommonStockMember" xlink:to="CLDI_SeriesDCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesDCommonStockMember_lbl" xml:lang="en-US">Series D Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SubscriptionAgreementMember" xlink:label="CLDI_SubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SubscriptionAgreementMember" xlink:to="CLDI_SubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SubscriptionAgreementMember_lbl" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_BoardOfDirectorsMember" xlink:label="CLDI_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_BoardOfDirectorsMember" xlink:to="CLDI_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SalesAgreementMember" xlink:label="CLDI_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SalesAgreementMember" xlink:to="CLDI_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MarketOfferingAgreementMember" xlink:label="CLDI_MarketOfferingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MarketOfferingAgreementMember" xlink:to="CLDI_MarketOfferingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_MarketOfferingAgreementMember_lbl" xml:lang="en-US">Market Offering Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SecuritiesPurchaseAgreementMember" xlink:label="CLDI_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SecuritiesPurchaseAgreementMember" xlink:to="CLDI_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesECommonWarrantsMember" xlink:label="CLDI_SeriesECommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesECommonWarrantsMember" xlink:to="CLDI_SeriesECommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesECommonWarrantsMember_lbl" xml:lang="en-US">Series E Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesFCommonWarrantsMember" xlink:label="CLDI_SeriesFCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesFCommonWarrantsMember" xlink:to="CLDI_SeriesFCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesFCommonWarrantsMember_lbl" xml:lang="en-US">Series F Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsMember" xlink:label="CLDI_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsMember" xlink:to="CLDI_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgencyAgreementMember" xlink:label="CLDI_PlacementAgencyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgencyAgreementMember" xlink:to="CLDI_PlacementAgencyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgencyAgreementMember_lbl" xml:lang="en-US">Placement Agency Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantsMember" xlink:label="CLDI_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PreFundedWarrantsMember" xlink:to="CLDI_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGCommonWarrantsMember" xlink:label="CLDI_SeriesGCommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGCommonWarrantsMember" xlink:to="CLDI_SeriesGCommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesGCommonWarrantsMember_lbl" xml:lang="en-US">Series G Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_JulyWarrantInducementOfferMember" xlink:label="CLDI_JulyWarrantInducementOfferMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_JulyWarrantInducementOfferMember" xlink:to="CLDI_JulyWarrantInducementOfferMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_JulyWarrantInducementOfferMember_lbl" xml:lang="en-US">July Warrant Inducement Offer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHCommonStockWarrantsMember" xlink:label="CLDI_SeriesHCommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesHCommonStockWarrantsMember" xlink:to="CLDI_SeriesHCommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesHCommonStockWarrantsMember_lbl" xml:lang="en-US">Series H Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritingAgreementMember" xlink:label="CLDI_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_UnderwritingAgreementMember" xlink:to="CLDI_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantUnitsMember" xlink:label="CLDI_PreFundedWarrantUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PreFundedWarrantUnitsMember" xlink:to="CLDI_PreFundedWarrantUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PreFundedWarrantUnitsMember_lbl" xml:lang="en-US">PreFunded Warrant Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepresentativeWarrantsMember" xlink:label="CLDI_RepresentativeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepresentativeWarrantsMember" xlink:to="CLDI_RepresentativeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Representative Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="CLDI_CommonStockOptionsIssuedAndOutstandingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockOptionsIssuedAndOutstandingMember" xlink:to="CLDI_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommonStockOptionsIssuedAndOutstandingMember_lbl" xml:lang="en-US">Common Stock Options Issued and Outstanding [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" xlink:label="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" xlink:to="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember_lbl" xml:lang="en-US">Restricted Stock Units Vested and Unreleased [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember_lbl" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2023 Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_PrivateWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PrivateWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_PrivateWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PrivateWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Private Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_PublicWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PublicWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_PublicWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PublicWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Public Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantsToPurchaseRestrictedSharesMember" xlink:label="CLDI_WarrantsToPurchaseRestrictedSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_WarrantsToPurchaseRestrictedSharesMember" xlink:to="CLDI_WarrantsToPurchaseRestrictedSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_WarrantsToPurchaseRestrictedSharesMember_lbl" xml:lang="en-US">Warrants to Purchase Restricted Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantsToPurchaseRestrictedSharesOneMember" xlink:label="CLDI_WarrantsToPurchaseRestrictedSharesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_WarrantsToPurchaseRestrictedSharesOneMember" xlink:to="CLDI_WarrantsToPurchaseRestrictedSharesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_WarrantsToPurchaseRestrictedSharesOneMember_lbl" xml:lang="en-US">Warrants to Purchase Restricted Shares One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember_lbl" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember_lbl" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember_lbl" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember_lbl" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember_lbl" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Representative Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesAWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesAWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesAWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesAWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesAWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series A Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesBWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesBWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesBWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series B Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember_lbl" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember_lbl" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember_lbl" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember_lbl" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series C-1 Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" xlink:to="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember_lbl" xml:lang="en-US">Series C-1 Warrants to Purchase Common Stock One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" xlink:to="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember_lbl" xml:lang="en-US">Series C-1 Warrants to Purchase Common Stock Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesDWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesDWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesDWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesDWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series D Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesEWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesEWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesEWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesEWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesEWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series E Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesFWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesFWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesFWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesFWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesFWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series F Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesGWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesGWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesGWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series G Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesHWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesHWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesHWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesHWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series H Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesIWarrantsToPurchaseCommonStockMember" xlink:label="CLDI_SeriesIWarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesIWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesIWarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesIWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Series I Warrants to Purchase Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RedemptionOfWarrantsMember" xlink:label="CLDI_RedemptionOfWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RedemptionOfWarrantsMember" xlink:to="CLDI_RedemptionOfWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RedemptionOfWarrantsMember_lbl" xml:lang="en-US">Redemption of Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TriggeringEventAxis" xlink:label="CLDI_TriggeringEventAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TriggeringEventAxis" xlink:to="CLDI_TriggeringEventAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TriggeringEventAxis_lbl" xml:lang="en-US">Triggering Event Axis</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" xlink:label="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" xlink:to="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_lbl" xml:lang="en-US">Share Price Equal Or Less Ten Point Zero Rupees Per Dollar [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:label="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:to="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_lbl" xml:lang="en-US">Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesAWarrantsMember" xlink:label="CLDI_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesAWarrantsMember" xlink:to="CLDI_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsMember" xlink:label="CLDI_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBWarrantsMember" xlink:to="CLDI_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsOneMember" xlink:label="CLDI_SeriesCOneWarrantsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesCOneWarrantsOneMember" xlink:to="CLDI_SeriesCOneWarrantsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_SeriesCOneWarrantsOneMember_lbl" xml:lang="en-US">Series C-1 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDWarrantsMember" xlink:label="CLDI_SeriesDWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesDWarrantsMember" xlink:to="CLDI_SeriesDWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesDWarrantsMember_lbl" xml:lang="en-US">Series D Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" xlink:label="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" xlink:to="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember_lbl" xml:lang="en-US">Series E Warrants and Series F Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGPreFundedWarrantsMember" xlink:label="CLDI_SeriesGPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGPreFundedWarrantsMember" xlink:to="CLDI_SeriesGPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesGPreFundedWarrantsMember_lbl" xml:lang="en-US">Series G Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesIPreFundedWarrantsMember" xlink:label="CLDI_SeriesIPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesIPreFundedWarrantsMember" xlink:to="CLDI_SeriesIPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesIPreFundedWarrantsMember_lbl" xml:lang="en-US">Series I Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="CLDI_TwoThousandTwentyThreePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreePlanMember" xlink:to="CLDI_TwoThousandTwentyThreePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TwoThousandTwentyThreePlanMember_lbl" xml:lang="en-US">2023 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdministratorMember" xlink:label="CLDI_AdministratorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AdministratorMember" xlink:to="CLDI_AdministratorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AdministratorMember_lbl" xml:lang="en-US">Administrator [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EmployeeStockPurchasePlanMember" xlink:label="CLDI_EmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EmployeeStockPurchasePlanMember" xlink:to="CLDI_EmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StatementOfIncomeLocationBalanceAxis" xlink:label="CLDI_StatementOfIncomeLocationBalanceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StatementOfIncomeLocationBalanceAxis" xlink:to="CLDI_StatementOfIncomeLocationBalanceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StatementOfIncomeLocationBalanceAxis_lbl" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ResearchAndDevelopmentExpensesMember" xlink:label="CLDI_ResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ResearchAndDevelopmentExpensesMember" xlink:to="CLDI_ResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GeneralAndAdministrativeExpensesMember" xlink:label="CLDI_GeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GeneralAndAdministrativeExpensesMember" xlink:to="CLDI_GeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AmericasMember" xlink:label="srt_AmericasMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AmericasMember" xlink:to="srt_AmericasMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AmericasMember_lbl" xml:lang="en-US">Americas [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonUsMember_lbl" xml:lang="en-US">Non-US [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PriorDecemberTwentySeventeenthMember" xlink:label="CLDI_PriorDecemberTwentySeventeenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PriorDecemberTwentySeventeenthMember" xlink:to="CLDI_PriorDecemberTwentySeventeenthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PriorDecemberTwentySeventeenthMember_lbl" xml:lang="en-US">Prior December 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AfterDecemberTwentySeventeenthMember" xlink:label="CLDI_AfterDecemberTwentySeventeenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AfterDecemberTwentySeventeenthMember" xlink:to="CLDI_AfterDecemberTwentySeventeenthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AfterDecemberTwentySeventeenthMember_lbl" xml:lang="en-US">After December 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU" xlink:label="country_AU" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">AUSTRALIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE" xlink:label="country_DE" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US">GERMANY</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SanDiegoLeaseAgreementMember" xlink:label="CLDI_SanDiegoLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SanDiegoLeaseAgreementMember" xlink:to="CLDI_SanDiegoLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SanDiegoLeaseAgreementMember_lbl" xml:lang="en-US">San Diego Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrCamaisaMember" xlink:label="CLDI_MrCamaisaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MrCamaisaMember" xlink:to="CLDI_MrCamaisaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_MrCamaisaMember_lbl" xml:lang="en-US">Mr Camaisa [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StemVacOfficeLeaseAgreementMember" xlink:label="CLDI_StemVacOfficeLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StemVacOfficeLeaseAgreementMember" xlink:to="CLDI_StemVacOfficeLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StemVacOfficeLeaseAgreementMember_lbl" xml:lang="en-US">Stem Vac Office Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NorthwesternAgreementMember" xlink:label="CLDI_NorthwesternAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NorthwesternAgreementMember" xlink:to="CLDI_NorthwesternAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_NorthwesternAgreementMember_lbl" xml:lang="en-US">Northwestern Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LicenseAgreementMember" xlink:label="CLDI_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_LicenseAgreementMember" xlink:to="CLDI_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationAndReleaseAgreementMember" xlink:label="CLDI_SeparationAndReleaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeparationAndReleaseAgreementMember" xlink:to="CLDI_SeparationAndReleaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeparationAndReleaseAgreementMember_lbl" xml:lang="en-US">Separation and Release Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GeorgeNgMember" xlink:label="CLDI_GeorgeNgMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GeorgeNgMember" xlink:to="CLDI_GeorgeNgMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GeorgeNgMember_lbl" xml:lang="en-US">George Ng [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrLeftwichMember" xlink:label="CLDI_MrLeftwichMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MrLeftwichMember" xlink:to="CLDI_MrLeftwichMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_MrLeftwichMember_lbl" xml:lang="en-US">Mr Leftwich [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SettlementOfDeferredCompensationMember" xlink:label="CLDI_SettlementOfDeferredCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SettlementOfDeferredCompensationMember" xlink:to="CLDI_SettlementOfDeferredCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SettlementOfDeferredCompensationMember_lbl" xml:lang="en-US">Settlement of Deferred Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StandbyEquityPurchaseAgreementMember" xlink:label="CLDI_StandbyEquityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StandbyEquityPurchaseAgreementMember" xlink:to="CLDI_StandbyEquityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_YorkvilleMember" xlink:label="CLDI_YorkvilleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_YorkvilleMember" xlink:to="CLDI_YorkvilleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_YorkvilleMember_lbl" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Dr.CamisaMember" xlink:label="CLDI_Dr.CamisaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Dr.CamisaMember" xlink:to="CLDI_Dr.CamisaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_Dr.CamisaMember_lbl" xml:lang="en-US">Dr. Camisa [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Dr.MinevMember" xlink:label="CLDI_Dr.MinevMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Dr.MinevMember" xlink:to="CLDI_Dr.MinevMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_Dr.MinevMember_lbl" xml:lang="en-US">Dr.Minev [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Ms.CampbellMember" xlink:label="CLDI_Ms.CampbellMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Ms.CampbellMember" xlink:to="CLDI_Ms.CampbellMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_Ms.CampbellMember_lbl" xml:lang="en-US">Ms.Campbell [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockUnitsMember" xlink:label="CLDI_CommonStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockUnitsMember" xlink:to="CLDI_CommonStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommonStockUnitsMember_lbl" xml:lang="en-US">Common Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritersWarrantMember" xlink:label="CLDI_UnderwritersWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_UnderwritersWarrantMember" xlink:to="CLDI_UnderwritersWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_UnderwritersWarrantMember_lbl" xml:lang="en-US">Underwriters Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesJWarrantsMember" xlink:label="CLDI_SeriesJWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesJWarrantsMember" xlink:to="CLDI_SeriesJWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesJWarrantsMember_lbl" xml:lang="en-US">Series J Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesKWarrantsMember" xlink:label="CLDI_SeriesKWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesKWarrantsMember" xlink:to="CLDI_SeriesKWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesKWarrantsMember_lbl" xml:lang="en-US">Series K Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesLWarrantsMember" xlink:label="CLDI_SeriesLWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesLWarrantsMember" xlink:to="CLDI_SeriesLWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesLWarrantsMember_lbl" xml:lang="en-US">Series L Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGCommonStockWarrantsMember" xlink:label="CLDI_SeriesGCommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGCommonStockWarrantsMember" xlink:to="CLDI_SeriesGCommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesGCommonStockWarrantsMember_lbl" xml:lang="en-US">Series G Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockPurchaseWarrantsAgreementMember" xlink:label="CLDI_CommonStockPurchaseWarrantsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockPurchaseWarrantsAgreementMember" xlink:to="CLDI_CommonStockPurchaseWarrantsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommonStockPurchaseWarrantsAgreementMember_lbl" xml:lang="en-US">Common Stock Purchase Warrants Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesICommonStockWarrantsMember" xlink:label="CLDI_SeriesICommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesICommonStockWarrantsMember" xlink:to="CLDI_SeriesICommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesICommonStockWarrantsMember_lbl" xml:lang="en-US">Series I Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NONCURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Machinery and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other noncurrent assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableCurrent" xlink:label="CLDI_TermNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TermNotesPayableCurrent" xlink:to="CLDI_TermNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_TermNotesPayableCurrent_lbl" xml:lang="en-US">Term notes payable, net of discount, including accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Related party bridge loan payable, including accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Related party other current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease right-of-use liability, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NONCURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease right-of-use liability, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liability, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNote" xlink:label="CLDI_PromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PromissoryNote" xlink:to="CLDI_PromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PromissoryNote_lbl" xml:lang="en-US">Promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantLiability" xlink:label="CLDI_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_WarrantLiability" xlink:to="CLDI_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelatedPartyWarrantLiability" xlink:label="CLDI_RelatedPartyWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RelatedPartyWarrantLiability" xlink:to="CLDI_RelatedPartyWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RelatedPartyWarrantLiability_lbl" xml:lang="en-US">Related party warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 330,000 shares authorized; 7,217 and 1,730 shares issued and outstanding as of December 31, 2025 and 2024, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSES), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_lbl" xml:lang="en-US">Change in fair value of other liabilities and derivatives</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_lbl" xml:lang="en-US">Change in fair value of other liabilities and derivatives &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantIncome" xlink:label="CLDI_GrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GrantIncome" xlink:to="CLDI_GrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xml:lang="en-US">Gain on sale of investment in Nova Cell</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeemedDividendOnWarrants" xlink:label="CLDI_DeemedDividendOnWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeemedDividendOnWarrants" xlink:to="CLDI_DeemedDividendOnWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DeemedDividendOnWarrants_lbl" xml:lang="en-US">Deemed dividend on warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US">Other comprehensive income, net of tax:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock through At the Market Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock through At the Market Offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_lbl" xml:lang="en-US">Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_lbl" xml:lang="en-US">Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_lbl" xml:lang="en-US">Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_lbl" xml:lang="en-US">Issuance of common stock through August Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:to="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares_lbl" xml:lang="en-US">Issuance of common stock through August Public Offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" xlink:label="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" xlink:to="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" xlink:label="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" xlink:to="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_lbl" xml:lang="en-US">Issuance of common stock through May Inducement Offer, net of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_lbl" xml:lang="en-US">Issuance of common shares through May Inducement Offer, net of financing costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="CLDI_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="CLDI_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Issuance of common stock for Reverse Stock Split fractional shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Issuance of common stock for Reverse Stock Split fractional shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock unit shares released</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock unit shares released, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" xlink:label="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" xlink:to="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment_lbl" xml:lang="en-US">Sale of investment in Nova Cell</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" xlink:label="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" xlink:to="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash for SEPA commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" xlink:label="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" xlink:to="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash for commitment fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Issuance of common stock to Calidi stockholders as result of Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Issuance of common stock to Calidi stockholders as result of Merger, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" xlink:label="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" xlink:to="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees_lbl" xml:lang="en-US">Financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_lbl" xml:lang="en-US">Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock per Convertible Note conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock per Convertible Note conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:label="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:to="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:to="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Exercise of common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:label="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:to="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_lbl" xml:lang="en-US">Issuance of restricted stock units for liability settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_lbl" xml:lang="en-US">Issuance of common stock and warrants for legal settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_lbl" xml:lang="en-US">Issuance of common stock and warrants for legal settlement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_lbl" xml:lang="en-US">Issuance of common stock for Reverse Stock Split fractional shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_lbl" xml:lang="en-US">Issuance of common stock for Reverse Stock Split fractional shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_lbl" xml:lang="en-US">Issuance of common stock and warrants per subscription agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_lbl" xml:lang="en-US">Issuance of common shares and warrants per subscription agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_lbl" xml:lang="en-US">Issuance of common stock and warrants for registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_lbl" xml:lang="en-US">Issuance of common stock and warrants for registered direct offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_lbl" xml:lang="en-US">Issuance of common stock through At the Market Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_lbl" xml:lang="en-US">Issuance of common stock through At the Market Offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_lbl" xml:lang="en-US">Issuance of common stock through November Public Offering, net of financing</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_lbl" xml:lang="en-US">Issuance of common stock through November Public Offering, net of financing, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueInvestment" xlink:label="CLDI_StockIssuedDuringPeriodValueInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueInvestment" xlink:to="CLDI_StockIssuedDuringPeriodValueInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueInvestment_lbl" xml:lang="en-US">Investment in Nova Cell</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock unit shares released</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock unit shares released, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount and financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives_lbl" xml:lang="en-US">Change in fair value of other liabilities and derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainOnSaleOfInvestments_2_lbl" xml:lang="en-US">Gain on sale of investment in Nova Cell</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Purchases of machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Cash disposed in sale of investment in Nova Cell</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromPublicOfferings" xlink:label="CLDI_ProceedsFromPublicOfferings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromPublicOfferings" xlink:to="CLDI_ProceedsFromPublicOfferings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ProceedsFromPublicOfferings_lbl" xml:lang="en-US">Proceeds from public offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromWarrantInducementFinancing" xlink:label="CLDI_ProceedsFromWarrantInducementFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromWarrantInducementFinancing" xlink:to="CLDI_ProceedsFromWarrantInducementFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ProceedsFromWarrantInducementFinancing_lbl" xml:lang="en-US">Proceeds from warrant inducement financing</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromRegisteredDirectOffering" xlink:label="CLDI_ProceedsFromRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromRegisteredDirectOffering" xlink:to="CLDI_ProceedsFromRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ProceedsFromRegisteredDirectOffering_lbl" xml:lang="en-US">Proceeds from registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from at the market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Repayment of financing lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of principal on term notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:label="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:to="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_lbl" xml:lang="en-US">Repayment of principal on related party bridge loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of principal on related party term notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" xlink:label="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" xlink:to="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest_lbl" xml:lang="en-US">Proceeds from issuance of noncontrolling interest in Nova Cell</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Related party proceeds from issuance of loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:label="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:to="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants per subscription agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepaymentOfConvertibleNotePayable" xlink:label="CLDI_RepaymentOfConvertibleNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepaymentOfConvertibleNotePayable" xlink:to="CLDI_RepaymentOfConvertibleNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_RepaymentOfConvertibleNotePayable_lbl" xml:lang="en-US">Repayment of convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PaymentOfDebtIssuanceCosts" xlink:label="CLDI_PaymentOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PaymentOfDebtIssuanceCosts" xlink:to="CLDI_PaymentOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_PaymentOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payment of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract_lbl" xml:lang="en-US">CASH AND RESTRICTED CASH BALANCE:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">At beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">At end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CashPaidForIncomeTaxes" xlink:label="CLDI_CashPaidForIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CashPaidForIncomeTaxes" xlink:to="CLDI_CashPaidForIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CashPaidForIncomeTaxes_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeemedDividendOnWarrants" xlink:to="CLDI_DeemedDividendOnWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_DeemedDividendOnWarrants_2_lbl" xml:lang="en-US">Deemed dividend on warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases" xlink:label="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases" xlink:to="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases_lbl" xml:lang="en-US">Machinery and equipment acquired through financing leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Financing fees included in accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote" xlink:label="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote" xlink:to="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote_lbl" xml:lang="en-US">Issuance of common stock per conversion of convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfConvertibleNoteForLegalSettlement" xlink:label="CLDI_IssuanceOfConvertibleNoteForLegalSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfConvertibleNoteForLegalSettlement" xlink:to="CLDI_IssuanceOfConvertibleNoteForLegalSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfConvertibleNoteForLegalSettlement_lbl" xml:lang="en-US">Issuance of convertible note for legal settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockInLieuOfCashForServices" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockInLieuOfCashForServices" xlink:to="CLDI_IssuanceOfCommonStockInLieuOfCashForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForServices_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash for services</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" xlink:label="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" xlink:to="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices_lbl" xml:lang="en-US">Related party issuance of common stock in lieu of cash for services</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement_lbl" xml:lang="en-US">Issuance of common stock and warrants for legal settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DebtDiscountOnConvertibleNotes" xlink:label="CLDI_DebtDiscountOnConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DebtDiscountOnConvertibleNotes" xlink:to="CLDI_DebtDiscountOnConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DebtDiscountOnConvertibleNotes_lbl" xml:lang="en-US">Debt discount on Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" xlink:to="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_lbl" xml:lang="en-US">Issuance of common stock in lieu of cash for SEPA commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:label="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:to="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement_lbl" xml:lang="en-US">Issuance of restricted stock units for liability settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NoInsiderTradingFlag" xlink:label="CLDI_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NoInsiderTradingFlag" xlink:to="CLDI_NoInsiderTradingFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_NoInsiderTradingFlag_lbl" xml:lang="en-US">No Insider Trading Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Nature of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Selected Balance Sheet Components</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Machinery and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Machinery and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GovernmentGrantsPolicyTextBlock" xlink:label="CLDI_GovernmentGrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GovernmentGrantsPolicyTextBlock" xlink:to="CLDI_GovernmentGrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GovernmentGrantsPolicyTextBlock_lbl" xml:lang="en-US">Government Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation Adjustments and Other Comprehensive Income or Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" xlink:label="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" xlink:to="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transaction Gains and Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:label="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:to="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Operating Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Fair Value of Level 3 Valued Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Machinery and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding Debt Obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Outstanding Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock" xlink:label="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock" xlink:to="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Reserved</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfOutstandingWarrantsTextBlock" xlink:label="CLDI_ScheduleOfOutstandingWarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfOutstandingWarrantsTextBlock" xlink:to="CLDI_ScheduleOfOutstandingWarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ScheduleOfOutstandingWarrantsTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Restricted Stock Unit Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Valuation Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income (Loss) Before Provision for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Expenses (Benefit) by Jurisdiction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfIncomeTaxPaidTableTextBlock" xlink:label="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock" xlink:to="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash Paid for Income Taxes, Net of Refunds Received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" xlink:label="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" xlink:to="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" xlink:label="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" xlink:to="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash included within prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted cash included within other noncurrent assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total cash and restricted cash as shown in the consolidated statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total common stock equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccountingPoliciesTable" xlink:label="CLDI_AccountingPoliciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AccountingPoliciesTable" xlink:to="CLDI_AccountingPoliciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AccountingPoliciesTable_lbl" xml:lang="en-US">AccountingPoliciesTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salaries and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="us-gaap_GeneralInsuranceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Consulting" xlink:label="CLDI_Consulting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Consulting" xlink:to="CLDI_Consulting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_Consulting_lbl" xml:lang="en-US">Consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RentAndMaintenance" xlink:label="CLDI_RentAndMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RentAndMaintenance" xlink:to="CLDI_RentAndMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_RentAndMaintenance_lbl" xml:lang="en-US">Rent and maintenance</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClinicalResearchAndDevelopment" xlink:label="CLDI_ClinicalResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClinicalResearchAndDevelopment" xlink:to="CLDI_ClinicalResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_ClinicalResearchAndDevelopment_lbl" xml:lang="en-US">Clinical &amp; research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:label="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:to="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_lbl" xml:lang="en-US">Change in fair value of other liabilities and derivatives</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OtherSegmentItems" xlink:label="CLDI_OtherSegmentItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OtherSegmentItems" xlink:to="CLDI_OtherSegmentItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_OtherSegmentItems_lbl" xml:lang="en-US">Other segment items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares sold and transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Purchase price for repurchased shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:label="us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:to="us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset_lbl" xml:lang="en-US">Promissory note, net cash offset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Indebtedness cancellation amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Deferred consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherOperatingActivities" xlink:label="us-gaap_ProceedsFromOtherOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherOperatingActivities" xlink:to="us-gaap_ProceedsFromOtherOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherOperatingActivities_lbl" xml:lang="en-US">Proceeds from Other Operating Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantsReceivableWithdrawn" xlink:label="CLDI_GrantsReceivableWithdrawn" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GrantsReceivableWithdrawn" xlink:to="CLDI_GrantsReceivableWithdrawn_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GrantsReceivableWithdrawn_lbl" xml:lang="en-US">Government grants award withdrawn</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total warrant liabilities, at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xml:lang="en-US">Balance, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xml:lang="en-US">Balance, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccruedCompensation" xlink:label="CLDI_AccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AccruedCompensation" xlink:to="CLDI_AccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AccruedCompensation_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccruedVendorAndOtherExpenses" xlink:label="CLDI_AccruedVendorAndOtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AccruedVendorAndOtherExpenses" xlink:to="CLDI_AccruedVendorAndOtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_AccruedVendorAndOtherExpenses_lbl" xml:lang="en-US">Accrued vendor and other expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrepaidExpenses" xlink:label="CLDI_PrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PrepaidExpenses" xlink:to="CLDI_PrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Machinery and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="us-gaap_OtherDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Related party transaction description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_2_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Officer loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ConsultingPay" xlink:label="CLDI_ConsultingPay" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ConsultingPay" xlink:to="CLDI_ConsultingPay_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ConsultingPay_lbl" xml:lang="en-US">Consulting pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Bonus payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl" xml:lang="en-US">Advisory fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Equity proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyOfLeaseAmount" xlink:label="CLDI_GuarantyOfLeaseAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GuarantyOfLeaseAmount" xlink:to="CLDI_GuarantyOfLeaseAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_GuarantyOfLeaseAmount_lbl" xml:lang="en-US">Guaranty of lease amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="us-gaap_LessorOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseDescription" xlink:to="us-gaap_LessorOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseDescription_lbl" xml:lang="en-US">Lease agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Lease payment due</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Deferred compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Officer loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationPay" xlink:label="CLDI_SeparationPay" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeparationPay" xlink:to="CLDI_SeparationPay_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeparationPay_lbl" xml:lang="en-US">Separation pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Expenses related to services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Unpaid Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Net Carrying Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Less: current portion of long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2028 and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Plus: accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_2_lbl" xml:lang="en-US">Total debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="us-gaap_DebtWeightedAverageInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Weighted average interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Debt principal and accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_3_lbl" xml:lang="en-US">Secured term notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Interest rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Installment payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Carrying value, including accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Loans received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Maturity period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_3_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xml:lang="en-US">Carrying value, including accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClassOfWarrantOrRighstIssuanceDate" xlink:label="CLDI_ClassOfWarrantOrRighstIssuanceDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClassOfWarrantOrRighstIssuanceDate" xlink:to="CLDI_ClassOfWarrantOrRighstIssuanceDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ClassOfWarrantOrRighstIssuanceDate_lbl" xml:lang="en-US">Issuance date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TriggeringEventAxis" xlink:to="CLDI_TriggeringEventAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_TriggeringEventAxis_2_lbl" xml:lang="en-US">Triggering Event Axis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantRedemptionDescription" xlink:label="CLDI_PublicWarrantRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PublicWarrantRedemptionDescription" xlink:to="CLDI_PublicWarrantRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PublicWarrantRedemptionDescription_lbl" xml:lang="en-US">Public warrant redemption description</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RedemptionOfOutstandingWarrantsPerShare" xlink:label="CLDI_RedemptionOfOutstandingWarrantsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RedemptionOfOutstandingWarrantsPerShare" xlink:to="CLDI_RedemptionOfOutstandingWarrantsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RedemptionOfOutstandingWarrantsPerShare_lbl" xml:lang="en-US">Redemption of outstanding warrants per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClassOfWarrantsRedemptionNoticePeriod" xlink:label="CLDI_ClassOfWarrantsRedemptionNoticePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClassOfWarrantsRedemptionNoticePeriod" xlink:to="CLDI_ClassOfWarrantsRedemptionNoticePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ClassOfWarrantsRedemptionNoticePeriod_lbl" xml:lang="en-US">Class of warrants, redemption notice period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Received dross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Deemeddividend" xlink:label="CLDI_Deemeddividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Deemeddividend" xlink:to="CLDI_Deemeddividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_Deemeddividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants, Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_lbl" xml:lang="en-US">Number of Warrants, Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockDividend" xlink:label="CLDI_CommonStockDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockDividend" xlink:to="CLDI_CommonStockDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommonStockDividend_lbl" xml:lang="en-US">Common stock dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Aggregate offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PercentageOfStrategicInvestment" xlink:label="CLDI_PercentageOfStrategicInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PercentageOfStrategicInvestment" xlink:to="CLDI_PercentageOfStrategicInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PercentageOfStrategicInvestment_lbl" xml:lang="en-US">Percentage of strategic investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CashCommissionPercentage" xlink:label="CLDI_CashCommissionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CashCommissionPercentage" xlink:to="CLDI_CashCommissionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CashCommissionPercentage_lbl" xml:lang="en-US">Cash commission percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DisbursementsCounsel" xlink:label="CLDI_DisbursementsCounsel" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DisbursementsCounsel" xlink:to="CLDI_DisbursementsCounsel_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DisbursementsCounsel_lbl" xml:lang="en-US">Disbursements counsel</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Proceeds from issued common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Purchase of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_3_lbl" xml:lang="en-US">Gross proceeds from warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:to="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares_2_lbl" xml:lang="en-US">Issuance of common stock through august public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:to="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockUnitPerShareDescription" xlink:label="CLDI_CommonStockUnitPerShareDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockUnitPerShareDescription" xlink:to="CLDI_CommonStockUnitPerShareDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommonStockUnitPerShareDescription_lbl" xml:lang="en-US">Common stock unit per share description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited or cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options forfeited or cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years), Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of Units Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Units Outstanding, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected option life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Number of shares reserved</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockDiscounRate" xlink:label="CLDI_CommonStockDiscounRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockDiscounRate" xlink:to="CLDI_CommonStockDiscounRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommonStockDiscounRate_lbl" xml:lang="en-US">Number of shares issued of common stock at discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Description of term and exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Descriptiion of options vesting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options granted approved for repricing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NoncashCompensation" xlink:label="CLDI_NoncashCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NoncashCompensation" xlink:to="CLDI_NoncashCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_NoncashCompensation_lbl" xml:lang="en-US">Noncash compensation charge in connection with repricing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unamortized stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Estimated weighted average life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average estimated fair value of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed tax benefit at U.S. federal statutory tax rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax, net of federal income tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:label="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:to="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws_lbl" xml:lang="en-US">Enactment of new tax laws</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_lbl" xml:lang="en-US">Enactment of new tax laws, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xml:lang="en-US">Effect of cross-border tax laws</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xml:lang="en-US">Effect of cross-border tax laws, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xml:lang="en-US">Nontaxable or non-deductible items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Non-deductible expenses, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="us-gaap_IncomeTaxReconciliationTaxSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxSettlements_lbl" xml:lang="en-US">Worldwide changes in unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xml:lang="en-US">Worldwide changes in unrecognized tax benefits, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Deferred tax adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Deferred tax adjustments, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_lbl" xml:lang="en-US">Non-controlling interest, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:label="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:to="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_lbl" xml:lang="en-US">Foreign employee stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_lbl" xml:lang="en-US">Foreign employee stock based compensation, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:to="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_lbl" xml:lang="en-US">Rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_lbl" xml:lang="en-US">Germany Rate differential, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:to="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_lbl" xml:lang="en-US">Germany Other, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:to="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_lbl" xml:lang="en-US">Rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_lbl" xml:lang="en-US">Australia Rate differential, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:to="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_lbl" xml:lang="en-US">Australia Change in valuation allowance, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">US Federal Statutory Tax Rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:label="CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:to="CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable_lbl" xml:lang="en-US">ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidFederalAfterRefundReceived_lbl" xml:lang="en-US">Federal taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxPaidStateAfterRefundReceived" xlink:label="CLDI_IncomeTaxPaidStateAfterRefundReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxPaidStateAfterRefundReceived" xlink:to="CLDI_IncomeTaxPaidStateAfterRefundReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxPaidStateAfterRefundReceived_lbl" xml:lang="en-US">State and local taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:to="us-gaap_IncomeTaxPaidForeignAfterRefundReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidForeignAfterRefundReceived_lbl" xml:lang="en-US">Germany</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Total cash paid for income taxes, net of refunds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based and other compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsLeaseLiabilities" xlink:label="CLDI_DeferredTaxAssetsLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxAssetsLeaseLiabilities" xlink:to="CLDI_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:to="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_lbl" xml:lang="en-US">Capitalized research and development expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="CLDI_DeferredTaxAssetsDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="CLDI_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:label="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:to="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_lbl" xml:lang="en-US">Right-of-use and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Additions based on tax positions related to current year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US">Adjustments based on tax positions related to prior years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Balance at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Federal statutory income tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_2_lbl" xml:lang="en-US">Cash income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xml:lang="en-US">Research and development credits carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flows from financing leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Financing cash flows from financing leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Right-of-use lease liabilities, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Right-of-use lease liabilities, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_lbl" xml:lang="en-US">Machinery and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_lbl" xml:lang="en-US">Machinery and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Noncurrent liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total financing lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Operating leases (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Financing leases (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Financing leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating Leases, 2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Operating Leases, 2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Operating Leases, 2029</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Operating Leases, 2030 and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Operating Leases, Less: amounts representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Financing Leases, 2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Financing Leases, 2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Financing Leases, 2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Financing Leases, 2029</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US">Financing Leases, 2030 and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Financing Leases, Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Financing Leases, Less: amounts representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GuarantyOfLeaseAmount" xlink:to="CLDI_GuarantyOfLeaseAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CLDI_GuarantyOfLeaseAmount_2_lbl" xml:lang="en-US">Guaranty of lease, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" xlink:label="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" xlink:to="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm_lbl" xml:lang="en-US">Operating lease, term of contract, lease initial term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" xlink:label="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" xlink:to="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent_lbl" xml:lang="en-US">Lease terms, operating leases annual increase in rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US">Letter of credit amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RemainingExpectedCommitments" xlink:label="CLDI_RemainingExpectedCommitments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RemainingExpectedCommitments" xlink:to="CLDI_RemainingExpectedCommitments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RemainingExpectedCommitments_lbl" xml:lang="en-US">Remaining expected commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Other Commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Other Commitments, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Payment to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommitmentFeePercentage" xlink:label="CLDI_CommitmentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommitmentFeePercentage" xlink:to="CLDI_CommitmentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_CommitmentFeePercentage_lbl" xml:lang="en-US">Commitment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US">Payment period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationEquity" xlink:label="us-gaap_DeferredCompensationEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationEquity_lbl" xml:lang="en-US">Deferred compensation equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_lbl" xml:lang="en-US">Deferred compensation and accrued interest amount in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EquityPurchaseDescription" xlink:label="CLDI_EquityPurchaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EquityPurchaseDescription" xlink:to="CLDI_EquityPurchaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EquityPurchaseDescription_lbl" xml:lang="en-US">Equity purchase description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xml:lang="en-US">Commitment Fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_2_lbl" xml:lang="en-US">Consulting pay</link:label>
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncurredCosts" xlink:label="CLDI_IncurredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncurredCosts" xlink:to="CLDI_IncurredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncurredCosts_lbl" xml:lang="en-US">Incurred costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Issuance and sale of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Shares price sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xml:lang="en-US">Warrant expire date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expire year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">warrants exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NoInsiderTradingFlag" xlink:to="CLDI_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_NoInsiderTradingFlag_doc" xml:lang="en-US">No Insider Trading Flag.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TermNotesPayableCurrent" xlink:to="CLDI_TermNotesPayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TermNotesPayableCurrent_doc" xml:lang="en-US">Term notes payable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PromissoryNote" xlink:to="CLDI_PromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PromissoryNote_doc" xml:lang="en-US">Promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_WarrantLiability" xlink:to="CLDI_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_WarrantLiability_doc" xml:lang="en-US">Warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RelatedPartyWarrantLiability" xlink:to="CLDI_RelatedPartyWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RelatedPartyWarrantLiability_doc" xml:lang="en-US">Related party warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives_doc" xml:lang="en-US">Change in fair value of other liabilities and derivatives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GrantIncome" xlink:to="CLDI_GrantIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GrantIncome_doc" xml:lang="en-US">Grant income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeemedDividendOnWarrants" xlink:to="CLDI_DeemedDividendOnWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DeemedDividendOnWarrants_doc" xml:lang="en-US">Deemed dividend on warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts_doc" xml:lang="en-US">Issuance of common stock and warrants through january confidentially marketed public offering net of financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares_doc" xml:lang="en-US">Issuance of common stock and warrants through january confidentially marketed public offering net of financing costs shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts_doc" xml:lang="en-US">Issuance of common stock and warrants for march registered direct offering and concurrent private placement net of financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares_doc" xml:lang="en-US">Issuance of common stock and warrants for march registered direct offering and concurrent private placement net of financing costs shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:to="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue_doc" xml:lang="en-US">Issuance of common shares through august public offering value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:to="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares_doc" xml:lang="en-US">Issuance of common shares through august public offering shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" xlink:to="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants_doc" xml:lang="en-US">Stock issued during period value exercise of common prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" xlink:to="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants_doc" xml:lang="en-US">Stock issued during period shares exercise of common prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="CLDI_StockIssuedDuringPeriodValueReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueReverseStockSplits_doc" xml:lang="en-US">Stock issued during period value reverse stock splits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueInvestment" xlink:to="CLDI_StockIssuedDuringPeriodValueInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueInvestment_doc" xml:lang="en-US">Stock issued during period value investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" xlink:to="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueSaleOfInvestment_doc" xml:lang="en-US">Stock issued during period value sale of investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" xlink:to="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee_doc" xml:lang="en-US">Stock issued during period value lieu of cash for commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" xlink:to="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee_doc" xml:lang="en-US">Stock issued during period shares lieu of cash for commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" xlink:to="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees_doc" xml:lang="en-US">Financing fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:to="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants_doc" xml:lang="en-US">Stock issued during period value exercise of common stock warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:to="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants_doc" xml:lang="en-US">Stock issued during period shares exercise of common stock warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromWarrantInducementFinancing" xlink:to="CLDI_ProceedsFromWarrantInducementFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ProceedsFromWarrantInducementFinancing_doc" xml:lang="en-US">Proceeds from warrant inducement financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromRegisteredDirectOffering" xlink:to="CLDI_ProceedsFromRegisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ProceedsFromRegisteredDirectOffering_doc" xml:lang="en-US">Proceeds from registered direct offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:to="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_doc" xml:lang="en-US">Repayment of principal on related party bridge loan payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" xlink:to="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ProceedsFromIssuanceOfNoncontrollingInterest_doc" xml:lang="en-US">Proceeds from issuance of noncontrolling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:to="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement_doc" xml:lang="en-US">Proceeds from issuance oif common shares and warrants per subscription agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepaymentOfConvertibleNotePayable" xlink:to="CLDI_RepaymentOfConvertibleNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RepaymentOfConvertibleNotePayable_doc" xml:lang="en-US">Repayment of convertible note payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PaymentOfDebtIssuanceCosts" xlink:to="CLDI_PaymentOfDebtIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PaymentOfDebtIssuanceCosts_doc" xml:lang="en-US">Payment of debt issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases" xlink:to="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases_doc" xml:lang="en-US">Machinery and equipment acquired through financing leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote" xlink:to="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote_doc" xml:lang="en-US">Issuance of common stock per conversion of convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfConvertibleNoteForLegalSettlement" xlink:to="CLDI_IssuanceOfConvertibleNoteForLegalSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfConvertibleNoteForLegalSettlement_doc" xml:lang="en-US">Issuance of convertible note for legal settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockInLieuOfCashForServices" xlink:to="CLDI_IssuanceOfCommonStockInLieuOfCashForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForServices_doc" xml:lang="en-US">Issuance of common stock in lieu of cash for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" xlink:to="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices_doc" xml:lang="en-US">Related party issuance of common stock in lieu of cash for services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DebtDiscountOnConvertibleNotes" xlink:to="CLDI_DebtDiscountOnConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DebtDiscountOnConvertibleNotes_doc" xml:lang="en-US">Debt discount on convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" xlink:to="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_doc" xml:lang="en-US">Issuance of common stock in lieu of cash for SEPA commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:to="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement_doc" xml:lang="en-US">Issuance of restricted stock units for liability settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement_doc" xml:lang="en-US">Issuance of common stock and warrants for legal settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NovaCellMember" xlink:to="CLDI_NovaCellMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_NovaCellMember_doc" xml:lang="en-US">Nova Cell [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GovernmentGrantsPolicyTextBlock" xlink:to="CLDI_GovernmentGrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GovernmentGrantsPolicyTextBlock_doc" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GovernmentGrantsMember" xlink:to="CLDI_GovernmentGrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GovernmentGrantsMember_doc" xml:lang="en-US">Government Grants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CaliforniaInstituteForRegenerativeMedicineMember" xlink:to="CLDI_CaliforniaInstituteForRegenerativeMedicineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CaliforniaInstituteForRegenerativeMedicineMember_doc" xml:lang="en-US">California Institute For Regenerative Medicine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GrantsReceivableWithdrawn" xlink:to="CLDI_GrantsReceivableWithdrawn_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GrantsReceivableWithdrawn_doc" xml:lang="en-US">Grants receivable withdrawn.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" xlink:to="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_doc" xml:lang="en-US">Foreign Currency Transaction Gains And Losses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Consulting" xlink:to="CLDI_Consulting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_Consulting_doc" xml:lang="en-US">Consulting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RentAndMaintenance" xlink:to="CLDI_RentAndMaintenance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RentAndMaintenance_doc" xml:lang="en-US">Rent and maintenance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClinicalResearchAndDevelopment" xlink:to="CLDI_ClinicalResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ClinicalResearchAndDevelopment_doc" xml:lang="en-US">Clinical research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:to="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_doc" xml:lang="en-US">Change in fair value of debt, other liabilities, and derivatives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:to="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_doc" xml:lang="en-US">New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:to="CLDI_ForwardPurchaseAgreementDerivativeAssetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ForwardPurchaseAgreementDerivativeAssetMember_doc" xml:lang="en-US">Forward Purchase Agreement Derivative Asset [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PublicWarrantsMember" xlink:to="CLDI_PublicWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PublicWarrantsMember_doc" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PrivateWarrantsMember" xlink:to="CLDI_PrivateWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PrivateWarrantsMember_doc" xml:lang="en-US">Private Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AccruedCompensation" xlink:to="CLDI_AccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AccruedCompensation_doc" xml:lang="en-US">Accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AccruedVendorAndOtherExpenses" xlink:to="CLDI_AccruedVendorAndOtherExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AccruedVendorAndOtherExpenses_doc" xml:lang="en-US">Accrued vendor and other expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PrepaidExpenses" xlink:to="CLDI_PrepaidExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PrepaidExpenses_doc" xml:lang="en-US">Prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAAndDirectorEMember" xlink:to="CLDI_DirectorAAndDirectorEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorAAndDirectorEMember_doc" xml:lang="en-US">Director A and Director E [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFAndRelativeOfOfficerAMember" xlink:to="CLDI_DirectorFAndRelativeOfOfficerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorFAndRelativeOfOfficerAMember_doc" xml:lang="en-US">Director F and Relative of Officer A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFMember" xlink:to="CLDI_DirectorFMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorFMember_doc" xml:lang="en-US">Director F [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorDMember" xlink:to="CLDI_DirectorDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorDMember_doc" xml:lang="en-US">Director D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAOneMember" xlink:to="CLDI_DirectorAOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorAOneMember_doc" xml:lang="en-US">Director A One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFOneMember" xlink:to="CLDI_DirectorFOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorFOneMember_doc" xml:lang="en-US">Director F One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorATwoMember" xlink:to="CLDI_DirectorATwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorATwoMember_doc" xml:lang="en-US">Director A Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorFAndDirectorAMember" xlink:to="CLDI_DirectorFAndDirectorAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorFAndDirectorAMember_doc" xml:lang="en-US">Director F and Director A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RelativeOfOfficerAMember" xlink:to="CLDI_RelativeOfOfficerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RelativeOfOfficerAMember_doc" xml:lang="en-US">Relative of OfficerA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OfficerGMember" xlink:to="CLDI_OfficerGMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_OfficerGMember_doc" xml:lang="en-US">Officer G [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OfficerAMember" xlink:to="CLDI_OfficerAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_OfficerAMember_doc" xml:lang="en-US">Officer A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CompanyARelatedToDirectorGMember" xlink:to="CLDI_CompanyARelatedToDirectorGMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CompanyARelatedToDirectorGMember_doc" xml:lang="en-US">Company A Related To Director G [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorsAAndEMember" xlink:to="CLDI_DirectorsAAndEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorsAAndEMember_doc" xml:lang="en-US">Directors A And E [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ConsultingPay" xlink:to="CLDI_ConsultingPay_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ConsultingPay_doc" xml:lang="en-US">Consulting payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAMember" xlink:to="CLDI_DirectorAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorAMember_doc" xml:lang="en-US">Director A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GuarantyOfLeaseAmount" xlink:to="CLDI_GuarantyOfLeaseAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GuarantyOfLeaseAmount_doc" xml:lang="en-US">Guaranty of lease amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AJCCapitalMember" xlink:to="CLDI_AJCCapitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AJCCapitalMember_doc" xml:lang="en-US">AJC Capital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GuarantyMember" xlink:to="CLDI_GuarantyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GuarantyMember_doc" xml:lang="en-US">Guaranty [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DirectorAThreeMember" xlink:to="CLDI_DirectorAThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DirectorAThreeMember_doc" xml:lang="en-US">Director A Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeparationPay" xlink:to="CLDI_SeparationPay_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeparationPay_doc" xml:lang="en-US">Separation payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PromissoryNoteMember" xlink:to="CLDI_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PromissoryNoteMember_doc" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TermNotesPayableMember" xlink:to="CLDI_TermNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TermNotesPayableMember_doc" xml:lang="en-US">Term Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_BridgeLoanPayableMember" xlink:to="CLDI_BridgeLoanPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_BridgeLoanPayableMember_doc" xml:lang="en-US">Bridge Loan Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyOneTermNoteMember" xlink:to="CLDI_TwoThousandTwentyOneTermNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyOneTermNoteMember_doc" xml:lang="en-US">2021 Term Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_InvestorAndDirectorMember" xlink:to="CLDI_InvestorAndDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_InvestorAndDirectorMember_doc" xml:lang="en-US">Investor and Director [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyTwoTermNotePayableMember" xlink:to="CLDI_TwoThousandTwentyTwoTermNotePayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyTwoTermNotePayableMember_doc" xml:lang="en-US">2022 Term Note Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeTermNotePayableMember" xlink:to="CLDI_TwoThousandTwentyThreeTermNotePayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyThreeTermNotePayableMember_doc" xml:lang="en-US">2023 Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" xlink:to="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember_doc" xml:lang="en-US">2023 Note Payable Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyFourBridgeLoanMember" xlink:to="CLDI_TwoThousandTwentyFourBridgeLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyFourBridgeLoanMember_doc" xml:lang="en-US">2024 Bridge Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyFourPurchaseAgreementMember" xlink:to="CLDI_TwoThousandTwentyFourPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyFourPurchaseAgreementMember_doc" xml:lang="en-US">2024 Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PromissoryNoteLoanAgreementMember" xlink:to="CLDI_PromissoryNoteLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PromissoryNoteLoanAgreementMember_doc" xml:lang="en-US">Promissory Note Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EarnoutSharesMember" xlink:to="CLDI_EarnoutSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EarnoutSharesMember_doc" xml:lang="en-US">Earnout Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ContingentlyIssuableWarrantMember" xlink:to="CLDI_ContingentlyIssuableWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ContingentlyIssuableWarrantMember_doc" xml:lang="en-US">Contingently Issuable Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_VotingCommonStockMember" xlink:to="CLDI_VotingCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_VotingCommonStockMember_doc" xml:lang="en-US">Voting Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockDividend" xlink:to="CLDI_CommonStockDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommonStockDividend_doc" xml:lang="en-US">Common stock dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock" xlink:to="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock_doc" xml:lang="en-US">Discloser of Common Stock Reserved for Furture [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" xlink:to="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesBWarrantsAndSeriesCWarrantsMember_doc" xml:lang="en-US">Series B Warrants And Series C Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_InducementOfferLetterAgreementMember" xlink:to="CLDI_InducementOfferLetterAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_InducementOfferLetterAgreementMember_doc" xml:lang="en-US">Inducement Offer Letter Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBOneWarrantsMember" xlink:to="CLDI_SeriesBOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesBOneWarrantsMember_doc" xml:lang="en-US">Series B One Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesCOneWarrantsMember" xlink:to="CLDI_SeriesCOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesCOneWarrantsMember_doc" xml:lang="en-US">Series C One Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesDCommonStockMember" xlink:to="CLDI_SeriesDCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesDCommonStockMember_doc" xml:lang="en-US">Series D Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SubscriptionAgreementMember" xlink:to="CLDI_SubscriptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SubscriptionAgreementMember_doc" xml:lang="en-US">Subscription Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_BoardOfDirectorsMember" xlink:to="CLDI_BoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_BoardOfDirectorsMember_doc" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PercentageOfStrategicInvestment" xlink:to="CLDI_PercentageOfStrategicInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PercentageOfStrategicInvestment_doc" xml:lang="en-US">Percentage of strategic investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SalesAgreementMember" xlink:to="CLDI_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CashCommissionPercentage" xlink:to="CLDI_CashCommissionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CashCommissionPercentage_doc" xml:lang="en-US">Cash commission percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DisbursementsCounsel" xlink:to="CLDI_DisbursementsCounsel_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DisbursementsCounsel_doc" xml:lang="en-US">Disbursements counsel.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MarketOfferingAgreementMember" xlink:to="CLDI_MarketOfferingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_MarketOfferingAgreementMember_doc" xml:lang="en-US">Market Offering Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SecuritiesPurchaseAgreementMember" xlink:to="CLDI_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesECommonWarrantsMember" xlink:to="CLDI_SeriesECommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesECommonWarrantsMember_doc" xml:lang="en-US">Series E Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesFCommonWarrantsMember" xlink:to="CLDI_SeriesFCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesFCommonWarrantsMember_doc" xml:lang="en-US">Series F Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsMember" xlink:to="CLDI_PlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsMember_doc" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgencyAgreementMember" xlink:to="CLDI_PlacementAgencyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgencyAgreementMember_doc" xml:lang="en-US">Placement Agency Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PreFundedWarrantsMember" xlink:to="CLDI_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGCommonWarrantsMember" xlink:to="CLDI_SeriesGCommonWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesGCommonWarrantsMember_doc" xml:lang="en-US">Series G Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_JulyWarrantInducementOfferMember" xlink:to="CLDI_JulyWarrantInducementOfferMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_JulyWarrantInducementOfferMember_doc" xml:lang="en-US">July Warrant Inducement Offer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesHCommonStockWarrantsMember" xlink:to="CLDI_SeriesHCommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesHCommonStockWarrantsMember_doc" xml:lang="en-US">Series H Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_UnderwritingAgreementMember" xlink:to="CLDI_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PreFundedWarrantUnitsMember" xlink:to="CLDI_PreFundedWarrantUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PreFundedWarrantUnitsMember_doc" xml:lang="en-US">PreFunded Warrant Units [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockUnitPerShareDescription" xlink:to="CLDI_CommonStockUnitPerShareDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommonStockUnitPerShareDescription_doc" xml:lang="en-US">Common stock unit per share description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepresentativeWarrantsMember" xlink:to="CLDI_RepresentativeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RepresentativeWarrantsMember_doc" xml:lang="en-US">Representative Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfOutstandingWarrantsTextBlock" xlink:to="CLDI_ScheduleOfOutstandingWarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ScheduleOfOutstandingWarrantsTextBlock_doc" xml:lang="en-US">Schedule Of Outstanding Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PrivateWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_PrivateWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PrivateWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Private Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClassOfWarrantOrRighstIssuanceDate" xlink:to="CLDI_ClassOfWarrantOrRighstIssuanceDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ClassOfWarrantOrRighstIssuanceDate_doc" xml:lang="en-US">Class of warrant or righst issuance date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember_doc" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series C-1 Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember_doc" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PublicWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_PublicWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PublicWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Public Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_WarrantsToPurchaseRestrictedSharesMember" xlink:to="CLDI_WarrantsToPurchaseRestrictedSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_WarrantsToPurchaseRestrictedSharesMember_doc" xml:lang="en-US">Warrants to Purchase Restricted Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_WarrantsToPurchaseRestrictedSharesOneMember" xlink:to="CLDI_WarrantsToPurchaseRestrictedSharesOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_WarrantsToPurchaseRestrictedSharesOneMember_doc" xml:lang="en-US">Warrants to Purchase Restricted Shares One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember_doc" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember_doc" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember_doc" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember_doc" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" xlink:to="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember_doc" xml:lang="en-US">Placement Agent Warrants to Purchase Common Stock Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RepresentativeWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Representative Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesAWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesAWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesAWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series A Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesBWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesBWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series B Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember_doc" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" xlink:to="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember_doc" xml:lang="en-US">Series B-1 Warrants to Purchase Common Stock Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" xlink:to="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember_doc" xml:lang="en-US">Series C-1 Warrants to Purchase Common Stock One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" xlink:to="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember_doc" xml:lang="en-US">Series C-1 Warrants to Purchase Common Stock Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesDWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesDWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesDWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series D Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesEWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesEWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesEWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series E Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesFWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesFWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesFWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series F Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesGWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesGWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series G Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesHWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesHWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesHWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series H Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesIWarrantsToPurchaseCommonStockMember" xlink:to="CLDI_SeriesIWarrantsToPurchaseCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesIWarrantsToPurchaseCommonStockMember_doc" xml:lang="en-US">Series I Warrants to Purchase Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PublicWarrantRedemptionDescription" xlink:to="CLDI_PublicWarrantRedemptionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PublicWarrantRedemptionDescription_doc" xml:lang="en-US">Public warrant redemption description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RedemptionOfOutstandingWarrantsPerShare" xlink:to="CLDI_RedemptionOfOutstandingWarrantsPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RedemptionOfOutstandingWarrantsPerShare_doc" xml:lang="en-US">Redemption of outstanding warrants per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClassOfWarrantsRedemptionNoticePeriod" xlink:to="CLDI_ClassOfWarrantsRedemptionNoticePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ClassOfWarrantsRedemptionNoticePeriod_doc" xml:lang="en-US">Class of warrants, redemption notice period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RedemptionOfWarrantsMember" xlink:to="CLDI_RedemptionOfWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RedemptionOfWarrantsMember_doc" xml:lang="en-US">Redemption Of Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TriggeringEventAxis" xlink:to="CLDI_TriggeringEventAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TriggeringEventAxis_doc" xml:lang="en-US">Triggering Event Axis</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" xlink:to="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_doc" xml:lang="en-US">Share Price Equal Or Less Ten Point Zero Rupees Per Dollar [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:to="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_doc" xml:lang="en-US">Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesAWarrantsMember" xlink:to="CLDI_SeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesAWarrantsMember_doc" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesBWarrantsMember" xlink:to="CLDI_SeriesBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesBWarrantsMember_doc" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesCOneWarrantsOneMember" xlink:to="CLDI_SeriesCOneWarrantsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesCOneWarrantsOneMember_doc" xml:lang="en-US">Series C One Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Deemeddividend" xlink:to="CLDI_Deemeddividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_Deemeddividend_doc" xml:lang="en-US">Deemed dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesDWarrantsMember" xlink:to="CLDI_SeriesDWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesDWarrantsMember_doc" xml:lang="en-US">Series D Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" xlink:to="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesEWarrantsAndSeriesFWarrantsMember_doc" xml:lang="en-US">Series E Warrants and Series F Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGPreFundedWarrantsMember" xlink:to="CLDI_SeriesGPreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesGPreFundedWarrantsMember_doc" xml:lang="en-US">Series G Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesIPreFundedWarrantsMember" xlink:to="CLDI_SeriesIPreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesIPreFundedWarrantsMember_doc" xml:lang="en-US">Series I Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option weighted average grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option outstanding weighted average remaining contractual terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options converted to Common Stock In Peroid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreePlanMember" xlink:to="CLDI_TwoThousandTwentyThreePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyThreePlanMember_doc" xml:lang="en-US">2023 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AdministratorMember" xlink:to="CLDI_AdministratorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AdministratorMember_doc" xml:lang="en-US">Administrator [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockDiscounRate" xlink:to="CLDI_CommonStockDiscounRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommonStockDiscounRate_doc" xml:lang="en-US">Common stock discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EmployeeStockPurchasePlanMember" xlink:to="CLDI_EmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EmployeeStockPurchasePlanMember_doc" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NoncashCompensation" xlink:to="CLDI_NoncashCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_NoncashCompensation_doc" xml:lang="en-US">Non-cash compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_doc" xml:lang="en-US">Effective income tax rate reconciliation other permanent differences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_doc" xml:lang="en-US">Effective income tax rate reconciliation change in fair value of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost_doc" xml:lang="en-US">Effective income tax rate reconciliation stock issuance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_doc" xml:lang="en-US">Effective income tax rate reconciliation acquired startup costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxAssetsLeaseLiabilities" xlink:to="CLDI_DeferredTaxAssetsLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DeferredTaxAssetsLeaseLiabilities_doc" xml:lang="en-US">Deferred tax assets lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:to="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_doc" xml:lang="en-US">Deferred tax assets capitalized research and development expenditures.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="CLDI_DeferredTaxAssetsDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DeferredTaxAssetsDepreciationAndAmortization_doc" xml:lang="en-US">Deferred tax assets depreciation and amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:to="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_doc" xml:lang="en-US">Deferred tax lliabilities right of use assets and other assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SanDiegoLeaseAgreementMember" xlink:to="CLDI_SanDiegoLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SanDiegoLeaseAgreementMember_doc" xml:lang="en-US">San Diego Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" xlink:to="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_OperatingLeaseTermOfContractLeaseInitialTerm_doc" xml:lang="en-US">Operating lease term of contract lease initial term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" xlink:to="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent_doc" xml:lang="en-US">Lease terms operating leases annual increase in rent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StemVacOfficeLeaseAgreementMember" xlink:to="CLDI_StemVacOfficeLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StemVacOfficeLeaseAgreementMember_doc" xml:lang="en-US">Stem Vac Office Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" xlink:to="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of cash flow supplemental disclosures operating and financing leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" xlink:to="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of supplemental balance sheet information related to operating and financing leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Lessee operating lease liability payments due after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour_doc" xml:lang="en-US">Finance lease liability payments due after year four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RemainingExpectedCommitments" xlink:to="CLDI_RemainingExpectedCommitments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RemainingExpectedCommitments_doc" xml:lang="en-US">Remaining expected commitments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_NorthwesternAgreementMember" xlink:to="CLDI_NorthwesternAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_NorthwesternAgreementMember_doc" xml:lang="en-US">Northwestern Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_LicenseAgreementMember" xlink:to="CLDI_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeparationAndReleaseAgreementMember" xlink:to="CLDI_SeparationAndReleaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeparationAndReleaseAgreementMember_doc" xml:lang="en-US">Separation and Release Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GeorgeNgMember" xlink:to="CLDI_GeorgeNgMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GeorgeNgMember_doc" xml:lang="en-US">George Ng [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommitmentFeePercentage" xlink:to="CLDI_CommitmentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommitmentFeePercentage_doc" xml:lang="en-US">Commitment fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MrCamaisaMember" xlink:to="CLDI_MrCamaisaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_MrCamaisaMember_doc" xml:lang="en-US">Mr Camaisa [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_MrLeftwichMember" xlink:to="CLDI_MrLeftwichMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_MrLeftwichMember_doc" xml:lang="en-US">Mr Leftwich [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SettlementOfDeferredCompensationMember" xlink:to="CLDI_SettlementOfDeferredCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SettlementOfDeferredCompensationMember_doc" xml:lang="en-US">Settlement Of Deferred Compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StandbyEquityPurchaseAgreementMember" xlink:to="CLDI_StandbyEquityPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StandbyEquityPurchaseAgreementMember_doc" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EquityPurchaseDescription" xlink:to="CLDI_EquityPurchaseDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EquityPurchaseDescription_doc" xml:lang="en-US">Equity purchase description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_YorkvilleMember" xlink:to="CLDI_YorkvilleMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_YorkvilleMember_doc" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Dr.MinevMember" xlink:to="CLDI_Dr.MinevMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_Dr.MinevMember_doc" xml:lang="en-US">Dr.Minev [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Ms.CampbellMember" xlink:to="CLDI_Ms.CampbellMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_Ms.CampbellMember_doc" xml:lang="en-US">Ms.Campbell [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Dr.CamisaMember" xlink:to="CLDI_Dr.CamisaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_Dr.CamisaMember_doc" xml:lang="en-US">Dr. Camisa [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockOptionsIssuedAndOutstandingMember" xlink:to="CLDI_CommonStockOptionsIssuedAndOutstandingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommonStockOptionsIssuedAndOutstandingMember_doc" xml:lang="en-US">Common Stock Options Issued and Outstanding [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" xlink:to="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_RestrictedStockUnitsVestedAndUnreleasedMember_doc" xml:lang="en-US">Restricted Stock Units Vested and Unreleased [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:to="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember_doc" xml:lang="en-US">2023 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_doc" xml:lang="en-US">2023 Employee Stock Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering_doc" xml:lang="en-US">Issuance of common stock through august public offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_doc" xml:lang="en-US">Issuance of common stock through July Inducement Offer, net of financing costs, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts_doc" xml:lang="en-US">Issuance of common stock through July Inducement Offer, net of financing costs, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_doc" xml:lang="en-US">Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts_doc" xml:lang="en-US">Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:to="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement_doc" xml:lang="en-US">Issuance of restricted stock units for liability settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement_doc" xml:lang="en-US">Issuance of common stock and warrants for legal settlement, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement_doc" xml:lang="en-US">Issuance of common stock and warrants for legal settlement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_doc" xml:lang="en-US">Issuance of common stock for Reverse Stock Split fractional, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_doc" xml:lang="en-US">Issuance of common stock for Reverse Stock Split fractional, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement_doc" xml:lang="en-US">Issuance of common stock and warrants per subscription agreement, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares_doc" xml:lang="en-US">Issuance of common stock and warrants per subscription agreement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_doc" xml:lang="en-US">Issuance of common stock and warrants for registered direct offering, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering_doc" xml:lang="en-US">Issuance of common stock and warrants for registered direct offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_doc" xml:lang="en-US">Issuance of common stock through At the Market Offering, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_doc" xml:lang="en-US">Issuance of common stock through At the Market Offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_doc" xml:lang="en-US">Issuance of common stock through November Public Offering, net of financing, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing_doc" xml:lang="en-US">Issuance of common stock through November Public Offering, net of financing, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ProceedsFromPublicOfferings" xlink:to="CLDI_ProceedsFromPublicOfferings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ProceedsFromPublicOfferings_doc" xml:lang="en-US">Proceeds from public offerings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OtherSegmentItems" xlink:to="CLDI_OtherSegmentItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_OtherSegmentItems_doc" xml:lang="en-US">Other segment items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_doc" xml:lang="en-US">Change in fair value of other liabilities and derivatives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_doc" xml:lang="en-US">Change in fair value of other liabilities and derivatives &#8211; related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities_doc" xml:lang="en-US">Financing fees included in accounts payable and accrued liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_doc" xml:lang="en-US">Enactment of new tax laws, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:to="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws_doc" xml:lang="en-US">Enactment of new tax laws.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock" xlink:to="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ScheduleOfIncomeTaxPaidTableTextBlock_doc" xml:lang="en-US">Schedule of Income Tax Paid [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PriorDecemberTwentySeventeenthMember" xlink:to="CLDI_PriorDecemberTwentySeventeenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_PriorDecemberTwentySeventeenthMember_doc" xml:lang="en-US">Prior December 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_AfterDecemberTwentySeventeenthMember" xlink:to="CLDI_AfterDecemberTwentySeventeenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_AfterDecemberTwentySeventeenthMember_doc" xml:lang="en-US">After December 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncurredCosts" xlink:to="CLDI_IncurredCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncurredCosts_doc" xml:lang="en-US">Incurred costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:to="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_doc" xml:lang="en-US">Income tax reconciliation germany income tax rates differential.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_doc" xml:lang="en-US">Effective income tax rate reconciliation germany income tax rates differential.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:to="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_doc" xml:lang="en-US">Income tax reconciliation germany income tax rates differential other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_doc" xml:lang="en-US">Effective income tax rate reconciliation germany income tax rate differential other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:to="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_doc" xml:lang="en-US">Income tax reconciliation australia income tax rates differential one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_doc" xml:lang="en-US">Effective income tax rate reconciliation australia income tax rate differential one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:to="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_doc" xml:lang="en-US">Income tax reconciliation australia income tax rate differential change in valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_doc" xml:lang="en-US">Effective income tax rate reconciliation australia income tax rate differential change in valuation allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StatementOfIncomeLocationBalanceAxis" xlink:to="CLDI_StatementOfIncomeLocationBalanceAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_StatementOfIncomeLocationBalanceAxis_doc" xml:lang="en-US">Location, Statement of Income, Balance [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ResearchAndDevelopmentExpensesMember" xlink:to="CLDI_ResearchAndDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_ResearchAndDevelopmentExpensesMember_doc" xml:lang="en-US">Research and Development Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_GeneralAndAdministrativeExpensesMember" xlink:to="CLDI_GeneralAndAdministrativeExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_GeneralAndAdministrativeExpensesMember_doc" xml:lang="en-US">General and Administrative Expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_doc" xml:lang="en-US">Effective income tax rate reconciliation foreign employee stock based compensation income tax rates differential.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:to="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_doc" xml:lang="en-US">Income tax reconciliation foreign employee stock based compensation income tax rates differential.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockUnitsMember" xlink:to="CLDI_CommonStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommonStockUnitsMember_doc" xml:lang="en-US">Common Stock Units [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_UnderwritersWarrantMember" xlink:to="CLDI_UnderwritersWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_UnderwritersWarrantMember_doc" xml:lang="en-US">Underwriters Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesJWarrantsMember" xlink:to="CLDI_SeriesJWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesJWarrantsMember_doc" xml:lang="en-US">Series J Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesKWarrantsMember" xlink:to="CLDI_SeriesKWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesKWarrantsMember_doc" xml:lang="en-US">Series K Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesLWarrantsMember" xlink:to="CLDI_SeriesLWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesLWarrantsMember_doc" xml:lang="en-US">Series L Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesGCommonStockWarrantsMember" xlink:to="CLDI_SeriesGCommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesGCommonStockWarrantsMember_doc" xml:lang="en-US">Series G Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CommonStockPurchaseWarrantsAgreementMember" xlink:to="CLDI_CommonStockPurchaseWarrantsAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CommonStockPurchaseWarrantsAgreementMember_doc" xml:lang="en-US">Common Stock Purchase Warrants Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesICommonStockWarrantsMember" xlink:to="CLDI_SeriesICommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_SeriesICommonStockWarrantsMember_doc" xml:lang="en-US">Series I Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxPaidStateAfterRefundReceived" xlink:to="CLDI_IncomeTaxPaidStateAfterRefundReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_IncomeTaxPaidStateAfterRefundReceived_doc" xml:lang="en-US">Income tax paid state after refund received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_CashPaidForIncomeTaxes" xlink:to="CLDI_CashPaidForIncomeTaxes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CLDI_CashPaidForIncomeTaxes_doc" xml:lang="en-US">Cash paid for income taxes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_SeriesCOneWarrantsOneMember" xlink:to="CLDI_SeriesCOneWarrantsOneMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_SeriesCOneWarrantsOneMember_3_lbl" xml:lang="en-US">Series C-1 Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty_3_lbl" xml:lang="en-US">ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:to="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty_3_lbl" xml:lang="en-US">ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:to="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:to="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:to="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable_3_lbl" xml:lang="en-US">Repayment of principal on related party bridge loan payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RepaymentOfConvertibleNotePayable" xlink:to="CLDI_RepaymentOfConvertibleNotePayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RepaymentOfConvertibleNotePayable_3_lbl" xml:lang="en-US">RepaymentOfConvertibleNotePayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_PaymentOfDebtIssuanceCosts" xlink:to="CLDI_PaymentOfDebtIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_PaymentOfDebtIssuanceCosts_3_lbl" xml:lang="en-US">PaymentOfDebtIssuanceCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockInLieuOfCashForServices" xlink:to="CLDI_IssuanceOfCommonStockInLieuOfCashForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForServices_3_lbl" xml:lang="en-US">IssuanceOfCommonStockInLieuOfCashForServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:to="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement_3_lbl" xml:lang="en-US">IssuanceOfCommonStockAndWarrantsForLegalSettlement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" xlink:to="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee_3_lbl" xml:lang="en-US">IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:to="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement_3_lbl" xml:lang="en-US">IssuanceOfRestrictedStockUnitsForLiabilitySettlement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_2_lbl" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_2_lbl" xml:lang="en-US">General Insurance Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_Consulting" xlink:to="CLDI_Consulting_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_Consulting_3_lbl" xml:lang="en-US">Consulting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_RentAndMaintenance" xlink:to="CLDI_RentAndMaintenance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_RentAndMaintenance_3_lbl" xml:lang="en-US">RentAndMaintenance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ClinicalResearchAndDevelopment" xlink:to="CLDI_ClinicalResearchAndDevelopment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ClinicalResearchAndDevelopment_3_lbl" xml:lang="en-US">ClinicalResearchAndDevelopment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:to="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_3_lbl" xml:lang="en-US">ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_OtherSegmentItems" xlink:to="CLDI_OtherSegmentItems_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_OtherSegmentItems_3_lbl" xml:lang="en-US">OtherSegmentItems</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_2_lbl" xml:lang="en-US">Grants Receivable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_2_lbl" xml:lang="en-US">Other Depreciation and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_2_lbl" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:to="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:to="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue_3_lbl" xml:lang="en-US">IssuanceOfCommonSharesThroughAugustPublicOfferingValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationStockIssuanceCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:to="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:to="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_3_lbl" xml:lang="en-US">IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:to="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_3_lbl" xml:lang="en-US">IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:to="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_3_lbl" xml:lang="en-US">IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:to="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_2_lbl" xml:lang="en-US">Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Description</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>cldi-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Cover" roleURI="http://calidibio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#BalanceSheets" roleURI="http://calidibio.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#BalanceSheetsParenthetical" roleURI="http://calidibio.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfOperations" roleURI="http://calidibio.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfTotalEquity" roleURI="http://calidibio.com/role/StatementsOfTotalEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#StatementsOfCashFlows" roleURI="http://calidibio.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#OrganizationAndNatureOfOperations" roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#FairValueMeasurements" roleURI="http://calidibio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SelectedBalanceSheetComponents" roleURI="http://calidibio.com/role/SelectedBalanceSheetComponents" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNet" roleURI="http://calidibio.com/role/MachineryAndEquipmentNet" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#RelatedPartyTransactions" roleURI="http://calidibio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Debt" roleURI="http://calidibio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquity" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensation" roleURI="http://calidibio.com/role/Stock-basedCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxes" roleURI="http://calidibio.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingencies" roleURI="http://calidibio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SubsequentEvents" roleURI="http://calidibio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#FairValueMeasurementsTables" roleURI="http://calidibio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SelectedBalanceSheetComponentsTables" roleURI="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNetTables" roleURI="http://calidibio.com/role/MachineryAndEquipmentNetTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#RelatedPartyTransactionsTables" roleURI="http://calidibio.com/role/RelatedPartyTransactionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#DebtTables" roleURI="http://calidibio.com/role/DebtTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensationTables" roleURI="http://calidibio.com/role/Stock-basedCompensationTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxesTables" roleURI="http://calidibio.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingenciesTables" roleURI="http://calidibio.com/role/CommitmentsAndContingenciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#OrganizationAndNatureOfOperationsDetailsNarrative" roleURI="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCashAndCashEquivalentsDetails" roleURI="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" roleURI="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOperatingSegmentDetails" roleURI="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" roleURI="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfMachineryAndEquipmentNetDetails" roleURI="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#MachineryAndEquipmentNetDetailsNarrative" roleURI="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfRelatedPartyTransactionsDetails" roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfRelatedPartyTransactionsDetailsParenthetical" roleURI="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingDebtObligationsDetails" roleURI="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfMaturitiesOfOutstandingDebtDetails" roleURI="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#DebtDetailsNarrative" roleURI="http://calidibio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCommonStockReservedDetails" roleURI="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingWarrantsDetails" roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfOutstandingWarrantsDetailsParenthetical" roleURI="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" roleURI="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfStockOptionActivityDetails" roleURI="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SummaryOfRestrictedStockUnitActivityDetails" roleURI="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" roleURI="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfStockOptionsValuationAssumptionsDetails" roleURI="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#Stock-basedCompensationDetailsNarrative" roleURI="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" roleURI="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" roleURI="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" roleURI="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" roleURI="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfUnrecognizedTaxBenefitDetails" roleURI="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#IncomeTaxesDetailsNarrative" roleURI="http://calidibio.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" roleURI="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" roleURI="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#ScheduleOfFutureMinimumLeaseCommitmentsDetails" roleURI="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="cldi-20251231.xsd#SubsequentEventsDetailsNarrative" roleURI="http://calidibio.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableCurrent" xlink:label="loc_CLDITermNotesPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_CLDITermNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNote" xlink:label="loc_CLDIPromissoryNote" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_CLDIPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantLiability" xlink:label="loc_CLDIWarrantLiability" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_CLDIWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelatedPartyWarrantLiability" xlink:label="loc_CLDIRelatedPartyWarrantLiability" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_CLDIRelatedPartyWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantIncome" xlink:label="loc_CLDIGrantIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_CLDIGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaapGainOnSaleOfInvestments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainOnSaleOfInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeemedDividendOnWarrants" xlink:label="loc_CLDIDeemedDividendOnWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_CLDIDeemedDividendOnWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement -  Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfTotalEquity" xlink:title="00000006 - Statement - Consolidated Statements of Total Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:label="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_CLDIStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueSaleOfInvestment" xlink:label="loc_CLDIStockIssuedDuringPeriodValueSaleOfInvestment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueSaleOfInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" xlink:label="loc_CLDIStockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueLieuOfCashForCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees" xlink:label="loc_CLDIAdjustmentsToAdditionalPaidInCapitalFinancingFees" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIAdjustmentsToAdditionalPaidInCapitalFinancingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueExerciseOfCommonStockWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:label="loc_CLDIAdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIAdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:label="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:label="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StockIssuedDuringPeriodValueInvestment" xlink:label="loc_CLDIStockIssuedDuringPeriodValueInvestment" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIStockIssuedDuringPeriodValueInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:label="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivatives" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CLDIChangeInFairValueOfOtherLiabilitiesAndDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaapGainOnSaleOfInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainOnSaleOfInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromPublicOfferings" xlink:label="loc_CLDIProceedsFromPublicOfferings" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIProceedsFromPublicOfferings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromWarrantInducementFinancing" xlink:label="loc_CLDIProceedsFromWarrantInducementFinancing" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIProceedsFromWarrantInducementFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromRegisteredDirectOffering" xlink:label="loc_CLDIProceedsFromRegisteredDirectOffering" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIProceedsFromRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:label="loc_CLDIRepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIRepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromIssuanceOfNoncontrollingInterest" xlink:label="loc_CLDIProceedsFromIssuanceOfNoncontrollingInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIProceedsFromIssuanceOfNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:label="loc_CLDIProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepaymentOfConvertibleNotePayable" xlink:label="loc_CLDIRepaymentOfConvertibleNotePayable" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIRepaymentOfConvertibleNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PaymentOfDebtIssuanceCosts" xlink:label="loc_CLDIPaymentOfDebtIssuanceCosts" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CLDIPaymentOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CashPaidForIncomeTaxes" xlink:label="loc_CLDICashPaidForIncomeTaxes" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CLDICashPaidForIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeemedDividendOnWarrants" xlink:label="loc_CLDIDeemedDividendOnWarrants" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIDeemedDividendOnWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases" xlink:label="loc_CLDIMachineryAndEquipmentAcquiredThroughFinancingLeases" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIMachineryAndEquipmentAcquiredThroughFinancingLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" xlink:label="loc_CLDIFinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIFinancingFeesIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote" xlink:label="loc_CLDIIssuanceOfCommonStockPerConversionOfConvertibleNote" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIIssuanceOfCommonStockPerConversionOfConvertibleNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfConvertibleNoteForLegalSettlement" xlink:label="loc_CLDIIssuanceOfConvertibleNoteForLegalSettlement" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIIssuanceOfConvertibleNoteForLegalSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockInLieuOfCashForServices" xlink:label="loc_CLDIIssuanceOfCommonStockInLieuOfCashForServices" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIIssuanceOfCommonStockInLieuOfCashForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" xlink:label="loc_CLDIRelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIRelatedPartyIssuanceOfCommonStockInLieuOfCashForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:label="loc_CLDIIssuanceOfCommonStockAndWarrantsForLegalSettlement" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIIssuanceOfCommonStockAndWarrantsForLegalSettlement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DebtDiscountOnConvertibleNotes" xlink:label="loc_CLDIDebtDiscountOnConvertibleNotes" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIDebtDiscountOnConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" xlink:label="loc_CLDIIssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIIssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:label="loc_CLDIIssuanceOfRestrictedStockUnitsForLiabilitySettlement" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CLDIIssuanceOfRestrictedStockUnitsForLiabilitySettlement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NoInsiderTradingFlag" xlink:label="loc_CLDINoInsiderTradingFlag" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_CLDINoInsiderTradingFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/OrganizationAndNatureOfOperations" xlink:title="999015 - Disclosure - Organization and Nature of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999016 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/FairValueMeasurements" xlink:title="999017 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SelectedBalanceSheetComponents" xlink:title="999018 - Disclosure - Selected Balance Sheet Components">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNet" xlink:title="999019 - Disclosure - Machinery and Equipment, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/RelatedPartyTransactions" xlink:title="999020 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Debt" xlink:title="999021 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity" xlink:title="999022 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensation" xlink:title="999023 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxes" xlink:title="999024 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SubsequentEvents" xlink:title="999026 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999027 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GovernmentGrantsPolicyTextBlock" xlink:label="loc_CLDIGovernmentGrantsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CLDIGovernmentGrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" xlink:label="loc_CLDIForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CLDIForeignCurrencyTransactionGainsAndLossesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:label="loc_CLDINewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CLDINewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999028 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/FairValueMeasurementsTables" xlink:title="999029 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SelectedBalanceSheetComponentsTables" xlink:title="999030 - Disclosure - Selected Balance Sheet Components (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNetTables" xlink:title="999031 - Disclosure - Machinery and Equipment, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/RelatedPartyTransactionsTables" xlink:title="999032 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/DebtTables" xlink:title="999033 - Disclosure - Debt (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables" xlink:title="999034 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock" xlink:label="loc_CLDIDiscloserOFCommonStockReservedForFurtureTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CLDIDiscloserOFCommonStockReservedForFurtureTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfOutstandingWarrantsTextBlock" xlink:label="loc_CLDIScheduleOfOutstandingWarrantsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_CLDIScheduleOfOutstandingWarrantsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensationTables" xlink:title="999035 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxesTables" xlink:title="999036 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfIncomeTaxPaidTableTextBlock" xlink:label="loc_CLDIScheduleOfIncomeTaxPaidTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIScheduleOfIncomeTaxPaidTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingenciesTables" xlink:title="999037 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" xlink:label="loc_CLDIScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CLDIScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" xlink:label="loc_CLDIScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CLDIScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_srtContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative" xlink:title="999038 - Disclosure - Organization and Nature of Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="999039 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails" xlink:title="999040 - Disclosure - Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EarnoutSharesMember" xlink:label="loc_CLDIEarnoutSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CLDIEarnoutSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ContingentlyIssuableWarrantMember" xlink:label="loc_CLDIContingentlyIssuableWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CLDIContingentlyIssuableWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOperatingSegmentDetails" xlink:title="999041 - Disclosure - Schedule of Operating Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccountingPoliciesTable" xlink:label="loc_CLDIAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CLDIAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIAccountingPoliciesTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIAccountingPoliciesTable" xlink:to="loc_srtConsolidationItemsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense" xlink:label="loc_us-gaapGeneralInsuranceExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralInsuranceExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Consulting" xlink:label="loc_CLDIConsulting" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIConsulting" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RentAndMaintenance" xlink:label="loc_CLDIRentAndMaintenance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIRentAndMaintenance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClinicalResearchAndDevelopment" xlink:label="loc_CLDIClinicalResearchAndDevelopment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIClinicalResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:label="loc_CLDIChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OtherSegmentItems" xlink:label="loc_CLDIOtherSegmentItems" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIOtherSegmentItems" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLDINovaCellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_CLDINovaCellMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GovernmentGrantsMember" xlink:label="loc_CLDIGovernmentGrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIGovernmentGrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CaliforniaInstituteForRegenerativeMedicineMember" xlink:label="loc_CLDICaliforniaInstituteForRegenerativeMedicineMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDICaliforniaInstituteForRegenerativeMedicineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:label="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherOperatingActivities" xlink:label="loc_us-gaapProceedsFromOtherOperatingActivities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromOtherOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="loc_us-gaapGrantsReceivableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGrantsReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GrantsReceivableWithdrawn" xlink:label="loc_CLDIGrantsReceivableWithdrawn" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CLDIGrantsReceivableWithdrawn" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="999043 - Disclosure - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:label="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaapFairValueByLiabilityClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByLiabilityClassAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByLiabilityClassAxis" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsMember" xlink:label="loc_CLDIPublicWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_CLDIPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsMember" xlink:label="loc_CLDIPrivateWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="loc_CLDIPrivateWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails" xlink:title="999044 - Disclosure - Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaapFairValueByBalanceSheetGroupingTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueByBalanceSheetGroupingTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByBalanceSheetGroupingTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ForwardPurchaseAgreementDerivativeAssetMember" xlink:label="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIForwardPurchaseAgreementDerivativeAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsMember" xlink:label="loc_CLDIPublicWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsMember" xlink:label="loc_CLDIPrivateWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIPrivateWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999045 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccruedCompensation" xlink:label="loc_CLDIAccruedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_CLDIAccruedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AccruedVendorAndOtherExpenses" xlink:label="loc_CLDIAccruedVendorAndOtherExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_CLDIAccruedVendorAndOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999046 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrepaidExpenses" xlink:label="loc_CLDIPrepaidExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_CLDIPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails" xlink:title="999047 - Disclosure - Schedule of Machinery and Equipment, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative" xlink:title="999048 - Disclosure - Machinery and Equipment, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization" xlink:label="loc_us-gaapOtherDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapOtherDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="999049 - Disclosure - Schedule of Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAAndDirectorEMember" xlink:label="loc_CLDIDirectorAAndDirectorEMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAAndDirectorEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFAndRelativeOfOfficerAMember" xlink:label="loc_CLDIDirectorFAndRelativeOfOfficerAMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFAndRelativeOfOfficerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFMember" xlink:label="loc_CLDIDirectorFMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorDMember" xlink:label="loc_CLDIDirectorDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAOneMember" xlink:label="loc_CLDIDirectorAOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFOneMember" xlink:label="loc_CLDIDirectorFOneMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorATwoMember" xlink:label="loc_CLDIDirectorATwoMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorATwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFAndDirectorAMember" xlink:label="loc_CLDIDirectorFAndDirectorAMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFAndDirectorAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelativeOfOfficerAMember" xlink:label="loc_CLDIRelativeOfOfficerAMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIRelativeOfOfficerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerGMember" xlink:label="loc_CLDIOfficerGMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerAMember" xlink:label="loc_CLDIOfficerAMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CompanyARelatedToDirectorGMember" xlink:label="loc_CLDICompanyARelatedToDirectorGMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDICompanyARelatedToDirectorGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical" xlink:title="999050 - Disclosure - Schedule of Related Party Transactions (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorsAAndEMember" xlink:label="loc_CLDIDirectorsAAndEMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorsAAndEMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorFMember" xlink:label="loc_CLDIDirectorFMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorFMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorDMember" xlink:label="loc_CLDIDirectorDMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAMember" xlink:label="loc_CLDIDirectorAMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AJCCapitalMember" xlink:label="loc_CLDIAJCCapitalMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIAJCCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DirectorAThreeMember" xlink:label="loc_CLDIDirectorAThreeMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDirectorAThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RelativeOfOfficerAMember" xlink:label="loc_CLDIRelativeOfOfficerAMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIRelativeOfOfficerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerGMember" xlink:label="loc_CLDIOfficerGMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OfficerAMember" xlink:label="loc_CLDIOfficerAMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIOfficerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CompanyARelatedToDirectorGMember" xlink:label="loc_CLDICompanyARelatedToDirectorGMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDICompanyARelatedToDirectorGMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="loc_us-gaapGuaranteeObligationsByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapGuaranteeObligationsByNatureAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="loc_us-gaapGuaranteeObligationsNatureDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteeObligationsByNatureAxis" xlink:to="loc_us-gaapGuaranteeObligationsNatureDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyMember" xlink:label="loc_CLDIGuarantyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGuaranteeObligationsNatureDomain" xlink:to="loc_CLDIGuarantyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableMember" xlink:label="loc_us-gaapLoansPayableMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapLoansPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ConsultingPay" xlink:label="loc_CLDIConsultingPay" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CLDIConsultingPay" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:label="loc_us-gaapNoninterestExpenseInvestmentAdvisoryFees" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNoninterestExpenseInvestmentAdvisoryFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyOfLeaseAmount" xlink:label="loc_CLDIGuarantyOfLeaseAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CLDIGuarantyOfLeaseAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorOperatingLeaseDescription" xlink:label="loc_us-gaapLessorOperatingLeaseDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="loc_us-gaapOperatingLeaseLeaseIncomeLeasePayments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapOperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationPay" xlink:label="loc_CLDISeparationPay" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CLDISeparationPay" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails" xlink:title="999051 - Disclosure - Schedule of Outstanding Debt Obligations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNoteMember" xlink:label="loc_CLDIPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDIPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TermNotesPayableMember" xlink:label="loc_CLDITermNotesPayableMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITermNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_BridgeLoanPayableMember" xlink:label="loc_CLDIBridgeLoanPayableMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDIBridgeLoanPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails" xlink:title="999052 - Disclosure - Schedule of Maturities of Outstanding Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/DebtDetailsNarrative" xlink:title="999053 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyOneTermNoteMember" xlink:label="loc_CLDITwoThousandTwentyOneTermNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyOneTermNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyTwoTermNotePayableMember" xlink:label="loc_CLDITwoThousandTwentyTwoTermNotePayableMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyTwoTermNotePayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeTermNotePayableMember" xlink:label="loc_CLDITwoThousandTwentyThreeTermNotePayableMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeTermNotePayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember" xlink:label="loc_CLDITwoThousandTwentyThreeTermNotePayableTwoMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeTermNotePayableTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyFourBridgeLoanMember" xlink:label="loc_CLDITwoThousandTwentyFourBridgeLoanMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CLDITwoThousandTwentyFourBridgeLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_InvestorAndDirectorMember" xlink:label="loc_CLDIInvestorAndDirectorMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIInvestorAndDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyFourPurchaseAgreementMember" xlink:label="loc_CLDITwoThousandTwentyFourPurchaseAgreementMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDITwoThousandTwentyFourPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PromissoryNoteLoanAgreementMember" xlink:label="loc_CLDIPromissoryNoteLoanAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIPromissoryNoteLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaapDebtWeightedAverageInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtWeightedAverageInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingVariableInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCommonStockReservedDetails" xlink:title="999054 - Disclosure - Schedule of Common Stock Reserved (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockOptionsIssuedAndOutstandingMember" xlink:label="loc_CLDICommonStockOptionsIssuedAndOutstandingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDICommonStockOptionsIssuedAndOutstandingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RestrictedStockUnitsVestedAndUnreleasedMember" xlink:label="loc_CLDIRestrictedStockUnitsVestedAndUnreleasedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDIRestrictedStockUnitsVestedAndUnreleasedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreeEquityIncentivePlanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreeEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails" xlink:title="999055 - Disclosure - Schedule of Outstanding Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PrivateWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIPrivateWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPrivateWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIPublicWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPublicWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantsToPurchaseRestrictedSharesMember" xlink:label="loc_CLDIWarrantsToPurchaseRestrictedSharesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIWarrantsToPurchaseRestrictedSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_WarrantsToPurchaseRestrictedSharesOneMember" xlink:label="loc_CLDIWarrantsToPurchaseRestrictedSharesOneMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIWarrantsToPurchaseRestrictedSharesOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockOneMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockTwoMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockThreeMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFourMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember" xlink:label="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFiveMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIPlacementAgentWarrantsToPurchaseCommonStockFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepresentativeWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDIRepresentativeWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIRepresentativeWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesAWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesAWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesAWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockOneMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockThreeMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockTwoMember" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember" xlink:label="loc_CLDISeriesB1WarrantsToPurchaseCommonStockFourMember" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesB1WarrantsToPurchaseCommonStockFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesC1WarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesC1WarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember" xlink:label="loc_CLDISeriesC1WarrantsToPurchaseCommonStockOneMember" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesC1WarrantsToPurchaseCommonStockOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember" xlink:label="loc_CLDISeriesC1WarrantsToPurchaseCommonStockTwoMember" />
      <link:presentationArc order="810" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesC1WarrantsToPurchaseCommonStockTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesDWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="850" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesDWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesEWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesEWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="890" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesEWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesFWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesFWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="930" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesFWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesGWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="970" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesGWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesHWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="1010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesHWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesIWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesIWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="1050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesIWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClassOfWarrantOrRighstIssuanceDate" xlink:label="loc_CLDIClassOfWarrantOrRighstIssuanceDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIClassOfWarrantOrRighstIssuanceDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical" xlink:title="999056 - Disclosure - Schedule of Outstanding Warrants (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RedemptionOfWarrantsMember" xlink:label="loc_CLDIRedemptionOfWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDIRedemptionOfWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesAWarrantsMember" xlink:label="loc_CLDISeriesAWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsMember" xlink:label="loc_CLDISeriesBWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsToPurchaseCommonStockMember" xlink:label="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBOneWarrantsMember" xlink:label="loc_CLDISeriesBOneWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesBOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsMember" xlink:label="loc_CLDISeriesCOneWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesCOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsOneMember" xlink:label="loc_CLDISeriesCOneWarrantsOneMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesCOneWarrantsOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDWarrantsMember" xlink:label="loc_CLDISeriesDWarrantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesDWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesEWarrantsAndSeriesFWarrantsMember" xlink:label="loc_CLDISeriesEWarrantsAndSeriesFWarrantsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesEWarrantsAndSeriesFWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGPreFundedWarrantsMember" xlink:label="loc_CLDISeriesGPreFundedWarrantsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesGPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesIPreFundedWarrantsMember" xlink:label="loc_CLDISeriesIPreFundedWarrantsMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CLDISeriesIPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TriggeringEventAxis" xlink:label="loc_CLDITriggeringEventAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_CLDITriggeringEventAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TriggeringEventDomain" xlink:label="loc_CLDITriggeringEventDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDITriggeringEventAxis" xlink:to="loc_CLDITriggeringEventDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" xlink:label="loc_CLDISharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDITriggeringEventDomain" xlink:to="loc_CLDISharePriceEqualOrLessTenPointZeroRupeesPerDollarMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:label="loc_CLDISharePriceEqualOrExceedsEighteenRupeesPerDollarMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDITriggeringEventDomain" xlink:to="loc_CLDISharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PublicWarrantRedemptionDescription" xlink:label="loc_CLDIPublicWarrantRedemptionDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIPublicWarrantRedemptionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RedemptionOfOutstandingWarrantsPerShare" xlink:label="loc_CLDIRedemptionOfOutstandingWarrantsPerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIRedemptionOfOutstandingWarrantsPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ClassOfWarrantsRedemptionNoticePeriod" xlink:label="loc_CLDIClassOfWarrantsRedemptionNoticePeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIClassOfWarrantsRedemptionNoticePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Deemeddividend" xlink:label="loc_CLDIDeemeddividend" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CLDIDeemeddividend" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999057 - Disclosure - Schedule of Warrant Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:label="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_CLDIShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative" xlink:title="999058 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_VotingCommonStockMember" xlink:label="loc_CLDIVotingCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDIVotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="loc_us-gaapNonvotingCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapNonvotingCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesECommonWarrantsMember" xlink:label="loc_CLDISeriesECommonWarrantsMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesECommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesFCommonWarrantsMember" xlink:label="loc_CLDISeriesFCommonWarrantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesFCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGCommonWarrantsMember" xlink:label="loc_CLDISeriesGCommonWarrantsMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesGCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHCommonStockWarrantsMember" xlink:label="loc_CLDISeriesHCommonStockWarrantsMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesHCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBWarrantsAndSeriesCWarrantsMember" xlink:label="loc_CLDISeriesBWarrantsAndSeriesCWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesBWarrantsAndSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesBOneWarrantsMember" xlink:label="loc_CLDISeriesBOneWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesBOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesCOneWarrantsMember" xlink:label="loc_CLDISeriesCOneWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesCOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesDCommonStockMember" xlink:label="loc_CLDISeriesDCommonStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDISeriesDCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgentWarrantsMember" xlink:label="loc_CLDIPlacementAgentWarrantsMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDIPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantsMember" xlink:label="loc_CLDIPreFundedWarrantsMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDIPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RepresentativeWarrantsMember" xlink:label="loc_CLDIRepresentativeWarrantsMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CLDIRepresentativeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_InducementOfferLetterAgreementMember" xlink:label="loc_CLDIInducementOfferLetterAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIInducementOfferLetterAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SubscriptionAgreementMember" xlink:label="loc_CLDISubscriptionAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SalesAgreementMember" xlink:label="loc_CLDISalesAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MarketOfferingAgreementMember" xlink:label="loc_CLDIMarketOfferingAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIMarketOfferingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SecuritiesPurchaseAgreementMember" xlink:label="loc_CLDISecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PlacementAgencyAgreementMember" xlink:label="loc_CLDIPlacementAgencyAgreementMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIPlacementAgencyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_JulyWarrantInducementOfferMember" xlink:label="loc_CLDIJulyWarrantInducementOfferMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIJulyWarrantInducementOfferMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritingAgreementMember" xlink:label="loc_CLDIUnderwritingAgreementMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_BoardOfDirectorsMember" xlink:label="loc_CLDIBoardOfDirectorsMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLDINovaCellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NovaCellMember" xlink:label="loc_CLDINovaCellMember_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_CLDINovaCellMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantUnitsMember" xlink:label="loc_CLDIPreFundedWarrantUnitsMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDIPreFundedWarrantUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockDividend" xlink:label="loc_CLDICommonStockDividend" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDICommonStockDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PercentageOfStrategicInvestment" xlink:label="loc_CLDIPercentageOfStrategicInvestment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIPercentageOfStrategicInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset" xlink:label="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDerivativeAssetCollateralObligationToReturnCashOffset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaapDebtInstrumentDecreaseForgiveness" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentDecreaseForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CashCommissionPercentage" xlink:label="loc_CLDICashCommissionPercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDICashCommissionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DisbursementsCounsel" xlink:label="loc_CLDIDisbursementsCounsel" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIDisbursementsCounsel" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:label="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:label="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDIIssuanceOfCommonSharesThroughAugustPublicOfferingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockUnitPerShareDescription" xlink:label="loc_CLDICommonStockUnitPerShareDescription" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CLDICommonStockUnitPerShareDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfStockOptionActivityDetails" xlink:title="999059 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails" xlink:title="999060 - Disclosure - Summary of Restricted Stock Unit Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999061 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StatementOfIncomeLocationBalanceAxis" xlink:label="loc_CLDIStatementOfIncomeLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_CLDIStatementOfIncomeLocationBalanceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StatementOfIncomeLocationBalanceDomain" xlink:label="loc_CLDIStatementOfIncomeLocationBalanceDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceAxis" xlink:to="loc_CLDIStatementOfIncomeLocationBalanceDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ResearchAndDevelopmentExpensesMember" xlink:label="loc_CLDIResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CLDIResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GeneralAndAdministrativeExpensesMember" xlink:label="loc_CLDIGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIStatementOfIncomeLocationBalanceDomain" xlink:to="loc_CLDIGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="999062 - Disclosure - Schedule of Stock Options Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999063 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_TwoThousandTwentyThreePlanMember" xlink:label="loc_CLDITwoThousandTwentyThreePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDITwoThousandTwentyThreePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EmployeeStockPurchasePlanMember" xlink:label="loc_CLDIEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CLDIEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AdministratorMember" xlink:label="loc_CLDIAdministratorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIAdministratorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockDiscounRate" xlink:label="loc_CLDICommonStockDiscounRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CLDICommonStockDiscounRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NoncashCompensation" xlink:label="loc_CLDINoncashCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CLDINoncashCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:title="999064 - Disclosure - Schedule of Income (Loss) Before Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AmericasMember" xlink:label="loc_srtAmericasMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAmericasMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaapNonUsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_us-gaapNonUsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails" xlink:title="999065 - Disclosure - Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="999066 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:label="loc_CLDIIncomeTaxReconciliationEnactmentOfNewTaxLaws" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIIncomeTaxReconciliationEnactmentOfNewTaxLaws" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCredits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxSettlements" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlements" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItemsAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxReconciliationOtherReconcilingItemsAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationOtherPermanentDifferences" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationStockIssuanceCost" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationStockIssuanceCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationAcquiredStartupCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:label="loc_CLDIIncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIIncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:label="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:label="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIIncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:label="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:label="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIIncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:label="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIEffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails" xlink:title="999067 - Disclosure - Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)">
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract" xlink:label="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:label="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract" xlink:to="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CLDIScheduleofCashPaidForIncomeTaxesRefundsReceivedTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_AU" xlink:label="loc_countryAU" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE" xlink:label="loc_countryDE" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryDE" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:label="loc_us-gaapIncomeTaxPaidFederalAfterRefundReceived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPaidFederalAfterRefundReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncomeTaxPaidStateAfterRefundReceived" xlink:label="loc_CLDIIncomeTaxPaidStateAfterRefundReceived" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CLDIIncomeTaxPaidStateAfterRefundReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidForeignAfterRefundReceived" xlink:label="loc_us-gaapIncomeTaxPaidForeignAfterRefundReceived" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxPaidForeignAfterRefundReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999068 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_CLDIDeferredTaxAssetsLeaseLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIDeferredTaxAssetsLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:label="loc_CLDIDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIDeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="loc_CLDIDeferredTaxAssetsDepreciationAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIDeferredTaxAssetsDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:label="loc_CLDIDeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CLDIDeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails" xlink:title="999069 - Disclosure - Schedule of Unrecognized Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/IncomeTaxesDetailsNarrative" xlink:title="999070 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PriorDecemberTwentySeventeenthMember" xlink:label="loc_CLDIPriorDecemberTwentySeventeenthMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_CLDIPriorDecemberTwentySeventeenthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_AfterDecemberTwentySeventeenthMember" xlink:label="loc_CLDIAfterDecemberTwentySeventeenthMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_CLDIAfterDecemberTwentySeventeenthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="999071 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="999072 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:label="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:title="999073 - Disclosure - Schedule of Future Minimum Lease Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_CLDILesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_CLDILesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_CLDIFinanceLeaseLiabilityPaymentsDueAfterYearFour" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_CLDIFinanceLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999074 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SanDiegoLeaseAgreementMember" xlink:label="loc_CLDISanDiegoLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISanDiegoLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrCamaisaMember" xlink:label="loc_CLDIMrCamaisaMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIMrCamaisaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StemVacOfficeLeaseAgreementMember" xlink:label="loc_CLDIStemVacOfficeLeaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIStemVacOfficeLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_NorthwesternAgreementMember" xlink:label="loc_CLDINorthwesternAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDINorthwesternAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LicenseAgreementMember" xlink:label="loc_CLDILicenseAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDILicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationAndReleaseAgreementMember" xlink:label="loc_CLDISeparationAndReleaseAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDISeparationAndReleaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_StandbyEquityPurchaseAgreementMember" xlink:label="loc_CLDIStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GeorgeNgMember" xlink:label="loc_CLDIGeorgeNgMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIGeorgeNgMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrLeftwichMember" xlink:label="loc_CLDIMrLeftwichMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIMrLeftwichMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Dr.CamisaMember" xlink:label="loc_CLDIDr.CamisaMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDr.CamisaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Dr.MinevMember" xlink:label="loc_CLDIDr.MinevMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIDr.MinevMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_Ms.CampbellMember" xlink:label="loc_CLDIMs.CampbellMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CLDIMs.CampbellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrCamaisaMember" xlink:label="loc_CLDIMrCamaisaMember_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIMrCamaisaMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_MrLeftwichMember" xlink:label="loc_CLDIMrLeftwichMember_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CLDIMrLeftwichMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SettlementOfDeferredCompensationMember" xlink:label="loc_CLDISettlementOfDeferredCompensationMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CLDISettlementOfDeferredCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_YorkvilleMember" xlink:label="loc_CLDIYorkvilleMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CLDIYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_GuarantyOfLeaseAmount" xlink:label="loc_CLDIGuarantyOfLeaseAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIGuarantyOfLeaseAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_OperatingLeaseTermOfContractLeaseInitialTerm" xlink:label="loc_CLDIOperatingLeaseTermOfContractLeaseInitialTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIOperatingLeaseTermOfContractLeaseInitialTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent" xlink:label="loc_CLDILeaseTermsOperatingLeasesAnnualIncreaseInRent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDILeaseTermsOperatingLeasesAnnualIncreaseInRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_RemainingExpectedCommitments" xlink:label="loc_CLDIRemainingExpectedCommitments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIRemainingExpectedCommitments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaapOtherCommitment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommitmentFeePercentage" xlink:label="loc_CLDICommitmentFeePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDICommitmentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaapLongtermPurchaseCommitmentPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLongtermPurchaseCommitmentPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCompensationEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCompensationLiabilityCurrentAndNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_EquityPurchaseDescription" xlink:label="loc_CLDIEquityPurchaseDescription" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIEquityPurchaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeparationPay" xlink:label="loc_CLDISeparationPay" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDISeparationPay" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_IncurredCosts" xlink:label="loc_CLDIIncurredCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CLDIIncurredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaapAccruedEmployeeBenefitsCurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccruedEmployeeBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://calidibio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999075 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockUnitsMember" xlink:label="loc_CLDICommonStockUnitsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDICommonStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_PreFundedWarrantUnitsMember" xlink:label="loc_CLDIPreFundedWarrantUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDIPreFundedWarrantUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritersWarrantMember" xlink:label="loc_CLDIUnderwritersWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CLDIUnderwritersWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_UnderwritingAgreementMember" xlink:label="loc_CLDIUnderwritingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDIUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_CommonStockPurchaseWarrantsAgreementMember" xlink:label="loc_CLDICommonStockPurchaseWarrantsAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CLDICommonStockPurchaseWarrantsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesJWarrantsMember" xlink:label="loc_CLDISeriesJWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesJWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesKWarrantsMember" xlink:label="loc_CLDISeriesKWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesKWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesLWarrantsMember" xlink:label="loc_CLDISeriesLWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesLWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesGCommonStockWarrantsMember" xlink:label="loc_CLDISeriesGCommonStockWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesGCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesHCommonStockWarrantsMember" xlink:label="loc_CLDISeriesHCommonStockWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesHCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cldi-20251231.xsd#CLDI_SeriesICommonStockWarrantsMember" xlink:label="loc_CLDISeriesICommonStockWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CLDISeriesICommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 20, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CALIDI
BIOTHERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001855485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-2967193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4475
    Executive Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">794-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLDI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,895,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">199<span></span>
</td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Calidi Biotherapeutics, Inc. (the &#8220;Company&#8221;) as of December 31,
2025 , the related consolidated statements of operations, comprehensive loss, total equity and cash flows for the year ended December
31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations
and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States
of America.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CBIZ
CPAs P.C<span></span>
</td>
<td class="text">Marcum
 LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Costa
Mesa, California<span></span>
</td>
<td class="text">Costa
Mesa, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 9,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,256<span></span>
</td>
<td class="nump">10,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NONCURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Machinery and equipment, net</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">8,857<span></span>
</td>
<td class="nump">14,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease right-of-use liability, current</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,935<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NONCURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease right-of-use liability, noncurrent</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liability, noncurrent</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_PromissoryNote', window );">Promissory note</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RelatedPartyWarrantLiability', window );">Related party warrant liability</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">5,098<span></span>
</td>
<td class="nump">12,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>TOTAL EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 330,000 shares authorized; 7,217 and 1,730 shares issued and outstanding as of December 31, 2025 and 2024, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">145,392<span></span>
</td>
<td class="nump">123,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net of tax</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(141,621)<span></span>
</td>
<td class="num">(121,715)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND TOTAL EQUITY</a></td>
<td class="nump">8,857<span></span>
</td>
<td class="nump">14,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_TermNotesPayableCurrent', window );">Term notes payable, net of discount, including accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_TermNotesPayableCurrent', window );">Term notes payable, net of discount, including accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Related party bridge loan payable, including accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party other current liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_PromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_PromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RelatedPartyWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RelatedPartyWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_TermNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term notes payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_TermNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, share issued</a></td>
<td class="nump">7,216,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,216,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (9,737)<span></span>
</td>
<td class="num">$ (8,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(10,503)<span></span>
</td>
<td class="num">(12,898)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="num">(20,240)<span></span>
</td>
<td class="num">(21,776)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,240)<span></span>
</td>
<td class="num">(21,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty', window );">Change in fair value of other liabilities and derivatives</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty', window );">Change in fair value of other liabilities and derivatives &#8211; related party</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_GrantIncome', window );">Grant income</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of investment in Nova Cell</a></td>
<td class="nump">244<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="nump">192<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(20,048)<span></span>
</td>
<td class="num">(22,195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(20,063)<span></span>
</td>
<td class="num">(22,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST</a></td>
<td class="num">(19,906)<span></span>
</td>
<td class="num">(22,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DeemedDividendOnWarrants', window );">Deemed dividend on warrants</a></td>
<td class="num">(5,673)<span></span>
</td>
<td class="num">(1,671)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (25,579)<span></span>
</td>
<td class="num">$ (23,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (5.95)<span></span>
</td>
<td class="num">$ (35.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (5.95)<span></span>
</td>
<td class="num">$ (35.70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">$ (131)<span></span>
</td>
<td class="num">$ (372)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (561)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of other liabilities and derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of other liabilities and derivatives &#8211; related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DeemedDividendOnWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DeemedDividendOnWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong> Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">$ (20,063)<span></span>
</td>
<td class="num">$ (22,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">(20,048)<span></span>
</td>
<td class="num">(22,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (19,891)<span></span>
</td>
<td class="num">$ (22,124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Total Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="num">$ (8,235)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 91,384<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="num">$ (99,572)<span></span>
</td>
<td class="num">$ (8,235)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts', window );">Issuance of common stock through May Inducement Offer, net of financing costs</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,818<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts', window );">Issuance of common shares through May Inducement Offer, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,957<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,957<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,957<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(22,209)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,143)<span></span>
</td>
<td class="num">(22,143)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">123,277<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(121,715)<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock in lieu of cash for services</a></td>
<td class="nump">369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock in lieu of cash for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee', window );">Issuance of common stock in lieu of cash for SEPA commitment fee</a></td>
<td class="nump">81<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee', window );">Issuance of common stock in lieu of cash for commitment fee, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Calidi stockholders as result of Merger</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Calidi stockholders as result of Merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees', window );">Financing fees</a></td>
<td class="num">(327)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts', window );">Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs</a></td>
<td class="nump">4,822<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,822<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,822<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts', window );">Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock per Convertible Note conversion</a></td>
<td class="nump">3,071<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,071<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock per Convertible Note conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants', window );">Exercise of common stock warrants</a></td>
<td class="nump">4,803<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,803<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Exercise of common stock warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement', window );">Issuance of restricted stock units for liability settlement</a></td>
<td class="nump">133<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement', window );">Issuance of common stock and warrants for legal settlement</a></td>
<td class="nump">308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement', window );">Issuance of common stock and warrants for legal settlement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares', window );">Issuance of common stock for Reverse Stock Split fractional shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares', window );">Issuance of common stock for Reverse Stock Split fractional shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement', window );">Issuance of common stock and warrants per subscription agreement</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares', window );">Issuance of common shares and warrants per subscription agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering', window );">Issuance of common stock and warrants for registered direct offering</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering', window );">Issuance of common stock and warrants for registered direct offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering', window );">Issuance of common stock through At the Market Offering</a></td>
<td class="nump">3,063<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,063<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,063<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering', window );">Issuance of common stock through At the Market Offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing', window );">Issuance of common stock through November Public Offering, net of financing</a></td>
<td class="nump">6,662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,662<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,662<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing', window );">Issuance of common stock through November Public Offering, net of financing, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueInvestment', window );">Investment in Nova Cell</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit shares released</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock unit shares released, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock through At the Market Offering</a></td>
<td class="nump">3,201<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock through At the Market Offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts', window );">Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs</a></td>
<td class="nump">3,607<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,607<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,607<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares', window );">Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts', window );">Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs</a></td>
<td class="nump">$ 3,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,423<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares', window );">Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering', window );">Issuance of common stock through August Public Offering</a></td>
<td class="nump">5,768,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">5,767,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,768,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares', window );">Issuance of common stock through August Public Offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,759,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts', window );">Issuance of common stock through May Inducement Offer, net of financing costs</a></td>
<td class="nump">4,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts', window );">Issuance of common shares through May Inducement Offer, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueReverseStockSplits', window );">Issuance of common stock for Reverse Stock Split fractional shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of common stock for Reverse Stock Split fractional shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock unit shares released</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock unit shares released, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StockIssuedDuringPeriodValueSaleOfInvestment', window );">Sale of investment in Nova Cell</a></td>
<td class="num">(277)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(20,063)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,906)<span></span>
</td>
<td class="num">(19,906)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 145,392<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (141,621)<span></span>
</td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,216,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted stock units for liability settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares through august public offering shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for march registered direct offering and concurrent private placement net of financing costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for march registered direct offering and concurrent private placement net of financing costs shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants through january confidentially marketed public offering net of financing costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants through january confidentially marketed public offering net of financing costs shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of common prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of common stock warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants per subscription agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for legal settlement, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for registered direct offering, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for Reverse Stock Split fractional, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through At the Market Offering, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through July Inducement Offer, net of financing costs, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through august public offering, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through November Public Offering, net of financing, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares lieu of cash for commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of common prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for legal settlement, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for registered direct offering, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants per subscription agreement, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for Reverse Stock Split fractional, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through At the Market Offering, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through July Inducement Offer, net of financing costs, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock through November Public Offering, net of financing, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value lieu of cash for commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value reverse stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StockIssuedDuringPeriodValueSaleOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value sale of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StockIssuedDuringPeriodValueSaleOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (20,063)<span></span>
</td>
<td class="num">$ (22,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,651<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="nump">2,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives', window );">Change in fair value of other liabilities and derivatives</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of investment in Nova Cell</a></td>
<td class="num">(244)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">1,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,328)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,993)<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease right of use liability</a></td>
<td class="num">(1,380)<span></span>
</td>
<td class="num">(1,017)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,293)<span></span>
</td>
<td class="num">(19,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of machinery and equipment</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Cash disposed in sale of investment in Nova Cell</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ProceedsFromPublicOfferings', window );">Proceeds from public offerings</a></td>
<td class="nump">9,883<span></span>
</td>
<td class="nump">13,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ProceedsFromWarrantInducementFinancing', window );">Proceeds from warrant inducement financing</a></td>
<td class="nump">4,136<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ProceedsFromRegisteredDirectOffering', window );">Proceeds from registered direct offering</a></td>
<td class="nump">3,503<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from at the market offering</a></td>
<td class="nump">3,268<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of pre-funded warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Repayment of financing lease obligations</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of principal on term notes payable</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable', window );">Repayment of principal on related party bridge loan payable</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of financing costs</a></td>
<td class="num">(846)<span></span>
</td>
<td class="num">(1,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of principal on related party term notes payable</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ProceedsFromIssuanceOfNoncontrollingInterest', window );">Proceeds from issuance of noncontrolling interest in Nova Cell</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party proceeds from issuance of loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of promissory note</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement', window );">Proceeds from issuance of common stock and warrants per subscription agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RepaymentOfConvertibleNotePayable', window );">Repayment of convertible note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_PaymentOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,459<span></span>
</td>
<td class="nump">27,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH</a></td>
<td class="num">(3,990)<span></span>
</td>
<td class="nump">7,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract', window );"><strong>CASH AND RESTRICTED CASH BALANCE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">At beginning of the year</a></td>
<td class="nump">9,809<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">At end of the year</a></td>
<td class="nump">5,819<span></span>
</td>
<td class="nump">9,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_CashPaidForIncomeTaxes', window );">Cash paid for income taxes</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DeemedDividendOnWarrants', window );">Deemed dividend on warrants</a></td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">1,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases', window );">Machinery and equipment acquired through financing leases</a></td>
<td class="nump">152<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities', window );">Financing fees included in accounts payable and accrued liabilities</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote', window );">Issuance of common stock per conversion of convertible note</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfConvertibleNoteForLegalSettlement', window );">Issuance of convertible note for legal settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockInLieuOfCashForServices', window );">Issuance of common stock in lieu of cash for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices', window );">Related party issuance of common stock in lieu of cash for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement', window );">Issuance of common stock and warrants for legal settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DebtDiscountOnConvertibleNotes', window );">Debt discount on Convertible Notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee', window );">Issuance of common stock in lieu of cash for SEPA commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement', window );">Issuance of restricted stock units for liability settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_CashPaidForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_CashPaidForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of other liabilities and derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DebtDiscountOnConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount on convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DebtDiscountOnConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DeemedDividendOnWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DeemedDividendOnWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing fees included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants for legal settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in lieu of cash for SEPA commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockInLieuOfCashForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in lieu of cash for services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockInLieuOfCashForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock per conversion of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfConvertibleNoteForLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of convertible note for legal settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfConvertibleNoteForLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of restricted stock units for liability settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Machinery and equipment acquired through financing leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_PaymentOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_PaymentOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance oif common shares and warrants per subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ProceedsFromIssuanceOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ProceedsFromIssuanceOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ProceedsFromPublicOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from public offerings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ProceedsFromPublicOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ProceedsFromRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from registered direct offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ProceedsFromRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ProceedsFromWarrantInducementFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrant inducement financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ProceedsFromWarrantInducementFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party issuance of common stock in lieu of cash for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RepaymentOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of convertible note payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RepaymentOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of principal on related party bridge loan payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (19,906)<span></span>
</td>
<td class="num">$ (22,143)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_NoInsiderTradingFlag', window );">No Insider Trading Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_NoInsiderTradingFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Insider Trading Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_NoInsiderTradingFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Risk Management and Strategy </b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our business operations, we use information technology, enterprise applications, communications tools, cloud network solutions, and related
systems to manage our operations, including to manage our building systems, vendor relationships, accounting and recordkeeping, and communications,
among other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and implemented a cybersecurity risk management program intended to protect our confidential and proprietary data, and
information technology and systems, from cybersecurity threats, including unauthorized access or attack. We leverage the <span style="background-color: white">SOC
2 TYPE II Cybersecurity Framework</span> as a guide to help us identify, assess, and manage cybersecurity risks relevant to the business.
This does not imply that we meet any particular technical standards, specifications, or requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_z8kUlrtVHL0h">Our
processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting
risks, reputational risks, personal data theft, fraud, and other potential risks, are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zEt31mjqkBc7">integrated</span> into our overall enterprise risk management
process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management
process to other legal, compliance, strategic, operational, and financial risk areas.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
cybersecurity risk management program includes the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zUWh7b63Blrh">a
    multidisciplinary team comprised of personnel from information technology (&#8220;IT&#8221;), internal audit, accounting, and legal,
    as well as third-party cybersecurity experts principally responsible for directing (i) our cybersecurity risk assessment processes,
    (ii) our security processes, and (iii) our response to cybersecurity incidents, and a third-party security operations center.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20250101__20251231_zHrhPwGDwmbd">risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, services, and our broader
    enterprise IT environment.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">internal
    and third-party security tools to monitor our systems, identify cybersecurity risks, and test our IT environment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    use of third-party cybersecurity experts, where appropriate, to assess, test or otherwise assist with aspects of our security processes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    cybersecurity incident response plan and business continuity plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cybersecurity
    training for employees and key business partners with access to our systems.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


&#160;<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zAZTzy62pWOl">a
    third-party cybersecurity risk management process for service providers and vendors who access our systems.</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    employees, as well as third parties who have access to our systems, to treat confidential and private information and data with care,
    including performing controls relating to such data; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cybersecurity
    risk insurance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also seek to engage reputable service providers that maintain cybersecurity programs or controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not identified risks from known cybersecurity threats within the prior fiscal year, including as a result of any prior cybersecurity
incident, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of
operations, or financial condition. Please refer to &#8220;Item 1A, Risk Factors&#8221; in this report for additional information about
certain ongoing risks related to our information technology that, if realized, are reasonably likely to materially affect us, including
our operations, business strategy, results of operations, or financial condition.</span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our
processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting
risks, reputational risks, personal data theft, fraud, and other potential risks, are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zEt31mjqkBc7">integrated</span> into our overall enterprise risk management
process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management
process to other legal, compliance, strategic, operational, and financial risk areas.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The
Board, in coordination with the Audit Committee, oversees the Company&#8217;s enterprise risk management process, including the management
of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party
cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management&#8217;s processes
to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
Governance </b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity
is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zRtHrDPYdBW6">The
Board, in coordination with the Audit Committee, oversees the Company&#8217;s enterprise risk management process, including the management
of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party
cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management&#8217;s processes
to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes.</span> The Audit
Committee periodically provides updates on these matters to the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including
an independent third-party expert we have retained to identify and assess material risks from cybersecurity threats, their severity,
and potential mitigation steps. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zfQOOwY64LW">The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zt0tw5FZIhHh">CISO</span> is primarily responsible for leading our cybersecurity risk assessment and management processes.
Our executive staff, supported by external IT, currently serves as our CISO. The CISO regularly reviews and assesses cybersecurity initiatives,
including our incident response plan, as well as cybersecurity compliance, training, and risk management efforts.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zt0tw5FZIhHh">CISO</span> is primarily responsible for leading our cybersecurity risk assessment and management processes.
Our executive staff, supported by external IT, currently serves as our CISO. The CISO regularly reviews and assesses cybersecurity initiatives,
including our incident response plan, as well as cybersecurity compliance, training, and risk management efforts.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><p id="xdx_808_eus-gaap--NatureOfOperations_zyRs3sqVBFpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82B_z6SIGxn0cgDl">Organization and Nature of Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2023, First Light Acquisition Group, Inc., a Delaware corporation (&#8220;FLAG&#8221;) consummated a series of transactions
that resulted in the merger of FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG and Calidi Biotherapeutics.
Inc., a Nevada corporation (&#8220;Calidi&#8221; and the transactions the &#8220;Business Combination&#8221;). Following the consummation
of the Business Combination, FLAG was renamed &#8220;Calidi Biotherapeutics, Inc.&#8221; and Calidi was renamed &#8220;Calidi Biotherapeutics
(Nevada), Inc. and became a wholly owned subsidiary of the Company. Unless the context otherwise requires, the &#8220;Company&#8221;
refers to Calidi Biotherapeutics, Inc., a Delaware corporation (f/k/a First Light Acquisition Group, Inc., a Delaware corporation) and
its consolidated subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a biotechnology company that is pioneering the development of targeted therapies with the potential to
deliver genetic medicines to distal sites of disease. The Company&#8217;s proprietary RedTail platform features an engineered
enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended
to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent
genetic medicine(s) to metastatic locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations to date have focused on organization and staffing, business planning, raising capital, licensing, acquiring
and developing technology, establishing intellectual property portfolio, identifying potential product candidates and undertaking preclinical
studies, process development and manufacturing for preclinical and clinical trials. The Company&#8217;s product candidates are subject
to long development cycles and the Company may be unsuccessful in its efforts to develop, obtain regulatory approval for or market its
product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, possible failure of preclinical studies or clinical trials, the need to obtain marketing approval for its product candidates, development
by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government
regulations, the need to successfully commercialize and gain market acceptance of any of the Company&#8217;s products that are approved
and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant
additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize
significant revenue from product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2024, the Company filed a First Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with
the Secretary of State of the State of Delaware to effect a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240710__20240710_zv1gDIQi7Eo4" title="Reverse stock split">1-for-10 reverse stock split</span> of the shares of the Company&#8217;s common
stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240710_z7bDjUWq4mf5" title="Common stock, par value">0.0001</span> per share (&#8220;Common Stock&#8221;), effective on July 15, 2024 (the &#8220;2024 Reverse Stock Split&#8221;).
As a result of the 2024 Reverse Stock Split, every ten shares of issued and outstanding Common Stock were automatically combined into
one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as
a result of the 2024 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2024 Reverse Stock Split
were rounded up to the next whole number. The number of authorized shares of Common Stock under the Company&#8217;s Second Amended and
Restated Certificate of Incorporation, as amended, remained unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2025, the Company filed a Second Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation,
as amended, with the Secretary of State of the State of Delaware to effect a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250801__20250801_zwAdhSjdvUa6" title="Reverse stock split">1-for-12 reverse stock split</span> of the shares of the Company&#8217;s
Common Stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250801_zfRjzpOigpL2" title="Common stock, par value">0.0001</span> per share, effective on August 4, 2025 (the &#8220;2025 Reverse Stock Split&#8221;). As a result of the
2025 Reverse Stock Split, every twelve shares of issued and outstanding Common Stock were automatically combined into one issued and
outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the
2025 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2025 Reverse Stock Split were rounded
up to the next whole number. The number of authorized shares of Common Stock under the Company&#8217;s Second Amended and Restated Certificate
of Incorporation, as amended, remained unchanged. Trading of the Company&#8217;s shares of Common Stock on the NYSE American, LLC commenced
on a split-adjusted basis on August 5, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to share and per share amounts for all periods presented in the consolidated financial statements have been retrospectively
restated to reflect the 2024 Reverse Stock Split and 2025 Reverse Stock Split. All rights to receive shares of common stock under outstanding
securities, including but not limited to, warrants, options, and restricted stock units (&#8220;RSUs&#8221;) were adjusted to give effect
to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise price and the number of shares
of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of shares of
Common Stock reserved for future issuance under the Company&#8217;s 2023 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement
of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has experienced recurring losses from operations and negative cash flows from operating activities, has a significant
accumulated deficit and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit
of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20251231_zk06nREp42Wf" title="Accumulated deficit">141.6</span>
million at December 31, 2025. During the year ended December 31, 2025, the Company used $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20251231_z2dAqc8NaTji" title="Net cash used in operating activities">21.3</span>
million in cash for operating activities. As of December 31, 2025, the Company had cash of $<span id="xdx_908_eus-gaap--Cash_iI_pn5n6_c20251231_zJ251Rwzisu9" title="Cash">5.6</span>
million and restricted cash of $<span id="xdx_907_eus-gaap--RestrictedCash_iI_pn5n6_c20251231_zFhtPyLf6uyf" title="Restricted cash">0.2</span>
million. Management expects operating losses and negative cash flows to continue for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
estimates that based on the Company&#8217;s liquidity resources, there is substantial doubt about the Company&#8217;s ability to continue
as a going concern within 12 months from the date of issuance of the consolidated financial statements. The accompanying consolidated
financial statements have been prepared on the basis of the Company continuing to operate in the normal course of business and does not
reflect any adjustments to the assets and liabilities related to the substantial doubt of its ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
ability to continue as a going concern is dependent upon its ability to raise additional funding. Management plans to raise additional
capital through public or private equity or debt financings to fulfill its operating and capital requirements for at least 12 months
from the date of the issuance of the financial statements. However, the Company may not be able to secure such financing in a timely
manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing
stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the
Company&#8217;s existing stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks
and Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in economic conditions, including rising interest rates, public health issues, lower consumer confidence, volatile equity capital markets,
ongoing supply chain disruptions and the impacts of geopolitical conflicts, may affect the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_ztW1lsLHlSw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_823_zEJl2lTSmiz">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaPR1G4GYZla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements as of and for the year ended December 31, 2025 and 2024, have been prepared in accordance
with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and in conformity with accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards
Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zXJtSJ4WYRZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles
of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company include the accounts of its wholly owned subsidiary, Calidi Biotherapeutics
(Nevada), Inc., a company incorporated in the state of Nevada Calidi Biotherapeutics, Inc., StemVac GmbH (&#8220;StemVac&#8221;), a company
organized under the laws of Germany, Calidi Biotherapeutics Australia Pty Ltd (&#8220;Calidi Australia&#8221;), a wholly owned Australian
subsidiary, Nova Cell, Inc. (&#8220;Nova Cell&#8221;), a subsidiary incorporated in the state of Nevada, and Redtail Biopharma, Inc.
(&#8220;Redtail&#8221;), a wholly owned subsidiary incorporated in the state of Nevada. StemVac&#8217;s primary operating activities
include process development and other research and development activities for the Company under a cost-plus intercompany development
agreement funded by the Company. Calidi Australia&#8217;s principal purpose is for conducting certain parts of the SNV1 clinical enabling
activities in Australia. Nova Cell&#8217;s primary operating activities were expanding potential uses of the Company&#8217;s AAA stem
cell programs from oncology to other fields that require regenerative medical applications, such as cosmetics, orthopedics, auto-immune
diseases, and various other therapies. Redtail&#8217;s primary operating activities will be to expand on the Company&#8217;s systemic
antitumor virotherapies. Both Nova Cell and Redtail were incorporated in May 2024. As of December 31, 2025, the Company no longer has
an investment in Nova Cell. Redtail has had no activity to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
interest entities (&#8220;VIEs&#8221;) are legal entities that either have an insufficient amount of equity at risk for the entity to
finance its activities without additional subordinated financial support or, as a group, the holders of equity investment at risk lack
the ability to direct the entity&#8217;s activities that most significantly impact economic performance through voting or similar rights,
or do not have the obligation to absorb the expected losses or the right to receive expected residual returns of the entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all VIEs in which the Company is involved, it assesses whether it is the primary beneficiary on an ongoing basis. In circumstances where
the Company has both the power to direct the activities that most significantly impact the VIEs performance and the obligation to absorb
losses or the right to receive the benefits of the VIE that could be significant, the Company would conclude that it is the primary beneficiary
of the VIE, and the Company consolidates the VIE. In situations where the Company is not deemed to be the primary beneficiary of the
VIE, it does not consolidate the VIE and only recognizes the Company&#8217;s interests in the VIE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to October 27, 2025, the Company owned 75% of Nova Cell&#8217;s fully-diluted capitalization, with the remaining 25% owned by a related
party investor (see Note 8). Under the rules of determining whether an entity was a VIE, the Company has a controlling financial interest
and is deemed to be the primary beneficiary of Nova Cell and therefore consolidated Nova Cell&#8217;s financial statements. Since the
Company owns less than 100% of Nova Cell, the Company recorded net loss attributable to noncontrolling interest in its consolidated statements
of operations equal to the percentage of the economic or ownership interests retained in Nova Cell by the noncontrolling party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#8220;SRA&#8221;) and Material Purchase Agreement (the
&#8220;MPA&#8221; and together with the SRA the &#8220;Agreements&#8221;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zpwpUeXfXZM7" title="Shares sold and transferred">22,500,000</span> of its shares of common stock in Nova Cell (the &#8220;Repurchased Shares&#8221;), representing an
ownership interest of <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_ztNgHQys4Usd" title="Ownership percentage">75</span>%, back to Nova Cell, for a purchase price of $<span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zylGdAbm1u0i" title="Purchase price for repurchased shares">6.0</span> million (the &#8220;Purchase Price&#8221;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $<span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zJqT9AIilb5l" title="Promissory note, net cash offset">50</span> thousand cash offset), resulting in an Indebtedness Cancellation Amount of $<span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zepHBhXDlXm4" title="Indebtedness cancellation amount">1.2</span> million,
and (B) the balance, by Deferred Consideration of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zYzDxd2VApd2" title="Deferred consideration">4.8</span> million payable after closing, as more fully described in the SRA. The Deferred Consideration is fully constrained until underlying uncertainties
are resolved, such that a significant reversal of cumulative consideration will not occur in future periods. Thus, the Company has not
recognized any Deferred Consideration as of December 31, 2025. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#8217;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for
a fair presentation of the Company&#8217;s financial condition and results of operations. All material intercompany accounts and transactions
have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_840_eus-gaap--UseOfEstimates_zSrrKuYyyr3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the
reported amounts during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment,
including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing
of potential commercialization of acquired in-process intangible assets, applicable discount rates, comparable companies or transactions,
liquidity events, determination of fair value of financial instruments under the fair value option of accounting, assumptions related
to the going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived assets, key assumptions
in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred
income taxes, assumptions used to value common stock, debt and debt-like instruments, warrants, and stock-based awards and other equity
instruments. Actual results may differ materially from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4NZUyodDGPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zU8kxk7y1Rr8">Reclassification</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on our previously reported results of operations or accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zxDisQ28BcAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and Restricted Cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity date of ninety days or less to be cash equivalents.
Cash and cash equivalents include cash in readily available checking, money market accounts and brokerage accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies cash that has contractual or legal restrictions imposed by third parties as restricted cash, which is restricted as
to withdrawal or use except for the specified purpose under a contract. The Company classifies restricted cash as either part of prepaids
and other current assets, or as part of other noncurrent assets, depending on the term and nature of the underlying contract with a financial
institution, which requires the Company to hold a fixed amount of funds in a restricted money market account as collateral to the financial
institution for the Company&#8217;s corporate credit card program with that financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none">Schedule of Cash and Cash Equivalents</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within prepaid expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    cash and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zONRAFzaFDbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zd0jFDmgJAZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Machinery
and Equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
and equipment are stated at cost, less accumulated depreciation, and includes assets purchased under financing leases. Depreciation is
computed using the straight-line method over the estimated useful lives of the assets, generally over a period of <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember_zhXYWkAGeupl" title="Estimated useful lives">3</span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember_z9vLH2fyzJn9" title="Estimated useful lives">5</span> years. For equipment
purchased under financing leases, the Company depreciates the equipment based on the shorter of the useful life of the equipment or the
term of the lease, ranging from <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zRKXfPGmJur3" title="Estimated useful lives">3</span> to <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zvVdMqTbK9ia" title="Estimated useful lives">5</span> years, depending on the nature and classification of the financing lease. Maintenance and repairs
are expensed as incurred, whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed
of, the cost and the related accumulated depreciation are removed from the respective accounts, and any resulting gain or loss is reflected
in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zHTo1XpBpLmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, <i>Leases</i>. The Company determines if an arrangement is a lease at inception.
Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated
statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define
criteria to determine &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the
fair value of the underlying asset.&#8221; For lease classification determination, the Company continues to use: (i) greater than or
equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset; and (ii) greater
than or equal to 90% to determine whether the present value of the sum of lease payments is substantially all of the fair value of the
underlying asset. The Company accounts for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
operating leases, the Company recognizes right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for leases with terms greater
than 12 months in the consolidated balance sheets, while leases with terms of 12 months or less are not capitalized. ROU assets represent
the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate commensurate with
the lease term, based on the information available at commencement date, in determining the present value of lease payments. The Company
uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes
lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will
exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company discloses
the amortization of ROU assets and operating lease payments as a net amount within &#8220;Depreciation and amortization&#8221; on the
consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
leases are included in machinery and equipment, and in finance lease liability, current and noncurrent, in the consolidated balance sheets.
The Company discloses the amortization of finance ROU assets within &#8220;Depreciation and amortization&#8221; on the consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 11 for further disclosures in accordance with ASC 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zrW6I3Z6DNB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the impairment of long-lived assets, which consist primarily of right-of-use assets for operating leases and machinery
and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not
be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected
undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to
the excess of the assets carrying value over its fair value is recorded in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCCQwj744sq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 820, <i>Fair Value Measurement</i>, which among other things, defines fair value, establishes a consistent framework
for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring
or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants. Accordingly, fair value is a market-based measurement determined based
on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value, which are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets and liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities;
    quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data
    for substantially the full term of the assets or liabilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which
    require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation
hierarchy. If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities
with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2
inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. See Note 3 for fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zWqPIpln7jfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives in accordance with ASC 815. The Company values its derivatives using the Black-Scholes option-pricing model or
other acceptable valuation models, as applicable, with the assistance of valuation specialists. Derivative instruments accounted for
as liabilities are valued at inception and subsequent valuation dates for each reporting period the derivative instrument remains outstanding.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at
each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates equity or liability classification for common stock warrants in accordance with ASC 480, <i>Distinguishing Liabilities
from Equity</i>, and ASC 815, <i>Derivatives and Hedging</i>, and accounts for common stock warrants as liabilities if the warrant requires
net cash settlement, or gives the holder the option of net cash settlement, or it otherwise does not meet other equity classification
criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement,
or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified
as equity. Warrants that meet the definition of a derivative financial instrument and the equity scope exception in ASC 815-10-15-74(a)
are classified as equity, are initially measured at fair value on the grant date, and are not subject to remeasurement provided that
the Company continues to meet the criteria for equity classification. Warrants that are classified as liabilities are accounted for at
fair value and remeasured at each reporting date until exercise, expiration, or modification that results in equity classification. Any
change in the fair value of the warrants is recorded and presented under change in fair value of other liabilities and derivatives or
change in fair value of other liabilities and derivatives &#8211; related party, as applicable, in the consolidated statements of operations.
The classification of warrants, including whether warrants should be recorded as liabilities or as equity, is re-assessed at the end
of each reporting period. The fair value of liability-classified warrants is determined using the Black-Scholes option-pricing model
(&#8220;Black-Scholes model&#8221;), which includes Level 3 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--DebtPolicyTextBlock_zRkBtHjrd9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
Issuance Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs incurred to obtain debt financings are deferred and are amortized over the term of the debt using the effective interest
method for all debt financings in which the fair value option has not been elected. Debt issuance costs on debt financings in which the
fair value option is not elected are recorded as a reduction to the carrying value of the debt and are amortized to interest expense
or interest expense &#8211; related party, as applicable, in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
any debt financing in which the Company has elected the fair value option, any debt issuance costs associated with the debt financing
are immediately recognized in interest expense in the consolidated statements of operations and are not deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zJS5yJ5MWWkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has not generated any revenues from commercial products. The Company analyzes its research collaboration arrangements
to assess whether they are within the scope of ASC 808, <i>Collaborative Arrangements</i>, to determine whether such arrangements involve
joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks
and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC
808, the Company assesses whether aspects of the arrangement are within the scope of other accounting literature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those
aspects of the arrangement within the scope of ASC 606, <i>Revenue from Contracts with Customers</i>, by applying the following five-step
model: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract,
including whether they are distinct within the context of the contract; (iii) determination of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition
of revenue when, or as, performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within the
contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service
is distinct. The Company considers the intended benefit of the contract in assessing whether a promised good or service is separately
identifiable from other promises in the contract. If a promised good or service is not distinct, the Company combines that good or service
with other promised goods or services until it identifies a bundle of goods or services that is distinct. The Company may provide options
to additional goods or services in such arrangements exercisable at a customer&#8217;s discretion. The Company assesses if these options
provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights
requires judgments related to the determination of the value of the underlying good and services to the optional price, if any, that
may be offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the transaction price based on the amount of consideration that the Company expects to receive for transferring the
promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company then allocates
the transaction price to each performance obligation based on the relative standalone selling prices (&#8220;SSP&#8221;). SSP is determined
at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors,
including factors that were contemplated in negotiating the agreement with the customer and estimated costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will
be entitled by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated
variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which
it is probable that a significant reversal of cumulative revenue recognized will not occur. At each reporting period, the Company re-evaluates
the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate
of the overall transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as)
the performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of
an output or input method. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in
the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve
months, deferred revenue will be classified in current liabilities. Revenue recognized, if any, prior to contractual billings made to
the customer, and if the Company expects to have an unconditional right to receive consideration in the next twelve months, these contractual
assets are included in other current assets in the Company&#8217;s consolidated balance sheets. As of December 31, 2025, and December
31, 2024, there are no deferred revenue or contractual assets recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company further analyzes changes to contracts from customers to assess whether they qualify as a contract modification within the scope
of ASC 606. The Company considers that a contract modification exists when the parties to a contract approve a modification that either
creates new, or changes, existing enforceable rights and obligations of the parties to the contract. The Company considers that a contract
approval could be approved in writing, by oral agreement, or implied by customary practices. Whenever a change in the scope or price,
or both, of a contract is approved by the parties to the contract, the Company analyzes whether the contract modification qualifies as
a separate contract or a contract combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract modification as a separate contract when (i) the scope of the contract increases because of the addition
of promised goods or services that are distinct and (ii) the price of the contract increases by an amount of consideration that reflects
the Company&#8217;s SSP of the additional promised goods or services and any appropriate adjustments to that price to reflect the circumstances
of the particular contract. If the modification is not accounted for as a separate contract, the Company analyzes whether one of the
following should occur: (i) a termination of the original contract and the creation of a new contract, (ii) a cumulative catch-up adjustment
to the original contract, or (iii) a combination of (i) and (ii) in a way that faithfully reflects the economics of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zlZPizkzwqT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, using the asset and liability method, which requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in
the consolidated financial statements or in the Company&#8217;s tax returns. Deferred taxes are determined based on the difference between
the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which
the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.
The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by analyzing
carryback capacity in periods with taxable income, reversal of existing taxable temporary differences and estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies. The Company&#8217;s judgments regarding future taxable
income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If the
Company&#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased,
which may have a material impact on the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized, if any. First, the tax position must be evaluated to determine the likelihood that
it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company recognizes any interest and penalties related to uncertain
tax positions in income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2025 and 2024.
The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material
deviation for the year ended December 31, 2025 and 2024. The Company is currently unaware of any tax issues under review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#8220;CAMT&#8221;) on adjusted
financial statement income on applicable corporations for taxable years beginning after December 31, 2022. The Company does not expect
the CAMT will have a material impact to its consolidated income tax provision (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted. The OBBBA included various provisions with multiple effective
dates, including, but not limited to, immediate expensing of domestic research and development expenditures and provision for immediate
expensing of machinery and equipment purchases. The OBBBA did not have a material impact on the Company&#8217;s results of operations.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an
&#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by 5% stockholders increases
by more than 50% over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income may be limited. The annual limitation may result in the expiration of net operating losses
before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31, 2021. There was an ownership
change identified on March 26, 2018 after the Company&#8217;s Series A-2 preferred stock issuance. The Company has not undertaken a Section
382 study through December 31, 2025. The Company&#8217;s ability to utilize their net operating loss carryforwards and other tax attributes
to offset future taxable income or tax liabilities may be limited as a result of ownership changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_ecustom--GovernmentGrantsPolicyTextBlock_zVDiXvjsr4Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2022, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) approved the Company&#8217;s application for
a CIRM grant for the Company&#8217;s continued development of the SNV1 program. CIRM awarded the Company approximately $<span id="xdx_90F_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zJ2bjw4tI9jb">3.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of CIRM funding conditioned that the Company co-fund
approximately $<span id="xdx_908_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember_zYGxk6lkwsUg">0.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the requirements of the CIRM application. On
December 28, 2022, the Company received the Notice of Award from CIRM for this grant. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from the CIRM grant are recognized over the period necessary to match the related research and development expenses when it is probable
that the Company has complied with the CIRM conditions and will receive the proceeds pursuant to the milestones defined in the grant
as reimbursement of those expenditures. The CIRM grant proceeds, if any, received in advance of having incurred the related research
and development expenses are recorded in accrued expenses and other current liabilities and recognized as grant income included in other
income, net, on the Company&#8217;s consolidated statements of operations when the related research and developments expenses are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025 and 2024, the Company recognized approximately $<span id="xdx_900_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20251231_zMHspUb7PSTk" title="Grant income">50,000</span> and $<span id="xdx_905_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20241231_zYUqCnBJGwse" title="Grant income">0.2</span> million, respectively, in grant income
in the accompanying consolidated statements of operations. The Company drew $<span id="xdx_90E_ecustom--GrantsReceivableWithdrawn_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zwakLFuBX1w9" title="Government grants award withdrawn">3.1</span> million in funds based on the operational
milestones defined in the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg1hra5jIUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are expensed as incurred. Research and development expenses consist of costs incurred to discover, research
and develop drug candidates, including compensation-related expenses for research and development personnel, preclinical and clinical
activities, costs of manufacturing, overhead expenses including facilities and laboratory expenses, materials and supplies, amounts paid
to consultants and outside service providers, and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
and annual license payments related to acquired technologies or technology licenses which have not yet reached technological feasibility
and have no alternative future use are also included in research and development expense in the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zMk4V2F5MIgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and compensation-related expenses for personnel in executive, finance and accounting,
operations, and administrative functions. General and administrative expenses also include fees for legal, patent
prosecution, legal settlements, consulting, accounting and audit services as well as insurance, outside service providers, direct and
allocated facility-related costs and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVnzNm7bwVwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Translation Adjustments and Other Comprehensive Income or Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">StemVac,
the Company&#8217;s wholly owned subsidiary, is located and operates in Germany and its functional currency is the Euro. Calidi Australia,
the Company&#8217;s wholly owned subsidiary, is located and operates in Australia and its functional currency is the Australian Dollar
(&#8220;AUD&#8221;). Accordingly, StemVac&#8217;s and Calidi Australia&#8217;s assets and liabilities are translated using respective
published exchange rates in effect at the consolidated balance sheet date. Expenses and cash flows are translated using respective approximate
weighted average exchange rates for the reporting period. Resulting foreign currency translation adjustments are recorded as other comprehensive
income or loss, net of tax, in the consolidated statements of comprehensive income or loss and included as a component of accumulated
other comprehensive income or loss on the consolidated balance sheets. For the year ended December 31, 2025 and 2024, comprehensive loss
includes such foreign currency translation adjustments and was insignificant for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_ecustom--ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_zGqMFuHbODu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Transaction Gains and Losses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
transactions denominated in currencies other than the U.S. dollar, the Company recognizes foreign currency transaction gains and losses
in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The Company&#8217;s
foreign currency transaction gains and losses are principally generated by intercompany transfers to StemVac denominated in Euros to
pay for the research and development activities performed by StemVac under an intercompany development agreement with the Company. Furthermore,
the Company&#8217;s foreign currency transaction gains and losses include intercompany transfers to Calidi Australia denominated in AUD
to pay for the research and development activities performed by Calidi Australia. These foreign currency remeasurement gains and losses
are included in other income, net, and were insignificant for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zTTPKIkGwNV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC
718, <i>Compensation &#8212; Stock Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service condition is recognized in the period of the forfeiture. Generally,
and unless otherwise specified, the Company grants stock options with service-based only vesting conditions and records the expense for
these awards using the straight-line method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award
recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company estimates its expected stock
volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics
similar to the Company. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221;
method for awards that qualify as &#8220;plain-vanilla&#8221; options provided under Staff Accounting Bulletin, Topic 14 (&#8220;SAB
Topic 14&#8221;), as necessary. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at
the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero,
based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdSJcb0wxfOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss per share of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that
determines earnings per share for the holders of the Company&#8217;s shares of Common Stock and participating securities. However, the
participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation
of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating)
are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per
share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock
method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share
attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common
stock shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic
net loss per share for the periods presented herein because common stock equivalent shares from the outstanding warrants, earnout shares,
stock option awards, restricted stock units, and contingently issuable warrants were antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zguB1VYdIPX4" style="display: none">Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    for common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">911</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout
    shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingently
    issuable warrants<sup id="xdx_F46_zns0PDiMhGnk">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    common stock equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,454</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zcSEsseQ4qb1">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.</span></td></tr>
  </table>
<p id="xdx_8A2_zAGEgYvJxZz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztqbLrgSIasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (or CODM), the Executive Management Team, consisting of the following individuals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Head of Technical Operations</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company views its operations and manages its business as a single reportable segment whose operations include the research, development
and commercialization efforts of platforms to potentiate oncolytic virus therapies on a consolidated basis, as further described in Note
1. The Company manages its Research and Development (&#8220;R&amp;D&#8221;) activities on a consolidated basis. The Company expects to
generate future income from a combination of license fees and other upfront payments, funded R&amp;D agreements, milestone payments,
product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing
of the successful commercialization of the Company&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss is the measure of segment profit or loss used by the CODM in making decisions regarding resource allocation and evaluating financial
performance, which is also reported on the consolidated statements of operations and comprehensive loss. The CODM does not evaluate its
reportable segment using asset or liability information.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected financial information with respect to the Company&#8217;s single operating segment for the year ended
December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zKYWOXFybRQj" style="display: none">Schedule
of Operating Segment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING
    EXPENSES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
    and benefits</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,561</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,249</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,442</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,951</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,059</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
    and maintenance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,358</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,136</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    &amp; research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items <sup id="xdx_F44_zsI0gVfAWZ5g">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provision</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,063</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,209</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0A_zCZCERNSjsG7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.</span></td></tr>
  </table>
<p id="xdx_8A3_zjzQiw5SfnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQmoR4lv77yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Adopted Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, <i>Improvements to Income Tax Disclosures (Topic 740)</i>. The ASU requires disaggregated
information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid.
The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for
annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 for the annual
period beginning January 1, 2025, on a prospective basis. The adoption of this guidance did not have a significant
impact on the Company&#8217;s financial statements, other than disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_ecustom--NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_z6lkr7Di3Vfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement </i>and in January 2025, issued ASU 2025-01 <i>Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i> to clarify the effective
date of ASU 2024-03. ASU 2024-03 requires the disaggregation of certain costs and expenses in the notes to the financial statements to
provide enhanced transparency into the expense captions presented on the face of the income statement. The ASU is effective for annual
periods beginning after December 15, 2026 and for interim reporting periods within annual reporting periods beginning after December
15, 2027. The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-06, <i>Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40): Targeted
Improvements to the Accounting for Internal-Use Software</i>. ASU 2025-06 updates the accounting for internal-use software by replacing
former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software
only when management has authorized and committed funding and it is probable that the project will be completed and the software will
be used to perform the intended function. ASU 2025-06 also supersedes website development cost guidance, moving it to ASC 350-40. These
amendments are effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting ASU 2025-06.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic
606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>.
ASU 2025-07 refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration
under ASC 606. This ASU is effective for annual periods and interim periods beginning after December 15, 2026, with early adoption permitted.
The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently evaluating
the impact of adopting ASU 2025-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the FASB issued ASU No. 2025-09, <i>Derivatives and Hedging (Topic 815): Hedge Accounting Improvements</i>. ASU 2025-09
clarifies certain aspects of the guidance on hedge accounting and addresses several incremental hedge accounting issues arising from
global reference rate reform. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within
those annual reporting periods The Company is currently evaluating the impact of adopting ASU 2025-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2025, the FASB issued ASU No. 2025-11, <i>Interim Reporting (Topic 270): Narrow-Scope Improvements,</i> which is intended to
improve the navigability of the guidance in ASC 270 and clarify when it applies. Under the amendments, an entity is subject to ASC 270
if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content of such
financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since
the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027, and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2025-11.</span></p>

<p id="xdx_85F_zmLcQ6ZXYX28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z1LDIbnIuC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span id="xdx_823_zLaSFEvqW13c">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zQoGr3VpRVdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, inclusive of
related party components, as of December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zYWW0lu5GxOi" style="display: none">Schedule
of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWmx7Qc7H0S6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziASyE6z4iTd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW2Ceu4JuOo5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zeUrRR3X8Fn7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z01xipjyNeTe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash held in money market accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1035">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1036">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zvdICRvuY924" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1040">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1041">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zzyhoyvStrb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zpu1J8KaEUW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1051">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zz40boSVcyfb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    warrant liabilities, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEM6Xl7O87W4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zv0XyOqlwQpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm97BMO9HOq3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_z1QWjKyP15Vi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zeruEnVVYona" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash held in money market accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1060">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_z0qTfmSaeADe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    Purchase Agreement Derivative Asset included in other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zs7M1XCLaB07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zpQ1D7GVfiJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1076">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zlFUkdiOREOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zRhOUeGFqiH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    warrant liabilities, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zyNvNTz385E6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial instruments consist of cash, prepaid expenses and other current assets, accounts payable, accrued expenses,
and other current liabilities. The carrying value of these financial instruments is generally considered to approximate their fair values
because of the short-term nature of those instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zqIlEF0l2MT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of valued instruments for the year ended December 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zSY7A1YXlaXe" style="display: none">Schedule
of Changes in Fair Value of Level 3 Valued Instruments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zg9NawD3tghe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    <br/> Purchase<br/> Agreement<br/> Derivative <br/> Asset, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRgqIL5PVQJj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    <br/> Warrants, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zG3wQ6iduqC9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    <br/> warrants, at <br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zfHUyIt0RyOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zNIOi0IXJTnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zumwr3PJozah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1099">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of valued instruments for the years ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zWfJAwNvg2se" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    <br/> Purchase<br/> Agreement<br/> Derivative <br/> Asset, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRXHCZ66zKMc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    <br/> Warrants, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_z0wHOCgTVSRe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    <br/> warrants, at <br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zchLF49GxBX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(230</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zRRZPdfYd0Oe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(230</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zjfr9zexva2d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(465</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(78</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zwfpjT1pTduh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zFX2CuEjR6m3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p id="xdx_8AA_z7BIDe6h7Sq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected Balance Sheet Components</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zcwJ5yn88KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_827_zfRVJFQVjqfl">Selected Balance Sheet Components</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accrued
Expenses and Other Current Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zl3HwUvYkCt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, accrued expenses and other current liabilities were comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B5_zC74RHRU2xGk" style="display: none">Schedule
of Accrued Expenses and Other Current Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20251231_z6RE0nZO3Mid" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zldBaOSXryB2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--AccruedCompensation_iI_pn3n3_maAPAOAzybc_zt0oc8Dog6d3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">884</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--AccruedVendorAndOtherExpenses_iI_pn3n3_maAPAOAzybc_z9diIryQWrKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    vendor and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">922</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">994</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzybc_zlQaTtvTOSQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,338</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_zgOEPSV6HWB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 11 for additional commitments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prepaid
Expenses and Other Current Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3rDlS7PfK6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, prepaid expenses and other current assets were comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zpYPMGNGVhLb" style="display: none">Schedule
of Prepaid Expenses and Other Current Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_zL5CzaHNFOna" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zcIA2pAU61j5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--PrepaidExpenses_iI_maPECz6zE_zlhRYKAUiHV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maPECz6zE_zQmOQo8zUkO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">302</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">288</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECz6zE_zE0XWeQF3IP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">234</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">249</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECz6zE_zE1XdS9Ryd86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">656</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zlTGJIuafnTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Machinery and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Machinery and Equipment, net</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmitJninqEB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82A_zmL0qBXF1oTk">Machinery and Equipment, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMMjj6pnDrvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, machinery and equipment, net, was comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zHnlGiayBZi9" style="display: none">Schedule
of Machinery and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20251231_zRQ7iMay90Vl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231_zv9ULlTW7Ivf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzw2F_znFRuAZbJnjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzw2F_zV4tavT1WV07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,794</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzw2F_zjoGaAtrKfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">869</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zjh4hp5LMYLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense amounted to approximately $<span id="xdx_906_eus-gaap--OtherDepreciationAndAmortization_pn5n6_c20250101__20251231_zF4SKmnZ00X6" title="Depreciation and amortization expense"><span id="xdx_901_eus-gaap--OtherDepreciationAndAmortization_pn5n6_c20240101__20241231_zQObO9v270tb" title="Depreciation and amortization expense">0.4</span></span> million for the year ended December 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFuzCwFJpwIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_828_zyZaQmqXs1Ki">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zP1Mzp0wj211" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the various significant related party transactions and investments in the Company for the periods presented
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zIbKqbn9Ytxg" style="display: none">Schedule
of Related Party Transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Party</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of investment or transaction</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250101__20251231_ztr38XZpt7Q1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zMA6Of7icfB8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_zEWw10UjFlga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A and Director E</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_fKDEp_zlWLI0MH4aBe" title="Description of investment or transaction">Current
    term notes payable, net of discount, including accrued interest</span><sup>(1) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,702</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_zR1WtBFW8XJ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F and relative of Officer A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_fKDIp_zeQY78y2Fs4j" title="Description of investment or transaction">Accounts
    payable and accrued expenses</span><sup>(2) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zesQnfyIvbod" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_fKDMp_z61oDwq1ner8" title="Description of investment or transaction">Severance
    accrual</span><sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zgvbYUb0hpj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_fKDQp_zgg77HjNBqEc" title="Description of investment or transaction">Severance
    accrual</span><sup>(4) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">434</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_zo2OQ8scPVpk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_fKDUp_zKdMvxbE8em3" title="Description of investment or transaction">Advisory
    services included in accrued expenses</span><sup>(5) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1191">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_zHvV1LI0GJD5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_fKDYp_zjClDrqjEaUd" title="Description of investment or transaction">Lease
    guaranty</span><sup>(6) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_zt5rXNeaWwY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_fKDcp_zDjXix5Ogoqg" title="Related party transaction description">Other
    liabilities</span><sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">638</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_zZIlg6Z8RiZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F and Director A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_fKDgp_zkWtDGrB7dA3" title="Related party transaction description">Warrant
    liability</span><sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_zdk3Fg2goI0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
    of Officer A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_fKDkp_zDM26tRjdZMe" title="Related party transaction description">Loan
    payable</span><sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z6ZAQI2hMW8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    G</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_fKDEwKQ_____zAnBEno9S9Bd" title="Related party transaction description">Severance
    accrual</span><sup>(10)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zBTlKfG8gpQh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_fKDExKQ_____z5loD8rJKBDi" title="Related party transaction description">Severance
    accrual</span><sup>(11)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1222">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zLyvD6ZMzaX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    A related to Director G</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zPHkzA353yU1" title="Related party transaction description">Accounts
    payable and accrued expenses</span><sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1227">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z1HHAGVCWrwl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zTM4EfyjiDKj" title="Related party transaction description">Accounts
    payable and accrued expenses</span><sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1232">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span id="xdx_F01_ztnzOa04RqCj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zSe82xXNXjfc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49" title="Related party note payable">2.7</span> million. See Note 7 for further details.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zeZVcS9Dqklc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z6UoF5ncbVI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj" title="Legal fees">48</span> thousand
and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04" title="Legal fees">38</span> thousand for the years ended December 31, 2025 and 2024, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span id="xdx_F06_zwaUnSY2Q1O7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_ziDxrKiIKwTh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb" title="Loans">0.5</span>
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1" title="Loan outstanding">0.2</span>
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2" title="Consulting pay">10,000</span>
    per month during the transition period. The agreement terminated on December 31, 2025 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j" title="Expenses">0.1</span>
    million was expensed under the agreement. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F06_zCwfBc4wtI2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zoKQxvM2cIa1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#8220;Ng Agreement&#8221;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck" title="Annual salary">0.5</span> million and a signing bonus of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4" title="Bonus payable">0.3</span> million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 23, 2023, the Company entered into a Separation and Release Agreement with Mr. Ng which included a severance accrual and accrued
    interest as of December 31, 2024 (see Note 11). The lump sum payment and accrued interest was settled in January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0B_zb3j8Q9Vyk9i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zmweNB3Xu47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6" title="Monthly advisory fee">9,166</span> per month not to exceed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5" title="Advisory fee">0.1</span> million per annum, accrued
    and payable upon the Company raising $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf" title="Equity proceeds">10</span> million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_zLX2J83iRIF8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zQ7YPE1vTlO8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#8220;Guaranty&#8221;) up to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P" title="Guaranty of lease amount">0.9</span> million to the lessor for the Company&#8217;s future performance under
    the San Diego Lease agreement. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok" title="Lease agreement description">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.</span> As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z" title="Lease payment due">14,000</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6" title="Lease payment due">0.2</span> million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0D_zW1ETmqueNwd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zSwPhnNeBrE5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc" title="Deferred compensation">0.5</span> million,
    which was paid in January 2025 (see Note 11). The $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj" title="Notes payable">0.5</span> million note bore interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4" title="Note bears interest percentage">24</span>% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne" title="Note bears interest percentage">14</span>% per annum. The deferred compensation and advisory fees were settled in
    January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zrzyrqrQZdM3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zZ51rLXa3lQe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    Note 8 for disclosures around Warrants. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F04_z9c88oDDUFK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_z5IDR1Bfps6b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8" title="Officer loans payable">0.2</span> million, which bears
    interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe" title="Officer loans payable">12</span>%. The loan was settled in full in January 2025. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zIlcmPGCq4w" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zj5egqFCgyC6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2" title="Bonus payable">0.1</span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc" title="Separation pay">0.2</span> million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#8217;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9" title="Severance pay">0.1</span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0D_zdfDOmomXt94" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zFrDDUS3lLNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1" title="Bonus payable">0.1</span> million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6" title="Severance pay">0.2</span> million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#8217;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf" title="Severance pay">0.2</span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span id="xdx_F07_zNo8J4qqMSEh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_z3zx8HiEP4Cj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#8220;CRO&#8221;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl" title="Accounts payable and accrued expenses">0.1</span>
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h" title="Expenses related to services">0.6</span>
    million in expenses related to services from Company A.</span></td></tr>
  </table>
<p id="xdx_8A3_zd3sjtf5v6f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zk6rljKHwxna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_828_zEr7zCsMUf1b">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zSxdPkDzMrL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s outstanding debt obligations as of December 31, 2025 and 2024, including related party components, are as follows (in
thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zirP9PQvheZ8" style="display: none">Schedule of Outstanding Debt Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMNeRAr6KClg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKCKbGpGiGI8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z6ZkdmTBDAy5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion of long-term debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20251231_zutYKlGSssd5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(90</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    debt, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_iI_pn3n3_c20251231_zA54mlhaoCTi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zihzq1dJs6U5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zLeuVlzlCvw5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">753</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zArGCDUwtam7" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,953</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bridge
    loan payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zTd7tM8TbDx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_z0lkMUcpXkx9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zdV8IJWhiNLl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zH2QKTdCPxZf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztY1VpfkvPGk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPWkTf1r0jR1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231_znzJmfZxSXSl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_zzRJejM3acQe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">821</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231_zCTWD2iLH2a4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,821</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion of long-term debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20241231_zp2GdBcNR8Rj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    debt, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20241231_zj6QHi1ArYGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zDOkMkUPN8Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbqjTc8gnZAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scheduled
maturities of outstanding debt, net of discounts as of December 31, 2025 are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_ziMD1VTWsl08" style="display: none">Schedule of Maturities of Outstanding Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending December 31:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20251231_zn9Uaygh0G7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDICAzCCI_zRtuHODsChNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDICAzCCI_z6a8msyqcAQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDICAzCCI_zZwEgYv3LbL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028
    and thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_pn3n3_maDICAzCCI_zDI0WWw1ZV54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plus:
    accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzCCI_zh5K2dMn52Xk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zElWa7uIzSU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion includes a description of the Company&#8217;s outstanding debt as of December 31, 2025 and 2024. The weighted average
interest rate related to the Company&#8217;s outstanding debt was approximately <span id="xdx_901_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20251231_zLMOiZwq2vVj" title="Weighted average interest rate">15</span>% and <span id="xdx_90D_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20241231_zxq292wWGFT1" title="Weighted average interest rate">14.4</span>% as of December 31, 2025 and 2024, respectively.
Interest expense related to the Company&#8217;s outstanding debt totaled approximately $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231_zEeQFQW2a7Wl" title="Interest expense debt">0.1</span> million and $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231_zsrU2GYoa16c" title="Interest expense debt">0.7</span> million for the year ended
December 31, 2025 and 2024, respectively, which is reported within other income, net, in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Term
Notes Payable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Term Note Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the Company entered into a note agreement with a related party investor and director to borrow up to $<span id="xdx_909_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20210131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember__srt--TitleOfIndividualAxis__custom--InvestorAndDirectorMember__srt--RangeAxis__srt--MaximumMember_zPCUkYAuKd6i" title="Line of credit">0.5</span> million (&#8220;2021
Term Note&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the interest rate of the 2021 Term Notes was <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember_zpxi9Nu7ycje" title="Interest rate">14</span>%, and the total carrying value, including accrued interest was
approximately $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember_za1KpnGuoDM5" title="Interest Payable">0.7</span> million. The total outstanding principal and accrued interest of 2021 Term Note of $<span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20250131_zRS3X9WUWiz9" title="Carrying value, including accrued interest">0.7</span> million was settled in full
in January 2025. As of that date, the 2021 Term Notes were no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2022
Term Notes Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November and December 2022, the Company issued $<span id="xdx_906_eus-gaap--NotesPayable_iI_pn5n6_c20221130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_z8gMvISByd35" title="Secured term notes payable"><span id="xdx_904_eus-gaap--NotesPayable_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zp8xTvJkFNVl" title="Secured term notes payable">1.5</span></span> million of secured term notes payable (the &#8220;2022 Term Notes&#8221;) to investors,
including to related parties (see Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3 and November 8, 2023, the Company settled in cash $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231003__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zQNcpdwoAcLf" title="Debt instrument, accrued interest">0.1</span> million and $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231108__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zVSwHFIA9a0l" title="Debt instrument, accrued interest">0.2</span> million, respectively, of the principal of 2022 Term
Notes plus accrued interest. Said term notes payable were no longer outstanding as of the settlement dates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the interest rate of the 2022 Term Notes was <span id="xdx_904_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zEtVm58JGAv7" title="Interest rate">14</span>% per annum, for a total principal of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_z3WJzxrZf2td" title="Principal amount">0.2</span> million, and <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember__srt--RangeAxis__srt--MaximumMember_zFex1oUhwKm2" title="Interest rate">16</span>% per
annum, for a total principal of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zjfD9Dsh4791" title="Principal amount">0.2</span> million. As of December 31, 2024, the total carrying value, including accrued interest, was $<span id="xdx_90F_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zRuTXnTszdRd" title="Carrying value, including accrued interest">0.4</span>
million. The total outstanding principal and accrued interest of 2022 Term Notes of $<span id="xdx_900_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20250131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zabwvSkTeJF1" title="Carrying value, including accrued interest">0.4</span> million was settled in full in January 2025.
As of that date, the 2022 Term Notes were no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
Term Notes Payable</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
January through September 2023, the Company issued $<span id="xdx_909_eus-gaap--NotesPayable_iI_pn5n6_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zwZ5GE64K3C9" title="Secured term notes payable">3.3</span> million of secured term notes payable (the &#8220;2023 Term Notes&#8221;) to
investors, including to related parties (see Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2023, as agreed upon above in connection with the Closing of the FLAG Merger, the Company settled in cash $<span id="xdx_904_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20231003__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zVk3j5LOsbci">0.6</span> million of
principal of 2023 Term Notes plus accrued interest and said term notes payable were no longer outstanding as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company settled in cash $<span id="xdx_901_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zTOb18T6Jsq8" title="Debt principal and accrued interest">0.3</span> million of principal of 2023 Term Notes plus accrued interest. On
December 23, 2024, the Company executed a debt amendment on $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zebUYr0Puvm2" title="Principal amount">1.0</span> million of the 2023 Term Notes, which modified the repayment terms commencing
on February 1, 2025, such that the Company will pay the holder, a related party, $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20241223__20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_z5MNxzDW0cZ6" title="Installment payable">0.1</span> million each month until the 2023 Term Notes&#8217;
principal and interest are fully paid. The principal shall continue accruing interest of <span id="xdx_902_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zZJ6HIVft6Wb" title="Interest rate percentage">14</span>% per annum until fully paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the interest rate was <span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zHZZ0f7E7Ivj" title="Interest rate percentage">14</span>% per annum for a total principal of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zqHfhlly4bI3" title="Principal amount">1.2</span> million and <span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zVIHn5rKhrhg" title="Interest rate percentage">18</span>% per annum for a total principal
of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_ztWWcIckxed4" title="Principal amount">0.2</span> million, respectively. As of December 31, 2024, the total carrying value, including accrued interest and net of debt discount,
was $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zLuyol1eX6ge" title="Carrying value, including accrued interest">1.9</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the total outstanding principal and accrued interest of the 2023 Term Notes of $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zpLSbX8UTXxb" title="Carrying value, including accrued interest">1.4</span> million was fully paid in accordance
with the agreement and was no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2024
Bridge Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 19, 2024, the Company received approximately $<span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zS69a7Md0Vj1" title="Loans received">0.2</span> million in aggregate proceeds from the issuance of certain bridge loans (the
&#8220;2024 Bridge Loan&#8221;), which mature <span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dc_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zGDZcVeJwNZ3" title="Maturity period">one year</span> from the issuance date and bear simple interest of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zQPYVz2I2Ku8" title="Interest rate">12</span>% per annum. As consideration
for the 2024 Term Loans, the Company issued an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zYlgl8FaClEd" title="Restricted shares">75</span> shares of restricted common stock to the Lender.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, the total carrying value of the 2024 Bridge Loan, including accrued interest and net of debt discount, was $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zmnHR9u3qfvb" title="Accrued interest">0.2</span>
million which was settled in full in January 2025. As of that date, the 2024 Bridge Loan was no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Promissory Notes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2024, the Company entered into a convertible promissory note purchase agreement (the &#8220;2024 Purchase Agreement&#8221;)
with an Accredited Investor (the &#8220;Investor&#8221;) for a loan in the principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_zJ6KKKp4zX7f" title="Principal amount">1.0</span> million (the &#8220;2024 Convertible
Note Loan&#8221;). In connection with the Convertible Note Loan, the Company issued a one-year convertible promissory note evidencing
the aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_zM2yFngD0Pf2" title="Principal amount">1.0</span> million under the Loan, which accrues at a <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_z2HH6dDJMttl" title="Interest rate">12</span>% simple interest rate per annum (the &#8220;2024
Convertible Note&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2024, pursuant to the April Public Offering, the Company&#8217;s $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240418__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zk2hKhuneAIl" title="Accrued interest">1.0</span> million convertible note, inclusive of outstanding principal
and accrued interest, was automatically converted into shares of Common Stock Units, with terms identical to those sold in the April
Public Offering. As of that date, the convertible note was no longer outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Promissory
Note Loan Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, the Company entered into a Loan Agreement with a third party lender (the &#8220;Lender&#8221;). Under the Loan Agreement,
the Lender agreed to loan the Company the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240701__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_zcGtfjzWbh7e" title="Principal amount">0.6</span> million pursuant to the terms of the promissory note dated July 1,
2024 (the &#8220;Promissory Note&#8221;), which bears a simple interest rate at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240701__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_zf9mn1ORfD33" title="Interest rate">15</span>% per annum and matures on the third calendar year
from July 1, 2024 (the &#8220;Maturity Date&#8221;) unless due earlier due to an event of a default. The Company agreed to pay annual
payments of accrued interest after each calendar year from the Payment Date until any remaining interest is paid in full on the Maturity
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the total carrying value of the promissory note, including accrued interest, was $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_z8UCwU5OT0rc" title="Carrying value, including accrued interest">0.7</span> million and $<span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_z2HXOsTVORL6" title="Carrying value, including accrued interest">0.6</span>
million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM94V1KZySP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_821_zbj6MRYVN0C7">Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Second Amended and Restated Certificate of Incorporation filed on September 19, 2023 (&#8220;the Amended Articles&#8221;), the
Company is authorized to issue a total of <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zFFI3bavVd54" title="Number of shares authorized">1,000,000</span> shares of preferred stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zt5GPi5ulNz6" title="Preferred stock par value per share">0.0001</span> per share. As of December 31, 2025 and
2024, there were <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zzKsbvgoPOz9" title="Preferred stock outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zBK3KuQbR9v1" title="Preferred stock outstanding">no</span></span> shares of preferred stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Amended Articles, the Company is authorized to issue <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zuWGhUQvuMDf" title="Common stock shares authorized">330,000,000</span> shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zaibsqOvDTMi" title="Common stock par value per share">0.0001</span> per share, of which
<span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zqzRxyBfiGX6" title="Common stock, shares authorized">312,000,000</span> shares are designated as Voting Common Stock (&#8220;Common Stock&#8221;) and <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zbkPSkRaUaaa" title="Common stock, shares authorized">18,000,000</span> are designated as Non-Voting Common
Stock (the &#8220;Non-Voting Common Stock&#8221;). As of December 31, 2025 and December 31, 2024, there were <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_z6qN0BsLNdp8" title="Common stock shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zTYNV53Rqexa" title="Common stock shares outstanding">7,216,994</span></span> and <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zmqA5YCSY3B8" title="Common stock shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zY68yBsxSRDf" title="Common stock shares outstanding">1,730,051</span></span>
shares of common stock issued and outstanding, respectively, and <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zptAcI6lGMq6" title="Common stock, shares outstanding">150,000</span> shares of non-voting common stock outstanding. Since inception
to date, <span id="xdx_90E_ecustom--CommonStockDividend_iI_do_c20251231_zY0FCQgzyTNe" title="Common stock dividend">no</span> dividends have been declared or paid. Issuance costs related to common stock issuances during all periods presented were
immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--DiscloserOFCommonStockReservedForFurtureTableTextBlock_zRT2pG2i2nji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, common stock reserved for future issuance consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zU95Wcr2GHmf" style="display: none">Schedule
of Common Stock Reserved</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231_zNEUsLzr3llb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zzu59mG1aF0e" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4T92FbIxBcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock warrants outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockOptionsIssuedAndOutstandingMember_ztr8eJzSXMEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock options issued and outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277,822</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--RestrictedStockUnitsVestedAndUnreleasedMember_z2JFgf5R1kV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units vested and unreleased</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1485">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zvq1KzbydcJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    available for future issuance under the 2023 Equity Incentive Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,497</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,409</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_zVwIf82UdAU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    reserved under the 2023 Employee Stock Purchase Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,815</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,815</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_zei2jceJH5S5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock reserved
    for future issuance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,433,747</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,029,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_z0aaoBJIT833" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>April
2024 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 18, 2024, in connection with the April Public Offering, the Company sold an aggregate of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlnJrnxICc3" title="Number of shares purchased">110,271</span> Common Stock Units and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418_zNDYTJcUkStf" title="Number of shares purchased">16,375</span>
Pre-Funded Warrant (&#8220;PFW&#8221;) Units at an effective combined purchase price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDd3OQifhFa" title="Purchase price">48.00</span> per Common Stock Unit or PFW Unit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consists of: (i) one share of the Company&#8217;s voting common stock, (ii) a Series A warrant to purchase one share
common stock, (iii) a Series B warrant to purchase one Series B Unit, with each Series B Unit consisting of (a) one share of common stock
and (b) a Series B-1 Warrant to purchase one share of common stock, and (iv) a Series C warrant to purchase one Series C Unit, with each
Series C Unit consisting of (a) one share of common stock and (b) a Series C-1 Warrant to purchase one share of common stock. See further
warrant details per each issued series below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
PFW Unit consists of: (i) a pre-funded warrant to purchase one share of common stock, (ii) a Series A warrant to purchase one share common
stock, (iii) a Series B warrant to purchase one Series B Unit, with each Series B Unit consisting of (a) one share of common stock and
(b) a Series B-1 Warrant to purchase one share of common stock, and (iv) a Series C warrant to purchase one Series C Unit, with each
Series C Unit consisting of (a) one share of common stock and (b) a Series C-1 Warrant to purchase one share of common stock. See further
warrant details per each issued series below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg Thalmann &amp; Co. Inc. (&#8220;Ladenburg&#8221;), acting as the &#8220;Placement Agent&#8221;, common stock
warrants to purchase up to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJdCNiHTUY83" title="Number of warrants">6,333</span> shares of common stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>May
2024 Warrant Inducement Offer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, following the closing of the May 2024 Warrant Inducement Offer, warrant holders immediately exercised some or all of their
respective outstanding Series B Warrants and Series C Warrants to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsAndSeriesCWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zkgc95lxOPZ9" title="Number of shares purchased">89,153</span> shares of the Company&#8217;s
common stock, Series B-1 Warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesBOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zYmEZUEbyAm2" title="Number of shares purchased">22,275</span> shares of common stock and Series C-1 Warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesCOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zrOQJqpD6ux2" title="Number of shares purchased">66,878</span> shares
of common stock, at a reduced exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesCOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zJi3X0R3szB6" title="Exercise price">24.00</span>. In consideration for the immediate exercise of some or all of the existing warrants
for cash, the Company agreed to issue unregistered new Series D Warrants to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesDCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zoOx82TBe9Cj" title="Number of shares purchased">89,153</span> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg, acting as the &#8220;Placement Agent&#8221;, common stock warrants to purchase up to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZSIhruMsAI3" title="Number of warrants">4,458</span> shares of common
stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Subscription
Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2024, the Board of Directors of the Company approved a Subscription Agreement dated July 28, 2024 with an accredited investor,
a related-party (the &#8220;Investor&#8221;). Pursuant to the Agreement, the Company sold to the Investor and the Investor purchased,
(i) <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240726_zo3q2wH3xf8b" title="Purchase of warrants">58,235</span> shares of Common Stock at a purchase price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxXptYUDOWNj" title="Exercise price">17.172</span> per share; and (ii) warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zdkTDAG7kCge" title="Purchase of warrants">50,000</span> shares of the Company&#8217;s
common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHz3nFOZIS87" title="Exercise price">22.80</span>, for an aggregate purchase price of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240726__20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wuFcZ8JFj3" title="Aggregate purchase price">1.0</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nova
Cell Investment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2024, the Board of Directors of the Company acknowledged a strategic investment of approximately $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zlx3Gm1SyoIg" title="Issuance of stock, value">2.0</span> million by an accredited
investor, a related-party, (the &#8220;Investor&#8221;) into Nova Cell, a subsidiary of the Company, in exchange for the issuance of
<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zlQuhOnDbH5k" title="Issuance of stock, shares">7,500,000</span> shares of Nova Cell&#8217;s common stock to the Investor, representing <span id="xdx_900_ecustom--PercentageOfStrategicInvestment_dp_uPure_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNXAGWB20l6e" title="Percentage of strategic investment">25</span>% of Nova Cell&#8217;s current fully-diluted capitalization.
Nova Cell&#8217;s common stock was not adjusted when the Company effected its 2024 Reverse Stock Split and 2025 Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#8220;SRA&#8221;) and Material Purchase Agreement (the
&#8220;MPA&#8221; and together with the SRA the &#8220;Agreements&#8221;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zKyazEqJf2C4" title="Shares sold and transferred">22,500,000</span> of its shares of common stock in Nova Cell (the &#8220;Repurchased Shares&#8221;), representing an
ownership interest of <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_zTibGf61lbzj" title="Ownership percentage">75</span>%, back to Nova Cell, for a purchase price of $<span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zsAHGqwc5L9c" title="Purchase price for repurchased shares">6.0</span> million (the &#8220;Purchase Price&#8221;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $<span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zgWHTV8g2Pud" title="Promissory note, net cash offset">50</span> thousand cash offset), resulting in an Indebtedness Cancellation Amount of $<span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zKhIIMN85uH8" title="Indebtedness cancellation amount">1.2</span> million,
and (B) the balance, by Deferred Consideration of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zrxAyHZmx1z1" title="Deferred consideration">4.8</span> million payable after closing, as more fully described in the SRA. As of December 31, 2025, no Deferred Consideration has been recognized,
and the full amount remains constrained until underlying uncertainties are resolved. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable
to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#8217;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell as listed on Schedule 1
to the MPA. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>At
The Market Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 11, 2024, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with Ladenburg, under
which the Company may, from time to time, in its sole discretion, issue and sell through Ladenburg, acting as agent or principal, shares
of the Company&#8217;s common stock, par value $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zATRFp0t7pni" title="Shares issued price per share">0.0001</span> per share, initially having an aggregate offering price of up to $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pn5n6_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zxw8H3D6x951" title="Common stock par value per share">5.1</span> million.
Pursuant to the Sales Agreement, Ladenburg may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221;
offering as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Ladenburg will use commercially
reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon instructions
from the Company (including any price or size limits or other customary parameters or conditions the Company may impose).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay Ladenburg a cash commission of <span id="xdx_904_ecustom--CashCommissionPercentage_iI_dp_uPure_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zLco14TltBDe" title="Cash commission percentage">3</span>% of the aggregate gross sales proceeds of shares sold through Ladenburg under the Sales
Agreement. The Company also agreed to reimburse Ladenburg for certain specified expenses, including the fees and disbursements of its
counsel, in an amount not to exceed $<span id="xdx_903_ecustom--DisbursementsCounsel_iI_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zlTSkmlso3cj" title="Disbursements counsel">50,000</span>, in addition to certain ongoing disbursements of its legal counsel up to $<span id="xdx_90B_eus-gaap--LegalFees_c20241011__20241011__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zKVxPed6qT0g" title="Legal fees">7,500</span> in connection
with diligence bring downs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Sales Agreement, the Company may also sell shares to Ladenburg as principal for its own account at prices agreed upon
at the time of sale. If the Company sells shares to Ladenburg as principal, it will enter into a separate terms agreement with Ladenburg
in substantially the form attached to the Sales Agreement. The Company is not obligated to sell any shares under the Sales Agreement.
The offering of the shares pursuant to the Sales Agreement may be terminated by either the Company or Ladenburg, as permitted therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2025, the Company increased the maximum aggregate offering amount of the shares of the Company&#8217;s common stock, par
value $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250204__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zNIwLLGsZ241" title="Shares issued price per share">0.0001</span> per share, issuable under the Sales Agreement from $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250204__20250204__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_zWpXErfvEhBf" title="Aggregate offering price">5.1</span> million to $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250205__20250205__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_z6XEU1lhgHvj" title="Aggregate offering price">11.2</span> million by filing a prospectus supplement under
the Sales Agreement for an aggregate of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240204__20250204__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zhijrDapBxcb" title="Sales agreement">6.1 </span>million. During the year ended December 31, 2025, the Company sold <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhdgPcCOZMB8" title="Issued common shares">534,265</span> shares of common
stock for gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsQ0s2wHznff" title="Proceeds from issued common shares">3.4</span> million under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>October
2024 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors (the &#8220;Purchasers&#8221;),
pursuant to which the Company agreed to issue to the Purchasers, (i) in a registered direct offering, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAWODDkNxvI">170,836</span> shares of the Company&#8217;s
common stock, par value $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmp6ucnQs2R5" title="Shares issued price per share">0.0001</span> per share, at a purchase price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8CeDtEXkqGc" title="Exercise price">12.00</span> per share, and (ii) in a concurrent private placement, Series
E common stock purchase warrants to purchase up to <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesECommonWarrantsMember_zQtx9VAvpSe9">170,836</span> shares of Common Stock (the &#8220;Series E Common Warrants&#8221;) and Series
F common stock purchase warrants to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFCommonWarrantsMember_zx3gS3IbMjw9">170,836</span> shares of Common Stock (the &#8220;Series F Common Warrants&#8221; and together
with the Series E Common Warrants, the &#8220;Common Warrants&#8221;). Such registered direct offering and concurrent private placement
are referred to herein as the &#8220;Transactions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the Transactions took place on October 24, 2024. The gross proceeds from the Transactions were approximately $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20241024__20241024__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zA4mwdSy7qOd" title="Gross proceeds">2.1</span> million,
before deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if any, from
the exercise of the Common Warrants or common stock warrants issued to the Placement Agent (defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg, acting as the &#8220;Placement Agent&#8221;, common stock warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241024__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zk3vZmOHGnr4" title="Number of shares purchased">8,542</span> shares of common
stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>November
2024 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 14, 2024, the Company conducted a CMPO with Ladenburg acting as the &#8220;Placement Agent&#8221;, pursuant to which the Company
agreed to issue in a public offering <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241114__20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQenvJcrGeb9" title="Public offering">369,823</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFQYZsBJEQNe" title="Shares issued price per share">0.0001</span> per share, at a purchase price
of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCGnD7TDtap9" title="Purchase price per share">20.28</span> per share. The gross proceeds from the offering, which closed on November 15, 2024, were approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241115__20241115__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdwp73nJ1Cfj" title="Gross proceeds from offering">7.5</span> million, before
deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise
of the Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by the Company pursuant to a shelf-registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Placement Agent common stock warrants to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241114__20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNoiqmApglwl" title="Placement agent common stock warrants">18,492</span> shares of common stock. See further warrant details
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>January
2025 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2025, the Company conducted a CMPO Agreement with Ladenburg acting as the &#8220;Placement Agent&#8221;, pursuant to which
the Company agreed to issue and sell in a public offering <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250109__20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyXHKCN4Utr7" title="Public offering">416,667</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKghwc1QyEq9" title="Shares issued price per share">0.0001</span> per share,
at a purchase price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfEVEkeIkRd4" title="Exercise price">10.20</span> per Share. The gross proceeds from the offering, which closed on January 10, 2025, were approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250109__20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS939R3HFnv7" title="Gross proceeds from offering">4.3</span>
million, before deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if
any, from the exercise of the Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the Placement Agent common stock warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOh1L0PPeuVh" title="Purchase of shares">20,834</span> shares of common stock. See further warrant details
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>March
2025 Registered Direct Offering and Concurrent Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2025, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the
Company agreed to issue to the Purchaser, (i) in a registered direct offering, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcg7xYmvn7Hd" title="Stock issued during period">277,084</span> shares of the Company&#8217;s common stock (the
&#8220;Shares&#8221;), par value $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWj5RdgHa0Li" title="Shares issued price per share">0.0001</span> per share, at a purchase price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zADv4gZFzzN" title="Exercise price">7.80 </span>per Share, (ii) pre-funded warrants (&#8220;PFW&#8221;)
to purchase up to an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_ziJaiBogf91f" title="Stock issued during period">227,334</span> shares of Common Stock at a purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zf2LO1kZZRTb" title="Shares issued price per share">7.788</span> per Pre-funded Warrant and an exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zMiMVwSuUnKj" title="Exercise price">0.001</span> per share (the &#8220;Pre-funded Warrant Shares&#8221; or the &#8220;PFW Shares&#8221;) and (iii) in a concurrent private
placement, Series G common stock purchase warrants to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonWarrantsMember_zWvxgXNs8rQa" title="Common stock shares">504,417</span> shares of common stock (the &#8220;Series G Warrants&#8221;
or the &#8220;Common Warrants&#8221;). Such registered direct offering and concurrent private placement are referred to herein as the
&#8220;March Registered Direct Offering and Concurrent Private Placement.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares, the PFW, and the PFW Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-284229),
which was declared effective by the Securities and Exchange Commission on February 7, 2025. The Series G Warrants were issued in a concurrent
private placement and without registration under the Securities Act, and in reliance on the exemption provided in Section 4(a)(2) under
the Securities Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued Ladenburg, acting as the &#8220;Placement Agent&#8221;, common stock warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250328__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKOuayq1fSe5" title="Purchase of shares">25,221</span> shares of common
stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>July
2025 Warrant Inducement Offer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 9, 2025, the Company entered into a warrant inducement offer agreement (the &#8220;July Warrant Inducement Offer&#8221;) with seven
holders of the Company&#8217;s existing Series A warrants, Series B-1 warrants, Series C-1 warrants, Series D warrants, Series E warrants,
and Series F warrants (together the &#8220;Existing Warrants&#8221;). Pursuant to the July Warrant Inducement Offer, such warrant holders
immediately exercised some, or all, of their respective outstanding Existing Warrants to purchase an aggregate of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_ztcMr4bRjMl2" title="Purchase of warrants, shares">549,596</span> shares of the
Company&#8217;s common stock, at a reduced exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_zD96unmtx4we" title="Exercise price">8.40</span>, for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250709__20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_zoAsyHihNHT2" title="Gross proceeds from warrants">4.6</span> million, prior to
deducting placement agent fees and offering expenses. Note that Ladenburg acted as the &#8220;Placement Agent&#8221; in the July Warrant
Inducement Offer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of some or all of the Existing Warrants for cash, the Company issued unregistered new Series
H common stock warrants (&#8220;Series H Warrants&#8221;) to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember_zjNTP2dpcyKj" title="Purchase of warrants, shares">549,587</span> shares of common stock. See further warrant details
below. The Company filed a resale registration statement on Form S-3 (File No. 333-288784), to register the shares underlying the Series
H Warrants, which registration statement was declared effective by the Securities and Exchange Commission on July 25, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August
2025 Public Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 20, 2025, the Company entered into an underwriting agreement with Ladenburg, as representative of the various underwriters (the
&#8220;Representative&#8221;), in connection with the issuance and public sale offering of various securities (the &#8220;August Public
Offering&#8221;), including: (i) <span id="xdx_903_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zr3sYXN8KRr9" title="Issuance of common stock through august public offering, shares">1,922,764</span> common stock units (&#8220;Common Stock Unit&#8221;), which includes the <span id="xdx_905_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zfj0IIfW79Fh" title="Issuance of common stock through august public offering, shares">450,000</span> Common Stock
Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) <span id="xdx_90D_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zP5P50Woz6ul" title="Issuance of common stock through august public offering, shares">1,528,000</span> pre-funded warrant units (&#8220;Pre-Funded
Unit&#8221;), resulting in gross proceeds of approximately $<span id="xdx_90D_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingValue_pn5n6_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zoQA6DZv5CW5" title="Gross proceeds">6.9</span> million, before deducting underwriting discounts and commissions and
other estimated offering expenses. The August Public Offering closed on August 21, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--CommonStockUnitPerShareDescription_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zYIsIAJqCzf9" title="Common stock unit per share description">Each
Common Stock Unit consists of (i) one share of common stock of the Company, par value $0.0001, and (ii) one Series I warrant to purchase
one share common stock, and each Pre-Funded Unit consists of (i) one pre-funded warrant to purchase one share common stock, and (ii)
one Series I warrant to purchase one share common stock. Each Common Stock Unit was sold to the public at a price of $2.00 per Common
Stock Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit.</span> See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units and Pre-Funded Units were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333- 289670),
which was declared effective by the Securities and Exchange Commission on August 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the August Public Offering, the Company also issued to the Representative (or its designees) certain warrants (the &#8220;Representative
Warrants&#8221;) to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250820__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_ziha8uwFcddg" title="Purchase of warrants">172,538</span> shares of common stock. See further warrant details below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--ScheduleOfOutstandingWarrantsTextBlock_zfUEjplfNhKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the Company had outstanding warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231_zwpIRC1k4m5d" title="Purchase of shares">5,026,613</span> and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zArg26kfajRk" title="Purchase of shares">910,299</span> shares of common stock, respectively,
consisting of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zaOCfoDFvQsc" style="display: none">Schedule
of Outstanding Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20251231_zt1cD7aewJkg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20241231_zGcjM197DTXl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    date</span></td></tr>
  <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgPI1YF6YQKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants to purchase Common Stock<sup id="xdx_F47_z6tyoNYW74H9">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zPnNjNrABJWc" title="Exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zBLrmU8MfELg" title="Exercise price">1,380.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zFOSnd84WJIg" title="Issuance date"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zUxUSFeE6PEe" title="Issuance date">September
    12, 2023</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zuuTiMLGd41l" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgi48eD4KR84" title="Expiration date">September
    12, 2028</span></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zUVdlL0BaiVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants to purchase Common Stock<sup id="xdx_F49_z0mrR375bVd2">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zyVFDM8eVpxb" title="Exercise price"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zQULLMXm97K6" title="Exercise price">1,380.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zxcbb1ukdC6k" title="Issuance date"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zDggh4IodK2g" title="Issuance date">September
    12, 2023</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_z4liAvuhhqxd" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zXqH06rbbU6h" title="Expiration date">September
    12, 2028</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zRVBT6OtXQeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Restricted Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zO5Z4ONebg69" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_z2qM0oU5XHMe" title="Exercise price">158.40</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zUJLcykvwPFf" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zAlM0j3fOEzl" title="Issuance date">February
    21, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zCrmwgfNzpjj" title="Expiration date"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zH6XTXdFLiV6" title="Expiration date">February
    21, 2029</span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z8vVu2fbocdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Restricted Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zV55UrC9J21j" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z5KnjmHS6E25" title="Exercise price">22.80</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zbLT0yqBgGgf" title="Issuance date"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zjpg5mki66jg" title="Issuance date">July
    28, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zoioWBZIMGhk" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_ziMWpzLjgupe" title="Expiration date">July
    28, 2027</span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zeZNWsyvHhpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zAwBxePIkUjb" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zmQB8auENy31" title="Exercise price">79.20</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zjCKIMye3hR2" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zyofz5iOEo6l" title="Issuance date">April
    18, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zlBByEOYXPMg" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zXIw0zFkiLIi" title="Expiration date">April
    18, 2029</span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zRG3mxhBCYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,458</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,458</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zKIgIbpzC1ig" title="Exercise price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zmpqo9cGiIh9" title="Exercise price">45.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zuC38sqnOXVe" title="Issuance date"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zcEimW9CHDwc" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zh52pGdW7iY5" title="Expiration date"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zB3FkifcG6m" title="Expiration date">June
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zGpRg5Cjwixd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,542</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,542</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zYqG1ppSgiUh" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zji1jYZc0pPj" title="Exercise price">15.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zOLqDczScrZf" title="Issuance date"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_z39r5jRN8Xgk" title="Issuance date">October
    24, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_znMKkRG0xyD7" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zEFPgYkpeVI5" title="Expiration date">April
    24, 2030</span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zZVb2ifZHIB8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zp5fzsTgXPRk" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zVOSoRBesXui" title="Exercise price">25.35</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zYgNY8sFtbV8" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_ziM0m1pNuWie" title="Issuance date">November
    15, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zIuC2g4Wt7A" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zvDPE8DF8yeh" title="Expiration date">May
    15, 2030</span></span></span></td></tr>
  <tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zXhwbxUCGCfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zRJ7x7PBpZ05" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zdDOtu5Gy3C" title="Exercise price">12.75</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zhjJtbjLxlkk" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_z96k4eclodXh" title="Issuance date">January
    10, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zGXxb2E388ah" title="Expiration date"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zl6zoeGXGbp3" title="Expiration date">January
    10, 2030</span></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_z2bnVOBJgyA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zfRSuMQ0VzV7" title="Exercise price"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zy4bYiOnjp3g" title="Exercise price">9.75</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_ztjFqf8aO60h" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zo8VkNfwBptg" title="Issuance date">March
    31, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zZepBsWw9Uml" title="Expiration date"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zGXqAA2tfpSf" title="Expiration date">March
    31, 2030</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zEuVwluocZK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative
    Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,538</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1791">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zJrrNhRqghwi" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zl162NBSwsic" title="Exercise price">3.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdEpCKIeJ7Ib" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zTQ3XXZ2mqV9" title="Issuance date">August
    21, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdpyOqOwiEle" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zHj8H0hmY7n5" title="Expiration date">August
    21, 2030</span></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z2qFIt86FJR1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A Warrants to purchase Common Stock<sup id="xdx_F4E_zxG56Br7YiY2">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87,643</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zcPrXXsxl0Ug" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z0T7YlqVq6A4" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zhx14koTOfI3" title="Issuance date"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zMH8vvPjIc8l" title="Issuance date">April
    18, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zxbeX8BwyTil" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zUzp6cT3xaN7" title="Expiration date">April
    18, 2029</span></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zRXRNz5giG4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B Warrants to purchase Common Stock<sup id="xdx_F4B_zNjffbTUWvC6">(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zmdUis4QApd1" title="Exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_z5zBuCDXO66l" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zuo4398kBeN1" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zl1V7NoF89Ue" title="Issuance date">April
    18, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zgXFtLgEU3Yk" title="Expiration date"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zTOmfaCvW7e5" title="Expiration date">April
    18, 2025</span></span></span></td></tr>
  <tr id="xdx_409_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zxK56C9OewM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F48_zi6B9OdyvFwl">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,442</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zMIYuaYfcbLa" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zKVxTROyMJFc" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zLtZZYwOpUhh" title="Issuance date"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zTBty83PwKeh" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_z9APXtma4jC4" title="Expiration date"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zSAZb5EBebHg" title="Expiration date">June
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zuSbugofQ88a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F48_zUhKoE2S0fgk">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1850">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_z6Q2iO7wrkh9" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zl2esj0kAFWh" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zLKKaPSxogyi"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zaV2ONdzup92">July
    19, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zNeVoftq6pge"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_ztFKpEwufmX4">July
    19, 2029</span></span></span></td></tr>
  <tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockThreeMember_zCkDawhXMcV9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F4B_zvinK6tDmePi">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1861">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKZS5M9IGtAb" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zb3bKc7Ydp18" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKjBW1bV4H51" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z7Uc62PczQ67" title="Issuance date">July
    22, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zFw4BJGU3RB6" title="Expiration date"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z9YgJj0yOcul" title="Expiration date">July
    22, 2029</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zi58jpi6AbWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F4D_zwXyMJUAW6sf">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1876">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,251</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zwJ8XnPvSTne" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zM3LfOlLY3H4" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zd6a768WbR78" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zeYk8d2n02P7" title="Issuance date">November
    13, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zZTv3yM7zNW9" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zWQrU2BdNnfl" title="Expiration date">November
    13, 2029</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z7ujrgbVlbr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F4E_zLwFIY6fTcya">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,586</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zgpBGmZrf6Ac" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zg5kyH8SM1cb" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z75eDQh1xCTf" title="Issuance date"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z1qOlKItkiF8" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zq5QIba6ar77" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zSZHwcDX2mz8" title="Expiration date">June
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zJzt3bIaEs03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F43_zc78ko79Ispk">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_z5wdghE4PKA6" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zenUJTI5yCBb" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zSBMp3LEQtQc" title="Issuance date"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zj7lqydZBNHa" title="Issuance date">August
    8, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zDJmd6Ur5tM8" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zvgGsMNGC1p4" title="Expiration date">August
    7, 2029</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zJkgO7hFEuW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F4F_zzxez496UVzc">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,168</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,168</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zrxgJl4GeaWg" title="Exercise price"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zxGPUeoRt4d" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_znsFzg1LuOEi" title="Issuance date"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zc8MccSdQq7f" title="Issuance date">August
    16, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zY7Qo5GVpeag" title="Expiration date"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_z6hpCbI1Lmi" title="Expiration date">August
    15, 2029</span></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z2JOJYvwMOEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    D Warrants to purchase Common Stock<sup id="xdx_F4B_zG5lQ2yItPt4">(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,318</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,153</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z16vwHbNh0Xg" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zUruHHO5ez2e" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zvGciJAxMT72" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zCJRExu8H2ed" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zF0K0c2rH383" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zVzpD6Ujyszl" title="Expiration date">December
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_40D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zIiCncH8XL19" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    E Warrants to purchase Common Stock<sup id="xdx_F45_zpm863jw6ng2">(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1951">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,836</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zlJJoSlZTg2k" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zEd7oC1C0zu9" title="Exercise price">13.56</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zbdKGTDqyMe5" title="Issuance date"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zU1nxSdCqZRc" title="Issuance date">October
    24, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z3zozdSBbRZ6" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z9z4SmAWT7Uj" title="Expiration date">April
    24, 2026</span></span></span></td></tr>
  <tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zcyV1hRWckwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    F Warrants to purchase Common Stock<sup id="xdx_F4A_zlTwV30ZGCpg">(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1966">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,836</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNa9hD16C08j" title="Exercise price"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNp6cIBAGzq7" title="Exercise price">13.56</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zC9N51yiELM6" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zLuJsjrmAE8h" title="Issuance date">October
    24, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zys2Z2jMKAzd" title="Expiration date"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zoQUUA1BJyS7" title="Expiration date">April
    24, 2030</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zd0cmXTTpCU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    G Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">504,417</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zhf66P3Rp22b" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBfcttBteGNj" title="Exercise price">8.34</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBun3MQzBom6" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zVGtsejpShZe" title="Issuance date">March
    31, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_z5gD9u8fUuB2" title="Expiration date"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zDZtzijcIfq6" title="Expiration date">September
    30, 2032</span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zYJrUiT4A1ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    H Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">549,587</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1997">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zQQ4PJRklOO5" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zeyBs7AL6XDb" title="Exercise price">8.40</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zJulfPSosXt3" title="Issuance date"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zLHZL6Dl1L04" title="Issuance date">July
    10, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zKP7QEZhGH0h" title="Expiration date"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zOprzkzV9Xg4" title="Expiration date">January
    10, 2031</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zrxXLSswYqoh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    I Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,450,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2012">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_znVkhYZ2rki4" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zzmaptg7Mxhi" title="Exercise price">2.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zf5M0aVWiWk6" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zwlQJh5khrwi" title="Issuance date">August
    21, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zObUZb63f0c6" title="Expiration date"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zUj54wVc0HX4" title="Expiration date">August
    21, 2030</span></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_zXPhLVZlmw2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F02_zklbGtvDjmx2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_znuGs7SC36K5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#8217;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zhchokdSYADf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1B_zxZ3YvKW1fL2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#8217;s common stock.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--PublicWarrantRedemptionDescription_pid_c20250101__20251231_ztb6ktS0f7Gb" title="Public warrant redemption description">The
    Company may redeem the outstanding Public Warrants for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--RedemptionOfOutstandingWarrantsPerShare_pid_c20250101__20251231_z0eZIco0ySvh" title="Redemption of outstanding warrants per share">0.12</span> per warrant upon at least <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--ClassOfWarrantsRedemptionNoticePeriod_dtD_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_zIroWV3Kn0of" title="Class of warrants, redemption notice period">30</span> days&#8217; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--SharePrice_iI_uUSDPShares_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_zKgdq3sn9i9g" title="Share Price">2,160.00</span> per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.</span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company accounts for the Public Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because
    the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accounting treatment of derivative financial instruments in accordance with ASC 815 requires that the Company record a derivative
    liability upon the closing of the FLAG Merger (see Note 2).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 17, 2024, the Company received notice from the NYSE that the Company&#8217;s Public Warrants to purchase common stock are
    no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of such public
    warrants, and that the NYSE Regulation has determined to commence proceedings to delist the public warrants. The Public Warrants
    may be traded on the OTC Pink Marketplace under the symbol CLDWW.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F00_za4loOSPtY25" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F19_z1lSebrMsjPb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the year ended December 31, 2024, Series A warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f" title="Number of shares purchased">60,418</span> shares of common stock
                                            were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7" title="Exercise price">18.24</span> per share and the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576" title="Received dross proceeds">1.1</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series A warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z5zyhc1WQVrb" title="Number of shares purchased">33,335</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zM4YvTH3n71e" title="Exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zoKof3dAYb4h" title="Received dross proceeds">0.3</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F00_zk1EX9rWw8s9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F14_zOJRQAZQHvG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
                                            B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased">22,275</span> shares of common stock were exercised at a reduced exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price">24.00</span> in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds">0.5</span> million. During the year ended December 31, 2024, Series B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased">68,335</span>
                                            shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price">18.24</span> per share and the Company received gross
                                            proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds">1.2</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outstanding Series B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zCjS5nkk7RNl" title="Number of shares purchased">57,451</span> shares of common stock expired in April 2025. As of December 31, 2025, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_do_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zJcPptm4wsz" title="Warrants outstanding">no</span> Series
    B warrants remained outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zCbhZ5JVIGuf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F10_zNpmXQC9ahDe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy" title="Number of shares purchased">27,082</span> shares of common
                                            stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1" title="Warrants exercise price">18.24</span> per share and the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob" title="Gross proceeds">0.5</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series B-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zJzhCq7uqT78" title="Number of shares purchased">62,086</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zKWSRj6VjYF9" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zpYGyKGAeYG2" title="Gross proceeds">0.5</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zCd37e8Jcx98" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1C_z7McP3RC7sPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f" title="Number of shares purchased">4,167</span> shares of
                                            common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg" title="Warrants exercise price">24.00</span> per share and the Company received gross proceeds of
                                            approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b" title="Gross proceeds">0.1</span> million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7" title="Number of shares purchased">47,936</span> shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8" title="Warrants exercise price">18.24</span> per share and the Company
                                            received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg" title="Gross proceeds">0.9</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series C-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zsOkklPTY0P5" title="Number of shares purchased">41,668</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zelVqow1sFad" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zV1AZQnnrJB7" title="Gross proceeds">0.4</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zPih12spboPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F19_z4prBB1WV3Ea" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3" title="Deemed dividend">1.7</span> million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series D warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zAy8T0RnQ5F8" title="Number of shares purchased">70,835</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zHckoL4rqJD2" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zExkhm7GdCK" title="Gross proceeds">0.6</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F08_z79dDFrQyW69" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zTzPNn9dfsxj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b" title="Number of shares purchased">341,672</span> shares of common stock each were exercised
    at a reduced exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk" title="Gross proceeds">2.8</span> million.</span></td></tr>
  </table>
<p id="xdx_8A3_zw2x6xA5wMr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025, Series G pre-funded warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn3n3_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zIMMlwKBj4P2" title="Number of shares purchased">227,334</span> shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zp9TKcGaDSE8" title="Warrants exercise price">0.012</span> per
share for gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pn3n3_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zzoladFoOXya" title="Gross proceeds">3,000</span>, and Series I pre-funded warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn3n3_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zhx59spSMne5" title="Number of shares purchased">1,528,000</span> shares of common stock were
exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zZsOTErFGnk1" title="Warrants exercise price">0.001</span> per share for gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ProceedsFromNotesPayable_pn3n3_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zU0n0BRUINl7" title="Gross proceeds">1,500</span>. As such, no Series G pre-funded warrants or Series I pre-funded
warrants were outstanding as of December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI9zvMdBUoVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s aggregate warrant activity for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zN4RTrBvgykj" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz2jDt26kuD4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjKyow3I4Dza" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgckS06Oe9s4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z38OhOA5wXR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,478,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyvU3Dx4CT4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,304,930</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetsFP6qOM73" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(57,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8GKp22zH831" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5c4cCUUR2d9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.97</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoKmLVctvhY1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s aggregate warrant activity for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price
                                            <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgX2i38dnYCe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111,772</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwS16fLKZb5f" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,380.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7sOYX74ZK9k" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9lVq9FwLa7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,176,804</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z71n7KcESiyc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(350,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted
    into Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z9Oku9Hupf42" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zAeJ5lPSI06f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo7VftXyfc8e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEGRpY5Qpcik" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AA_zs7323Dd0Ihi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zD2T4dlLrNlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_825_zP7G4TGIwXpi">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Incentive Plans</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
completion of the Business Combination on September 12, 2023, the Company adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;).
The 2023 Plan reserved the right for the Compensation Committee or by the Board of Directors acting as the Compensation Committee, as
the administrator of the plan (the &#8220;Administrator&#8221;) to issue up to <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230912__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--TitleOfIndividualAxis__custom--AdministratorMember_zupByNRwm5ti" title="Number of shares reserved">32,815</span> equity awards, including stock options (&#8220;Options&#8221;),
restricted stock awards (&#8220;Restricted Stock&#8221;), dividend equivalents awards, stock payment awards, restricted stock units (&#8220;RSUs&#8221;)
and/or stock appreciation rights (&#8220;SARs&#8221;, together with Options, Restricted Stock and RSUs, &#8220;Awards&#8221;), according
to its discretion. On July 9, 2025, the Company&#8217;s stockholders approved an amendment to the 2023 Plan to increase the aggregate
number of shares of common stock authorized for grant under the 2023 Plan from <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250709__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--RangeAxis__srt--MinimumMember_zqTyX4QSO8X3" title="Number of shares reserved">32,815</span> to <span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250709__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--RangeAxis__srt--MaximumMember_zQGP7s8uYCcb" title="Number of shares reserved">282,815</span>. Awards may be granted under the 2023
Plan to our employees, directors, and consultants. As of December 31, 2025, the Administrator has issued RSUs and stock options under
the 2023 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 2023 Plan, Awards may vest and thereby become exercisable, subject to forfeiture restrictions, (1) on the date of grant, (2) in periodic
installments, (3) upon the attainment of performance goals, or (4) upon the occurrence of specified events depending on the Administrator&#8217;s
discretion. The Administrator has broad authority to determine the terms and conditions of any Award granted pursuant to the 2023 Plan
including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations
on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations
or waivers thereof as the Administrator, in its sole discretion may determine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Awards may be granted under the 2023 Plan with a term of more than ten years and no Awards granted may be exercised after the expiration
of ten years from the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2024 and August 4, 2025, the Company effected a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20240715__20240715_zYwzsdIzoCs6" title="Reverse stock split">1-for-10</span> Reverse Stock Split and a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20250804__20250804_zliZ8Lhl9p94" title="Reverse stock split">1-for-12</span> Reverse Stock Split, respectively.
As a result of each respective Reverse Stock Split, proportionate adjustments were made to the per share exercise price and the number
of shares of common stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of
shares of common stock reserved for future issuance under the Company&#8217;s 2023 Plan. All stock option activity presented in these
statements has been retrospectively adjusted to reflect the Reverse Stock Split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023
Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2023, the Company approved the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;), which became effective on
the consummation of the FLAG Merger. Under the 2023 ESPP, eligible employees may purchase a limited number of shares of common stock
at a discount of up to <span id="xdx_906_ecustom--CommonStockDiscounRate_pid_dp_uPure_c20230828__20230828__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_z9scwl30pMf3" title="Number of shares issued of common stock at discount rate">15</span>% of the market value of such stock at pre-determined and plan-defined dates. There have been no issuances of
common stock under the 2023 ESPP to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the 2023 Plan may be either &#8220;incentive stock options&#8221; within the meaning of Section 422(b) of the Internal
Revenue Code of 1986, as amended (the &#8220;Code&#8221;), or &#8220;non-qualified&#8221; stock options that do not qualify incentive
stock options. Incentive stock options may be granted only to the Company&#8217;s employees and employees of domestic subsidiaries, as
applicable. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztWXzM30ZAk1" title="Description of term and exercise price of options">The exercise price of stock options shall be equal to or greater than the fair market value of common stock on the date the
option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the
grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined
as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee
in any calendar year may not exceed $0.1 million, otherwise it will be classified as a non-qualified stock option.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of an option may be payable in cash or in common stock, or in a combination of cash and common stock, or other legal consideration
for the issuance of stock as the Board or Administrator may approve.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrLY2NWF4j4f" title="Descriptiion of options vesting">options vest over four years and will be exercisable only while the optionee remains an employee, director or consultant, or during the
three months thereafter, but in the case of the termination of an optionee&#8217;s services due to death or disability, the period for
exercising a vested option shall be extended to the earlier of twelve months after termination or the expiration date of the option.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employee
Benefit Plans Securities Registration Statement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2024, the Company filed a Registration Statement on Form S-8, which includes a Reoffer Prospectus which may be used for reoffers
and resales of shares of the Company. The Reoffer Prospectus covers the shares issuable to the holders pursuant to awards granted by
the Company under the 2023 Plan. The Company will not receive any proceeds from the sale of the shares offered by the Reoffer Prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Awards Activity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z7xIaenxH4sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the 2023 Plan option activity and related information follows (in thousands, except weighted averages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zfEuhibvMzL2" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic
                                            Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK7kC1ajijW2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Options Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztRaZJZJFvU2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">220.92</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSpaP75uL3ci" title="Weighted Average Remaining Contractual Life (Years), Outstanding">5.67</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zefFLnTWCDKg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKe1Ruauxv7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">217</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCWFrdBuwki" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpYflv2WEsYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2199">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0rvqdIRJlL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2201">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    forfeited or cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYBD9YroCVBg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0buq0fQQjLd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">252.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoM6ZjChWrv5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTFSrkB3V5kl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.57</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HXOYBinOu4" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.39</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEh0gbt0G4c" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2213">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVY2amDXb4Li" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAhQUpKWRJRd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160.73</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHcrzjARNxw4" title="Weighted Average Remaining Contractual Life (Years), Exercisable">5.54</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ0Xgxt9ks5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zRooPPLh8yNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0V8ViB7a2cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the 2023 Plan restricted stock unit (RSU) activity and related information follows (in thousands, except weighted average
grant date fair value):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zwCCANd9cbH3" style="display: none">Summary
of Restricted Stock Unit Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant-Date
                                            Fair Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYP9cSw5Qb6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Units Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRgmbX7LNmcj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    and released</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZugKRLLFGo1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpw41DTyfZe6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzEsqaDp2sml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2233">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLgdS2RSgSTg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2235">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zqFcJcwzXpna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zCzZoUFkWN5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations
for the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDiKQSAqinMj" style="display: none">Schedule
of Stock-Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zKOpDXF8G51l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zr8StlecTXPh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zraVVi4t1ank" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">426</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">751</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zUGIRtAM3tRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zBL22iwa4ICg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,108</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,957</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zpUqrOZ5dV71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 18, 2023, the Board approved a repricing of approximately <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn5n6_c20230118__20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJRMOsgG1w1d" title="Options granted approved for repricing">0.2 </span>million stock options previously granted at an exercise price of
$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbbkayw0naG3" title="Exercise price">1,112.40</span> per share to the then current fair value of $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO02JJ1mcZDc" title="Exercise price">853.20</span> per share pursuant to an updated valuation report. For each of the years
ended December 31, 2025 and 2024, the Company recorded a noncash compensation charge of approximately $<span id="xdx_906_ecustom--NoncashCompensation_pn5n6_c20250101__20251231_z3rzkqROs8l" title="Noncash compensation charge in connection with repricing"><span id="xdx_901_ecustom--NoncashCompensation_pn5n6_c20240101__20241231_z2zc3dDlsrGj" title="Noncash compensation charge in connection with repricing">0.1</span></span> million in connection with
this repricing. The stock option repricing and the acceleration of vesting were accounted for as a modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025, the total unamortized stock-based compensation expense related to stock options was approximately $<span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20251231_zf2gMDpc4HJl" title="Total unamortized stock-based compensation expense">0.8</span> million,
expected to be amortized over an estimated weighted average life of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231_zEMBRRQxq2Pl" title="Estimated weighted average life">1.9</span> years. The weighted-average estimated fair value of stock options
with service-conditions granted during the year ended December 31, 2025 and 2024 was $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231_zhBIl59XK0ik" title="Weighted-average estimated fair value of stock options">3.11</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zwllCtCMkreb" title="Weighted-average estimated fair value of stock options">17.28</span> per share, respectively, using
the Black-Scholes option pricing model with the following weighted-average assumptions:</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zu40kxVf1Mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zdpUKtuCZav8" style="display: none">Schedule
of Stock Options Valuation Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20251231_zYwzAD1nqNb7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zzjUP5wAMfF2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20251231_zH4VG3ESa7eb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zz8KbtNzL8nk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    option life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231_zGfjSZ8LnwK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.78</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zftGv0RrkSD7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_zBtbVzIc1lTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zO5GP7caLrCh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>


<p id="xdx_8AD_zigRZD3ZpVj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when
a disqualified disposition has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zHExlPqNWiEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_82C_z5Z5FPvHfbp1">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zmI7X7eorJAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income/(Loss)
before provision for income taxes consisted of the following for the year ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zaVuKwfY3u7l" style="display: none">Schedule
of Income (Loss) Before Provision for Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_z1eur2KiQjJ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z0n1aWp4zFjd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zqb4CfXSPFlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(20,100<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,215</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--NonUsMember_zYhOssVld3l2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zrDgzR435E9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,048</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,195</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p id="xdx_8A1_zQ3h5mKaKxIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkQC7wARcWlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax expense (benefit) by jurisdiction for the year ended December 31, 2025 and 2024, were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zckABzOflrB9" style="display: none">Schedule
of Income Tax Expenses (Benefit) by Jurisdiction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zdfhLeHvkoCb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zx5hjdGzc0rb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_znNSLSOmYZ31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zAup2wou2llc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2302">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2303">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zVp9UCS1JTDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    and local</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2306">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zBvgZLB1XXee" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pn3n3_mtCITEBziCv_maITEBzUqw_zZMx6aSiZtwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">15</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zKTEcVxovTUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_z1kpVraKSUdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2317">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2318">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zK1WBnJwE7Za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    and local</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2320">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2321">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zBsepxvobkVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2323">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2324">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pn3n3_mtDITEBzDw6_maITEBzUqw_zbTUpQrnkXRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2326">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2327">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUqw_zxpscxQO7gtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">15</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_z2cPIjZ0vmW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has incurred net operating losses primarily for U.S. federal and state income tax purposes and has not reflected
any benefit of such net operating loss carryforwards for any periods presented herein. For the year ended December 31, 2025 and 2024,
no U.S. provision or benefit for income taxes was recorded and an insignificant amount of German provision for income taxes was recorded
as presented on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuqKCNsp7pKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the benefit for income taxes to the amount computed
by applying the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zQYz2ZJJiQ1k" title="Federal statutory income tax rate">21</span>% statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2025, after the
adoption of ASU 2023-09, is as follows (in thousands, except for percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span id="xdx_8BA_zi89feMC8pgg" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231_zvsulSOwOOFf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjN0_zihwnEwvat8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">U.S. Federal statutory tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(4,210</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zdCaSR0PS2I" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S. Federal statutory tax rate, percentage">21</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjN0_zMd2U5dnfb7c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State tax, net of federal income tax effect<sup id="xdx_F49_zfMUB8EowxWh">(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20250101__20251231_fKDEp_ziSPJNckHKx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax, net of federal income tax effect, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationEnactmentOfNewTaxLaws_maITEBzjN0_zeb36ZS0ig89" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Enactment of new tax laws</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_pid_dp_uPure_maABC_c20250101__20251231_znorpo3hbvr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enactment of new tax laws, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2346">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maITEBzjN0_zrh65z92s1pl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of cross-border tax laws</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_c20250101__20251231_zT42c40qxkWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effect of cross-border tax laws, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2350">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBzjN0_zvDLKSApPOKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(299</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20250101__20251231_z7oSHzsu1zi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Tax credits, percentage">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjN0_zq5pT7QibJ4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,519</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zs8DOk37luLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance, percentage">(17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAbstract_iB_zUKpPQtL6vtl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Nontaxable or non-deductible items</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_i01_maITEBzjN0_zWye46LLe00l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-deductible expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maABC_c20250101__20251231_ztk6cDIBHb0k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible expenses, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2364">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_maITEBzjN0_z0CPv64gkyJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20250101__20251231_zlb9t8L8Gc91" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation, percentage">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxSettlements_maITEBzjN0_z6MunjaJDdIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Worldwide changes in unrecognized tax benefits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">342</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maABC_c20250101__20251231_zY4B7GQpnN93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Worldwide changes in unrecognized tax benefits, percentage">(2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherReconcilingItemsAbstract_iB_zjqX7cLSigw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i01_maITEBzjN0_zgknsduMTri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred tax adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">139</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zbbFMSpxyShc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred tax adjustments, percentage">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_i01N_di_msITEBzjN0_zwrlSKQZHIo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">348</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_iN_pid_dpi_uPure_msABC_c20250101__20251231_zd8usvK6Y6u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-controlling interest, percentage">(2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i01_maITEBzjN0_zh8MyuRsHJ49" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20250101__20251231_zaR1I0mJwQM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2386">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_maABC_zJLZG6onMXka" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_maABC_zepi2og8IZJf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_maABC_znEh3CYo1Nz8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issuance cost</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_maABC_z2J7LMVTXxBk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    startup costs</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign tax effects</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Germany</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_maITEBzjN0_zeeaLUSXxKVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Foreign employee stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zcO0S1CaBQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Foreign employee stock based compensation, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2398">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_maITEBzjN0_zR99C4Yh4P63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rate differential</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zHo20NYC5TK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Rate differential, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_maITEBzjN0_zvmJdpCP8Q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_pid_dp_uPure_maABC_c20250101__20251231_zmN6R4wflEAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Other, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2406">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_maITEBzjN0_zAlI68y5rrZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rate differential</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_pid_dp_uPure_maABC_c20250101__20251231_zkS90xGUv0H1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Rate differential, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2410">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_maITEBzjN0_zMgrgYgslGr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zAIEDsplK743" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Change in valuation allowance, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2414">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjN0_zbJfxINKh827" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20250101__20251231_zyyiiUtlerG6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reconciliation of income tax benefit, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2418">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zct2ZTKa2Ewf" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zpfi7Hnizt45" style="font-size: 10pt">California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 2023-09 on a prospective basis. A reconciliation of the benefit for income taxes to the amount computed by
applying the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_z0obmmRCZSM3" title="Federal statutory income tax rate">21</span>%
statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2024, before the adoption of ASU
2023-09, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none">Schedule
of U.S. Federal Income Tax Rates Indicated to Pretax Loss From Operations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed
    tax benefit at U.S. federal statutory tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20240101__20241231_zUtR4pIQ7Qn2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Computed tax benefit at U.S. federal statutory tax rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent
    differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20240101__20241231_zPeXQHLDEdz6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2425">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    tax benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20240101__20241231_zm3EOrHZAze5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20240101__20241231_zyCqFkjZl2x2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_uPure_maABC_c20240101__20241231_zo82EFPPaf47" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20240101__20241231_ze35NAHYbBfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20240101__20241231_zrz97QRAWPJ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2435">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_uPure_maABC_c20240101__20241231_z4Th7nho2OHb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issuance cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_uPure_maABC_c20240101__20241231_zV3fgVtZr0z" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2439">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    startup costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_uPure_maABC_c20240101__20241231_zRUZsXSHTcE3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2441">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Pretax loss from operations
    rates total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20240101__20241231_zptrl9LReBn" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2443">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p id="xdx_8A9_zUTggjNHmEM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfIncomeTaxPaidTableTextBlock_zsK4I0lG0F21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon adoption of ASU 2023-09, cash paid for income taxes, net of refunds
received, were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zQCoIBBAqDQ5" style="display: none">Schedule
of Cash Paid for Income Taxes, Net of Refunds Received</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zOyPWllijAh9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNztd0_zu9pWrQTBJn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Federal taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2447">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxPaidStateAfterRefundReceived_maITPNztd0_zjijZGDohw26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State and local taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNztd0_zEoebRvZdd0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign taxes:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--AU_maITPNztd0_zUyGgN4WEJqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2453">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--DE_maITPNztd0_zlvxgcoZqgNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 80%; padding-bottom: 1pt">Germany</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_iT_mtITPNztd0_zo5AniFJEie9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total cash paid for income taxes, net of refunds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zD74HNRTmYHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of cash paid for income taxes during the year ended December&#160;31,
2024 was $<span id="xdx_904_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20240101__20241231_zG3AOyO0UAfl" title="Cash income taxes paid">14</span> thousand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQS7jlZ9G3md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary components of the deferred tax assets and liabilities at December 31, 2025 and 2024 were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zxgqp710OTae" style="display: none">Schedule
of Components of Deferred Tax Assets and Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zcGtguKFDa0c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231_zrgbsgdOSbd7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax assets/(liabilities):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzO0o_zYioH31KvUH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">25,920</p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzO0o_zKla1Ij2pK0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development credit carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">931</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzO0o_ziwHtGMhOVu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    and other compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_pn3n3_maDTAGzO0o_zuiGZRyvi3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">479</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">859</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_pn3n3_maDTAGzO0o_zQnEXaYAVlJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
    research and development expenditures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGzO0o_zoJFXsy61izl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,315</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,393</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzO0o_zKs7xlP8fKhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities and other reserves</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">446</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzO0o_maDTANzVsW_zTwaQun8fFn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,232</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_iNI_pn3n3_di_maDITLzwdK_zkSeahFfBNNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    and other assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(480</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(830</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzwdK_msDTANzVsW_zMlbqVgsTI8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(480</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(830</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzVsW_zNGTS671QiE1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34,215</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzVsW_zL10150kJI13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2496">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2497">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_zM2uJ66TQeWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2025, the Company had net operating loss carryforwards
of approximately $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOgZIAc6JSd8" title="Operating loss carryforwards">89.2</span> million for U.S. federal income tax purposes and $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkj1HGtiNLS5" title="Operating loss carryforwards">106.2</span> million for state income tax purposes. Federal net operating
losses of $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--TaxPeriodAxis__custom--PriorDecemberTwentySeventeenthMember_zDSgOvW7VeK3" title="Operating loss carryforwards">8.0</span> million generated on or prior to December 31, 2017, expire in varying amounts between 2034 and 2037, while federal net
operating losses of $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--TaxPeriodAxis__custom--AfterDecemberTwentySeventeenthMember_zKRERLRCduHg" title="Operating loss carryforwards">81.2</span> million generated after December 31, 2017 carryforward indefinitely. The state net operating losses expire in
varying amounts between 2034 and 2044.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2025, the Company has research and development credit
carryforwards for federal purposes of $<span id="xdx_908_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMfHFTCzX1uf" title="Research and development credits carryforwards">1.4</span> million and for state purposes of $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z7ppTV09XF6f" title="Research and development credits carryforwards">1.3</span> million. The federal credits will expire between 2040
and 2045, while the state credits have no expiration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization
of the net operating loss carryforwards and credits may be subject to substantial annual limitation due to the ownership change limitations
provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration
of net operating losses before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31,
2021. There was an ownership change identified on March 26, 2018 after the Company&#8217;s Series A-2 preferred stock issuance. The Company
has not undertaken a Section 382 study through December 31, 2025. Our ability to utilize our net operating loss carryforwards and other
tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The Company established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits
from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20250101__20251231_zC9sAWgi96Cj" title="Valuation allowance">4.8</span> million and $<span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zdHZENlEVbre" title="Valuation allowance">5.5</span>
million for the year ended December 31, 2025 and 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has uncertain tax benefits (&#8220;UTBs&#8221;) totaling approximately $<span id="xdx_907_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20251231_zAtjKiUsot7f">2.4</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> million and $<span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20241231_z4IoYphUDlyh">1.8</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
as of December 31, 2025 and 2024, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs
had no effect on the effective tax rate and there would be no cash tax impact for any period presented. The Company does not expect its
UTBs to change significantly over the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zy6NAeHPiGFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zgihqkianum3" style="display: none">Schedule
of Unrecognized Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_zcFoJl7Bw0Hg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_z0TYewQukNRi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_zrCnkqJg47k4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at the beginning of the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,799</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,517</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_pn3n3_zSm0LSQLFUhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions
    based on tax positions related to current year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_zlmPVM42Odcg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    based on tax positions related to prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">283</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2526">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_zd71cGelRVnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,364</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A7_zGtiHAveAKi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files tax returns in the U.S. for federal purposes and California for state purposes, and in Germany and Australia for its foreign subsidiaries. For jurisdictions in which tax filings
have been filed, all tax years remain open for examination by the federal and California state authorities for three and four years,
respectively, from the date of utilization of any net operating losses or credits. The Company is not currently under audit by any taxing
jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in
assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes
the Company has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments,
if any, could be significantly different than the amounts recorded in the consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPOK3y5GljO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span id="xdx_829_zn3eriuoQBCj">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
and Financing Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2022, the Company entered into an Office Lease Agreement (the &#8220;San Diego Lease&#8221;) of a building containing <span id="xdx_90D_eus-gaap--AreaOfLand_iI_usqft_c20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_ziLzBvAbzwbj" title="Area of land">15,197</span>
square feet of rentable space located in San Diego, California (the &#8220;Premises&#8221;), which serves as the Company&#8217;s principal
executive and administrative offices and laboratory facility. The Company completed constructing tenant improvements at the Premises
on February 27, 2023, and moved into the Premises by the end of March 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
secure and execute the San Diego Lease, Mr. Allan J. Camaisa (or &#8220;Mr. Camaisa&#8221;) provided a personal Guaranty of Lease of
up to $<span id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z8hJaebAkvAi" title="Guaranty of lease, value">0.9</span>
million (the &#8220;Guaranty&#8221;) to the lessor for the Company&#8217;s future performance under the San Diego Lease agreement. <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20221010__20221010_zpGz8husti7a" title="Lease agreement description">As
consideration for the Guaranty, the Company agreed to pay Mr. Camaisa 10% of the Guaranty amount for the first year of the San Diego
Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease</span>, with all amounts accrued and payable
at the termination of the San Diego Lease or release of Mr. Camaisa from the Guaranty by the lessor, whichever occurs
first. Mr. Camaisa received $<span id="xdx_906_ecustom--GuarantyOfLeaseAmount_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MrCamaisaMember_z5NWwFd03aH9" title="Guaranty of lease, value">0.2</span> million during the fiscal year ended 2025 in connection with the lease guarantee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
San Diego Lease has an initial term of <span id="xdx_90A_ecustom--OperatingLeaseTermOfContractLeaseInitialTerm_dtM_c20230301__20230301_zDGppQxXD3l3" title="Operating lease, term of contract, lease initial term">48</span> calendar months, from the first day of the first full month following which the &#8220;Commencement
Date&#8221; occurs (the &#8220;Term&#8221;), which was March 1, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
on the Commencement Date, the Company pays base monthly rent in the amount of $<span id="xdx_902_eus-gaap--PaymentsForRent_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zsejvp3Zi0r6" title="Payments for rent">0.1</span> million during the first 12 months of the Term, plus
a management fee equal to <span id="xdx_904_ecustom--LeaseTermsOperatingLeasesAnnualIncreaseInRent_pid_dp_uPure_c20221010__20221010_zAeCqlq9r4R1" title="Lease terms, operating leases annual increase in rent">3</span>% of base rent. Base monthly rent will increase annually, over the base monthly rent then in effect, by <span id="xdx_90A_ecustom--LeaseTermsOperatingLeasesAnnualIncreaseInRent_pid_dp_uPure_c20221010__20221010_zyLsYlU4yYA4" title="Lease terms, operating leases annual increase in rent">3</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to base monthly rent and management fees, the Company pays in monthly installments its share of (a) all costs and expenses,
other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing
(including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the
Premises are located (&#8220;Expenses&#8221;), and (b) all real estate taxes and assessments on the Premises and the building in which
the Premises are located, all personal property taxes for property that is owned by Landlord and used in connection with the operation,
maintenance and repair of the Premises (&#8220;Taxes&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
execution of the San Diego Lease, the Company provided the lessor a payment of $<span id="xdx_90C_eus-gaap--OperatingLeasePayments_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zE0y0yEwxzN" title="Lease payment">0.1</span> million as first month base rent and prepaid operating
expenses, and a letter of credit in the amount of $<span id="xdx_909_eus-gaap--LettersOfCreditOutstandingAmount_iI_pn5n6_c20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zRzXSPkGVVTi" title="Letter of credit amount">0.1</span> million issued by a bank in the name of the lessor. To obtain the letter of credit,
the Company has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws
on the letter of credit by the lessor. The restricted cash may not be used for any other purpose (see Note 2). The prepaid rent was included
in the initial accounting of the San Diego Lease, as presented in the tables below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2022, StemVac entered into an office lease which includes laboratory space which expires on March 31, 2027, with monthly payments
of &#8364;<span id="xdx_90B_eus-gaap--PaymentsForRent_uEUR_c20220401__20220401__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_z3shSbxrFqQ2" title="Payments for rent">4,047</span> Euros per month. On July 1, 2025, StemVac entered into a finance lease agreement for laboratory equipment with an initial
term that expires on May 31, 2029, with monthly payments of approximately &#8364;<span id="xdx_906_eus-gaap--PaymentsForRent_uEUR_c20250701__20250701__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_zVndkENgfev" title="Payments for rent">2,976</span> Euros per month. The lease commencement date was
June 1, 2025. The lease agreement includes an option to renew the lease for an additional twelve months, which must be exercised by providing
six months&#8217; prior notice before the end of the initial lease term; however, the Company is not reasonably certain to extend the
initial lease term and therefore additional lease payments associated with the automatic renewal are excluded from the lease term. The
lease also contains a purchase option that the Company is not reasonably certain to exercise at the lease commencement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease expense recognized during each of the years ended December 31, 2025 and 2024 was approximately $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_zdtbhpHcMHW" title="Operating lease expense"><span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_z9eQRvEs82f3" title="Operating lease expense">1.5</span></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also party to certain financing leases for machinery and equipment (see Note 5).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_zjJcUdsV82A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents supplemental cash flow information related to operating and financing leases for the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zIEWyOnuK0Hh" style="display: none">Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250101__20251231_zVgR4TMa6cWi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20240101__20241231_z2O3hxNxW3p5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for amounts included in the measurement of lease liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zE9lHKMwv1dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,467</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zwgbEPczKbpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    cash flows from financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zMCqdQoMchmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    cash flows from financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zfZL4LbEGWXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_z7POe9VVVW36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents supplemental balance sheet information related to operating and financing leases for the periods presented (in
thousands, except weighted averages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zzivUjMbH66g" style="display: none">Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20251231_zeUZUbKLDkCl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zg5QPJAo5gIk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zjptdiItgEMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,934</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzLs4_zhvI1rU3CG7d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease liabilities, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzLs4_zErKs72ddsR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease liabilities, noncurrent</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,845</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzLs4_zmbAHBUGsGbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,049</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_iI_pn3n3_maPPAENzCH7_zXL1SWMuK1Kf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">588</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iNI_pn3n3_di_msPPAENzCH7_zp0geCKJ9JDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(463</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(333</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_iTI_pn3n3_mtPPAENzCH7_zfNhCxxzcpSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">316</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">255</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_maFLLzNvC_zGD0wv9kWj3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_maFLLzNvC_zQP67sLDO6P7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncurrent
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_mtFLLzNvC_zoLsaW172gHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    financing lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">211</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average remaining lease term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zXh8NPFoUwj2" title="Weighted average remaining lease term, Operating leases (in years)">1.2</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zWdlNhVMVNL8" title="Weighted average remaining lease term, Operating leases (in years)">2.2</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zeWhdokfJzNj" title="Weighted average remaining lease term, Financing leases (in years)">2.7</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3QXnlbPtHuf" title="Weighted average remaining lease term, Financing leases (in years)">3.2</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr8xPw3WQtL1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zZdFtnio05D7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.05</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<p id="xdx_8A3_zzHqzMuAkbk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zOihmUTUOme4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents future minimum lease commitments as of December 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zrbvmxSlKA3h" style="display: none">Schedule
of Future Minimum Lease Commitments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zrCrNBg9wKvk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Leases, 2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,512</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zcoYAGtcgefj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Financing Leases, 2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zECw0oPKmbX6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zFAwlGX09Rjl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zexL69dvRUje" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmReNXTKils8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z5cozyuTQpJc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2632">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zlZ2svW4Kw3k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030
    and thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zM7iUfRRvjF8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2030 and thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2636">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zruLPX0rgbri" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2030 and thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2638">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmtaJlAhhCB1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Total minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z8cP0VsZT5x5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Total minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">319</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    amounts representing interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_ztrK0QO5otPe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Less: amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(127</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_zOMifW6juZWl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Less: amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present
    value of net minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z3YOipHV72nb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Present value of net minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zHO9irHCvb7i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Present value of net minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8AE_z2YRPJqUptc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation
&#8212; General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation,
business transactions, employee-related matters, and other matters. At each reporting date, the Company evaluates whether a potential
loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that
addresses accounting for contingencies. If it is probable that a loss will result and the amount of the loss can be reasonably estimated,
the Company will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated,
the Company discloses the claim if the likelihood of a potential loss is reasonably possible, and the amount involved could be material.
The Company expenses the costs related to legal proceedings as incurred. See other legal matters discussed below. Other than the matters
discussed below, the Company is not currently party to any material legal proceedings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
Proceedings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former
Chief Accounting Officer and Interim Chief Financial Officer, and Controller</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 15, 2023, Tony Kalajian, the Company&#8217;s prior Chief Accounting Officer and interim Chief Financial Officer, filed a complaint
in the Superior Court of the State of California County of San Diego against the Company, Mr. Camaisa, the Company&#8217;s director and
former Chief Executive Officer, and Ms. Pizarro, the Company&#8217;s former Chief Corporate Development Officer and Chief Legal Officer,
alleging defamation and constructive discharge of Mr. Kalajian&#8217;s position of Chief Accounting Officer and interim Chief Financial
Officer (Case No. 37-2023-00049813-CU-DF-CTL) (the &#8220;Primary Case&#8221;). Mr. Kalajian is seeking an unspecified amount in damages
under his employment contract, damages to be proven at trial, punitive damages, and attorney&#8217;s fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company initiated arbitration proceedings against Mr. Kalajian for breach of fiduciary duty, constructive fraud,
conversation, and declaratory relief, seeking to recover from Mr. Kalajian bonuses Mr. Kalajian caused to be paid to himself, Hazel Sanchez,
the former Controller, and his accounting team. The bonuses (the &#8220;Accounting Bonuses&#8221;) were not authorized by the Company&#8217;s
Board of Directors or Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2023, Hazel Sanchez, the Company&#8217;s prior Controller, filed a complaint in the Superior Court of the State of California
County of San Diego against the Company, Mr. Camaisa, and Ms. Pizarro, alleging defamation, constructive discharge, violation of California
Family Rights Act, and wrongful discharge. Ms. Sanchez is seeking an unspecified amount in damages under her employment contract, damages
to be proven at trial, punitive damages, and attorney&#8217;s fees. In February 2024, the Company filed a Cross-Complaint against Ms.
Sanchez for breach of fiduciary duty, constructive fraud, conversation, and declaratory relief seeking to recover the Accounting Bonuses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, Mr. Kalajian also filed a Petition for Writ of Mandate in the Superior Court of California, County of San Diego, seeking
to compel the production of certain corporate records from the Company. This case is deemed related to the Primary Case above and was
dismissed by stipulation in March 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2024, Mr. Kalajian filed a complaint in the Superior Court of the State of California, County of San Diego against the Company
alleging intentional conversion and violation of Section 158 of the Delaware General Corporations Code due to the Company&#8217;s failure
to remove a restrictive legend from <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240501__20240501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTyT8tLsHB79" title="Shares issued">1,162</span> shares of the Company&#8217;s Common Stock. Mr. Kalajian is seeking compensatory damages to
be proven at trial, punitive damages and attorney&#8217;s fees, and an order requiring removal of the restrictive legend from his share
certificates. The Company intends to vigorously defend itself. This case is deemed related to and consolidated with the Primary Case
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The Primary Case,
Kalajian Arbitration, Sanchez Case, and Conversion Case were deemed related and ultimately consolidated. A trial date has been set for
November 6, 2026.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former
Executive Assistant</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2025, the Company filed a lawsuit in San Diego Superior Court against a former executive assistant alleging breach of fiduciary
duty to the Company, constructive fraud, conversion, and misappropriation and improper disclosure of confidential and proprietary information
in violation of her proprietary information and inventions agreement, non-disclosure agreement, and severance agreement with the Company
(Case No. 25CU034887C). The Company is seeking injunctive relief and damages. The case is in its early stages, and the outcome is uncertain.
Management does not currently expect this matter to have a material adverse effect on the Company&#8217;s financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Securities
Matter</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 29, 2024, Mr. Yian Zeng filed a complaint against the Company related to securities fraud under California Corporations Code
&#167;25401, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive
fraud in the U.S. District Court, Southern District of California (Case Number 3:24-cv-02026-H-KSC). The Company vigorously opposes this
case and categorically denies all claims. On April 9, 2025, the parties engaged in a mandatory settlement conference which resulted in
no resolution of the case. Discovery has been completed. A pre-trial conference has been set for
October 19, 2026, but no trial date has been set. At this time, the Company is unable to evaluate the outcome of this case or estimate the amount or range of potential
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Contracts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into employment and severance benefit contracts with certain executive officers and other employees. Under the provisions
of the contracts, the Company may be required to incur severance obligations for matters relating to changes in control, as defined,
and certain terminations of those executives and employees. As of December 31, 2025, the Company incurred severance obligations for certain
executive officers and other employees, as discussed below. See Note 6 for further information on the accruals for such severance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Manufacturing
and Other Supplier Contracts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into certain manufacturing and other supplier agreements with vendors principally for manufacturing drug products
for clinical trials and continued development of the CLD-101, CLD-201, and CLD-401 programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the remaining expected commitments were approximately $<span id="xdx_90B_ecustom--RemainingExpectedCommitments_iI_pn5n6_c20251231_zJLI1WUoJ1je" title="Remaining expected commitments">0.5</span> million and $<span id="xdx_908_ecustom--RemainingExpectedCommitments_iI_pn5n6_c20241231_ztENlLBFixs3" title="Remaining expected commitments">0.3</span> million,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreements with Northwestern University</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2021, the Company entered into a License Agreement with Northwestern University (&#8220;Northwestern&#8221;) (the &#8220;Northwestern
Agreement&#8221;) for the exclusive commercialization rights to the investigational new drug (&#8220;IND&#8221;) and with a non-exclusive
license to data generated from Northwestern&#8217;s phase 1 clinical trial treating malignant glioma patients with an engineered oncolytic
adenovirus delivered by neural stem cells (&#8220;<i>NSC-CRAd-S-pk7</i>&#8221;). Under the Northwestern Agreement, among other rights,
Northwestern granted to the Company a worldwide, twelve-year exclusive license for the commercial development of <i>NSC-CRAd-S-pk7</i>
or other oncolytic viruses for therapeutic and preventive uses in oncology, a right of reference to Northwestern&#8217;s IND application
which relates to the treatment of newly diagnosed High Grade Glioma (&#8220;HGG&#8221;), and right of reference to Northwestern&#8217;s
IND 17365.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Northwestern Agreement, the Company agreed to a best-efforts commitment to fund up to $<span id="xdx_90E_eus-gaap--OtherCommitment_iI_pn6n6_c20210607__us-gaap--TypeOfArrangementAxis__custom--NorthwesternAgreementMember_zXYEzR4wNTBc">10
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million towards a phase 2 clinical trial of <i>NSC-CRAd-S-pk7</i>
or other oncolytic viruses. Subject to the terms and conditions of the Northwestern Agreement, Northwestern may become entitled to receive
contingent payments from the Company based on (i) sublicense royalty payments of double-digit percentage for any sublicensing revenue
that the Company earns, if any, and, (ii) in the event of an assignment or transfer of licensed data, with the consent of Northwestern,
a low single digit percentage of the fair market value of any consideration received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2021, the Company entered into a Material License Agreement with Northwestern to license the <i>NSC-CRAd-S-pk7</i> oncolytic
virus materials which the Company intends to use to continue advancing its research, development and commercialization efforts of the
NNV1 and NNV2 programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2024, the Company entered into an Investigator-Initiated Clinical Trial Agreement for Northwestern to conduct a clinical
trial (the &#8220;CTA&#8221;) under the protocol referenced &#8220;A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in
Combination with N-Acetylcysteine amid and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma&#8221; (the &#8220;Study&#8221;).
In connection with the Study, Northwestern granted the Company a non-exclusive, transferable and sublicensable license to use all available
de-identified data collected from the Study, including, but not limited to, survival data, patient pathology, and immune studies data.
Under the CTA, among other rights, Northwestern also granted to the Company a worldwide, twelve-year exclusive license to the data, a
right of reference to Northwestern&#8217;s IND application which relates to the treatment of newly diagnosed HGG, and right of reference
to Northwestern&#8217;s IND 17365.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the data use license granted by Northwestern to the Company under the CTA, the Company shall pay Northwestern the following:
<span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--NorthwesternAgreementMember_zYfuOv26S2Gg">a non-creditable and non-refundable one-time milestone payment of $0.3 million upon reaching an aggregate of $2.0 million of net sales
of a licensed product; (b) a non-creditable and nonrefundable one-time milestone payment of $0.5 million upon reaching an aggregate of
$10.0 million of net sales of a licensed product; (c) sublicensing royalty of 20% of any sublicensing revenue resulting from the grant
of rights hereunder; and (d) in the event of an assignment or transfer of licensed data, with the consent of Northwestern, a low single
digit percentage of the fair market value of any consideration received. This sublicensing royalty shall be cumulative, meaning it shall
be imposed only once with respect to a single unit of sublicensing revenue, regardless of whether the sublicensing revenue derives from
the CTA, or the June 7, 2021 Northwestern Agreement described above, or both.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to terminate the CTA upon 30 days&#8217; notice, and the right to terminate the License and Material Transfer Agreements
upon 90 days&#8217; notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of issuance of these consolidated financial statements, it is not probable that the Company will incur these payments, if
any at all. The Company will record the contingent payments if and when they become payable, in accordance with the applicable guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreement with City of Hope and the University of Chicago</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2021, the Company entered into an Exclusive License Agreement with the University of Chicago (the &#8220;University of Chicago
Agreement&#8221;) for patents jointly owned by the University of Chicago, City of Hope, and the University of Alabama at Birmingham covering
cancer therapies using an oncolytic adenovirus loaded into allogeneic neural stem cells for treatment of HGG. Pursuant to the University
of Chicago Agreement, University of Chicago transferred its IND to the Company for the commercial development of a licensed product,
as defined in the University of Chicago Agreement. This agreement grants to the Company commercial sublicensable exclusive license to
neural stem cells with the adenovirus known as CRAd-S-pk7 for oncolytic virotherapy, as well as a non-exclusive license to associated
know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
University of Chicago Agreement provides for the Company to pay royalties in low single digit percentage of net sales generated for any
product of the licensed patents for specific periods, and to pay up to $<span id="xdx_909_eus-gaap--PaymentsForRoyalties_pn5n6_c20210722__20210722__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z2ssViZg1wzf" title="Payments for royalties">18.7 </span>million if certain milestones are achieved during the clinical
trials and post commercialization of the licensed product. The Company is further obligated to pay a sublicensing royalty of 20% of any
sublicensing revenue resulting from the grant of rights, and in the event of an assignment or transfer of licensed data, with the consent
of Northwestern, a low single digit percentage of the fair market value of any consideration received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of the issuance of these consolidated financial statements, it is not probable that the Company will incur these payments.
The Company will record the contingent payments if and when they become payable, in accordance with the applicable guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the normal course of business, the Company may provide indemnification of varying scope under the Company&#8217;s agreements with other
companies or consultants, typically the Company&#8217;s clinical research organizations, investigators, clinical sites, suppliers and
others. Pursuant to these agreements, the Company will generally agree to indemnify, hold harmless, and reimburse the indemnified parties
for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties that relate to certain situations
such as Company&#8217;s negligent actions, breaching agreements, failure to comply with laws and regulations, and third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to the Company. The Company&#8217;s office
and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of
the lessor for environmental law matters and injuries to persons or property of others, arising from the Company&#8217;s use or occupancy
of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration
of the particular research, development, services, lease, or other agreement to which they relate. The potential future payments the
Company could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts.
Historically, the Company has not been subject to any claims or demands for indemnification. The Company also maintains various liability
insurance policies that limit the Company&#8217;s financial exposure. As a result, the Company&#8217;s management believes that the fair
value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements
as of December 31, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Separation
Agreement with Former Chief Operating Officer and President</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2023, the Company entered into a Separation and Release Agreement (&#8220;Separation Agreement&#8221;) with George K. Ng,
former Chief Operating Officer and President, effective on that date. In accordance with the provisions of the Separation Agreement,
the Company will pay Mr. Ng in the amount of $<span id="xdx_903_eus-gaap--OtherLiabilities_iI_pn5n6_c20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zYRWYMTHa72c" title="Payment to related party">0.5</span>
million payable in a lump sum due one year after the effective date, and in the event that this amount is not paid when due, the
unpaid amount will accrue interest at the rate of <span id="xdx_906_ecustom--CommitmentFeePercentage_iI_pid_dp_uPure_c20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zjFo9rmvfVaf" title="Commitment fee percentage">8</span>%
per annum to be paid no later than the <span id="xdx_90C_eus-gaap--LongtermPurchaseCommitmentPeriod_dc_c20230622__20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zn6xquaSUapf" title="Payment period">two
year</span> anniversary of the effective date. The Company also paid for certain benefits, including healthcare for six months
following the effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2024, the Company made a payment of $<span id="xdx_904_eus-gaap--OtherLiabilities_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_z5gpwYQb0Dca" title="Payment to related party">50,000</span> and executed an Amendment to extend the due date to January 2025. The liability was
settled in full in January 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Settlement,
Deferral or Payment of Deferred Compensation of Certain Executives and a Director</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023, Mr. Camaisa, a director and former Chief Executive Officer of the Company, and Mr. Leftwich, a director of the Company,
entered into certain amendments with respect to their deferred compensation arrangements in connection with the FLAG Merger. Mr. Camaisa
agreed to settle approximately $<span id="xdx_909_eus-gaap--DeferredCompensationEquity_iI_pn5n6_c20230831__srt--TitleOfIndividualAxis__custom--MrCamaisaMember_zw53qiiC6G9e" title="Deferred compensation">0.7</span> million of deferred compensation with <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230831__srt--TitleOfIndividualAxis__custom--MrCamaisaMember_zrSDfcHAQuJk" title="Warrants">46,972</span> FLAG warrants which were issued at the closing of the
FLAG Merger in September 2023, and Mr. Leftwich agreed to defer approximately $<span id="xdx_905_eus-gaap--DeferredCompensationEquity_iI_pn5n6_c20230831__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zG2D0PKtAXhd" title="Deferred compensation equity">0.5</span> million of deferred compensation, combined with the
deferral of certain term notes discussed above, to January 1, 2025, which include accrued interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zqkWKCh2JDS7" title="Interest rate">24</span>% per annum payable at maturity.
All notes and deferred compensation of Mr. Leftwich were amended on August 12, 2024, to reduce the interest rate to <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zVn6dHO4gx6" title="Interest rate">14</span>% per annum. This
deferred compensation was included in accrued expenses and other current liabilities in the consolidated balance sheet at December 31,
2024. On January 3, 2025, the $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_iI_pn5n6_c20250103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrLeftwichMember__us-gaap--AwardTypeAxis__custom--SettlementOfDeferredCompensationMember_zgRqf47Anmi5" title="Deferred compensation and accrued interest amount in cash">0.6</span> million of deferred compensation and accrued interest due to Mr. Leftwich was settled in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Standby
Equity Purchase Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd., a Cayman
Island exempt limited partnership (&#8220;Yorkville&#8221;). Pursuant to the SEPA, the Company will have the right, but not the obligation,
to sell to Yorkville up to $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20231210__20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z1ZeRpcOkqpj" title="Proceeds from issuance of common stock">25.0</span> million of its shares of common stock, par value $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zTkBrySF5WZ6" title="Shares issued price per share">0.0001</span> per share, at the Company&#8217;s request any
time during the 36 months following the execution of the SEPA. The maximum advance under the SEPA is the lower of <span id="xdx_901_ecustom--EquityPurchaseDescription_c20231210__20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zUqg26h3468c" title="Equity purchase description">(i) an amount equal
to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an advance notice, or
(ii) 41,667 shares. For the SEPA to be utilized, the shares underlying the agreement need to be registered on a Form S-1 filed with the
SEC.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for Yorkville&#8217;s commitment to purchase the common stock at the Company&#8217;s direction upon the terms and subject
to the conditions set forth in the SEPA, upon execution of the SEPA, the Company paid a structuring fee of $<span id="xdx_906_eus-gaap--PaymentsForFees_c20231210__20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleMember_zRpSevxekAj5" title="Payments  for fees">25,000</span> to an affiliate of
Yorkville and issued <span id="xdx_905_eus-gaap--SharesIssued_iI_pid_c20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleMember_zxOtkyDESjcc" title="Shares issued">1,157</span> shares of common stock to Yorkville (the &#8220;Commitment Fee Shares&#8221;). The Commitment Fee Shares were
determined by dividing $<span id="xdx_902_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn5n6_c20231210__20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zsx1s96g7en1" title="Commitment Fee">0.3</span> million by the lowest daily VWAP of the common stock during the 10 trading days immediately prior to December
10, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 23, 2025, the Company delivered a Notice of Termination of the SEPA, dated as of December 10, 2023, by and between the Company
and Yorkville. Termination of the SEPA was mutually agreed upon and became effective as of January 23, 2025. At the time of the termination,
there were no outstanding borrowings, advance notices or shares of common stock to be issued under the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Release of Claims and Transition Agreement with Former Chief Executive Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr.
Camaisa, a director and former Chief Executive Officer of the Company. Mr. Camaisa will continue to serve as a Class III director of
the Company, and will assume the title of &#8220;CEO Emeritus&#8221;. Pursuant to the Release Agreement, the Company is obligated to
pay Mr. Camisa $<span id="xdx_902_ecustom--SeparationPay_pn5n6_c20250822__20250822__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_zJpunbg4kFwd" title="Separation pay">0.5</span> million separation pay in the form of compensation continuation over 12 months pursuant to the Company&#8217;s regular
and customary payroll schedule, less all regular and customary payroll withholdings and shall also be liable to pay Mr. Camisa COBRA
premiums for 12 months, commencing May 2025. Mr. Camaisa shall also be entitled to receive a transition/consulting pay of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20250822__20250822__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_z7ecSrhVJx0j" title="Consulting pay">10,000</span> per
month during the transition period and incurred costs of $<span id="xdx_90C_ecustom--IncurredCosts_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_zRznM8jUs8wh" title="Incurred costs">0.1</span> million for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Release of Claims and Separation Agreement with Former Executive Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Dr. Minev (the &#8220;Agreement&#8221;),
Executive Officer, effective August 15, 2025. Pursuant to the terms of the Agreement, the Company is obligated to pay Dr. Minev, (i)
$<span id="xdx_905_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.MinevMember_z5DGSNbN1uac" title="Bonus payable">0.1</span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals within 10 days following the Revocation Period (which
is seven business days from August 8, 2025, and excluding such date), and (ii) $<span id="xdx_90F_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.MinevMember_zOuolHyyAw87" title="Separation pay">0.2</span> million severance pay in the form of compensation
continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary payroll
withholdings and shall pay Dr. Minev&#8217;s COBRA premiums for six months, commencing August 2025, upon timely election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
Release of Claims and Separation Agreement with Former Chief Legal Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2025, the Company executed a General Release of Claims and Separation Agreement (the &#8220;Agreement&#8221;) with Ms.
Campbell, former Chief Legal Officer, effective September 24, 2025 (the &#8220;Effective Date&#8221;). Pursuant to the terms of the Agreement,
on the Effective Date, the Company is obligated to pay $<span id="xdx_900_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Ms.CampbellMember_zl0Z6qodxaF7" title="Bonus payable">0.2</span> million severance pay in the form of compensation continuation over six months
pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary payroll withholdings, and shall
pay Ms. Campbell&#8217;s COBRA premiums for six months, commencing October 2025, upon timely election. Note that pursuant to the terms
of the Agreement, as of December 31, 2025, the Company also paid Ms. Campbell a bonus in the amount of approximately $<span id="xdx_90C_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Ms.CampbellMember_zd9kploJxh6h" title="Severance pay">0.1</span> million, upon
the successful and effective sale of the investment in Nova Cell (see Note 6).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zg8RNugb7Sfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span id="xdx_825_zTzMiazaCqE7">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>March
2026 Confidentially Marketed Public Offering (CMPO)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann
&amp; Co. Inc., as sole underwriter (&#8220;Underwriter&#8221;), in connection with the issuance and sale (the &#8220;Offering&#8221;)
of: (i) <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zF5TOIoGeTea" title="Issuance and sale of shares">2,278,731</span> common stock units (&#8220;Common Stock Units&#8221;), which includes <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zOLZwurE570g" title="Shares purchased">1,575,000</span> Common Stock Units purchased pursuant
to the exercise, in full, of the Over-Allotment Option, sold to the public at a price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zx2s4GJSj2Hb" title="Shares price sold">0.50</span> per Common Stock Unit, and (ii) <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zzhESGsqTUig" title="Issuance and sale of shares">9,815,900</span>
pre-funded warrant units (&#8220;Pre-Funded Units&#8221;), sold to the public at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_ztVRmFdp3PAi" title="Shares price sold">0.499</span> per Pre-Funded Unit, resulting in
gross proceeds of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zGt837EmyFEd" title="Gross proceeds">6.0</span> million, before deducting underwriting discounts and commissions and other estimated offering expenses.
In connection with the Offering, the Company also issued to the Underwriter (or its designees) a warrant (the &#8220;Underwriter&#8217;s
Warrant&#8221;) to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zF438ZVnCZtk" title="Warrant purchase">604,732</span> shares of Common Stock of the Company, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zza2ndLR3dgl" title="Common stock, par value">0.0001</span>. The Underwriter&#8217;s Warrant has
an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zBCcXqgmg6rd" title="Warrant exercise price">0.625</span>, is exercisable on or after the date of issuance, and will expire on <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zNEKKbCI3Zdf" title="Warrant expire date">March 9, 2031</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Common Stock Unit consisted of (i) one share of Common Stock, (ii) one Series J common stock warrant (&#8220;Series J Warrants&#8221;)
to purchase one share of Common Stock (or pre-funded warrants to purchase one share of Common Stock in lieu thereof), (iii) one Series
K common stock warrant (&#8220;Series K Warrants&#8221;) to purchase one share of Common Stock (or pre-funded warrants to purchase one
share of Common Stock in lieu thereof), and (iv) one Series L common stock warrant (&#8220;Series L Warrants&#8221; and together with
the Series J Warrants and the Series K Warrants, the &#8220;Common Warrants&#8221;) to purchase one share of Common Stock (or pre-funded
warrants to purchase one share of Common Stock in lieu thereof). Each Pre-Funded Unit consisted of (i) one pre-funded warrant (the &#8220;Pre-Funded
Warrants&#8221;), (ii) one Series J Warrant, (iii) one Series K Warrant, and (iv) one Series L Warrant. The Common Warrants included
in the Pre-Funded Units are identical to the Common Warrants included in the Common Stock Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series J Warrants have an initial exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zdNnmvomwAb3" title="Initial exercise price">0.50</span> per share. The Series J Warrants are exercisable immediately, subject to certain
limitations described herein. The Series J Warrants expire five (<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zTqcuerND9zl" title="Warrants expire year">5</span>) years from the date of issuance. The Series K Warrants have an initial
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zeewpThVX86j" title="Initial exercise price">0.50</span> per share. The Series K Warrants are exercisable immediately, subject to certain limitations described herein.
The Series K Warrants will expire one (<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zq3wApjM7Rjb" title="Warrants expire year">1</span>) year from the date of issuance. The Series L Warrants have an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z1MsjJ57uqbj" title="Initial exercise price">0.50</span>
per share. The Series L Warrants are exercisable immediately, subject to certain limitations described herein. The Series L Warrants
expire six (<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_za6v92U1WAzh" title="Warrants expire year">6</span>) months from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock Units, the Pre-Funded Units, the shares of Common Stock comprising the Common Stock Units, the Common Warrants, the Pre-Funded
Warrants, the shares of Common Stock issuable upon exercise of the Common Warrants, and the Pre-Funded Warrants were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-284229), that was filed with the Securities Exchange Commission
(&#8220;SEC&#8221;) on January 10, 2025 and declared effective on February 7, 2025, including the prospectus forming a part of the registration
statement, a final prospectus supplement thereto, which was filed with the SEC on March 9, 2026, pursuant to Rule 424(b) under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the related registration statement filed with the SEC on March 5, 2026
under Rule 462(b) of the Securities Act, which became automatically effective upon filing. The Offering closed on March 9, 2026 (the
&#8220;Closing Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 6, 2026, the Company also entered into a warrant agency agreement (the &#8220;Warrant Agency Agreement&#8221;) with Equiniti Trust
Company, LLC, as warrant agent (the &#8220;Warrant Agent&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in">Since the
closing of the Offering, <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz16vwaTY8Ij" title="Pre funded warrants">2,291,000</span> Pre-Funded Warrants have been exercised.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2026, the Company entered into an Amendment to Common Stock Purchase Warrants Agreement (the &#8220;Warrant Amendment&#8221;)
with certain investors, that participated in the March 2026 CMPO described above, in connection with the terms of certain
of the Company&#8217;s outstanding common warrants to purchase shares of Common Stock (the &#8220;Existing Warrants&#8221;). As originally
issued, the Existing Warrants provided for the purchase of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<span id="xdx_905_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkRTwAEJNS" title="Shares of common stock">504,417</span> shares of common stock, on exercise of the series G common stock warrants at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_z9tr0uLm5m13" title="warrants exercise price">8.3448</span> per share;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<span id="xdx_90B_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCXakqVOMz9" title="Shares of common stock">279,168</span> shares of common stock, on exercise of the series H common stock warrants at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zki4nAVQ3ke1" title="warrants exercise price">8.40</span> per share; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<span id="xdx_900_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesICommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy6jP8a536K7" title="Shares of common stock">2,190,000</span> shares of common stock, on exercise of the series I common stock warrants at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesICommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zU8uxZuGH2El" title="warrants exercise price">2.00</span> per share.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
the Warrant Amendment, the exercise price for each of such Existing Warrants was reduced to $<span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_c20260305__20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zEUR3pHvlgQd" title="warrants exercise price">0.50</span> per share, subject to further adjustment
as set forth in the Existing Warrants and any other document governing the terms thereunder. All other terms and conditions of the Existing
Warrants remain unchanged and in full force and effect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaPR1G4GYZla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
of Presentation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements as of and for the year ended December 31, 2025 and 2024, have been prepared in accordance
with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and in conformity with accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards
Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zXJtSJ4WYRZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Principles
of Consolidation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company include the accounts of its wholly owned subsidiary, Calidi Biotherapeutics
(Nevada), Inc., a company incorporated in the state of Nevada Calidi Biotherapeutics, Inc., StemVac GmbH (&#8220;StemVac&#8221;), a company
organized under the laws of Germany, Calidi Biotherapeutics Australia Pty Ltd (&#8220;Calidi Australia&#8221;), a wholly owned Australian
subsidiary, Nova Cell, Inc. (&#8220;Nova Cell&#8221;), a subsidiary incorporated in the state of Nevada, and Redtail Biopharma, Inc.
(&#8220;Redtail&#8221;), a wholly owned subsidiary incorporated in the state of Nevada. StemVac&#8217;s primary operating activities
include process development and other research and development activities for the Company under a cost-plus intercompany development
agreement funded by the Company. Calidi Australia&#8217;s principal purpose is for conducting certain parts of the SNV1 clinical enabling
activities in Australia. Nova Cell&#8217;s primary operating activities were expanding potential uses of the Company&#8217;s AAA stem
cell programs from oncology to other fields that require regenerative medical applications, such as cosmetics, orthopedics, auto-immune
diseases, and various other therapies. Redtail&#8217;s primary operating activities will be to expand on the Company&#8217;s systemic
antitumor virotherapies. Both Nova Cell and Redtail were incorporated in May 2024. As of December 31, 2025, the Company no longer has
an investment in Nova Cell. Redtail has had no activity to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable
interest entities (&#8220;VIEs&#8221;) are legal entities that either have an insufficient amount of equity at risk for the entity to
finance its activities without additional subordinated financial support or, as a group, the holders of equity investment at risk lack
the ability to direct the entity&#8217;s activities that most significantly impact economic performance through voting or similar rights,
or do not have the obligation to absorb the expected losses or the right to receive expected residual returns of the entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
all VIEs in which the Company is involved, it assesses whether it is the primary beneficiary on an ongoing basis. In circumstances where
the Company has both the power to direct the activities that most significantly impact the VIEs performance and the obligation to absorb
losses or the right to receive the benefits of the VIE that could be significant, the Company would conclude that it is the primary beneficiary
of the VIE, and the Company consolidates the VIE. In situations where the Company is not deemed to be the primary beneficiary of the
VIE, it does not consolidate the VIE and only recognizes the Company&#8217;s interests in the VIE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to October 27, 2025, the Company owned 75% of Nova Cell&#8217;s fully-diluted capitalization, with the remaining 25% owned by a related
party investor (see Note 8). Under the rules of determining whether an entity was a VIE, the Company has a controlling financial interest
and is deemed to be the primary beneficiary of Nova Cell and therefore consolidated Nova Cell&#8217;s financial statements. Since the
Company owns less than 100% of Nova Cell, the Company recorded net loss attributable to noncontrolling interest in its consolidated statements
of operations equal to the percentage of the economic or ownership interests retained in Nova Cell by the noncontrolling party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#8220;SRA&#8221;) and Material Purchase Agreement (the
&#8220;MPA&#8221; and together with the SRA the &#8220;Agreements&#8221;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zpwpUeXfXZM7" title="Shares sold and transferred">22,500,000</span> of its shares of common stock in Nova Cell (the &#8220;Repurchased Shares&#8221;), representing an
ownership interest of <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_ztNgHQys4Usd" title="Ownership percentage">75</span>%, back to Nova Cell, for a purchase price of $<span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zylGdAbm1u0i" title="Purchase price for repurchased shares">6.0</span> million (the &#8220;Purchase Price&#8221;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $<span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zJqT9AIilb5l" title="Promissory note, net cash offset">50</span> thousand cash offset), resulting in an Indebtedness Cancellation Amount of $<span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zepHBhXDlXm4" title="Indebtedness cancellation amount">1.2</span> million,
and (B) the balance, by Deferred Consideration of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zYzDxd2VApd2" title="Deferred consideration">4.8</span> million payable after closing, as more fully described in the SRA. The Deferred Consideration is fully constrained until underlying uncertainties
are resolved, such that a significant reversal of cumulative consideration will not occur in future periods. Thus, the Company has not
recognized any Deferred Consideration as of December 31, 2025. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#8217;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for
a fair presentation of the Company&#8217;s financial condition and results of operations. All material intercompany accounts and transactions
have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_840_eus-gaap--UseOfEstimates_zSrrKuYyyr3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use
of Estimates</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the
reported amounts during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment,
including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing
of potential commercialization of acquired in-process intangible assets, applicable discount rates, comparable companies or transactions,
liquidity events, determination of fair value of financial instruments under the fair value option of accounting, assumptions related
to the going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived assets, key assumptions
in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred
income taxes, assumptions used to value common stock, debt and debt-like instruments, warrants, and stock-based awards and other equity
instruments. Actual results may differ materially from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4NZUyodDGPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zU8kxk7y1Rr8">Reclassification</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on our previously reported results of operations or accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Restricted Cash</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zxDisQ28BcAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
and Restricted Cash</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity date of ninety days or less to be cash equivalents.
Cash and cash equivalents include cash in readily available checking, money market accounts and brokerage accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies cash that has contractual or legal restrictions imposed by third parties as restricted cash, which is restricted as
to withdrawal or use except for the specified purpose under a contract. The Company classifies restricted cash as either part of prepaids
and other current assets, or as part of other noncurrent assets, depending on the term and nature of the underlying contract with a financial
institution, which requires the Company to hold a fixed amount of funds in a restricted money market account as collateral to the financial
institution for the Company&#8217;s corporate credit card program with that financial institution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none">Schedule of Cash and Cash Equivalents</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within prepaid expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    cash and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zONRAFzaFDbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Machinery and Equipment</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zd0jFDmgJAZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Machinery
and Equipment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
and equipment are stated at cost, less accumulated depreciation, and includes assets purchased under financing leases. Depreciation is
computed using the straight-line method over the estimated useful lives of the assets, generally over a period of <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember_zhXYWkAGeupl" title="Estimated useful lives">3</span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember_z9vLH2fyzJn9" title="Estimated useful lives">5</span> years. For equipment
purchased under financing leases, the Company depreciates the equipment based on the shorter of the useful life of the equipment or the
term of the lease, ranging from <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zRKXfPGmJur3" title="Estimated useful lives">3</span> to <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zvVdMqTbK9ia" title="Estimated useful lives">5</span> years, depending on the nature and classification of the financing lease. Maintenance and repairs
are expensed as incurred, whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed
of, the cost and the related accumulated depreciation are removed from the respective accounts, and any resulting gain or loss is reflected
in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zHTo1XpBpLmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for leases in accordance with ASC 842, <i>Leases</i>. The Company determines if an arrangement is a lease at inception.
Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated
statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define
criteria to determine &#8220;major part of remaining economic life of the underlying asset&#8221; and &#8220;substantially all of the
fair value of the underlying asset.&#8221; For lease classification determination, the Company continues to use: (i) greater than or
equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset; and (ii) greater
than or equal to 90% to determine whether the present value of the sum of lease payments is substantially all of the fair value of the
underlying asset. The Company accounts for the lease and non-lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
operating leases, the Company recognizes right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for leases with terms greater
than 12 months in the consolidated balance sheets, while leases with terms of 12 months or less are not capitalized. ROU assets represent
the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate commensurate with
the lease term, based on the information available at commencement date, in determining the present value of lease payments. The Company
uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes
lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will
exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company discloses
the amortization of ROU assets and operating lease payments as a net amount within &#8220;Depreciation and amortization&#8221; on the
consolidated statements of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
leases are included in machinery and equipment, and in finance lease liability, current and noncurrent, in the consolidated balance sheets.
The Company discloses the amortization of finance ROU assets within &#8220;Depreciation and amortization&#8221; on the consolidated statements
of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 11 for further disclosures in accordance with ASC 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zrW6I3Z6DNB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses the impairment of long-lived assets, which consist primarily of right-of-use assets for operating leases and machinery
and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not
be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected
undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to
the excess of the assets carrying value over its fair value is recorded in the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCCQwj744sq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value Measurements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 820, <i>Fair Value Measurement</i>, which among other things, defines fair value, establishes a consistent framework
for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring
or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants. Accordingly, fair value is a market-based measurement determined based
on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
820 establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value, which are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices in active markets for identical assets and liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs
    other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities;
    quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data
    for substantially the full term of the assets or liabilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#8201;3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable
    inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which
    require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation
hierarchy. If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities
with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2
inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. See Note 3 for fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zWqPIpln7jfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives in accordance with ASC 815. The Company values its derivatives using the Black-Scholes option-pricing model or
other acceptable valuation models, as applicable, with the assistance of valuation specialists. Derivative instruments accounted for
as liabilities are valued at inception and subsequent valuation dates for each reporting period the derivative instrument remains outstanding.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at
each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates equity or liability classification for common stock warrants in accordance with ASC 480, <i>Distinguishing Liabilities
from Equity</i>, and ASC 815, <i>Derivatives and Hedging</i>, and accounts for common stock warrants as liabilities if the warrant requires
net cash settlement, or gives the holder the option of net cash settlement, or it otherwise does not meet other equity classification
criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement,
or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified
as equity. Warrants that meet the definition of a derivative financial instrument and the equity scope exception in ASC 815-10-15-74(a)
are classified as equity, are initially measured at fair value on the grant date, and are not subject to remeasurement provided that
the Company continues to meet the criteria for equity classification. Warrants that are classified as liabilities are accounted for at
fair value and remeasured at each reporting date until exercise, expiration, or modification that results in equity classification. Any
change in the fair value of the warrants is recorded and presented under change in fair value of other liabilities and derivatives or
change in fair value of other liabilities and derivatives &#8211; related party, as applicable, in the consolidated statements of operations.
The classification of warrants, including whether warrants should be recorded as liabilities or as equity, is re-assessed at the end
of each reporting period. The fair value of liability-classified warrants is determined using the Black-Scholes option-pricing model
(&#8220;Black-Scholes model&#8221;), which includes Level 3 inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p id="xdx_847_eus-gaap--DebtPolicyTextBlock_zRkBtHjrd9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Debt
Issuance Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs incurred to obtain debt financings are deferred and are amortized over the term of the debt using the effective interest
method for all debt financings in which the fair value option has not been elected. Debt issuance costs on debt financings in which the
fair value option is not elected are recorded as a reduction to the carrying value of the debt and are amortized to interest expense
or interest expense &#8211; related party, as applicable, in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
any debt financing in which the Company has elected the fair value option, any debt issuance costs associated with the debt financing
are immediately recognized in interest expense in the consolidated statements of operations and are not deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zJS5yJ5MWWkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has not generated any revenues from commercial products. The Company analyzes its research collaboration arrangements
to assess whether they are within the scope of ASC 808, <i>Collaborative Arrangements</i>, to determine whether such arrangements involve
joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks
and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC
808, the Company assesses whether aspects of the arrangement are within the scope of other accounting literature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those
aspects of the arrangement within the scope of ASC 606, <i>Revenue from Contracts with Customers</i>, by applying the following five-step
model: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract,
including whether they are distinct within the context of the contract; (iii) determination of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition
of revenue when, or as, performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within the
contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service
is distinct. The Company considers the intended benefit of the contract in assessing whether a promised good or service is separately
identifiable from other promises in the contract. If a promised good or service is not distinct, the Company combines that good or service
with other promised goods or services until it identifies a bundle of goods or services that is distinct. The Company may provide options
to additional goods or services in such arrangements exercisable at a customer&#8217;s discretion. The Company assesses if these options
provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights
requires judgments related to the determination of the value of the underlying good and services to the optional price, if any, that
may be offered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the transaction price based on the amount of consideration that the Company expects to receive for transferring the
promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company then allocates
the transaction price to each performance obligation based on the relative standalone selling prices (&#8220;SSP&#8221;). SSP is determined
at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors,
including factors that were contemplated in negotiating the agreement with the customer and estimated costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will
be entitled by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated
variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which
it is probable that a significant reversal of cumulative revenue recognized will not occur. At each reporting period, the Company re-evaluates
the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate
of the overall transaction price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as)
the performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of
an output or input method. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in
the Company&#8217;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve
months, deferred revenue will be classified in current liabilities. Revenue recognized, if any, prior to contractual billings made to
the customer, and if the Company expects to have an unconditional right to receive consideration in the next twelve months, these contractual
assets are included in other current assets in the Company&#8217;s consolidated balance sheets. As of December 31, 2025, and December
31, 2024, there are no deferred revenue or contractual assets recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company further analyzes changes to contracts from customers to assess whether they qualify as a contract modification within the scope
of ASC 606. The Company considers that a contract modification exists when the parties to a contract approve a modification that either
creates new, or changes, existing enforceable rights and obligations of the parties to the contract. The Company considers that a contract
approval could be approved in writing, by oral agreement, or implied by customary practices. Whenever a change in the scope or price,
or both, of a contract is approved by the parties to the contract, the Company analyzes whether the contract modification qualifies as
a separate contract or a contract combination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for a contract modification as a separate contract when (i) the scope of the contract increases because of the addition
of promised goods or services that are distinct and (ii) the price of the contract increases by an amount of consideration that reflects
the Company&#8217;s SSP of the additional promised goods or services and any appropriate adjustments to that price to reflect the circumstances
of the particular contract. If the modification is not accounted for as a separate contract, the Company analyzes whether one of the
following should occur: (i) a termination of the original contract and the creation of a new contract, (ii) a cumulative catch-up adjustment
to the original contract, or (iii) a combination of (i) and (ii) in a way that faithfully reflects the economics of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zlZPizkzwqT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>, using the asset and liability method, which requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in
the consolidated financial statements or in the Company&#8217;s tax returns. Deferred taxes are determined based on the difference between
the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which
the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.
The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by analyzing
carryback capacity in periods with taxable income, reversal of existing taxable temporary differences and estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies. The Company&#8217;s judgments regarding future taxable
income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If the
Company&#8217;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased,
which may have a material impact on the Company&#8217;s consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized, if any. First, the tax position must be evaluated to determine the likelihood that
it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company recognizes any interest and penalties related to uncertain
tax positions in income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2025 and 2024.
The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material
deviation for the year ended December 31, 2025 and 2024. The Company is currently unaware of any tax issues under review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#8220;CAMT&#8221;) on adjusted
financial statement income on applicable corporations for taxable years beginning after December 31, 2022. The Company does not expect
the CAMT will have a material impact to its consolidated income tax provision (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 4, 2025, the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted. The OBBBA included various provisions with multiple effective
dates, including, but not limited to, immediate expensing of domestic research and development expenditures and provision for immediate
expensing of machinery and equipment purchases. The OBBBA did not have a material impact on the Company&#8217;s results of operations.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an
&#8220;ownership change,&#8221; which generally occurs if the percentage of the corporation&#8217;s stock owned by 5% stockholders increases
by more than 50% over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income may be limited. The annual limitation may result in the expiration of net operating losses
before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31, 2021. There was an ownership
change identified on March 26, 2018 after the Company&#8217;s Series A-2 preferred stock issuance. The Company has not undertaken a Section
382 study through December 31, 2025. The Company&#8217;s ability to utilize their net operating loss carryforwards and other tax attributes
to offset future taxable income or tax liabilities may be limited as a result of ownership changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p id="xdx_849_ecustom--GovernmentGrantsPolicyTextBlock_zVDiXvjsr4Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Government
Grants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 27, 2022, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) approved the Company&#8217;s application for
a CIRM grant for the Company&#8217;s continued development of the SNV1 program. CIRM awarded the Company approximately $<span id="xdx_90F_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zJ2bjw4tI9jb">3.1</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of CIRM funding conditioned that the Company co-fund
approximately $<span id="xdx_908_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember_zYGxk6lkwsUg">0.8</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million under the requirements of the CIRM application. On
December 28, 2022, the Company received the Notice of Award from CIRM for this grant. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
from the CIRM grant are recognized over the period necessary to match the related research and development expenses when it is probable
that the Company has complied with the CIRM conditions and will receive the proceeds pursuant to the milestones defined in the grant
as reimbursement of those expenditures. The CIRM grant proceeds, if any, received in advance of having incurred the related research
and development expenses are recorded in accrued expenses and other current liabilities and recognized as grant income included in other
income, net, on the Company&#8217;s consolidated statements of operations when the related research and developments expenses are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2025 and 2024, the Company recognized approximately $<span id="xdx_900_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20251231_zMHspUb7PSTk" title="Grant income">50,000</span> and $<span id="xdx_905_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20241231_zYUqCnBJGwse" title="Grant income">0.2</span> million, respectively, in grant income
in the accompanying consolidated statements of operations. The Company drew $<span id="xdx_90E_ecustom--GrantsReceivableWithdrawn_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zwakLFuBX1w9" title="Government grants award withdrawn">3.1</span> million in funds based on the operational
milestones defined in the grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg1hra5jIUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are expensed as incurred. Research and development expenses consist of costs incurred to discover, research
and develop drug candidates, including compensation-related expenses for research and development personnel, preclinical and clinical
activities, costs of manufacturing, overhead expenses including facilities and laboratory expenses, materials and supplies, amounts paid
to consultants and outside service providers, and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upfront
and annual license payments related to acquired technologies or technology licenses which have not yet reached technological feasibility
and have no alternative future use are also included in research and development expense in the period in which they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zMk4V2F5MIgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and compensation-related expenses for personnel in executive, finance and accounting,
operations, and administrative functions. General and administrative expenses also include fees for legal, patent
prosecution, legal settlements, consulting, accounting and audit services as well as insurance, outside service providers, direct and
allocated facility-related costs and depreciation and amortization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation Adjustments and Other Comprehensive Income or Loss</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVnzNm7bwVwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Translation Adjustments and Other Comprehensive Income or Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">StemVac,
the Company&#8217;s wholly owned subsidiary, is located and operates in Germany and its functional currency is the Euro. Calidi Australia,
the Company&#8217;s wholly owned subsidiary, is located and operates in Australia and its functional currency is the Australian Dollar
(&#8220;AUD&#8221;). Accordingly, StemVac&#8217;s and Calidi Australia&#8217;s assets and liabilities are translated using respective
published exchange rates in effect at the consolidated balance sheet date. Expenses and cash flows are translated using respective approximate
weighted average exchange rates for the reporting period. Resulting foreign currency translation adjustments are recorded as other comprehensive
income or loss, net of tax, in the consolidated statements of comprehensive income or loss and included as a component of accumulated
other comprehensive income or loss on the consolidated balance sheets. For the year ended December 31, 2025 and 2024, comprehensive loss
includes such foreign currency translation adjustments and was insignificant for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock', window );">Foreign Currency Transaction Gains and Losses</a></td>
<td class="text"><p id="xdx_847_ecustom--ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_zGqMFuHbODu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Transaction Gains and Losses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
transactions denominated in currencies other than the U.S. dollar, the Company recognizes foreign currency transaction gains and losses
in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The Company&#8217;s
foreign currency transaction gains and losses are principally generated by intercompany transfers to StemVac denominated in Euros to
pay for the research and development activities performed by StemVac under an intercompany development agreement with the Company. Furthermore,
the Company&#8217;s foreign currency transaction gains and losses include intercompany transfers to Calidi Australia denominated in AUD
to pay for the research and development activities performed by Calidi Australia. These foreign currency remeasurement gains and losses
are included in other income, net, and were insignificant for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zTTPKIkGwNV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-Based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC
718, <i>Compensation &#8212; Stock Compensation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service condition is recognized in the period of the forfeiture. Generally,
and unless otherwise specified, the Company grants stock options with service-based only vesting conditions and records the expense for
these awards using the straight-line method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award
recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company estimates its expected stock
volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics
similar to the Company. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221;
method for awards that qualify as &#8220;plain-vanilla&#8221; options provided under Staff Accounting Bulletin, Topic 14 (&#8220;SAB
Topic 14&#8221;), as necessary. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at
the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero,
based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per share of Common Stock</a></td>
<td class="text"><p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdSJcb0wxfOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss per share of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that
determines earnings per share for the holders of the Company&#8217;s shares of Common Stock and participating securities. However, the
participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation
of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating)
are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per
share of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock
method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share
attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common
stock shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic
net loss per share for the periods presented herein because common stock equivalent shares from the outstanding warrants, earnout shares,
stock option awards, restricted stock units, and contingently issuable warrants were antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zguB1VYdIPX4" style="display: none">Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    for common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">911</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout
    shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingently
    issuable warrants<sup id="xdx_F46_zns0PDiMhGnk">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    common stock equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,454</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zcSEsseQ4qb1">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.</span></td></tr>
  </table>
<p id="xdx_8A2_zAGEgYvJxZz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztqbLrgSIasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Segments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (or CODM), the Executive Management Team, consisting of the following individuals:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer and Head of Technical Operations</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company views its operations and manages its business as a single reportable segment whose operations include the research, development
and commercialization efforts of platforms to potentiate oncolytic virus therapies on a consolidated basis, as further described in Note
1. The Company manages its Research and Development (&#8220;R&amp;D&#8221;) activities on a consolidated basis. The Company expects to
generate future income from a combination of license fees and other upfront payments, funded R&amp;D agreements, milestone payments,
product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing
of the successful commercialization of the Company&#8217;s products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss is the measure of segment profit or loss used by the CODM in making decisions regarding resource allocation and evaluating financial
performance, which is also reported on the consolidated statements of operations and comprehensive loss. The CODM does not evaluate its
reportable segment using asset or liability information.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected financial information with respect to the Company&#8217;s single operating segment for the year ended
December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zKYWOXFybRQj" style="display: none">Schedule
of Operating Segment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING
    EXPENSES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
    and benefits</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,561</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,249</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,442</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,951</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,059</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
    and maintenance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,358</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,136</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    &amp; research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items <sup id="xdx_F44_zsI0gVfAWZ5g">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provision</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,063</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,209</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0A_zCZCERNSjsG7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.</span></td></tr>
  </table>
<p id="xdx_8A3_zjzQiw5SfnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQmoR4lv77yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Adopted Accounting Pronouncements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU No. 2023-09, <i>Improvements to Income Tax Disclosures (Topic 740)</i>. The ASU requires disaggregated
information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid.
The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for
annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 for the annual
period beginning January 1, 2025, on a prospective basis. The adoption of this guidance did not have a significant
impact on the Company&#8217;s financial statements, other than disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_846_ecustom--NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_z6lkr7Di3Vfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recently
Issued Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU No. 2024-03, <i>Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement </i>and in January 2025, issued ASU 2025-01 <i>Income Statement&#8212;Reporting
Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i> to clarify the effective
date of ASU 2024-03. ASU 2024-03 requires the disaggregation of certain costs and expenses in the notes to the financial statements to
provide enhanced transparency into the expense captions presented on the face of the income statement. The ASU is effective for annual
periods beginning after December 15, 2026 and for interim reporting periods within annual reporting periods beginning after December
15, 2027. The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-06, <i>Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40): Targeted
Improvements to the Accounting for Internal-Use Software</i>. ASU 2025-06 updates the accounting for internal-use software by replacing
former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software
only when management has authorized and committed funding and it is probable that the project will be completed and the software will
be used to perform the intended function. ASU 2025-06 also supersedes website development cost guidance, moving it to ASC 350-40. These
amendments are effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting ASU 2025-06.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2025, the FASB issued ASU No. 2025-07, <i>Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic
606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</i>.
ASU 2025-07 refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration
under ASC 606. This ASU is effective for annual periods and interim periods beginning after December 15, 2026, with early adoption permitted.
The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently evaluating
the impact of adopting ASU 2025-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2025, the FASB issued ASU No. 2025-09, <i>Derivatives and Hedging (Topic 815): Hedge Accounting Improvements</i>. ASU 2025-09
clarifies certain aspects of the guidance on hedge accounting and addresses several incremental hedge accounting issues arising from
global reference rate reform. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within
those annual reporting periods The Company is currently evaluating the impact of adopting ASU 2025-07.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2025, the FASB issued ASU No. 2025-11, <i>Interim Reporting (Topic 270): Narrow-Scope Improvements,</i> which is intended to
improve the navigability of the guidance in ASC 270 and clarify when it applies. Under the amendments, an entity is subject to ASC 270
if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content of such
financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since
the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027, and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2025-11.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Transaction Gains And Losses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Grants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none">Schedule of Cash and Cash Equivalents</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within prepaid expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash included within other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    cash and restricted cash as shown in the consolidated statements of cash flows</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,819</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zguB1VYdIPX4" style="display: none">Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    for common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">911</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout
    shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingently
    issuable warrants<sup id="xdx_F46_zns0PDiMhGnk">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0981">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    common stock equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,454</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0C_zcSEsseQ4qb1">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Segment</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents selected financial information with respect to the Company&#8217;s single operating segment for the year ended
December 31, 2025 and 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zKYWOXFybRQj" style="display: none">Schedule
of Operating Segment</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING
    EXPENSES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries
    and benefits</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,561</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,249</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,442</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,951</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,059</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,578</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
    and maintenance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,358</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,136</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    &amp; research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,760</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(386</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of other liabilities and derivatives</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">324</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items <sup id="xdx_F44_zsI0gVfAWZ5g">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,801</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,408</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provision</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    LOSS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,063</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,209</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup id="xdx_F0A_zCZCERNSjsG7">(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zQoGr3VpRVdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, inclusive of
related party components, as of December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BB_zYWW0lu5GxOi" style="display: none">Schedule
of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWmx7Qc7H0S6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziASyE6z4iTd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW2Ceu4JuOo5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zeUrRR3X8Fn7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z01xipjyNeTe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash held in money market accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1035">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1036">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zvdICRvuY924" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1040">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1041">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zzyhoyvStrb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1045">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1046">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zpu1J8KaEUW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1049">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1051">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zz40boSVcyfb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    warrant liabilities, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEM6Xl7O87W4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zv0XyOqlwQpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm97BMO9HOq3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_z1QWjKyP15Vi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zeruEnVVYona" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash held in money market accounts</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1060">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1061">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_z0qTfmSaeADe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    Purchase Agreement Derivative Asset included in other noncurrent assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1065">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zs7M1XCLaB07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">218</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1070">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zpQ1D7GVfiJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1076">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zlFUkdiOREOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1079">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1081">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zRhOUeGFqiH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    warrant liabilities, at fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1086">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Level 3 Valued Instruments</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zqIlEF0l2MT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of valued instruments for the year ended December 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B2_zSY7A1YXlaXe" style="display: none">Schedule
of Changes in Fair Value of Level 3 Valued Instruments</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zg9NawD3tghe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    <br/> Purchase<br/> Agreement<br/> Derivative <br/> Asset, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRgqIL5PVQJj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    <br/> Warrants, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zG3wQ6iduqC9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    <br/> warrants, at <br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zfHUyIt0RyOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zNIOi0IXJTnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zumwr3PJozah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1099">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of valued instruments for the years ended December 31, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zWfJAwNvg2se" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward
    <br/> Purchase<br/> Agreement<br/> Derivative <br/> Asset, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRXHCZ66zKMc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    <br/> Warrants, at<br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_z0wHOCgTVSRe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    <br/> warrants, at <br/> fair value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zchLF49GxBX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(230</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zRRZPdfYd0Oe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, beginning</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(230</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zjfr9zexva2d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(465</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(78</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zwfpjT1pTduh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zFX2CuEjR6m3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zl3HwUvYkCt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, accrued expenses and other current liabilities were comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B5_zC74RHRU2xGk" style="display: none">Schedule
of Accrued Expenses and Other Current Liabilities</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20251231_z6RE0nZO3Mid" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20241231_zldBaOSXryB2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--AccruedCompensation_iI_pn3n3_maAPAOAzybc_zt0oc8Dog6d3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">884</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,344</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--AccruedVendorAndOtherExpenses_iI_pn3n3_maAPAOAzybc_z9diIryQWrKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    vendor and other expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">922</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">994</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzybc_zlQaTtvTOSQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,338</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3rDlS7PfK6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, prepaid expenses and other current assets were comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B6_zpYPMGNGVhLb" style="display: none">Schedule
of Prepaid Expenses and Other Current Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20251231_zL5CzaHNFOna" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20241231_zcIA2pAU61j5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--PrepaidExpenses_iI_maPECz6zE_zlhRYKAUiHV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;99</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maPECz6zE_zQmOQo8zUkO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">302</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">288</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECz6zE_zE0XWeQF3IP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">234</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">249</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECz6zE_zE1XdS9Ryd86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">656</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">636</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Machinery and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Machinery and Equipment, Net</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMMjj6pnDrvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and December 31, 2024, machinery and equipment, net, was comprised of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BF_zHnlGiayBZi9" style="display: none">Schedule
of Machinery and Equipment, Net</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20251231_zRQ7iMay90Vl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20241231_zv9ULlTW7Ivf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzw2F_znFRuAZbJnjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzw2F_zV4tavT1WV07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,794</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzw2F_zjoGaAtrKfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">781</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">869</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zP1Mzp0wj211" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the various significant related party transactions and investments in the Company for the periods presented
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BD_zIbKqbn9Ytxg" style="display: none">Schedule
of Related Party Transactions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Party</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of investment or transaction</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_490_20250101__20251231_ztr38XZpt7Q1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zMA6Of7icfB8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_zEWw10UjFlga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A and Director E</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_fKDEp_zlWLI0MH4aBe" title="Description of investment or transaction">Current
    term notes payable, net of discount, including accrued interest</span><sup>(1) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,702</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_zR1WtBFW8XJ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F and relative of Officer A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_fKDIp_zeQY78y2Fs4j" title="Description of investment or transaction">Accounts
    payable and accrued expenses</span><sup>(2) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zesQnfyIvbod" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_fKDMp_z61oDwq1ner8" title="Description of investment or transaction">Severance
    accrual</span><sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1182">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zgvbYUb0hpj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    D</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_fKDQp_zgg77HjNBqEc" title="Description of investment or transaction">Severance
    accrual</span><sup>(4) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">434</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_zo2OQ8scPVpk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_fKDUp_zKdMvxbE8em3" title="Description of investment or transaction">Advisory
    services included in accrued expenses</span><sup>(5) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1191">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_zHvV1LI0GJD5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_fKDYp_zjClDrqjEaUd" title="Description of investment or transaction">Lease
    guaranty</span><sup>(6) </sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_zt5rXNeaWwY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_fKDcp_zDjXix5Ogoqg" title="Related party transaction description">Other
    liabilities</span><sup>(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">638</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_zZIlg6Z8RiZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    F and Director A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_fKDgp_zkWtDGrB7dA3" title="Related party transaction description">Warrant
    liability</span><sup>(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_zdk3Fg2goI0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
    of Officer A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_fKDkp_zDM26tRjdZMe" title="Related party transaction description">Loan
    payable</span><sup>(9)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z6ZAQI2hMW8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    G</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_fKDEwKQ_____zAnBEno9S9Bd" title="Related party transaction description">Severance
    accrual</span><sup>(10)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zBTlKfG8gpQh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officer
    A</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_fKDExKQ_____z5loD8rJKBDi" title="Related party transaction description">Severance
    accrual</span><sup>(11)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1222">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zLyvD6ZMzaX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    A related to Director G</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zPHkzA353yU1" title="Related party transaction description">Accounts
    payable and accrued expenses</span><sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1227">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z1HHAGVCWrwl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zTM4EfyjiDKj" title="Related party transaction description">Accounts
    payable and accrued expenses</span><sup>(12)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1232">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><span id="xdx_F01_ztnzOa04RqCj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zSe82xXNXjfc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49" title="Related party note payable">2.7</span> million. See Note 7 for further details.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F03_zeZVcS9Dqklc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z6UoF5ncbVI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj" title="Legal fees">48</span> thousand
and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04" title="Legal fees">38</span> thousand for the years ended December 31, 2025 and 2024, respectively.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span id="xdx_F06_zwaUnSY2Q1O7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_ziDxrKiIKwTh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb" title="Loans">0.5</span>
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1" title="Loan outstanding">0.2</span>
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2" title="Consulting pay">10,000</span>
    per month during the transition period. The agreement terminated on December 31, 2025 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j" title="Expenses">0.1</span>
    million was expensed under the agreement. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F06_zCwfBc4wtI2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_zoKQxvM2cIa1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#8220;Ng Agreement&#8221;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck" title="Annual salary">0.5</span> million and a signing bonus of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4" title="Bonus payable">0.3</span> million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 23, 2023, the Company entered into a Separation and Release Agreement with Mr. Ng which included a severance accrual and accrued
    interest as of December 31, 2024 (see Note 11). The lump sum payment and accrued interest was settled in January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0B_zb3j8Q9Vyk9i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zmweNB3Xu47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6" title="Monthly advisory fee">9,166</span> per month not to exceed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5" title="Advisory fee">0.1</span> million per annum, accrued
    and payable upon the Company raising $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf" title="Equity proceeds">10</span> million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F03_zLX2J83iRIF8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zQ7YPE1vTlO8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#8220;Guaranty&#8221;) up to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P" title="Guaranty of lease amount">0.9</span> million to the lessor for the Company&#8217;s future performance under
    the San Diego Lease agreement. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok" title="Lease agreement description">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.</span> As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z" title="Lease payment due">14,000</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6" title="Lease payment due">0.2</span> million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0D_zW1ETmqueNwd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zSwPhnNeBrE5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc" title="Deferred compensation">0.5</span> million,
    which was paid in January 2025 (see Note 11). The $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj" title="Notes payable">0.5</span> million note bore interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4" title="Note bears interest percentage">24</span>% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne" title="Note bears interest percentage">14</span>% per annum. The deferred compensation and advisory fees were settled in
    January 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zrzyrqrQZdM3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zZ51rLXa3lQe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    Note 8 for disclosures around Warrants. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F04_z9c88oDDUFK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_z5IDR1Bfps6b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8" title="Officer loans payable">0.2</span> million, which bears
    interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe" title="Officer loans payable">12</span>%. The loan was settled in full in January 2025. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zIlcmPGCq4w" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zj5egqFCgyC6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2" title="Bonus payable">0.1</span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc" title="Separation pay">0.2</span> million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#8217;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9" title="Severance pay">0.1</span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0D_zdfDOmomXt94" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zFrDDUS3lLNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1" title="Bonus payable">0.1</span> million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6" title="Severance pay">0.2</span> million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#8217;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf" title="Severance pay">0.2</span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"><span id="xdx_F07_zNo8J4qqMSEh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_z3zx8HiEP4Cj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#8220;CRO&#8221;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl" title="Accounts payable and accrued expenses">0.1</span>
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h" title="Expenses related to services">0.6</span>
    million in expenses related to services from Company A.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Debt Obligations</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zSxdPkDzMrL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s outstanding debt obligations as of December 31, 2025 and 2024, including related party components, are as follows (in
thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8BC_zirP9PQvheZ8" style="display: none">Schedule of Outstanding Debt Obligations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMNeRAr6KClg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKCKbGpGiGI8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z6ZkdmTBDAy5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion of long-term debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20251231_zutYKlGSssd5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(90</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    debt, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--LongTermDebt_iI_pn3n3_c20251231_zA54mlhaoCTi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unpaid</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
                                            Carrying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zihzq1dJs6U5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,200</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zLeuVlzlCvw5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">753</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zArGCDUwtam7" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,953</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bridge
    loan payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zTd7tM8TbDx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_z0lkMUcpXkx9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zdV8IJWhiNLl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
    note</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zH2QKTdCPxZf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztY1VpfkvPGk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPWkTf1r0jR1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">645</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231_znzJmfZxSXSl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_zzRJejM3acQe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">821</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231_zCTWD2iLH2a4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,821</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    current portion of long-term debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20241231_zp2GdBcNR8Rj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
    debt, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20241231_zj6QHi1ArYGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Outstanding Debt</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbqjTc8gnZAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scheduled
maturities of outstanding debt, net of discounts as of December 31, 2025 are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_ziMD1VTWsl08" style="display: none">Schedule of Maturities of Outstanding Debt</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending December 31:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20251231_zn9Uaygh0G7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDICAzCCI_zRtuHODsChNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDICAzCCI_z6a8msyqcAQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDICAzCCI_zZwEgYv3LbL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028
    and thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_pn3n3_maDICAzCCI_zDI0WWw1ZV54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plus:
    accrued interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzCCI_zh5K2dMn52Xk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">690</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock', window );">Schedule of Common Stock Reserved</a></td>
<td class="text"><p id="xdx_89D_ecustom--DiscloserOFCommonStockReservedForFurtureTableTextBlock_zRT2pG2i2nji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, common stock reserved for future issuance consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zU95Wcr2GHmf" style="display: none">Schedule
of Common Stock Reserved</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20251231_zNEUsLzr3llb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zzu59mG1aF0e" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4T92FbIxBcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock warrants outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockOptionsIssuedAndOutstandingMember_ztr8eJzSXMEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock options issued and outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277,822</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,245</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--RestrictedStockUnitsVestedAndUnreleasedMember_z2JFgf5R1kV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    stock units vested and unreleased</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1485">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,039</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zvq1KzbydcJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    available for future issuance under the 2023 Equity Incentive Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,497</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,409</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_zVwIf82UdAU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    reserved under the 2023 Employee Stock Purchase Plan</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,815</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,815</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_zei2jceJH5S5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock reserved
    for future issuance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,433,747</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,029,807</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ScheduleOfOutstandingWarrantsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfOutstandingWarrantsTextBlock_zfUEjplfNhKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2025 and 2024, the Company had outstanding warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231_zwpIRC1k4m5d" title="Purchase of shares">5,026,613</span> and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zArg26kfajRk" title="Purchase of shares">910,299</span> shares of common stock, respectively,
consisting of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zaOCfoDFvQsc" style="display: none">Schedule
of Outstanding Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20251231_zt1cD7aewJkg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_491_20241231_zGcjM197DTXl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    date</span></td></tr>
  <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgPI1YF6YQKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
    Warrants to purchase Common Stock<sup id="xdx_F47_z6tyoNYW74H9">(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zPnNjNrABJWc" title="Exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zBLrmU8MfELg" title="Exercise price">1,380.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zFOSnd84WJIg" title="Issuance date"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zUxUSFeE6PEe" title="Issuance date">September
    12, 2023</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zuuTiMLGd41l" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgi48eD4KR84" title="Expiration date">September
    12, 2028</span></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zUVdlL0BaiVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Warrants to purchase Common Stock<sup id="xdx_F49_z0mrR375bVd2">(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zyVFDM8eVpxb" title="Exercise price"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zQULLMXm97K6" title="Exercise price">1,380.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zxcbb1ukdC6k" title="Issuance date"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zDggh4IodK2g" title="Issuance date">September
    12, 2023</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_z4liAvuhhqxd" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zXqH06rbbU6h" title="Expiration date">September
    12, 2028</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zRVBT6OtXQeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Restricted Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zO5Z4ONebg69" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_z2qM0oU5XHMe" title="Exercise price">158.40</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zUJLcykvwPFf" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zAlM0j3fOEzl" title="Issuance date">February
    21, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zCrmwgfNzpjj" title="Expiration date"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zH6XTXdFLiV6" title="Expiration date">February
    21, 2029</span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z8vVu2fbocdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase Restricted Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zV55UrC9J21j" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z5KnjmHS6E25" title="Exercise price">22.80</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zbLT0yqBgGgf" title="Issuance date"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zjpg5mki66jg" title="Issuance date">July
    28, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zoioWBZIMGhk" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_ziMWpzLjgupe" title="Expiration date">July
    28, 2027</span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zeZNWsyvHhpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zAwBxePIkUjb" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zmQB8auENy31" title="Exercise price">79.20</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zjCKIMye3hR2" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zyofz5iOEo6l" title="Issuance date">April
    18, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zlBByEOYXPMg" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zXIw0zFkiLIi" title="Expiration date">April
    18, 2029</span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zRG3mxhBCYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,458</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,458</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zKIgIbpzC1ig" title="Exercise price"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zmpqo9cGiIh9" title="Exercise price">45.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zuC38sqnOXVe" title="Issuance date"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zcEimW9CHDwc" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zh52pGdW7iY5" title="Expiration date"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zB3FkifcG6m" title="Expiration date">June
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zGpRg5Cjwixd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,542</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,542</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zYqG1ppSgiUh" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zji1jYZc0pPj" title="Exercise price">15.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zOLqDczScrZf" title="Issuance date"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_z39r5jRN8Xgk" title="Issuance date">October
    24, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_znMKkRG0xyD7" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zEFPgYkpeVI5" title="Expiration date">April
    24, 2030</span></span></span></td></tr>
  <tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zZVb2ifZHIB8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,492</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zp5fzsTgXPRk" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zVOSoRBesXui" title="Exercise price">25.35</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zYgNY8sFtbV8" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_ziM0m1pNuWie" title="Issuance date">November
    15, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zIuC2g4Wt7A" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zvDPE8DF8yeh" title="Expiration date">May
    15, 2030</span></span></span></td></tr>
  <tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zXhwbxUCGCfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1761">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zRJ7x7PBpZ05" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zdDOtu5Gy3C" title="Exercise price">12.75</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zhjJtbjLxlkk" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_z96k4eclodXh" title="Issuance date">January
    10, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zGXxb2E388ah" title="Expiration date"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zl6zoeGXGbp3" title="Expiration date">January
    10, 2030</span></span></span></td></tr>
  <tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_z2bnVOBJgyA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Agent Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zfRSuMQ0VzV7" title="Exercise price"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zy4bYiOnjp3g" title="Exercise price">9.75</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_ztjFqf8aO60h" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zo8VkNfwBptg" title="Issuance date">March
    31, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zZepBsWw9Uml" title="Expiration date"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zGXqAA2tfpSf" title="Expiration date">March
    31, 2030</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zEuVwluocZK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative
    Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172,538</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1791">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zJrrNhRqghwi" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zl162NBSwsic" title="Exercise price">3.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdEpCKIeJ7Ib" title="Issuance date"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zTQ3XXZ2mqV9" title="Issuance date">August
    21, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdpyOqOwiEle" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zHj8H0hmY7n5" title="Expiration date">August
    21, 2030</span></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z2qFIt86FJR1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A Warrants to purchase Common Stock<sup id="xdx_F4E_zxG56Br7YiY2">(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87,643</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zcPrXXsxl0Ug" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z0T7YlqVq6A4" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zhx14koTOfI3" title="Issuance date"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zMH8vvPjIc8l" title="Issuance date">April
    18, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zxbeX8BwyTil" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zUzp6cT3xaN7" title="Expiration date">April
    18, 2029</span></span></span></td></tr>
  <tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zRXRNz5giG4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B Warrants to purchase Common Stock<sup id="xdx_F4B_zNjffbTUWvC6">(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1820">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zmdUis4QApd1" title="Exercise price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_z5zBuCDXO66l" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zuo4398kBeN1" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zl1V7NoF89Ue" title="Issuance date">April
    18, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zgXFtLgEU3Yk" title="Expiration date"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zTOmfaCvW7e5" title="Expiration date">April
    18, 2025</span></span></span></td></tr>
  <tr id="xdx_409_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zxK56C9OewM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F48_zi6B9OdyvFwl">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,442</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,276</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zMIYuaYfcbLa" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zKVxTROyMJFc" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zLtZZYwOpUhh" title="Issuance date"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zTBty83PwKeh" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_z9APXtma4jC4" title="Expiration date"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zSAZb5EBebHg" title="Expiration date">June
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zuSbugofQ88a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F48_zUhKoE2S0fgk">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1850">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_z6Q2iO7wrkh9" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zl2esj0kAFWh" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zLKKaPSxogyi"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zaV2ONdzup92">July
    19, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zNeVoftq6pge"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_ztFKpEwufmX4">July
    19, 2029</span></span></span></td></tr>
  <tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockThreeMember_zCkDawhXMcV9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F4B_zvinK6tDmePi">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1861">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKZS5M9IGtAb" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zb3bKc7Ydp18" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKjBW1bV4H51" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z7Uc62PczQ67" title="Issuance date">July
    22, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zFw4BJGU3RB6" title="Expiration date"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z9YgJj0yOcul" title="Expiration date">July
    22, 2029</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zi58jpi6AbWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    B-1 Warrants to purchase Common Stock<sup id="xdx_F4D_zwXyMJUAW6sf">(5)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1876">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,251</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zwJ8XnPvSTne" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zM3LfOlLY3H4" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zd6a768WbR78" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zeYk8d2n02P7" title="Issuance date">November
    13, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zZTv3yM7zNW9" title="Expiration date"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zWQrU2BdNnfl" title="Expiration date">November
    13, 2029</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z7ujrgbVlbr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F4E_zLwFIY6fTcya">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,918</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,586</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zgpBGmZrf6Ac" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zg5kyH8SM1cb" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z75eDQh1xCTf" title="Issuance date"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z1qOlKItkiF8" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zq5QIba6ar77" title="Expiration date"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zSZHwcDX2mz8" title="Expiration date">June
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zJzt3bIaEs03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F43_zc78ko79Ispk">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,167</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_z5wdghE4PKA6" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zenUJTI5yCBb" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zSBMp3LEQtQc" title="Issuance date"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zj7lqydZBNHa" title="Issuance date">August
    8, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zDJmd6Ur5tM8" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zvgGsMNGC1p4" title="Expiration date">August
    7, 2029</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zJkgO7hFEuW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C-1 Warrants to purchase Common Stock<sup id="xdx_F4F_zzxez496UVzc">(6)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,168</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,168</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zrxgJl4GeaWg" title="Exercise price"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zxGPUeoRt4d" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_znsFzg1LuOEi" title="Issuance date"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zc8MccSdQq7f" title="Issuance date">August
    16, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zY7Qo5GVpeag" title="Expiration date"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_z6hpCbI1Lmi" title="Expiration date">August
    15, 2029</span></span></span></td></tr>
  <tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z2JOJYvwMOEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    D Warrants to purchase Common Stock<sup id="xdx_F4B_zG5lQ2yItPt4">(7)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,318</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,153</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z16vwHbNh0Xg" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zUruHHO5ez2e" title="Exercise price">18.24</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zvGciJAxMT72" title="Issuance date"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zCJRExu8H2ed" title="Issuance date">June
    3, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zF0K0c2rH383" title="Expiration date"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zVzpD6Ujyszl" title="Expiration date">December
    3, 2029</span></span></span></td></tr>
  <tr id="xdx_40D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zIiCncH8XL19" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    E Warrants to purchase Common Stock<sup id="xdx_F45_zpm863jw6ng2">(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1951">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,836</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zlJJoSlZTg2k" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zEd7oC1C0zu9" title="Exercise price">13.56</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zbdKGTDqyMe5" title="Issuance date"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zU1nxSdCqZRc" title="Issuance date">October
    24, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z3zozdSBbRZ6" title="Expiration date"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z9z4SmAWT7Uj" title="Expiration date">April
    24, 2026</span></span></span></td></tr>
  <tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zcyV1hRWckwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    F Warrants to purchase Common Stock<sup id="xdx_F4A_zlTwV30ZGCpg">(8)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1966">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,836</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNa9hD16C08j" title="Exercise price"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNp6cIBAGzq7" title="Exercise price">13.56</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zC9N51yiELM6" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zLuJsjrmAE8h" title="Issuance date">October
    24, 2024</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zys2Z2jMKAzd" title="Expiration date"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zoQUUA1BJyS7" title="Expiration date">April
    24, 2030</span></span></span></td></tr>
  <tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zd0cmXTTpCU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    G Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">504,417</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zhf66P3Rp22b" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBfcttBteGNj" title="Exercise price">8.34</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBun3MQzBom6" title="Issuance date"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zVGtsejpShZe" title="Issuance date">March
    31, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_z5gD9u8fUuB2" title="Expiration date"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zDZtzijcIfq6" title="Expiration date">September
    30, 2032</span></span></span></td></tr>
  <tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zYJrUiT4A1ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    H Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">549,587</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1997">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zQQ4PJRklOO5" title="Exercise price"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zeyBs7AL6XDb" title="Exercise price">8.40</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zJulfPSosXt3" title="Issuance date"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zLHZL6Dl1L04" title="Issuance date">July
    10, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zKP7QEZhGH0h" title="Expiration date"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zOprzkzV9Xg4" title="Expiration date">January
    10, 2031</span></span></span></td></tr>
  <tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zrxXLSswYqoh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    I Warrants to purchase Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,450,764</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2012">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_znVkhYZ2rki4" title="Exercise price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zzmaptg7Mxhi" title="Exercise price">2.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zf5M0aVWiWk6" title="Issuance date"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zwlQJh5khrwi" title="Issuance date">August
    21, 2025</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zObUZb63f0c6" title="Expiration date"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zUj54wVc0HX4" title="Expiration date">August
    21, 2030</span></span></span></td></tr>
  <tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_zXPhLVZlmw2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F02_zklbGtvDjmx2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_znuGs7SC36K5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#8217;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zhchokdSYADf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1B_zxZ3YvKW1fL2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#8217;s common stock.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--PublicWarrantRedemptionDescription_pid_c20250101__20251231_ztb6ktS0f7Gb" title="Public warrant redemption description">The
    Company may redeem the outstanding Public Warrants for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--RedemptionOfOutstandingWarrantsPerShare_pid_c20250101__20251231_z0eZIco0ySvh" title="Redemption of outstanding warrants per share">0.12</span> per warrant upon at least <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--ClassOfWarrantsRedemptionNoticePeriod_dtD_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_zIroWV3Kn0of" title="Class of warrants, redemption notice period">30</span> days&#8217; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--SharePrice_iI_uUSDPShares_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_zKgdq3sn9i9g" title="Share Price">2,160.00</span> per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.</span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company accounts for the Public Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because
    the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    accounting treatment of derivative financial instruments in accordance with ASC 815 requires that the Company record a derivative
    liability upon the closing of the FLAG Merger (see Note 2).</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    October 17, 2024, the Company received notice from the NYSE that the Company&#8217;s Public Warrants to purchase common stock are
    no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of such public
    warrants, and that the NYSE Regulation has determined to commence proceedings to delist the public warrants. The Public Warrants
    may be traded on the OTC Pink Marketplace under the symbol CLDWW.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F00_za4loOSPtY25" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F19_z1lSebrMsjPb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the year ended December 31, 2024, Series A warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f" title="Number of shares purchased">60,418</span> shares of common stock
                                            were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7" title="Exercise price">18.24</span> per share and the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576" title="Received dross proceeds">1.1</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series A warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z5zyhc1WQVrb" title="Number of shares purchased">33,335</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zM4YvTH3n71e" title="Exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zoKof3dAYb4h" title="Received dross proceeds">0.3</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F00_zk1EX9rWw8s9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F14_zOJRQAZQHvG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
                                            B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased">22,275</span> shares of common stock were exercised at a reduced exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price">24.00</span> in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds">0.5</span> million. During the year ended December 31, 2024, Series B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased">68,335</span>
                                            shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price">18.24</span> per share and the Company received gross
                                            proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds">1.2</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outstanding Series B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zCjS5nkk7RNl" title="Number of shares purchased">57,451</span> shares of common stock expired in April 2025. As of December 31, 2025, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_do_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zJcPptm4wsz" title="Warrants outstanding">no</span> Series
    B warrants remained outstanding.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zCbhZ5JVIGuf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F10_zNpmXQC9ahDe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy" title="Number of shares purchased">27,082</span> shares of common
                                            stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1" title="Warrants exercise price">18.24</span> per share and the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob" title="Gross proceeds">0.5</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series B-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zJzhCq7uqT78" title="Number of shares purchased">62,086</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zKWSRj6VjYF9" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zpYGyKGAeYG2" title="Gross proceeds">0.5</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zCd37e8Jcx98" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F1C_z7McP3RC7sPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f" title="Number of shares purchased">4,167</span> shares of
                                            common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg" title="Warrants exercise price">24.00</span> per share and the Company received gross proceeds of
                                            approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b" title="Gross proceeds">0.1</span> million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7" title="Number of shares purchased">47,936</span> shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8" title="Warrants exercise price">18.24</span> per share and the Company
                                            received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg" title="Gross proceeds">0.9</span> million.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series C-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zsOkklPTY0P5" title="Number of shares purchased">41,668</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zelVqow1sFad" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zV1AZQnnrJB7" title="Gross proceeds">0.4</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F02_zPih12spboPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_F19_z4prBB1WV3Ea" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3" title="Deemed dividend">1.7</span> million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series D warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zAy8T0RnQ5F8" title="Number of shares purchased">70,835</span> shares of common stock were exercised at a reduced exercise
    price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zHckoL4rqJD2" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zExkhm7GdCK" title="Gross proceeds">0.6</span> million.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F08_z79dDFrQyW69" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zTzPNn9dfsxj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b" title="Number of shares purchased">341,672</span> shares of common stock each were exercised
    at a reduced exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk" title="Gross proceeds">2.8</span> million.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI9zvMdBUoVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s aggregate warrant activity for the year ended December 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zN4RTrBvgykj" style="display: none">Schedule
of Warrant Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz2jDt26kuD4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjKyow3I4Dza" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgckS06Oe9s4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z38OhOA5wXR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,478,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyvU3Dx4CT4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,304,930</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetsFP6qOM73" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(57,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8GKp22zH831" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,026,613</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5c4cCUUR2d9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.97</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoKmLVctvhY1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.79</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s aggregate warrant activity for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price
                                            <sup>(1)</sup></b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
                                            Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgX2i38dnYCe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111,772</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwS16fLKZb5f" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,380.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7sOYX74ZK9k" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.72</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9lVq9FwLa7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,176,804</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z71n7KcESiyc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(350,222</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Converted
    into Common Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z9Oku9Hupf42" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2024</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zAeJ5lPSI06f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">910,299</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo7VftXyfc8e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">185.16</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEGRpY5Qpcik" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloser of Common Stock Reserved for Furture [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ScheduleOfOutstandingWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Outstanding Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ScheduleOfOutstandingWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z7xIaenxH4sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the 2023 Plan option activity and related information follows (in thousands, except weighted averages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zfEuhibvMzL2" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic
                                            Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK7kC1ajijW2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Options Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztRaZJZJFvU2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">220.92</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSpaP75uL3ci" title="Weighted Average Remaining Contractual Life (Years), Outstanding">5.67</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zefFLnTWCDKg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKe1Ruauxv7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">217</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCWFrdBuwki" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpYflv2WEsYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2199">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0rvqdIRJlL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2201">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    forfeited or cancelled</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYBD9YroCVBg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0buq0fQQjLd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">252.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoM6ZjChWrv5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTFSrkB3V5kl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49.57</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HXOYBinOu4" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.39</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEh0gbt0G4c" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2213">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVY2amDXb4Li" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAhQUpKWRJRd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">160.73</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHcrzjARNxw4" title="Weighted Average Remaining Contractual Life (Years), Exercisable">5.54</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ0Xgxt9ks5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0V8ViB7a2cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the 2023 Plan restricted stock unit (RSU) activity and related information follows (in thousands, except weighted average
grant date fair value):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zwCCANd9cbH3" style="display: none">Summary
of Restricted Stock Unit Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant-Date
                                            Fair Value</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at January 1, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYP9cSw5Qb6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Units Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRgmbX7LNmcj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    and released</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZugKRLLFGo1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpw41DTyfZe6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.80</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at December 31, 2025</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzEsqaDp2sml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2233">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLgdS2RSgSTg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2235">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zCzZoUFkWN5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations
for the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zDiKQSAqinMj" style="display: none">Schedule
of Stock-Based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zKOpDXF8G51l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_496_20240101__20241231_zr8StlecTXPh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zraVVi4t1ank" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">426</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">751</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zUGIRtAM3tRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zBL22iwa4ICg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,108</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,957</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zu40kxVf1Mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zdpUKtuCZav8" style="display: none">Schedule
of Stock Options Valuation Assumptions</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20251231_zYwzAD1nqNb7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87.84</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zzjUP5wAMfF2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85.63</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20251231_zH4VG3ESa7eb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.93</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zz8KbtNzL8nk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    option life (in years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231_zGfjSZ8LnwK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.78</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zftGv0RrkSD7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.64</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_zBtbVzIc1lTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zO5GP7caLrCh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Provision for Income Taxes</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zmI7X7eorJAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income/(Loss)
before provision for income taxes consisted of the following for the year ended December 31, 2025 and 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zaVuKwfY3u7l" style="display: none">Schedule
of Income (Loss) Before Provision for Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_z1eur2KiQjJ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20240101__20241231_z0n1aWp4zFjd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zqb4CfXSPFlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    States</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(20,100<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,215</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--NonUsMember_zYhOssVld3l2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zrDgzR435E9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before provision for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,048</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,195</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expenses (Benefit) by Jurisdiction</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkQC7wARcWlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax expense (benefit) by jurisdiction for the year ended December 31, 2025 and 2024, were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BF_zckABzOflrB9" style="display: none">Schedule
of Income Tax Expenses (Benefit) by Jurisdiction</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_498_20250101__20251231_zdfhLeHvkoCb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_zx5hjdGzc0rb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_znNSLSOmYZ31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zAup2wou2llc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2302">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2303">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zVp9UCS1JTDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    and local</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2306">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zBvgZLB1XXee" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pn3n3_mtCITEBziCv_maITEBzUqw_zZMx6aSiZtwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">15</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zKTEcVxovTUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_z1kpVraKSUdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl2317">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2318">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zK1WBnJwE7Za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    and local</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2320">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2321">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zBsepxvobkVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2323">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2324">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pn3n3_mtDITEBzDw6_maITEBzUqw_zbTUpQrnkXRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2326">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2327">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUqw_zxpscxQO7gtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">15</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Benefit</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuqKCNsp7pKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the benefit for income taxes to the amount computed
by applying the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zQYz2ZJJiQ1k" title="Federal statutory income tax rate">21</span>% statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2025, after the
adoption of ASU 2023-09, is as follows (in thousands, except for percentages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span id="xdx_8BA_zi89feMC8pgg" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20250101__20251231_zvsulSOwOOFf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjN0_zihwnEwvat8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">U.S. Federal statutory tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(4,210</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zdCaSR0PS2I" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S. Federal statutory tax rate, percentage">21</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjN0_zMd2U5dnfb7c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State tax, net of federal income tax effect<sup id="xdx_F49_zfMUB8EowxWh">(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20250101__20251231_fKDEp_ziSPJNckHKx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax, net of federal income tax effect, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationEnactmentOfNewTaxLaws_maITEBzjN0_zeb36ZS0ig89" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Enactment of new tax laws</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2344">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_pid_dp_uPure_maABC_c20250101__20251231_znorpo3hbvr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enactment of new tax laws, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2346">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maITEBzjN0_zrh65z92s1pl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of cross-border tax laws</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2348">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_c20250101__20251231_zT42c40qxkWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effect of cross-border tax laws, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2350">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBzjN0_zvDLKSApPOKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax credits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(299</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20250101__20251231_z7oSHzsu1zi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Tax credits, percentage">2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjN0_zq5pT7QibJ4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,519</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zs8DOk37luLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance, percentage">(17</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAbstract_iB_zUKpPQtL6vtl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Nontaxable or non-deductible items</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_i01_maITEBzjN0_zWye46LLe00l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-deductible expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maABC_c20250101__20251231_ztk6cDIBHb0k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible expenses, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2364">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_maITEBzjN0_z0CPv64gkyJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">121</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20250101__20251231_zlb9t8L8Gc91" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation, percentage">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxSettlements_maITEBzjN0_z6MunjaJDdIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Worldwide changes in unrecognized tax benefits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">342</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maABC_c20250101__20251231_zY4B7GQpnN93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Worldwide changes in unrecognized tax benefits, percentage">(2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherReconcilingItemsAbstract_iB_zjqX7cLSigw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i01_maITEBzjN0_zgknsduMTri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred tax adjustments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">139</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zbbFMSpxyShc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred tax adjustments, percentage">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_i01N_di_msITEBzjN0_zwrlSKQZHIo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">348</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_iN_pid_dpi_uPure_msABC_c20250101__20251231_zd8usvK6Y6u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-controlling interest, percentage">(2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i01_maITEBzjN0_zh8MyuRsHJ49" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20250101__20251231_zaR1I0mJwQM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2386">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_maABC_zJLZG6onMXka" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_maABC_zepi2og8IZJf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_maABC_znEh3CYo1Nz8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issuance cost</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_maABC_z2J7LMVTXxBk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    startup costs</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign tax effects</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Germany</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_maITEBzjN0_zeeaLUSXxKVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Foreign employee stock based compensation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zcO0S1CaBQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Foreign employee stock based compensation, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2398">&#8212;</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_maITEBzjN0_zR99C4Yh4P63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rate differential</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zHo20NYC5TK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Rate differential, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2402">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_400_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_maITEBzjN0_zvmJdpCP8Q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_pid_dp_uPure_maABC_c20250101__20251231_zmN6R4wflEAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Other, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2406">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_maITEBzjN0_zAlI68y5rrZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rate differential</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_pid_dp_uPure_maABC_c20250101__20251231_zkS90xGUv0H1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Rate differential, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2410">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_maITEBzjN0_zMgrgYgslGr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zAIEDsplK743" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Change in valuation allowance, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2414">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjN0_zbJfxINKh827" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20250101__20251231_zyyiiUtlerG6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reconciliation of income tax benefit, percentage"><span style="-sec-ix-hidden: xdx2ixbrl2418">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F03_zct2ZTKa2Ewf" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zpfi7Hnizt45" style="font-size: 10pt">California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 2023-09 on a prospective basis. A reconciliation of the benefit for income taxes to the amount computed by
applying the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_z0obmmRCZSM3" title="Federal statutory income tax rate">21</span>%
statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2024, before the adoption of ASU
2023-09, is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none">Schedule
of U.S. Federal Income Tax Rates Indicated to Pretax Loss From Operations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computed
    tax benefit at U.S. federal statutory tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20240101__20241231_zUtR4pIQ7Qn2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Computed tax benefit at U.S. federal statutory tax rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent
    differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20240101__20241231_zPeXQHLDEdz6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2425">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    tax benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20240101__20241231_zm3EOrHZAze5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20240101__20241231_zyCqFkjZl2x2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    permanent differences</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_uPure_maABC_c20240101__20241231_zo82EFPPaf47" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20240101__20241231_ze35NAHYbBfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20240101__20241231_zrz97QRAWPJ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2435">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_uPure_maABC_c20240101__20241231_z4Th7nho2OHb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    issuance cost</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_uPure_maABC_c20240101__20241231_zV3fgVtZr0z" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2439">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired
    startup costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_uPure_maABC_c20240101__20241231_zRUZsXSHTcE3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2441">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Pretax loss from operations
    rates total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20240101__20241231_zptrl9LReBn" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2443">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ScheduleOfIncomeTaxPaidTableTextBlock', window );">Schedule of Cash Paid for Income Taxes, Net of Refunds Received</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfIncomeTaxPaidTableTextBlock_zsK4I0lG0F21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon adoption of ASU 2023-09, cash paid for income taxes, net of refunds
received, were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zQCoIBBAqDQ5" style="display: none">Schedule
of Cash Paid for Income Taxes, Net of Refunds Received</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20250101__20251231_zOyPWllijAh9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31, 2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNztd0_zu9pWrQTBJn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Federal taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2447">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxPaidStateAfterRefundReceived_maITPNztd0_zjijZGDohw26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">State and local taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNztd0_zEoebRvZdd0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Foreign taxes:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--AU_maITPNztd0_zUyGgN4WEJqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Australia</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2453">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--DE_maITPNztd0_zlvxgcoZqgNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 80%; padding-bottom: 1pt">Germany</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_iT_mtITPNztd0_zo5AniFJEie9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total cash paid for income taxes, net of refunds</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQS7jlZ9G3md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary components of the deferred tax assets and liabilities at December 31, 2025 and 2024 were as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zxgqp710OTae" style="display: none">Schedule
of Components of Deferred Tax Assets and Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20251231_zcGtguKFDa0c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20241231_zrgbsgdOSbd7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax assets/(liabilities):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzO0o_zYioH31KvUH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">25,920</p></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,221</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzO0o_zKla1Ij2pK0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development credit carryforwards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">931</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzO0o_ziwHtGMhOVu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    and other compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,355</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,135</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_pn3n3_maDTAGzO0o_zuiGZRyvi3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">479</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">859</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_pn3n3_maDTAGzO0o_zQnEXaYAVlJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized
    research and development expenditures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,247</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGzO0o_zoJFXsy61izl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,315</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,393</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzO0o_zKs7xlP8fKhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    liabilities and other reserves</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">446</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzO0o_maDTANzVsW_zTwaQun8fFn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,695</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,232</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_iNI_pn3n3_di_maDITLzwdK_zkSeahFfBNNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    and other assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(480</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(830</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzwdK_msDTANzVsW_zMlbqVgsTI8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(480</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(830</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzVsW_zNGTS671QiE1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34,215</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzVsW_zL10150kJI13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2496">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2497">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefit</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zy6NAeHPiGFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BC_zgihqkianum3" style="display: none">Schedule
of Unrecognized Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20250101__20251231_zcFoJl7Bw0Hg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20240101__20241231_z0TYewQukNRi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_zrCnkqJg47k4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at the beginning of the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,799</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,517</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_pn3n3_zSm0LSQLFUhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions
    based on tax positions related to current year</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_zlmPVM42Odcg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    based on tax positions related to prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">283</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2526">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_zd71cGelRVnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at end of year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,364</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,799</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ScheduleOfIncomeTaxPaidTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Income Tax Paid [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ScheduleOfIncomeTaxPaidTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_zjJcUdsV82A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents supplemental cash flow information related to operating and financing leases for the periods presented (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zIEWyOnuK0Hh" style="display: none">Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20250101__20251231_zVgR4TMa6cWi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20240101__20241231_z2O3hxNxW3p5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for amounts included in the measurement of lease liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zE9lHKMwv1dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    cash flows from operating leases</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,467</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,424</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zwgbEPczKbpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    cash flows from financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zMCqdQoMchmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    cash flows from financing leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_z7POe9VVVW36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents supplemental balance sheet information related to operating and financing leases for the periods presented (in
thousands, except weighted averages):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zzivUjMbH66g" style="display: none">Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20251231_zeUZUbKLDkCl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2025</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20241231_zg5QPJAo5gIk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
                                            31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zjptdiItgEMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    assets, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,934</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzLs4_zhvI1rU3CG7d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease liabilities, current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,204</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzLs4_zErKs72ddsR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    lease liabilities, noncurrent</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">277</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,845</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzLs4_zmbAHBUGsGbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,049</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    Leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_iI_pn3n3_maPPAENzCH7_zXL1SWMuK1Kf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, gross</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">779</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">588</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iNI_pn3n3_di_msPPAENzCH7_zp0geCKJ9JDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(463</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(333</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_iTI_pn3n3_mtPPAENzCH7_zfNhCxxzcpSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">316</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">255</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_maFLLzNvC_zGD0wv9kWj3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_maFLLzNvC_zQP67sLDO6P7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncurrent
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_mtFLLzNvC_zoLsaW172gHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    financing lease liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">211</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average remaining lease term</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zXh8NPFoUwj2" title="Weighted average remaining lease term, Operating leases (in years)">1.2</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zWdlNhVMVNL8" title="Weighted average remaining lease term, Operating leases (in years)">2.2</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zeWhdokfJzNj" title="Weighted average remaining lease term, Financing leases (in years)">2.7</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3QXnlbPtHuf" title="Weighted average remaining lease term, Financing leases (in years)">3.2</span>
                                            years</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average discount rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr8xPw3WQtL1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr id="xdx_40A_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zZdFtnio05D7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.05</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Future Minimum Lease Commitments</a></td>
<td class="text"><p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zOihmUTUOme4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents future minimum lease commitments as of December 31, 2025 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zrbvmxSlKA3h" style="display: none">Schedule
of Future Minimum Lease Commitments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zrCrNBg9wKvk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Leases, 2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,512</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zcoYAGtcgefj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Financing Leases, 2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zECw0oPKmbX6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zFAwlGX09Rjl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zexL69dvRUje" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmReNXTKils8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z5cozyuTQpJc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2632">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zlZ2svW4Kw3k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030
    and thereafter</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zM7iUfRRvjF8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2030 and thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2636">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zruLPX0rgbri" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2030 and thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2638">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmtaJlAhhCB1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Total minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z8cP0VsZT5x5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Total minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">319</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    amounts representing interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_ztrK0QO5otPe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Less: amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(127</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_zOMifW6juZWl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Less: amounts representing interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present
    value of net minimum lease payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--OperatingLeaseLiability_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z3YOipHV72nb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Present value of net minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,682</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zHO9irHCvb7i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Present value of net minimum lease payments"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash flow supplemental disclosures operating and financing leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to operating and financing leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>Jul. 10, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">1-for-12 reverse stock split<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">1-for-10 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,621<span></span>
</td>
<td class="nump">$ 121,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,293<span></span>
</td>
<td class="nump">19,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">$ 9,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 9,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash included within prepaid expenses and other current assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included within other noncurrent assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash as shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 5,819<span></span>
</td>
<td class="nump">$ 9,809<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,454<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,026<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">278<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CLDI_EarnoutSharesMember', window );">Earnout Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CLDI_ContingentlyIssuableWarrantMember', window );">Contingently Issuable Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CLDI_EarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CLDI_EarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CLDI_ContingentlyIssuableWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CLDI_ContingentlyIssuableWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Operating Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,906)<span></span>
</td>
<td class="num">(22,143)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,561)<span></span>
</td>
<td class="num">(10,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(801)<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,324)<span></span>
</td>
<td class="num">(1,951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_Consulting', window );">Consulting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,059)<span></span>
</td>
<td class="num">(1,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RentAndMaintenance', window );">Rent and maintenance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,358)<span></span>
</td>
<td class="num">(2,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClinicalResearchAndDevelopment', window );">Clinical &amp; research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,760)<span></span>
</td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(386)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives', window );">Change in fair value of other liabilities and derivatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_OtherSegmentItems', window );">Other segment items</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,801)<span></span>
</td>
<td class="num">(3,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (20,063)<span></span>
</td>
<td class="num">$ (22,209)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of debt, other liabilities, and derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ClinicalResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ClinicalResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_Consulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_Consulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_OtherSegmentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other segment items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_OtherSegmentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RentAndMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent and maintenance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RentAndMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Oct. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_GovernmentGrantsMember', window );">Government Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Proceeds from Other Operating Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_GovernmentGrantsMember', window );">Government Grants [Member] | California Institute For Regenerative Medicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Proceeds from Other Operating Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_GrantsReceivableWithdrawn', window );">Government grants award withdrawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CLDI_NovaCellMember', window );">Nova Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CLDI_NovaCellMember', window );">Nova Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold and transferred</a></td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase price for repurchased shares</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset', window );">Promissory note, net cash offset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Indebtedness cancellation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_GrantsReceivableWithdrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grants receivable withdrawn.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_GrantsReceivableWithdrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from operating activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_GovernmentGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_GovernmentGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CaliforniaInstituteForRegenerativeMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CaliforniaInstituteForRegenerativeMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CLDI_NovaCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CLDI_NovaCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLDI_NovaCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLDI_NovaCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=CLDI_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=CLDI_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=CLDI_ForwardPurchaseAgreementDerivativeAssetMember', window );">Forward Purchase Agreement Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Forward Purchase Agreement Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Forward Purchase Agreement Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total warrant liabilities, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Forward Purchase Agreement Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=CLDI_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=CLDI_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=CLDI_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=CLDI_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=CLDI_ForwardPurchaseAgreementDerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=CLDI_ForwardPurchaseAgreementDerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_ForwardPurchaseAgreementDerivativeAssetMember', window );">Forward Purchase Agreement Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance, beginning</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance, beginning</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance, ending</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance, beginning</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance, ending</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_ForwardPurchaseAgreementDerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_ForwardPurchaseAgreementDerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_AccruedCompensation', window );">Accrued compensation</a></td>
<td class="nump">$ 884<span></span>
</td>
<td class="nump">$ 1,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_AccruedVendorAndOtherExpenses', window );">Accrued vendor and other expenses</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="nump">$ 2,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_AccruedVendorAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued vendor and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_AccruedVendorAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Machinery and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">$ 2,575<span></span>
</td>
<td class="nump">$ 2,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,794)<span></span>
</td>
<td class="num">(1,355)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Machinery and equipment, net</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Machinery and Equipment, net (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAAndDirectorEMember', window );">Director A and Director E [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Current
    term notes payable, net of discount, including accrued interest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFAndRelativeOfOfficerAMember', window );">Director F and Relative of Officer A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">Accounts
    payable and accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFMember', window );">Director F [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 195<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">Severance
    accrual<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorDMember', window );">Director D [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">Severance
    accrual<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAOneMember', window );">Director A One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">Advisory
    services included in accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFOneMember', window );">Director F One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">Lease
    guaranty<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorATwoMember', window );">Director A Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">Other
    liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFAndDirectorAMember', window );">Director F and Director A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">Warrant
    liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_RelativeOfOfficerAMember', window );">Relative of OfficerA [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">Loan
    payable<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerGMember', window );">Officer G [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 65<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="text">Severance
    accrual<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerAMember', window );">Officer A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 158<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[11]</sup></td>
<td class="text">Severance
    accrual<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CompanyARelatedToDirectorGMember', window );">Company A related to Director G [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 130<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction description</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[12]</sup></td>
<td class="text">Accounts
    payable and accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49" title="Related party note payable">2.7</span> million. See Note 7 for further details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj" title="Legal fees">48</span> thousand
and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04" title="Legal fees">38</span> thousand for the years ended December 31, 2025 and 2024, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#8220;Release Agreement&#8221;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb" title="Loans">0.5</span>
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1" title="Loan outstanding">0.2</span>
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2" title="Consulting pay">10,000</span>
    per month during the transition period. The agreement terminated on December 31, 2025 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j" title="Expenses">0.1</span>
    million was expensed under the agreement.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#8220;Ng Agreement&#8221;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck" title="Annual salary">0.5</span> million and a signing bonus of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4" title="Bonus payable">0.3</span> million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6" title="Monthly advisory fee">9,166</span> per month not to exceed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5" title="Advisory fee">0.1</span> million per annum, accrued
    and payable upon the Company raising $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf" title="Equity proceeds">10</span> million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#8220;Guaranty&#8221;) up to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P" title="Guaranty of lease amount">0.9</span> million to the lessor for the Company&#8217;s future performance under
    the San Diego Lease agreement. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok" title="Lease agreement description">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.</span> As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z" title="Lease payment due">14,000</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6" title="Lease payment due">0.2</span> million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc" title="Deferred compensation">0.5</span> million,
    which was paid in January 2025 (see Note 11). The $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj" title="Notes payable">0.5</span> million note bore interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4" title="Note bears interest percentage">24</span>% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne" title="Note bears interest percentage">14</span>% per annum. The deferred compensation and advisory fees were settled in
    January 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">See
    Note 8 for disclosures around Warrants.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8" title="Officer loans payable">0.2</span> million, which bears
    interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe" title="Officer loans payable">12</span>%. The loan was settled in full in January 2025.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2" title="Bonus payable">0.1</span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc" title="Separation pay">0.2</span> million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#8217;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9" title="Severance pay">0.1</span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[11]</td>
<td style="vertical-align: top;" valign="top">On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1" title="Bonus payable">0.1</span> million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6" title="Severance pay">0.2</span> million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#8217;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#8217;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf" title="Severance pay">0.2</span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[12]</td>
<td style="vertical-align: top;" valign="top">On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#8220;CRO&#8221;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl" title="Accounts payable and accrued expenses">0.1</span>
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h" title="Expenses related to services">0.6</span>
    million in expenses related to services from Company A.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAAndDirectorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAAndDirectorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFAndRelativeOfOfficerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFAndRelativeOfOfficerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorATwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorATwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFAndDirectorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFAndDirectorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_RelativeOfOfficerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_RelativeOfOfficerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CompanyARelatedToDirectorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CompanyARelatedToDirectorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Related Party Transactions (Details) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 17, 2025</div></th>
<th class="th"><div>Aug. 08, 2025</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 22, 2025</div></th>
<th class="th"><div>Aug. 12, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,026,613<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorsAAndEMember', window );">Directors A and E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFMember', window );">Director F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Officer loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ConsultingPay', window );">Consulting pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorDMember', window );">Director D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Bonus payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAMember', window );">Director A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees', window );">Advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Equity proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAMember', window );">Director A [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees', window );">Advisory fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_AJCCapitalMember', window );">AJC Capital [Member] | Guaranty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseDescription', window );">Lease agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_AJCCapitalMember', window );">AJC Capital [Member] | Maximum [Member] | Guaranty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_GuarantyOfLeaseAmount', window );">Guaranty of lease amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAThreeMember', window );">Director A Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Officer loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_RelativeOfOfficerAMember', window );">Relative of OfficerA [Member] | Loans Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Officer loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Officer loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerGMember', window );">Officer G [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Bonus payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_SeparationPay', window );">Separation pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerAMember', window );">Officer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Bonus payable</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CompanyARelatedToDirectorGMember', window );">Company A related to Director G [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Expenses related to services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ConsultingPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consulting payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ConsultingPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_GuarantyOfLeaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranty of lease amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_GuarantyOfLeaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_SeparationPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Separation payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_SeparationPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment advisory service, including, but not limited to, managing money in fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseInvestmentAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorsAAndEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorsAAndEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_AJCCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_AJCCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=CLDI_GuarantyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=CLDI_GuarantyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_DirectorAThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_RelativeOfOfficerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_RelativeOfOfficerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_OfficerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CompanyARelatedToDirectorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_CompanyARelatedToDirectorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Outstanding Debt Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Unpaid Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net Carrying Value</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Unpaid Balance</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net Carrying Value</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TermNotesPayableMember', window );">Term Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Unpaid Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_BridgeLoanPayableMember', window );">Bridge Loan Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Unpaid Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_TermNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_TermNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_BridgeLoanPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_BridgeLoanPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities of Outstanding Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Plus: accrued interest</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 3,821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2024</div></th>
<th class="th"><div>Jan. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Jan. 26, 2024</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value, including accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loans received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Carrying value, including accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_PromissoryNoteLoanAgreementMember', window );">Promissory Note Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Carrying value, including accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member] | 2024 Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyOneTermNoteMember', window );">2021 Term Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyOneTermNoteMember', window );">2021 Term Note [Member] | Investor and Director [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyTwoTermNotePayableMember', window );">2022 Term Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyTwoTermNotePayableMember', window );">2022 Term Note Payable [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Secured term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyTwoTermNotePayableMember', window );">2022 Term Note Payable [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableMember', window );">2023 Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Installment payable</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value, including accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableMember', window );">2023 Notes Payable [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Secured term notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember', window );">2023 Note Payable Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyFourBridgeLoanMember', window );">2024 Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Loans received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_PromissoryNoteLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_PromissoryNoteLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_TwoThousandTwentyFourPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_TwoThousandTwentyFourPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyOneTermNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyOneTermNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLDI_InvestorAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLDI_InvestorAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyTwoTermNotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyTwoTermNotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyFourBridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CLDI_TwoThousandTwentyFourBridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Common Stock Reserved (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,433,747<span></span>
</td>
<td class="nump">1,029,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_RestrictedStockUnitsVestedAndUnreleasedMember', window );">Restricted Stock Units Vested and Unreleased [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember', window );">2023 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">96,497<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">32,815<span></span>
</td>
<td class="nump">32,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_CommonStockOptionsIssuedAndOutstandingMember', window );">Common Stock Options Issued and Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">277,822<span></span>
</td>
<td class="nump">77,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">5,026,613<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_RestrictedStockUnitsVestedAndUnreleasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_RestrictedStockUnitsVestedAndUnreleasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_CommonStockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_CommonStockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Outstanding Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,026,613<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
<td class="nump">58,235<span></span>
</td>
<td class="nump">16,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PrivateWarrantsToPurchaseCommonStockMember', window );">Private Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">15,938,000<span></span>
</td>
<td class="nump">15,938,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,380.00<span></span>
</td>
<td class="nump">$ 1,380.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Sep. 12,  2023<span></span>
</td>
<td class="text">Sep. 12,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Sep. 12,  2028<span></span>
</td>
<td class="text">Sep. 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PublicWarrantsToPurchaseCommonStockMember', window );">Public Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">95,834,000<span></span>
</td>
<td class="nump">95,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,380,000.00<span></span>
</td>
<td class="nump">$ 1,380,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Sep. 12,  2023<span></span>
</td>
<td class="text">Sep. 12,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Sep. 12,  2028<span></span>
</td>
<td class="text">Sep. 12,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_WarrantsToPurchaseRestrictedSharesMember', window );">Warrants to Purchase Restricted Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,334,000<span></span>
</td>
<td class="nump">3,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 158.40<span></span>
</td>
<td class="nump">$ 158.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Feb. 21,  2024<span></span>
</td>
<td class="text">Feb. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Feb. 21,  2029<span></span>
</td>
<td class="text">Feb. 21,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_WarrantsToPurchaseRestrictedSharesOneMember', window );">Warrants to Purchase Restricted Shares One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 28,  2024<span></span>
</td>
<td class="text">Jul. 28,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 28,  2027<span></span>
</td>
<td class="text">Jul. 28,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember', window );">Placement Agent Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,333,000<span></span>
</td>
<td class="nump">6,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 79.20<span></span>
</td>
<td class="nump">$ 79.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 18,  2024<span></span>
</td>
<td class="text">Apr. 18,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 18,  2029<span></span>
</td>
<td class="text">Apr. 18,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember', window );">Placement Agent Warrants to Purchase Common Stock One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,458,000<span></span>
</td>
<td class="nump">4,458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2029<span></span>
</td>
<td class="text">Jun.  03,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember', window );">Placement Agent Warrants to Purchase Common Stock Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,542,000<span></span>
</td>
<td class="nump">8,542,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oct. 24,  2024<span></span>
</td>
<td class="text">Oct. 24,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 24,  2030<span></span>
</td>
<td class="text">Apr. 24,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember', window );">Placement Agent Warrants to Purchase Common Stock Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,492,000<span></span>
</td>
<td class="nump">18,492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25.35<span></span>
</td>
<td class="nump">$ 25.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 15,  2024<span></span>
</td>
<td class="text">Nov. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">May 15,  2030<span></span>
</td>
<td class="text">May 15,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember', window );">Placement Agent Warrants to Purchase Common Stock Four [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,834,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
<td class="text">Jan. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jan. 10,  2030<span></span>
</td>
<td class="text">Jan. 10,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember', window );">Placement Agent Warrants to Purchase Common Stock Five [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,221,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mar. 31,  2030<span></span>
</td>
<td class="text">Mar. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_RepresentativeWarrantsToPurchaseCommonStockMember', window );">Representative Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">172,538,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Aug. 21,  2025<span></span>
</td>
<td class="text">Aug. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Aug. 21,  2030<span></span>
</td>
<td class="text">Aug. 21,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesAWarrantsToPurchaseCommonStockMember', window );">Series A Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">54,308,000<span></span>
</td>
<td class="nump">87,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 18,  2024<span></span>
</td>
<td class="text">Apr. 18,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 18,  2029<span></span>
</td>
<td class="text">Apr. 18,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsToPurchaseCommonStockMember', window );">Series B Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">57,451,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 18,  2024<span></span>
</td>
<td class="text">Apr. 18,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 18,  2025<span></span>
</td>
<td class="text">Apr. 18,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockMember', window );">Series B-1 Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">1,442,000<span></span>
</td>
<td class="nump">22,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2029<span></span>
</td>
<td class="text">Jun.  03,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember', window );">Series B-1 Warrants to Purchase Common Stock One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 19,  2024<span></span>
</td>
<td class="text">Jul. 19,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 19,  2029<span></span>
</td>
<td class="text">Jul. 19,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember', window );">Series B-1 Warrants to Purchase Common Stock Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember', window );">Series B-1 Warrants to Purchase Common Stock Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 22,  2024<span></span>
</td>
<td class="text">Jul. 22,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 22,  2029<span></span>
</td>
<td class="text">Jul. 22,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember', window );">Series B-1 Warrants to Purchase Common Stock Four [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 13,  2024<span></span>
</td>
<td class="text">Nov. 13,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Nov. 13,  2029<span></span>
</td>
<td class="text">Nov. 13,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockMember', window );">Series C-1 Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">17,918,000<span></span>
</td>
<td class="nump">59,586,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2029<span></span>
</td>
<td class="text">Jun.  03,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember', window );">Series C-1 Warrants to Purchase Common Stock One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">4,167,000<span></span>
</td>
<td class="nump">4,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
<td class="text">Aug.  08,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Aug.  07,  2029<span></span>
</td>
<td class="text">Aug.  07,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember', window );">Series C-1 Warrants to Purchase Common Stock Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">4,168,000<span></span>
</td>
<td class="nump">4,168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Aug. 16,  2024<span></span>
</td>
<td class="text">Aug. 16,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Aug. 15,  2029<span></span>
</td>
<td class="text">Aug. 15,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesDWarrantsToPurchaseCommonStockMember', window );">Series D Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">18,318,000<span></span>
</td>
<td class="nump">89,153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Dec.  03,  2029<span></span>
</td>
<td class="text">Dec.  03,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesEWarrantsToPurchaseCommonStockMember', window );">Series E Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">170,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oct. 24,  2024<span></span>
</td>
<td class="text">Oct. 24,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 24,  2026<span></span>
</td>
<td class="text">Apr. 24,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesFWarrantsToPurchaseCommonStockMember', window );">Series F Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">170,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="nump">$ 13.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oct. 24,  2024<span></span>
</td>
<td class="text">Oct. 24,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 24,  2030<span></span>
</td>
<td class="text">Apr. 24,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesGWarrantsToPurchaseCommonStockMember', window );">Series G Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">504,417,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Sep. 30,  2032<span></span>
</td>
<td class="text">Sep. 30,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesHWarrantsToPurchaseCommonStockMember', window );">Series H Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">549,587,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jul. 10,  2025<span></span>
</td>
<td class="text">Jul. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Jan. 10,  2031<span></span>
</td>
<td class="text">Jan. 10,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesIWarrantsToPurchaseCommonStockMember', window );">Series I Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,450,764,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantOrRighstIssuanceDate', window );">Issuance date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 21,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#8217;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#8217;s common stock.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">During
                                            the year ended December 31, 2024, Series A warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f" title="Number of shares purchased">60,418</span> shares of common stock
                                            were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7" title="Exercise price">18.24</span> per share and the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576" title="Received dross proceeds">1.1</span> million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Series
                                            B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased">22,275</span> shares of common stock were exercised at a reduced exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price">24.00</span> in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds">0.5</span> million. During the year ended December 31, 2024, Series B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased">68,335</span>
                                            shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price">18.24</span> per share and the Company received gross
                                            proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds">1.2</span> million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy" title="Number of shares purchased">27,082</span> shares of common
                                            stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1" title="Warrants exercise price">18.24</span> per share and the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob" title="Gross proceeds">0.5</span> million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f" title="Number of shares purchased">4,167</span> shares of
                                            common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg" title="Warrants exercise price">24.00</span> per share and the Company received gross proceeds of
                                            approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b" title="Gross proceeds">0.1</span> million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7" title="Number of shares purchased">47,936</span> shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8" title="Warrants exercise price">18.24</span> per share and the Company
                                            received gross proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg" title="Gross proceeds">0.9</span> million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3" title="Deemed dividend">1.7</span> million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b" title="Number of shares purchased">341,672</span> shares of common stock each were exercised
    at a reduced exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute" title="Warrants exercise price">8.40</span> per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk" title="Gross proceeds">2.8</span> million.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ClassOfWarrantOrRighstIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or righst issuance date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ClassOfWarrantOrRighstIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PrivateWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PrivateWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PublicWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PublicWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_WarrantsToPurchaseRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_WarrantsToPurchaseRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_WarrantsToPurchaseRestrictedSharesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_WarrantsToPurchaseRestrictedSharesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_RepresentativeWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_RepresentativeWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesAWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesAWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesDWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesDWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesEWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesEWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesFWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesFWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesGWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesGWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesHWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesHWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesIWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesIWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Outstanding Warrants (Details) (Parenthetical) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_PublicWarrantRedemptionDescription', window );">Public warrant redemption description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">The
    Company may redeem the outstanding Public Warrants for $0.12 per warrant upon at least 30 days&#8217; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $2,160.00 per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RedemptionOfOutstandingWarrantsPerShare', window );">Redemption of outstanding warrants per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,026,613<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
<td class="nump">58,235<span></span>
</td>
<td class="nump">16,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Received dross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_RedemptionOfWarrantsMember', window );">Redemption of Warrants [Member] | Share Price Equal Or Less Ten Point Zero Rupees Per Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ClassOfWarrantsRedemptionNoticePeriod', window );">Class of warrants, redemption notice period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_RedemptionOfWarrantsMember', window );">Redemption of Warrants [Member] | Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,160,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,335,000<span></span>
</td>
<td class="nump">60,418,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Received dross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,275,000<span></span>
</td>
<td class="nump">68,335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsToPurchaseCommonStockMember', window );">Series B Warrants to Purchase Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">57,451,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBOneWarrantsMember', window );">Series B-1 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,086,000<span></span>
</td>
<td class="nump">27,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesCOneWarrantsMember', window );">Series C-1 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,167,000<span></span>
</td>
<td class="nump">47,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesCOneWarrantsOneMember', window );">Series C-1 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,668,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesDWarrantsMember', window );">Series D Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_Deemeddividend', window );">Deemed dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesEWarrantsAndSeriesFWarrantsMember', window );">Series E Warrants and Series F Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">341,672,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesGPreFundedWarrantsMember', window );">Series G Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesIPreFundedWarrantsMember', window );">Series I Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,528,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Series
                                            B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased">22,275</span> shares of common stock were exercised at a reduced exercise
                                            price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price">24.00</span> in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds">0.5</span> million. During the year ended December 31, 2024, Series B warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased">68,335</span>
                                            shares of common stock were exercised at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price">18.24</span> per share and the Company received gross
                                            proceeds of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds">1.2</span> million.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ClassOfWarrantsRedemptionNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants, redemption notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ClassOfWarrantsRedemptionNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_Deemeddividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_Deemeddividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_PublicWarrantRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public warrant redemption description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_PublicWarrantRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RedemptionOfOutstandingWarrantsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of outstanding warrants per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RedemptionOfOutstandingWarrantsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_RedemptionOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_RedemptionOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_TriggeringEventAxis=CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_TriggeringEventAxis=CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_TriggeringEventAxis=CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_TriggeringEventAxis=CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesBOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesCOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesCOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesCOneWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesCOneWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesEWarrantsAndSeriesFWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesEWarrantsAndSeriesFWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesGPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesGPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesIPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CLDI_SeriesIPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">910,299<span></span>
</td>
<td class="nump">111,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 185.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 9 months 14 days<span></span>
</td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,478,695<span></span>
</td>
<td class="nump">1,176,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,304,930)<span></span>
</td>
<td class="num">(350,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(57,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,026,613<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
<td class="nump">111,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34.97<span></span>
</td>
<td class="nump">$ 185.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 185.16<span></span>
</td>
<td class="nump">$ 1,380.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
<td class="text">4 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid', window );">Number of Warrants, Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185.16<span></span>
</td>
<td class="nump">$ 1,380.00<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options converted to Common Stock In Peroid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option outstanding weighted average remaining contractual terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock, Common Stock and Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2025</div></th>
<th class="th"><div>Aug. 20, 2025</div></th>
<th class="th"><div>Jul. 09, 2025</div></th>
<th class="th"><div>Mar. 28, 2025</div></th>
<th class="th"><div>Feb. 05, 2025</div></th>
<th class="th"><div>Feb. 04, 2025</div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
<th class="th"><div>Nov. 15, 2024</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Oct. 24, 2024</div></th>
<th class="th"><div>Oct. 23, 2024</div></th>
<th class="th"><div>Oct. 11, 2024</div></th>
<th class="th"><div>Sep. 17, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 04, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Jul. 10, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Sep. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,216,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,216,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_CommonStockDividend', window );">Common stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,026,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CLDI_NovaCellMember', window );">Nova Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CLDI_NovaCellMember', window );">Nova Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold and transferred</a></td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Purchase price for repurchased shares</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset', window );">Promissory note, net cash offset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Indebtedness cancellation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CLDI_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_PercentageOfStrategicInvestment', window );">Percentage of strategic investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_MarketOfferingAgreementMember', window );">Market Offering Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_JulyWarrantInducementOfferMember', window );">July Warrant Inducement Offer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
<td class="nump">534,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issued common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares', window );">Issuance of common stock through august public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_CashCommissionPercentage', window );">Cash commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DisbursementsCounsel', window );">Disbursements counsel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issued common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Placement Agency Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares', window );">Issuance of common stock through august public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_CommonStockUnitPerShareDescription', window );">Common stock unit per share description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each
Common Stock Unit consists of (i) one share of common stock of the Company, par value $0.0001, and (ii) one Series I warrant to purchase
one share common stock, and each Pre-Funded Unit consists of (i) one pre-funded warrant to purchase one share common stock, and (ii)
one Series I warrant to purchase one share common stock. Each Common Stock Unit was sold to the public at a price of $2.00 per Common
Stock Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Underwriting Agreement [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares', window );">Issuance of common stock through august public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Underwriting Agreement [Member] | PreFunded Warrant Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares', window );">Issuance of common stock through august public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesBWarrantsAndSeriesCWarrantsMember', window );">Series B Warrants And Series C Warrants [Member] | Inducement Offer Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesBOneWarrantsMember', window );">Series B-1 Warrants [Member] | Inducement Offer Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesCOneWarrantsMember', window );">Series C-1 Warrants [Member] | Inducement Offer Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesCOneWarrantsMember', window );">Series C-1 Warrants [Member] | Inducement Offer Letter Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesDCommonStockMember', window );">Series D Common Stock [Member] | Inducement Offer Letter Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
<td class="nump">6,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Placement Agency Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CLDI_RepresentativeWarrantsMember', window );">Representative Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesECommonWarrantsMember', window );">Series E Common Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesFCommonWarrantsMember', window );">Series F Common Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesGCommonWarrantsMember', window );">Series G Common Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesHCommonStockWarrantsMember', window );">Series H Common Stock Warrants [Member] | July Warrant Inducement Offer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_CashCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_CashCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_CommonStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock dividend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_CommonStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_CommonStockUnitPerShareDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock unit per share description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_CommonStockUnitPerShareDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DisbursementsCounsel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disbursements counsel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DisbursementsCounsel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares through august public offering shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares through august public offering value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_PercentageOfStrategicInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of strategic investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_PercentageOfStrategicInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CLDI_NovaCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=CLDI_NovaCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLDI_NovaCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLDI_NovaCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLDI_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLDI_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_MarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_MarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_JulyWarrantInducementOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_JulyWarrantInducementOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_PlacementAgencyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_PlacementAgencyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CLDI_PreFundedWarrantUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CLDI_PreFundedWarrantUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesBWarrantsAndSeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_SeriesBWarrantsAndSeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_InducementOfferLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_InducementOfferLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesBOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_SeriesBOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesCOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_SeriesCOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_SeriesDCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_SeriesDCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_SubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_SubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CLDI_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CLDI_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesECommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesECommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesFCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesFCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesGCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesGCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesHCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesHCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">$ 1,112.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years), Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited or cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options forfeited or cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.57<span></span>
</td>
<td class="nump">$ 220.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Restricted Stock Unit Activity (Details) - 2023 Plan [Member] - Restricted Stock Units (RSUs) [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Units Outstanding, Beginning | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Balance | $ / shares</a></td>
<td class="nump">$ 13.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Units Outstanding, Vested | shares</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 13.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,108<span></span>
</td>
<td class="nump">$ 2,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StatementOfIncomeLocationBalanceAxis=CLDI_ResearchAndDevelopmentExpensesMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_StatementOfIncomeLocationBalanceAxis=CLDI_GeneralAndAdministrativeExpensesMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StatementOfIncomeLocationBalanceAxis=CLDI_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StatementOfIncomeLocationBalanceAxis=CLDI_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_StatementOfIncomeLocationBalanceAxis=CLDI_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_StatementOfIncomeLocationBalanceAxis=CLDI_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.84%<span></span>
</td>
<td class="nump">85.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>Jul. 10, 2024</div></th>
<th class="th"><div>Aug. 28, 2023</div></th>
<th class="th"><div>Jan. 18, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 09, 2025</div></th>
<th class="th"><div>Sep. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,433,747<span></span>
</td>
<td class="nump">1,029,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-12<span></span>
</td>
<td class="text">1-for-12 reverse stock split<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">1-for-10 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_NoncashCompensation', window );">Noncash compensation charge in connection with repricing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unamortized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="nump">$ 17.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Description of term and exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The exercise price of stock options shall be equal to or greater than the fair market value of common stock on the date the
option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the
grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined
as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee
in any calendar year may not exceed $0.1 million, otherwise it will be classified as a non-qualified stock option.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Descriptiion of options vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">options vest over four years and will be exercisable only while the optionee remains an employee, director or consultant, or during the
three months thereafter, but in the case of the termination of an optionee&#8217;s services due to death or disability, the period for
exercising a vested option shall be extended to the earlier of twelve months after termination or the expiration date of the option.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted approved for repricing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,112.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 853.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted approved for repricing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.57<span></span>
</td>
<td class="nump">$ 220.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member] | Administrator [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CLDI_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_CommonStockDiscounRate', window );">Number of shares issued of common stock at discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_CommonStockDiscounRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_CommonStockDiscounRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_NoncashCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_NoncashCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLDI_AdministratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLDI_AdministratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CLDI_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CLDI_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (20,048)<span></span>
</td>
<td class="num">$ (22,195)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(20,100)<span></span>
</td>
<td class="num">(22,215)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,210)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Computed tax benefit at U.S. federal statutory tax rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal income tax effect</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws', window );">Enactment of new tax laws</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws', window );">Enactment of new tax laws, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount', window );">Effect of cross-border tax laws</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent', window );">Effect of cross-border tax laws, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (299)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract', window );"><strong>Nontaxable or non-deductible items</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Worldwide changes in unrecognized tax benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Worldwide changes in unrecognized tax benefits, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract', window );"><strong>Other</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Deferred tax adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred tax adjustments, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Non-controlling interest, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential', window );">Foreign employee stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential', window );">Foreign employee stock based compensation, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential', window );">Rate differential</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential', window );">Germany Rate differential, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther', window );">Germany Other, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne', window );">Rate differential</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne', window );">Australia Rate differential, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance', window );">Australia Change in valuation allowance, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">US Federal Statutory Tax Rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation acquired startup costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation australia income tax rate differential change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation australia income tax rate differential one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change in fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enactment of new tax laws, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation foreign employee stock based compensation income tax rates differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation germany income tax rate differential other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation germany income tax rates differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation other permanent differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation australia income tax rate differential change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation australia income tax rates differential one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Enactment of new tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation foreign employee stock based compensation income tax rates differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation germany income tax rates differential.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation germany income tax rates differential other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived', window );">Federal taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncomeTaxPaidStateAfterRefundReceived', window );">State and local taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived', window );">Germany</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Total cash paid for income taxes, net of refunds</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived', window );">Germany</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived', window );">Germany</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncomeTaxPaidStateAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax paid state after refund received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncomeTaxPaidStateAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidFederalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidForeignAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidForeignAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 25,920<span></span>
</td>
<td class="nump">$ 20,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based and other compensation</a></td>
<td class="nump">2,355<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures', window );">Capitalized research and development expenditures</a></td>
<td class="nump">3,520<span></span>
</td>
<td class="nump">4,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,315<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued liabilities and other reserves</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">34,695<span></span>
</td>
<td class="nump">30,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets', window );">Right-of-use and other assets</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(830)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(480)<span></span>
</td>
<td class="num">(830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34,215)<span></span>
</td>
<td class="num">(29,402)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax lliabilities right of use assets and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unrecognized Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 1,799<span></span>
</td>
<td class="nump">$ 1,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Adjustments based on tax positions related to prior years</a></td>
<td class="nump">283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 2,364<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash income taxes paid</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits carryforwards</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">2,364<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
<td class="nump">$ 1,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=CLDI_PriorDecemberTwentySeventeenthMember', window );">Prior December 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=CLDI_AfterDecemberTwentySeventeenthMember', window );">After December 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">81,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">89,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits carryforwards</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits carryforwards</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=CLDI_PriorDecemberTwentySeventeenthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=CLDI_PriorDecemberTwentySeventeenthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=CLDI_AfterDecemberTwentySeventeenthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=CLDI_AfterDecemberTwentySeventeenthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from financing leases</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from financing leases</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">$ 2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use lease liabilities, current</a></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use lease liabilities, noncurrent</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation', window );">Machinery and equipment, gross</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="num">(463)<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation', window );">Machinery and equipment, net</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current liabilities</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Operating leases (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Financing leases (in years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">11.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Financing leases</a></td>
<td class="nump">9.05%<span></span>
</td>
<td class="nump">12.13%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of accumulated amortization, depreciation, depletion for physical asset used in normal conduct of business to create and distribute product and service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Lease Commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, 2026</a></td>
<td class="nump">$ 1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Leases, 2027</a></td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating Leases, 2028</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating Leases, 2029</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Operating Leases, 2030 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Leases, Total minimum lease payments</a></td>
<td class="nump">1,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Leases, Less: amounts representing interest</a></td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">$ 3,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Financing Leases, 2026</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Financing Leases, 2027</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Financing Leases, 2028</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Financing Leases, 2029</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour', window );">Financing Leases, 2030 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Financing Leases, Total minimum lease payments</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Financing Leases, Less: amounts representing interest</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 22, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 15, 2024</div></th>
<th class="th">
<div>May 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 12, 2024</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 07, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As
consideration for the Guaranty, the Company agreed to pay Mr. Camaisa 10% of the Guaranty amount for the first year of the San Diego
Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_OperatingLeaseTermOfContractLeaseInitialTerm', window );">Operating lease, term of contract, lease initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent', window );">Lease terms, operating leases annual increase in rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,467,000<span></span>
</td>
<td class="nump">$ 1,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_RemainingExpectedCommitments', window );">Remaining expected commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CLDI_MrCamaisaMember', window );">Mr Camaisa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Deferred compensation equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CLDI_MrLeftwichMember', window );">Mr Leftwich [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Deferred compensation equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_MrLeftwichMember', window );">Mr Leftwich [Member] | Settlement of Deferred Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation and accrued interest amount in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Dr.CamisaMember', window );">Dr. Camisa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_SeparationPay', window );">Separation pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Consulting pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_IncurredCosts', window );">Incurred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Dr.MinevMember', window );">Dr.Minev [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_SeparationPay', window );">Separation pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Bonus payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Ms.CampbellMember', window );">Ms.Campbell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Bonus payable</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_SanDiegoLeaseAgreementMember', window );">San Diego Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_SanDiegoLeaseAgreementMember', window );">San Diego Lease Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_GuarantyOfLeaseAmount', window );">Guaranty of lease, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_MrCamaisaMember', window );">Mr Camaisa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_GuarantyOfLeaseAmount', window );">Guaranty of lease, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_StemVacOfficeLeaseAgreementMember', window );">Stem Vac Office Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_NorthwesternAgreementMember', window );">Northwestern Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Other Commitments, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a non-creditable and non-refundable one-time milestone payment of $0.3 million upon reaching an aggregate of $2.0 million of net sales
of a licensed product; (b) a non-creditable and nonrefundable one-time milestone payment of $0.5 million upon reaching an aggregate of
$10.0 million of net sales of a licensed product; (c) sublicensing royalty of 20% of any sublicensing revenue resulting from the grant
of rights hereunder; and (d) in the event of an assignment or transfer of licensed data, with the consent of Northwestern, a low single
digit percentage of the fair market value of any consideration received. This sublicensing royalty shall be cumulative, meaning it shall
be imposed only once with respect to a single unit of sublicensing revenue, regardless of whether the sublicensing revenue derives from
the CTA, or the June 7, 2021 Northwestern Agreement described above, or both.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_SeparationAndReleaseAgreementMember', window );">Separation and Release Agreement [Member] | George Ng [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Payment to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_CommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Commitment Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CLDI_EquityPurchaseDescription', window );">Equity purchase description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) an amount equal
to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an advance notice, or
(ii) 41,667 shares. For the SEPA to be utilized, the shares underlying the agreement need to be registered on a Form S-1 filed with the
SEC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CLDI_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement [Member] | Common Stock [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_CommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_CommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_EquityPurchaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity purchase description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_EquityPurchaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_GuarantyOfLeaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guaranty of lease amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_GuarantyOfLeaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_IncurredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incurred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_IncurredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease terms operating leases annual increase in rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_OperatingLeaseTermOfContractLeaseInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease term of contract lease initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_OperatingLeaseTermOfContractLeaseInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_RemainingExpectedCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining expected commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_RemainingExpectedCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CLDI_SeparationPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Separation payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CLDI_SeparationPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CLDI_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLDI_MrCamaisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLDI_MrCamaisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CLDI_MrLeftwichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CLDI_MrLeftwichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_MrLeftwichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_MrLeftwichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CLDI_SettlementOfDeferredCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CLDI_SettlementOfDeferredCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Dr.CamisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Dr.CamisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Dr.MinevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Dr.MinevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Ms.CampbellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_Ms.CampbellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_SanDiegoLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_SanDiegoLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_MrCamaisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_MrCamaisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_StemVacOfficeLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_StemVacOfficeLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_NorthwesternAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_NorthwesternAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_SeparationAndReleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_SeparationAndReleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_GeorgeNgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CLDI_GeorgeNgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CLDI_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CLDI_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2026</div></th>
<th class="th"><div>Mar. 05, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Jul. 10, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">2,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member] | Series J Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire year</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member] | Series K Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire year</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement [Member] | Series L Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire year</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member] | Series G Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.3448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member] | Series G Common Stock Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member] | Series H Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member] | Series H Common Stock Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member] | Series I Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Purchase Warrants Agreement [Member] | Series I Common Stock Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock Units [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance and sale of shares</a></td>
<td class="nump">2,278,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares purchased</a></td>
<td class="nump">1,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Over-Allotment Option [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares price sold</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | PreFunded Warrant Units [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance and sale of shares</a></td>
<td class="nump">9,815,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares price sold</a></td>
<td class="nump">$ 0.499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriters Warrant [Member] | Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">604,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">warrants exercise price</a></td>
<td class="nump">$ 0.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized', window );">Warrant expire date</a></td>
<td class="text">March 9, 2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of expense or revenue offset related to the warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesJWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesJWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesKWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesKWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesLWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesLWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CLDI_CommonStockPurchaseWarrantsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CLDI_CommonStockPurchaseWarrantsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesGCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesGCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesHCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesHCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CLDI_SeriesICommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CLDI_SeriesICommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CLDI_CommonStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CLDI_CommonStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CLDI_PreFundedWarrantUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CLDI_PreFundedWarrantUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CLDI_UnderwritersWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CLDI_UnderwritersWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>480</ContextCount>
  <ElementCount>522</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>172</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement -  Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName> Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Total Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/StatementsOfTotalEquity</Role>
      <ShortName>Consolidated Statements of Total Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/OrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Selected Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SelectedBalanceSheetComponents</Role>
      <ShortName>Selected Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Machinery and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/MachineryAndEquipmentNet</Role>
      <ShortName>Machinery and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://calidibio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Selected Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SelectedBalanceSheetComponentsTables</Role>
      <ShortName>Selected Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/SelectedBalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Machinery and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/MachineryAndEquipmentNetTables</Role>
      <ShortName>Machinery and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/MachineryAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/Stock-basedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://calidibio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Organization and Nature of Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative</Role>
      <ShortName>Organization and Nature of Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/OrganizationAndNatureOfOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails</Role>
      <ShortName>Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Schedule of Operating Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfOperatingSegmentDetails</Role>
      <ShortName>Schedule of Operating Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails</Role>
      <ShortName>Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Schedule of Machinery and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails</Role>
      <ShortName>Schedule of Machinery and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Machinery and Equipment, net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative</Role>
      <ShortName>Machinery and Equipment, net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/MachineryAndEquipmentNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Schedule of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails</Role>
      <ShortName>Schedule of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Schedule of Related Party Transactions (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical</Role>
      <ShortName>Schedule of Related Party Transactions (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Schedule of Outstanding Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails</Role>
      <ShortName>Schedule of Outstanding Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Maturities of Outstanding Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails</Role>
      <ShortName>Schedule of Maturities of Outstanding Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/DebtTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Schedule of Common Stock Reserved (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfCommonStockReservedDetails</Role>
      <ShortName>Schedule of Common Stock Reserved (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails</Role>
      <ShortName>Schedule of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Schedule of Outstanding Warrants (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical</Role>
      <ShortName>Schedule of Outstanding Warrants (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Schedule of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>Schedule of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative</Role>
      <ShortName>Convertible Preferred Stock, Common Stock and Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Schedule of Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Schedule of Income (Loss) Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails</Role>
      <ShortName>Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Schedule of Reconciliation of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails</Role>
      <ShortName>Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Schedule of Unrecognized Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails</Role>
      <ShortName>Schedule of Unrecognized Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Future Minimum Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Schedule of Future Minimum Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://calidibio.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://calidibio.com/role/SubsequentEvents</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cldi-20251231.xsd</File>
    <File>cldi-20251231_cal.xml</File>
    <File>cldi-20251231_def.xml</File>
    <File>cldi-20251231_lab.xml</File>
    <File>cldi-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="1193">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "CLDI",
   "nsuri": "http://calidibio.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "cldi-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cldi-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cldi-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cldi-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cldi-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 395,
   "keyCustom": 127,
   "axisStandard": 25,
   "axisCustom": 2,
   "memberStandard": 32,
   "memberCustom": 128,
   "hidden": {
    "total": 281,
    "http://calidibio.com/20251231": 118,
    "http://fasb.org/us-gaap/2025": 160,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 480,
   "entityCount": 1,
   "segmentCount": 172,
   "elementCount": 929,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1193,
    "http://xbrl.sec.gov/dei/2025": 44,
    "http://xbrl.sec.gov/cyd/2025": 10,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://calidibio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://calidibio.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://calidibio.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://calidibio.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "00000005 - Statement -  Consolidated Statements of Comprehensive Loss",
     "shortName": " Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://calidibio.com/role/StatementsOfTotalEquity",
     "longName": "00000006 - Statement - Consolidated Statements of Total Equity",
     "shortName": "Consolidated Statements of Total Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://calidibio.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:NoInsiderTradingFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://calidibio.com/role/OrganizationAndNatureOfOperations",
     "longName": "999015 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://calidibio.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999016 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://calidibio.com/role/FairValueMeasurements",
     "longName": "999017 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://calidibio.com/role/SelectedBalanceSheetComponents",
     "longName": "999018 - Disclosure - Selected Balance Sheet Components",
     "shortName": "Selected Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://calidibio.com/role/MachineryAndEquipmentNet",
     "longName": "999019 - Disclosure - Machinery and Equipment, net",
     "shortName": "Machinery and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://calidibio.com/role/RelatedPartyTransactions",
     "longName": "999020 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://calidibio.com/role/Debt",
     "longName": "999021 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity",
     "longName": "999022 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://calidibio.com/role/Stock-basedCompensation",
     "longName": "999023 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://calidibio.com/role/IncomeTaxes",
     "longName": "999024 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://calidibio.com/role/CommitmentsAndContingencies",
     "longName": "999025 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://calidibio.com/role/SubsequentEvents",
     "longName": "999026 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999027 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://calidibio.com/role/FairValueMeasurementsTables",
     "longName": "999029 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://calidibio.com/role/SelectedBalanceSheetComponentsTables",
     "longName": "999030 - Disclosure - Selected Balance Sheet Components (Tables)",
     "shortName": "Selected Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://calidibio.com/role/MachineryAndEquipmentNetTables",
     "longName": "999031 - Disclosure - Machinery and Equipment, net (Tables)",
     "shortName": "Machinery and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://calidibio.com/role/RelatedPartyTransactionsTables",
     "longName": "999032 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://calidibio.com/role/DebtTables",
     "longName": "999033 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables",
     "longName": "999034 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity (Tables)",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://calidibio.com/role/Stock-basedCompensationTables",
     "longName": "999035 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://calidibio.com/role/IncomeTaxesTables",
     "longName": "999036 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://calidibio.com/role/CommitmentsAndContingenciesTables",
     "longName": "999037 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
     "longName": "999038 - Disclosure - Organization and Nature of Operations (Details Narrative)",
     "shortName": "Organization and Nature of Operations (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-08-042025-08-04",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails",
     "longName": "999039 - Disclosure - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails",
     "longName": "999040 - Disclosure - Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)",
     "shortName": "Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails",
     "longName": "999041 - Disclosure - Schedule of Operating Segment (Details)",
     "shortName": "Schedule of Operating Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CLDI:GovernmentGrantsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:GrantsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "CLDI:GovernmentGrantsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "999043 - Disclosure - Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails",
     "longName": "999044 - Disclosure - Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)",
     "shortName": "Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "999045 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "CLDI:AccruedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "CLDI:AccruedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "999046 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "CLDI:PrepaidExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "CLDI:PrepaidExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails",
     "longName": "999047 - Disclosure - Schedule of Machinery and Equipment, Net (Details)",
     "shortName": "Schedule of Machinery and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative",
     "longName": "999048 - Disclosure - Machinery and Equipment, net (Details Narrative)",
     "shortName": "Machinery and Equipment, net (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
     "longName": "999049 - Disclosure - Schedule of Related Party Transactions (Details)",
     "shortName": "Schedule of Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_DirectorAAndDirectorEMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_DirectorAAndDirectorEMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
     "longName": "999050 - Disclosure - Schedule of Related Party Transactions (Details) (Parenthetical)",
     "shortName": "Schedule of Related Party Transactions (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "CLDI:ScheduleOfOutstandingWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_DirectorsAAndEMember",
      "name": "us-gaap:NotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails",
     "longName": "999051 - Disclosure - Schedule of Outstanding Debt Obligations (Details)",
     "shortName": "Schedule of Outstanding Debt Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails",
     "longName": "999052 - Disclosure - Schedule of Maturities of Outstanding Debt (Details)",
     "shortName": "Schedule of Maturities of Outstanding Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://calidibio.com/role/DebtDetailsNarrative",
     "longName": "999053 - Disclosure - Debt (Details Narrative)",
     "shortName": "Debt (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
     "longName": "999054 - Disclosure - Schedule of Common Stock Reserved (Details)",
     "shortName": "Schedule of Common Stock Reserved (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
     "longName": "999055 - Disclosure - Schedule of Outstanding Warrants (Details)",
     "shortName": "Schedule of Outstanding Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "CLDI:ScheduleOfOutstandingWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfOutstandingWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical",
     "longName": "999056 - Disclosure - Schedule of Outstanding Warrants (Details) (Parenthetical)",
     "shortName": "Schedule of Outstanding Warrants (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:PublicWarrantRedemptionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfOutstandingWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:PublicWarrantRedemptionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfOutstandingWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://calidibio.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "999057 - Disclosure - Schedule of Warrant Activity (Details)",
     "shortName": "Schedule of Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_WarrantMember11030265",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_us-gaap_WarrantMember11030281",
      "name": "CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
     "longName": "999058 - Disclosure - Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "CLDI:CommonStockDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://calidibio.com/role/SummaryOfStockOptionActivityDetails",
     "longName": "999059 - Disclosure - Summary of Stock Option Activity (Details)",
     "shortName": "Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2023-01-182023-01-18_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
     "longName": "999060 - Disclosure - Summary of Restricted Stock Unit Activity (Details)",
     "shortName": "Summary of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999061 - Disclosure - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails",
     "longName": "999062 - Disclosure - Schedule of Stock Options Valuation Assumptions (Details)",
     "shortName": "Schedule of Stock Options Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999063 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:NoncashCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
     "longName": "999064 - Disclosure - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "shortName": "Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-12-31_srt_AmericasMember",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails",
     "longName": "999065 - Disclosure - Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)",
     "shortName": "Schedule of Income Tax Expenses (Benefit) by Jurisdiction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails",
     "longName": "999066 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)",
     "shortName": "Schedule of Reconciliation of Income Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails",
     "longName": "999067 - Disclosure - Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)",
     "shortName": "Schedule of Cash Paid for Income Taxes, Net of Refunds Received (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:IncomeTaxPaidStateAfterRefundReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfIncomeTaxPaidTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "CLDI:IncomeTaxPaidStateAfterRefundReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfIncomeTaxPaidTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999068 - Disclosure - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails",
     "longName": "999069 - Disclosure - Schedule of Unrecognized Tax Benefit (Details)",
     "shortName": "Schedule of Unrecognized Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://calidibio.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999070 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails",
     "longName": "999071 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)",
     "shortName": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails",
     "longName": "999072 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)",
     "shortName": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CLDI:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails",
     "longName": "999073 - Disclosure - Schedule of Future Minimum Lease Commitments (Details)",
     "shortName": "Schedule of Future Minimum Lease Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999074 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2022-10-102022-10-10",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-102022-10-10",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://calidibio.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999075 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-06_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "CLDI_AJCCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AJCCapitalMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AJC Capital [Member]",
        "documentation": "AJC Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "AU",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountingPoliciesTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses related to services",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r901"
     ]
    },
    "CLDI_AccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AccruedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Accrued compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus payable",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "CLDI_AccruedVendorAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AccruedVendorAndOtherExpenses",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued vendor and other expenses",
        "documentation": "Accrued vendor and other expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r188",
      "r693"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r549",
      "r550",
      "r551",
      "r552",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss, net of tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r77",
      "r196",
      "r687",
      "r711",
      "r712",
      "r1165"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r549",
      "r550",
      "r551",
      "r552",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r20",
      "r544",
      "r547",
      "r615",
      "r707",
      "r708",
      "r1067",
      "r1068",
      "r1069",
      "r1092",
      "r1093",
      "r1094",
      "r1095"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r901",
      "r1234"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1166",
      "r1240"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "CLDI_AdjustmentsToAdditionalPaidInCapitalFinancingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalFinancingFees",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing fees",
        "documentation": "Financing fees."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted stock units for liability settlement",
        "documentation": "Issuance of restricted stock units for liability settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_AdministratorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AdministratorMember",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administrator [Member]",
        "documentation": "Administrator [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_AfterDecemberTwentySeventeenthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "AfterDecemberTwentySeventeenthMember",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After December 2017 [Member]",
        "documentation": "After December 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r981",
      "r1008"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r984",
      "r1011"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1003",
      "r1012",
      "r1016",
      "r1024"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r470",
      "r471"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "AmericasMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Americas [Member]",
        "documentation": "Continents of North and South America."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1242",
      "r1243",
      "r1244",
      "r1245"
     ]
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount and financing costs",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r84",
      "r356",
      "r1180"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total common stock equivalents",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r130",
      "r190",
      "r221",
      "r224",
      "r225",
      "r261",
      "r272",
      "r285",
      "r288",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r528",
      "r532",
      "r582",
      "r673",
      "r674",
      "r681",
      "r769",
      "r862",
      "r863",
      "r873",
      "r901",
      "r912",
      "r914",
      "r926",
      "r1114",
      "r1115",
      "r1188"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r197",
      "r221",
      "r224",
      "r225",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r528",
      "r532",
      "r582",
      "r901",
      "r1114",
      "r1115",
      "r1188"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets, at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r892"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r940",
      "r963"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r940",
      "r963"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r940",
      "r963"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "CLDI_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors [Member]",
        "documentation": "Board of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_BridgeLoanPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "BridgeLoanPayableMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Loan Payable [Member]",
        "documentation": "Bridge Loan Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_CaliforniaInstituteForRegenerativeMedicineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CaliforniaInstituteForRegenerativeMedicineMember",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Institute For Regenerative Medicine [Member]",
        "documentation": "California Institute For Regenerative Medicine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r685",
      "r740",
      "r764",
      "r901",
      "r912",
      "r914",
      "r926",
      "r1062"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r115"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails",
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "At beginning of the year",
        "periodEndLabel": "At end of the year",
        "totalLabel": "Total cash and restricted cash as shown in the consolidated statements of cash flows",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r89",
      "r218"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND RESTRICTED CASH BALANCE:"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_CashCommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CashCommissionPercentage",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash commission percentage",
        "documentation": "Cash commission percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_CashPaidForIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CashPaidForIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Cash paid for income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of other liabilities and derivatives",
        "documentation": "Change in fair value of debt, other liabilities, and derivatives.",
        "label": "ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ChangeInFairValueOfOtherLiabilitiesAndDerivatives",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of other liabilities and derivatives",
        "documentation": "Change in fair value of other liabilities and derivatives."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of other liabilities and derivatives",
        "documentation": "Change in fair value of other liabilities and derivatives.",
        "label": "ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of other liabilities and derivatives \u2013 related party",
        "documentation": "Change in fair value of other liabilities and derivatives \u2013 related party.",
        "label": "ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r193",
      "r194",
      "r195",
      "r221",
      "r225",
      "r251",
      "r252",
      "r255",
      "r257",
      "r264",
      "r265",
      "r298",
      "r323",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r365",
      "r366",
      "r368",
      "r369",
      "r371",
      "r373",
      "r376",
      "r377",
      "r380",
      "r383",
      "r390",
      "r582",
      "r717",
      "r718",
      "r719",
      "r720",
      "r728",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r756",
      "r777",
      "r799",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r1045",
      "r1083",
      "r1085",
      "r1096"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r264",
      "r368",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r388",
      "r390",
      "r540",
      "r717",
      "r718",
      "r719",
      "r720",
      "r874",
      "r1045",
      "r1081",
      "r1083"
     ]
    },
    "CLDI_ClassOfWarrantOrRighstIssuanceDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ClassOfWarrantOrRighstIssuanceDate",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance date",
        "documentation": "Class of warrant or righst issuance date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrants exercise price",
        "terseLabel": "warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r227",
      "r391"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExpenseOrRevenueRecognized",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expire date",
        "documentation": "Description of expense or revenue offset related to the warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants",
        "verboseLabel": "Total",
        "terseLabel": "Number of shares purchased",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "verboseLabel": "Purchase of warrants",
        "terseLabel": "Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "CLDI_ClassOfWarrantsRedemptionNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ClassOfWarrantsRedemptionNoticePeriod",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrants, redemption notice period",
        "documentation": "Class of warrants, redemption notice period."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ClinicalResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ClinicalResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Clinical &amp; research and development",
        "documentation": "Clinical research and development",
        "label": "ClinicalResearchAndDevelopment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "CLDI_CommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommitmentFeePercentage",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fee percentage",
        "documentation": "Commitment fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r122",
      "r684",
      "r755"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r309",
      "r310",
      "r828",
      "r1106",
      "r1111"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future issuance",
        "verboseLabel": "Number of shares reserved",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "CLDI_CommonStockDiscounRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommonStockDiscounRate",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued of common stock at discount rate",
        "documentation": "Common stock discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_CommonStockDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommonStockDividend",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividend",
        "documentation": "Common stock dividend."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/StatementsOfTotalEquity",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r918",
      "r920",
      "r921",
      "r922",
      "r923",
      "r1092",
      "r1093",
      "r1095",
      "r1166",
      "r1232",
      "r1240"
     ]
    },
    "CLDI_CommonStockOptionsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommonStockOptionsIssuedAndOutstandingMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Options Issued and Outstanding [Member]",
        "documentation": "Common Stock Options Issued and Outstanding [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://calidibio.com/role/BalanceSheetsParenthetical",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value per share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "CLDI_CommonStockPurchaseWarrantsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommonStockPurchaseWarrantsAgreementMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Purchase Warrants Agreement [Member]",
        "documentation": "Common Stock Purchase Warrants Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://calidibio.com/role/BalanceSheetsParenthetical",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r756"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://calidibio.com/role/BalanceSheetsParenthetical",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, share issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://calidibio.com/role/BalanceSheetsParenthetical",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r756",
      "r775",
      "r1240",
      "r1241"
     ]
    },
    "CLDI_CommonStockUnitPerShareDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommonStockUnitPerShareDescription",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock unit per share description",
        "documentation": "Common stock unit per share description."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_CommonStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CommonStockUnitsMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Units [Member]",
        "documentation": "Common Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value, 330,000 shares authorized; 7,217 and 1,730 shares issued and outstanding as of December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r366",
      "r372",
      "r686",
      "r901"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "CLDI_CompanyARelatedToDirectorGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "CompanyARelatedToDirectorGMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company A related to Director G [Member]",
        "documentation": "Company A Related To Director G [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r110"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "COMPREHENSIVE LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r199",
      "r201",
      "r208",
      "r671",
      "r700",
      "r702"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss attributable to noncontrolling interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r50",
      "r54",
      "r199",
      "r201",
      "r207",
      "r670",
      "r700",
      "r701"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "COMPREHENSIVE LOSS",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r113",
      "r199",
      "r201",
      "r206",
      "r669",
      "r700"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r221",
      "r222",
      "r229",
      "r231",
      "r261",
      "r273",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r677",
      "r862",
      "r863",
      "r1057",
      "r1058",
      "r1114",
      "r1115"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r145",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r221",
      "r222",
      "r229",
      "r231",
      "r261",
      "r273",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r677",
      "r862",
      "r863",
      "r1057",
      "r1058",
      "r1114",
      "r1115"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r852"
     ]
    },
    "CLDI_Consulting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "Consulting",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Consulting",
        "documentation": "Consulting",
        "label": "Consulting"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ConsultingPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ConsultingPay",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting pay",
        "documentation": "Consulting payments."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ContingentlyIssuableWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ContingentlyIssuableWarrantMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingently Issuable Warrant [Member]",
        "documentation": "Contingently Issuable Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Lease Commitments",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r117"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1081",
      "r1087",
      "r1159"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1081",
      "r1087"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r1081",
      "r1087"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and local",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1081",
      "r1087",
      "r1159"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1039"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1030"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r1031"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1032"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1034"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1034"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1033"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "DE",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r221",
      "r223",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r321",
      "r322",
      "r334",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r350",
      "r357",
      "r358",
      "r359",
      "r540",
      "r592"
     ]
    },
    "CLDI_DebtDiscountOnConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DebtDiscountOnConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount on Convertible Notes",
        "documentation": "Debt discount on convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt principal and accrued interest",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r59",
      "r60",
      "r117",
      "r121",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r899",
      "r1081",
      "r1082",
      "r1084",
      "r1091",
      "r1107",
      "r1108",
      "r1109",
      "r1179",
      "r1181",
      "r1199"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Carrying Value",
        "totalLabel": "Total debt",
        "verboseLabel": "Accrued interest",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r121",
      "r360"
     ]
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indebtedness cancellation amount",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1084"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid Balance",
        "verboseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r592",
      "r593",
      "r869",
      "r870",
      "r899"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest",
        "verboseLabel": "Carrying value, including accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1084"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Officer loans payable",
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r336"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r899",
      "r1081",
      "r1082",
      "r1084",
      "r1091",
      "r1107",
      "r1108",
      "r1109",
      "r1179",
      "r1181",
      "r1199"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Installment payable",
        "verboseLabel": "Consulting pay",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r56"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity period",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average interest rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DeemedDividendOnWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DeemedDividendOnWarrants",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend on warrants",
        "negatedLabel": "Deemed dividend on warrants",
        "documentation": "Deemed dividend on warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_Deemeddividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "Deemeddividend",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend",
        "documentation": "Deemed dividend."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationEquity",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation equity",
        "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r74"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r104"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation and accrued interest amount in cash",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/SelectedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1087",
      "r1158",
      "r1159"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1087",
      "r1158"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r141",
      "r1081",
      "r1087"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r118",
      "r500"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State and local",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1087",
      "r1158",
      "r1159"
     ]
    },
    "CLDI_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development expenditures",
        "documentation": "Deferred tax assets capitalized research and development expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DeferredTaxAssetsDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "Deferred tax assets depreciation and amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "CLDI_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit carryforwards",
        "verboseLabel": "Research and development credits carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based and other compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities and other reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "CLDI_DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use and other assets",
        "documentation": "Deferred tax lliabilities right of use assets and other assets.",
        "label": "DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r32",
      "r211",
      "r845",
      "r846",
      "r848",
      "r850"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r32"
     ]
    },
    "us-gaap_DerivativeAssetCollateralObligationToReturnCashOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAssetCollateralObligationToReturnCashOffset",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note, net cash offset",
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements offset against derivative assets."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r1066",
      "r1164"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r230",
      "r247",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r541",
      "r542"
     ]
    },
    "CLDI_DirectorAAndDirectorEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorAAndDirectorEMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director A and Director E [Member]",
        "documentation": "Director A and Director E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorAMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director A [Member]",
        "documentation": "Director A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorAOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorAOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director A One [Member]",
        "documentation": "Director A One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorAThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorAThreeMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director A Three [Member]",
        "documentation": "Director A Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorATwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorATwoMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director A Two [Member]",
        "documentation": "Director A Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorDMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director D [Member]",
        "documentation": "Director D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorFAndDirectorAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorFAndDirectorAMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director F and Director A [Member]",
        "documentation": "Director F and Director A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorFAndRelativeOfOfficerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorFAndRelativeOfOfficerAMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director F and Relative of Officer A [Member]",
        "documentation": "Director F and Relative of Officer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorFMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorFMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director F [Member]",
        "documentation": "Director F [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorFOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorFOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director F One [Member]",
        "documentation": "Director F One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DirectorsAAndEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DirectorsAAndEMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors A and E [Member]",
        "documentation": "Directors A And E [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DisbursementsCounsel": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DisbursementsCounsel",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disbursements counsel",
        "documentation": "Disbursements counsel."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_DiscloserOFCommonStockReservedForFurtureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "DiscloserOFCommonStockReservedForFurtureTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Reserved",
        "documentation": "Discloser of Common Stock Reserved for Furture [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r436",
      "r465",
      "r466",
      "r468",
      "r883"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r940",
      "r963"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r940",
      "r963",
      "r1004"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "CLDI_Dr.CamisaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "Dr.CamisaMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Camisa [Member]",
        "documentation": "Dr. Camisa [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_Dr.MinevMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "Dr.MinevMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr.Minev [Member]",
        "documentation": "Dr.Minev [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r209",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r248",
      "r251",
      "r255",
      "r256",
      "r257",
      "r260",
      "r364",
      "r469",
      "r522",
      "r525",
      "r555",
      "r556",
      "r672",
      "r703",
      "r853"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r209",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r251",
      "r255",
      "r256",
      "r257",
      "r260",
      "r364",
      "r469",
      "r522",
      "r525",
      "r555",
      "r556",
      "r672",
      "r703",
      "r853"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share of Common Stock",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r259"
     ]
    },
    "CLDI_EarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EarnoutSharesMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Shares [Member]",
        "documentation": "Earnout Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "US Federal Statutory Tax Rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r885"
     ]
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "documentation": "Effective income tax rate reconciliation acquired startup costs.",
        "label": "EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computed tax benefit at U.S. federal statutory tax rate, percentage",
        "verboseLabel": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r226",
      "r481",
      "r512",
      "r885"
     ]
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia Change in valuation allowance, percentage",
        "documentation": "Effective income tax rate reconciliation australia income tax rate differential change in valuation allowance."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia Rate differential, percentage",
        "documentation": "Effective income tax rate reconciliation australia income tax rate differential one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r885",
      "r1081",
      "r1088",
      "r1150"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax adjustments, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r885",
      "r1081",
      "r1088",
      "r1150"
     ]
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "documentation": "Effective income tax rate reconciliation change in fair value of debt.",
        "label": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of cross-border tax laws",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r489"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of cross-border tax laws, percentage",
        "documentation": "Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r489"
     ]
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws": {
     "xbrltype": "pureItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enactment of new tax laws, percentage",
        "documentation": "Enactment of new tax laws, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign employee stock based compensation, percentage",
        "documentation": "Effective income tax rate reconciliation foreign employee stock based compensation income tax rates differential."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany Other, percentage",
        "documentation": "Effective income tax rate reconciliation germany income tax rate differential other."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany Rate differential, percentage",
        "documentation": "Effective income tax rate reconciliation germany income tax rates differential."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r885"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interest, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1088",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1081",
      "r1088",
      "r1150",
      "r1152"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1081",
      "r1088",
      "r1150",
      "r1152"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1081",
      "r1088",
      "r1150",
      "r1151"
     ]
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "documentation": "Effective income tax rate reconciliation other permanent differences",
        "label": "EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Federal Statutory Tax Rate, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r885",
      "r1081",
      "r1088",
      "r1150"
     ]
    },
    "CLDI_EffectiveIncomeTaxRateReconciliationStockIssuanceCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationStockIssuanceCost",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal Statutory Tax Rate, percentage",
        "documentation": "Effective income tax rate reconciliation stock issuance cost.",
        "label": "EffectiveIncomeTaxRateReconciliationStockIssuanceCost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r885"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "US Federal Statutory Tax Rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489",
      "r1081",
      "r1088",
      "r1150"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Worldwide changes in unrecognized tax benefits, percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1088",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated weighted average life",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total unamortized stock-based compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "CLDI_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails",
      "http://calidibio.com/role/StatementsOfTotalEquity",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r179",
      "r181",
      "r182",
      "r203",
      "r204",
      "r205",
      "r232",
      "r233",
      "r234",
      "r236",
      "r243",
      "r245",
      "r247",
      "r263",
      "r299",
      "r300",
      "r301",
      "r363",
      "r392",
      "r469",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r596",
      "r615",
      "r699",
      "r707",
      "r708",
      "r709",
      "r728",
      "r799"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r518",
      "r582",
      "r1046",
      "r1047",
      "r1048",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r582"
     ]
    },
    "CLDI_EquityPurchaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "EquityPurchaseDescription",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity purchase description",
        "documentation": "Equity purchase description."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r967",
      "r981",
      "r1008"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r964",
      "r978",
      "r1005"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r1167",
      "r1168",
      "r1173"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r573",
      "r842",
      "r893",
      "r898"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://calidibio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Fair Value of Level 3 Valued Instruments",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r568",
      "r573",
      "r893"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r573",
      "r842",
      "r893",
      "r898"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r581",
      "r842",
      "r898",
      "r1176",
      "r1177"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r413",
      "r414",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r571",
      "r572",
      "r574",
      "r579",
      "r627",
      "r628",
      "r629",
      "r842",
      "r869",
      "r870",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r892",
      "r894",
      "r898"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r573"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://calidibio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r567",
      "r569",
      "r570",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r668",
      "r892",
      "r895"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r402",
      "r407",
      "r413",
      "r559",
      "r572",
      "r579",
      "r627",
      "r842",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r892",
      "r898"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r402",
      "r407",
      "r413",
      "r415",
      "r559",
      "r560",
      "r572",
      "r579",
      "r628",
      "r842",
      "r869",
      "r870",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r892",
      "r898"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r413",
      "r414",
      "r559",
      "r560",
      "r561",
      "r562",
      "r572",
      "r579",
      "r629",
      "r842",
      "r869",
      "r870",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r892",
      "r894",
      "r898"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r573"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1174"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning",
        "periodEndLabel": "Balance, ending",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r573",
      "r893"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r413",
      "r414",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r571",
      "r572",
      "r574",
      "r579",
      "r627",
      "r628",
      "r629",
      "r842",
      "r869",
      "r870",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r892",
      "r894",
      "r898"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r680"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from financing leases",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r604"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financing lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r607"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability, current",
        "verboseLabel": "Current liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liability, noncurrent",
        "verboseLabel": "Noncurrent liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financing Leases, Total minimum lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "CLDI_FinanceLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Leases, 2030 and thereafter",
        "documentation": "Finance lease liability payments due after year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Leases, 2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Leases, 2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Leases, 2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Leases, 2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing Leases, Less: amounts representing interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing cash flows from financing leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r604"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r900"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term, Financing leases (in years)",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r900"
     ]
    },
    "CLDI_FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing fees included in accounts payable and accrued liabilities",
        "documentation": "Financing fees included in accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gains and Losses",
        "documentation": "Foreign Currency Transaction Gains And Losses [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation Adjustments and Other Comprehensive Income or Loss",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1012"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1012"
     ]
    },
    "CLDI_ForwardPurchaseAgreementDerivativeAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ForwardPurchaseAgreementDerivativeAssetMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Purchase Agreement Derivative Asset [Member]",
        "documentation": "Forward Purchase Agreement Derivative Asset [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of investment in Nova Cell",
        "negatedLabel": "Gain on sale of investment in Nova Cell",
        "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1078",
      "r1198"
     ]
    },
    "CLDI_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Member]",
        "documentation": "General and Administrative Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance",
        "label": "General Insurance Expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "CLDI_GeorgeNgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GeorgeNgMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "George Ng [Member]",
        "documentation": "George Ng [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_GovernmentGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GovernmentGrantsMember",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Grants [Member]",
        "documentation": "Government Grants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_GovernmentGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GovernmentGrantsPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Grants",
        "documentation": "Government Grants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_GrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GrantIncome",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income",
        "documentation": "Grant income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Grant income",
        "label": "Grants Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "CLDI_GrantsReceivableWithdrawn": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GrantsReceivableWithdrawn",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government grants award withdrawn",
        "documentation": "Grants receivable withdrawn."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320"
     ]
    },
    "CLDI_GuarantyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GuarantyMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guaranty [Member]",
        "documentation": "Guaranty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_GuarantyOfLeaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "GuarantyOfLeaseAmount",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guaranty of lease amount",
        "verboseLabel": "Guaranty of lease, value",
        "documentation": "Guaranty of lease amount."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r940",
      "r963"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r96"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r126",
      "r129",
      "r673",
      "r675",
      "r695",
      "r847",
      "r849",
      "r851",
      "r859",
      "r862",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r481",
      "r482",
      "r493",
      "r506",
      "r885",
      "r1155"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r481",
      "r482",
      "r493",
      "r506",
      "r885",
      "r1155"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r226",
      "r475",
      "r481",
      "r490",
      "r491",
      "r492",
      "r497",
      "r504",
      "r513",
      "r515",
      "r516",
      "r517",
      "r679",
      "r714",
      "r722",
      "r885"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 10.0
      },
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeTaxExpensesBenefitByJurisdictionDetails",
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails",
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax provision",
        "totalLabel": "Total tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r142",
      "r221",
      "r246",
      "r247",
      "r261",
      "r275",
      "r288",
      "r480",
      "r481",
      "r514",
      "r704",
      "r847",
      "r849",
      "r851",
      "r885"
     ]
    },
    "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidFederalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal taxes",
        "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r505"
     ]
    },
    "us-gaap_IncomeTaxPaidForeignAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidForeignAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany",
        "documentation": "Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r505"
     ]
    },
    "CLDI_IncomeTaxPaidStateAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxPaidStateAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and local taxes",
        "documentation": "Income tax paid state after refund received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r478",
      "r479",
      "r497",
      "r498",
      "r503",
      "r508",
      "r716"
     ]
    },
    "CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "documentation": "Income tax reconciliation australia income tax rate differential change in valuation allowance.",
        "label": "IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Rate differential",
        "documentation": "Income tax reconciliation australia income tax rates differential one.",
        "label": "IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r885",
      "r1150"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r481",
      "r485",
      "r885"
     ]
    },
    "CLDI_IncomeTaxReconciliationEnactmentOfNewTaxLaws": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxReconciliationEnactmentOfNewTaxLaws",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enactment of new tax laws",
        "documentation": "Enactment of new tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign employee stock based compensation",
        "documentation": "Income tax reconciliation foreign employee stock based compensation income tax rates differential."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate differential",
        "documentation": "Income tax reconciliation germany income tax rates differential."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "documentation": "Income tax reconciliation germany income tax rates differential other.",
        "label": "IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Federal statutory tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r885"
     ]
    },
    "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-controlling interest",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAbstract",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontaxable or non-deductible items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1150",
      "r1152"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1150",
      "r1152"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherReconcilingItemsAbstract",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax, net of federal income tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r885",
      "r1150"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r489",
      "r1150"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Worldwide changes in unrecognized tax benefits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash paid for income taxes, net of refunds",
        "label": "Cash income taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r217",
      "r505",
      "r506"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1077"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "CLDI_IncurredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IncurredCosts",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred costs",
        "documentation": "Incurred costs."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r985",
      "r1003",
      "r1012",
      "r1016",
      "r1024"
     ]
    },
    "CLDI_InducementOfferLetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "InducementOfferLetterAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Offer Letter Agreement [Member]",
        "documentation": "Inducement Offer Letter Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1028"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1028"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1028"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r354",
      "r362",
      "r871",
      "r872",
      "r1237"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r847",
      "r851",
      "r1073"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r215",
      "r216"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus: accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1200"
     ]
    },
    "CLDI_InvestorAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "InvestorAndDirectorMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor and Director [Member]",
        "documentation": "Investor and Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonSharesThroughAugustPublicOfferingShares",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through August Public Offering, shares",
        "verboseLabel": "Issuance of common stock through august public offering, shares",
        "documentation": "Issuance of common shares through august public offering shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonSharesThroughAugustPublicOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonSharesThroughAugustPublicOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds",
        "documentation": "Issuance of common shares through august public offering value.",
        "label": "IssuanceOfCommonSharesThroughAugustPublicOfferingValue"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockAndWarrantsForLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockAndWarrantsForLegalSettlement",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock and warrants for legal settlement",
        "documentation": "Issuance of common stock and warrants for legal settlement.",
        "label": "IssuanceOfCommonStockAndWarrantsForLegalSettlement"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs",
        "documentation": "Issuance of common stock and warrants for march registered direct offering and concurrent private placement net of financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs, shares",
        "documentation": "Issuance of common stock and warrants for march registered direct offering and concurrent private placement net of financing costs shares"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs",
        "documentation": "Issuance of common stock and warrants through january confidentially marketed public offering net of financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs, shares",
        "documentation": "Issuance of common stock and warrants through january confidentially marketed public offering net of financing costs shares"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in lieu of cash for SEPA commitment fee",
        "documentation": "Issuance of common stock in lieu of cash for SEPA commitment fee.",
        "label": "IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockInLieuOfCashForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockInLieuOfCashForServices",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in lieu of cash for services",
        "documentation": "Issuance of common stock in lieu of cash for services",
        "label": "IssuanceOfCommonStockInLieuOfCashForServices"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfCommonStockPerConversionOfConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfCommonStockPerConversionOfConvertibleNote",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock per conversion of convertible note",
        "documentation": "Issuance of common stock per conversion of convertible note."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfConvertibleNoteForLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfConvertibleNoteForLegalSettlement",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of convertible note for legal settlement",
        "documentation": "Issuance of convertible note for legal settlement."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_IssuanceOfRestrictedStockUnitsForLiabilitySettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "IssuanceOfRestrictedStockUnitsForLiabilitySettlement",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of restricted stock units for liability settlement",
        "documentation": "Issuance of restricted stock units for liability settlement.",
        "label": "IssuanceOfRestrictedStockUnitsForLiabilitySettlement"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_JulyWarrantInducementOfferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "JulyWarrantInducementOfferMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Warrant Inducement Offer [Member]",
        "documentation": "July Warrant Inducement Offer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_LeaseTermsOperatingLeasesAnnualIncreaseInRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "LeaseTermsOperatingLeasesAnnualIncreaseInRent",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease terms, operating leases annual increase in rent",
        "documentation": "Lease terms operating leases annual increase in rent."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Legal",
        "label": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1238",
      "r1239"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease agreement description",
        "label": "Lessee, Operating Lease, Description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Leases, Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "CLDI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, 2030 and thereafter",
        "documentation": "Lessee operating lease liability payments due after year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, 2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, 2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, 2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, 2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating Leases, Less: amounts representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LessorOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorOperatingLeaseDescription",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease agreement description",
        "documentation": "Description of lessor's operating lease."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of credit amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r915"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r59",
      "r60",
      "r61",
      "r64",
      "r65",
      "r66",
      "r69",
      "r221",
      "r224",
      "r225",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r529",
      "r532",
      "r533",
      "r582",
      "r754",
      "r858",
      "r873",
      "r926",
      "r1114",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND TOTAL EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r124",
      "r690",
      "r901",
      "r912",
      "r914",
      "r1081",
      "r1086",
      "r1103",
      "r1178"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND TOTAL EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r185",
      "r221",
      "r224",
      "r225",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r529",
      "r532",
      "r533",
      "r582",
      "r901",
      "r1114",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total warrant liabilities, at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1167"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment Fee",
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r63",
      "r322"
     ]
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r117"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer loans payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r121",
      "r1201"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party bridge loan payable, including accrued interest",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, net of current portion",
        "verboseLabel": "Carrying value, including accrued interest",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r121",
      "r222",
      "r231",
      "r347",
      "r361",
      "r677",
      "r869",
      "r870",
      "r899",
      "r1201"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r222",
      "r231",
      "r352",
      "r677"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028 and thereafter",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r222",
      "r231",
      "r352",
      "r677"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfMaturitiesOfOutstandingDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r222",
      "r231",
      "r352",
      "r677"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r311",
      "r312",
      "r313",
      "r316",
      "r472",
      "r867",
      "r1112",
      "r1113"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r311",
      "r312",
      "r313",
      "r316",
      "r472",
      "r867",
      "r1112",
      "r1113"
     ]
    },
    "CLDI_MachineryAndEquipmentAcquiredThroughFinancingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "MachineryAndEquipmentAcquiredThroughFinancingLeases",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment acquired through financing leases",
        "documentation": "Machinery and equipment acquired through financing leases"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_MarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "MarketOfferingAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Offering Agreement [Member]",
        "documentation": "Market Offering Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r975"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r976"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r977"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r977"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r977"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r977"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r164",
      "r166",
      "r167",
      "r177",
      "r178",
      "r271",
      "r312",
      "r313",
      "r314",
      "r315",
      "r431",
      "r460",
      "r461",
      "r462",
      "r472",
      "r562",
      "r632",
      "r705",
      "r706",
      "r713",
      "r745",
      "r746",
      "r807",
      "r809",
      "r811",
      "r812",
      "r814",
      "r823",
      "r824",
      "r826",
      "r827",
      "r838",
      "r839",
      "r865",
      "r874",
      "r882",
      "r886",
      "r887",
      "r888",
      "r894",
      "r895",
      "r896",
      "r897",
      "r910",
      "r1116",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r164",
      "r166",
      "r167",
      "r177",
      "r178",
      "r271",
      "r312",
      "r313",
      "r314",
      "r315",
      "r431",
      "r460",
      "r461",
      "r462",
      "r472",
      "r562",
      "r632",
      "r705",
      "r706",
      "r713",
      "r745",
      "r746",
      "r807",
      "r809",
      "r811",
      "r812",
      "r814",
      "r823",
      "r824",
      "r826",
      "r827",
      "r838",
      "r839",
      "r865",
      "r874",
      "r882",
      "r886",
      "r887",
      "r888",
      "r894",
      "r895",
      "r896",
      "r910",
      "r1116",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r123",
      "r221",
      "r224",
      "r225",
      "r298",
      "r323",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r689",
      "r758",
      "r1178"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1118",
      "r1119"
     ]
    },
    "CLDI_MrCamaisaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "MrCamaisaMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Camaisa [Member]",
        "documentation": "Mr Camaisa [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_MrLeftwichMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "MrLeftwichMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Leftwich [Member]",
        "documentation": "Mr Leftwich [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_Ms.CampbellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "Ms.CampbellMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms.Campbell [Member]",
        "documentation": "Ms.Campbell [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://calidibio.com/role/OrganizationAndNatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Operations",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r267",
      "r855",
      "r856"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails",
      "http://calidibio.com/role/StatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r92",
      "r127",
      "r182",
      "r183",
      "r198",
      "r200",
      "r205",
      "r221",
      "r224",
      "r225",
      "r229",
      "r235",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r253",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r364",
      "r367",
      "r370",
      "r374",
      "r469",
      "r522",
      "r525",
      "r556",
      "r582",
      "r698",
      "r776",
      "r797",
      "r798",
      "r847",
      "r849",
      "r851",
      "r924",
      "r1114"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r114",
      "r198",
      "r200",
      "r243",
      "r246",
      "r247",
      "r697",
      "r1069"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r210",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248",
      "r249",
      "r254",
      "r257",
      "r367",
      "r370",
      "r374",
      "r525"
     ]
    },
    "CLDI_NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "documentation": "New Accounting Pronouncements Issued But Not Yet Adopted [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_NoInsiderTradingFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "NoInsiderTradingFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Insider Trading Flag",
        "documentation": "No Insider Trading Flag."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonUsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1242",
      "r1243",
      "r1244",
      "r1245"
     ]
    },
    "CLDI_NoncashCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "NoncashCompensation",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash compensation charge in connection with repricing",
        "documentation": "Non-cash compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r392",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1240"
     ]
    },
    "us-gaap_NoninterestExpenseInvestmentAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseInvestmentAdvisoryFees",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory fee",
        "documentation": "Amount of expense for investment advisory service, including, but not limited to, managing money in fund."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r779",
      "r924",
      "r1235"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expenses), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSES), NET"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvoting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_NorthwesternAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "NorthwesternAgreementMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Northwestern Agreement [Member]",
        "documentation": "Northwestern Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration",
        "verboseLabel": "Notes payable",
        "terseLabel": "Secured term notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r121",
      "r1201",
      "r1202"
     ]
    },
    "CLDI_NovaCellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "NovaCellMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nova Cell [Member]",
        "documentation": "Nova Cell [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_OfficerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "OfficerAMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer A [Member]",
        "documentation": "Officer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_OfficerGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "OfficerGMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer G [Member]",
        "documentation": "Officer G [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OfficerMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "documentation": "Person with designation of officer."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r1059",
      "r1233"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expense",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r847",
      "r851",
      "r859",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1182"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease payment due",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r613"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfFutureMinimumLeaseCommitmentsDetails",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use liability, current",
        "verboseLabel": "Right-of-use lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use liability, noncurrent",
        "verboseLabel": "Right-of-use lease liabilities, noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "verboseLabel": "Lease payment",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r604"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "verboseLabel": "Right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "CLDI_OperatingLeaseTermOfContractLeaseInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "OperatingLeaseTermOfContractLeaseInitialTerm",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, term of contract, lease initial term",
        "documentation": "Operating lease term of contract lease initial term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r900"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term, Operating leases (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r900"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r862",
      "r863"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other noncurrent assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1091",
      "r1199"
     ]
    },
    "us-gaap_OtherCommitmentsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsDescription",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments, Description",
        "documentation": "Description of the nature and terms of commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustments",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r12",
      "r113"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r699"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/MachineryAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r32",
      "r80"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r912",
      "r914"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment to related party",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r682",
      "r750",
      "r751",
      "r873",
      "r912",
      "r914",
      "r926",
      "r1202",
      "r1233"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party other current liability",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r901"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r891"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1064",
      "r1104"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "CLDI_OtherSegmentItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "OtherSegmentItems",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other segment items",
        "documentation": "Other segment items.",
        "label": "OtherSegmentItems"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r983",
      "r1010"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r972",
      "r986",
      "r1013"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r972",
      "r986",
      "r1013"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r990"
     ]
    },
    "CLDI_PaymentOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PaymentOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of debt issuance costs",
        "documentation": "Payment of debt issuance costs.",
        "label": "PaymentOfDebtIssuanceCosts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of financing costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash disposed in sale of investment in Nova Cell",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of machinery and equipment",
        "label": "Payments to Acquire Machinery and Equipment",
        "documentation": "The cash outflow for acquisition of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "CLDI_PercentageOfStrategicInvestment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PercentageOfStrategicInvestment",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of strategic investment",
        "documentation": "Percentage of strategic investment."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgencyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgencyAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agency Agreement [Member]",
        "documentation": "Placement Agency Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]",
        "documentation": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsToPurchaseCommonStockFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsToPurchaseCommonStockFiveMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants to Purchase Common Stock Five [Member]",
        "documentation": "Placement Agent Warrants to Purchase Common Stock Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsToPurchaseCommonStockFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsToPurchaseCommonStockFourMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants to Purchase Common Stock Four [Member]",
        "documentation": "Placement Agent Warrants to Purchase Common Stock Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants to Purchase Common Stock [Member]",
        "documentation": "Placement Agent Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsToPurchaseCommonStockOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsToPurchaseCommonStockOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants to Purchase Common Stock One [Member]",
        "documentation": "Placement Agent Warrants to Purchase Common Stock One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsToPurchaseCommonStockThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsToPurchaseCommonStockThreeMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants to Purchase Common Stock Three [Member]",
        "documentation": "Placement Agent Warrants to Purchase Common Stock Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PlacementAgentWarrantsToPurchaseCommonStockTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PlacementAgentWarrantsToPurchaseCommonStockTwoMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants to Purchase Common Stock Two [Member]",
        "documentation": "Placement Agent Warrants to Purchase Common Stock Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "CLDI_PreFundedWarrantUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PreFundedWarrantUnitsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PreFunded Warrant Units [Member]",
        "documentation": "PreFunded Warrant Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]",
        "documentation": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r920",
      "r921",
      "r922",
      "r923",
      "r1232",
      "r1240"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock par value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r376"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r756"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r756",
      "r775",
      "r1240",
      "r1241"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "CLDI_PrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r866",
      "r1104"
     ]
    },
    "CLDI_PriorDecemberTwentySeventeenthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PriorDecemberTwentySeventeenthMember",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior December 2017 [Member]",
        "documentation": "Prior December 2017 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "CLDI_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrants [Member]",
        "documentation": "Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PrivateWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PrivateWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrants to Purchase Common Stock [Member]",
        "documentation": "Private Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible notes payable",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from at the market offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "CLDI_ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and warrants per subscription agreement",
        "documentation": "Proceeds from issuance oif common shares and warrants per subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from offering",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory note",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "CLDI_ProceedsFromIssuanceOfNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ProceedsFromIssuanceOfNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of noncontrolling interest in Nova Cell",
        "documentation": "Proceeds from issuance of noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical",
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of common stock warrants",
        "verboseLabel": "Received dross proceeds",
        "terseLabel": "Gross proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity proceeds",
        "verboseLabel": "Proceeds from issued common shares",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r717"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromOtherOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Operating Activity",
        "documentation": "Amount of cash inflow from operating activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "CLDI_ProceedsFromPublicOfferings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ProceedsFromPublicOfferings",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from public offerings",
        "documentation": "Proceeds from public offerings."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ProceedsFromRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ProceedsFromRegisteredDirectOffering",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from registered direct offering",
        "documentation": "Proceeds from registered direct offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party proceeds from issuance of loan payable",
        "verboseLabel": "Loans received",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of pre-funded warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "CLDI_ProceedsFromWarrantInducementFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ProceedsFromWarrantInducementFinancing",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrant inducement financing",
        "documentation": "Proceeds from warrant inducement financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://calidibio.com/role/StatementsOfCashFlows",
      "http://calidibio.com/role/StatementsOfOperations",
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r198",
      "r200",
      "r213",
      "r221",
      "r224",
      "r225",
      "r229",
      "r235",
      "r243",
      "r246",
      "r247",
      "r298",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r364",
      "r469",
      "r522",
      "r525",
      "r527",
      "r530",
      "r531",
      "r556",
      "r582",
      "r673",
      "r675",
      "r696",
      "r727",
      "r776",
      "r797",
      "r798",
      "r889",
      "r890",
      "r925",
      "r1069",
      "r1114"
     ]
    },
    "CLDI_PromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PromissoryNote",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note",
        "documentation": "Promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PromissoryNoteLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PromissoryNoteLoanAgreementMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Loan Agreement [Member]",
        "documentation": "Promissory Note Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r609"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/MachineryAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r138",
      "r139",
      "r140"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation",
        "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of accumulated amortization, depreciation, depletion for physical asset used in normal conduct of business to create and distribute product and service."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r610"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Machinery and equipment, net",
        "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation",
        "documentation": "Amount, after accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1183"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment, gross",
        "documentation": "Amount, before accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r610"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r187",
      "r694"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/ScheduleOfMachineryAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment, net",
        "totalLabel": "Machinery and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r609",
      "r678",
      "r694",
      "r901"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r138",
      "r139",
      "r692"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://calidibio.com/role/MachineryAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Machinery and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r609"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PublicWarrantRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PublicWarrantRedemptionDescription",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public warrant redemption description",
        "documentation": "Public warrant redemption description."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails",
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_PublicWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "PublicWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants to Purchase Common Stock [Member]",
        "documentation": "Public Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r164",
      "r166",
      "r167",
      "r177",
      "r178",
      "r271",
      "r312",
      "r313",
      "r314",
      "r315",
      "r401",
      "r431",
      "r460",
      "r461",
      "r462",
      "r468",
      "r472",
      "r562",
      "r630",
      "r631",
      "r632",
      "r705",
      "r706",
      "r713",
      "r745",
      "r746",
      "r807",
      "r809",
      "r811",
      "r812",
      "r814",
      "r823",
      "r824",
      "r826",
      "r827",
      "r838",
      "r839",
      "r865",
      "r874",
      "r882",
      "r886",
      "r887",
      "r888",
      "r894",
      "r895",
      "r896",
      "r897",
      "r910",
      "r918",
      "r1110",
      "r1116",
      "r1170",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r148",
      "r150",
      "r151",
      "r153",
      "r164",
      "r166",
      "r167",
      "r177",
      "r178",
      "r271",
      "r312",
      "r313",
      "r314",
      "r315",
      "r401",
      "r431",
      "r460",
      "r461",
      "r462",
      "r468",
      "r472",
      "r562",
      "r630",
      "r631",
      "r632",
      "r705",
      "r706",
      "r713",
      "r745",
      "r746",
      "r807",
      "r809",
      "r811",
      "r812",
      "r814",
      "r823",
      "r824",
      "r826",
      "r827",
      "r838",
      "r839",
      "r865",
      "r874",
      "r882",
      "r886",
      "r887",
      "r888",
      "r894",
      "r895",
      "r896",
      "r897",
      "r910",
      "r918",
      "r1110",
      "r1116",
      "r1170",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r953",
      "r964",
      "r978",
      "r1005"
     ]
    },
    "CLDI_RedemptionOfOutstandingWarrantsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RedemptionOfOutstandingWarrantsPerShare",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of outstanding warrants per share",
        "documentation": "Redemption of outstanding warrants per share."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RedemptionOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RedemptionOfWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Warrants [Member]",
        "documentation": "Redemption Of Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/StatementsOfOperations",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r294",
      "r408",
      "r427",
      "r619",
      "r620",
      "r683",
      "r691",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r774",
      "r806",
      "r1236"
     ]
    },
    "CLDI_RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party issuance of common stock in lieu of cash for services",
        "documentation": "Related party issuance of common stock in lieu of cash for services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r619",
      "r620",
      "r621",
      "r622",
      "r683",
      "r691",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r774",
      "r806"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction description",
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r192",
      "r608",
      "r612",
      "r614",
      "r618"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r294",
      "r619",
      "r620",
      "r622",
      "r780",
      "r781",
      "r784"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/StatementsOfOperations",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r294",
      "r408",
      "r427",
      "r619",
      "r620",
      "r683",
      "r691",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r774",
      "r806",
      "r1187",
      "r1236"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r617",
      "r618",
      "r620",
      "r623",
      "r723",
      "r724",
      "r725",
      "r782",
      "r783",
      "r784",
      "r803",
      "r805"
     ]
    },
    "CLDI_RelatedPartyWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RelatedPartyWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party warrant liability",
        "documentation": "Related party warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RelativeOfOfficerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RelativeOfOfficerAMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relative of OfficerA [Member]",
        "documentation": "Relative of OfficerA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RemainingExpectedCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RemainingExpectedCommitments",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining expected commitments",
        "documentation": "Remaining expected commitments."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RentAndMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RentAndMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Rent and maintenance",
        "documentation": "Rent and maintenance",
        "label": "RentAndMaintenance"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RepaymentOfConvertibleNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RepaymentOfConvertibleNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of convertible note payable",
        "documentation": "Repayment of convertible note payable",
        "label": "RepaymentOfConvertibleNotePayable"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of principal on related party bridge loan payable",
        "documentation": "Repayment of principal on related party bridge loan payable.",
        "label": "Repayment of principal on related party bridge loan payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of financing lease obligations",
        "label": "Repayments of Debt and Lease Obligation",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of principal on term notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of principal on related party term notes payable",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "CLDI_RepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RepresentativeWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative Warrants [Member]",
        "documentation": "Representative Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_RepresentativeWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RepresentativeWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative Warrants to Purchase Common Stock [Member]",
        "documentation": "Representative Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r840",
      "r847",
      "r848",
      "r862",
      "r1196"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "CLDI_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Member]",
        "documentation": "Research and Development Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r965",
      "r979",
      "r1006"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r966",
      "r980",
      "r1007"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r973",
      "r987",
      "r1014"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1079",
      "r1197",
      "r1203"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash included within prepaid expenses and other current assets",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r186",
      "r218"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash included within other noncurrent assets",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r134",
      "r218"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146"
     ]
    },
    "CLDI_RestrictedStockUnitsVestedAndUnreleasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "RestrictedStockUnitsVestedAndUnreleasedMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Vested and Unreleased [Member]",
        "documentation": "Restricted Stock Units Vested and Unreleased [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r102",
      "r688",
      "r710",
      "r712",
      "r721",
      "r757",
      "r901"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r182",
      "r232",
      "r233",
      "r234",
      "r236",
      "r243",
      "r245",
      "r247",
      "r299",
      "r300",
      "r301",
      "r363",
      "r469",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r543",
      "r545",
      "r546",
      "r548",
      "r554",
      "r594",
      "r596",
      "r707",
      "r709",
      "r728",
      "r1240"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r841"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Salaries and benefits",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares sold and transferred",
        "verboseLabel": "Issuance and sale of shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share",
        "verboseLabel": "Shares price sold",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]",
        "documentation": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SanDiegoLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SanDiegoLeaseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "San Diego Lease Agreement [Member]",
        "documentation": "San Diego Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/SelectedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Computation of Diluted Net Loss per Common Share including Antidilutive",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Leases",
        "documentation": "Schedule of cash flow supplemental disclosures operating and financing leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Expenses (Benefit) by Jurisdiction",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://calidibio.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Debt Obligations",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r36",
      "r39",
      "r55",
      "r100",
      "r101",
      "r869",
      "r871",
      "r1082",
      "r1091",
      "r1179",
      "r1199"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r41",
      "r42",
      "r43",
      "r44",
      "r409",
      "r410",
      "r411",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Income Tax Benefit",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r885",
      "r1150"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r518",
      "r582",
      "r1046",
      "r1047",
      "r1048",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risk [Table]",
        "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r680",
      "r1175"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income (Loss) Before Provision for Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1087"
     ]
    },
    "CLDI_ScheduleOfIncomeTaxPaidTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ScheduleOfIncomeTaxPaidTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Paid for Income Taxes, Net of Refunds Received",
        "documentation": "Schedule of Income Tax Paid [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Outstanding Debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "CLDI_ScheduleOfOutstandingWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ScheduleOfOutstandingWarrantsTextBlock",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Warrants",
        "documentation": "Schedule Of Outstanding Warrants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r609"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228",
      "r229",
      "r619",
      "r620",
      "r622",
      "r780",
      "r781",
      "r784"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Restricted Stock Unit Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r100",
      "r101",
      "r102",
      "r193",
      "r194",
      "r195",
      "r264",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r388",
      "r390",
      "r540",
      "r717",
      "r718",
      "r719",
      "r720",
      "r874",
      "r1045",
      "r1081",
      "r1083"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "CLDI_ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases",
        "documentation": "Schedule of supplemental balance sheet information related to operating and financing leases [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefit",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r884"
     ]
    },
    "CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ScheduleofCashPaidForIncomeTaxesRefundsReceivedAbstract",
     "auth_ref": []
    },
    "CLDI_ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleofCashPaidForIncomeTaxesRefundsReceivedTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails",
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r268",
      "r292",
      "r293",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r673",
      "r674",
      "r675",
      "r676",
      "r742",
      "r743",
      "r744",
      "r808",
      "r810",
      "r813",
      "r815",
      "r823",
      "r825",
      "r826",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r843",
      "r854",
      "r875",
      "r876",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r911",
      "r918",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r291",
      "r292",
      "r860",
      "r861",
      "r864"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r846",
      "r847",
      "r848",
      "r851",
      "r1074"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "CLDI_SeparationAndReleaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeparationAndReleaseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Separation and Release Agreement [Member]",
        "documentation": "Separation and Release Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeparationPay": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeparationPay",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Separation pay",
        "documentation": "Separation payments."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "documentation": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesAWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesAWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants to Purchase Common Stock [Member]",
        "documentation": "Series A Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesB1WarrantsToPurchaseCommonStockFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesB1WarrantsToPurchaseCommonStockFourMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Warrants to Purchase Common Stock Four [Member]",
        "documentation": "Series B-1 Warrants to Purchase Common Stock Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesB1WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesB1WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Warrants to Purchase Common Stock [Member]",
        "documentation": "Series B-1 Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesB1WarrantsToPurchaseCommonStockOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesB1WarrantsToPurchaseCommonStockOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Warrants to Purchase Common Stock One [Member]",
        "documentation": "Series B-1 Warrants to Purchase Common Stock One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesB1WarrantsToPurchaseCommonStockThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesB1WarrantsToPurchaseCommonStockThreeMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Warrants to Purchase Common Stock Three [Member]",
        "documentation": "Series B-1 Warrants to Purchase Common Stock Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesB1WarrantsToPurchaseCommonStockTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesB1WarrantsToPurchaseCommonStockTwoMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Warrants to Purchase Common Stock Two [Member]",
        "documentation": "Series B-1 Warrants to Purchase Common Stock Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesBOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesBOneWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B-1 Warrants [Member]",
        "documentation": "Series B One Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesBWarrantsAndSeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesBWarrantsAndSeriesCWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants And Series C Warrants [Member]",
        "documentation": "Series B Warrants And Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "documentation": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesBWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesBWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants to Purchase Common Stock [Member]",
        "documentation": "Series B Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesC1WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesC1WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C-1 Warrants to Purchase Common Stock [Member]",
        "documentation": "Series C-1 Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesC1WarrantsToPurchaseCommonStockOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesC1WarrantsToPurchaseCommonStockOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C-1 Warrants to Purchase Common Stock One [Member]",
        "documentation": "Series C-1 Warrants to Purchase Common Stock One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesC1WarrantsToPurchaseCommonStockTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesC1WarrantsToPurchaseCommonStockTwoMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C-1 Warrants to Purchase Common Stock Two [Member]",
        "documentation": "Series C-1 Warrants to Purchase Common Stock Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesCOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesCOneWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C-1 Warrants [Member]",
        "documentation": "Series C One Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesCOneWarrantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesCOneWarrantsOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series C-1 Warrants [Member]",
        "documentation": "Series C One Warrants [Member]",
        "label": "Series C-1 Warrants [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesDCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesDCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Common Stock [Member]",
        "documentation": "Series D Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Warrants [Member]",
        "documentation": "Series D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesDWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesDWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Warrants to Purchase Common Stock [Member]",
        "documentation": "Series D Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesECommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesECommonWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Common Warrants [Member]",
        "documentation": "Series E Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesEWarrantsAndSeriesFWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesEWarrantsAndSeriesFWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Warrants and Series F Warrants [Member]",
        "documentation": "Series E Warrants and Series F Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesEWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesEWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Warrants to Purchase Common Stock [Member]",
        "documentation": "Series E Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesFCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesFCommonWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Common Warrants [Member]",
        "documentation": "Series F Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesFWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesFWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Warrants to Purchase Common Stock [Member]",
        "documentation": "Series F Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesGCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesGCommonStockWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Common Stock Warrants [Member]",
        "documentation": "Series G Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesGCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesGCommonWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Common Warrants [Member]",
        "documentation": "Series G Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesGPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesGPreFundedWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Pre-Funded Warrants [Member]",
        "documentation": "Series G Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesGWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesGWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Warrants to Purchase Common Stock [Member]",
        "documentation": "Series G Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesHCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesHCommonStockWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series H Common Stock Warrants [Member]",
        "documentation": "Series H Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesHWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesHWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series H Warrants to Purchase Common Stock [Member]",
        "documentation": "Series H Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesICommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesICommonStockWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series I Common Stock Warrants [Member]",
        "documentation": "Series I Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesIPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesIPreFundedWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series I Pre-Funded Warrants [Member]",
        "documentation": "Series I Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesIWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesIWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series I Warrants to Purchase Common Stock [Member]",
        "documentation": "Series I Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesJWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesJWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series J Warrants [Member]",
        "documentation": "Series J Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesKWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesKWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series K Warrants [Member]",
        "documentation": "Series K Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SeriesLWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SeriesLWarrantsMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series L Warrants [Member]",
        "documentation": "Series L Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SettlementOfDeferredCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SettlementOfDeferredCompensationMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of Deferred Compensation [Member]",
        "documentation": "Settlement Of Deferred Compensation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://calidibio.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Descriptiion of options vesting",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Cancelled",
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options converted to Common Stock In Peroid",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Warrants, Balance",
        "periodStartLabel": "Number of Units Outstanding, Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Units Outstanding, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Issued",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Balance",
        "periodEndLabel": "Number of Warrants, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108"
     ]
    },
    "CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (Years)",
        "documentation": "Share based compensation arrangement by share based payment award non option outstanding weighted average remaining contractual terms."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance",
        "documentation": "Share based compensation arrangement by share based payment award non option weighted average grant date fair value.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Forfeited or cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Granted",
        "verboseLabel": "Options granted approved for repricing",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average estimated fair value of stock options",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Outstanding, Beginning",
        "periodEndLabel": "Number of Options Outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance",
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of term and exercise price of options",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Options granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Options forfeited or cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SharePriceEqualOrExceedsEighteenRupeesPerDollarMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]",
        "documentation": "Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Equal Or Less Ten Point Zero Rupees Per Dollar [Member]",
        "documentation": "Share Price Equal Or Less Ten Point Zero Rupees Per Dollar [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected option life (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (Years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssued",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "verboseLabel": "Shares of common stock",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r1107",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "CLDI_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Member]",
        "documentation": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r193",
      "r194",
      "r195",
      "r221",
      "r225",
      "r251",
      "r252",
      "r255",
      "r257",
      "r264",
      "r265",
      "r298",
      "r323",
      "r326",
      "r327",
      "r328",
      "r332",
      "r333",
      "r365",
      "r366",
      "r368",
      "r369",
      "r371",
      "r373",
      "r376",
      "r377",
      "r380",
      "r383",
      "r390",
      "r582",
      "r717",
      "r718",
      "r719",
      "r720",
      "r728",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r741",
      "r756",
      "r777",
      "r799",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r1045",
      "r1083",
      "r1085",
      "r1096"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails",
      "http://calidibio.com/role/StatementsOfTotalEquity",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r74",
      "r75",
      "r179",
      "r181",
      "r182",
      "r203",
      "r204",
      "r205",
      "r232",
      "r233",
      "r234",
      "r236",
      "r243",
      "r245",
      "r247",
      "r263",
      "r299",
      "r300",
      "r301",
      "r363",
      "r392",
      "r469",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r554",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r594",
      "r596",
      "r615",
      "r699",
      "r707",
      "r708",
      "r709",
      "r728",
      "r799"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails",
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r268",
      "r292",
      "r293",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r673",
      "r674",
      "r675",
      "r676",
      "r742",
      "r743",
      "r744",
      "r808",
      "r810",
      "r813",
      "r815",
      "r823",
      "r825",
      "r826",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r843",
      "r854",
      "r875",
      "r876",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r911",
      "r918",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCashPaidForIncomeTaxesNetOfRefundsReceivedDetails",
      "http://calidibio.com/role/ScheduleOfChangesInFairValueOfLevel3ValuedInstrumentsDetails",
      "http://calidibio.com/role/ScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
      "http://calidibio.com/role/ScheduleOfOperatingSegmentDetails",
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r263",
      "r365",
      "r366",
      "r368",
      "r371",
      "r596",
      "r633",
      "r715",
      "r729",
      "r741",
      "r747",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r778",
      "r779",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r799",
      "r849",
      "r851",
      "r919",
      "r1236"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StatementOfIncomeLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StatementOfIncomeLocationBalanceAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location, Statement of Income, Balance [Axis]",
        "documentation": "Location, Statement of Income, Balance [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StatementOfIncomeLocationBalanceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StatementOfIncomeLocationBalanceDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r263",
      "r294",
      "r365",
      "r366",
      "r368",
      "r371",
      "r596",
      "r633",
      "r715",
      "r729",
      "r741",
      "r747",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r778",
      "r779",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r799",
      "r849",
      "r851",
      "r919",
      "r1236"
     ]
    },
    "CLDI_StemVacOfficeLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StemVacOfficeLeaseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stem Vac Office Lease Agreement [Member]",
        "documentation": "Stem Vac Office Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r982",
      "r1009"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock to Calidi stockholders as result of Merger, shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock per Convertible Note conversion, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r36",
      "r71",
      "r74",
      "r102",
      "r351"
     ]
    },
    "CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants, shares",
        "documentation": "Stock issued during period shares exercise of common prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants, shares",
        "documentation": "Stock issued during period shares exercise of common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares and warrants per subscription agreement, shares",
        "documentation": "Issuance of common stock and warrants per subscription agreement, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs, shares",
        "documentation": "Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for legal settlement, shares",
        "documentation": "Issuance of common stock and warrants for legal settlement, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for registered direct offering, shares",
        "documentation": "Issuance of common stock and warrants for registered direct offering, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for Reverse Stock Split fractional shares, shares",
        "documentation": "Issuance of common stock for Reverse Stock Split fractional, shares.",
        "label": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock through At the Market Offering, shares",
        "documentation": "Issuance of common stock through At the Market Offering, shares.",
        "label": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares through May Inducement Offer, net of financing costs, shares",
        "documentation": "Issuance of common stock through July Inducement Offer, net of financing costs, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through August Public Offering",
        "documentation": "Issuance of common stock through august public offering, shares."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through November Public Offering, net of financing, shares",
        "documentation": "Issuance of common stock through November Public Offering, net of financing, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in lieu of cash for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in lieu of cash for commitment fee, shares",
        "documentation": "Stock issued during period shares lieu of cash for commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through At the Market Offering, shares",
        "verboseLabel": "Common stock shares",
        "terseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r71",
      "r102",
      "r717",
      "r799",
      "r817"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock unit shares released, shares",
        "verboseLabel": "Restricted shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock unit shares released, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r71",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Reverse Stock Split fractional shares, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Exercised",
        "label": "Shares purchased",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r71",
      "r102",
      "r445"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock to Calidi stockholders as result of Merger",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r74",
      "r75",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock per Convertible Note conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r74",
      "r75",
      "r102"
     ]
    },
    "CLDI_StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants",
        "documentation": "Stock issued during period value exercise of common prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of common stock warrants",
        "documentation": "Stock issued during period value exercise of common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueInvestment",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Nova Cell",
        "documentation": "Stock issued during period value investment."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs",
        "documentation": "Issuance of common stock and pre-funded warrants through April Public Offering, net of financing costs, value."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for legal settlement",
        "documentation": "Issuance of common stock and warrants for legal settlement, value."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants for registered direct offering",
        "documentation": "Issuance of common stock and warrants for registered direct offering, value."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants per subscription agreement",
        "documentation": "Issuance of common stock and warrants per subscription agreement, value."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for Reverse Stock Split fractional shares",
        "documentation": "Issuance of common stock for Reverse Stock Split fractional, value.",
        "label": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock through At the Market Offering",
        "documentation": "Issuance of common stock through At the Market Offering, value.",
        "label": "StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through May Inducement Offer, net of financing costs",
        "documentation": "Issuance of common stock through July Inducement Offer, net of financing costs, value."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through November Public Offering, net of financing",
        "documentation": "Issuance of common stock through November Public Offering, net of financing, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in lieu of cash for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in lieu of cash for SEPA commitment fee",
        "documentation": "Stock issued during period value lieu of cash for commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/StatementsOfTotalEquity",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock through At the Market Offering",
        "verboseLabel": "Aggregate offering price",
        "terseLabel": "Gross proceeds",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r71",
      "r102",
      "r728",
      "r799",
      "r817",
      "r925"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock unit shares released",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r71",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock unit shares released",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102"
     ]
    },
    "CLDI_StockIssuedDuringPeriodValueReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for Reverse Stock Split fractional shares",
        "documentation": "Stock issued during period value reverse stock splits."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_StockIssuedDuringPeriodValueSaleOfInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "StockIssuedDuringPeriodValueSaleOfInvestment",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of investment in Nova Cell",
        "documentation": "Stock issued during period value sale of investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price for repurchased shares",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r70",
      "r71",
      "r102",
      "r728",
      "r799",
      "r819",
      "r925"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r75",
      "r93",
      "r758",
      "r775",
      "r800",
      "r801",
      "r901",
      "r926",
      "r1081",
      "r1085",
      "r1086",
      "r1103",
      "r1178",
      "r1240"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TOTAL EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets",
      "http://calidibio.com/role/StatementsOfTotalEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r52",
      "r179",
      "r180",
      "r181",
      "r182",
      "r204",
      "r232",
      "r233",
      "r234",
      "r236",
      "r243",
      "r245",
      "r299",
      "r300",
      "r301",
      "r363",
      "r392",
      "r469",
      "r510",
      "r511",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r554",
      "r585",
      "r586",
      "r590",
      "r595",
      "r615",
      "r708",
      "r709",
      "r726",
      "r758",
      "r775",
      "r800",
      "r801",
      "r821",
      "r912",
      "r914",
      "r925",
      "r1081",
      "r1085",
      "r1086",
      "r1103",
      "r1178",
      "r1240"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Common Stock and Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r375",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r389",
      "r392",
      "r540",
      "r553",
      "r802",
      "r804",
      "r822"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://calidibio.com/role/OrganizationAndNatureOfOperationsDetailsNarrative",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "CLDI_SubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "SubscriptionAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement [Member]",
        "documentation": "Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r625"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://calidibio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://calidibio.com/role/SelectedBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://calidibio.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "CLDI_TermNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TermNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term notes payable, net of discount, including accrued interest",
        "documentation": "Term notes payable current."
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TermNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TermNotesPayableMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Notes Payable [Member]",
        "documentation": "Term Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1186"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "CLDI_TriggeringEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TriggeringEventAxis",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Triggering Event Axis",
        "verboseLabel": "Triggering Event Axis [Axis]",
        "documentation": "Triggering Event Axis"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TriggeringEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TriggeringEventDomain",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetailsParenthetical"
     ],
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyFourBridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyFourBridgeLoanMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Bridge Loan [Member]",
        "documentation": "2024 Bridge Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyFourPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyFourPurchaseAgreementMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Purchase Agreement [Member]",
        "documentation": "2024 Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyOneTermNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyOneTermNoteMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Term Note [Member]",
        "documentation": "2021 Term Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyThreeEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Employee Stock Purchase Plan [Member]",
        "documentation": "2023 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Equity Incentive Plan [Member]",
        "documentation": "2023 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://calidibio.com/role/Stock-basedCompensationDetailsNarrative",
      "http://calidibio.com/role/SummaryOfRestrictedStockUnitActivityDetails",
      "http://calidibio.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Plan [Member]",
        "documentation": "2023 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyThreeTermNotePayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyThreeTermNotePayableMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Notes Payable [Member]",
        "documentation": "2023 Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyThreeTermNotePayableTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyThreeTermNotePayableTwoMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Note Payable Two [Member]",
        "documentation": "2023 Note Payable Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_TwoThousandTwentyTwoTermNotePayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "TwoThousandTwentyTwoTermNotePayableMember",
     "presentation": [
      "http://calidibio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Term Note Payable [Member]",
        "documentation": "2022 Term Note Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/DebtDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative",
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "CLDI_UnderwritersWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "UnderwritersWarrantMember",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Warrant [Member]",
        "documentation": "Underwriters Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the year",
        "periodEndLabel": "Balance at end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r494",
      "r884"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions based on tax positions related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r884"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments based on tax positions related to prior years",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r884"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://calidibio.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r266",
      "r269",
      "r270",
      "r271",
      "r673",
      "r675",
      "r857"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://calidibio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "CLDI_VotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "VotingCommonStockMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voting Common Stock [Member]",
        "documentation": "Voting Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "warrants exercise price",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "CLDI_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://calidibio.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://calidibio.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "documentation": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://calidibio.com/role/ConvertiblePreferredStockCommonStockAndStockholdersEquityDetailsNarrative",
      "http://calidibio.com/role/ScheduleOfCommonStockReservedDetails",
      "http://calidibio.com/role/ScheduleOfComputationOfDilutedNetLossPerCommonShareIncludingAntidilutiveDetails",
      "http://calidibio.com/role/ScheduleOfRelatedPartyTransactionsDetailsParenthetical",
      "http://calidibio.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://calidibio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expire year",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "CLDI_WarrantsToPurchaseRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "WarrantsToPurchaseRestrictedSharesMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Restricted Shares [Member]",
        "documentation": "Warrants to Purchase Restricted Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CLDI_WarrantsToPurchaseRestrictedSharesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "WarrantsToPurchaseRestrictedSharesOneMember",
     "presentation": [
      "http://calidibio.com/role/ScheduleOfOutstandingWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Restricted Shares One [Member]",
        "documentation": "Warrants to Purchase Restricted Shares One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r257"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://calidibio.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r257"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://calidibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "CLDI_YorkvilleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://calidibio.com/20251231",
     "localname": "YorkvilleMember",
     "presentation": [
      "http://calidibio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville [Member]",
        "documentation": "Yorkville [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481440/840-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(j)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-7"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479741/842-40-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-15"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001493152-26-013242-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-26-013242-xbrl.zip
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M:N !Y;2IC ?$;=5Y0#S%],8W-[[N6%AC\"9P R.74ZLR1M8>*8L-8V_7KHD
MU1L'8V@#JY8"@/7) ?WFH$-?U64#:/IJ$[B!56MC?W69!'U/W9=5*Y[,Z8C;
M;.^WM:$\$WOW3^RTC]9%H7A 3X0\14+(W=0G<U37KYL1#"Q='\';MJ"25#)M
M]'V[U>HJC)C<D93,IEU@-6(86+<<N,NML9(F*FW=V]<D#:QZ15598V O36I8
MOTKJ=IB69'3=@_!LC3W]"9D.TL!F]?&K;'I70KSO6MVFQ5^%^^O#DS60!F:L
MC3IE!\>$=F_%O5BQ=EUKBF9@W]J84KU]^\5L:WO'2AS OF!-PHVFQVJ@#*Q9
M&SR*R3H)W;ZGOEQR=?7Z9W_D#'RA%'+:7\)UO_#JD+D@]'FWDFF%E=W? -#
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M,,S1N;^=?'%!UL1[PW]PS_TH#I/5 +O38X()9.XX(4SVY0=SY(0)XCI^!(L
M3(:9!:'T%&]G\..3" '7DTUE.*0*V(^Z3I#')TRVG>A'3"NTJ3=2O:PG'MCX
M_)?MD?KQOQ7:[ 1T/V?N"WJ"N"*)><4*> JV9[Q^\.C2'B =!+PI%GC,#MC
M/-80Z+O&VP&.N;/OM:2;!TX2A^=;[UL2D7!-W-[!M130I)K]#\:>W@&("M"<
M: \Q,VBHXQ.4S7<$=FU-XTT_&<B :,]M]5JY(\XV_L:-37K]Q-,6?42&@3,Z
MTF!.XI Z<<;&;S[MIV]=X(V_4B09PRQL[K=PD# G(B:5?\0V:FDB+(J2U=.
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M"5T^QAPY/?PM'XKE9V)(#4$-QDGGM5;I=.""2<)+$6Q;P:8L$ GOC>?R31A
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MZ3V_5ZHX^JY]J3MBDW.\>A8N(=(D]3ER7<I(MCU6PWGNG]A/-&974Z0)3=D
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M31(27[0](JFV<;H+1[J*#,<'DR2WC>+/@/@T39@ XMNL2MIR3.C)\^4'[+.
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M76XRBZ[H+T?!8-FE-F4 /-V%*OTE/I#PW30(3248-R1TE/UN!@/67<HRBUE
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ME"#.GEU+'B+R/6%.;"V(2DG1NYK,"B!6"D5.1::@[/\>0)KPFW\!4$L#!!0
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MV>"!4+EXX':S *C]CZJ*EQ/F MJ E4#*E2KJ:@&2W9W?$#\@A,8<#JT[L R
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M$G/K$_K%"Z-B-E=26<M(\S,O"7W9Y4\XD%.X[L$BB+@Q7\TZO^X.D8>%1Y
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MON0ZP#@]#+EVY8HQ"^@>R)&[_O(5I2*GFYJ\D]ED-@M]1,92@N=U->6(5(-
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M]$,N^B$7_9"+?LA%/^2B.P'3(1>]C^)Q 5KFI3:WYQ9!1#34H0=X^HE\YC(
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M3MI #AB-XK3242(O\B&#> 12_^K]")?9DB?W6I/A;\X!;<4\^L#S\)%>E[%
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MENDZM".[PTS!ZAP-M 1^03%[%9I2,PZ65&34@L]?C99"1Z[SM&U9L!<@!:;
M==!<*$*Q,:.@?=\N>>#$*$CUGWXT=/"5-3X5V)#PHYL\9:[/S_147%A>29(M
MB]]QSIG'PG-F^4)),MJ,/*H,73EJ;J6@G=/V4W3YY5OVMA:;=VW\G33X@\[.
M:T9&F_$. =^'@.]#P/<AX/L0\-V$_Q#P?0CX/@1\'P*^7W? -R#Z6B'WNXR>
MT>G2*92\H)>I#%6QY&4(AR1_JG<+2$A:68OH3]MUB/XP?626/SO'!^%+&&3T
M;-Z^5].V0-/7MV'#O X34J *V>]ANKA'4<YTL@B?'_%EG++D7FA?:6-0-,C
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MS;YB;OT[HUI7*\1<C3\]6VW;E-7,<KHWQ-,5_R[R8I9,(TPM[>5K1A<OT3W
M3C,32U./$+<O:Z(L#>U!=VE:W%!-9FUEQ071!'*=7REP*B*P<4MZ)%[^?&=%
M*-LENR2&_>>)BHC^YO\#4$L#!!0    (  ^(>UR]"J(HU<H   Y-#  5
M8VQD:2TR,#(U,3(S,5]L86(N>&UL[+UMD^,X<B[Z_4;<_X [ON'8C>B>F>ZV
MO=Y=^YQ05:EZM%M=JE-2SYP]$XX)E@BIZ*%(#4A5M_SK+P"^$Z^D*"!K?1WA
MG2XQ,_DD\0!(O"7^[7]^W<?H!9,L2I-__^;=M]]_@W"R2<,HV?W[-Y]7;V>K
MZ\7B&Y3E01(&<9K@?_\F2;_YG__C__Z_$/V_?_M_WKY%MQ&.PS^AFW3S=I%L
MTS^C^V"/_X0^X@23($_)G]&/07QDOZ2W48P)ND[WAQCGF#XH7OPG]"_?_G.
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M^I:D^W&XRL^<CM'^)7ZJ$10%14$J7.V($9RE1[+!@WC2]G=T0920]S$UP8)
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MOM_$85&P[]X7B]W_<'UWLZ#\? FN<2P?@DDE7!2N!AHK7,EC[X6KQB36[Y<
M,:D+]QL9R5M]!OVKJ=?TCU_8EH_P&./EMIA2^H3SYY2._EYH6]/,2;5_Q9CM
M/Y$T N>;<T&JJ9QF##S7EG>Z3N1 G]N-\AN^6>FBDY,&@C]28"JVMIZYHIX
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M+KV]"C)^".'$P]76L.8-*FQ<.G9E+65ZS#D:S2!&*N8L M6 K(-,B8QW;AB
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ML04!Y(+N&* #VE! )@6$ QIH @D*66<LN$W)EX"$#]39YR##LQW!?)/!#>9
MHA?,AW]J=@PTX(PUHQRKV31(&P;+QD 6XIW"!JJ,H-H*:LQ4QWB@Q#]U"D;>
M:2ZW?/G:)BFF*.\E(:8*MC099E_8._=L$0K+?3S"2;=5?L-+ACHW$<$;*CR;
M)6'U[[FZ2=.*.VO +$#7S95&UCM!+ 'V^5%)H1E?*JG_G%^Z1ZS>=$NA\E3
MM,E;;I?;;;3!9&9FC5[/.7ULW!!XI%."12@+I$IFW7)F5=JL+2KU*>=<D<R"
M3_ZH8V()2$+8EKVC$KXQE_"-MQ*^,93P#<02OK$KX1M7)3Q;ZD[OR:3<QQ "
M1#%T6,(Z8Z?$I0D4EA.>DC,UW%:%?NNST$6(8@L.M- %7)IVW&&AS]9?4HN:
MWI)R7],%B&)-KT5@%;J 2U/3J:C+<4 -T2[\%\2]1/T*T-)@OR<+BQAJ@(;0
MOD68"Y-ER$ 1P.#0>D (>Q X<. G&>E=G!CE>SZJZ="7<$8".;2ZZ+N/812X
M%).P [P<Q']T5+::JNZM@ANJ-<3*;%6%G4W0L)P!07*:E9>!K=.J+]'49+..
MP_-H=O!;Q]'T"C X8HE2<I,24Z.LJ6X!S-,F.+AX.U&]*6.SWQ;K#ETYY[&C
M#*80-+:%8'!#@TP5)F;EXL)T:PJC#B26C9J4&)+GKHX?2F%5IPX[#[T30(5(
MU7VXFB^PF"SP-U-@FB8 4K8:4)H)@@N7\.POU[J+[Q0RSLI8!:\NY+X C%)6
MH!(.I/SE&MY-=1^/ =NPA?'R*8YV07G/]7V0'XDNJ;%9S>6>%%LGVEM33#K>
MJ340J) SLE"CK4I+CUV-P/0NG$FT>+7\8FBIA+O,H5)H3<;0SF/O%%!C4I3V
M=/<^&Y<4J)C-\F%'SL.R@@A3LK#0",$H<@TRW>("$X;3L]S@IYSE!R5'0SIJ
MF:#+WD,-M-U?B%+>N6*$)I"%"J)&$LJQV+LT2+*'X,1R[4B;%)V@2Z:H@;:9
M(DJ!88H2FG@- A5$I>3ECW2D^RC+4G*Z3W--IR*7<WB@0PVS=9Y#%/)>_"9D
MXFF.2A0QV4N7_QJ3/7N/M@W02CKC@!YJS0*Y& P>:+'UF<"$.0><-097) IW
MF+4_1C8H19W1P0"VYH-"#@8A].#ZC"BD$1-W18GUEW3]G!ZS( G77VC<<EHF
MN&*QIJVPT'+7;EB[T+0A1A48]+'&V6<2+>AWJ&Y@_*YEK*.<W4:Y2,+H)0J/
M@2RCF4;.U=J&%F:UQB$5\LX5$S*AYV&R?)GK(<VB(G'T)2>MBOM#Z9B[V;2E
M;ELTPLZ:%"/@NB512GHGA14\^4VO*>GNE7/=![$?RE;.'+;:*_OKD4P.J3LF
ME28,>@V%*^FFWK>Z*5\Q#Y_=.X-Q&G6/G#,ZI6&=4A<J[TR )<S[X';P9859
M>YI@J 58W%.?0ABF_HH8:#J]4).PYJ"#0PP"\EOZ59IQZ@#ZR17]L4[GB)IL
M,BV@'-- E5#KGU![/@',VM7J.24YJRALQ61]TM[OK)!UFI-#![>3CT,FZ)U(
M-NC$RX:H[%L>EC'I-XC)0UG0ND[I$(7D[/)HX[RVI8Y+.EG!;]-*JP"&7C8H
M);<[5#J>(S'6K@I)D@9VA$I]O_VAP2U]MZA0]LZZL8BEG:0DL973-5G6.UN0
MSD+)TVJMQ@'%TJU$ P:G;&&:%G5YQ#4]G\[N/!^H&4Q(>0F8ML^4B[KL*G5@
MVSVD3,X[G2S B20J1:O\9Y=MA7Y,V94XU^E^GR9J.NA%G;4X!K!U.Z.0\TX'
M"W!].A32J!"?F!)G-R3W-':SXH^-@LM&Q0R\W;2HI;TSRAIBGU>UPF6HI6AM
M5IA$.+NJ<MC.DK#XY=J<;-A:U5EK--"9NG6RU//.K1%@A3D$+HNNFJS%U  J
M?[UVELMXD83'#0_"EEO:N=[A/,?$(MJVTW.X'FWO1FMIVJP$@VH#D(H+UI4J
MXKJH4'8WF"NKR3*Q2)NNEG7=="GA]MLJ01 &8PSH5*W1VW?.6IZRL1S "YFL
M8UZHX?9X(0I"XH42G8(7U\YY<6,U[E++.N:%&FZ/%Z(@)%XHT2EX<>,V1#X^
M91L2'=A^/(L012ONCA]FT U%U+) 6&($*!"EI>$NYKA* Q(NMW7.$LTV?H6D
MNUW\6JC-)GZI& Q6:+$)6_B9,,LFUR24N72S$<0XLVDOI'+N&@H-S*:%D C!
M(($&F= F,%%WC4%QER8?_$3)SH((!@5GC+ "7E-#*PV#(S80A?M0BYM0*R67
MX];-D40Y#7,&K'Q;*#F,3"T=:(6H!@T8-+*%*0:ME9Z'->TB8IX7\;+MB%<A
M[GAPHP7=&]](9:'0Q@10,<J95Z,<MT/@VV%<48@[YHH6=(\K4EE(7-$!5'#E
MUC57'N*@F-Z=[>C_6-Q,J95WMT/& G:S.48C#(,O%@B%W0R5"N(Z?@BS.=GL
MK#)H^"&-$KJ<-H(X0.*H,.JILSFYW)F';X])B$.;*W 5H@YWX6G!MO;>2>6
M$$0+3K)%"A7BCH.5C\."%86XXV!%"[H7K$AE85#$#% 1K'QT':S\Y1B?RG?U
MEK35A#'K.&.-+?R:.B8%&/RQ1-DG$5.KF(.$;09.6IT?6NM5MDV/3L=Q^V.&
MWVN$U HPF&2)4M$<_=!=3735*'VFW27YPB:&K&:'M>+."&0!NN:.1A8&;<P
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M#Q BWIY%1#MMU]<$C2>BC2HD(@[ J[Q3" @1/YY%1#MMUU= C">BC2HD(@[
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MOAQ4O\ _$52*77[#"M[_&&R6VVVTP=8-@UG)X5852P=:^U0,&C"88@M3G*'
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M"+ $5G,$N/40! EDB,0CP,7L22'DNI@91PD.%"U"][&S0I: JLNX]0Q&$8N
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MY8A4%!!7=/@4G*E44*%3I=3U0YZO34+Q(LNBVE.)J&/:*,'V."/(02*,"IS
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M!+6&JN-D6$AZIYT8\EK'QKX'&W:##%CS($I\\DT'64O\'__A7VEH^&=^,!W
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MW:=EJ<59&73TO!-3:,5M6WO/?:=5G^F#1&O3Y*T*I7QA(*T/1I;9O^ PIMD
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MADO.C7*OS<1!!L#P<PQJX=Z&T@8*"B,L8R(_DR@<1H32)BJ\+BNG[6'8P58
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M+*?_Q.A30'[%.5INMYA 2%>L\+FH>".I*B@#X*K"(0NR]C2ALU4.=R*Z3M7
M*K;#5ZB6V];FUED25ANTUP6XOP3),2"GZS39LAW9>13$\:E BL.'XU,<;2K
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M)8DMH+<)JA$'0SXS1O'.6J:!J K0@;G$)5-3JE?Q3#%M(ZB3ATPR4_/5L S
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M.PNG:85LQ4>SN ]@VM3+F-,@'2)$4"$_ )T_H'DO[2CXK>4EM3\9A"8M"3G
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M9$-:]J&JBP#=YZHF##06YL2FM3)!U& @,[7[*+_+11=SOLQK"C3Y(H<S/9M
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MV>__G*G,MRO/_(9>8YIC""U6Z'N4H$VE[T%4@AOH:-9=3/1/_\$S,:#:-XV
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M;5D/+P.];)[3W?,@B]X?HBTO1SZ%]YZ:@779^TS2#S-Z>/3R MR0O&&'!1_
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M#!/)U522_H5M)RF$17"D:'V%1/5G@EA2RT=>9NDKS<N$.2UX*^:P+*@Q<%F
M*[M&E[\]8_(7<K5S#S+W:W%XT='*ZM29DWI07#JR\JGK%\14$S.4\^3CN5%!
M)M+7:/N<I#1_9PX%BL0?@<'-EOT;"PFK))!F2\#;1\OZ&D #ER*'"]#7<$.)
M>T]:TR)11:S)@CGGQ?$VVS@RXGC5,>CP"6ZC8(,E.1^W'$\S#5RZ'RZ <W8E
MK)W;AIS*,0?/@NO(=YWEMW0?'1YH61[4,9<'+EYUNS%N5G-O@86[C .0(45#
M)[AR&[.^23MW.0\T?TVVKHG;&F2\ZG7DW'D:)ZE\;U54M$*_AQ^E[J&$<*E^
MI!3F-_:ZQDI&HPCT</BIO$J*+?16N$M[3D[U?-@$CDO#3KS*3XE9H!U76'#T
MU??9B%X42Q9ZC,S)!X.HX%+J&!%&N>Z'S_<;#'D'YP'X3HLR3[;,Z_!!^"5-
M^/N@IAJ(4SSF3@2K'7A+8#*#O"%6F<()R(DXK2:(,E;KOA'SB<?=2&#5OB?_
MPY^XH0C3OV6OT24]'+Y2J+8OJ;7[,RZ5*7F3"].]1@2@R&\";NF^#J+>2\96
M_!2D^2).S+-#LGU_I+^7GPZ])J(N\+CTX,:L5."FP2("C?PF$ E@$HZ*0E>:
MF:$&PZT9XTQ1*"3@C+F,#@ESDFD207^PI#SQ Y+O=$]3FO-R4U]IG&R3E&KT
MXTL E^8&<B^5\FK(D(8.881(FQ*I285UD=SFOM,M35[ABN@O2?D<Y]&;W!E7
M"XE+A38VE16_"A8OU@CDK<8($ADP,Z')/A4%1YD_/S?>^1(E*=S_WF9%0:UK
MV4 ZN)0Y3@@I05E0(S4YTJ)'.$'"*!)!$LNZ>.ZZ*/O:YB=<6I/XTG>2#'-^
MFI9,SU\CR(F!VSA5TD ?!-<(:_F33S/A$I(9]<L9-(@5LS\DV^C ]OB4X3SS
MBIBO]) =E=M:,S@N73CQ*LV "@G.*3A65=2SP4-2RA5.4<>7<[530:;2$2*X
MEG6%1) +N;CK!8KJKM_HVV;+3\[A84">I>Q?19IWU6KBTZG\EI5_I>4FSHYP
M^V*)1L82Q&4?$TDC'9K0-W*F2[J$B:!,&&G":!-&G%34L80J++YZB_+XOFH0
MV"0DGB?)AD56I6;GZ(6-RQZ&L*X(3H$&J8F0A@HYDR&<3M -HZ@)5)_/:G2I
M L*E,@.'4O:>J%C4M"P*.OJBWIIM^%50R,;?P**<N2R*S*'0 '/0^0FZJK]
M?[6.?.<'P3(,KM'7,]@?^PH2[E0:T##/M 4CO](TSG(6>?%@K&IRIWB2;8)&
MJ0LCJSJMO'(D'C**2))6>(&>>=!CE,1:I?1^QZ4&-7.R*^)08<=9//=CQ@(;
MD.K?/VN6 @,LKO&W,RIE^%109,,G0/.?GX.N#S4;U] 1$7+)6-AVM[O;[9(M
MS3<6+9F0<*K+@6.MWJZYWFILV!17^$RC*%1HTQ9JQ;CJ ,-(7UE&^@KS2%^Y
MC?05BI'>W&FO;F40G.,M\6=8&.X"7Z\VL]$^[-?(AUWBS^!3L S[YO$MLUE[
M X)SV"7^#-;.0%$,^W4KAG,)>7JP.!6A9]02X+04%%(YSL'H.@)0SZ!3$66&
M54?%Q!>-$KH_XQIZ)6_] :]#^2\81EEGZI@-W,FL<6R8X!PQ2M\WU=NIQZQV
M>3KKMB'@TH0CMW*6"T=CNJG?E#UFY\4@[+RHV2C@N,5V=M0&PJ49 X>Z1;E@
M^H LK["G1.<,J/M(;F+<^177B*M8TZ=WD:HH2>!S4ML6 +-I.X::81> +Z<(
M;N;>[W:\2L;F!7(8I/%60N$:=1.+4N9P!0LA)2_F02(.'N9Z[,^75:E>C;'W
M 7"-NX8[Z=[KSY>D@D-A[[I'*IV?<8VTDC>M:6.(43:/SSFU'EJV@' -N(%#
MTU$.  <=?GA\G7.I5"%*YU=< ZYB32I6W,"$#5'NV;\F19'E[U#+0)O.(P/A
M&G(#AXHRA!4HI#&&-?%'FK_P&A)5;3W-^*O!<&G R&-?!P#,1[\@%7A0-4AE
M;35ZT,#A4H29R;XF!#0!<!2J>'S+'I^S4Q&E\>,;A4 XI;5IZ6:'%067@ISY
M[>OJY__X^2?23)V@:A*MF7BZ6!TS:+2CA<2E%!N;4KF'"KY[P8)JYL ?*K.R
M+"^NF+A4YLNV8CK]W)I.*+T?C\*':E&+BUV/-L85FOP3HG#"22!]8H ?^@IU
M:4LH:-39:#-T7H$DUC4;NG.@Y:I(%19R_1E85JCMOY%V/(E.8]+[*!_%:9!7
MH#\SYTHU*AZ!A7UUU-[>@W'95&C%P*4W5W9MAQE\WN'0V><H3[-3*;I&:+2D
M@,&E%SV#?4U4D$2 AK[;A;M/)M=!%*2%*C3BZ9HV'<*"@4LKKNPJ[H4;/%(C
MUJ_Z@JKLUPP8:Y4@U"A* X=+/68F^TH1T$2 $]'$+W N4<WW5?*:Q#2-%?-%
M@L&E CV#BB2A<ZW*N((-E"U1; ]90?.[ZQ;[4-4D?Z7Q=99?G_+RE--'OH?0
M5GH81@:7^D;)(%_J5<0@3Z SS6J"O"QI19+\]BBV7&%+.3S0/*'%I_K%]2:-
MQ5\N+2_/'?%PJ=N/:?DJ$6#)I_/S=$@OJ_YZB>/1^KG-)V\2>4O+DN:V&-X%
M"9<B/3B6#Y2;1J8<EPAD),%\9:%WJ:WR@PX0EYXL7&IG&#PK0C&?*O_@J@\9
M$*,^M%QJ]'&)31]7]@!>!XA1'UHN-?JXPA/$*_M2ZE2BAT6F%2NCDF+:C3-Q
MK"2?LBB/[W9--KPNU4()ADL?1AZE1 L A@C\_ X@Z(DJ9:/!9-O3N]U#F4<E
MW2=;<:FM+(AI@<>E&#=FI;/4!@O45-1X)&D0@VR+'Z(#+:P^3 &$2R<&#B6O
M!:!(W!4T N(=@ IHH7@V$?E(2 .(2PL6+N4Z\L6S:%7$X:&A9(40ZH3HZ907
MHA[E979*BS-8^_Q' L*E! .'BK.;,RC9"MA _7KS?U"QK4W2O<T?&:%Q:<.%
M5;G;+N"0&@F)KWJ@VU/.B_BZ7G1;,7"IRI5=>7]2XV&[V!8[I\]BW^2TE5?"
M8E.3C5'-!O)SO8%$M*>_]M"-$A:C;DR,:G1SC4HW]X=(')9NX#;75HW6 (Q+
M.PZ<2KN6&H5P'(3JV;Y;DW6,X(A5I./5K*3M.Y+5YSZGUZ<TIK%M JGAD"G&
MR*2BCBH1X#AFC/"R7SP6&R4L+I78&=4L-E]0+39_/AW>*T9Z%WP:!=D0<&G)
MD=N^J@"MR9V2;B_#SZ7_;-U>.$TH/0(N?3ERJYE:_]F]I$$QP7YA?CA_@QV:
M_63! (M+379&^QIJ8R"-$'A/;,<HH06+2S-V1A710C=8(!P'2YXB,'-/<YYZ
M?$6;&S_YC-J*@DM1SOP:DQJA\3J<7),"D$E\Q@YRD/J='J'G&A?[U9:^80+&
MI2L'3N62F&T4'$O1P_:9QJ<#5/4\E449I3%SQC5G^J13-S1<&O/B68HF*F06
M[I$6>DN)@1-(>_U]'K/ZY->>H^..BDNAWGQ;^QR5V?G '$UNS^4A*HJ[7<7D
M7?X]V3\7)7_.P1"OF #RPF=%P:5)9W[EMIX,$=(7WJHX)<M)SI%)4F&3F*$'
MS"']R6B?\%[1G%KJBH]+H\.8UR6B_OB3PQP%:@CVX9=FF<UYJRZX&!7MP[@N
MN]5)R>'U:[%I4^T\7P(8->W-_:@Y';XJ7[=OI5=8Y8J)2\V^;-NZ=Z*<RK)X
MWVE1YLFVI+'Q!;<K(BZ=>G+=5ZE2EV<*&-Z VR74-P3RP%V;6FTMA!PU&[J]
MD#I/P,L9^U+ I>FA[#MG3Z#TTAY2ZV?W$"*K5;YMOOOK?T537U]B; B1U=J
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MG47[PB;O=E?TJ61.YS(Z)F5TN(68X>[ID.PY?TK=NV,CTOT IN7'0S4).,8
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M9MM!.G7!1ZA9+[:U^N541%<[H(-9SRQR9TM .F36&C$1ZM:18?VL%?B8M3E
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MR_Z-_;G^$_L_*.?"_O+_ 5!+ P04    "  /B'M<51;=&X2"  "+W@@ %0
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M0%D/2@WF)4Z X$BKH/1PT8L$%[L'_EP+#U-X(E^R"_:AW]2+(D!U*#^H&87
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M/PH(Q;KOAL@>]NO;&)0[Y%B\85AAG)^-Q:"^-2B%R$%M ]%RU;H*%9S[A:.
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MVW@[M#>MW;*](VLOTBK'V!^!JH3#(7G]L75I^SB6)O3_"E05D.^N6D+7%:/
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MAE P5:;MX&5S[<MB/Z30"=X?5,/7/=(:>&E4>R]N--)CSG>2=ZB+G'I\IO[
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MR>OHL!5KCXLYFV IW3'IQ((;:N8 #6%O6?J\6]4'*N<IOD]B7SSLHMR;P-O
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M2",T^B+\T8L\RH;S+]Z:\(MDB]4J] E-ZRG"%),%J#;R$EH^^S5G#0,L3CK
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M!.WH3(]JERSH,6Q2JW6Q>V*?55\Y!U4^;3MM(FDM]L$Q,GD?=?>[097=(--
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M*)U!3[/K;!S- &[?DEX?KX^F4=_6-]'S!9^"EDJ8<NHB_0-)62?]K'QBDN<
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M2P,$%     @ #XA[7-./ -+_ @  W!4   H   !E>#(Q+3$N:'1M[5C;;MI
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M'ZD.7',R6YB;B0"?J$0IRH&4MM$RU^OTI\3S\]@VQ\W\_&F.J=\!4$L#!!0
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MQF-6&B;84J8QT+*TKFU49N62U Q0&9!G4,E!22GZ2B8HZCTPT")91&U0S<6
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MW#VP2!H;Q^&PR_ $1/#!,?<"UH'%MW%6-@G+WQ$6;XVI2*U:16)C8<A\P\?
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M \M#++?M?\34A*52.3[Z@RK8-\O_+)#R>?F735JP#TKX"D(5%3!5]*40--$
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M>*@AJCU-)J]_DN7W&IC]J_/SUM5Y\L=>WGP?]K^C/:K7X,$_SN!;,_GM%S<
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MI=W30JW$-W;Q3T1SMK8Y.+'MA/[LLLGQ,D^_&S,1Y=G:YV",UM=60/X.^>[
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MT1ZBNZO!I:S7P@-Y@9_OQ9=W$)WM[ODD@L^8@8O,I)X&/1U#-\T;W8#)$M6
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M=:0D-_]%-_\%/LSM+7#QZ8-#)2E4^/3#P9(TMWFK&$2R=*/=AG<ZG[OEA\R
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M7A*'6M&@5C%?:?2B<X!%R8/[2APJQ89**7PE#IH"@.8P?"4.M:)!K6J^$G8
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M^O/C"%"L(V"$..[F4Z1O>:1[@!H_>O#P_FGZM$[_8Z '>_3@T5?<(T\VW>E
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M"XXP7W&$*1;EJ" ==Q#!^FI"O23 QT>R.%9P5[/NS?QB1]XZVV #ITHCWB0
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MA8&>R3IF7L#PM9(] N5 !PV?!1S,"+$_( USND?#?(?,W)VSVR:\F(-3E3;
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MYOKD2_1S692?PS@_?@P^+YU/OG3NA@'[XMT-V,-L-F%'N YG$S8OG3MOPGY
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M [1JMUM$6GQR+W8F]<CJ&<'2HTAT2<LI<=P0 VM2:! 5,J\*VU *% "3.J'
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M>Q5W*5UG(&N'V)6/M;[DT,FS-I.O!:;F3J_M;'$RLL6>XVQ[M>O(3L$]A)F
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M >K3'=@$T9X1VF3PDTTJZ49M5*B1<LF8/22/VLB<*J\9ZRR9V.%[^+V1CZW
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M90_^_1@ZWTAC.J+-4-+DX-Q%[*Q)P,YJK4V'V%DGM!@L$PD+#:QW$".Q\Z3
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MH1]K62BUZI*1:S]Q3)\XA6]AZUP=B^])%3,<4J1#8C 2>P5__E\J+77,2W9
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MKOZT9B61/%"=.CZ#8BG"WID2" \8S*#)L:Y'$BE-6FD 7SD9O?$[4F0B]1V
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MU)=,<KG#<OF>RB#)] <5D^6J_-@$)Q49[FJM*H_5)::?U.<8JNOI.-VVH65
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M2S*&Y<T/'T4K>-9U+:T2<GUKD)FMS+W9 Y?8='<M44^Z^%H2W589,M<:%_]
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M!!)MQ!3QAC12Z#WIA1V>T)O"O$Y@GR)FZCV)_2N@+-S%)B*S:A$#SRM4%_?
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M++*7:D+QGY&,V'1$>W 0_93V]L<?1#C#_C$F^\?OA1)-E30F\3R@8\55[C]
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M-$UX:"\D#YT 3#@;31V:IAR:]99L"H=QAEY$#8WX%4HBEG"=)W5C SQ"N:M
M81Q4HH!SQE JP3<&/TTICH\<57Q'J7F '&*"7N6#Z))"54'Z1SXIWR.\%VXC
MU20I%2:LTD:Z%\%?+=L:9))SS=ASS>B=5RU<0%C?$J[/I+0^9?'CDZGX\:L6
M/SZ:BA^GXL=O4+E\V6I(#WXAN@M^X2[4EC[@PE3DN&.;_Z:MC!?.[!5)28R\
M9I3H3O!3=UTW',Q-QNF)@Q:8+<+A^<&FF[<;@N6P;^P]R6^[LP(LU0)%FFC=
M#SOR!>.-C#[>^(6"^IJ60>W8@&ZR?&M1HLU3S=*KK&#PLCR/B<(!@XMEE6ZK
M?_3:E\S 0MM=(8_ ]17::AQ;^! /PI^'^SA5UGSEZ%50W6 ;+<D'++C_F6),
M.;B1F$^H4EOB4#>PR]K:?>_2FRE<^;7#E?"QG%E\)#8IT6;N7BV<?_B2?,?L
M*I&L@\6P"=!O%,3FY6_/:H=B0S6L!#+K(5:31(@D=23&.$S^SE\F@=DE#2'U
M3[;H22M757/$DRKX=G;65P4_9XB<B!F#5]D<.P]\I"IWRG]^=>9H2'SU,0H_
M-I+P4L/)O'AVYC6)^X]AKB2LFIDDY2M+"H,+-JE??=LQ&3!26B=+K,U6R\#O
M[1=K]?W!Y8&"BZ4PZH\KJIODX"O+ 5(NS?*LOO9=\K#F:)ZLV;QG2!<&I1FM
M,0JK9A$U)U<(@I'GETLS"<=.^_6V7(F//#==9 7]@,VJTJ+'M",U\3GB=C;2
MU!>B*:9_@#=98_7D9E(,NZL8\@3Y!+N!NBU]EA(,67"^R)4WP(]D""2YA"NH
M?37/DYG/&\_6PK3MNW;D[3E/O/9S#Q=)# 2ID-%>SR'S4%NOK%DP[?77;HH8
M4.=AT&!X+\=.^FR#MT'&9 ^4W,:Z &I97JV0_' CM<_.=%@GFW(Z]3MWZM?*
MG>"I^MJQ+Q/(=J<&C70\%ZI-_MUNGNUE<@-7+B6&$3H3TZ4,  %>'><#_*)&
MHN7LGM3)8OMV#G&*#%["Z+I(ERE!.31ICKRZ+=><KU/<6B')Y;!_DJWN6\<Z
M59CNX*YSZXCK+ #_?KD,FI?%-X^CFF#Z,#.I<"7"V.:Z3*:BK1W9WI=+XU+8
MW"Z6=O._8<TIV>P2$%YABJ:2]K $4\>W6NCG\2;X>6II;Z8*2WB4R^_V\HN6
MV""]HU..R1T\PC=B7/-!DZF$TTUS6R3Z+IR> 2B6$43X2<1W1,2Y= AK2-*"
M&J3 T[P!?P2D+[K)*H'?30L8;IIB$!J$J,1B!M!?=9.NJ+QMR/6L4N%'Q/(&
ML'QRAH5'6!04"W1VP'2MTH0;?[G! G_$-A[O3,ROX8TIUN9CX='!5'FT.[(C
MK&$>@U(2K;-U2A7-H!JW2=1]Q<B3/,IU7:=)WEQO0%L59662109>4[J_@!%B
ME=L*)6Y^O5G1'2R/929K:>]IU#3+,P2R+XMYF6\:& 4-+:VU1+QI5PCMD_'G
M:9YHQQ'/$FK!EE#4N"J;W>\039D%')3KV>)&8'OYIJ"S,#33[<)O^*6>33'5
M_'QE;P\^FZU;P2'H0\^-9&P)H%L2>FCJTU:[;I0! Z+#@] %1S'$HA4TM_D&
M CU[<A,_91O TZD-X*NV 3R>V@"F-H#=5BY?MK0,Z38"KKUM5P*7!V2<510#
MBJZ>(FTKB5ZDJWV?<@)M,^:>)MPM;"5TU0<C%>#3E?.5I8((6+']<*'VB=!S
MXX](#9GLDQ$=])9F%D7'MIKBQA/Z G[86MK.N@[Y,!"*39BXBA1K7C%K88;)
M:5AHD'98[:0*S')DFU3PX3JKT6S/-QXJ["18.^+^W4O0J*E#]1,QUUNO;,IJ
M[*SN0%H8]FLTFVR#TQ@83"H+[FIA,R)"BA6J4:\RX5YH'$HQ%#R17-XZ91XV
MRV5Z@YGN24"^]N526^' (+*8!)3<E(WRQ*&VE')66,:W=EQF//P>BL=+!C5'
M\ ,&)F8"MLZ+AU\3*X^7I4-*HD4*+C5&(V& PNLDJ'(IHHPF<T*5LS'+20B_
MLA!:&C&":9$B& G#7:>KD@LC-@+O _<16A;PE_F'=9D1V.1U-LMLWH8"=8PK
M*NP,Z=U0A$9 QAAD7D&,^"'#!V'2:#LI3%R[P:@EO<Q7K)?3?=HL6)UHLZ:7
MZK,\&P&H:6%)YT&2S9\)F]L"("X#I\CS5":P S)EZ_R)KY(J>3E.K,T:094_
M]V=O%T-N?0X; Z]<_W*GDE S;Z((IZ3KCGA.G'0]XPO ,)0/^L3.M+:'>W^6
M8,@EPUI.>Z&QJRU6B^;V[87B3)<@S3_A-NR6$)SE<&.T5]=&N'30IFT;4 ;_
M(>*BU:S:@&7CZ7FNL>"/I!2MZV0Y,85.0D&,I1JI8?+0E,BMB=&5<I(D*4[R
M%FV** 5I<ZWQPXAX@7(A_<#/HXZJVZHJV\*Z?T(U1(8WCT+@P508JQ035T3-
MYIE!CBE8AQ_#>(L%7J!SXQBNW>VVZ>2]B"NEM8A>'G\%C46Z9@GW=5461+0E
M]&Z<AG5W)JZ]V/=DE\T[%3/"U[6=9YEY6BTI/9H&\ZK-&O&*=,1>\9=SJ'&Z
M7#AJD<^OB%(W)-%"XHRS]JIEM.SCPZ/'L:-22BM"/%L17MV'HKPMT&*YA-5]
MB9HCC>%1\P/+0L4&B9V6)PCT1+5TP*XM*Y@)$<DL>.3IPK0U\UWAXZ-SW*-S
MVINXQR;5_41MMX">C_AHE+W!%Q!K.A;,I@ND2<-]J!J&F\OS] K-H:S,$\5G
M(Y"W%_+9%V6YB*6K'G;KO*Q7*>%VGLV;@^CW:XQ%Z#(5*2;^BV3%KY.Q6!I[
MO(RY5S\.N>5OT01,5R#.204''HF:JW8-4S7*.>35\N&'J1"4HN4U0GTP\KPL
MJ)Z?509/QXU+/#KD69OE"_4\X "UC$KG[$>U0@G[S3,4C&>%.BHP[YQ>MRO2
M7E9G"(V/=\CQ@,&($4.F3J]6ZI+COJ;-QI9Y>69M3XA,<D5<3,Y?E[4*%]2R
M72=RGM(_TCD3U'LK2:I"_L(P[\%#$ AALFL^87;[Y'#*;G_5[/:3*;L]9;<_
M4KE\A^:QQ;1#YGIG8GF0JG[!_9)M4JUE#KDI0^.,+!Q\*"8>""_6K\_F>NE9
MZMW>5)4=FRJE9"5\(\783D%<>WA-LH72C5L/<L%B>(;9*!VE2)(WY15UZTXN
MVH[)(")-^_L(6SQ.BHI$E"IC5"I:@R5#('4HC<0B3'9N8@M"QRH$&>W!K*MT
MWSD]J8.JM[\,R9&J$HTJ#TO.I5M@A;3*D$8DK-G[.8/4+(:'8LY?/=L_.CPB
M([Q(;\GH3:Z*$K]QG5V1GP)>W56>P7):<)M??_G%8MN(3UI;@!/P.:*+:SP"
M1UV/KEXCPU]%Q&[F-_ :KV]3C,$7T?LB(]NTV3"N7IUBZ%^/5<3)*)S"90OG
MZK?R)H$!G#PY1OF87Q<(R;/IC4(#M.OK30UF:U*8S")UE=6^&PWNP\O?GN&9
MA15+9BEHBJ(LP$5;E"N0%K!BL08Y1>H@-M01N87:LZF7BQLW$;HYO676.K3(
M7^*]5"2BO]!',I<M"#ZNQR4;V_ 9&$[3RF?>TA.BG\ND6@@L.+\(QEWF-S2I
M=__8YS92:E2QM<T41\XTD"S%SSP6<!EP?<#SU6IJ>"K8W/#"FZ2>@V=1@0V>
MS&5BUG.@5N1@2<&9 J_TR4%T243K2O((?Q3V:*H%P!''UHO!30&G,:40 0H+
M;,*^>BD,?\.S(]FW0XT^;JB5=9)21'Y<<-/L@/=(64$3N(_BDU'%+K;EH"18
MN$IVDGV,MH*/4%BCZ\Z<=-<LZ#$.J@>>9_1Y1 FM.$%C9V6T=B+",PO;P"=/
M@D6UGS?84C-O7$Y!#_/9L_W7E^?V/%-I_S\O]@_A#7F9+-31EW+Y-&=YC^3;
MYV>OCN2[X^*('F!6T,DVU/QJ#[;;>LF)X#\[W\;7,U("#)M$8(6QLP3&F5%>
M#U9Z/T5;@..J)%0'L,>%#3WXY-SLA]Z#0'V0#=Z"/5JFNI@(23,23E3^"$=O
M@J:H0,W[:)!6"K8 _C&TAWQ.B4OD+X5$T0:N&)3R=5O5K:0LQQCW% *U3M,/
M(QA3\?T8X+M$;09C%RV%%@8QS_#!=[#&6RJ"+54F >MZGVF]5RCO]IX8!MD
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M\B^]+IT^W5W1E4+-@+.O1"]+2>9Y]&SQ.;SY)%>,Q _#$PN0>%/5@R@GSPP
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M)P\QOV7;V9><3=PJ4^^)]E+W_5W%430W"7,>9(9-0YIU\T PS&@,XQE%C>I
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MNBV6O-AJ&^[;AY)A(P53M#B12'F5YEY4R5F&8-NN!SG[PQM1@F!%^2@I1YY
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M@+F41EJRNA=R#$Q8Z&8MA3AEEK!@KN[^B*(7<TKN1J3V*#3XE>G.06D.S'C
M<&B&LE-5S7^XM&$$??:XE]Q7*'_$*ET+DADM'Y'H4RQ^W[79#A1T+ G0[@6C
M+36K$Z &EE7I#^"$\U])OU",;2=3+D0>IM61>YNW0:)9\-[7[FW5I._F/\0(
ME,K6-U./NNIU%Q,45JF1VT (I3I7<Z\BD'::H9$>%9>GF,##7B$^,)#PRN=S
M8G+LE&"PB5DW3(U6<&>>"K;+S26CK<Z03JK62D_C;KS' UT'H))1LO!6#H#'
M1!O8D(7LRL-=N^'US>7BD;#.TV\<VM.I-1T0&SZ<24E.C]O<EL3""@YZ1YN6
MS;U0(""8!JLGKVQB(10R1HQ4[.]0\P^)O-CJUA617$16K16UHAH.PT%'HW^:
M5WFQZQ=BU[=.#,"4\3'2X#((/[<JIOHK3/[964^,M%Q3.^A"Z\"9/DG5GU7U
M:M5+,0$E=[ <8O6>T).#;%:)2!AT-0L*%PH?J22[B+]<RLH7LU 9D@N.+<?X
MO#/L6>&,$#!9>X9()'_R)X/?+ TZ;M6UQ280?(2&QW"\F3XB;O;C1:E=;6'5
M*C,C9.J*>J&3N[BU=[KO]^FK#,1P2K0R!_/T?ZR]#86+<PKQ"4OHI.-VV"L9
M>]!<I+ J:;M]\LIF'>;9MK]$%3E4B7.7^!Q,#;TN2$GR2'S(WXRWQ<\>KK35
MF)7IU%-T4^Q(HBK=+TB2"T@Z66S<T]=D;^6;Y[)3VCN^30#4U'D\MYF<;J;C
M7+]SJ"_H 2*_T.L8KKW<PJU34#2U TGCDO"E*\(PMVU:SD3(,;:AS8=6RR55
M^H%7K97[!7=^T36D0T\T\Q1(B8,<&M&"<7\?Y^.1D\#-GP3+ZK@ FX8(P3MK
M.-A(YS- KK>QBYHY"HJ^;]<5V; S',*QJS]V,./30;;AJ(#7=7M5;'P,5O4'
MJ"ZBH>0?I;-9%M7E.)MVD9GT761ZC6(>3S]+C3C5,M$?V'J,2Q_>2R@[9%3N
M#=6PG[/:_[RQA-.=)&HYC9?P0]='?Q(-S?HNGDQ-6>B26*;\$@Z,D*ZE-O70
MB^)/BP+:->5[!909LMGADX:A>A^<EOEUE;L8S\G5YS_X<8_[9.&<Q^E^ON!T
M/RA.]W<+3O=_ $[W_UE.H ]Y DEC7R.Y2^K8DQ;98MSIS&J&W9$8LU+JL7#6
M:,F3*C*VAX3S(\(7K=WNH1,2Y$KRS25T^61#ER TBY"6RLH_0_Q'H!^WL;E5
M2?&(:F>9^ NP*KTW"- 4)5*M6(N#\+*5(U;9+H(H!,82*9Y50)]18S"SO04(
MSWU,ARR3?6&[/%"6(BNZ+BE#FG!H"4VBM,*GY*?_ZC!CF=:?/:T=:A"W0L78
M'X1Y#HPQWG%8INO"IDOJ:W&&-(M 4 )ILE"KS+6TV\5GNKQY'$&: J]@K.^_
M1W9HF=W+GEWI@#+L-H>[JMM<(>C!<>K#?V+M 8M*M5L-74]%Y65:+VQ:"2.@
MF?QN'&"G#'!'M-!<M=NK?;MFGY<A!JN^#"SYTS6P],Y<X+1/R(BRNM)EP,SO
M"VST0J;LU=;]K"IIYL-655530G8B2"__F\3I:A =4O4N MQ61\-T9;)A8#ED
M6%Q"/![PG^882(#+3WYPJ@:NJ>$")\:.&FJ%/;XNK[.ON$'OM@/M87/KDD,E
MH)[R*8Q/&*J9E(YEEPTFBY&L[X'IBP3_Q+B(&%#Z^_N0BDQP5D0;ITBK,]@J
MMK \]-?9:_]$WB5N._X#&DSX:>?@C8$8I^UNBT88Y[63(MIC&8]BA3Y(XK8V
MQ''OA2#6X03W <E-T+3W_AIKH8FC!0(\">O*JN3J8E,NQ*8$>7.22;1Z]Z;U
M3%'@*<>[:L- '0. (<!5C5#,2%?"I$T2T!AO9U&Z='&%U,= <+II%Q3YA2T;
MH,B?I'6!DLL\#_1==7M7'VUZE-@U:1W:MD=N4BM^1"=+0L"?,X]H 4[S]"_<
MHU:U05B ;^--8L"'R^)]HOPG43\3+2KM$I% 2ILSTPO-:J2F*D!]6;X[*\12
M6>5W&ASM2<69.!J+]'6IC)4H[W#B1"565:AUHI,05%/'>N$NZ(434W?'C,K2
M%QL&]Z'MW@G?IMYCMLQU7H\\HCHV%=AQ" 2RS6J<JN\SU?X[]P7+K6+Q"L<X
M729[C\M$G=U4Q!X'W'\ G-*5UO!-!C7BH&)#9:"JO8'_\7_] ;PN\NPK$.&V
M]=4W1RS.M_YP7:WR[$]5C5;;MVOJ:O.[\AO_#._R[%OOZ72'JL_=FZU_'FX%
M_JY=WY7_\2=_P08OLQRT%V(QWWJ7UJ7$O*''5?:$K"'ID1[U&F.1!>62GCQL
MHE FC]=[];;O/+0T%U2W4'O%]LWI-^P^&YLOH_,UHUHGLN51)S":FXDRC'=A
M@XT8E\%<^O[)*^+].M*1J+;;L@O./;TJ\S!WDE'D%W_M[^SOF&??E?NZ\D];
MYMG-S@<F>?9JMRO\X^39UV6'2(6>]]6Z;5[_S?_6V1,A'^_F>?,5Q.C(+'@;
M0O'RK%&S<%<U__30%"/X6UQG;S0&=\F,(V!0,U&L"Z:M0.-]=1@DJ# B6:@L
M!P(ID<T1_4)@]+KJ'H$#NL"+#GC;)$00L3!JF'?ZF9R/*# FL^[@09I,B**J
M1T!6]7<,"5JUD,="8-GYR.RVC/8N7LTX#- +:@8T/ U=+-",_(?%=EV([?I&
MU%^UBUK.^NB/%+<%UJ5JC8U_G6@U"@5\C!C]'E>QI*C)%J+(R(?F3SI2G A+
MF.KR)]<4Q-S*V&7%XAZ6M7O:@G66N7M4?W(AN[+IAMO>!BLXGV]Q@',7HS_%
M^XJWF0S$H[Z'2$M5(<S6F(NJT\VA4__:(<?"% YFQ,B>%:P< +W-P$4Q9MS(
MWLI'@,>&3, 54^S'2<;M0^:B%*RV#?>M8*-+% <.=UT[W)ZU#W2.L#^6V!0"
MQ<@CJ$KFQ#0F!"T##6[D:7<,L-'YC"PB]NBD^6P*?AK F'LTTA%?8WR6Z4H1
M:I!([D_E2!6-')-Z."7U8&U96@]D\Q+9,R8GH(Q0A[)*SD*'"(;Q"W_1((?Y
MKU3G^Z# Y3\LP.4/"ES^_0)<7H#+%V<S/F[7Z0>P+8 [P[O2I-D:D(%=)IR3
M5A;6,#.TA#%DN>)JRCVEZ96QYVRBRQ /0HO9QSGD)@1\3<Z.V+9\X/._1J67
M6C]QP&_TDSVK<_E?"E$4R):DR$"_IN_!06N(N9C\()/]BD&/2$5&=T"+,D'6
M]O4XYE6E'<$82&LQ3 ?(EN?D520$JPQRC[TC'[=M8D[9F:N.J59Z37>/!<+'
M4Y"X" 4 26U0R<Q8[-[/K&2X)>I32C8R#I3>X\]S:NI=F21$54TD*WC2A-?"
M<'9X[^TD/U%".T$S5;U#0,T^' ^2LAGD#FL$#!EA@J49&!"ZDO'*AIR V8]"
MX=![KYID\&-(Q4"H.YG\J(KYC!L&D_*=HUROC6E#*#NM7RW1X0=X^/^]^O^^
M@]Z4^RX*NO\ISM=W0=^6IN[%7$4 F_R-+-<78;DNQ9W+.;.X)H@2SYR%%>&T
M,O3=P"K;>L,<S8.<%,#60W^MVM%)T@\[3?Y4S1TE^4!!V/C ?5.MI>#/K&XJ
MWJSVDVUWKHW$4S%.#>7S2*@R%]3G0:]NPB)KSU1;%2>%]G-4+]K9?);?S2D\
M0I@0H)K;<?<SZ\D37]M2];RDC8$M06LW+"G# *_[P]"@/+HKJCY=[3E!=0['
M/<(.'-7%.\K!>'?J6!8=D@MUW3X@OQ'8!_VZ#_6S,8\H)<A8H(Q(MIK!KVF4
MPZ944^)9Q/H_ZOJ=TB4*Z=O<2UR[5Q$+DQL[T:*C L,95<_9F:04N0]%.3^V
M@S1N\O1^(Q4F]X%-DXPPI1COD$7*-IP^/A"I&=P(<HJF^_+?_^T/SY]]_F5O
M;C*J7N.B][@=9\]^]!?N,2UX:DU!F0%(M-H-%,8QLLB'UK+U1ZDC9-%;[P*G
M0R_:C\=(WQ0^ISSTAK[I+9>]<8K29[*;H!:2_0IO^ORS+]^^N:&?GGWY:V<(
M!I6>#\OSR\"06P1US"1GJO*([?@M3/U#$4!F:$A)GI<=GL@4+(H:5J_R^VW5
M%MV&%L.K[[Z*B^;+P!ST4"'E1R2S,T;=R"EB;_U8AFZKHM&1H@H"*=^S$KG]
M/OHVM]X1A0V/6SCLZICRY1# V&;AP\%/Y).?I.],T&\L8ZFYT2F'K 78F)LA
M34PW6 T]J+3\HHD9<DR>[#DC6=#NRTZW6N]7QSMVX,65%X;2:W74+),89II3
M\_-&0#&^(S\@;)ZNW&*VL/@)1FA7K4:\'.VMJXW!VV&W.V;+-N!!DN346W$N
MEQ?:_%K-XPH-W%.R?$D4.MHG['&JTB, VR-#+"036];Q@>WA]0#^*TR>W1*I
M\JD(AO,BH566"T>FD;V?X?2<MU%D9=PLJ_?,IIS18)5(6SAFPVKF(MS4D:/H
M&OB(4K74";9%T^PF3\<1GPKOLAJYXA_OA$9[*CA;]:*,Q&>EGX:.EK&&@^9H
ML!:. 31NNF7L:-V</6G^N0>-BP=-]B\\:,+ =,$O/+%>48Y[9*V>-M^Y\@A'
MJY.8VE9TGXND:F5M;D';&,@<![\9\\6IAHD!?G7 (MBW?4_2RA.8;?2FIVM.
M"),9/RI&>JR=-%NI2PHG O959RG,F?+3?C+NZ2?G;R="#;P1V0_@K5TVWHM5
MW]><"_[T\OX&+NRG>C?4MR'W,+(/5=\/2N=Z._@E1S$D[W2SDYS=04G!69J"
MBXY+$_$)1^ZR>#UZ9&ZIW.IWGC]J_38C 1)9E&;OY).-Z69VXEGOYVL*CPN4
M%JFH^=+O"SI>GG_V_'ENO,W"[Q:65O^Z;3>T*5]VPVWV>M=4WOGP_H)_YEUV
MLS[D&(VO7[[^[B;/7G@#!GL>SYK>1QD],I8& $B4@O2BWFR\K. _P5FZX:=^
M4Q<<QK^\>9/'D7ESAV/F-Q,Z=A;JI@/>B:N[K^[;@]B[HSB];)T!/D5U'E];
M551J7<=&%_7J]S4U-L#DEJAH4W861AXCPNO,*$!3-GE3,2NBX.V=Y1KQPXS4
MF%;21T<T1MA'AK(VXL2SF_*7H2DQ-[\E@E6_13:%2&;(B&MDB95+T(-B>PA+
MU[7#H6;_&)]C5[1.0Y4MC[2_W5\;Y(/]^_0'L_C;]< ?E#O$:)9O[K\;/_UP
M5S;DD1(<DHTU7$B&K;8=[ZRZ> B"$?0:C-O=2HQ+L6_ QLHW=UJ<;TK*]_,"
MZGM9YW@#KFSPE9@I#@.CSW:=O6[<7XIFP"'P_/,<H_J[G#$"M$C%R<C^^%.Y
M'BC9_AH50_/>;_PG*PIAON^&W1Z>4;C@,[V@_V58TGGV1S_2!T;?OD)T1P>D
MENSC[/G)(.0(2;RD<\C'.'HQ'LH5< 98I?Y3!>^6KJB0>?OO :XG.4VAB4/=
M)RM#Y,T@162KNKH5O\&_M6Q&'D3-RP,]=HS>BY*QW57-.W$+5_Z>1FEY>\(J
M?D)Y^?-PA2\6N,('A2M\OL 5%KC"QV%(/FXW_.NA@[^5N[$SP\Y!U65-0>40
MPD'_'3B'GGS.(*\Y5G<RY&S7V0\$)@]2?#/*63BD],_>/:?O(0 N?_)QY0#]
MJ(YJZ\I=G0(83D3J#"R YI6/LH>&>MC@Q,"G*4;X5((H=C./1HDK>@Q.<,QG
M08CDN&S,"YEO4:8KJ[TK#<2VGX*6&.A09_B$CM*/>P?\M4$6BZ(\ERPM\FIC
MOT;LFS4Z8B=EFI" <Q%>XI]=%*?FLG5S[/HGJDI;C9(ZPH=PHP&YR+$304+H
M*GBI_K9#LRWNVTXD(N"%%YKYM1@3E0F("FN)PD C%Z9[^;NB"<3P?"?]+Z'V
MB10IJU4%HC6JG_+-.%"UJ&-&JP0M UM,6;4_81N'OY <:)&V8E,R'"&)_L+<
MQ_O3#JZS!$PQE82'TU4@,8DVJTY[%W)-=\?YG<1A8*3RQL6;@<-5S!)K5AF=
M]MZXW9<^JF(I)C/O\4KVU;_[XS=O2=!CUS: *$DC$ U5VR72)78:<L4F^^7:
MA+PUJH2(149-O 2LEBH'(^6ISM''0@?R:N-.\FG-W KH496&%M-(J\(/GE\,
MG!N532,X(RF3K[G, $*^6OOIIPGWH!0K.42%:$]W)L+B.,G)5L?WHP!6/-($
M[Z6;3B%7+BQRFND429:\E]\Q:3-,0%B$G#O6<.5#3UN-G>/$2B<6*X;$67R(
M^<"6Q:29>&2DK53-$7?IEQM10B+-K[#>J1PE%L^0%-#"%,X&0<'CSUM4K+ Z
M?_2'J^2LQ>CL C@.V?CJOJ+$SKHC.*1W$DK__U1:7LZ_RSC_1LPCCR!@X(J-
M=$+ZDMIPW4A.!,GY4_N-%APW"U+SCVUP')J(L5$6$N%H+5;^2=HF*;MH/</^
MDON9BL.,NX9B@0B;TN'%Z:=1CB^>9N?>0/JC_<[QN[M$=V^U[B-L5H57#KFS
M\%MA0U ^%MI_L*X%29Y?"5T'-:SL&<S+\%%#-'NE?=^IN\(;G2O7ZHM+TPP/
MBFA%Q2Q24%2W#% BI5E*MV.EJ6BU;Y=%*K347=X7 /BA7R4*07M/K*.\^R@;
M&S*5*A_4!5\5B=GL5_BR% @X?7N3?%#!,7GVU^NWUXY*R,=0P2'#0XK%E;9E
MX4Q$ 8. Y'XS"*;"E)T$DD1ZU !::^T3#<RH8A^$2AP)[^RN?? 1H*:>"SD@
M ZP& .WBG;\_C OOR6!\TQ>F!CW>T!(?Q*&)L!1_*^_"><.+S/),V("'%9R1
M/ H=THS2)/?Y$%S[4[=H;I']@7?C7>@*$M^4%[^].RCZ1/5L40O#?>X%!2<B
M+P@X:BFOYPGNQ<F8-.4M=1$&[Z_<>.<Q3$%]9(]I;L*C-0:J((!7M^6&BB0&
M="Y&<@-I\[J\K?JZ4)A-J!Z2KJ[ #N18F@,&Z?.S>X,>5[^"N(_B#HV7S:UE
MI_7?+9O[JFOY.;!:_% ,O!&2NJ.Z;^XD[\HI]_:[$HD^>[4@@DYU)6TW;YIV
M,,C"@JID]$A4F$/1H6BJ743!N"V=6DV[KFDW $"T:B-4197":0JH93977Y7S
M()3"47Q)"98L+M;[1ZKV<'6ECD*^9;'&NJ/Q-* :NJPCLG\_ULD5I=?4S]&1
M^V)G=0(F<>;@I^(0F+;(QV N&$I9O6O:AX:"(1 >;$K9A06VO?1V@+9FTU7W
MG#;B6JO?<L2H1KV^$0LS'7/4+X&AY\)7V85M]VTA-N>-=ZM(JNUOK0^?RM ?
M*O&EM- Z(2PGL)),!,Q>UNAUA(-LSY?322/,B9]>OV[XC/N>,US>8M,SSE!4
M^!W JD[<B%/U]!+W_'1N7]7M09\Q-!9%P)^"?QCX4^T+YKI)5*_]GO:>!:Q
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M 3B 9:<_@5OGC6@P'@;7HHN>CR=S@=@8RBW=M'G'&I4%$R;27F5.?)%#26W
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M&/()+8NH9-X>;/!SVP3Q#-9SN<Z^\4<T$A$40:TA1W/@C&>'K&UQ,!JZXL+
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M[+7JK\PH[LH'76S$QJ.H\F)0/]3SH/QIS^AJ&3W)T2FG-K$F&74Q(4X\D_3
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MU78%J1#Z1XTZGD_&-IVU-<O!>2$V@^MC%--4_3MD\^_;^E[)]8A>.YR8>M0
MT?^S#D^FHCIP)8L/4+-7W/0(/;=7DJI-5ZZ[H0I/07!6;M?@!R7ZJXRD>\&/
MH,4]]"-(;[U\U6G+ $1;8(\(;UD70[.^(RP.%U."^>*_L-SYHQ:+GG'T3")K
M)SY)&$R7#!Q)S?DG8J[M35NR.&P+'<5@.8%01=7+W\J0;8+0E2INW*\]- UH
M1ONBJZBAA+;R1@;7^A6,ME4Z">'V$)D\U!?J(_L+4:"8<=^*B:M1<.+,LQ0$
MQ6(S8VG;,WMSL,6CM>1GW;],4RZQVJ58"C]3)#XO^.2E/'0A\V(3D55C4I'!
MWE!JF?O2-N5_#S!,+/+ R,_0AW]V'RXIRNG#8RI_@1>(^:PXOR"ZHND*$V3;
M#]FEQN&I) Y<:B\A 0"BH9EU8#[JOSA(*3WU[Y:RTB6L @)CBO"HT%0P.BF(
MCH#<&QH0#$D?+90\BYDN-'4,A&<J$@UO'\45@4F,T2FL/!O0"^RM$=,FX7AZ
MEOX6S31 )9:L^ 6>$@.88+VO5S:"$F$I%?;R(-7=KEG"@Z:7V'?8,P;\B'1\
MR;N?.2DL?N43<MK.XZB_6'#4'Q1'_?F"HUYPU!^'(?FXSP^&A-K2QWR6<RYS
M\WC>F(2A3.+8-%TBK*$<C-(N.,&5IGK>RNR:?I8]6<H\"N:;G2.E;"Q4IEPE
M5E7,G-K0J'1S?%IE1=$!&X &VCT>VU_@7I*ZL0_Y7%GG=&KLQ #C$=W/J"YQ
MJII2.;$PMO'7:]'8BPYFHP&W!;F<?FCH">)M ?3(,CD_!X<Z4EB3LL"T)8PS
M1M*]ZZ=K1T^Q+:J:>Z?OVX,R=7*.BFJZ_JV4-K0XD)B>RF5,:FON26\?(M[Z
MJ.UU4C<Y7QQ,4G)QZI )$Z0Y)[0H34*:>":1SMQOXUGD;!V&\1\O])E7C%R4
M"78YG^=7R^>:)D?L)MJ1K>QO];1*OF3U+\9::SG<8:\]GI8F'IPYT'S(-&OA
MCCHF@I7T2W5_8+(?(D6)*81@XGNKK>4$:A'4QU0H"^M\:$+O<#3?8E5#^9F
M&^B8X/VIJU)JEDM%^L+6X1_]/+IJ>ZJU]\S2$X5S/2MOHQ+]^R^[@/ )9=P@
MC3=9@) IF=2FB22,UAJ'P$1;4D-IBNPXL5=R7>@DFC?5A;>>PTJZNJ]PJ:,^
M:TK?$M5LZ;6C1@\Q;ADX%'V9^U(V)<F!^AM/QZTEE7DWJ;4_2/$++XF7LFK
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M*7W?'_0@^<[>[J53]'Q6)^=,4Q0:5 -.6GQ9$25C*+,[2D8Z692W$61_ZU&
MWURK3DN"VAJ7^BD.R_;,R T(-[1'F/*OC<VE=?C,%H2T#M_6-[>49\0J0,Z
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M5=(F#L&)K9MWVG=C22SIAZAK0O86RAWR;[(RTA%3 96HFPPG.-VPWO-1S:J
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M*,..PY;I1LB-?Q.R;J!!8=D%$;*A>?A#W=ENP3DU.<7YY8FW\.KZCR_52R"
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MR#3*)+1Z8#:!=.;CT'D )R =G-V$,H<NJY"C(1;[SMH&TLKCLWG,G<6EV!F
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MFR_R;\="!R6WN'C_R&_(#2%.DO>*>0:GFL"A$8(Z(>TR;)D'9IWEQ;/I@@W
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MN9-3UY%>6>RV*%".U/CIY"*=(J-*;#ME6M7_IOG2=K%:<6[I+6$NTNCJ@2Z
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M4G@D5)D-+<2]L8-D&1X3/V% P?R N.=<RWZTE:HB#;Q*83&@+&G0^E94SXG
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MEMU67Q-TB9^_5P3V 1TN'_2:8 :8IU.:I>9,(<V$$L?Z%H)L<^IDPCL<F[3
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M/%S#R2=F3IRX.Q;<NQ8:"_&S+Q0;=3&VY52%^'-<6Z\_"^_JN(9J&SG19IJ
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M<RQZMC0AB9KIQ=:F !,YD>%-ZMFE4I4$V.'1@T(FQ&.&? K"4/*THO3=\^H
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MA!X9%LK0= Z\)>$ZQO46%^W\C!U\U3YVM.#@&U#7!0R5X*\RVCR]\D\/C[J
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M<7G@$NFT8>1$QV>1"'DV(W1X)*:;?\HE.'=AW15Z@W7+V68)NHLR10V9,\P
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M]&YNO%I@#0<_ID?&X=;1X'AU<5)26#Q;0G9W7SFFY3A60.@5;URR\/01IIC
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M?9WQV<Y89[S5.N/3L<XXUAGOB/=R&S;_<WKR[[+Z8QV]<UP8Q]1?=)$MT'U
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M[GAAZQ(-7OU;\3I/D%V=8RSP-;_C]B(CHC@PT./3@_B0 Z^WE4%Z5+L*80M
M9,*/IY?KKM#8K5"]!4;#E()AH=E++^)P27;K'<CX<.^<<?J]\$[3%?EI[/*A
M;<16/R6$.7H&1GG8I DH0E\"/$6+"S'(^BK'(W.X5C'#-=AK1N$;!BDW%PI!
M6?W,#(-9,R<"7*8FF\@!B/C4%/8X[)^S =O3Y,&#AVO[MAI>7IE";/R*PE]V
MD[T=K$NXLL2V6R^\@*)@!:Q_OMH=H_J>J,?4!0<+-&U36>;>]S2FY]8E"/.4
MU(@'86.P_E+?CH_!PII%8RCPW]U+XKV=O0=)0%,G&XVQXK/5)=$#<#\HU:'#
M=T56<(F:^%'R:&<W&L;%X6JU<+'KYLD)M*BE][W7O63GT1-]JY:8T>1FXJ$R
M(QGC=GSXVP2>W\H20\A<$S9/,:'X@^"2FAP(+V@?FAAV2G] G=8_^*/H3>E<
MJ,:V*#%Q>:2 ZX0-=M=,R[9WMC&SMXQLS6_LNXK(66*('G?K+TB-"XL][@R5
ME%)@.Y3$$&X6["<&;6ECP?I]8TO<D?>XCJ-9;0/+1I$?6C!Q(L[^3#B4*WD6
M?C,U)S+D%1C6U_%M3^.QV?D%)!HM-[EW\.@W7Z*)Y'ZZ$Y?5_OM,=1UP.HAQ
M@]W?1-XT(-E9KG?WY-WEDL'$_V7O(<ZQTQH7!BB&V9F/P_&>ULM<UQA.E$Q-
M%-36++44OK\5R 1K.H?>N;<LI +KQI$*\_Q048^V"[.5TZ*0F';&LVBY/E>^
MG(%!!4/1#%'_]:F;Z=L>/%LC;_^K7$R@MIUA\R,V#>@A,_A<9&<IMW2>7=+;
MD.4ACR@O_H:+!7<:KP&_;-YQG-5H,1 U7<K#K_"F9ZVT#0V&?G8PT?5VYQ[%
M8NO1F7LC.O,VT9G/=D9TYHC.O!N&Y.X,'A,X=+%L^K=OZL4O.SN[%E-Q='KX
M.MI]'F_%[]^\.SPY?O73X8OXY'3_Y<OXX/CUZ\,WIR=C8F5S$BMORJ_;EGCO
M %%?=E_M=?;5 >RK@^49EG,DRW/O-A,^^V_3WWYY]G3O%S-93K>V@@=&5KG7
MEE_C+?._FQI\S7W\_YB .")=E1D2*^T74_HR_.?I!<(@ZU-XIN=Y.?GX2_;\
ME\G>SMZCG=V=W5]^P?_:W7NP^\OY\Y<'[UZ_?;E_M/_Z=.OM_O$OO\]>G7_\
MQ^+?SW;*Z3=,:<)#7%P4S2_O?LA__WGOM\O)@Y^6_SK9;XX.WSSZ>?[3<K+W
MTZ_3__W'8OKCQ_/W\_SW=/G\S<\?'EW\:^^GYE\?'NT<_?"R_=?!\]/IC_^X
MF/[P4V%.GA^F__OFU[,?GOT.O\OW]W_YY9LO_"JSW_Y:E,6;ENJ%5&B&K[TS
ML[]]\Q+"&IR2K9U=^-^FI/_>W=MZL/N-*TCO-W_[YJ LWN_ _SQZ"-_[)C;U
M)%V@UU"UYAMZER_32<-?^(:(??_V#;S4OWZ9=_J9-V,PR A'&;MA4JATPN7#
MSC8,IO6K;DO=/ <[SX86\O'_3IZ\^,>''SX</N6W+Z^24R(KW^L>O\GP57\Y
M0] 95\>\H=_M'O/)T&/^[^/\MX_S9_/]GQ]_RF,^Z#\FVM\[?1X>%8$F<2"/
M<(6Z5D1:CCQ.C.HRDXNBS,OS9<+%BT5%V !/P3>AO&U;6$7?IBQS_#0O6ZS6
M-U=E]1'#U]938="LO(IX4[6WH$IVD&T**N7!=XBYGZJ^?(DDOC3%E!!Z+#Y-
M=&T)5G\P$^)DR5"/]Z,Q"\I,<XN]/_PD2N<EI@^;->K(HX>TP0_TP7 R4$ ,
MHI*3H>#,G.G[TW@2^$PD0.U(NC"%?5ZE<\)&D,Q.3P"301F-PC)]@7/4_:*%
M%0UO),9QZJ)E<;A@- T?8O[2;XNT;2[*BEHH8$73SD7VQ29%3,L'0X21A 3!
M1%LPEV?PE7,2D,9,05G]%=.TC?GF[R?'!]%>?/KSV\/XZ*CC1;Z$QS>X<65=
M<.7IO$7M.YB,"Y.CMH HULW .*1T,"=2BJ%=VI_CV@GH2.[2;B@I6Y:&.2$S
M@A#:_*HQC-9U7'P\H<36Y\%,55A+C0>9 T]UYQZM\GNW;4.'Y1F<Y#?W]H]@
MHYX3@ZISYX=\^=^??GR?5\U//[[:N?C*GOL?=:[7.-"//M6!'I@F%D59Z#=8
MI%"=[,1N<'M8SL73EOU\,_-ESW,LFN/O?%@[,S A:%'^!!^T3>?K<(&:R710
M51$LQZQ!VYFV0N',I[7'?L$_P[)2=UWM_J%U]3)/SW^9GIT.+ZO#YL'N_-=_
M?WP^>7)'EA6?3'_[)ONM^>L9.&P&C')_A3W^XRL,)^R;OV?VW_THB \6 D*0
MTW=)>K^^F]DYER.K[N9:(00SP,IU>+X2]M&N*53S*0J3RV_.\2:L3>R6/)TR
M+/N63JJRYB+U]<,@(AM:=[DY1S)9!Y-.'(XT\5<_C\);^WCE%$%LVROFYQX9
M^'MW8J'EO*DC28K M?2["G_M7^_17 R]7%?,\HM7W>+6)S]T4&R*XMBK9MW\
M(@-UKV^D-N5*79\^IB\ZJ<WTSX]P9WL/WOQ72.4^>_SDV6<:^I?.LG<<A,>K
M' 0(4:KI6PA!EL=$[GQ^T>P74\E$2M#ADI5K'8;W'RZ>G#U^\#RO[HH?>C.'
MX<E:A^&3)_";OZ>T;.9MWF38P)G! 5M@E-V8E,7K\82>4DL>N8APUK-3NB+X
M5BCMT:DB9A-N@4#G$MQ)U,)U*2,^K_EXIX&D*+V,O'YHRN%AMC B778\8*)&
M(#5[:;*C#@?BO;?BR].L$J%[[&^DI$+_)&%'7$\2GA8>!W4I>AT?2^\+-&;N
M!"0908]Q/[P'CF[*J#]N^_0?R7[+@WYQN?]:5T4+_QMAF_^PI?B\YO=SVK"[
M-;)[L!16'LV;^A[NV8G\<'7(KERG^Z+G>5R]TUZRY2O"-)Z6W6^]$V+.HEE_
M2/]87;R]^N'%U?SL:Y=YO^PA_?2:J/[/S^DW?\?S2TY,/<.P*P5QP9Q/IQ2R
MII><Q,50TE@2!!-L(*2$KR;/O3,>54:JR\P2U5*U!B513$7#\,+YHU/XUV56
ME05UD8RGV>:=&9L[LGNP%,;3[.N.5<,+-H>$IQ]PLZEJ3C7NLL@:51VPEDX-
MY8!]E X%[&7$W_3,V[U:O'?+6FSNR.[!4ACMV-<=*W9)XMA(BF)V??X#^\%,
M2,*>4)N;0 788@GU^Q7!BNH:^:"XFSM$WO3S'*-E&RW;:-DVXSW<<<O&2>;A
MY*C+GR[RE-4:+7A2D*-DEN"/HT4:+=)HD3;C/=QQBQ38(AIE4PFA)U:/E!Z,
MJ2\^FJ6S22I6+5[4Q")57#@Y;*>D2_.SX1">[F*7Z_50A*UG+N7[Q5JR!WH(
ML!EU;:OV@[%5^U9;M7?'5NVQ5?O.F)UNO]7+H4:D^7%1''XX>_KHU[-/:41Z
MV&]$>N!>WLKVJ-5=4@=#@WM[4#TX^ZTR;R_33QG<H_[@'@;;8P1_C>"OC76T
MNJ7F_>O1X0[%=%B<PV?78,/W_W7Z^_+QWN+#<7ZOJLC/;H@-'YPNC;E7)Q$'
MH+3DRJ+[*Z5>_.Q2>+[!#>;^OUHT<+A'*G!ZQSKOID7&FSNR>[ 4QIC]ZXZ5
M.PVQD8D )QJB)SW0:*PTX6BIJ%5U,$Q/F ;=(.%>O^&4&==]E"M^3NU1%/E/
MD-Z-1N+ZL!:FPJ^SD /8=*PX<[LTMU<3Z1Y>XGN\V#W;#G?+_FSNR.[!4A@M
MXVUG,\F[RPK1'?DZ"4GJ>=J8YJ@[W>WUP42DGD'$L7!P&/+LI7,7X_Z^ATY=
MED[K*O#UI4V.M8?D8!I[]3?X@91B@Z@:I'W'3/V>\(]%>=5]S=(93OY)IF31
M&;SS658CKA?)X_VV<>*<8,D4%07C[X?V1"NU":\Q&MC<PI-%)(:E99EF6+',
ML:I%E/WOQVT==+#[G#G2V[M,K)98.8M\SAIZI)X4V7;\-D>Y"OC5C)7AM!<)
MO+UX=S^)B5'J)2F1*:%_K+IQW-+,_?F.J3GP_\[*MHE4]:0LSDO7IR]\.^IA
MKFB.PODCOF*5:TW^\(Q%71Z?M;,7WV#VPNVSJJ!S:]O*)5<?#F9^EX]V3_^G
M.?[WPR<#R=5N O71K;%I^7Q[+U;EPMZ5N3F>>2F>M:0;-!OOCE^?/M\Z^?G=
M3[_\_J]_-;/_K9?OGN]^'.GS5M#G/=Z[AC[O\=[:_-O*5_1%*?%^</P*FTJ
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M65:@7[&HZ%R _W@X+H(-?J /)CHS>68NQ8J@(2"CPD(K!G,C&1F5\[*<.H@
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M'F( &)UCI]H4+GF)T= J</2V8JIQ#;JECBL)#V5YK?");@DDU"C;!AN=P+^
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M4,)C9X^I'Z![ \=QT+F&ID"&4228+'LP8!\,K^!Y*#.B9GAK8%^NTQK0DT"
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MXE#UP8$5 "7K@_)"25+9?5W(I /5KRAL<\BUFU7]R4D'[K%YZ@R?,KVKJ,@
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MZ1*Q4CM6K,1$8S'F._#"%;[57A#P9'V -[A7R.JZ1M,(TT"JK.63#W/KE=D
M+!X_AD$3]Q_^"/2(PQ2MWZ#E<;\Q6:SF2V[)U;&RR$*_7R!KYEZ!B;!:!58B
M2IQQ0!%]&0215C="$<@W6G$FVV23BSWGI\_D@Z:%M,[$_<E!_M7V#CH=;V]W
MNVI$<X]T94$?\E?<M/H+?#7=D5I:0%SAO;VSZ6UN;KHS3^56<$JQ D>R8>4A
M\#BP$<>>VD%L[K71!1[(2!EG8UUC2(RJ[>UT]FD\V/X-6;.C7#RTC"GXI2G/
M"<:7D/5^BT;D G+>[+8.C&^$E5S+,U(A%+0VTU+U;@RT$2U])621(@+)B$1
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M2H9H37X4$+QMA^AL6<M8@-]Z5"- 9>A_I1EE*%\G,E$;A(./B&V&!H'=.'X
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M076.P*1"]P-9Y!>R1L(ON/Q&U0>DF4. 516WBDJOQZ98><%F\J44ZFY7Z6/
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M<:C,QZGD(B@S8LTMX/)90?( 6W +DBM*$N0L**DI^!7,-2US+4I(+,#S+^@
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M85@*R'VV_#%N$*<R@E39-%JNHRP%^ W^]ATL0"VVX=XO>,&UWF[RVE5=WMH
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M%_,OY(%JBF&=F6]?8U0N\X*0H]K(E39# G82* "7ZFT)!8(A]YCI(48D?%*
MU<"]EN#>=E1SG3M NSF+0;O!9!#H^R8\,;>;)$C*%W3Q\59;H&]_TF1)=43U
M$J])@O!HJG? =VP&K(045=!; ZE>V,_JGS<W87GTP+-^?^,MBQ7GDL1*US+*
M&B3CY:&T/P7H?*&!IK0D.\OS'#6B'/.;I*O%8%E*3VK,IK0GLQ[[&U,*A77R
MY$T+19^X \NXRZ-#-ROCYOXN]8(0\!H=< QV;'FK9'? !($DT2I "YRZD"C_
M-ZGJ5R!P4+?KDT=D#DJ'A#2[ <<#P5'CB<,6OUV D(OL*@KXV;0OR(!A(P75
M+>HS@$.C_@HBRP_QQYZE>]KSDXJ;?"-_9!!FRPP;(^8M1X..RK:QLQ41\D4X
MYPAKQ:8PH=68TC0ATX7U4_M%85;J.@R>S!1.B<-H*!J*F;3[V:A'G8LE+7S*
M>7JS66U5JZ"Y5>L^=.]$A?3]?DROR2_N:,NHR'R<FV(**9?](C, +2 :E:/:
M-[$A1 B6"28,DB<+M6IX#CWPV$VAA ,U=ETYANEM;8+M,J%=P^(14 @*D3@P
ML#Y1W'7*.+6-"(W%RMU]<43NE6!UNM&615[QQRHU'Y4,W/$7SJ=N2=S>:Q*W
MGS=Q>Z=)W&X2MU^W,G*<.*8+Q;64PW209#.#@J)JLLDWF4[\&(';#4M',5J?
MFDN268ETW:_ADL)G=EA)NOL<U<Y#U857JB=UK?B8*BPQ.8!";/+U%50R"\B'
M!;JN.3+EZK(P:4Q"/:= ,:[2@2%3#%E3I#J.\;^\Z(CC2M,%3"U@*)4R=BGS
M[ 6BU)/NOM!$#O'?4FS#5/#VTI<J\N5,9_LIAR$Y!M#G!7NB'(IR; Y-6N*6
M77&D I#+D3*Q.5CKL^>A+^0;Z>!1-H_]B(NN]+J=.=(< T<@R*N/RV@K.S[E
M((J$8#!SDDK;P1_8JD-/!'Z9"WI>TYXI_S=J#G%'TFRJNHKW6,J*O4Y'K]-$
M5RU"R0RIS5O<A#4VXV@FTL955V$4I :)$=)"KU36(3OL3/T*BQVF:<BT'-@1
M7WMPM:"O27J=5*YG,6FAY\E5B3@VFCW<)C\+I3H\M4.)<6E;\6M8)$)JJ1Y:
MTJR1ZZC?;# VN(%6+OCDX4INR.X/R(ZB(H:MEM&&3Y(JNOIQ&79P<$UR./G;
MXT*,W';+?2MMJ*G.$BX23=1T8EP6G] OO5__I\1LH,+'/ VB;_@@EG^[[W24
M1L4:9"/!BRC_VOC"EH<*_Q2.8C?&M04B+,W9 VU[KV7&009':#?!!#,7&".Y
M172;Q8RL;<5%IUK!H-"BO#!4**Y .B><-:&>!B6<_?!1<@5_6C(RRDE(<KR-
M,HV*R1@U89BT-,(Q1:D??6.MR$P&67V4RWXC-&NID<08%Z@TAW"J/1/U#[@)
M%/%=F<D%HQ59J1+*9+Z1ZO*(;P2>+TINKT@!BI#779D9B2NS]]9&.;1"&M:?
MVEN9,96[5[!3[$; 5C9QB7*:X%I):LP[F8:/+O&"'O9*HJ8%#\A7!?@F_I8I
MX6=W*)U;QJH8C>-T OJFH]U54@54[=?8&3FI=&Y3O^%?J%&5PT\'C^,TH$G"
MS([*C,&.[5: \/D' 2H-0A)0",[!?GMC(8F>$^503[P>@MT\V<!DR9"24Z,P
M\A$1^1(TB3_\P/TPZGVD[GVJGVMGL].A5?IQGE*47&!;JQ@>=-]&=+']L0#%
M.\C=;HDI=W'DN^=PSS\5H>?X\X;$.>O?>^SOE2[3:D(^:3RL?5$3/6I-Y%(J
M 2?"DM,R!F5<3$,S6S5$CFIE>'GZ1UOEW3%'M/)09-8;S/(OE94KF0.GJ=Q*
M&%5UL&$82[R@XZ0?<_*.E1!$V364FM.;J Z=JD07BT60WBC'E /8J4R]M*RQ
M2+T6V +P 6U?8:(CM0%-*IFMGHG&.R93*LWF)$I90;>%PO-->N/SJ/E'(X$C
M#YP/7"-YR)5$="Z7(Z U.*P+G0^EOL4$M;()>B\1DY!:!;Q-6MQ"'JPJ?I4E
M8IZRO%7.X-&'0Y4MZ%E](G\K1V/0:;.")(\RV_'@LZ(<YYC\A3>^L]D&H;MF
M6?J_G;V]=.!;DX)X*6W\]N:>RL_#']$K$!\H"E5R-,P>ID.%*93U[X=7H 6A
M*UH^1^49Y-4"'3QG%L0Q??4F4CWDB,[>FK^^UEE?>[NN7G!I*BAP> H^8F$5
MI<B1:I/ EA-7NXKR:L(EIN6%?A9BM<@0XWC6="GEG'UM83I6 E\:(4[=2US\
M  M)4G2WZ$^GD\,1I6'"S7^Y=H;/,;+=A0)]OJP94BV&21K7N9$X/1$Z]N06
M6"AR 6_*HZ?JQRS5@XM@1CH)7[LE:;CY SG60+DI#D*W0]0DO"\-:^FBI8"4
MKNLM2,.>O:'*YA;?A$KLY$QJ+, (K;3:"IU8/$=R!8Q.:.)2+S7YH:"KY_+N
M/66CQP9XJ $>>NPYKDYA^K5$'*1^]Y1,1]9'@L+J.B6=G_-TRS":G\I+S5RG
M'U&.CA,_\3EVA[I$>^_GG/S.5BU'5]9RT%3@R?=ZD,-*+<>%,5'.M(G2X"^L
M_*P:H(ZE.Y)7S@]).YZCA&NUB.MCV&#AS$IFDVFF&9U?8",W%?E550D*?RV3
MF:!%EL(X5\*J8J-96 5,, D,Y*$FI>RP[<WMM9ZQB/RLYX-MMW'V+1835+\:
M>E_Y636,<>F.I&&,BS+&*8<,Y4 9@]& "?2DLP54Q1[[7LX9#4EY*:V*[3.$
M<L!Z?9K,V]3/0NT!.S_LGKTU/C"3:#-"[P3GKR%[!B:;C=PLE6R9HCN4"B_G
MQ8Z0:4XNN;?%[0VB <[%SO$Q99L\H,HRJB\LYOPA/[>'=>=4.S=7=>5GU?#T
MI3N25\[3V?A7?$VY^:P*?N9GJ+7*G-<K]E^+))<,S\K/;< S7\2L&C:U=$?R
MRMF4QE246B3FH/>B1"IC5U&.&MY56G!EP1Q.E2)I:4@TW=F$H0@F[@ _IO(*
M/QB6A<FO?QI(SJ7)M+FEU&Z_*;5[WE*[W:;4KBFU>]WA[#^%0Q(A$R,NZJ8D
M#I6-(5SA9W$D.(-N+5J?R5G;]>!C^)P*HWSX7>A/E">C#[HO" 7*>(-WZT:
M$I>QH.I_JL4:9&F>.PIA%9]_TVYUMG;<GBQ:Q]HERKF P>1HC' U_5J9\TZH
M.L40EO.FK5\"<Z""JVD\4AL2 _,RTA+F K>'/\R$V* E<&H-H3NN15=S)C$#
M:>/#MF1 TPA:%E-F+X;_,)',A/JM/)PCE9?:#0I$Y&H?;&U3X1\PKX10'NWT
M(OO7.L7H!5'G2[QNE)B&*2.^.L5<9A::0,5T>MI(^ E3HZR>E*GP&L:,L)=0
M(W.'(B8/(%*ZW\>F-Y3@/([+7%)X2LGUCC\8H',/Z-<TRJ-[B#\)&,0XI3I&
MK#+AO%:^V007R&#%6)418RH<W[6]S4V-,Z$Z2,@KKM!4KWWK">=-VWK"NH<C
M3-K%8EBJ!U!HWZ'-4G3)J9V83Q=N[GZZ?K^@*U=90=\1$16ZK$G.<N?-K6Y"
M9\<LB7@%O+9F(ZH/P3XXW[</VB]ZSVE;9]>PD"5>T''?D7+F1DJWJJP1W9SJ
M6.4%J::OV=<G0WSGM)*SQD$(5=%NO%EVUIJ!2]3HUU2[,V=V7'(O,:PQ@9\%
MW VK45,=IBDO0V;9R'P97.AUZEB7Q;X@MV?>1!Q,GH][QZF?>00GYA,V,6P@
M5L'-7R!#G-9X >W:9Q-<J;>SFZ3/YRD#N" :LC&.S[,T@7\'#;[=LK'#,Q3=
M#HDPA)[CB\:)[P9+<R%PXALQ,34K\*P"7]4%@K/U)XX6U-(*J<TB)W.+2X--
ME9'"U$^F4)BMV2$:%CY:DPV?5LKA&J[Q/%R#7Q:%__KAX^__V6SO_Z!XQ/'G
MHQ-GK^MNN/_SI7OZ^?AS]_/Q'T=N]_0=?O!)_?WN^/+PT]GEEXNC2[?[]NS+
M9_>D>_'[T6?WXOCR]X;E+ _+^3P4CLJJB&Y67"PT3-"_+TI0C-J=WD9'N4AL
M YX4>7B?Y9P/6=>A6A[Z?14#A7^CD7"PY!^X17/_E^+^'U3O_SY<__?'I]W3
MP^/N)_<2[OS1R='IYTMB Y=?SL\_T=_=BW^[[[J?N\U]7Z[[?E-/ )EQ):\?
MF%@#-"@2\O6[[S?:JD<-7M]0?#-=HZ9>UT_C.+TV"5QU/VHN]S)<[LYF]7(?
MP.4^_-@]_0"B^_B4KC1(\^Z'BR-YR?\\_OS1[1X>GGV!*XX?G)VJ/X]//] #
MACD81:#A LO#!4[3I$&&6!;JFKV1[:D;B>KVX=GIYXNS3RQCSR_.#H_>H7;=
MW*KG UB@!FRJ]XX!3L,2-:S?X"JX<PQ A(BGUK246NX%80.4D:Y,](RFPSA'
MT=BWX7X.AY'H@\VC?)UGV-)5< 2#OS,UB_([SQV"#268;"2 )T.RP NX_RJ]
MV[%<K(%-2V--2^Z:98V!AH;66.ZVM_R-]LZ:6*=?MW="^9>)SMHVVKK58DDD
MH?JG1%W !HYHD"EUD.U!;CN%/5-4P._VN>K(W_VFC- 3'D4/\^I(JBNFWAN"
M;5-6JW;GAP+QM]@,%0E-6*'ES)BA,KI@/'"P"_J5C@18XAU1/3 +BH23:RLO
M>Z.H4O]>,8UI,QF/UN-IYSG^,R]'<!F ($-97,\]K9@0Y9@4 Y&]+AS9.I.W
MDV+O1X>F.H&VE\#E8'EYRV90\XA*0J[RB)C@2XT6?<8NGO.0\V#[ZG[_OCIR
M7_T@*$<E%QDK9.(2T;@DB ;W(:+1]$;95][@(>,XNMF!%=+@Q:O/C563\A7/
M/>J&"__ F C\%_> ?*8RWM(O$]7GU,\YV1!>1QAI*?8(3:_IC!%/$ XWGPJM
MZ'TTMZYE55,370T2("$5QDHF[@(7U$VP"5R!\>0A3(!PF?6QTA5C'#>@181$
M44X<"EB9;F?4]ROS):JNAI#&W@M19K>69A#(V\G1=-:S:4R-?NO [LS +TA8
MW3U#\Z#)T'S>#,V])D.SR=!\W2KV6Q^SM; ).6+N"FU >=^K4J/LT'#X$HA^
M <ERC?BD6O56"2:U$B7&#@%24YX!.7Q6B=)9=8/N@>WQDQE4&<>DOQPK< 5I
MG#.X@J$GC83X5%8Z\Z^5/K_'YA;F0&5S8]>*5,(U'H-R3)G/U"XM1U8?Y4/5
MT0QSP#'1BXN!0-JBDGT+QH:)>K*A>UBU%9R%'^=8JC3NC/IJ+)>\'&/3MEQZ
M%(K9P6K-#VEF.+>8(;?JR96>$Y@J)_L%4[Y[W7I48N9LQ^F9><^)!V6$\4B[
MIU&6:QIE+]H:N^6^99!ZG$9$B6]#;C]LC-;<6_S *2F/VK-04FN!!B=VAP7#
M<A3E5M#*[<;QS&N=?)+##VXVI3R9UE\S42(WA<6(XROX2'YMI4\MF=!&>%D6
MF3/7(I.X\GAI%*KT["G9ARLE)F4FT@>P;@UO@%F.,.1?##N3JU(Y47&(5CU;
M.*+LU,?>"_+)3$%-$AJZ1-J6@IOA(*C="4Q876/5GP"A"0UBN@4DZ%(#8;]P
M&",3^YAPU_'1&$A=$QM1M.KGFU:<2-3T&G<]2@GLOY$)2R$3OB '=6HX:+T;
MYS:UTGQ?XZV])@42.U&2&\2B;\FRG3KO[1U8CFXU3Q'R#"S&ZS3[BJ0\HZYL
MT$<#KKEY;WY*R7F.#+(?4L?*@FG]$L5C2BF 9]G 3Z*_?7U;\<>?L17\-5 Y
M/<7 (FN=S?:6F0D[91$PGXS5PAV4$;-JYA0FO&_>H;R2W-L#V;[**!HSAHM.
M*YZK5+MOU;[<UTQP[F\FN*MN)JRZE?#X&3%1[MR0+A^F(K<;KQ&H6PV(6[TR
MA-,>"YH[*EU1SHW_Y%VP-!N$('*J:MD,=ZD?8$%N0PYGNE!RQM/I>2'7310F
M(U /DA,J_"V5#4TZS_/8O8<< JF3&L]MY+Z$TWJ"C+Q,.";6D52Z "URY?/Y
M&H95?B>KB$"!SM ZF=.VP^/ $4U'9?3KKB2"*X:YHZ84@A-NCTBY^S,/>/=C
M60U'689TI,VI[/^#MZ"-GGW^>'3A'I^^/[LXZ7X^/CMM6,KRL!1S?M_";_\Y
MV-S^#^C*>9&.-C9.T^,DC\"&^ISYJ&B\C_W!?\+>Y_\$>/LWVYOM__P'_]7N
M;+7_\_?I?X_^'&YM'^W%^S^XU"/T7S^<IJY\A2O?X>)+?G"#&-1A'G(\3(K_
M7'R(__YWY]M5L/7'Y/\NN\7Q45P&G?CK__WO\>"/C[\-_^]#7/[?Y.W;(/EM
MV!N%<>_//\KPXTD7YA]]^RE)D]-R! L,B$W ?EV(_K]^>)^E(YS?QF8;_J](
MZ=_MSL96^P>7\PW^]4/TK?BIEZ:Q\(&]E.('VHGW?E!LPO]V]WYP$[!O_O7#
MX:=WQS_5[0?G1_[RS\HL%'$_$D\B;_[K4.@?EUE-E2H<' *S,DG([L71A^[%
M.\Q3!LYU=/SAU/WMR\7QY;OC0V1B[N>/W<_N^<71'Y3I?'QZ>7Y$7S1YEDO$
MWD[3PNF.QV! H1'>* DWIF709X_K9)RM%S()S.?=B\_.\?'QTX;5IBAP>\=(
MQ:4[NF=GF>VI I#V)K',"^!\9Q>7GGOTOT>'7ZBJ\^S]^^/#HPO.03\\NS@_
MN^A^/G(_G/UQ=($%'TV-QS-FHRM_J/)YLC?S792!'8:=7)NS61X)AJGF5BR;
M8Q?D3$]M+*V0#D_&&S#&V2-X<_@C5,?*<6JNMB-+G_S2N>"0*W8'E' GU71<
MZ69T"$R >Q7/1IF9@O10Y$"D@"8CDT>9BB>2<WP@^!<PNQ,_"X9N9Y-1U5Z2
M@'[)K;RF$D![TPF@=UY.!U/R'I3)85)EA8\]1+>OSH/.\G9PWP??Y_T?GT##
MZPZ:G9]9P.[^0U/X9W2R3&]T X.]BK-ZXMR.%[=_CSNKEWFGCK(HH'F<P\^7
M_Q"6]6KM;+_<O7O(65&Z#4VD/AU'69\O_^)UDS 3US23WT"KR--DV<YJA6[?
MWLO=N\>Y?3/)B\MZX;I)D291ZKYON9=^4D1A%OG)/3?4*OIZ6(K>WG_^F<E3
M=B^#"#LQP^%6&.Q'X9,_Z+,(AECG'%MMD)?O\.,8*/^WEGOHC_PH]Y]_=^O/
M?7?W^6<&?$([RK3[ZX=?C4 =+]_E?D!I"H1"\[@ /E&(:S\KEHWYKHXXW>V\
MEKU[!">POG!Y.?YUK;V^MK4.\R['K\ _<QFD!7=5_23ZQ744#%\+'3W"'=QY
MN7OW>->M\YJNVV\^?$T3Z8+0"X:I2$3P==D.:(6NW/[+W;O'N'*R?LJ/,GA*
M59M0/VTM^U[5??P@TFS ?2:/6NZY2+'J>-D.;X6N8^-2_2X)>,-U>YI>HRN=
MR/.0DP<.Z)QPM8QJPD, <U1Q^[1)+FH?8:P;0;_:FPWH%S_Q7*!?^PWHU]*"
M?CWA+5TE-M>QV9Q"S-3MLI^)XSW@^K:FUY>DHRCQ->I)D&9CPOQP!UB8F%!]
M_\HO>Z5%+W6MT#FN?L8-9'I1.LC\\9# 6_H2U$&E.^-)SF:T_K2B&[#2IU>?
MG=[DHR]//CJ>$%9:8M:0YYX/6^]:=#[OLA9]1IUN_?$XQ=+M4.9_WPC$HBXB
M7LQ#6$P864 JW7$6Q6ZGH_!>3NS.L)X+HSHT:BZR*Q[N\.B,7DL(%*,*]Y[-
MB4>@EI,TAFDAXO)G,1K'U"-V[;1[^:[[/S^Y)Y^/3M8]1)Z.(XJ:;N0%*@7
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MM'(Z(+5?M-V>JX0O[83'1B$%^V+JWD,#:<6"8EY&O@!9(0?%U'61<:M/#JZ
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M5(P>X< C(0HL"O*E_D^5_)'<4)E-"F82Y=5F@I$4FAR.)5[0<>(@$EE&M&)
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M!-^E%W7G3K$D7#775T1-K^YZ'*=%-HMR%14MBO#3,X@81<ER629G&I0V_O$
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MK_87[.DP=>B#Y]D"A.O;X3[C&XZC(I;F@ME\4=&;!$OSAJ&I:\5F<=HLH9^
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MEAI6]R=-")F[E\=@CS>LK9Y6+DN=XEH[7*W[>V^-HTP$P2$G2U@V4_?"8FJ
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M@O2RH"TKS"LMP<!3].93UY];OA%KSD8X=E$$Q\?'5EE3=1W*:4;P8#6GQ-R
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M:EM^;,Z/KGWGOF*C+..JY;(I7\WT!1XN8 QJ;8=.7U<S0B$6F42'5D(3,2K
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M.FF;EV#/YCHSR;44$IH^S*G-L>E*S[FFXCURW>9F?,ZJ)D\MY=W':8<_E N
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MN[H2C>0ZFX5,/$YX/A\I],>^^MA_Q_1+.O*B=>8-@^.R8:-A5$YB9YYM%LW
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MN=$O2\&7@0"8]PG5?N!J?: ;.NAY\&J;W.GD'@AI-K,MI!*\$0,^<PB) \&
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MZR.T%KEECU53_QGJ)W[8:/?Z,G!W!X4W0@+4#-U$4O$+:=+9A7?@'>:#\_V
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MLK9C/KYEDWO13I85/Y:=!;$_UDZIO(NAC@6\3=W5XQ_14/;C[:SS @%PCK!
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M-/6*HAU=BD7S,Y^K']5-)^A:DNZ2J=2HR*\';U[+E3<8PWU-QKY/YN;HCS)
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M#N?#, G! J]"(WTTA9WR@A2/H@'-WO7AHBVJZ/,76%$@K%B7AID)V4:,#<.
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MV-LQ,6$T _85/B<SW'2=(=T7DU(GA3FG!'/K4(Y30Z&S>-M1!.@KIA#J/<P
M!50 IGGI2K75,?#]A)*]++^7/EIXJ%T+8,(V"R>,"G@BMQ-26HW82: B4<0?
M$&("\Y&9BOBE.HXWQ:?=B>K&$.->![Q!R::;'D'\4*6QQ<?!,SZ6.HXT!>.^
M-/*0=8<@W6Q]P'@7/6^27(Z]<$+?X<!^Z"-@80"W>\O^3M^HSG1$[2&!#W1B
M:@!X^&T "(^B;/0AA'G"3 &3D*&#$&RKN@.[,1Q2[(,WC3R3?3)%@44!#>R[
M,4,T^JP#)Z+"3.-@=RS!MCH$U\C>Y;!WP]<'\'W8#)RFY0U<21U87FS'*"<T
MW\/K![H!B%>"X1_=O\_ 36-Z-,&CR&&X;H#C,9HYS&\)XP/PN]0"LN%=AF,E
M;3>=_ HR*$7(8&BA3,/=-;PAO [%PQ IE'U,*6&*+DLN%*01Z#1TI;!B(#C"
MA(ON2!ZN!+?1G1?+#"BN60PS/U$=W2FA#.8:8N$644RX!8A)A%7D2:Y"S8#Y
M=,;^"QI8P.+3@.N/I4O0!1>>TBELD0=4 !&I?%U1XK;?PNN29S10'6!^BRF;
M5,4_EKX2!A[2C+FZ(JK82+>GB#B^,XRJ:C@8]XKY"!YM)78':$0Q@OIC2J]C
MFMH;Z357AVD 3:C] _#B)&S4S[GZ/""2'@G,H6-S[3:\MF'CHQ(,4["'U!@)
M9OGE^.98&H&9:"/.$9 9 -UPN(9Z[P3ZK3J;P5*H0]_V#"Y 8,V>P84"/ZZ;
M\'G\1N]!FZCFF,YAJCL.GH3_2KJV8N%> 1D/+%64QIZ&Y!70\RI:0"$]!((,
MSI,=$DA&RXE^RBF0";M[0@4O/5A0!=!B831#1P(BM 8HY$HV41U0+Y"&4&^R
MZ=!,#[B?$+2$5QITE.Q'-J&R,[#BD*+\KY2#=PQ!7T ,L&V >/C_R(:),.'.
M.:$$*($B/,I'J-R5X:\V+ ?&@C41<PQ(0S_DJT)SCZ^*VWDZ.MA18T)-Q;8,
MR0+&CJS IHYSX'BJ[H'.2)\,CJ%T3Y88FFT6C@1*&* $[CE"!HZXZ6C2 /84
M5^A;FC//GN$)PDLX-N*W0GCT76-D-&)&NHGPN0*"MUDTI3'X$8UPW%,.S*8%
M*J$V\8<7*)#QE$%2EGS&IVIKP*G,EV!I9.C!R3"'C(-'1$6R[GQW5K*<3Q])
M#+N2'4N4'<M1L%B< F(*$^M<@T?*I5,YEFZ0:B)?#I9#'F!K3'A5&06W"AOJ
MN"C(=9@*N=.'] *6F07P)7HWHDY1'#-!-=0=#4PC_LZ5RV(Z!]M):D>$X]^I
MAJ>ZS!8D*SPU'NH5U'P*+;(23%3'_47=!NR)P3RBXY31\KDG8$K"?Q>&0*Y#
MIQ;W=:E1OU7RW+^B^6KHY(X#=R@.8$=QCYR2*D50FFX?Q9"(UTWP:L93QB9^
MRV^[4X'_<+K.% []"&Q^Y]6'[DG_?U+W"D3+U7$W/)C]+S8ZK8WBE@IX+HLQ
M["?QJQ6, 4F^3NF-/_;//WUJUN\VBF!?FS/1E!-N.W!X1A EGR!6Q+(_"P._
M! +Q+X4<8M]1WV"R>XN=%X@ E$A*16Y+KZDNA"XGR56_4PF$<IB)$"Y.0$&,
M7TV@1PM%G <OXLH:5M[PIIN"AV',^/:BS(E#2:@(2A<@9^C-!+N8J+T1]+,G
M@*G& >;<TJB,3P89?>00_>'.N^@UTP$9)0%D_"E@&# H%J7/Q%'+]#83E 13
M5U<@3J%.@9:O*2V5KSG0**9'0T4;(BHTS:C0=74D"AX5FA@ 78A;A\RF>T!U
M#!9B0Y6%V-#2]@FB^RE](&Q*$0V:LRF+:-!GO?]]<=&@N9YYOB(I:RD%4L)Y
ME/$HGAI/67M1\92U[.(I:WN*IRP"RQ43MD7\9*ZF+.(G1?RDB)]\<>J:B)\4
M\9,[Q$\Z(H!2!% 6D_-$ *4(H!0!E"\=!40 I0B@% &4Q9@R!E"R4"AIZU H
M$=NTG]BF^HK@R:7RO[WQ^4>S1N[FW>HF<4UKRO\VJRM#)WGPG'1^?I6C,*:7
M0!N@86\6,DD=07"T"DHU#%P3)_+\D8A+''LYZ=W8K0M#J[72X-C:BXY#],N!
M2*_) ]Y%!08),S0"$\,FZ!!!"]/2OA\Y,P-TDD27N$I5U/N)KC&#E48=@Y+2
M\<:P!DFNL_'>[",V9S]M28HR]VV*>#9%9&::D9E5$9F9HU#'8H>0[B$6<T^M
ML_:_L%#O\#M"\*5T+R]N+F'1G=O>:>FD<]ZYZ/:DFT^]7I%[:+W^5?_0-TON
MQ/(<U1RBGR64\3/5EM!=024T*C0?,A+)68O?S:2*KVM6*XUOLBQ_FYE5L_KM
MYS^J^>7RX^7(N@7!XTUA 7/ZO7=AL)YT%*]+'F\9LD/]PLTDVZ[]QMZCIVQF
MJ'-L$&N2S?N:;SI AN<9;W:9CPD%VP2GA'_][9424E.M?19)D3KK7UL/VNW=
M9;VU-5F\L%W-W836'',G8G_^T]!'GS\Y+:<E[\#]>V]IG+>=9LT04NE_43 H
M&UC&<*-U<D$6F$]RI@U@$ZF_L6B(K33UMEQ;MO0?Q#?C@JIRN:#GD6J7&,$E
M6<J((G))S+5=K#,HT%0/B5QJ!3V#EPRDSSVAQ^@_'S/,W9;E;D)IG*&P>6(P
M%!B5V*38<X[&JCH[.NHX#G&=SL!Q;55SO^DGWW[^W=;D3Y?:'TU'VV'/D\'K
M*>T"-T3Y-'>R<W-#/; Y/MIT6A#RBZA\\43&71(SF&,NMU'0GZ"_C"5);TF2
M=#&ST'1#@5*10:3T+_YNRQ=MY69<SU2D/+'#<+:;VOUR?=V[N*63$P(F/\PC
M&%S0GZ"_9]_&1 %3C0@8;,$.\D3I?YNJG>[/J7W^[>?(4L<?FW^XY\-F+FR5
M34;EE^T-C"+S'5.XO_$@U50D#NS8D\F 3U?Y):_L[@<O_)(MR?X[K9V4&[]D
M#  \./D,-3#,_6%QQIR1WB%5O(I%+'><R]&J>JDMY17&[4Q5][=7^H/[SO2F
M0\L=$DV?JL8KB?_@_/;JJ H<",P$(\%/GJFS=W^Y.7WUH5YN5"I^\+(_K0^I
M;6C&)Y\2G@I&>BF,E!CPWZJFP$CM<KTM'Q(CK34KK["DCC[L/<R(Z9"..;S$
MY-&8L;FH%#2G=_6?%R</C=\GQ;(V$R^JLE82^ ;351"VRRSSE5:>DS2VQS3Y
M%PL(/I'2GN\V=*L;T!SJQUDO8<_@N0%?;Z&DU%/ UD:]D3ZR)C)T 905P:>"
M3Y_$I\DZ4",-/JT>*)\FZD+R*A<[:CVWH/:X7.T!_>?GE3W\]E-W](OSP=^?
M.X-&87PB6>[T+9:JI5-+59?)JQ57 .'RC'"VJX+12@.X@$TR@*[<'[C@E,/D
ME&01WTZ!4^1*65&:A6>51('>61+H%Y:I)5Z;WVC_[5GW'T\&S4&Q'!EI[NO%
MY86X.7\AB%3,FTM!?X+^<B=F*C$?.I9B=^=7A@HRQASV?GCZ#'/,+TCH/&?&
MH]$^Z5W?S>1>@2[45[O1L_&8?U:UB6X2>TZGC*YRXF]H63*)*\ A#XRW=S_9
M:A[;W,YLUU+0GINM#*X(<W_Z@FU>!-LD&IWM-.Y_6HUVX=DF417H1E2!2]:3
MQ1R?$]4AUWC8EZ,O#J&6Z((N8%[][^K\OO;'X'27Y*M<W*-GHP $FTBG;.!.
M,KXYLD9'GD.X@UDH R\5U1[ELBVT@68:OK1RHZ44'M@$YPC.V48A2..^1BFW
MJ[7"<TZB2J!$58+P0C_T1"^H NU:I?8_[7OGSX_Z ;@%]AA=1S>7KL$,]E;$
MTCTW3QQ8C$XB!V^L9LB52AIJ1K5UF%$Y@C,%9^Z!,Y/4&+DBI\&9]0S4_SQP
MYH8IZ7B9S@+EF"XS[_P]Z7S_<7]OMHOJUO!W73FNIXLLMY>WG?/T[MGW,.,=
ML9#.@[8<-DA>X'!58E1F"WB6B*(M])(T,J9:Y58]@TBB1+HNI&XB.%)PY,;Z
M2!K7DW*M+&?AD<P'2R8J);6(4G*NLT;V.G$ZYO &^QI-+ ,;NN+=ESN/U6*;
M_>/U_OCK4Z?WWUUJ?C];+;9L=_V\WSGIG_=O^[T;IJI<G$I4<9%Z__W2O_U;
M.(X/TG%<S. L07^"_G+G_F\ERZ/DXFT7\[KQM5+_[]77:K'LY:R*MT7DCV#U
M/+"18'5!?X+^GGT;U\:A=S0- -]UKM0Y-D^+E6^9!-^Z)@8V/+M2;7=^:ZNF
MPPQ$YV0>_:3SH#O?O@4/75BF'?GT,^W& O93];MW-G)O/GW/-H2MR.'L_JG0
M&<_8T0A<2<U7E!-(6>,(2N3,QURU/NM]2^2\N-M(3J6&7+M>^%@<P4F"DY9<
MK%MQ4AI7(DJYTBQ^1&BBMG&Z'VWC.D'5N+_^<JMW;W\,;T?%,I.SUB_X9G'U
M G9,4OG)"&TC3Q9"?H%R4>589K\%E$PC'4C.()XM]Q0A6.G 66E1YUC+2FE4
M;#M09:/S;,K&5#WO_CR_U;[]K%Q\GKO-*X/\[_L.6L=&+=L/0@GI")5#X&26
M*D<:"4="Y1"L='BLM+7*D48%N0-1.59G[<$!V!X9+M_>9WF=\K_3?YQY?6BU
MU:&X3EFM:>#!K*NG;X0')P#T90)H,O^F=>FBI)([5%::HF2MX*E#Y*D=KE^4
M-"XRY7*K7GQ%/]$C4M^;@I)T _-G[9_&]>T_#XV[;(L4%,[YD7@#@X<C%!0!
MIMDH*.N,/"6-3*)Z-8.F@KFG"L%.A\].V_I,E#1N/&NMXK-3HEIR]IQJ27A7
M\]'^K]XS[C[^?C<6=S7K/2A".1%H^DS*21IU%X5R(MCI,-EI:^4DC;O1@U%.
MEE03S7- <A\=W1)[>F&Y9(_I,4[UIWEFS;[J_\LVM;/(]SEX++R (YR-'S]"
M:SM+U@C5,GH36I9T4S,\G$C@7=&!=6SBB!K0!XJIT3<=.40[TA^.)OIP2& T
M8&]%?QC81D6N5G ]+456P@45"[@$S1X,S2;J =WST_Z[%?(GK;N3:AKWD4J]
M^*U-$ET4S?WH 4G7)B?-\?V7SZ?_M?O9!G44S@^Q?&T"XGPJ] "!J3OJ 56A
M!PB:S0G-9J,'K',%5-.X]E/*S<J!Q'<NJ@&-9U,#PFN*IOGCRWFS]M_3\2XU
M!U_.-05U# AE0 #K;LI 0R@#@F9S0K//I RD<<UV0,K DD<@K-%H@6#?MQ[P
MSX_YCW^TS_<?_VR(RX&-700#6Q^.B63 B85J@= "7AJB;JH%M(46(&@V)S3[
M:(A @@A*10FHI=%\3%&JAZ$"+/H#VHM]&I\C;M&Z=#_^/;J=_NP7K #T_J5_
M<I3B7"#F82+FAE*^I@@I+V@V)S2[OE]A1F& M31J5S:R:#.:!TD?K5QYIINJ
MJ1': ML_C'E,W(?"^?+AK[9W,?G8_$R$E;[B#/A^T@D;N*FA9"[[PEK W0N$
MN\<8;?,^A;54RDW*Q8]L$FPCV&;S9H*U-$I+-HI?G61MRN+EC-BJ"^)Q(X5@
M_NG\XNK\I.G=:T6UUF--I;-5#8*]C2@'E)N.K-&1EX6F(+K#IX&3A]$=_E'&
MWD(!2:7X9+E6R:##1AX:Q0LF%4RZ3R9-5G?2*&LIE\$&/TPF352#3AYM5(FJ
MSRW5?7YVKBK?IJZO W5_SD>F^WDV_6@<C%,D[>A%RU4-.EM14R%'8N<Y;WBW
M*J80![=Z&LE=U7*[*GI\"78Y*'9)U 7J:=21;)=K[0/U?K23Q?Z%96J)+:IM
MY4PV[Z;]4ZVP/H],A/S%Y85H7/V2(*N8C8,%_0GZRYT,:JWWP(?R*'#"4T/T
MYZAS_>6D\Z7WI9MM)>(B7\IOXWDW@XT6N)$'GLR'"RYDORT,U51RCIK-PNO=
M@G<$[VQKM:9SS=2J%=_)DZ@Q5-:%\*W4%P;5\>]ZK?GC850KMOVZU\@]H16\
M:&1;PV*;ZP2--%*0Y*:(WQ.<<[B<DZ@1-%+I,7:H^D O+.9S95M3W7$L>X[%
M%!:D_\7W@?V3U&<_OPAGP8HM#_<O*,4KD.L%(1>M11)GHBWD>RJ)1Y7BUQ\7
M7"*X9+4L3Z,TWR%P2:(LKX6R_*MJVZKI!HK3@C1W+BY5>V:-#5D1MGQTJ_F^
M,5M>9,:_5'Q:9)\MY'@:"4-R1?CN!9\<"I\D2_(T[KADN5UX/EE78C=:L6"-
M5/_K:[79^N_/ZNF/0X@HWV."W7*-G'NVTZGI ")7)PU +'2N#@7,Q[AY"R4C
MC32=#&J4Y"%%1_"FX,T]\6:B8M-,XZ(N [4F#[RY3?H<1LUCWIS+\^;4\\Y-
M[Z<\P%I__W4__NGI[O!'MI&+>Z@>H!S7E]6;E+6;V\O;SGG*L?4K5I(#U*3S
MD(:6-S!(<8$SC54\7Z[1YII,,XTDHWJYTMZ#-L-YM8#ZC.!-P9N/\F:R)I/&
ME:2LE!5Y#]4 GH<YURHT76LZU=TI,5VG8PZ[\$J8-#$UKN#T8WJ-T]'_N?U=
M;S_4Q@?@O\E$EXGL)YVS:@XI/0>[*KW&&T5)EM\(;W1>O=$+[;>>AGO1%S]2
MWKA9?_7AB*^LF E@@H1?.@DWBD[":\7EC6MIWR>6 4J7T_L!)OY\(8G^8^^'
M\WO#G#>=YO.9_@.8X+-O;VC5]_[[I7_[M\"*O&)%WN:8RVT4]"?H+_M0]YA=
M9IE4W/RI&EX0[0ZFF&W]_/;S?S_^=C_]-5.Z7]H'8XJE?6O.]I#.U\&-+$O_
M9B_WM[P=:Q@0V?(KU;ZT;UR\;:&[?T7LFXEJPRGTO\WTX3<-W86R4I6__;S[
M\[]D_+EY_;^[ZBO)U5V<-7N3/^A,M:4[?(N_MG#XQN[#U]CPG:_>W=^_*^WK
MO_[98/A'?3 ;3&!SOVEKTT#8_L59W"5S14=RLIIMHB>IM6E0W.K95H[Q10E^
MI%6.)?J?\'3*TB)QM).)@PW8\=R)90.Q#RE1F%6S&J7*R5\_]7.WV>C_:*P@
M"X>^1E*#]RQ39W67"7"Z'/\<7W_Z<3=O/JA;3&#3$U^<PA9T^<3TZZV)<Z.I
M)A)E^XD7M?Y4J]5*N9(84OXX:2X=T/LE$CU[C$+ZCN.M(,^_KB]'YJ3QY]\U
MXW'JT.D[EDEST849&_C2<QU7-5&R)(Y^WC$G?S1_-JXFJS"3CVZ%+]KZQ-GJ
M-R?,]A,OFG8DS,A>;3'7)V8Y^'-MEA4Y*9#X<;I$E^HB/;2V)40.4P_GAO-E
M_O7[IQ^UQTAA)1U6=J)#/GCC1G&;[?[5PW_7<$%&=)B,.D^,#\^(#I/GFA*8
MR^5F=6=\9*1!J3)R3I(*QS:23HE&FWA)5;DL(3O1[^%ZRE0OA1?,"+S]CA@B
MBR,7QM^>+SX7[;PM-)E4TL8+'YXN&.5@&&7#:X96X1N!KDJI"%2)SG"H(S>J
MQI6J#_MF5YWIKFHL.H&^]!^^7';_^>OR>[;W\87+D@SWCZ=,Z,,CW90TMHT"
M/PX3/QX5M"M8:F-YJU12*7!4JY>K;45(7<$U!\<U22::4DE%2U6JY4,H%YHH
M]Z->UHZF>5./9GG0)M)@'<QL,B&F Q9BW]2L*3FW'.>"N)>C6_5A41\XKW7/
MJ[+^EW(Q$9="JU2#<(OII"W<9R#GR$9+!NQQ63*)BR:\JSX(Z#M(Z'N]!ONV
M8\8M-(G=XI8=V 7XVQ(X5HN%BR+N57#3CMR4K&'L=AFQ@IN4#/)T]L=-:\-*
MKHFKZB89]E3;!!GK1$[EE(QT37<7=8JSJ?=P-3.^.E\;1?4Q[+%0PZ)V,62;
M*A+ <X"3!4D 7X.CZSEX"T5DM[N^58I(32XWE QN%/:>&?Y4%47PJ^#7)_)K
MLJJS6TVJ5?RJR.6F? C=RC=0@I1'DSC\'L@NUWI0_>E?=7Z>?SS_]K-R>W9;
M'9_/AW]5A5=E5;)'T C9B6PNO:5KOI<(W61A]QVDW?<X_"WSVA;J21I5I*KE
M9KWX1?@$NPAV6:<=R*E<4);KU0RJ(>3AHJ4340$^ZZ9EP^[V86MMXD2\'H'8
MER\_GO]A_:%]G7T7CH^UAX"-3^!OMF48?C=*G>^M,*9R@'X%,:8VC %3Y/1C
MP/)0?TYPA^".G76'19FVA>:01B&E6A9Z0QZ8<@=_0M_4# \G?F79N!$=U[7U
M@>>J X/<6G%9&55!N _"UT&BM9=.__@R^*-7'4Q'HP/P0NQ1,PE=$ZFX(03@
M"L!=::SMPO>;^T/D>G[](7D :L',@IGSR,S).E<J?7C*[<:!ELE/U+I.DTMQ
M=\QAXIT.K\\=Z%!W7\;C7K<^[GTI8G&N/93-3:S$+74N3B7Z23J5O$3YWVV6
M\N^74_DWD8VW4(^>F W.FHZ46_4,$@WR40U8\*K@U;WS:K+VD\;5KEPKRZT,
M<NGRP:R^ O26*IP?2J5?9]LO9:K:8]VD5:[#?^)+T0CJKADN9E:DN?^J?[B=
MD)*J84:0:LZQE <V2G<D+ .#M5]@Q+&M&K0/&\T/FA"'(.%3:P?CNJ21;JJF
MIL.7'*Q*1JN!'P.=?BCFGB2<9^G7_W=T))WIQ!B^DZ[4,2#8#?GA$5/#IVJM
M]Q*M9@$_2T=''-"'^MVF%B-;9O!Y@YX,Y0-8GF%P!OWM5>45_1TFIOF_QT<
MA=Q09PY,Q/_IO72O#]T)KJWR2Q(!@,'!W[&H\+O6+!$%0HQ9/H?8<*\^G!U%
M-\[?LO?2[7P&,^C8@*_:>^D"4)=MZX6%^U>+/O36?PH_":'"QXE?W\(^)^RX
M3=3O1P,"H NOGM$3X[L,R_*W.*#(")V%YS^+O3PZ)9PJ/>CTB#I5IAX$:Q@4
ME =A"=W.>?^T7SKI7]Y^ZEUWKGI?;OO=F[+4O^@>%WIA85&M3W]\JU2JK_RE
M="\O;BYAT9W;WFGIYA;^\[EW<7LC79Y)EU>P!;=]^$*!EZY_>-TW2^[$\AS5
M',(WR8-&8.09L7G=,9 GZIN#DAP;PKCO\ZE6ZM]DN<J+I_W\?/9/<W2M7LU,
M4"@=;PJKFM,O ICZHE8ZDKI1:1Q\0"MR7<+FJJ@G.CNX@#:3*J]\Q]76[U^H
MVI_L<4KK1B[SXT[2OS?V?CV?8Q[.%/_ZVRLE),-:N_4-_0X5N2)_^Q:6DCP]
MLZH__ZQ>_'F^J'FL\8;OY 5,_\1P)04]KP)-=0UIM9&@:@%I\>J0JO:76OMT
MU:K5OQ>6MFH%/3!F?.\$X0*SGY6Q&L7DE;^):K->*>805)9HV=""'DWT D\P
M49Y/*E$Z%9&)A#(CR.4EZ2>+T1%R)#J"F[GFN/<P(Z9#G+!/V<FWG__<=4[T
MSK7W9:KE(I@T%PW+N$OIXB,3Q']=]2YNGMR'7*3AY3,-KYAMHP3]"?I[SFU<
MFU=Y31RP9+1)QQR>DCMB6#-TO'(9A!%Y%]^&^K>I>MG[>5:_^_:S<?7G_5?Y
M1^_/VB#?29;<O=O .\-]%U?P-S5H*#T,M_;)%,07IOR25Z3P'>L)&[^/V)WM
M)]KX)6/L6%MQYA$>C(?HG-G6E(;3563XOVNM"JU3GMCPAX;KM,O-:@:A=7NB
MCZ?7A!*<)CBMQCAM55B<DD:&3ZO<:F:0%/ L?):H<$0;(]X0FG_QD9A@[QIP
M$)WA5#=UM'6QJ])JS>.OJ_^=F?\[G9$_E5R8P.ED!.PAGY)O=:",J+$-%PE9
M.;!Q"I*0M09=-V/M'16:W2KI+<0?5\KU2@;5MT6]2\&U+Y%KURE':>3WR$JY
MU3Z$E,D-]*3F8_<!5"6ZI3J1RW6BJ7/9/_\YOE"__?RG.OIR^4_O[^OO.??+
M[*02*2FK1&&)"<O?9HFP?1;(*I U)61=8N'=5)]J&F4"E4I9J26US"TVC H&
M%0R:-8.NT7*J:31,P\K>S<;!L>?F40]A0QE:!N+;5.V?GW4O?S8__H7ZCJ_F
M&-4_OE]7:ZW/G[.M\9FE$RC-[<8-HS,; :WZRHQE.N(2.EV\*QB>A=RTH\J1
M:L.SK'2//*L9@H,.FH/6Z03IMCC+2#EX9CT@VC_]PC*M^-9SE2P6!=D_<2MG
MVN_W7Z^R+:F933FH5$,?,:.8SJ]_T;W\W)->^^&/;\K21>]6H-?_9^]-FQ-'
MLOWA]WP*W7JF_]$=@:O9E^F>BL L+JILH RN[0TAI 1D"PEKL0V?_LE,K6 )
MA"S9DGQNW)EQV2!EGOR=?<E,2J]T%J$!_@!_;TE&3^U3=6D?:QBDJ7/<RL@N
M1%BZ2B;I96 C5M$V$X655$,?J^<;]U]:3X(ZG;H5G.+ZZQ7M%IMN'[N;\A?N
M3OQ:J*;6GXV[?L$Z'6,D="11>I OR90O1ZSS WQZR,]UO%R+'Z>>[+AGPT<R
M\:P<P_6:X/<FBV;OD+.>^;^G<%8EBH16N1[#(,$$1<9?P2:Y]C!(MN)*T6NL
MS"EB6NL(7L\*8>B-1L5_&!/Q=,0@7)L)$O1%MLESMMP3GZ4(Q&>ZXXG 5<!5
M)]HE1[DJBBNUJK54F_N>1DGOS8V2E3KH=[?]QL5T^U1?_OA=^?%CR-5"F">!
MIO5EUUH!$0HB-%;#)(IF.#!,@*LRR%4O,$RBN'<J"X;)KEE2F2).5[&^/CMK
M+UEI@?I2CQ44.L5^.!]J2Z3LWG[1P6]Z8$E+B[H7HW*:31U#0Q6N[T>B=+70
M$21F?,[(H+MY=3@SQ]1G'@CYR=1FF1P (SHG8,[!L,\ Q&8FQ::WU&Q?=OK_
M?2F;ABMEK(1K0O,IQ4J9%(5B#&"UR%CM2,UC)5R^U*_FL5%-/:OYY7A"VRW7
M1XR6R_730YF[NBYV('<3F:$"21Z0J:%DZO6+;9=JN-8RL%V SX#/ ALNU7#Y
M5!\N*S=3SV8>T9:>8[5<**RD&3T:Q :9KEC;_O@^7CU=_EK/&E#-ZDMO2C[3
M%"$T! 'WW@2<BX%"F@51#/>LIJPA$\P!X)8PRCV*G&2QD7[;V3,8T7;5=ERP
M@C24QI@"PWE?PG:51J]@W-?Q0IF]NR_4!@NM#D&&'<6.Z6>,E,+/PU0DP07!
MIB,)/ SD!Y9I(U$$*?:.I)B5,?;AKY F0!3C,$N52NK%&G!/9KC'_:0S%7%G
MPM/94N!YA-^&U55)>)HI(H9^@^RG42J6G VE"[-'IR'0>(?O2(1]C=PZ[SS]
MOA'GW[XDXVZHERGG5QR,3<GL<L7SC(1>?C\'C)=[N4A*R7BY([-D#G)Q.+U?
MBZ)UKIB)&=@1Z31@5V#7L.QZ)/90BV(R9 SIA"2PJJ<-5 HR$<IK/J1M"_V:
MK:Z>QNWSK[5%6J,3KV@ N<9@TRH(PPQB_C0;1M2_P"("$1NAB(W:&(JB9:_8
MC&&.0!(D+' J<&KX_I9H#:%(QV%6BEFPB0)TWA9V.F^M>:2$Y&W\-$'2\8*'
M]LCG<X1)C(S/3=@GI':?-(7%8!0D5MGT-;0B5;[D\!29WOABM3!-!6Q.:2YS
MBAU=;N\F7Z9;46^VM3MTS5TU$Q%92L3HS<OA>$R7=][M#:^[U@#.2>LGW#V>
MT=#TT5[ V'@SI&$4KF70?WQWH1+##4S0E9LLF@$GGLR)Q^R><%E:/SXLY8O-
ME'7%G#STS#P7T]@\1Q*:"]A",3M=+,/DY^AW[>[N\;IZ'>]=L-D(\QA4I9O0
MV"=FK<@/@HJA ^YB @1K-MQ%'\8-:;Y$,GDU!DD)EYT!B[X+%CUBU]0CR4+'
M4'R6Q"B.>]#\2)$QR8U;SDC0Q;1G2#'/96NR;;<GTVUOS0N#SXON>)V,<I[0
M09?GQU'Z6(U6_ RZ$[IH$I.)'#R1KS:DL*3K8'A9GXDH*?+R/Z>(RB@V\-K2
MTN'4<#9,/=*F0A*"J;U"T0X]J;29-,"GP*<A[VFK1WO/82E?*KQ";NK5N?1X
ML0[2G-!;2],48:9K+(;11/;).9&I);;)<ZW^_'H^W@S+<Q[".<>-'F3T#XN8
MU@SK(C:CR62RK8O<C&#2&_Q(\".CJ@PXE==#&E#A&C?]9I]4ZYGS-H&-@8W?
MFHV/V5>1)J)K,8R&3F+$Z-S/LC*"1H[A9,>-/J^F6VG5Y[_,;D=/EW<0-SHA
M;L2T)I/K_OG-I'5^V64F0Z8]'$RNAY>7_<$%TQ],NM?=\4OOTP6G-5[IFT;/
M=8>S0]I(T<ZV;>:;A5<0L1!D G[-)+\>,X:B'9!;RA<K60P)^YE$UORY#D(K
MQ'>$!X%'$C^4?K *&1&D[EI#_8;<1?K5??\)*H2.GX!!4[H)WB0L&6/S:)(6
MW,ZD"M+4N)UTEI<?ZX:S?AJ13L>MYFOU++3%0XP(F/7UF?6(Z=.(-!M>Q*P:
MPT"^)(:"VKY)M@=6$(UP75M>K61IK,G<W5(6,>S4<U85N)U@$3&)ML+L5_]J
M?'/[?08!HI<%B*ZNA@-F/!FVOWX>7G:ZUU!\E&S)FWI_\SB[A[2A(NW,+57S
MU7H6"R" HX&CD\'1QPRM2+/FI7*^\1IEVF\98WJKV%"BK1]WA=$:82(M6061
M+6)8&O<C":*N(1Z$Y"L*R?37<AI/LKR;9J'N\FZZK")A)*@CI(P)V@P?9BWP
M4XX8+X5BH3B=DI^*I7)QNEW_W-Y?/5S_E 3L6FJ"1M:&8;L'V;P!62Q)1595
MC=>NEY(VO2E?+_F+[]KO']5"OUU8?"LU=:[45-D?]/=W_=Z@\.OGM3C[\5WG
M/U\M9J5?BTGY7.16O0+[ W_VL35]OI_*@?UT#([QW]&F-/IQO:[U[\CHL@,[
M,EDOKCT=T6&>QQ32]@S:'=T?]'Q4U(BN03TV=\KG+$(N.V@:)\"RJQ\]&[K]
M].WN_Z16^X*B $5QFJ*H!E84%5NL5DQ%<7&W1JU116I7DZ,H"B<HBF<[NE@*
MJW'WZ[I!Q$T&%,41EZ89-,WSJFKBV**#-I8$6'2Y^K'N=5E3QK7$Z_AH60A6
M_T!$_IKY>Q;OG5T@C%D25,#/E[&0IQ)!961=4S7LON'5@#,'$:\8%'7'I=@L
M6+8,1 [TU0PIP[DAUH8.%(]X>HW;[?U%[_OZO.(H<.O1S]#^#.>OK-CKQ_=O
M:I5G9/"GP)B=+W\5).T><:$H$+,A<%BIGH2"<!Y9,VC0DRI;6\<&,PI./,60
M.SC)%7ZV@TJ^7/":8IPY"R&F,<>@J-Z=HBJ^6%$]\\NX=4=;S&_5$IHG7U$U
M(E!4SRAP>?U[+OY^$BY_O$<]=<PE/"EN^ 9:ZO#ZRX63_/!GZZ_5O#IPWX.&
MLAS9OVE[Y:=<+O?O^O2]K%AE(> %DX_:_]G=RZVN:L)\$^-VUI]B6SR'2)]I
MM'=1?)HL48[EL,C!S]R0>0B2K.%G8$0R1!KB-RX45L0X431R7:NV1"J14!*M
MTF2)V)H+$BMQ OX0YAT-T2L[/V+<?HJ')C&?7>[?_SL[8WH"$OG_,B,L*/[!
MW[[7D<21;U6:_S#?65$G/S-G9Z;-P@L/0:M:C2W9?Z_14S!&4W!(%$UV_-^'
MP@?Z;[PPSOKW[ALX6139M8H78OWT#_,H\-J2[*WPA]=A.V&B_>"/)J\]>=Z1
M*,]QN/.Z#Y]Z9V["623[AYELUG@%+86="=P_S "+9(.L YG0K^K^TM_6M\A?
M',%@285__\9T]J"X@MB[LQD=6OQ?C%-R8B:5\;8L$MOH<V'*.?_USL/=2R)+
MI0>=3 #_.[/W,(N)WV*70;-/[=9EO]//G?>'D\_=Z]:H>S/IM\=Y<F_ QU1O
MS#$I/W^=%@J5#]96VL/!>(@WW9IT.[GQ!/_/57<P&3/#'BF='5UW/W<'X_[W
MKCFV+[4D$#[]V9=RVE+656Q6J7^E5BT$E-&6]U NE*?%8GFZELI2>;J]N+Q^
M:FY_7S[JMUB.ZRN\@PW]():4ELYDSABF[=:K]E]4HGC;6$,K:(DD57A C-%@
M>3+E@NF.#Z&3"KR@KD464QQ;K,@OQQ!5*V#T< T0.PF<Y'B[%B%\IN2W__M0
M<O!8:5:F7G%347N0BN///W6VL6]@'&G,"97MB?[(R%92>F I6NH1;/6F7J&.
MV]7HO%4?H=[O4FJQ54GI@1D>=82)X?!".P7![3?@G]J)+!&:&U)C*LX^_4*L
M<==\T/_K2CS)R>]8QTR:=MQ!'")AR)-V72[F]_:<(DZ(H68%[,G7T_DI5>-@
M(@)<WHW5M]\@W_&_78-M]P?#R7:C_9QN?]_6KW^,OLTZWVOIZGTW(Q<U$O2.
M,V\5Z4T:YJ)+?[QN3<7)"RS&3%2_0OS3%UK[(^;ZB'BOPR@7HAVT']-U&*\$
MBY=WPP"#O3,&.U:;$>T8AYCNL7@3]CIJ-0RU)5)V$A!.D_X :</YA'T:R0HA
MP>Z8[!&K8/NL-5,U0J&I<#[=+NO?OO_ZO-"D^V6ZI@Y&27]*4+HT;B>M(U"R
MYAD)&<46[--_X9;FMXH2QBKK8EAC(LD(^ /\Q>S?=@-JJIZL(+S0MJY@I<1M
M)@HKJ8;>;DD\_9?(TG_QI$J0)-XMW385"L5=9_G;9:G;+UWU;BZ2,2CNE'"$
M,Q\WX&C=* _5/ 1#]YDGP6@.\1G6IGZ*TSRQIG;>OGTA>5,Z#WL.\4B%D&X^
MW-R=E60N</E[Y?(CL89B))=_O\*4R+?@<4\;SMT4['&$UF'@?XDZV8%GM,'G
M'DTZY->QW2P[;GDUGF[%6_[7[!O[H%^\X;6:$0Y.B%CX[=0BQW>-.(CLDT*W
M*9'61\*Y$;-Y.&NL&/D=Y)5&!L0VW)  +)X2%C]FBD5]?7FQZ35H*MT,?O2*
MS0,'&? J<Y?-Q?_JM+I/#6W[-1F%)LFTO-P4A[O,$RJ^L^!4AY?A,9IE<+,Y
MV&3 U*EBZF.&&-QS'L((ZP4SPMPQ+FIC_5SPLR]LN3>:B)F(:T4^?LP[L@7W
M6"5LM%KZYW2'E\0A3:>H+SQO-%_A(D$8L ^,FVW&/68>17[S>2G+MU+9@^)@
M3MPKS?&!.7&GS(FK%F!.7)1SXFHP)^YE# QSXI*\L;TY<=4@<^(FPTGKDNE^
MN^E/?J5W\]C*^N2>$)=GT!.'B!Q<4M6RDG6L)HB6^.LU-OA*>O_487+%:;%8
ML8;)C;ZU:[+0KRN+NT/#Y [,DIO(&M;"W7M=T#8P10ZF?F1QC(,Q5#NEIY"B
MI1X>#7=>F=KQ:UL&&8*'.-"8O[%(:CT)ZM0=YK:N>KZBPY&FV]]W8K4J/MQ?
M-.?I!&.+JK&4GG"*EGH$C*63P=C"&R"A$U8<L0+?E]KL6L"ZTP+FIOW4;58O
M[D?KE([/-/>3TN-.T5*C1R;'Z2M=)-:=7^.#A=+1?(6^G0NCL7KJU,&$H-38
M#B7AGZ2;XW H/[D@2-%2C^"U=C)>KY'&"A+BK1M$+7"N-N<C<5*X^>F:!Y$J
M<';07. $4.YO#<GRR9 TII-80-Q>H_'YE7I;*;#I!**QV90>;HJ6>@2'W9-Q
MZ%UD9>&R^\A_6:^;V]XPM=H[0%%R<H\[14L]@LSJ=/O0?IIO.Y?]%5M-)YC2
M+>22,Y4=@J"QCFM/"+<8L32Z'1I02^EYI&BIA^+G+U][['%*.]SU[TSYV]@,
M"7R="5)*SR-%2TTY=)QXE(,=&IFB_]R]ORJE)Y2BI68'3.FD?XJ6FFZHT%H&
M1^)0,V>)UXL4]?_]?XU2L9[68TG14M.-H(%I(;MB,"D]AQ0M-=V0,81..BD/
M-S"EY:2@%BL)IY"BI68&,% O!8"!.J8D+C4SB(&:(L .E/PD?*F904RZT];I
M66IF  -%,P"9=R5CO,9?E8M3CLRY*10+Q>F4_%0LX=\A5X&=$^TWMA]N0OQX
MNAVOOC<?/S]IG^]1:J:26G=<-B*]Y/*<%5F),TQC5F.L.^K)O?/,T<N13UGV
M>[^:TUML6NAO-G:03D-H0UU3-58B^":@70N\)X,$K4 ]V'0GLJM>:S[X4;Q@
M/S":H)'MFM#(&]W9:@A&,4E;C?LNT</#>YY1<W=D3TL=SIU!/1:5IL^(M#O"
MIQ1TA$]_T',-[#'6\N%3,5\O%_*%:@S3MMX4SR >(AZAE3QF,XC[_+]WWG"F
M(NY,>#I;"CR/\"JPC"L)3S-%Q)Q3),]HE(HEYX0 \@#Y!$/^B'Z)Q"X-I)0.
M=BCO*:APEYWL380LE?.E>@P#M8%C@6/?<)[C:[)LT-;M/?:-]BJ3&.XI>I/;
MZX%[@7M?DWN]&]GW6+42Z1#F$O8-X[CR%?@5^#7K]K&[R7^/2<-=,K/'F_EJ
M.89!RV , WN^"_8\-/M@CUW#72"SRZX58%9@5F#6TYAUCP_KD:C-9BV]#FC0
M6\W;^ZGJOJKJB._H"CD<_'"9IT/B\9OI7]3IMMT?ZI7*IOKTNQ%K&OK@Q4VG
MUC)$35]"##L%+<\Q-$GB#3\:DY#1EG@CBR73TL@E \P5J]PAC1G.YT@YUKEU
M?%])E8EOF88N'4>QD<-T8$P2T[KQR_@2U.V+WE6O??%4>>3M!+6%G!-1\X*$
M]EM+_J.'<>@:*><2J:!)[O++DMS86<J7:C&$,A)O>(%DB>1LHV>Q@#GJ<O0Y
MZL23'C";4,R&40N[EN:)6N&$+',YBBQS.5\JQ% (E7C@ ,<EE..":HDR: G
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M4N:=V2V5 N0[ +-IPRSD.P"S:<,LY#L LVG#+.0[ +-IPRSD.P"S:<,LY#L
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M@/F2PGQ!%09DR@"S:<,L9,H LTG![!L;.?[YLD84^3*P:8#7DL-K0?4#I,L
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M&G28Z^YX<MUO3[H=^CN0_2#[(Y+]KRLR0II^X5H:?11#.=^,XT;J-]8-( 5
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M)I:^L7JZ+.NU:BXX'6B2@DC"9X^D1NVCK(N\*S!.(Q=V=H3:)H>>GZ/KHH7
M^./ZF@@UPRI_TFBD'O^HD[2/X<T;/U.33\<T4; <YUWGLW,0A@WLQ=W/Q70N
MD)C&Q, (,KZ5QYM<L?14L1E'#X4''SW1.\*:OJ4O\,N8(A4?56]5;Z(C+EV?
MS[E!9$?@HU+\C1"*OUIH8$4VM7_:/K;XY?B6?[AA:R]5_-6S0L.H"C5_VM4R
M]>)+%'\I:L6?VQ6\\2A^D\CSZ]OM>B@LUI>EMU+\WD<2M%#WY8I_3[>;W%DQ
MN'-?N5</*G?FN7+/^7W)5NZ/2'Q $>MW9E>_Y]Y$OY] BLCTN^?S&;=^S[V9
M?O<4S;F3]3LS45C>S"YZO=AGI;)QF(-?XRY9E$+B-WGF\K)M!+Y(,C)'\CJ&
M_#IC>:(1\8MGK"JH+L8PK-YJULT,6B6'GNB5;9\.5R-7H!HYRFKD8B$MY<A4
MMU@826AM<O8LZ)8H&E5-!!4TO6EH-")A'6_>"LR3#!'6C^0O@LR3; A2"5;M
MHKFCK16&MIDA1/*FFB*K:ZN8(J=8 IVDV-!<I-FV XXF7:.?EL+6 PFRDQHK
MU7@@AX0=RV!G0(.A>5R*/4=3-S1!X,Z1["7F&)*8LT8>YAEY;6:AC/2(9T.I
M%1BY'M^H=I6B88%82@(O=T'6:EA2.5._>MC%'YF>KA ]OI*)Y45R9R3!@36^
M9CW.(#I]_HKED:6LG:-%3R1-HY*DC\ A.R7NJ&V#8KE]#4A-"3-AOM85K$]5
MZN[C#]B/Q-_9L94,U6D0B5D0HA&5N'$KWKSO"O!/.[8\S6TI#V;QT%RG=;_V
M,&E_4X(4FC*&&T)L!5+;@&D]$ED)DBQODV2Y%/!I\/@\: KU0C8,=)))D[+5
MB)5R74$J(DX1\%@[8&_'*'=BF04]5\XX5\,0QK)S*7!+PX]=D3)"I)JRSLX;
M4\]!59%F5%PX'?A$(KDN6;<TD$3\7!$_4E<,"6154YEE>#*5W^8U[M1-<@O*
M/=7CU%P8XL60R*IE_F.E0LH0S(1_SDB5X\4:WLCNXHGF-+6H]^?<>[&%J^GR
MV4X9%J=8;YF!)'>^6=MDW8=(^8[<Y4185V(E28PHZBD2'.D*+8(3,>"069+J
M*B(DB)'0@J6JRI@@)<J/NY\CE3S$E#)MEB4-&>R4A7"<OM+I;'*&1_B7I@E%
M5L(9V">,*) *!!(1E?"B\%LU:U$T%$) 2/P %2'688R=PCS\:N*A,Q[O(SQ[
M,.YVC33JH7=9A10^JBWG&1WC$5-AT)^NI:I4F_*"$7PKELK%Z?:N4).NN^M*
MZ<?<#KZUGB_A6.#M^ I\XFX>#?+UP%>?5>T&^9KO%>+%2O%CS2\"E\.H%&DI
MJ<9TL*U+;:>R&17_R'1TNX9\@UB%,<(HSSZX&SZGI:H'CVN -#+Z9Z3(#P)^
MX/GF1B57L@\M1+9L0.)CVSNU0M&*4!OG5^);]UQCP$YN!?O\\/,-N-.E8 GO
MA?5C)QI\D9Y#$#S;]W9..?"TP2"G7"I^]!V(8!\RIH0]1\Z+)#1V2O,+!P^8
M,"I]CA=;NM,.A'XTWDU/T,5T7_ /UX];0=6;3L0;?_AH>)M\)C@?!4U<[U)X
ME[#5(,RSZ[?YTJ:^([*LS_M2J;?41IO+>4W?S%W)EYW7'!=+[K<$)UTC\ 41
M!TB'M>$QTGUDKEB)72"C1L[4* XT317BI\?<JH=@VD?+9,D>R)Z%XP @1\I$
M5Z8UCQ72C#6;'KS\<='R_@CG8:N=,UOPJ#=/.]LTUN@_X&5]ADV6&4FL>#W)
M57AKH8EF9O=<#Y*;P0*T6&)6^%-+U;&N>3,MZ[Z2*E!4R[!_=@:1N+^3.\%1
MHA7B1I9@)R-A;8FJ<=ED+734ZS&='GP2V.W)6;Z-A]M#*Y<=/\OMC2C&A3;6
MIYX?"2&9YDE_YCG]@8L3O2.'B^T,>K!S)=QJ%?IK1B!P#Q2DB6FG&)Y4P.,G
M[.@.TO.D>GTZ9Y?.+Q597RR9M3X3!8ZA;4/" V$&9$3U9%(GCV%I<ATVXHUR
M>W%."J^%'<5$?7'SP69)NL$2--2-?1_$DNH22U;DGLD*\O.^O/ 6$9_EQ^>U
MX,3))P&)&>D;$)&K:4#5N:6S!<+H++8=5B12CL]10K3!"!-YSC[(BO%=I*Q4
M6G-.6A-$<2\\O%OA;F2658MF3KC;]Z3(HTDGU)- FP",4DJSK(/NPW%I&5X0
M=3/_:H5S,0*?OXM\S<@_TT@]B6$[R0B:@\!'*XAH@?^I(LEL+M"6LFH1^UGO
MG;4^QKT^$#I)"8N2HGK2/T6C93?N_BF(]28(8VU:'Z'FL-@AI1?RRJ@%,P3"
M3DI,,3I324\I<9T8Q6@8,Z7S$K&BMC2%31[[ 8]8<!EC)HP?Y@)M#,LS#S)I
MXA)M*6Y)9:-#2\WG9,G0-ZJ^7HNTK 8OCA=415\[43(JCK% X(PVH@62US(Q
M8SAJ'4ESO"8B9HC<88V".R]+TM65E?%I"ON5=5%/,VJ4GU4#.B')%D<O?<"'
M.L*'Q&$9,,%O.Q>QW-Z;<-1QUT &>L!TJ_THBNKE9W'\6$S3U*/2\ZE'Y>FV
M^T4LB9/Q2MA^^#0F(UK,LE)7]YA##,:B1C8G'T6.T6<3M\Z) S:<[\%K8_RW
M#T8K/1=&@SU@NF5'U\6+RL6OWR*;'HP*G^CV2#!_9!2 4%D)^CM!^OO98-3C
MB5O6:+R5>#L$=RA58%7?5/)>@0R!IG]DA:<CUNV2>$6WQBZXFK;MJGC'+2"?
MZ#Z9A;/T1@%5=4_ &G?;=NV,T0),E;NLK(CE0%_'.M(0^Q!XLVO\:CIV1:$5
MOD;'MU.Y1&8CXW_1.FO5; \@99WV.V\^CC\R%ZW6R"Y0SA)>LL<!+6GC5+:9
MIZPB<T P=B)9;$7B\R6.\T(7*%!)"&.%6*,CA'[7CHP9M<N:$;FVH4!X9DXJ
MH2T4N73PF)0]L0I/.A!X)]-OP:DUWH6PUS>9FS4-,SC?N;&_8S)-S^9DSP><
MR_A_G,EXK?'Y>T'O"27'52@YCK3DN @EQY%:6]:&]LVKV'VW9RW<;=N(P*+L
ML#5<W^FF\O_:=/OSBS;^4OGQZ_IWFDS@D6-4T-)8UP[!$$Z0:@AA".\EWJQ:
M0<U,\5DC:D@PW&?R:-YG/NC>%%,RY9-SWF*V+3DVJ6KUB9K#8 \/'1WC]7]G
M.>9B-?OL6,K&+YW6>_N-.7,"'>)=Q=(B^TCW=H&4%:W&]GXETR(SJ_"?6&:$
M#>Y+C=\;3NM\P/WF'6K9GY!R;L(-Y >\4:PFS4&OUG/MW[L?Z)KU&H!^>;-O
MC-?(U$J\I?62Q=LT7I2S"_.-O_NN^[1W?F1<)V!.D!*,Z(U'W4[.PIK?R#QZ
M"OY3G9PGV3Z<7<Q%SYB<OJJ=K47=&(JI6/!SS_=B%PHRDG%SHXE_MT3_(^-U
MQM;>B% D@Z!T3!B56M1D)21TK'-TM]: )'(GA^/[#;X7G3%32"*S"LE 0V<_
M@N2\[R.S@X:C9#7Z']#3VFQ$<$8:ZJK_Q)!6J\60B:0Y8K21$UDH[,JJN22#
M3,GX-I**IV<R)[:%6>]@S;;"3B[U-ZG30"=]DH%:AM]AQM%IEH\EXTG4%3*X
M65:PK[$FGR8UR[HFGQG#27/F8%:SDOF!5009'Z/Q>GL"[$?&!>  E"$IT9G1
M@$[IXU>F84UGS9',OS'=U!F,2M][CO_A',P.KQFMK'O<<L5N:  A8+&:9,QQ
MQ']?DFD7I CN 1D%#.1I]HMM M 26%+BAK]I[GACC>/,NO>3\AU]Q]@F[D'.
MSBH1?J6 M<3T]W[7Z9\BC4PB6E#1H;E*Z)% F8,&J"AB5'U.:GB1/6R. ,],
M.!'&%=0[6W+21Q'$F.4[R*AG</..V>3MY,FQ<L"N')F2OFM<Z&O2F859.V]6
M3ABCOLEKK RZLQ 7L*TU$9<SMS=<D,<BQLQ?&4MU"J&<-1J=!%CFNTO!L2XS
M<F1.;@_+!EHF2+9I%5@\R,;<93+;&)\CJUA9^ARIL# :*2AI:6<"EM@+(\1!
M@BLS559FQMIH,2 FAUD#:%*7/LK=F6=_#I^WP.NT'D/3%2<^:&P2.#?1.^K)
M2HYTB!+V9.@81-+@LUMW0@ NBP^D(Y^T(!!4$& \+A'E5F.2(FV_,377#&M1
MPK94BY$J7<;*!=-*N8_8@&,X0>'TE4IG>-)G*2BW6^NLDJM*K>'HCT9LS\5#
MP9F&?)KNS\TT5O+9BP]R1Z!/:_[H'AV+"+_ 6 ='QS7,=B9E[LV3I)\@95BF
MGT)FQQ\B8LYYAU.@XZHSM/PCU?H4I;"*U;X9L:?DW3]5(@YX8CC22L$9\C]"
MHW"'OAVOTZI.=+_9)H%AD=!1ZYR\(.Z*ZFF>6(K"[@,CJ\X28V5/5(S(K%C2
MW3SD-)G8?:6ZE]UG>%WUZA_4J7IF]]/IOF>TW@S9I7QF[Z!K&),Q^H.(C!)Y
M$GTF=FM8J[@U1]P12_5B/OU310B_#2.Q\1>Y.,1RD(T,%KDE 9%R.^.1EN2B
MUQY0H^&1:GF*\'TAQ-+(G((]2CKUW+81+ 33PBA:2QF,E78M;EHX3:*FNW$.
M#[IYUBB.!<, <'K5,*E4QKPV!>^/!(9WWKJ[0<*E"G$9K;XQ;,%HBC#3-:NZ
M42*ND[-_V\ SYZSO7FMBKXQ(+%<_')D#++IZV4GTFL1T+4O!LFI(A20^:D5=
M"FN7B%#,'J\=O\'R<O<62'$!DB2&'0VEW&'.IRD):P83:W;]7R-KV@#3LN,4
M[KE2X^O63F+M"F.(C$%G1M[?RYG?NQI9WS,825X83.W,<[MN,:[WV$]1G5 1
M_:S+$^V[T^#.DYRO[FPXAY%OS#:B=SG-D4)V3ZRI_?ZCMKL<BA71<$Z),Z C
M$_ _Z,"$/AT=U9<FSL509E-2H50W.^_H3SP2SLXNB?O4I=*K]22HTZEUSSS9
M#MG-%77.I]OUX_H&_9S__'U5MYN9C!<R7NL_UMATRO)]^O.*A;-2W?G)7/ET
M=^%[J8UPHU"M:6BE4KY:*.3QDWPGHID!8I]Y(SN"QXU>!]X\8[S-09>"S'DK
M1N%Z[KEH(^\YU,=GC+VXPL"6,64M+W-H/6=D2U)KN!V_=D-&532,-VZ)>)T<
MFO?3GO\6(9(B/(PJ;;#X_&VC5FY4WD:5O2Z7B#\&I\ []&NA"XJ@9M#&.HH@
ML[/NK.0"$Y9'>#OUJA^$_LAC]X9,6I'=VI;V)=@35\RI+5X]BJW]L9$N:!GM
MP",ZQ8>FOJ=KJ6;W++Y(/&S$"[XU6Q7U@M/&.]I=+=F"XL*Y:G+5$4%Q; _1
M28=FX(O-:_Y-D[6/_L+!ZC=U<[Y-I!$ADC,%D726[?XM9T6HG@L+:GC*=+:/
M$==5L<6DS@7\@3];?S%FV)V8.AQ12:)1@D6%E41Z9A!/F\:<A)#KDL:Z-4U]
MC4DKJ-BQW>1(-4V>&GMD3L\:$X:^2Y[/:2?9GTZ9./L<H4T70CN(]O!@;[A%
MFM#:I/Y!(Z5:0]N?GLC7-"!$&F"'] 5&LVU9*IO3MYO%D^'ZY7[2;/4%<585
M';C:^V.<_9F]P.2UQY ::B]^8[R;9\5@F T\:Z!L8[;\K$?:'[(DU*D:W5(V
M(:A.(@-*K 8E"5L\+ABUW1AKV?'69T H[P!AIO4E<IT'$=P=,D,7X[LG*V0D
M%GFJJ[W://&P9X_6G\^7/SOBSY4S#']G_3L\8L2+CY_]D>5[2BGSG$\\\7!S
M!_:&2OBW=EM2*D\]TC_/_S)[4T7C?CPL0SK(M%%)^8/ F^Z9YQ&[BZ.)6ZV.
MV UQ"7?[Y4,=XZ]MYXDO?6^M>6?JKKTRSKVRHY,B7 M[,3]&,;.@\K%Q5(>L
MC?4R[%PC'378Z39NZ%$9TO9GQ$?(18L<=L.=-#5V9@S5XG.&@AE9H03$YKPY
M-E431$,YB+268N?^JQQ+4YZJ&=JEF4WCEB1F_Y(;1<7^&+&)C=$JQCT][M?3
MM"2)"<H<F4*#%VU.8#(G#Y*UZ^KSX(K1Y&Q&"HTIN#X;9+USCA^9%J6CYB)-
MSH<TMF[-V_XA/E&9Z$<R:<3L(76"U8J\844CT<0R<^$)\7NQBS:9)H5_>Z&0
MR,FU>1O0?@2%MK=:&L8*>:Q,+Y?TT],A@F1,GFFI,RTK5()]W#PIZ*9I'0,(
M)!-."@DD@1[+7DS)%2XBMZ68=Q+ER)U$>]VEF)[4M##7X^/B>KJ(=DF LPFW
MS?OLDF(#XEYO<GPJ&H^V$L;L@4N!(:23R!V%*-NR9[J14*@SW"!OB!:C)YBF
M$LB%=<:\!&?PULX7)$2*;PA8YB2=16[<4ZQ9I[:*\\I"..NR>R6MF3+82J(2
MQWWA&QE1:F%^MQS'KC.S6<6ZJ]QIMD!D"*ED55-P[@K$K,<K3RCNKD%Q=Z3%
MW24H[LY"<7>S\.R:CAN5Q/2LR3U[Y=P%E_V^^\'I=JPH7_5?FXU2%M)4P8VW
M0=)*]D:@;#M!0I_H?Z.;T%:X/DK_6><?;<PR2S#)A!%[M RY7YV]0XPSG8K>
ME*&J^LJ<(&"X*\Y< ./&4'*WJ^MF4L\A248=A3$>9T$KM_P^ICT;'W/4M+&+
M-'+6@NQ9LKPSV-&^WM1TDCXRP^>U,GDW01"YB(02PB&)4;#CND";CJ1Q^6^W
M.K\@W\[G_"\LIG/1C8>3PUO1<+Q*ISCF=PAN').U ]V8ZF*]@;S9["AUD07[
M(+?&?<'$M2 FT(*PL5/3^^SJ67IJ]))T:BJ=6<75V.)BI06=[VN<5M[=%/C_
ML_>N36TKR_[P>WT*_:FSGUJKRK!]!U;63I6YAH1;@(0D;URR-;8%LN1(,F!_
M^F>Z9T8:R3(8D$%RYM0^>P?;&LVENZ>OOS8M'W4P 6B!JAD#VHE:.H,C5M+.
M2EJ$9@;6&PPI$@4B.@9MDK6 B5&U%;J-9 >L_.M1M!I1ZY?<3I;,P,V].#X3
M2[02!$4MJ@A[F*=!L5):_@?DXSF8;4R/!3JAV]1"A"IAWZ73A4-&;@,3:QV^
M,L--A ;/TJRT.&ZG8TJH1C8F-$MH(O1?#(&);@A5G#QF]O$CP(2"D,>ZR$\1
ME<&2[EGZEX189@HC'M*/A]3>-1Z0#:5=0W!1^E.VR]U8PR8$DF)I]IV KO.6
MR.<D@_\C.C4\M,[@[J"QE^E+6?LLNU.3'J<60#=@F8[,/@!8$M/J0>&IL OL
MB<"G@W3ZD$]SH.%'JMA;J"LS."*8/L3"/Q<D#J?="HVY/?1[C;CS3U9H9)_S
M<X=J3^NGO[Y-7'/O\+SW&I7G+=2<!)A(L]Z>?MNZ?;C=G%0NO*VUC\D5AX25
MI3:4&\NQX&K1+O.4::S/.N(SI"@,H78@-UL1I\P;9G"G"!6CDR@QA;>;9P/+
M#@_T%?M$&H97L&B\P()W+X3K9(R/WD%Q"N9M<HTEU0>"L/BS(-TYD&Z%AEW:
M+L] VD"DL>4@>C#D2-"[#FZ@.*SP[/>L6#<A.O<2R- O';8]?=BS_*_5K9UN
MJU\DRQ%6HXD>=!S$&3Y3K>'SOJ(K*;-51)Q\]!@/K/Z BBNFOTLE.+[4W8@!
MRU 1YUET08A-%P!DS20TYQS+(?CG!$4;RYO%#%X,FY.(!38TH!@]C*A+7X6>
M;/S" N%MF!9@UMP9ELTLD 'IWJ+Z3W55,N$@>7&W<<=S;ZF<[4=5RZK!42[I
M4%S,/CMP=$(,#&;I0-07+ 0DICXS%5#DX.UI#:'(EA?H6IZ)(3@$4/*3./:B
MUXX5^\;PP58$NC8]:K#@>\ *)P^ CA26PD69/:*N-RHG9G.,=P"1EI2$TX?6
M)ZPJ3X0+T<2W3(8(RDPEH8<(BQ*TA"B^R'X#>=J)GS'XX5APTQLRT'D#H\?<
MX2)%L,7\.6]'VA3::5; 46S9WH5.)3FB2?=O@$%-'M*-Z@H1-)<!]TJ[D,:P
MK )8I F):&WJ7)*%W6'L*2RNU:D%;5J0L00$P<J6A8IG! F' Q]UY16NS!6L
M&6R4*"\6!'M"X:$JT.6 ZL%7E""CM%3_"H3Y' 25[:J<P/GJP=O3VM=I][+1
M^70]JB]5V7H3X=F+4@+P0@QS+@RL0:$$;ENA>ZLK;MJD, J-$]X30$IPTOT!
MH0PJRN"P$&](S2Z?%>,$;D#Y4C0@IX3 *_FYX>4/W'LGM2EF'&=$ZH'Q%_Z:
M)=GY?_^3%X8,Z7'GH#W]53_^,A[?C7N;9DA"IN6/;(,>(^4OLO8Q3#J!?!:Q
M[_@/B6+%XI;*\L\*TBZ^KXN%<]<@,BD%<!<?/QGJ99'G-1[IC *\BXZX1,D*
M\=[G3^B#SL\C#*I7T*Y:XBS#O:-G!9_^;ZVZ%E)V?7M+:D-5.3C:/!^=7IP/
M&LD(_MP<@<57/AN5ER/=F3)W.'R6X,0B7PXW=-'_JU5*"01BO4AK!MI(S+]
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MX>('1[M98NT-P>48@RUWR#U 4R.T @E 5*#+$88)V\X1<T._'A GA/]#2/0
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M"E-F0$>1-1QN*['&[^"P],(V\&!?<.>A_AL%9&@@,!D)$M&G>KEM>$(>2O8
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MT8]C9?+ITTLPJ<4,*_YUF/RB0;T6RFEJ:@8V88F]=- ^OAQM,=<V>?T8DTK
M7?,>LP(95$C<'$-"^.=BR^.[' )&/ (&,'>5?$2^0)#B8!!'Z3VCP<3'\&@T
M5?18@5MA]JL2I&7QL<0\!H:?6/[SQ@RS.<)IXX8P3Q;.,KQ%.S*,B!:N;D._
M%H^R] _Q/.; 66):ABSUTJ[+*(&9;9K?=4<L=W@D8$4X':Y7RNOTOS?K?QE_
M:RGH)OA\B9=U63QX,3_]#=[91\IC!:1(Q-QW0.^(&])%WR#L1)0?QBMAF2M1
MFXN]$6Y&"#O2<^<06G(?9Q>6O-AB-Q\(^D3"8#AC7'3B%L Z8?JT9>NBPK,$
M*I+%DJ:18^BU'4D;G!2#QD(!,V<1+6>BL41WD;,]ZU"-Y)24X0TSY@F$(;AA
M-%!\$,:OL?UPS(32I+W\84POKWP(L<4@P6\RH[T\W5]!2D&?HPE$:N'LW1_N
MTI-W/@+B1(2/N[HN:0",K1Q 4$M7:V92$:%J0UP[ZQ(5RB<GI4@^1U74!+I
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M8+^89146X^%;0U^=<(;A N36(IHLQ+IC1.61(R;,))<.B3O:$J5EJ2?WA$@
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M,SW/#UR/T&4SSUTWYAVB AW_9,4Y3]P+%>E>>/&8[>EW9WHZW.S<?[\OU-7
M5ZR))>O2(NE=$:&6 45CZ@;Z##TR@+J&.TA/%]FLQZ[_UM>(4MB?O:++@ R_
M&]U2*M;=_<#%='Y,RO?''2H;+40&MWQ=B$ TZ/ B8* %AP1PB%E-"V3"BUL
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MFH$\C]@(LSVO^';0^Y)!Y$,]:+K:^+R-$MZ'^7N2U.Z2FT-U18AXO&IKDN]
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M=1AHL5CTZJ5WL6;1R74#&#>M\7W:EI3X#4MWQ@&R$D2XH43-PI-G;Z'W*WE
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ME-#3!W' U!EIKD,Y\Y[>!91:'#H1O' &X.L8!P/7H\.9N-U4D@FGPM@Q46K
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MRX"*QU<UJ>AOGQKW>[6@/R#%;$$O-Y#XM^/]]V/81H+]%6X ^U-J*,&_A]V
M@ _[<\&H3WX)K$!3?8(7:J_FA?2"TXO^[Z/CQOGWKY]OBDGR4K$H(UJQ0D7&
M.23C_=>3<7J"_6'M_FO3,L>_=[<+2L=2\CLCVWN)D/55H>34)(^#-'.)&TI
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M)?6Z)99'*S?T.16LJ2D2+0KAMCD&:8AFD%O@Y&KW9:6RQ<=^!X1'05FRLE7
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MB*II^R"!+[Q-\6]<OFQ<E#115/.*)4D!+X;7+J'*A13#>WN?0P*-9:QZ+3Y
M-Q5[FW%JQJD9IQ[83S[\;ML>,NT:J"P/N\#H0>_-&G31-CUC7G0XQTM]^G(E
MG=]K&L\X+J$$)G6S.8TYT12YH/W>-!%Y9=?6N;@>-Y9-:%!]<+7P5\JS.)L=
M6.J4B=B%-<4*K1J*5IZ0!=0BYQ'"R-DA<EHRSR!Q:_0]\U3L;L:M&;=FW+JO
M+XO60?"*WI.$I+BS(5-33I_,#]M=5AEZ+(TXI=X5;??5Y:4&F=+UWFL4>W9@
MK-:Y5^$=5RKTM.A#9Z^3H0B\;: I;[;+VH"R-J"?TP9$I_14LC:@A!U(5F:=
MM0&E@E'3L<I,G+(VH)2P:CI6F0E4U@:4M0$E(X&TK@THTEDM9L((]OI8(]VB
M*V%-*LY^_&I4<NO^'7J+2E1XKK!:TGN/JSA:?I+\I59Z8#9U\&R_F8FJ,]W0
MH4.[:TS]]\N#<D;1HT/EJ9B[=%*0Y,C4PT;U4-NCMX:V>FNB4!G7@OXH+:7Z
M;,YL[JY)N=+8IGN&MKIG=M$E4?3/E)EBIDDR31)+VTL4FJ.JGM<;#_,I-RZ'
M:7Q)N>X(T=BRBZ*(HK6%RE>^EZI(:1]+E+M24T5^**"U20HG1Q2Z)56-'K,J
M.EB!1A&IX7.\!D?HT9Y=OCR]8;N]QA<=7:B6&&VY77@6L$D>51E%^70LT5GB
M':E,[%?%GCIX!!:H"@K2Q\U#?_+\\56),@1+C#*().P*I2.*452J43'X4IF*
M2*&**,<>6@6J!/Z1;5T"![5]+44;6R5&*6P?3X73 )&@N-] !:0O*?8MYN%E
MK:J1J-YBK$&9_R"7"^K/59>OWWZ]#@XW_BXQ^GB[B&WST)9B%!#X09H&LB[X
M'Z5:J@</_/S5S?2%?)P,/F:WYQ^''&N7&(4325080@]%@;#33*:&,C5T(#44
M57#IKW9NGSZZ U(MO-^1AQU7EQC%LWWD&4++1 %.E[ZKFDEI/N\ [=I=9<I)
MUDB/K+W\@ IZ34T%LV/TN927E^/!Z]?]\[VT4PB9PI;R7:)(M^ZDHP#MB_G"
M]VTPSU3!T51!< Y@^VAQN;R[%-YOBES_C[!CR)=Z!;%7U.?1&U% _2Q%9EHC
MTQH1:XW@XH+-P=VRWGUJ4.+U!<71.T=HJ=<3X8,TCU*( G8NYK^Q6L@2@QMW
M+9L7GA"X+%GE#=D4YHQ3,TY-P=X>G5._1XJ"VG9>N.' 3JASOM9OW[%W[]F\
M\%#SPOU=V2@RE\4\=0A7]EN.#$]C0B&;$YX4/?HC/((,V<JX->/6;\FMWP&'
MK86:$VZXK>^E/Q<B655?' 5YV9SP;1S62(I@OF\:=W5.N$%H6Q^#I_3AH#R3
M=]GJV=NRT?FX^7BX;;,WPQU:?9(S4=Q%Y9JKBJ>*<P2] %AD I8S56&VP\EH
M3.&7AV'O^R.!UR6A,[CAIKHJ3D4!,*J3C;MPS[O@O35)Z7_\<NUUQ9GEW?91
M;\O>YWNWSP[EUVH_-<=D4LGGQA:54+,I^E2;<C*4%K?*XT6M#U,Q&L&A#YJS
MM,TYV@S!J0+\VT"1)&6N$;]%F9B.%%T#3]/^^MO-$0<9D&^=;PW(DGC3(!^[
M3YI48*U# C1-) [L'N!.P=X32-Z-:U<ZCEUI.%#_6*7F6\WAWR='M-/T^*CU
M^8O X;GQ9R8;6/S_]Y[VZ0AS7TW1H"O5-_NF%+GRP"V&H\)Y>92TUM(4-#D[
M42EK?PMG 2ZHK6#NA FW@#EO8&9N55'NBQ-.:LEML)W=N2#-A!OP[I%F^ZQC
MKM&J5Y?U>NMM>3?5+SH-K3YJ\SL<V3<9E@,XN)1HUDCFMJ4!"7 ]Z403^B?B
MU\E(Y'D!O U(&"5^]50)N(04I(>E2,HF*$*Z#EN786N/H(NN-FH/:*ZZ<\5?
M:90X=JPM/OO5/W2L2B.&D<EL(>9Q9$"7E+.YA<G2,.9JO>.RCXB*A!7 \+>L
M,8EMF$[$($!;)S)[Z<21*@C^6O%U?C9\F16O>]?%'^U*L6AE(-H%X;N@"MQ@
M*JB9=_6SO:O2M_2NG 4N9B>",5O(JG'QTQ2-5N'I:4Z^/C+I\9\./UU'THTB
M6LYH<1&MFWZR^JZC:Z"4%%BM]\C\A78+GRN*C%7EF\ZH\569X<<6="W-.;4U
MYXBYHO@;F:&>/X[G8^V,)V<-X3^JCN";)?6W;K#R59FE2"X#/X3.3$.2GWU;
MGDE/7%EO+>\?*K%FCXU?BC)P[L'#"Z<4(\IQ9_YCS?/&3E%W).1P.ANEPT6M
MKVL:%"Q1[DLZ#Y[% 8;7^JHX,<O90<A,U)4Q6,$"!4SE?[25G'IP!AW$W+"X
MYI0 ;R;F M0/P&_F@-WCAD+.])\)E9L*A"I('/SK5 GWTCEX*S>9J,H7$-"I
M("T(=Y:\4O#>6?9D+*"*WV\Z6W?@VR@N$ODW?O*FW^JJ@.JHC"SB]4U'?)U_
M4K-'N_S_R4,+X:(EC.9:LY@ME%?8EO%6NVEIKQ/*H;X@L;_^)0,']?P'':)W
M9QM[[JQ1H?;U256H^=-YLTL><6=]:[]*8='+33M+G])K]G:#X.2!5&@3 7QK
M!AC\-&?20@A?$T'6MA>:*73'X.:Z!.=_O.=;] $2SO K4;GA1&;D$I81:R:$
M(2UGPI_FGR>**S_9(V-6EHU:8T+&0H[W^DY5\*VU<AUEZ+X3QCK)DM?"%TX#
MNTX(H(PEN'YX:BM;Z8?)^&_ERG@-37V@SE\4CBSU#[.5&P94E$)'EVLWLKQQ
M(\%+$#LO!$XE!& .^5Q8&<D3\Y'8'Q&B!GX-RUD!L\_%Z4@$U@S"O]#4*6,!
ME8'E"532)<"M0"@!$B4@,%,!@>VH?FP"E A<I';ZG3R!@_LVD88%/<#O^"Y8
M=!\5<6M>)B3^Z[GV-TUDI?M,1)AJ(7/P5 AX*NY#225-WR\ :,FY2T[6.74!
M52?0I ZG@4!7<6-86P&! !P?3W!#54#*$"E1\%O3X9APZG0!/CH#9@5H:ZB,
M>5$%6ABJ;@469:K*G- G\!\K-K'BS'B*,JQ'KH,WBU-7EL*TB\ JAK_;;ZYT
MC1K=[AS\==&1!?/>.F-BZ)NF3L$'H3GM#%K -YJ)O,Y)[N>T#,*J,M\PR')]
M_8Z3AP+^"OKW#0><*7UL#26M/WR\5/4KOB3:K1> 4-1K@2C=F)OWV19?[Q4:
M;.<E?9LWP/AD,(F HC<706XWH!P:,5GK!@2&')8;\!OZL53A'[=B0;\D__DK
ML\>)IJBJY7Q"&QJK''?D;\ ,\)@)ZY@U%.!O"CR=@]CL,.\>NG#\K:#VP1]
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MH'.Y%J; -ZV"O4"_,PW?Q[!?8:2OSNUK);D@/^,HEPR[3\;'P^R"QY;M5R/
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M5?J"P&N.\0FXQ\X;KCD="_A-NP$4)[>LBE.(V=D3,51!'(.O Z?!?A*:HF&
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ML,J,CU%<O)NQ78/J5_9#]2G8RQ@\WR@5J/[WTS(1XZ$W'&!]C(;>V0V@#=P
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M%^BD&#Z*Z=.M>B+P$7U.&[D]3P.JT&4'V"R#=1KW\UP$@!&_W3CWQ>HE/Q'
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M.8\8H\8J]4:]7U]6)IS_8$!S1\$ ?UN2[A\?*V3U8MQ:-@<\6# @ K[>?D%
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MS6NK,4<@MLMO%OV<W8U<NC=49/ J1"/6AOP($)QLWZ+ JYBVX8>1G-;0@UK
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M+TZ,"EYL$X]17HL)4BZW+]E3IMYJ_.B2FTUHT&]6WF)S)7L,%=-E]LJ!8:_
MKUD_=-#T9V[8H+>YN;&8VB:2P'!-Z?9ES/Q(*\,?15$;^FZP<4%GLHM+M#-.
MQ^+YVA*W&#N)>[Z0Y ;?^;(JMZY%D-9G+$6[14<X0YLAM;<@,WFJM(Q$E\G<
M@^4R-QY5&(M)\DV];3>4YJGX\:-[ 6]"A9NWL( R-[NX=\#41QA(YI:V+G,7
M4]MC5LQ6'Q[/;X2?65CADZ(VM"2,E--,?C&@X;$RJLX.,H0H+;=V(<EYR.8#
M^W5L=S@',#'> VN.]\F1X.4:<3D\E]"&)DVIXY  \/YDY!%3=#!#!5"7=U-B
MBQT 3A<@J+4<^;.-3YW7QH@R9Z&N#1=0%> [#UW^U[+321'XF9W)>7GR=<U5
M'Z6G?K)]N*C,H"<)@C3"K5FP^U35AW"%\$VJ,^;R?_^O1)'%/RK!]/L*Z$/$
MM3.K$8-]P4/#(+W*P[2/S. 2.Z5JKC.YR3VTE>I7?_PQ37G@>%46&/@MD%?
MX8E%?@<0,DQ2(RKF2=IGY#RJM9S;_H_3GQO\,+2T&<-C'SQS)N(,H2"),.9]
MV,$($CO*MY%R!>\*_?5_A]1L6&-AX"18?H\1JHBL&LM^?&B']F_WQ##/UBJ=
MD'K__MUU\EU4%021;-B26#-[2!!A)V.5*?OYHD: U"; )9FC*E!Z,7V0Y"U8
M3H$D[P$[-%)42U%M]Z28HEHLMO" I[5"_DCR)FKP;\@]I3/"6EKJ%=]+].7]
M>@6,HOY.,*"'64=BK!H:XA!3^XJDBQPRQB7E'T+I=W]1V5R&HDL9*I__O<AH
M[DH"Y^NK38,^5_@KS/-QC(:VLLLO&%%GE#%A.GTV%H;FPJE0UQUF*9/E*OG+
M,_TO8MW"CGB4LD[_)@J<5%$X%;GP@*@RR ]>029B'R=75\?3M]PQ8_2GRHA1
MN!M)O)71>PU?Z+FH:HJ.>P<X;MHPKCM\:QJB6Q@^:5G-!XP'HN5((GJ>$4*Q
MWV?:KW:: O5>UZC"AU[/><2,+6,W0U09@1%9$,#W9=U:;N;:%"3C0P6]I7&6
M;=S4TA:WYD(ZK@L@R2R=I0IYMV^>#M;@UHKWE<ELABHO["NZ,4+LA@%3/ NX
MY/\NAC)JVO5G<_ZPM'93\SU%5%Z'H-1D> 6GH4<*9.^78VE$G^?JDVF^E;4B
MPEP28=GI!#9V$XQJN"'1%JXL-$3;O-")+.6/R85EXRFH_2Q06Z6DT6$BFT/0
MSW",;2([S,PV4(9JA]->5S1G#PAT??:CE2W<@K*:6PQT]KH(Q\*P34N8AF$"
M,&])LL-\Z_8E8%1RJU-'*F#_X70%1=!G4"I_&"Z^!B"<PQ/ZN$#/%;@E%^6V
M8\8_#W@-Q"/@?8[[06YX8W&%]UUB>C-:PQMK/X"+3D6E2[>#VTI^]/*PU-0V
MZ"< /N^7=6U>A\\\R!7P[T+Y8-W-[>'DF5RQE"F4%W9P"P[2L=<_4U0*Y6Y#
M9\X(UAC+8TSI+Z6_I&FF?@-,VZ5^RQ.6ZJGAZZE4M'JJ?74=_@8KJQP?C;XZ
M_GJDZ]^Y6CO'+E58[07%36?]M76EU7$4H:NMP8JO[;K_# U!J$PO+-J))VS_
M3O$I#M(XU1A2^DOI;^?'F A?:N2Y8HUOF5<VUEQWF?T;:<;OMM5=,FIU%]XV
M?HP:M<(+-+5Y5_B\O2[22Q7>&DH:0$TH(L[=W@N%V+Z]\%7BW&9Y4OEB)I=?
MV!@A5%R)MY*<0F$86D-",""ZTIE$:)4II:>4GCQ*CY>KVG<MQ.S14<?Y<-G-
MHRQBKAM&Z 00^BX"@@9>!\%)>E< \<:-J;%0W7KQ1".ZA([2Z:5,49.S$DVN
M53P1V6TF/^O#7TW%:EN!)JD96R%8!K)M*V2R5"%3(.GHS05,"(G4I5)@#%2%
MT=AR%4:$B)AG<VSM\?&!XLK!JS"2#H\[+<X( HV;MYBD<\?EA3.H4VA,H7'#
M?(IXU'*$#I?2Y?#JB=6^!J]D*+4<B4/.U?TL_7N&?95XY(IQ*/'('1?+H9=X
MQ ,L9T<U1=Q^,IU(LVQ'6V\]FMMFZ]&H[SYM!KJ%%):$.?'3OET+)?H/;@:Z
MUI;_577YY!>)@K8ZZLB4V 9-B5AERKF^"#GMN!>'+>Q-']$4$&.[RA004T!,
MS!;2%J0)WG?:@O1GM2#-I=VMMA01*>VP!6GX#:U>*)XN<>)K#:0M2"-)EZ&7
M!5!FXB.;59F2))DI%A<.^$UB_ZH4QR))>@FE:FB>'[0!4-H#QN07%7+.%U"A
M'K]6<]+0(6[4(@N]J\NW;K[W YJ3;HQW(5[KIGB8#U9BY&I<FJ%+: 1K"HHI
M*/I1[@I;0<9-\F!H&Q_I</"QJ-Z^OA1S;Y?ECY_;TY2V$UY6X).O1)<\/3??
M-4ZTA'-@J+3-Z79+\],VIPE(=\QMM\UIZ,KN4UEX^BPW1U=,,>USNEF?T[7;
M7+LD0+"T[JG:2A8+F5(VEZR&46G7GOATQ(EK16_LCS&EOY3^DJ::IGU.?P9'
MNF:L[*+/:>@*:Y$4BY=LH\6/TSZGH?0YW4QMW:P]/YW/9B@J@@A4G!LXI>B4
MZ@NIOIK @TOI+ZFNU/E3B3Q!K8:BGHH&.+QF7M0D5+TWA/*^I4GL1X)3D2--
M/]ZV6IP/H5Q]9<C%IH6V9-  )H%S\0XH$A^UQMR[K#?DSJ1\^Z&7SW2YEZ-^
M5+O4S2K'-[S:"!3N8"E?CZWZX0E5RF3S$4S"2ENH_BST3!8N[%%CR9324TK_
M&90>+R]XHEJH;E[8D;;#"L^^*&\W<WJ^CVI$YD0%7.2%N]9YMM!+NZE&>9>>
M.=$^#(="WFTX%#8;OU FLQFJ7$Z[!J8P&7)M23%VM271@>=$*C[UM)=QCRV!
MG]MR-?8E)T'@-5C':E?I22E_3!92A$T1-@I%M!'[0I70P;9Q^B"_YN]EE@^G
M4"5QN+ND?F5M)[2O.A:$BK&N8Z&/"_2/Z>4ZNT_9AH-2I=*9J$6:HNM<]GS
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M1P,I@V0UCH-!X'#$_J01HGG;C4EF;;'/XA1%R )?$L[LDZ61H3:A';$"HZI
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M9'G[2"*KNE]\")[01B-H(TO3G]8=79DK^06_O U^!8^>)Y!0Y]"/,/D&$JJ
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M_HX$$%+J:O"1O*C#-=[*9G,W=49U FKC6U,8>(&\R"CC<PT,45=*I!XJ4$3
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M:+TET9H7<)O0QL19R)*"TGF/IKLFH'0;_@BK(\Q')@F)XW]V*]MGK<&^M]H
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MJ^-%H@=/$->Z %2"SL%#3.$CA8\8G^HB:VT=^,!98.>JJJ.J*&=.F0D<8F-
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M_P@,NFH@'CVVH-4*OQJ*%1'JG;AG$=_5-;A<32*T 8!T_8Z[ Q&_^@J Z*7
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MS"Z <&,J[RIN:4B@^_#UQG'9;I(QW!Q!C!GFGQ_!,3Z1/._A;M\B>38"D.=
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M7>U1F2NK0)0-^%&,%Q2+2L_-2T_00!J2OZ$>]R+U\6H1S?X=F;)J45!"(02
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MM+/'6*[QJBV&3GO&_"LNY!I,OXE&-KGDWO/\GMBJM@R'L@<YN#MPJ&LBM$E
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M$;1; )YR%YBEK2H.9@!,OXIC8S$2X+NV*3E85\7?8=AM4;L&(2@%82T5O]#
M]V$-$;-2U*5P3)F@4^,[\/U&/_CREJ$[H& &OI0EQZ(J)I"TI)*/7;5O(0T_
M]UR:( VDG]Q%$ZHX<\'CGL]T5, T/ON"C:3^L0#Z+7^KGVU]\N&4_LR95Q@A
M$Q%UDYDT)J"3CL-$8.34D$RBFA>9=+4$(M7[H$C3#:']^VR$#@RWTS/R,UPB
MQADN2'V+D(*/&&?.?6'=<S_RL7-_YM@..5ZC<\[6J#!4#4UR3U%O+&6RHD(#
M_%$6/EAM^J*1:>B=MJ-YCS@F+V>+M<ZIQPR+8!=:=.I%-G#J8>@OE%'+=$#F
M0??BH%#E6U<P#<LZ*K@;Z(I2ZSC")[BV)!56D:1A@A1&."NP#@)EIV>$!8I'
M:+DH([; R2=IEN&27!W9%,,"73V8*I$/EYA(0#K,%2 >GT;#E 7W7 ;> 7F$
MI1FSWRN.S)D=(U\;TS>^@(-X:A:WZ!'N8Q X4%4P;V.4C/^K(-1'BM]*#-?Z
M(;$@M3 )4X$A$2MO7Z56WC%>977@,)&#WWXIF9B5P,%\H.R=GA&F[$MI+(BA
M-/WYPR^4D,-./T][!+5.!SK"NB43LER3#)QJ341I7DQE^0"*F'9'$D9\S)WK
M:K+$N54P%'RL.(B3]HP.+*F:8Z(($=9]0NG@HL('$Q7\>'P(#X*P4;!!="[F
MC[=KVH;<JUB6@Y2B8^(IU6&ME"8^5Y&%=X;\9)&(EF0L%1-?7KQ/OH?@M82C
ML_3FJ/88QFKH$*R2?U<MWW4 20V=O/*2 )Z7R>WX-FO7K//33,Z-CZ$OQVP.
MHUH6/K+:!(+Q)*P1?/(H!KW@O4]\I"\S YV*.5DU#:YR5?:%FM Q05R;F)X;
M;R)8=/:,2J;WG8Y,($.;K^W+7!& X]U3W2.K@)CY&(;!&UT@_A1,;GBW8<4I
M!6(*9F.>1X<@P,GL(B#W,223P7U,525/N<0,I1 [PU#M&*;A6!@"8A0)3U%M
M4,V6'@7<C@/^(_+=2+6[,P=$A!P0!XF_TS/:W%S6&C]8W=7O7,';*6*-1EPV
MSWM&EZBK\Y!KN/. GT($!A&CPA2/P'6.1F,"M'& 5XZ%/!4,).)#Z$H6UGRP
MO+"0#2+/4U73M(O4,5FD Y5MV4^)*9(S]][Z]SP7F6?XSUN6:MF2;N_WO+YE
M;[;.%A4]<N%HQ%J1"K=68 1K.2I!VAY@GL+;'#]+W'R*W-V7^.Y[]J(0NT8$
M[!I3.'BAF<,U<F"-3QI@P#/  LWU\*A]^ :/@X4_811-5%%#QV]D04YP';T/
MV2""59W"/8C"Q',-0'LP'LVYEGE^AE1% +NXB0A.C@H8^1WY!N#[!>ZQ$)X'
M"6-S?_! #%="/)=1/%6XBR62V6RF\',*3GF84-5?'9TN%S/X$#L0!7WT+@ZI
M\!0A]!!)I@;*LF?:(G&*CHWA);D./X\J\,=8+]/Q962@BH&FHZ8@P NB(0&W
MT;@K8FJ7B-KB1E%)"NP>$E"[#5<;>KCFX_H[\98IS/MFLO@\*X)WQ*#9*WC%
MMX3N]DQZ;'BX6)?%BA9D0.!=M^UM1BD<P/$2<\BU;!O$4Q>P\ST!3GQ&$.LZ
M8Q0),6?X=2?+W5PJ5)F%/! 9,&6FB,#*9OZ-IY(Q,>H3X&!"UB4:G]J!2-*V
M!"(,Y C^A.4OP@_5.U'\"E@Q >E8:>Q2(0@JI&H[%.3.MW5/>^PC=,S,\'-W
MW#S&9Q)51NEIA!<3RR\LLG7OAV#@ Y.J#O7'_!-/'LG#HQA W:/SHVIS6L#Z
ME%1C,&#!M*H5(:*4# ^O++X$8@>)(JO#TN+/+![\6+C&D!X?'II MY"=M!!G
M"E?B3<1RE4P))"4894&GQW#<UA#W5K0QQH?#8M152= V2$)R3T0'\Q &]PX_
MK6PFYLG"$"/_V /YA$H0TP(&)CJBFH#O#3/Z "= D8X>:P4MQ\;2?YX206++
MR3F U0\T$VSKZ#3ZVG##RP-G#ID U_VQT.>!S8%H:-.+, _&H^_U:;!&Q&WR
M$'&[R8C;9.P0<;M7>.<K-+Z2ZRZ.%)B[^!![NTO@R)^0!0<0D0?D4(3#Q7/V
M!]6M%M)16_5" "RJ=G$_I:>Z&C1NS_)E3_$,*WRFWX7D*T7XZ<L?'3S\^M*8
M9NV 49UB,9+CXAN<T=)8EA>)@70S70A\8YY[N0MG'U'A9!H9$H5T&07/2H?\
M'P))V&SPS7VL3-E>-A6DE;ESI'/SS2I/KBHBF06KB-$0TP!/S%DP;O;^R&JK
M2<<_G<P#63]7^'07TN21;8SMX"Z_\LWT1TF634?2Z*LM!P.DT)$=' &[(HNP
M=+V4=*>->80X] C-TN2MIC,8:"H/P3O(W!TCNX4RETN=OG]O?0QO\;UU35Y,
M^&(M4H$ 1ZPDZ;(Z('H4%7_^!RFFT^'1)5:$B!FL70* I*J(/_/601  Y46+
M<U]KK7@D@@X+'^+P@3A4\!]8LX5G=TRI?Q 4NSVC/#EH9PXILI5>V)V)^I@6
M@6ZH:9+DJ$*\+*,[<)H1T_$[=Y+]SW04Q:G7NZ'!GU9B#RMXSWI1*R\#/:6G
M_55!+FH5\>'.N!!];74;"X<T+PP"4V?EGT7O7Z.2QLI%(%-N)8WT="6-V'%J
M;F0#WE"-6\5GEC/[D>5,LJJAI2NM=EI6WZW$MRQG,G0Y5ZYDMW Y$\N6,QHQ
M$82X I#2Q@?IM"O'.ZG=(4->>R0_=:)=&1BMCI!E@QWR3E>)T\H>'[#,#M'>
M-3@_=21DR/DA3M6^\ ,;26#[+.2#SKHYVRS\S5)!_+^[22#^7!'_!1X1N9?R
M>A'$XF.!'@42#IG@'%,G5 DR:? \\YZ"+]+BI4(P,M+Q<A#@Q(=4N2JZCR>A
ML\1B3[R5[ELB&ILN?J@BV9+0(0&,(&%)F-?TM&BR0A=,MN(4*,/_CZCJVB?;
M"]Z"#A9J?4D8X.\]CL&;BG1,&H@LNZ'+AC:V53DBX>W'"K;I@(JKP0K3"%\=
M.1!2B<?0IS9*=X:8+:^:A:-"(Z\<-8\&/2@5^I^7/^=I[H'=R_O\LWT#CY=B
M5KJZT4C@6HP2=5]0,J<921@9IJ:,5 7,WB.D#='1&$FF;_OXPO*-];9S&JZ&
MSB*";Z/C<A=((&N#+/Y(4QH@![ZG'FY$7-/XS>0:5:<W&AUPK=#)P<M,Q,W_
M>$JANXO)!N"2!A%]X"/GC@B-U(=A"T'VFD\ 4QZX0U2IHQN@UI_CEPEG)MY/
MX8P2 -^P\[,SOCT4D*\^K@B,2\PDTE\:V'V0JPMKM#JFY6 &B3"JF,=F =:!
MKVEHI]#"EQZA-J9G+!L\1 <_MAV(:QO QQEXZ:]T3VP)'J:CD#+-(*482\<R
MOIAE\ U<M_,F\2G!Y32FF6-5__#=T?/@YL>GTJ21'%W=GLI+*VX&QQ0*,\6C
M6/H(#XZ^^V7!JZ>0:&95))J>CT3%V P0C4PU2-L8C7!%P39&$B2#2.SXB$\?
M'Q^0A,="TZO-1<02,KVR7#2>Q(V^GD><@>^IY9;X)T&:VAHE51.KH'!:NJ6F
M;+>&XTQVB]"2+'*N"7^K/Z%X&#\)3&,L:?;8NQ,/C%9W/%+4CHH?B<\'_ ,X
M@-HDQW[LW4Y#L[&(=U"$U+,*0!C)A+)@*H0!44]Z%+\<OYTYS\G10(H_Z21.
MJZ-3T6W2NF)M6-LV/[$4 @2B7HP2..79_?ZUBD:@I-9(@*%ID ,X-06V["0\
M ,NL'O*5Q(1!PV/Q^<E2CMD**P>=9Z=GY M3$9,KH.E+'@^V"JPFQ>\8',6/
M#)4&/KQ(H2*/.+-8Q$30?^$F(#@4XW*;(<2GL;JM*JE09B%('(L&L!F5(],H
MG)]7E+XC5U?W(KD2?X@?#(O[,2-,QJY5D55T22ZB8UVHN-J681Y5W*H)!7Z&
MW1(J]Z@;!/@T<<.9Y,@0/<N/O@@]^OQZ8N$V[VIM@5*)MH$)W\/)BEN$0*B3
M [4B-&U'(0EO#31 9'A75'5J@NI4P*J3<$K.IGO5-*@" 3P"9OX6\QTRKCS*
MRP@OLSS&8\>*&M:35)IIT+0A;,E4A(:D^.)P"UW4=Y](IDY4@N)\E8#-,3!U
M,GY7?8M4B-M39]EV[G%$KIHZMETU+:"C!33=J'O6N>4IW<.5?./3A$%80%B7
M-)14#7Z,*.B(!A23W'.B*4,8#+5%N@B #<TM[LD#J&S\< P&"9:(XM>:0W5(
M ZKP.<N48_AOE^MK)+2Y#R8+"S\28L?@VN.(I]%B,@E57X/K0G*#/Z_#LCOI
M>*7(QY5)X0/*Y-G9/%4QLNBM7ZXJ'L3PVC.JZ)$@"F28D? 7,"$G0$["K?&,
M4/63M!-D#_]/5A<8&D/OJ0>02C :QK&87?^)A#@RYFF:5A%9LJD.8-S<?R&F
M:$HM_;01M?.I[5P/X^EF_*SCJIVLVG=X&JP8/Q)3WJ?U%<SLC\7JK'_B/_ZC
M4E;&1Z5JNX(5OL)<BK>#5KC5T1%$B(*7 X\ _\EU(-CP_XD=)UQWDC,@NH D
M=UG)#ZF#!]MAZ=W_$S^.N9>RROH65G&)FU#R%!CF.L:G2^NG,&^$ZPPPM=H
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MY:N\-[4H1+11M I#))?1:@UT@;!VU#4T1>A*9E\C2TK;VJK]%EEMFH?#%I/
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M),B9-TA\"*<,";KA>IG@BJ1"YIU)2K.P^WP$UZ9]IK"VR]P[<"5IP"F-+:A
MC:#(-]A7!Y LKO"2IXS8>+4VPXR0;A-),9I.9YCT/(9X>H\2:4P>?HN&H8Y"
M@0 3LX1FM3$?E)>]HS.#+\F_Z:B6S1I&880"L?I"\TC$4]#\1L1FJ?"'UL7<
M\QGEK:E2T! ^%X"5-&$TT"3(Y6M>SX<?U?.D+W5)NG5\>2::Q<O!0Q(5;V;D
MZR"#E5P8C]WE5A\*9LDS0H5S$.C2 &<!#&R\PRT$[X:%U*3#ZYF4$;*6R.%-
MR-"-2'4%J4='-=21M!)TT)DR([E;RL5V8]!$PW?4R[^F9JNHT'[@:*T**K!6
M*V+5-63V<LD_-;,I(?_A\)QX:F%X#JU*)K6Q'%19$6I//R)Q^12S+=*1_ !M
M$43=5Q)[O[9[XV*I^2K+X8AV'02[$+1^'4'E5C43AKMTQ:B8FN]R#]=_@KIW
MH&>))Y4Q]PGT)9XI@(52SUY"/#(1!=%L8)H*3YP>(")G9&/<'ZF/+\?:*2GJ
M7F;)VX$LASP!.RLI]QM!G]:[:.72G0S2Q;!D#3RB942VXI0V+]JF"&LS&4=+
M6QWSL@>@FX!]F2#5^X=\G9^C =+S@58QM@BFJ@ Z#=?Q$N$6M(-!>J=G!"F<
M/ (TX!;C&,KK""L)5T3O #JY]9<1\,,OZH^;RM+VK*F8]N!L;"%[A&C%(OXB
M4AG"E7+'\]Y ?!]]!TI1:&Y/2X('Z7-EJ>]/\J #F9[AL9"G,)48 MC3?941
M2#JGB:C?6C<$PPL)$EJ&:1(+ =1[".AC).]_O@1ON7$Y05O!H0K8]SAGSFAQ
MB A/1(;(6EJ^ 2B)>&?58)9O2+;Z3(#F%WMT#A+O0P&Y^+C2>-WA*7GGA=P+
MC$*$-2B$^V5FLMN#GI]+\SBRD0#@0%@M=>RXY5^(Y\:D0E 22*RC4*E4_.'!
M_K3U*.M53@K26DX?,0D)X;GXI1QQEJZ%$IAW;(<#S5F7T\SL@TNL6H'ZD!&>
M*H^G ;,(PY^S:2I8\0P$6F198BC[]*F0BZ)Y3,?"0>;%P-%;G62O//)B#'UU
M / $%J8!!T8=BB-3$,I#\CS9)XXCIX8R!1F_*IS0"LR5&V/@U>RD\X(8&/FQ
M@WL(IW^<6]<'4W0R:Z.':E8F@0)T_G!JXS>:!J9*2^XBQ8&:AJ0'D$2*(Y(;
MA/ ;@-6@BA@<UM301'H6D:32%DV-T1 O4.HCP,+U:2,?&9BHKSI]6H?&G4.4
M%D>E'4PO)9YJX^?"X%O0;#=CS(VV*SQ.6-4V>!Z,(\PXE9D;[T;S;E69F6&^
M@A<R2&Z:W?N+]]BK3^'RSV&]L+>I*6R2/5:-EIRQ_8B+4[,&6+\AY.!7C[PM
M9?G=K#H#*S8G&Q;M73NSNP5/O%78U06X>"J.3*1;*L8AUG6S6]J8Z)?9USLK
M.^KZ AG] U\HW@*CGK=_(OZ'?,)JLA?NNGC_5K7=+19O\[V&7+SQ&MRT"R>)
M4IVI,'708_<&NX=5Z E@]P-JW[L9>6ETV4^A]OFT480<-55'PX"%=0; 1R,S
MU.,O*L5#VU/<TC"-C:G;BZ'XU0 RP07N\*+"W^K/R,+8JSP-(BWU!YHQ1NB4
MU<LHA(<H9V/9SQ\H9&AN:G?QK'G5NA(=R;/[GQJZ8_&4@F4(8?$$YD4&9_$_
MOH/%-Z3 N9*);2;2=_FYHNHTC1T^DXA!'74,UL"\1=:#GSQN,_LF?&#-FTUC
M*+%.(_A)(NVF-A6BTD!#@Q5@I$!*^)ODXD2@;R?4A'*K$K.[(51MFI-HL"$O
MI4**UH(=[R?]A808S-!;>26E#$AK2T1V[1C:^7B<'V4S6]3),()>C[8V8\6?
MG_3GJ600<4+*@B[6R"*S&IE7'6=5E6R.AK6N2A:9HY(%!)S[;J*'"0$]S!MY
M0!%C!$VIF488X.-$P^>"1L,.#D;6O01JU A&',[?!-5^A]H57P'.O#1B,;-Y
M@+80D3&3JD5,JH,6TK1HT(@:H!\_6//E/B=9'6'_FTKNA45\)LV/L)\#Z2(L
MT"GXF.5(;V&(\WK0+B=F/IM]9AWS5>4'KQ9[3K\9RKM4SGPENLL=X<GPO*_I
M44T=PINQBV[P$ XQB_I*U'WM(1RPBT:]4YC:X2UBR"1+^X&#^%JV#59+8-Y)
M#%YDUA-G>MZ$D2*SNM&<HM]!5O)J!?KG@.4-1=HS17B7U#'PEZ=L\FTF%BYQ
MEL6VQVQ*KH>YY.*]F^[Z4*Z/ZI:&4 7'/@_I G>MSV>K&E@_J4A12B+.*JR<
MR)C*VXY&M197MD(#/+=Q$VE>0DX.O.U76(T2"D +?UL(4?)+_]P4(J2E^/#E
M,R40R7<AM0=W$QQ^XSR",UBY8F7F4+%RHQ4K$W]<Q<H=X]WI](FE:3+,K6(;
MGF/EAX"PH!T F6",-26NL],%?9M.RR+[;)>@?+AUBU]PJM&DQ8%[&&8#T?%S
M[WF9=+*-*Z?3RC3;K1][HY2U_A/CQY'@\9^-IUXFMY-+59I(A;=2YL=_WJP%
M.FUWZUI;4N7V]:1@WP'#_+/QVH^7T(\("GJD,>[3VZ2G@TI" 2])VTVL1=5)
M$U%0]T@[;>'OPF7]^N<&5>X=DQI?LX_3,_M"TP+9<R%-,']Z<9-X$EDY,E4[
MT$=MJ@&\[Y(YMH0:]/1N.69'N,6*$1ZF'OG_, S^%[\7&H7(QT0EP3 ">6_$
M>LG?TZ] INLUFE<BT<T:)VJ8-!7?SXF8/P;K1O^ ^R>L%8,GH"6H8D3R&O#9
M@4$[_L.71U'1?>H(46+2L01^P(OW:9ZL]TK-S+MB-MD$_ZXJ*E8_?<,*:CV^
M/(P[K!E8ZV:I^G=T)CV@G+J]KAAGZ!9Y588K,VN.]0:+)6@LT:;66-M052M]
M%(-*_MXG-QTE?"69(C9GC=BO"U8@B #$SR6OQ*/Q3#::2<Q7V )!SW"_Y7(%
MG8) YB"027C,$2@?9RUL%4'NIZM=),$WU.U%ATA^O"99NU;I'5I86TCY[6G\
MNO8\<LQ2*A/K3*=9\43-Y9E6:R_K+I+WY\IMBM%49G'2WRP->ROL6K-X'BMB
M*Q7EY;:CW#YQC96^H[RF&=1&05<V"@>*PDUA XIB)!M*P9LLZV+&2'4:+O9G
M:E_(7TWW7GEZ/%5WIG2B&Z7]][B5/+MHOL;/6S.T3Y8-%G4-J;Z\3L9JA,U_
MG3__M8E[$T4T4@N#&F?IVQ<!L*B Y[Y!CKJ)RH#<%%;Z=_,R>=(M-<^LM]L[
MM;//N&/10JU-P&L5+YV1SKEH5DQ%<_.E,T1L'[7):'E5Y"D(@F=S1*<S#4#6
M%[V9716]7T?C]GVC7U8&B7I>W2G9NPW:7:MZZASAF\SE%DK?*?*,LGZ]H*BJ
M>J1C&A8L+*LYMMR#E5F.FHG]'"OCY!=_P/EO+Y_/[&PB4^J/RR4OH^<LL,(?
M1,S!)=U561S?1 AD>GEAMZA G0'XB8HC$U(.V&B@N#CIN$U=U9!U;]%NJUX1
M8&39A,85Z"%/;7J\5/!QI!)N5N&&DQ 7,4O"9<+^SF^_@5[=>"A8!54[.D+6
M3WP"\),DU(9$#3S@(X^P37$-2?XJ.;1<XB*;S:J=$KZ%&WW3M=@(-VNC22:R
MS_=ZX=F>:>'@KN%66CFLQ7[S5V%MYON<FIJ.):.9Q/S@%"\%/0#GISO'+*BI
M6/)3IJ>:UR7SVJ25R8F4VPF8LVWBG$AQ7:DU$DI'"]07"2E.N91&ER_E3I'I
MMJLVT@(U(<)4X-R/.3\BZ:XE90$<CRT3IMQN14"F^Z/%?K7$WYJ(3PORXUNG
MWTF;RHR$#2[NA^3LLK7=*:K^F!8:I.IT?&[.=!1B.MF:DE@2B/?S]_!66#=M
M[OGQY=UC6*.:Y(Y%V3USMH @(OP7)'TXJ(%DHZ-#R<==P//;IN^K4K7:*E02
MSTH[A+[)HBK^?AP+8BH^",XW2* S41IK;O@/ZB47<N Q]7PU4U4YORC^;3>\
MR'^>W[PDR=W(C#F7U)R%>JZ@2Q%'LJ&S<K#3>#%*K;[P.[P#O_PBZ-US%2->
MWYY?Q<6_Z[3VJT)SWT>TKUD+GB6L=K>J"YJ*'($4;C+:/\GP ^./5%<:?W5F
M_"N.8,7Q1U8=/S6\#P-;4%MI"K7I*9!GV48'$7T:E&022SNS8_0Z[Q=O+:@>
M'?3D;F2=(I_<YV,!*'W:=!9.YR'V8;]6[STC,CVU,&9@U\P2FK=L\S:1_>P5
M:/2MIML:*<(BUJ>-U@(L"PU\DB7-ES(0^A0>]S[KN3P< +_UC&^A*/<,@Y.N
M'X L,06HDK:*9A7?8<V*5[)EXPI!GG0)+OB@-HHZE2N]/S3ZHWPKX2N;$K:P
M.ZI5A2_.NH U\;&@HK4<T^0PH/(RY-0R44#C\A4FC?+BXH+7\3A"&NI(M,(X
M;4S0PH(2#A15G_<.ID60POU_+PK#X'= 4WFR3SXC)-2T!&Y0[*??DR-NWV0'
MF5?%W$2;:<;+EQ"*["Q4Q+Z6DGV4>V0A^1_%,<D(@R0>G];)EFWSC_]2<Q2O
MGV0%6"6&,(- @ 2K<V5W9 797?X-9'=U*Y2*T&APV[U_S*9?]UEV3R_.VK+[
M"X**9F5W]<.R6U@HNR/A[PC:UD+D=W[_Y/=VN.(M,<H/7B\SC=?6=\COCU#S
M:O([O;[\GF<XH_)[1?%=^Q3T%G\#\5W;"J&*E];K12KCO+7V6GQ/+\[:XGL3
M84GSQ7<D7'S7MB2^P]\187('*@[,2.[BVI+[\O=D""D]S,7OQ(?\I/L=DOLC
MA!PBN4E%B2"))V/KB^[T7-'-V_S-%=Y_DHGHSS2*S5I"HZ%VUD"KO&DS--1V
M,56+5^&;]\PIJ^STBR+!'^:\B]!FBW3=-7RQ$%X\3_ 5W(;OFX^'A!$QJ;=)
MTB3K \/[;_B+L4 1:Z2U6?<_5H[)XA(.'-2L#V!"^+NL:E!4XUA()!)'\6PR
M'L_]C-+Z+M"K(]@G$.^,[( \P/,LO<M=D'2T11$)^XNXGHQ2P74KX+?Q!AZL
MD4B*3!*?;IH$$_&*@,# 4,LDU[IEJ*@IG&_5P#2L ;Z<%E_LDT11TEJ9+ZA_
MSA%WSE"FOZWJ&%[X'F Y@P%M,T_]$;;!4]G"9EXJP/A\OEG(9O6O>L/!*YF,
M)_]N_?3W"'%7+)*7R2C%7")!,E"Q6"3[&V@S[2TPOMQS8'"R,&GUF7E;NVC0
MM*9I.D+'1D>;CL-H>8.6P+OY6K"F+)(#98B(TP+* ;E[1J@:NJCI'8H W,QM
M63,LVG<RL&ADNA'NB\+7P+6!"EU_DDC[\X3XXI1P$N.+@HW:N;=/ZB!='L])
M#.?Q(GEZT9S4<&CH!7J&<&OBZ4;<:,I:K4!8TO^J^<^WOY54=[VFX7=.YKNF
ML1XS-55((P,Q*#/YQS-+W;CW:4TI]XW1YI.)F!Z.I-NG;,53U^O@3@G&2GQ?
MD/>4SO&Y .UX-)X3%^81AV$S8A]J05<T#O&48T*"!T8Z"+?-3(;16B0/N)&T
M[3V4Q=ES#)1:I2R.N]^@901T2]Z9U!-#X45W7?#"G^0&]Q%4Q,U[M/"B85I,
M 02]2I75 =$X6"02'3<MX719O_:9 :66,41S*^6X57:Y&S^8T.+F#OB;-;)H
MN= 8LSG:=J  ,#[<2)K:=#S8L9"';H]J!S1";1RA.65T$V9N HUQJ(*LY]7^
MO3BW]C^;HEH?0:[-C_NIJ^S'C'/I3.[?R*)X_NDNX!QYI;['/GWF2U/ZJ*G:
MG^G$:-VUVFZA+_FDV6O<CO*EBZOF="+Z5"/63S<<IV@RM8YM?,&"SI:_6;9<
M_+TSBS"%8#_FU^<(-A5+1I/BNGW*HT*(?=*B_IRST,AEBU196"G!*[E)7^B?
MP5J3G&W&G%H_U1>] ,61YQ3Z3C?IMW'0%)]\/ALL>YQ()K/+(V#^L'-O3T[Z
M'1[:UD'(Z>Z"D/,]!"%.X5'JO=U?7TYR.XA"%JSH]E#(Q\)37#M:)A<5T_-%
MZ_HHY/RS*&2%/-R=1R%?S%N3GIK4\_<WB1X2]QJ%;)*#@GR2^GP&1?8XN4(4
M+LD$W(-3^<_#(5L_[&.[>]A7]O"P'Z=?ZUDIE4A7,SMXV"]8T:T=]JG/.LW$
MW.*NZ^L?]Y7/'O?%W^"X_V+NFMQEG?=GY^P\7M+V^KC?) ]-<<KGDV[BQPL8
MQ8O:#AQ\O__)]Z=Y >O()(4<9KQST4 !<B;@P/N$H%@"5!V&'L^SGBH(6S2A
M4B,MD+@PGY#=%&#'(I)-Z.GIEWE;D7X;E%>ENT9B<#[4.C?*9^75HB594 DT
MM:Z ^K#@V43MJU6R_0*Y'VW')'5') 7X L86@>XIR(:QV%WN%YZE1@A9!7<V
M+0.J&+)#_-(=:)^I\WA>ZA8FX;<D+O58R&L:NX7^1BN+ZHI*TTX81."O<V.P
M,>'WP8?MZ#0L62$WLM+],%16N)M&KNY_X-["UF.^YE]B_&6"8E*J<"6-4\7N
MIAI[;5GR1Q;W#LS^R[HN6/\(-<FR#PT$-]! ,/G!!H)A/?XVVTB-DD3X_X)3
MM?F\,.W_*U2*Y,-++'OZ@A<-Z;0V,8R/W(8N)E>/R(XG)U*S;52S^5CF1'E]
MMY]3U>=>XM>X5=2JB0NIGGF\B?=3E^VKO'ZA7Q5ZIV^WEO@ZJ0RMZU^I^U:W
M8>1+-Q>%9B\5F\C9)UN\OB\F[Y_R!>NN?AY+_GHLH]JP6K@\N6J73V[$U*!P
MTJKT>X8C*>:XKS[?O16>:HF3M&X53Q*YJZO'5]FJ-H:_;K-W23-9.,];N<0@
ME^UGBX[>OA3-OB[6ZWIF8I]<G9Q<)[+7)Z^OO^(G)\T'J5W7Q^54^_KM\5I^
MKCU;V>I=M_GL-*_O[YV'V/BYB\;GW<NVUM24QYK>'Z9ORWWE_M=C(G4]B1GC
M5_RI]BN+QG*B+ W']\/RR=OKQ41.9$>BK)\4<^UVJ]L7'Y*U^[+2/M,,]2+3
M>TOG'>-M=)_X)?ZZOK 3][?MQ_')0UP\O:Y>6CWT\'S>3STT;B].>\9)^W5T
M4C^QD[EN(HONK4;SKM(KWIVI=QF4;60'J/7FG(EZ^Z*NX^>>3\Y'U<J5BN_)
MITKMDV1&/"U<-"O=Q^?":[59,,W;IZI6/,^]CBZD$U-UQ,9;.MZOH;I:KW1/
MF@TUGNG%4?WZOIQPWNVS5O6N7)+>TQGDB.=.M=Y\RS1%=5*,.S=:^?2Q4K@?
M/BH]!*L[N)K</+>TBCQ\2E4?GV/V?5*<I&X&%[=]^SE^'V_>Z[_ZK[>I:O;^
M.G\AGE<;C]9%X>3BK-.\N4\U\F^O#X.[RO-#L7>1;&1%Z5)"YY?%X9O\%!<?
MGY\'N69%NAW7>Z=2OMB<C.).]?9FF*G73D[OS^];3V^#9]%\2!4ZE4&O5YGD
M1X.+LOF:>]<>4;;9S]\_2.^O6DU\3,7*MX/S^.G51?OD_>RI):6&^CD>^VFL
M^'"NM,Y/M%K^I%IL93-O>B66NY,NNC=/ERT4>Y!BC^A&:R;O3R9O3KIP7S ;
MKP7ML=DW[\9JW$A>7)Q5"ZV3TN#M-*8UKA[?&H[E/%;QHMS<]DS)N"Z(^4[A
M,F^5VX/ZT_"R_5J4L[72Y?7I))Y5AB?I6KHG&J>_'ASQ-1XO->3'O.CT)P^G
MIUW]J=EXC[]*U8O+8K75O-2K^O#7!0;:L8=F]O71:.:O.H^W9Y9<'USV2T^G
ME7>[:^-U>=5N7BOWUFGW872O]:[/1Q.G^*LZ;#VWC22Z.RF^GL;$]BC],&JU
MU.YY+=UW8O&;L\?Z76(R..\F+QXK8U1H5)RW8KOSZQ8#DO3-5?YI"(^NG%[<
MG9\Y)_7JJ9'.=#(7F61A,#:[FFFF;C3CXM9\*+8O6R;2&OI5HF3ERK'[<<VP
M>X^GK\]R7V\VI7)3U\Z*9J.22IW>)^7\H-BX*=NU1B]?51/I8D]--1[.;O-#
MJSKN]9#M%##YW'5+HUJO7W52:KZ7U-3'9"<;K\6[9BF=S8K)4=,NQGJGM[>-
M9V64L.*%_/E3Z_4B?9-.-^\K)Z/L^&K8?-1[7>GNM=>X[12*J'Z7O]-_Y9JU
MI['U]I#M%\Y;KY>UI_>31UERRGK<3,5&K;KX-&E5+I5N^;[?:"2:STE[G.B/
M)\].+U:U[HWK0>Q1BY>J1O(]D2A*R6Q,?+)&LIS*#/*W[Z-7L]1P.N<%^_5-
MNZI:CU8M_O V4#2[>U4;]),%E/DU0)<=J5^_Z5_E%"O3J)D6)FGQNCWHEF_3
MPZ?3]T%9E'.)9BM3*YV]31Z3]UJAV+JO6DV]GFAGS\>MTM7P[:UYUQA?Q.NY
M2L$Z?8@W.[?.W4 3+^O%TOMSOI"J=E][2KT8SR,K43,N[5]Y]?[AL?CV5LE7
MQN\UNY10NM6Q<I9*%:3'<K$_&L;5\^?X]3A^EAY9K\GX>>*^*EN)7Q>E2\7"
MJ_T0JW=&=B9AO&N=RXN;Y.-=5R\TJ]<]E"H]U_/GV5;9ZO5/Q_77-Z4Q<M*R
MG9_\>DN_-AIB[+DZ&=_GI$&S<7[NO#GB\^GIH&&+K=YC.JV?#<:-W*0WK.;Z
M1?TM<3+,JO%JO_HX*H]&E?1M\>WF,57L9089NWI3EL_MYL53I7=G/,?+FC-T
MM%/UR91/8O5BX5U_O8ZWZ@E\5%P]3S0K>=^HR;?WQ6[QRJX^/9>S2;R)3O7T
MJB>>_AJESXK2XVVJUJV4K>Z59,5^I8S3MX?[-S,WNM+,A"X]-L]R[]9K[61P
MH=CCJGS2BBO)]%/1ZF5/LF-]-*RBXFU6U![?VO=%X[D:?^@/$MU>MUC)79:<
M>B_^$%?N[E!Y^#08]I*%]E5Z<''^EG&>]3/G'I^0YWTL1=^4SO-3QDE-:GIW
MU$I?%]_Z]J1BWR1K+:.!B3OU(*OMQ$/=,IXN'U.%AY.32N>I\5A]O)+*%R?&
M^/U*B^N_I.3374WKEJR+VJ^+I)W+U1.2]JBU;Y38X Z-,0W>#.*C$_O\U]M#
MJIHOV/>O5^=7Z9AV852EDT++*-Q6;B;#\TRA9G0OJ^FWZWXS8=]8#XKY>-4;
M5\Y_I904AFGF13\7;Y<KI6XR45"M_#!_BRFXHESHF<'(OGHO6>_USD7Z*6^H
MS:?KZO,DYTS*Z42W?I=Z.TEV:]EF+IE]'K^GJB>]MT$\9P\*_:>!>C54[>*M
M.,I?36Z1YIP6BIE.OI!6&V7Q5R4]OK-C4CS]=C9HG3Z=_6K<X(??=$;OW4NK
M6ZET*IA'44DMO9X]UQK2"7HSSY5R+%$OF,HO11UUDN7X8[QZ=Y8H7<5.I6&]
M+6>SI[':^U.YD"PERXF^=%_+MTKM]T3EI-TV$TW#-N/UNXNRFKN4+E)/C_=-
M*=6,/9Y,.K''UWX=R\;RB6)73VZ*]OMCZU<J]7J>ONH-4TGC,=.XE^ZSU?;3
MP]6]>I'HOTOQXO.OU%W<2D^DY)NAI/LWG=?6K:H6XO5"I52Z.*W<-._R_=Y=
MI=B6[D[*_4)ZXJ3B3^?VZ*1U^YJP!_;I(#Z4Y5BC-[@S'M^JSTW9OKJN6:E)
M 8V5I[/:C5@5'TU]5+AY4YNE]VY'JJ)SO71W?G_3NTT[2K]SH3W>/][$.B.I
MG+^4JJ51\3IO9ZU"VKBX.7.<"[.@))*OS>+)[>6;]?2:O_QU54W_JES8,>=Q
MT'R<].S,+Z3^$J\N,G:LTWEU[I_3K9O+7_4S_5V^'C>*YZ=&_J:;-K._L@/M
M2;RO/'?'G1,'W4M*WJAT?Y5.[XJ=.CZ$AKG[M'V?+C:R=O^F.:J9O:?W)!IU
MXS>%?$%\Z@T;[6[^5$V,.Z^G6NP<_YLYU29GA>>QDT#Q4DR\',3SPQ'F.>LR
M?=]-*NU&=5B_3[:KUEFZ4[K3]4&LV:OE;G\YM?2Y=':JY]KR>UT43])/+>?$
ML%.M.Z-==>Y[VB2C5+5WZT&LRL64$4-OUJAU'6L\B:?GY>M;R\S=GJ6;YV-;
M>R@HZ>9-3!6E5MIZ>&N-C%H;4^_MR'H^3SM6\NHNC49WO=O'\KGS6C3TL6A>
M:U;YPAK>H4RJFJLKUXG&71/]_RV=M=*&W!5&;R4]!6Y-9G!W^8 .?W'7JP]_
MDHIA3H/L_>RUH#C3!5MT;?*/CQA.>XA1K.D$2L#X5M3;74 #3\9.\'@LOXTV
MX#1<6CUZ0H'O$?2_:UM[5DTR0W] Z^8)^@6UI!WV#;P'%&C*.AD_QUR<WUHE
M9K 3R,H9MR_9#A@*]*)+(@3!K+W]"1+J$T'+SK)0+ /EAA"-NC^E?^(2-QJU
MT9Q'C1/] &?"O*[C%VN*HH8ZWK'WBLTG7)KOGNX_C@> P+T$-8S"8NA E@)L
M0ER2[H3Z*$$;9,[(/EW70W1F8]QZXW LH;[_Q!%P>@>.96E&LMTWXB+\-8,P
M6;+>7/+;DK#\@[JNMG5"AQ<G+-PG=&*5-95]N>GIASGR77P84(H'N#^W5OS1
M/@%%-:+LR)>+ZO4S\JD&.$+ YU.?+;>2@F]219QWK)%G'61_U2HCN*(63Q4V
M\C[$VHS&!%@S<2^ "O!>[9H>=:XIK6>F[VH7>$4MTNMO*OTEMX\0NEA6<,./
MVN![>UAL)<V=U[YS"$:,A]_NT+2]>:4X'-F+.2C^@M5-):.]SYB@H#^*+>.M
M3.74LBN[(5L\A7C;4U9MFJWJQ:)N:LX7T:2<(?QWD5H=!Z](32.B?87^U]P<
M^$+,8"B<$)&^H!_K^<#D^%)2P'G_;#8B"+YMD;]?&YL9?W,8^?:*^H@<2Z(,
MBXLD+[068[K%9M*Y\=,BG!;_ @<)D_</2/@_P&OV_K+XB%EH6B%;)];*;XX(
M-6S!4H;6F8[_FIE8_[Q@^R-06-_(.?44L]U@9$5R8MAD#YUFZ<]9G*Z&B]6E
MTMRV9[4#=^"3"<#Z3.+IS=965]?%W'7.@YTA,Z'I*/=T(KK,IEDF!Y,28/?W
M0+D^' 8<F#.KHJ=Z&=CM=&-4RG\ON/]QJ(4#Y742]QSG("W6H<K&'<HP3B5:
M[40E;,ARO;M+6.NR,LS")1&#UX?62Y%NG6QKR>2<Q73>&F]*6GJ$>FOYO,]*
M8\ZPF<NPL<LH"G2FTC0=ZDBPC)@]"03RUU@4M..:C""D/KE)]/H$("JO%-(L
MBUS3DB@6[UXLV"R$7BGA<[UE)[P29O8914/'!A0Y#$C6*]RN<EOK/T?1(Z1#
MM_*7"L.PLWO'4GF0,>P"WK5.*BP"N4[QDVE>055T9!\IJ6$_4-'??0R2M7BV
MT<K0@^Y9EV/IY\[\+$/BFB)2POQAKWI#:*+NT?$+DO=G;GR:#\S4.0WJLH2W
M!R_@"0=U*'DO."#@ /#QW^\7_PK>)3-BK8/!RDOP=:>XB$WW*N#+%Y@2%/J#
M(O3NJMLQJ(&=R]]+$W5J3TN[DI627CIN%%\SY3PXK">^-C,R1QY.J%9\K/#D
M:3-!A^G3-S> OF]DG1>\'5U:4/4HPC\94@E3 31URFD9,*C,_?W4]2=U^CH.
M\?%.G'PC7 E!OHB*(NE/*O?S0P;:R"VE4 9VUF/06(<?B&X^/5T#=W+]P0)"
MBC G&]E'ON(?(;14;5U"&WCF?754E/WH28CSI<JAEQB>)/)R/$9'20&#',ZK
M)9O?O_<;CA21M0<5VF>.+^.67^/-N/YK&BQNW60L<V]3^S.^MJ?D6&N>L]?V
ME0(!$)'#+1:QE8SCLK1O[#!GNW18Y P0Y4(#E^(+!^DBVB?[@\M9:62[G)X<
M&,FM--"@N(X3\9#$!],Q425Z4=5*[O%% _X4#Y_%O ,?L(81< G(:LH96@.4
MB5<1F&3Y,LT)]!M3.?Z^64KGOU,U$?L0D0^^A,/<?\(!=-;D9XI#R,<-#52V
MKCG?P[)(6](6M$?QQ"N1-.>\"*7G11)H-MJ1B:IQ_7^M^-:(_Z\9=O#*H,&,
MK\=A*'Z$P6OLZB 4#UW<-46WW3ADT,^ES!(#_O!BD*VC;X?&7F*Q<RV,1N!,
M0L*QOG&8Z.&)P04%>9&V"#,4P<C@'%(6IN$%%1!B58-G\FK=#W&U$D;/-H'-
MV])MQ!-]L2%4[A@T5F6R6+OT@''2+TSQ*^MJ:Y\WSZK1I.AXR28/P%_9?MZL
MGR@U9?)_&#9Z0/J*17.["N8R<S Z(I';$0<XB2Y)T##$$!""DR(#/ZQ8S KN
M0K=4 ,(*4!&^%"S4%:XVQ\MRZD9F558(7"4^&(/3NC_''C11D0BT@G]IQ1_&
MA+X7TN.%OWB^*#Q)[^RHT+!K4N?9L6-:O%0'];$PI)%3(K&^8UI:*S=#YWTZ
M\29?4J@8L.BX+Q6GW=CZ4F-W=H[ ,)W!GU!NMNGM7^ )@0*S]5^+;;[H+[7L
M>C783H[*LCJ."OP]L(D[*,DLVY;_JVI!K.U JI3#$F3_KLB^<X9='5EESHIK
MT 7Q>^B:2M';WJV?[DO45.'?=)XBI <A4PSS%W+M5, (*%B]<"EPJ3MUPA#'
M? TZ@FU\Z2=HJR2=P5BHK*P]<4S*41.E_'O1-1+6Q'X 38.()3;;<SL:^:^_
M< VJW2YB0#^3)3EOWF8QO#>:D2V>:\[=A5"0)A?*;+.&%W5HD>XC!$P^;3%Z
M%-!N,C?5(YO%%(/0D$W7^3U\AYQ6*#2[W+21&5+]>]]GB@R^T?P]G</+75]A
M0]\V"3K(4 L0EQ\C#PLL>G'*(;F+HK4:1,SH?6ZRKK+62:*C>/._VAO5/YI]
M:PIRBIG0<9J@:+=BNRB]CNV-:UPJQP&'Z.Q#G!8*)0\,R<T<Y2[8_"_)-!AM
M;U.%KS]F,%V!3]>O-6[@97(Y6N(7E.5YJ\BPA&[7WCZAIHVJX_#U"TE50LA7
ML;SS!':6CF;%@YZS2\&!K>D%67YQ+Q"$KYXCU\:3ZM?WO1W%T0<?RX=VXZI<
M>;*3KZ0I*[*;_&>K[/P7!I]R#->RPW]?4C<'Q(3<="/0!\Q2BL+!6*LU[P-%
MORC>$:LEYIVXQW*EY.GO/;H;4EWLK ;Z DP//SX_VU),D)>VWHK[2+T)$J^0
M=O#/C,LAL[,R$FB,[WT>&@7\L8)3=[/QRT8UQ- YTXIG>)%@%080HDA"L29C
MLI()Z@QZ$ 2WVVM9_'O_3CIO\.^*@U57*A*^@E6+/6%^.0J/]3IX'P^[H,I@
M!BO;()O"%.30'_H]EE'0@/[J95BUN/&WZS@&7$VC3UG8'R73_3K]J^SFJ0Y,
MH53P;XYQ=?=E8=]%:'Z>B]!UY;31_(_$\X?$RDR6^7Z&L]1BQ69DI5AUW]KS
M )K4?[]CE^9+EFX&84B]I:38XWJI"D8)=COS \5R?GC*@3R7\2>VQ/M8,;N+
M2AT@:)>VLRI+(P[XM].(!DNPJK@TA16MWT]FB1H])WV=D72)W_0W,2EZ\*O)
MPX/J_C<-=X-6;ZC/56]#JG;>?P8!PYWK85M[40$];0\:B%]K69*_R#<K&JD9
M+5Y9\_Q=!\Y1^=*&YL)4I+0!N@@+W(9&NR7I+_OG% \L5N3QV_C ?D.XQ@TM
MX\=>$AN+J,U$&9;Y$E7&0-5 9!,&\!YV%@!?5ZE\=;2(Z8A7= @.&O0UCP$_
MBU*O(Q=L&7!CFWA<U?_HU7><950H),7?4DN3E6\!UOBH+C>%UR7N^#KP@*>(
MM,N=S1#/1#IR_%1"5>0#,,D"Q1BJ>C:DTIXLB#N(.$1H_FO>@]<X"Y5@BZ&H
M\H#U.-*]%K9GZ346QCIQGKRM6*5UALC_9/I6ZFU/B-V*P)TCB1\!Q+N/4W37
MA[=+^BN.DOP"//W!4EX[#WB.>NA9ZJQTM_L[]UMQFBO5+-QIT;JC%3@R;7Q/
M-G(Y:3RGIK\;G=M&/^-,Y$L"4N:2V+OBP52&"JPQH_](!8Q.F1TQDQ/581W;
M%P''&0:>[B2(65N>[@9@!*#;_JB<LRKM<?#0>Q7#C89!X&)XR2LQ)Q5=U44,
M?@>* +*TP95E]5$SU<-FI+=E&$[)B,G*LAX">&Q>J00V7V!\R5]7/*)%XZGR
MO&=Q'HA\X2&':K?V&-KPIQ7BYV5?7X) .S&)UP/TT4>!5"%B*IQ-E#+EM]*,
MU%/1LK1KV',O(\[I:Q2[OP*?L)8TD*@'B48V'@3Q]?"L\%"]+AKLO9.RTM0G
M"KKE&GFWF:, MP#])03(EPC ^>A=J?:JRF]H[!&5)T$*>4ZKH5'>3[HZG\5/
M&W+0 NZW"G?I!'!J"=:H(I.^#,2N,SY]IVIPA@5[C6C!N@$<W&2D!?L4.D'Y
MO5B#R,KE*,A3N.03,D=NXDP2NO@)HS#'%GL0O_:;>Y+GNDP #&6&4ZRSK!*:
MR@1L"^<G_?/VVT4S;)5KY;JJSPNFG#22!&C)U93C\2#!UA3NU07).,UF](Y-
MN+0+J5.I8]/)-1/F#2-!#-%/"P0$HA5[I5Y##$;S!^Y;]8E3(G@MZ6S\KL.>
M::P>J8=C%VP4>WG/>"\=[+6]>ZW"[V89/MM0$O'1*5N,5#'NPAF0!NQ9Z]XK
MG#9J>J@6:]R0$76!3^H8\ZU=_7<2T"RK#246F!5T[J56G#R!;&-346)GR^!+
M(L5N9T;:H^T ^8<:56*[A$78/(92+0BK=\GWK7U]9*T:S8UN#)[VH$IH7OW)
MH,,WS-T4 S-6-_3>Y5SJSN&IG\4#PE-SK.7(9ARWVJ!P'H%KN>P+YUG^G8,H
M.)4ZZ.9;70F0_F2P[S)"G1BAMNX.Z"0*OI%^1RA@A?TR(83=6UT#]70Q&F--
M9=B"W0\I>YI& AO/#8''F\=7$](BX6^GTD,>&T%SJ2/#N0/=LG&2GG#+56'_
MTP7ZY(5JQN\;8+]*: _B$N@\^^2BV-=\X::X+;/5-V/:1^"S.,6$S=EOHH96
M_[G_AFB-*9B..:4S#+*;9B'<YX!2(9@FS%G$;!Z!3\&"J0'9H.!GQ%4]ID[$
M61N5M=VP]+(9IOC(.0=;F@*%X+G'4UB#.6&(ZHYN4W1<*<SDM$#BQ@99@N3>
M-C(T9#.N'H3N"?Z!H9]Q0)M]4"/#X=(U3:'#ZX9Y*R 3NYE&$G\ABN 3W&+0
MYC>^+:EJ@Z^Z)DX@%'R (^)G-,"G&H\]DJP]'5?'!A^"6P,:GO<,I;;@W,4?
MB6#30"(:B<,OH],\F&WR/4$L0SRY#2/A;?6>K<Z@.P%.KQ.D=M*PWQ':.?^-
M&-81L^[H8E_PEV65*O$AQW)W7^S"&QH3Y_$&]Q)E$6I,A.21)U$P:O@,,\Y9
MB9<F&FX?VQ6:1#:<=?OE<XON-BW)LX _.*2!V^SLO:W\18>SEL]P_7KS$7NR
MT]!M.%H(\NA^]0C/YFB<8_O)!A8-!6F"=P)R<&9H$[B_Q7@[J=-:^N >5/B+
MA"0S%-VSR/,WS_6YH(]>&O094U'4#^-()-#]5TEVN6>*&IO^[2$':%\/[</2
MQ^8/S!3O8F:5_9?]D"K%*_[]RYH<!4"_ R^>:1-Z_-]_?#";BN>?XV\?^G__
M!U!+ 0(4 Q0    (  ^(>UQ5VJX1FAT  ,QY 0 1              "  0
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M+3(P,C4Q,C,Q7W!R92YX;6Q02P$"% ,4    "  /B'M<TX\ TO\"  #<%0
M"@              @ &QX@$ 97@R,2TQ+FAT;5!+ 0(4 Q0    (  ^(>UQ#
M]PZ^6@,  *T.   *              "  =CE 0!E>#(S+3$N:'1M4$L! A0#
M%     @ #XA[7"*3I+$\ P  K0X   H              ( !6ND! &5X,C,M
M,BYH=&U02P$"% ,4    "  /B'M<'>HS1W<(  ##1P  "@
M@ &^[ $ 97@S,2TQ+FAT;5!+ 0(4 Q0    (  ^(>UQ"'UK_;P@  #-(   *
M              "  5WU 0!E>#,Q+3(N:'1M4$L! A0#%     @ #XA[7 F;
M>I"8!   BQX   H              ( !]/T! &5X,S(M,2YH=&U02P$"% ,4
M    "  /B'M<A"?4^IX$   M'@  "@              @ &T @( 97@S,BTR
M+FAT;5!+ 0(4 Q0    (  ^(>UP^A$C%^S,& $9?0  ,              "
G 7H' @!F;W)M,3 M:RYH=&U02P4&      T #0 - P  GSL(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CLDI="http://calidibio.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cldi-20251231.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-102024-07-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2024-07-10</startDate>
            <endDate>2024-07-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2024-07-10</instant>
        </period>
    </context>
    <context id="From2025-08-012025-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="From2025-10-272025-10-27_custom_NovaCellMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-27</startDate>
            <endDate>2025-10-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-27_custom_NovaCellMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-27</instant>
        </period>
    </context>
    <context id="AsOf2024-09-17_custom_NovaCellMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-17</instant>
        </period>
    </context>
    <context id="From2024-09-172024-09-17_custom_NovaCellMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:NovaCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MinimumMember_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_srt_MaximumMember_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-272022-10-27_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:GovernmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-27</startDate>
            <endDate>2022-10-27</endDate>
        </period>
    </context>
    <context id="From2022-10-272022-10-27_custom_GovernmentGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:GovernmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-27</startDate>
            <endDate>2022-10-27</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:GovernmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_EarnoutSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:EarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ContingentlyIssuableWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:ContingentlyIssuableWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ContingentlyIssuableWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CLDI:ContingentlyIssuableWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsMember11025046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivateWarrantsMember11025062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicWarrantsMember11025078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrivateWarrantsMember11025078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:ForwardPurchaseAgreementDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorAAndDirectorEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAAndDirectorEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorAAndDirectorEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAAndDirectorEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorFAndRelativeOfOfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndRelativeOfOfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorFAndRelativeOfOfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndRelativeOfOfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorFOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorFOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorATwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorATwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorATwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorATwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_DirectorFAndDirectorAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndDirectorAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DirectorFAndDirectorAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFAndDirectorAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RelativeOfOfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:RelativeOfOfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RelativeOfOfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:RelativeOfOfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OfficerGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OfficerGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_OfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_OfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CompanyARelatedToDirectorGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CompanyARelatedToDirectorGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CompanyARelatedToDirectorGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DirectorsAAndEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorsAAndEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-22_custom_DirectorFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-22</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_DirectorFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2022-02-012022-02-01_custom_DirectorDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-01_custom_DirectorDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-01</instant>
        </period>
    </context>
    <context id="From2022-04-012022-04-01_custom_DirectorAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-01_custom_DirectorAMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-31_custom_AJCCapitalMember_srt_MaximumMember_custom_GuarantyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-31_custom_AJCCapitalMember_custom_GuarantyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_AJCCapitalMember_custom_GuarantyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AJCCapitalMember_custom_GuarantyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">CLDI:GuarantyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:AJCCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-31_custom_DirectorAThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-12_custom_DirectorAThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:DirectorAThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_custom_RelativeOfOfficerAMember_us-gaap_LoansPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:RelativeOfOfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-08-08_custom_OfficerGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <context id="From2025-08-082025-08-08_custom_OfficerGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-08</startDate>
            <endDate>2025-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-17_custom_OfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-17</instant>
        </period>
    </context>
    <context id="From2025-09-172025-09-17_custom_OfficerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:OfficerAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CompanyARelatedToDirectorGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:CompanyARelatedToDirectorGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-18_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TermNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TermNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TermNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TermNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_BridgeLoanPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:BridgeLoanPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BridgeLoanPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:BridgeLoanPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-01-31_custom_TwoThousandTwentyOneTermNoteMember_custom_InvestorAndDirectorMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:InvestorAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyOneTermNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyOneTermNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyOneTermNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2022-11-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_TwoThousandTwentyTwoTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2023-11-08_custom_TwoThousandTwentyTwoTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-08</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_TwoThousandTwentyTwoTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyTwoTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyThreeTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_TwoThousandTwentyThreeTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-23</instant>
        </period>
    </context>
    <context id="From2024-12-232024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-23</startDate>
            <endDate>2024-12-23</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyThreeTermNotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyFourBridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyFourBridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-19</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_TwoThousandTwentyFourBridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CLDI:TwoThousandTwentyFourBridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:TwoThousandTwentyFourPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="AsOf2024-04-18_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_PromissoryNoteLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PromissoryNoteLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PromissoryNoteLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PromissoryNoteLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PromissoryNoteLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PromissoryNoteLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-19_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-19</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_VotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NonvotingCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-04-18_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="AsOf2024-04-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_SeriesBWarrantsAndSeriesCWarrantsMember_custom_InducementOfferLetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesBWarrantsAndSeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_SeriesBOneWarrantsMember_custom_InducementOfferLetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-31_custom_SeriesDCommonStockMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:SeriesDCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:InducementOfferLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="AsOf2024-07-26_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="AsOf2024-07-26_us-gaap_WarrantMember_custom_SubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="AsOf2024-07-26_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="From2024-07-262024-07-26_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="From2024-07-262024-07-26_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-11</instant>
        </period>
    </context>
    <context id="From2024-10-112024-10-11_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-04</instant>
        </period>
    </context>
    <context id="From2025-02-042025-02-04_custom_MarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-04</startDate>
            <endDate>2025-02-04</endDate>
        </period>
    </context>
    <context id="From2025-02-052025-02-05_custom_MarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:MarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-05</startDate>
            <endDate>2025-02-05</endDate>
        </period>
    </context>
    <context id="From2024-02-042025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-04</startDate>
            <endDate>2025-02-04</endDate>
        </period>
    </context>
    <context id="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-23</startDate>
            <endDate>2024-10-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-23</instant>
        </period>
    </context>
    <context id="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesECommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesECommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-23</startDate>
            <endDate>2024-10-23</endDate>
        </period>
    </context>
    <context id="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesFCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesFCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-23</startDate>
            <endDate>2024-10-23</endDate>
        </period>
    </context>
    <context id="From2024-10-242024-10-24_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-24</startDate>
            <endDate>2024-10-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-24_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-24</instant>
        </period>
    </context>
    <context id="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="From2024-11-152024-11-15_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-15</startDate>
            <endDate>2024-11-15</endDate>
        </period>
    </context>
    <context id="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="From2025-01-092025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-28</instant>
        </period>
    </context>
    <context id="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-28</instant>
        </period>
    </context>
    <context id="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGCommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesGCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-28_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-28</instant>
        </period>
    </context>
    <context id="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:JulyWarrantInducementOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="From2025-07-092025-07-09_custom_JulyWarrantInducementOfferMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:JulyWarrantInducementOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-09</startDate>
            <endDate>2025-07-09</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember_custom_SeriesHCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesHCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:JulyWarrantInducementOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-20</startDate>
            <endDate>2025-08-20</endDate>
        </period>
    </context>
    <context id="From2025-08-202025-08-20_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-20</startDate>
            <endDate>2025-08-20</endDate>
        </period>
    </context>
    <context id="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:PreFundedWarrantUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-20</startDate>
            <endDate>2025-08-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-20_custom_RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-20</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CLDI:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:RestrictedStockUnitsVestedAndUnreleasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:RestrictedStockUnitsVestedAndUnreleasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PrivateWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:WarrantsToPurchaseRestrictedSharesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:PlacementAgentWarrantsToPurchaseCommonStockFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RepresentativeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesB1WarrantsToPurchaseCommonStockFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesC1WarrantsToPurchaseCommonStockTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesFWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesHWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CLDI:TriggeringEventAxis">CLDI:SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RedemptionOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CLDI:TriggeringEventAxis">CLDI:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:RedemptionOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesBOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesBOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesBOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesBOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesBOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesCOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesCOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesCOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SeriesCOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesCOneWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesCOneWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesCOneWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsAndSeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesEWarrantsAndSeriesFWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesGPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesGPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesGPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_SeriesIPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_SeriesIPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CLDI:SeriesIPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember11030265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember11030281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_WarrantMember11030281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_WarrantMember11030312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-12_custom_TwoThousandTwentyThreePlanMember_custom_AdministratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:AdministratorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-12</instant>
        </period>
    </context>
    <context id="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-09</instant>
        </period>
    </context>
    <context id="From2024-07-152024-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="From2025-08-042025-08-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2025-08-04</startDate>
            <endDate>2025-08-04</endDate>
        </period>
    </context>
    <context id="From2023-08-282023-08-28_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-28</startDate>
            <endDate>2023-08-28</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember11030718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-182023-01-18_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-18</startDate>
            <endDate>2023-01-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-18_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-18</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CLDI:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="CLDI:StatementOfIncomeLocationBalanceAxis">CLDI:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_srt_AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_PriorDecemberTwentySeventeenthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">CLDI:PriorDecemberTwentySeventeenthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_AfterDecemberTwentySeventeenthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">CLDI:AfterDecemberTwentySeventeenthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_country_DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-10_custom_SanDiegoLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SanDiegoLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SanDiegoLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="From2022-10-102022-10-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_MrCamaisaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:MrCamaisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SanDiegoLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-01_custom_StemVacOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-07-01_custom_StemVacOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_StemVacOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_StemVacOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StemVacOfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-05-01_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-07_custom_NorthwesternAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:NorthwesternAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-07</instant>
        </period>
    </context>
    <context id="From2024-12-152024-12-15_custom_NorthwesternAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:NorthwesternAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-15</startDate>
            <endDate>2024-12-15</endDate>
        </period>
    </context>
    <context id="From2021-07-222021-07-22_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-22</startDate>
            <endDate>2021-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:GeorgeNgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-23</instant>
        </period>
    </context>
    <context id="From2023-06-222023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:GeorgeNgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:GeorgeNgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:SeparationAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-31_custom_MrCamaisaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:MrCamaisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="AsOf2023-08-31_custom_MrLeftwichMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:MrLeftwichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-12_custom_MrLeftwichMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CLDI:MrLeftwichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="AsOf2025-01-03_custom_MrLeftwichMember_custom_SettlementOfDeferredCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CLDI:SettlementOfDeferredCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:MrLeftwichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-03</instant>
        </period>
    </context>
    <context id="From2023-12-102023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-10</instant>
        </period>
    </context>
    <context id="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CLDI:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-10</instant>
        </period>
    </context>
    <context id="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-10</startDate>
            <endDate>2023-12-10</endDate>
        </period>
    </context>
    <context id="From2025-08-222025-08-22_custom_Dr.CamisaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.CamisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-22</startDate>
            <endDate>2025-08-22</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-12-31_custom_Dr.CamisaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.CamisaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-08_custom_Dr.MinevMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.MinevMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <context id="From2025-08-082025-08-08_custom_Dr.MinevMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Dr.MinevMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-08</startDate>
            <endDate>2025-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-17_custom_Ms.CampbellMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Ms.CampbellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-17</instant>
        </period>
    </context>
    <context id="From2025-09-172025-09-17_custom_Ms.CampbellMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CLDI:Ms.CampbellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <context id="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_CommonStockUnitsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:CommonStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-06</startDate>
            <endDate>2026-03-06</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:PreFundedWarrantUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-06</startDate>
            <endDate>2026-03-06</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:PreFundedWarrantUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:UnderwritersWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CLDI:UnderwritersWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-06</startDate>
            <endDate>2026-03-06</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesJWarrantsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesJWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesKWarrantsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesKWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesLWarrantsMember_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesLWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="AsOf2026-03-06_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-06</instant>
        </period>
    </context>
    <context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesGCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesGCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesHCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesHCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesICommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CLDI:SeriesICommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="From2026-03-052026-03-05_us-gaap_SubsequentEventMember_custom_CommonStockPurchaseWarrantsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001855485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CLDI:CommonStockPurchaseWarrantsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-05</startDate>
            <endDate>2026-03-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-12-31" id="Fact000005">0001855485</dei:EntityCentralIndexKey>
    <CLDI:TermNotesPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:TermNotesPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:TermNotesPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0363"
      unitRef="Shares"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="Shares"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0366"
      unitRef="Shares"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0740"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:ProceedsFromRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:ProceedsFromIssuanceOfNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0778"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0784"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0787"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0793"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:RepaymentOfConvertibleNotePayable
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0796"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:PaymentOfDebtIssuanceCosts
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0799"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:MachineryAndEquipmentAcquiredThroughFinancingLeases
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockPerConversionOfConvertibleNote
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfConvertibleNoteForLegalSettlement
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockInLieuOfCashForServices
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0853"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:DebtDiscountOnConvertibleNotes
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0856"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:IssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0978"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_ContingentlyIssuableWarrantMember"
      id="xdx2ixbrl0981"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_ContingentlyIssuableWarrantMember"
      id="xdx2ixbrl0982"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl1035"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl1036"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1040"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1041"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember"
      id="xdx2ixbrl1045"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember"
      id="xdx2ixbrl1046"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember"
      id="xdx2ixbrl1049"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember"
      id="xdx2ixbrl1051"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl1060"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_MoneyMarketFundsMember"
      id="xdx2ixbrl1061"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      id="xdx2ixbrl1064"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      id="xdx2ixbrl1065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PublicWarrantsMember"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PublicWarrantsMember"
      id="xdx2ixbrl1076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PrivateWarrantsMember"
      id="xdx2ixbrl1079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_PrivateWarrantsMember"
      id="xdx2ixbrl1081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      id="xdx2ixbrl1099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorAAndDirectorEMember"
      id="xdx2ixbrl1171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFAndRelativeOfOfficerAMember"
      id="xdx2ixbrl1176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorFMember"
      id="xdx2ixbrl1182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorDMember"
      id="xdx2ixbrl1186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorAOneMember"
      id="xdx2ixbrl1191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorATwoMember"
      id="xdx2ixbrl1201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_RelativeOfOfficerAMember"
      id="xdx2ixbrl1211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_OfficerGMember"
      id="xdx2ixbrl1217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_OfficerAMember"
      id="xdx2ixbrl1222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_CompanyARelatedToDirectorGMember"
      id="xdx2ixbrl1227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_CompanyARelatedToDirectorGMember"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl1356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember"
      id="xdx2ixbrl1485"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      id="xdx2ixbrl1761"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      id="xdx2ixbrl1776"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl1791"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl1820"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      id="xdx2ixbrl1850"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember"
      id="xdx2ixbrl1861"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      id="xdx2ixbrl1876"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl1951"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl1966"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl1982"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl1997"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      id="xdx2ixbrl2012"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl2199"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl2201"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl2213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl2221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2233"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl2235"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2342"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:IncomeTaxReconciliationEnactmentOfNewTaxLaws
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2344"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2346"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2350"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2364"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2386"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2398"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2402"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2406"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2410"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2414"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2418"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2425"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2435"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationStockIssuanceCost
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2439"
      unitRef="Pure"
      xsi:nil="true"/>
    <CLDI:EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2441"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2443"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxPaidForeignAfterRefundReceived
      contextRef="From2025-01-01to2025-12-31"
      id="xdx2ixbrl2451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxPaidForeignAfterRefundReceived
      contextRef="From2025-01-012025-12-31_country_AU"
      id="xdx2ixbrl2453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2024-01-012024-12-31"
      id="xdx2ixbrl2526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2632"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2636"
      unitRef="USD"
      xsi:nil="true"/>
    <CLDI:FinanceLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="AsOf2025-12-31"
      id="xdx2ixbrl2638"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-12-31" id="Fact000015">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2025-01-01to2025-12-31" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000017">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-12-31" id="Fact000018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-12-31" id="Fact000019">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-12-31" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-12-31" id="Fact000021">001-40789</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-12-31" id="Fact000022">CALIDI BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-12-31" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-12-31" id="Fact000024">86-2967193</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-12-31" id="Fact000025">4475     Executive Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-01-01to2025-12-31" id="Fact000026">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-12-31" id="Fact000027">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-12-31" id="Fact000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-12-31" id="Fact000029">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-12-31" id="Fact000030">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-12-31" id="Fact000031">794-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-12-31" id="Fact000032">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-12-31" id="Fact000033">CLDI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-12-31" id="Fact000034">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2025-01-01to2025-12-31" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2025-01-01to2025-12-31" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-12-31" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-12-31" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-12-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-12-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-12-31" id="Fact000041">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-01-01to2025-12-31" id="Fact000042">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2025-01-01to2025-12-31" id="Fact000043">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2025-01-01to2025-12-31" id="Fact000044">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-12-31" id="Fact000045">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2025-06-30"
      decimals="-5"
      id="Fact000046"
      unitRef="USD">8000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-20"
      decimals="INF"
      id="Fact000047"
      unitRef="Shares">10895725</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000048">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000054">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Risk Management and Strategy &lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
our business operations, we use information technology, enterprise applications, communications tools, cloud network solutions, and related
systems to manage our operations, including to manage our building systems, vendor relationships, accounting and recordkeeping, and communications,
among other aspects of our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have developed and implemented a cybersecurity risk management program intended to protect our confidential and proprietary data, and
information technology and systems, from cybersecurity threats, including unauthorized access or attack. We leverage the &lt;span style="background-color: white"&gt;SOC
2 TYPE II Cybersecurity Framework&lt;/span&gt; as a guide to help us identify, assess, and manage cybersecurity risks relevant to the business.
This does not imply that we meet any particular technical standards, specifications, or requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20250101__20251231_z8kUlrtVHL0h"&gt;Our
processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting
risks, reputational risks, personal data theft, fraud, and other potential risks, are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zEt31mjqkBc7"&gt;integrated&lt;/span&gt; into our overall enterprise risk management
process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management
process to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
cybersecurity risk management program includes the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zUWh7b63Blrh"&gt;a
    multidisciplinary team comprised of personnel from information technology (&#x201c;IT&#x201d;), internal audit, accounting, and legal,
    as well as third-party cybersecurity experts principally responsible for directing (i) our cybersecurity risk assessment processes,
    (ii) our security processes, and (iii) our response to cybersecurity incidents, and a third-party security operations center.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20250101__20251231_zHrhPwGDwmbd"&gt;risk
    assessments designed to help identify material cybersecurity risks to our critical systems, information, services, and our broader
    enterprise IT environment.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;internal
    and third-party security tools to monitor our systems, identify cybersecurity risks, and test our IT environment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    use of third-party cybersecurity experts, where appropriate, to assess, test or otherwise assist with aspects of our security processes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a
    cybersecurity incident response plan and business continuity plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cybersecurity
    training for employees and key business partners with access to our systems.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&#160;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zAZTzy62pWOl"&gt;a
    third-party cybersecurity risk management process for service providers and vendors who access our systems.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;requiring
    employees, as well as third parties who have access to our systems, to treat confidential and private information and data with care,
    including performing controls relating to such data; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cybersecurity
    risk insurance.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
also seek to engage reputable service providers that maintain cybersecurity programs or controls.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have not identified risks from known cybersecurity threats within the prior fiscal year, including as a result of any prior cybersecurity
incident, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of
operations, or financial condition. Please refer to &#x201c;Item 1A, Risk Factors&#x201d; in this report for additional information about
certain ongoing risks related to our information technology that, if realized, are reasonably likely to materially affect us, including
our operations, business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000055">Our
processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting
risks, reputational risks, personal data theft, fraud, and other potential risks, are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zEt31mjqkBc7"&gt;integrated&lt;/span&gt; into our overall enterprise risk management
process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management
process to other legal, compliance, strategic, operational, and financial risk areas.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2025-01-01to2025-12-31" id="Fact000057">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2025-01-01to2025-12-31" id="Fact000058">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2025-01-01to2025-12-31" id="Fact000059">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000062">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cybersecurity
Governance &lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cybersecurity
is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zRtHrDPYdBW6"&gt;The
Board, in coordination with the Audit Committee, oversees the Company&#x2019;s enterprise risk management process, including the management
of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party
cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management&#x2019;s processes
to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes.&lt;/span&gt; The Audit
Committee periodically provides updates on these matters to the Board of Directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including
an independent third-party expert we have retained to identify and assess material risks from cybersecurity threats, their severity,
and potential mitigation steps. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_904_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20250101__20251231_zfQOOwY64LW"&gt;The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zt0tw5FZIhHh"&gt;CISO&lt;/span&gt; is primarily responsible for leading our cybersecurity risk assessment and management processes.
Our executive staff, supported by external IT, currently serves as our CISO. The CISO regularly reviews and assesses cybersecurity initiatives,
including our incident response plan, as well as cybersecurity compliance, training, and risk management efforts.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000063">The
Board, in coordination with the Audit Committee, oversees the Company&#x2019;s enterprise risk management process, including the management
of material risks arising from cybersecurity threats. The Audit Committee regularly receives updates from management and third-party
cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management&#x2019;s processes
to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000064">The &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20250101__20251231_zt0tw5FZIhHh"&gt;CISO&lt;/span&gt; is primarily responsible for leading our cybersecurity risk assessment and management processes.
Our executive staff, supported by external IT, currently serves as our CISO. The CISO regularly reviews and assesses cybersecurity initiatives,
including our incident response plan, as well as cybersecurity compliance, training, and risk management efforts.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2025-01-01to2025-12-31" id="Fact000065">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <CLDI:NoInsiderTradingFlag contextRef="From2025-01-01to2025-12-31" id="Fact000067">true</CLDI:NoInsiderTradingFlag>
    <dei:AuditorFirmId contextRef="From2025-01-01to2025-12-31" id="Fact000068">199</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2024-01-012024-12-31" id="Fact000069">688</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000070">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have audited the accompanying consolidated balance sheet of Calidi Biotherapeutics, Inc. (the &#x201c;Company&#x201d;) as of December 31,
2025 , the related consolidated statements of operations, comprehensive loss, total equity and cash flows for the year ended December
31, 2025, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations
and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States
of America.&lt;/span&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2025-01-01to2025-12-31" id="Fact000071">CBIZ CPAs P.C</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2025-01-01to2025-12-31" id="Fact000072">Costa Mesa, California</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2024-01-012024-12-31" id="Fact000073">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-012024-12-31" id="Fact000074">Costa Mesa, California</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">5600000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">9591000</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">656000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">6256000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">10227000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">781000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">869000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">1682000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">2934000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">138000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">152000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">8857000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">14182000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">595000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">2072000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">18000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">2000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">18000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">2000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">1276000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">1858000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">530000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">480000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">530000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">480000</us-gaap:AccruedLiabilitiesCurrent>
    <CLDI:TermNotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">251000</CLDI:TermNotesPayableCurrent>
    <CLDI:TermNotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">2702000</CLDI:TermNotesPayableCurrent>
    <CLDI:TermNotesPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">2702000</CLDI:TermNotesPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">223000</us-gaap:LoansPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">638000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">111000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000146"
      unitRef="USD">66000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">1405000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">1204000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000151"
      unitRef="USD">3935000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">9496000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000157"
      unitRef="USD">277000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">1845000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">171000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">145000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <CLDI:PromissoryNote
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">600000</CLDI:PromissoryNote>
    <CLDI:PromissoryNote
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">600000</CLDI:PromissoryNote>
    <CLDI:WarrantLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">107000</CLDI:WarrantLiability>
    <CLDI:WarrantLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">119000</CLDI:WarrantLiability>
    <CLDI:RelatedPartyWarrantLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">8000</CLDI:RelatedPartyWarrantLiability>
    <CLDI:RelatedPartyWarrantLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">9000</CLDI:RelatedPartyWarrantLiability>
    <us-gaap:Liabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000172"
      unitRef="USD">5098000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">12214000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact000184"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000186"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000188"
      unitRef="Shares">330000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000190"
      unitRef="Shares">330000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000192"
      unitRef="Shares">7217000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000194"
      unitRef="Shares">7217000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000196"
      unitRef="Shares">1730000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000198"
      unitRef="Shares">1730000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">145392000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">123277000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000204"
      unitRef="USD">-28000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">-141621000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">-121715000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">3759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">1534000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">434000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">3759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">1968000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">8857000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">14182000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">9737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">8878000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">10503000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">12898000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">20240000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">21776000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-20240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">-21776000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">131000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">372000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">76000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">561000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">76000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">561000</us-gaap:InterestExpenseNonoperating>
    <CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">-1000</CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty>
    <CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">-285000</CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesNonrelatedParty>
    <CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">-1000</CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty>
    <CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">-39000</CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivativesRelatedParty>
    <CLDI:GrantIncome
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">50000</CLDI:GrantIncome>
    <CLDI:GrantIncome
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">181000</CLDI:GrantIncome>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">244000</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">103000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">192000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">-419000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">-20048000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">-22195000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">-20063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">-22209000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">-157000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">-66000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">-19906000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">-22143000</us-gaap:NetIncomeLoss>
    <CLDI:DeemedDividendOnWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">-5673000</CLDI:DeemedDividendOnWarrants>
    <CLDI:DeemedDividendOnWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">-1671000</CLDI:DeemedDividendOnWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">-25579000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">-23814000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000287"
      unitRef="USDPShares">-5.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000289"
      unitRef="USDPShares">-5.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000291"
      unitRef="USDPShares">-35.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000293"
      unitRef="USDPShares">-35.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">4302</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">4302</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">-20063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">-22209000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">15000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">19000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">-20048000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">-22190000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">-157000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">-66000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000318"
      unitRef="USD">-19891000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">-22124000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000329"
      unitRef="Shares">1730051</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">123277000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">-28000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">-121715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">1534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">434000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000327"
      unitRef="USD">1968000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000339"
      unitRef="Shares">534265</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">3201000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">3201000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">3201000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">416667</CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCostsShares>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000342"
      unitRef="USD">3607000</CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">3607000</CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts>
    <CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">3607000</CLDI:IssuanceOfCommonStockAndWarrantsThroughJanuaryConfidentiallyMarketedPublicOfferingNetOfFinancingCosts>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">277084</CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCostsShares>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">3423000</CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">3423000</CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts>
    <CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">3423000</CLDI:IssuanceOfCommonStockAndWarrantsForMarchRegisteredDirectOfferingAndConcurrentPrivatePlacementNetOfFinancingCosts>
    <CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">1922764</CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000361"
      unitRef="Shares">1000</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000362"
      unitRef="Shares">5767000</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000365"
      unitRef="Shares">5768000</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000367"
      unitRef="Shares">5768000</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOffering>
    <CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">1759500</CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">5000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000375"
      unitRef="USD">5000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">5000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000389"
      unitRef="Shares">549596</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">4004000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">4004000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">4004000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">25029</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000409"
      unitRef="Shares">2038</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">-277000</CLDI:StockIssuedDuringPeriodValueSaleOfInvestment>
    <CLDI:StockIssuedDuringPeriodValueSaleOfInvestment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">-277000</CLDI:StockIssuedDuringPeriodValueSaleOfInvestment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000420"
      unitRef="USD">2108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">2108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">2108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">15000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000431"
      unitRef="USD">15000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">15000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">-19906000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">-19906000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-012025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">-157000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">-20063000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000451"
      unitRef="Shares">7216994</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">145392000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">-141621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">3759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">3759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000461"
      unitRef="Shares">296019</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">91384000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">-47000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">-99572000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">-8235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">-8235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000471"
      unitRef="Shares">296019</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000464"
      unitRef="USD">91384000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">-47000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">-99572000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">-8235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">-8235000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000481"
      unitRef="Shares">14589000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">369000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">369000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">369000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <CLDI:StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000491"
      unitRef="Shares">1157000</CLDI:StockIssuedDuringPeriodSharesLieuOfCashForCommitmentFee>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">81000</CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">81000</CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee>
    <CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">81000</CLDI:StockIssuedDuringPeriodValueLieuOfCashForCommitmentFee>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000501"
      unitRef="Shares">132</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">-327000</CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">-327000</CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">-327000</CLDI:AdjustmentsToAdditionalPaidInCapitalFinancingFees>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000519"
      unitRef="Shares">110271</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000512"
      unitRef="USD">4822000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">4822000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">4822000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndPrefundedWarrantsThroughPublicOfferingNetOfFinancingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">176731</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">3071000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">3071000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">3071000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000539"
      unitRef="Shares">89151</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">1818000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">1818000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">1818000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughInducementOfferNetOfFinancingCosts>
    <CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">256886</CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">4803000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">4803000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">4803000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants>
    <CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000559"
      unitRef="Shares">16375</CLDI:StockIssuedDuringPeriodSharesExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">2000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">2000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants>
    <CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">2000</CLDI:StockIssuedDuringPeriodValueExerciseOfCommonPrefundedWarrants>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">133000</CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000565"
      unitRef="USD">133000</CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement>
    <CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000567"
      unitRef="USD">133000</CLDI:AdjustmentsToAdditionalPaidInCapitalIssuanceOfRestrictedStockUnitsForLiabilitySettlement>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000577"
      unitRef="Shares">1667</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForLegalSettlement>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000570"
      unitRef="USD">308000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000573"
      unitRef="USD">308000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000575"
      unitRef="USD">308000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForLegalSettlement>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000587"
      unitRef="Shares">6621</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForReverseStockSplitFractionalShares>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">58235</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreementShares>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">1000000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000593"
      unitRef="USD">1000000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000595"
      unitRef="USD">1000000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPerSubscriptionAgreement>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000607"
      unitRef="Shares">170834</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">1631000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">1631000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">1631000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForRegisteredDirectOffering>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">158355</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughAtMarketOffering>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">3063000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">3063000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">3063000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughAtMarketOffering>
    <CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">369823</CLDI:StockIssuedDuringPeriodSharesIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000620"
      unitRef="USD">6662000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">6662000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing>
    <CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">6662000</CLDI:StockIssuedDuringPeriodValueIssuanceOfCommonStockThroughPublicOfferingNetOfFinancing>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">1500000</CLDI:StockIssuedDuringPeriodValueInvestment>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">1500000</CLDI:StockIssuedDuringPeriodValueInvestment>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000634"
      unitRef="USD">500000</CLDI:StockIssuedDuringPeriodValueInvestment>
    <CLDI:StockIssuedDuringPeriodValueInvestment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">2000000</CLDI:StockIssuedDuringPeriodValueInvestment>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000645"
      unitRef="Shares">3205</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">2957000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">2957000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">2957000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">19000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">-22143000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">-22143000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000668"
      unitRef="USD">-66000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000669"
      unitRef="USD">-22209000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000679"
      unitRef="Shares">1730051</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000672"
      unitRef="USD">123277000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000673"
      unitRef="USD">-28000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000674"
      unitRef="USD">-121715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">1534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000676"
      unitRef="USD">434000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">1968000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Shares">1730051</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000682"
      unitRef="USD">123277000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000683"
      unitRef="USD">-28000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">-121715000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_ParentMember"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">1534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000686"
      unitRef="USD">434000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">1968000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000694"
      unitRef="USD">-20063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000695"
      unitRef="USD">-22209000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000700"
      unitRef="USD">1651000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000701"
      unitRef="USD">1535000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000704"
      unitRef="USD">45000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000706"
      unitRef="USD">2108000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000707"
      unitRef="USD">2957000</us-gaap:ShareBasedCompensation>
    <CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivatives
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000709"
      unitRef="USD">-2000</CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivatives>
    <CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivatives
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000710"
      unitRef="USD">-324000</CLDI:ChangeInFairValueOfOtherLiabilitiesAndDerivatives>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">244000</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">42000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000719"
      unitRef="USD">-1801000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">-1328000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">-628000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">-1993000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000725"
      unitRef="USD">-1854000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000727"
      unitRef="USD">-1380000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000728"
      unitRef="USD">-1017000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000730"
      unitRef="USD">-21293000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000731"
      unitRef="USD">-19694000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000736"
      unitRef="USD">120000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000737"
      unitRef="USD">16000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000739"
      unitRef="USD">50000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000742"
      unitRef="USD">-170000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000743"
      unitRef="USD">-16000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <CLDI:ProceedsFromPublicOfferings
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">9883000</CLDI:ProceedsFromPublicOfferings>
    <CLDI:ProceedsFromPublicOfferings
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000749"
      unitRef="USD">13946000</CLDI:ProceedsFromPublicOfferings>
    <CLDI:ProceedsFromWarrantInducementFinancing
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000751"
      unitRef="USD">4136000</CLDI:ProceedsFromWarrantInducementFinancing>
    <CLDI:ProceedsFromWarrantInducementFinancing
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000752"
      unitRef="USD">2140000</CLDI:ProceedsFromWarrantInducementFinancing>
    <CLDI:ProceedsFromRegisteredDirectOffering
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000754"
      unitRef="USD">3503000</CLDI:ProceedsFromRegisteredDirectOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000757"
      unitRef="USD">3268000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000758"
      unitRef="USD">3119000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000760"
      unitRef="USD">5000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000761"
      unitRef="USD">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000763"
      unitRef="USD">90000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000764"
      unitRef="USD">82000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000766"
      unitRef="USD">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000767"
      unitRef="USD">300000</us-gaap:RepaymentsOfNotesPayable>
    <CLDI:RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000769"
      unitRef="USD">200000</CLDI:RepaymentOfPrincipalOnRelatedPartyBridgeLoanPayable>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000772"
      unitRef="USD">846000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">1554000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000775"
      unitRef="USD">2000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <CLDI:ProceedsFromIssuanceOfNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">2000000</CLDI:ProceedsFromIssuanceOfNoncontrollingInterest>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000782"
      unitRef="USD">3000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000785"
      unitRef="USD">200000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000788"
      unitRef="USD">600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <CLDI:ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000791"
      unitRef="USD">1000000</CLDI:ProceedsFromIssuanceOfCommonSharesAndWarrantsPerSubscriptionAgreement>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">4803000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <CLDI:RepaymentOfConvertibleNotePayable
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">1500000</CLDI:RepaymentOfConvertibleNotePayable>
    <CLDI:PaymentOfDebtIssuanceCosts
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000800"
      unitRef="USD">9000</CLDI:PaymentOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000802"
      unitRef="USD">17459000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000803"
      unitRef="USD">27365000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000805"
      unitRef="USD">14000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000806"
      unitRef="USD">-13000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000808"
      unitRef="USD">-3990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000809"
      unitRef="USD">7642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000814"
      unitRef="USD">9809000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000815"
      unitRef="USD">2167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000817"
      unitRef="USD">5819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000818"
      unitRef="USD">9809000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">1265000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">140000</us-gaap:InterestPaidNet>
    <CLDI:CashPaidForIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000826"
      unitRef="USD">17000</CLDI:CashPaidForIncomeTaxes>
    <CLDI:CashPaidForIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">14000</CLDI:CashPaidForIncomeTaxes>
    <CLDI:DeemedDividendOnWarrants
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000832"
      unitRef="USD">-5673000</CLDI:DeemedDividendOnWarrants>
    <CLDI:DeemedDividendOnWarrants
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">-1671000</CLDI:DeemedDividendOnWarrants>
    <CLDI:MachineryAndEquipmentAcquiredThroughFinancingLeases
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">152000</CLDI:MachineryAndEquipmentAcquiredThroughFinancingLeases>
    <CLDI:FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000838"
      unitRef="USD">27000</CLDI:FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities>
    <CLDI:FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">-91000</CLDI:FinancingFeesIncludedInAccountsPayableAndAccruedLiabilities>
    <CLDI:IssuanceOfCommonStockPerConversionOfConvertibleNote
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">3071000</CLDI:IssuanceOfCommonStockPerConversionOfConvertibleNote>
    <CLDI:IssuanceOfConvertibleNoteForLegalSettlement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">1500000</CLDI:IssuanceOfConvertibleNoteForLegalSettlement>
    <CLDI:IssuanceOfCommonStockInLieuOfCashForServices
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">289000</CLDI:IssuanceOfCommonStockInLieuOfCashForServices>
    <CLDI:RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">80000</CLDI:RelatedPartyIssuanceOfCommonStockInLieuOfCashForServices>
    <CLDI:IssuanceOfCommonStockAndWarrantsForLegalSettlement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">308000</CLDI:IssuanceOfCommonStockAndWarrantsForLegalSettlement>
    <CLDI:DebtDiscountOnConvertibleNotes
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">109000</CLDI:DebtDiscountOnConvertibleNotes>
    <CLDI:IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000860"
      unitRef="USD">81000</CLDI:IssuanceOfCommonStockInLieuOfCashForSepaCommitmentFee>
    <CLDI:IssuanceOfRestrictedStockUnitsForLiabilitySettlement
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000863"
      unitRef="USD">133000</CLDI:IssuanceOfRestrictedStockUnitsForLiabilitySettlement>
    <us-gaap:NatureOfOperations contextRef="From2025-01-01to2025-12-31" id="Fact000865">&lt;p id="xdx_808_eus-gaap--NatureOfOperations_zyRs3sqVBFpl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82B_z6SIGxn0cgDl"&gt;Organization and Nature of Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 12, 2023, First Light Acquisition Group, Inc., a Delaware corporation (&#x201c;FLAG&#x201d;) consummated a series of transactions
that resulted in the merger of FLAG Merger Sub Inc., a Nevada corporation and a wholly-owned subsidiary of FLAG and Calidi Biotherapeutics.
Inc., a Nevada corporation (&#x201c;Calidi&#x201d; and the transactions the &#x201c;Business Combination&#x201d;). Following the consummation
of the Business Combination, FLAG was renamed &#x201c;Calidi Biotherapeutics, Inc.&#x201d; and Calidi was renamed &#x201c;Calidi Biotherapeutics
(Nevada), Inc. and became a wholly owned subsidiary of the Company. Unless the context otherwise requires, the &#x201c;Company&#x201d;
refers to Calidi Biotherapeutics, Inc., a Delaware corporation (f/k/a First Light Acquisition Group, Inc., a Delaware corporation) and
its consolidated subsidiaries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a biotechnology company that is pioneering the development of targeted therapies with the potential to
deliver genetic medicines to distal sites of disease. The Company&#x2019;s proprietary RedTail platform features an engineered
enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended
to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent
genetic medicine(s) to metastatic locations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations to date have focused on organization and staffing, business planning, raising capital, licensing, acquiring
and developing technology, establishing intellectual property portfolio, identifying potential product candidates and undertaking preclinical
studies, process development and manufacturing for preclinical and clinical trials. The Company&#x2019;s product candidates are subject
to long development cycles and the Company may be unsuccessful in its efforts to develop, obtain regulatory approval for or market its
product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited
to, possible failure of preclinical studies or clinical trials, the need to obtain marketing approval for its product candidates, development
by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government
regulations, the need to successfully commercialize and gain market acceptance of any of the Company&#x2019;s products that are approved
and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant
additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize
significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 10, 2024, the Company filed a First Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with
the Secretary of State of the State of Delaware to effect a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240710__20240710_zv1gDIQi7Eo4" title="Reverse stock split"&gt;1-for-10 reverse stock split&lt;/span&gt; of the shares of the Company&#x2019;s common
stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240710_z7bDjUWq4mf5" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share (&#x201c;Common Stock&#x201d;), effective on July 15, 2024 (the &#x201c;2024 Reverse Stock Split&#x201d;).
As a result of the 2024 Reverse Stock Split, every ten shares of issued and outstanding Common Stock were automatically combined into
one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as
a result of the 2024 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2024 Reverse Stock Split
were rounded up to the next whole number. The number of authorized shares of Common Stock under the Company&#x2019;s Second Amended and
Restated Certificate of Incorporation, as amended, remained unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2025, the Company filed a Second Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation,
as amended, with the Secretary of State of the State of Delaware to effect a &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250801__20250801_zwAdhSjdvUa6" title="Reverse stock split"&gt;1-for-12 reverse stock split&lt;/span&gt; of the shares of the Company&#x2019;s
Common Stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250801_zfRjzpOigpL2" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, effective on August 4, 2025 (the &#x201c;2025 Reverse Stock Split&#x201d;). As a result of the
2025 Reverse Stock Split, every twelve shares of issued and outstanding Common Stock were automatically combined into one issued and
outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the
2025 Reverse Stock Split, and any fractional shares that would otherwise have resulted from the 2025 Reverse Stock Split were rounded
up to the next whole number. The number of authorized shares of Common Stock under the Company&#x2019;s Second Amended and Restated Certificate
of Incorporation, as amended, remained unchanged. Trading of the Company&#x2019;s shares of Common Stock on the NYSE American, LLC commenced
on a split-adjusted basis on August 5, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references to share and per share amounts for all periods presented in the consolidated financial statements have been retrospectively
restated to reflect the 2024 Reverse Stock Split and 2025 Reverse Stock Split. All rights to receive shares of common stock under outstanding
securities, including but not limited to, warrants, options, and restricted stock units (&#x201c;RSUs&#x201d;) were adjusted to give effect
to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise price and the number of shares
of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of shares of
Common Stock reserved for future issuance under the Company&#x2019;s 2023 Equity Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement
of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has experienced recurring losses from operations and negative cash flows from operating activities, has a significant
accumulated deficit and expects to continue to incur net losses into the foreseeable future. The Company had an accumulated deficit
of $&lt;span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20251231_zk06nREp42Wf" title="Accumulated deficit"&gt;141.6&lt;/span&gt;
million at December 31, 2025. During the year ended December 31, 2025, the Company used $&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20250101__20251231_z2dAqc8NaTji" title="Net cash used in operating activities"&gt;21.3&lt;/span&gt;
million in cash for operating activities. As of December 31, 2025, the Company had cash of $&lt;span id="xdx_908_eus-gaap--Cash_iI_pn5n6_c20251231_zJ251Rwzisu9" title="Cash"&gt;5.6&lt;/span&gt;
million and restricted cash of $&lt;span id="xdx_907_eus-gaap--RestrictedCash_iI_pn5n6_c20251231_zFhtPyLf6uyf" title="Restricted cash"&gt;0.2&lt;/span&gt;
million. Management expects operating losses and negative cash flows to continue for the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
estimates that based on the Company&#x2019;s liquidity resources, there is substantial doubt about the Company&#x2019;s ability to continue
as a going concern within 12 months from the date of issuance of the consolidated financial statements. The accompanying consolidated
financial statements have been prepared on the basis of the Company continuing to operate in the normal course of business and does not
reflect any adjustments to the assets and liabilities related to the substantial doubt of its ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management&#x2019;s
ability to continue as a going concern is dependent upon its ability to raise additional funding. Management plans to raise additional
capital through public or private equity or debt financings to fulfill its operating and capital requirements for at least 12 months
from the date of the issuance of the financial statements. However, the Company may not be able to secure such financing in a timely
manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing
stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the
Company&#x2019;s existing stockholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
in economic conditions, including rising interest rates, public health issues, lower consumer confidence, volatile equity capital markets,
ongoing supply chain disruptions and the impacts of geopolitical conflicts, may affect the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-07-102024-07-10" id="Fact000867">1-for-10 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-07-10"
      decimals="INF"
      id="Fact000869"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-08-012025-08-01" id="Fact000871">1-for-12 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-08-01"
      decimals="INF"
      id="Fact000873"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000875"
      unitRef="USD">-141600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact000877"
      unitRef="USD">-21300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000879"
      unitRef="USD">5600000</us-gaap:Cash>
    <us-gaap:RestrictedCash
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000881"
      unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000883">&lt;p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_ztW1lsLHlSw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_823_zEJl2lTSmiz"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaPR1G4GYZla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements as of and for the year ended December 31, 2025 and 2024, have been prepared in accordance
with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and in conformity with accounting principles
generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards
Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zXJtSJ4WYRZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company include the accounts of its wholly owned subsidiary, Calidi Biotherapeutics
(Nevada), Inc., a company incorporated in the state of Nevada Calidi Biotherapeutics, Inc., StemVac GmbH (&#x201c;StemVac&#x201d;), a company
organized under the laws of Germany, Calidi Biotherapeutics Australia Pty Ltd (&#x201c;Calidi Australia&#x201d;), a wholly owned Australian
subsidiary, Nova Cell, Inc. (&#x201c;Nova Cell&#x201d;), a subsidiary incorporated in the state of Nevada, and Redtail Biopharma, Inc.
(&#x201c;Redtail&#x201d;), a wholly owned subsidiary incorporated in the state of Nevada. StemVac&#x2019;s primary operating activities
include process development and other research and development activities for the Company under a cost-plus intercompany development
agreement funded by the Company. Calidi Australia&#x2019;s principal purpose is for conducting certain parts of the SNV1 clinical enabling
activities in Australia. Nova Cell&#x2019;s primary operating activities were expanding potential uses of the Company&#x2019;s AAA stem
cell programs from oncology to other fields that require regenerative medical applications, such as cosmetics, orthopedics, auto-immune
diseases, and various other therapies. Redtail&#x2019;s primary operating activities will be to expand on the Company&#x2019;s systemic
antitumor virotherapies. Both Nova Cell and Redtail were incorporated in May 2024. As of December 31, 2025, the Company no longer has
an investment in Nova Cell. Redtail has had no activity to date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Variable
interest entities (&#x201c;VIEs&#x201d;) are legal entities that either have an insufficient amount of equity at risk for the entity to
finance its activities without additional subordinated financial support or, as a group, the holders of equity investment at risk lack
the ability to direct the entity&#x2019;s activities that most significantly impact economic performance through voting or similar rights,
or do not have the obligation to absorb the expected losses or the right to receive expected residual returns of the entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
all VIEs in which the Company is involved, it assesses whether it is the primary beneficiary on an ongoing basis. In circumstances where
the Company has both the power to direct the activities that most significantly impact the VIEs performance and the obligation to absorb
losses or the right to receive the benefits of the VIE that could be significant, the Company would conclude that it is the primary beneficiary
of the VIE, and the Company consolidates the VIE. In situations where the Company is not deemed to be the primary beneficiary of the
VIE, it does not consolidate the VIE and only recognizes the Company&#x2019;s interests in the VIE.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to October 27, 2025, the Company owned 75% of Nova Cell&#x2019;s fully-diluted capitalization, with the remaining 25% owned by a related
party investor (see Note 8). Under the rules of determining whether an entity was a VIE, the Company has a controlling financial interest
and is deemed to be the primary beneficiary of Nova Cell and therefore consolidated Nova Cell&#x2019;s financial statements. Since the
Company owns less than 100% of Nova Cell, the Company recorded net loss attributable to noncontrolling interest in its consolidated statements
of operations equal to the percentage of the economic or ownership interests retained in Nova Cell by the noncontrolling party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#x201c;SRA&#x201d;) and Material Purchase Agreement (the
&#x201c;MPA&#x201d; and together with the SRA the &#x201c;Agreements&#x201d;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zpwpUeXfXZM7" title="Shares sold and transferred"&gt;22,500,000&lt;/span&gt; of its shares of common stock in Nova Cell (the &#x201c;Repurchased Shares&#x201d;), representing an
ownership interest of &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_ztNgHQys4Usd" title="Ownership percentage"&gt;75&lt;/span&gt;%, back to Nova Cell, for a purchase price of $&lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zylGdAbm1u0i" title="Purchase price for repurchased shares"&gt;6.0&lt;/span&gt; million (the &#x201c;Purchase Price&#x201d;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $&lt;span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zJqT9AIilb5l" title="Promissory note, net cash offset"&gt;50&lt;/span&gt; thousand cash offset), resulting in an Indebtedness Cancellation Amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zepHBhXDlXm4" title="Indebtedness cancellation amount"&gt;1.2&lt;/span&gt; million,
and (B) the balance, by Deferred Consideration of $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zYzDxd2VApd2" title="Deferred consideration"&gt;4.8&lt;/span&gt; million payable after closing, as more fully described in the SRA. The Deferred Consideration is fully constrained until underlying uncertainties
are resolved, such that a significant reversal of cumulative consideration will not occur in future periods. Thus, the Company has not
recognized any Deferred Consideration as of December 31, 2025. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#x2019;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for
a fair presentation of the Company&#x2019;s financial condition and results of operations. All material intercompany accounts and transactions
have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--UseOfEstimates_zSrrKuYyyr3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the
reported amounts during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment,
including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing
of potential commercialization of acquired in-process intangible assets, applicable discount rates, comparable companies or transactions,
liquidity events, determination of fair value of financial instruments under the fair value option of accounting, assumptions related
to the going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived assets, key assumptions
in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred
income taxes, assumptions used to value common stock, debt and debt-like instruments, warrants, and stock-based awards and other equity
instruments. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4NZUyodDGPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zU8kxk7y1Rr8"&gt;Reclassification&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on our previously reported results of operations or accumulated deficit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zxDisQ28BcAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and Restricted Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity date of ninety days or less to be cash equivalents.
Cash and cash equivalents include cash in readily available checking, money market accounts and brokerage accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies cash that has contractual or legal restrictions imposed by third parties as restricted cash, which is restricted as
to withdrawal or use except for the specified purpose under a contract. The Company classifies restricted cash as either part of prepaids
and other current assets, or as part of other noncurrent assets, depending on the term and nature of the underlying contract with a financial
institution, which requires the Company to hold a fixed amount of funds in a restricted money market account as collateral to the financial
institution for the Company&#x2019;s corporate credit card program with that financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,591&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash included within prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash included within other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    cash and restricted cash as shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,819&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,809&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zONRAFzaFDbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zd0jFDmgJAZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Machinery
and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
and equipment are stated at cost, less accumulated depreciation, and includes assets purchased under financing leases. Depreciation is
computed using the straight-line method over the estimated useful lives of the assets, generally over a period of &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember_zhXYWkAGeupl" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember_z9vLH2fyzJn9" title="Estimated useful lives"&gt;5&lt;/span&gt; years. For equipment
purchased under financing leases, the Company depreciates the equipment based on the shorter of the useful life of the equipment or the
term of the lease, ranging from &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zRKXfPGmJur3" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zvVdMqTbK9ia" title="Estimated useful lives"&gt;5&lt;/span&gt; years, depending on the nature and classification of the financing lease. Maintenance and repairs
are expensed as incurred, whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed
of, the cost and the related accumulated depreciation are removed from the respective accounts, and any resulting gain or loss is reflected
in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zHTo1XpBpLmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. The Company determines if an arrangement is a lease at inception.
Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated
statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define
criteria to determine &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the
fair value of the underlying asset.&#x201d; For lease classification determination, the Company continues to use: (i) greater than or
equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset; and (ii) greater
than or equal to 90% to determine whether the present value of the sum of lease payments is substantially all of the fair value of the
underlying asset. The Company accounts for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
operating leases, the Company recognizes right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for leases with terms greater
than 12 months in the consolidated balance sheets, while leases with terms of 12 months or less are not capitalized. ROU assets represent
the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate commensurate with
the lease term, based on the information available at commencement date, in determining the present value of lease payments. The Company
uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes
lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will
exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company discloses
the amortization of ROU assets and operating lease payments as a net amount within &#x201c;Depreciation and amortization&#x201d; on the
consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
leases are included in machinery and equipment, and in finance lease liability, current and noncurrent, in the consolidated balance sheets.
The Company discloses the amortization of finance ROU assets within &#x201c;Depreciation and amortization&#x201d; on the consolidated statements
of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 11 for further disclosures in accordance with ASC 842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zrW6I3Z6DNB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the impairment of long-lived assets, which consist primarily of right-of-use assets for operating leases and machinery
and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not
be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected
undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to
the excess of the assets carrying value over its fair value is recorded in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCCQwj744sq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, which among other things, defines fair value, establishes a consistent framework
for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring
or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants. Accordingly, fair value is a market-based measurement determined based
on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820 establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value, which are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#x2009;1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#x2009;2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities;
    quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data
    for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#x2009;3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which
    require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation
hierarchy. If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities
with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2
inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. See Note 3 for fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zWqPIpln7jfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Derivative
Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives in accordance with ASC 815. The Company values its derivatives using the Black-Scholes option-pricing model or
other acceptable valuation models, as applicable, with the assistance of valuation specialists. Derivative instruments accounted for
as liabilities are valued at inception and subsequent valuation dates for each reporting period the derivative instrument remains outstanding.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at
each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates equity or liability classification for common stock warrants in accordance with ASC 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;, and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, and accounts for common stock warrants as liabilities if the warrant requires
net cash settlement, or gives the holder the option of net cash settlement, or it otherwise does not meet other equity classification
criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement,
or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified
as equity. Warrants that meet the definition of a derivative financial instrument and the equity scope exception in ASC 815-10-15-74(a)
are classified as equity, are initially measured at fair value on the grant date, and are not subject to remeasurement provided that
the Company continues to meet the criteria for equity classification. Warrants that are classified as liabilities are accounted for at
fair value and remeasured at each reporting date until exercise, expiration, or modification that results in equity classification. Any
change in the fair value of the warrants is recorded and presented under change in fair value of other liabilities and derivatives or
change in fair value of other liabilities and derivatives &#x2013; related party, as applicable, in the consolidated statements of operations.
The classification of warrants, including whether warrants should be recorded as liabilities or as equity, is re-assessed at the end
of each reporting period. The fair value of liability-classified warrants is determined using the Black-Scholes option-pricing model
(&#x201c;Black-Scholes model&#x201d;), which includes Level 3 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--DebtPolicyTextBlock_zRkBtHjrd9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
issuance costs incurred to obtain debt financings are deferred and are amortized over the term of the debt using the effective interest
method for all debt financings in which the fair value option has not been elected. Debt issuance costs on debt financings in which the
fair value option is not elected are recorded as a reduction to the carrying value of the debt and are amortized to interest expense
or interest expense &#x2013; related party, as applicable, in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
any debt financing in which the Company has elected the fair value option, any debt issuance costs associated with the debt financing
are immediately recognized in interest expense in the consolidated statements of operations and are not deferred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zJS5yJ5MWWkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has not generated any revenues from commercial products. The Company analyzes its research collaboration arrangements
to assess whether they are within the scope of ASC 808, &lt;i&gt;Collaborative Arrangements&lt;/i&gt;, to determine whether such arrangements involve
joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks
and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC
808, the Company assesses whether aspects of the arrangement are within the scope of other accounting literature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those
aspects of the arrangement within the scope of ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, by applying the following five-step
model: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract,
including whether they are distinct within the context of the contract; (iii) determination of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition
of revenue when, or as, performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within the
contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service
is distinct. The Company considers the intended benefit of the contract in assessing whether a promised good or service is separately
identifiable from other promises in the contract. If a promised good or service is not distinct, the Company combines that good or service
with other promised goods or services until it identifies a bundle of goods or services that is distinct. The Company may provide options
to additional goods or services in such arrangements exercisable at a customer&#x2019;s discretion. The Company assesses if these options
provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights
requires judgments related to the determination of the value of the underlying good and services to the optional price, if any, that
may be offered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the transaction price based on the amount of consideration that the Company expects to receive for transferring the
promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company then allocates
the transaction price to each performance obligation based on the relative standalone selling prices (&#x201c;SSP&#x201d;). SSP is determined
at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors,
including factors that were contemplated in negotiating the agreement with the customer and estimated costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will
be entitled by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated
variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which
it is probable that a significant reversal of cumulative revenue recognized will not occur. At each reporting period, the Company re-evaluates
the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate
of the overall transaction price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as)
the performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of
an output or input method. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in
the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve
months, deferred revenue will be classified in current liabilities. Revenue recognized, if any, prior to contractual billings made to
the customer, and if the Company expects to have an unconditional right to receive consideration in the next twelve months, these contractual
assets are included in other current assets in the Company&#x2019;s consolidated balance sheets. As of December 31, 2025, and December
31, 2024, there are no deferred revenue or contractual assets recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company further analyzes changes to contracts from customers to assess whether they qualify as a contract modification within the scope
of ASC 606. The Company considers that a contract modification exists when the parties to a contract approve a modification that either
creates new, or changes, existing enforceable rights and obligations of the parties to the contract. The Company considers that a contract
approval could be approved in writing, by oral agreement, or implied by customary practices. Whenever a change in the scope or price,
or both, of a contract is approved by the parties to the contract, the Company analyzes whether the contract modification qualifies as
a separate contract or a contract combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for a contract modification as a separate contract when (i) the scope of the contract increases because of the addition
of promised goods or services that are distinct and (ii) the price of the contract increases by an amount of consideration that reflects
the Company&#x2019;s SSP of the additional promised goods or services and any appropriate adjustments to that price to reflect the circumstances
of the particular contract. If the modification is not accounted for as a separate contract, the Company analyzes whether one of the
following should occur: (i) a termination of the original contract and the creation of a new contract, (ii) a cumulative catch-up adjustment
to the original contract, or (iii) a combination of (i) and (ii) in a way that faithfully reflects the economics of the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zlZPizkzwqT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, using the asset and liability method, which requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in
the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred taxes are determined based on the difference between
the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which
the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.
The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by analyzing
carryback capacity in periods with taxable income, reversal of existing taxable temporary differences and estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies. The Company&#x2019;s judgments regarding future taxable
income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If the
Company&#x2019;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased,
which may have a material impact on the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized, if any. First, the tax position must be evaluated to determine the likelihood that
it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company recognizes any interest and penalties related to uncertain
tax positions in income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2025 and 2024.
The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material
deviation for the year ended December 31, 2025 and 2024. The Company is currently unaware of any tax issues under review.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#x201c;CAMT&#x201d;) on adjusted
financial statement income on applicable corporations for taxable years beginning after December 31, 2022. The Company does not expect
the CAMT will have a material impact to its consolidated income tax provision (see Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted. The OBBBA included various provisions with multiple effective
dates, including, but not limited to, immediate expensing of domestic research and development expenditures and provision for immediate
expensing of machinery and equipment purchases. The OBBBA did not have a material impact on the Company&#x2019;s results of operations.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an
&#x201c;ownership change,&#x201d; which generally occurs if the percentage of the corporation&#x2019;s stock owned by 5% stockholders increases
by more than 50% over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income may be limited. The annual limitation may result in the expiration of net operating losses
before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31, 2021. There was an ownership
change identified on March 26, 2018 after the Company&#x2019;s Series A-2 preferred stock issuance. The Company has not undertaken a Section
382 study through December 31, 2025. The Company&#x2019;s ability to utilize their net operating loss carryforwards and other tax attributes
to offset future taxable income or tax liabilities may be limited as a result of ownership changes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--GovernmentGrantsPolicyTextBlock_zVDiXvjsr4Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Government
Grants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 27, 2022, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) approved the Company&#x2019;s application for
a CIRM grant for the Company&#x2019;s continued development of the SNV1 program. CIRM awarded the Company approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zJ2bjw4tI9jb"&gt;3.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of CIRM funding conditioned that the Company co-fund
approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember_zYGxk6lkwsUg"&gt;0.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million under the requirements of the CIRM application. On
December 28, 2022, the Company received the Notice of Award from CIRM for this grant. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
from the CIRM grant are recognized over the period necessary to match the related research and development expenses when it is probable
that the Company has complied with the CIRM conditions and will receive the proceeds pursuant to the milestones defined in the grant
as reimbursement of those expenditures. The CIRM grant proceeds, if any, received in advance of having incurred the related research
and development expenses are recorded in accrued expenses and other current liabilities and recognized as grant income included in other
income, net, on the Company&#x2019;s consolidated statements of operations when the related research and developments expenses are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025 and 2024, the Company recognized approximately $&lt;span id="xdx_900_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20251231_zMHspUb7PSTk" title="Grant income"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20241231_zYUqCnBJGwse" title="Grant income"&gt;0.2&lt;/span&gt; million, respectively, in grant income
in the accompanying consolidated statements of operations. The Company drew $&lt;span id="xdx_90E_ecustom--GrantsReceivableWithdrawn_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zwakLFuBX1w9" title="Government grants award withdrawn"&gt;3.1&lt;/span&gt; million in funds based on the operational
milestones defined in the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg1hra5jIUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and Development Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are expensed as incurred. Research and development expenses consist of costs incurred to discover, research
and develop drug candidates, including compensation-related expenses for research and development personnel, preclinical and clinical
activities, costs of manufacturing, overhead expenses including facilities and laboratory expenses, materials and supplies, amounts paid
to consultants and outside service providers, and depreciation and amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upfront
and annual license payments related to acquired technologies or technology licenses which have not yet reached technological feasibility
and have no alternative future use are also included in research and development expense in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zMk4V2F5MIgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries and compensation-related expenses for personnel in executive, finance and accounting,
operations, and administrative functions. General and administrative expenses also include fees for legal, patent
prosecution, legal settlements, consulting, accounting and audit services as well as insurance, outside service providers, direct and
allocated facility-related costs and depreciation and amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVnzNm7bwVwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
Currency Translation Adjustments and Other Comprehensive Income or Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;StemVac,
the Company&#x2019;s wholly owned subsidiary, is located and operates in Germany and its functional currency is the Euro. Calidi Australia,
the Company&#x2019;s wholly owned subsidiary, is located and operates in Australia and its functional currency is the Australian Dollar
(&#x201c;AUD&#x201d;). Accordingly, StemVac&#x2019;s and Calidi Australia&#x2019;s assets and liabilities are translated using respective
published exchange rates in effect at the consolidated balance sheet date. Expenses and cash flows are translated using respective approximate
weighted average exchange rates for the reporting period. Resulting foreign currency translation adjustments are recorded as other comprehensive
income or loss, net of tax, in the consolidated statements of comprehensive income or loss and included as a component of accumulated
other comprehensive income or loss on the consolidated balance sheets. For the year ended December 31, 2025 and 2024, comprehensive loss
includes such foreign currency translation adjustments and was insignificant for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_zGqMFuHbODu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
Currency Transaction Gains and Losses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
transactions denominated in currencies other than the U.S. dollar, the Company recognizes foreign currency transaction gains and losses
in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The Company&#x2019;s
foreign currency transaction gains and losses are principally generated by intercompany transfers to StemVac denominated in Euros to
pay for the research and development activities performed by StemVac under an intercompany development agreement with the Company. Furthermore,
the Company&#x2019;s foreign currency transaction gains and losses include intercompany transfers to Calidi Australia denominated in AUD
to pay for the research and development activities performed by Calidi Australia. These foreign currency remeasurement gains and losses
are included in other income, net, and were insignificant for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zTTPKIkGwNV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC
718, &lt;i&gt;Compensation &#x2014; Stock Compensation&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service condition is recognized in the period of the forfeiture. Generally,
and unless otherwise specified, the Company grants stock options with service-based only vesting conditions and records the expense for
these awards using the straight-line method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award
recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company estimates its expected stock
volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics
similar to the Company. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d;
method for awards that qualify as &#x201c;plain-vanilla&#x201d; options provided under Staff Accounting Bulletin, Topic 14 (&#x201c;SAB
Topic 14&#x201d;), as necessary. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at
the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero,
based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdSJcb0wxfOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net
Loss per share of Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that
determines earnings per share for the holders of the Company&#x2019;s shares of Common Stock and participating securities. However, the
participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation
of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating)
are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per
share of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock
method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share
attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common
stock shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic
net loss per share for the periods presented herein because common stock equivalent shares from the outstanding warrants, earnout shares,
stock option awards, restricted stock units, and contingently issuable warrants were antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BC_zguB1VYdIPX4" style="display: none"&gt;Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    for common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnout
    shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contingently
    issuable warrants&lt;sup id="xdx_F46_zns0PDiMhGnk"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,454&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0C_zcSEsseQ4qb1"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zAGEgYvJxZz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztqbLrgSIasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (or CODM), the Executive Management Team, consisting of the following individuals:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Financial Officer &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Scientific Officer and Head of Technical Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company views its operations and manages its business as a single reportable segment whose operations include the research, development
and commercialization efforts of platforms to potentiate oncolytic virus therapies on a consolidated basis, as further described in Note
1. The Company manages its Research and Development (&#x201c;R&amp;amp;D&#x201d;) activities on a consolidated basis. The Company expects to
generate future income from a combination of license fees and other upfront payments, funded R&amp;amp;D agreements, milestone payments,
product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing
of the successful commercialization of the Company&#x2019;s products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss is the measure of segment profit or loss used by the CODM in making decisions regarding resource allocation and evaluating financial
performance, which is also reported on the consolidated statements of operations and comprehensive loss. The CODM does not evaluate its
reportable segment using asset or liability information.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the year ended
December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B6_zKYWOXFybRQj" style="display: none"&gt;Schedule
of Operating Segment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OPERATING
    EXPENSES&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salaries
    and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,561&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10,249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,324&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,951&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consulting&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,059&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,578&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
    and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,136&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    &amp;amp; research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(386&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of other liabilities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items &lt;sup id="xdx_F44_zsI0gVfAWZ5g"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,408&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
    tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NET
    LOSS&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20,063&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0A_zCZCERNSjsG7"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zjzQiw5SfnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQmoR4lv77yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &lt;i&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/i&gt;. The ASU requires disaggregated
information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid.
The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for
annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 for the annual
period beginning January 1, 2025, on a prospective basis. The adoption of this guidance did not have a significant
impact on the Company&#x2019;s financial statements, other than disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_ecustom--NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_z6lkr7Di3Vfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement &lt;/i&gt;and in January 2025, issued ASU 2025-01 &lt;i&gt;Income Statement&#x2014;Reporting
Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/i&gt; to clarify the effective
date of ASU 2024-03. ASU 2024-03 requires the disaggregation of certain costs and expenses in the notes to the financial statements to
provide enhanced transparency into the expense captions presented on the face of the income statement. The ASU is effective for annual
periods beginning after December 15, 2026 and for interim reporting periods within annual reporting periods beginning after December
15, 2027. The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU No. 2025-06, &lt;i&gt;Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40): Targeted
Improvements to the Accounting for Internal-Use Software&lt;/i&gt;. ASU 2025-06 updates the accounting for internal-use software by replacing
former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software
only when management has authorized and committed funding and it is probable that the project will be completed and the software will
be used to perform the intended function. ASU 2025-06 also supersedes website development cost guidance, moving it to ASC 350-40. These
amendments are effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting ASU 2025-06.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU No. 2025-07, &lt;i&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic
606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/i&gt;.
ASU 2025-07 refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration
under ASC 606. This ASU is effective for annual periods and interim periods beginning after December 15, 2026, with early adoption permitted.
The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently evaluating
the impact of adopting ASU 2025-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2025, the FASB issued ASU No. 2025-09, &lt;i&gt;Derivatives and Hedging (Topic 815): Hedge Accounting Improvements&lt;/i&gt;. ASU 2025-09
clarifies certain aspects of the guidance on hedge accounting and addresses several incremental hedge accounting issues arising from
global reference rate reform. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within
those annual reporting periods The Company is currently evaluating the impact of adopting ASU 2025-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU No. 2025-11, &lt;i&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements,&lt;/i&gt; which is intended to
improve the navigability of the guidance in ASC 270 and clarify when it applies. Under the amendments, an entity is subject to ASC 270
if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content of such
financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since
the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027, and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2025-11.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85F_zmLcQ6ZXYX28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000885">&lt;p id="xdx_84F_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaPR1G4GYZla" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements as of and for the year ended December 31, 2025 and 2024, have been prepared in accordance
with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and in conformity with accounting principles
generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards
Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000887">&lt;p id="xdx_847_eus-gaap--ConsolidationPolicyTextBlock_zXJtSJ4WYRZ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Principles
of Consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company include the accounts of its wholly owned subsidiary, Calidi Biotherapeutics
(Nevada), Inc., a company incorporated in the state of Nevada Calidi Biotherapeutics, Inc., StemVac GmbH (&#x201c;StemVac&#x201d;), a company
organized under the laws of Germany, Calidi Biotherapeutics Australia Pty Ltd (&#x201c;Calidi Australia&#x201d;), a wholly owned Australian
subsidiary, Nova Cell, Inc. (&#x201c;Nova Cell&#x201d;), a subsidiary incorporated in the state of Nevada, and Redtail Biopharma, Inc.
(&#x201c;Redtail&#x201d;), a wholly owned subsidiary incorporated in the state of Nevada. StemVac&#x2019;s primary operating activities
include process development and other research and development activities for the Company under a cost-plus intercompany development
agreement funded by the Company. Calidi Australia&#x2019;s principal purpose is for conducting certain parts of the SNV1 clinical enabling
activities in Australia. Nova Cell&#x2019;s primary operating activities were expanding potential uses of the Company&#x2019;s AAA stem
cell programs from oncology to other fields that require regenerative medical applications, such as cosmetics, orthopedics, auto-immune
diseases, and various other therapies. Redtail&#x2019;s primary operating activities will be to expand on the Company&#x2019;s systemic
antitumor virotherapies. Both Nova Cell and Redtail were incorporated in May 2024. As of December 31, 2025, the Company no longer has
an investment in Nova Cell. Redtail has had no activity to date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Variable
interest entities (&#x201c;VIEs&#x201d;) are legal entities that either have an insufficient amount of equity at risk for the entity to
finance its activities without additional subordinated financial support or, as a group, the holders of equity investment at risk lack
the ability to direct the entity&#x2019;s activities that most significantly impact economic performance through voting or similar rights,
or do not have the obligation to absorb the expected losses or the right to receive expected residual returns of the entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
all VIEs in which the Company is involved, it assesses whether it is the primary beneficiary on an ongoing basis. In circumstances where
the Company has both the power to direct the activities that most significantly impact the VIEs performance and the obligation to absorb
losses or the right to receive the benefits of the VIE that could be significant, the Company would conclude that it is the primary beneficiary
of the VIE, and the Company consolidates the VIE. In situations where the Company is not deemed to be the primary beneficiary of the
VIE, it does not consolidate the VIE and only recognizes the Company&#x2019;s interests in the VIE.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to October 27, 2025, the Company owned 75% of Nova Cell&#x2019;s fully-diluted capitalization, with the remaining 25% owned by a related
party investor (see Note 8). Under the rules of determining whether an entity was a VIE, the Company has a controlling financial interest
and is deemed to be the primary beneficiary of Nova Cell and therefore consolidated Nova Cell&#x2019;s financial statements. Since the
Company owns less than 100% of Nova Cell, the Company recorded net loss attributable to noncontrolling interest in its consolidated statements
of operations equal to the percentage of the economic or ownership interests retained in Nova Cell by the noncontrolling party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#x201c;SRA&#x201d;) and Material Purchase Agreement (the
&#x201c;MPA&#x201d; and together with the SRA the &#x201c;Agreements&#x201d;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zpwpUeXfXZM7" title="Shares sold and transferred"&gt;22,500,000&lt;/span&gt; of its shares of common stock in Nova Cell (the &#x201c;Repurchased Shares&#x201d;), representing an
ownership interest of &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_ztNgHQys4Usd" title="Ownership percentage"&gt;75&lt;/span&gt;%, back to Nova Cell, for a purchase price of $&lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zylGdAbm1u0i" title="Purchase price for repurchased shares"&gt;6.0&lt;/span&gt; million (the &#x201c;Purchase Price&#x201d;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $&lt;span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zJqT9AIilb5l" title="Promissory note, net cash offset"&gt;50&lt;/span&gt; thousand cash offset), resulting in an Indebtedness Cancellation Amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zepHBhXDlXm4" title="Indebtedness cancellation amount"&gt;1.2&lt;/span&gt; million,
and (B) the balance, by Deferred Consideration of $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zYzDxd2VApd2" title="Deferred consideration"&gt;4.8&lt;/span&gt; million payable after closing, as more fully described in the SRA. The Deferred Consideration is fully constrained until underlying uncertainties
are resolved, such that a significant reversal of cumulative consideration will not occur in future periods. Thus, the Company has not
recognized any Deferred Consideration as of December 31, 2025. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#x2019;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for
a fair presentation of the Company&#x2019;s financial condition and results of operations. All material intercompany accounts and transactions
have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-10-272025-10-27_custom_NovaCellMember"
      decimals="INF"
      id="Fact000889"
      unitRef="Shares">22500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-10-27_custom_NovaCellMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Pure">0.75</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-10-272025-10-27_custom_NovaCellMember"
      decimals="-6"
      id="Fact000893"
      unitRef="USD">6000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset
      contextRef="AsOf2024-09-17_custom_NovaCellMember"
      decimals="-3"
      id="Fact000895"
      unitRef="USD">50000</us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2024-09-172024-09-17_custom_NovaCellMember"
      decimals="-5"
      id="Fact000897"
      unitRef="USD">1200000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-09-17_custom_NovaCellMember"
      decimals="-5"
      id="Fact000899"
      unitRef="USD">4800000</us-gaap:NotesPayable>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-12-31" id="Fact000901">&lt;p id="xdx_840_eus-gaap--UseOfEstimates_zSrrKuYyyr3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the
reported amounts during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment,
including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections, timing
of potential commercialization of acquired in-process intangible assets, applicable discount rates, comparable companies or transactions,
liquidity events, determination of fair value of financial instruments under the fair value option of accounting, assumptions related
to the going concern assessments, allocation of direct and indirect expenses, useful lives associated with long-lived assets, key assumptions
in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred
income taxes, assumptions used to value common stock, debt and debt-like instruments, warrants, and stock-based awards and other equity
instruments. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2025-01-01to2025-12-31" id="Fact000903">&lt;p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4NZUyodDGPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zU8kxk7y1Rr8"&gt;Reclassification&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on our previously reported results of operations or accumulated deficit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2025-01-01to2025-12-31" id="Fact000905">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zxDisQ28BcAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and Restricted Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity date of ninety days or less to be cash equivalents.
Cash and cash equivalents include cash in readily available checking, money market accounts and brokerage accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies cash that has contractual or legal restrictions imposed by third parties as restricted cash, which is restricted as
to withdrawal or use except for the specified purpose under a contract. The Company classifies restricted cash as either part of prepaids
and other current assets, or as part of other noncurrent assets, depending on the term and nature of the underlying contract with a financial
institution, which requires the Company to hold a fixed amount of funds in a restricted money market account as collateral to the financial
institution for the Company&#x2019;s corporate credit card program with that financial institution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,591&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash included within prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash included within other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    cash and restricted cash as shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,819&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,809&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zONRAFzaFDbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000907">&lt;p id="xdx_892_eus-gaap--ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_z3QzcS5bHWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides a reconciliation of cash and restricted cash reported within the balance sheet dates that comprise the total
of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BF_zZ4LKuuvuf7d" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_z1FI7PpNRPh5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20241231_zV0GkZnWgBfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Cash_iI_pn3n3_maCCERCzBVq_zrlVVvtiIbij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,591&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maCCERCzBVq_zcEhGUmlMEjc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash included within prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RestrictedCashAndCashEquivalentsNoncurrent_iI_pn3n3_maCCERCzBVq_zCwPrfzHjsy6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash included within other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;119&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;118&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_pn3n3_mtCCERCzBVq_zWKWSJnOwR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    cash and restricted cash as shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,819&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,809&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">5600000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000910"
      unitRef="USD">9591000</us-gaap:Cash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000913"
      unitRef="USD">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000915"
      unitRef="USD">119000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">118000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000918"
      unitRef="USD">5819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000919"
      unitRef="USD">9809000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000921">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zd0jFDmgJAZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Machinery
and Equipment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
and equipment are stated at cost, less accumulated depreciation, and includes assets purchased under financing leases. Depreciation is
computed using the straight-line method over the estimated useful lives of the assets, generally over a period of &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember_zhXYWkAGeupl" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember_z9vLH2fyzJn9" title="Estimated useful lives"&gt;5&lt;/span&gt; years. For equipment
purchased under financing leases, the Company depreciates the equipment based on the shorter of the useful life of the equipment or the
term of the lease, ranging from &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zRKXfPGmJur3" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20251231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zvVdMqTbK9ia" title="Estimated useful lives"&gt;5&lt;/span&gt; years, depending on the nature and classification of the financing lease. Maintenance and repairs
are expensed as incurred, whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed
of, the cost and the related accumulated depreciation are removed from the respective accounts, and any resulting gain or loss is reflected
in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_srt_MinimumMember"
      id="Fact000923">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_srt_MaximumMember"
      id="Fact000925">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_srt_MinimumMember_us-gaap_EquipmentMember"
      id="Fact000927">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-12-31_srt_MaximumMember_us-gaap_EquipmentMember"
      id="Fact000929">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000931">&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_zHTo1XpBpLmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. The Company determines if an arrangement is a lease at inception.
Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated
statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define
criteria to determine &#x201c;major part of remaining economic life of the underlying asset&#x201d; and &#x201c;substantially all of the
fair value of the underlying asset.&#x201d; For lease classification determination, the Company continues to use: (i) greater than or
equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset; and (ii) greater
than or equal to 90% to determine whether the present value of the sum of lease payments is substantially all of the fair value of the
underlying asset. The Company accounts for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
operating leases, the Company recognizes right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for leases with terms greater
than 12 months in the consolidated balance sheets, while leases with terms of 12 months or less are not capitalized. ROU assets represent
the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising
from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments
over the lease term. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate commensurate with
the lease term, based on the information available at commencement date, in determining the present value of lease payments. The Company
uses the implicit rate when it is readily determinable. The operating lease ROU asset also includes any lease payments made and excludes
lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will
exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company discloses
the amortization of ROU assets and operating lease payments as a net amount within &#x201c;Depreciation and amortization&#x201d; on the
consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finance
leases are included in machinery and equipment, and in finance lease liability, current and noncurrent, in the consolidated balance sheets.
The Company discloses the amortization of finance ROU assets within &#x201c;Depreciation and amortization&#x201d; on the consolidated statements
of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 11 for further disclosures in accordance with ASC 842.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000933">&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zrW6I3Z6DNB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses the impairment of long-lived assets, which consist primarily of right-of-use assets for operating leases and machinery
and equipment, whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not
be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected
undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss equal to
the excess of the assets carrying value over its fair value is recorded in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000935">&lt;p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zCCQwj744sq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, which among other things, defines fair value, establishes a consistent framework
for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring
or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer
a liability in an orderly transaction between market participants. Accordingly, fair value is a market-based measurement determined based
on assumptions that market participants would use in pricing an asset or liability. The fair value hierarchy requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
820 establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value, which are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#x2009;1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#x2009;2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inputs
    other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities;
    quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data
    for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#x2009;3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable
    inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which
    require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
quoted market prices are available in active markets, the fair value of assets and liabilities is estimated within Level 1 of the valuation
hierarchy. If quoted prices are not available, then fair values are estimated by using pricing models, quoted prices of assets and liabilities
with similar characteristics, or discounted cash flows, within Level 2 of the valuation hierarchy. In cases where Level 1 or Level 2
inputs are not available, the fair values are estimated by using inputs within Level 3 of the hierarchy. See Note 3 for fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000937">&lt;p id="xdx_84A_eus-gaap--DerivativesPolicyTextBlock_zWqPIpln7jfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Derivative
Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify
as embedded derivatives in accordance with ASC 815. The Company values its derivatives using the Black-Scholes option-pricing model or
other acceptable valuation models, as applicable, with the assistance of valuation specialists. Derivative instruments accounted for
as liabilities are valued at inception and subsequent valuation dates for each reporting period the derivative instrument remains outstanding.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is reassessed at
each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates equity or liability classification for common stock warrants in accordance with ASC 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;, and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, and accounts for common stock warrants as liabilities if the warrant requires
net cash settlement, or gives the holder the option of net cash settlement, or it otherwise does not meet other equity classification
criteria. The Company accounts for common stock warrants as equity if the contract requires physical settlement or net physical settlement,
or if the Company has the option of physical settlement or net physical settlement and the warrants meet the requirements to be classified
as equity. Warrants that meet the definition of a derivative financial instrument and the equity scope exception in ASC 815-10-15-74(a)
are classified as equity, are initially measured at fair value on the grant date, and are not subject to remeasurement provided that
the Company continues to meet the criteria for equity classification. Warrants that are classified as liabilities are accounted for at
fair value and remeasured at each reporting date until exercise, expiration, or modification that results in equity classification. Any
change in the fair value of the warrants is recorded and presented under change in fair value of other liabilities and derivatives or
change in fair value of other liabilities and derivatives &#x2013; related party, as applicable, in the consolidated statements of operations.
The classification of warrants, including whether warrants should be recorded as liabilities or as equity, is re-assessed at the end
of each reporting period. The fair value of liability-classified warrants is determined using the Black-Scholes option-pricing model
(&#x201c;Black-Scholes model&#x201d;), which includes Level 3 inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000939">&lt;p id="xdx_847_eus-gaap--DebtPolicyTextBlock_zRkBtHjrd9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Debt
issuance costs incurred to obtain debt financings are deferred and are amortized over the term of the debt using the effective interest
method for all debt financings in which the fair value option has not been elected. Debt issuance costs on debt financings in which the
fair value option is not elected are recorded as a reduction to the carrying value of the debt and are amortized to interest expense
or interest expense &#x2013; related party, as applicable, in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
any debt financing in which the Company has elected the fair value option, any debt issuance costs associated with the debt financing
are immediately recognized in interest expense in the consolidated statements of operations and are not deferred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000941">&lt;p id="xdx_84F_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zJS5yJ5MWWkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has not generated any revenues from commercial products. The Company analyzes its research collaboration arrangements
to assess whether they are within the scope of ASC 808, &lt;i&gt;Collaborative Arrangements&lt;/i&gt;, to determine whether such arrangements involve
joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks
and rewards that are dependent on the commercial success of such activities. To the extent the arrangement is within the scope of ASC
808, the Company assesses whether aspects of the arrangement are within the scope of other accounting literature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the Company concludes that some or all aspects of the arrangement represent a transaction with a customer, the Company accounts for those
aspects of the arrangement within the scope of ASC 606, &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;, by applying the following five-step
model: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract,
including whether they are distinct within the context of the contract; (iii) determination of the transaction price, including the constraint
on variable consideration; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition
of revenue when, or as, performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
a contract is determined to be within the scope of ASC 606 at inception, the Company assesses the goods or services promised within the
contract, determines which of those goods and services are performance obligations, and assesses whether each promised good or service
is distinct. The Company considers the intended benefit of the contract in assessing whether a promised good or service is separately
identifiable from other promises in the contract. If a promised good or service is not distinct, the Company combines that good or service
with other promised goods or services until it identifies a bundle of goods or services that is distinct. The Company may provide options
to additional goods or services in such arrangements exercisable at a customer&#x2019;s discretion. The Company assesses if these options
provide a material right to the customer and if so, they are considered performance obligations. The identification of material rights
requires judgments related to the determination of the value of the underlying good and services to the optional price, if any, that
may be offered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the transaction price based on the amount of consideration that the Company expects to receive for transferring the
promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company then allocates
the transaction price to each performance obligation based on the relative standalone selling prices (&#x201c;SSP&#x201d;). SSP is determined
at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied.
In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors,
including factors that were contemplated in negotiating the agreement with the customer and estimated costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will
be entitled by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated
variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which
it is probable that a significant reversal of cumulative revenue recognized will not occur. At each reporting period, the Company re-evaluates
the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate
of the overall transaction price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as)
the performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of
an output or input method. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in
the Company&#x2019;s consolidated balance sheets. If the related performance obligation is expected to be satisfied within the next twelve
months, deferred revenue will be classified in current liabilities. Revenue recognized, if any, prior to contractual billings made to
the customer, and if the Company expects to have an unconditional right to receive consideration in the next twelve months, these contractual
assets are included in other current assets in the Company&#x2019;s consolidated balance sheets. As of December 31, 2025, and December
31, 2024, there are no deferred revenue or contractual assets recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company further analyzes changes to contracts from customers to assess whether they qualify as a contract modification within the scope
of ASC 606. The Company considers that a contract modification exists when the parties to a contract approve a modification that either
creates new, or changes, existing enforceable rights and obligations of the parties to the contract. The Company considers that a contract
approval could be approved in writing, by oral agreement, or implied by customary practices. Whenever a change in the scope or price,
or both, of a contract is approved by the parties to the contract, the Company analyzes whether the contract modification qualifies as
a separate contract or a contract combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for a contract modification as a separate contract when (i) the scope of the contract increases because of the addition
of promised goods or services that are distinct and (ii) the price of the contract increases by an amount of consideration that reflects
the Company&#x2019;s SSP of the additional promised goods or services and any appropriate adjustments to that price to reflect the circumstances
of the particular contract. If the modification is not accounted for as a separate contract, the Company analyzes whether one of the
following should occur: (i) a termination of the original contract and the creation of a new contract, (ii) a cumulative catch-up adjustment
to the original contract, or (iii) a combination of (i) and (ii) in a way that faithfully reflects the economics of the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000943">&lt;p id="xdx_84C_eus-gaap--IncomeTaxPolicyTextBlock_zlZPizkzwqT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, using the asset and liability method, which requires
the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in
the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred taxes are determined based on the difference between
the consolidated financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which
the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.
The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation
allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by analyzing
carryback capacity in periods with taxable income, reversal of existing taxable temporary differences and estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies. The Company&#x2019;s judgments regarding future taxable
income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If the
Company&#x2019;s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased,
which may have a material impact on the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to
determine the amount of tax benefit to be recognized, if any. First, the tax position must be evaluated to determine the likelihood that
it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained,
the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount
of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. The Company recognizes any interest and penalties related to uncertain
tax positions in income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2025 and 2024.
The Company is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material
deviation for the year ended December 31, 2025 and 2024. The Company is currently unaware of any tax issues under review.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#x201c;CAMT&#x201d;) on adjusted
financial statement income on applicable corporations for taxable years beginning after December 31, 2022. The Company does not expect
the CAMT will have a material impact to its consolidated income tax provision (see Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 4, 2025, the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted. The OBBBA included various provisions with multiple effective
dates, including, but not limited to, immediate expensing of domestic research and development expenditures and provision for immediate
expensing of machinery and equipment purchases. The OBBBA did not have a material impact on the Company&#x2019;s results of operations.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an
&#x201c;ownership change,&#x201d; which generally occurs if the percentage of the corporation&#x2019;s stock owned by 5% stockholders increases
by more than 50% over a three-year period, the corporation&#x2019;s ability to use its pre-change NOL carryforwards and other pre-change
tax attributes to offset its post-change income may be limited. The annual limitation may result in the expiration of net operating losses
before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31, 2021. There was an ownership
change identified on March 26, 2018 after the Company&#x2019;s Series A-2 preferred stock issuance. The Company has not undertaken a Section
382 study through December 31, 2025. The Company&#x2019;s ability to utilize their net operating loss carryforwards and other tax attributes
to offset future taxable income or tax liabilities may be limited as a result of ownership changes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <CLDI:GovernmentGrantsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000945">&lt;p id="xdx_849_ecustom--GovernmentGrantsPolicyTextBlock_zVDiXvjsr4Y5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Government
Grants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 27, 2022, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) approved the Company&#x2019;s application for
a CIRM grant for the Company&#x2019;s continued development of the SNV1 program. CIRM awarded the Company approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zJ2bjw4tI9jb"&gt;3.1&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of CIRM funding conditioned that the Company co-fund
approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromOtherOperatingActivities_pn5n6_c20221027__20221027__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember_zYGxk6lkwsUg"&gt;0.8&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million under the requirements of the CIRM application. On
December 28, 2022, the Company received the Notice of Award from CIRM for this grant. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Proceeds
from the CIRM grant are recognized over the period necessary to match the related research and development expenses when it is probable
that the Company has complied with the CIRM conditions and will receive the proceeds pursuant to the milestones defined in the grant
as reimbursement of those expenditures. The CIRM grant proceeds, if any, received in advance of having incurred the related research
and development expenses are recorded in accrued expenses and other current liabilities and recognized as grant income included in other
income, net, on the Company&#x2019;s consolidated statements of operations when the related research and developments expenses are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025 and 2024, the Company recognized approximately $&lt;span id="xdx_900_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20251231_zMHspUb7PSTk" title="Grant income"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--GrantsReceivableCurrent_iI_pn5n6_c20241231_zYUqCnBJGwse" title="Grant income"&gt;0.2&lt;/span&gt; million, respectively, in grant income
in the accompanying consolidated statements of operations. The Company drew $&lt;span id="xdx_90E_ecustom--GrantsReceivableWithdrawn_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--GovernmentGrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CaliforniaInstituteForRegenerativeMedicineMember_zwakLFuBX1w9" title="Government grants award withdrawn"&gt;3.1&lt;/span&gt; million in funds based on the operational
milestones defined in the grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CLDI:GovernmentGrantsPolicyTextBlock>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="From2022-10-272022-10-27_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember"
      decimals="-5"
      id="Fact000946"
      unitRef="USD">3100000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="From2022-10-272022-10-27_custom_GovernmentGrantsMember"
      decimals="-5"
      id="Fact000947"
      unitRef="USD">800000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:GrantsReceivableCurrent
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact000949"
      unitRef="USD">50000000000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact000951"
      unitRef="USD">200000</us-gaap:GrantsReceivableCurrent>
    <CLDI:GrantsReceivableWithdrawn
      contextRef="AsOf2025-12-31_custom_GovernmentGrantsMember_custom_CaliforniaInstituteForRegenerativeMedicineMember"
      decimals="-5"
      id="Fact000953"
      unitRef="USD">3100000</CLDI:GrantsReceivableWithdrawn>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2025-01-01to2025-12-31" id="Fact000955">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zg1hra5jIUx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Research
and Development Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are expensed as incurred. Research and development expenses consist of costs incurred to discover, research
and develop drug candidates, including compensation-related expenses for research and development personnel, preclinical and clinical
activities, costs of manufacturing, overhead expenses including facilities and laboratory expenses, materials and supplies, amounts paid
to consultants and outside service providers, and depreciation and amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upfront
and annual license payments related to acquired technologies or technology licenses which have not yet reached technological feasibility
and have no alternative future use are also included in research and development expense in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000957">&lt;p id="xdx_844_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zMk4V2F5MIgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries and compensation-related expenses for personnel in executive, finance and accounting,
operations, and administrative functions. General and administrative expenses also include fees for legal, patent
prosecution, legal settlements, consulting, accounting and audit services as well as insurance, outside service providers, direct and
allocated facility-related costs and depreciation and amortization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000959">&lt;p id="xdx_841_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zVnzNm7bwVwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
Currency Translation Adjustments and Other Comprehensive Income or Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;StemVac,
the Company&#x2019;s wholly owned subsidiary, is located and operates in Germany and its functional currency is the Euro. Calidi Australia,
the Company&#x2019;s wholly owned subsidiary, is located and operates in Australia and its functional currency is the Australian Dollar
(&#x201c;AUD&#x201d;). Accordingly, StemVac&#x2019;s and Calidi Australia&#x2019;s assets and liabilities are translated using respective
published exchange rates in effect at the consolidated balance sheet date. Expenses and cash flows are translated using respective approximate
weighted average exchange rates for the reporting period. Resulting foreign currency translation adjustments are recorded as other comprehensive
income or loss, net of tax, in the consolidated statements of comprehensive income or loss and included as a component of accumulated
other comprehensive income or loss on the consolidated balance sheets. For the year ended December 31, 2025 and 2024, comprehensive loss
includes such foreign currency translation adjustments and was insignificant for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <CLDI:ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000961">&lt;p id="xdx_847_ecustom--ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock_zGqMFuHbODu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
Currency Transaction Gains and Losses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
transactions denominated in currencies other than the U.S. dollar, the Company recognizes foreign currency transaction gains and losses
in the consolidated statements of operations and classifies the gain or loss based on the nature of the item that generated it. The Company&#x2019;s
foreign currency transaction gains and losses are principally generated by intercompany transfers to StemVac denominated in Euros to
pay for the research and development activities performed by StemVac under an intercompany development agreement with the Company. Furthermore,
the Company&#x2019;s foreign currency transaction gains and losses include intercompany transfers to Calidi Australia denominated in AUD
to pay for the research and development activities performed by Calidi Australia. These foreign currency remeasurement gains and losses
are included in other income, net, and were insignificant for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CLDI:ForeignCurrencyTransactionGainsAndLossesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000963">&lt;p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zTTPKIkGwNV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC
718, &lt;i&gt;Compensation &#x2014; Stock Compensation&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant
and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the
respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized
for an award that is forfeited because of a failure to satisfy a service condition is recognized in the period of the forfeiture. Generally,
and unless otherwise specified, the Company grants stock options with service-based only vesting conditions and records the expense for
these awards using the straight-line method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award
recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company estimates its expected stock
volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics
similar to the Company. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d;
method for awards that qualify as &#x201c;plain-vanilla&#x201d; options provided under Staff Accounting Bulletin, Topic 14 (&#x201c;SAB
Topic 14&#x201d;), as necessary. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at
the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero,
based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000965">&lt;p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdSJcb0wxfOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Net
Loss per share of Common Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that
determines earnings per share for the holders of the Company&#x2019;s shares of Common Stock and participating securities. However, the
participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation
of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating)
are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per
share of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted
net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock
method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share
attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common
stock shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic
net loss per share for the periods presented herein because common stock equivalent shares from the outstanding warrants, earnout shares,
stock option awards, restricted stock units, and contingently issuable warrants were antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BC_zguB1VYdIPX4" style="display: none"&gt;Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    for common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnout
    shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contingently
    issuable warrants&lt;sup id="xdx_F46_zns0PDiMhGnk"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,454&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0C_zcSEsseQ4qb1"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zAGEgYvJxZz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000967">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zC6kXWHIA6xd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company reported a net loss attributable to common stockholders for all periods presented herein, the following common stock equivalents
were excluded from the computation of diluted net loss per share of Common Stock for the years ended December 31, 2025 and 2024, because
including them would have been antidilutive (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BC_zguB1VYdIPX4" style="display: none"&gt;Schedule
of Computation of Diluted Net Loss per Common Share including Antidilutive&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250101__20251231_z0UnLaChYtg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zoZbdxWO7MK9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zvFQmVrgvjVb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    for common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;911&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_znXU22BPqWC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
    stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--EarnoutSharesMember_zVHv5omxvEql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnout
    shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zihNj5GbsfYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ContingentlyIssuableWarrantMember_zymK3dShWPo" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contingently
    issuable warrants&lt;sup id="xdx_F46_zns0PDiMhGnk"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zXFaklXo27e2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,454&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0C_zcSEsseQ4qb1"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zkT018ENk4Mi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000969"
      unitRef="Shares">5026000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact000970"
      unitRef="Shares">911000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact000972"
      unitRef="Shares">278000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact000973"
      unitRef="Shares">77000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-12-31_custom_EarnoutSharesMember"
      decimals="-3"
      id="Fact000975"
      unitRef="Shares">150000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_custom_EarnoutSharesMember"
      decimals="-3"
      id="Fact000976"
      unitRef="Shares">150000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact000979"
      unitRef="Shares">2000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact000984"
      unitRef="Shares">5454000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact000985"
      unitRef="Shares">1140000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000988">&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ztqbLrgSIasf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker (or CODM), the Executive Management Team, consisting of the following individuals:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Executive Officer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Financial Officer &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Scientific Officer and Head of Technical Operations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company views its operations and manages its business as a single reportable segment whose operations include the research, development
and commercialization efforts of platforms to potentiate oncolytic virus therapies on a consolidated basis, as further described in Note
1. The Company manages its Research and Development (&#x201c;R&amp;amp;D&#x201d;) activities on a consolidated basis. The Company expects to
generate future income from a combination of license fees and other upfront payments, funded R&amp;amp;D agreements, milestone payments,
product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing
of the successful commercialization of the Company&#x2019;s products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss is the measure of segment profit or loss used by the CODM in making decisions regarding resource allocation and evaluating financial
performance, which is also reported on the consolidated statements of operations and comprehensive loss. The CODM does not evaluate its
reportable segment using asset or liability information.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the year ended
December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B6_zKYWOXFybRQj" style="display: none"&gt;Schedule
of Operating Segment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OPERATING
    EXPENSES&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salaries
    and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,561&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10,249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,324&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,951&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consulting&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,059&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,578&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
    and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,136&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    &amp;amp; research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(386&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of other liabilities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items &lt;sup id="xdx_F44_zsI0gVfAWZ5g"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,408&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
    tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NET
    LOSS&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20,063&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0A_zCZCERNSjsG7"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zjzQiw5SfnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact000990">&lt;p id="xdx_89B_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zS5gwqhiTe15" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents selected financial information with respect to the Company&#x2019;s single operating segment for the year ended
December 31, 2025 and 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B6_zKYWOXFybRQj" style="display: none"&gt;Schedule
of Operating Segment&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLSwrehf5IWe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDdJNaMDshl6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OPERATING
    EXPENSES&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--SalariesWagesAndOfficersCompensation_iN_di_msNILzRFG_zgm5jAbJRAE2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salaries
    and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9,561&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10,249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--GeneralInsuranceExpense_iN_di_msNILzRFG_zU560PcKHCE" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LegalFees_iN_di_msNILzRFG_zleitBVc1hj8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,324&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,951&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--Consulting_iN_di_msNILzRFG_zxQtfcn4rgA" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consulting&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,059&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,578&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--RentAndMaintenance_iN_di_msNILzRFG_zFg2jv6k2E9d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
    and maintenance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,136&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ClinicalResearchAndDevelopment_iN_di_msNILzRFG_zyX7Bz6uSTP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clinical
    &amp;amp; research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,353&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Depreciation_iN_di_msNILzRFG_zYuPgRewFCH1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(386&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives_iN_di_msNILzRFG_zZyxasFWWGXi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of other liabilities and derivatives&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;324&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--OtherSegmentItems_iN_di_msNILzRFG_zPNgWDye79V5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items &lt;sup id="xdx_F44_zsI0gVfAWZ5g"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,801&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,408&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzRFG_zIKQFbUwnIX7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
    tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzRFG_zd9hgLUyouFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NET
    LOSS&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20,063&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,209&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;sup id="xdx_F0A_zCZCERNSjsG7"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zp03qZu3anj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000992"
      unitRef="USD">9561000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000993"
      unitRef="USD">10249000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000995"
      unitRef="USD">801000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000996"
      unitRef="USD">1442000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:LegalFees
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">1324000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact000999"
      unitRef="USD">1951000</us-gaap:LegalFees>
    <CLDI:Consulting
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001001"
      unitRef="USD">2059000</CLDI:Consulting>
    <CLDI:Consulting
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001002"
      unitRef="USD">1578000</CLDI:Consulting>
    <CLDI:RentAndMaintenance
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001004"
      unitRef="USD">2358000</CLDI:RentAndMaintenance>
    <CLDI:RentAndMaintenance
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001005"
      unitRef="USD">2136000</CLDI:RentAndMaintenance>
    <CLDI:ClinicalResearchAndDevelopment
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001007"
      unitRef="USD">1760000</CLDI:ClinicalResearchAndDevelopment>
    <CLDI:ClinicalResearchAndDevelopment
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001008"
      unitRef="USD">1353000</CLDI:ClinicalResearchAndDevelopment>
    <us-gaap:Depreciation
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001010"
      unitRef="USD">386000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001011"
      unitRef="USD">402000</us-gaap:Depreciation>
    <CLDI:ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001013"
      unitRef="USD">-2000</CLDI:ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives>
    <CLDI:ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001014"
      unitRef="USD">-324000</CLDI:ChangeInFairValueOfDebtOtherLiabilitiesAndDerivatives>
    <CLDI:OtherSegmentItems
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001016"
      unitRef="USD">1801000</CLDI:OtherSegmentItems>
    <CLDI:OtherSegmentItems
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001017"
      unitRef="USD">3408000</CLDI:OtherSegmentItems>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001019"
      unitRef="USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001020"
      unitRef="USD">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001022"
      unitRef="USD">-20063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      id="Fact001023"
      unitRef="USD">-22209000</us-gaap:NetIncomeLoss>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001026">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQmoR4lv77yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Adopted Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU No. 2023-09, &lt;i&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/i&gt;. The ASU requires disaggregated
information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid.
The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for
annual financial statements that have not yet been issued or made available for issuance. The Company adopted ASU 2023-09 for the annual
period beginning January 1, 2025, on a prospective basis. The adoption of this guidance did not have a significant
impact on the Company&#x2019;s financial statements, other than disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <CLDI:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001028">&lt;p id="xdx_846_ecustom--NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock_z6lkr7Di3Vfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU No. 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of Income Statement &lt;/i&gt;and in January 2025, issued ASU 2025-01 &lt;i&gt;Income Statement&#x2014;Reporting
Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/i&gt; to clarify the effective
date of ASU 2024-03. ASU 2024-03 requires the disaggregation of certain costs and expenses in the notes to the financial statements to
provide enhanced transparency into the expense captions presented on the face of the income statement. The ASU is effective for annual
periods beginning after December 15, 2026 and for interim reporting periods within annual reporting periods beginning after December
15, 2027. The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU No. 2025-06, &lt;i&gt;Intangibles - Goodwill and Other - Internal Use Software (Subtopic 350-40): Targeted
Improvements to the Accounting for Internal-Use Software&lt;/i&gt;. ASU 2025-06 updates the accounting for internal-use software by replacing
former stage-based rules with a principles-based framework. Entities will now capitalize costs associated with internal-use software
only when management has authorized and committed funding and it is probable that the project will be completed and the software will
be used to perform the intended function. ASU 2025-06 also supersedes website development cost guidance, moving it to ASC 350-40. These
amendments are effective for interim and annual periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting ASU 2025-06.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2025, the FASB issued ASU No. 2025-07, &lt;i&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic
606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/i&gt;.
ASU 2025-07 refines the scope of derivative accounting under Topic 815 and clarifies the treatment of share-based noncash consideration
under ASC 606. This ASU is effective for annual periods and interim periods beginning after December 15, 2026, with early adoption permitted.
The guidance may be applied on a prospective or retrospective basis and early adoption is permitted. The Company is currently evaluating
the impact of adopting ASU 2025-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2025, the FASB issued ASU No. 2025-09, &lt;i&gt;Derivatives and Hedging (Topic 815): Hedge Accounting Improvements&lt;/i&gt;. ASU 2025-09
clarifies certain aspects of the guidance on hedge accounting and addresses several incremental hedge accounting issues arising from
global reference rate reform. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within
those annual reporting periods The Company is currently evaluating the impact of adopting ASU 2025-07.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2025, the FASB issued ASU No. 2025-11, &lt;i&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements,&lt;/i&gt; which is intended to
improve the navigability of the guidance in ASC 270 and clarify when it applies. Under the amendments, an entity is subject to ASC 270
if it provides interim financial statements and notes in accordance with GAAP. ASU 2025-11 also addresses the form and content of such
financial statements, interim disclosures requirements, and establishes a principle under which an entity must disclose events since
the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim reporting
periods within annual reporting periods beginning after December 15, 2027, and early adoption is permitted. The Company is currently
evaluating the impact of adopting ASU 2025-11.&lt;/span&gt;&lt;/p&gt;

</CLDI:NewAccountingPronouncementsIssuedButNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001030">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z1LDIbnIuC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span id="xdx_823_zLaSFEvqW13c"&gt;Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zQoGr3VpRVdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, inclusive of
related party components, as of December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BB_zYWW0lu5GxOi" style="display: none"&gt;Schedule
of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWmx7Qc7H0S6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziASyE6z4iTd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW2Ceu4JuOo5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231_zeUrRR3X8Fn7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z01xipjyNeTe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash held in money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1035"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zvdICRvuY924" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    assets, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1040"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zzyhoyvStrb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1046"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zpu1J8KaEUW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zz40boSVcyfb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    warrant liabilities, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEM6Xl7O87W4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zv0XyOqlwQpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm97BMO9HOq3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_z1QWjKyP15Vi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zeruEnVVYona" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash held in money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1061"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_z0qTfmSaeADe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
    Purchase Agreement Derivative Asset included in other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zs7M1XCLaB07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    assets, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zpQ1D7GVfiJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1076"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zlFUkdiOREOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zRhOUeGFqiH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    warrant liabilities, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zyNvNTz385E6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s financial instruments consist of cash, prepaid expenses and other current assets, accounts payable, accrued expenses,
and other current liabilities. The carrying value of these financial instruments is generally considered to approximate their fair values
because of the short-term nature of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zqIlEF0l2MT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of valued instruments for the year ended December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B2_zSY7A1YXlaXe" style="display: none"&gt;Schedule
of Changes in Fair Value of Level 3 Valued Instruments&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zg9NawD3tghe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
    &lt;br/&gt; Purchase&lt;br/&gt; Agreement&lt;br/&gt; Derivative &lt;br/&gt; Asset, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRgqIL5PVQJj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    &lt;br/&gt; Warrants, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zG3wQ6iduqC9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    &lt;br/&gt; warrants, at &lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zfHUyIt0RyOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zNIOi0IXJTnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zumwr3PJozah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1099"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of valued instruments for the years ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zWfJAwNvg2se" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
    &lt;br/&gt; Purchase&lt;br/&gt; Agreement&lt;br/&gt; Derivative &lt;br/&gt; Asset, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRXHCZ66zKMc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    &lt;br/&gt; Warrants, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_z0wHOCgTVSRe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    &lt;br/&gt; warrants, at &lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zchLF49GxBX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(230&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;575&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zRRZPdfYd0Oe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, beginning&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(230&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;575&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zjfr9zexva2d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(465&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zwfpjT1pTduh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zFX2CuEjR6m3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_z7BIDe6h7Sq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001032">&lt;p id="xdx_89D_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zQoGr3VpRVdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, inclusive of
related party components, as of December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BB_zYWW0lu5GxOi" style="display: none"&gt;Schedule
of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zWmx7Qc7H0S6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziASyE6z4iTd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zW2Ceu4JuOo5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231_zeUrRR3X8Fn7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_z01xipjyNeTe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash held in money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1035"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1036"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zvdICRvuY924" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    assets, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1040"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zzyhoyvStrb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1046"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zpu1J8KaEUW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1051"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zz40boSVcyfb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    warrant liabilities, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEM6Xl7O87W4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zv0XyOqlwQpc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm97BMO9HOq3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_z1QWjKyP15Vi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zeruEnVVYona" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    cash held in money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1061"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByAssetClassAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_z0qTfmSaeADe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
    Purchase Agreement Derivative Asset included in other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1065"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_pn3n3_zs7M1XCLaB07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    assets, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;218&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PublicWarrantsMember_zpQ1D7GVfiJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1076"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantsMember_zlFUkdiOREOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1079"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1081"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_iI_pn3n3_zRhOUeGFqiH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    warrant liabilities, at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1086"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;128&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact001034"
      unitRef="USD">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact001037"
      unitRef="USD">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001039"
      unitRef="USD">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001042"
      unitRef="USD">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001044"
      unitRef="USD">99000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001047"
      unitRef="USD">99000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001050"
      unitRef="USD">16000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001052"
      unitRef="USD">16000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001054"
      unitRef="USD">99000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact001055"
      unitRef="USD">16000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001057"
      unitRef="USD">115000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact001059"
      unitRef="USD">218000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact001062"
      unitRef="USD">218000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      decimals="-3"
      id="Fact001066"
      unitRef="USD">11000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      decimals="-3"
      id="Fact001067"
      unitRef="USD">11000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">218000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001071"
      unitRef="USD">11000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001072"
      unitRef="USD">229000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001077"
      unitRef="USD">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001080"
      unitRef="USD">18000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001082"
      unitRef="USD">18000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001084"
      unitRef="USD">110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="Fact001085"
      unitRef="USD">18000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001087"
      unitRef="USD">128000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001089">&lt;p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zqIlEF0l2MT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of valued instruments for the year ended December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B2_zSY7A1YXlaXe" style="display: none"&gt;Schedule
of Changes in Fair Value of Level 3 Valued Instruments&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zg9NawD3tghe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
    &lt;br/&gt; Purchase&lt;br/&gt; Agreement&lt;br/&gt; Derivative &lt;br/&gt; Asset, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRgqIL5PVQJj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    &lt;br/&gt; Warrants, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zG3wQ6iduqC9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    &lt;br/&gt; warrants, at &lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zfHUyIt0RyOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zNIOi0IXJTnl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zumwr3PJozah" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1099"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of valued instruments for the years ended December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ForwardPurchaseAgreementDerivativeAssetMember_zWfJAwNvg2se" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forward
    &lt;br/&gt; Purchase&lt;br/&gt; Agreement&lt;br/&gt; Derivative &lt;br/&gt; Asset, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PublicWarrantsMember_zRXHCZ66zKMc" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    &lt;br/&gt; Warrants, at&lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_z0wHOCgTVSRe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    &lt;br/&gt; warrants, at &lt;br/&gt; fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zchLF49GxBX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(230&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;575&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iS_pn3n3_zRRZPdfYd0Oe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, beginning&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(230&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;575&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_zjfr9zexva2d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;219&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(465&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zwfpjT1pTduh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_iE_pn3n3_zFX2CuEjR6m3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance, ending&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046"
      decimals="-3"
      id="Fact001091"
      unitRef="USD">-11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember11025046"
      decimals="-3"
      id="Fact001092"
      unitRef="USD">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember11025062"
      decimals="-3"
      id="Fact001093"
      unitRef="USD">18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2025-01-012025-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      decimals="-3"
      id="Fact001095"
      unitRef="USD">11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2025-01-012025-12-31_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001096"
      unitRef="USD">-11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2025-01-012025-12-31_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001097"
      unitRef="USD">-2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2025-12-31_custom_PublicWarrantsMember11025078"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">99000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2025-12-31_custom_PrivateWarrantsMember11025078"
      decimals="-3"
      id="Fact001101"
      unitRef="USD">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">-230000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">575000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001105"
      unitRef="USD">96000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      decimals="-3"
      id="Fact001107"
      unitRef="USD">-230000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001108"
      unitRef="USD">575000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-12-31_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001109"
      unitRef="USD">96000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember"
      decimals="-3"
      id="Fact001111"
      unitRef="USD">219000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_PublicWarrantsMember"
      decimals="-3"
      id="Fact001112"
      unitRef="USD">-465000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_PrivateWarrantsMember"
      decimals="-3"
      id="Fact001113"
      unitRef="USD">-78000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046"
      decimals="-3"
      id="Fact001115"
      unitRef="USD">-11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember11025046"
      decimals="-3"
      id="Fact001116"
      unitRef="USD">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember11025062"
      decimals="-3"
      id="Fact001117"
      unitRef="USD">18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_ForwardPurchaseAgreementDerivativeAssetMember11025046"
      decimals="-3"
      id="Fact001119"
      unitRef="USD">-11000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember11025046"
      decimals="-3"
      id="Fact001120"
      unitRef="USD">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsMember11025062"
      decimals="-3"
      id="Fact001121"
      unitRef="USD">18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001123">&lt;p id="xdx_804_eus-gaap--SupplementalBalanceSheetDisclosuresTextBlock_zcwJ5yn88KLc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_827_zfRVJFQVjqfl"&gt;Selected Balance Sheet Components&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued
Expenses and Other Current Liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zl3HwUvYkCt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and December 31, 2024, accrued expenses and other current liabilities were comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B5_zC74RHRU2xGk" style="display: none"&gt;Schedule
of Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_z6RE0nZO3Mid" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zldBaOSXryB2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedCompensation_iI_pn3n3_maAPAOAzybc_zt0oc8Dog6d3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;884&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,344&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AccruedVendorAndOtherExpenses_iI_pn3n3_maAPAOAzybc_z9diIryQWrKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    vendor and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;922&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;994&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzybc_zlQaTtvTOSQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,806&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,338&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zgOEPSV6HWB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 11 for additional commitments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Prepaid
Expenses and Other Current Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3rDlS7PfK6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and December 31, 2024, prepaid expenses and other current assets were comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B6_zpYPMGNGVhLb" style="display: none"&gt;Schedule
of Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zL5CzaHNFOna" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zcIA2pAU61j5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PrepaidExpenses_iI_maPECz6zE_zlhRYKAUiHV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maPECz6zE_zQmOQo8zUkO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;302&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECz6zE_zE0XWeQF3IP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;234&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECz6zE_zE1XdS9Ryd86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;656&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;636&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zlTGJIuafnTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001125">&lt;p id="xdx_893_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zl3HwUvYkCt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and December 31, 2024, accrued expenses and other current liabilities were comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B5_zC74RHRU2xGk" style="display: none"&gt;Schedule
of Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20251231_z6RE0nZO3Mid" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zldBaOSXryB2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedCompensation_iI_pn3n3_maAPAOAzybc_zt0oc8Dog6d3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;884&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,344&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AccruedVendorAndOtherExpenses_iI_pn3n3_maAPAOAzybc_z9diIryQWrKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    vendor and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;922&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;994&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAOAzybc_zlQaTtvTOSQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,806&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,338&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <CLDI:AccruedCompensation
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001127"
      unitRef="USD">884000</CLDI:AccruedCompensation>
    <CLDI:AccruedCompensation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001128"
      unitRef="USD">1344000</CLDI:AccruedCompensation>
    <CLDI:AccruedVendorAndOtherExpenses
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001130"
      unitRef="USD">922000</CLDI:AccruedVendorAndOtherExpenses>
    <CLDI:AccruedVendorAndOtherExpenses
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001131"
      unitRef="USD">994000</CLDI:AccruedVendorAndOtherExpenses>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001133"
      unitRef="USD">1806000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001134"
      unitRef="USD">2338000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001136">&lt;p id="xdx_899_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3rDlS7PfK6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and December 31, 2024, prepaid expenses and other current assets were comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B6_zpYPMGNGVhLb" style="display: none"&gt;Schedule
of Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20251231_zL5CzaHNFOna" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20241231_zcIA2pAU61j5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--PrepaidExpenses_iI_maPECz6zE_zlhRYKAUiHV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;120&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;99&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maPECz6zE_zQmOQo8zUkO3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;302&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPECz6zE_zE0XWeQF3IP4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;234&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;249&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPECz6zE_zE1XdS9Ryd86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;656&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;636&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <CLDI:PrepaidExpenses
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001138"
      unitRef="USD">120000</CLDI:PrepaidExpenses>
    <CLDI:PrepaidExpenses
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001139"
      unitRef="USD">99000</CLDI:PrepaidExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001141"
      unitRef="USD">302000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001142"
      unitRef="USD">288000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">234000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001145"
      unitRef="USD">249000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001147"
      unitRef="USD">656000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001148"
      unitRef="USD">636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001150">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmitJninqEB9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82A_zmL0qBXF1oTk"&gt;Machinery and Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMMjj6pnDrvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and December 31, 2024, machinery and equipment, net, was comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BF_zHnlGiayBZi9" style="display: none"&gt;Schedule
of Machinery and Equipment, Net&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20251231_zRQ7iMay90Vl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zv9ULlTW7Ivf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzw2F_znFRuAZbJnjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,575&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,224&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzw2F_zV4tavT1WV07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accumulated
    depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,794&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzw2F_zjoGaAtrKfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;781&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zjh4hp5LMYLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
and amortization expense amounted to approximately $&lt;span id="xdx_906_eus-gaap--OtherDepreciationAndAmortization_pn5n6_c20250101__20251231_zF4SKmnZ00X6" title="Depreciation and amortization expense"&gt;&lt;span id="xdx_901_eus-gaap--OtherDepreciationAndAmortization_pn5n6_c20240101__20241231_zQObO9v270tb" title="Depreciation and amortization expense"&gt;0.4&lt;/span&gt;&lt;/span&gt; million for the year ended December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001152">&lt;p id="xdx_89E_eus-gaap--PropertyPlantAndEquipmentTextBlock_zMMjj6pnDrvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and December 31, 2024, machinery and equipment, net, was comprised of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BF_zHnlGiayBZi9" style="display: none"&gt;Schedule
of Machinery and Equipment, Net&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20251231_zRQ7iMay90Vl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241231_zv9ULlTW7Ivf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzw2F_znFRuAZbJnjd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,575&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,224&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzw2F_zV4tavT1WV07" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accumulated
    depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,794&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzw2F_zjoGaAtrKfOg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;781&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001154"
      unitRef="USD">2575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001155"
      unitRef="USD">2224000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001157"
      unitRef="USD">1794000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001158"
      unitRef="USD">1355000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001160"
      unitRef="USD">781000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001161"
      unitRef="USD">869000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001163"
      unitRef="USD">400000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001165"
      unitRef="USD">400000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001167">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFuzCwFJpwIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_828_zyZaQmqXs1Ki"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zP1Mzp0wj211" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the various significant related party transactions and investments in the Company for the periods presented
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BD_zIbKqbn9Ytxg" style="display: none"&gt;Schedule
of Related Party Transactions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
    Party&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Description
    of investment or transaction&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231_ztr38XZpt7Q1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zMA6Of7icfB8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_zEWw10UjFlga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    A and Director E&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_fKDEp_zlWLI0MH4aBe" title="Description of investment or transaction"&gt;Current
    term notes payable, net of discount, including accrued interest&lt;/span&gt;&lt;sup&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,702&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_zR1WtBFW8XJ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F and relative of Officer A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_fKDIp_zeQY78y2Fs4j" title="Description of investment or transaction"&gt;Accounts
    payable and accrued expenses&lt;/span&gt;&lt;sup&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zesQnfyIvbod" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_fKDMp_z61oDwq1ner8" title="Description of investment or transaction"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zgvbYUb0hpj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_fKDQp_zgg77HjNBqEc" title="Description of investment or transaction"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(4) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;434&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_zo2OQ8scPVpk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_fKDUp_zKdMvxbE8em3" title="Description of investment or transaction"&gt;Advisory
    services included in accrued expenses&lt;/span&gt;&lt;sup&gt;(5) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1191"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_zHvV1LI0GJD5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_fKDYp_zjClDrqjEaUd" title="Description of investment or transaction"&gt;Lease
    guaranty&lt;/span&gt;&lt;sup&gt;(6) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;186&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_zt5rXNeaWwY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_fKDcp_zDjXix5Ogoqg" title="Related party transaction description"&gt;Other
    liabilities&lt;/span&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;638&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_zZIlg6Z8RiZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F and Director A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_fKDgp_zkWtDGrB7dA3" title="Related party transaction description"&gt;Warrant
    liability&lt;/span&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_zdk3Fg2goI0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Relative
    of Officer A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_fKDkp_zDM26tRjdZMe" title="Related party transaction description"&gt;Loan
    payable&lt;/span&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z6ZAQI2hMW8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Officer
    G&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_fKDEwKQ_____zAnBEno9S9Bd" title="Related party transaction description"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(10)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zBTlKfG8gpQh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Officer
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_fKDExKQ_____z5loD8rJKBDi" title="Related party transaction description"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(11)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1222"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zLyvD6ZMzaX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company
    A related to Director G&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zPHkzA353yU1" title="Related party transaction description"&gt;Accounts
    payable and accrued expenses&lt;/span&gt;&lt;sup&gt;(12)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1227"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z1HHAGVCWrwl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related Party&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zTM4EfyjiDKj" title="Related party transaction description"&gt;Accounts
    payable and accrued expenses&lt;/span&gt;&lt;sup&gt;(12)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"&gt;&lt;span id="xdx_F01_ztnzOa04RqCj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zSe82xXNXjfc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49" title="Related party note payable"&gt;2.7&lt;/span&gt; million. See Note 7 for further details.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F03_zeZVcS9Dqklc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_z6UoF5ncbVI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj" title="Legal fees"&gt;48&lt;/span&gt; thousand
and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04" title="Legal fees"&gt;38&lt;/span&gt; thousand for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"&gt;&lt;span id="xdx_F06_zwaUnSY2Q1O7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_ziDxrKiIKwTh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#x201c;Release Agreement&#x201d;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb" title="Loans"&gt;0.5&lt;/span&gt;
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1" title="Loan outstanding"&gt;0.2&lt;/span&gt;
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2" title="Consulting pay"&gt;10,000&lt;/span&gt;
    per month during the transition period. The agreement terminated on December 31, 2025 and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j" title="Expenses"&gt;0.1&lt;/span&gt;
    million was expensed under the agreement. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F06_zCwfBc4wtI2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zoKQxvM2cIa1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#x201c;Ng Agreement&#x201d;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck" title="Annual salary"&gt;0.5&lt;/span&gt; million and a signing bonus of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4" title="Bonus payable"&gt;0.3&lt;/span&gt; million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    June 23, 2023, the Company entered into a Separation and Release Agreement with Mr. Ng which included a severance accrual and accrued
    interest as of December 31, 2024 (see Note 11). The lump sum payment and accrued interest was settled in January 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0B_zb3j8Q9Vyk9i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zmweNB3Xu47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6" title="Monthly advisory fee"&gt;9,166&lt;/span&gt; per month not to exceed $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5" title="Advisory fee"&gt;0.1&lt;/span&gt; million per annum, accrued
    and payable upon the Company raising $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf" title="Equity proceeds"&gt;10&lt;/span&gt; million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F03_zLX2J83iRIF8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zQ7YPE1vTlO8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#x201c;Guaranty&#x201d;) up to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P" title="Guaranty of lease amount"&gt;0.9&lt;/span&gt; million to the lessor for the Company&#x2019;s future performance under
    the San Diego Lease agreement. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok" title="Lease agreement description"&gt;As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.&lt;/span&gt; As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z" title="Lease payment due"&gt;14,000&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6" title="Lease payment due"&gt;0.2&lt;/span&gt; million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0D_zW1ETmqueNwd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zSwPhnNeBrE5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc" title="Deferred compensation"&gt;0.5&lt;/span&gt; million,
    which was paid in January 2025 (see Note 11). The $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj" title="Notes payable"&gt;0.5&lt;/span&gt; million note bore interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4" title="Note bears interest percentage"&gt;24&lt;/span&gt;% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne" title="Note bears interest percentage"&gt;14&lt;/span&gt;% per annum. The deferred compensation and advisory fees were settled in
    January 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zrzyrqrQZdM3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zZ51rLXa3lQe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
    Note 8 for disclosures around Warrants. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F04_z9c88oDDUFK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_z5IDR1Bfps6b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8" title="Officer loans payable"&gt;0.2&lt;/span&gt; million, which bears
    interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe" title="Officer loans payable"&gt;12&lt;/span&gt;%. The loan was settled in full in January 2025. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zIlcmPGCq4w" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zj5egqFCgyC6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2" title="Bonus payable"&gt;0.1&lt;/span&gt; million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc" title="Separation pay"&gt;0.2&lt;/span&gt; million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#x2019;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9" title="Severance pay"&gt;0.1&lt;/span&gt; million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0D_zdfDOmomXt94" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zFrDDUS3lLNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1" title="Bonus payable"&gt;0.1&lt;/span&gt; million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6" title="Severance pay"&gt;0.2&lt;/span&gt; million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#x2019;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf" title="Severance pay"&gt;0.2&lt;/span&gt; million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"&gt;&lt;span id="xdx_F07_zNo8J4qqMSEh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(12)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_z3zx8HiEP4Cj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#x201c;CRO&#x201d;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl" title="Accounts payable and accrued expenses"&gt;0.1&lt;/span&gt;
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h" title="Expenses related to services"&gt;0.6&lt;/span&gt;
    million in expenses related to services from Company A.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zd3sjtf5v6f9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001169">&lt;p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zP1Mzp0wj211" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the various significant related party transactions and investments in the Company for the periods presented
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BD_zIbKqbn9Ytxg" style="display: none"&gt;Schedule
of Related Party Transactions&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
    Party&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Description
    of investment or transaction&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20251231_ztr38XZpt7Q1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zMA6Of7icfB8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_zEWw10UjFlga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    A and Director E&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAAndDirectorEMember_fKDEp_zlWLI0MH4aBe" title="Description of investment or transaction"&gt;Current
    term notes payable, net of discount, including accrued interest&lt;/span&gt;&lt;sup&gt;(1) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,702&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_zR1WtBFW8XJ5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F and relative of Officer A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndRelativeOfOfficerAMember_fKDIp_zeQY78y2Fs4j" title="Description of investment or transaction"&gt;Accounts
    payable and accrued expenses&lt;/span&gt;&lt;sup&gt;(2) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zesQnfyIvbod" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_fKDMp_z61oDwq1ner8" title="Description of investment or transaction"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zgvbYUb0hpj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    D&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_fKDQp_zgg77HjNBqEc" title="Description of investment or transaction"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(4) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;434&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_zo2OQ8scPVpk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAOneMember_fKDUp_zKdMvxbE8em3" title="Description of investment or transaction"&gt;Advisory
    services included in accrued expenses&lt;/span&gt;&lt;sup&gt;(5) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1191"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_zHvV1LI0GJD5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFOneMember_fKDYp_zjClDrqjEaUd" title="Description of investment or transaction"&gt;Lease
    guaranty&lt;/span&gt;&lt;sup&gt;(6) &lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;186&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_zt5rXNeaWwY2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorATwoMember_fKDcp_zDjXix5Ogoqg" title="Related party transaction description"&gt;Other
    liabilities&lt;/span&gt;&lt;sup&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;638&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_zZIlg6Z8RiZ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    F and Director A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFAndDirectorAMember_fKDgp_zkWtDGrB7dA3" title="Related party transaction description"&gt;Warrant
    liability&lt;/span&gt;&lt;sup&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_zdk3Fg2goI0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Relative
    of Officer A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember_fKDkp_zDM26tRjdZMe" title="Related party transaction description"&gt;Loan
    payable&lt;/span&gt;&lt;sup&gt;(9)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z6ZAQI2hMW8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Officer
    G&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_fKDEwKQ_____zAnBEno9S9Bd" title="Related party transaction description"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(10)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;65&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zBTlKfG8gpQh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Officer
    A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_fKDExKQ_____z5loD8rJKBDi" title="Related party transaction description"&gt;Severance
    accrual&lt;/span&gt;&lt;sup&gt;(11)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1222"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zLyvD6ZMzaX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company
    A related to Director G&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zPHkzA353yU1" title="Related party transaction description"&gt;Accounts
    payable and accrued expenses&lt;/span&gt;&lt;sup&gt;(12)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1227"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z1HHAGVCWrwl" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related Party&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_fKDEyKQ_____zTM4EfyjiDKj" title="Related party transaction description"&gt;Accounts
    payable and accrued expenses&lt;/span&gt;&lt;sup&gt;(12)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in"&gt;&lt;span id="xdx_F01_ztnzOa04RqCj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zSe82xXNXjfc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49" title="Related party note payable"&gt;2.7&lt;/span&gt; million. See Note 7 for further details.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F03_zeZVcS9Dqklc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_z6UoF5ncbVI7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj" title="Legal fees"&gt;48&lt;/span&gt; thousand
and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04" title="Legal fees"&gt;38&lt;/span&gt; thousand for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"&gt;&lt;span id="xdx_F06_zwaUnSY2Q1O7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_ziDxrKiIKwTh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#x201c;Release Agreement&#x201d;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb" title="Loans"&gt;0.5&lt;/span&gt;
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1" title="Loan outstanding"&gt;0.2&lt;/span&gt;
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2" title="Consulting pay"&gt;10,000&lt;/span&gt;
    per month during the transition period. The agreement terminated on December 31, 2025 and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j" title="Expenses"&gt;0.1&lt;/span&gt;
    million was expensed under the agreement. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F06_zCwfBc4wtI2f" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F13_zoKQxvM2cIa1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#x201c;Ng Agreement&#x201d;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck" title="Annual salary"&gt;0.5&lt;/span&gt; million and a signing bonus of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4" title="Bonus payable"&gt;0.3&lt;/span&gt; million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    June 23, 2023, the Company entered into a Separation and Release Agreement with Mr. Ng which included a severance accrual and accrued
    interest as of December 31, 2024 (see Note 11). The lump sum payment and accrued interest was settled in January 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0B_zb3j8Q9Vyk9i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zmweNB3Xu47" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6" title="Monthly advisory fee"&gt;9,166&lt;/span&gt; per month not to exceed $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5" title="Advisory fee"&gt;0.1&lt;/span&gt; million per annum, accrued
    and payable upon the Company raising $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf" title="Equity proceeds"&gt;10&lt;/span&gt; million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F03_zLX2J83iRIF8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zQ7YPE1vTlO8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#x201c;Guaranty&#x201d;) up to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P" title="Guaranty of lease amount"&gt;0.9&lt;/span&gt; million to the lessor for the Company&#x2019;s future performance under
    the San Diego Lease agreement. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok" title="Lease agreement description"&gt;As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.&lt;/span&gt; As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z" title="Lease payment due"&gt;14,000&lt;/span&gt; and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6" title="Lease payment due"&gt;0.2&lt;/span&gt; million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0D_zW1ETmqueNwd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zSwPhnNeBrE5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc" title="Deferred compensation"&gt;0.5&lt;/span&gt; million,
    which was paid in January 2025 (see Note 11). The $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj" title="Notes payable"&gt;0.5&lt;/span&gt; million note bore interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4" title="Note bears interest percentage"&gt;24&lt;/span&gt;% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne" title="Note bears interest percentage"&gt;14&lt;/span&gt;% per annum. The deferred compensation and advisory fees were settled in
    January 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zrzyrqrQZdM3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1A_zZ51rLXa3lQe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
    Note 8 for disclosures around Warrants. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F04_z9c88oDDUFK2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(9)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_z5IDR1Bfps6b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8" title="Officer loans payable"&gt;0.2&lt;/span&gt; million, which bears
    interest at &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe" title="Officer loans payable"&gt;12&lt;/span&gt;%. The loan was settled in full in January 2025. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zIlcmPGCq4w" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(10)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zj5egqFCgyC6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2" title="Bonus payable"&gt;0.1&lt;/span&gt; million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc" title="Separation pay"&gt;0.2&lt;/span&gt; million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#x2019;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9" title="Severance pay"&gt;0.1&lt;/span&gt; million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0D_zdfDOmomXt94" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(11)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zFrDDUS3lLNd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1" title="Bonus payable"&gt;0.1&lt;/span&gt; million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6" title="Severance pay"&gt;0.2&lt;/span&gt; million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#x2019;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf" title="Severance pay"&gt;0.2&lt;/span&gt; million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.3in; text-align: justify"&gt;&lt;span id="xdx_F07_zNo8J4qqMSEh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(12)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_z3zx8HiEP4Cj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#x201c;CRO&#x201d;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl" title="Accounts payable and accrued expenses"&gt;0.1&lt;/span&gt;
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h" title="Expenses related to services"&gt;0.6&lt;/span&gt;
    million in expenses related to services from Company A.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorAAndDirectorEMember"
      id="Fact001174">Current
    term notes payable, net of discount, including accrued interest</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorAAndDirectorEMember"
      decimals="-3"
      id="Fact001172"
      unitRef="USD">2702000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFAndRelativeOfOfficerAMember"
      id="Fact001179">Accounts
    payable and accrued expenses</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorFAndRelativeOfOfficerAMember"
      decimals="-3"
      id="Fact001177"
      unitRef="USD">30000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFMember"
      id="Fact001184">Severance
    accrual</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFMember"
      decimals="-3"
      id="Fact001181"
      unitRef="USD">195000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorDMember"
      id="Fact001189">Severance
    accrual</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorDMember"
      decimals="-3"
      id="Fact001187"
      unitRef="USD">434000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorAOneMember"
      id="Fact001194">Advisory
    services included in accrued expenses</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorAOneMember"
      decimals="-3"
      id="Fact001192"
      unitRef="USD">18000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFOneMember"
      id="Fact001199">Lease
    guaranty</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFOneMember"
      decimals="-3"
      id="Fact001196"
      unitRef="USD">14000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorFOneMember"
      decimals="-3"
      id="Fact001197"
      unitRef="USD">186000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorATwoMember"
      id="Fact001204">Other
    liabilities</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorATwoMember"
      decimals="-3"
      id="Fact001202"
      unitRef="USD">638000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFAndDirectorAMember"
      id="Fact001209">Warrant
    liability</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_DirectorFAndDirectorAMember"
      decimals="-3"
      id="Fact001206"
      unitRef="USD">8000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_DirectorFAndDirectorAMember"
      decimals="-3"
      id="Fact001207"
      unitRef="USD">9000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_RelativeOfOfficerAMember"
      id="Fact001214">Loan
    payable</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_RelativeOfOfficerAMember"
      decimals="-3"
      id="Fact001212"
      unitRef="USD">223000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_OfficerGMember"
      id="Fact001219">Severance
    accrual</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_OfficerGMember"
      decimals="-3"
      id="Fact001216"
      unitRef="USD">65000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_OfficerAMember"
      id="Fact001224">Severance
    accrual</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_OfficerAMember"
      decimals="-3"
      id="Fact001221"
      unitRef="USD">158000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember"
      id="Fact001229">Accounts
    payable and accrued expenses</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember"
      decimals="-3"
      id="Fact001226"
      unitRef="USD">130000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction
      contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember"
      id="Fact001234">Accounts
    payable and accrued expenses</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2025-01-012025-12-31_custom_CompanyARelatedToDirectorGMember"
      decimals="-3"
      id="Fact001231"
      unitRef="USD">130000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-12-31_custom_DirectorsAAndEMember"
      decimals="-5"
      id="Fact001237"
      unitRef="USD">2700000</us-gaap:NotesPayable>
    <us-gaap:LegalFees
      contextRef="From2025-01-012025-12-31_srt_OfficerMember"
      decimals="-3"
      id="Fact001240"
      unitRef="USD">48000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2024-01-012024-12-31_srt_OfficerMember"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">38000</us-gaap:LegalFees>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-04-22_custom_DirectorFMember"
      decimals="-5"
      id="Fact001245"
      unitRef="USD">500000</us-gaap:LoansPayable>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-12-31_custom_DirectorFMember"
      decimals="-5"
      id="Fact001247"
      unitRef="USD">200000</us-gaap:LoansPayable>
    <CLDI:ConsultingPay
      contextRef="AsOf2025-12-31_custom_DirectorFMember"
      decimals="-3"
      id="Fact001249"
      unitRef="USD">10000000</CLDI:ConsultingPay>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-012025-12-31_custom_DirectorFMember"
      decimals="-5"
      id="Fact001251"
      unitRef="USD">100000</us-gaap:OtherExpenses>
    <us-gaap:SalariesAndWages
      contextRef="From2022-02-012022-02-01_custom_DirectorDMember"
      decimals="-5"
      id="Fact001254"
      unitRef="USD">500000</us-gaap:SalariesAndWages>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2022-02-01_custom_DirectorDMember"
      decimals="-5"
      id="Fact001256"
      unitRef="USD">300000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:NoninterestExpenseInvestmentAdvisoryFees
      contextRef="From2022-04-012022-04-01_custom_DirectorAMember"
      decimals="-3"
      id="Fact001259"
      unitRef="USD">9166000</us-gaap:NoninterestExpenseInvestmentAdvisoryFees>
    <us-gaap:NoninterestExpenseInvestmentAdvisoryFees
      contextRef="From2022-04-012022-04-01_custom_DirectorAMember_srt_MaximumMember"
      decimals="-5"
      id="Fact001261"
      unitRef="USD">100000</us-gaap:NoninterestExpenseInvestmentAdvisoryFees>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-04-012022-04-01_custom_DirectorAMember"
      decimals="-6"
      id="Fact001263"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <CLDI:GuarantyOfLeaseAmount
      contextRef="From2022-10-012022-10-31_custom_AJCCapitalMember_srt_MaximumMember_custom_GuarantyMember"
      decimals="-5"
      id="Fact001266"
      unitRef="USD">900000</CLDI:GuarantyOfLeaseAmount>
    <us-gaap:LessorOperatingLeaseDescription
      contextRef="From2022-10-012022-10-31_custom_AJCCapitalMember_custom_GuarantyMember"
      id="Fact001268">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.</us-gaap:LessorOperatingLeaseDescription>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="From2025-01-012025-12-31_custom_AJCCapitalMember_custom_GuarantyMember"
      decimals="-3"
      id="Fact001270"
      unitRef="USD">14000000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="From2024-01-012024-12-31_custom_AJCCapitalMember_custom_GuarantyMember"
      decimals="-5"
      id="Fact001272"
      unitRef="USD">200000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2023-08-31_custom_DirectorAThreeMember"
      decimals="-5"
      id="Fact001275"
      unitRef="USD">500000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-08-31_custom_DirectorAThreeMember"
      decimals="-5"
      id="Fact001277"
      unitRef="USD">500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-08-31_custom_DirectorAThreeMember"
      decimals="INF"
      id="Fact001279"
      unitRef="Pure">0.24</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-08-12_custom_DirectorAThreeMember"
      decimals="INF"
      id="Fact001281"
      unitRef="Pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LoansPayable
      contextRef="AsOf2024-01-31_custom_RelativeOfOfficerAMember_us-gaap_LoansPayableMember"
      decimals="-5"
      id="Fact001285"
      unitRef="USD">200000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-31_custom_RelativeOfOfficerAMember_us-gaap_LoansPayableMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-08-08_custom_OfficerGMember"
      decimals="-5"
      id="Fact001290"
      unitRef="USD">100000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <CLDI:SeparationPay
      contextRef="From2025-08-082025-08-08_custom_OfficerGMember"
      decimals="-5"
      id="Fact001292"
      unitRef="USD">200000</CLDI:SeparationPay>
    <us-gaap:SeveranceCosts1
      contextRef="From2025-01-012025-12-31_custom_OfficerGMember"
      decimals="-5"
      id="Fact001294"
      unitRef="USD">100000</us-gaap:SeveranceCosts1>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-09-17_custom_OfficerAMember"
      decimals="-5"
      id="Fact001297"
      unitRef="USD">100000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:SeveranceCosts1
      contextRef="From2025-09-172025-09-17_custom_OfficerAMember"
      decimals="-5"
      id="Fact001299"
      unitRef="USD">200000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2025-01-012025-12-31_custom_OfficerAMember"
      decimals="-5"
      id="Fact001301"
      unitRef="USD">200000</us-gaap:SeveranceCosts1>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-12-31_custom_CompanyARelatedToDirectorGMember"
      decimals="-5"
      id="Fact001304"
      unitRef="USD">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2025-12-31_custom_CompanyARelatedToDirectorGMember"
      decimals="-5"
      id="Fact001306"
      unitRef="USD">600000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001308">&lt;p id="xdx_804_eus-gaap--DebtDisclosureTextBlock_zk6rljKHwxna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_828_zEr7zCsMUf1b"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zSxdPkDzMrL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s outstanding debt obligations as of December 31, 2025 and 2024, including related party components, are as follows (in
thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BC_zirP9PQvheZ8" style="display: none"&gt;Schedule of Outstanding Debt Obligations&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unpaid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
                                            Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Promissory
    note&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMNeRAr6KClg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKCKbGpGiGI8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z6ZkdmTBDAy5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;690&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20251231_zutYKlGSssd5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
    debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LongTermDebt_iI_pn3n3_c20251231_zA54mlhaoCTi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unpaid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
                                            Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zihzq1dJs6U5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zLeuVlzlCvw5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;753&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zArGCDUwtam7" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,953&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bridge
    loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zTd7tM8TbDx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_z0lkMUcpXkx9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zdV8IJWhiNLl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Promissory
    note&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zH2QKTdCPxZf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztY1VpfkvPGk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPWkTf1r0jR1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;645&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231_znzJmfZxSXSl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_zzRJejM3acQe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;821&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231_zCTWD2iLH2a4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,821&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20241231_zp2GdBcNR8Rj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
    debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20241231_zj6QHi1ArYGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zDOkMkUPN8Mg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbqjTc8gnZAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Scheduled
maturities of outstanding debt, net of discounts as of December 31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_ziMD1VTWsl08" style="display: none"&gt;Schedule of Maturities of Outstanding Debt&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20251231_zn9Uaygh0G7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDICAzCCI_zRtuHODsChNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDICAzCCI_z6a8msyqcAQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDICAzCCI_zZwEgYv3LbL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028
    and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_pn3n3_maDICAzCCI_zDI0WWw1ZV54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Plus:
    accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzCCI_zh5K2dMn52Xk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;690&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zElWa7uIzSU9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following discussion includes a description of the Company&#x2019;s outstanding debt as of December 31, 2025 and 2024. The weighted average
interest rate related to the Company&#x2019;s outstanding debt was approximately &lt;span id="xdx_901_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20251231_zLMOiZwq2vVj" title="Weighted average interest rate"&gt;15&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20241231_zxq292wWGFT1" title="Weighted average interest rate"&gt;14.4&lt;/span&gt;% as of December 31, 2025 and 2024, respectively.
Interest expense related to the Company&#x2019;s outstanding debt totaled approximately $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20251231_zEeQFQW2a7Wl" title="Interest expense debt"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20240101__20241231_zsrU2GYoa16c" title="Interest expense debt"&gt;0.7&lt;/span&gt; million for the year ended
December 31, 2025 and 2024, respectively, which is reported within other income, net, in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Term
Notes Payable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2021
Term Note Payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2021, the Company entered into a note agreement with a related party investor and director to borrow up to $&lt;span id="xdx_909_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20210131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember__srt--TitleOfIndividualAxis__custom--InvestorAndDirectorMember__srt--RangeAxis__srt--MaximumMember_zPCUkYAuKd6i" title="Line of credit"&gt;0.5&lt;/span&gt; million (&#x201c;2021
Term Note&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the interest rate of the 2021 Term Notes was &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember_zpxi9Nu7ycje" title="Interest rate"&gt;14&lt;/span&gt;%, and the total carrying value, including accrued interest was
approximately $&lt;span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyOneTermNoteMember_za1KpnGuoDM5" title="Interest Payable"&gt;0.7&lt;/span&gt; million. The total outstanding principal and accrued interest of 2021 Term Note of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20250131_zRS3X9WUWiz9" title="Carrying value, including accrued interest"&gt;0.7&lt;/span&gt; million was settled in full
in January 2025. As of that date, the 2021 Term Notes were no longer outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2022
Term Notes Payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November and December 2022, the Company issued $&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_pn5n6_c20221130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_z8gMvISByd35" title="Secured term notes payable"&gt;&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_pn5n6_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zp8xTvJkFNVl" title="Secured term notes payable"&gt;1.5&lt;/span&gt;&lt;/span&gt; million of secured term notes payable (the &#x201c;2022 Term Notes&#x201d;) to investors,
including to related parties (see Note 6).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3 and November 8, 2023, the Company settled in cash $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231003__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zQNcpdwoAcLf" title="Debt instrument, accrued interest"&gt;0.1&lt;/span&gt; million and $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231108__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zVSwHFIA9a0l" title="Debt instrument, accrued interest"&gt;0.2&lt;/span&gt; million, respectively, of the principal of 2022 Term
Notes plus accrued interest. Said term notes payable were no longer outstanding as of the settlement dates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the interest rate of the 2022 Term Notes was &lt;span id="xdx_904_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zEtVm58JGAv7" title="Interest rate"&gt;14&lt;/span&gt;% per annum, for a total principal of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_z3WJzxrZf2td" title="Principal amount"&gt;0.2&lt;/span&gt; million, and &lt;span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember__srt--RangeAxis__srt--MaximumMember_zFex1oUhwKm2" title="Interest rate"&gt;16&lt;/span&gt;% per
annum, for a total principal of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zjfD9Dsh4791" title="Principal amount"&gt;0.2&lt;/span&gt; million. As of December 31, 2024, the total carrying value, including accrued interest, was $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zRuTXnTszdRd" title="Carrying value, including accrued interest"&gt;0.4&lt;/span&gt;
million. The total outstanding principal and accrued interest of 2022 Term Notes of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20250131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoTermNotePayableMember_zabwvSkTeJF1" title="Carrying value, including accrued interest"&gt;0.4&lt;/span&gt; million was settled in full in January 2025.
As of that date, the 2022 Term Notes were no longer outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2023
Term Notes Payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
January through September 2023, the Company issued $&lt;span id="xdx_909_eus-gaap--NotesPayable_iI_pn5n6_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zwZ5GE64K3C9" title="Secured term notes payable"&gt;3.3&lt;/span&gt; million of secured term notes payable (the &#x201c;2023 Term Notes&#x201d;) to
investors, including to related parties (see Note 6).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2023, as agreed upon above in connection with the Closing of the FLAG Merger, the Company settled in cash $&lt;span id="xdx_904_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20231003__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zVk3j5LOsbci"&gt;0.6&lt;/span&gt; million of
principal of 2023 Term Notes plus accrued interest and said term notes payable were no longer outstanding as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company settled in cash $&lt;span id="xdx_901_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zTOb18T6Jsq8" title="Debt principal and accrued interest"&gt;0.3&lt;/span&gt; million of principal of 2023 Term Notes plus accrued interest. On
December 23, 2024, the Company executed a debt amendment on $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zebUYr0Puvm2" title="Principal amount"&gt;1.0&lt;/span&gt; million of the 2023 Term Notes, which modified the repayment terms commencing
on February 1, 2025, such that the Company will pay the holder, a related party, $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_pn5n6_c20241223__20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_z5MNxzDW0cZ6" title="Installment payable"&gt;0.1&lt;/span&gt; million each month until the 2023 Term Notes&#x2019;
principal and interest are fully paid. The principal shall continue accruing interest of &lt;span id="xdx_902_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241223__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zZJ6HIVft6Wb" title="Interest rate percentage"&gt;14&lt;/span&gt;% per annum until fully paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the interest rate was &lt;span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zHZZ0f7E7Ivj" title="Interest rate percentage"&gt;14&lt;/span&gt;% per annum for a total principal of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zqHfhlly4bI3" title="Principal amount"&gt;1.2&lt;/span&gt; million and &lt;span id="xdx_90F_eus-gaap--LongTermDebtPercentageBearingVariableInterestRate_iI_pid_dp_uPure_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_zVIHn5rKhrhg" title="Interest rate percentage"&gt;18&lt;/span&gt;% per annum for a total principal
of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableTwoMember_ztWWcIckxed4" title="Principal amount"&gt;0.2&lt;/span&gt; million, respectively. As of December 31, 2024, the total carrying value, including accrued interest and net of debt discount,
was $&lt;span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20241231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zLuyol1eX6ge" title="Carrying value, including accrued interest"&gt;1.9&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the total outstanding principal and accrued interest of the 2023 Term Notes of $&lt;span id="xdx_90A_eus-gaap--LongTermDebt_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeTermNotePayableMember_zpLSbX8UTXxb" title="Carrying value, including accrued interest"&gt;1.4&lt;/span&gt; million was fully paid in accordance
with the agreement and was no longer outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2024
Bridge Loan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 19, 2024, the Company received approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromRelatedPartyDebt_pn5n6_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zS69a7Md0Vj1" title="Loans received"&gt;0.2&lt;/span&gt; million in aggregate proceeds from the issuance of certain bridge loans (the
&#x201c;2024 Bridge Loan&#x201d;), which mature &lt;span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dc_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zGDZcVeJwNZ3" title="Maturity period"&gt;one year&lt;/span&gt; from the issuance date and bear simple interest of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zQPYVz2I2Ku8" title="Interest rate"&gt;12&lt;/span&gt;% per annum. As consideration
for the 2024 Term Loans, the Company issued an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240119__20240119__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zYlgl8FaClEd" title="Restricted shares"&gt;75&lt;/span&gt; shares of restricted common stock to the Lender.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024, the total carrying value of the 2024 Bridge Loan, including accrued interest and net of debt discount, was $&lt;span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20250131__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyFourBridgeLoanMember_zmnHR9u3qfvb" title="Accrued interest"&gt;0.2&lt;/span&gt;
million which was settled in full in January 2025. As of that date, the 2024 Bridge Loan was no longer outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Promissory Notes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 26, 2024, the Company entered into a convertible promissory note purchase agreement (the &#x201c;2024 Purchase Agreement&#x201d;)
with an Accredited Investor (the &#x201c;Investor&#x201d;) for a loan in the principal amount of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_zJ6KKKp4zX7f" title="Principal amount"&gt;1.0&lt;/span&gt; million (the &#x201c;2024 Convertible
Note Loan&#x201d;). In connection with the Convertible Note Loan, the Company issued a one-year convertible promissory note evidencing
the aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_zM2yFngD0Pf2" title="Principal amount"&gt;1.0&lt;/span&gt; million under the Loan, which accrues at a &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240126__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFourPurchaseAgreementMember_z2HH6dDJMttl" title="Interest rate"&gt;12&lt;/span&gt;% simple interest rate per annum (the &#x201c;2024
Convertible Note&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 18, 2024, pursuant to the April Public Offering, the Company&#x2019;s $&lt;span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_pn5n6_c20240418__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zk2hKhuneAIl" title="Accrued interest"&gt;1.0&lt;/span&gt; million convertible note, inclusive of outstanding principal
and accrued interest, was automatically converted into shares of Common Stock Units, with terms identical to those sold in the April
Public Offering. As of that date, the convertible note was no longer outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Promissory
Note Loan Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 1, 2024, the Company entered into a Loan Agreement with a third party lender (the &#x201c;Lender&#x201d;). Under the Loan Agreement,
the Lender agreed to loan the Company the principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20240701__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_zcGtfjzWbh7e" title="Principal amount"&gt;0.6&lt;/span&gt; million pursuant to the terms of the promissory note dated July 1,
2024 (the &#x201c;Promissory Note&#x201d;), which bears a simple interest rate at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240701__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_zf9mn1ORfD33" title="Interest rate"&gt;15&lt;/span&gt;% per annum and matures on the third calendar year
from July 1, 2024 (the &#x201c;Maturity Date&#x201d;) unless due earlier due to an event of a default. The Company agreed to pay annual
payments of accrued interest after each calendar year from the Payment Date until any remaining interest is paid in full on the Maturity
Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the total carrying value of the promissory note, including accrued interest, was $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_z8UCwU5OT0rc" title="Carrying value, including accrued interest"&gt;0.7&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PromissoryNoteLoanAgreementMember_z2HXOsTVORL6" title="Carrying value, including accrued interest"&gt;0.6&lt;/span&gt;
million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001310">&lt;p id="xdx_898_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zSxdPkDzMrL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s outstanding debt obligations as of December 31, 2025 and 2024, including related party components, are as follows (in
thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8BC_zirP9PQvheZ8" style="display: none"&gt;Schedule of Outstanding Debt Obligations&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unpaid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
                                            Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Promissory
    note&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zMNeRAr6KClg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20250101__20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zKCKbGpGiGI8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20251231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z6ZkdmTBDAy5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;690&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20251231_zutYKlGSssd5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
    debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LongTermDebt_iI_pn3n3_c20251231_zA54mlhaoCTi" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unpaid&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Net
                                            Carrying&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Term
    notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zihzq1dJs6U5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,200&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zLeuVlzlCvw5" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;753&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--TermNotesPayableMember_zArGCDUwtam7" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,953&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bridge
    loan payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zTd7tM8TbDx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_z0lkMUcpXkx9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--BridgeLoanPayableMember_zdV8IJWhiNLl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;223&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Promissory
    note&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zH2QKTdCPxZf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_ztY1VpfkvPGk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zPWkTf1r0jR1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;645&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20241231_znzJmfZxSXSl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unpaid Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_c20240101__20241231_zzRJejM3acQe" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;821&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_c20241231_zCTWD2iLH2a4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net Carrying Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,821&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_c20241231_zp2GdBcNR8Rj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: current portion of long-term debt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
    debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LongTermDebt_iI_pn3n3_c20241231_zj6QHi1ArYGk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Long-term debt, net of current portion"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001312"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2025-01-012025-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001314"
      unitRef="USD">90000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001316"
      unitRef="USD">690000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001318"
      unitRef="USD">90000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_TermNotesPayableMember"
      decimals="-3"
      id="Fact001322"
      unitRef="USD">2200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_TermNotesPayableMember"
      decimals="-3"
      id="Fact001324"
      unitRef="USD">753000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_TermNotesPayableMember"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">2953000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_BridgeLoanPayableMember"
      decimals="-3"
      id="Fact001328"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_BridgeLoanPayableMember"
      decimals="-3"
      id="Fact001330"
      unitRef="USD">23000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_BridgeLoanPayableMember"
      decimals="-3"
      id="Fact001332"
      unitRef="USD">223000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001334"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001336"
      unitRef="USD">45000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31_custom_PromissoryNoteMember"
      decimals="-3"
      id="Fact001338"
      unitRef="USD">645000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001340"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001342"
      unitRef="USD">821000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001344"
      unitRef="USD">3821000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001346"
      unitRef="USD">3221000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001348"
      unitRef="USD">600000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001350">&lt;p id="xdx_897_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zbqjTc8gnZAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Scheduled
maturities of outstanding debt, net of discounts as of December 31, 2025 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_ziMD1VTWsl08" style="display: none"&gt;Schedule of Maturities of Outstanding Debt&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20251231_zn9Uaygh0G7h" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maDICAzCCI_zRtuHODsChNd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maDICAzCCI_z6a8msyqcAQ4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;600&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maDICAzCCI_zZwEgYv3LbL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028
    and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_pn3n3_maDICAzCCI_zDI0WWw1ZV54" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Plus:
    accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iTI_pn3n3_mtDICAzCCI_zh5K2dMn52Xk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;690&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001354"
      unitRef="USD">600000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001358"
      unitRef="USD">90000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact001360"
      unitRef="USD">690000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001362"
      unitRef="Pure">0.15</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001364"
      unitRef="Pure">0.144</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:InterestExpenseDebt
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact001366"
      unitRef="USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact001368"
      unitRef="USD">700000</us-gaap:InterestExpenseDebt>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2021-01-31_custom_TwoThousandTwentyOneTermNoteMember_custom_InvestorAndDirectorMember_srt_MaximumMember"
      decimals="-5"
      id="Fact001370"
      unitRef="USD">500000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyOneTermNoteMember"
      decimals="INF"
      id="Fact001372"
      unitRef="Pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyOneTermNoteMember"
      decimals="-5"
      id="Fact001374"
      unitRef="USD">700000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2025-01-31"
      decimals="-5"
      id="Fact001376"
      unitRef="USD">700000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-11-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001378"
      unitRef="USD">1500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001380"
      unitRef="USD">1500000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-10-03_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001382"
      unitRef="USD">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-08_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001384"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="INF"
      id="Fact001386"
      unitRef="Pure">0.14</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001388"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001390"
      unitRef="Pure">0.16</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001392"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001394"
      unitRef="USD">400000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2025-01-31_custom_TwoThousandTwentyTwoTermNotePayableMember"
      decimals="-5"
      id="Fact001396"
      unitRef="USD">400000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-09-30_us-gaap_RelatedPartyMember_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001398"
      unitRef="USD">3300000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2023-10-03_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001399"
      unitRef="USD">600000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001401"
      unitRef="USD">300000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001403"
      unitRef="USD">1000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-12-232024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001405"
      unitRef="USD">100000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2024-12-23_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Pure">0.14</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember"
      decimals="INF"
      id="Fact001409"
      unitRef="Pure">0.14</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember"
      decimals="-5"
      id="Fact001411"
      unitRef="USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Pure">0.18</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableTwoMember"
      decimals="-5"
      id="Fact001415"
      unitRef="USD">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001417"
      unitRef="USD">1900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeTermNotePayableMember"
      decimals="-5"
      id="Fact001419"
      unitRef="USD">1400000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember"
      decimals="-5"
      id="Fact001421"
      unitRef="USD">200000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember"
      id="Fact001423">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember"
      decimals="INF"
      id="Fact001425"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-01-192024-01-19_custom_TwoThousandTwentyFourBridgeLoanMember"
      decimals="INF"
      id="Fact001427"
      unitRef="Shares">75</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2025-01-31_custom_TwoThousandTwentyFourBridgeLoanMember"
      decimals="-5"
      id="Fact001429"
      unitRef="USD">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember"
      decimals="-5"
      id="Fact001431"
      unitRef="USD">1000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember"
      decimals="-5"
      id="Fact001433"
      unitRef="USD">1000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-01-26_us-gaap_ConvertibleNotesPayableMember_custom_TwoThousandTwentyFourPurchaseAgreementMember"
      decimals="INF"
      id="Fact001435"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2024-04-18_us-gaap_ConvertibleNotesPayableMember"
      decimals="-5"
      id="Fact001437"
      unitRef="USD">1000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-07-01_custom_PromissoryNoteLoanAgreementMember"
      decimals="-5"
      id="Fact001439"
      unitRef="USD">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-07-01_custom_PromissoryNoteLoanAgreementMember"
      decimals="INF"
      id="Fact001441"
      unitRef="Pure">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2025-01-012025-12-31_custom_PromissoryNoteLoanAgreementMember"
      decimals="-5"
      id="Fact001443"
      unitRef="USD">700000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2024-01-012024-12-31_custom_PromissoryNoteLoanAgreementMember"
      decimals="-5"
      id="Fact001445"
      unitRef="USD">600000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001447">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zM94V1KZySP1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_821_zbj6MRYVN0C7"&gt;Convertible Preferred Stock, Common Stock and Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Second Amended and Restated Certificate of Incorporation filed on September 19, 2023 (&#x201c;the Amended Articles&#x201d;), the
Company is authorized to issue a total of &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zFFI3bavVd54" title="Number of shares authorized"&gt;1,000,000&lt;/span&gt; shares of preferred stock, par value $&lt;span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230919__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zt5GPi5ulNz6" title="Preferred stock par value per share"&gt;0.0001&lt;/span&gt; per share. As of December 31, 2025 and
2024, there were &lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zzKsbvgoPOz9" title="Preferred stock outstanding"&gt;&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zBK3KuQbR9v1" title="Preferred stock outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Amended Articles, the Company is authorized to issue &lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zuWGhUQvuMDf" title="Common stock shares authorized"&gt;330,000,000&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20251231_zaibsqOvDTMi" title="Common stock par value per share"&gt;0.0001&lt;/span&gt; per share, of which
&lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--VotingCommonStockMember_zqzRxyBfiGX6" title="Common stock, shares authorized"&gt;312,000,000&lt;/span&gt; shares are designated as Voting Common Stock (&#x201c;Common Stock&#x201d;) and &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zbkPSkRaUaaa" title="Common stock, shares authorized"&gt;18,000,000&lt;/span&gt; are designated as Non-Voting Common
Stock (the &#x201c;Non-Voting Common Stock&#x201d;). As of December 31, 2025 and December 31, 2024, there were &lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20251231_z6qN0BsLNdp8" title="Common stock shares issued"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231_zTYNV53Rqexa" title="Common stock shares outstanding"&gt;7,216,994&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zmqA5YCSY3B8" title="Common stock shares issued"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zY68yBsxSRDf" title="Common stock shares outstanding"&gt;1,730,051&lt;/span&gt;&lt;/span&gt;
shares of common stock issued and outstanding, respectively, and &lt;span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--NonvotingCommonStockMember_zptAcI6lGMq6" title="Common stock, shares outstanding"&gt;150,000&lt;/span&gt; shares of non-voting common stock outstanding. Since inception
to date, &lt;span id="xdx_90E_ecustom--CommonStockDividend_iI_do_c20251231_zY0FCQgzyTNe" title="Common stock dividend"&gt;no&lt;/span&gt; dividends have been declared or paid. Issuance costs related to common stock issuances during all periods presented were
immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--DiscloserOFCommonStockReservedForFurtureTableTextBlock_zRT2pG2i2nji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zU95Wcr2GHmf" style="display: none"&gt;Schedule
of Common Stock Reserved&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zNEUsLzr3llb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zzu59mG1aF0e" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4T92FbIxBcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
    stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026,613&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockOptionsIssuedAndOutstandingMember_ztr8eJzSXMEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
    stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;277,822&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--RestrictedStockUnitsVestedAndUnreleasedMember_z2JFgf5R1kV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    stock units vested and unreleased&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1485"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zvq1KzbydcJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
    available for future issuance under the 2023 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;96,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,409&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_zVwIf82UdAU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
    reserved under the 2023 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,815&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,815&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_zei2jceJH5S5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock reserved
    for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,433,747&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,029,807&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z0aaoBJIT833" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2024 Public Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 18, 2024, in connection with the April Public Offering, the Company sold an aggregate of &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlnJrnxICc3" title="Number of shares purchased"&gt;110,271&lt;/span&gt; Common Stock Units and &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418_zNDYTJcUkStf" title="Number of shares purchased"&gt;16,375&lt;/span&gt;
Pre-Funded Warrant (&#x201c;PFW&#x201d;) Units at an effective combined purchase price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuDd3OQifhFa" title="Purchase price"&gt;48.00&lt;/span&gt; per Common Stock Unit or PFW Unit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
Common Stock Unit consists of: (i) one share of the Company&#x2019;s voting common stock, (ii) a Series A warrant to purchase one share
common stock, (iii) a Series B warrant to purchase one Series B Unit, with each Series B Unit consisting of (a) one share of common stock
and (b) a Series B-1 Warrant to purchase one share of common stock, and (iv) a Series C warrant to purchase one Series C Unit, with each
Series C Unit consisting of (a) one share of common stock and (b) a Series C-1 Warrant to purchase one share of common stock. See further
warrant details per each issued series below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
PFW Unit consists of: (i) a pre-funded warrant to purchase one share of common stock, (ii) a Series A warrant to purchase one share common
stock, (iii) a Series B warrant to purchase one Series B Unit, with each Series B Unit consisting of (a) one share of common stock and
(b) a Series B-1 Warrant to purchase one share of common stock, and (iv) a Series C warrant to purchase one Series C Unit, with each
Series C Unit consisting of (a) one share of common stock and (b) a Series C-1 Warrant to purchase one share of common stock. See further
warrant details per each issued series below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued Ladenburg Thalmann &amp;amp; Co. Inc. (&#x201c;Ladenburg&#x201d;), acting as the &#x201c;Placement Agent&#x201d;, common stock
warrants to purchase up to &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240418__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJdCNiHTUY83" title="Number of warrants"&gt;6,333&lt;/span&gt; shares of common stock. See further warrant details below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;May
2024 Warrant Inducement Offer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2024, following the closing of the May 2024 Warrant Inducement Offer, warrant holders immediately exercised some or all of their
respective outstanding Series B Warrants and Series C Warrants to purchase up to an aggregate of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesBWarrantsAndSeriesCWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zkgc95lxOPZ9" title="Number of shares purchased"&gt;89,153&lt;/span&gt; shares of the Company&#x2019;s
common stock, Series B-1 Warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesBOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zYmEZUEbyAm2" title="Number of shares purchased"&gt;22,275&lt;/span&gt; shares of common stock and Series C-1 Warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesCOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zrOQJqpD6ux2" title="Number of shares purchased"&gt;66,878&lt;/span&gt; shares
of common stock, at a reduced exercise price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesCOneWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember_zJi3X0R3szB6" title="Exercise price"&gt;24.00&lt;/span&gt;. In consideration for the immediate exercise of some or all of the existing warrants
for cash, the Company agreed to issue unregistered new Series D Warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__custom--SeriesDCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--InducementOfferLetterAgreementMember__srt--RangeAxis__srt--MaximumMember_zoOx82TBe9Cj" title="Number of shares purchased"&gt;89,153&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued Ladenburg, acting as the &#x201c;Placement Agent&#x201d;, common stock warrants to purchase up to &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZSIhruMsAI3" title="Number of warrants"&gt;4,458&lt;/span&gt; shares of common
stock. See further warrant details below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Subscription
Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 26, 2024, the Board of Directors of the Company approved a Subscription Agreement dated July 28, 2024 with an accredited investor,
a related-party (the &#x201c;Investor&#x201d;). Pursuant to the Agreement, the Company sold to the Investor and the Investor purchased,
(i) &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240726_zo3q2wH3xf8b" title="Purchase of warrants"&gt;58,235&lt;/span&gt; shares of Common Stock at a purchase price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxXptYUDOWNj" title="Exercise price"&gt;17.172&lt;/span&gt; per share; and (ii) warrants to purchase &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zdkTDAG7kCge" title="Purchase of warrants"&gt;50,000&lt;/span&gt; shares of the Company&#x2019;s
common stock at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHz3nFOZIS87" title="Exercise price"&gt;22.80&lt;/span&gt;, for an aggregate purchase price of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240726__20240726__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wuFcZ8JFj3" title="Aggregate purchase price"&gt;1.0&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Nova
Cell Investment&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 26, 2024, the Board of Directors of the Company acknowledged a strategic investment of approximately $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zlx3Gm1SyoIg" title="Issuance of stock, value"&gt;2.0&lt;/span&gt; million by an accredited
investor, a related-party, (the &#x201c;Investor&#x201d;) into Nova Cell, a subsidiary of the Company, in exchange for the issuance of
&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zlQuhOnDbH5k" title="Issuance of stock, shares"&gt;7,500,000&lt;/span&gt; shares of Nova Cell&#x2019;s common stock to the Investor, representing &lt;span id="xdx_900_ecustom--PercentageOfStrategicInvestment_dp_uPure_c20240726__20240726__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zNXAGWB20l6e" title="Percentage of strategic investment"&gt;25&lt;/span&gt;% of Nova Cell&#x2019;s current fully-diluted capitalization.
Nova Cell&#x2019;s common stock was not adjusted when the Company effected its 2024 Reverse Stock Split and 2025 Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;On
October 27, 2025, the Company entered into a Stock Repurchase Agreement (the &#x201c;SRA&#x201d;) and Material Purchase Agreement (the
&#x201c;MPA&#x201d; and together with the SRA the &#x201c;Agreements&#x201d;), with Nova Cell. In accordance with the Agreements, the Company
sold and transferred all &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zKyazEqJf2C4" title="Shares sold and transferred"&gt;22,500,000&lt;/span&gt; of its shares of common stock in Nova Cell (the &#x201c;Repurchased Shares&#x201d;), representing an
ownership interest of &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20251027__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NovaCellMember_zTibGf61lbzj" title="Ownership percentage"&gt;75&lt;/span&gt;%, back to Nova Cell, for a purchase price of $&lt;span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodValue_pn6n6_c20251027__20251027__dei--LegalEntityAxis__custom--NovaCellMember_zsAHGqwc5L9c" title="Purchase price for repurchased shares"&gt;6.0&lt;/span&gt; million (the &#x201c;Purchase Price&#x201d;). The Purchase Price
for the Repurchased Shares was or shall be satisfied (A) in part by cancellation of indebtedness under the September 17, 2024, promissory
note, net of specified offsets (including a $&lt;span id="xdx_909_eus-gaap--DerivativeAssetCollateralObligationToReturnCashOffset_iI_pn3n3_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zgWHTV8g2Pud" title="Promissory note, net cash offset"&gt;50&lt;/span&gt; thousand cash offset), resulting in an Indebtedness Cancellation Amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentDecreaseForgiveness_pn5n6_c20240917__20240917__dei--LegalEntityAxis__custom--NovaCellMember_zKhIIMN85uH8" title="Indebtedness cancellation amount"&gt;1.2&lt;/span&gt; million,
and (B) the balance, by Deferred Consideration of $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_pn5n6_c20240917__dei--LegalEntityAxis__custom--NovaCellMember_zrxAyHZmx1z1" title="Deferred consideration"&gt;4.8&lt;/span&gt; million payable after closing, as more fully described in the SRA. As of December 31, 2025, no Deferred Consideration has been recognized,
and the full amount remains constrained until underlying uncertainties are resolved. After the Deferred
Consideration is fully satisfied, the SRA also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue attributable
to or derivative of the materials listed on Schedule A to the MPA, ending on the tenth anniversary of Nova Cell&#x2019;s first product
sale. Furthermore, as part of the Agreements, the Company sold and transferred certain materials to Nova Cell as listed on Schedule 1
to the MPA. Following the closing of the Agreements, Nova Cell is no longer a subsidiary of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;At
The Market Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 11, 2024, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with Ladenburg, under
which the Company may, from time to time, in its sole discretion, issue and sell through Ladenburg, acting as agent or principal, shares
of the Company&#x2019;s common stock, par value $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zATRFp0t7pni" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share, initially having an aggregate offering price of up to $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pn5n6_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zxw8H3D6x951" title="Common stock par value per share"&gt;5.1&lt;/span&gt; million.
Pursuant to the Sales Agreement, Ladenburg may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d;
offering as defined in Rule 415 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). Ladenburg will use commercially
reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon instructions
from the Company (including any price or size limits or other customary parameters or conditions the Company may impose).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will pay Ladenburg a cash commission of &lt;span id="xdx_904_ecustom--CashCommissionPercentage_iI_dp_uPure_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zLco14TltBDe" title="Cash commission percentage"&gt;3&lt;/span&gt;% of the aggregate gross sales proceeds of shares sold through Ladenburg under the Sales
Agreement. The Company also agreed to reimburse Ladenburg for certain specified expenses, including the fees and disbursements of its
counsel, in an amount not to exceed $&lt;span id="xdx_903_ecustom--DisbursementsCounsel_iI_c20241011__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zlTSkmlso3cj" title="Disbursements counsel"&gt;50,000&lt;/span&gt;, in addition to certain ongoing disbursements of its legal counsel up to $&lt;span id="xdx_90B_eus-gaap--LegalFees_c20241011__20241011__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zKVxPed6qT0g" title="Legal fees"&gt;7,500&lt;/span&gt; in connection
with diligence bring downs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Sales Agreement, the Company may also sell shares to Ladenburg as principal for its own account at prices agreed upon
at the time of sale. If the Company sells shares to Ladenburg as principal, it will enter into a separate terms agreement with Ladenburg
in substantially the form attached to the Sales Agreement. The Company is not obligated to sell any shares under the Sales Agreement.
The offering of the shares pursuant to the Sales Agreement may be terminated by either the Company or Ladenburg, as permitted therein.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 4, 2025, the Company increased the maximum aggregate offering amount of the shares of the Company&#x2019;s common stock, par
value $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250204__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zNIwLLGsZ241" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share, issuable under the Sales Agreement from $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250204__20250204__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_zWpXErfvEhBf" title="Aggregate offering price"&gt;5.1&lt;/span&gt; million to $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20250205__20250205__us-gaap--TypeOfArrangementAxis__custom--MarketOfferingAgreementMember_z6XEU1lhgHvj" title="Aggregate offering price"&gt;11.2&lt;/span&gt; million by filing a prospectus supplement under
the Sales Agreement for an aggregate of $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240204__20250204__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zhijrDapBxcb" title="Sales agreement"&gt;6.1 &lt;/span&gt;million. During the year ended December 31, 2025, the Company sold &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhdgPcCOZMB8" title="Issued common shares"&gt;534,265&lt;/span&gt; shares of common
stock for gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsQ0s2wHznff" title="Proceeds from issued common shares"&gt;3.4&lt;/span&gt; million under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;October
2024 Public Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 23, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors (the &#x201c;Purchasers&#x201d;),
pursuant to which the Company agreed to issue to the Purchasers, (i) in a registered direct offering, &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAWODDkNxvI"&gt;170,836&lt;/span&gt; shares of the Company&#x2019;s
common stock, par value $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmp6ucnQs2R5" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share, at a purchase price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8CeDtEXkqGc" title="Exercise price"&gt;12.00&lt;/span&gt; per share, and (ii) in a concurrent private placement, Series
E common stock purchase warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesECommonWarrantsMember_zQtx9VAvpSe9"&gt;170,836&lt;/span&gt; shares of Common Stock (the &#x201c;Series E Common Warrants&#x201d;) and Series
F common stock purchase warrants to purchase up to &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241023__20241023__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFCommonWarrantsMember_zx3gS3IbMjw9"&gt;170,836&lt;/span&gt; shares of Common Stock (the &#x201c;Series F Common Warrants&#x201d; and together
with the Series E Common Warrants, the &#x201c;Common Warrants&#x201d;). Such registered direct offering and concurrent private placement
are referred to herein as the &#x201c;Transactions.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
closing of the Transactions took place on October 24, 2024. The gross proceeds from the Transactions were approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20241024__20241024__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zA4mwdSy7qOd" title="Gross proceeds"&gt;2.1&lt;/span&gt; million,
before deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if any, from
the exercise of the Common Warrants or common stock warrants issued to the Placement Agent (defined below).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued Ladenburg, acting as the &#x201c;Placement Agent&#x201d;, common stock warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241024__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentWarrantsMember_zk3vZmOHGnr4" title="Number of shares purchased"&gt;8,542&lt;/span&gt; shares of common
stock. See further warrant details below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;November
2024 Confidentially Marketed Public Offering (CMPO)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 14, 2024, the Company conducted a CMPO with Ladenburg acting as the &#x201c;Placement Agent&#x201d;, pursuant to which the Company
agreed to issue in a public offering &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241114__20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQenvJcrGeb9" title="Public offering"&gt;369,823&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFQYZsBJEQNe" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share, at a purchase price
of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCGnD7TDtap9" title="Purchase price per share"&gt;20.28&lt;/span&gt; per share. The gross proceeds from the offering, which closed on November 15, 2024, were approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241115__20241115__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdwp73nJ1Cfj" title="Gross proceeds from offering"&gt;7.5&lt;/span&gt; million, before
deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise
of the Placement Agent Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of common stock were offered by the Company pursuant to a shelf-registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued the Placement Agent common stock warrants to purchase up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241114__20241114__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNoiqmApglwl" title="Placement agent common stock warrants"&gt;18,492&lt;/span&gt; shares of common stock. See further warrant details
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;January
2025 Confidentially Marketed Public Offering (CMPO)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 9, 2025, the Company conducted a CMPO Agreement with Ladenburg acting as the &#x201c;Placement Agent&#x201d;, pursuant to which
the Company agreed to issue and sell in a public offering &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250109__20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyXHKCN4Utr7" title="Public offering"&gt;416,667&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKghwc1QyEq9" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share,
at a purchase price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfEVEkeIkRd4" title="Exercise price"&gt;10.20&lt;/span&gt; per Share. The gross proceeds from the offering, which closed on January 10, 2025, were approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20250109__20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS939R3HFnv7" title="Gross proceeds from offering"&gt;4.3&lt;/span&gt;
million, before deducting placement agent fees and other offering expenses payable by the Company and excluding the net proceeds, if
any, from the exercise of the Placement Agent Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of common stock were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which
was declared effective by the Securities and Exchange Commission on October 10, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued the Placement Agent common stock warrants to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250109__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOh1L0PPeuVh" title="Purchase of shares"&gt;20,834&lt;/span&gt; shares of common stock. See further warrant details
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;March
2025 Registered Direct Offering and Concurrent Private Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 28, 2025, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the
Company agreed to issue to the Purchaser, (i) in a registered direct offering, &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcg7xYmvn7Hd" title="Stock issued during period"&gt;277,084&lt;/span&gt; shares of the Company&#x2019;s common stock (the
&#x201c;Shares&#x201d;), par value $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWj5RdgHa0Li" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share, at a purchase price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zADv4gZFzzN" title="Exercise price"&gt;7.80 &lt;/span&gt;per Share, (ii) pre-funded warrants (&#x201c;PFW&#x201d;)
to purchase up to an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_ziJaiBogf91f" title="Stock issued during period"&gt;227,334&lt;/span&gt; shares of Common Stock at a purchase price of $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zf2LO1kZZRTb" title="Shares issued price per share"&gt;7.788&lt;/span&gt; per Pre-funded Warrant and an exercise
price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zMiMVwSuUnKj" title="Exercise price"&gt;0.001&lt;/span&gt; per share (the &#x201c;Pre-funded Warrant Shares&#x201d; or the &#x201c;PFW Shares&#x201d;) and (iii) in a concurrent private
placement, Series G common stock purchase warrants to purchase up to &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250328__20250328__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonWarrantsMember_zWvxgXNs8rQa" title="Common stock shares"&gt;504,417&lt;/span&gt; shares of common stock (the &#x201c;Series G Warrants&#x201d;
or the &#x201c;Common Warrants&#x201d;). Such registered direct offering and concurrent private placement are referred to herein as the
&#x201c;March Registered Direct Offering and Concurrent Private Placement.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Shares, the PFW, and the PFW Shares were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-284229),
which was declared effective by the Securities and Exchange Commission on February 7, 2025. The Series G Warrants were issued in a concurrent
private placement and without registration under the Securities Act, and in reliance on the exemption provided in Section 4(a)(2) under
the Securities Act and Regulation D promulgated thereunder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued Ladenburg, acting as the &#x201c;Placement Agent&#x201d;, common stock warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250328__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKOuayq1fSe5" title="Purchase of shares"&gt;25,221&lt;/span&gt; shares of common
stock. See further warrant details below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;July
2025 Warrant Inducement Offer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 9, 2025, the Company entered into a warrant inducement offer agreement (the &#x201c;July Warrant Inducement Offer&#x201d;) with seven
holders of the Company&#x2019;s existing Series A warrants, Series B-1 warrants, Series C-1 warrants, Series D warrants, Series E warrants,
and Series F warrants (together the &#x201c;Existing Warrants&#x201d;). Pursuant to the July Warrant Inducement Offer, such warrant holders
immediately exercised some, or all, of their respective outstanding Existing Warrants to purchase an aggregate of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_ztcMr4bRjMl2" title="Purchase of warrants, shares"&gt;549,596&lt;/span&gt; shares of the
Company&#x2019;s common stock, at a reduced exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_zD96unmtx4we" title="Exercise price"&gt;8.40&lt;/span&gt;, for total gross proceeds of approximately $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250709__20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember_zoAsyHihNHT2" title="Gross proceeds from warrants"&gt;4.6&lt;/span&gt; million, prior to
deducting placement agent fees and offering expenses. Note that Ladenburg acted as the &#x201c;Placement Agent&#x201d; in the July Warrant
Inducement Offer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for the immediate exercise of some or all of the Existing Warrants for cash, the Company issued unregistered new Series
H common stock warrants (&#x201c;Series H Warrants&#x201d;) to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250709__us-gaap--TypeOfArrangementAxis__custom--JulyWarrantInducementOfferMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember_zjNTP2dpcyKj" title="Purchase of warrants, shares"&gt;549,587&lt;/span&gt; shares of common stock. See further warrant details
below. The Company filed a resale registration statement on Form S-3 (File No. 333-288784), to register the shares underlying the Series
H Warrants, which registration statement was declared effective by the Securities and Exchange Commission on July 25, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;August
2025 Public Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 20, 2025, the Company entered into an underwriting agreement with Ladenburg, as representative of the various underwriters (the
&#x201c;Representative&#x201d;), in connection with the issuance and public sale offering of various securities (the &#x201c;August Public
Offering&#x201d;), including: (i) &lt;span id="xdx_903_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zr3sYXN8KRr9" title="Issuance of common stock through august public offering, shares"&gt;1,922,764&lt;/span&gt; common stock units (&#x201c;Common Stock Unit&#x201d;), which includes the &lt;span id="xdx_905_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zfj0IIfW79Fh" title="Issuance of common stock through august public offering, shares"&gt;450,000&lt;/span&gt; Common Stock
Units purchased pursuant to the exercise, in full, of the Over-Allotment Option and (ii) &lt;span id="xdx_90D_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingShares_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zP5P50Woz6ul" title="Issuance of common stock through august public offering, shares"&gt;1,528,000&lt;/span&gt; pre-funded warrant units (&#x201c;Pre-Funded
Unit&#x201d;), resulting in gross proceeds of approximately $&lt;span id="xdx_90D_ecustom--IssuanceOfCommonSharesThroughAugustPublicOfferingValue_pn5n6_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zoQA6DZv5CW5" title="Gross proceeds"&gt;6.9&lt;/span&gt; million, before deducting underwriting discounts and commissions and
other estimated offering expenses. The August Public Offering closed on August 21, 2025&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--CommonStockUnitPerShareDescription_c20250820__20250820__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zYIsIAJqCzf9" title="Common stock unit per share description"&gt;Each
Common Stock Unit consists of (i) one share of common stock of the Company, par value $0.0001, and (ii) one Series I warrant to purchase
one share common stock, and each Pre-Funded Unit consists of (i) one pre-funded warrant to purchase one share common stock, and (ii)
one Series I warrant to purchase one share common stock. Each Common Stock Unit was sold to the public at a price of $2.00 per Common
Stock Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit.&lt;/span&gt; See further warrant details below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Stock Units and Pre-Funded Units were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333- 289670),
which was declared effective by the Securities and Exchange Commission on August 20, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the August Public Offering, the Company also issued to the Representative (or its designees) certain warrants (the &#x201c;Representative
Warrants&#x201d;) to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250820__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_ziha8uwFcddg" title="Purchase of warrants"&gt;172,538&lt;/span&gt; shares of common stock. See further warrant details below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfOutstandingWarrantsTextBlock_zfUEjplfNhKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the Company had outstanding warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231_zwpIRC1k4m5d" title="Purchase of shares"&gt;5,026,613&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zArg26kfajRk" title="Purchase of shares"&gt;910,299&lt;/span&gt; shares of common stock, respectively,
consisting of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zaOCfoDFvQsc" style="display: none"&gt;Schedule
of Outstanding Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zt1cD7aewJkg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zGcjM197DTXl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expiration
    date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgPI1YF6YQKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    Warrants to purchase Common Stock&lt;sup id="xdx_F47_z6tyoNYW74H9"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,938&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,938&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zPnNjNrABJWc" title="Exercise price"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zBLrmU8MfELg" title="Exercise price"&gt;1,380.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zFOSnd84WJIg" title="Issuance date"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zUxUSFeE6PEe" title="Issuance date"&gt;September
    12, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zuuTiMLGd41l" title="Expiration date"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgi48eD4KR84" title="Expiration date"&gt;September
    12, 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zUVdlL0BaiVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    Warrants to purchase Common Stock&lt;sup id="xdx_F49_z0mrR375bVd2"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zyVFDM8eVpxb" title="Exercise price"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zQULLMXm97K6" title="Exercise price"&gt;1,380.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zxcbb1ukdC6k" title="Issuance date"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zDggh4IodK2g" title="Issuance date"&gt;September
    12, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_z4liAvuhhqxd" title="Expiration date"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zXqH06rbbU6h" title="Expiration date"&gt;September
    12, 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zRVBT6OtXQeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    to purchase Restricted Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zO5Z4ONebg69" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_z2qM0oU5XHMe" title="Exercise price"&gt;158.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zUJLcykvwPFf" title="Issuance date"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zAlM0j3fOEzl" title="Issuance date"&gt;February
    21, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zCrmwgfNzpjj" title="Expiration date"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zH6XTXdFLiV6" title="Expiration date"&gt;February
    21, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z8vVu2fbocdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    to purchase Restricted Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zV55UrC9J21j" title="Exercise price"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z5KnjmHS6E25" title="Exercise price"&gt;22.80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zbLT0yqBgGgf" title="Issuance date"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zjpg5mki66jg" title="Issuance date"&gt;July
    28, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zoioWBZIMGhk" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_ziMWpzLjgupe" title="Expiration date"&gt;July
    28, 2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zeZNWsyvHhpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,333&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,333&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zAwBxePIkUjb" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zmQB8auENy31" title="Exercise price"&gt;79.20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zjCKIMye3hR2" title="Issuance date"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zyofz5iOEo6l" title="Issuance date"&gt;April
    18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zlBByEOYXPMg" title="Expiration date"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zXIw0zFkiLIi" title="Expiration date"&gt;April
    18, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zRG3mxhBCYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,458&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,458&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zKIgIbpzC1ig" title="Exercise price"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zmpqo9cGiIh9" title="Exercise price"&gt;45.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zuC38sqnOXVe" title="Issuance date"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zcEimW9CHDwc" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zh52pGdW7iY5" title="Expiration date"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zB3FkifcG6m" title="Expiration date"&gt;June
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zGpRg5Cjwixd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,542&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,542&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zYqG1ppSgiUh" title="Exercise price"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zji1jYZc0pPj" title="Exercise price"&gt;15.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zOLqDczScrZf" title="Issuance date"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_z39r5jRN8Xgk" title="Issuance date"&gt;October
    24, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_znMKkRG0xyD7" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zEFPgYkpeVI5" title="Expiration date"&gt;April
    24, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zZVb2ifZHIB8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,492&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,492&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zp5fzsTgXPRk" title="Exercise price"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zVOSoRBesXui" title="Exercise price"&gt;25.35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zYgNY8sFtbV8" title="Issuance date"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_ziM0m1pNuWie" title="Issuance date"&gt;November
    15, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zIuC2g4Wt7A" title="Expiration date"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zvDPE8DF8yeh" title="Expiration date"&gt;May
    15, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zXhwbxUCGCfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zRJ7x7PBpZ05" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zdDOtu5Gy3C" title="Exercise price"&gt;12.75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zhjJtbjLxlkk" title="Issuance date"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_z96k4eclodXh" title="Issuance date"&gt;January
    10, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zGXxb2E388ah" title="Expiration date"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zl6zoeGXGbp3" title="Expiration date"&gt;January
    10, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_z2bnVOBJgyA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1776"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zfRSuMQ0VzV7" title="Exercise price"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zy4bYiOnjp3g" title="Exercise price"&gt;9.75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_ztjFqf8aO60h" title="Issuance date"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zo8VkNfwBptg" title="Issuance date"&gt;March
    31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zZepBsWw9Uml" title="Expiration date"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zGXqAA2tfpSf" title="Expiration date"&gt;March
    31, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zEuVwluocZK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Representative
    Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,538&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1791"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zJrrNhRqghwi" title="Exercise price"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zl162NBSwsic" title="Exercise price"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdEpCKIeJ7Ib" title="Issuance date"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zTQ3XXZ2mqV9" title="Issuance date"&gt;August
    21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdpyOqOwiEle" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zHj8H0hmY7n5" title="Expiration date"&gt;August
    21, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z2qFIt86FJR1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    A Warrants to purchase Common Stock&lt;sup id="xdx_F4E_zxG56Br7YiY2"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;54,308&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;87,643&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zcPrXXsxl0Ug" title="Exercise price"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z0T7YlqVq6A4" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zhx14koTOfI3" title="Issuance date"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zMH8vvPjIc8l" title="Issuance date"&gt;April
    18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zxbeX8BwyTil" title="Expiration date"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zUzp6cT3xaN7" title="Expiration date"&gt;April
    18, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zRXRNz5giG4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B Warrants to purchase Common Stock&lt;sup id="xdx_F4B_zNjffbTUWvC6"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;57,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zmdUis4QApd1" title="Exercise price"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_z5zBuCDXO66l" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zuo4398kBeN1" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zl1V7NoF89Ue" title="Issuance date"&gt;April
    18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zgXFtLgEU3Yk" title="Expiration date"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zTOmfaCvW7e5" title="Expiration date"&gt;April
    18, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zxK56C9OewM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F48_zi6B9OdyvFwl"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,276&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zMIYuaYfcbLa" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zKVxTROyMJFc" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zLtZZYwOpUhh" title="Issuance date"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zTBty83PwKeh" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_z9APXtma4jC4" title="Expiration date"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zSAZb5EBebHg" title="Expiration date"&gt;June
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zuSbugofQ88a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F48_zUhKoE2S0fgk"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_z6Q2iO7wrkh9" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zl2esj0kAFWh" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zLKKaPSxogyi"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zaV2ONdzup92"&gt;July
    19, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zNeVoftq6pge"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_ztFKpEwufmX4"&gt;July
    19, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockThreeMember_zCkDawhXMcV9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4B_zvinK6tDmePi"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1861"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKZS5M9IGtAb" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zb3bKc7Ydp18" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKjBW1bV4H51" title="Issuance date"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z7Uc62PczQ67" title="Issuance date"&gt;July
    22, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zFw4BJGU3RB6" title="Expiration date"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z9YgJj0yOcul" title="Expiration date"&gt;July
    22, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zi58jpi6AbWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4D_zwXyMJUAW6sf"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1876"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16,251&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zwJ8XnPvSTne" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zM3LfOlLY3H4" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zd6a768WbR78" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zeYk8d2n02P7" title="Issuance date"&gt;November
    13, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zZTv3yM7zNW9" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zWQrU2BdNnfl" title="Expiration date"&gt;November
    13, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z7ujrgbVlbr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    C-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4E_zLwFIY6fTcya"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17,918&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;59,586&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zgpBGmZrf6Ac" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zg5kyH8SM1cb" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z75eDQh1xCTf" title="Issuance date"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z1qOlKItkiF8" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zq5QIba6ar77" title="Expiration date"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zSZHwcDX2mz8" title="Expiration date"&gt;June
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zJzt3bIaEs03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    C-1 Warrants to purchase Common Stock&lt;sup id="xdx_F43_zc78ko79Ispk"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_z5wdghE4PKA6" title="Exercise price"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zenUJTI5yCBb" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zSBMp3LEQtQc" title="Issuance date"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zj7lqydZBNHa" title="Issuance date"&gt;August
    8, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zDJmd6Ur5tM8" title="Expiration date"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zvgGsMNGC1p4" title="Expiration date"&gt;August
    7, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zJkgO7hFEuW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    C-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4F_zzxez496UVzc"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,168&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,168&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zrxgJl4GeaWg" title="Exercise price"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zxGPUeoRt4d" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_znsFzg1LuOEi" title="Issuance date"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zc8MccSdQq7f" title="Issuance date"&gt;August
    16, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zY7Qo5GVpeag" title="Expiration date"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_z6hpCbI1Lmi" title="Expiration date"&gt;August
    15, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z2JOJYvwMOEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    D Warrants to purchase Common Stock&lt;sup id="xdx_F4B_zG5lQ2yItPt4"&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,318&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89,153&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z16vwHbNh0Xg" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zUruHHO5ez2e" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zvGciJAxMT72" title="Issuance date"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zCJRExu8H2ed" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zF0K0c2rH383" title="Expiration date"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zVzpD6Ujyszl" title="Expiration date"&gt;December
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zIiCncH8XL19" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    E Warrants to purchase Common Stock&lt;sup id="xdx_F45_zpm863jw6ng2"&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1951"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170,836&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zlJJoSlZTg2k" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zEd7oC1C0zu9" title="Exercise price"&gt;13.56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zbdKGTDqyMe5" title="Issuance date"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zU1nxSdCqZRc" title="Issuance date"&gt;October
    24, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z3zozdSBbRZ6" title="Expiration date"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z9z4SmAWT7Uj" title="Expiration date"&gt;April
    24, 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zcyV1hRWckwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    F Warrants to purchase Common Stock&lt;sup id="xdx_F4A_zlTwV30ZGCpg"&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1966"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170,836&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNa9hD16C08j" title="Exercise price"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNp6cIBAGzq7" title="Exercise price"&gt;13.56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zC9N51yiELM6" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zLuJsjrmAE8h" title="Issuance date"&gt;October
    24, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zys2Z2jMKAzd" title="Expiration date"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zoQUUA1BJyS7" title="Expiration date"&gt;April
    24, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zd0cmXTTpCU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    G Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;504,417&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zhf66P3Rp22b" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBfcttBteGNj" title="Exercise price"&gt;8.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBun3MQzBom6" title="Issuance date"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zVGtsejpShZe" title="Issuance date"&gt;March
    31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_z5gD9u8fUuB2" title="Expiration date"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zDZtzijcIfq6" title="Expiration date"&gt;September
    30, 2032&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zYJrUiT4A1ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    H Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;549,587&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1997"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zQQ4PJRklOO5" title="Exercise price"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zeyBs7AL6XDb" title="Exercise price"&gt;8.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zJulfPSosXt3" title="Issuance date"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zLHZL6Dl1L04" title="Issuance date"&gt;July
    10, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zKP7QEZhGH0h" title="Expiration date"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zOprzkzV9Xg4" title="Expiration date"&gt;January
    10, 2031&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zrxXLSswYqoh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    I Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,450,764&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2012"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_znVkhYZ2rki4" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zzmaptg7Mxhi" title="Exercise price"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zf5M0aVWiWk6" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zwlQJh5khrwi" title="Issuance date"&gt;August
    21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zObUZb63f0c6" title="Expiration date"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zUj54wVc0HX4" title="Expiration date"&gt;August
    21, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_zXPhLVZlmw2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026,613&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F02_zklbGtvDjmx2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_znuGs7SC36K5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#x2019;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F07_zhchokdSYADf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F1B_zxZ3YvKW1fL2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--PublicWarrantRedemptionDescription_pid_c20250101__20251231_ztb6ktS0f7Gb" title="Public warrant redemption description"&gt;The
    Company may redeem the outstanding Public Warrants for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--RedemptionOfOutstandingWarrantsPerShare_pid_c20250101__20251231_z0eZIco0ySvh" title="Redemption of outstanding warrants per share"&gt;0.12&lt;/span&gt; per warrant upon at least &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--ClassOfWarrantsRedemptionNoticePeriod_dtD_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_zIroWV3Kn0of" title="Class of warrants, redemption notice period"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--SharePrice_iI_uUSDPShares_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_zKgdq3sn9i9g" title="Share Price"&gt;2,160.00&lt;/span&gt; per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company accounts for the Public Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because
    the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    accounting treatment of derivative financial instruments in accordance with ASC 815 requires that the Company record a derivative
    liability upon the closing of the FLAG Merger (see Note 2).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    October 17, 2024, the Company received notice from the NYSE that the Company&#x2019;s Public Warrants to purchase common stock are
    no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of such public
    warrants, and that the NYSE Regulation has determined to commence proceedings to delist the public warrants. The Public Warrants
    may be traded on the OTC Pink Marketplace under the symbol CLDWW.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F00_za4loOSPtY25" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F19_z1lSebrMsjPb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the year ended December 31, 2024, Series A warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f" title="Number of shares purchased"&gt;60,418&lt;/span&gt; shares of common stock
                                            were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7" title="Exercise price"&gt;18.24&lt;/span&gt; per share and the Company received gross proceeds of approximately
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576" title="Received dross proceeds"&gt;1.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series A warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z5zyhc1WQVrb" title="Number of shares purchased"&gt;33,335&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zM4YvTH3n71e" title="Exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zoKof3dAYb4h" title="Received dross proceeds"&gt;0.3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F00_zk1EX9rWw8s9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F14_zOJRQAZQHvG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
                                            B warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased"&gt;22,275&lt;/span&gt; shares of common stock were exercised at a reduced exercise
                                            price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price"&gt;24.00&lt;/span&gt; in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds"&gt;0.5&lt;/span&gt; million. During the year ended December 31, 2024, Series B warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased"&gt;68,335&lt;/span&gt;
                                            shares of common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price"&gt;18.24&lt;/span&gt; per share and the Company received gross
                                            proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds"&gt;1.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    outstanding Series B warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zCjS5nkk7RNl" title="Number of shares purchased"&gt;57,451&lt;/span&gt; shares of common stock expired in April 2025. As of December 31, 2025, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_do_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zJcPptm4wsz" title="Warrants outstanding"&gt;no&lt;/span&gt; Series
    B warrants remained outstanding.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zCbhZ5JVIGuf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F10_zNpmXQC9ahDe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy" title="Number of shares purchased"&gt;27,082&lt;/span&gt; shares of common
                                            stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1" title="Warrants exercise price"&gt;18.24&lt;/span&gt; per share and the Company received gross proceeds of approximately
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob" title="Gross proceeds"&gt;0.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series B-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zJzhCq7uqT78" title="Number of shares purchased"&gt;62,086&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zKWSRj6VjYF9" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zpYGyKGAeYG2" title="Gross proceeds"&gt;0.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0E_zCd37e8Jcx98" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F1C_z7McP3RC7sPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f" title="Number of shares purchased"&gt;4,167&lt;/span&gt; shares of
                                            common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg" title="Warrants exercise price"&gt;24.00&lt;/span&gt; per share and the Company received gross proceeds of
                                            approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b" title="Gross proceeds"&gt;0.1&lt;/span&gt; million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7" title="Number of shares purchased"&gt;47,936&lt;/span&gt; shares of common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8" title="Warrants exercise price"&gt;18.24&lt;/span&gt; per share and the Company
                                            received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg" title="Gross proceeds"&gt;0.9&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series C-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zsOkklPTY0P5" title="Number of shares purchased"&gt;41,668&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zelVqow1sFad" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zV1AZQnnrJB7" title="Gross proceeds"&gt;0.4&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zPih12spboPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F19_z4prBB1WV3Ea" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3" title="Deemed dividend"&gt;1.7&lt;/span&gt; million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series D warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zAy8T0RnQ5F8" title="Number of shares purchased"&gt;70,835&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zHckoL4rqJD2" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zExkhm7GdCK" title="Gross proceeds"&gt;0.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F08_z79dDFrQyW69" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zTzPNn9dfsxj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b" title="Number of shares purchased"&gt;341,672&lt;/span&gt; shares of common stock each were exercised
    at a reduced exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk" title="Gross proceeds"&gt;2.8&lt;/span&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zw2x6xA5wMr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2025, Series G pre-funded warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn3n3_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zIMMlwKBj4P2" title="Number of shares purchased"&gt;227,334&lt;/span&gt; shares of common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zp9TKcGaDSE8" title="Warrants exercise price"&gt;0.012&lt;/span&gt; per
share for gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_pn3n3_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGPreFundedWarrantsMember_zzoladFoOXya" title="Gross proceeds"&gt;3,000&lt;/span&gt;, and Series I pre-funded warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn3n3_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zhx59spSMne5" title="Number of shares purchased"&gt;1,528,000&lt;/span&gt; shares of common stock were
exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zZsOTErFGnk1" title="Warrants exercise price"&gt;0.001&lt;/span&gt; per share for gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ProceedsFromNotesPayable_pn3n3_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIPreFundedWarrantsMember_zU0n0BRUINl7" title="Gross proceeds"&gt;1,500&lt;/span&gt;. As such, no Series G pre-funded warrants or Series I pre-funded
warrants were outstanding as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI9zvMdBUoVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s aggregate warrant activity for the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zN4RTrBvgykj" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
                                            Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz2jDt26kuD4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjKyow3I4Dza" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;185.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgckS06Oe9s4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z38OhOA5wXR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,478,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyvU3Dx4CT4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,304,930&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetsFP6qOM73" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(57,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8GKp22zH831" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026,613&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5c4cCUUR2d9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoKmLVctvhY1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s aggregate warrant activity for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
                                            &lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price
                                            &lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
                                            Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgX2i38dnYCe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;111,772&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwS16fLKZb5f" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,380.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7sOYX74ZK9k" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9lVq9FwLa7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,176,804&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z71n7KcESiyc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(350,222&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted
    into Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z9Oku9Hupf42" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(28,055&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zAeJ5lPSI06f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo7VftXyfc8e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;185.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEGRpY5Qpcik" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zs7323Dd0Ihi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-19_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001449"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-19_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001451"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001453"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001457"
      unitRef="Shares">330000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001459"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_custom_VotingCommonStockMember"
      decimals="INF"
      id="Fact001461"
      unitRef="Shares">312000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="Fact001463"
      unitRef="Shares">18000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001465"
      unitRef="Shares">7216994</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001467"
      unitRef="Shares">7216994</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001469"
      unitRef="Shares">1730051</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">1730051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_NonvotingCommonStockMember"
      decimals="INF"
      id="Fact001473"
      unitRef="Shares">150000</us-gaap:CommonStockSharesOutstanding>
    <CLDI:CommonStockDividend
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact001475"
      unitRef="USD">0</CLDI:CommonStockDividend>
    <CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001477">&lt;p id="xdx_89D_ecustom--DiscloserOFCommonStockReservedForFurtureTableTextBlock_zRT2pG2i2nji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zU95Wcr2GHmf" style="display: none"&gt;Schedule
of Common Stock Reserved&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20251231_zNEUsLzr3llb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31, &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zzu59mG1aF0e" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4T92FbIxBcd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
    stock warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026,613&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockOptionsIssuedAndOutstandingMember_ztr8eJzSXMEk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common
    stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;277,822&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--RestrictedStockUnitsVestedAndUnreleasedMember_z2JFgf5R1kV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
    stock units vested and unreleased&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1485"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,039&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_zvq1KzbydcJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
    available for future issuance under the 2023 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;96,497&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7,409&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_hus-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_zVwIf82UdAU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
    reserved under the 2023 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,815&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,815&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_zei2jceJH5S5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Common stock reserved
    for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,433,747&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,029,807&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CLDI:DiscloserOFCommonStockReservedForFurtureTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001479"
      unitRef="Shares">5026613</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001480"
      unitRef="Shares">910299</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember"
      decimals="INF"
      id="Fact001482"
      unitRef="Shares">277822</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_CommonStockOptionsIssuedAndOutstandingMember"
      decimals="INF"
      id="Fact001483"
      unitRef="Shares">77245</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_RestrictedStockUnitsVestedAndUnreleasedMember"
      decimals="INF"
      id="Fact001486"
      unitRef="Shares">2039</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001488"
      unitRef="Shares">96497</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001489"
      unitRef="Shares">7409</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001491"
      unitRef="Shares">32815</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact001492"
      unitRef="Shares">32815</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001494"
      unitRef="Shares">5433747</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001495"
      unitRef="Shares">1029807</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-18_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001497"
      unitRef="Shares">110271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-18"
      decimals="INF"
      id="Fact001499"
      unitRef="Shares">16375</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-04-18_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001501"
      unitRef="USDPShares">48.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-04-18_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001503"
      unitRef="Shares">6333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-31_custom_SeriesBWarrantsAndSeriesCWarrantsMember_custom_InducementOfferLetterAgreementMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Shares">89153</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-31_custom_SeriesBOneWarrantsMember_custom_InducementOfferLetterAgreementMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Shares">22275</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001509"
      unitRef="Shares">66878</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-05-31_custom_SeriesCOneWarrantsMember_custom_InducementOfferLetterAgreementMember"
      decimals="INF"
      id="Fact001511"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-31_custom_SeriesDCommonStockMember_custom_InducementOfferLetterAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001513"
      unitRef="Shares">89153</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001515"
      unitRef="Shares">4458</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-07-26"
      decimals="INF"
      id="Fact001517"
      unitRef="Shares">58235</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-26_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">17.172</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-07-26_us-gaap_WarrantMember_custom_SubscriptionAgreementMember"
      decimals="INF"
      id="Fact001521"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-26_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001523"
      unitRef="USDPShares">22.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-262024-07-26_us-gaap_WarrantMember"
      decimals="-5"
      id="Fact001525"
      unitRef="USD">1000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-262024-07-26_custom_BoardOfDirectorsMember"
      decimals="-5"
      id="Fact001527"
      unitRef="USD">2000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-262024-07-26_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact001529"
      unitRef="Shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <CLDI:PercentageOfStrategicInvestment
      contextRef="From2024-07-262024-07-26_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact001531"
      unitRef="Pure">0.25</CLDI:PercentageOfStrategicInvestment>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-10-272025-10-27_custom_NovaCellMember"
      decimals="INF"
      id="Fact001533"
      unitRef="Shares">22500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2025-10-27_custom_NovaCellMember"
      decimals="INF"
      id="Fact001535"
      unitRef="Pure">0.75</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-10-272025-10-27_custom_NovaCellMember"
      decimals="-6"
      id="Fact001537"
      unitRef="USD">6000000.0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset
      contextRef="AsOf2024-09-17_custom_NovaCellMember"
      decimals="-3"
      id="Fact001539"
      unitRef="USD">50000</us-gaap:DerivativeAssetCollateralObligationToReturnCashOffset>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="From2024-09-172024-09-17_custom_NovaCellMember"
      decimals="-5"
      id="Fact001541"
      unitRef="USD">1200000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-09-17_custom_NovaCellMember"
      decimals="-5"
      id="Fact001543"
      unitRef="USD">4800000</us-gaap:NotesPayable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact001545"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="-5"
      id="Fact001547"
      unitRef="USDPShares">5100000</us-gaap:CommonStockParOrStatedValuePerShare>
    <CLDI:CashCommissionPercentage
      contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact001549"
      unitRef="Pure">0.03</CLDI:CashCommissionPercentage>
    <CLDI:DisbursementsCounsel
      contextRef="AsOf2024-10-11_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact001551"
      unitRef="USD">50000</CLDI:DisbursementsCounsel>
    <us-gaap:LegalFees
      contextRef="From2024-10-112024-10-11_custom_SalesAgreementMember"
      decimals="0"
      id="Fact001553"
      unitRef="USD">7500</us-gaap:LegalFees>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact001555"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-02-042025-02-04_custom_MarketOfferingAgreementMember"
      decimals="-5"
      id="Fact001557"
      unitRef="USD">5100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-02-052025-02-05_custom_MarketOfferingAgreementMember"
      decimals="-5"
      id="Fact001559"
      unitRef="USD">11200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-02-042025-02-04_us-gaap_CommonStockMember_custom_SalesAgreementMember"
      decimals="-5"
      id="Fact001561"
      unitRef="USD">6100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001563"
      unitRef="Shares">534265</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-01-012025-12-31_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001565"
      unitRef="USD">3400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001566"
      unitRef="Shares">170836</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001568"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-23_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001570"
      unitRef="USDPShares">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesECommonWarrantsMember"
      decimals="INF"
      id="Fact001571"
      unitRef="Shares">170836</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-232024-10-23_custom_SecuritiesPurchaseAgreementMember_custom_SeriesFCommonWarrantsMember"
      decimals="INF"
      id="Fact001572"
      unitRef="Shares">170836</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-10-242024-10-24_custom_PlacementAgentWarrantsMember"
      decimals="-5"
      id="Fact001574"
      unitRef="USD">2100000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-10-24_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001576"
      unitRef="Shares">8542</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001578"
      unitRef="Shares">369823</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001580"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001582"
      unitRef="USDPShares">20.28</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-11-152024-11-15_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001584"
      unitRef="USD">7500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-11-142024-11-14_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001586"
      unitRef="Shares">18492</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-092025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001588"
      unitRef="Shares">416667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001590"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001592"
      unitRef="USDPShares">10.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-092025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001594"
      unitRef="USD">4300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-09_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001596"
      unitRef="Shares">20834</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001598"
      unitRef="Shares">277084</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001600"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001602"
      unitRef="USDPShares">7.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001604"
      unitRef="Shares">227334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001606"
      unitRef="USDPShares">7.788</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001608"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-03-282025-03-28_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGCommonWarrantsMember"
      decimals="INF"
      id="Fact001610"
      unitRef="Shares">504417</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-03-28_custom_PlacementAgencyAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001612"
      unitRef="Shares">25221</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember"
      decimals="INF"
      id="Fact001614"
      unitRef="Shares">549596</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember"
      decimals="INF"
      id="Fact001616"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-07-092025-07-09_custom_JulyWarrantInducementOfferMember"
      decimals="-5"
      id="Fact001618"
      unitRef="USD">4600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-09_custom_JulyWarrantInducementOfferMember_custom_SeriesHCommonStockWarrantsMember"
      decimals="INF"
      id="Fact001620"
      unitRef="Shares">549587</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares
      contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact001622"
      unitRef="Shares">1922764</CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares>
    <CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares
      contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact001624"
      unitRef="Shares">450000</CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares>
    <CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares
      contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact001626"
      unitRef="Shares">1528000</CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingShares>
    <CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingValue
      contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember"
      decimals="-5"
      id="Fact001628"
      unitRef="USD">6900000</CLDI:IssuanceOfCommonSharesThroughAugustPublicOfferingValue>
    <CLDI:CommonStockUnitPerShareDescription
      contextRef="From2025-08-202025-08-20_us-gaap_CommonStockMember_custom_UnderwritingAgreementMember"
      id="Fact001630">Each
Common Stock Unit consists of (i) one share of common stock of the Company, par value $0.0001, and (ii) one Series I warrant to purchase
one share common stock, and each Pre-Funded Unit consists of (i) one pre-funded warrant to purchase one share common stock, and (ii)
one Series I warrant to purchase one share common stock. Each Common Stock Unit was sold to the public at a price of $2.00 per Common
Stock Unit and each Pre-Funded Unit was sold to the public at a price of $1.999 per Pre-Funded Unit.</CLDI:CommonStockUnitPerShareDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-08-20_custom_RepresentativeWarrantsMember"
      decimals="INF"
      id="Fact001632"
      unitRef="Shares">172538</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CLDI:ScheduleOfOutstandingWarrantsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact001634">&lt;p id="xdx_89A_ecustom--ScheduleOfOutstandingWarrantsTextBlock_zfUEjplfNhKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the Company had outstanding warrants to purchase &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231_zwpIRC1k4m5d" title="Purchase of shares"&gt;5,026,613&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231_zArg26kfajRk" title="Purchase of shares"&gt;910,299&lt;/span&gt; shares of common stock, respectively,
consisting of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zaOCfoDFvQsc" style="display: none"&gt;Schedule
of Outstanding Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20251231_zt1cD7aewJkg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20241231_zGcjM197DTXl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance
    date&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expiration
    date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgPI1YF6YQKe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
    Warrants to purchase Common Stock&lt;sup id="xdx_F47_z6tyoNYW74H9"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,938&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15,938&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zPnNjNrABJWc" title="Exercise price"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zBLrmU8MfELg" title="Exercise price"&gt;1,380.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zFOSnd84WJIg" title="Issuance date"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zUxUSFeE6PEe" title="Issuance date"&gt;September
    12, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zuuTiMLGd41l" title="Expiration date"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsToPurchaseCommonStockMember_zgi48eD4KR84" title="Expiration date"&gt;September
    12, 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zUVdlL0BaiVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Public
    Warrants to purchase Common Stock&lt;sup id="xdx_F49_z0mrR375bVd2"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zyVFDM8eVpxb" title="Exercise price"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zQULLMXm97K6" title="Exercise price"&gt;1,380.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zxcbb1ukdC6k" title="Issuance date"&gt;&lt;span id="xdx_908_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zDggh4IodK2g" title="Issuance date"&gt;September
    12, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_z4liAvuhhqxd" title="Expiration date"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsToPurchaseCommonStockMember_zXqH06rbbU6h" title="Expiration date"&gt;September
    12, 2028&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zRVBT6OtXQeg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    to purchase Restricted Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zO5Z4ONebg69" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_z2qM0oU5XHMe" title="Exercise price"&gt;158.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zUJLcykvwPFf" title="Issuance date"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zAlM0j3fOEzl" title="Issuance date"&gt;February
    21, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zCrmwgfNzpjj" title="Expiration date"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesMember_zH6XTXdFLiV6" title="Expiration date"&gt;February
    21, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z8vVu2fbocdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
    to purchase Restricted Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zV55UrC9J21j" title="Exercise price"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_z5KnjmHS6E25" title="Exercise price"&gt;22.80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zbLT0yqBgGgf" title="Issuance date"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zjpg5mki66jg" title="Issuance date"&gt;July
    28, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_zoioWBZIMGhk" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsToPurchaseRestrictedSharesOneMember_ziMWpzLjgupe" title="Expiration date"&gt;July
    28, 2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zeZNWsyvHhpd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,333&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,333&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zAwBxePIkUjb" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zmQB8auENy31" title="Exercise price"&gt;79.20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zjCKIMye3hR2" title="Issuance date"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zyofz5iOEo6l" title="Issuance date"&gt;April
    18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zlBByEOYXPMg" title="Expiration date"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockMember_zXIw0zFkiLIi" title="Expiration date"&gt;April
    18, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zRG3mxhBCYJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,458&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,458&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zKIgIbpzC1ig" title="Exercise price"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zmpqo9cGiIh9" title="Exercise price"&gt;45.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zuC38sqnOXVe" title="Issuance date"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zcEimW9CHDwc" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zh52pGdW7iY5" title="Expiration date"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockOneMember_zB3FkifcG6m" title="Expiration date"&gt;June
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zGpRg5Cjwixd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,542&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,542&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zYqG1ppSgiUh" title="Exercise price"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zji1jYZc0pPj" title="Exercise price"&gt;15.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zOLqDczScrZf" title="Issuance date"&gt;&lt;span id="xdx_90D_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_z39r5jRN8Xgk" title="Issuance date"&gt;October
    24, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_znMKkRG0xyD7" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockTwoMember_zEFPgYkpeVI5" title="Expiration date"&gt;April
    24, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zZVb2ifZHIB8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,492&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,492&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zp5fzsTgXPRk" title="Exercise price"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zVOSoRBesXui" title="Exercise price"&gt;25.35&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zYgNY8sFtbV8" title="Issuance date"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_ziM0m1pNuWie" title="Issuance date"&gt;November
    15, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zIuC2g4Wt7A" title="Expiration date"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockThreeMember_zvDPE8DF8yeh" title="Expiration date"&gt;May
    15, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zXhwbxUCGCfk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zRJ7x7PBpZ05" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zdDOtu5Gy3C" title="Exercise price"&gt;12.75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zhjJtbjLxlkk" title="Issuance date"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_z96k4eclodXh" title="Issuance date"&gt;January
    10, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zGXxb2E388ah" title="Expiration date"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFourMember_zl6zoeGXGbp3" title="Expiration date"&gt;January
    10, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_z2bnVOBJgyA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Placement
    Agent Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1776"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zfRSuMQ0VzV7" title="Exercise price"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zy4bYiOnjp3g" title="Exercise price"&gt;9.75&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_ztjFqf8aO60h" title="Issuance date"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zo8VkNfwBptg" title="Issuance date"&gt;March
    31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zZepBsWw9Uml" title="Expiration date"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--PlacementAgentWarrantsToPurchaseCommonStockFiveMember_zGXqAA2tfpSf" title="Expiration date"&gt;March
    31, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zEuVwluocZK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Representative
    Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,538&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1791"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zJrrNhRqghwi" title="Exercise price"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zl162NBSwsic" title="Exercise price"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdEpCKIeJ7Ib" title="Issuance date"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zTQ3XXZ2mqV9" title="Issuance date"&gt;August
    21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zdpyOqOwiEle" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsToPurchaseCommonStockMember_zHj8H0hmY7n5" title="Expiration date"&gt;August
    21, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z2qFIt86FJR1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    A Warrants to purchase Common Stock&lt;sup id="xdx_F4E_zxG56Br7YiY2"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;54,308&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;87,643&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zcPrXXsxl0Ug" title="Exercise price"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_z0T7YlqVq6A4" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zhx14koTOfI3" title="Issuance date"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zMH8vvPjIc8l" title="Issuance date"&gt;April
    18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zxbeX8BwyTil" title="Expiration date"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsToPurchaseCommonStockMember_zUzp6cT3xaN7" title="Expiration date"&gt;April
    18, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zRXRNz5giG4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B Warrants to purchase Common Stock&lt;sup id="xdx_F4B_zNjffbTUWvC6"&gt;(4)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1820"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;57,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zmdUis4QApd1" title="Exercise price"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_z5zBuCDXO66l" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zuo4398kBeN1" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zl1V7NoF89Ue" title="Issuance date"&gt;April
    18, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zgXFtLgEU3Yk" title="Expiration date"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zTOmfaCvW7e5" title="Expiration date"&gt;April
    18, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zxK56C9OewM" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F48_zi6B9OdyvFwl"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,276&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zMIYuaYfcbLa" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zKVxTROyMJFc" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zLtZZYwOpUhh" title="Issuance date"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zTBty83PwKeh" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_z9APXtma4jC4" title="Expiration date"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockMember_zSAZb5EBebHg" title="Expiration date"&gt;June
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zuSbugofQ88a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F48_zUhKoE2S0fgk"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1850"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_z6Q2iO7wrkh9" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zl2esj0kAFWh" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zLKKaPSxogyi"&gt;&lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zaV2ONdzup92"&gt;July
    19, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_zNeVoftq6pge"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockOneMember_ztFKpEwufmX4"&gt;July
    19, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockThreeMember_zCkDawhXMcV9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4B_zvinK6tDmePi"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1861"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,334&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKZS5M9IGtAb" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zb3bKc7Ydp18" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zKjBW1bV4H51" title="Issuance date"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z7Uc62PczQ67" title="Issuance date"&gt;July
    22, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zFw4BJGU3RB6" title="Expiration date"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_z9YgJj0yOcul" title="Expiration date"&gt;July
    22, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zi58jpi6AbWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    B-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4D_zwXyMJUAW6sf"&gt;(5)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1876"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16,251&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zwJ8XnPvSTne" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockTwoMember_zM3LfOlLY3H4" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zd6a768WbR78" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zeYk8d2n02P7" title="Issuance date"&gt;November
    13, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zZTv3yM7zNW9" title="Expiration date"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesB1WarrantsToPurchaseCommonStockFourMember_zWQrU2BdNnfl" title="Expiration date"&gt;November
    13, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z7ujrgbVlbr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    C-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4E_zLwFIY6fTcya"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17,918&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;59,586&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zgpBGmZrf6Ac" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zg5kyH8SM1cb" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z75eDQh1xCTf" title="Issuance date"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_z1qOlKItkiF8" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zq5QIba6ar77" title="Expiration date"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockMember_zSZHwcDX2mz8" title="Expiration date"&gt;June
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zJzt3bIaEs03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    C-1 Warrants to purchase Common Stock&lt;sup id="xdx_F43_zc78ko79Ispk"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,167&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_z5wdghE4PKA6" title="Exercise price"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zenUJTI5yCBb" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zSBMp3LEQtQc" title="Issuance date"&gt;&lt;span id="xdx_902_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zj7lqydZBNHa" title="Issuance date"&gt;August
    8, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zDJmd6Ur5tM8" title="Expiration date"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockOneMember_zvgGsMNGC1p4" title="Expiration date"&gt;August
    7, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zJkgO7hFEuW3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    C-1 Warrants to purchase Common Stock&lt;sup id="xdx_F4F_zzxez496UVzc"&gt;(6)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,168&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,168&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zrxgJl4GeaWg" title="Exercise price"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zxGPUeoRt4d" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_znsFzg1LuOEi" title="Issuance date"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zc8MccSdQq7f" title="Issuance date"&gt;August
    16, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_zY7Qo5GVpeag" title="Expiration date"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesC1WarrantsToPurchaseCommonStockTwoMember_z6hpCbI1Lmi" title="Expiration date"&gt;August
    15, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z2JOJYvwMOEb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    D Warrants to purchase Common Stock&lt;sup id="xdx_F4B_zG5lQ2yItPt4"&gt;(7)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18,318&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89,153&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_z16vwHbNh0Xg" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zUruHHO5ez2e" title="Exercise price"&gt;18.24&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zvGciJAxMT72" title="Issuance date"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zCJRExu8H2ed" title="Issuance date"&gt;June
    3, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zF0K0c2rH383" title="Expiration date"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsToPurchaseCommonStockMember_zVzpD6Ujyszl" title="Expiration date"&gt;December
    3, 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zIiCncH8XL19" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    E Warrants to purchase Common Stock&lt;sup id="xdx_F45_zpm863jw6ng2"&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1951"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170,836&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zlJJoSlZTg2k" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zEd7oC1C0zu9" title="Exercise price"&gt;13.56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zbdKGTDqyMe5" title="Issuance date"&gt;&lt;span id="xdx_901_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_zU1nxSdCqZRc" title="Issuance date"&gt;October
    24, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z3zozdSBbRZ6" title="Expiration date"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsToPurchaseCommonStockMember_z9z4SmAWT7Uj" title="Expiration date"&gt;April
    24, 2026&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zcyV1hRWckwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    F Warrants to purchase Common Stock&lt;sup id="xdx_F4A_zlTwV30ZGCpg"&gt;(8)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1966"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;170,836&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNa9hD16C08j" title="Exercise price"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zNp6cIBAGzq7" title="Exercise price"&gt;13.56&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zC9N51yiELM6" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zLuJsjrmAE8h" title="Issuance date"&gt;October
    24, 2024&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zys2Z2jMKAzd" title="Expiration date"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFWarrantsToPurchaseCommonStockMember_zoQUUA1BJyS7" title="Expiration date"&gt;April
    24, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zd0cmXTTpCU3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    G Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;504,417&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1982"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zhf66P3Rp22b" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBfcttBteGNj" title="Exercise price"&gt;8.34&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zBun3MQzBom6" title="Issuance date"&gt;&lt;span id="xdx_903_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zVGtsejpShZe" title="Issuance date"&gt;March
    31, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_z5gD9u8fUuB2" title="Expiration date"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsToPurchaseCommonStockMember_zDZtzijcIfq6" title="Expiration date"&gt;September
    30, 2032&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zYJrUiT4A1ga" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    H Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;549,587&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1997"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zQQ4PJRklOO5" title="Exercise price"&gt;&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zeyBs7AL6XDb" title="Exercise price"&gt;8.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zJulfPSosXt3" title="Issuance date"&gt;&lt;span id="xdx_905_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zLHZL6Dl1L04" title="Issuance date"&gt;July
    10, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zKP7QEZhGH0h" title="Expiration date"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHWarrantsToPurchaseCommonStockMember_zOprzkzV9Xg4" title="Expiration date"&gt;January
    10, 2031&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zrxXLSswYqoh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
    I Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,450,764&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2012"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_znVkhYZ2rki4" title="Exercise price"&gt;&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zzmaptg7Mxhi" title="Exercise price"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zf5M0aVWiWk6" title="Issuance date"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRighstIssuanceDate_dd_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zwlQJh5khrwi" title="Issuance date"&gt;August
    21, 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zObUZb63f0c6" title="Expiration date"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIWarrantsToPurchaseCommonStockMember_zUj54wVc0HX4" title="Expiration date"&gt;August
    21, 2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_zXPhLVZlmw2a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026,613&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span id="xdx_F02_zklbGtvDjmx2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_znuGs7SC36K5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#x2019;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F07_zhchokdSYADf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F1B_zxZ3YvKW1fL2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--PublicWarrantRedemptionDescription_pid_c20250101__20251231_ztb6ktS0f7Gb" title="Public warrant redemption description"&gt;The
    Company may redeem the outstanding Public Warrants for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_ecustom--RedemptionOfOutstandingWarrantsPerShare_pid_c20250101__20251231_z0eZIco0ySvh" title="Redemption of outstanding warrants per share"&gt;0.12&lt;/span&gt; per warrant upon at least &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_ecustom--ClassOfWarrantsRedemptionNoticePeriod_dtD_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember_zIroWV3Kn0of" title="Class of warrants, redemption notice period"&gt;30&lt;/span&gt; days&#x2019; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--SharePrice_iI_uUSDPShares_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--RedemptionOfWarrantsMember__custom--TriggeringEventAxis__custom--SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_zKgdq3sn9i9g" title="Share Price"&gt;2,160.00&lt;/span&gt; per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company accounts for the Public Warrants in accordance with the guidance contained in ASC 815-40. Such guidance provides that because
    the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    accounting treatment of derivative financial instruments in accordance with ASC 815 requires that the Company record a derivative
    liability upon the closing of the FLAG Merger (see Note 2).&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
    October 17, 2024, the Company received notice from the NYSE that the Company&#x2019;s Public Warrants to purchase common stock are
    no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of such public
    warrants, and that the NYSE Regulation has determined to commence proceedings to delist the public warrants. The Public Warrants
    may be traded on the OTC Pink Marketplace under the symbol CLDWW.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F00_za4loOSPtY25" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F19_z1lSebrMsjPb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the year ended December 31, 2024, Series A warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f" title="Number of shares purchased"&gt;60,418&lt;/span&gt; shares of common stock
                                            were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7" title="Exercise price"&gt;18.24&lt;/span&gt; per share and the Company received gross proceeds of approximately
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576" title="Received dross proceeds"&gt;1.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series A warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_z5zyhc1WQVrb" title="Number of shares purchased"&gt;33,335&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zM4YvTH3n71e" title="Exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zoKof3dAYb4h" title="Received dross proceeds"&gt;0.3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F00_zk1EX9rWw8s9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F14_zOJRQAZQHvG1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
                                            B warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1" title="Number of shares purchased"&gt;22,275&lt;/span&gt; shares of common stock were exercised at a reduced exercise
                                            price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8" title="Warrants exercise price"&gt;24.00&lt;/span&gt; in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5" title="Gross proceeds"&gt;0.5&lt;/span&gt; million. During the year ended December 31, 2024, Series B warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3" title="Number of shares purchased"&gt;68,335&lt;/span&gt;
                                            shares of common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8" title="Warrants exercise price"&gt;18.24&lt;/span&gt; per share and the Company received gross
                                            proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb" title="Gross proceeds"&gt;1.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    outstanding Series B warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zCjS5nkk7RNl" title="Number of shares purchased"&gt;57,451&lt;/span&gt; shares of common stock expired in April 2025. As of December 31, 2025, &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_do_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsToPurchaseCommonStockMember_zJcPptm4wsz" title="Warrants outstanding"&gt;no&lt;/span&gt; Series
    B warrants remained outstanding.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zCbhZ5JVIGuf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F10_zNpmXQC9ahDe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy" title="Number of shares purchased"&gt;27,082&lt;/span&gt; shares of common
                                            stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1" title="Warrants exercise price"&gt;18.24&lt;/span&gt; per share and the Company received gross proceeds of approximately
                                            $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob" title="Gross proceeds"&gt;0.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series B-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zJzhCq7uqT78" title="Number of shares purchased"&gt;62,086&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zKWSRj6VjYF9" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zpYGyKGAeYG2" title="Gross proceeds"&gt;0.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0E_zCd37e8Jcx98" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F1C_z7McP3RC7sPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f" title="Number of shares purchased"&gt;4,167&lt;/span&gt; shares of
                                            common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg" title="Warrants exercise price"&gt;24.00&lt;/span&gt; per share and the Company received gross proceeds of
                                            approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b" title="Gross proceeds"&gt;0.1&lt;/span&gt; million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7" title="Number of shares purchased"&gt;47,936&lt;/span&gt; shares of common stock were exercised at $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8" title="Warrants exercise price"&gt;18.24&lt;/span&gt; per share and the Company
                                            received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg" title="Gross proceeds"&gt;0.9&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series C-1 warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zsOkklPTY0P5" title="Number of shares purchased"&gt;41,668&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zelVqow1sFad" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsOneMember_zV1AZQnnrJB7" title="Gross proceeds"&gt;0.4&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F02_zPih12spboPj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_F19_z4prBB1WV3Ea" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3" title="Deemed dividend"&gt;1.7&lt;/span&gt; million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series D warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zAy8T0RnQ5F8" title="Number of shares purchased"&gt;70,835&lt;/span&gt; shares of common stock were exercised at a reduced exercise
    price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zHckoL4rqJD2" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received gross proceeds of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zExkhm7GdCK" title="Gross proceeds"&gt;0.6&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F08_z79dDFrQyW69" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zTzPNn9dfsxj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b" title="Number of shares purchased"&gt;341,672&lt;/span&gt; shares of common stock each were exercised
    at a reduced exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute" title="Warrants exercise price"&gt;8.40&lt;/span&gt; per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk" title="Gross proceeds"&gt;2.8&lt;/span&gt; million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</CLDI:ScheduleOfOutstandingWarrantsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact001636"
      unitRef="Shares">5026613</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact001638"
      unitRef="Shares">910299</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001640"
      unitRef="Shares">15938000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001641"
      unitRef="Shares">15938000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001643"
      unitRef="USDPShares">1380.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001645"
      unitRef="USDPShares">1380.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      id="Fact001647">2023-09-12</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      id="Fact001649">2023-09-12</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      id="Fact001651">2028-09-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PrivateWarrantsToPurchaseCommonStockMember"
      id="Fact001653">2028-09-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001655"
      unitRef="Shares">95834000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001656"
      unitRef="Shares">95834000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001658"
      unitRef="USDPShares">1380000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001660"
      unitRef="USDPShares">1380000.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      id="Fact001662">2023-09-12</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      id="Fact001664">2023-09-12</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      id="Fact001666">2028-09-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PublicWarrantsToPurchaseCommonStockMember"
      id="Fact001668">2028-09-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      decimals="-3"
      id="Fact001670"
      unitRef="Shares">3334000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      decimals="-3"
      id="Fact001671"
      unitRef="Shares">3334000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      decimals="INF"
      id="Fact001673"
      unitRef="USDPShares">158.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      decimals="INF"
      id="Fact001675"
      unitRef="USDPShares">158.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      id="Fact001677">2024-02-21</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      id="Fact001679">2024-02-21</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      id="Fact001681">2029-02-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesMember"
      id="Fact001683">2029-02-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      decimals="-3"
      id="Fact001685"
      unitRef="Shares">50000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      decimals="-3"
      id="Fact001686"
      unitRef="Shares">50000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      decimals="INF"
      id="Fact001688"
      unitRef="USDPShares">22.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      decimals="INF"
      id="Fact001690"
      unitRef="USDPShares">22.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      id="Fact001692">2024-07-28</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      id="Fact001694">2024-07-28</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      id="Fact001696">2027-07-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_WarrantsToPurchaseRestrictedSharesOneMember"
      id="Fact001698">2027-07-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001700"
      unitRef="Shares">6333000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001701"
      unitRef="Shares">6333000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001703"
      unitRef="USDPShares">79.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001705"
      unitRef="USDPShares">79.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      id="Fact001707">2024-04-18</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      id="Fact001709">2024-04-18</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      id="Fact001711">2029-04-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockMember"
      id="Fact001713">2029-04-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      decimals="-3"
      id="Fact001715"
      unitRef="Shares">4458000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      decimals="-3"
      id="Fact001716"
      unitRef="Shares">4458000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      decimals="INF"
      id="Fact001718"
      unitRef="USDPShares">45.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      decimals="INF"
      id="Fact001720"
      unitRef="USDPShares">45.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      id="Fact001722">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      id="Fact001724">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      id="Fact001726">2029-06-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockOneMember"
      id="Fact001728">2029-06-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      decimals="-3"
      id="Fact001730"
      unitRef="Shares">8542000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      decimals="-3"
      id="Fact001731"
      unitRef="Shares">8542000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001733"
      unitRef="USDPShares">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001735"
      unitRef="USDPShares">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      id="Fact001737">2024-10-24</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      id="Fact001739">2024-10-24</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      id="Fact001741">2030-04-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockTwoMember"
      id="Fact001743">2030-04-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      decimals="-3"
      id="Fact001745"
      unitRef="Shares">18492000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      decimals="-3"
      id="Fact001746"
      unitRef="Shares">18492000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">25.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      decimals="INF"
      id="Fact001750"
      unitRef="USDPShares">25.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      id="Fact001752">2024-11-15</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      id="Fact001754">2024-11-15</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      id="Fact001756">2030-05-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockThreeMember"
      id="Fact001758">2030-05-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      decimals="-3"
      id="Fact001760"
      unitRef="Shares">20834000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      decimals="INF"
      id="Fact001763"
      unitRef="USDPShares">12.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      decimals="INF"
      id="Fact001765"
      unitRef="USDPShares">12.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      id="Fact001767">2025-01-10</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      id="Fact001769">2025-01-10</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      id="Fact001771">2030-01-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFourMember"
      id="Fact001773">2030-01-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      decimals="-3"
      id="Fact001775"
      unitRef="Shares">25221000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      decimals="INF"
      id="Fact001778"
      unitRef="USDPShares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      decimals="INF"
      id="Fact001780"
      unitRef="USDPShares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      id="Fact001782">2025-03-31</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      id="Fact001784">2025-03-31</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      id="Fact001786">2030-03-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PlacementAgentWarrantsToPurchaseCommonStockFiveMember"
      id="Fact001788">2030-03-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001790"
      unitRef="Shares">172538000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001793"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001795"
      unitRef="USDPShares">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      id="Fact001797">2025-08-21</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      id="Fact001799">2025-08-21</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      id="Fact001801">2030-08-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_RepresentativeWarrantsToPurchaseCommonStockMember"
      id="Fact001803">2030-08-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001805"
      unitRef="Shares">54308000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001806"
      unitRef="Shares">87643000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001808"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001810"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      id="Fact001812">2024-04-18</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      id="Fact001814">2024-04-18</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      id="Fact001816">2029-04-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsToPurchaseCommonStockMember"
      id="Fact001818">2029-04-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001821"
      unitRef="Shares">57451000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001823"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001825"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      id="Fact001827">2024-04-18</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      id="Fact001829">2024-04-18</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      id="Fact001831">2025-04-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      id="Fact001833">2025-04-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001835"
      unitRef="Shares">1442000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001836"
      unitRef="Shares">22276000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001838"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001840"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      id="Fact001842">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      id="Fact001844">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      id="Fact001846">2029-06-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockMember"
      id="Fact001848">2029-06-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      decimals="-3"
      id="Fact001851"
      unitRef="Shares">16667000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      decimals="INF"
      id="Fact001853"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      decimals="INF"
      id="Fact001855"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001856">2024-07-19</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001857">2024-07-19</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001858">2029-07-19</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001859">2029-07-19</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockThreeMember"
      decimals="-3"
      id="Fact001862"
      unitRef="Shares">8334000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001864"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001866"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001868">2024-07-22</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001870">2024-07-22</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001872">2029-07-22</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001874">2029-07-22</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      decimals="-3"
      id="Fact001877"
      unitRef="Shares">16251000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      decimals="INF"
      id="Fact001879"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001881"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      id="Fact001883">2024-11-13</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      id="Fact001885">2024-11-13</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      id="Fact001887">2029-11-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesB1WarrantsToPurchaseCommonStockFourMember"
      id="Fact001889">2029-11-13</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001891"
      unitRef="Shares">17918000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001892"
      unitRef="Shares">59586000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001894"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001896"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      id="Fact001898">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      id="Fact001900">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      id="Fact001902">2029-06-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockMember"
      id="Fact001904">2029-06-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      decimals="-3"
      id="Fact001906"
      unitRef="Shares">4167000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      decimals="-3"
      id="Fact001907"
      unitRef="Shares">4167000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      decimals="INF"
      id="Fact001909"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      decimals="INF"
      id="Fact001911"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001913">2024-08-08</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001915">2024-08-08</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001917">2029-08-07</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockOneMember"
      id="Fact001919">2029-08-07</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      decimals="-3"
      id="Fact001921"
      unitRef="Shares">4168000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      decimals="-3"
      id="Fact001922"
      unitRef="Shares">4168000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001924"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      decimals="INF"
      id="Fact001926"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001928">2024-08-16</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001930">2024-08-16</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001932">2029-08-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesC1WarrantsToPurchaseCommonStockTwoMember"
      id="Fact001934">2029-08-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001936"
      unitRef="Shares">18318000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001937"
      unitRef="Shares">89153000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001939"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001941"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      id="Fact001943">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      id="Fact001945">2024-06-03</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      id="Fact001947">2029-12-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesDWarrantsToPurchaseCommonStockMember"
      id="Fact001949">2029-12-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001952"
      unitRef="Shares">170836000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001954"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001956"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      id="Fact001958">2024-10-24</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      id="Fact001960">2024-10-24</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      id="Fact001962">2026-04-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesEWarrantsToPurchaseCommonStockMember"
      id="Fact001964">2026-04-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001967"
      unitRef="Shares">170836000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001969"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001971"
      unitRef="USDPShares">13.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      id="Fact001973">2024-10-24</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      id="Fact001975">2024-10-24</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      id="Fact001977">2030-04-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesFWarrantsToPurchaseCommonStockMember"
      id="Fact001979">2030-04-24</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001981"
      unitRef="Shares">504417000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001984"
      unitRef="USDPShares">8.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001986"
      unitRef="USDPShares">8.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      id="Fact001988">2025-03-31</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      id="Fact001990">2025-03-31</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      id="Fact001992">2032-09-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesGWarrantsToPurchaseCommonStockMember"
      id="Fact001994">2032-09-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact001996"
      unitRef="Shares">549587000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact001999"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact002001"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2025-01-012025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      id="Fact002003">2025-07-10</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      id="Fact002005">2025-07-10</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2025-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      id="Fact002007">2031-01-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesHWarrantsToPurchaseCommonStockMember"
      id="Fact002009">2031-01-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact002011"
      unitRef="Shares">3450764000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact002014"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="Fact002016"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      id="Fact002018">2025-08-21</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <CLDI:ClassOfWarrantOrRighstIssuanceDate
      contextRef="From2024-01-012024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      id="Fact002020">2025-08-21</CLDI:ClassOfWarrantOrRighstIssuanceDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      id="Fact002022">2030-08-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SeriesIWarrantsToPurchaseCommonStockMember"
      id="Fact002024">2030-08-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact002026"
      unitRef="Shares">5026613</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002027"
      unitRef="Shares">910299</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CLDI:PublicWarrantRedemptionDescription contextRef="From2025-01-01to2025-12-31" id="Fact002031">The
    Company may redeem the outstanding Public Warrants for $0.12 per warrant upon at least 30 days&#x2019; prior written notice of redemption
    given after the warrants become exercisable, if the reported last sale price of the common stock equals or exceeds $2,160.00 per
    share (as adjusted for stock dividends, sub-divisions, reorganizations, recapitalizations and the like) for any 20 trading days within
    a 30-trading day period commencing after the warrants become exercisable and ending on the third trading day before the Company sends
    the notice of redemption to the warrant holders. Upon issuance of a redemption notice by the Company, the warrant holders may, at
    any time after the redemption notice, exercise the public warrants on a cashless basis.</CLDI:PublicWarrantRedemptionDescription>
    <CLDI:RedemptionOfOutstandingWarrantsPerShare
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002033"
      unitRef="USDPShares">0.12</CLDI:RedemptionOfOutstandingWarrantsPerShare>
    <CLDI:ClassOfWarrantsRedemptionNoticePeriod
      contextRef="From2025-01-012025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrLessTenPointZeroRupeesPerDollarMember"
      id="Fact002035">P30D</CLDI:ClassOfWarrantsRedemptionNoticePeriod>
    <us-gaap:SharePrice
      contextRef="AsOf2025-12-31_custom_RedemptionOfWarrantsMember_custom_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember"
      decimals="-3"
      id="Fact002037"
      unitRef="USDPShares">2160000.00</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsMember"
      decimals="-3"
      id="Fact002040"
      unitRef="Shares">60418000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact002042"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-12-31_custom_SeriesAWarrantsMember"
      decimals="-5"
      id="Fact002044"
      unitRef="USD">1100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember"
      decimals="-3"
      id="Fact002046"
      unitRef="Shares">33335000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact002048"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-012025-12-31_custom_SeriesAWarrantsMember"
      decimals="-5"
      id="Fact002050"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember"
      decimals="-3"
      id="Fact002053"
      unitRef="Shares">22275000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact002055"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesBWarrantsMember"
      decimals="-5"
      id="Fact002057"
      unitRef="USD">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsMember"
      decimals="-3"
      id="Fact002059"
      unitRef="Shares">68335000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact002061"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-012024-12-31_custom_SeriesBWarrantsMember"
      decimals="-5"
      id="Fact002063"
      unitRef="USD">1200000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact002065"
      unitRef="Shares">57451000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-12-31_custom_SeriesBWarrantsToPurchaseCommonStockMember"
      decimals="-3"
      id="Fact002067"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesBOneWarrantsMember"
      decimals="-3"
      id="Fact002070"
      unitRef="Shares">27082000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesBOneWarrantsMember"
      decimals="INF"
      id="Fact002072"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-012024-12-31_custom_SeriesBOneWarrantsMember"
      decimals="-5"
      id="Fact002074"
      unitRef="USD">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesBOneWarrantsMember"
      decimals="-3"
      id="Fact002076"
      unitRef="Shares">62086000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesBOneWarrantsMember"
      decimals="INF"
      id="Fact002078"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesBOneWarrantsMember"
      decimals="-5"
      id="Fact002080"
      unitRef="USD">500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsMember"
      decimals="-3"
      id="Fact002083"
      unitRef="Shares">4167000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsMember"
      decimals="INF"
      id="Fact002085"
      unitRef="USDPShares">24.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesCOneWarrantsMember"
      decimals="-5"
      id="Fact002087"
      unitRef="USD">100000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_SeriesCOneWarrantsMember"
      decimals="-3"
      id="Fact002089"
      unitRef="Shares">47936000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SeriesCOneWarrantsMember"
      decimals="INF"
      id="Fact002091"
      unitRef="USDPShares">18.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-012024-12-31_custom_SeriesCOneWarrantsMember"
      decimals="-5"
      id="Fact002093"
      unitRef="USD">900000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsOneMember"
      decimals="-3"
      id="Fact002095"
      unitRef="Shares">41668000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesCOneWarrantsOneMember"
      decimals="INF"
      id="Fact002097"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesCOneWarrantsOneMember"
      decimals="-5"
      id="Fact002099"
      unitRef="USD">400000</us-gaap:ProceedsFromNotesPayable>
    <CLDI:Deemeddividend
      contextRef="AsOf2025-12-31_custom_SeriesDWarrantsMember"
      decimals="-5"
      id="Fact002102"
      unitRef="USD">1700000</CLDI:Deemeddividend>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesDWarrantsMember"
      decimals="-3"
      id="Fact002104"
      unitRef="Shares">70835000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesDWarrantsMember"
      decimals="INF"
      id="Fact002106"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesDWarrantsMember"
      decimals="-5"
      id="Fact002108"
      unitRef="USD">600000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember"
      decimals="-3"
      id="Fact002111"
      unitRef="Shares">341672000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember"
      decimals="INF"
      id="Fact002113"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesEWarrantsAndSeriesFWarrantsMember"
      decimals="-5"
      id="Fact002115"
      unitRef="USD">2800000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesGPreFundedWarrantsMember"
      decimals="-3"
      id="Fact002117"
      unitRef="Shares">227334000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesGPreFundedWarrantsMember"
      decimals="INF"
      id="Fact002119"
      unitRef="USDPShares">0.012</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesGPreFundedWarrantsMember"
      decimals="-3"
      id="Fact002121"
      unitRef="USD">3000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-12-31_custom_SeriesIPreFundedWarrantsMember"
      decimals="-3"
      id="Fact002123"
      unitRef="Shares">1528000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-12-31_custom_SeriesIPreFundedWarrantsMember"
      decimals="INF"
      id="Fact002125"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-01-012025-12-31_custom_SeriesIPreFundedWarrantsMember"
      decimals="-3"
      id="Fact002127"
      unitRef="USD">1500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002129">&lt;p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zI9zvMdBUoVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s aggregate warrant activity for the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zN4RTrBvgykj" style="display: none"&gt;Schedule
of Warrant Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
                                            Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz2jDt26kuD4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjKyow3I4Dza" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;185.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgckS06Oe9s4" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z38OhOA5wXR" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6,478,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyvU3Dx4CT4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,304,930&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zetsFP6qOM73" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(57,451&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8GKp22zH831" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,026,613&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5c4cCUUR2d9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoKmLVctvhY1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.79&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s aggregate warrant activity for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants
                                            &lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price
                                            &lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual
                                            Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgX2i38dnYCe" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;111,772&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwS16fLKZb5f" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,380.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7sOYX74ZK9k" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9lVq9FwLa7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Issued"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,176,804&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z71n7KcESiyc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(350,222&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Converted
    into Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_z9Oku9Hupf42" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(28,055&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKDEp_zAeJ5lPSI06f" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Warrants, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;910,299&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo7VftXyfc8e" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;185.16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEGRpY5Qpcik" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Remaining Contractual Life (Years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265"
      decimals="INF"
      id="Fact002131"
      unitRef="Shares">910299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265"
      decimals="INF"
      id="Fact002133"
      unitRef="USDPShares">185.16</CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue>
    <CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281"
      id="Fact002135">P3Y7M17D</CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281"
      decimals="INF"
      id="Fact002137"
      unitRef="Shares">6478695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281"
      decimals="INF"
      id="Fact002139"
      unitRef="Shares">2304930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281"
      decimals="INF"
      id="Fact002141"
      unitRef="Shares">57451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember11030312"
      decimals="INF"
      id="Fact002143"
      unitRef="Shares">5026613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-12-31_us-gaap_WarrantMember11030312"
      decimals="INF"
      id="Fact002145"
      unitRef="USDPShares">34.97</CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWeightedAverageGrantDateFairValue>
    <CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2025-01-012025-12-31_us-gaap_WarrantMember11030281"
      id="Fact002147">P4Y9M14D</CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002149"
      unitRef="Shares">111772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002151"
      unitRef="USDPShares">1380.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact002153">P4Y8M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281"
      decimals="INF"
      id="Fact002155"
      unitRef="Shares">1176804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281"
      decimals="INF"
      id="Fact002157"
      unitRef="Shares">350222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281"
      decimals="INF"
      id="Fact002159"
      unitRef="USD">28055</CLDI:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedToCommonStockInPeroid>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265"
      decimals="INF"
      id="Fact002161"
      unitRef="Shares">910299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember11030265"
      decimals="INF"
      id="Fact002163"
      unitRef="USDPShares">185.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember11030281"
      id="Fact002165">P3Y7M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002167">&lt;p id="xdx_80D_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zD2T4dlLrNlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_825_zP7G4TGIwXpi"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Equity
Incentive Plans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
completion of the Business Combination on September 12, 2023, the Company adopted the 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;).
The 2023 Plan reserved the right for the Compensation Committee or by the Board of Directors acting as the Compensation Committee, as
the administrator of the plan (the &#x201c;Administrator&#x201d;) to issue up to &lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230912__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--TitleOfIndividualAxis__custom--AdministratorMember_zupByNRwm5ti" title="Number of shares reserved"&gt;32,815&lt;/span&gt; equity awards, including stock options (&#x201c;Options&#x201d;),
restricted stock awards (&#x201c;Restricted Stock&#x201d;), dividend equivalents awards, stock payment awards, restricted stock units (&#x201c;RSUs&#x201d;)
and/or stock appreciation rights (&#x201c;SARs&#x201d;, together with Options, Restricted Stock and RSUs, &#x201c;Awards&#x201d;), according
to its discretion. On July 9, 2025, the Company&#x2019;s stockholders approved an amendment to the 2023 Plan to increase the aggregate
number of shares of common stock authorized for grant under the 2023 Plan from &lt;span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250709__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--RangeAxis__srt--MinimumMember_zqTyX4QSO8X3" title="Number of shares reserved"&gt;32,815&lt;/span&gt; to &lt;span id="xdx_903_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20250709__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__srt--RangeAxis__srt--MaximumMember_zQGP7s8uYCcb" title="Number of shares reserved"&gt;282,815&lt;/span&gt;. Awards may be granted under the 2023
Plan to our employees, directors, and consultants. As of December 31, 2025, the Administrator has issued RSUs and stock options under
the 2023 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the 2023 Plan, Awards may vest and thereby become exercisable, subject to forfeiture restrictions, (1) on the date of grant, (2) in periodic
installments, (3) upon the attainment of performance goals, or (4) upon the occurrence of specified events depending on the Administrator&#x2019;s
discretion. The Administrator has broad authority to determine the terms and conditions of any Award granted pursuant to the 2023 Plan
including, but not limited to, the exercise price, grant price, or purchase price, any reload provision, any restrictions or limitations
on the Award, any schedule for lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations
or waivers thereof as the Administrator, in its sole discretion may determine.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
Awards may be granted under the 2023 Plan with a term of more than ten years and no Awards granted may be exercised after the expiration
of ten years from the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 15, 2024 and August 4, 2025, the Company effected a &lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20240715__20240715_zYwzsdIzoCs6" title="Reverse stock split"&gt;1-for-10&lt;/span&gt; Reverse Stock Split and a &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20250804__20250804_zliZ8Lhl9p94" title="Reverse stock split"&gt;1-for-12&lt;/span&gt; Reverse Stock Split, respectively.
As a result of each respective Reverse Stock Split, proportionate adjustments were made to the per share exercise price and the number
of shares of common stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of
shares of common stock reserved for future issuance under the Company&#x2019;s 2023 Plan. All stock option activity presented in these
statements has been retrospectively adjusted to reflect the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;2023
Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 28, 2023, the Company approved the 2023 Employee Stock Purchase Plan (the &#x201c;2023 ESPP&#x201d;), which became effective on
the consummation of the FLAG Merger. Under the 2023 ESPP, eligible employees may purchase a limited number of shares of common stock
at a discount of up to &lt;span id="xdx_906_ecustom--CommonStockDiscounRate_pid_dp_uPure_c20230828__20230828__us-gaap--PlanNameAxis__custom--EmployeeStockPurchasePlanMember_z9scwl30pMf3" title="Number of shares issued of common stock at discount rate"&gt;15&lt;/span&gt;% of the market value of such stock at pre-determined and plan-defined dates. There have been no issuances of
common stock under the 2023 ESPP to date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
granted under the 2023 Plan may be either &#x201c;incentive stock options&#x201d; within the meaning of Section 422(b) of the Internal
Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), or &#x201c;non-qualified&#x201d; stock options that do not qualify incentive
stock options. Incentive stock options may be granted only to the Company&#x2019;s employees and employees of domestic subsidiaries, as
applicable. &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztWXzM30ZAk1" title="Description of term and exercise price of options"&gt;The exercise price of stock options shall be equal to or greater than the fair market value of common stock on the date the
option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the
grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined
as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee
in any calendar year may not exceed $0.1 million, otherwise it will be classified as a non-qualified stock option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price of an option may be payable in cash or in common stock, or in a combination of cash and common stock, or other legal consideration
for the issuance of stock as the Board or Administrator may approve.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Generally,
&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrLY2NWF4j4f" title="Descriptiion of options vesting"&gt;options vest over four years and will be exercisable only while the optionee remains an employee, director or consultant, or during the
three months thereafter, but in the case of the termination of an optionee&#x2019;s services due to death or disability, the period for
exercising a vested option shall be extended to the earlier of twelve months after termination or the expiration date of the option.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Employee
Benefit Plans Securities Registration Statement &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2024, the Company filed a Registration Statement on Form S-8, which includes a Reoffer Prospectus which may be used for reoffers
and resales of shares of the Company. The Reoffer Prospectus covers the shares issuable to the holders pursuant to awards granted by
the Company under the 2023 Plan. The Company will not receive any proceeds from the sale of the shares offered by the Reoffer Prospectus.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Option
Awards Activity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z7xIaenxH4sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the 2023 Plan option activity and related information follows (in thousands, except weighted averages):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zfEuhibvMzL2" style="display: none"&gt;Summary
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic
                                            Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK7kC1ajijW2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Options Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztRaZJZJFvU2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;220.92&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSpaP75uL3ci" title="Weighted Average Remaining Contractual Life (Years), Outstanding"&gt;5.67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zefFLnTWCDKg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKe1Ruauxv7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;217&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCWFrdBuwki" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpYflv2WEsYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2199"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0rvqdIRJlL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2201"&gt;-&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    forfeited or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYBD9YroCVBg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Forfeited or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0buq0fQQjLd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options forfeited or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;252.37&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoM6ZjChWrv5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTFSrkB3V5kl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.57&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HXOYBinOu4" title="Weighted Average Remaining Contractual Life (Years), Outstanding"&gt;8.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEh0gbt0G4c" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2213"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVY2amDXb4Li" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAhQUpKWRJRd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;160.73&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHcrzjARNxw4" title="Weighted Average Remaining Contractual Life (Years), Exercisable"&gt;5.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ0Xgxt9ks5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zRooPPLh8yNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0V8ViB7a2cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the 2023 Plan restricted stock unit (RSU) activity and related information follows (in thousands, except weighted average
grant date fair value):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zwCCANd9cbH3" style="display: none"&gt;Summary
of Restricted Stock Unit Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Units&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Grant-Date
                                            Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYP9cSw5Qb6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Units Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRgmbX7LNmcj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested
    and released&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZugKRLLFGo1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpw41DTyfZe6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzEsqaDp2sml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2233"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLgdS2RSgSTg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zqFcJcwzXpna" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zCzZoUFkWN5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations
for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zDiKQSAqinMj" style="display: none"&gt;Schedule
of Stock-Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231_zKOpDXF8G51l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zr8StlecTXPh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zraVVi4t1ank" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;426&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zUGIRtAM3tRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,206&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zBL22iwa4ICg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,108&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,957&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zpUqrOZ5dV71" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 18, 2023, the Board approved a repricing of approximately &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn5n6_c20230118__20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJRMOsgG1w1d" title="Options granted approved for repricing"&gt;0.2 &lt;/span&gt;million stock options previously granted at an exercise price of
$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zbbkayw0naG3" title="Exercise price"&gt;1,112.40&lt;/span&gt; per share to the then current fair value of $&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20230118__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zO02JJ1mcZDc" title="Exercise price"&gt;853.20&lt;/span&gt; per share pursuant to an updated valuation report. For each of the years
ended December 31, 2025 and 2024, the Company recorded a noncash compensation charge of approximately $&lt;span id="xdx_906_ecustom--NoncashCompensation_pn5n6_c20250101__20251231_z3rzkqROs8l" title="Noncash compensation charge in connection with repricing"&gt;&lt;span id="xdx_901_ecustom--NoncashCompensation_pn5n6_c20240101__20241231_z2zc3dDlsrGj" title="Noncash compensation charge in connection with repricing"&gt;0.1&lt;/span&gt;&lt;/span&gt; million in connection with
this repricing. The stock option repricing and the acceleration of vesting were accounted for as a modification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025, the total unamortized stock-based compensation expense related to stock options was approximately $&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20251231_zf2gMDpc4HJl" title="Total unamortized stock-based compensation expense"&gt;0.8&lt;/span&gt; million,
expected to be amortized over an estimated weighted average life of &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20250101__20251231_zEMBRRQxq2Pl" title="Estimated weighted average life"&gt;1.9&lt;/span&gt; years. The weighted-average estimated fair value of stock options
with service-conditions granted during the year ended December 31, 2025 and 2024 was $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231_zhBIl59XK0ik" title="Weighted-average estimated fair value of stock options"&gt;3.11&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231_zwllCtCMkreb" title="Weighted-average estimated fair value of stock options"&gt;17.28&lt;/span&gt; per share, respectively, using
the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zu40kxVf1Mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zdpUKtuCZav8" style="display: none"&gt;Schedule
of Stock Options Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20251231_zYwzAD1nqNb7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;87.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zzjUP5wAMfF2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;85.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20251231_zH4VG3ESa7eb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zz8KbtNzL8nk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.21&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    option life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231_zGfjSZ8LnwK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zftGv0RrkSD7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_zBtbVzIc1lTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zO5GP7caLrCh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AD_zigRZD3ZpVj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when
a disqualified disposition has occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-09-12_custom_TwoThousandTwentyThreePlanMember_custom_AdministratorMember"
      decimals="INF"
      id="Fact002169"
      unitRef="Shares">32815</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002171"
      unitRef="Shares">32815</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-07-09_custom_TwoThousandTwentyThreePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002173"
      unitRef="Shares">282815</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2024-07-152024-07-15" id="Fact002175">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-08-042025-08-04" id="Fact002177">1-for-12</us-gaap:StockholdersEquityReverseStockSplit>
    <CLDI:CommonStockDiscounRate
      contextRef="From2023-08-282023-08-28_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact002179"
      unitRef="Pure">0.15</CLDI:CommonStockDiscounRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember11030718"
      id="Fact002181">The exercise price of stock options shall be equal to or greater than the fair market value of common stock on the date the
option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes
of stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the
grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined
as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee
in any calendar year may not exceed $0.1 million, otherwise it will be classified as a non-qualified stock option.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="From2025-01-012025-12-31_us-gaap_EmployeeStockOptionMember11030718"
      id="Fact002183">options vest over four years and will be exercisable only while the optionee remains an employee, director or consultant, or during the
three months thereafter, but in the case of the termination of an optionee&#x2019;s services due to death or disability, the period for
exercising a vested option shall be extended to the earlier of twelve months after termination or the expiration date of the option.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002185">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z7xIaenxH4sd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the 2023 Plan option activity and related information follows (in thousands, except weighted averages):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zfEuhibvMzL2" style="display: none"&gt;Summary
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Intrinsic
                                            Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zK7kC1ajijW2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Options Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;77&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztRaZJZJFvU2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;220.92&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSpaP75uL3ci" title="Weighted Average Remaining Contractual Life (Years), Outstanding"&gt;5.67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zefFLnTWCDKg" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKe1Ruauxv7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;217&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsCWFrdBuwki" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.23&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpYflv2WEsYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2199"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0rvqdIRJlL" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options granted"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2201"&gt;-&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    forfeited or cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYBD9YroCVBg" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Forfeited or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0buq0fQQjLd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options forfeited or cancelled"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;252.37&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoM6ZjChWrv5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTFSrkB3V5kl" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;49.57&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1HXOYBinOu4" title="Weighted Average Remaining Contractual Life (Years), Outstanding"&gt;8.39&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znEh0gbt0G4c" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2213"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVY2amDXb4Li" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAhQUpKWRJRd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;160.73&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHcrzjARNxw4" title="Weighted Average Remaining Contractual Life (Years), Exercisable"&gt;5.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwJ0Xgxt9ks5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002187"
      unitRef="Shares">77000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002189"
      unitRef="USDPShares">220.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="Fact002191">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002193"
      unitRef="USD">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002195"
      unitRef="Shares">217000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002197"
      unitRef="USDPShares">4.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002203"
      unitRef="Shares">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002205"
      unitRef="USDPShares">252.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002207"
      unitRef="Shares">277000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002209"
      unitRef="USDPShares">49.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="Fact002211">P8Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002215"
      unitRef="Shares">78000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002217"
      unitRef="USDPShares">160.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_EmployeeStockOptionMember"
      id="Fact002219">P5Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002223">&lt;p id="xdx_894_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z0V8ViB7a2cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the 2023 Plan restricted stock unit (RSU) activity and related information follows (in thousands, except weighted average
grant date fair value):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zwCCANd9cbH3" style="display: none"&gt;Summary
of Restricted Stock Unit Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Units&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Grant-Date
                                            Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYP9cSw5Qb6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Units Outstanding, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRgmbX7LNmcj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested
    and released&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zZugKRLLFGo1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpw41DTyfZe6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzEsqaDp2sml" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Units Outstanding, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2233"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLgdS2RSgSTg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2235"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact002225"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002227"
      unitRef="USDPShares">13.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact002229"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-012025-12-31_custom_TwoThousandTwentyThreePlanMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002231"
      unitRef="USDPShares">13.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002237">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zCzZoUFkWN5f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations
for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zDiKQSAqinMj" style="display: none"&gt;Schedule
of Stock-Based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231_zKOpDXF8G51l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zr8StlecTXPh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_zraVVi4t1ank" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;426&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hcustom--StatementOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zUGIRtAM3tRl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,206&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zBL22iwa4ICg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,108&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,957&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002239"
      unitRef="USD">426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_ResearchAndDevelopmentExpensesMember"
      decimals="-3"
      id="Fact002240"
      unitRef="USD">751000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-012025-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact002242"
      unitRef="USD">1682000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_custom_GeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact002243"
      unitRef="USD">2206000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002245"
      unitRef="USD">2108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002246"
      unitRef="USD">2957000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-182023-01-18_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact002248"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-01-18_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002250"
      unitRef="USDPShares">1112.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-01-18_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact002252"
      unitRef="USDPShares">853.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <CLDI:NoncashCompensation
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact002254"
      unitRef="USD">100000</CLDI:NoncashCompensation>
    <CLDI:NoncashCompensation
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact002256"
      unitRef="USD">100000</CLDI:NoncashCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact002258"
      unitRef="USD">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2025-01-01to2025-12-31" id="Fact002260">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002262"
      unitRef="USDPShares">3.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002264"
      unitRef="USDPShares">17.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002266">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zu40kxVf1Mnk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zdpUKtuCZav8" style="display: none"&gt;Schedule
of Stock Options Valuation Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20251231_zYwzAD1nqNb7" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;87.84&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_zzjUP5wAMfF2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Expected volatility"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;85.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20251231_zH4VG3ESa7eb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.93&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_zz8KbtNzL8nk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.21&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    option life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20251231_zGfjSZ8LnwK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zftGv0RrkSD7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected option life (in years)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.64&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20251231_zBtbVzIc1lTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zO5GP7caLrCh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Expected dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002268"
      unitRef="Pure">0.8784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002270"
      unitRef="Pure">0.8563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002272"
      unitRef="Pure">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002274"
      unitRef="Pure">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2025-01-01to2025-12-31" id="Fact002276">P5Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-01-012024-12-31" id="Fact002278">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002280"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002282"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002284">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zHExlPqNWiEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_82C_z5Z5FPvHfbp1"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zmI7X7eorJAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income/(Loss)
before provision for income taxes consisted of the following for the year ended December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zaVuKwfY3u7l" style="display: none"&gt;Schedule
of Income (Loss) Before Provision for Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20251231_z1eur2KiQjJ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z0n1aWp4zFjd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zqb4CfXSPFlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;United
    States&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(20,100&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,215&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--NonUsMember_zYhOssVld3l2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zrDgzR435E9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
    before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20,048&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,195&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zQ3h5mKaKxIl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkQC7wARcWlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax expense (benefit) by jurisdiction for the year ended December 31, 2025 and 2024, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zckABzOflrB9" style="display: none"&gt;Schedule
of Income Tax Expenses (Benefit) by Jurisdiction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231_zdfhLeHvkoCb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zx5hjdGzc0rb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_znNSLSOmYZ31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zAup2wou2llc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2302"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2303"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zVp9UCS1JTDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    and local&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2306"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zBvgZLB1XXee" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pn3n3_mtCITEBziCv_maITEBzUqw_zZMx6aSiZtwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zKTEcVxovTUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_z1kpVraKSUdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2318"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zK1WBnJwE7Za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    and local&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2320"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zBsepxvobkVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2323"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2324"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pn3n3_mtDITEBzDw6_maITEBzUqw_zbTUpQrnkXRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2326"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUqw_zxpscxQO7gtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z2cPIjZ0vmW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
inception, the Company has incurred net operating losses primarily for U.S. federal and state income tax purposes and has not reflected
any benefit of such net operating loss carryforwards for any periods presented herein. For the year ended December 31, 2025 and 2024,
no U.S. provision or benefit for income taxes was recorded and an insignificant amount of German provision for income taxes was recorded
as presented on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuqKCNsp7pKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A reconciliation of the benefit for income taxes to the amount computed
by applying the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zQYz2ZJJiQ1k" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;% statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2025, after the
adoption of ASU 2023-09, is as follows (in thousands, except for percentages):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span id="xdx_8BA_zi89feMC8pgg" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231_zvsulSOwOOFf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjN0_zihwnEwvat8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;U.S. Federal statutory tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(4,210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zdCaSR0PS2I" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S. Federal statutory tax rate, percentage"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjN0_zMd2U5dnfb7c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State tax, net of federal income tax effect&lt;sup id="xdx_F49_zfMUB8EowxWh"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20250101__20251231_fKDEp_ziSPJNckHKx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax, net of federal income tax effect, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationEnactmentOfNewTaxLaws_maITEBzjN0_zeb36ZS0ig89" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Enactment of new tax laws&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2344"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_pid_dp_uPure_maABC_c20250101__20251231_znorpo3hbvr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enactment of new tax laws, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maITEBzjN0_zrh65z92s1pl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Effect of cross-border tax laws&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2348"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_c20250101__20251231_zT42c40qxkWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effect of cross-border tax laws, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2350"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBzjN0_zvDLKSApPOKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(299&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20250101__20251231_z7oSHzsu1zi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Tax credits, percentage"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjN0_zq5pT7QibJ4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,519&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zs8DOk37luLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance, percentage"&gt;(17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAbstract_iB_zUKpPQtL6vtl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Nontaxable or non-deductible items&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_i01_maITEBzjN0_zWye46LLe00l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maABC_c20250101__20251231_ztk6cDIBHb0k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible expenses, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2364"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_maITEBzjN0_z0CPv64gkyJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20250101__20251231_zlb9t8L8Gc91" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation, percentage"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxSettlements_maITEBzjN0_z6MunjaJDdIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Worldwide changes in unrecognized tax benefits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;342&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maABC_c20250101__20251231_zY4B7GQpnN93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Worldwide changes in unrecognized tax benefits, percentage"&gt;(2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherReconcilingItemsAbstract_iB_zjqX7cLSigw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i01_maITEBzjN0_zgknsduMTri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Deferred tax adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;139&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zbbFMSpxyShc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred tax adjustments, percentage"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_i01N_di_msITEBzjN0_zwrlSKQZHIo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_iN_pid_dpi_uPure_msABC_c20250101__20251231_zd8usvK6Y6u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-controlling interest, percentage"&gt;(2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i01_maITEBzjN0_zh8MyuRsHJ49" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20250101__20251231_zaR1I0mJwQM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_maABC_zJLZG6onMXka" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_maABC_zepi2og8IZJf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_maABC_znEh3CYo1Nz8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_maABC_z2J7LMVTXxBk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquired
    startup costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Foreign tax effects&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Germany&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_maITEBzjN0_zeeaLUSXxKVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Foreign employee stock based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zcO0S1CaBQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Foreign employee stock based compensation, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2398"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_maITEBzjN0_zR99C4Yh4P63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"&gt;Rate differential&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zHo20NYC5TK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Rate differential, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2402"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_maITEBzjN0_zvmJdpCP8Q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_pid_dp_uPure_maABC_c20250101__20251231_zmN6R4wflEAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Other, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2406"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Australia&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_maITEBzjN0_zAlI68y5rrZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"&gt;Rate differential&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_pid_dp_uPure_maABC_c20250101__20251231_zkS90xGUv0H1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Rate differential, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2410"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_maITEBzjN0_zMgrgYgslGr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zAIEDsplK743" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Change in valuation allowance, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2414"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjN0_zbJfxINKh827" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20250101__20251231_zyyiiUtlerG6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reconciliation of income tax benefit, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2418"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F03_zct2ZTKa2Ewf" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zpfi7Hnizt45" style="font-size: 10pt"&gt;California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASC 2023-09 on a prospective basis. A reconciliation of the benefit for income taxes to the amount computed by
applying the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_z0obmmRCZSM3" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;%
statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2024, before the adoption of ASU
2023-09, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;Schedule
of U.S. Federal Income Tax Rates Indicated to Pretax Loss From Operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computed
    tax benefit at U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20240101__20241231_zUtR4pIQ7Qn2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Computed tax benefit at U.S. federal statutory tax rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent
    differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20240101__20241231_zPeXQHLDEdz6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2425"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20240101__20241231_zm3EOrHZAze5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20240101__20241231_zyCqFkjZl2x2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_uPure_maABC_c20240101__20241231_zo82EFPPaf47" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20240101__20241231_ze35NAHYbBfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20240101__20241231_zrz97QRAWPJ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2435"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_uPure_maABC_c20240101__20241231_z4Th7nho2OHb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_uPure_maABC_c20240101__20241231_zV3fgVtZr0z" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2439"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquired
    startup costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_uPure_maABC_c20240101__20241231_zRUZsXSHTcE3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2441"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pretax loss from operations
    rates total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20240101__20241231_zptrl9LReBn" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2443"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zUTggjNHmEM3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfIncomeTaxPaidTableTextBlock_zsK4I0lG0F21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon adoption of ASU 2023-09, cash paid for income taxes, net of refunds
received, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zQCoIBBAqDQ5" style="display: none"&gt;Schedule
of Cash Paid for Income Taxes, Net of Refunds Received&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20251231_zOyPWllijAh9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31, 2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNztd0_zu9pWrQTBJn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Federal taxes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2447"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxPaidStateAfterRefundReceived_maITPNztd0_zjijZGDohw26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State and local taxes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNztd0_zEoebRvZdd0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Foreign taxes:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2451"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--AU_maITPNztd0_zUyGgN4WEJqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Australia&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2453"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--DE_maITPNztd0_zlvxgcoZqgNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 80%; padding-bottom: 1pt"&gt;Germany&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_iT_mtITPNztd0_zo5AniFJEie9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total cash paid for income taxes, net of refunds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zD74HNRTmYHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The amount of cash paid for income taxes during the year ended December&#160;31,
2024 was $&lt;span id="xdx_904_eus-gaap--IncomeTaxesPaidNet_pn3n3_c20240101__20241231_zG3AOyO0UAfl" title="Cash income taxes paid"&gt;14&lt;/span&gt; thousand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQS7jlZ9G3md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
primary components of the deferred tax assets and liabilities at December 31, 2025 and 2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zxgqp710OTae" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231_zcGtguKFDa0c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zrgbsgdOSbd7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax assets/(liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzO0o_zYioH31KvUH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;25,920&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzO0o_zKla1Ij2pK0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;931&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzO0o_ziwHtGMhOVu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
    and other compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_pn3n3_maDTAGzO0o_zuiGZRyvi3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;479&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;859&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_pn3n3_maDTAGzO0o_zQnEXaYAVlJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized
    research and development expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGzO0o_zoJFXsy61izl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
    and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,315&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,393&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzO0o_zKs7xlP8fKhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    liabilities and other reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;178&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;446&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzO0o_maDTANzVsW_zTwaQun8fFn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,232&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_iNI_pn3n3_di_maDITLzwdK_zkSeahFfBNNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(480&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(830&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzwdK_msDTANzVsW_zMlbqVgsTI8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(480&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(830&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzVsW_zNGTS671QiE1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(34,215&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(29,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzVsW_zL10150kJI13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2496"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zM2uJ66TQeWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2025, the Company had net operating loss carryforwards
of approximately $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zOgZIAc6JSd8" title="Operating loss carryforwards"&gt;89.2&lt;/span&gt; million for U.S. federal income tax purposes and $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zkj1HGtiNLS5" title="Operating loss carryforwards"&gt;106.2&lt;/span&gt; million for state income tax purposes. Federal net operating
losses of $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--TaxPeriodAxis__custom--PriorDecemberTwentySeventeenthMember_zDSgOvW7VeK3" title="Operating loss carryforwards"&gt;8.0&lt;/span&gt; million generated on or prior to December 31, 2017, expire in varying amounts between 2034 and 2037, while federal net
operating losses of $&lt;span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20251231__us-gaap--TaxPeriodAxis__custom--AfterDecemberTwentySeventeenthMember_zKRERLRCduHg" title="Operating loss carryforwards"&gt;81.2&lt;/span&gt; million generated after December 31, 2017 carryforward indefinitely. The state net operating losses expire in
varying amounts between 2034 and 2044.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of December 31, 2025, the Company has research and development credit
carryforwards for federal purposes of $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMfHFTCzX1uf" title="Research and development credits carryforwards"&gt;1.4&lt;/span&gt; million and for state purposes of $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn5n6_c20251231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z7ppTV09XF6f" title="Research and development credits carryforwards"&gt;1.3&lt;/span&gt; million. The federal credits will expire between 2040
and 2045, while the state credits have no expiration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Utilization
of the net operating loss carryforwards and credits may be subject to substantial annual limitation due to the ownership change limitations
provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration
of net operating losses before utilization. The Company performed a Section 382 study for the period February 15, 2015 to December 31,
2021. There was an ownership change identified on March 26, 2018 after the Company&#x2019;s Series A-2 preferred stock issuance. The Company
has not undertaken a Section 382 study through December 31, 2025. Our ability to utilize our net operating loss carryforwards and other
tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The Company established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits
from its net operating loss carryforwards and other deferred tax assets. The change in the valuation allowance was $&lt;span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20250101__20251231_zC9sAWgi96Cj" title="Valuation allowance"&gt;4.8&lt;/span&gt; million and $&lt;span id="xdx_906_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zdHZENlEVbre" title="Valuation allowance"&gt;5.5&lt;/span&gt;
million for the year ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has uncertain tax benefits (&#x201c;UTBs&#x201d;) totaling approximately $&lt;span id="xdx_907_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20251231_zAtjKiUsot7f"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; million and $&lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefits_iI_pn5n6_c20241231_z4IoYphUDlyh"&gt;1.8&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
as of December 31, 2025 and 2024, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs
had no effect on the effective tax rate and there would be no cash tax impact for any period presented. The Company does not expect its
UTBs to change significantly over the next twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zy6NAeHPiGFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zgihqkianum3" style="display: none"&gt;Schedule
of Unrecognized Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20251231_zcFoJl7Bw0Hg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_z0TYewQukNRi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_zrCnkqJg47k4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;1,799&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,517&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_pn3n3_zSm0LSQLFUhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additions
    based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_zlmPVM42Odcg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
    based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2526"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_zd71cGelRVnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,364&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zGtiHAveAKi3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files tax returns in the U.S. for federal purposes and California for state purposes, and in Germany and Australia for its foreign subsidiaries. For jurisdictions in which tax filings
have been filed, all tax years remain open for examination by the federal and California state authorities for three and four years,
respectively, from the date of utilization of any net operating losses or credits. The Company is not currently under audit by any taxing
jurisdiction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in
assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes
the Company has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments,
if any, could be significantly different than the amounts recorded in the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002286">&lt;p id="xdx_89F_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zmI7X7eorJAc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income/(Loss)
before provision for income taxes consisted of the following for the year ended December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zaVuKwfY3u7l" style="display: none"&gt;Schedule
of Income (Loss) Before Provision for Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20251231_z1eur2KiQjJ5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240101__20241231_z0n1aWp4zFjd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zqb4CfXSPFlj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;United
    States&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(20,100&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,215&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--NonUsMember_zYhOssVld3l2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;52&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zrDgzR435E9h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
    before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(20,048&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(22,195&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_srt_AmericasMember"
      decimals="-3"
      id="Fact002288"
      unitRef="USD">-20100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_srt_AmericasMember"
      decimals="-3"
      id="Fact002289"
      unitRef="USD">-22215000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-12-31_us-gaap_NonUsMember"
      decimals="-3"
      id="Fact002291"
      unitRef="USD">52000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31_us-gaap_NonUsMember"
      decimals="-3"
      id="Fact002292"
      unitRef="USD">20000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002294"
      unitRef="USD">-20048000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002295"
      unitRef="USD">-22195000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002297">&lt;p id="xdx_89C_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zkQC7wARcWlj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
income tax expense (benefit) by jurisdiction for the year ended December 31, 2025 and 2024, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BF_zckABzOflrB9" style="display: none"&gt;Schedule
of Income Tax Expenses (Benefit) by Jurisdiction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250101__20251231_zdfhLeHvkoCb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_zx5hjdGzc0rb" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_znNSLSOmYZ31" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zAup2wou2llc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2302"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2303"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zVp9UCS1JTDe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    and local&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2306"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pn3n3_maCITEBziCv_zBvgZLB1XXee" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pn3n3_mtCITEBziCv_maITEBzUqw_zZMx6aSiZtwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB_zKTEcVxovTUa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_z1kpVraKSUdd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2318"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zK1WBnJwE7Za" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    and local&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2320"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_i01_pn3n3_maDITEBzDw6_zBsepxvobkVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2323"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2324"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pn3n3_mtDITEBzDw6_maITEBzUqw_zbTUpQrnkXRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2326"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2327"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzUqw_zxpscxQO7gtg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002305"
      unitRef="USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002308"
      unitRef="USD">14000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002309"
      unitRef="USD">14000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002311"
      unitRef="USD">15000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002312"
      unitRef="USD">14000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002329"
      unitRef="USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002330"
      unitRef="USD">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002332">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zuqKCNsp7pKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A reconciliation of the benefit for income taxes to the amount computed
by applying the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20250101__20251231_zQYz2ZJJiQ1k" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;% statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2025, after the
adoption of ASU 2023-09, is as follows (in thousands, except for percentages):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span id="xdx_8BA_zi89feMC8pgg" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20251231_zvsulSOwOOFf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Percent&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjN0_zihwnEwvat8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;U.S. Federal statutory tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;(4,210&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zdCaSR0PS2I" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="U.S. Federal statutory tax rate, percentage"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjN0_zMd2U5dnfb7c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State tax, net of federal income tax effect&lt;sup id="xdx_F49_zfMUB8EowxWh"&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20250101__20251231_fKDEp_ziSPJNckHKx4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State tax, net of federal income tax effect, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2342"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationEnactmentOfNewTaxLaws_maITEBzjN0_zeb36ZS0ig89" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Enactment of new tax laws&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2344"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationEnactmentOfNewTaxLaws_pid_dp_uPure_maABC_c20250101__20251231_znorpo3hbvr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enactment of new tax laws, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_maITEBzjN0_zrh65z92s1pl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Effect of cross-border tax laws&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2348"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_pid_dp_uPure_maABC_c20250101__20251231_zT42c40qxkWh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effect of cross-border tax laws, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2350"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationTaxCredits_iN_di_msITEBzjN0_zvDLKSApPOKf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Tax credits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(299&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20250101__20251231_z7oSHzsu1zi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Tax credits, percentage"&gt;2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjN0_zq5pT7QibJ4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,519&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zs8DOk37luLg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance, percentage"&gt;(17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseAbstract_iB_zUKpPQtL6vtl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Nontaxable or non-deductible items&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseOther_i01_maITEBzjN0_zWye46LLe00l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_uPure_maABC_c20250101__20251231_ztk6cDIBHb0k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-deductible expenses, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2364"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i01_maITEBzjN0_z0CPv64gkyJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;121&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20250101__20251231_zlb9t8L8Gc91" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock based compensation, percentage"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationTaxSettlements_maITEBzjN0_z6MunjaJDdIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Worldwide changes in unrecognized tax benefits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;342&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxSettlements_pid_dp_uPure_maABC_c20250101__20251231_zY4B7GQpnN93" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Worldwide changes in unrecognized tax benefits, percentage"&gt;(2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationOtherReconcilingItemsAbstract_iB_zjqX7cLSigw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i01_maITEBzjN0_zgknsduMTri" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Deferred tax adjustments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;139&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_pid_dp_uPure_maABC_c20250101__20251231_zbbFMSpxyShc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Deferred tax adjustments, percentage"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxReconciliationMinorityInterestIncomeExpense_i01N_di_msITEBzjN0_zwrlSKQZHIo3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Non-controlling interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_iN_pid_dpi_uPure_msABC_c20250101__20251231_zd8usvK6Y6u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-controlling interest, percentage"&gt;(2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i01_maITEBzjN0_zh8MyuRsHJ49" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20250101__20251231_zaR1I0mJwQM6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_maABC_zJLZG6onMXka" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_maABC_zepi2og8IZJf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_maABC_znEh3CYo1Nz8" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_maABC_z2J7LMVTXxBk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquired
    startup costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Other, percentage"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Foreign tax effects&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Germany&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_maITEBzjN0_zeeaLUSXxKVh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Foreign employee stock based compensation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zcO0S1CaBQZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Foreign employee stock based compensation, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2398"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential_maITEBzjN0_zR99C4Yh4P63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"&gt;Rate differential&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRatesDifferential_pid_dp_uPure_maABC_c20250101__20251231_zHo20NYC5TK6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Rate differential, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2402"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther_maITEBzjN0_zvmJdpCP8Q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationGermanyIncomeTaxRateDifferentialOther_pid_dp_uPure_maABC_c20250101__20251231_zmN6R4wflEAj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Germany Other, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2406"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Australia&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne_maITEBzjN0_zAlI68y5rrZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"&gt;Rate differential&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialOne_pid_dp_uPure_maABC_c20250101__20251231_zkS90xGUv0H1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Rate differential, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2410"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_maITEBzjN0_zMgrgYgslGr2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectiveIncomeTaxRateReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance_pid_dp_uPure_maABC_c20250101__20251231_zAIEDsplK743" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Australia Change in valuation allowance, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2414"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjN0_zbJfxINKh827" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20250101__20251231_zyyiiUtlerG6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reconciliation of income tax benefit, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2418"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F03_zct2ZTKa2Ewf" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zpfi7Hnizt45" style="font-size: 10pt"&gt;California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted ASC 2023-09 on a prospective basis. A reconciliation of the benefit for income taxes to the amount computed by
applying the &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEluY29tZSBUYXhlcyAoRGV0YWlscyBOYXJyYXRpdmUpAA__" id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_z0obmmRCZSM3" title="Federal statutory income tax rate"&gt;21&lt;/span&gt;%
statutory U.S. federal income tax rate to loss before income taxes for the year ended December 31, 2024, before the adoption of ASU
2023-09, is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;Schedule
of U.S. Federal Income Tax Rates Indicated to Pretax Loss From Operations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computed
    tax benefit at U.S. federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_c20240101__20241231_zUtR4pIQ7Qn2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Computed tax benefit at U.S. federal statutory tax rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Permanent
    differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maABC_c20240101__20241231_zPeXQHLDEdz6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2425"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_c20240101__20241231_zm3EOrHZAze5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maABC_c20240101__20241231_zyCqFkjZl2x2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
    permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences_pid_dp_uPure_maABC_c20240101__20241231_zo82EFPPaf47" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_c20240101__20241231_ze35NAHYbBfj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(25&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development credit&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_c20240101__20241231_zrz97QRAWPJ3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2435"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change
    in fair value of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt_pid_dp_uPure_maABC_c20240101__20241231_z4Th7nho2OHb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--EffectiveIncomeTaxRateReconciliationStockIssuanceCost_pid_dp_uPure_maABC_c20240101__20241231_zV3fgVtZr0z" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2439"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquired
    startup costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--EffectiveIncomeTaxRateReconciliationAcquiredStartupCosts_pid_dp_uPure_maABC_c20240101__20241231_zRUZsXSHTcE3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2441"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pretax loss from operations
    rates total&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_c20240101__20241231_zptrl9LReBn" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="US Federal Statutory Tax Rate, percentage"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2443"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002334"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002336"
      unitRef="USD">-4210000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002338"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002340"
      unitRef="USD">1000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002352"
      unitRef="USD">299000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002354"
      unitRef="Pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002356"
      unitRef="USD">3519000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002358"
      unitRef="Pure">-0.17</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002362"
      unitRef="USD">30000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002366"
      unitRef="USD">121000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002368"
      unitRef="Pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002370"
      unitRef="USD">342000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002372"
      unitRef="Pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002376"
      unitRef="USD">139000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002378"
      unitRef="Pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002380"
      unitRef="USD">-348000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="From2025-01-01to2025-12-31"
      decimals="INF"
      id="Fact002382"
      unitRef="Pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002384"
      unitRef="USD">10000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <CLDI:IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002396"
      unitRef="USD">11000</CLDI:IncomeTaxReconciliationForeignEmployeeStockBasedCompensationIncomeTaxRatesDifferential>
    <CLDI:IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002400"
      unitRef="USD">-4000</CLDI:IncomeTaxReconciliationGermanyIncomeTaxRatesDifferential>
    <CLDI:IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002404"
      unitRef="USD">1000</CLDI:IncomeTaxReconciliationGermanyIncomeTaxRatesDifferentialOther>
    <CLDI:IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002408"
      unitRef="USD">-1000</CLDI:IncomeTaxReconciliationAustraliaIncomeTaxRatesDifferentialOne>
    <CLDI:IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002412"
      unitRef="USD">7000</CLDI:IncomeTaxReconciliationAustraliaIncomeTaxRateDifferentialChangeInValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002416"
      unitRef="USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002421"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002423"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002427"
      unitRef="Pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002429"
      unitRef="Pure">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <CLDI:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002431"
      unitRef="Pure">-0.01</CLDI:EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002433"
      unitRef="Pure">-0.25</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <CLDI:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt
      contextRef="From2024-01-012024-12-31"
      decimals="INF"
      id="Fact002437"
      unitRef="Pure">0.01</CLDI:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDebt>
    <CLDI:ScheduleOfIncomeTaxPaidTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002445">&lt;p id="xdx_892_ecustom--ScheduleOfIncomeTaxPaidTableTextBlock_zsK4I0lG0F21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon adoption of ASU 2023-09, cash paid for income taxes, net of refunds
received, were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zQCoIBBAqDQ5" style="display: none"&gt;Schedule
of Cash Paid for Income Taxes, Net of Refunds Received&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20251231_zOyPWllijAh9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31, 2025&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeTaxPaidFederalAfterRefundReceived_maITPNztd0_zu9pWrQTBJn" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Federal taxes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2447"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--IncomeTaxPaidStateAfterRefundReceived_maITPNztd0_zjijZGDohw26" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;State and local taxes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_maITPNztd0_zEoebRvZdd0b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Foreign taxes:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2451"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--AU_maITPNztd0_zUyGgN4WEJqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Australia&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2453"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxPaidForeignAfterRefundReceived_hsrt--StatementGeographicalAxis__country--DE_maITPNztd0_zlvxgcoZqgNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 80%; padding-bottom: 1pt"&gt;Germany&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeTaxesPaidNet_iT_mtITPNztd0_zo5AniFJEie9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Total cash paid for income taxes, net of refunds&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CLDI:ScheduleOfIncomeTaxPaidTableTextBlock>
    <CLDI:IncomeTaxPaidStateAfterRefundReceived
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002449"
      unitRef="USD">1000</CLDI:IncomeTaxPaidStateAfterRefundReceived>
    <us-gaap:IncomeTaxPaidForeignAfterRefundReceived
      contextRef="From2025-01-012025-12-31_country_DE"
      decimals="-3"
      id="Fact002455"
      unitRef="USD">16000</us-gaap:IncomeTaxPaidForeignAfterRefundReceived>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002457"
      unitRef="USD">17000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002459"
      unitRef="USD">14000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002461">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQS7jlZ9G3md" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
primary components of the deferred tax assets and liabilities at December 31, 2025 and 2024 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zxgqp710OTae" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20251231_zcGtguKFDa0c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zrgbsgdOSbd7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    tax assets/(liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzO0o_zYioH31KvUH7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;25,920&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20,221&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzO0o_zKla1Ij2pK0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and development credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;928&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;931&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzO0o_ziwHtGMhOVu6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
    and other compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,355&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,135&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_pn3n3_maDTAGzO0o_zuiGZRyvi3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
    liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;479&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;859&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures_iI_pn3n3_maDTAGzO0o_zQnEXaYAVlJb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Capitalized
    research and development expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,520&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,247&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsDepreciationAndAmortization_iI_pn3n3_maDTAGzO0o_zoJFXsy61izl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
    and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,315&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,393&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzO0o_zKs7xlP8fKhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
    liabilities and other reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;178&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;446&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzO0o_maDTANzVsW_zTwaQun8fFn8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;34,695&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30,232&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets_iNI_pn3n3_di_maDITLzwdK_zkSeahFfBNNe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(480&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(830&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_pn3n3_di_mtDITLzwdK_msDTANzVsW_zMlbqVgsTI8f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(480&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(830&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzVsW_zNGTS671QiE1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(34,215&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(29,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzVsW_zL10150kJI13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
    deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2496"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2497"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002463"
      unitRef="USD">25920000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002464"
      unitRef="USD">20221000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002466"
      unitRef="USD">928000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002467"
      unitRef="USD">931000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002469"
      unitRef="USD">2355000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002470"
      unitRef="USD">2135000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <CLDI:DeferredTaxAssetsLeaseLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002472"
      unitRef="USD">479000</CLDI:DeferredTaxAssetsLeaseLiabilities>
    <CLDI:DeferredTaxAssetsLeaseLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002473"
      unitRef="USD">859000</CLDI:DeferredTaxAssetsLeaseLiabilities>
    <CLDI:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002475"
      unitRef="USD">3520000</CLDI:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures>
    <CLDI:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002476"
      unitRef="USD">4247000</CLDI:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenditures>
    <CLDI:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002478"
      unitRef="USD">1315000</CLDI:DeferredTaxAssetsDepreciationAndAmortization>
    <CLDI:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002479"
      unitRef="USD">1393000</CLDI:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002481"
      unitRef="USD">178000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002482"
      unitRef="USD">446000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002484"
      unitRef="USD">34695000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002485"
      unitRef="USD">30232000</us-gaap:DeferredTaxAssetsGross>
    <CLDI:DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002487"
      unitRef="USD">480000</CLDI:DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets>
    <CLDI:DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002488"
      unitRef="USD">830000</CLDI:DeferredTaxLiabilitiesRightOfUseAssetsAndOtherAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002490"
      unitRef="USD">480000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002491"
      unitRef="USD">830000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002493"
      unitRef="USD">34215000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002494"
      unitRef="USD">29402000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact002499"
      unitRef="USD">89200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact002501"
      unitRef="USD">106200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31_custom_PriorDecemberTwentySeventeenthMember"
      decimals="-5"
      id="Fact002503"
      unitRef="USD">8000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-12-31_custom_AfterDecemberTwentySeventeenthMember"
      decimals="-5"
      id="Fact002505"
      unitRef="USD">81200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-12-31_us-gaap_DomesticCountryMember"
      decimals="-5"
      id="Fact002507"
      unitRef="USD">1400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact002509"
      unitRef="USD">1300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2025-01-01to2025-12-31"
      decimals="-5"
      id="Fact002511"
      unitRef="USD">4800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-012024-12-31"
      decimals="-5"
      id="Fact002513"
      unitRef="USD">5500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact002514"
      unitRef="USD">2400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact002515"
      unitRef="USD">1800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002517">&lt;p id="xdx_898_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zy6NAeHPiGFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BC_zgihqkianum3" style="display: none"&gt;Schedule
of Unrecognized Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20250101__20251231_zcFoJl7Bw0Hg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240101__20241231_z0TYewQukNRi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_zrCnkqJg47k4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;1,799&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,517&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_pn3n3_zSm0LSQLFUhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additions
    based on tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_pn3n3_zlmPVM42Odcg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
    based on tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2526"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_zd71cGelRVnf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance
    at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,364&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,799&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002519"
      unitRef="USD">1799000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002520"
      unitRef="USD">1517000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002522"
      unitRef="USD">282000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002523"
      unitRef="USD">282000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002525"
      unitRef="USD">283000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002528"
      unitRef="USD">2364000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002529"
      unitRef="USD">1799000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002531">&lt;p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPOK3y5GljO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span id="xdx_829_zn3eriuoQBCj"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Operating
and Financing Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 10, 2022, the Company entered into an Office Lease Agreement (the &#x201c;San Diego Lease&#x201d;) of a building containing &lt;span id="xdx_90D_eus-gaap--AreaOfLand_iI_usqft_c20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_ziLzBvAbzwbj" title="Area of land"&gt;15,197&lt;/span&gt;
square feet of rentable space located in San Diego, California (the &#x201c;Premises&#x201d;), which serves as the Company&#x2019;s principal
executive and administrative offices and laboratory facility. The Company completed constructing tenant improvements at the Premises
on February 27, 2023, and moved into the Premises by the end of March 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
secure and execute the San Diego Lease, Mr. Allan J. Camaisa (or &#x201c;Mr. Camaisa&#x201d;) provided a personal Guaranty of Lease of
up to $&lt;span id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember__srt--RangeAxis__srt--MaximumMember_z8hJaebAkvAi" title="Guaranty of lease, value"&gt;0.9&lt;/span&gt;
million (the &#x201c;Guaranty&#x201d;) to the lessor for the Company&#x2019;s future performance under the San Diego Lease agreement. &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20221010__20221010_zpGz8husti7a" title="Lease agreement description"&gt;As
consideration for the Guaranty, the Company agreed to pay Mr. Camaisa 10% of the Guaranty amount for the first year of the San Diego
Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease&lt;/span&gt;, with all amounts accrued and payable
at the termination of the San Diego Lease or release of Mr. Camaisa from the Guaranty by the lessor, whichever occurs
first. Mr. Camaisa received $&lt;span id="xdx_906_ecustom--GuarantyOfLeaseAmount_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--MrCamaisaMember_z5NWwFd03aH9" title="Guaranty of lease, value"&gt;0.2&lt;/span&gt; million during the fiscal year ended 2025 in connection with the lease guarantee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
San Diego Lease has an initial term of &lt;span id="xdx_90A_ecustom--OperatingLeaseTermOfContractLeaseInitialTerm_dtM_c20230301__20230301_zDGppQxXD3l3" title="Operating lease, term of contract, lease initial term"&gt;48&lt;/span&gt; calendar months, from the first day of the first full month following which the &#x201c;Commencement
Date&#x201d; occurs (the &#x201c;Term&#x201d;), which was March 1, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
on the Commencement Date, the Company pays base monthly rent in the amount of $&lt;span id="xdx_902_eus-gaap--PaymentsForRent_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zsejvp3Zi0r6" title="Payments for rent"&gt;0.1&lt;/span&gt; million during the first 12 months of the Term, plus
a management fee equal to &lt;span id="xdx_904_ecustom--LeaseTermsOperatingLeasesAnnualIncreaseInRent_pid_dp_uPure_c20221010__20221010_zAeCqlq9r4R1" title="Lease terms, operating leases annual increase in rent"&gt;3&lt;/span&gt;% of base rent. Base monthly rent will increase annually, over the base monthly rent then in effect, by &lt;span id="xdx_90A_ecustom--LeaseTermsOperatingLeasesAnnualIncreaseInRent_pid_dp_uPure_c20221010__20221010_zyLsYlU4yYA4" title="Lease terms, operating leases annual increase in rent"&gt;3&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to base monthly rent and management fees, the Company pays in monthly installments its share of (a) all costs and expenses,
other than certain excluded expenses, incurred by the lessor in each calendar year in connection with operating, maintaining, repairing
(including replacements if repairs are not feasible or would not be effective) and managing the Premises and the building in which the
Premises are located (&#x201c;Expenses&#x201d;), and (b) all real estate taxes and assessments on the Premises and the building in which
the Premises are located, all personal property taxes for property that is owned by Landlord and used in connection with the operation,
maintenance and repair of the Premises (&#x201c;Taxes&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
execution of the San Diego Lease, the Company provided the lessor a payment of $&lt;span id="xdx_90C_eus-gaap--OperatingLeasePayments_pn5n6_c20221010__20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zE0y0yEwxzN" title="Lease payment"&gt;0.1&lt;/span&gt; million as first month base rent and prepaid operating
expenses, and a letter of credit in the amount of $&lt;span id="xdx_909_eus-gaap--LettersOfCreditOutstandingAmount_iI_pn5n6_c20221010__us-gaap--TypeOfArrangementAxis__custom--SanDiegoLeaseAgreementMember_zRzXSPkGVVTi" title="Letter of credit amount"&gt;0.1&lt;/span&gt; million issued by a bank in the name of the lessor. To obtain the letter of credit,
the Company has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its obligation to pay any draws
on the letter of credit by the lessor. The restricted cash may not be used for any other purpose (see Note 2). The prepaid rent was included
in the initial accounting of the San Diego Lease, as presented in the tables below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 1, 2022, StemVac entered into an office lease which includes laboratory space which expires on March 31, 2027, with monthly payments
of &#x20ac;&lt;span id="xdx_90B_eus-gaap--PaymentsForRent_uEUR_c20220401__20220401__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_z3shSbxrFqQ2" title="Payments for rent"&gt;4,047&lt;/span&gt; Euros per month. On July 1, 2025, StemVac entered into a finance lease agreement for laboratory equipment with an initial
term that expires on May 31, 2029, with monthly payments of approximately &#x20ac;&lt;span id="xdx_906_eus-gaap--PaymentsForRent_uEUR_c20250701__20250701__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_zVndkENgfev" title="Payments for rent"&gt;2,976&lt;/span&gt; Euros per month. The lease commencement date was
June 1, 2025. The lease agreement includes an option to renew the lease for an additional twelve months, which must be exercised by providing
six months&#x2019; prior notice before the end of the initial lease term; however, the Company is not reasonably certain to extend the
initial lease term and therefore additional lease payments associated with the automatic renewal are excluded from the lease term. The
lease also contains a purchase option that the Company is not reasonably certain to exercise at the lease commencement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease expense recognized during each of the years ended December 31, 2025 and 2024 was approximately $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_zdtbhpHcMHW" title="Operating lease expense"&gt;&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StemVacOfficeLeaseAgreementMember_z9eQRvEs82f3" title="Operating lease expense"&gt;1.5&lt;/span&gt;&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is also party to certain financing leases for machinery and equipment (see Note 5).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_zjJcUdsV82A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents supplemental cash flow information related to operating and financing leases for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zIEWyOnuK0Hh" style="display: none"&gt;Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231_zVgR4TMa6cWi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_z2O3hxNxW3p5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zE9lHKMwv1dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,467&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,424&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zwgbEPczKbpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    cash flows from financing leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zMCqdQoMchmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    cash flows from financing leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zfZL4LbEGWXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_z7POe9VVVW36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents supplemental balance sheet information related to operating and financing leases for the periods presented (in
thousands, except weighted averages):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zzivUjMbH66g" style="display: none"&gt;Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zeUZUbKLDkCl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zg5QPJAo5gIk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zjptdiItgEMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,934&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzLs4_zhvI1rU3CG7d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,405&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,204&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzLs4_zErKs72ddsR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,845&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzLs4_zmbAHBUGsGbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,049&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_iI_pn3n3_maPPAENzCH7_zXL1SWMuK1Kf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;779&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;588&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iNI_pn3n3_di_msPPAENzCH7_zp0geCKJ9JDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accumulated
    depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(463&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(333&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_iTI_pn3n3_mtPPAENzCH7_zfNhCxxzcpSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;255&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_maFLLzNvC_zGD0wv9kWj3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;111&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_maFLLzNvC_zQP67sLDO6P7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Noncurrent
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;145&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_mtFLLzNvC_zoLsaW172gHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;211&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zXh8NPFoUwj2" title="Weighted average remaining lease term, Operating leases (in years)"&gt;1.2&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zWdlNhVMVNL8" title="Weighted average remaining lease term, Operating leases (in years)"&gt;2.2&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zeWhdokfJzNj" title="Weighted average remaining lease term, Financing leases (in years)"&gt;2.7&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3QXnlbPtHuf" title="Weighted average remaining lease term, Financing leases (in years)"&gt;3.2&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr8xPw3WQtL1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.70&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zZdFtnio05D7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.05&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zzHqzMuAkbk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zOihmUTUOme4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents future minimum lease commitments as of December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zrbvmxSlKA3h" style="display: none"&gt;Schedule
of Future Minimum Lease Commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financing&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zrCrNBg9wKvk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Leases, 2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,512&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zcoYAGtcgefj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Financing Leases, 2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;132&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zECw0oPKmbX6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zFAwlGX09Rjl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zexL69dvRUje" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmReNXTKils8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z5cozyuTQpJc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2029"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2632"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zlZ2svW4Kw3k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2029"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2030
    and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zM7iUfRRvjF8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2030 and thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2636"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zruLPX0rgbri" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2030 and thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2638"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmtaJlAhhCB1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Total minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,809&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z8cP0VsZT5x5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Total minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;319&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_ztrK0QO5otPe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Less: amounts representing interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_zOMifW6juZWl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Less: amounts representing interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(37&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present
    value of net minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseLiability_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z3YOipHV72nb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Present value of net minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zHO9irHCvb7i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Present value of net minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z2YRPJqUptc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Litigation
&#x2014; General&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation,
business transactions, employee-related matters, and other matters. At each reporting date, the Company evaluates whether a potential
loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that
addresses accounting for contingencies. If it is probable that a loss will result and the amount of the loss can be reasonably estimated,
the Company will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated,
the Company discloses the claim if the likelihood of a potential loss is reasonably possible, and the amount involved could be material.
The Company expenses the costs related to legal proceedings as incurred. See other legal matters discussed below. Other than the matters
discussed below, the Company is not currently party to any material legal proceedings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Legal
Proceedings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Former
Chief Accounting Officer and Interim Chief Financial Officer, and Controller&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 15, 2023, Tony Kalajian, the Company&#x2019;s prior Chief Accounting Officer and interim Chief Financial Officer, filed a complaint
in the Superior Court of the State of California County of San Diego against the Company, Mr. Camaisa, the Company&#x2019;s director and
former Chief Executive Officer, and Ms. Pizarro, the Company&#x2019;s former Chief Corporate Development Officer and Chief Legal Officer,
alleging defamation and constructive discharge of Mr. Kalajian&#x2019;s position of Chief Accounting Officer and interim Chief Financial
Officer (Case No. 37-2023-00049813-CU-DF-CTL) (the &#x201c;Primary Case&#x201d;). Mr. Kalajian is seeking an unspecified amount in damages
under his employment contract, damages to be proven at trial, punitive damages, and attorney&#x2019;s fees.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2023, the Company initiated arbitration proceedings against Mr. Kalajian for breach of fiduciary duty, constructive fraud,
conversation, and declaratory relief, seeking to recover from Mr. Kalajian bonuses Mr. Kalajian caused to be paid to himself, Hazel Sanchez,
the former Controller, and his accounting team. The bonuses (the &#x201c;Accounting Bonuses&#x201d;) were not authorized by the Company&#x2019;s
Board of Directors or Compensation Committee.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 30, 2023, Hazel Sanchez, the Company&#x2019;s prior Controller, filed a complaint in the Superior Court of the State of California
County of San Diego against the Company, Mr. Camaisa, and Ms. Pizarro, alleging defamation, constructive discharge, violation of California
Family Rights Act, and wrongful discharge. Ms. Sanchez is seeking an unspecified amount in damages under her employment contract, damages
to be proven at trial, punitive damages, and attorney&#x2019;s fees. In February 2024, the Company filed a Cross-Complaint against Ms.
Sanchez for breach of fiduciary duty, constructive fraud, conversation, and declaratory relief seeking to recover the Accounting Bonuses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 29, 2024, Mr. Kalajian also filed a Petition for Writ of Mandate in the Superior Court of California, County of San Diego, seeking
to compel the production of certain corporate records from the Company. This case is deemed related to the Primary Case above and was
dismissed by stipulation in March 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2024, Mr. Kalajian filed a complaint in the Superior Court of the State of California, County of San Diego against the Company
alleging intentional conversion and violation of Section 158 of the Delaware General Corporations Code due to the Company&#x2019;s failure
to remove a restrictive legend from &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240501__20240501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTyT8tLsHB79" title="Shares issued"&gt;1,162&lt;/span&gt; shares of the Company&#x2019;s Common Stock. Mr. Kalajian is seeking compensatory damages to
be proven at trial, punitive damages and attorney&#x2019;s fees, and an order requiring removal of the restrictive legend from his share
certificates. The Company intends to vigorously defend itself. This case is deemed related to and consolidated with the Primary Case
above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The Primary Case,
Kalajian Arbitration, Sanchez Case, and Conversion Case were deemed related and ultimately consolidated. A trial date has been set for
November 6, 2026.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Former
Executive Assistant&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025, the Company filed a lawsuit in San Diego Superior Court against a former executive assistant alleging breach of fiduciary
duty to the Company, constructive fraud, conversion, and misappropriation and improper disclosure of confidential and proprietary information
in violation of her proprietary information and inventions agreement, non-disclosure agreement, and severance agreement with the Company
(Case No. 25CU034887C). The Company is seeking injunctive relief and damages. The case is in its early stages, and the outcome is uncertain.
Management does not currently expect this matter to have a material adverse effect on the Company&#x2019;s financial condition or results
of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Securities
Matter&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 29, 2024, Mr. Yian Zeng filed a complaint against the Company related to securities fraud under California Corporations Code
&#xa7;25401, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive
fraud in the U.S. District Court, Southern District of California (Case Number 3:24-cv-02026-H-KSC). The Company vigorously opposes this
case and categorically denies all claims. On April 9, 2025, the parties engaged in a mandatory settlement conference which resulted in
no resolution of the case. Discovery has been completed. A pre-trial conference has been set for
October 19, 2026, but no trial date has been set. At this time, the Company is unable to evaluate the outcome of this case or estimate the amount or range of potential
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Employment
Contracts&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into employment and severance benefit contracts with certain executive officers and other employees. Under the provisions
of the contracts, the Company may be required to incur severance obligations for matters relating to changes in control, as defined,
and certain terminations of those executives and employees. As of December 31, 2025, the Company incurred severance obligations for certain
executive officers and other employees, as discussed below. See Note 6 for further information on the accruals for such severance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Manufacturing
and Other Supplier Contracts&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into certain manufacturing and other supplier agreements with vendors principally for manufacturing drug products
for clinical trials and continued development of the CLD-101, CLD-201, and CLD-401 programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2025 and 2024, the remaining expected commitments were approximately $&lt;span id="xdx_90B_ecustom--RemainingExpectedCommitments_iI_pn5n6_c20251231_zJLI1WUoJ1je" title="Remaining expected commitments"&gt;0.5&lt;/span&gt; million and $&lt;span id="xdx_908_ecustom--RemainingExpectedCommitments_iI_pn5n6_c20241231_ztENlLBFixs3" title="Remaining expected commitments"&gt;0.3&lt;/span&gt; million,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Agreements with Northwestern University&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 7, 2021, the Company entered into a License Agreement with Northwestern University (&#x201c;Northwestern&#x201d;) (the &#x201c;Northwestern
Agreement&#x201d;) for the exclusive commercialization rights to the investigational new drug (&#x201c;IND&#x201d;) and with a non-exclusive
license to data generated from Northwestern&#x2019;s phase 1 clinical trial treating malignant glioma patients with an engineered oncolytic
adenovirus delivered by neural stem cells (&#x201c;&lt;i&gt;NSC-CRAd-S-pk7&lt;/i&gt;&#x201d;). Under the Northwestern Agreement, among other rights,
Northwestern granted to the Company a worldwide, twelve-year exclusive license for the commercial development of &lt;i&gt;NSC-CRAd-S-pk7&lt;/i&gt;
or other oncolytic viruses for therapeutic and preventive uses in oncology, a right of reference to Northwestern&#x2019;s IND application
which relates to the treatment of newly diagnosed High Grade Glioma (&#x201c;HGG&#x201d;), and right of reference to Northwestern&#x2019;s
IND 17365.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Northwestern Agreement, the Company agreed to a best-efforts commitment to fund up to $&lt;span id="xdx_90E_eus-gaap--OtherCommitment_iI_pn6n6_c20210607__us-gaap--TypeOfArrangementAxis__custom--NorthwesternAgreementMember_zXYEzR4wNTBc"&gt;10
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million towards a phase 2 clinical trial of &lt;i&gt;NSC-CRAd-S-pk7&lt;/i&gt;
or other oncolytic viruses. Subject to the terms and conditions of the Northwestern Agreement, Northwestern may become entitled to receive
contingent payments from the Company based on (i) sublicense royalty payments of double-digit percentage for any sublicensing revenue
that the Company earns, if any, and, (ii) in the event of an assignment or transfer of licensed data, with the consent of Northwestern,
a low single digit percentage of the fair market value of any consideration received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 14, 2021, the Company entered into a Material License Agreement with Northwestern to license the &lt;i&gt;NSC-CRAd-S-pk7&lt;/i&gt; oncolytic
virus materials which the Company intends to use to continue advancing its research, development and commercialization efforts of the
NNV1 and NNV2 programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 15, 2024, the Company entered into an Investigator-Initiated Clinical Trial Agreement for Northwestern to conduct a clinical
trial (the &#x201c;CTA&#x201d;) under the protocol referenced &#x201c;A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in
Combination with N-Acetylcysteine amid and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma&#x201d; (the &#x201c;Study&#x201d;).
In connection with the Study, Northwestern granted the Company a non-exclusive, transferable and sublicensable license to use all available
de-identified data collected from the Study, including, but not limited to, survival data, patient pathology, and immune studies data.
Under the CTA, among other rights, Northwestern also granted to the Company a worldwide, twelve-year exclusive license to the data, a
right of reference to Northwestern&#x2019;s IND application which relates to the treatment of newly diagnosed HGG, and right of reference
to Northwestern&#x2019;s IND 17365.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration of the data use license granted by Northwestern to the Company under the CTA, the Company shall pay Northwestern the following:
&lt;span id="xdx_908_eus-gaap--OtherCommitmentsDescription_c20241215__20241215__us-gaap--TypeOfArrangementAxis__custom--NorthwesternAgreementMember_zYfuOv26S2Gg"&gt;a non-creditable and non-refundable one-time milestone payment of $0.3 million upon reaching an aggregate of $2.0 million of net sales
of a licensed product; (b) a non-creditable and nonrefundable one-time milestone payment of $0.5 million upon reaching an aggregate of
$10.0 million of net sales of a licensed product; (c) sublicensing royalty of 20% of any sublicensing revenue resulting from the grant
of rights hereunder; and (d) in the event of an assignment or transfer of licensed data, with the consent of Northwestern, a low single
digit percentage of the fair market value of any consideration received. This sublicensing royalty shall be cumulative, meaning it shall
be imposed only once with respect to a single unit of sublicensing revenue, regardless of whether the sublicensing revenue derives from
the CTA, or the June 7, 2021 Northwestern Agreement described above, or both.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has the right to terminate the CTA upon 30 days&#x2019; notice, and the right to terminate the License and Material Transfer Agreements
upon 90 days&#x2019; notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of issuance of these consolidated financial statements, it is not probable that the Company will incur these payments, if
any at all. The Company will record the contingent payments if and when they become payable, in accordance with the applicable guidance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;License
Agreement with City of Hope and the University of Chicago&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2021, the Company entered into an Exclusive License Agreement with the University of Chicago (the &#x201c;University of Chicago
Agreement&#x201d;) for patents jointly owned by the University of Chicago, City of Hope, and the University of Alabama at Birmingham covering
cancer therapies using an oncolytic adenovirus loaded into allogeneic neural stem cells for treatment of HGG. Pursuant to the University
of Chicago Agreement, University of Chicago transferred its IND to the Company for the commercial development of a licensed product,
as defined in the University of Chicago Agreement. This agreement grants to the Company commercial sublicensable exclusive license to
neural stem cells with the adenovirus known as CRAd-S-pk7 for oncolytic virotherapy, as well as a non-exclusive license to associated
know-how.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
University of Chicago Agreement provides for the Company to pay royalties in low single digit percentage of net sales generated for any
product of the licensed patents for specific periods, and to pay up to $&lt;span id="xdx_909_eus-gaap--PaymentsForRoyalties_pn5n6_c20210722__20210722__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z2ssViZg1wzf" title="Payments for royalties"&gt;18.7 &lt;/span&gt;million if certain milestones are achieved during the clinical
trials and post commercialization of the licensed product. The Company is further obligated to pay a sublicensing royalty of 20% of any
sublicensing revenue resulting from the grant of rights, and in the event of an assignment or transfer of licensed data, with the consent
of Northwestern, a low single digit percentage of the fair market value of any consideration received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of the date of the issuance of these consolidated financial statements, it is not probable that the Company will incur these payments.
The Company will record the contingent payments if and when they become payable, in accordance with the applicable guidance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the normal course of business, the Company may provide indemnification of varying scope under the Company&#x2019;s agreements with other
companies or consultants, typically the Company&#x2019;s clinical research organizations, investigators, clinical sites, suppliers and
others. Pursuant to these agreements, the Company will generally agree to indemnify, hold harmless, and reimburse the indemnified parties
for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties that relate to certain situations
such as Company&#x2019;s negligent actions, breaching agreements, failure to comply with laws and regulations, and third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to the Company. The Company&#x2019;s office
and laboratory facility leases also will generally contain indemnification obligations, including obligations for indemnification of
the lessor for environmental law matters and injuries to persons or property of others, arising from the Company&#x2019;s use or occupancy
of the leased property. The term of these indemnification agreements will generally continue in effect after the termination or expiration
of the particular research, development, services, lease, or other agreement to which they relate. The potential future payments the
Company could be required to make under these indemnification agreements will generally not be subject to any specified maximum amounts.
Historically, the Company has not been subject to any claims or demands for indemnification. The Company also maintains various liability
insurance policies that limit the Company&#x2019;s financial exposure. As a result, the Company&#x2019;s management believes that the fair
value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements
as of December 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Separation
Agreement with Former Chief Operating Officer and President&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 23, 2023, the Company entered into a Separation and Release Agreement (&#x201c;Separation Agreement&#x201d;) with George K. Ng,
former Chief Operating Officer and President, effective on that date. In accordance with the provisions of the Separation Agreement,
the Company will pay Mr. Ng in the amount of $&lt;span id="xdx_903_eus-gaap--OtherLiabilities_iI_pn5n6_c20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zYRWYMTHa72c" title="Payment to related party"&gt;0.5&lt;/span&gt;
million payable in a lump sum due one year after the effective date, and in the event that this amount is not paid when due, the
unpaid amount will accrue interest at the rate of &lt;span id="xdx_906_ecustom--CommitmentFeePercentage_iI_pid_dp_uPure_c20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zjFo9rmvfVaf" title="Commitment fee percentage"&gt;8&lt;/span&gt;%
per annum to be paid no later than the &lt;span id="xdx_90C_eus-gaap--LongtermPurchaseCommitmentPeriod_dc_c20230622__20230623__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_zn6xquaSUapf" title="Payment period"&gt;two
year&lt;/span&gt; anniversary of the effective date. The Company also paid for certain benefits, including healthcare for six months
following the effective date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2024, the Company made a payment of $&lt;span id="xdx_904_eus-gaap--OtherLiabilities_iI_c20240630__us-gaap--TypeOfArrangementAxis__custom--SeparationAndReleaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GeorgeNgMember_z5gpwYQb0Dca" title="Payment to related party"&gt;50,000&lt;/span&gt; and executed an Amendment to extend the due date to January 2025. The liability was
settled in full in January 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Settlement,
Deferral or Payment of Deferred Compensation of Certain Executives and a Director&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 31, 2023, Mr. Camaisa, a director and former Chief Executive Officer of the Company, and Mr. Leftwich, a director of the Company,
entered into certain amendments with respect to their deferred compensation arrangements in connection with the FLAG Merger. Mr. Camaisa
agreed to settle approximately $&lt;span id="xdx_909_eus-gaap--DeferredCompensationEquity_iI_pn5n6_c20230831__srt--TitleOfIndividualAxis__custom--MrCamaisaMember_zw53qiiC6G9e" title="Deferred compensation"&gt;0.7&lt;/span&gt; million of deferred compensation with &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230831__srt--TitleOfIndividualAxis__custom--MrCamaisaMember_zrSDfcHAQuJk" title="Warrants"&gt;46,972&lt;/span&gt; FLAG warrants which were issued at the closing of the
FLAG Merger in September 2023, and Mr. Leftwich agreed to defer approximately $&lt;span id="xdx_905_eus-gaap--DeferredCompensationEquity_iI_pn5n6_c20230831__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zG2D0PKtAXhd" title="Deferred compensation equity"&gt;0.5&lt;/span&gt; million of deferred compensation, combined with the
deferral of certain term notes discussed above, to January 1, 2025, which include accrued interest at &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zqkWKCh2JDS7" title="Interest rate"&gt;24&lt;/span&gt;% per annum payable at maturity.
All notes and deferred compensation of Mr. Leftwich were amended on August 12, 2024, to reduce the interest rate to &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__srt--TitleOfIndividualAxis__custom--MrLeftwichMember_zVn6dHO4gx6" title="Interest rate"&gt;14&lt;/span&gt;% per annum. This
deferred compensation was included in accrued expenses and other current liabilities in the consolidated balance sheet at December 31,
2024. On January 3, 2025, the $&lt;span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_iI_pn5n6_c20250103__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrLeftwichMember__us-gaap--AwardTypeAxis__custom--SettlementOfDeferredCompensationMember_zgRqf47Anmi5" title="Deferred compensation and accrued interest amount in cash"&gt;0.6&lt;/span&gt; million of deferred compensation and accrued interest due to Mr. Leftwich was settled in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Standby
Equity Purchase Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#x201c;SEPA&#x201d;) with YA II PN, Ltd., a Cayman
Island exempt limited partnership (&#x201c;Yorkville&#x201d;). Pursuant to the SEPA, the Company will have the right, but not the obligation,
to sell to Yorkville up to $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20231210__20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_z1ZeRpcOkqpj" title="Proceeds from issuance of common stock"&gt;25.0&lt;/span&gt; million of its shares of common stock, par value $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zTkBrySF5WZ6" title="Shares issued price per share"&gt;0.0001&lt;/span&gt; per share, at the Company&#x2019;s request any
time during the 36 months following the execution of the SEPA. The maximum advance under the SEPA is the lower of &lt;span id="xdx_901_ecustom--EquityPurchaseDescription_c20231210__20231210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zUqg26h3468c" title="Equity purchase description"&gt;(i) an amount equal
to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an advance notice, or
(ii) 41,667 shares. For the SEPA to be utilized, the shares underlying the agreement need to be registered on a Form S-1 filed with the
SEC.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
consideration for Yorkville&#x2019;s commitment to purchase the common stock at the Company&#x2019;s direction upon the terms and subject
to the conditions set forth in the SEPA, upon execution of the SEPA, the Company paid a structuring fee of $&lt;span id="xdx_906_eus-gaap--PaymentsForFees_c20231210__20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleMember_zRpSevxekAj5" title="Payments  for fees"&gt;25,000&lt;/span&gt; to an affiliate of
Yorkville and issued &lt;span id="xdx_905_eus-gaap--SharesIssued_iI_pid_c20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--YorkvilleMember_zxOtkyDESjcc" title="Shares issued"&gt;1,157&lt;/span&gt; shares of common stock to Yorkville (the &#x201c;Commitment Fee Shares&#x201d;). The Commitment Fee Shares were
determined by dividing $&lt;span id="xdx_902_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_pn5n6_c20231210__20231210__us-gaap--TypeOfArrangementAxis__custom--StandbyEquityPurchaseAgreementMember_zsx1s96g7en1" title="Commitment Fee"&gt;0.3&lt;/span&gt; million by the lowest daily VWAP of the common stock during the 10 trading days immediately prior to December
10, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 23, 2025, the Company delivered a Notice of Termination of the SEPA, dated as of December 10, 2023, by and between the Company
and Yorkville. Termination of the SEPA was mutually agreed upon and became effective as of January 23, 2025. At the time of the termination,
there were no outstanding borrowings, advance notices or shares of common stock to be issued under the SEPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
Release of Claims and Transition Agreement with Former Chief Executive Officer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#x201c;Release Agreement&#x201d;) with Mr.
Camaisa, a director and former Chief Executive Officer of the Company. Mr. Camaisa will continue to serve as a Class III director of
the Company, and will assume the title of &#x201c;CEO Emeritus&#x201d;. Pursuant to the Release Agreement, the Company is obligated to
pay Mr. Camisa $&lt;span id="xdx_902_ecustom--SeparationPay_pn5n6_c20250822__20250822__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_zJpunbg4kFwd" title="Separation pay"&gt;0.5&lt;/span&gt; million separation pay in the form of compensation continuation over 12 months pursuant to the Company&#x2019;s regular
and customary payroll schedule, less all regular and customary payroll withholdings and shall also be liable to pay Mr. Camisa COBRA
premiums for 12 months, commencing May 2025. Mr. Camaisa shall also be entitled to receive a transition/consulting pay of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20250822__20250822__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_z7ecSrhVJx0j" title="Consulting pay"&gt;10,000&lt;/span&gt; per
month during the transition period and incurred costs of $&lt;span id="xdx_90C_ecustom--IncurredCosts_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.CamisaMember_zRznM8jUs8wh" title="Incurred costs"&gt;0.1&lt;/span&gt; million for the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
Release of Claims and Separation Agreement with Former Executive Officer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Dr. Minev (the &#x201c;Agreement&#x201d;),
Executive Officer, effective August 15, 2025. Pursuant to the terms of the Agreement, the Company is obligated to pay Dr. Minev, (i)
$&lt;span id="xdx_905_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.MinevMember_z5DGSNbN1uac" title="Bonus payable"&gt;0.1&lt;/span&gt; million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals within 10 days following the Revocation Period (which
is seven business days from August 8, 2025, and excluding such date), and (ii) $&lt;span id="xdx_90F_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Dr.MinevMember_zOuolHyyAw87" title="Separation pay"&gt;0.2&lt;/span&gt; million severance pay in the form of compensation
continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less all regular and customary payroll
withholdings and shall pay Dr. Minev&#x2019;s COBRA premiums for six months, commencing August 2025, upon timely election.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;General
Release of Claims and Separation Agreement with Former Chief Legal Officer&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 17, 2025, the Company executed a General Release of Claims and Separation Agreement (the &#x201c;Agreement&#x201d;) with Ms.
Campbell, former Chief Legal Officer, effective September 24, 2025 (the &#x201c;Effective Date&#x201d;). Pursuant to the terms of the Agreement,
on the Effective Date, the Company is obligated to pay $&lt;span id="xdx_900_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Ms.CampbellMember_zl0Z6qodxaF7" title="Bonus payable"&gt;0.2&lt;/span&gt; million severance pay in the form of compensation continuation over six months
pursuant to the Company&#x2019;s regular and customary payroll schedule, less all regular and customary payroll withholdings, and shall
pay Ms. Campbell&#x2019;s COBRA premiums for six months, commencing October 2025, upon timely election. Note that pursuant to the terms
of the Agreement, as of December 31, 2025, the Company also paid Ms. Campbell a bonus in the amount of approximately $&lt;span id="xdx_90C_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Ms.CampbellMember_zd9kploJxh6h" title="Severance pay"&gt;0.1&lt;/span&gt; million, upon
the successful and effective sale of the investment in Nova Cell (see Note 6).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2022-10-10_custom_SanDiegoLeaseAgreementMember"
      decimals="INF"
      id="Fact002533"
      unitRef="sqft">15197</us-gaap:AreaOfLand>
    <CLDI:GuarantyOfLeaseAmount
      contextRef="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember_srt_MaximumMember"
      decimals="-5"
      id="Fact002535"
      unitRef="USD">900000</CLDI:GuarantyOfLeaseAmount>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2022-10-102022-10-10" id="Fact002537">As
consideration for the Guaranty, the Company agreed to pay Mr. Camaisa 10% of the Guaranty amount for the first year of the San Diego
Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease</us-gaap:LesseeOperatingLeaseDescription>
    <CLDI:GuarantyOfLeaseAmount
      contextRef="From2025-01-012025-12-31_custom_MrCamaisaMember"
      decimals="-5"
      id="Fact002539"
      unitRef="USD">200000</CLDI:GuarantyOfLeaseAmount>
    <CLDI:OperatingLeaseTermOfContractLeaseInitialTerm contextRef="From2023-03-012023-03-01" id="Fact002541">P48M</CLDI:OperatingLeaseTermOfContractLeaseInitialTerm>
    <us-gaap:PaymentsForRent
      contextRef="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember"
      decimals="-5"
      id="Fact002543"
      unitRef="USD">100000</us-gaap:PaymentsForRent>
    <CLDI:LeaseTermsOperatingLeasesAnnualIncreaseInRent
      contextRef="From2022-10-102022-10-10"
      decimals="INF"
      id="Fact002545"
      unitRef="Pure">0.03</CLDI:LeaseTermsOperatingLeasesAnnualIncreaseInRent>
    <CLDI:LeaseTermsOperatingLeasesAnnualIncreaseInRent
      contextRef="From2022-10-102022-10-10"
      decimals="INF"
      id="Fact002547"
      unitRef="Pure">0.03</CLDI:LeaseTermsOperatingLeasesAnnualIncreaseInRent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-10-102022-10-10_custom_SanDiegoLeaseAgreementMember"
      decimals="-5"
      id="Fact002549"
      unitRef="USD">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="AsOf2022-10-10_custom_SanDiegoLeaseAgreementMember"
      decimals="-5"
      id="Fact002551"
      unitRef="USD">100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:PaymentsForRent
      contextRef="From2022-04-012022-04-01_custom_StemVacOfficeLeaseAgreementMember"
      decimals="0"
      id="Fact002553"
      unitRef="EUR">4047</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2025-07-012025-07-01_custom_StemVacOfficeLeaseAgreementMember"
      decimals="0"
      id="Fact002555"
      unitRef="EUR">2976</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-01-012025-12-31_custom_StemVacOfficeLeaseAgreementMember"
      decimals="-5"
      id="Fact002557"
      unitRef="USD">1500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-01-012024-12-31_custom_StemVacOfficeLeaseAgreementMember"
      decimals="-5"
      id="Fact002559"
      unitRef="USD">1500000</us-gaap:OperatingLeaseExpense>
    <CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002561">&lt;p id="xdx_89F_ecustom--ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock_zjJcUdsV82A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents supplemental cash flow information related to operating and financing leases for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zIEWyOnuK0Hh" style="display: none"&gt;Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250101__20251231_zVgR4TMa6cWi" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_z2O3hxNxW3p5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
    paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zE9lHKMwv1dj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,467&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,424&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zwgbEPczKbpi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    cash flows from financing leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zMCqdQoMchmf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    cash flows from financing leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CLDI:ScheduleOfCashFlowSupplementalDisclosuresOperatingAndFinancingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002563"
      unitRef="USD">1467000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002564"
      unitRef="USD">1424000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002566"
      unitRef="USD">28000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002567"
      unitRef="USD">30000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2025-01-01to2025-12-31"
      decimals="-3"
      id="Fact002569"
      unitRef="USD">90000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact002570"
      unitRef="USD">82000</us-gaap:FinanceLeasePrincipalPayments>
    <CLDI:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002572">&lt;p id="xdx_891_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock_z7POe9VVVW36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents supplemental balance sheet information related to operating and financing leases for the periods presented (in
thousands, except weighted averages):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zzivUjMbH66g" style="display: none"&gt;Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20251231_zeUZUbKLDkCl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20241231_zg5QPJAo5gIk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
                                            31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zjptdiItgEMh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,934&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzLs4_zhvI1rU3CG7d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,405&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,204&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzLs4_zErKs72ddsR2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Right-of-use
    lease liabilities, noncurrent&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,845&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzLs4_zmbAHBUGsGbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,049&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_iI_pn3n3_maPPAENzCH7_zXL1SWMuK1Kf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;779&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;588&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iNI_pn3n3_di_msPPAENzCH7_zp0geCKJ9JDf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accumulated
    depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(463&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(333&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation_iTI_pn3n3_mtPPAENzCH7_zfNhCxxzcpSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery
    and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;255&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_maFLLzNvC_zGD0wv9kWj3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;111&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_maFLLzNvC_zQP67sLDO6P7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Noncurrent
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;145&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_mtFLLzNvC_zoLsaW172gHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;211&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zXh8NPFoUwj2" title="Weighted average remaining lease term, Operating leases (in years)"&gt;1.2&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zWdlNhVMVNL8" title="Weighted average remaining lease term, Operating leases (in years)"&gt;2.2&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20251231_zeWhdokfJzNj" title="Weighted average remaining lease term, Financing leases (in years)"&gt;2.7&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_z3QXnlbPtHuf" title="Weighted average remaining lease term, Financing leases (in years)"&gt;3.2&lt;/span&gt;
                                            years&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zr8xPw3WQtL1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.70&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_zZdFtnio05D7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financing
    leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.05&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CLDI:ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002574"
      unitRef="USD">1682000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002575"
      unitRef="USD">2934000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002577"
      unitRef="USD">1405000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002578"
      unitRef="USD">1204000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002580"
      unitRef="USD">277000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002581"
      unitRef="USD">1845000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002583"
      unitRef="USD">1682000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002584"
      unitRef="USD">3049000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002586"
      unitRef="USD">779000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002587"
      unitRef="USD">588000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002589"
      unitRef="USD">463000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002590"
      unitRef="USD">333000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002592"
      unitRef="USD">316000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002593"
      unitRef="USD">255000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002595"
      unitRef="USD">111000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002596"
      unitRef="USD">66000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002598"
      unitRef="USD">171000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002599"
      unitRef="USD">145000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002601"
      unitRef="USD">282000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002602"
      unitRef="USD">211000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact002604">P1Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact002606">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-12-31" id="Fact002608">P2Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact002610">P3Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact002612"
      unitRef="Pure">0.1170</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002613"
      unitRef="Pure">0.1175</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-12-31"
      decimals="INF"
      id="Fact002615"
      unitRef="Pure">0.0905</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002616"
      unitRef="Pure">0.1213</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002618">&lt;p id="xdx_89C_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zOihmUTUOme4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents future minimum lease commitments as of December 31, 2025 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zrbvmxSlKA3h" style="display: none"&gt;Schedule
of Future Minimum Lease Commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financing&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zrCrNBg9wKvk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Operating Leases, 2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,512&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zcoYAGtcgefj" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Financing Leases, 2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;132&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zECw0oPKmbX6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;295&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zFAwlGX09Rjl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zexL69dvRUje" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmReNXTKils8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;76&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z5cozyuTQpJc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2029"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2632"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zlZ2svW4Kw3k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2029"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2030
    and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zM7iUfRRvjF8" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, 2030 and thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2636"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zruLPX0rgbri" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, 2030 and thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2638"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zmtaJlAhhCB1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Total minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,809&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z8cP0VsZT5x5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Total minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;319&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_ztrK0QO5otPe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Less: amounts representing interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(127&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20251231_zOMifW6juZWl" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Less: amounts representing interest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(37&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present
    value of net minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseLiability_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_z3YOipHV72nb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Operating Leases, Present value of net minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,682&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiability_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20251231_zHO9irHCvb7i" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Financing Leases, Present value of net minimum lease payments"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002620"
      unitRef="USD">1512000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002622"
      unitRef="USD">132000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002624"
      unitRef="USD">295000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002626"
      unitRef="USD">94000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002628"
      unitRef="USD">2000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002630"
      unitRef="USD">76000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002634"
      unitRef="USD">17000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002640"
      unitRef="USD">1809000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002642"
      unitRef="USD">319000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002644"
      unitRef="USD">127000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002646"
      unitRef="USD">37000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002648"
      unitRef="USD">1682000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact002650"
      unitRef="USD">282000</us-gaap:FinanceLeaseLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-05-012024-05-01_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002652"
      unitRef="Shares">1162</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <CLDI:RemainingExpectedCommitments
      contextRef="AsOf2025-12-31"
      decimals="-5"
      id="Fact002654"
      unitRef="USD">500000</CLDI:RemainingExpectedCommitments>
    <CLDI:RemainingExpectedCommitments
      contextRef="AsOf2024-12-31"
      decimals="-5"
      id="Fact002656"
      unitRef="USD">300000</CLDI:RemainingExpectedCommitments>
    <us-gaap:OtherCommitment
      contextRef="AsOf2021-06-07_custom_NorthwesternAgreementMember"
      decimals="-6"
      id="Fact002657"
      unitRef="USD">10000000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitmentsDescription
      contextRef="From2024-12-152024-12-15_custom_NorthwesternAgreementMember"
      id="Fact002658">a non-creditable and non-refundable one-time milestone payment of $0.3 million upon reaching an aggregate of $2.0 million of net sales
of a licensed product; (b) a non-creditable and nonrefundable one-time milestone payment of $0.5 million upon reaching an aggregate of
$10.0 million of net sales of a licensed product; (c) sublicensing royalty of 20% of any sublicensing revenue resulting from the grant
of rights hereunder; and (d) in the event of an assignment or transfer of licensed data, with the consent of Northwestern, a low single
digit percentage of the fair market value of any consideration received. This sublicensing royalty shall be cumulative, meaning it shall
be imposed only once with respect to a single unit of sublicensing revenue, regardless of whether the sublicensing revenue derives from
the CTA, or the June 7, 2021 Northwestern Agreement described above, or both.</us-gaap:OtherCommitmentsDescription>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2021-07-222021-07-22_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact002660"
      unitRef="USD">18700000</us-gaap:PaymentsForRoyalties>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember"
      decimals="-5"
      id="Fact002662"
      unitRef="USD">500000</us-gaap:OtherLiabilities>
    <CLDI:CommitmentFeePercentage
      contextRef="AsOf2023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember"
      decimals="INF"
      id="Fact002664"
      unitRef="Pure">0.08</CLDI:CommitmentFeePercentage>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="From2023-06-222023-06-23_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember"
      id="Fact002666">P2Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2024-06-30_custom_SeparationAndReleaseAgreementMember_custom_GeorgeNgMember"
      decimals="0"
      id="Fact002668"
      unitRef="USD">50000</us-gaap:OtherLiabilities>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2023-08-31_custom_MrCamaisaMember"
      decimals="-5"
      id="Fact002670"
      unitRef="USD">700000</us-gaap:DeferredCompensationEquity>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-08-31_custom_MrCamaisaMember"
      decimals="INF"
      id="Fact002672"
      unitRef="Shares">46972</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2023-08-31_custom_MrLeftwichMember"
      decimals="-5"
      id="Fact002674"
      unitRef="USD">500000</us-gaap:DeferredCompensationEquity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-08-31_custom_MrLeftwichMember"
      decimals="INF"
      id="Fact002676"
      unitRef="Pure">0.24</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-08-12_custom_MrLeftwichMember"
      decimals="INF"
      id="Fact002678"
      unitRef="Pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="AsOf2025-01-03_custom_MrLeftwichMember_custom_SettlementOfDeferredCompensationMember"
      decimals="-5"
      id="Fact002680"
      unitRef="USD">600000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-12-102023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact002682"
      unitRef="USD">25000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002684"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <CLDI:EquityPurchaseDescription
      contextRef="From2023-12-102023-12-10_us-gaap_CommonStockMember_custom_StandbyEquityPurchaseAgreementMember"
      id="Fact002686">(i) an amount equal
to 100% of the average of the daily traded amount during the five consecutive trading days immediately preceding an advance notice, or
(ii) 41,667 shares. For the SEPA to be utilized, the shares underlying the agreement need to be registered on a Form S-1 filed with the
SEC.</CLDI:EquityPurchaseDescription>
    <us-gaap:PaymentsForFees
      contextRef="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember"
      decimals="0"
      id="Fact002688"
      unitRef="USD">25000</us-gaap:PaymentsForFees>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-10_custom_StandbyEquityPurchaseAgreementMember_us-gaap_CommonStockMember_custom_YorkvilleMember"
      decimals="INF"
      id="Fact002690"
      unitRef="Shares">1157</us-gaap:SharesIssued>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="From2023-12-102023-12-10_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-5"
      id="Fact002692"
      unitRef="USD">300000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <CLDI:SeparationPay
      contextRef="From2025-08-222025-08-22_custom_Dr.CamisaMember"
      decimals="-5"
      id="Fact002694"
      unitRef="USD">500000</CLDI:SeparationPay>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-08-222025-08-22_custom_Dr.CamisaMember"
      decimals="0"
      id="Fact002696"
      unitRef="USD">10000</us-gaap:DebtInstrumentPeriodicPayment>
    <CLDI:IncurredCosts
      contextRef="From2025-01-012025-12-31_custom_Dr.CamisaMember"
      decimals="-5"
      id="Fact002698"
      unitRef="USD">100000</CLDI:IncurredCosts>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-08-08_custom_Dr.MinevMember"
      decimals="-5"
      id="Fact002700"
      unitRef="USD">100000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <CLDI:SeparationPay
      contextRef="From2025-08-082025-08-08_custom_Dr.MinevMember"
      decimals="-5"
      id="Fact002702"
      unitRef="USD">200000</CLDI:SeparationPay>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="AsOf2025-09-17_custom_Ms.CampbellMember"
      decimals="-5"
      id="Fact002704"
      unitRef="USD">200000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:SeveranceCosts1
      contextRef="From2025-09-172025-09-17_custom_Ms.CampbellMember"
      decimals="-5"
      id="Fact002706"
      unitRef="USD">100000</us-gaap:SeveranceCosts1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-12-31" id="Fact002708">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zg8RNugb7Sfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span id="xdx_825_zTzMiazaCqE7"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;March
2026 Confidentially Marketed Public Offering (CMPO)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 6, 2026, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Ladenburg Thalmann
&amp;amp; Co. Inc., as sole underwriter (&#x201c;Underwriter&#x201d;), in connection with the issuance and sale (the &#x201c;Offering&#x201d;)
of: (i) &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zF5TOIoGeTea" title="Issuance and sale of shares"&gt;2,278,731&lt;/span&gt; common stock units (&#x201c;Common Stock Units&#x201d;), which includes &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--CommonStockUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zOLZwurE570g" title="Shares purchased"&gt;1,575,000&lt;/span&gt; Common Stock Units purchased pursuant
to the exercise, in full, of the Over-Allotment Option, sold to the public at a price of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zx2s4GJSj2Hb" title="Shares price sold"&gt;0.50&lt;/span&gt; per Common Stock Unit, and (ii) &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zzhESGsqTUig" title="Issuance and sale of shares"&gt;9,815,900&lt;/span&gt;
pre-funded warrant units (&#x201c;Pre-Funded Units&#x201d;), sold to the public at a price of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_ztVRmFdp3PAi" title="Shares price sold"&gt;0.499&lt;/span&gt; per Pre-Funded Unit, resulting in
gross proceeds of approximately $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--PreFundedWarrantUnitsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zGt837EmyFEd" title="Gross proceeds"&gt;6.0&lt;/span&gt; million, before deducting underwriting discounts and commissions and other estimated offering expenses.
In connection with the Offering, the Company also issued to the Underwriter (or its designees) a warrant (the &#x201c;Underwriter&#x2019;s
Warrant&#x201d;) to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zF438ZVnCZtk" title="Warrant purchase"&gt;604,732&lt;/span&gt; shares of Common Stock of the Company, par value $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zza2ndLR3dgl" title="Common stock, par value"&gt;0.0001&lt;/span&gt;. The Underwriter&#x2019;s Warrant has
an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zBCcXqgmg6rd" title="Warrant exercise price"&gt;0.625&lt;/span&gt;, is exercisable on or after the date of issuance, and will expire on &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20260306__20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersWarrantMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zNEKKbCI3Zdf" title="Warrant expire date"&gt;March 9, 2031&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
Common Stock Unit consisted of (i) one share of Common Stock, (ii) one Series J common stock warrant (&#x201c;Series J Warrants&#x201d;)
to purchase one share of Common Stock (or pre-funded warrants to purchase one share of Common Stock in lieu thereof), (iii) one Series
K common stock warrant (&#x201c;Series K Warrants&#x201d;) to purchase one share of Common Stock (or pre-funded warrants to purchase one
share of Common Stock in lieu thereof), and (iv) one Series L common stock warrant (&#x201c;Series L Warrants&#x201d; and together with
the Series J Warrants and the Series K Warrants, the &#x201c;Common Warrants&#x201d;) to purchase one share of Common Stock (or pre-funded
warrants to purchase one share of Common Stock in lieu thereof). Each Pre-Funded Unit consisted of (i) one pre-funded warrant (the &#x201c;Pre-Funded
Warrants&#x201d;), (ii) one Series J Warrant, (iii) one Series K Warrant, and (iv) one Series L Warrant. The Common Warrants included
in the Pre-Funded Units are identical to the Common Warrants included in the Common Stock Units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series J Warrants have an initial exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zdNnmvomwAb3" title="Initial exercise price"&gt;0.50&lt;/span&gt; per share. The Series J Warrants are exercisable immediately, subject to certain
limitations described herein. The Series J Warrants expire five (&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesJWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zTqcuerND9zl" title="Warrants expire year"&gt;5&lt;/span&gt;) years from the date of issuance. The Series K Warrants have an initial
exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zeewpThVX86j" title="Initial exercise price"&gt;0.50&lt;/span&gt; per share. The Series K Warrants are exercisable immediately, subject to certain limitations described herein.
The Series K Warrants will expire one (&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesKWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zq3wApjM7Rjb" title="Warrants expire year"&gt;1&lt;/span&gt;) year from the date of issuance. The Series L Warrants have an initial exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z1MsjJ57uqbj" title="Initial exercise price"&gt;0.50&lt;/span&gt;
per share. The Series L Warrants are exercisable immediately, subject to certain limitations described herein. The Series L Warrants
expire six (&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesLWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_za6v92U1WAzh" title="Warrants expire year"&gt;6&lt;/span&gt;) months from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Common Stock Units, the Pre-Funded Units, the shares of Common Stock comprising the Common Stock Units, the Common Warrants, the Pre-Funded
Warrants, the shares of Common Stock issuable upon exercise of the Common Warrants, and the Pre-Funded Warrants were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-284229), that was filed with the Securities Exchange Commission
(&#x201c;SEC&#x201d;) on January 10, 2025 and declared effective on February 7, 2025, including the prospectus forming a part of the registration
statement, a final prospectus supplement thereto, which was filed with the SEC on March 9, 2026, pursuant to Rule 424(b) under the Securities
Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and the related registration statement filed with the SEC on March 5, 2026
under Rule 462(b) of the Securities Act, which became automatically effective upon filing. The Offering closed on March 9, 2026 (the
&#x201c;Closing Date&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 6, 2026, the Company also entered into a warrant agency agreement (the &#x201c;Warrant Agency Agreement&#x201d;) with Equiniti Trust
Company, LLC, as warrant agent (the &#x201c;Warrant Agent&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;Since the
closing of the Offering, &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260306__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz16vwaTY8Ij" title="Pre funded warrants"&gt;2,291,000&lt;/span&gt; Pre-Funded Warrants have been exercised.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Amendments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 5, 2026, the Company entered into an Amendment to Common Stock Purchase Warrants Agreement (the &#x201c;Warrant Amendment&#x201d;)
with certain investors, that participated in the March 2026 CMPO described above, in connection with the terms of certain
of the Company&#x2019;s outstanding common warrants to purchase shares of Common Stock (the &#x201c;Existing Warrants&#x201d;). As originally
issued, the Existing Warrants provided for the purchase of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;span id="xdx_905_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkRTwAEJNS" title="Shares of common stock"&gt;504,417&lt;/span&gt; shares of common stock, on exercise of the series G common stock warrants at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_z9tr0uLm5m13" title="warrants exercise price"&gt;8.3448&lt;/span&gt; per share;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;span id="xdx_90B_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuCXakqVOMz9" title="Shares of common stock"&gt;279,168&lt;/span&gt; shares of common stock, on exercise of the series H common stock warrants at an exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesHCommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zki4nAVQ3ke1" title="warrants exercise price"&gt;8.40&lt;/span&gt; per share; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;span id="xdx_900_eus-gaap--SharesIssued_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesICommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy6jP8a536K7" title="Shares of common stock"&gt;2,190,000&lt;/span&gt; shares of common stock, on exercise of the series I common stock warrants at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesICommonStockWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zU8uxZuGH2El" title="warrants exercise price"&gt;2.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Per
the Warrant Amendment, the exercise price for each of such Existing Warrants was reduced to $&lt;span id="xdx_90F_eus-gaap--WarrantExercisePriceDecrease_c20260305__20260305__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--CommonStockPurchaseWarrantsAgreementMember_zEUR3pHvlgQd" title="warrants exercise price"&gt;0.50&lt;/span&gt; per share, subject to further adjustment
as set forth in the Existing Warrants and any other document governing the terms thereunder. All other terms and conditions of the Existing
Warrants remain unchanged and in full force and effect.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_CommonStockUnitsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002710"
      unitRef="Shares">2278731</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_CommonStockUnitsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002712"
      unitRef="Shares">1575000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_us-gaap_OverAllotmentOptionMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002714"
      unitRef="USDPShares">0.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002716"
      unitRef="Shares">9815900</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002718"
      unitRef="USDPShares">0.499</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_PreFundedWarrantUnitsMember_custom_UnderwritingAgreementMember"
      decimals="-5"
      id="Fact002720"
      unitRef="USD">6000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002722"
      unitRef="Shares">604732</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002724"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002726"
      unitRef="USDPShares">0.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized
      contextRef="From2026-03-062026-03-06_us-gaap_SubsequentEventMember_custom_UnderwritersWarrantMember_custom_UnderwritingAgreementMember"
      id="Fact002728">March 9, 2031</us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesJWarrantsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002730"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesJWarrantsMember_custom_UnderwritingAgreementMember"
      id="Fact002732">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesKWarrantsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002734"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesKWarrantsMember_custom_UnderwritingAgreementMember"
      id="Fact002736">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesLWarrantsMember_custom_UnderwritingAgreementMember"
      decimals="INF"
      id="Fact002738"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember_custom_SeriesLWarrantsMember_custom_UnderwritingAgreementMember"
      id="Fact002740">P6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-03-06_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002742"
      unitRef="Shares">2291000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002744"
      unitRef="Shares">504417</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesGCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember"
      decimals="INF"
      id="Fact002746"
      unitRef="USDPShares">8.3448</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002748"
      unitRef="Shares">279168</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesHCommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember"
      decimals="INF"
      id="Fact002750"
      unitRef="USDPShares">8.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002752"
      unitRef="Shares">2190000</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-03-05_us-gaap_SubsequentEventMember_custom_SeriesICommonStockWarrantsMember_custom_CommonStockPurchaseWarrantsAgreementMember"
      decimals="INF"
      id="Fact002754"
      unitRef="USDPShares">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2026-03-052026-03-05_us-gaap_SubsequentEventMember_custom_CommonStockPurchaseWarrantsAgreementMember"
      decimals="INF"
      id="Fact002756"
      unitRef="USDPShares">0.50</us-gaap:WarrantExercisePriceDecrease>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0981"
          xlink:label="xdx2ixbrl0981"
          xlink:type="locator"/>
        <link:footnote id="Footnote000986" xlink:label="Footnote000986" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    contingently issuable warrants were not included for purposes of calculating the number of diluted shares outstanding as of December
    31, 2024, as the number of dilutive shares is based on a contingency not yet resolved as of period end and the contingently resulting
    number of dilutive shares is not determinable until the contingency is resolved. As of December 31, 2025, the contingency was resolved
    in full and there were no contingently issuable warrants outstanding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0981"
          xlink:to="Footnote000986"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0982"
          xlink:label="xdx2ixbrl0982"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0982"
          xlink:to="Footnote000986"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001016"
          xlink:label="Fact001016"
          xlink:type="locator"/>
        <link:footnote id="Footnote001024" xlink:label="Footnote001024" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other
    segment items primarily include interest expense, grant income, office expenses, marketing expenses, gain on sale of investment in
    Nova Cell, and other income, net.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001016"
          xlink:to="Footnote001024"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001017"
          xlink:label="Fact001017"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001017"
          xlink:to="Footnote001024"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001174"
          xlink:label="Fact001174"
          xlink:type="locator"/>
        <link:footnote id="Footnote001235" xlink:label="Footnote001235" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    of December 31,
    2024, related party term note payable amounts due to Directors A and E totaled $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90C_eus-gaap--NotesPayable_iI_pn5n6_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsAAndEMember_zIMGCvx7Rd49"
  title="Related party note payable">2.7</xhtml:span> million. See Note 7 for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001174"
          xlink:to="Footnote001235"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001179"
          xlink:label="Fact001179"
          xlink:type="locator"/>
        <link:footnote id="Footnote001238" xlink:label="Footnote001238" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts
    owed to Director F and the relative of Officer A as of December 31, 2024, for reimbursable expenses; in addition, amounts owed to
    a relative of Officer A for certain legal fees, included in accounts payable and accrued expenses. Legal fees incurred to a relative of Officer A were approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90A_eus-gaap--LegalFees_pn3n3_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_z59bBMlkeEDj"
  title="Legal fees">48</xhtml:span> thousand
and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--LegalFees_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--OfficerMember_zalpzGv7CJ04"
  title="Legal fees">38</xhtml:span> thousand for the years ended December 31, 2025 and 2024, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001179"
          xlink:to="Footnote001238"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001184"
          xlink:label="Fact001184"
          xlink:type="locator"/>
        <link:footnote id="Footnote001243" xlink:label="Footnote001243" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    April 22, 2025, the Company executed a General Release of Claims and Transition Agreement (&#x201c;Release Agreement&#x201d;) with Mr.
    Camaisa, (Director F referenced above), and is obligated to pay Director F $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--LoansPayable_iI_pn5n6_c20250422__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zF7AKppGO5cb"
  title="Loans">0.5</xhtml:span>
    million separation pay in the form of compensation continuation over 12 months pursuant to our regular and customary payroll
    schedule, less all regular and customary payroll withholdings and shall also be liable to pay Director F COBRA premiums for 12
    months, commencing May 2025, of which $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_908_eus-gaap--LoansPayable_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zHyUNqOlpBJ1"
  title="Loan outstanding">0.2</xhtml:span>
    million is outstanding as of December 31, 2025. Director F shall also be entitled to receive transition and consulting pay of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_908_ecustom--ConsultingPay_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zZpvjLo5bzS2"
  title="Consulting pay">10,000</xhtml:span>
    per month during the transition period. The agreement terminated on December 31, 2025 and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--OtherExpenses_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorFMember_zxupRL1MmZ1j"
  title="Expenses">0.1</xhtml:span>
    million was expensed under the agreement.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001184"
          xlink:to="Footnote001243"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001189"
          xlink:label="Fact001189"
          xlink:type="locator"/>
        <link:footnote id="Footnote001252" xlink:label="Footnote001252" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    February 1, 2022, the Company appointed a then current board member (Director D referenced above), George K. Ng, as President and
    Chief Operating Officer of the Company under an Employment Agreement (the &#x201c;Ng Agreement&#x201d;). Under the Ng Agreement, Mr.
    Ng was entitled to a base annual salary of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_eus-gaap--SalariesAndWages_pn5n6_c20220201__20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_zONRA6gMNGck"
  title="Annual salary">0.5</xhtml:span> million and a signing bonus of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20220201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorDMember_z9tJ9frmw9k4"
  title="Bonus payable">0.3</xhtml:span> million, payable in three equal monthly installments.
    Mr. Ng was eligible for standard change in control and severance benefits.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001189"
          xlink:to="Footnote001252"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001194"
          xlink:label="Fact001194"
          xlink:type="locator"/>
        <link:footnote id="Footnote001257" xlink:label="Footnote001257" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    April 1, 2022, the Company entered into an Advisory Agreement with Scott Leftwich (Director A referenced above), for providing certain
    strategic and advisory services. Director A received an advisory fee of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn3n3_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zhdUF0hR1gf6"
  title="Monthly advisory fee">9,166</xhtml:span> per month not to exceed $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90D_eus-gaap--NoninterestExpenseInvestmentAdvisoryFees_pn5n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember__srt--RangeAxis__srt--MaximumMember_zDUicRbyJAZ5"
  title="Advisory fee">0.1</xhtml:span> million per annum, accrued
    and payable upon the Company raising $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20220401__20220401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAMember_zBxI57KV5bxf"
  title="Equity proceeds">10</xhtml:span> million or more in equity proceeds, as defined in the Advisory Agreement. The Advisory Agreement
    terminated on August 31, 2023. The accrued advisory fees were settled in January 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001194"
          xlink:to="Footnote001257"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001199"
          xlink:label="Fact001199"
          xlink:type="locator"/>
        <link:footnote id="Footnote001264" xlink:label="Footnote001264" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In
    October 2022, in order for the Company to secure and execute the San Diego Lease discussed in Note 11, Director F, provided a personal
    Guaranty of Lease of (the &#x201c;Guaranty&#x201d;) up to $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_ecustom--GuarantyOfLeaseAmount_pn5n6_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__srt--RangeAxis__srt--MaximumMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zVuT0TktG7P"
  title="Guaranty of lease amount">0.9</xhtml:span> million to the lessor for the Company&#x2019;s future performance under
    the San Diego Lease agreement. <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_908_eus-gaap--LessorOperatingLeaseDescription_c20221001__20221031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zvJFsRMX66ok"
  title="Lease agreement description">As consideration for the Guaranty, the Company agreed to pay Director F 10% of the Guaranty amount
    for the first year of the San Diego Lease, and 5% per annum of the Guaranty amount thereafter through the life of the lease, with
    all amounts accrued and payable at the termination of the San Diego Lease or release of Director F from the Guaranty by the lessor,
    whichever occurs first.</xhtml:span> As of December 31, 2025 and December 31, 2024, the amounts shown in the table above represent the present
    value, including accrued interest as of the period shown, of approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_ziVh49kZU1Z"
  title="Lease payment due">14,000</xhtml:span> and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn5n6_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AJCCapitalMember__us-gaap--GuaranteeObligationsByNatureAxis__custom--GuarantyMember_zKN999k2h1y6"
  title="Lease payment due">0.2</xhtml:span> million, respectively, payment due to
    Director F upon the release or termination of the Guaranty, which is included in non-current operating lease right-of-use liability.
    The amount due to Director F was partially settled in April 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001199"
          xlink:to="Footnote001264"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001204"
          xlink:label="Fact001204"
          xlink:type="locator"/>
        <link:footnote id="Footnote001273" xlink:label="Footnote001273" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In
    August 2023, the Company entered into an agreement with Director A for deferred compensation including advisory fees for $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zyXHDJNFUNPc"
  title="Deferred compensation">0.5</xhtml:span> million,
    which was paid in January 2025 (see Note 11). The $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--NotesPayable_iI_pn5n6_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_z48frnPGzgPj"
  title="Notes payable">0.5</xhtml:span> million note bore interest at <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zDMM7xtMzPz4"
  title="Note bears interest percentage">24</xhtml:span>% through August 12, 2024, at which time the
    note was amended and replaced with an interest rate of <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240812__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorAThreeMember_zpf08mHWUCne"
  title="Note bears interest percentage">14</xhtml:span>% per annum. The deferred compensation and advisory fees were settled in
    January 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001204"
          xlink:to="Footnote001273"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001209"
          xlink:label="Fact001209"
          xlink:type="locator"/>
        <link:footnote id="Footnote001282" xlink:label="Footnote001282" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    Note 8 for disclosures around Warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001209"
          xlink:to="Footnote001282"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001214"
          xlink:label="Fact001214"
          xlink:type="locator"/>
        <link:footnote id="Footnote001283" xlink:label="Footnote001283" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In
    January 2024, the Company entered into a loan agreement with a relative of Officer A for a loan payable for $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90D_eus-gaap--LoansPayable_iI_pn5n6_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zjwEot3QXbE8"
  title="Officer loans payable">0.2</xhtml:span> million, which bears
    interest at <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelativeOfOfficerAMember__us-gaap--DebtInstrumentAxis__us-gaap--LoansPayableMember_zhsavoO6GHWe"
  title="Officer loans payable">12</xhtml:span>%. The loan was settled in full in January 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001214"
          xlink:to="Footnote001283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001219"
          xlink:label="Fact001219"
          xlink:type="locator"/>
        <link:footnote id="Footnote001288" xlink:label="Footnote001288" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    August 8, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer G, and is obligated to pay
    to Officer G $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_903_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8d1dgpry9g2"
  title="Bonus payable">0.1</xhtml:span> million in relation to a negotiated bonus for the NNV1 and SNV1 IND approvals and $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90C_ecustom--SeparationPay_pn5n6_c20250808__20250808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_zs9OB3BxpGnc"
  title="Separation pay">0.2</xhtml:span> million severance pay in
    the form of compensation continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less
    all regular and customary payroll withholdings and shall pay Officer G&#x2019;s COBRA premiums for six months, commencing August 2025.
    As of December 31, 2025, $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_901_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerGMember_z8HoM1XOrQA9"
  title="Severance pay">0.1</xhtml:span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001219"
          xlink:to="Footnote001288"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001224"
          xlink:label="Fact001224"
          xlink:type="locator"/>
        <link:footnote id="Footnote001295" xlink:label="Footnote001295" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    September 17, 2025, the Company executed a General Release of Claims and Separation Agreement with Officer A, and is obligated to
    pay to Officer A i) a bonus in the amount of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90F_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn5n6_c20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zbXiYHNnsfD1"
  title="Bonus payable">0.1</xhtml:span> million, upon the successful and effective corporate spin-off, out-licensing, or
    similar transaction relating to Nova Cell prior to October 31, 2025, and (ii) $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_eus-gaap--SeveranceCosts1_pn5n6_c20250917__20250917__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zW289VEhGRq6"
  title="Severance pay">0.2</xhtml:span> million severance pay in the form of compensation
    continuation over six months pursuant to the Company&#x2019;s regular and customary payroll schedule, less all regular and customary
    payroll withholdings and shall pay Officer A&#x2019;s COBRA premiums for six months, commencing October 2025. As of December 31, 2025,
    $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_902_eus-gaap--SeveranceCosts1_pn5n6_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficerAMember_zb64eTEih0qf"
  title="Severance pay">0.2</xhtml:span> million of severance pay and related benefits were included in related party accrued
expenses and other liabilities.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001224"
          xlink:to="Footnote001295"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001229"
          xlink:label="Fact001229"
          xlink:type="locator"/>
        <link:footnote id="Footnote001302" xlink:label="Footnote001302" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On
    December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for
    contract research organization (&#x201c;CRO&#x201d;) services and other clinical development services. As part of the Master Services
    Agreement, the Company is obligated to pay to Company A i) all reimbursable expenses, and (ii) all undisputed invoiced amounts for
    services. As of December 31, 2025, the Company accrued $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_909_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_zZjGpIr2V6Hl"
  title="Accounts payable and accrued expenses">0.1</xhtml:span>
    million due to Company A, included in related party accounts payable and accrued expenses. Furthermore, during the year ended
    December 31, 2025, the Company incurred $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFJlbGF0ZWQgUGFydHkgVHJhbnNhY3Rpb25zIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CompanyARelatedToDirectorGMember_z3aWjlrLIi7h"
  title="Expenses related to services">0.6</xhtml:span>
    million in expenses related to services from Company A.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001229"
          xlink:to="Footnote001302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001234"
          xlink:label="Fact001234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001234"
          xlink:to="Footnote001302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001640"
          xlink:label="Fact001640"
          xlink:type="locator"/>
        <link:footnote id="Footnote002028" xlink:label="Footnote002028" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
    Private Warrants (and shares of common stock issued or issuable upon exercise of the Private Warrants) in general, will not be transferable,
    assignable or salable until 30 days after the Closing (excluding permitted transferees) and they will not be redeemable under certain
    redemption scenarios by us so long as they are held by the Sponsor, Metric or their respective permitted transferees. Otherwise,
    the Private Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price,
    exercisability and exercise period. If the Private Warrants are held by holders other than the Company&#x2019;s sponsor, Metric or
    their respective permitted transferees, the Private Warrants will be redeemable by the Company under all redemption scenarios and
    exercisable by the holders on the same basis as the Public Warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001640"
          xlink:to="Footnote002028"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001641"
          xlink:label="Fact001641"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001641"
          xlink:to="Footnote002028"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001655"
          xlink:label="Fact001655"
          xlink:type="locator"/>
        <link:footnote id="Footnote002029" xlink:label="Footnote002029" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                            Public Warrants became exercisable 30 days after the closing of the FLAG Merger. Each whole
                                            share of the warrant is exercisable for one share of the Company&#x2019;s common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001655"
          xlink:to="Footnote002029"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001656"
          xlink:label="Fact001656"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001656"
          xlink:to="Footnote002029"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001805"
          xlink:label="Fact001805"
          xlink:type="locator"/>
        <link:footnote id="Footnote002038" xlink:label="Footnote002038" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During
                                            the year ended December 31, 2024, Series A warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zCjkHqdunk3f"
  title="Number of shares purchased">60,418</xhtml:span> shares of common stock
                                            were exercised at $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zPT8BskwlAz7"
  title="Exercise price">18.24</xhtml:span> per share and the Company received gross proceeds of approximately
                                            $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesAWarrantsMember_zEMSeMcPb576"
  title="Received dross proceeds">1.1</xhtml:span> million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001805"
          xlink:to="Footnote002038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001806"
          xlink:label="Fact001806"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001806"
          xlink:to="Footnote002038"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1820"
          xlink:label="xdx2ixbrl1820"
          xlink:type="locator"/>
        <link:footnote id="Footnote002051" xlink:label="Footnote002051" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Series
                                            B warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zf8FOHGPZTc1"
  title="Number of shares purchased">22,275</xhtml:span> shares of common stock were exercised at a reduced exercise
                                            price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zzuJKZKYOhM8"
  title="Warrants exercise price">24.00</xhtml:span> in connection with the May Inducement Offer. Pursuant to the issuance of
                                            common stock per the Series B warrant exercises, the Company received gross proceeds of approximately
                                            $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zGLjI04R1ZF5"
  title="Gross proceeds">0.5</xhtml:span> million. During the year ended December 31, 2024, Series B warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zk2l9to9EpN3"
  title="Number of shares purchased">68,335</xhtml:span>
                                            shares of common stock were exercised at $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zU7bxz8xESV8"
  title="Warrants exercise price">18.24</xhtml:span> per share and the Company received gross
                                            proceeds of approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBWarrantsMember_zCcLjLw0EARb"
  title="Gross proceeds">1.2</xhtml:span> million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1820"
          xlink:to="Footnote002051"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001821"
          xlink:label="Fact001821"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001821"
          xlink:to="Footnote002051"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001835"
          xlink:label="Fact001835"
          xlink:type="locator"/>
        <link:footnote id="Footnote002068" xlink:label="Footnote002068" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During
                                            the year ended December 31, 2024, Series B-1 warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zBLLcDgTdCy"
  title="Number of shares purchased">27,082</xhtml:span> shares of common
                                            stock were exercised at $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zmQDcU3KHzp1"
  title="Warrants exercise price">18.24</xhtml:span> per share and the Company received gross proceeds of approximately
                                            $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_901_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesBOneWarrantsMember_zFLyYRkQgdob"
  title="Gross proceeds">0.5</xhtml:span> million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001835"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001836"
          xlink:label="Fact001836"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001836"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1850"
          xlink:label="xdx2ixbrl1850"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1850"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001851"
          xlink:label="Fact001851"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001851"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1861"
          xlink:label="xdx2ixbrl1861"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1861"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001862"
          xlink:label="Fact001862"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001862"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1876"
          xlink:label="xdx2ixbrl1876"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1876"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001877"
          xlink:label="Fact001877"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001877"
          xlink:to="Footnote002068"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001891"
          xlink:label="Fact001891"
          xlink:type="locator"/>
        <link:footnote id="Footnote002081" xlink:label="Footnote002081" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In
                                            connection with the May Inducement Offer, Series C-1 warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zKPNR6ClnD7f"
  title="Number of shares purchased">4,167</xhtml:span> shares of
                                            common stock were exercised at $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zaszH3QFHDqg"
  title="Warrants exercise price">24.00</xhtml:span> per share and the Company received gross proceeds of
                                            approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_902_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zuZjFRPF7T4b"
  title="Gross proceeds">0.1</xhtml:span> million. During the year ended December 31, 2024, Series C-1 warrants
                                            to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zpHaIjfa2fO7"
  title="Number of shares purchased">47,936</xhtml:span> shares of common stock were exercised at $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zUUvBZMUKLD8"
  title="Warrants exercise price">18.24</xhtml:span> per share and the Company
                                            received gross proceeds of approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_906_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCOneWarrantsMember_zyPqiyEadpZg"
  title="Gross proceeds">0.9</xhtml:span> million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001891"
          xlink:to="Footnote002081"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001892"
          xlink:label="Fact001892"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001892"
          xlink:to="Footnote002081"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001906"
          xlink:label="Fact001906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001906"
          xlink:to="Footnote002081"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001907"
          xlink:label="Fact001907"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001907"
          xlink:to="Footnote002081"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001921"
          xlink:label="Fact001921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001921"
          xlink:to="Footnote002081"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001922"
          xlink:label="Fact001922"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001922"
          xlink:to="Footnote002081"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001936"
          xlink:label="Fact001936"
          xlink:type="locator"/>
        <link:footnote id="Footnote002100" xlink:label="Footnote002100" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The
                                            Series D Warrants were issued as additional consideration to the Holders as part of the May
                                            Inducement Offer. The fair value of the Series D Warrants totaling $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_ecustom--Deemeddividend_iI_pn5n6_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesDWarrantsMember_zx7OeKeehXC3"
  title="Deemed dividend">1.7</xhtml:span> million was recorded
                                            as part of a deemed dividend to the warrant holders, and accordingly was treated as a reduction
                                            from total loss attributable to common stockholders in the calculations of net loss per share
                                            in the consolidated statements of operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001936"
          xlink:to="Footnote002100"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001937"
          xlink:label="Fact001937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001937"
          xlink:to="Footnote002100"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1951"
          xlink:label="xdx2ixbrl1951"
          xlink:type="locator"/>
        <link:footnote id="Footnote002109" xlink:label="Footnote002109" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During
    the year ended December 31, 2025, Series E warrants and Series F warrants to purchase <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zNzDXbVL663b"
  title="Number of shares purchased">341,672</xhtml:span> shares of common stock each were exercised
    at a reduced exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zCMw7OuV3ute"
  title="Warrants exercise price">8.40</xhtml:span> per share through the July Inducement Offer and the Company received total gross proceeds of
    approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE91dHN0YW5kaW5nIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20250101__20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEWarrantsAndSeriesFWarrantsMember_zB1dF7sr5iHk"
  title="Gross proceeds">2.8</xhtml:span> million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1951"
          xlink:to="Footnote002109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001952"
          xlink:label="Fact001952"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001952"
          xlink:to="Footnote002109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1966"
          xlink:label="xdx2ixbrl1966"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1966"
          xlink:to="Footnote002109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001967"
          xlink:label="Fact001967"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001967"
          xlink:to="Footnote002109"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002159"
          xlink:label="Fact002159"
          xlink:type="locator"/>
        <link:footnote id="Footnote002419" xlink:label="Footnote002419" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">California contributes to the majority (greater than 50%) of the tax effect in this category for 2025.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002159"
          xlink:to="Footnote002419"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002161"
          xlink:label="Fact002161"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002161"
          xlink:to="Footnote002419"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002340"
          xlink:label="Fact002340"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002340"
          xlink:to="Footnote002419"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl2342"
          xlink:label="xdx2ixbrl2342"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl2342"
          xlink:to="Footnote002419"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
